Compound ID,Uniprot ID,Compound Name,Standard inchi key,Max Phase,Target Pref Name,Gene Names,Target Class,Wild type or mutant,Mutation information,PubMed ID,End Point Standard Type,End Point Standard Relation,End Point Standard Value,End Point Standard Units,Endpoint Mode of Action,Assay Format,Assay Type,Assay Sub Type,Inhibitor Type,Detection Technology,Compound concentration value,Compound concentration value units,Substrate type,Substrate Type Standard Relation,Substrate Type Standard Value,Substrate Type Standard Units,Assay cell line,Assay Description,Activity Comments,Title,Journal,Year,Volume,Issue,Authors,Annotation Comments,Assay ID,DTC Tid,DTC Activity ID,DTC Molregno,Record ID,DTC Document ID
CHEMBL10,P14780,SB-203580,CDMGBJANTYXAIV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7484161,DTCC00132413,2089752,46191
CHEMBL10,P14780,SB-203580,CDMGBJANTYXAIV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7484162,DTCC00132413,2089752,46191
CHEMBL100081,P14780,,QDBZCMIHMMMYES-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11677139,IC50,=,7,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.,Bioorg. Med. Chem. Lett.,2001,11,22,"Levin JI, Chen JM, Du MT, Nelson FC, Wehr T, DiJoseph JF, Killar LM, Skala S, Sung A, Sharr MA, Roth CE, Jin G, Cowling R, Di L, Sherman M, Xu ZB, March CJ, Mohler KM, Black RA, Skotnicki JS",,105530,DTCT0024844,1609703,DTCC00269343,453142,4590
CHEMBL100134,P14780,,AWDZLFOJMUGNPS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11677139,IC50,=,14,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.,Bioorg. Med. Chem. Lett.,2001,11,22,"Levin JI, Chen JM, Du MT, Nelson FC, Wehr T, DiJoseph JF, Killar LM, Skala S, Sung A, Sharr MA, Roth CE, Jin G, Cowling R, Di L, Sherman M, Xu ZB, March CJ, Mohler KM, Black RA, Skotnicki JS",,105530,DTCT0024844,1600776,DTCC00269627,841776,4590
CHEMBL100146,P14780,,ZLOBLTFULLQWKZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12270165,IC50,=,18,NM,,,,,,,,,,,,,,Concentration required in vitro to inhibit Matrix metalloprotease-9,,Benzodiazepine inhibitors of the MMPs and TACE.,Bioorg. Med. Chem. Lett.,2002,12,20,"Nelson FC, Delos Santos E, Levin JI, Chen JM, Skotnicki JS, DiJoseph JF, Sharr MA, Sung A, Killar LM, Cowling R, Jin G, Roth CE, Albright JD",,105515,DTCT0024844,1532838,DTCC00263161,1882578,5143
CHEMBL100280,P14780,,WGMQZHYPIKBUML-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11677139,IC50,=,5,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.,Bioorg. Med. Chem. Lett.,2001,11,22,"Levin JI, Chen JM, Du MT, Nelson FC, Wehr T, DiJoseph JF, Killar LM, Skala S, Sung A, Sharr MA, Roth CE, Jin G, Cowling R, Di L, Sherman M, Xu ZB, March CJ, Mohler KM, Black RA, Skotnicki JS",,105530,DTCT0024844,1612116,DTCC00269055,1968639,4590
CHEMBL100512,P14780,,YIIGCCOQJNYBNF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11677139,IC50,=,1,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.,Bioorg. Med. Chem. Lett.,2001,11,22,"Levin JI, Chen JM, Du MT, Nelson FC, Wehr T, DiJoseph JF, Killar LM, Skala S, Sung A, Sharr MA, Roth CE, Jin G, Cowling R, Di L, Sherman M, Xu ZB, March CJ, Mohler KM, Black RA, Skotnicki JS",,105530,DTCT0024844,1621221,DTCC00269127,1326740,4590
CHEMBL100564,P14780,,CFEKPCYWRLBSBI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11677139,IC50,=,5,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.,Bioorg. Med. Chem. Lett.,2001,11,22,"Levin JI, Chen JM, Du MT, Nelson FC, Wehr T, DiJoseph JF, Killar LM, Skala S, Sung A, Sharr MA, Roth CE, Jin G, Cowling R, Di L, Sherman M, Xu ZB, March CJ, Mohler KM, Black RA, Skotnicki JS",,105530,DTCT0024844,1603357,DTCC00269128,422247,4590
CHEMBL100570,P14780,,RNCWXNOSFWYLTA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15163180,KI,=,46.7,NM,,,,,,,,,,,,,,Inhibition of recombinant human Matrix metalloprotease-9,,Sultam hydroxamates as novel matrix metalloproteinase inhibitors.,J. Med. Chem.,2004,47,12,"Cherney RJ, Mo R, Meyer DT, Hardman KD, Liu RQ, Covington MB, Qian M, Wasserman ZR, Christ DD, Trzaskos JM, Newton RC, Decicco CP",,105386,DTCT0024844,674930,DTCC00106694,970630,18131
CHEMBL100570,P14780,,RNCWXNOSFWYLTA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16289878,KI,=,46.7,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,Conversion of potent MMP inhibitors into selective TACE inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,4,"Cherney RJ, King BW, Gilmore JL, Liu RQ, Covington MB, Duan JJ, Decicco CP",,334536,DTCT0024844,469044,DTCC00106694,984001,20373
CHEMBL100570,P14780,,RNCWXNOSFWYLTA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19095454,KI,=,46.7,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Current perspective of TACE inhibitors: a review.,Bioorg. Med. Chem.,2009,17,2,"DasGupta S, Murumkar PR, Giridhar R, Yadav MR",,495050,DTCT0024844,2594689,DTCC00106694,985007,32093
CHEMBL100584,P14780,,IFHBUYGFCSEHIF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11212095,IC50,=,3.6,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.,Bioorg. Med. Chem. Lett.,2001,11,3,"Chollet AM, Le Diguarher T, Murray L, Bertrand M, Tucker GC, Sabatini M, Pierré A, Atassi G, Bonnet J, Casara P",,105358,DTCT0024844,628944,DTCC00269547,161928,4635
CHEMBL1006,P14780,AMIFOSTINE,JKOQGQFVAUAYPM-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7291281,DTCC00224760,898282,46191
CHEMBL1006,P14780,AMIFOSTINE,JKOQGQFVAUAYPM-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7291282,DTCC00224760,898282,46191
CHEMBL100754,P14780,,CMALBPMZEURNBK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15163180,KI,=,446.7,NM,,,,,,,,,,,,,,Inhibition of recombinant human Matrix metalloprotease-9,,Sultam hydroxamates as novel matrix metalloproteinase inhibitors.,J. Med. Chem.,2004,47,12,"Cherney RJ, Mo R, Meyer DT, Hardman KD, Liu RQ, Covington MB, Qian M, Wasserman ZR, Christ DD, Trzaskos JM, Newton RC, Decicco CP",,105386,DTCT0024844,693864,DTCC00269176,1326745,18131
CHEMBL100777,P14780,,QAFRSDWNZLQCBN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11677139,IC50,=,2,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.,Bioorg. Med. Chem. Lett.,2001,11,22,"Levin JI, Chen JM, Du MT, Nelson FC, Wehr T, DiJoseph JF, Killar LM, Skala S, Sung A, Sharr MA, Roth CE, Jin G, Cowling R, Di L, Sherman M, Xu ZB, March CJ, Mohler KM, Black RA, Skotnicki JS",,105530,DTCT0024844,1633952,DTCC00269096,1935386,4590
CHEMBL100805,P14780,,XYVVUCAHUUIYFV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11212095,IC50,=,25,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.,Bioorg. Med. Chem. Lett.,2001,11,3,"Chollet AM, Le Diguarher T, Murray L, Bertrand M, Tucker GC, Sabatini M, Pierré A, Atassi G, Bonnet J, Casara P",,105358,DTCT0024844,637873,DTCC00269559,582958,4635
CHEMBL1009,P14780,LEVODOPA,WTDRDQBEARUVNC-LURJTMIESA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7425243,DTCC00224903,1351112,46191
CHEMBL1009,P14780,LEVODOPA,WTDRDQBEARUVNC-LURJTMIESA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7425244,DTCC00224903,1351112,46191
CHEMBL100950,P14780,,LYVGWVHFXOYMDJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11677139,IC50,=,3,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.,Bioorg. Med. Chem. Lett.,2001,11,22,"Levin JI, Chen JM, Du MT, Nelson FC, Wehr T, DiJoseph JF, Killar LM, Skala S, Sung A, Sharr MA, Roth CE, Jin G, Cowling R, Di L, Sherman M, Xu ZB, March CJ, Mohler KM, Black RA, Skotnicki JS",,105530,DTCT0024844,1630086,DTCC00268342,1714206,4590
CHEMBL101,P14780,PHENYLBUTAZONE,VYMDGNCVAMGZFE-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7400198,DTCC00142582,217583,46191
CHEMBL101,P14780,PHENYLBUTAZONE,VYMDGNCVAMGZFE-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7400199,DTCC00142582,217583,46191
CHEMBL101121,P14780,,VVZTYGQJDUUATC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11212095,IC50,=,5,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.,Bioorg. Med. Chem. Lett.,2001,11,3,"Chollet AM, Le Diguarher T, Murray L, Bertrand M, Tucker GC, Sabatini M, Pierré A, Atassi G, Bonnet J, Casara P",,105358,DTCT0024844,619917,DTCC00269629,2001205,4635
CHEMBL101168,P14780,1-AMINOBENZOTRIAZOLE,JCXKHYLLVKZPKE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7302876,DTCC01742000,2057641,46191
CHEMBL101168,P14780,1-AMINOBENZOTRIAZOLE,JCXKHYLLVKZPKE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7302877,DTCC01742000,2057641,46191
CHEMBL101210,P14780,,FMQWWPFJFLUCHZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11677139,IC50,=,7,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.,Bioorg. Med. Chem. Lett.,2001,11,22,"Levin JI, Chen JM, Du MT, Nelson FC, Wehr T, DiJoseph JF, Killar LM, Skala S, Sung A, Sharr MA, Roth CE, Jin G, Cowling R, Di L, Sherman M, Xu ZB, March CJ, Mohler KM, Black RA, Skotnicki JS",,105530,DTCT0024844,1627641,DTCC00269368,193780,4590
CHEMBL101413,P14780,,AJXYMDJBIXFLCO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11677139,IC50,=,10,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.,Bioorg. Med. Chem. Lett.,2001,11,22,"Levin JI, Chen JM, Du MT, Nelson FC, Wehr T, DiJoseph JF, Killar LM, Skala S, Sung A, Sharr MA, Roth CE, Jin G, Cowling R, Di L, Sherman M, Xu ZB, March CJ, Mohler KM, Black RA, Skotnicki JS",,105530,DTCT0024844,1615940,DTCC00269089,422246,4590
CHEMBL1016,P14780,CANDESARTAN,HTQMVQVXFRQIKW-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7270450,DTCC00228418,413969,46191
CHEMBL1016,P14780,CANDESARTAN,HTQMVQVXFRQIKW-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7270451,DTCC00228418,413969,46191
CHEMBL101612,P14780,,LGVIBWRSRHZDQG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11677139,IC50,=,0.5,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.,Bioorg. Med. Chem. Lett.,2001,11,22,"Levin JI, Chen JM, Du MT, Nelson FC, Wehr T, DiJoseph JF, Killar LM, Skala S, Sung A, Sharr MA, Roth CE, Jin G, Cowling R, Di L, Sherman M, Xu ZB, March CJ, Mohler KM, Black RA, Skotnicki JS",,105530,DTCT0024844,1602205,DTCC00269291,776640,4590
CHEMBL101789,P14780,,XBJDUGZISLIDRA-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15163180,KI,<,2.1,NM,,,,,,,,,,,,,,Inhibition of recombinant human Matrix metalloprotease-9,,Sultam hydroxamates as novel matrix metalloproteinase inhibitors.,J. Med. Chem.,2004,47,12,"Cherney RJ, Mo R, Meyer DT, Hardman KD, Liu RQ, Covington MB, Qian M, Wasserman ZR, Christ DD, Trzaskos JM, Newton RC, Decicco CP",,105386,DTCT0024844,678777,DTCC00269210,1968643,18131
CHEMBL101864,P14780,,DPCXVXNEMYTZOE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11677139,IC50,=,2,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.,Bioorg. Med. Chem. Lett.,2001,11,22,"Levin JI, Chen JM, Du MT, Nelson FC, Wehr T, DiJoseph JF, Killar LM, Skala S, Sung A, Sharr MA, Roth CE, Jin G, Cowling R, Di L, Sherman M, Xu ZB, March CJ, Mohler KM, Black RA, Skotnicki JS",,105530,DTCT0024844,1631272,DTCC00268937,1326739,4590
CHEMBL101981,P14780,,CNEKWCSJAXATCC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11677139,IC50,=,8,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.,Bioorg. Med. Chem. Lett.,2001,11,22,"Levin JI, Chen JM, Du MT, Nelson FC, Wehr T, DiJoseph JF, Killar LM, Skala S, Sung A, Sharr MA, Roth CE, Jin G, Cowling R, Di L, Sherman M, Xu ZB, March CJ, Mohler KM, Black RA, Skotnicki JS",,105530,DTCT0024844,1632653,DTCC00269080,1903394,4590
CHEMBL1020,P14780,TOLMETIN,UPSPUYADGBWSHF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7474822,DTCC00229841,477924,46191
CHEMBL1020,P14780,TOLMETIN,UPSPUYADGBWSHF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7474823,DTCC00229841,477924,46191
CHEMBL102057,P14780,,CLPQPSHMBDAYLR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11677139,IC50,=,2,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.,Bioorg. Med. Chem. Lett.,2001,11,22,"Levin JI, Chen JM, Du MT, Nelson FC, Wehr T, DiJoseph JF, Killar LM, Skala S, Sung A, Sharr MA, Roth CE, Jin G, Cowling R, Di L, Sherman M, Xu ZB, March CJ, Mohler KM, Black RA, Skotnicki JS",,105530,DTCT0024844,1600784,DTCC00269097,1196589,4590
CHEMBL1024,P14780,IFOSFAMIDE,HOMGKSMUEGBAAB-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7308751,DTCC00230672,703982,46191
CHEMBL1024,P14780,IFOSFAMIDE,HOMGKSMUEGBAAB-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7308752,DTCC00230672,703982,46191
CHEMBL102415,P14780,,RNMJVOBQCWORLK-GFOWMXPYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11543676,IC50,=,0.9,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors.,J. Med. Chem.,2001,44,19,"Hanessian S, MacKay DB, Moitessier N",,105231,DTCT0024844,1202334,DTCC00273885,226190,16385
CHEMBL102438,P14780,,BSGLIFPGYIIUAJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11543675,IC50,=,0.2,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.",J. Med. Chem.,2001,44,19,"Hanessian S, Moitessier N, Gauchet C, Viau M",,105230,DTCT0024844,1389496,DTCC00273957,885822,16392
CHEMBL102441,P14780,,AGLYKFTUNLOGBT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11543675,IC50,=,149,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.",J. Med. Chem.,2001,44,19,"Hanessian S, Moitessier N, Gauchet C, Viau M",,105230,DTCT0024844,1379268,DTCC00273131,465265,16392
CHEMBL102459,P14780,,YMFBAKCSKQKFMX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11212095,IC50,=,33,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.,Bioorg. Med. Chem. Lett.,2001,11,3,"Chollet AM, Le Diguarher T, Murray L, Bertrand M, Tucker GC, Sabatini M, Pierré A, Atassi G, Bonnet J, Casara P",,105358,DTCT0024844,650233,DTCC00269592,1326752,4635
CHEMBL102504,P14780,,MEVLEABHOAUFQW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11543675,IC50,=,0.2,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.",J. Med. Chem.,2001,44,19,"Hanessian S, Moitessier N, Gauchet C, Viau M",,105230,DTCT0024844,1371787,DTCC00273508,1661708,16392
CHEMBL102698,P14780,,WYWVSRVZNIIISU-BPGUCPLFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11543676,IC50,=,2.8,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors.,J. Med. Chem.,2001,44,19,"Hanessian S, MacKay DB, Moitessier N",,105231,DTCT0024844,1194615,DTCC00273956,97110,16385
CHEMBL102785,P14780,,PECNGMJVFOGIBW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11543675,IC50,=,0.2,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.",J. Med. Chem.,2001,44,19,"Hanessian S, Moitessier N, Gauchet C, Viau M",,105230,DTCT0024844,1398098,DTCC00273055,723954,16392
CHEMBL102798,P14780,,MAOGHLYYLNCNCI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11543675,IC50,=,0.2,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.",J. Med. Chem.,2001,44,19,"Hanessian S, Moitessier N, Gauchet C, Viau M",,105230,DTCT0024844,1399291,DTCC00273086,2077525,16392
CHEMBL103,P14780,PROGESTERONE,RJKFOVLPORLFTN-LEKSSAKUSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7374897,DTCC00142899,1092348,46191
CHEMBL103,P14780,PROGESTERONE,RJKFOVLPORLFTN-LEKSSAKUSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7374898,DTCC00142899,1092348,46191
CHEMBL103418,P14780,,QVCXUWWKONKLBL-GOSISDBHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15163180,KI,=,0.9,NM,,,,,,,,,,,,,,Inhibition of recombinant human Matrix metalloprotease-9,,Sultam hydroxamates as novel matrix metalloproteinase inhibitors.,J. Med. Chem.,2004,47,12,"Cherney RJ, Mo R, Meyer DT, Hardman KD, Liu RQ, Covington MB, Qian M, Wasserman ZR, Christ DD, Trzaskos JM, Newton RC, Decicco CP",,105386,DTCT0024844,367652,DTCC00269253,1003161,18131
CHEMBL103418,P14780,,QVCXUWWKONKLBL-GOSISDBHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,KI,=,0.9,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278523,DTCC00269253,1021673,25112
CHEMBL103442,P14780,,KFTWEWMQNRZZNL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11212095,IC50,=,16,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.,Bioorg. Med. Chem. Lett.,2001,11,3,"Chollet AM, Le Diguarher T, Murray L, Bertrand M, Tucker GC, Sabatini M, Pierré A, Atassi G, Bonnet J, Casara P",,105358,DTCT0024844,621141,DTCC00269617,1003168,4635
CHEMBL103563,P14780,,QAIMUZSIIGFZOG-HXUWFJFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15163180,KI,=,8.5,NM,,,,,,,,,,,,,,Inhibition of recombinant human Matrix metalloprotease-9,,Sultam hydroxamates as novel matrix metalloproteinase inhibitors.,J. Med. Chem.,2004,47,12,"Cherney RJ, Mo R, Meyer DT, Hardman KD, Liu RQ, Covington MB, Qian M, Wasserman ZR, Christ DD, Trzaskos JM, Newton RC, Decicco CP",,105386,DTCT0024844,692555,DTCC00269250,324184,18131
CHEMBL104,P14780,CLOTRIMAZOLE,VNFPBHJOKIVQEB-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7358721,DTCC00143452,1960074,46191
CHEMBL104,P14780,CLOTRIMAZOLE,VNFPBHJOKIVQEB-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7358722,DTCC00143452,1960074,46191
CHEMBL104021,P14780,,NKRKWSFHPLAZOP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11543675,IC50,=,0.9,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.",J. Med. Chem.,2001,44,19,"Hanessian S, Moitessier N, Gauchet C, Viau M",,105230,DTCT0024844,1381857,DTCC00106784,1240704,16392
CHEMBL104022,P14780,,TWQZYQBXMVVVCY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11543675,IC50,<,0.1,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.",J. Med. Chem.,2001,44,19,"Hanessian S, Moitessier N, Gauchet C, Viau M",,105230,DTCT0024844,1385695,DTCC00273200,433728,16392
CHEMBL104022,P14780,,TWQZYQBXMVVVCY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16392792,IC50,<,0.1,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.,J. Med. Chem.,2006,49,1,"Pirard B, Matter H",,329822,DTCT0024844,1880218,DTCC00273200,423989,20214
CHEMBL1042,P14780,CHOLECALCIFEROL,QYSXJUFSXHHAJI-YRZJJWOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7356019,DTCC00235252,1992802,46191
CHEMBL1042,P14780,CHOLECALCIFEROL,QYSXJUFSXHHAJI-YRZJJWOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7356020,DTCC00235252,1992802,46191
CHEMBL104446,P14780,,BMPCLJPYXFVWKY-ARLHGKGLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11543676,IC50,=,138,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors.,J. Med. Chem.,2001,44,19,"Hanessian S, MacKay DB, Moitessier N",,105231,DTCT0024844,1194610,DTCC00273526,1228796,16385
CHEMBL10454,P14780,,UXURFMZZZWZYFW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472202,IC50,=,553,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.,J. Med. Chem.,2001,44,16,"Pikul S, Ohler NE, Ciszewski G, Laufersweiler MC, Almstead NG, De B, Natchus MG, Hsieh LC, Janusz MJ, Peng SX, Branch TM, King SL, Taiwo YO, Mieling GE",,105229,DTCT0024844,1321640,DTCC00138391,578578,16328
CHEMBL104599,P14780,,XOOXBIFEOHDRHE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11543675,IC50,=,0.5,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.",J. Med. Chem.,2001,44,19,"Hanessian S, Moitessier N, Gauchet C, Viau M",,105230,DTCT0024844,1398103,DTCC00273602,1564726,16392
CHEMBL1046,P14780,AMINOCAPROIC ACID,SLXKOJJOQWFEFD-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7299537,DTCC00237384,574618,46191
CHEMBL1046,P14780,AMINOCAPROIC ACID,SLXKOJJOQWFEFD-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7299538,DTCC00237384,574618,46191
CHEMBL104722,P14780,,CQIQKDQFHVTTKM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11543675,IC50,=,8,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.",J. Med. Chem.,2001,44,19,"Hanessian S, Moitessier N, Gauchet C, Viau M",,105230,DTCT0024844,1385699,DTCC00273620,659487,16392
CHEMBL105,P14780,MITOMYCIN,NWIBSHFKIJFRCO-WUDYKRTCSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7432705,DTCC00143504,542580,46191
CHEMBL105,P14780,MITOMYCIN,NWIBSHFKIJFRCO-WUDYKRTCSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7432706,DTCC00143504,542580,46191
CHEMBL105142,P14780,,FCYBWLNLMVDLRH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11543675,IC50,=,7,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.",J. Med. Chem.,2001,44,19,"Hanessian S, Moitessier N, Gauchet C, Viau M",,105230,DTCT0024844,1401772,DTCC00273509,1207889,16392
CHEMBL105279,P14780,,ACXYSVKNGLLDLY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11543675,IC50,=,3.2,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.",J. Med. Chem.,2001,44,19,"Hanessian S, Moitessier N, Gauchet C, Viau M",,105230,DTCT0024844,1369049,DTCC00273107,1500350,16392
CHEMBL105311,P14780,,SWRNCXLTVBBIMK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11543675,IC50,=,0.2,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.",J. Med. Chem.,2001,44,19,"Hanessian S, Moitessier N, Gauchet C, Viau M",,105230,DTCT0024844,1402984,DTCC00274052,205240,16392
CHEMBL1054,P14780,TRICHLORMETHIAZIDE,LMJSLTNSBFUCMU-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7449933,DTCC00242621,2025646,46191
CHEMBL1054,P14780,TRICHLORMETHIAZIDE,LMJSLTNSBFUCMU-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7449934,DTCC00242621,2025646,46191
CHEMBL105422,P14780,,AXBFSSCCVFPFFC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11543675,IC50,=,29,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.",J. Med. Chem.,2001,44,19,"Hanessian S, Moitessier N, Gauchet C, Viau M",,105230,DTCT0024844,1371783,DTCC00273155,1079676,16392
CHEMBL1055,P14780,CHLORTHALIDONE,JIVPVXMEBJLZRO-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7345395,DTCC00242796,1798406,46191
CHEMBL1055,P14780,CHLORTHALIDONE,JIVPVXMEBJLZRO-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7347408,DTCC00242796,1798406,46191
CHEMBL105535,P14780,,SSFOEYVZLXDDTG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11543675,IC50,=,3,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.",J. Med. Chem.,2001,44,19,"Hanessian S, Moitessier N, Gauchet C, Viau M",,105230,DTCT0024844,1384508,DTCC00273105,659486,16392
CHEMBL105962,P14780,,ZPNXAVJYHSAOKF-SJBAFXMYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11543676,IC50,=,3.6,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors.,J. Med. Chem.,2001,44,19,"Hanessian S, MacKay DB, Moitessier N",,105231,DTCT0024844,1200051,DTCC00273570,389552,16385
CHEMBL106,P14780,FLUCONAZOLE,RFHAOTPXVQNOHP-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7305365,DTCC00143630,51470,46191
CHEMBL106,P14780,FLUCONAZOLE,RFHAOTPXVQNOHP-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7305366,DTCC00143630,51470,46191
CHEMBL106016,P14780,,MMOBDSFVSOBMOV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11543675,IC50,=,0.2,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.",J. Med. Chem.,2001,44,19,"Hanessian S, Moitessier N, Gauchet C, Viau M",,105230,DTCT0024844,1389491,DTCC00273742,335997,16392
CHEMBL1062,P14780,HYDROXYPROGESTERONE,DBPWSSGDRRHUNT-CEGNMAFCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7315085,DTCC00245885,1092342,46191
CHEMBL1062,P14780,HYDROXYPROGESTERONE,DBPWSSGDRRHUNT-CEGNMAFCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7315086,DTCC00245885,1092342,46191
CHEMBL1064,P14780,SIMVASTATIN,RYMZZMVNJRMUDD-HGQWONQESA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7484260,DTCC00246331,217585,46191
CHEMBL1064,P14780,SIMVASTATIN,RYMZZMVNJRMUDD-HGQWONQESA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7484261,DTCC00246331,217585,46191
CHEMBL1065,P14780,METHYSERGIDE,KPJZHOPZRAFDTN-ZRGWGRIASA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7408890,DTCC00246366,1124452,46191
CHEMBL1065,P14780,METHYSERGIDE,KPJZHOPZRAFDTN-ZRGWGRIASA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7408891,DTCC00246366,1124452,46191
CHEMBL1068,P14780,OXCARBAZEPINE,CTRLABGOLIVAIY-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7391052,DTCC00246694,1285880,46191
CHEMBL1068,P14780,OXCARBAZEPINE,CTRLABGOLIVAIY-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7391053,DTCC00246694,1285880,46191
CHEMBL106889,P14780,,HECCDGMGLZRKDV-XWUOBKMESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,36000,NM,,,,,,,,,,,,,,"Inhibition of Gelatinase B, matrix metalloprotease-9",,,Bioorg. Med. Chem. Lett.,1997,7,24,,,71655,DTCT0024844,1268922,DTCC00276363,788306,2375
CHEMBL1069,P14780,VALSARTAN,ACWBQPMHZXGDFX-QFIPXVFZSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7445760,DTCC00246716,1992811,46191
CHEMBL1069,P14780,VALSARTAN,ACWBQPMHZXGDFX-QFIPXVFZSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7445761,DTCC00246716,1992811,46191
CHEMBL107,P14780,COLCHICINE,IAKHMKGGTNLKSZ-INIZCTEOSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7348173,DTCC00144185,153441,46191
CHEMBL107,P14780,COLCHICINE,IAKHMKGGTNLKSZ-INIZCTEOSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7348174,DTCC00144185,153441,46191
CHEMBL1070,P14780,NABUMETONE,BLXXJMDCKKHMKV-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7428652,DTCC00246857,1992808,46191
CHEMBL1070,P14780,NABUMETONE,BLXXJMDCKKHMKV-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7428653,DTCC00246857,1992808,46191
CHEMBL1071,P14780,OXAPROZIN,OFPXSFXSNFPTHF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7386741,DTCC00246868,1092346,46191
CHEMBL1071,P14780,OXAPROZIN,OFPXSFXSNFPTHF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7386742,DTCC00246868,1092346,46191
CHEMBL1073,P14780,GLIPIZIDE,ZJJXGWJIGJFDTL-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7329475,DTCC00246919,1285876,46191
CHEMBL1073,P14780,GLIPIZIDE,ZJJXGWJIGJFDTL-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7329476,DTCC00246919,1285876,46191
CHEMBL1076211,P14780,TOLPERISONE,FSKFPVLPFLJRQB-UHFFFAOYSA-N,2,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7483471,DTCC00627461,315671,46191
CHEMBL1076211,P14780,TOLPERISONE,FSKFPVLPFLJRQB-UHFFFAOYSA-N,2,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7483472,DTCC00627461,315671,46191
CHEMBL1077,P14780,BROMFENAC,ZBPLOVFIXSTCRZ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7263101,DTCC00247634,930077,46191
CHEMBL1077,P14780,BROMFENAC,ZBPLOVFIXSTCRZ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7263102,DTCC00247634,930077,46191
CHEMBL1077203,P14780,,CNUCYIDHDPTDOD-SFHVURJKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20172725,KI,>,40000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Discovery and SAR of hydantoin TACE inhibitors.,Bioorg. Med. Chem. Lett.,2010,20,6,"Yu W, Guo Z, Orth P, Madison V, Chen L, Dai C, Feltz RJ, Girijavallabhan VM, Kim SH, Kozlowski JA, Lavey BJ, Li D, Lundell D, Niu X, Piwinski JJ, Popovici-Muller J, Rizvi R, Rosner KE, Shankar BB, Shih NY, Siddiqui MA, Sun J, Tong L, Umland S, Wong MK, Yang DY, Zhou G",,615267,DTCT0024844,3227038,DTCC00631173,1104573,38167
CHEMBL1078281,P14780,,GRSFKJZRDUZQPW-ONUMYQOESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21417219,IC50,=,58,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 after 60 mins by fluorescence plate reader,,"Discovery of (1S,2R,3R)-2,3-Dimethyl-2-phenyl-1-sulfamidocyclopropanecarboxylates: Novel and Highly Selective Aggrecanase Inhibitors.",J. Med. Chem.,2011,54,8,"Shiozaki M, Maeda K, Miura T, Kotoku M, Yamasaki T, Matsuda I, Aoki K, Yasue K, Imai H, Ubukata M, Suma A, Yokota M, Hotta T, Tanaka M, Hase Y, Haas J, Fryer AM, Laird ER, Littmann NM, Andrews SW, Josey JA, Mimura T, Shinozaki Y, Yoshiuchi H, Inaba T",,743612,DTCT0024844,5927582,DTCC00632907,1007708,44276
CHEMBL1078396,P14780,,PIEMRKVLYXWKFP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20172725,KI,=,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Discovery and SAR of hydantoin TACE inhibitors.,Bioorg. Med. Chem. Lett.,2010,20,6,"Yu W, Guo Z, Orth P, Madison V, Chen L, Dai C, Feltz RJ, Girijavallabhan VM, Kim SH, Kozlowski JA, Lavey BJ, Li D, Lundell D, Niu X, Piwinski JJ, Popovici-Muller J, Rizvi R, Rosner KE, Shankar BB, Shih NY, Siddiqui MA, Sun J, Tong L, Umland S, Wong MK, Yang DY, Zhou G",,615267,DTCT0024844,3227037,DTCC00631942,1232705,38167
CHEMBL108,P14780,CARBAMAZEPINE,FFGPTBGBLSHEPO-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7263564,DTCC00144764,249939,46191
CHEMBL108,P14780,CARBAMAZEPINE,FFGPTBGBLSHEPO-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7263565,DTCC00144764,249939,46191
CHEMBL1082,P14780,AMOXICILLIN,LSQZJLSUYDQPKJ-NJBDSQKTSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7287540,DTCC00250356,51444,46191
CHEMBL1082,P14780,AMOXICILLIN,LSQZJLSUYDQPKJ-NJBDSQKTSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7287541,DTCC00250356,51444,46191
CHEMBL1082317,P14780,,QOWJHUFMPPFELP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20529685,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,MMP-13 selective isonipecotamide alpha-sulfone hydroxamates.,Bioorg. Med. Chem. Lett.,2010,20,12,"Kolodziej SA, Hockerman SL, DeCrescenzo GA, McDonald JJ, Mischke DA, Munie GE, Fletcher TR, Stehle N, Swearingen C, Becker DP",,634123,DTCT0024844,3346216,DTCC00647799,780673,35540
CHEMBL1082318,P14780,,HWZVYNMATDDRGV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20529685,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,MMP-13 selective isonipecotamide alpha-sulfone hydroxamates.,Bioorg. Med. Chem. Lett.,2010,20,12,"Kolodziej SA, Hockerman SL, DeCrescenzo GA, McDonald JJ, Mischke DA, Munie GE, Fletcher TR, Stehle N, Swearingen C, Becker DP",,634123,DTCT0024844,3346217,DTCC00647800,2038151,35540
CHEMBL1082370,P14780,,XZDDXHHQKBWEQB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20529684,IC50,=,2501,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.",Bioorg. Med. Chem. Lett.,2010,20,12,"Kolodziej SA, Hockerman SL, Boehm TL, Carroll JN, DeCrescenzo GA, McDonald JJ, Mischke DA, Munie GE, Fletcher TR, Rico JG, Stehle NW, Swearingen C, Becker DP",,634106,DTCT0024844,3345333,DTCC00647469,954160,35532
CHEMBL1082371,P14780,,PYJCXRBSZSSHDD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20529684,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.",Bioorg. Med. Chem. Lett.,2010,20,12,"Kolodziej SA, Hockerman SL, Boehm TL, Carroll JN, DeCrescenzo GA, McDonald JJ, Mischke DA, Munie GE, Fletcher TR, Rico JG, Stehle NW, Swearingen C, Becker DP",,634106,DTCT0024844,3345334,DTCC00647470,2049561,35532
CHEMBL1082381,P14780,SC-276,WXNWNNKHEJMQOM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16220987,KI,=,1.5,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14742623,DTCC00031197,2108114,69259
CHEMBL1082381,P14780,SC-276,WXNWNNKHEJMQOM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20529684,IC50,=,1.5,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.",Bioorg. Med. Chem. Lett.,2010,20,12,"Kolodziej SA, Hockerman SL, Boehm TL, Carroll JN, DeCrescenzo GA, McDonald JJ, Mischke DA, Munie GE, Fletcher TR, Rico JG, Stehle NW, Swearingen C, Becker DP",,634106,DTCT0024844,3346101,DTCC00031197,792376,35532
CHEMBL1082381,P14780,SC-276,WXNWNNKHEJMQOM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,1.5,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005824,DTCC00031197,781480,45214
CHEMBL1082381,P14780,SC-276,WXNWNNKHEJMQOM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21493063,IC50,=,1.5,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,MMP-13 selective alpha-sulfone hydroxamates: Identification of selective P1' amides.,Bioorg. Med. Chem. Lett.,2011,21,10,"Fobian YM, Freskos JN, Barta TE, Bedell LJ, Heintz R, Kassab DJ, Kiefer JR, Mischke BV, Molyneaux JM, Mullins P, Munie GE, Becker DP",,744871,DTCT0024844,5936658,DTCC00031197,799452,44425
CHEMBL1082966,P14780,,NHBOIMAIUCLQKQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20529684,IC50,=,356,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.",Bioorg. Med. Chem. Lett.,2010,20,12,"Kolodziej SA, Hockerman SL, Boehm TL, Carroll JN, DeCrescenzo GA, McDonald JJ, Mischke DA, Munie GE, Fletcher TR, Rico JG, Stehle NW, Swearingen C, Becker DP",,634106,DTCT0024844,3345322,DTCC00647118,1051282,35532
CHEMBL1083322,P14780,,FSVPEOOPDJVOOW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20529684,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.",Bioorg. Med. Chem. Lett.,2010,20,12,"Kolodziej SA, Hockerman SL, Boehm TL, Carroll JN, DeCrescenzo GA, McDonald JJ, Mischke DA, Munie GE, Fletcher TR, Rico JG, Stehle NW, Swearingen C, Becker DP",,634106,DTCT0024844,3345332,DTCC00647405,112725,35532
CHEMBL1083609,P14780,,KWMLNYHZDJEOKG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20478708,INHIBITION,=,6,%,,,,,,,,,,,,,,Inhibition of MMP9 at 1 uM,,New hydroxypyrimidinone-containing sulfonamides as carbonic anhydrase inhibitors also acting as MMP inhibitors.,Bioorg. Med. Chem. Lett.,2010,20,12,"Esteves MA, Ortet O, Capelo A, Supuran CT, Marques SM, Santos MA",,635101,DTCT0024844,3350488,DTCC00647058,274642,39108
CHEMBL1083609,P14780,,KWMLNYHZDJEOKG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20478708,INHIBITION,=,9,%,,,,,,,,,,,,,,Inhibition of MMP9 at 10 uM,,New hydroxypyrimidinone-containing sulfonamides as carbonic anhydrase inhibitors also acting as MMP inhibitors.,Bioorg. Med. Chem. Lett.,2010,20,12,"Esteves MA, Ortet O, Capelo A, Supuran CT, Marques SM, Santos MA",,635100,DTCT0024844,3350487,DTCC00647058,274642,39108
CHEMBL1083609,P14780,,KWMLNYHZDJEOKG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20478708,INHIBITION,=,67,%,,,,,,,,,,,,,,Inhibition of MMP9 at 100 uM,,New hydroxypyrimidinone-containing sulfonamides as carbonic anhydrase inhibitors also acting as MMP inhibitors.,Bioorg. Med. Chem. Lett.,2010,20,12,"Esteves MA, Ortet O, Capelo A, Supuran CT, Marques SM, Santos MA",,635099,DTCT0024844,3350484,DTCC00647058,274642,39108
CHEMBL1083906,P14780,,HYKTXCHYRXFJMV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20529684,IC50,=,2860,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.",Bioorg. Med. Chem. Lett.,2010,20,12,"Kolodziej SA, Hockerman SL, Boehm TL, Carroll JN, DeCrescenzo GA, McDonald JJ, Mischke DA, Munie GE, Fletcher TR, Rico JG, Stehle NW, Swearingen C, Becker DP",,634106,DTCT0024844,3345323,DTCC00647119,1665937,35532
CHEMBL1083907,P14780,,XFCISDUWYSMJOU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20529684,IC50,=,2090,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.",Bioorg. Med. Chem. Lett.,2010,20,12,"Kolodziej SA, Hockerman SL, Boehm TL, Carroll JN, DeCrescenzo GA, McDonald JJ, Mischke DA, Munie GE, Fletcher TR, Rico JG, Stehle NW, Swearingen C, Becker DP",,634106,DTCT0024844,3345324,DTCC00647120,534358,35532
CHEMBL1083918,P14780,,NBVVLRJKURZELV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20478708,INHIBITION,=,1,%,,,,,,,,,,,,,,Inhibition of MMP9 at 30 nM,,New hydroxypyrimidinone-containing sulfonamides as carbonic anhydrase inhibitors also acting as MMP inhibitors.,Bioorg. Med. Chem. Lett.,2010,20,12,"Esteves MA, Ortet O, Capelo A, Supuran CT, Marques SM, Santos MA",,635103,DTCT0024844,3350491,DTCC00647059,1277543,39108
CHEMBL1083918,P14780,,NBVVLRJKURZELV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20478708,INHIBITION,=,6,%,,,,,,,,,,,,,,Inhibition of MMP9 at 3 uM,,New hydroxypyrimidinone-containing sulfonamides as carbonic anhydrase inhibitors also acting as MMP inhibitors.,Bioorg. Med. Chem. Lett.,2010,20,12,"Esteves MA, Ortet O, Capelo A, Supuran CT, Marques SM, Santos MA",,635102,DTCT0024844,3350489,DTCC00647059,1277543,39108
CHEMBL1083918,P14780,,NBVVLRJKURZELV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20478708,INHIBITION,=,26,%,,,,,,,,,,,,,,Inhibition of MMP9 at 100 uM,,New hydroxypyrimidinone-containing sulfonamides as carbonic anhydrase inhibitors also acting as MMP inhibitors.,Bioorg. Med. Chem. Lett.,2010,20,12,"Esteves MA, Ortet O, Capelo A, Supuran CT, Marques SM, Santos MA",,635099,DTCT0024844,3350485,DTCC00647059,1277543,39108
CHEMBL1083931,P14780,,VGQUGXBRZGFKOH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20529684,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.",Bioorg. Med. Chem. Lett.,2010,20,12,"Kolodziej SA, Hockerman SL, Boehm TL, Carroll JN, DeCrescenzo GA, McDonald JJ, Mischke DA, Munie GE, Fletcher TR, Rico JG, Stehle NW, Swearingen C, Becker DP",,634106,DTCT0024844,3345328,DTCC00647257,824921,35532
CHEMBL1083932,P14780,,BADHAWRYSSJDAG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20529684,IC50,=,265,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.",Bioorg. Med. Chem. Lett.,2010,20,12,"Kolodziej SA, Hockerman SL, Boehm TL, Carroll JN, DeCrescenzo GA, McDonald JJ, Mischke DA, Munie GE, Fletcher TR, Rico JG, Stehle NW, Swearingen C, Becker DP",,634106,DTCT0024844,3345329,DTCC00647258,1472207,35532
CHEMBL108412,P14780,,OYZQESBTDIZNIE-HKBOAZHASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10560745,IC50,=,850,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease (MMP-9),,Selective inhibition of low affinity IgE receptor (CD23) processing: P1' bicyclomethyl substituents.,Bioorg. Med. Chem. Lett.,1999,9,21,"Bailey S, Bolognese B, Faller A, Louis-Flamberg P, MacPherson DT, Mayer RJ, Marshall LA, Milner PH, Mistry J, Smith DG, Ward JG",,105820,DTCT0024844,1412072,DTCC00278610,1850573,3450
CHEMBL1084206,P14780,,RMMYIAVIROFVLC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20529684,IC50,=,163,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.",Bioorg. Med. Chem. Lett.,2010,20,12,"Kolodziej SA, Hockerman SL, Boehm TL, Carroll JN, DeCrescenzo GA, McDonald JJ, Mischke DA, Munie GE, Fletcher TR, Rico JG, Stehle NW, Swearingen C, Becker DP",,634106,DTCT0024844,3345325,DTCC00647201,1697970,35532
CHEMBL1084208,P14780,,QQPOIMHFFPBDQM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20529684,IC50,=,722,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.",Bioorg. Med. Chem. Lett.,2010,20,12,"Kolodziej SA, Hockerman SL, Boehm TL, Carroll JN, DeCrescenzo GA, McDonald JJ, Mischke DA, Munie GE, Fletcher TR, Rico JG, Stehle NW, Swearingen C, Becker DP",,634106,DTCT0024844,3345326,DTCC00647203,1727327,35532
CHEMBL1084209,P14780,,HBPYDCJRDHWDAE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20529684,IC50,=,682,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.",Bioorg. Med. Chem. Lett.,2010,20,12,"Kolodziej SA, Hockerman SL, Boehm TL, Carroll JN, DeCrescenzo GA, McDonald JJ, Mischke DA, Munie GE, Fletcher TR, Rico JG, Stehle NW, Swearingen C, Becker DP",,634106,DTCT0024844,3345327,DTCC00647204,1018809,35532
CHEMBL1084220,P14780,,DPDYQDPIBOABCX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20529684,IC50,=,6700,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.",Bioorg. Med. Chem. Lett.,2010,20,12,"Kolodziej SA, Hockerman SL, Boehm TL, Carroll JN, DeCrescenzo GA, McDonald JJ, Mischke DA, Munie GE, Fletcher TR, Rico JG, Stehle NW, Swearingen C, Becker DP",,634106,DTCT0024844,3345330,DTCC00647323,1886832,35532
CHEMBL1084221,P14780,,FNEPKOHTWFANAW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20529684,IC50,=,350,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.",Bioorg. Med. Chem. Lett.,2010,20,12,"Kolodziej SA, Hockerman SL, Boehm TL, Carroll JN, DeCrescenzo GA, McDonald JJ, Mischke DA, Munie GE, Fletcher TR, Rico JG, Stehle NW, Swearingen C, Becker DP",,634106,DTCT0024844,3345331,DTCC00647324,598800,35532
CHEMBL1084238,P14780,,UFKFLDDRYBWLPH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20529684,IC50,=,5000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.",Bioorg. Med. Chem. Lett.,2010,20,12,"Kolodziej SA, Hockerman SL, Boehm TL, Carroll JN, DeCrescenzo GA, McDonald JJ, Mischke DA, Munie GE, Fletcher TR, Rico JG, Stehle NW, Swearingen C, Becker DP",,634106,DTCT0024844,3346098,DTCC00647546,80529,35532
CHEMBL1084509,P14780,,VCKIKUWRRCAZBI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20529684,IC50,=,270,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.",Bioorg. Med. Chem. Lett.,2010,20,12,"Kolodziej SA, Hockerman SL, Boehm TL, Carroll JN, DeCrescenzo GA, McDonald JJ, Mischke DA, Munie GE, Fletcher TR, Rico JG, Stehle NW, Swearingen C, Becker DP",,634106,DTCT0024844,3346099,DTCC00647547,1601315,35532
CHEMBL1084510,P14780,,HMVRHAWMVBUIKM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20529684,IC50,=,729,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.",Bioorg. Med. Chem. Lett.,2010,20,12,"Kolodziej SA, Hockerman SL, Boehm TL, Carroll JN, DeCrescenzo GA, McDonald JJ, Mischke DA, Munie GE, Fletcher TR, Rico JG, Stehle NW, Swearingen C, Becker DP",,634106,DTCT0024844,3346100,DTCC00647548,1375495,35532
CHEMBL108494,P14780,,MBSMJAHZPVXQCK-HIGJEIRPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11563922,KI,>,15000,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.",J. Med. Chem.,2001,44,20,"Schröder J, Henke A, Wenzel H, Brandstetter H, Stammler HG, Stammler A, Pfeiffer WD, Tschesche H",,105381,DTCT0024844,1704493,DTCC00282283,1196752,16424
CHEMBL108494,P14780,,MBSMJAHZPVXQCK-HIGJEIRPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,KI,>,15000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2457384,DTCC00282283,1210750,32556
CHEMBL1085257,P14780,,WVNVANHURONWTG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20529685,IC50,=,1230,NM,,,,,,,,,,,,,,Inhibition of MMP9,,MMP-13 selective isonipecotamide alpha-sulfone hydroxamates.,Bioorg. Med. Chem. Lett.,2010,20,12,"Kolodziej SA, Hockerman SL, DeCrescenzo GA, McDonald JJ, Mischke DA, Munie GE, Fletcher TR, Stehle N, Swearingen C, Becker DP",,634123,DTCT0024844,3346225,DTCC00647802,262531,35540
CHEMBL1085263,P14780,,JOMDWNBZLUPPTA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20529684,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.",Bioorg. Med. Chem. Lett.,2010,20,12,"Kolodziej SA, Hockerman SL, Boehm TL, Carroll JN, DeCrescenzo GA, McDonald JJ, Mischke DA, Munie GE, Fletcher TR, Rico JG, Stehle NW, Swearingen C, Becker DP",,634106,DTCT0024844,3345335,DTCC00647471,1051285,35532
CHEMBL108545,P14780,METHYL SALICYLATE,OSWPMRLSEDHDFF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7421727,DTCC00280235,1705877,46191
CHEMBL108545,P14780,METHYL SALICYLATE,OSWPMRLSEDHDFF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7421728,DTCC00280235,1705877,46191
CHEMBL1085602,P14780,,XFIZGIIZTOASLY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20529684,IC50,=,450,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.",Bioorg. Med. Chem. Lett.,2010,20,12,"Kolodziej SA, Hockerman SL, Boehm TL, Carroll JN, DeCrescenzo GA, McDonald JJ, Mischke DA, Munie GE, Fletcher TR, Rico JG, Stehle NW, Swearingen C, Becker DP",,634106,DTCT0024844,3345321,DTCC00647043,1568775,35532
CHEMBL1085725,P14780,,ZAPMQYOCCLDIJN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20478708,INHIBITION,=,3,%,,,,,,,,,,,,,,Inhibition of MMP9 at 3 uM,,New hydroxypyrimidinone-containing sulfonamides as carbonic anhydrase inhibitors also acting as MMP inhibitors.,Bioorg. Med. Chem. Lett.,2010,20,12,"Esteves MA, Ortet O, Capelo A, Supuran CT, Marques SM, Santos MA",,635102,DTCT0024844,3350490,DTCC00647060,405782,39108
CHEMBL1085725,P14780,,ZAPMQYOCCLDIJN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20478708,INHIBITION,=,23,%,,,,,,,,,,,,,,Inhibition of MMP9 at 100 uM,,New hydroxypyrimidinone-containing sulfonamides as carbonic anhydrase inhibitors also acting as MMP inhibitors.,Bioorg. Med. Chem. Lett.,2010,20,12,"Esteves MA, Ortet O, Capelo A, Supuran CT, Marques SM, Santos MA",,635099,DTCT0024844,3350486,DTCC00647060,405782,39108
CHEMBL1087,P14780,MEPIVACAINE,INWLQCZOYSRPNW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7434340,DTCC00254348,1416035,46191
CHEMBL1087,P14780,MEPIVACAINE,INWLQCZOYSRPNW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7434341,DTCC00254348,1416035,46191
CHEMBL1088878,P14780,,WMJKIJLFVOMJDF-HSZRJFAPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20180536,IC50,=,13,NM,,,,,,,,,,,,,,Inhibition of MMP9 by fluorometric assay,,Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.,J. Med. Chem.,2010,53,6,"Nuti E, Casalini F, Avramova SI, Santamaria S, Fabbi M, Ferrini S, Marinelli L, La Pietra V, Limongelli V, Novellino E, Cercignani G, Orlandini E, Nencetti S, Rossello A",,624094,DTCT0024844,3287146,DTCC00635636,2081582,38228
CHEMBL1089,P14780,PHENELZINE,RMUCZJUITONUFY-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7376319,DTCC00254379,1188072,46191
CHEMBL1089,P14780,PHENELZINE,RMUCZJUITONUFY-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7376320,DTCC00254379,1188072,46191
CHEMBL1089842,P14780,,YAYGKNVDBLFWFW-HXUWFJFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20180536,IC50,=,46,NM,,,,,,,,,,,,,,Inhibition of MMP9 by fluorometric assay,,Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.,J. Med. Chem.,2010,53,6,"Nuti E, Casalini F, Avramova SI, Santamaria S, Fabbi M, Ferrini S, Marinelli L, La Pietra V, Limongelli V, Novellino E, Cercignani G, Orlandini E, Nencetti S, Rossello A",,624094,DTCT0024844,3287134,DTCC00635634,1211870,38228
CHEMBL1089843,P14780,,MWMRJYLEVAWDDL-LJQANCHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20180536,IC50,=,3.5,NM,,,,,,,,,,,,,,Inhibition of MMP9 by fluorometric assay,,Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.,J. Med. Chem.,2010,53,6,"Nuti E, Casalini F, Avramova SI, Santamaria S, Fabbi M, Ferrini S, Marinelli L, La Pietra V, Limongelli V, Novellino E, Cercignani G, Orlandini E, Nencetti S, Rossello A",,624094,DTCT0024844,3287140,DTCC00635635,1375373,38228
CHEMBL109,P14780,VALPROIC ACID,NIJJYAXOARWZEE-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7444046,DTCC00144879,413980,46191
CHEMBL109,P14780,VALPROIC ACID,NIJJYAXOARWZEE-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7444047,DTCC00144879,413980,46191
CHEMBL1090035,P14780,,BBUAWDNXWDAMGY-CQSZACIVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20180536,IC50,=,170,NM,,,,,,,,,,,,,,Inhibition of MMP9 by fluorometric assay,,Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.,J. Med. Chem.,2010,53,6,"Nuti E, Casalini F, Avramova SI, Santamaria S, Fabbi M, Ferrini S, Marinelli L, La Pietra V, Limongelli V, Novellino E, Cercignani G, Orlandini E, Nencetti S, Rossello A",,624094,DTCT0024844,3286030,DTCC00635487,566470,38228
CHEMBL1090283,P14780,,AKOBMMAQXVKOJR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20180536,IC50,=,290,NM,,,,,,,,,,,,,,Inhibition of MMP9 by fluorometric assay,,Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.,J. Med. Chem.,2010,53,6,"Nuti E, Casalini F, Avramova SI, Santamaria S, Fabbi M, Ferrini S, Marinelli L, La Pietra V, Limongelli V, Novellino E, Cercignani G, Orlandini E, Nencetti S, Rossello A",,624094,DTCT0024844,3286024,DTCC00635486,760177,38228
CHEMBL1090284,P14780,,KLOYCYLPVRADHA-OAHLLOKOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20180536,IC50,=,7.2,NM,,,,,,,,,,,,,,Inhibition of MMP9 by fluorometric assay,,Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.,J. Med. Chem.,2010,53,6,"Nuti E, Casalini F, Avramova SI, Santamaria S, Fabbi M, Ferrini S, Marinelli L, La Pietra V, Limongelli V, Novellino E, Cercignani G, Orlandini E, Nencetti S, Rossello A",,624094,DTCT0024844,3286036,DTCC00635488,824786,38228
CHEMBL1090284,P14780,,KLOYCYLPVRADHA-OAHLLOKOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26638045,IC50,=,7.2,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP9 after 2 hrs using FS-6 as substrate by fluorometry,,"Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors.",Eur. J. Med. Chem.,2016,108,,"Sjli S, Nuti E, Camodeca C, Bilto I, Rossello A, Winberg JO, Sylte I, Adekoya OA.",,1550087,DTCT0024844,59801,DTCC00635488,807189,65811
CHEMBL1090647,P14780,,RLHOCYLKSSHKMW-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20180536,IC50,=,8.6,NM,,,,,,,,,,,,,,Inhibition of MMP9 by fluorometric assay,,Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.,J. Med. Chem.,2010,53,6,"Nuti E, Casalini F, Avramova SI, Santamaria S, Fabbi M, Ferrini S, Marinelli L, La Pietra V, Limongelli V, Novellino E, Cercignani G, Orlandini E, Nencetti S, Rossello A",,624094,DTCT0024844,3286048,DTCC00635564,792230,38228
CHEMBL1092104,P14780,,MTDVSXPXWCWOED-OAHLLOKOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20180536,IC50,=,1.1,NM,,,,,,,,,,,,,,Inhibition of MMP9 by fluorometric assay,,Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.,J. Med. Chem.,2010,53,6,"Nuti E, Casalini F, Avramova SI, Santamaria S, Fabbi M, Ferrini S, Marinelli L, La Pietra V, Limongelli V, Novellino E, Cercignani G, Orlandini E, Nencetti S, Rossello A",,624094,DTCT0024844,3287128,DTCC00635567,1310213,38228
CHEMBL109214,P14780,,PDKBAEDNMKVROV-CQSZACIVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11563922,KI,=,210,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.",J. Med. Chem.,2001,44,20,"Schröder J, Henke A, Wenzel H, Brandstetter H, Stammler HG, Stammler A, Pfeiffer WD, Tschesche H",,105381,DTCT0024844,1718166,DTCC00282259,422410,16424
CHEMBL109353,P14780,,JXHAGXRDZALSLG-GFCCVEGCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11563922,KI,=,80,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.",J. Med. Chem.,2001,44,20,"Schröder J, Henke A, Wenzel H, Brandstetter H, Stammler HG, Stammler A, Pfeiffer WD, Tschesche H",,105381,DTCT0024844,1716616,DTCC00282683,357026,16424
CHEMBL1093689,P14780,,HOKBADYASDUFAM-OAQYLSRUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20180536,IC50,=,430,NM,,,,,,,,,,,,,,Inhibition of MMP9 by fluorometric assay,,Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.,J. Med. Chem.,2010,53,6,"Nuti E, Casalini F, Avramova SI, Santamaria S, Fabbi M, Ferrini S, Marinelli L, La Pietra V, Limongelli V, Novellino E, Cercignani G, Orlandini E, Nencetti S, Rossello A",,624094,DTCT0024844,3287116,DTCC00635565,177119,38228
CHEMBL1093690,P14780,,XXZNXULRAJJTRV-LLVKDONJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20180536,IC50,=,190,NM,,,,,,,,,,,,,,Inhibition of MMP9 by fluorometric assay,,Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.,J. Med. Chem.,2010,53,6,"Nuti E, Casalini F, Avramova SI, Santamaria S, Fabbi M, Ferrini S, Marinelli L, La Pietra V, Limongelli V, Novellino E, Cercignani G, Orlandini E, Nencetti S, Rossello A",,624094,DTCT0024844,3287122,DTCC00635566,340097,38228
CHEMBL1095699,P14780,AZASERINE,MZZGOOYMKKIOOX-VKHMYHEASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7260970,DTCC00644151,1960073,46191
CHEMBL1095699,P14780,AZASERINE,MZZGOOYMKKIOOX-VKHMYHEASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7260971,DTCC00644151,1960073,46191
CHEMBL109579,P14780,,LEDMBBYIVRLZAS-LBPRGKRZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11563922,KI,=,160,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.",J. Med. Chem.,2001,44,20,"Schröder J, Henke A, Wenzel H, Brandstetter H, Stammler HG, Stammler A, Pfeiffer WD, Tschesche H",,105381,DTCT0024844,1713952,DTCC00282314,258563,16424
CHEMBL109603,P14780,,JOKZNFFZUNYVMR-SFHVURJKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11563922,KI,=,200,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.",J. Med. Chem.,2001,44,20,"Schröder J, Henke A, Wenzel H, Brandstetter H, Stammler HG, Stammler A, Pfeiffer WD, Tschesche H",,105381,DTCT0024844,1693273,DTCC00281761,2034295,16424
CHEMBL109655,P14780,,PDKBAEDNMKVROV-AWEZNQCLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11563922,KI,=,160,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.",J. Med. Chem.,2001,44,20,"Schröder J, Henke A, Wenzel H, Brandstetter H, Stammler HG, Stammler A, Pfeiffer WD, Tschesche H",,105381,DTCT0024844,1689449,DTCC00281762,2066041,16424
CHEMBL109770,P14780,,MYFWCGILTGDUAM-LBPRGKRZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11563922,KI,=,240,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.",J. Med. Chem.,2001,44,20,"Schröder J, Henke A, Wenzel H, Brandstetter H, Stammler HG, Stammler A, Pfeiffer WD, Tschesche H",,105381,DTCT0024844,1685581,DTCC00282704,1553370,16424
CHEMBL109806,P14780,,JJTWETADXAELLS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11563922,KI,=,90,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.",J. Med. Chem.,2001,44,20,"Schröder J, Henke A, Wenzel H, Brandstetter H, Stammler HG, Stammler A, Pfeiffer WD, Tschesche H",,105381,DTCT0024844,1709910,DTCC00281760,1871211,16424
CHEMBL109861,P14780,,BTMGFNYLYGWAKT-JTQLQIEISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11563922,KI,=,800,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.",J. Med. Chem.,2001,44,20,"Schröder J, Henke A, Wenzel H, Brandstetter H, Stammler HG, Stammler A, Pfeiffer WD, Tschesche H",,105381,DTCT0024844,1703224,DTCC00282336,1003340,16424
CHEMBL1103,P14780,FURAZOLIDONE,PLHJDBGFXBMTGZ-WEVVVXLNSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7320633,DTCC00257236,1512809,46191
CHEMBL1103,P14780,FURAZOLIDONE,PLHJDBGFXBMTGZ-WEVVVXLNSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7320634,DTCC00257236,1512809,46191
CHEMBL1105,P14780,6-METHOXY-2-NAPHTHYLACETIC ACID,PHJFLPMVEFKEPL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7281048,DTCC00257334,1830683,46191
CHEMBL1105,P14780,6-METHOXY-2-NAPHTHYLACETIC ACID,PHJFLPMVEFKEPL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7281049,DTCC00257334,1830683,46191
CHEMBL110691,P14780,CHLORMADINONE ACETATE,QMBJSIBWORFWQT-DFXBJWIESA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7355932,DTCC00283843,217574,46191
CHEMBL110691,P14780,CHLORMADINONE ACETATE,QMBJSIBWORFWQT-DFXBJWIESA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7355933,DTCC00283843,217574,46191
CHEMBL110750,P14780,,WOIMZSMDPIJLFO-LBPRGKRZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11563922,KI,=,160,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.",J. Med. Chem.,2001,44,20,"Schröder J, Henke A, Wenzel H, Brandstetter H, Stammler HG, Stammler A, Pfeiffer WD, Tschesche H",,105381,DTCT0024844,1683058,DTCC00281785,518969,16424
CHEMBL1108,P14780,DROPERIDOL,RMEDXOLNCUSCGS-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7334479,DTCC00258432,542573,46191
CHEMBL1108,P14780,DROPERIDOL,RMEDXOLNCUSCGS-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7334480,DTCC00258432,542573,46191
CHEMBL1109,P14780,SULFAPHENAZOLE,QWCJHSGMANYXCW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7473984,DTCC00258904,1544901,46191
CHEMBL1109,P14780,SULFAPHENAZOLE,QWCJHSGMANYXCW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7473985,DTCC00258904,1544901,46191
CHEMBL110970,P14780,,WOIMZSMDPIJLFO-GFCCVEGCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11563922,KI,=,40,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.",J. Med. Chem.,2001,44,20,"Schröder J, Henke A, Wenzel H, Brandstetter H, Stammler HG, Stammler A, Pfeiffer WD, Tschesche H",,105381,DTCT0024844,1713944,DTCC00281754,1035753,16424
CHEMBL1110,P14780,ALOSETRON,JSWZEAMFRNKZNL-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7289841,DTCC00258915,1318437,46191
CHEMBL1110,P14780,ALOSETRON,JSWZEAMFRNKZNL-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7289842,DTCC00258915,1318437,46191
CHEMBL111179,P14780,,GINBTQGVSPUJLE-ZDUSSCGKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11563922,KI,=,40,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.",J. Med. Chem.,2001,44,20,"Schröder J, Henke A, Wenzel H, Brandstetter H, Stammler HG, Stammler A, Pfeiffer WD, Tschesche H",,105381,DTCT0024844,1715091,DTCC00282652,389663,16424
CHEMBL111257,P14780,,JXHAGXRDZALSLG-LBPRGKRZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11563922,KI,=,60,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.",J. Med. Chem.,2001,44,20,"Schröder J, Henke A, Wenzel H, Brandstetter H, Stammler HG, Stammler A, Pfeiffer WD, Tschesche H",,105381,DTCT0024844,1696859,DTCC00282583,809139,16424
CHEMBL1113,P14780,AMOXAPINE,QWGDMFLQWFTERH-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7284605,DTCC00260398,1059327,46191
CHEMBL1113,P14780,AMOXAPINE,QWGDMFLQWFTERH-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7284606,DTCC00260398,1059327,46191
CHEMBL111450,P14780,,IIABJCHWKFZJBK-CYBMUJFWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11563922,KI,=,80,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.",J. Med. Chem.,2001,44,20,"Schröder J, Henke A, Wenzel H, Brandstetter H, Stammler HG, Stammler A, Pfeiffer WD, Tschesche H",,105381,DTCT0024844,1701966,DTCC00282684,291838,16424
CHEMBL111678,P14780,,WJWOJAKOSRCFKB-JTQLQIEISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11563922,KI,=,170,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.",J. Med. Chem.,2001,44,20,"Schröder J, Henke A, Wenzel H, Brandstetter H, Stammler HG, Stammler A, Pfeiffer WD, Tschesche H",,105381,DTCT0024844,1688177,DTCC00282653,809140,16424
CHEMBL1117,P14780,IDARUBICIN,XDXDZDZNSLXDNA-TZNDIEGXSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7327891,DTCC00263156,153444,46191
CHEMBL1117,P14780,IDARUBICIN,XDXDZDZNSLXDNA-TZNDIEGXSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7327892,DTCC00263156,153444,46191
CHEMBL111856,P14780,,ZBRHTUMWSDPCMI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15177439,IC50,=,12,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.,Bioorg. Med. Chem. Lett.,2004,14,13,"Reiter LA, Robinson RP, McClure KF, Jones CS, Reese MR, Mitchell PG, Otterness IG, Bliven ML, Liras J, Cortina SR, Donahue KM, Eskra JD, Griffiths RJ, Lame ME, Lopez-Anaya A, Martinelli GJ, McGahee SM, Yocum SA, Lopresti-Morrow LL, Tobiassen LM, Vaughn-Bowser ML",,105526,DTCT0024844,1496218,DTCC00287961,76527,6475
CHEMBL111861,P14780,CORTISONE,LPYXTAPPNYMYOP-XDBTXSBWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7361088,DTCC00283836,671786,46191
CHEMBL111861,P14780,CORTISONE,LPYXTAPPNYMYOP-XDBTXSBWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7361089,DTCC00283836,671786,46191
CHEMBL112,P14780,ACETAMINOPHEN,RZVAJINKPMORJF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7300478,DTCC00145865,1544892,46191
CHEMBL112,P14780,ACETAMINOPHEN,RZVAJINKPMORJF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7300479,DTCC00145865,1544892,46191
CHEMBL1123,P14780,DICYCLOMINE,CURUTKGFNZGFSE-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7350983,DTCC00269590,1798408,46191
CHEMBL1123,P14780,DICYCLOMINE,CURUTKGFNZGFSE-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7350984,DTCC00269590,1798408,46191
CHEMBL113,P14780,CAFFEINE,RYYVLZVUVIJVGH-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7264887,DTCC00145890,51450,46191
CHEMBL113,P14780,CAFFEINE,RYYVLZVUVIJVGH-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7264888,DTCC00145890,51450,46191
CHEMBL1130,P14780,DOXIFLURIDINE,ZWAOHEXOSAUJHY-ZIYNGMLESA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7317381,DTCC00272346,1124449,46191
CHEMBL1130,P14780,DOXIFLURIDINE,ZWAOHEXOSAUJHY-ZIYNGMLESA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7317382,DTCC00272346,1124449,46191
CHEMBL11306,P14780,,MOPRTFSMCQNUCT-CABCVRRESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17719700,IC50,=,0.38,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,Peptidyl 3-substituted 1-hydroxyureas as isosteric analogues of succinylhydroxamate MMP inhibitors.,Eur. J. Med. Chem.,2008,43,5,"Campestre C, Tortorella P, Agamennone M, Preziuso S, Biasone A, Nuti E, Rossello A, Gallina C",,510908,DTCT0024844,2438453,DTCC00139917,359575,30977
CHEMBL11306,P14780,,MOPRTFSMCQNUCT-CABCVRRESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,1.4,NM,,,,,,,,,,,,,,Inhibition of human Matrix metalloprotease-9,,,Bioorg. Med. Chem. Lett.,1995,5,4,,,105391,DTCT0024844,832559,DTCC00139917,368874,1497
CHEMBL114,P14780,SAQUINAVIR,QWAXKHKRTORLEM-UGJKXSETSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7475544,DTCC00146405,703985,46191
CHEMBL114,P14780,SAQUINAVIR,QWAXKHKRTORLEM-UGJKXSETSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7475545,DTCC00146405,703985,46191
CHEMBL1140,P14780,NIACINAMIDE,DFPAKSUCGFBDDF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7392638,DTCC00277524,800582,46191
CHEMBL1140,P14780,NIACINAMIDE,DFPAKSUCGFBDDF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7392639,DTCC00277524,800582,46191
CHEMBL114357,P14780,,ZFCJDZRVAOLEGY-ZTNFWEORSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11585439,KI,=,15500,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors.",J. Med. Chem.,2001,44,21,"Yao W, Wasserman ZR, Chao M, Reddy G, Shi E, Liu RQ, Covington MB, Arner EC, Pratta MA, Tortorella M, Magolda RL, Newton R, Qian M, Ribadeneira MD, Christ D, Wexler RR, Decicco CP",,105382,DTCT0024844,1443599,DTCC00287866,433860,16438
CHEMBL1144,P14780,PRAVASTATIN,TUZYXOIXSAXUGO-PZAWKZKUSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7378971,DTCC00280505,413976,46191
CHEMBL1144,P14780,PRAVASTATIN,TUZYXOIXSAXUGO-PZAWKZKUSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7378972,DTCC00280505,413976,46191
CHEMBL1148,P14780,TORSEMIDE,NGBFQHCMQULJNZ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7459634,DTCC00281790,1830692,46191
CHEMBL1148,P14780,TORSEMIDE,NGBFQHCMQULJNZ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7459635,DTCC00281790,1830692,46191
CHEMBL114804,P14780,,VUKNURXXGDIFMO-ZTNFWEORSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11585439,KI,=,203,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors.",J. Med. Chem.,2001,44,21,"Yao W, Wasserman ZR, Chao M, Reddy G, Shi E, Liu RQ, Covington MB, Arner EC, Pratta MA, Tortorella M, Magolda RL, Newton R, Qian M, Ribadeneira MD, Christ D, Wexler RR, Decicco CP",,105382,DTCT0024844,1413779,DTCC00287203,917654,16438
CHEMBL114815,P14780,,SQQHSADBIVCBBM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23287054,IC50,,,,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin),Not Determined,Sulphonamides: Deserving class as MMP inhibitors?,Eur. J. Med. Chem.,2013,60,,"Jain P, Saravanan C, Singh SK",,944094,DTCT0024844,11835653,DTCC00288372,1612260,53820
CHEMBL114878,P14780,,LCWWOMJWYGNKJF-IARZGTGTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11585440,KI,>,2000,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.",J. Med. Chem.,2001,44,21,"Xue CB, He X, Corbett RL, Roderick J, Wasserman ZR, Liu RQ, Jaffee BD, Covington MB, Qian M, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105383,DTCT0024844,1322672,DTCC00286952,724080,16439
CHEMBL1149,P14780,LEVOCARNITINE,PHIQHXFUZVPYII-ZCFIWIBFSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7420969,DTCC00283052,51485,46191
CHEMBL1149,P14780,LEVOCARNITINE,PHIQHXFUZVPYII-ZCFIWIBFSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7420970,DTCC00283052,51485,46191
CHEMBL115,P14780,INDINAVIR,CBVCZFGXHXORBI-PXQQMZJSSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7426677,DTCC00146406,51478,46191
CHEMBL115,P14780,INDINAVIR,CBVCZFGXHXORBI-PXQQMZJSSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7426678,DTCC00146406,51478,46191
CHEMBL115082,P14780,,PUKQZUALFZRFQE-KKVAFCGZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11585439,KI,=,22000,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors.",J. Med. Chem.,2001,44,21,"Yao W, Wasserman ZR, Chao M, Reddy G, Shi E, Liu RQ, Covington MB, Arner EC, Pratta MA, Tortorella M, Magolda RL, Newton R, Qian M, Ribadeneira MD, Christ D, Wexler RR, Decicco CP",,105382,DTCT0024844,1427167,DTCC00287445,1818512,16438
CHEMBL115145,P14780,NSC-622445,JWQFKVGACKJIAV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16913712,IC50,=,43400,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening.,J. Med. Chem.,2006,49,17,"Schepetkin IA, Khlebnikov AI, Kirpotina LN, Quinn MT",,386349,DTCT0024844,1958899,DTCC01742432,532017,21205
CHEMBL115189,P14780,,OCSMOTCMPXTDND-JKIOLJMWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669559,IC50,=,3,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9).,,Protease inhibitors: current status and future prospects.,J. Med. Chem.,2000,43,3,"Leung D, Abbenante G, Fairlie DP",,105240,DTCT0024844,1072596,DTCC00289405,1035817,16063
CHEMBL115263,P14780,,SOPDPCOBVSOXIM-ZDXQCDESSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11585440,KI,>,2000,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.",J. Med. Chem.,2001,44,21,"Xue CB, He X, Corbett RL, Roderick J, Wasserman ZR, Liu RQ, Jaffee BD, Covington MB, Qian M, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105383,DTCT0024844,1309690,DTCC00287904,433861,16439
CHEMBL115460,P14780,,FOOIUOKCYUZPDW-YCLCTBJKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12877590,IC50,=,30400,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9 (MMP-9),,"A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.",J. Med. Chem.,2003,46,16,"Fray MJ, Dickinson RP, Huggins JP, Occleston NL",,105239,DTCT0024844,1548443,DTCC00293174,1871336,17445
CHEMBL115653,P14780,CIPEMASTAT,GFUITADOEPNRML-SJORKVTESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669559,KI,=,59,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9).,,Protease inhibitors: current status and future prospects.,J. Med. Chem.,2000,43,3,"Leung D, Abbenante G, Fairlie DP",,105389,DTCT0024844,1065651,DTCC00288838,1839322,16063
CHEMBL115653,P14780,CIPEMASTAT,GFUITADOEPNRML-SJORKVTESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12930146,IC50,=,58,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP9),,Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.,J. Med. Chem.,2003,46,18,"Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P",,105365,DTCT0024844,527938,DTCC00288838,1850867,13726
CHEMBL115653,P14780,CIPEMASTAT,GFUITADOEPNRML-SJORKVTESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19422229,IC50,=,2.4,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13.",J. Med. Chem.,2009,52,11,"Monovich LG, Tommasi RA, Fujimoto RA, Blancuzzi V, Clark K, Cornell WD, Doti R, Doughty J, Fang J, Farley D, Fitt J, Ganu V, Goldberg R, Goldstein R, Lavoie S, Kulathila R, Macchia W, Parker DT, Melton R, O'Byrne E, Pastor G, Pellas T, Quadros E, Reel N, Roland DM, Sakane Y, Singh H, Skiles J, Somers J, Toscano K, Wigg A, Zhou S, Zhu L, Shieh WC, Xue S, McQuire LW",,500585,DTCT0024844,2824184,DTCC00288838,1841984,33635
CHEMBL115712,P14780,,ZYIMYAJZHPOFQU-IVMMDQJWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11585439,KI,=,4200,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors.",J. Med. Chem.,2001,44,21,"Yao W, Wasserman ZR, Chao M, Reddy G, Shi E, Liu RQ, Covington MB, Arner EC, Pratta MA, Tortorella M, Magolda RL, Newton R, Qian M, Ribadeneira MD, Christ D, Wexler RR, Decicco CP",,105382,DTCT0024844,1442406,DTCC00287104,917655,16438
CHEMBL115727,P14780,,MCSWSPNUKWMZHM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9733482,IC50,=,2.7,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,"Discovery of potent, achiral matrix metalloproteinase inhibitors.",J. Med. Chem.,1998,41,19,"Pikul S, McDow Dunham KL, Almstead NG, De B, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Rydel T, Dunaway CM, Gu F, Mieling GE",,105360,DTCT0024844,1542947,DTCC00288787,1585709,14767
CHEMBL115727,P14780,,MCSWSPNUKWMZHM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669559,KI,=,30,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9).,,Protease inhibitors: current status and future prospects.,J. Med. Chem.,2000,43,3,"Leung D, Abbenante G, Fairlie DP",,105663,DTCT0024844,1080948,DTCC00288787,1585632,16063
CHEMBL115727,P14780,,MCSWSPNUKWMZHM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,IC50,=,1.8,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain incubated for 20 mins by fluorimetric assay,,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827436,DTCT0024844,10535427,DTCC00288787,1591034,48665
CHEMBL115727,P14780,,MCSWSPNUKWMZHM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,INHIBITION,>,30,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain at 10 uM incubated for 20 mins by fluorimetric assay,,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827442,DTCT0024844,10535524,DTCC00288787,1591034,48665
CHEMBL115769,P14780,RWJ-68354,ADQZGIYHFQQPRB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7466692,DTCC01742367,2057653,46191
CHEMBL115769,P14780,RWJ-68354,ADQZGIYHFQQPRB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7466693,DTCC01742367,2057653,46191
CHEMBL115774,P14780,,YQEMFOGNUTYMTJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14711305,KI,=,10,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Evaluation of P1'-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11.,J. Med. Chem.,2004,47,2,"Matziari M, Beau F, Cuniasse P, Dive V, Yiotakis A",,105371,DTCT0024844,1264837,DTCC00287265,336153,17924
CHEMBL115774,P14780,,YQEMFOGNUTYMTJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16392792,KI,=,10,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.,J. Med. Chem.,2006,49,1,"Pirard B, Matter H",,329822,DTCT0024844,1880224,DTCC00287265,325923,20214
CHEMBL1159650,P14780,CLOBETASOL PROPIONATE,CBGUOGMQLZIXBE-XGQKBEPLSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7354269,DTCC00648029,703979,46191
CHEMBL1159650,P14780,CLOBETASOL PROPIONATE,CBGUOGMQLZIXBE-XGQKBEPLSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7354270,DTCC00648029,703979,46191
CHEMBL116,P14780,AMPRENAVIR,YMARZQAQMVYCKC-OEMFJLHTSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7298352,DTCC00146541,833155,46191
CHEMBL116,P14780,AMPRENAVIR,YMARZQAQMVYCKC-OEMFJLHTSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7298353,DTCC00146541,833155,46191
CHEMBL1160559,P14780,QUINALDIC ACID,LOAUVZALPPNFOQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,37,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103977,DTCC00648701,183412,43205
CHEMBL1160685,P14780,CYCLOHEXANAMINIUM HYDROGEN (ISOBUTYLAMINO)CARBONYLPHOSPHONATE,JAOQWUBVSCNFML-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15139760,IC50,>,100000,NM,,,,,,,,,,,,,,In vitro inhibitory activity against recombinant matrix metalloprotease-9 was determined,,"Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.",J. Med. Chem.,2004,47,11,"Breuer E, Salomon CJ, Katz Y, Chen W, Lu S, Röschenthaler GV, Hadar R, Reich R",,105518,DTCT0024844,1301427,DTCC00648810,401328,17838
CHEMBL1160686,P14780,,SPZJLPXBRLFGFY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15139760,IC50,>,100000,NM,,,,,,,,,,,,,,In vitro inhibitory activity against recombinant matrix metalloprotease-9 was determined,,"Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.",J. Med. Chem.,2004,47,11,"Breuer E, Salomon CJ, Katz Y, Chen W, Lu S, Röschenthaler GV, Hadar R, Reich R",,105518,DTCT0024844,1302616,DTCC00648811,1273344,17838
CHEMBL1161012,P14780,,DLGBEGBHXSAQOC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,2,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103099,DTCC00649095,1057326,43205
CHEMBL1161830,P14780,CARBOXYLATED GLUCOSAMINE,PTKIBGLZJSEXPT-KOOJSXSQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16616490,INHIBITION,=,50,%,,cell_based,,,,,,,,,,,,Inhibition of PMA-stimulated MMP9 in HT1080 cells at 100 ug/ml assessed as reduction in fluorescence intensity,,Carboxy derivatized glucosamine is a potent inhibitor of matrix metalloproteinase-9 in HT1080 cells.,Bioorg. Med. Chem. Lett.,2006,16,12,"Mendis E, Kim MM, Rajapakse N, Kim SK",,359974,DTCT0024844,1936810,DTCC00649726,163609,20856
CHEMBL1161830,P14780,CARBOXYLATED GLUCOSAMINE,PTKIBGLZJSEXPT-KOOJSXSQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16616490,INHIBITION,=,50,%,,cell_based,,,,,,,,,,,,Inhibition of MMP9-pGL3 luciferase reporter gene expression in HT1080 cells at 100 ug/ml,,Carboxy derivatized glucosamine is a potent inhibitor of matrix metalloproteinase-9 in HT1080 cells.,Bioorg. Med. Chem. Lett.,2006,16,12,"Mendis E, Kim MM, Rajapakse N, Kim SK",,359977,DTCT0024844,1936812,DTCC00649726,163609,20856
CHEMBL1161830,P14780,CARBOXYLATED GLUCOSAMINE,PTKIBGLZJSEXPT-KOOJSXSQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16616490,INHIBITION,=,62,%,,cell_based,,,,,,,,,,,,Inhibition of MMP9-mediated gelatinolytic activity in PMA-induced HT1080 cells at 500 ug/ml,,Carboxy derivatized glucosamine is a potent inhibitor of matrix metalloproteinase-9 in HT1080 cells.,Bioorg. Med. Chem. Lett.,2006,16,12,"Mendis E, Kim MM, Rajapakse N, Kim SK",,359972,DTCT0024844,1936807,DTCC00649726,163609,20856
CHEMBL1161830,P14780,CARBOXYLATED GLUCOSAMINE,PTKIBGLZJSEXPT-KOOJSXSQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16616490,INHIBITION,=,66,%,,cell_based,,,,,,,,,,,,Inhibition of PMA-stimulated MMP9 in HT1080 cells at 500 ug/ml assessed as reduction in fluorescence intensity,,Carboxy derivatized glucosamine is a potent inhibitor of matrix metalloproteinase-9 in HT1080 cells.,Bioorg. Med. Chem. Lett.,2006,16,12,"Mendis E, Kim MM, Rajapakse N, Kim SK",,359973,DTCT0024844,1936809,DTCC00649726,163609,20856
CHEMBL1161830,P14780,CARBOXYLATED GLUCOSAMINE,PTKIBGLZJSEXPT-KOOJSXSQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16616490,INHIBITION,,,,,cell_based,,,,,,,,,,,,Inhibition of MMP9-pGL3 luciferase reporter gene expression in HT1080 cells at 500 ug/ml,Active,Carboxy derivatized glucosamine is a potent inhibitor of matrix metalloproteinase-9 in HT1080 cells.,Bioorg. Med. Chem. Lett.,2006,16,12,"Mendis E, Kim MM, Rajapakse N, Kim SK",,359976,DTCT0024844,1936811,DTCC00649726,163609,20856
CHEMBL1162,P14780,NORETHINDRONE,VIKNJXKGJWUCNN-XGXHKTLJSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7384243,DTCC00288264,510305,46191
CHEMBL1162,P14780,NORETHINDRONE,VIKNJXKGJWUCNN-XGXHKTLJSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7384244,DTCC00288264,510305,46191
CHEMBL1162966,P14780,,YKGQQUOXWATGTB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,101000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266640,DTCC00650352,1231185,24949
CHEMBL116318,P14780,,UICDMTYNXJBPNZ-PKTZIBPZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,1.3,NM,,,,,,,,,,,,,,Inhibition of human Matrix metalloprotease-9,,,Bioorg. Med. Chem. Lett.,1995,5,4,,,105391,DTCT0024844,839743,DTCC00293444,1723601,1497
CHEMBL1163444,P14780,,MLPHDUQOZKAGHK-KRXBUXKQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,7.29,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833635,DTCC00652632,1962738,53968
CHEMBL1163454,P14780,,DVEFFLBSEMHSOV-SOFGYWHQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,1632.42,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833642,DTCC00652696,480716,53968
CHEMBL1163455,P14780,,MGXQKQSEWXXTPE-YCRREMRBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,3.33,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833641,DTCC00652754,416567,53968
CHEMBL1163867,P14780,,ZBVTYCHAECZWPS-SOFGYWHQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,8.19,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833634,DTCC00652627,706502,53968
CHEMBL1163869,P14780,,PXFQYERIXZVNLU-FNORWQNLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,1869.59,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833636,DTCC00652629,1418673,53968
CHEMBL116438,P14780,CURCUMIN,ZIUSSTSXXLLKKK-KOBPDPAPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19128977,IC50,=,8500,NM,,cell_based,,,,,,,,,,,Caco-2,Reduction of MMP9 activity in TNF-alpha/IL1-beta-stimulated human Caco-2 cells treated 1 hr before stimulation by zymography,,Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloproteinases.,Bioorg. Med. Chem.,2009,17,3,"Claramunt RM, Bouissane L, Cabildo MP, Cornago MP, Elguero J, Radziwon A, Medina C",,516050,DTCT0024844,2701379,DTCC00290109,36186,32369
CHEMBL1164630,P14780,,HQSAGGSYGVYRMT-FNORWQNLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,1921.13,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833633,DTCC00652630,803174,53968
CHEMBL1164826,P14780,4-HYDROXY-CINNAMANILIDE,YAGRPHZXEPGAOZ-DHZHZOJOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,7.8,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833612,DTCC00652814,123575,53968
CHEMBL1165106,P14780,,LAIQRLYWSPLUFU-WEVVVXLNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,3.64,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833638,DTCC00652694,1095001,53968
CHEMBL1165150,P14780,,QLFZPAXTWPSTQC-KRXBUXKQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,7.89,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833632,DTCC00652690,706503,53968
CHEMBL1165152,P14780,,PDBFFXOPMVKXDS-VQHVLOKHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,5.91,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833640,DTCC00652692,1929600,53968
CHEMBL1165241,P14780,,KFABJEHFICPFBB-SOFGYWHQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,1753.85,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833639,DTCC00652693,1255979,53968
CHEMBL1165574,P14780,,OOOVNHOIFALTIZ-SOFGYWHQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,7.81,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833637,DTCC00652626,318271,53968
CHEMBL1165627,P14780,,AWFUHISUKJQLHQ-VQHVLOKHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,5.67,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833643,DTCC00652695,220269,53968
CHEMBL1167,P14780,SPECTINOMYCIN,UNFWWIHTNXNPBV-WXKVUWSESA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7484403,DTCC00289197,249944,46191
CHEMBL1167,P14780,SPECTINOMYCIN,UNFWWIHTNXNPBV-WXKVUWSESA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7484404,DTCC00289197,249944,46191
CHEMBL1168,P14780,RAMIPRIL,HDACQVRGBOVJII-JBDAPHQKSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7483690,DTCC00289284,1765979,46191
CHEMBL1168,P14780,RAMIPRIL,HDACQVRGBOVJII-JBDAPHQKSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7483691,DTCC00289284,1765979,46191
CHEMBL1169,P14780,AMINOSALICYLIC ACID,WUBBRNOQWQTFEX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,24,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103746,DTCC00290367,669653,43205
CHEMBL1169,P14780,AMINOSALICYLIC ACID,WUBBRNOQWQTFEX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7288857,DTCC00290367,671785,46191
CHEMBL1169,P14780,AMINOSALICYLIC ACID,WUBBRNOQWQTFEX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7288858,DTCC00290367,671785,46191
CHEMBL116944,P14780,,BLBHPKKKTVUSPA-ZFWWWQNUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12877587,IC50,=,0.8,NM,,,,,,,,,,,,,,Inhibition of human Matrix metalloprotease-9 (MMP-9),,Development of a water-soluble matrix metalloproteinase inhibitor as an intra-arterial infusion drug for prevention of restenosis after angioplasty.,J. Med. Chem.,2003,46,16,"Masuda T, Nakayama Y",,105237,DTCT0024844,1325410,DTCC00292720,1435874,17442
CHEMBL1169492,P14780,,BDCJZZXWIQJYLP-UXHICEINSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11206468,IC50,=,318,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2001,11,2,"Levin JI, Gu Y, Nelson FC, Zask A, DiJoseph JF, Sharr MA, Sung A, Jin G, Cowling R, Chanda P, Cosmi S, Hsiao CL, Edris W, Wilhelm J, Killar LM, Skotnicki JS",,105521,DTCT0024844,1294655,DTCC00656884,1014366,4516
CHEMBL1172,P14780,DESLORATADINE,JAUOIFJMECXRGI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7361396,DTCC00291020,1674143,46191
CHEMBL1172,P14780,DESLORATADINE,JAUOIFJMECXRGI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7361397,DTCC00291020,1674143,46191
CHEMBL117225,P14780,UK-356618,JJHRUUKMPWUYIB-HVOSOHGQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11229774,IC50,=,840,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1).,Bioorg. Med. Chem. Lett.,2001,11,4,"Fray MJ, Dickinson RP",,105224,DTCT0024844,573965,DTCC01742560,174043,4692
CHEMBL117225,P14780,UK-356618,JJHRUUKMPWUYIB-HVOSOHGQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12877590,IC50,=,840,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9 (MMP-9),,"A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.",J. Med. Chem.,2003,46,16,"Fray MJ, Dickinson RP, Huggins JP, Occleston NL",,105239,DTCT0024844,1551208,DTCC01742560,162203,17445
CHEMBL117225,P14780,UK-356618,JJHRUUKMPWUYIB-HVOSOHGQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,IC50,=,840,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2457460,DTCC01742560,176034,32556
CHEMBL117296,P14780,,MCDVAZDSWVFMGC-OAHLLOKOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,5600,NM,,,,,,,,,,,,,,Inhibition of human Matrix metalloprotease-9,,,Bioorg. Med. Chem. Lett.,1995,5,4,,,105391,DTCT0024844,828556,DTCC00293413,1338924,1497
CHEMBL117405,P14780,S(-)-PINDOLOL,JZQKKSLKJUAGIC-NSHDSACASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7289088,DTCC01742455,1992798,46191
CHEMBL117405,P14780,S(-)-PINDOLOL,JZQKKSLKJUAGIC-NSHDSACASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7289089,DTCC01742455,1992798,46191
CHEMBL1177,P14780,PEMOLINE,NRNCYVBFPDDJNE-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7393382,DTCC00292515,1576126,46191
CHEMBL1177,P14780,PEMOLINE,NRNCYVBFPDDJNE-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7393383,DTCC00292515,1576126,46191
CHEMBL117720,P14780,,XJLATMLVMSFZBN-BZEOVNSFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,330,NM,,,,,,,,,,,,,,Inhibition of human Matrix metalloprotease-9,,,Bioorg. Med. Chem. Lett.,1995,5,4,,,105391,DTCT0024844,817078,DTCC00293037,76595,1497
CHEMBL118,P14780,CELECOXIB,RZEKVGVHFLEQIL-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7355824,DTCC01738574,51454,46191
CHEMBL118,P14780,CELECOXIB,RZEKVGVHFLEQIL-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7355825,DTCC01738574,51454,46191
CHEMBL118497,P14780,,STDLDNSJNOVMBK-RDJZCZTQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12877587,IC50,=,2.8,NM,,,,,,,,,,,,,,Inhibition of human Matrix metalloprotease-9 (MMP-9),,Development of a water-soluble matrix metalloproteinase inhibitor as an intra-arterial infusion drug for prevention of restenosis after angioplasty.,J. Med. Chem.,2003,46,16,"Masuda T, Nakayama Y",,105237,DTCT0024844,1331808,DTCC00292723,917731,17442
CHEMBL118744,P14780,,CMBPIMDJJHAVBX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9733482,IC50,=,4.7,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,"Discovery of potent, achiral matrix metalloproteinase inhibitors.",J. Med. Chem.,1998,41,19,"Pikul S, McDow Dunham KL, Almstead NG, De B, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Rydel T, Dunaway CM, Gu F, Mieling GE",,105360,DTCT0024844,1535792,DTCC00294723,744900,14767
CHEMBL118848,P14780,,XWGUPBCCRWJAMM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9733482,IC50,=,15.6,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,"Discovery of potent, achiral matrix metalloproteinase inhibitors.",J. Med. Chem.,1998,41,19,"Pikul S, McDow Dunham KL, Almstead NG, De B, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Rydel T, Dunaway CM, Gu F, Mieling GE",,105360,DTCT0024844,1553920,DTCC00295131,1327053,14767
CHEMBL119083,P14780,,IQXWFHDFTAZGNB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,31,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5104045,DTCC00298384,701897,43205
CHEMBL1191,P14780,SULFAMETHIZOLE,VACCAVUAMIDAGB-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7460840,DTCC00301538,1577010,46191
CHEMBL1191,P14780,SULFAMETHIZOLE,VACCAVUAMIDAGB-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7460841,DTCC00301538,1577010,46191
CHEMBL119385,P14780,VX-745,VEPKQEUBKLEPRA-UHFFFAOYSA-N,2,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7447744,DTCC00293200,1092352,46191
CHEMBL119385,P14780,VX-745,VEPKQEUBKLEPRA-UHFFFAOYSA-N,2,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7447745,DTCC00293200,1092352,46191
CHEMBL1194,P14780,PRILOCAINE,MVFGUOIZUNYYSO-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7404908,DTCC00305352,898295,46191
CHEMBL1194,P14780,PRILOCAINE,MVFGUOIZUNYYSO-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7404909,DTCC00305352,898295,46191
CHEMBL119443,P14780,ERGONOVINE,WVVSZNPYNCNODU-XTQGRXLLSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7328295,DTCC00295305,1798410,46191
CHEMBL119443,P14780,ERGONOVINE,WVVSZNPYNCNODU-XTQGRXLLSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7328296,DTCC00295305,1798410,46191
CHEMBL1196,P14780,PROPARACAINE,KCLANYCVBBTKTO-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7394375,DTCC00305570,1927021,46191
CHEMBL1196,P14780,PROPARACAINE,KCLANYCVBBTKTO-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7394376,DTCC00305570,1927021,46191
CHEMBL119647,P14780,,UFVLIVCXTIGACT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,100,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103999,DTCC00292472,540481,43205
CHEMBL1198,P14780,PRAMOXINE,DQKXQSGTHWVTAD-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7374678,DTCC00305773,1674146,46191
CHEMBL1198,P14780,PRAMOXINE,DQKXQSGTHWVTAD-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7374679,DTCC00305773,1674146,46191
CHEMBL12,P14780,DIAZEPAM,AAOVKJBEBIDNHE-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7363800,DTCC00132806,51463,46191
CHEMBL12,P14780,DIAZEPAM,AAOVKJBEBIDNHE-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7363801,DTCC00132806,51463,46191
CHEMBL1200391,P14780,TROMETHAMINE,LENZDBCJOHFCAS-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7451917,DTCC00678381,1092351,46191
CHEMBL1200391,P14780,TROMETHAMINE,LENZDBCJOHFCAS-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7451918,DTCC00678381,1092351,46191
CHEMBL1200396,P14780,BUPIVACAINE HYDROCHLORIDE,SIEYLFHKZGLBNX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7260282,DTCC00678386,1155677,46191
CHEMBL1200396,P14780,BUPIVACAINE HYDROCHLORIDE,SIEYLFHKZGLBNX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7260283,DTCC00678386,1155677,46191
CHEMBL1200406,P14780,DIMENHYDRINATE,NFLLKCVHYJRNRH-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7366261,DTCC00678394,736259,46191
CHEMBL1200406,P14780,DIMENHYDRINATE,NFLLKCVHYJRNRH-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7366262,DTCC00678394,736259,46191
CHEMBL1200431,P14780,GADOPENTETATE DIMEGLUMINE,,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7333501,DTCC00678414,1544899,46191
CHEMBL1200431,P14780,GADOPENTETATE DIMEGLUMINE,,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7333502,DTCC00678414,1544899,46191
CHEMBL120049,P14780,,HHJKMUMZRIIHIU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,122,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1632997,DTCC00107516,917812,15919
CHEMBL120049,P14780,,HHJKMUMZRIIHIU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,123.03,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258499,DTCC00107516,909279,24803
CHEMBL1200528,P14780,CHROMIC CHLORIDE,,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7338960,DTCC00678493,1447878,46191
CHEMBL1200528,P14780,CHROMIC CHLORIDE,,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7338961,DTCC00678493,1447878,46191
CHEMBL1200545,P14780,DIFLORASONE DIACETATE,BOBLHFUVNSFZPJ-JOYXJVLSSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7368290,DTCC00678506,1734055,46191
CHEMBL1200545,P14780,DIFLORASONE DIACETATE,BOBLHFUVNSFZPJ-JOYXJVLSSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7368291,DTCC00678506,1734055,46191
CHEMBL1200558,P14780,BACITRACIN,CLKOFPXJLQSYAH-ABRJDSQDSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7258182,DTCC00678469,1734054,46191
CHEMBL1200558,P14780,BACITRACIN,CLKOFPXJLQSYAH-ABRJDSQDSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7258183,DTCC00678469,1734054,46191
CHEMBL1200559,P14780,LACTIC ACID,JVTAAEKCZFNVCJ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7437779,DTCC00678516,1124450,46191
CHEMBL1200559,P14780,LACTIC ACID,JVTAAEKCZFNVCJ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7437780,DTCC00678516,1124450,46191
CHEMBL1200585,P14780,OXYMETHOLONE,ICMWWNHDUZJFDW-DHODBPELSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7380288,DTCC00678533,1577006,46191
CHEMBL1200585,P14780,OXYMETHOLONE,ICMWWNHDUZJFDW-DHODBPELSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7380289,DTCC00678533,1577006,46191
CHEMBL1200600,P14780,FLUOROMETHOLONE,FAOZLTXFLGPHNG-KNAQIMQKSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7316333,DTCC00678548,1027053,46191
CHEMBL1200600,P14780,FLUOROMETHOLONE,FAOZLTXFLGPHNG-KNAQIMQKSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7316334,DTCC00678548,1027053,46191
CHEMBL1200604,P14780,TROPICAMIDE,BGDKAVGWHJFAGW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7452983,DTCC00678551,1416038,46191
CHEMBL1200604,P14780,TROPICAMIDE,BGDKAVGWHJFAGW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7452984,DTCC00678551,1416038,46191
CHEMBL1200623,P14780,ETHYLESTRENOL,AOXRBFRFYPMWLR-XGXHKTLJSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7319940,DTCC00678568,1544897,46191
CHEMBL1200623,P14780,ETHYLESTRENOL,AOXRBFRFYPMWLR-XGXHKTLJSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7319941,DTCC00678568,1544897,46191
CHEMBL1200624,P14780,ETHYNODIOL DIACETATE,ONKUMRGIYFNPJW-KIEAKMPYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7324192,DTCC00678569,88628,46191
CHEMBL1200624,P14780,ETHYNODIOL DIACETATE,ONKUMRGIYFNPJW-KIEAKMPYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7324193,DTCC00678569,88628,46191
CHEMBL1200629,P14780,VECURONIUM BROMIDE,VEPSYABRBFXYIB-PWXDFCLTSA-M,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7449495,DTCC00678574,703989,46191
CHEMBL1200629,P14780,VECURONIUM BROMIDE,VEPSYABRBFXYIB-PWXDFCLTSA-M,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7449496,DTCC00678574,703989,46191
CHEMBL1200633,P14780,IVERMECTIN,SPBDXSGPUHCETR-JFUDTMANSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7418364,DTCC00678578,606970,46191
CHEMBL1200633,P14780,IVERMECTIN,SPBDXSGPUHCETR-JFUDTMANSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7418365,DTCC00678578,606970,46191
CHEMBL1200656,P14780,NATAMYCIN,NCXMLFZGDNKEPB-FFPOYIOWSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7383062,DTCC00678594,1351116,46191
CHEMBL1200656,P14780,NATAMYCIN,NCXMLFZGDNKEPB-FFPOYIOWSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7383063,DTCC00678594,1351116,46191
CHEMBL1200679,P14780,ZINC CHLORIDE,JIAARYAFYJHUJI-UHFFFAOYSA-L,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7450652,DTCC00678612,315674,46191
CHEMBL1200679,P14780,ZINC CHLORIDE,JIAARYAFYJHUJI-UHFFFAOYSA-L,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7450653,DTCC00678612,315674,46191
CHEMBL1200693,P14780,MANGANESE CHLORIDE,,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7436120,DTCC00678623,671789,46191
CHEMBL1200693,P14780,MANGANESE CHLORIDE,,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7436121,DTCC00678623,671789,46191
CHEMBL1200709,P14780,CROTAMITON,DNTGGZPQPQTDQF-XBXARRHUSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7344034,DTCC00678636,1188066,46191
CHEMBL1200709,P14780,CROTAMITON,DNTGGZPQPQTDQF-XBXARRHUSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7344035,DTCC00678636,1188066,46191
CHEMBL1200748,P14780,CARBIDOPA,QTAOMKOIBXZKND-PPHPATTJSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7479780,DTCC00678662,606973,46191
CHEMBL1200748,P14780,CARBIDOPA,QTAOMKOIBXZKND-PPHPATTJSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7479781,DTCC00678662,606973,46191
CHEMBL1200845,P14780,HALCINONIDE,MUQNGPZZQDCDFT-JNQJZLCISA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7331966,DTCC00678745,1765972,46191
CHEMBL1200845,P14780,HALCINONIDE,MUQNGPZZQDCDFT-JNQJZLCISA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7331967,DTCC00678745,1765972,46191
CHEMBL1200862,P14780,METYROSINE,NHTGHBARYWONDQ-JTQLQIEISA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7434659,DTCC00678758,88631,46191
CHEMBL1200862,P14780,METYROSINE,NHTGHBARYWONDQ-JTQLQIEISA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7434660,DTCC00678758,88631,46191
CHEMBL1200993,P14780,GALLAMINE TRIETHIODIDE,REEUVFCVXKWOFE-UHFFFAOYSA-K,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7307944,DTCC00678870,381013,46191
CHEMBL1200993,P14780,GALLAMINE TRIETHIODIDE,REEUVFCVXKWOFE-UHFFFAOYSA-K,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7307945,DTCC00678870,381013,46191
CHEMBL1201010,P14780,FLUDROCORTISONE ACETATE,SYWHXTATXSMDSB-GSLJADNHSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7318228,DTCC00678884,381011,46191
CHEMBL1201010,P14780,FLUDROCORTISONE ACETATE,SYWHXTATXSMDSB-GSLJADNHSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7318229,DTCC00678884,381011,46191
CHEMBL1201012,P14780,FLURANDRENOLIDE,POPFMWWJOGLOIF-XWCQMRHXSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7333362,DTCC00678886,381012,46191
CHEMBL1201012,P14780,FLURANDRENOLIDE,POPFMWWJOGLOIF-XWCQMRHXSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7333363,DTCC00678886,381012,46191
CHEMBL1201024,P14780,METHSCOPOLAMINE BROMIDE,CXYRUNPLKGGUJF-XKTSLVMZSA-M,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7413082,DTCC00678896,1059334,46191
CHEMBL1201024,P14780,METHSCOPOLAMINE BROMIDE,CXYRUNPLKGGUJF-XKTSLVMZSA-M,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7413083,DTCC00678896,1059334,46191
CHEMBL1201117,P14780,METHOCARBAMOL,GNXFOGHNGIVQEH-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7434425,DTCC00678968,800581,46191
CHEMBL1201117,P14780,METHOCARBAMOL,GNXFOGHNGIVQEH-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7434426,DTCC00678968,800581,46191
CHEMBL1201139,P14780,MEGESTROL ACETATE,RQZAXGRLVPAYTJ-GQFGMJRRSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7412885,DTCC00678986,639582,46191
CHEMBL1201139,P14780,MEGESTROL ACETATE,RQZAXGRLVPAYTJ-GQFGMJRRSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7412886,DTCC00678986,639582,46191
CHEMBL1201146,P14780,NORETHINDRONE ACETATE,IMONTRJLAWHYGT-ZCPXKWAGSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7388600,DTCC00678989,703984,46191
CHEMBL1201146,P14780,NORETHINDRONE ACETATE,IMONTRJLAWHYGT-ZCPXKWAGSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7388601,DTCC00678989,703984,46191
CHEMBL1201151,P14780,MESTRANOL,IMSSROKUHAOUJS-MJCUULBUSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7412998,DTCC00678994,542579,46191
CHEMBL1201151,P14780,MESTRANOL,IMSSROKUHAOUJS-MJCUULBUSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7412999,DTCC00678994,542579,46191
CHEMBL1201193,P14780,LEVOBUPIVACAINE,LEBVLXFERQHONN-INIZCTEOSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7416686,DTCC00679027,282998,46191
CHEMBL1201193,P14780,LEVOBUPIVACAINE,LEBVLXFERQHONN-INIZCTEOSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7416687,DTCC00679027,282998,46191
CHEMBL1201195,P14780,CEFMETAZOLE,SNBUBQHDYVFSQF-HIFRSBDPSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7347231,DTCC00679029,833158,46191
CHEMBL1201195,P14780,CEFMETAZOLE,SNBUBQHDYVFSQF-HIFRSBDPSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7347232,DTCC00679029,833158,46191
CHEMBL1201203,P14780,BENZTROPINE,GIJXKZJWITVLHI-PMOLBWCYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7277045,DTCC00679037,1609543,46191
CHEMBL1201203,P14780,BENZTROPINE,GIJXKZJWITVLHI-PMOLBWCYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7277046,DTCC00679037,1609543,46191
CHEMBL1201207,P14780,BETAMETHASONE PHOSPHORIC ACID,VQODGRNSFPNSQE-DVTGEIKXSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7280131,DTCC00679040,444634,46191
CHEMBL1201207,P14780,BETAMETHASONE PHOSPHORIC ACID,VQODGRNSFPNSQE-DVTGEIKXSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7280132,DTCC00679040,444634,46191
CHEMBL1201216,P14780,DAPIPRAZOLE,RFWZESUMWJKKRN-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7344220,DTCC00679045,1544895,46191
CHEMBL1201216,P14780,DAPIPRAZOLE,RFWZESUMWJKKRN-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7344221,DTCC00679045,1544895,46191
CHEMBL1201220,P14780,DIATRIZOIC ACID,YVPYQUNUQOZFHG-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7359505,DTCC00679049,444639,46191
CHEMBL1201220,P14780,DIATRIZOIC ACID,YVPYQUNUQOZFHG-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7359506,DTCC00679049,444639,46191
CHEMBL1201237,P14780,LEVOBUNOLOL,IXHBTMCLRNMKHZ-LBPRGKRZSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7412322,DTCC00679063,736261,46191
CHEMBL1201237,P14780,LEVOBUNOLOL,IXHBTMCLRNMKHZ-LBPRGKRZSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7412323,DTCC00679063,736261,46191
CHEMBL1201346,P14780,BALSALAZID,IPOKCKJONYRRHP-FMQUCBEESA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7264042,DTCC00679132,1512805,46191
CHEMBL1201346,P14780,BALSALAZID,IPOKCKJONYRRHP-FMQUCBEESA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7264043,DTCC00679132,1512805,46191
CHEMBL1201353,P14780,DEXCHLORPHENIRAMINE,SOYKEARSMXGVTM-HNNXBMFYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7337979,DTCC00679137,185552,46191
CHEMBL1201353,P14780,DEXCHLORPHENIRAMINE,SOYKEARSMXGVTM-HNNXBMFYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7337980,DTCC00679137,185552,46191
CHEMBL1201356,P14780,METHYLERGONOVINE,UNBRKDKAWYKMIV-QWQRMKEZSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7430292,DTCC00679140,1124451,46191
CHEMBL1201356,P14780,METHYLERGONOVINE,UNBRKDKAWYKMIV-QWQRMKEZSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7430293,DTCC00679140,1124451,46191
CHEMBL1201469,P14780,GRAMICIDIN,,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7329612,DTCC00679278,217579,46191
CHEMBL1201469,P14780,GRAMICIDIN,,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7329613,DTCC00679278,217579,46191
CHEMBL1201631,P14780,INSULIN HUMAN,,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7435221,DTCC00679306,1798411,46191
CHEMBL1201631,P14780,INSULIN HUMAN,,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7435222,DTCC00679306,1798411,46191
CHEMBL120305,P14780,,URZNSEWPQRLLLE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9733482,IC50,,,,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (not determined),Not Determined,"Discovery of potent, achiral matrix metalloproteinase inhibitors.",J. Med. Chem.,1998,41,19,"Pikul S, McDow Dunham KL, Almstead NG, De B, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Rydel T, Dunaway CM, Gu F, Mieling GE",,105361,DTCT0024844,1528766,DTCC00295327,258700,14767
CHEMBL1204013,P14780,,RUFCUNSVBIYRLT-CPLNNKCJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19635666,IC50,>,5000,NM,,,,,,,,,,,,,,Inhibition of MMP-9,,Discovery of novel selective HER-2 sheddase inhibitors through optimization of P1 moiety.,Bioorg. Med. Chem. Lett.,2009,19,17,"Li YL, Shi E, Burns D, Li Y, Covington MB, Pan M, Scherle P, Friedman S, Metcalf B, Yao W",,598558,DTCT0024844,3101272,DTCC00681531,910637,36106
CHEMBL120526,P14780,METHANANDAMIDE,SQKRUBZPTNJQEM-FQPARAGTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19161308,ACTIVITY,=,5,%,,,,,,,,,,,,,,Stimulation of MMP9 activity in HUVEC assessed as increase in enzyme activity at 100 nM relative to control,,Total synthesis of photoactivatable or fluorescent anandamide probes: novel bioactive compounds with angiogenic activity.,J. Med. Chem.,2009,52,4,"Balas L, Durand T, Saha S, Johnson I, Mukhopadhyay S",,494405,DTCT0024844,2595835,DTCC00297313,132088,32132
CHEMBL120526,P14780,METHANANDAMIDE,SQKRUBZPTNJQEM-FQPARAGTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19161308,ACTIVITY,=,10,%,,,,,,,,,,,,,,Stimulation of MMP9 activity in CB1 receptor knockout HUVEC assessed as increase in enzyme activity at 100 nM relative to control,,Total synthesis of photoactivatable or fluorescent anandamide probes: novel bioactive compounds with angiogenic activity.,J. Med. Chem.,2009,52,4,"Balas L, Durand T, Saha S, Johnson I, Mukhopadhyay S",,494411,DTCT0024844,2595841,DTCC00297313,132088,32132
CHEMBL120526,P14780,METHANANDAMIDE,SQKRUBZPTNJQEM-FQPARAGTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19161308,ACTIVITY,=,20,%,,,,,,,,,,,,,,Stimulation of MMP9 activity in HUVEC assessed as increase in enzyme activity at 10 nM relative to control,,Total synthesis of photoactivatable or fluorescent anandamide probes: novel bioactive compounds with angiogenic activity.,J. Med. Chem.,2009,52,4,"Balas L, Durand T, Saha S, Johnson I, Mukhopadhyay S",,494403,DTCT0024844,2595832,DTCC00297313,132088,32132
CHEMBL120526,P14780,METHANANDAMIDE,SQKRUBZPTNJQEM-FQPARAGTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19161308,ACTIVITY,=,25,%,,,,,,,,,,,,,,Stimulation of MMP9 activity in CB1 receptor knockout HUVEC assessed as increase in enzyme activity at 10 nM relative to control,,Total synthesis of photoactivatable or fluorescent anandamide probes: novel bioactive compounds with angiogenic activity.,J. Med. Chem.,2009,52,4,"Balas L, Durand T, Saha S, Johnson I, Mukhopadhyay S",,494409,DTCT0024844,2595839,DTCC00297313,132088,32132
CHEMBL120526,P14780,METHANANDAMIDE,SQKRUBZPTNJQEM-FQPARAGTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19161308,ACTIVITY,=,28,%,,,,,,,,,,,,,,Stimulation of MMP9 activity in HUVEC assessed as increase in enzyme activity at 1 uM relative to control,,Total synthesis of photoactivatable or fluorescent anandamide probes: novel bioactive compounds with angiogenic activity.,J. Med. Chem.,2009,52,4,"Balas L, Durand T, Saha S, Johnson I, Mukhopadhyay S",,494407,DTCT0024844,2595837,DTCC00297313,132088,32132
CHEMBL120526,P14780,METHANANDAMIDE,SQKRUBZPTNJQEM-FQPARAGTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19161308,ACTIVITY,=,33,%,,,,,,,,,,,,,,Stimulation of MMP9 activity in CB1 receptor knockout HUVEC assessed as increase in enzyme activity at 1 uM relative to control,,Total synthesis of photoactivatable or fluorescent anandamide probes: novel bioactive compounds with angiogenic activity.,J. Med. Chem.,2009,52,4,"Balas L, Durand T, Saha S, Johnson I, Mukhopadhyay S",,494598,DTCT0024844,2595843,DTCC00297313,132088,32132
CHEMBL1208572,P14780,SALINOMYCIN,KQXDHUJYNAXLNZ-XQSDOZFQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7466821,DTCC00685596,1641853,46191
CHEMBL1208572,P14780,SALINOMYCIN,KQXDHUJYNAXLNZ-XQSDOZFQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7466822,DTCC00685596,1641853,46191
CHEMBL12089,P14780,BERBERINE CHLORIDE,VKJGBAJNNALVAV-UHFFFAOYSA-M,1,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7259978,DTCC00140102,1416025,46191
CHEMBL12089,P14780,BERBERINE CHLORIDE,VKJGBAJNNALVAV-UHFFFAOYSA-M,1,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7259979,DTCC00140102,1416025,46191
CHEMBL120934,P14780,,YNOGLIGOUAHYJD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,69000,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1636619,DTCC00298635,1468303,15919
CHEMBL121,P14780,ROSIGLITAZONE,YASAKCUCGLMORW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7483926,DTCC00148715,51506,46191
CHEMBL121,P14780,ROSIGLITAZONE,YASAKCUCGLMORW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7483927,DTCC00148715,51506,46191
CHEMBL121188,P14780,TROPOLONE,MDYOLVRUBBJPFM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,91,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103700,DTCC00298736,183415,43205
CHEMBL12131,P14780,CLOSANTEL,JMPFSEBWVLAJKM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7354448,DTCC00140760,1674142,46191
CHEMBL12131,P14780,CLOSANTEL,JMPFSEBWVLAJKM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7354449,DTCC00140760,1674142,46191
CHEMBL1214185,P14780,ROXITHROMYCIN,RXZBMPWDPOLZGW-XMRMVWPWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7462300,DTCC00688811,2057652,46191
CHEMBL1214185,P14780,ROXITHROMYCIN,RXZBMPWDPOLZGW-XMRMVWPWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7462301,DTCC00688811,2057652,46191
CHEMBL121501,P14780,,CDRGZNIXJYUKQP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,23000,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1610016,DTCC00299141,238022,15919
CHEMBL121557,P14780,E637,YIKYNHJUKRTCJL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,28,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103744,DTCC00298041,1445791,43205
CHEMBL121559,P14780,,XMJJPCJUQLGGND-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,60000,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1620369,DTCC00298606,950358,15919
CHEMBL121592,P14780,,YNYVAXYTOIAEND-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,13000,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1639320,DTCC00298632,691932,15919
CHEMBL121729,P14780,,UYGXLIUFUDWVHR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,14000,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1602504,DTCC00298661,1047445,15919
CHEMBL1219,P14780,RABEPRAZOLE,YREYEVIYCVEVJK-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7477134,DTCC00316485,574625,46191
CHEMBL1219,P14780,RABEPRAZOLE,YREYEVIYCVEVJK-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7477135,DTCC00316485,574625,46191
CHEMBL121916,P14780,,SUEBJDNLBVTIQP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,126,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1629119,DTCC00299015,1564995,15919
CHEMBL121916,P14780,,SUEBJDNLBVTIQP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,125.89,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258445,DTCC00299015,1555532,24803
CHEMBL122,P14780,ROFECOXIB,RZJQGNCSTQAWON-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7479661,DTCC00150159,1830689,46191
CHEMBL122,P14780,ROFECOXIB,RZJQGNCSTQAWON-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7479662,DTCC00150159,1830689,46191
CHEMBL1220,P14780,TINIDAZOLE,HJLSLZFTEKNLFI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7487576,DTCC00316820,1318449,46191
CHEMBL1220,P14780,TINIDAZOLE,HJLSLZFTEKNLFI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7487577,DTCC00316820,1318449,46191
CHEMBL1221,P14780,SULCONAZOLE,AFNXATANNDIXLG-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7465123,DTCC00317729,1830690,46191
CHEMBL1221,P14780,SULCONAZOLE,AFNXATANNDIXLG-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7465124,DTCC00317729,1830690,46191
CHEMBL122109,P14780,,XSOOLQYDISZIKZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,21000,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1608689,DTCC00298851,1500649,15919
CHEMBL1221512,P14780,L-744832,PGOKBMWPBDRDGN-IBXSQZDTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7416445,DTCC00031822,1927016,46191
CHEMBL1221512,P14780,L-744832,PGOKBMWPBDRDGN-IBXSQZDTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7416446,DTCC00031822,1927016,46191
CHEMBL1222867,P14780,,XMSHNXONZBWQTA-DEOSSOPVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20663669,INH,=,124,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Biaryl substituted hydantoin compounds as TACE inhibitors.,Bioorg. Med. Chem. Lett.,2010,20,17,"Yu W, Tong L, Kim SH, Wong MK, Chen L, Yang DY, Shankar BB, Lavey BJ, Zhou G, Kosinski A, Rizvi R, Li D, Feltz RJ, Piwinski JJ, Rosner KE, Shih NY, Siddiqui MA, Guo Z, Orth P, Shah H, Sun J, Umland S, Lundell DJ, Niu X, Kozlowski JA",,651600,DTCT0024844,3456520,DTCC00691619,307666,40340
CHEMBL1223007,P14780,,JHADKVOWWKZBNS-QHCPKHFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20663669,INH,=,122,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Biaryl substituted hydantoin compounds as TACE inhibitors.,Bioorg. Med. Chem. Lett.,2010,20,17,"Yu W, Tong L, Kim SH, Wong MK, Chen L, Yang DY, Shankar BB, Lavey BJ, Zhou G, Kosinski A, Rizvi R, Li D, Feltz RJ, Piwinski JJ, Rosner KE, Shih NY, Siddiqui MA, Guo Z, Orth P, Shah H, Sun J, Umland S, Lundell DJ, Niu X, Kozlowski JA",,651600,DTCT0024844,3456546,DTCC00691756,1310511,40340
CHEMBL1223075,P14780,,HGPPYGXNQCWPLJ-VWLOTQADSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20663669,INH,=,212,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Biaryl substituted hydantoin compounds as TACE inhibitors.,Bioorg. Med. Chem. Lett.,2010,20,17,"Yu W, Tong L, Kim SH, Wong MK, Chen L, Yang DY, Shankar BB, Lavey BJ, Zhou G, Kosinski A, Rizvi R, Li D, Feltz RJ, Piwinski JJ, Rosner KE, Shih NY, Siddiqui MA, Guo Z, Orth P, Shah H, Sun J, Umland S, Lundell DJ, Niu X, Kozlowski JA",,651600,DTCT0024844,3456563,DTCC00691820,922026,40340
CHEMBL122651,P14780,,LEWMAZXEBPMBSY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,39,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1630523,DTCC00298572,1435960,15919
CHEMBL122651,P14780,,LEWMAZXEBPMBSY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,38.9,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258493,DTCC00298572,1426639,24803
CHEMBL122711,P14780,,ROMGJVVZNVJOPW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,1.3,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1613751,DTCC00298574,1500650,15919
CHEMBL122711,P14780,,ROMGJVVZNVJOPW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,1.29,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258494,DTCC00298574,1491217,24803
CHEMBL122719,P14780,,ZHENEPVPETWBJM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,4.6,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1629127,DTCC00299183,270685,15919
CHEMBL122719,P14780,,ZHENEPVPETWBJM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,4.57,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258495,DTCC00299183,260720,24803
CHEMBL122831,P14780,,DUCBSHDQTBWWLC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,5,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1634316,DTCC00299399,173533,15919
CHEMBL122831,P14780,,DUCBSHDQTBWWLC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,5.01,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258483,DTCC00299399,164156,24803
CHEMBL122836,P14780,,UGZOJBSDACNWAB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,1.5,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1599885,DTCC00299434,2077808,15919
CHEMBL122836,P14780,,UGZOJBSDACNWAB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,1.51,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258486,DTCC00299434,2068202,24803
CHEMBL122868,P14780,,MBKXTRZDNQFIJG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,12000,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1627955,DTCC00299111,303682,15919
CHEMBL122925,P14780,,FPJLTHNGOJRXMU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,1300,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1612449,DTCC00299110,530554,15919
CHEMBL122950,P14780,,LSHFFFVFHVCTTH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,9000,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1617700,DTCC00298794,465561,15919
CHEMBL1229516,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26871660,IC50,=,5.1,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate after 3 hrs by fluorometric assay,,Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models.,Eur. J. Med. Chem.,2016,111,,"Camodeca C, Nuti E, Tepshi L, Boero S, Tuccinardi T, Stura EA, Poggi A, Zocchi MR, Rossello A.",,1559054,DTCT0024844,101498,DTCC00046206,581272,66304
CHEMBL1229868,P14780,SC-77774,FOSWRYKPHVPIDJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,1.2,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005855,DTCC00032045,781475,45214
CHEMBL1230333,P14780,,VYTXLSQVYGNWLV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7298869,DTCC00693927,2089742,46191
CHEMBL1230333,P14780,,VYTXLSQVYGNWLV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7298870,DTCC00693927,2089742,46191
CHEMBL123041,P14780,,IWTGCCHOUSDKHV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,4.3,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1634308,DTCC00299582,38898,15919
CHEMBL123041,P14780,,IWTGCCHOUSDKHV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,4.27,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258506,DTCC00299582,1716216,24803
CHEMBL123064,P14780,,RRPKGUUYTHFUPN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,34000,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1627947,DTCC00298793,595002,15919
CHEMBL1230813,P14780,ALFADEX,HFHDHCJBZVLPGP-RWMJIURBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7292394,DTCC00693991,1155676,46191
CHEMBL1230813,P14780,ALFADEX,HFHDHCJBZVLPGP-RWMJIURBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7292395,DTCC00693991,1155676,46191
CHEMBL1231,P14780,OXYBUTYNIN,XIQVNETUBQGFHX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7403978,DTCC00321776,542581,46191
CHEMBL1231,P14780,OXYBUTYNIN,XIQVNETUBQGFHX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7403979,DTCC00321776,542581,46191
CHEMBL123105,P14780,,HBZIAYRTJNOIOI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,24000,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1611263,DTCC00299584,31106,15919
CHEMBL1231107,P14780,CYROMAZINE,LVQDKIWDGQRHTE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7344111,DTCC00694021,1027050,46191
CHEMBL1231107,P14780,CYROMAZINE,LVQDKIWDGQRHTE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7344112,DTCC00694021,1027050,46191
CHEMBL1231530,P14780,BETAMIPRON,CWXYHOHYCJXYFQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7260087,DTCC00694066,1830684,46191
CHEMBL1231530,P14780,BETAMIPRON,CWXYHOHYCJXYFQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7260088,DTCC00694066,1830684,46191
CHEMBL123167,P14780,,WWQRPJINVFSPDF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,100,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1627915,DTCC00299223,853820,15919
CHEMBL123167,P14780,,WWQRPJINVFSPDF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,100,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258511,DTCC00299223,844214,24803
CHEMBL12318,P14780,CLODRONIC ACID,ACSIXWWBWUQEHA-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17583333,IC50,=,320000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 after 1 hr,,"Platinum complexes can inhibit matrix metalloproteinase activity: platinum-diethyl[(methylsulfinyl)methyl]phosphonate complexes as inhibitors of matrix metalloproteinases 2, 3, 9, and 12.",J. Med. Chem.,2007,50,15,"Sasanelli R, Boccarelli A, Giordano D, Laforgia M, Arnesano F, Natile G, Cardellicchio C, Capozzi MA, Coluccia M",,439903,DTCT0024844,2112263,DTCC00140920,1523158,23003
CHEMBL123233,P14780,,UIBGOVKOYKPDFL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,10000,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1631614,DTCC00298759,2013481,15919
CHEMBL1232487,P14780,,KOVQMCGGWATESY-VXKWHMMOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,565,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247673,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,163353,DTCC00694177,1422152,64498
CHEMBL1232489,P14780,,LIIRZRQVACDFBI-HOTGVXAUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247684,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,164478,DTCC00694178,484290,64498
CHEMBL1232492,P14780,,MMIHYNVQXYWTFM-GOTSBHOMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247765,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,183827,DTCC00694179,1680179,64498
CHEMBL1232492,P14780,,MMIHYNVQXYWTFM-GOTSBHOMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,10000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247764,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,169476,DTCC00694179,1680179,64498
CHEMBL123292,P14780,CYCLOHEXIMIDE,YPHMISFOHDHNIV-FSZOTQKASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7356927,DTCC00297204,477915,46191
CHEMBL123292,P14780,CYCLOHEXIMIDE,YPHMISFOHDHNIV-FSZOTQKASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7356928,DTCC00297204,477915,46191
CHEMBL123320,P14780,,CAPSVCHNNRHIDK-LOACHALJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,4.4,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1704455,DTCC00302421,1035964,16065
CHEMBL123382,P14780,,CPWMZTRXCCYTDM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,78,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1630515,DTCC00298903,498461,15919
CHEMBL123382,P14780,,CPWMZTRXCCYTDM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,77.62,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258443,DTCC00298903,488945,24803
CHEMBL123404,P14780,,PORUPJYSNWMWCH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,66000,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1631622,DTCC00299414,788555,15919
CHEMBL1234326,P14780,3-HYDROXYPICOLINIC ACID,BRARRAHGNDUELT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,19,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5102604,DTCC00032094,1607385,43205
CHEMBL1234370,P14780,,CYYCSKFJEOSZTF-CYBMUJFWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10579818,IC50,=,1390,NM,,,,,,,,,,,,,,Inhibition of gelatinase-B (Matrix metalloprotease-9),,"Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.",J. Med. Chem.,1999,42,22,"Almstead NG, Bradley RS, Pikul S, De B, Natchus MG, Taiwo YO, Gu F, Williams LE, Hynd BA, Janusz MJ, Dunaway CM, Mieling GE",,105226,DTCT0024844,1371840,DTCC00694384,1883251,15412
CHEMBL123443,P14780,,STWCTQDLUUVJMC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,36,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1599877,DTCC00299356,562771,15919
CHEMBL123443,P14780,,STWCTQDLUUVJMC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,36.31,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258444,DTCC00299356,553251,24803
CHEMBL123463,P14780,,SNYKGOMEURTYMK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,1.4,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1610008,DTCC00299603,36667,15919
CHEMBL123463,P14780,,SNYKGOMEURTYMK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,1.41,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258505,DTCC00299603,1716217,24803
CHEMBL123499,P14780,,JCCRVIZMNYULMQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,6,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1688100,DTCC00303217,486972,16065
CHEMBL123503,P14780,,DZFFLJXATZFATL-MZBJOSPHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12930146,IC50,=,26,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP9),,Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.,J. Med. Chem.,2003,46,18,"Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P",,105365,DTCT0024844,515825,DTCC00304831,1371678,13726
CHEMBL1235242,P14780,,XWHHYOYVRVGJJY-QMMMGPOBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7283908,DTCC00694481,413967,46191
CHEMBL1235242,P14780,,XWHHYOYVRVGJJY-QMMMGPOBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7283909,DTCC00694481,413967,46191
CHEMBL1235568,P14780,,XYEPUTZVZYUENX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,59,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103182,DTCC00694512,1283744,43205
CHEMBL123563,P14780,,XVZWTHXPJUVJAU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,2.4,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1711247,DTCC00302702,874710,16065
CHEMBL123615,P14780,,IAENNQHKVZEBQT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,1.7,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1709798,DTCC00302858,1682780,16065
CHEMBL123627,P14780,,INSQINPAEQOIQL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,1.6,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1704460,DTCC00302808,744987,16065
CHEMBL1236282,P14780,THIAMPHENICOL,OTVAEFIXJLOWRX-NXEZZACHSA-N,1,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7474629,DTCC00694596,1894975,46191
CHEMBL1236282,P14780,THIAMPHENICOL,OTVAEFIXJLOWRX-NXEZZACHSA-N,1,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7474630,DTCC00694596,1894975,46191
CHEMBL1237,P14780,LISINOPRIL,RLAWWYSOJDYHDC-BZSNNMDCSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7416818,DTCC00323141,88630,46191
CHEMBL1237,P14780,LISINOPRIL,RLAWWYSOJDYHDC-BZSNNMDCSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7416819,DTCC00323141,88630,46191
CHEMBL1237044,P14780,TRAMADOL,TVYLLZQTGLZFBW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7457469,DTCC00694678,381017,46191
CHEMBL1237044,P14780,TRAMADOL,TVYLLZQTGLZFBW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7457470,DTCC00694678,381017,46191
CHEMBL1237174,P14780,HYDRAZINE,OAKJQQAXSVQMHS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7332030,DTCC00126200,639581,46191
CHEMBL1237174,P14780,HYDRAZINE,OAKJQQAXSVQMHS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7332031,DTCC00126200,639581,46191
CHEMBL123775,P14780,,DJASZHFLBWUJAJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,0.6,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1625332,DTCC00299432,950355,15919
CHEMBL123775,P14780,,DJASZHFLBWUJAJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,0.603,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258485,DTCC00299432,940925,24803
CHEMBL123967,P14780,,RYRSPABEKSPRKC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,0.6,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1700453,DTCC00302821,777059,16065
CHEMBL124026,P14780,,GOLRDGXHDIYHCN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,7.6,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1681646,DTCC00302820,1585795,16065
CHEMBL124100,P14780,,ZFYWVXBCKVCYOL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,2.6,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1691928,DTCC00303263,1164479,16065
CHEMBL1241348,P14780,FALDAPREVIR,LLGDPTDZOVKFDU-XUHJSTDZSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20823284,INHIBITION,=,13,%,,,,,,,,,,,,,,Inhibition of human MMP-9 at 10 uM,,"Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.",Antimicrob. Agents Chemother.,2010,54,11,"White PW, Llinàs-Brunet M, Amad M, Bethell RC, Bolger G, Cordingley MG, Duan J, Garneau M, Lagacé L, Thibeault D, Kukolj G",,724365,DTCT0024844,5125909,DTCC00126282,118904,43507
CHEMBL124237,P14780,,ACUCWGGAKLORQX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,>,100000,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1605172,DTCC00298788,1597483,15919
CHEMBL124265,P14780,,YWZUYEWFBPKKSJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,17,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1712477,DTCC00303495,1521506,16065
CHEMBL1243,P14780,SULFABENZAMIDE,PBCZLFBEBARBBI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7469475,DTCC00325694,217587,46191
CHEMBL1243,P14780,SULFABENZAMIDE,PBCZLFBEBARBBI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7469476,DTCC00325694,217587,46191
CHEMBL124514,P14780,,QMHSEIOSCQWTPQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,13,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1680210,DTCC00303304,97463,16065
CHEMBL124558,P14780,,VUANPBMJTLCNSC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,1.2,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1707028,DTCC00302325,1262121,16065
CHEMBL124680,P14780,,NDGWYSJFTMSGNY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,6.9,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1703160,DTCC00303465,1650647,16065
CHEMBL124681,P14780,,GTRBSPVJGOLISO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,25,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1696748,DTCC00303466,1585794,16065
CHEMBL125068,P14780,,KEWGKOQZKWDXBX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,2.3,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1712482,DTCC00303279,1489255,16065
CHEMBL125104,P14780,,BHBDAWJEKOCFGP-TUSQITKMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12930146,IC50,=,3.8,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP9),,Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.,J. Med. Chem.,2003,46,18,"Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P",,105365,DTCT0024844,541128,DTCC00304856,627570,13726
CHEMBL125138,P14780,,UROHLDAMBMAOKL-DPSWKAHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12930146,IC50,=,661,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP9),,Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.,J. Med. Chem.,2003,46,18,"Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P",,105365,DTCT0024844,514822,DTCC00304556,1468365,13726
CHEMBL125281,P14780,,FGCFPKFVQOUMFJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,32,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1720792,DTCC00302814,2001625,16065
CHEMBL125302,P14780,,KZZHUKUOPGQIRQ-YSSFQJQWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12930146,IC50,>,6,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP9),,Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.,J. Med. Chem.,2003,46,18,"Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P",,105365,DTCT0024844,514819,DTCC00304565,917876,13726
CHEMBL125384,P14780,,PQRKDBIFJONDMB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,8.3,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1694287,DTCC00302906,519185,16065
CHEMBL1255834,P14780,BW-723C86,ALFGDCNSEBJYSP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7277451,DTCC00032296,1124446,46191
CHEMBL1255834,P14780,BW-723C86,ALFGDCNSEBJYSP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7277452,DTCC00032296,1124446,46191
CHEMBL1255837,P14780,DIHYDROERGOCRISTINE MESYLATE,SPXACGZWWVIDGR-SPZWACKZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7355345,DTCC00699500,1447881,46191
CHEMBL1255837,P14780,DIHYDROERGOCRISTINE MESYLATE,SPXACGZWWVIDGR-SPZWACKZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7355346,DTCC00699500,1447881,46191
CHEMBL1255901,P14780,HUPERZINE A,ZRJBHWIHUMBLCN-HZRLMBICSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7323442,DTCC00699536,930079,46191
CHEMBL1255901,P14780,HUPERZINE A,ZRJBHWIHUMBLCN-HZRLMBICSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7323443,DTCC00699536,930079,46191
CHEMBL1255934,P14780,,SWELIMKTDYHAOY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,2,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103917,DTCC00699570,1672007,43205
CHEMBL125598,P14780,,KXZZWRQJKQVMKR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,0.9,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1689342,DTCC00303280,777060,16065
CHEMBL125601,P14780,,FKPCCEUCLYUJQA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,20,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1703170,DTCC00302219,1164478,16065
CHEMBL1256017,P14780,ARCAINE SULFATE,RWTGFMPOODRXIM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7265161,DTCC00699626,994589,46191
CHEMBL1256017,P14780,ARCAINE SULFATE,RWTGFMPOODRXIM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7265162,DTCC00699626,994589,46191
CHEMBL125755,P14780,,DYVJPNSKJGHBKT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,3.6,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1688105,DTCC00302953,680411,16065
CHEMBL125901,P14780,,LAXIFXUCVNKYRQ-TZYHBYERSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12930146,IC50,=,341,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP9),,Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.,J. Med. Chem.,2003,46,18,"Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P",,105365,DTCT0024844,513864,DTCC00304596,270760,13726
CHEMBL126044,P14780,,HWRVCRDVLWYPOY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,2.1,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1713841,DTCC00302324,1262120,16065
CHEMBL1261,P14780,CITRIC ACID,KRKNYBCHXYNGOX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7358493,DTCC00331493,1609544,46191
CHEMBL1261,P14780,CITRIC ACID,KRKNYBCHXYNGOX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7358494,DTCC00331493,1609544,46191
CHEMBL1262,P14780,OXICONAZOLE,QRJJEGAJXVEBNE-HKOYGPOVSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7399656,DTCC00332757,1059336,46191
CHEMBL1262,P14780,OXICONAZOLE,QRJJEGAJXVEBNE-HKOYGPOVSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7399657,DTCC00332757,1059336,46191
CHEMBL126380,P14780,,QKYPFBUZQDJQHX-NWVWQQAFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12930146,IC50,=,2.9,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP9),,Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.,J. Med. Chem.,2003,46,18,"Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P",,105365,DTCT0024844,518979,DTCC00304598,853892,13726
CHEMBL126380,P14780,,QKYPFBUZQDJQHX-NWVWQQAFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12930146,IC50,=,43,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP9),,Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.,J. Med. Chem.,2003,46,18,"Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P",,105365,DTCT0024844,541123,DTCC00304598,853893,13726
CHEMBL126380,P14780,,QKYPFBUZQDJQHX-NWVWQQAFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12930146,IC50,=,93,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP9),,Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.,J. Med. Chem.,2003,46,18,"Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P",,105365,DTCT0024844,536421,DTCC00304598,853891,13726
CHEMBL126388,P14780,,DEZZFUOGAFLCST-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,6.6,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1700463,DTCC00302969,583382,16065
CHEMBL126461,P14780,,NOCFVGZKPITVEY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12930146,IC50,=,0.5,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP9),,Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.,J. Med. Chem.,2003,46,18,"Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P",,105365,DTCT0024844,533624,DTCC00304599,108960,13726
CHEMBL126711,P14780,,BOXAYSWQFMJSDX-OEOAZWSVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12930146,IC50,=,35,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP9),,Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.,J. Med. Chem.,2003,46,18,"Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P",,105365,DTCT0024844,514827,DTCC00304242,1500715,13726
CHEMBL126712,P14780,,DRINIAFHXKEERM-VDGAXYAQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12930146,IC50,=,3.3,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP9),,Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.,J. Med. Chem.,2003,46,18,"Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P",,105365,DTCT0024844,516920,DTCC00304243,205585,13726
CHEMBL126923,P14780,,UVAFSUYDCCCUTO-HRNNMHKYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12930146,IC50,=,12,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP9),,Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.,J. Med. Chem.,2003,46,18,"Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P",,105365,DTCT0024844,530746,DTCC00304832,820979,13726
CHEMBL126977,P14780,,CXRYZROMBCZZFO-IGKWTDBASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12930146,IC50,=,76,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP9),,Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.,J. Med. Chem.,2003,46,18,"Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P",,105365,DTCT0024844,537437,DTCC00304833,1241046,13726
CHEMBL1269994,P14780,,RCTYLDJWEDNGIO-LJQANCHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22342144,KI,>,50000,NM,,,,,,,,,,,,,,Inhibition of MMP-9 using OmniMMP as substrate,,Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain.,Bioorg. Med. Chem. Lett.,2012,22,6,"Jiao GS, Kim S, Moayeri M, Crown D, Thai A, Cregar-Hernandez L, McKasson L, Sankaran B, Lehrer A, Wong T, Johns L, Margosiak SA, Leppla SH, Johnson AT",,811339,DTCT0024844,10427383,DTCC00703250,1719078,47718
CHEMBL127,P14780,MEROPENEM,DMJNNHOOLUXYBV-PQTSNVLCSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7438576,DTCC00154030,51487,46191
CHEMBL127,P14780,MEROPENEM,DMJNNHOOLUXYBV-PQTSNVLCSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7438577,DTCC00154030,51487,46191
CHEMBL127035,P14780,,IHWAKJKUYYZNCF-NDXORKPFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12930146,IC50,=,62,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP9),,Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.,J. Med. Chem.,2003,46,18,"Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P",,105365,DTCT0024844,517914,DTCC00304827,595069,13726
CHEMBL127093,P14780,,DOIKBNWTWCOTKR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,3.8,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1700458,DTCC00302970,2066273,16065
CHEMBL127138,P14780,,XJZZRJAENCZOAK-APTRMMRNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12930146,IC50,=,3.8,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP9),,Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.,J. Med. Chem.,2003,46,18,"Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P",,105365,DTCT0024844,530751,DTCC00304826,1047499,13726
CHEMBL127168,P14780,,GQVFUZHQNCWOMM-SSPYTLHUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12930146,IC50,=,31,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP9),,Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.,J. Med. Chem.,2003,46,18,"Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P",,105365,DTCT0024844,538392,DTCC00304825,1565048,13726
CHEMBL127516,P14780,BUTAMBEN,IUWVALYLNVXWKX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7271561,DTCC00306410,381006,46191
CHEMBL127516,P14780,BUTAMBEN,IUWVALYLNVXWKX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7271562,DTCC00306410,381006,46191
CHEMBL127559,P14780,,AKWUAHDLDRSRDC-MZBJOSPHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12930146,IC50,=,39,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP9),,Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.,J. Med. Chem.,2003,46,18,"Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P",,105365,DTCT0024844,522123,DTCC00304754,724286,13726
CHEMBL1276308,P14780,MIFEPRISTONE,VKHAHZOOUSRJNA-GCNJZUOMSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7419858,DTCC00706050,120974,46191
CHEMBL1276308,P14780,MIFEPRISTONE,VKHAHZOOUSRJNA-GCNJZUOMSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7419859,DTCC00706050,120974,46191
CHEMBL127787,P14780,,IYWLZQLIFMUDCK-MZBJOSPHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12930146,IC50,=,132,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP9),,Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.,J. Med. Chem.,2003,46,18,"Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P",,105365,DTCT0024844,521082,DTCC00304726,498524,13726
CHEMBL127867,P14780,,SPHCUXPEUQITEV-HARLFGEKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12930146,IC50,=,37,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP9),,Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.,J. Med. Chem.,2003,46,18,"Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P",,105365,DTCT0024844,539255,DTCC00304547,530612,13726
CHEMBL128,P14780,SUMATRIPTAN,KQKPFRSPSRPDEB-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7480756,DTCC00154636,671796,46191
CHEMBL128,P14780,SUMATRIPTAN,KQKPFRSPSRPDEB-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7480757,DTCC00154636,671796,46191
CHEMBL1282,P14780,IMIQUIMOD,DOUYETYNHWVLEO-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7306593,DTCC00339893,1927015,46191
CHEMBL1282,P14780,IMIQUIMOD,DOUYETYNHWVLEO-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7306594,DTCC00339893,1927015,46191
CHEMBL12856,P14780,INAMRINONE,RNLQIBCLLYYYFJ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7301087,DTCC00141434,1447876,46191
CHEMBL12856,P14780,INAMRINONE,RNLQIBCLLYYYFJ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7301088,DTCC00141434,1447876,46191
CHEMBL1287851,P14780,,FYZPCUXRTDXRBF-HXUWFJFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21106451,IC50,=,1010,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Novel TNF-a converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases.,Bioorg. Med. Chem. Lett.,2010,20,24,"Girijavallabhan VM, Chen L, Dai C, Feltz RJ, Firmansjah L, Li D, Kim SH, Kozlowski JA, Lavey BJ, Kosinski A, Piwinski JJ, Popovici-Muller J, Rizvi R, Rosner KE, Shankar BB, Shih NY, Siddiqui MA, Tong L, Wong MK, Yang DY, Yang L, Yu W, Zhou G, Guo Z, Orth P, Madison V, Bian H, Lundell D, Niu X, Shah H, Sun J, Umland S",,686068,DTCT0024844,3618672,DTCC00707887,40801,42108
CHEMBL1289,P14780,HALOPROGIN,CTETYYAZBPJBHE-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7306357,DTCC00108442,1512810,46191
CHEMBL1289,P14780,HALOPROGIN,CTETYYAZBPJBHE-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7306358,DTCC00108442,1512810,46191
CHEMBL1289079,P14780,N6-CYCLOBUTYLMETHYLADENOSINE,YXOMSFFSNLTAOQ-SDBHATRESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21035348,ACTIVITY,,,,,cell_based,,,,,,,,,,,,Induction of MMP9 activity in human T24 cells after 1 hr by zymography,Not Active,N6-Alkyladenosines: Synthesis and evaluation of in vitro anticancer activity.,Bioorg. Med. Chem.,2010,18,23,"Ottria R, Casati S, Baldoli E, Maier JA, Ciuffreda P",,687669,DTCT0024844,3605392,DTCC00032744,40834,42024
CHEMBL129,P14780,ZIDOVUDINE,HBOMLICNUCNMMY-XLPZGREQSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7446923,DTCC00154782,51517,46191
CHEMBL129,P14780,ZIDOVUDINE,HBOMLICNUCNMMY-XLPZGREQSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7446924,DTCC00154782,51517,46191
CHEMBL1290747,P14780,N6-ISOPENTYLADENOSINE,AYGMJXUCSYBOMJ-SDBHATRESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21035348,ACTIVITY,,,,,cell_based,,,,,,,,,,,,Induction of MMP9 activity in human T24 cells after 1 hr by zymography,Not Active,N6-Alkyladenosines: Synthesis and evaluation of in vitro anticancer activity.,Bioorg. Med. Chem.,2010,18,23,"Ottria R, Casati S, Baldoli E, Maier JA, Ciuffreda P",,687669,DTCT0024844,3605386,DTCC00032761,1116822,42024
CHEMBL1290748,P14780,N6-BUTYLADENOSINE,YJRFEVRDDAASMO-IDTAVKCVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21035348,ACTIVITY,,,,,cell_based,,,,,,,,,,,,Induction of MMP9 activity in human T24 cells after 1 hr by zymography,Not Active,N6-Alkyladenosines: Synthesis and evaluation of in vitro anticancer activity.,Bioorg. Med. Chem.,2010,18,23,"Ottria R, Casati S, Baldoli E, Maier JA, Ciuffreda P",,687669,DTCT0024844,3605388,DTCC00032762,1952111,42024
CHEMBL1290749,P14780,N6-ALLYLADENOSINE,WTYYPLSFICPDGL-QYVSTXNMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21035348,ACTIVITY,,,,,cell_based,,,,,,,,,,,,Induction of MMP9 activity in human T24 cells after 1 hr by zymography,Not Active,N6-Alkyladenosines: Synthesis and evaluation of in vitro anticancer activity.,Bioorg. Med. Chem.,2010,18,23,"Ottria R, Casati S, Baldoli E, Maier JA, Ciuffreda P",,687669,DTCT0024844,3605390,DTCC00032763,1051627,42024
CHEMBL12948,P14780,SEMUSTINE,FVLVBPDQNARYJU-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7466929,DTCC00141274,1318442,46191
CHEMBL12948,P14780,SEMUSTINE,FVLVBPDQNARYJU-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7466930,DTCC00141274,1318442,46191
CHEMBL1297,P14780,FENOPROFEN,RDJGLLICXDHJDY-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7309528,DTCC00343797,1830685,46191
CHEMBL1297,P14780,FENOPROFEN,RDJGLLICXDHJDY-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7309529,DTCC00343797,1830685,46191
CHEMBL129795,P14780,ISOLIQUIRITIGENIN,DXDRHHKMWQZJHT-FPYGCLRLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21866899,ACTIVITY,=,67,%,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as remaining activity at 100 ug/ml after 4 hrs by fluorimetric analysis relative to control,,"Comparative evaluation of two structurally related flavonoids, isoliquiritigenin and liquiritigenin, for their oral infection therapeutic potential.",J. Nat. Prod.,2011,74,9,"Feldman M, Santos J, Grenier D",,776396,DTCT0024844,7503904,DTCC00306694,1351138,46204
CHEMBL129795,P14780,ISOLIQUIRITIGENIN,DXDRHHKMWQZJHT-FPYGCLRLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21866899,ACTIVITY,=,91,%,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as remaining activity at 25 ug/ml after 4 hrs by fluorimetric analysis relative to control,,"Comparative evaluation of two structurally related flavonoids, isoliquiritigenin and liquiritigenin, for their oral infection therapeutic potential.",J. Nat. Prod.,2011,74,9,"Feldman M, Santos J, Grenier D",,776395,DTCT0024844,7503906,DTCC00306694,1351138,46204
CHEMBL129795,P14780,ISOLIQUIRITIGENIN,DXDRHHKMWQZJHT-FPYGCLRLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21866899,ACTIVITY,=,97,%,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as remaining activity at 5 ug/ml after 4 hrs by fluorimetric analysis relative to control,,"Comparative evaluation of two structurally related flavonoids, isoliquiritigenin and liquiritigenin, for their oral infection therapeutic potential.",J. Nat. Prod.,2011,74,9,"Feldman M, Santos J, Grenier D",,776394,DTCT0024844,7503908,DTCC00306694,1351138,46204
CHEMBL13,P14780,METOPROLOL,IUBSYMUCCVWXPE-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7421822,DTCC00132868,1798412,46191
CHEMBL13,P14780,METOPROLOL,IUBSYMUCCVWXPE-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7421823,DTCC00132868,1798412,46191
CHEMBL130,P14780,CHLORAMPHENICOL,WIIZWVCIJKGZOK-RKDXNWHRSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7347328,DTCC00154805,51455,46191
CHEMBL130,P14780,CHLORAMPHENICOL,WIIZWVCIJKGZOK-RKDXNWHRSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7347329,DTCC00154805,51455,46191
CHEMBL1305393,P14780,N-PHENETHYLCINNAMAMIDE,BOSUEWCVNFFBGV-VAWYXSNFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,8.19,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833591,DTCC00032768,1708382,53968
CHEMBL1306,P14780,TERCONAZOLE,BLSQLHNBWJLIBQ-OZXSUGGESA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7476558,DTCC00347547,1830691,46191
CHEMBL1306,P14780,TERCONAZOLE,BLSQLHNBWJLIBQ-OZXSUGGESA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7476559,DTCC00347547,1830691,46191
CHEMBL1308,P14780,FOMEPIZOLE,RIKMMFOAQPJVMX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7286852,DTCC00348807,1862712,46191
CHEMBL1308,P14780,FOMEPIZOLE,RIKMMFOAQPJVMX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7286853,DTCC00348807,1862712,46191
CHEMBL131,P14780,PREDNISOLONE,OIGNJSKKLXVSLS-VWUMJDOOSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7391948,DTCC00154827,1734061,46191
CHEMBL131,P14780,PREDNISOLONE,OIGNJSKKLXVSLS-VWUMJDOOSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7391949,DTCC00154827,1734061,46191
CHEMBL1319362,P14780,HOMATROPINE HYDROBROMIDE,DWSGTFTVBLXELC-RDYJJYPNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7319189,DTCC00729363,1027054,46191
CHEMBL1319362,P14780,HOMATROPINE HYDROBROMIDE,DWSGTFTVBLXELC-RDYJJYPNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7319190,DTCC00729363,1027054,46191
CHEMBL13209,P14780,NITRAZEPAM,KJONHKAYOJNZEC-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7397040,DTCC00141996,477919,46191
CHEMBL13209,P14780,NITRAZEPAM,KJONHKAYOJNZEC-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7397041,DTCC00141996,477919,46191
CHEMBL1321,P14780,PROCARBAZINE,CPTBDICYNRMXFX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7400697,DTCC00352822,671792,46191
CHEMBL1321,P14780,PROCARBAZINE,CPTBDICYNRMXFX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7400698,DTCC00352822,671792,46191
CHEMBL1321154,P14780,ROXARSONE,XMVJITFPVVRMHC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7457929,DTCC00731018,542582,46191
CHEMBL1321154,P14780,ROXARSONE,XMVJITFPVVRMHC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7457930,DTCC00731018,542582,46191
CHEMBL132928,P14780,,UIQCNEYBEDSLMK-UNMCSNQZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643313,KI,>,2128,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105546,DTCT0024844,1038168,DTCC00318186,109128,6011
CHEMBL133028,P14780,,RNWQPFKNMGJQAE-OZXSUGGESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643313,KI,>,2128,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105546,DTCT0024844,1025786,DTCC00318196,1818903,6011
CHEMBL1330588,P14780,METHYLTHIOURACIL,HWGBHCRJGXAGEU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,27,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103356,DTCC00739824,896233,43205
CHEMBL133259,P14780,,HMHMTFRLVFSEQY-DQEYMECFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643313,KI,>,2128,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105546,DTCT0024844,1024630,DTCC00317771,1630030,6011
CHEMBL133314,P14780,,VUYBRUBUOZYSQS-FSSWDIPSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11708926,IC50,=,379,NM,,,,,,,,,,,,,,Inhibition potency was determined by fluorescence-based peptide assay against matrix metalloprotease-9,,Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,J. Med. Chem.,2001,44,24,"Rabinowitz MH, Andrews RC, Becherer JD, Bickett DM, Bubacz DG, Conway JG, Cowan DJ, Gaul M, Glennon K, Lambert MH, Leesnitzer MA, McDougald DL, Moss ML, Musso DL, Rizzolio MC",,105523,DTCT0024844,1258561,DTCC00317457,357423,16522
CHEMBL1333512,P14780,"N,N'-DIPHENYL-P-PHENYLENEDIAMINE",UTGQNNCQYDRXCH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7424361,DTCC00742601,1155682,46191
CHEMBL1333512,P14780,"N,N'-DIPHENYL-P-PHENYLENEDIAMINE",UTGQNNCQYDRXCH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7424362,DTCC00742601,1155682,46191
CHEMBL133369,P14780,,JERYKMOBMXUTFQ-AABGKKOBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11708926,IC50,=,43,NM,,,,,,,,,,,,,,Inhibition potency was determined by fluorescence-based peptide assay against matrix metalloprotease-9,,Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,J. Med. Chem.,2001,44,24,"Rabinowitz MH, Andrews RC, Becherer JD, Bickett DM, Bubacz DG, Conway JG, Cowan DJ, Gaul M, Glennon K, Lambert MH, Leesnitzer MA, McDougald DL, Moss ML, Musso DL, Rizzolio MC",,105523,DTCT0024844,1268067,DTCC00317456,583574,16522
CHEMBL13341,P14780,NIMETAZEPAM,GWUSZQUVEVMBPI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7384129,DTCC00141962,606971,46191
CHEMBL13341,P14780,NIMETAZEPAM,GWUSZQUVEVMBPI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7384130,DTCC00141962,606971,46191
CHEMBL13378,P14780,"(R,S)-AMPA",UUDAMDVQRQNNHZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7286430,DTCC00141891,1220272,46191
CHEMBL13378,P14780,"(R,S)-AMPA",UUDAMDVQRQNNHZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7286431,DTCC00141891,1220272,46191
CHEMBL134,P14780,CLONIDINE,GJSURZIOUXUGAL-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7341604,DTCC00155022,51459,46191
CHEMBL134,P14780,CLONIDINE,GJSURZIOUXUGAL-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7341605,DTCC00155022,51459,46191
CHEMBL134342,P14780,LIPOIC ACID,AGBQKNBQESQNJD-SSDOTTSWSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7487504,DTCC00318217,1220281,46191
CHEMBL134342,P14780,LIPOIC ACID,AGBQKNBQESQNJD-SSDOTTSWSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7487505,DTCC00318217,1220281,46191
CHEMBL134640,P14780,,DTKRCIBCJDXQMT-FPOVZHCZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643313,KI,>,2128,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105546,DTCT0024844,1024617,DTCC00318261,1723887,6011
CHEMBL134782,P14780,,WKVGPQBRJBFDSN-ZEQRLZLVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643313,KI,>,2128,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105546,DTCT0024844,1024637,DTCC00318183,1786352,6011
CHEMBL134849,P14780,,JLPMPXKOGZSSRK-SQNIBIBYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11708926,IC50,=,49,NM,,,,,,,,,,,,,,Inhibition potency was determined by fluorescence-based peptide assay against matrix metalloprotease-9,,Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,J. Med. Chem.,2001,44,24,"Rabinowitz MH, Andrews RC, Becherer JD, Bickett DM, Bubacz DG, Conway JG, Cowan DJ, Gaul M, Glennon K, Lambert MH, Leesnitzer MA, McDougald DL, Moss ML, Musso DL, Rizzolio MC",,105523,DTCT0024844,1262172,DTCC00317832,1774765,16522
CHEMBL1349,P14780,VALACYCLOVIR,HDOVUKNUBWVHOX-QMMMGPOBSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7453096,DTCC00378678,930089,46191
CHEMBL1349,P14780,VALACYCLOVIR,HDOVUKNUBWVHOX-QMMMGPOBSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7453097,DTCC00378678,930089,46191
CHEMBL134908,P14780,IM-491,RJSKOAOWDAMMHR-GMAHTHKFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643313,KI,>,2128,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105546,DTCT0024844,1017094,DTCC01743223,1015228,6011
CHEMBL135,P14780,ESTRADIOL,VOXZDWNPVJITMN-ZBRFXRBCSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7265810,DTCC00155036,51448,46191
CHEMBL135,P14780,ESTRADIOL,VOXZDWNPVJITMN-ZBRFXRBCSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7265811,DTCC00155036,51448,46191
CHEMBL1350,P14780,TILUDRONIC ACID,DKJJVAGXPKPDRL-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24071448,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain (unknown origin) using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured after 2 to 4 hrs by fluorometric assay,,Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.,Bioorg. Med. Chem.,2013,21,21,"Tauro M, Laghezza A, Loiodice F, Agamennone M, Campestre C, Tortorella P",,990168,DTCT0024844,12629019,DTCC00380285,609949,56259
CHEMBL135034,P14780,,MQLHBSAEUUVJRX-BDXSIMOUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11708926,IC50,=,12,NM,,,,,,,,,,,,,,Inhibition potency was determined by fluorescence-based peptide assay against matrix metalloprotease-9,,Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,J. Med. Chem.,2001,44,24,"Rabinowitz MH, Andrews RC, Becherer JD, Bickett DM, Bubacz DG, Conway JG, Cowan DJ, Gaul M, Glennon K, Lambert MH, Leesnitzer MA, McDougald DL, Moss ML, Musso DL, Rizzolio MC",,105523,DTCT0024844,1280317,DTCC00317167,842336,16522
CHEMBL135075,P14780,,JEFVBTZAXMPPTH-SQNIBIBYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11708926,IC50,=,190,NM,,,,,,,,,,,,,,Inhibition potency was determined by fluorescence-based peptide assay against matrix metalloprotease-9,,Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,J. Med. Chem.,2001,44,24,"Rabinowitz MH, Andrews RC, Becherer JD, Bickett DM, Bubacz DG, Conway JG, Cowan DJ, Gaul M, Glennon K, Lambert MH, Leesnitzer MA, McDougald DL, Moss ML, Musso DL, Rizzolio MC",,105523,DTCT0024844,1281519,DTCC00317266,551473,16522
CHEMBL1351,P14780,CARBOPLATIN,OLESAACUTLOWQZ-UHFFFAOYSA-L,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7355732,DTCC00380917,1480344,46191
CHEMBL1351,P14780,CARBOPLATIN,OLESAACUTLOWQZ-UHFFFAOYSA-L,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7355733,DTCC00380917,1480344,46191
CHEMBL135177,P14780,,JFZMYYGJKATRJG-VXKWHMMOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643312,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 1: lead identification.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105545,DTCT0024844,496344,DTCC00318325,939099,6009
CHEMBL135251,P14780,,VNCIHKLPBWTDIP-PBDJWPIDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11708926,IC50,=,35,NM,,,,,,,,,,,,,,Inhibition potency was determined by fluorescence-based peptide assay against matrix metalloprotease-9,,Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,J. Med. Chem.,2001,44,24,"Rabinowitz MH, Andrews RC, Becherer JD, Bickett DM, Bubacz DG, Conway JG, Cowan DJ, Gaul M, Glennon K, Lambert MH, Leesnitzer MA, McDougald DL, Moss ML, Musso DL, Rizzolio MC",,105523,DTCT0024844,1250394,DTCC00317233,551474,16522
CHEMBL135499,P14780,,XKFUMWBMSCFOSW-ZEQRLZLVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643313,KI,>,2128,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105546,DTCT0024844,1044370,DTCC00318657,1662237,6011
CHEMBL135590,P14780,,HUBNMJYLBBXLHV-BARDWOONSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11708926,IC50,=,19,NM,,,,,,,,,,,,,,Inhibition potency was determined by fluorescence-based peptide assay against matrix metalloprotease-9,,Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,J. Med. Chem.,2001,44,24,"Rabinowitz MH, Andrews RC, Becherer JD, Bickett DM, Bubacz DG, Conway JG, Cowan DJ, Gaul M, Glennon K, Lambert MH, Leesnitzer MA, McDougald DL, Moss ML, Musso DL, Rizzolio MC",,105523,DTCT0024844,1274750,DTCC00317635,874877,16522
CHEMBL135696,P14780,,CTQQHSLVVFZJEY-OALUTQOASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643312,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 1: lead identification.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105545,DTCT0024844,498819,DTCC00318328,1650827,6009
CHEMBL135696,P14780,,CTQQHSLVVFZJEY-OALUTQOASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643313,KI,>,2128,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105546,DTCT0024844,1033004,DTCC00318328,1662236,6011
CHEMBL135766,P14780,,KCZGFJPNYDYQHF-UNMCSNQZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643313,KI,>,2128,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105546,DTCT0024844,1022177,DTCC00317823,982926,6011
CHEMBL135783,P14780,,QUEIBYWBRFSDLX-QXSJWSMHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11708926,IC50,=,8.5,NM,,,,,,,,,,,,,,Inhibition potency was determined by fluorescence-based peptide assay against matrix metalloprotease-9,,Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,J. Med. Chem.,2001,44,24,"Rabinowitz MH, Andrews RC, Becherer JD, Bickett DM, Bubacz DG, Conway JG, Cowan DJ, Gaul M, Glennon K, Lambert MH, Leesnitzer MA, McDougald DL, Moss ML, Musso DL, Rizzolio MC",,105523,DTCT0024844,1273686,DTCC00317321,1903974,16522
CHEMBL135886,P14780,,YBQLENDMILTZBB-IKGGRYGDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11708926,IC50,=,22,NM,,,,,,,,,,,,,,Inhibition potency was determined by fluorescence-based peptide assay against matrix metalloprotease-9,,Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,J. Med. Chem.,2001,44,24,"Rabinowitz MH, Andrews RC, Becherer JD, Bickett DM, Bubacz DG, Conway JG, Cowan DJ, Gaul M, Glennon K, Lambert MH, Leesnitzer MA, McDougald DL, Moss ML, Musso DL, Rizzolio MC",,105523,DTCT0024844,1252550,DTCC00317762,1164665,16522
CHEMBL135931,P14780,,HZRAYMWLJLWNAA-QYZOEREBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11708926,IC50,=,602,NM,,,,,,,,,,,,,,Inhibition potency was determined by fluorescence-based peptide assay against matrix metalloprotease-9,,Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,J. Med. Chem.,2001,44,24,"Rabinowitz MH, Andrews RC, Becherer JD, Bickett DM, Bubacz DG, Conway JG, Cowan DJ, Gaul M, Glennon K, Lambert MH, Leesnitzer MA, McDougald DL, Moss ML, Musso DL, Rizzolio MC",,105523,DTCT0024844,1265783,DTCC00317627,712874,16522
CHEMBL135983,P14780,,UBBKFTZMBAKVDC-OSBIAPMOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11708926,IC50,=,71,NM,,,,,,,,,,,,,,Inhibition potency was determined by fluorescence-based peptide assay against matrix metalloprotease-9,,Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,J. Med. Chem.,2001,44,24,"Rabinowitz MH, Andrews RC, Becherer JD, Bickett DM, Bubacz DG, Conway JG, Cowan DJ, Gaul M, Glennon K, Lambert MH, Leesnitzer MA, McDougald DL, Moss ML, Musso DL, Rizzolio MC",,105523,DTCT0024844,1281525,DTCC00317483,1294774,16522
CHEMBL136353,P14780,,RFVBJRNTFIODDG-GMAHTHKFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643313,KI,>,2128,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105546,DTCT0024844,1018278,DTCC00318993,1851030,6011
CHEMBL136478,P14780,SODIUM NITROPRUSSIDE,,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7462636,DTCC00320064,1155687,46191
CHEMBL136478,P14780,SODIUM NITROPRUSSIDE,,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7462637,DTCC00320064,1155687,46191
CHEMBL1365675,P14780,AMITRAZ,QXAITBQSYVNQDR-ZIOPAAQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7295442,DTCC00772476,1027047,46191
CHEMBL1365675,P14780,AMITRAZ,QXAITBQSYVNQDR-ZIOPAAQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7295443,DTCC00772476,1027047,46191
CHEMBL1366,P14780,AURANOFIN,,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7275092,DTCC00388917,833156,46191
CHEMBL1366,P14780,AURANOFIN,,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7275093,DTCC00388917,833156,46191
CHEMBL1368601,P14780,,UHBIKXOBLZWFKM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,68,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103717,DTCC00775206,734154,43205
CHEMBL137,P14780,METRONIDAZOLE,VAOCPAMSLUNLGC-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7426105,DTCC00155250,51489,46191
CHEMBL137,P14780,METRONIDAZOLE,VAOCPAMSLUNLGC-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7426106,DTCC00155250,51489,46191
CHEMBL1370,P14780,BUDESONIDE,VOVIALXJUBGFJZ-KWVAZRHASA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,1989,NM,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7277339,DTCC00392952,898284,46191
CHEMBL1370,P14780,BUDESONIDE,VOVIALXJUBGFJZ-KWVAZRHASA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Note: corresponding IC50 reported as Active,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7277340,DTCC00392952,898284,46191
CHEMBL137013,P14780,,ZNCOVHFRMJEGMK-ZEQRLZLVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643313,KI,>,2128,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105546,DTCT0024844,1039506,DTCC00318972,1371830,6011
CHEMBL1370561,P14780,AMINOPHYLLINE,FQPFAHBPWDRTLU-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7283100,DTCC00777070,1383772,46191
CHEMBL1370561,P14780,AMINOPHYLLINE,FQPFAHBPWDRTLU-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7283101,DTCC00777070,1383772,46191
CHEMBL137065,P14780,,BPBXDIWULCWTST-ZEQRLZLVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643313,KI,=,366,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105546,DTCT0024844,1027094,DTCC00319115,2045980,6011
CHEMBL1371,P14780,CHLORZOXAZONE,TZFWDZFKRBELIQ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7351679,DTCC00394427,1992801,46191
CHEMBL1371,P14780,CHLORZOXAZONE,TZFWDZFKRBELIQ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7351680,DTCC00394427,1992801,46191
CHEMBL1371125,P14780,BENZO[E]PYRENE,TXVHTIQJNYSSKO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7267056,DTCC00777599,2025635,46191
CHEMBL1371125,P14780,BENZO[E]PYRENE,TXVHTIQJNYSSKO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7267057,DTCC00777599,2025635,46191
CHEMBL1371684,P14780,,SEZPRMPVJMVCBV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22018790,INHIBITION,=,7,%,,,,,,,,,,,,,,Inhibition of recombinant MMP9 using triple-helical fTHP-15 as substrate at 40 uM after 4 hrs by FRET assay,,"Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.",Bioorg. Med. Chem. Lett.,2011,21,23,"Roth J, Minond D, Darout E, Liu Q, Lauer J, Hodder P, Fields GB, Roush WR",,799265,DTCT0024844,7596113,DTCC00778134,283182,47025
CHEMBL1371684,P14780,,SEZPRMPVJMVCBV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25330343,INHIBITION,>,10,%,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 using GRIGFL substrate up to 20 uM,,Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.,J. Med. Chem.,2014,57,22,"Spicer TP, Jiang J, Taylor AB, Choi JY, Hart PJ, Roush WR, Fields GB, Hodder PS, Minond D",,1435007,DTCT0024844,14018302,DTCC00778134,266421,60192
CHEMBL1371937,P14780,PANTHENOL,SNPLKNRPJHDVJA-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7397573,DTCC00778371,1059337,46191
CHEMBL1371937,P14780,PANTHENOL,SNPLKNRPJHDVJA-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7397574,DTCC00778371,1059337,46191
CHEMBL1372,P14780,OXIGLUTATIONE,YPZRWBKMTBYPTK-BJDJZHNGSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7333742,DTCC00395874,898290,46191
CHEMBL1372,P14780,OXIGLUTATIONE,YPZRWBKMTBYPTK-BJDJZHNGSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7333743,DTCC00395874,898290,46191
CHEMBL137297,P14780,,VVYSJNRLNVGHLZ-SFTDATJTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643313,KI,>,2128,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105546,DTCT0024844,1020897,DTCC00318978,109127,6011
CHEMBL1373,P14780,MODAFINIL,YFGHCGITMMYXAQ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7415690,DTCC00396162,1512812,46191
CHEMBL1373,P14780,MODAFINIL,YFGHCGITMMYXAQ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7415691,DTCC00396162,1512812,46191
CHEMBL137315,P14780,,XXYKPFAJBJFQQP-VXKWHMMOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643313,KI,>,2128,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105546,DTCT0024844,1028418,DTCC00318846,141536,6011
CHEMBL137323,P14780,,AOAODEKDRRDLGQ-DQEYMECFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643313,KI,=,296,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105546,DTCT0024844,1031992,DTCC00318979,1145156,6011
CHEMBL137365,P14780,,DQLBBYKDXWLUIC-ZEQRLZLVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643313,KI,=,209,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105546,DTCT0024844,1024622,DTCC00318937,854058,6011
CHEMBL137383,P14780,,KVBHIVSGXGLJKE-ZEQRLZLVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643313,KI,=,252,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105546,DTCT0024844,1022182,DTCC00319054,369188,6011
CHEMBL137406,P14780,,PYZZBYJLLRVFDM-OALUTQOASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643312,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 1: lead identification.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105545,DTCT0024844,486622,DTCC00318806,1327341,6009
CHEMBL137646,P14780,,BZSVSBCWCXTKOM-SFTDATJTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643313,KI,>,2128,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105546,DTCT0024844,1029543,DTCC00319385,109126,6011
CHEMBL13766,P14780,GUAIACOL,LHGVFZTZFXWLCP-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,-6,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103132,DTCC00143437,798492,43205
CHEMBL137703,P14780,,QOGHJMHAONXOFF-ZEQRLZLVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643313,KI,>,2128,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105546,DTCT0024844,1030750,DTCC00319034,756588,6011
CHEMBL137732,P14780,,RETDRIUBVHKDAA-VXKWHMMOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643313,KI,=,767,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105546,DTCT0024844,1029538,DTCC00319086,692161,6011
CHEMBL1381098,P14780,1-NAPHTHYLISOTHIOCYANATE,JBDOSUUXMYMWQH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7286511,DTCC00786869,866013,46191
CHEMBL1381098,P14780,1-NAPHTHYLISOTHIOCYANATE,JBDOSUUXMYMWQH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7286512,DTCC00786869,866013,46191
CHEMBL13826,P14780,,ZVSMTZWKNHRQHX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14980648,IC50,=,1000,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,New heteroarylbenzenesulphonamides as matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,5,"Delbecq F, Cordonnier G, Pommery N, Barbry D, Hénichart JP",,105506,DTCT0024844,764375,DTCC00143020,1837727,6676
CHEMBL1384,P14780,KANAMYCIN,SBUJHOSQTJFQJX-NOAMYHISSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7422644,DTCC00402979,51482,46191
CHEMBL1384,P14780,KANAMYCIN,SBUJHOSQTJFQJX-NOAMYHISSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7422645,DTCC00402979,51482,46191
CHEMBL13849,P14780,,GUXHGWLTAOJOHK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14980648,IC50,,,,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (No data),Not Determined,New heteroarylbenzenesulphonamides as matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,5,"Delbecq F, Cordonnier G, Pommery N, Barbry D, Hénichart JP",,105507,DTCT0024844,757992,DTCC00103659,256946,6676
CHEMBL1385840,P14780,ERGOCORNINE,UJYGDMFEEDNVBF-OGGGUQDZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7323992,DTCC00791188,444641,46191
CHEMBL1385840,P14780,ERGOCORNINE,UJYGDMFEEDNVBF-OGGGUQDZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7323993,DTCC00791188,444641,46191
CHEMBL138594,P14780,,STALJGVVURZIBK-DQEYMECFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643313,KI,>,2128,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105546,DTCT0024844,1019670,DTCC00319390,1883178,6011
CHEMBL1386,P14780,TRANSPLATIN,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7449819,DTCC00405544,315673,46191
CHEMBL1386,P14780,TRANSPLATIN,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7449820,DTCC00405544,315673,46191
CHEMBL1388,P14780,MONOBENZONE,VYQNWZOUAUKGHI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7419978,DTCC00405603,833163,46191
CHEMBL1388,P14780,MONOBENZONE,VYQNWZOUAUKGHI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7419979,DTCC00405603,833163,46191
CHEMBL139,P14780,DICLOFENAC,DCOPUUMXTXDBNB-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7342431,DTCC00156996,1220275,46191
CHEMBL139,P14780,DICLOFENAC,DCOPUUMXTXDBNB-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7342432,DTCC00156996,1220275,46191
CHEMBL13927,P14780,,SOGUXTBLQCIBBA-MZYLBHOOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14980648,IC50,=,200,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,New heteroarylbenzenesulphonamides as matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,5,"Delbecq F, Cordonnier G, Pommery N, Barbry D, Hénichart JP",,105506,DTCT0024844,768328,DTCC00142930,1227361,6676
CHEMBL1393,P14780,SPIRONOLACTONE,LXMSZDCAJNLERA-ZHYRCANASA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7456245,DTCC00405635,1512816,46191
CHEMBL1393,P14780,SPIRONOLACTONE,LXMSZDCAJNLERA-ZHYRCANASA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7456246,DTCC00405635,1512816,46191
CHEMBL1395,P14780,METHYLTESTOSTERONE,GCKMFJBGXUYNAG-HLXURNFRSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7297291,DTCC00405823,1798403,46191
CHEMBL1395,P14780,METHYLTESTOSTERONE,GCKMFJBGXUYNAG-HLXURNFRSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7297292,DTCC00405823,1798403,46191
CHEMBL13965,P14780,,BDLOAWYPUGHWAJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14980648,IC50,=,50,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,New heteroarylbenzenesulphonamides as matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,5,"Delbecq F, Cordonnier G, Pommery N, Barbry D, Hénichart JP",,105506,DTCT0024844,750494,DTCC00142990,905349,6676
CHEMBL13974,P14780,,PTDAGIOFVRAOTJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14980648,IC50,=,900,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,New heteroarylbenzenesulphonamides as matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,5,"Delbecq F, Cordonnier G, Pommery N, Barbry D, Hénichart JP",,105506,DTCT0024844,767138,DTCC00142959,1999866,6676
CHEMBL139835,P14780,CYPROTERONE ACETATE,UWFYSQMTEOIJJG-FDTZYFLXSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7339816,DTCC00327558,153442,46191
CHEMBL139835,P14780,CYPROTERONE ACETATE,UWFYSQMTEOIJJG-FDTZYFLXSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7339817,DTCC00327558,153442,46191
CHEMBL1399,P14780,ANASTROZOLE,YBBLVLTVTVSKRW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7286203,DTCC00413581,1992800,46191
CHEMBL1399,P14780,ANASTROZOLE,YBBLVLTVTVSKRW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7286204,DTCC00413581,1992800,46191
CHEMBL14,P14780,CARBACHOL,AIXAANGOTKPUOY-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7259164,DTCC00132960,1862714,46191
CHEMBL14,P14780,CARBACHOL,AIXAANGOTKPUOY-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7259165,DTCC00132960,1862714,46191
CHEMBL1400945,P14780,PREGNENOLONE CARBONITRILE ,VSBHRRMYCDQLJF-ZDNYCOCVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7400552,DTCC00805254,1220279,46191
CHEMBL1400945,P14780,PREGNENOLONE CARBONITRILE ,VSBHRRMYCDQLJF-ZDNYCOCVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7400553,DTCC00805254,1220279,46191
CHEMBL140152,P14780,,TVNINFNNQVBJHI-AWEZNQCLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10579818,IC50,=,0.5,NM,,,,,,,,,,,,,,Inhibition of gelatinase-B (Matrix metalloprotease-9),,"Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.",J. Med. Chem.,1999,42,22,"Almstead NG, Bradley RS, Pikul S, De B, Natchus MG, Taiwo YO, Gu F, Williams LE, Hynd BA, Janusz MJ, Dunaway CM, Mieling GE",,105226,DTCT0024844,1390649,DTCC00326357,1080274,15412
CHEMBL1403281,P14780,ERGOCRYPTINE,YDOTUXAWKBPQJW-NSLWYYNWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7295092,DTCC00807428,381005,46191
CHEMBL1403281,P14780,ERGOCRYPTINE,YDOTUXAWKBPQJW-NSLWYYNWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7295093,DTCC00807428,381005,46191
CHEMBL1405,P14780,ESTRONE,DNXHEGUUPJUMQT-CBZIJGRNSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7319824,DTCC00418600,606969,46191
CHEMBL1405,P14780,ESTRONE,DNXHEGUUPJUMQT-CBZIJGRNSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7319825,DTCC00418600,606969,46191
CHEMBL14053,P14780,TRICHLOROACETIC ACID,YNJBWRMUSHSURL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7451794,DTCC00143400,444644,46191
CHEMBL14053,P14780,TRICHLOROACETIC ACID,YNJBWRMUSHSURL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7451795,DTCC00143400,444644,46191
CHEMBL14060,P14780,PHENOL,ISWSIDIOOBJBQZ-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7389341,DTCC00143418,413974,46191
CHEMBL14060,P14780,PHENOL,ISWSIDIOOBJBQZ-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7389342,DTCC00143418,413974,46191
CHEMBL140970,P14780,,CYYCSKFJEOSZTF-ZDUSSCGKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10579818,IC50,=,1.9,NM,,,,,,,,,,,,,,Inhibition of gelatinase-B (Matrix metalloprotease-9),,"Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.",J. Med. Chem.,1999,42,22,"Almstead NG, Bradley RS, Pikul S, De B, Natchus MG, Taiwo YO, Gu F, Williams LE, Hynd BA, Janusz MJ, Dunaway CM, Mieling GE",,105226,DTCT0024844,1385757,DTCC00325595,692228,15412
CHEMBL141,P14780,LAMIVUDINE,JTEGQNOMFQHVDC-NKWVEPMBSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7407888,DTCC00160169,51484,46191
CHEMBL141,P14780,LAMIVUDINE,JTEGQNOMFQHVDC-NKWVEPMBSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7407889,DTCC00160169,51484,46191
CHEMBL141080,P14780,,ULILDPSFFUSXJH-LBPRGKRZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10579818,IC50,=,0.9,NM,,,,,,,,,,,,,,Inhibition of gelatinase-B (Matrix metalloprotease-9),,"Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.",J. Med. Chem.,1999,42,22,"Almstead NG, Bradley RS, Pikul S, De B, Natchus MG, Taiwo YO, Gu F, Williams LE, Hynd BA, Janusz MJ, Dunaway CM, Mieling GE",,105226,DTCT0024844,1401848,DTCC00108095,821220,15412
CHEMBL1411979,P14780,METHAPYRILENE,HNJJXZKZRAWDPF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7425865,DTCC00815629,153445,46191
CHEMBL1411979,P14780,METHAPYRILENE,HNJJXZKZRAWDPF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7425866,DTCC00815629,153445,46191
CHEMBL1413,P14780,CICLOPIROX,SCKYRAXSEDYPSA-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7343261,DTCC00427786,1416026,46191
CHEMBL1413,P14780,CICLOPIROX,SCKYRAXSEDYPSA-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7343262,DTCC00427786,1416026,46191
CHEMBL141343,P14780,U-78517F,KPZQRBACZSLMPH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7447506,DTCC01743360,671797,46191
CHEMBL141343,P14780,U-78517F,KPZQRBACZSLMPH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7447507,DTCC01743360,671797,46191
CHEMBL1419,P14780,SIBUTRAMINE,UNAANXDKBXWMLN-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7475634,DTCC00432414,1765981,46191
CHEMBL1419,P14780,SIBUTRAMINE,UNAANXDKBXWMLN-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7475635,DTCC00432414,1765981,46191
CHEMBL14192,P14780,BENZYLIMIDAZOLE,KKKDZZRICRFGSD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7283578,DTCC00143373,381004,46191
CHEMBL14192,P14780,BENZYLIMIDAZOLE,KKKDZZRICRFGSD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7283579,DTCC00143373,381004,46191
CHEMBL1425,P14780,MERCAPTOPURINE,GLVAUDGFNGKCSF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7300366,DTCC00110799,51440,46191
CHEMBL1425,P14780,MERCAPTOPURINE,GLVAUDGFNGKCSF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7300367,DTCC00110799,51440,46191
CHEMBL1427458,P14780,,KUELMQAVLKNHFA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21669521,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Selective non zinc binding inhibitors of MMP13.,Bioorg. Med. Chem. Lett.,2011,21,14,"De Savi C, Morley AD, Ting A, Nash I, Karabelas K, Wood CM, James M, Norris SJ, Karoutchi G, Rankine N, Hamlin G, Macfaul PA, Ryan D, Baker SV, Hargreaves D, Gerhardt S",,754263,DTCT0024844,5996237,DTCC00829882,605884,45042
CHEMBL1427477,P14780,QUINOLINE-8-CARBOXYLIC ACID,QRDZFPUVLYEQTA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,31,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103904,DTCC00032919,86518,43205
CHEMBL1428,P14780,NIMODIPINE,UIAGMCDKSXEBJQ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7388484,DTCC00437760,930083,46191
CHEMBL1428,P14780,NIMODIPINE,UIAGMCDKSXEBJQ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7388485,DTCC00437760,930083,46191
CHEMBL1430,P14780,PENICILLAMINE,VVNCNSJFMMFHPL-VKHMYHEASA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7402034,DTCC00441311,898294,46191
CHEMBL1430,P14780,PENICILLAMINE,VVNCNSJFMMFHPL-VKHMYHEASA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7402035,DTCC00441311,898294,46191
CHEMBL1431,P14780,METFORMIN,XZWYZXLIPXDOLR-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7421606,DTCC00441526,1318443,46191
CHEMBL1431,P14780,METFORMIN,XZWYZXLIPXDOLR-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7421607,DTCC00441526,1318443,46191
CHEMBL1432,P14780,"2,3-DIHYDROXYBENZOIC ACID",GLDQAMYCGOIJDV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,11,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103148,DTCC00442073,540482,43205
CHEMBL1433,P14780,DOXYCYCLINE,JBIWCJUYHHGXTC-AKNGSSGZSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19375915,INHIBITION,,,,,cell_based,,,,,,,,,,,,Inhibition of MMP9 gelatinolytic activity in human HT1080 cells at upto 60 ug/ml by gelatin zymography relative to control,Not Active,The inhibitory mechanism of a novel cationic glucosamine derivative against MMP-2 and MMP-9 expressions.,Bioorg. Med. Chem. Lett.,2009,19,10,"Mendis E, Kim MM, Rajapakse N, Kim SK",,578144,DTCT0024844,2884711,DTCC00443319,371915,34969
CHEMBL1433,P14780,DOXYCYCLINE,JBIWCJUYHHGXTC-AKNGSSGZSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7330218,DTCC00443319,381009,46191
CHEMBL1433,P14780,DOXYCYCLINE,JBIWCJUYHHGXTC-AKNGSSGZSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7330219,DTCC00443319,381009,46191
CHEMBL143451,P14780,,FLJLPPYUZKFFLM-CMJOXMDJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12408705,KI,>,2000,NM,,,,,,,,,,,,,,Affinity towards Matrix metalloprotease-9 (MMP-9),,"Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.",J. Med. Chem.,2002,45,23,"Duan JJ, Chen L, Wasserman ZR, Lu Z, Liu RQ, Covington MB, Qian M, Hardman KD, Magolda RL, Newton RC, Christ DD, Wexler RR, Decicco CP",,105374,DTCT0024844,726190,DTCC00333147,756748,17028
CHEMBL1440,P14780,TETRACYCLINE,OFVLGDICTFRJMM-WESIUVDSSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7457124,DTCC00445351,51511,46191
CHEMBL1440,P14780,TETRACYCLINE,OFVLGDICTFRJMM-WESIUVDSSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7457125,DTCC00445351,51511,46191
CHEMBL144049,P14780,,ADBJQPXZUYOOEQ-VLIAUNLRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12408705,KI,<,2.1,NM,,,,,,,,,,,,,,Affinity towards Matrix metalloprotease-9 (MMP-9),,"Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.",J. Med. Chem.,2002,45,23,"Duan JJ, Chen L, Wasserman ZR, Lu Z, Liu RQ, Covington MB, Qian M, Hardman KD, Magolda RL, Newton RC, Christ DD, Wexler RR, Decicco CP",,105374,DTCT0024844,699734,DTCC00333594,1176449,17028
CHEMBL144081,P14780,,UGIVRDOCHMXQLW-SZNDQCEHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12408705,KI,=,66,NM,,,,,,,,,,,,,,Affinity towards Matrix metalloprotease-9 (MMP-9),,"Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.",J. Med. Chem.,2002,45,23,"Duan JJ, Chen L, Wasserman ZR, Lu Z, Liu RQ, Covington MB, Qian M, Hardman KD, Magolda RL, Newton RC, Christ DD, Wexler RR, Decicco CP",,105374,DTCT0024844,700977,DTCC00333593,1565398,17028
CHEMBL144320,P14780,,WTYPBULLPNGNTN-ASSNKEHSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12408705,KI,>,2000,NM,,,,,,,,,,,,,,Affinity towards Matrix metalloprotease-9 (MMP-9),,"Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.",J. Med. Chem.,2002,45,23,"Duan JJ, Chen L, Wasserman ZR, Lu Z, Liu RQ, Covington MB, Qian M, Hardman KD, Magolda RL, Newton RC, Christ DD, Wexler RR, Decicco CP",,105374,DTCT0024844,722686,DTCC00333146,1786527,17028
CHEMBL1444,P14780,LETROZOLE,HPJKCIUCZWXJDR-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7433673,DTCC00445802,1285878,46191
CHEMBL1444,P14780,LETROZOLE,HPJKCIUCZWXJDR-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7433674,DTCC00445802,1285878,46191
CHEMBL144548,P14780,,AHGKFZKBVGBMPT-HXOBKFHXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12408705,KI,=,1634,NM,,,,,,,,,,,,,,Affinity towards Matrix metalloprotease-9 (MMP-9),,"Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.",J. Med. Chem.,2002,45,23,"Duan JJ, Chen L, Wasserman ZR, Lu Z, Liu RQ, Covington MB, Qian M, Hardman KD, Magolda RL, Newton RC, Christ DD, Wexler RR, Decicco CP",,105374,DTCT0024844,723896,DTCC00333182,2046153,17028
CHEMBL1447,P14780,LINCOMYCIN,OJMMVQQUTAEWLP-KIDUDLJLSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7408153,DTCC00448831,1059331,46191
CHEMBL1447,P14780,LINCOMYCIN,OJMMVQQUTAEWLP-KIDUDLJLSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7408154,DTCC00448831,1059331,46191
CHEMBL145,P14780,CAFFEIC ACID,QAIPRVGONGVQAS-DUXPYHPUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,10,NM,,cell_based,,,,,,,,,,,,Inhibition of MMP9 in human Hep3B cells using gelatin as substrate,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948147,DTCT0024844,11833431,DTCC00163351,2060256,53968
CHEMBL145,P14780,CAFFEIC ACID,QAIPRVGONGVQAS-DUXPYHPUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,21.22,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833428,DTCC00163351,2060256,53968
CHEMBL1451,P14780,TRIAMCINOLONE,GFNANZIMVAIWHM-OBYCQNJPSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7442770,DTCC00451754,1512818,46191
CHEMBL1451,P14780,TRIAMCINOLONE,GFNANZIMVAIWHM-OBYCQNJPSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7442771,DTCC00451754,1512818,46191
CHEMBL1454,P14780,LEVAMISOLE,HLFSDGLLUJUHTE-SNVBAGLBSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7408023,DTCC00454681,1927017,46191
CHEMBL1454,P14780,LEVAMISOLE,HLFSDGLLUJUHTE-SNVBAGLBSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7408024,DTCC00454681,1927017,46191
CHEMBL1454946,P14780,FLUBENDAZOLE,CPEUVMUXAHMANV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7335217,DTCC00855742,51469,46191
CHEMBL1454946,P14780,FLUBENDAZOLE,CPEUVMUXAHMANV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7335218,DTCC00855742,51469,46191
CHEMBL1455,P14780,ALTRETAMINE,UUVWYPNAQBNQJQ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7282975,DTCC00455954,800569,46191
CHEMBL1455,P14780,ALTRETAMINE,UUVWYPNAQBNQJQ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7282976,DTCC00455954,800569,46191
CHEMBL1456,P14780,MYCOPHENOLATE MOFETIL,RTGDFNSFWBGLEC-SYZQJQIISA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7437028,DTCC00456082,477918,46191
CHEMBL1456,P14780,MYCOPHENOLATE MOFETIL,RTGDFNSFWBGLEC-SYZQJQIISA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7437029,DTCC00456082,477918,46191
CHEMBL1458880,P14780,CADMIUM DICHLORIDE,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7259046,DTCC00859394,800572,46191
CHEMBL1458880,P14780,CADMIUM DICHLORIDE,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7259047,DTCC00859394,800572,46191
CHEMBL1460,P14780,DIDANOSINE,BXZVVICBKDXVGW-NKWVEPMBSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7355279,DTCC00459811,348398,46191
CHEMBL1460,P14780,DIDANOSINE,BXZVVICBKDXVGW-NKWVEPMBSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7355280,DTCC00459811,348398,46191
CHEMBL1461,P14780,GENTISIC ACID,WXTMDXOMEHJXQO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,40,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5102602,DTCC00460344,1731965,43205
CHEMBL146289,P14780,,NOENPCOHNDAVLW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14684295,IC50,=,335,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,1,"Ma D, Wu W, Yang G, Li J, Li J, Ye Q",,105527,DTCT0024844,891476,DTCC00334082,1371999,6330
CHEMBL1463,P14780,FLUCYTOSINE,XRECTZIEBJDKEO-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7309670,DTCC00462514,1674145,46191
CHEMBL1463,P14780,FLUCYTOSINE,XRECTZIEBJDKEO-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7309671,DTCC00462514,1674145,46191
CHEMBL1464,P14780,WARFARIN,PJVWKTKQMONHTI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7449601,DTCC00462727,2089753,46191
CHEMBL1464,P14780,WARFARIN,PJVWKTKQMONHTI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7449602,DTCC00462727,2089753,46191
CHEMBL1466,P14780,DICUMAROL,DOBMPNYZJYQDGZ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7346714,DTCC00462777,1480345,46191
CHEMBL1466,P14780,DICUMAROL,DOBMPNYZJYQDGZ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7346715,DTCC00462777,1480345,46191
CHEMBL1467,P14780,ALLOPURINOL,OFCNXPDARWKPPY-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7284230,DTCC00463996,51443,46191
CHEMBL1467,P14780,ALLOPURINOL,OFCNXPDARWKPPY-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7284231,DTCC00463996,51443,46191
CHEMBL146718,P14780,,RILFWDKQYPJIOQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14684295,IC50,=,130,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,1,"Ma D, Wu W, Yang G, Li J, Li J, Ye Q",,105527,DTCT0024844,886401,DTCC00333495,173918,6330
CHEMBL146896,P14780,,JRSHTLSUFIPCSG-BMIGLBTASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12408705,KI,=,9,NM,,,,,,,,,,,,,,Affinity towards Matrix metalloprotease-9 (MMP-9),,"Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.",J. Med. Chem.,2002,45,23,"Duan JJ, Chen L, Wasserman ZR, Lu Z, Liu RQ, Covington MB, Qian M, Hardman KD, Magolda RL, Newton RC, Christ DD, Wexler RR, Decicco CP",,105374,DTCT0024844,715588,DTCC00333056,563126,17028
CHEMBL147489,P14780,,YVJXBWDNNWDVMN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14684295,IC50,=,258,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,1,"Ma D, Wu W, Yang G, Li J, Li J, Ye Q",,105527,DTCT0024844,881343,DTCC00333722,886509,6330
CHEMBL147489,P14780,,YVJXBWDNNWDVMN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23287054,IC50,=,0.25,NM,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin),,Sulphonamides: Deserving class as MMP inhibitors?,Eur. J. Med. Chem.,2013,60,,"Jain P, Saravanan C, Singh SK",,944094,DTCT0024844,11835649,DTCC00333722,900923,53820
CHEMBL1475,P14780,TRIOXSALEN,FMHHVULEAZTJMA-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7448203,DTCC00470391,153447,46191
CHEMBL1475,P14780,TRIOXSALEN,FMHHVULEAZTJMA-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7448204,DTCC00470391,153447,46191
CHEMBL147604,P14780,,XLTGYQNRFLYPNU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14684295,IC50,=,3118,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,1,"Ma D, Wu W, Yang G, Li J, Li J, Ye Q",,105527,DTCT0024844,885130,DTCC00334132,1436341,6330
CHEMBL1476898,P14780,CADMIUM ACETATE,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7279068,DTCC00876074,51449,46191
CHEMBL1476898,P14780,CADMIUM ACETATE,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7279069,DTCC00876074,51449,46191
CHEMBL1477,P14780,CERIVASTATIN,SEERZIQQUAZTOL-ANMDKAQQSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7364448,DTCC00471235,736257,46191
CHEMBL1477,P14780,CERIVASTATIN,SEERZIQQUAZTOL-ANMDKAQQSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7364449,DTCC00471235,736257,46191
CHEMBL147881,P14780,,YVCCTHCWKOIESX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14684295,IC50,=,35,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,1,"Ma D, Wu W, Yang G, Li J, Li J, Ye Q",,105527,DTCT0024844,878655,DTCC00333744,1339403,6330
CHEMBL147882,P14780,,PFIFGQWOKBQYID-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14684295,IC50,=,40,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,1,"Ma D, Wu W, Yang G, Li J, Li J, Ye Q",,105527,DTCT0024844,874874,DTCC00333745,1113042,6330
CHEMBL1479,P14780,DANAZOL,POZRVZJJTULAOH-LHZXLZLDSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7370062,DTCC00472761,1512807,46191
CHEMBL1479,P14780,DANAZOL,POZRVZJJTULAOH-LHZXLZLDSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7370063,DTCC00472761,1512807,46191
CHEMBL1480,P14780,FELODIPINE,RZTAMFZIAATZDJ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7328647,DTCC00472762,1894965,46191
CHEMBL1480,P14780,FELODIPINE,RZTAMFZIAATZDJ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7328648,DTCC00472762,1894965,46191
CHEMBL1480987,P14780,CYCLANDELATE,WZHCOOQXZCIUNC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7348311,DTCC00879865,444638,46191
CHEMBL1480987,P14780,CYCLANDELATE,WZHCOOQXZCIUNC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7348312,DTCC00879865,444638,46191
CHEMBL1481,P14780,GLIMEPIRIDE,WIGIZIANZCJQQY-RUCARUNLSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7325153,DTCC00472763,1641848,46191
CHEMBL1481,P14780,GLIMEPIRIDE,WIGIZIANZCJQQY-RUCARUNLSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7325154,DTCC00472763,1641848,46191
CHEMBL148118,P14780,,NIUYUCAJYPRIRB-ACJLOTCBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12408705,KI,=,586,NM,,,,,,,,,,,,,,Affinity towards Matrix metalloprotease-9 (MMP-9),,"Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.",J. Med. Chem.,2002,45,23,"Duan JJ, Chen L, Wasserman ZR, Lu Z, Liu RQ, Covington MB, Qian M, Hardman KD, Magolda RL, Newton RC, Christ DD, Wexler RR, Decicco CP",,105374,DTCT0024844,697251,DTCC00333022,854230,17028
CHEMBL148169,P14780,IK-682,YDMIPBHQKFOFQW-NSYGIPOTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12408705,KI,=,10340,NM,,,,,,,,,,,,,,Affinity towards Matrix metalloprotease-9 (MMP-9),,"Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.",J. Med. Chem.,2002,45,23,"Duan JJ, Chen L, Wasserman ZR, Lu Z, Liu RQ, Covington MB, Qian M, Hardman KD, Magolda RL, Newton RC, Christ DD, Wexler RR, Decicco CP",,105374,DTCT0024844,697261,DTCC01743557,205947,17028
CHEMBL148169,P14780,IK-682,YDMIPBHQKFOFQW-NSYGIPOTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17064892,IC50,=,10340,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Identification of potent and selective TACE inhibitors via the S1 pocket.,Bioorg. Med. Chem. Lett.,2007,17,1,"Condon JS, Joseph-McCarthy D, Levin JI, Lombart HG, Lovering FE, Sun L, Wang W, Xu W, Zhang Y",,440763,DTCT0024844,2153859,DTCC01743557,195837,23077
CHEMBL148169,P14780,IK-682,YDMIPBHQKFOFQW-NSYGIPOTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,KI,=,10340,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2457292,DTCC01743557,208203,32556
CHEMBL148171,P14780,,JOGYGVFUVCZABB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14684295,IC50,=,100,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,1,"Ma D, Wu W, Yang G, Li J, Li J, Ye Q",,105527,DTCT0024844,877392,DTCC00334131,1851209,6330
CHEMBL148214,P14780,,AYFCYVLVRYQGME-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14684295,IC50,=,46,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,1,"Ma D, Wu W, Yang G, Li J, Li J, Ye Q",,105527,DTCT0024844,878664,DTCC00334130,1501033,6330
CHEMBL1483,P14780,ALBENDAZOLE,HXHWSAZORRCQMX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7297841,DTCC00474063,315661,46191
CHEMBL1483,P14780,ALBENDAZOLE,HXHWSAZORRCQMX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7297842,DTCC00474063,315661,46191
CHEMBL148406,P14780,,VVZFBVIPGIVQRI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14684295,IC50,=,248,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,1,"Ma D, Wu W, Yang G, Li J, Li J, Ye Q",,105527,DTCT0024844,870995,DTCC00333693,1754320,6330
CHEMBL1487,P14780,ATORVASTATIN,XUKUURHRXDUEBC-KAYWLYCHSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7266686,DTCC00483650,1480343,46191
CHEMBL1487,P14780,ATORVASTATIN,XUKUURHRXDUEBC-KAYWLYCHSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7266687,DTCC00483650,1480343,46191
CHEMBL1489,P14780,AZACITIDINE,NMUSYJAQQFHJEW-KVTDHHQDSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7278052,DTCC00484776,1416024,46191
CHEMBL1489,P14780,AZACITIDINE,NMUSYJAQQFHJEW-KVTDHHQDSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7278053,DTCC00484776,1416024,46191
CHEMBL1489254,P14780,TRIACETIN,URAYPUMNDPQOKB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7441161,DTCC00887628,249945,46191
CHEMBL1489254,P14780,TRIACETIN,URAYPUMNDPQOKB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7441162,DTCC00887628,249945,46191
CHEMBL1490,P14780,TRIHEXYPHENIDYL,HWHLPVGTWGOCJO-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7442893,DTCC00112203,703988,46191
CHEMBL1490,P14780,TRIHEXYPHENIDYL,HWHLPVGTWGOCJO-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7442894,DTCC00112203,703988,46191
CHEMBL1491,P14780,AMLODIPINE,HTIQEAQVCYTUBX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7300997,DTCC00112206,217573,46191
CHEMBL1491,P14780,AMLODIPINE,HTIQEAQVCYTUBX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7300998,DTCC00112206,217573,46191
CHEMBL1493,P14780,FLAVOXATE,SPIUTQOUKAMGCX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7326609,DTCC00112214,1960075,46191
CHEMBL1493,P14780,FLAVOXATE,SPIUTQOUKAMGCX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7326610,DTCC00112214,1960075,46191
CHEMBL1501,P14780,FLUOCINONIDE,WJOHZNCJWYWUJD-IUGZLZTKSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7307737,DTCC00485637,1253323,46191
CHEMBL1501,P14780,FLUOCINONIDE,WJOHZNCJWYWUJD-IUGZLZTKSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7307738,DTCC00485637,1253323,46191
CHEMBL1502,P14780,PANTOPRAZOLE,IQPSEEYGBUAQFF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7401912,DTCC00485677,1027057,46191
CHEMBL1502,P14780,PANTOPRAZOLE,IQPSEEYGBUAQFF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7401913,DTCC00485677,1027057,46191
CHEMBL1503,P14780,OMEPRAZOLE,SUBDBMMJDZJVOS-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7401582,DTCC00485679,1609551,46191
CHEMBL1503,P14780,OMEPRAZOLE,SUBDBMMJDZJVOS-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7401583,DTCC00485679,1609551,46191
CHEMBL1504,P14780,TRIAMCINOLONE ACETONIDE,YNDXUCZADRHECN-JNQJZLCISA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7444352,DTCC00485699,833165,46191
CHEMBL1504,P14780,TRIAMCINOLONE ACETONIDE,YNDXUCZADRHECN-JNQJZLCISA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7444353,DTCC00485699,833165,46191
CHEMBL151,P14780,LUTEOLIN,IQPNAANSBPBGFQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,IC50,=,5620,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain incubated for 20 mins by fluorimetric assay,,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827436,DTCT0024844,10535416,DTCC00171064,458853,48665
CHEMBL151,P14780,LUTEOLIN,IQPNAANSBPBGFQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,INHIBITION,>,30,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain at 10 uM incubated for 20 mins by fluorimetric assay,,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827442,DTCT0024844,10535517,DTCC00171064,458853,48665
CHEMBL1512,P14780,FLUNISOLIDE,XSFJVAJPIHIPKU-XWCQMRHXSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7329008,DTCC00486813,703980,46191
CHEMBL1512,P14780,FLUNISOLIDE,XSFJVAJPIHIPKU-XWCQMRHXSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7329009,DTCC00486813,703980,46191
CHEMBL1513,P14780,IRBESARTAN,YOSHYTLCDANDAN-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7418245,DTCC00486818,1609548,46191
CHEMBL1513,P14780,IRBESARTAN,YOSHYTLCDANDAN-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7418246,DTCC00486818,1609548,46191
CHEMBL1515,P14780,METHIMAZOLE,PMRYVIKBURPHAH-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7430163,DTCC00486838,153446,46191
CHEMBL1515,P14780,METHIMAZOLE,PMRYVIKBURPHAH-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7430164,DTCC00486838,153446,46191
CHEMBL1515611,P14780,BROMISOVALUM,CMCCHHWTTBEZNM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7268796,DTCC00912063,1220274,46191
CHEMBL1515611,P14780,BROMISOVALUM,CMCCHHWTTBEZNM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7268797,DTCC00912063,1220274,46191
CHEMBL1515648,P14780,,XDOXZFXJIASILF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22018790,INHIBITION,=,16,%,,,,,,,,,,,,,,Inhibition of recombinant MMP9 using triple-helical fTHP-15 as substrate at 40 uM after 4 hrs by FRET assay,,"Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.",Bioorg. Med. Chem. Lett.,2011,21,23,"Roth J, Minond D, Darout E, Liu Q, Lauer J, Hodder P, Fields GB, Roush WR",,799265,DTCT0024844,7596114,DTCC00912100,185710,47025
CHEMBL1515648,P14780,,XDOXZFXJIASILF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25330343,INHIBITION,>,10,%,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 using GRIGFL substrate up to 20 uM,,Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.,J. Med. Chem.,2014,57,22,"Spicer TP, Jiang J, Taylor AB, Choi JY, Hart PJ, Roush WR, Fields GB, Hodder PS, Minond D",,1435007,DTCT0024844,13947382,DTCC00912100,169412,60192
CHEMBL1517,P14780,OXYTETRACYCLINE,IWVCMVBTMGNXQD-PXOLEDIWSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7388988,DTCC00486898,413973,46191
CHEMBL1517,P14780,OXYTETRACYCLINE,IWVCMVBTMGNXQD-PXOLEDIWSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7388989,DTCC00486898,413973,46191
CHEMBL151741,P14780,,FGDQQAHGMHOQDV-NGXZDTIWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,30,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1382335,DTCC00344136,787756,14854
CHEMBL1518,P14780,PROPYLTHIOURACIL,KNAHARQHSZJURB-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7377183,DTCC00486945,348404,46191
CHEMBL1518,P14780,PROPYLTHIOURACIL,KNAHARQHSZJURB-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7377184,DTCC00486945,348404,46191
CHEMBL1521,P14780,ZALEPLON,HUNXMJYCHXQEGX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7443483,DTCC00487037,994596,46191
CHEMBL1521,P14780,ZALEPLON,HUNXMJYCHXQEGX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7443484,DTCC00487037,994596,46191
CHEMBL152104,P14780,,FGDQQAHGMHOQDV-WVQWTBLQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,100,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1369659,DTCC00343439,172749,14854
CHEMBL15245,P14780,YOHIMBINE,BLGXFZZNTVWLAY-SCYLSFHTSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7453333,DTCC00144859,88638,46191
CHEMBL15245,P14780,YOHIMBINE,BLGXFZZNTVWLAY-SCYLSFHTSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7453334,DTCC00144859,88638,46191
CHEMBL1527608,P14780,DOXOFYLLINE,HWXIGFIVGWUZAO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7321620,DTCC00923329,88626,46191
CHEMBL1527608,P14780,DOXOFYLLINE,HWXIGFIVGWUZAO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7321621,DTCC00923329,88626,46191
CHEMBL153062,P14780,4-NONYLPHENOL,IGFHQQFPSIBGKE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7289515,DTCC00341324,1609541,46191
CHEMBL153062,P14780,4-NONYLPHENOL,IGFHQQFPSIBGKE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7289516,DTCC00341324,1609541,46191
CHEMBL1532097,P14780,DIHYDRODAPHNODORIN B,YXPCHLHMGOFXRA-DHGPJANISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,IC50,=,10170,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain incubated for 20 mins by fluorimetric assay,,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827436,DTCT0024844,10535418,DTCC00927565,717882,48665
CHEMBL1532097,P14780,DIHYDRODAPHNODORIN B,YXPCHLHMGOFXRA-DHGPJANISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,INHIBITION,>,30,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain at 10 uM incubated for 20 mins by fluorimetric assay,,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827442,DTCT0024844,10535519,DTCC00927565,717882,48665
CHEMBL153479,P14780,AMBROXOL,JBDGDEWWOUBZPM-XYPYZODXSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7288729,DTCC00342236,2057643,46191
CHEMBL153479,P14780,AMBROXOL,JBDGDEWWOUBZPM-XYPYZODXSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7288730,DTCC00342236,2057643,46191
CHEMBL1535,P14780,HYDROXYCHLOROQUINE,XXSMGPRMXLTPCZ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7310785,DTCC00494467,1416033,46191
CHEMBL1535,P14780,HYDROXYCHLOROQUINE,XXSMGPRMXLTPCZ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7310786,DTCC00494467,1416033,46191
CHEMBL1536,P14780,ERGOCALCIFEROL,MECHNRXZTMCUDQ-RKHKHRCZSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7319750,DTCC00494790,348400,46191
CHEMBL1536,P14780,ERGOCALCIFEROL,MECHNRXZTMCUDQ-RKHKHRCZSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7319751,DTCC00494790,348400,46191
CHEMBL1537,P14780,AZLOCILLIN,JTWOMNBEOCYFNV-NFFDBFGFSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7275238,DTCC00495073,1059328,46191
CHEMBL1537,P14780,AZLOCILLIN,JTWOMNBEOCYFNV-NFFDBFGFSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7275239,DTCC00495073,1059328,46191
CHEMBL1539,P14780,SULFADOXINE,PJSFRIWCGOHTNF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7482530,DTCC00495107,1512817,46191
CHEMBL1539,P14780,SULFADOXINE,PJSFRIWCGOHTNF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7482531,DTCC00495107,1512817,46191
CHEMBL154,P14780,NAPROXEN,CMWTZPSULFXXJA-VIFPVBQESA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7392522,DTCC00174165,1992809,46191
CHEMBL154,P14780,NAPROXEN,CMWTZPSULFXXJA-VIFPVBQESA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7392523,DTCC00174165,1992809,46191
CHEMBL1540,P14780,PENCICLOVIR,JNTOCHDNEULJHD-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7397695,DTCC00495142,1577007,46191
CHEMBL1540,P14780,PENCICLOVIR,JNTOCHDNEULJHD-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7397696,DTCC00495142,1577007,46191
CHEMBL154111,P14780,SALSALATE,WVYADZUPLLSGPU-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7471182,DTCC00343795,1894974,46191
CHEMBL154111,P14780,SALSALATE,WVYADZUPLLSGPU-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7471183,DTCC00343795,1894974,46191
CHEMBL1542,P14780,AZATHIOPRINE,LMEKQMALGUDUQG-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7266814,DTCC00495633,962447,46191
CHEMBL1542,P14780,AZATHIOPRINE,LMEKQMALGUDUQG-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7266815,DTCC00495633,962447,46191
CHEMBL1544,P14780,LIOTHYRONINE,AUYYCJSJGJYCDS-LBPRGKRZSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7296052,DTCC00497321,1480341,46191
CHEMBL1544,P14780,LIOTHYRONINE,AUYYCJSJGJYCDS-LBPRGKRZSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7296053,DTCC00497321,1480341,46191
CHEMBL154438,P14780,,OATYFBJQDLKLNJ-SMWWQBHQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11844676,KI,>,800,NM,,,,,,,,,,,,,,Inhibitory constant against recombinant human gelatinase B (Matrix metalloprotease-9),,Encounter with unexpected collagenase-1 selective inhibitor: switchover of inhibitor binding pocket induced by fluorine atom.,Bioorg. Med. Chem. Lett.,2002,12,4,"Sawa M, Kondo H, Nishimura S",,105400,DTCT0024844,1426944,DTCC00345360,1197504,5346
CHEMBL154706,P14780,,KFUADVZPCULIED-WRHNGFHOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831905,KI,=,10.5,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,New strategy for antedrug application: development of metalloproteinase inhibitors as antipsoriatic drugs.,J. Med. Chem.,2002,45,4,"Sawa M, Tsukamoto T, Kiyoi T, Kurokawa K, Nakajima F, Nakada Y, Yokota K, Inoue Y, Kondo H, Yoshino K",,105379,DTCT0024844,546173,DTCC00345406,109753,17148
CHEMBL154706,P14780,,KFUADVZPCULIED-WRHNGFHOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11844676,KI,=,10.5,NM,,,,,,,,,,,,,,Inhibitory constant against recombinant human gelatinase B (Matrix metalloprotease-9),,Encounter with unexpected collagenase-1 selective inhibitor: switchover of inhibitor binding pocket induced by fluorine atom.,Bioorg. Med. Chem. Lett.,2002,12,4,"Sawa M, Kondo H, Nishimura S",,105400,DTCT0024844,1431904,DTCC00345406,97950,5346
CHEMBL154828,P14780,,SQYRXZTYDRVAMZ-ROTAYESASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11844676,KI,>,800,NM,,,,,,,,,,,,,,Inhibitory constant against recombinant human gelatinase B (Matrix metalloprotease-9),,Encounter with unexpected collagenase-1 selective inhibitor: switchover of inhibitor binding pocket induced by fluorine atom.,Bioorg. Med. Chem. Lett.,2002,12,4,"Sawa M, Kondo H, Nishimura S",,105400,DTCT0024844,1415956,DTCC00345691,649011,5346
CHEMBL154999,P14780,,DZWVTHAIOWIVNT-BJLXPSRBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11844676,KI,=,358,NM,,,,,,,,,,,,,,Inhibitory constant against recombinant human gelatinase B (Matrix metalloprotease-9),,Encounter with unexpected collagenase-1 selective inhibitor: switchover of inhibitor binding pocket induced by fluorine atom.,Bioorg. Med. Chem. Lett.,2002,12,4,"Sawa M, Kondo H, Nishimura S",,105400,DTCT0024844,1437186,DTCC00345359,97949,5346
CHEMBL15511,P14780,ENROFLOXACIN,SPFYMRJSYKOXGV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7332478,DTCC00145113,1577005,46191
CHEMBL15511,P14780,ENROFLOXACIN,SPFYMRJSYKOXGV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7332479,DTCC00145113,1577005,46191
CHEMBL155134,P14780,,ZJYCLDORACELQK-WHUARKNTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11844676,KI,=,5.53,NM,,,,,,,,,,,,,,Inhibitory constant against recombinant human gelatinase B (Matrix metalloprotease-9),,Encounter with unexpected collagenase-1 selective inhibitor: switchover of inhibitor binding pocket induced by fluorine atom.,Bioorg. Med. Chem. Lett.,2002,12,4,"Sawa M, Kondo H, Nishimura S",,105400,DTCT0024844,1407589,DTCC00345301,194683,5346
CHEMBL1554,P14780,DACTINOMYCIN,RJURFGZVJUQBHK-IIXSONLDSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7365670,DTCC00113195,2089745,46191
CHEMBL1554,P14780,DACTINOMYCIN,RJURFGZVJUQBHK-IIXSONLDSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7365671,DTCC00113195,2089745,46191
CHEMBL155815,P14780,,FGYWYFYJBJBYQH-HSZRJFAPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,7800,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,625213,DTCC00350621,1339618,15057
CHEMBL155848,P14780,,DVIJGAWVVKJCSM-HSZRJFAPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,649724,DTCC00350492,2014126,15057
CHEMBL155874,P14780,,FUXIPODKBLQFAK-JOCHJYFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,2.7,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,621899,DTCC00350429,821520,15057
CHEMBL155874,P14780,,FUXIPODKBLQFAK-JOCHJYFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23688254,IC50,=,1,NM,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dpa(Dnp)-Ala-Arg-NH2 as substrate measured up to 120 mins by fluorescence assay,,"Design, synthesis, and initial evaluation of a high affinity positron emission tomography probe for imaging matrix metalloproteinases 2 and 9.",J. Med. Chem.,2013,56,12,"Selivanova SV, Stellfeld T, Heinrich TK, Müller A, Krämer SD, Schubiger PA, Schibli R, Ametamey SM, Vos B, Meding J, Bauser M, Hütter J, Dinkelborg LM",,960848,DTCT0024844,12447052,DTCC00350429,835978,54747
CHEMBL155923,P14780,,QFYHJFQVDPPYCL-JOCHJYFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,5,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,629618,DTCC00350500,821519,15057
CHEMBL155959,P14780,,NLDJVWRAKUUGKI-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,2100,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,654241,DTCC00350758,499059,15057
CHEMBL1560,P14780,CAPTOPRIL,FAKRSMQSSFJEIM-RQJHMYQMSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7279182,DTCC00507377,1092341,46191
CHEMBL1560,P14780,CAPTOPRIL,FAKRSMQSSFJEIM-RQJHMYQMSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7279183,DTCC00507377,1092341,46191
CHEMBL156455,P14780,"1,1-DICHLOROETHENE",LGXVIGDEPROXKC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7289172,DTCC00349580,866014,46191
CHEMBL156455,P14780,"1,1-DICHLOROETHENE",LGXVIGDEPROXKC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7289173,DTCC00349580,866014,46191
CHEMBL1566,P14780,ACARBOSE,XUFXOAAUWZOOIT-SXARVLRPSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7289603,DTCC00510603,994587,46191
CHEMBL1566,P14780,ACARBOSE,XUFXOAAUWZOOIT-SXARVLRPSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7289604,DTCC00510603,994587,46191
CHEMBL1566249,P14780,AMPIROXICAM,LSNWBKACGXCGAJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7295490,DTCC00959245,800570,46191
CHEMBL1566249,P14780,AMPIROXICAM,LSNWBKACGXCGAJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7295491,DTCC00959245,800570,46191
CHEMBL1566956,P14780,TROXIPIDE,YSIITVVESCNIPR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7443936,DTCC00959918,283002,46191
CHEMBL1566956,P14780,TROXIPIDE,YSIITVVESCNIPR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7443937,DTCC00959918,283002,46191
CHEMBL1567463,P14780,CHOLINE ALFOSCERATE,SUHOQUVVVLNYQR-MRVPVSSYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7364651,DTCC00960399,315662,46191
CHEMBL1567463,P14780,CHOLINE ALFOSCERATE,SUHOQUVVVLNYQR-MRVPVSSYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7364652,DTCC00960399,315662,46191
CHEMBL1568,P14780,FLUDARABINE,HBUBKKRHXORPQB-FJFJXFQQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7313980,DTCC00513782,1894966,46191
CHEMBL1568,P14780,FLUDARABINE,HBUBKKRHXORPQB-FJFJXFQQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7313981,DTCC00513782,1894966,46191
CHEMBL157138,P14780,LISURIDE,BKRGVLQUQGGVSM-KBXCAEBGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7421079,DTCC00350629,1447884,46191
CHEMBL157138,P14780,LISURIDE,BKRGVLQUQGGVSM-KBXCAEBGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7421080,DTCC00350629,1447884,46191
CHEMBL1572,P14780,NETILMICIN,CIDUJQMULVCIBT-MQDUPKMGSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7379656,DTCC00514638,1734059,46191
CHEMBL1572,P14780,NETILMICIN,CIDUJQMULVCIBT-MQDUPKMGSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7379657,DTCC00514638,1734059,46191
CHEMBL157243,P14780,,VAHNPPHUNSPFKI-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,3400,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,647361,DTCC00350826,1819289,15057
CHEMBL157289,P14780,,ZMQMSFHTPLCGRT-HXUWFJFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,1500,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,642998,DTCC00350576,1372168,15057
CHEMBL157363,P14780,,OKLASKXZKFHVBH-XMMPIXPASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,240,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,652060,DTCC00350695,1048039,15057
CHEMBL157548,P14780,DANOFLOXACIN,QMLVECGLEOSESV-RYUDHWBXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7339930,DTCC00348763,1798407,46191
CHEMBL157548,P14780,DANOFLOXACIN,QMLVECGLEOSESV-RYUDHWBXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7339931,DTCC00348763,1798407,46191
CHEMBL157592,P14780,,ISEJBTOGHVVSRR-HXUWFJFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,>,50000,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,626300,DTCC00350525,174107,15057
CHEMBL15763,P14780,,STFPAYMUYSBAKD-ANYOKISRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871727,IC50,=,1.4,NM,,,,,,,,,,,,,,In vitro inhibitory activity against gelatinase-B (MMP-9).,,"Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.",Bioorg. Med. Chem. Lett.,1998,8,10,"Campbell DA, Xiao XY, Harris D, Ida S, Mortezaei R, Ngu K, Shi L, Tien D, Wang Y, Navre M, Patel DV, Sharr MA, DiJoseph JF, Killar LM, Leone CL, Levin JI, Skotnicki JS",,105234,DTCT0024844,1536220,DTCC00146582,1340953,2559
CHEMBL15770,P14780,SULINDAC,MLKXDPUZXIRXEP-MFOYZWKCSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7460980,DTCC00145905,930088,46191
CHEMBL15770,P14780,SULINDAC,MLKXDPUZXIRXEP-MFOYZWKCSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7460981,DTCC00145905,930088,46191
CHEMBL157704,P14780,,YLMQYIQDNAUTDZ-HSZRJFAPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,81,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,625207,DTCC00350751,1468897,15057
CHEMBL157704,P14780,,YLMQYIQDNAUTDZ-HSZRJFAPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23688254,IC50,=,28,NM,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dpa(Dnp)-Ala-Arg-NH2 as substrate measured up to 120 mins by fluorescence assay,,"Design, synthesis, and initial evaluation of a high affinity positron emission tomography probe for imaging matrix metalloproteinases 2 and 9.",J. Med. Chem.,2013,56,12,"Selivanova SV, Stellfeld T, Heinrich TK, Müller A, Krämer SD, Schubiger PA, Schibli R, Ametamey SM, Vos B, Meding J, Bauser M, Hütter J, Dinkelborg LM",,960848,DTCT0024844,12447040,DTCC00350751,1483079,54747
CHEMBL157705,P14780,,JXFQCSDDKGGRKY-JOCHJYFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,250,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,626302,DTCC00350752,304324,15057
CHEMBL15796,P14780,,UVHJPRIQTAISRK-KOENEWCDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871727,IC50,,,,,,,,,,,,,,,,,In vitro inhibitory activity against gelatinase-B (MMP-9.,Not Tested,"Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.",Bioorg. Med. Chem. Lett.,1998,8,10,"Campbell DA, Xiao XY, Harris D, Ida S, Mortezaei R, Ngu K, Shi L, Tien D, Wang Y, Navre M, Patel DV, Sharr MA, DiJoseph JF, Killar LM, Leone CL, Levin JI, Skotnicki JS",,105235,DTCT0024844,1533822,DTCC00146496,1788056,2559
CHEMBL158,P14780,AZTREONAM,WZPBZJONDBGPKJ-VEHQQRBSSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7278198,DTCC00182933,510296,46191
CHEMBL158,P14780,AZTREONAM,WZPBZJONDBGPKJ-VEHQQRBSSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7278199,DTCC00182933,510296,46191
CHEMBL158366,P14780,,XSZFUUHZPTXVJI-UXHICEINSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,124,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1427031,DTCC00352918,1080604,12880
CHEMBL158571,P14780,,UAZHKINNICKCCP-VTFDQJKESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,76,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1423458,DTCC00108674,628130,12880
CHEMBL1586,P14780,BECLOMETHASONE,NBMKJKDGKREAPL-DVTGEIKXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7272410,DTCC00514882,1188063,46191
CHEMBL1586,P14780,BECLOMETHASONE,NBMKJKDGKREAPL-DVTGEIKXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7272411,DTCC00514882,1188063,46191
CHEMBL158622,P14780,,GSCAICSUTUHIKD-JZGSEIKYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,18,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1443439,DTCC00353256,1208819,12880
CHEMBL158622,P14780,,GSCAICSUTUHIKD-JZGSEIKYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,70,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1414867,DTCC00353256,1208820,12880
CHEMBL158625,P14780,,LGAMBGLWTORDNW-ZRBLBEILSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,27,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1443457,DTCC00353340,886729,12880
CHEMBL158674,P14780,,XDOAIHGEJMOGJF-HXUWFJFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,646288,DTCC00351214,1274349,15057
CHEMBL158696,P14780,,WKFUXNDEVSIEGA-PKTNWEFCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,63,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1414876,DTCC00353538,1754553,12880
CHEMBL158739,P14780,,QWIPRZJIZDEZJZ-ZNZIZOMTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,28,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1407677,DTCC00353336,660388,12880
CHEMBL158798,P14780,,UXRZVXKHVDNOPK-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,1100,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,636338,DTCC00350948,1724284,15057
CHEMBL158823,P14780,,HGYBTJHBZBLHNW-FSSWDIPSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,5,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1423511,DTCC00352751,336990,12880
CHEMBL159,P14780,VINBLASTINE,JXLYSJRDGCGARV-CFWMRBGOSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7440971,DTCC00190732,1577012,46191
CHEMBL159,P14780,VINBLASTINE,JXLYSJRDGCGARV-CFWMRBGOSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7440972,DTCC00190732,1577012,46191
CHEMBL159013,P14780,,WUMGWKJNFKXXRX-OAQYLSRUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,60,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,632933,DTCC00350734,1015610,15057
CHEMBL159033,P14780,,YSOWDIROXDYGJM-FTJBHMTQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,35,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1427022,DTCC00353589,1404663,12880
CHEMBL159141,P14780,,BDRKJDRHTIDJDK-DSITVLBTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,7.5,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1433412,DTCC00353503,1015638,12880
CHEMBL159159,P14780,,QQTWJGZZLJPVHO-OEBVTXOESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,75,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1434757,DTCC00353284,660387,12880
CHEMBL1592,P14780,QUINAPRIL,JSDRRTOADPPCHY-HSQYWUDLSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7379439,DTCC00515121,1705879,46191
CHEMBL1592,P14780,QUINAPRIL,JSDRRTOADPPCHY-HSQYWUDLSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7379440,DTCC00515121,1705879,46191
CHEMBL15920,P14780,,IMJNDIHWKZAXJD-XLQDAESGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871727,IC50,,,,,,,,,,,,,,,,,In vitro inhibitory activity against gelatinase-B (MMP-9.,Not Tested,"Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.",Bioorg. Med. Chem. Lett.,1998,8,10,"Campbell DA, Xiao XY, Harris D, Ida S, Mortezaei R, Ngu K, Shi L, Tien D, Wang Y, Navre M, Patel DV, Sharr MA, DiJoseph JF, Killar LM, Leone CL, Levin JI, Skotnicki JS",,105235,DTCT0024844,1550578,DTCC00146385,887973,2559
CHEMBL159229,P14780,,DORIMXJPMPAGRK-VQAHOFKPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,350,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,649726,DTCC00351197,1339621,15057
CHEMBL15930,P14780,,DDSRTXCZNKYQPZ-GEVKEYJPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871727,IC50,,,,,,,,,,,,,,,,,In vitro inhibitory activity against gelatinase-B (MMP-9.,Not Tested,"Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.",Bioorg. Med. Chem. Lett.,1998,8,10,"Campbell DA, Xiao XY, Harris D, Ida S, Mortezaei R, Ngu K, Shi L, Tien D, Wang Y, Navre M, Patel DV, Sharr MA, DiJoseph JF, Killar LM, Leone CL, Levin JI, Skotnicki JS",,105235,DTCT0024844,1553071,DTCC00146418,1275585,2559
CHEMBL15962,P14780,,UXIXVZBLORSHJF-KBWCOIMZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871727,IC50,=,640,NM,,,,,,,,,,,,,,In vitro inhibitory activity against gelatinase-B (MMP-9).,,"Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.",Bioorg. Med. Chem. Lett.,1998,8,10,"Campbell DA, Xiao XY, Harris D, Ida S, Mortezaei R, Ngu K, Shi L, Tien D, Wang Y, Navre M, Patel DV, Sharr MA, DiJoseph JF, Killar LM, Leone CL, Levin JI, Skotnicki JS",,105234,DTCT0024844,1519657,DTCC00146495,790450,2559
CHEMBL15964,P14780,,HXRVPYPXJBAKAT-BBMPLOMVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871727,IC50,=,4,NM,,,,,,,,,,,,,,In vitro inhibitory activity against gelatinase-B (MMP-9).,,"Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.",Bioorg. Med. Chem. Lett.,1998,8,10,"Campbell DA, Xiao XY, Harris D, Ida S, Mortezaei R, Ngu K, Shi L, Tien D, Wang Y, Navre M, Patel DV, Sharr MA, DiJoseph JF, Killar LM, Leone CL, Levin JI, Skotnicki JS",,105234,DTCT0024844,1550581,DTCC00146331,952237,2559
CHEMBL159645,P14780,,CLDWFWQEHSJBDI-MOPGFXCFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,706,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1443363,DTCC00353775,1981339,12880
CHEMBL1598608,P14780,AZASETRON,WUKZPHOXUVCQOR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7263898,DTCC00989336,1734053,46191
CHEMBL1598608,P14780,AZASETRON,WUKZPHOXUVCQOR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7263899,DTCC00989336,1734053,46191
CHEMBL16,P14780,PHENYTOIN,CXOFVDLJLONNDW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7374439,DTCC00132980,51500,46191
CHEMBL16,P14780,PHENYTOIN,CXOFVDLJLONNDW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7374440,DTCC00132980,51500,46191
CHEMBL160,P14780,CYCLOSPORINE,PMATZTZNYRCHOR-CGLBZJNRSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7365567,DTCC00191777,51461,46191
CHEMBL160,P14780,CYCLOSPORINE,PMATZTZNYRCHOR-CGLBZJNRSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7365568,DTCC00191777,51461,46191
CHEMBL160153,P14780,,CTGTUEAFFDISNJ-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,5.9,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,622988,DTCC00350890,1080568,15057
CHEMBL1601669,P14780,ALFACALCIDOL,OFHCOWSQAMBJIW-AVJTYSNKSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7281282,DTCC00992187,217572,46191
CHEMBL1601669,P14780,ALFACALCIDOL,OFHCOWSQAMBJIW-AVJTYSNKSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7281283,DTCC00992187,217572,46191
CHEMBL160232,P14780,,UYOKHXXMEWHQPZ-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,16,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,624096,DTCC00350784,1145546,15057
CHEMBL160245,P14780,,KJEQWEFXIVEWJZ-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,270,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,645182,DTCC00350785,238596,15057
CHEMBL160305,P14780,,LHTMZOJLNGMCKG-HXUWFJFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,24,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,645176,DTCC00350470,2014127,15057
CHEMBL160461,P14780,,ZYFGPOVGVCHWKW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,1000,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,621908,DTCC00350714,141920,15057
CHEMBL160465,P14780,,IQJYLIPOZQSCPF-JOCHJYFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,680,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,642996,DTCC00351043,1786735,15057
CHEMBL160667,P14780,,PUJWEAOLJGFEFS-XMMPIXPASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,8800,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,636341,DTCC00351060,1915722,15057
CHEMBL16068,P14780,BROMOBENZENE,QARVLSVVCXYDNA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7271454,DTCC00145980,2057646,46191
CHEMBL16068,P14780,BROMOBENZENE,QARVLSVVCXYDNA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7271455,DTCC00145980,2057646,46191
CHEMBL160712,P14780,,PECSXFVCAXHEGF-JOCHJYFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,653067,DTCC00351216,174105,15057
CHEMBL16073,P14780,PHENACETIN,CPJSUEIXXCENMM-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7372065,DTCC00145899,120977,46191
CHEMBL16073,P14780,PHENACETIN,CPJSUEIXXCENMM-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7372066,DTCC00145899,120977,46191
CHEMBL16087,P14780,,DIXLCLWTVQJIDG-FQNRMIAFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871727,IC50,=,19,NM,,,,,,,,,,,,,,In vitro inhibitory activity against gelatinase-B (MMP-9).,,"Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.",Bioorg. Med. Chem. Lett.,1998,8,10,"Campbell DA, Xiao XY, Harris D, Ida S, Mortezaei R, Ngu K, Shi L, Tien D, Wang Y, Navre M, Patel DV, Sharr MA, DiJoseph JF, Killar LM, Leone CL, Levin JI, Skotnicki JS",,105234,DTCT0024844,1535058,DTCC00146398,435942,2559
CHEMBL160940,P14780,,UVXTZZTWBQFLQL-OAHLLOKOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,72,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,622985,DTCC00350934,402419,15057
CHEMBL160969,P14780,,ROOYIIGYFULNCM-RUZDIDTESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,16,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,639675,DTCC00351062,1339619,15057
CHEMBL16099,P14780,,VRGMRZYBJKCBRL-ZBCRRDGASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871727,IC50,=,4500,NM,,,,,,,,,,,,,,In vitro inhibitory activity against gelatinase-B (MMP-9).,,"Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.",Bioorg. Med. Chem. Lett.,1998,8,10,"Campbell DA, Xiao XY, Harris D, Ida S, Mortezaei R, Ngu K, Shi L, Tien D, Wang Y, Navre M, Patel DV, Sharr MA, DiJoseph JF, Killar LM, Leone CL, Levin JI, Skotnicki JS",,105234,DTCT0024844,1529101,DTCC00146618,1081902,2559
CHEMBL16114,P14780,,LXJCNSMDGYASPQ-GMONCZTGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871727,IC50,,,,,,,,,,,,,,,,,In vitro inhibitory activity against gelatinase-B (MMP-9.,Not Tested,"Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.",Bioorg. Med. Chem. Lett.,1998,8,10,"Campbell DA, Xiao XY, Harris D, Ida S, Mortezaei R, Ngu K, Shi L, Tien D, Wang Y, Navre M, Patel DV, Sharr MA, DiJoseph JF, Killar LM, Leone CL, Levin JI, Skotnicki JS",,105235,DTCT0024844,1522247,DTCC00146362,1755857,2559
CHEMBL16115,P14780,,RBSCETUBICKNGC-CBNMVNINSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871727,IC50,=,30,NM,,,,,,,,,,,,,,In vitro inhibitory activity against gelatinase-B (MMP-9).,,"Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.",Bioorg. Med. Chem. Lett.,1998,8,10,"Campbell DA, Xiao XY, Harris D, Ida S, Mortezaei R, Ngu K, Shi L, Tien D, Wang Y, Navre M, Patel DV, Sharr MA, DiJoseph JF, Killar LM, Leone CL, Levin JI, Skotnicki JS",,105234,DTCT0024844,1521043,DTCC00146400,1884840,2559
CHEMBL16118,P14780,,BEWFNUZAYXMBNS-AWKYBWMHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871727,IC50,=,0.3,NM,,,,,,,,,,,,,,In vitro inhibitory activity against gelatinase-B (MMP-9).,,"Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.",Bioorg. Med. Chem. Lett.,1998,8,10,"Campbell DA, Xiao XY, Harris D, Ida S, Mortezaei R, Ngu K, Shi L, Tien D, Wang Y, Navre M, Patel DV, Sharr MA, DiJoseph JF, Killar LM, Leone CL, Levin JI, Skotnicki JS",,105234,DTCT0024844,1522250,DTCC00146346,78543,2559
CHEMBL1612004,P14780,,VMPITZXILSNTON-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7384333,DTCC01001920,736263,46191
CHEMBL1612004,P14780,,VMPITZXILSNTON-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7384334,DTCC01001920,736263,46191
CHEMBL161224,P14780,,DMYQQPUOQMOFJU-RPBOFIJWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,74,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1419516,DTCC00352681,1015636,12880
CHEMBL1614641,P14780,FLUNOXAPROFEN,ARPYQKTVRGFPIS-VIFPVBQESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7333300,DTCC01003541,510300,46191
CHEMBL1614641,P14780,FLUNOXAPROFEN,ARPYQKTVRGFPIS-VIFPVBQESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7333301,DTCC01003541,510300,46191
CHEMBL161536,P14780,,XRAGTWOVABKXJS-SGNDLWITSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,11,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1408867,DTCC00352864,141957,12880
CHEMBL16154,P14780,,CISYKXQCUSYTKA-WLXPTCNVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871727,IC50,,,,,,,,,,,,,,,,,In vitro inhibitory activity against gelatinase-B (MMP-9.,Not Tested,"Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.",Bioorg. Med. Chem. Lett.,1998,8,10,"Campbell DA, Xiao XY, Harris D, Ida S, Mortezaei R, Ngu K, Shi L, Tien D, Wang Y, Navre M, Patel DV, Sharr MA, DiJoseph JF, Killar LM, Leone CL, Levin JI, Skotnicki JS",,105235,DTCT0024844,1553068,DTCC00146269,1308346,2559
CHEMBL161562,P14780,,ICYVDMBWMGFEMP-RPWUZVMVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,36,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1424562,DTCC00353371,1339664,12880
CHEMBL161572,P14780,,OVKVSVACJPYFHM-ULNSLHSMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,13,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1443453,DTCC00353335,563378,12880
CHEMBL16172,P14780,,ALGKSUNHOBFZJP-LZBANZJXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871727,IC50,,,,,,,,,,,,,,,,,In vitro inhibitory activity against gelatinase-B (MMP-9.,Not Tested,"Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.",Bioorg. Med. Chem. Lett.,1998,8,10,"Campbell DA, Xiao XY, Harris D, Ida S, Mortezaei R, Ngu K, Shi L, Tien D, Wang Y, Navre M, Patel DV, Sharr MA, DiJoseph JF, Killar LM, Leone CL, Levin JI, Skotnicki JS",,105235,DTCT0024844,1550572,DTCC00146425,661592,2559
CHEMBL1618305,P14780,NALOXONAZINE,AJPSBXJNFJCCBI-YOHUGVJRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7413741,DTCC01006289,120976,46191
CHEMBL1618305,P14780,NALOXONAZINE,AJPSBXJNFJCCBI-YOHUGVJRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7413742,DTCC01006289,120976,46191
CHEMBL1619,P14780,CLADRIBINE,PTOAARAWEBMLNO-KVQBGUIXSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7367170,DTCC00525900,217575,46191
CHEMBL1619,P14780,CLADRIBINE,PTOAARAWEBMLNO-KVQBGUIXSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7367171,DTCC00525900,217575,46191
CHEMBL162072,P14780,,PCKJJBIMKAITOP-FTJBHMTQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,57,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1430689,DTCC00353290,1981338,12880
CHEMBL162128,P14780,,RMLJJALZEPRGDU-PVHODMMVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,49,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1428329,DTCC00353480,1436585,12880
CHEMBL16213,P14780,,HSAXQLHVOUBVRZ-JNLGVIEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871727,IC50,,,,,,,,,,,,,,,,,In vitro inhibitory activity against gelatinase-B (MMP-9.,Not Tested,"Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.",Bioorg. Med. Chem. Lett.,1998,8,10,"Campbell DA, Xiao XY, Harris D, Ida S, Mortezaei R, Ngu K, Shi L, Tien D, Wang Y, Navre M, Patel DV, Sharr MA, DiJoseph JF, Killar LM, Leone CL, Levin JI, Skotnicki JS",,105235,DTCT0024844,1550575,DTCC00146315,790451,2559
CHEMBL16235,P14780,,NTKMAVFFDZGDKA-VNXZQDSDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871727,IC50,,,,,,,,,,,,,,,,,In vitro inhibitory activity against gelatinase-B (MMP-9.,Not Tested,"Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.",Bioorg. Med. Chem. Lett.,1998,8,10,"Campbell DA, Xiao XY, Harris D, Ida S, Mortezaei R, Ngu K, Shi L, Tien D, Wang Y, Navre M, Patel DV, Sharr MA, DiJoseph JF, Killar LM, Leone CL, Levin JI, Skotnicki JS",,105235,DTCT0024844,1547973,DTCC00146379,1916979,2559
CHEMBL16258,P14780,,QTXQZEVSCFUJCN-YMAMQOFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871727,IC50,,,,,,,,,,,,,,,,,In vitro inhibitory activity against gelatinase-B (MMP-9.,Not Tested,"Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.",Bioorg. Med. Chem. Lett.,1998,8,10,"Campbell DA, Xiao XY, Harris D, Ida S, Mortezaei R, Ngu K, Shi L, Tien D, Wang Y, Navre M, Patel DV, Sharr MA, DiJoseph JF, Killar LM, Leone CL, Levin JI, Skotnicki JS",,105235,DTCT0024844,1527946,DTCC00146519,1373481,2559
CHEMBL1626,P14780,CLEMASTINE,YNNUSGIPVFPVBX-NHCUHLMSSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7341415,DTCC00527946,639576,46191
CHEMBL1626,P14780,CLEMASTINE,YNNUSGIPVFPVBX-NHCUHLMSSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7341416,DTCC00527946,639576,46191
CHEMBL1627009,P14780,LITHIUM ETHYL (CYCLOHEXYLAMINO)CARBONYLPHOSPHONATE,UNVAKRAJEPVVLT-UHFFFAOYSA-M,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15139760,IC50,>,100000,NM,,,,,,,,,,,,,,In vitro inhibitory activity against recombinant matrix metalloprotease-9 was determined,,"Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.",J. Med. Chem.,2004,47,11,"Breuer E, Salomon CJ, Katz Y, Chen W, Lu S, Röschenthaler GV, Hadar R, Reich R",,105518,DTCT0024844,1288022,DTCC01014520,627063,17838
CHEMBL1628227,P14780,DOXEPIN,ODQWQRRAPPTVAG-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7349260,DTCC01015577,898288,46191
CHEMBL1628227,P14780,DOXEPIN,ODQWQRRAPPTVAG-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7349261,DTCC01015577,898288,46191
CHEMBL1629810,P14780,2-HYDROXYPROPYL-BETA-CYCLODEXTRIN,BIIFEDMBGOQTDO-USCPGHQQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7302963,DTCC00033243,510295,46191
CHEMBL1629810,P14780,2-HYDROXYPROPYL-BETA-CYCLODEXTRIN,BIIFEDMBGOQTDO-USCPGHQQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7302964,DTCC00033243,510295,46191
CHEMBL163,P14780,RITONAVIR,NCDNCNXCDXHOMX-XGKFQTDJSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7470918,DTCC00204116,51505,46191
CHEMBL163,P14780,RITONAVIR,NCDNCNXCDXHOMX-XGKFQTDJSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7470919,DTCC00204116,51505,46191
CHEMBL1630091,P14780,,UNOIUBNRWWBQDJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21078557,IC50,=,23000,NM,,,,,,,,,,,,,,Inhibition of human MMP9 in cell-free system by fluorescent spectroscopy,,Structure based optimization of chromen-based TNF-a converting enzyme (TACE) inhibitors on S1' pocket and their quantitative structure-activity relationship (QSAR) study.,Bioorg. Med. Chem.,2010,18,24,"Yang JS, Chun K, Park JE, Cho M, Seo J, Song D, Yoon H, Park CH, Joe BY, Choi JH, Kim MH, Han G",,697253,DTCT0024844,5021793,DTCC01015985,490921,42159
CHEMBL1630098,P14780,DPC-333,VINTZLVANMVXOH-ZEQKJWHPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21078557,IC50,=,460000,NM,,,,,,,,,,,,,,Inhibition of human MMP9 in cell-free system by fluorescent spectroscopy,,Structure based optimization of chromen-based TNF-a converting enzyme (TACE) inhibitors on S1' pocket and their quantitative structure-activity relationship (QSAR) study.,Bioorg. Med. Chem.,2010,18,24,"Yang JS, Chun K, Park JE, Cho M, Seo J, Song D, Yoon H, Park CH, Joe BY, Choi JH, Kim MH, Han G",,697253,DTCT0024844,5021792,DTCC00033248,716707,42159
CHEMBL1630578,P14780,TIRILIZAD,RBKASMJPSJDQKY-RBFSKHHSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7457327,DTCC01016434,1798419,46191
CHEMBL1630578,P14780,TIRILIZAD,RBKASMJPSJDQKY-RBFSKHHSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7457328,DTCC01016434,1798419,46191
CHEMBL1630579,P14780,MYRTECAINE,BZRYYBWNOUALTQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7411442,DTCC01016435,1416036,46191
CHEMBL1630579,P14780,MYRTECAINE,BZRYYBWNOUALTQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7411443,DTCC01016435,1416036,46191
CHEMBL16398,P14780,,AIYJHCBHVDDOHF-KEKNWZKVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871727,IC50,=,5,NM,,,,,,,,,,,,,,In vitro inhibitory activity against gelatinase-B (MMP-9).,,"Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.",Bioorg. Med. Chem. Lett.,1998,8,10,"Campbell DA, Xiao XY, Harris D, Ida S, Mortezaei R, Ngu K, Shi L, Tien D, Wang Y, Navre M, Patel DV, Sharr MA, DiJoseph JF, Killar LM, Leone CL, Levin JI, Skotnicki JS",,105234,DTCT0024844,1543266,DTCC00146306,1696030,2559
CHEMBL16402,P14780,,SURPMIPINKUUFC-KOENEWCDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871727,IC50,,,,,,,,,,,,,,,,,In vitro inhibitory activity against gelatinase-B (MMP-9.,Not Tested,"Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.",Bioorg. Med. Chem. Lett.,1998,8,10,"Campbell DA, Xiao XY, Harris D, Ida S, Mortezaei R, Ngu K, Shi L, Tien D, Wang Y, Navre M, Patel DV, Sharr MA, DiJoseph JF, Killar LM, Leone CL, Levin JI, Skotnicki JS",,105235,DTCT0024844,1522244,DTCC00146342,1405920,2559
CHEMBL164290,P14780,N-NITROSODIETHYLAMINE,WBNQDOYYEUMPFS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7415794,DTCC00108812,703983,46191
CHEMBL164290,P14780,N-NITROSODIETHYLAMINE,WBNQDOYYEUMPFS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7415795,DTCC00108812,703983,46191
CHEMBL1643,P14780,RIBAVIRIN,IWUCXVSUMQZMFG-AFCXAGJDSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7470798,DTCC00540588,217584,46191
CHEMBL1643,P14780,RIBAVIRIN,IWUCXVSUMQZMFG-AFCXAGJDSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7470799,DTCC00540588,217584,46191
CHEMBL16474,P14780,,WFNGARIUMCOWHM-KBWCOIMZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871727,IC50,,,,,,,,,,,,,,,,,In vitro inhibitory activity against gelatinase-B (MMP-9.,Not Tested,"Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.",Bioorg. Med. Chem. Lett.,1998,8,10,"Campbell DA, Xiao XY, Harris D, Ida S, Mortezaei R, Ngu K, Shi L, Tien D, Wang Y, Navre M, Patel DV, Sharr MA, DiJoseph JF, Killar LM, Leone CL, Levin JI, Skotnicki JS",,105235,DTCT0024844,1525597,DTCC00146277,693820,2559
CHEMBL164837,P14780,,DOETVZCFKJCYJV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20155918,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of human MMP9,Not Active,Synthesis and biological evaluation of botulinum neurotoxin a protease inhibitors.,J. Med. Chem.,2010,53,5,"Li B, Pai R, Cardinale SC, Butler MM, Peet NP, Moir DT, Bavari S, Bowlin TL",,609719,DTCT0024844,3205561,DTCC00108883,38635,37163
CHEMBL16487,P14780,,PNVAEBBFARFVNB-ANYOKISRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871727,IC50,=,6,NM,,,,,,,,,,,,,,In vitro inhibitory activity against gelatinase-B (MMP-9).,,"Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.",Bioorg. Med. Chem. Lett.,1998,8,10,"Campbell DA, Xiao XY, Harris D, Ida S, Mortezaei R, Ngu K, Shi L, Tien D, Wang Y, Navre M, Patel DV, Sharr MA, DiJoseph JF, Killar LM, Leone CL, Levin JI, Skotnicki JS",,105234,DTCT0024844,1529104,DTCC00146304,532480,2559
CHEMBL1649594,P14780,,PVQRWPNLEMQCSX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,100,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103998,DTCC01022968,960351,43205
CHEMBL165,P14780,RESVERATROL,LUKBXSAWLPMMSZ-OWOJBTEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7466438,DTCC00217176,930085,46191
CHEMBL165,P14780,RESVERATROL,LUKBXSAWLPMMSZ-OWOJBTEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7466439,DTCC00217176,930085,46191
CHEMBL1650,P14780,CORTISONE ACETATE,ITRJWOMZKQRYTA-RFZYENFJSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7365447,DTCC00542150,1705875,46191
CHEMBL1650,P14780,CORTISONE ACETATE,ITRJWOMZKQRYTA-RFZYENFJSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7365448,DTCC00542150,1705875,46191
CHEMBL1650458,P14780,6-METHYLPICOLINIC ACID,LTUUGSGSUZRPRV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,-6,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103047,DTCC00033455,604860,43205
CHEMBL16505,P14780,,UOLDAWOAHWACHY-JHJVBQTASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871728,IC50,=,250,NM,,,,,,,,,,,,,,"Inhibition of matrix metalloprotease-9, gelatinase-B",,The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,1998,8,10,"Levin JI, DiJoseph JF, Killar LM, Sharr MA, Skotnicki JS, Patel DV, Xiao XY, Shi L, Navre M, Campbell DA",,105236,DTCT0024844,1021980,DTCC00147183,661596,2560
CHEMBL1650601,P14780,8-HYDROXYQUINOLINE 1-OXIDE,FJKUOCCQEBLPNX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,67,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103970,DTCC00033473,1024885,43205
CHEMBL1650602,P14780,6-HYDROXYPICOLINIC ACID,VRCWSYYXUCKEED-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,16,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5102605,DTCC00033474,1731964,43205
CHEMBL1650603,P14780,6-BROMOPICOLINIC ACID,XURXQNUIGWHWHU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,4,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103755,DTCC00033475,442587,43205
CHEMBL1650604,P14780,,PHQBKLKZIXCRIX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,-10,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103218,DTCC01022962,280902,43205
CHEMBL1650605,P14780,CLOPYRALID,HUBANNPOLNYSAD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,18,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103002,DTCC01022963,1990718,43205
CHEMBL1650606,P14780,ISOQUINOLINE-1-CARBOXYLIC ACID,XAAKCCMYRKZRAK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,26,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5102670,DTCC00033476,798490,43205
CHEMBL1650607,P14780,PYRIMIDIN-2-OL,VTGOHKSTWXHQJK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,51,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103792,DTCC00033477,830994,43205
CHEMBL1650608,P14780,2-THIOURACIL,OVONXEQGWXGFJD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,90,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5104037,DTCC00033478,1860584,43205
CHEMBL1650609,P14780,,RAFAYWADRVMWFA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,56,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103893,DTCC01022964,1024886,43205
CHEMBL1650610,P14780,,PZVLJGKJIMBYNP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,-4,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103764,DTCC01022965,346294,43205
CHEMBL1650611,P14780,,STUQITWXBMZUGY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,15,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103305,DTCC01022966,280898,43205
CHEMBL1650612,P14780,,BPSGVKFIQZZFNH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,4,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103983,DTCC00127529,572604,43205
CHEMBL1650613,P14780,,UQFHLJKWYIJISA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,1,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103758,DTCC00127530,1478226,43205
CHEMBL1650614,P14780,,SHVCSCWHWMSGTE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,1,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103162,DTCC01022967,1639739,43205
CHEMBL1650615,P14780,,GKLSXUGPECNEMX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,100,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103923,DTCC01022969,1672008,43205
CHEMBL1650616,P14780,,KKEBDEYRNMMBPM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,41,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5104044,DTCC01022970,1413986,43205
CHEMBL1650617,P14780,,NFPVFWUVBGEVHR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,51,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103343,DTCC01022971,378880,43205
CHEMBL1650618,P14780,,LIPRKYKMVQPYPG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,70,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103967,DTCC01022972,1574896,43205
CHEMBL1650619,P14780,,YBBJKCMMCRQZMA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,77,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103279,DTCC01022973,572605,43205
CHEMBL1650620,P14780,,SVOBTPSWHFSTQO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,100,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103997,DTCC01022974,896235,43205
CHEMBL1650621,P14780,,SQEXIHSVVCJZTQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,96,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103856,DTCC01022975,798491,43205
CHEMBL1650622,P14780,,QJEZBSWVHDOAFS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,66,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103139,DTCC01022976,572606,43205
CHEMBL1650623,P14780,,HMXGIMVMTIFQHT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,100,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103996,DTCC01022977,1763873,43205
CHEMBL1650624,P14780,,XTMONGQRZFRDAJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,100,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103995,DTCC01022978,1381650,43205
CHEMBL1650625,P14780,4-METHYLSALICYLIC ACID,NJESAXZANHETJV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,10,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103152,DTCC00033479,1892888,43205
CHEMBL1650626,P14780,,TTZOLDXHOCCNMF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,5,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5102665,DTCC01022979,766406,43205
CHEMBL1650627,P14780,,KXZQYLBVMZGIKC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,84,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103868,DTCC01022980,1185923,43205
CHEMBL1650628,P14780,"1,4,7-TRIAZONANE",ITWBWJFEJCHKSN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,100,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103994,DTCC00033480,1542780,43205
CHEMBL1650629,P14780,,RRXGRDMHWYLJSY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,58,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103337,DTCC01022981,1122425,43205
CHEMBL1650630,P14780,,IQGMRVWUTCYCST-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,59,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103229,DTCC01022982,1445793,43205
CHEMBL1650631,P14780,,GHGZVWOTJDLREY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,-20,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103171,DTCC01022983,1024888,43205
CHEMBL1650632,P14780,,MVVGSPCXHRFDDR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,3,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103756,DTCC01022984,1607386,43205
CHEMBL1650633,P14780,,GSOHKPVFCOWKPU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,-4,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5102631,DTCC01022985,1763874,43205
CHEMBL1650634,P14780,,GUARKOVVHJSMRW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,1,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103833,DTCC01022986,1796211,43205
CHEMBL1650635,P14780,,VLRGXXKFHVJQOL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,-14,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103322,DTCC01022987,151277,43205
CHEMBL1651842,P14780,,IEHSRERHOYOHOA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,ACTIVITY,=,0.1,10'-3/M/S,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain assessed as dissociation rate constant by substrate hydrolysis based fluorescence spectrophotometry,,,ACS Med. Chem. Lett.,2011,2,2,,,702129,DTCT0024844,5066043,DTCC01024067,523282,42713
CHEMBL1651842,P14780,,IEHSRERHOYOHOA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,ACTIVITY,=,21,10'-3/M/S,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain assessed as association rate constant by substrate hydrolysis based fluorescence spectrophotometry,,,ACS Med. Chem. Lett.,2011,2,2,,,702121,DTCT0024844,5066014,DTCC01024067,523282,42713
CHEMBL1651842,P14780,,IEHSRERHOYOHOA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,5,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain by substrate hydrolysis based fluorescence spectrophotometry,,,ACS Med. Chem. Lett.,2011,2,2,,,702135,DTCT0024844,5066081,DTCC01024067,523282,42713
CHEMBL1651842,P14780,,IEHSRERHOYOHOA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,5,NM,,,,,,,,,,,,,,Competitive inhibition of human MMP9 using fluorogenic substrate by Dixon plot analysis,,,ACS Med. Chem. Lett.,2012,3,6,,,831079,DTCT0024844,10566542,DTCC01024067,543746,48923
CHEMBL1651843,P14780,,KPYDTDKHTIUCAB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,ACTIVITY,=,1.5,10'-3/M/S,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain assessed as dissociation rate constant by substrate hydrolysis based fluorescence spectrophotometry,,,ACS Med. Chem. Lett.,2011,2,2,,,702129,DTCT0024844,5066044,DTCC01024068,328820,42713
CHEMBL1651843,P14780,,KPYDTDKHTIUCAB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,ACTIVITY,=,4.6,10'-3/M/S,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain assessed as association rate constant by substrate hydrolysis based fluorescence spectrophotometry,,,ACS Med. Chem. Lett.,2011,2,2,,,702121,DTCT0024844,5066015,DTCC01024068,328820,42713
CHEMBL1651843,P14780,,KPYDTDKHTIUCAB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,330,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain by substrate hydrolysis based fluorescence spectrophotometry,,,ACS Med. Chem. Lett.,2011,2,2,,,702135,DTCT0024844,5066082,DTCC01024068,328820,42713
CHEMBL1651844,P14780,,GODQVOUTCHZIOJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,ACTIVITY,=,1.6,10'-3/M/S,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain assessed as dissociation rate constant by substrate hydrolysis based fluorescence spectrophotometry,,,ACS Med. Chem. Lett.,2011,2,2,,,702129,DTCT0024844,5066045,DTCC01024069,1364047,42713
CHEMBL1651844,P14780,,GODQVOUTCHZIOJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,ACTIVITY,=,3.2,10'-3/M/S,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain assessed as association rate constant by substrate hydrolysis based fluorescence spectrophotometry,,,ACS Med. Chem. Lett.,2011,2,2,,,702121,DTCT0024844,5066016,DTCC01024069,1364047,42713
CHEMBL1651844,P14780,,GODQVOUTCHZIOJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,520,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain by substrate hydrolysis based fluorescence spectrophotometry,,,ACS Med. Chem. Lett.,2011,2,2,,,702135,DTCT0024844,5066083,DTCC01024069,1364047,42713
CHEMBL1651845,P14780,,IQVPMSHPSMKSIK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,ACTIVITY,=,2,10'-3/M/S,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain assessed as dissociation rate constant by substrate hydrolysis based fluorescence spectrophotometry,,,ACS Med. Chem. Lett.,2011,2,2,,,702129,DTCT0024844,5066046,DTCC01024070,846384,42713
CHEMBL1651845,P14780,,IQVPMSHPSMKSIK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,ACTIVITY,=,5.3,10'-3/M/S,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain assessed as association rate constant by substrate hydrolysis based fluorescence spectrophotometry,,,ACS Med. Chem. Lett.,2011,2,2,,,702121,DTCT0024844,5066017,DTCC01024070,846384,42713
CHEMBL1651845,P14780,,IQVPMSHPSMKSIK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,380,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain by substrate hydrolysis based fluorescence spectrophotometry,,,ACS Med. Chem. Lett.,2011,2,2,,,702135,DTCT0024844,5066084,DTCC01024070,846384,42713
CHEMBL1651846,P14780,,LWHDLJDNHJFUSI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,ACTIVITY,=,0.25,10'-3/M/S,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain assessed as dissociation rate constant by substrate hydrolysis based fluorescence spectrophotometry,,,ACS Med. Chem. Lett.,2011,2,2,,,702129,DTCT0024844,5066047,DTCC01024071,716794,42713
CHEMBL1651846,P14780,,LWHDLJDNHJFUSI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,ACTIVITY,=,0.26,10'-3/M/S,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain assessed as association rate constant by substrate hydrolysis based fluorescence spectrophotometry,,,ACS Med. Chem. Lett.,2011,2,2,,,702121,DTCT0024844,5066018,DTCC01024071,716794,42713
CHEMBL1651846,P14780,,LWHDLJDNHJFUSI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,3900,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain by substrate hydrolysis based fluorescence spectrophotometry,,,ACS Med. Chem. Lett.,2011,2,2,,,702135,DTCT0024844,5066085,DTCC01024071,716794,42713
CHEMBL1651847,P14780,,BXWKQAHPQICDHI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,ACTIVITY,=,0.15,10'-3/M/S,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain assessed as association rate constant by substrate hydrolysis based fluorescence spectrophotometry,,,ACS Med. Chem. Lett.,2011,2,2,,,702121,DTCT0024844,5065825,DTCC01024072,198194,42713
CHEMBL1651847,P14780,,BXWKQAHPQICDHI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,ACTIVITY,=,1.8,10'-3/M/S,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain assessed as dissociation rate constant by substrate hydrolysis based fluorescence spectrophotometry,,,ACS Med. Chem. Lett.,2011,2,2,,,702129,DTCT0024844,5066048,DTCC01024072,198194,42713
CHEMBL1651847,P14780,,BXWKQAHPQICDHI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,12000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain by substrate hydrolysis based fluorescence spectrophotometry,,,ACS Med. Chem. Lett.,2011,2,2,,,702135,DTCT0024844,5066086,DTCC01024072,198194,42713
CHEMBL1651848,P14780,,FDPYTWXXVNVJLZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,ACTIVITY,=,0.15,10'-3/M/S,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain assessed as association rate constant by substrate hydrolysis based fluorescence spectrophotometry,,,ACS Med. Chem. Lett.,2011,2,2,,,702121,DTCT0024844,5066019,DTCC01024073,1137429,42713
CHEMBL1651848,P14780,,FDPYTWXXVNVJLZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,ACTIVITY,=,0.9,10'-3/M/S,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain assessed as dissociation rate constant by substrate hydrolysis based fluorescence spectrophotometry,,,ACS Med. Chem. Lett.,2011,2,2,,,702129,DTCT0024844,5066049,DTCC01024073,1137429,42713
CHEMBL1651848,P14780,,FDPYTWXXVNVJLZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,6200,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain by substrate hydrolysis based fluorescence spectrophotometry,,,ACS Med. Chem. Lett.,2011,2,2,,,702135,DTCT0024844,5066087,DTCC01024073,1137429,42713
CHEMBL1651849,P14780,,NMRGHYQXKHANMB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,ACTIVITY,=,0.54,10'-3/M/S,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain assessed as association rate constant by substrate hydrolysis based fluorescence spectrophotometry,,,ACS Med. Chem. Lett.,2011,2,2,,,702121,DTCT0024844,5066020,DTCC01024074,198195,42713
CHEMBL1651849,P14780,,NMRGHYQXKHANMB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,ACTIVITY,=,1.9,10'-3/M/S,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain assessed as dissociation rate constant by substrate hydrolysis based fluorescence spectrophotometry,,,ACS Med. Chem. Lett.,2011,2,2,,,702129,DTCT0024844,5066050,DTCC01024074,198195,42713
CHEMBL1651849,P14780,,NMRGHYQXKHANMB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,3500,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain by substrate hydrolysis based fluorescence spectrophotometry,,,ACS Med. Chem. Lett.,2011,2,2,,,702135,DTCT0024844,5066088,DTCC01024074,198195,42713
CHEMBL16519,P14780,,PNKICJSNJYXQOE-OWCLPIDISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871728,IC50,=,0.14,NM,,,,,,,,,,,,,,"Inhibition of matrix metalloprotease-9, gelatinase-B",,The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,1998,8,10,"Levin JI, DiJoseph JF, Killar LM, Sharr MA, Skotnicki JS, Patel DV, Xiao XY, Shi L, Navre M, Campbell DA",,105236,DTCT0024844,1047975,DTCC00147199,758311,2560
CHEMBL1651906,P14780,STREPTOZOTOCIN,ZSJLQEPLLKMAKR-YDEIVXIUSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7482415,DTCC01024120,1318448,46191
CHEMBL1651906,P14780,STREPTOZOTOCIN,ZSJLQEPLLKMAKR-YDEIVXIUSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7482416,DTCC01024120,1318448,46191
CHEMBL16520,P14780,RO-319790,QRXOZHSEEGNRFC-ZYHUDNBSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9548812,IC50,=,12,NM,,,,,,,,,,,,,,Activity against Matrix metalloprotease-9 (MMP-9).,,Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.,J. Med. Chem.,1998,41,8,"Yamamoto M, Tsujishita H, Hori N, Ohishi Y, Inoue S, Ikeda S, Okada Y",,105225,DTCT0024844,1000674,DTCC00147200,984635,15116
CHEMBL16520,P14780,RO-319790,QRXOZHSEEGNRFC-ZYHUDNBSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871728,IC50,=,12,NM,,,,,,,,,,,,,,"Inhibition of matrix metalloprotease-9, gelatinase-B",,The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,1998,8,10,"Levin JI, DiJoseph JF, Killar LM, Sharr MA, Skotnicki JS, Patel DV, Xiao XY, Shi L, Navre M, Campbell DA",,105236,DTCT0024844,1039271,DTCC00147200,984592,2560
CHEMBL16520,P14780,RO-319790,QRXOZHSEEGNRFC-ZYHUDNBSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514157,KI,=,2,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution.,Bioorg. Med. Chem. Lett.,2001,11,16,"Musso DL, Andersen MW, Andrews RC, Austin R, Beaudet EJ, Becherer JD, Bubacz DG, Bickett DM, Chan JH, Conway JG, Cowan DJ, Gaul MD, Glennon KC, Hedeen KM, Lambert MH, Leesnitzer MA, McDougald DL, Mitchell JL, Moss ML, Rabinowitz MH, Rizzolio MC, Schaller LT, Stanford JB, Tippin T, Warner JR, Whitesell LG, Wiethe RW",,105661,DTCT0024844,926822,DTCC00147200,981874,4390
CHEMBL16554,P14780,,ZWDYAHGBOJEURS-GDBMZVCRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871728,IC50,=,0.14,NM,,,,,,,,,,,,,,"Inhibition of matrix metalloprotease-9, gelatinase-B",,The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,1998,8,10,"Levin JI, DiJoseph JF, Killar LM, Sharr MA, Skotnicki JS, Patel DV, Xiao XY, Shi L, Navre M, Campbell DA",,105236,DTCT0024844,1050549,DTCC00147128,919813,2560
CHEMBL165790,P14780,IPRIFLAVONE,SFBODOKJTYAUCM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7409588,DTCC00358921,542578,46191
CHEMBL165790,P14780,IPRIFLAVONE,SFBODOKJTYAUCM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7409589,DTCC00358921,542578,46191
CHEMBL16595,P14780,,ITKSAJKSHOIQGV-FQXDTITESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871728,IC50,=,20,NM,,,,,,,,,,,,,,"Inhibition of matrix metalloprotease-9, gelatinase-B",,The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,1998,8,10,"Levin JI, DiJoseph JF, Killar LM, Sharr MA, Skotnicki JS, Patel DV, Xiao XY, Shi L, Navre M, Campbell DA",,105236,DTCT0024844,1040682,DTCC00147096,239873,2560
CHEMBL1660,P14780,RIFAPENTINE,WDZCUPBHRAEYDL-GZAUEHORSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7483817,DTCC00550275,930086,46191
CHEMBL1660,P14780,RIFAPENTINE,WDZCUPBHRAEYDL-GZAUEHORSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7483818,DTCC00550275,930086,46191
CHEMBL16630,P14780,,UOLDAWOAHWACHY-FRRDWIJNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871728,IC50,=,8,NM,,,,,,,,,,,,,,"Inhibition of matrix metalloprotease-9, gelatinase-B",,The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,1998,8,10,"Levin JI, DiJoseph JF, Killar LM, Sharr MA, Skotnicki JS, Patel DV, Xiao XY, Shi L, Navre M, Campbell DA",,105236,DTCT0024844,1030635,DTCC00147118,1631662,2560
CHEMBL16650,P14780,,PNKICJSNJYXQOE-BZUAXINKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871728,IC50,=,12,NM,,,,,,,,,,,,,,"Inhibition of matrix metalloprotease-9, gelatinase-B",,The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,1998,8,10,"Levin JI, DiJoseph JF, Killar LM, Sharr MA, Skotnicki JS, Patel DV, Xiao XY, Shi L, Navre M, Campbell DA",,105236,DTCT0024844,1041951,DTCC00147268,1852726,2560
CHEMBL166564,P14780,,JYIVEWZWGSXEIG-NPPFBWRTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871551,KI,=,2,NM,,,,,,,,,,,,,,Binding affinity was evaluated against matrix metalloprotease-9,,Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,1998,8,7,"Jacobson IC, Reddy PG, Wasserman ZR, Hardman KD, Covington MB, Arner EC, Copeland RA, Decicco CP, Magolda RL",,105373,DTCT0024844,501102,DTCC00365442,842894,3059
CHEMBL16664,P14780,,ORNRXHLQXJIHAY-XLQDAESGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871727,IC50,,,,,,,,,,,,,,,,,In vitro inhibitory activity against gelatinase-B (MMP-9.,Not Tested,"Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.",Bioorg. Med. Chem. Lett.,1998,8,10,"Campbell DA, Xiao XY, Harris D, Ida S, Mortezaei R, Ngu K, Shi L, Tien D, Wang Y, Navre M, Patel DV, Sharr MA, DiJoseph JF, Killar LM, Leone CL, Levin JI, Skotnicki JS",,105235,DTCT0024844,1533825,DTCC00146389,1146850,2559
CHEMBL166793,P14780,,ATPROROBDLVBNF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION RATIO,~,12,%,,,,,,,,,,,,,,Inhibition of collagen IV degradation by matrix metalloprotease-9 at 100 uM,,,Bioorg. Med. Chem. Lett.,1997,7,7,,,105537,DTCT0024844,673107,DTCC00364454,1662785,2474
CHEMBL166793,P14780,,ATPROROBDLVBNF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION RATIO,,,,,,,,,,,,,,,,,Inhibition of collagen IV degradation by matrix metalloprotease-9 at 10 uM (no data),Not Determined,,Bioorg. Med. Chem. Lett.,1997,7,7,,,105539,DTCT0024844,673059,DTCC00364454,1662785,2474
CHEMBL1668126,P14780,,GZVYRVDFHLLJPP-IDRUGXTQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21130662,ACTIVITY,,,,,,,,,,,,,,,,,Activity at MMP9,Not Active,Functional in vivo imaging of cysteine cathepsin activity in murine model of inflammation.,Bioorg. Med. Chem.,2011,19,3,"Caglic D, Globisch A, Kindermann M, Lim NH, Jeske V, Juretschke HP, Bartnik E, Weithmann KU, Nagase H, Turk B, Wendt KU",,717559,DTCT0024844,5112233,DTCC01024969,1122449,43232
CHEMBL1668626,P14780,,YGGOSFPNPAAKEW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23428964,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin) up to 50 uM,Not Active,Selective aminopeptidase-N (CD13) inhibitors with relevance to cancer chemotherapy.,Bioorg. Med. Chem.,2013,21,7,"Schmitt C, Voegelin M, Marin A, Schmitt M, Schegg F, Hénon P, Guenot D, Tarnus C",,951225,DTCT0024844,11846961,DTCC01025454,330824,54192
CHEMBL1670,P14780,MITOTANE,JWBOIMRXGHLCPP-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7436936,DTCC00555980,2057649,46191
CHEMBL1670,P14780,MITOTANE,JWBOIMRXGHLCPP-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7436937,DTCC00555980,2057649,46191
CHEMBL167232,P14780,,QVZSRIQXJCGDLT-PSAQOYSPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871551,KI,=,149,NM,,,,,,,,,,,,,,Binding affinity was evaluated against matrix metalloprotease-9,,Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,1998,8,7,"Jacobson IC, Reddy PG, Wasserman ZR, Hardman KD, Covington MB, Arner EC, Copeland RA, Decicco CP, Magolda RL",,105373,DTCT0024844,486586,DTCC00365117,292807,3059
CHEMBL167233,P14780,,VZLQRHVGUTYXBQ-IBGGVINMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871551,KI,=,1,NM,,,,,,,,,,,,,,Binding affinity was evaluated against matrix metalloprotease-9,,Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,1998,8,7,"Jacobson IC, Reddy PG, Wasserman ZR, Hardman KD, Covington MB, Arner EC, Copeland RA, Decicco CP, Magolda RL",,105373,DTCT0024844,487674,DTCC00365118,2035237,3059
CHEMBL167278,P14780,,OSDJVSPJKNBXKV-MZLICYQSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871551,KI,=,2,NM,,,,,,,,,,,,,,Binding affinity was evaluated against matrix metalloprotease-9,,Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,1998,8,7,"Jacobson IC, Reddy PG, Wasserman ZR, Hardman KD, Covington MB, Arner EC, Copeland RA, Decicco CP, Magolda RL",,105373,DTCT0024844,478555,DTCC00364305,1101849,3059
CHEMBL1679,P14780,LEUCOVORIN,VVIAGPKUTFNRDU-ABLWVSNPSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7437914,DTCC00560549,1188068,46191
CHEMBL1679,P14780,LEUCOVORIN,VVIAGPKUTFNRDU-ABLWVSNPSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7437915,DTCC00560549,1188068,46191
CHEMBL167911,P14780,DICHLORVOS,OEBRKCOSUFCWJD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7338109,DTCC00362299,1544896,46191
CHEMBL167911,P14780,DICHLORVOS,OEBRKCOSUFCWJD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7338110,DTCC00362299,1544896,46191
CHEMBL168231,P14780,,PMFODAOPNPIVJM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION RATIO,=,32,%,,,,,,,,,,,,,,Inhibition of collagen IV degradation by matrix metalloprotease-9 at 10 uM,,,Bioorg. Med. Chem. Lett.,1997,7,7,,,105538,DTCT0024844,675669,DTCC00364032,1694936,2474
CHEMBL168231,P14780,,PMFODAOPNPIVJM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION RATIO,=,57,%,,,,,,,,,,,,,,Inhibition of collagen IV degradation by matrix metalloprotease-9 at 100 uM,,,Bioorg. Med. Chem. Lett.,1997,7,7,,,105537,DTCT0024844,675670,DTCC00364032,1694936,2474
CHEMBL168601,P14780,,IGWLPPHUCLZWTC-TWOQFEAHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871551,KI,=,5,NM,,,,,,,,,,,,,,Binding affinity was evaluated against matrix metalloprotease-9,,Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,1998,8,7,"Jacobson IC, Reddy PG, Wasserman ZR, Hardman KD, Covington MB, Arner EC, Copeland RA, Decicco CP, Magolda RL",,105373,DTCT0024844,504946,DTCC00364721,1619197,3059
CHEMBL1687,P14780,TUBOCURARINE CHLORIDE,MHXYWXHKLBMJKL-QBYKQQEBSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7357029,DTCC00570867,1253320,46191
CHEMBL1687,P14780,TUBOCURARINE CHLORIDE,MHXYWXHKLBMJKL-QBYKQQEBSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7357030,DTCC00570867,1253320,46191
CHEMBL168802,P14780,,JBYQQXSCANNDNP-STWLZBDKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871551,KI,<,1,NM,,,,,,,,,,,,,,Binding affinity was evaluated against matrix metalloprotease-9,,Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,1998,8,7,"Jacobson IC, Reddy PG, Wasserman ZR, Hardman KD, Covington MB, Arner EC, Copeland RA, Decicco CP, Magolda RL",,105373,DTCT0024844,487671,DTCC00364268,1101848,3059
CHEMBL168804,P14780,,TVGCTSIRFSSYKF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION RATIO,~,46,%,,,,,,,,,,,,,,Inhibition of collagen IV degradation by matrix metalloprotease-9 at 10 uM,,,Bioorg. Med. Chem. Lett.,1997,7,7,,,105538,DTCT0024844,683377,DTCC00364029,789340,2474
CHEMBL168804,P14780,,TVGCTSIRFSSYKF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION RATIO,~,55,%,,,,,,,,,,,,,,Inhibition of collagen IV degradation by matrix metalloprotease-9 at 100 uM,,,Bioorg. Med. Chem. Lett.,1997,7,7,,,105537,DTCT0024844,683378,DTCC00364029,789340,2474
CHEMBL169084,P14780,,RCJJPUINEATAJF-GCKMJXCFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871551,KI,<,1,NM,,,,,,,,,,,,,,Binding affinity was evaluated against matrix metalloprotease-9,,Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,1998,8,7,"Jacobson IC, Reddy PG, Wasserman ZR, Hardman KD, Covington MB, Arner EC, Copeland RA, Decicco CP, Magolda RL",,105373,DTCT0024844,475039,DTCC00364247,6546,3059
CHEMBL169088,P14780,,WFZLIJWVROBOFI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION RATIO,~,53,%,,,,,,,,,,,,,,Inhibition of collagen IV degradation by matrix metalloprotease-9 at 10 uM,,,Bioorg. Med. Chem. Lett.,1997,7,7,,,105538,DTCT0024844,657294,DTCC00364060,983448,2474
CHEMBL169088,P14780,,WFZLIJWVROBOFI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION RATIO,~,69,%,,,,,,,,,,,,,,Inhibition of collagen IV degradation by matrix metalloprotease-9 at 100 uM,,,Bioorg. Med. Chem. Lett.,1997,7,7,,,105537,DTCT0024844,657295,DTCC00364060,983448,2474
CHEMBL16933,P14780,,SPVUAASKZWLIQS-DGCLKSJQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871728,IC50,=,8,NM,,,,,,,,,,,,,,"Inhibition of matrix metalloprotease-9, gelatinase-B",,The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,1998,8,10,"Levin JI, DiJoseph JF, Killar LM, Sharr MA, Skotnicki JS, Patel DV, Xiao XY, Shi L, Navre M, Campbell DA",,105236,DTCT0024844,1034093,DTCC00147150,2047616,2560
CHEMBL1697694,P14780,AFLATOXIN,OQIQSTLJSLGHID-WNWIJWBNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7292276,DTCC00127800,1092339,46191
CHEMBL1697694,P14780,AFLATOXIN,OQIQSTLJSLGHID-WNWIJWBNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7292277,DTCC00127800,1092339,46191
CHEMBL169996,P14780,,BIDYRGOZWOVNRZ-BCQCSXDESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871551,KI,=,34,NM,,,,,,,,,,,,,,Binding affinity was evaluated against matrix metalloprotease-9,,Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,1998,8,7,"Jacobson IC, Reddy PG, Wasserman ZR, Hardman KD, Covington MB, Arner EC, Copeland RA, Decicco CP, Magolda RL",,105373,DTCT0024844,478558,DTCC00108963,1165232,3059
CHEMBL170103,P14780,,BNPMWDDIMRPKMZ-JTSKRJEESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,INHIBITION,=,5,%,,,,,,,,,,,,,,Percent remaining enzyme activity (RA) in human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105368,DTCT0024844,1129974,DTCC00371438,777871,5419
CHEMBL170103,P14780,,BNPMWDDIMRPKMZ-JTSKRJEESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,KI,=,800,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105399,DTCT0024844,1129973,DTCC00371438,777871,5419
CHEMBL170315,P14780,,RTKNMWBYPISZDZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,=,2.03,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1418816,DTCC00370641,1948587,17147
CHEMBL170346,P14780,,BNFQSPBDDPIXCF-VIFPVBQESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,INHIBITION,=,67,%,,,,,,,,,,,,,,Percent remaining enzyme activity (RA) in human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105368,DTCT0024844,1126112,DTCC00371364,584245,5419
CHEMBL170429,P14780,,FITSVZFOIGFQQI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,=,6.57,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1418821,DTCC00372567,1501478,17147
CHEMBL170625,P14780,,AEAOFBYNIYSJQK-HNNXBMFYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,INHIBITION,=,2,%,,,,,,,,,,,,,,Percent remaining enzyme activity (RA) in human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105368,DTCT0024844,1111700,DTCC00371444,1036734,5419
CHEMBL17082,P14780,,PAGLSWGGXPHWJN-DBSNRUDNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871728,IC50,=,24,NM,,,,,,,,,,,,,,"Inhibition of matrix metalloprotease-9, gelatinase-B",,The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,1998,8,10,"Levin JI, DiJoseph JF, Killar LM, Sharr MA, Skotnicki JS, Patel DV, Xiao XY, Shi L, Navre M, Campbell DA",,105236,DTCT0024844,1045543,DTCC00147253,500351,2560
CHEMBL171292,P14780,,NQUUIXIBNFFYTG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,=,16.7,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1405727,DTCC00370477,499303,17147
CHEMBL1712923,P14780,IRSOGLADINE MALEATE,PJLVTVAIERNDEQ-BTJKTKAUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7426802,DTCC01047420,1894969,46191
CHEMBL1712923,P14780,IRSOGLADINE MALEATE,PJLVTVAIERNDEQ-BTJKTKAUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7426803,DTCC01047420,1894969,46191
CHEMBL171466,P14780,,XVXXOYBXUAACNT-YWZLYKJASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,INHIBITION,=,1,%,,,,,,,,,,,,,,Percent remaining enzyme activity (RA) in human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105368,DTCT0024844,1123504,DTCC00371065,843002,5419
CHEMBL171466,P14780,,XVXXOYBXUAACNT-YWZLYKJASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,KI,=,150,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105399,DTCT0024844,1123503,DTCC00371065,843002,5419
CHEMBL17157,P14780,TERFENADINE,GUGOEEXESWIERI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7478864,DTCC00148306,510307,46191
CHEMBL17157,P14780,TERFENADINE,GUGOEEXESWIERI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7478865,DTCC00148306,510307,46191
CHEMBL171949,P14780,,HRMFOWHCPWWSTB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,INHIBITION,=,3,%,,,,,,,,,,,,,,Percent remaining enzyme activity (RA) in human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105368,DTCT0024844,1133852,DTCC00373680,1230017,5419
CHEMBL171949,P14780,,HRMFOWHCPWWSTB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,KI,=,800,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105399,DTCT0024844,1133851,DTCC00373680,1230017,5419
CHEMBL171962,P14780,,DPQCHTZYBRQXQC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,=,11,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1409278,DTCC00371624,1404889,17147
CHEMBL171986,P14780,,RLVHPDACJUGNSL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,=,278,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1416481,DTCC00371044,725093,17147
CHEMBL172180,P14780,,WKWHTFBYSLLKLG-YWZLYKJASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,INHIBITION,=,5,%,,,,,,,,,,,,,,Percent remaining enzyme activity (RA) in human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105368,DTCT0024844,1103406,DTCC00371752,1490105,5419
CHEMBL172180,P14780,,WKWHTFBYSLLKLG-YWZLYKJASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,KI,=,500,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105399,DTCT0024844,1103405,DTCC00371752,1490105,5419
CHEMBL172181,P14780,,MDDQQIMYYBMNMU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,=,316,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1440108,DTCC00371829,369785,17147
CHEMBL172249,P14780,,OHBFRMUALPHZIT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,=,1.13,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1411442,DTCC00371713,757267,17147
CHEMBL172251,P14780,,FRRIILVFUOBZCJ-MBABXSBOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,INHIBITION,=,2,%,,,,,,,,,,,,,,Percent remaining enzyme activity (RA) in human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105368,DTCT0024844,1110247,DTCC00371594,1619276,5419
CHEMBL172415,P14780,,KADFIIKJGHEHDF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,=,80.1,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1443813,DTCC00371652,1754773,17147
CHEMBL172548,P14780,,MXGYLPKHTGTZKG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,=,42.7,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1408026,DTCC00109174,466432,17147
CHEMBL1726,P14780,NISOLDIPINE,VKQFCGNPDRICFG-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7392745,DTCC00583129,1830687,46191
CHEMBL1726,P14780,NISOLDIPINE,VKQFCGNPDRICFG-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7392746,DTCC00583129,1830687,46191
CHEMBL1727,P14780,CEPHALEXIN,ZAIPMKNFIOOWCQ-UEKVPHQBSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7360146,DTCC00584128,444636,46191
CHEMBL1727,P14780,CEPHALEXIN,ZAIPMKNFIOOWCQ-UEKVPHQBSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7360147,DTCC00584128,444636,46191
CHEMBL172722,P14780,,IAZFWEJODMHVIO-OUKQBFOZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,=,88.8,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1418826,DTCC00372096,1113479,17147
CHEMBL172874,P14780,,QXLUKDZXPBRJKE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,INHIBITION,=,3,%,,,,,,,,,,,,,,Percent remaining enzyme activity (RA) in human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105368,DTCT0024844,1124717,DTCC00370663,1715183,5419
CHEMBL172874,P14780,,QXLUKDZXPBRJKE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,KI,=,250,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105399,DTCT0024844,1124716,DTCC00370663,1715183,5419
CHEMBL172885,P14780,,NQYWUYPYYFALAI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,=,51.9,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1409283,DTCC00372088,466433,17147
CHEMBL172886,P14780,,USYXNFCQBGQYRW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,=,41.8,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1417567,DTCC00372089,238852,17147
CHEMBL1729,P14780,CISAPRIDE,DCSUBABJRXZOMT-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7345621,DTCC00585645,315663,46191
CHEMBL1729,P14780,CISAPRIDE,DCSUBABJRXZOMT-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7345622,DTCC00585645,315663,46191
CHEMBL1730,P14780,CEFOTAXIME,GPRBEKHLDVQUJE-QSWIMTSFSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7351504,DTCC00585909,51453,46191
CHEMBL1730,P14780,CEFOTAXIME,GPRBEKHLDVQUJE-QSWIMTSFSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7351505,DTCC00585909,51453,46191
CHEMBL173027,P14780,,TZNUGSCRBFBAFR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,=,3.42,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1426180,DTCC00372005,1981537,17147
CHEMBL173075,P14780,,LWBGXTORWSRDHX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11327602,IC50,=,330,NM,,,,,,,,,,,,,,"Inhibition of Gelatinase B, matrix metalloprotease-9",,"Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors.",Bioorg. Med. Chem. Lett.,2001,11,8,"Foley LH, Palermo R, Dunten P, Wang P",,71657,DTCT0024844,970224,DTCC00372720,174400,4784
CHEMBL1732,P14780,DIHYDROERGOTAMINE,LUZRJRNZXALNLM-JGRZULCMSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7359666,DTCC00586321,381008,46191
CHEMBL1732,P14780,DIHYDROERGOTAMINE,LUZRJRNZXALNLM-JGRZULCMSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7359667,DTCC00586321,381008,46191
CHEMBL173235,P14780,,LXKHXLQQHKRMFP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,=,5.2,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1433785,DTCC00372426,2014370,17147
CHEMBL173284,P14780,,IHNYAHCZDRILEC-YPMHNXCESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,INHIBITION,=,60,%,,,,,,,,,,,,,,Percent remaining enzyme activity (RA) in human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105368,DTCT0024844,1119535,DTCC00370419,1904589,5419
CHEMBL173316,P14780,,CDUNTBSHRUTDFM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,=,3.8,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1418811,DTCC00372427,1851654,17147
CHEMBL173326,P14780,,PIHNCDLSZQOOPU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,=,32.1,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1436534,DTCC00371345,1630613,17147
CHEMBL173382,P14780,,HCKYIMJMJTUVAP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,INHIBITION,=,2,%,,,,,,,,,,,,,,Percent remaining enzyme activity (RA) in human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105368,DTCT0024844,1119539,DTCC00370756,1586614,5419
CHEMBL173382,P14780,,HCKYIMJMJTUVAP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,KI,=,350,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105399,DTCT0024844,1119538,DTCC00370756,1586614,5419
CHEMBL173533,P14780,,ODZPYMWQRDBEPD-LOSJGSFVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,INHIBITION,=,3,%,,,,,,,,,,,,,,Percent remaining enzyme activity (RA) in human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105368,DTCT0024844,1100873,DTCC00372545,971793,5419
CHEMBL173533,P14780,,ODZPYMWQRDBEPD-LOSJGSFVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,KI,=,1000,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105399,DTCT0024844,1100872,DTCC00372545,971793,5419
CHEMBL173544,P14780,,VLUPODOOTLRMGI-NSHDSACASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,INHIBITION,=,40,%,,,,,,,,,,,,,,Percent remaining enzyme activity (RA) in human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105368,DTCT0024844,1095528,DTCC00371020,358059,5419
CHEMBL173686,P14780,,IBUXWZOBVVWCHD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,=,0.6,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1417582,DTCC00370729,918694,17147
CHEMBL173744,P14780,,XUDSOJRUANECGX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,=,23.2,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1408021,DTCC00372566,692792,17147
CHEMBL173754,P14780,,PCAPSCAFNCUGDE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,=,6.47,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1443808,DTCC00370762,725092,17147
CHEMBL173818,P14780,,KKZUWROSSZALIB-ZETCQYMHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,INHIBITION,=,55,%,,,,,,,,,,,,,,Percent remaining enzyme activity (RA) in human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105368,DTCT0024844,1122326,DTCC00370650,259623,5419
CHEMBL173846,P14780,,KMYAHTGTYRRWEK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,=,4.56,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1439002,DTCC00109119,983530,17147
CHEMBL174,P14780,AMPICILLIN,AVKUERGKIZMTKX-NJBDSQKTSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7292798,DTCC00385816,51446,46191
CHEMBL174,P14780,AMPICILLIN,AVKUERGKIZMTKX-NJBDSQKTSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7292799,DTCC00385816,51446,46191
CHEMBL174014,P14780,,RBLCSCFFNCADJO-XRHLQHRESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,>,800,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1424993,DTCC00371948,1695013,17147
CHEMBL174084,P14780,,RJZVOLUHBQERAD-AWEZNQCLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,INHIBITION,=,15,%,,,,,,,,,,,,,,Percent remaining enzyme activity (RA) in human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105368,DTCT0024844,1104964,DTCC00371209,1743527,5419
CHEMBL174084,P14780,,RJZVOLUHBQERAD-AWEZNQCLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,KI,=,8200,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105399,DTCT0024844,1104963,DTCC00371209,1743527,5419
CHEMBL1741,P14780,CLARITHROMYCIN,AGOYDEPGAOXOCK-KCBOHYOISA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7371572,DTCC00596664,1641846,46191
CHEMBL1741,P14780,CLARITHROMYCIN,AGOYDEPGAOXOCK-KCBOHYOISA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7371573,DTCC00596664,1641846,46191
CHEMBL174315,P14780,,AIBDPCDNFOFGFS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,=,5.22,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1440113,DTCC00370676,1565857,17147
CHEMBL174373,P14780,,AIDZFVBIMNVQQY-LBPRGKRZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,INHIBITION,=,25,%,,,,,,,,,,,,,,Percent remaining enzyme activity (RA) in human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105368,DTCT0024844,1096961,DTCC00371066,584244,5419
CHEMBL174373,P14780,,AIDZFVBIMNVQQY-LBPRGKRZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,KI,=,4400,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105399,DTCT0024844,1096960,DTCC00371066,584244,5419
CHEMBL174422,P14780,,LQPUQCAPJTUCIA-YOEHRIQHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,INHIBITION,=,6,%,,,,,,,,,,,,,,Percent remaining enzyme activity (RA) in human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105368,DTCT0024844,1114184,DTCC00371013,745783,5419
CHEMBL174422,P14780,,LQPUQCAPJTUCIA-YOEHRIQHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,KI,=,3300,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105399,DTCT0024844,1114183,DTCC00371013,745783,5419
CHEMBL1744448,P14780,BLEOMYCIN A2,LOLFAJUUOFBGSF-KYIYJVAASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7277247,DTCC00127875,898283,46191
CHEMBL1744448,P14780,BLEOMYCIN A2,LOLFAJUUOFBGSF-KYIYJVAASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7277248,DTCC00127875,898283,46191
CHEMBL174641,P14780,,FYEUWTVOOOULEH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11327602,IC50,=,118,NM,,,,,,,,,,,,,,"Inhibition of Gelatinase B, matrix metalloprotease-9",,"Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors.",Bioorg. Med. Chem. Lett.,2001,11,8,"Foley LH, Palermo R, Dunten P, Wang P",,71657,DTCT0024844,959836,DTCC00375021,1404933,4784
CHEMBL1747,P14780,TOBRAMYCIN,NLVFBUXFDBBNBW-PBSUHMDJSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7461700,DTCC00603485,1734066,46191
CHEMBL1747,P14780,TOBRAMYCIN,NLVFBUXFDBBNBW-PBSUHMDJSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7461701,DTCC00603485,1734066,46191
CHEMBL174865,P14780,,MKXCYCNTSAOKDX-LRDDRELGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,INHIBITION,=,0,%,,,,,,,,,,,,,,Percent remaining enzyme activity (RA) in human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105368,DTCT0024844,1123509,DTCC00372935,520000,5419
CHEMBL174865,P14780,,MKXCYCNTSAOKDX-LRDDRELGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,KI,=,600,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105399,DTCT0024844,1123508,DTCC00372935,520000,5419
CHEMBL174993,P14780,,WFYLXIFCLIAISI-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,INHIBITION,=,7,%,,,,,,,,,,,,,,Percent remaining enzyme activity (RA) in human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105368,DTCT0024844,1121067,DTCC00373042,745782,5419
CHEMBL174993,P14780,,WFYLXIFCLIAISI-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,KI,=,3000,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105399,DTCT0024844,1121066,DTCC00373042,745782,5419
CHEMBL175,P14780,DEXIBUPROFEN,HEFNNWSXXWATRW-JTQLQIEISA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7346577,DTCC00396784,1862715,46191
CHEMBL175,P14780,DEXIBUPROFEN,HEFNNWSXXWATRW-JTQLQIEISA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7346578,DTCC00396784,1862715,46191
CHEMBL175009,P14780,,JQVKKTYOFNLOIP-MBSDFSHPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,INHIBITION,=,11,%,,,,,,,,,,,,,,Percent remaining enzyme activity (RA) in human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105368,DTCT0024844,1135123,DTCC00372934,713481,5419
CHEMBL1751,P14780,DIGOXIN,LTMHDMANZUZIPE-PUGKRICDSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7351060,DTCC00607566,51464,46191
CHEMBL1751,P14780,DIGOXIN,LTMHDMANZUZIPE-PUGKRICDSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7351061,DTCC00607566,51464,46191
CHEMBL175164,P14780,,DWFUVVZGNJNHKO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,=,38.3,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1429942,DTCC00372915,271599,17147
CHEMBL1752,P14780,DYPHYLLINE,KSCFJBIXMNOVSH-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7304634,DTCC00607571,2089746,46191
CHEMBL1752,P14780,DYPHYLLINE,KSCFJBIXMNOVSH-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7304635,DTCC00607571,2089746,46191
CHEMBL175282,P14780,,KYTLMUVGULFASG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11327602,IC50,=,863,NM,,,,,,,,,,,,,,"Inhibition of Gelatinase B, matrix metalloprotease-9",,"Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors.",Bioorg. Med. Chem. Lett.,2001,11,8,"Foley LH, Palermo R, Dunten P, Wang P",,71657,DTCT0024844,953315,DTCC00374234,32720,4784
CHEMBL1753,P14780,CLINDAMYCIN,KDLRVYVGXIQJDK-AWPVFWJPSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7349965,DTCC00607595,898286,46191
CHEMBL1753,P14780,CLINDAMYCIN,KDLRVYVGXIQJDK-AWPVFWJPSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7349966,DTCC00607595,898286,46191
CHEMBL1754,P14780,DOXAPRAM,XFDJYSQDBULQSI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7342732,DTCC00607599,1027051,46191
CHEMBL1754,P14780,DOXAPRAM,XFDJYSQDBULQSI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7342733,DTCC00607599,1027051,46191
CHEMBL1760,P14780,TERBUTALINE,XWTYSIMOBUGWOL-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7472222,DTCC00609006,542583,46191
CHEMBL1760,P14780,TERBUTALINE,XWTYSIMOBUGWOL-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7472223,DTCC00609006,542583,46191
CHEMBL1760318,P14780,,SZPWYHRMRFNOHH-GHTZIAJQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22342144,KI,=,21000,NM,,,,,,,,,,,,,,Inhibition of MMP-9 using OmniMMP as substrate,,Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain.,Bioorg. Med. Chem. Lett.,2012,22,6,"Jiao GS, Kim S, Moayeri M, Crown D, Thai A, Cregar-Hernandez L, McKasson L, Sankaran B, Lehrer A, Wong T, Johns L, Margosiak SA, Leppla SH, Johnson AT",,811339,DTCT0024844,10427384,DTCC01075303,1687706,47718
CHEMBL1760322,P14780,,DUBRLRRJAJGWMU-LJQANCHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22342144,KI,>,50000,NM,,,,,,,,,,,,,,Inhibition of MMP-9 using OmniMMP as substrate,,Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain.,Bioorg. Med. Chem. Lett.,2012,22,6,"Jiao GS, Kim S, Moayeri M, Crown D, Thai A, Cregar-Hernandez L, McKasson L, Sankaran B, Lehrer A, Wong T, Johns L, Margosiak SA, Leppla SH, Johnson AT",,811339,DTCT0024844,10427379,DTCC01075307,1201801,47718
CHEMBL1760324,P14780,,PVPXSRWESCVIBD-IBGZPJMESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22342144,KI,>,50000,NM,,,,,,,,,,,,,,Inhibition of MMP-9 using OmniMMP as substrate,,Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain.,Bioorg. Med. Chem. Lett.,2012,22,6,"Jiao GS, Kim S, Moayeri M, Crown D, Thai A, Cregar-Hernandez L, McKasson L, Sankaran B, Lehrer A, Wong T, Johns L, Margosiak SA, Leppla SH, Johnson AT",,811339,DTCT0024844,10427381,DTCC01075309,976029,47718
CHEMBL1762,P14780,TOCAINIDE,BUJAGSGYPOAWEI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7466091,DTCC00609197,1544903,46191
CHEMBL1762,P14780,TOCAINIDE,BUJAGSGYPOAWEI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7466092,DTCC00609197,1544903,46191
CHEMBL176467,P14780,,RTBMLCLTYAPKIF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11327602,IC50,=,52,NM,,,,,,,,,,,,,,"Inhibition of Gelatinase B, matrix metalloprotease-9",,"Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors.",Bioorg. Med. Chem. Lett.,2001,11,8,"Foley LH, Palermo R, Dunten P, Wang P",,71657,DTCT0024844,970229,DTCC00374112,1662912,4784
CHEMBL176467,P14780,,RTBMLCLTYAPKIF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15908214,KI,=,52,NM,,,,,,,,,,,,,,In vitro binding affinity against matrix metalloprotease 9,,"Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.",Bioorg. Med. Chem. Lett.,2005,15,12,"Duan JJ, Lu Z, Wasserman ZR, Liu RQ, Covington MB, Decicco CP",,302347,DTCT0024844,1800059,DTCC00374112,1651773,16433
CHEMBL176517,P14780,,NNRYJLARUIVRRO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11327602,IC50,=,14000,NM,,,,,,,,,,,,,,"Inhibition of Gelatinase B, matrix metalloprotease-9",,"Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors.",Bioorg. Med. Chem. Lett.,2001,11,8,"Foley LH, Palermo R, Dunten P, Wang P",,71657,DTCT0024844,941524,DTCC00372839,434882,4784
CHEMBL1766,P14780,DESOXIMETASONE,VWVSBHGCDBMOOT-IIEHVVJPSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7365747,DTCC00610116,348397,46191
CHEMBL1766,P14780,DESOXIMETASONE,VWVSBHGCDBMOOT-IIEHVVJPSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7365748,DTCC00610116,348397,46191
CHEMBL176602,P14780,,KGUVBHLPMGERAT-NIYFSFCBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9888835,IC50,=,20.6,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease 9,,Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.,J. Med. Chem.,1999,42,1,"Pikul S, McDow Dunham KL, Almstead NG, De B, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Mieling GE",,105359,DTCT0024844,1151840,DTCC00373473,2078653,15162
CHEMBL1767014,P14780,,RDRCRROFSMSFED-KHIBUBOWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21417219,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 after 60 mins by fluorescence plate reader,,"Discovery of (1S,2R,3R)-2,3-Dimethyl-2-phenyl-1-sulfamidocyclopropanecarboxylates: Novel and Highly Selective Aggrecanase Inhibitors.",J. Med. Chem.,2011,54,8,"Shiozaki M, Maeda K, Miura T, Kotoku M, Yamasaki T, Matsuda I, Aoki K, Yasue K, Imai H, Ubukata M, Suma A, Yokota M, Hotta T, Tanaka M, Hase Y, Haas J, Fryer AM, Laird ER, Littmann NM, Andrews SW, Josey JA, Mimura T, Shinozaki Y, Yoshiuchi H, Inaba T",,743612,DTCT0024844,5927583,DTCC01079536,2005992,44276
CHEMBL176832,P14780,,CQGUKDZSAPDCJL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11327602,IC50,=,18,NM,,,,,,,,,,,,,,"Inhibition of Gelatinase B, matrix metalloprotease-9",,"Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors.",Bioorg. Med. Chem. Lett.,2001,11,8,"Foley LH, Palermo R, Dunten P, Wang P",,71657,DTCT0024844,959841,DTCC00374111,1209081,4784
CHEMBL176876,P14780,,RHCPIVUQTCESEP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11327602,IC50,=,12000,NM,,,,,,,,,,,,,,"Inhibition of Gelatinase B, matrix metalloprotease-9",,"Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors.",Bioorg. Med. Chem. Lett.,2001,11,8,"Foley LH, Palermo R, Dunten P, Wang P",,71657,DTCT0024844,968889,DTCC00372847,1787020,4784
CHEMBL176993,P14780,,VMVSKQSBVKMLRK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,INHIBITION,=,0,%,,,,,,,,,,,,,,Percent remaining enzyme activity (RA) in human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105368,DTCT0024844,1103416,DTCC00109233,1490104,5419
CHEMBL176993,P14780,,VMVSKQSBVKMLRK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,KI,=,100,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105399,DTCT0024844,1103415,DTCC00109233,1490104,5419
CHEMBL177,P14780,AMIKACIN,LKCWBDHBTVXHDL-RMDFUYIESA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7293991,DTCC00409875,1253318,46191
CHEMBL177,P14780,AMIKACIN,LKCWBDHBTVXHDL-RMDFUYIESA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7293992,DTCC00409875,1253318,46191
CHEMBL1770157,P14780,,STMMWXRQAOVQNP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21493063,IC50,=,23,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,MMP-13 selective alpha-sulfone hydroxamates: Identification of selective P1' amides.,Bioorg. Med. Chem. Lett.,2011,21,10,"Fobian YM, Freskos JN, Barta TE, Bedell LJ, Heintz R, Kassab DJ, Kiefer JR, Mischke BV, Molyneaux JM, Mullins P, Munie GE, Becker DP",,744871,DTCT0024844,5936670,DTCC01080448,961249,44425
CHEMBL177048,P14780,,IFKOWFBQQCCFPQ-AWEZNQCLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,INHIBITION,=,19,%,,,,,,,,,,,,,,Percent remaining enzyme activity (RA) in human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105368,DTCT0024844,1122330,DTCC00373478,1262886,5419
CHEMBL177048,P14780,,IFKOWFBQQCCFPQ-AWEZNQCLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,KI,=,44000,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105399,DTCT0024844,1122329,DTCC00373478,1262886,5419
CHEMBL1770629,P14780,,IIBLNMYMPDUKOQ-HKDUHGGJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20638281,KI,=,88400,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Structure and activity relationships of tartrate-based TACE inhibitors.,Bioorg. Med. Chem. Lett.,2010,20,16,"Li D, Popovici-Muller J, Belanger DB, Caldwell J, Dai C, David M, Girijavallabhan VM, Lavey BJ, Lee JF, Liu Z, Mazzola R, Rizvi R, Rosner KE, Shankar B, Spitler J, Ting PC, Vaccaro H, Yu W, Zhou G, Zhu Z, Niu X, Sun J, Guo Z, Orth P, Chen S, Kozlowski JA, Lundell DJ, Madison V, McKittrick B, Piwinski JJ, Shih NY, Shipps GW, Siddiqui MA, Strickland CO",,748391,DTCT0024844,5959019,DTCC01080384,652661,44590
CHEMBL1770629,P14780,,IIBLNMYMPDUKOQ-HKDUHGGJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21458257,KI,=,88420,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors.",Bioorg. Med. Chem. Lett.,2011,21,10,"Dai C, Li D, Popovici-Muller J, Zhao L, Girijavallabhan VM, Rosner KE, Lavey BJ, Rizvi R, Shankar BB, Wong MK, Guo Z, Orth P, Strickland CO, Sun J, Niu X, Chen S, Kozlowski JA, Lundell DJ, Piwinski JJ, Shih NY, Siddiqui MA",,744287,DTCT0024844,5930520,DTCC01080384,652615,44403
CHEMBL1770649,P14780,,PRUCBZGVKSTGBL-FPHUIIFBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21458257,KI,>,40000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors.",Bioorg. Med. Chem. Lett.,2011,21,10,"Dai C, Li D, Popovici-Muller J, Zhao L, Girijavallabhan VM, Rosner KE, Lavey BJ, Rizvi R, Shankar BB, Wong MK, Guo Z, Orth P, Strickland CO, Sun J, Niu X, Chen S, Kozlowski JA, Lundell DJ, Piwinski JJ, Shih NY, Siddiqui MA",,744287,DTCT0024844,5930521,DTCC01080402,1266399,44403
CHEMBL1770697,P14780,,CLXRDURJLYSMHZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21493063,IC50,=,380,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,MMP-13 selective alpha-sulfone hydroxamates: Identification of selective P1' amides.,Bioorg. Med. Chem. Lett.,2011,21,10,"Fobian YM, Freskos JN, Barta TE, Bedell LJ, Heintz R, Kassab DJ, Kiefer JR, Mischke BV, Molyneaux JM, Mullins P, Munie GE, Becker DP",,744871,DTCT0024844,5936672,DTCC01080449,799451,44425
CHEMBL1770698,P14780,,RCSWIFOOANTXTQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21493063,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,MMP-13 selective alpha-sulfone hydroxamates: Identification of selective P1' amides.,Bioorg. Med. Chem. Lett.,2011,21,10,"Fobian YM, Freskos JN, Barta TE, Bedell LJ, Heintz R, Kassab DJ, Kiefer JR, Mischke BV, Molyneaux JM, Mullins P, Munie GE, Becker DP",,744871,DTCT0024844,5936659,DTCC01080450,49638,44425
CHEMBL1770699,P14780,,WBIKMXRYXWFRCE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21493063,IC50,=,1100,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,MMP-13 selective alpha-sulfone hydroxamates: Identification of selective P1' amides.,Bioorg. Med. Chem. Lett.,2011,21,10,"Fobian YM, Freskos JN, Barta TE, Bedell LJ, Heintz R, Kassab DJ, Kiefer JR, Mischke BV, Molyneaux JM, Mullins P, Munie GE, Becker DP",,744871,DTCT0024844,5936660,DTCC01080451,831943,44425
CHEMBL1770700,P14780,,MASDJPGVHCTFLM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21493063,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP9,Not Determined,MMP-13 selective alpha-sulfone hydroxamates: Identification of selective P1' amides.,Bioorg. Med. Chem. Lett.,2011,21,10,"Fobian YM, Freskos JN, Barta TE, Bedell LJ, Heintz R, Kassab DJ, Kiefer JR, Mischke BV, Molyneaux JM, Mullins P, Munie GE, Becker DP",,744871,DTCT0024844,5936661,DTCC01080452,1058218,44425
CHEMBL1770700,P14780,,MASDJPGVHCTFLM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21507637,KI,>,10000,NM,,,,,,,,,,,,,,Inhibition of human MMP-9,,MMP-13 selective a-sulfone hydroxamates: A survey of P1' heterocyclic amide isosteres.,Bioorg. Med. Chem. Lett.,2011,21,10,"Barta TE, Becker DP, Bedell LJ, Easton AM, Hockerman SL, Kiefer J, Munie GE, Mathis KJ, Li MH, Rico JG, Villamil CI, Williams JM",,744954,DTCT0024844,5930579,DTCC01080452,1040141,44430
CHEMBL1770701,P14780,,OICBVOJTVMMIHN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21493063,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP9,Not Determined,MMP-13 selective alpha-sulfone hydroxamates: Identification of selective P1' amides.,Bioorg. Med. Chem. Lett.,2011,21,10,"Fobian YM, Freskos JN, Barta TE, Bedell LJ, Heintz R, Kassab DJ, Kiefer JR, Mischke BV, Molyneaux JM, Mullins P, Munie GE, Becker DP",,744871,DTCT0024844,5936662,DTCC01080453,314520,44425
CHEMBL1770702,P14780,,JNMYIRAUFFFDQS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21493063,IC50,=,2200,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,MMP-13 selective alpha-sulfone hydroxamates: Identification of selective P1' amides.,Bioorg. Med. Chem. Lett.,2011,21,10,"Fobian YM, Freskos JN, Barta TE, Bedell LJ, Heintz R, Kassab DJ, Kiefer JR, Mischke BV, Molyneaux JM, Mullins P, Munie GE, Becker DP",,744871,DTCT0024844,5936663,DTCC01080454,1025844,44425
CHEMBL1770703,P14780,,KLRCKSDGEDNMNL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21493063,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP9,Not Determined,MMP-13 selective alpha-sulfone hydroxamates: Identification of selective P1' amides.,Bioorg. Med. Chem. Lett.,2011,21,10,"Fobian YM, Freskos JN, Barta TE, Bedell LJ, Heintz R, Kassab DJ, Kiefer JR, Mischke BV, Molyneaux JM, Mullins P, Munie GE, Becker DP",,744871,DTCT0024844,5936664,DTCC01080455,1186873,44425
CHEMBL1770704,P14780,,UKBSDNIYHDAZDN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21493063,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP9,Not Determined,MMP-13 selective alpha-sulfone hydroxamates: Identification of selective P1' amides.,Bioorg. Med. Chem. Lett.,2011,21,10,"Fobian YM, Freskos JN, Barta TE, Bedell LJ, Heintz R, Kassab DJ, Kiefer JR, Mischke BV, Molyneaux JM, Mullins P, Munie GE, Becker DP",,744871,DTCT0024844,5936665,DTCC01080456,767291,44425
CHEMBL1770705,P14780,,NVZOQOOLHGCJGV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21493063,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP9,Not Determined,MMP-13 selective alpha-sulfone hydroxamates: Identification of selective P1' amides.,Bioorg. Med. Chem. Lett.,2011,21,10,"Fobian YM, Freskos JN, Barta TE, Bedell LJ, Heintz R, Kassab DJ, Kiefer JR, Mischke BV, Molyneaux JM, Mullins P, Munie GE, Becker DP",,744871,DTCT0024844,5936666,DTCC01080457,638469,44425
CHEMBL1770706,P14780,,SJTWWQWUAQAYAB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21493063,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP9,Not Determined,MMP-13 selective alpha-sulfone hydroxamates: Identification of selective P1' amides.,Bioorg. Med. Chem. Lett.,2011,21,10,"Fobian YM, Freskos JN, Barta TE, Bedell LJ, Heintz R, Kassab DJ, Kiefer JR, Mischke BV, Molyneaux JM, Mullins P, Munie GE, Becker DP",,744871,DTCT0024844,5936667,DTCC01080458,87486,44425
CHEMBL1770707,P14780,,CADOQGNFDXDEHI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21493063,IC50,=,930,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,MMP-13 selective alpha-sulfone hydroxamates: Identification of selective P1' amides.,Bioorg. Med. Chem. Lett.,2011,21,10,"Fobian YM, Freskos JN, Barta TE, Bedell LJ, Heintz R, Kassab DJ, Kiefer JR, Mischke BV, Molyneaux JM, Mullins P, Munie GE, Becker DP",,744871,DTCT0024844,5936668,DTCC01080459,1829540,44425
CHEMBL1770708,P14780,,WWVWMBFCEZHXFR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21493063,IC50,=,960,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,MMP-13 selective alpha-sulfone hydroxamates: Identification of selective P1' amides.,Bioorg. Med. Chem. Lett.,2011,21,10,"Fobian YM, Freskos JN, Barta TE, Bedell LJ, Heintz R, Kassab DJ, Kiefer JR, Mischke BV, Molyneaux JM, Mullins P, Munie GE, Becker DP",,744871,DTCT0024844,5936669,DTCC01080460,1349992,44425
CHEMBL1770709,P14780,,PCOMQZCYLOTKTN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21493063,IC50,=,180,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,MMP-13 selective alpha-sulfone hydroxamates: Identification of selective P1' amides.,Bioorg. Med. Chem. Lett.,2011,21,10,"Fobian YM, Freskos JN, Barta TE, Bedell LJ, Heintz R, Kassab DJ, Kiefer JR, Mischke BV, Molyneaux JM, Mullins P, Munie GE, Becker DP",,744871,DTCT0024844,5936671,DTCC01080461,1349993,44425
CHEMBL1770710,P14780,,DZVDZJSJBKHJOK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21493063,IC50,=,670,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,MMP-13 selective alpha-sulfone hydroxamates: Identification of selective P1' amides.,Bioorg. Med. Chem. Lett.,2011,21,10,"Fobian YM, Freskos JN, Barta TE, Bedell LJ, Heintz R, Kassab DJ, Kiefer JR, Mischke BV, Molyneaux JM, Mullins P, Munie GE, Becker DP",,744871,DTCT0024844,5936673,DTCC01080462,1446682,44425
CHEMBL1770711,P14780,,WNBNYVCTXXPOJB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21493063,IC50,=,500,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,MMP-13 selective alpha-sulfone hydroxamates: Identification of selective P1' amides.,Bioorg. Med. Chem. Lett.,2011,21,10,"Fobian YM, Freskos JN, Barta TE, Bedell LJ, Heintz R, Kassab DJ, Kiefer JR, Mischke BV, Molyneaux JM, Mullins P, Munie GE, Becker DP",,744871,DTCT0024844,5936674,DTCC01080463,1414913,44425
CHEMBL1770712,P14780,,DLMROZSTEBHAOO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21493063,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP9,Not Determined,MMP-13 selective alpha-sulfone hydroxamates: Identification of selective P1' amides.,Bioorg. Med. Chem. Lett.,2011,21,10,"Fobian YM, Freskos JN, Barta TE, Bedell LJ, Heintz R, Kassab DJ, Kiefer JR, Mischke BV, Molyneaux JM, Mullins P, Munie GE, Becker DP",,744871,DTCT0024844,5936675,DTCC01080464,1349994,44425
CHEMBL177072,P14780,,JFMSSTVXWKCAJH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,=,7,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1414018,DTCC00373025,1372408,17147
CHEMBL177077,P14780,,UXMLHHOBOIXMAT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11327602,IC50,=,164,NM,,,,,,,,,,,,,,"Inhibition of Gelatinase B, matrix metalloprotease-9",,"Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors.",Bioorg. Med. Chem. Lett.,2001,11,8,"Foley LH, Palermo R, Dunten P, Wang P",,71657,DTCT0024844,937709,DTCC00372846,1404932,4784
CHEMBL1770826,P14780,,LOTUNSOIIWVNBG-JUJUEEDWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21458257,KI,=,10100,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors.",Bioorg. Med. Chem. Lett.,2011,21,10,"Dai C, Li D, Popovici-Muller J, Zhao L, Girijavallabhan VM, Rosner KE, Lavey BJ, Rizvi R, Shankar BB, Wong MK, Guo Z, Orth P, Strickland CO, Sun J, Niu X, Chen S, Kozlowski JA, Lundell DJ, Piwinski JJ, Shih NY, Siddiqui MA",,744287,DTCT0024844,5930522,DTCC01080561,749314,44403
CHEMBL1771,P14780,CLOPIDOGREL,GKTWGGQPFAXNFI-HNNXBMFYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7345889,DTCC00616891,639577,46191
CHEMBL1771,P14780,CLOPIDOGREL,GKTWGGQPFAXNFI-HNNXBMFYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7345890,DTCC00616891,639577,46191
CHEMBL1771212,P14780,SD-2590,NXUHVWMBPOFLMA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,0.18,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005833,DTCC00033985,1557982,45214
CHEMBL1771212,P14780,SD-2590,NXUHVWMBPOFLMA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21507637,IC50,=,0.2,NM,,,,,,,,,,,,,,Inhibition of human MMP-9,,MMP-13 selective a-sulfone hydroxamates: A survey of P1' heterocyclic amide isosteres.,Bioorg. Med. Chem. Lett.,2011,21,10,"Barta TE, Becker DP, Bedell LJ, Easton AM, Hockerman SL, Kiefer J, Munie GE, Mathis KJ, Li MH, Rico JG, Villamil CI, Williams JM",,744954,DTCT0024844,5930577,DTCC00033985,1557806,44430
CHEMBL1771213,P14780,,QCRPOQONCVCBFI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21507637,IC50,=,1200,NM,,,,,,,,,,,,,,Inhibition of human MMP-9,,MMP-13 selective a-sulfone hydroxamates: A survey of P1' heterocyclic amide isosteres.,Bioorg. Med. Chem. Lett.,2011,21,10,"Barta TE, Becker DP, Bedell LJ, Easton AM, Hockerman SL, Kiefer J, Munie GE, Mathis KJ, Li MH, Rico JG, Villamil CI, Williams JM",,744954,DTCT0024844,5930578,DTCC01080938,1040140,44430
CHEMBL1771214,P14780,,UIGGXLFLAQCMAY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21507637,IC50,=,1100,NM,,,,,,,,,,,,,,Inhibition of human MMP-9,,MMP-13 selective a-sulfone hydroxamates: A survey of P1' heterocyclic amide isosteres.,Bioorg. Med. Chem. Lett.,2011,21,10,"Barta TE, Becker DP, Bedell LJ, Easton AM, Hockerman SL, Kiefer J, Munie GE, Mathis KJ, Li MH, Rico JG, Villamil CI, Williams JM",,744954,DTCT0024844,5930580,DTCC01080939,134084,44430
CHEMBL1771215,P14780,,BNPWNBBKUMLEJM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21507637,KI,=,1200,NM,,,,,,,,,,,,,,Inhibition of human MMP-9,,MMP-13 selective a-sulfone hydroxamates: A survey of P1' heterocyclic amide isosteres.,Bioorg. Med. Chem. Lett.,2011,21,10,"Barta TE, Becker DP, Bedell LJ, Easton AM, Hockerman SL, Kiefer J, Munie GE, Mathis KJ, Li MH, Rico JG, Villamil CI, Williams JM",,744954,DTCT0024844,5930581,DTCC01080940,361645,44430
CHEMBL1771216,P14780,,MTRATHZFTCSGDT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21507637,KI,=,160,NM,,,,,,,,,,,,,,Inhibition of human MMP-9,,MMP-13 selective a-sulfone hydroxamates: A survey of P1' heterocyclic amide isosteres.,Bioorg. Med. Chem. Lett.,2011,21,10,"Barta TE, Becker DP, Bedell LJ, Easton AM, Hockerman SL, Kiefer J, Munie GE, Mathis KJ, Li MH, Rico JG, Villamil CI, Williams JM",,744954,DTCT0024844,5930582,DTCC01080941,1233526,44430
CHEMBL1771217,P14780,,MMCUCOOPEAHRPL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21507637,KI,=,2400,NM,,,,,,,,,,,,,,Inhibition of human MMP-9,,MMP-13 selective a-sulfone hydroxamates: A survey of P1' heterocyclic amide isosteres.,Bioorg. Med. Chem. Lett.,2011,21,10,"Barta TE, Becker DP, Bedell LJ, Easton AM, Hockerman SL, Kiefer J, Munie GE, Mathis KJ, Li MH, Rico JG, Villamil CI, Williams JM",,744954,DTCT0024844,5930583,DTCC01080942,1040142,44430
CHEMBL1771218,P14780,,LIQFLIXIOKMDTJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21507637,KI,=,430,NM,,,,,,,,,,,,,,Inhibition of human MMP-9,,MMP-13 selective a-sulfone hydroxamates: A survey of P1' heterocyclic amide isosteres.,Bioorg. Med. Chem. Lett.,2011,21,10,"Barta TE, Becker DP, Bedell LJ, Easton AM, Hockerman SL, Kiefer J, Munie GE, Mathis KJ, Li MH, Rico JG, Villamil CI, Williams JM",,744954,DTCT0024844,5930584,DTCC01080943,1908020,44430
CHEMBL1771219,P14780,,VCIBNYPUVKINDS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21507637,KI,=,1600,NM,,,,,,,,,,,,,,Inhibition of human MMP-9,,MMP-13 selective a-sulfone hydroxamates: A survey of P1' heterocyclic amide isosteres.,Bioorg. Med. Chem. Lett.,2011,21,10,"Barta TE, Becker DP, Bedell LJ, Easton AM, Hockerman SL, Kiefer J, Munie GE, Mathis KJ, Li MH, Rico JG, Villamil CI, Williams JM",,744954,DTCT0024844,5930585,DTCC01080944,975250,44430
CHEMBL1771220,P14780,,NVQGQIYFJRAZLX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21507637,KI,=,370,NM,,,,,,,,,,,,,,Inhibition of human MMP-9,,MMP-13 selective a-sulfone hydroxamates: A survey of P1' heterocyclic amide isosteres.,Bioorg. Med. Chem. Lett.,2011,21,10,"Barta TE, Becker DP, Bedell LJ, Easton AM, Hockerman SL, Kiefer J, Munie GE, Mathis KJ, Li MH, Rico JG, Villamil CI, Williams JM",,744954,DTCT0024844,5930586,DTCC01080945,1590129,44430
CHEMBL1771221,P14780,,JRPLACGAMSWTCU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21507637,KI,=,1800,NM,,,,,,,,,,,,,,Inhibition of human MMP-9,,MMP-13 selective a-sulfone hydroxamates: A survey of P1' heterocyclic amide isosteres.,Bioorg. Med. Chem. Lett.,2011,21,10,"Barta TE, Becker DP, Bedell LJ, Easton AM, Hockerman SL, Kiefer J, Munie GE, Mathis KJ, Li MH, Rico JG, Villamil CI, Williams JM",,744954,DTCT0024844,5930587,DTCC01080946,230822,44430
CHEMBL1771222,P14780,,FVPQYGSYGOKFLW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21507637,KI,>,10000,NM,,,,,,,,,,,,,,Inhibition of human MMP-9,,MMP-13 selective a-sulfone hydroxamates: A survey of P1' heterocyclic amide isosteres.,Bioorg. Med. Chem. Lett.,2011,21,10,"Barta TE, Becker DP, Bedell LJ, Easton AM, Hockerman SL, Kiefer J, Munie GE, Mathis KJ, Li MH, Rico JG, Villamil CI, Williams JM",,744954,DTCT0024844,5930588,DTCC01080947,1105335,44430
CHEMBL1771223,P14780,,UAFRGDNTZQMZFA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21507637,KI,=,1700,NM,,,,,,,,,,,,,,Inhibition of human MMP-9,,MMP-13 selective a-sulfone hydroxamates: A survey of P1' heterocyclic amide isosteres.,Bioorg. Med. Chem. Lett.,2011,21,10,"Barta TE, Becker DP, Bedell LJ, Easton AM, Hockerman SL, Kiefer J, Munie GE, Mathis KJ, Li MH, Rico JG, Villamil CI, Williams JM",,744954,DTCT0024844,5930589,DTCC01080948,587727,44430
CHEMBL177740,P14780,,DDHOTWKNHXEMKO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11327602,IC50,=,17,NM,,,,,,,,,,,,,,"Inhibition of Gelatinase B, matrix metalloprotease-9",,"Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors.",Bioorg. Med. Chem. Lett.,2001,11,8,"Foley LH, Palermo R, Dunten P, Wang P",,71657,DTCT0024844,961210,DTCC00374388,1404931,4784
CHEMBL177756,P14780,FLUORESCEIN,YKGGGCXBWXHKIZ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7312053,DTCC00376005,1894967,46191
CHEMBL177756,P14780,FLUORESCEIN,YKGGGCXBWXHKIZ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7312054,DTCC00376005,1894967,46191
CHEMBL1779630,P14780,,BXLWVAKSQMYQKF-HRUVVLKGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20638281,KI,=,11000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Structure and activity relationships of tartrate-based TACE inhibitors.,Bioorg. Med. Chem. Lett.,2010,20,16,"Li D, Popovici-Muller J, Belanger DB, Caldwell J, Dai C, David M, Girijavallabhan VM, Lavey BJ, Lee JF, Liu Z, Mazzola R, Rizvi R, Rosner KE, Shankar B, Spitler J, Ting PC, Vaccaro H, Yu W, Zhou G, Zhu Z, Niu X, Sun J, Guo Z, Orth P, Chen S, Kozlowski JA, Lundell DJ, Madison V, McKittrick B, Piwinski JJ, Shih NY, Shipps GW, Siddiqui MA, Strickland CO",,748391,DTCT0024844,5959056,DTCC01085211,1875737,44590
CHEMBL178,P14780,DAUNORUBICIN,STQGQHZAVUOBTE-VGBVRHCVSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7348492,DTCC00413150,477916,46191
CHEMBL178,P14780,DAUNORUBICIN,STQGQHZAVUOBTE-VGBVRHCVSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7348493,DTCC00413150,477916,46191
CHEMBL178163,P14780,,WKXRIMLOWDOHMN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15686921,KI,=,1.9,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13).,Bioorg. Med. Chem. Lett.,2005,15,4,"Kim SH, Pudzianowski AT, Leavitt KJ, Barbosa J, McDonnell PA, Metzler WJ, Rankin BM, Liu R, Vaccaro W, Pitts W",,302481,DTCT0024844,1744906,DTCC00381624,130640,18787
CHEMBL178163,P14780,,WKXRIMLOWDOHMN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,1.91,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258724,DTCC00381624,131667,24803
CHEMBL1784338,P14780,,FUEVUWZQRYWTIH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21536437,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 assessed as substrate cleavage after 20 hrs by fluorescence assay,,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,2011,21,11,"De Savi C, Pape A, Sawyer Y, Milne D, Davies C, Cumming JG, Ting A, Lamont S, Smith PD, Tart J, Page K, Moore P",,751108,DTCT0024844,5969369,DTCC01087874,1991668,44768
CHEMBL1784339,P14780,,NYSZVCQWENKRKM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21536437,IC50,=,3100,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 assessed as substrate cleavage after 20 hrs by fluorescence assay,,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,2011,21,11,"De Savi C, Pape A, Sawyer Y, Milne D, Davies C, Cumming JG, Ting A, Lamont S, Smith PD, Tart J, Page K, Moore P",,751108,DTCT0024844,5969370,DTCC01087875,1219147,44768
CHEMBL1784340,P14780,,ISHINUUQDKDNHQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21536437,IC50,>,25000,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 assessed as substrate cleavage after 20 hrs by fluorescence assay,,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,2011,21,11,"De Savi C, Pape A, Sawyer Y, Milne D, Davies C, Cumming JG, Ting A, Lamont S, Smith PD, Tart J, Page K, Moore P",,751108,DTCT0024844,5970281,DTCC01087876,314584,44768
CHEMBL1784341,P14780,,DDRRRYMVRWYNKI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21536437,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 assessed as substrate cleavage after 20 hrs by fluorescence assay,,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,2011,21,11,"De Savi C, Pape A, Sawyer Y, Milne D, Davies C, Cumming JG, Ting A, Lamont S, Smith PD, Tart J, Page K, Moore P",,751108,DTCT0024844,5970366,DTCC01087877,248843,44768
CHEMBL1784342,P14780,,OGDMRINQXHOSNB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21536437,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 assessed as substrate cleavage after 20 hrs by fluorescence assay,,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,2011,21,11,"De Savi C, Pape A, Sawyer Y, Milne D, Davies C, Cumming JG, Ting A, Lamont S, Smith PD, Tart J, Page K, Moore P",,751108,DTCT0024844,5970368,DTCC01087878,1991670,44768
CHEMBL1784343,P14780,,XRFARLVFDBABAU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21536437,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 assessed as substrate cleavage after 20 hrs by fluorescence assay,,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,2011,21,11,"De Savi C, Pape A, Sawyer Y, Milne D, Davies C, Cumming JG, Ting A, Lamont S, Smith PD, Tart J, Page K, Moore P",,751108,DTCT0024844,5970369,DTCC01087879,767362,44768
CHEMBL1784344,P14780,,DTSDNCVLJXFMRH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21536437,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 assessed as substrate cleavage after 20 hrs by fluorescence assay,,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,2011,21,11,"De Savi C, Pape A, Sawyer Y, Milne D, Davies C, Cumming JG, Ting A, Lamont S, Smith PD, Tart J, Page K, Moore P",,751108,DTCT0024844,5970370,DTCC01087880,1732985,44768
CHEMBL1784345,P14780,,IIJIMCYNCLMHHL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21536437,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 assessed as substrate cleavage after 20 hrs by fluorescence assay,,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,2011,21,11,"De Savi C, Pape A, Sawyer Y, Milne D, Davies C, Cumming JG, Ting A, Lamont S, Smith PD, Tart J, Page K, Moore P",,751108,DTCT0024844,5970371,DTCC01087881,184445,44768
CHEMBL1784346,P14780,,OUTUIYKUSHWASL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21536437,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 assessed as substrate cleavage after 20 hrs by fluorescence assay,,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,2011,21,11,"De Savi C, Pape A, Sawyer Y, Milne D, Davies C, Cumming JG, Ting A, Lamont S, Smith PD, Tart J, Page K, Moore P",,751108,DTCT0024844,5970372,DTCC01087882,1252217,44768
CHEMBL1784347,P14780,,IWRJDNKXMJBFEA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21536437,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 assessed as substrate cleavage after 20 hrs by fluorescence assay,,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,2011,21,11,"De Savi C, Pape A, Sawyer Y, Milne D, Davies C, Cumming JG, Ting A, Lamont S, Smith PD, Tart J, Page K, Moore P",,751108,DTCT0024844,5970373,DTCC01087883,897249,44768
CHEMBL1784348,P14780,,JHWOJEJVRYYQFM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21536437,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 assessed as substrate cleavage after 20 hrs by fluorescence assay,,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,2011,21,11,"De Savi C, Pape A, Sawyer Y, Milne D, Davies C, Cumming JG, Ting A, Lamont S, Smith PD, Tart J, Page K, Moore P",,751108,DTCT0024844,5970374,DTCC01087884,541502,44768
CHEMBL1784349,P14780,,CCTJPVSDIZDFJW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21536437,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 assessed as substrate cleavage after 20 hrs by fluorescence assay,,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,2011,21,11,"De Savi C, Pape A, Sawyer Y, Milne D, Davies C, Cumming JG, Ting A, Lamont S, Smith PD, Tart J, Page K, Moore P",,751108,DTCT0024844,5969365,DTCC01087885,1284804,44768
CHEMBL1784350,P14780,,PSAIRTKPKUWNNP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21536437,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 assessed as substrate cleavage after 20 hrs by fluorescence assay,,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,2011,21,11,"De Savi C, Pape A, Sawyer Y, Milne D, Davies C, Cumming JG, Ting A, Lamont S, Smith PD, Tart J, Page K, Moore P",,751108,DTCT0024844,5970375,DTCC01087886,1284805,44768
CHEMBL1784351,P14780,,IHEWXNWFNBGUFE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21536437,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 assessed as substrate cleavage after 20 hrs by fluorescence assay,,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,2011,21,11,"De Savi C, Pape A, Sawyer Y, Milne D, Davies C, Cumming JG, Ting A, Lamont S, Smith PD, Tart J, Page K, Moore P",,751108,DTCT0024844,5970376,DTCC01087887,1350068,44768
CHEMBL1784352,P14780,,YIKZSHOVCXXIBY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21536437,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 assessed as substrate cleavage after 20 hrs by fluorescence assay,,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,2011,21,11,"De Savi C, Pape A, Sawyer Y, Milne D, Davies C, Cumming JG, Ting A, Lamont S, Smith PD, Tart J, Page K, Moore P",,751108,DTCT0024844,5970377,DTCC01087888,1704803,44768
CHEMBL1784353,P14780,,CAFLLFZUWQCIHM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21536437,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 assessed as substrate cleavage after 20 hrs by fluorescence assay,,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,2011,21,11,"De Savi C, Pape A, Sawyer Y, Milne D, Davies C, Cumming JG, Ting A, Lamont S, Smith PD, Tart J, Page K, Moore P",,751108,DTCT0024844,5970378,DTCC01087889,735158,44768
CHEMBL1784358,P14780,,VLNVWKDSFQRXHZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21536437,IC50,=,1200,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 assessed as substrate cleavage after 20 hrs by fluorescence assay,,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,2011,21,11,"De Savi C, Pape A, Sawyer Y, Milne D, Davies C, Cumming JG, Ting A, Lamont S, Smith PD, Tart J, Page K, Moore P",,751108,DTCT0024844,5969358,DTCC01087894,1543800,44768
CHEMBL1784359,P14780,,BZUGNOPIQMYMFU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21536437,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 assessed as substrate cleavage after 20 hrs by fluorescence assay,,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,2011,21,11,"De Savi C, Pape A, Sawyer Y, Milne D, Davies C, Cumming JG, Ting A, Lamont S, Smith PD, Tart J, Page K, Moore P",,751108,DTCT0024844,5969359,DTCC01087895,184446,44768
CHEMBL1784360,P14780,,VYEJHVQIVKCLHC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21536437,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 assessed as substrate cleavage after 20 hrs by fluorescence assay,,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,2011,21,11,"De Savi C, Pape A, Sawyer Y, Milne D, Davies C, Cumming JG, Ting A, Lamont S, Smith PD, Tart J, Page K, Moore P",,751108,DTCT0024844,5969360,DTCC01087896,509332,44768
CHEMBL1784361,P14780,,STVUCRKRBAWCPC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21536437,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 assessed as substrate cleavage after 20 hrs by fluorescence assay,,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,2011,21,11,"De Savi C, Pape A, Sawyer Y, Milne D, Davies C, Cumming JG, Ting A, Lamont S, Smith PD, Tart J, Page K, Moore P",,751108,DTCT0024844,5969361,DTCC01087897,1186951,44768
CHEMBL1784362,P14780,,AWLKOGZBGNQOBA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21536437,IC50,=,670,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 assessed as substrate cleavage after 20 hrs by fluorescence assay,,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,2011,21,11,"De Savi C, Pape A, Sawyer Y, Milne D, Davies C, Cumming JG, Ting A, Lamont S, Smith PD, Tart J, Page K, Moore P",,751108,DTCT0024844,5969362,DTCC01087898,1025922,44768
CHEMBL1784363,P14780,,DVWZDEQXQWWQOU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21536437,IC50,>,1800,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 assessed as substrate cleavage after 20 hrs by fluorescence assay,,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,2011,21,11,"De Savi C, Pape A, Sawyer Y, Milne D, Davies C, Cumming JG, Ting A, Lamont S, Smith PD, Tart J, Page K, Moore P",,751108,DTCT0024844,5969363,DTCC01087899,184447,44768
CHEMBL1784364,P14780,,IBSGSCYXBWXQDW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21536437,IC50,=,8500,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 assessed as substrate cleavage after 20 hrs by fluorescence assay,,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,2011,21,11,"De Savi C, Pape A, Sawyer Y, Milne D, Davies C, Cumming JG, Ting A, Lamont S, Smith PD, Tart J, Page K, Moore P",,751108,DTCT0024844,5969364,DTCC01087900,2024514,44768
CHEMBL1784365,P14780,,OFQBKLDPHHFEPJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21536437,IC50,=,8900,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 assessed as substrate cleavage after 20 hrs by fluorescence assay,,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,2011,21,11,"De Savi C, Pape A, Sawyer Y, Milne D, Davies C, Cumming JG, Ting A, Lamont S, Smith PD, Tart J, Page K, Moore P",,751108,DTCT0024844,5969366,DTCC01087901,1861581,44768
CHEMBL1784366,P14780,,BTKROMQYNIJXLC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21536437,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 assessed as substrate cleavage after 20 hrs by fluorescence assay,,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,2011,21,11,"De Savi C, Pape A, Sawyer Y, Milne D, Davies C, Cumming JG, Ting A, Lamont S, Smith PD, Tart J, Page K, Moore P",,751108,DTCT0024844,5969367,DTCC01087902,1317331,44768
CHEMBL1784367,P14780,,QVHFARCMIMVLSZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21536437,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 assessed as substrate cleavage after 20 hrs by fluorescence assay,,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,2011,21,11,"De Savi C, Pape A, Sawyer Y, Milne D, Davies C, Cumming JG, Ting A, Lamont S, Smith PD, Tart J, Page K, Moore P",,751108,DTCT0024844,5969368,DTCC01087903,1446758,44768
CHEMBL178509,P14780,,TVKGACNFKXXAEF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15686921,KI,=,4.7,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13).,Bioorg. Med. Chem. Lett.,2005,15,4,"Kim SH, Pudzianowski AT, Leavitt KJ, Barbosa J, McDonnell PA, Metzler WJ, Rankin BM, Liu R, Vaccaro W, Pitts W",,302481,DTCT0024844,1744346,DTCC00381771,227480,18787
CHEMBL178509,P14780,,TVKGACNFKXXAEF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,4.68,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258722,DTCC00381771,228502,24803
CHEMBL1790041,P14780,RANITIDINE,VMXUWOKSQNHOCA-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7487919,DTCC01089619,2025642,46191
CHEMBL1790041,P14780,RANITIDINE,VMXUWOKSQNHOCA-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7487920,DTCC01089619,2025642,46191
CHEMBL179166,P14780,SODIUM ORTHOVANAD,IHIXIJGXTJIKRB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7467038,DTCC00382287,217586,46191
CHEMBL179166,P14780,SODIUM ORTHOVANAD,IHIXIJGXTJIKRB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7467039,DTCC00382287,217586,46191
CHEMBL179288,P14780,,DGZZVIWCMGVHGV-LJQANCHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15713379,IC50,=,6.7,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.,Bioorg. Med. Chem. Lett.,2005,15,5,"Rossello A, Nuti E, Carelli P, Orlandini E, Macchia M, Nencetti S, Zandomeneghi M, Balzano F, Uccello Barretta G, Albini A, Benelli R, Cercignani G, Murphy G, Balsamo A",,305737,DTCT0024844,1747875,DTCC00381940,1069270,18841
CHEMBL179288,P14780,,DGZZVIWCMGVHGV-LJQANCHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19775099,IC50,=,6.7,NM,,,,,,,,,,,,,,Inhibition of para-aminophenylmercuric acetate-activated human recombinant pro-MMP9 catalytic domain after 4 hrs by fluorimetry,,"Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.",J. Med. Chem.,2009,52,20,"Nuti E, Panelli L, Casalini F, Avramova SI, Orlandini E, Santamaria S, Nencetti S, Tuccinardi T, Martinelli A, Cercignani G, D'Amelio N, Maiocchi A, Uggeri F, Rossello A",,591599,DTCT0024844,3044913,DTCC00381940,1071500,35647
CHEMBL179288,P14780,,DGZZVIWCMGVHGV-LJQANCHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26638045,IC50,=,6.7,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP9 after 2 hrs using FS-6 as substrate by fluorometry,,"Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors.",Eur. J. Med. Chem.,2016,108,,"Sjli S, Nuti E, Camodeca C, Bilto I, Rossello A, Winberg JO, Sylte I, Adekoya OA.",,1550087,DTCT0024844,59800,DTCC00381940,1066000,65811
CHEMBL1795351,P14780,,YZKJTNXYLZWHHJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21514700,IC50,=,79,NM,,,,,,,,,,,,,,Inhibition of human MMP9 by fluorometric assay,,Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.,Eur. J. Med. Chem.,2011,46,7,"Nuti E, Casalini F, Santamaria S, Gabelloni P, Bendinelli S, Da Pozzo E, Costa B, Marinelli L, La Pietra V, Novellino E, Margarida Bernardo M, Fridman R, Da Settimo F, Martini C, Rossello A",,753770,DTCT0024844,6000211,DTCC01091696,1893893,44948
CHEMBL1795857,P14780,,VZNWQFCLBMVARX-SSEXGKCCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21514700,IC50,=,63,NM,,,,,,,,,,,,,,Inhibition of human MMP9 by fluorometric assay,,Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.,Eur. J. Med. Chem.,2011,46,7,"Nuti E, Casalini F, Santamaria S, Gabelloni P, Bendinelli S, Da Pozzo E, Costa B, Marinelli L, La Pietra V, Novellino E, Margarida Bernardo M, Fridman R, Da Settimo F, Martini C, Rossello A",,753770,DTCT0024844,6000218,DTCC01091697,1673074,44948
CHEMBL1795858,P14780,,ABUCHUKPMIVSQV-GDLZYMKVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21514700,IC50,=,50,NM,,,,,,,,,,,,,,Inhibition of human MMP9 by fluorometric assay,,Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.,Eur. J. Med. Chem.,2011,46,7,"Nuti E, Casalini F, Santamaria S, Gabelloni P, Bendinelli S, Da Pozzo E, Costa B, Marinelli L, La Pietra V, Novellino E, Margarida Bernardo M, Fridman R, Da Settimo F, Martini C, Rossello A",,753770,DTCT0024844,6000225,DTCC01091698,638553,44948
CHEMBL1795859,P14780,,RSAGFYGPXOAVNX-RUZDIDTESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21514700,IC50,=,77,NM,,,,,,,,,,,,,,Inhibition of human MMP9 by fluorometric assay,,Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.,Eur. J. Med. Chem.,2011,46,7,"Nuti E, Casalini F, Santamaria S, Gabelloni P, Bendinelli S, Da Pozzo E, Costa B, Marinelli L, La Pietra V, Novellino E, Margarida Bernardo M, Fridman R, Da Settimo F, Martini C, Rossello A",,753770,DTCT0024844,6000232,DTCC01091699,119860,44948
CHEMBL1795860,P14780,,YPLZYOZJLNQLST-XMMPIXPASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21514700,IC50,=,650,NM,,,,,,,,,,,,,,Inhibition of human MMP9 by fluorometric assay,,Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.,Eur. J. Med. Chem.,2011,46,7,"Nuti E, Casalini F, Santamaria S, Gabelloni P, Bendinelli S, Da Pozzo E, Costa B, Marinelli L, La Pietra V, Novellino E, Margarida Bernardo M, Fridman R, Da Settimo F, Martini C, Rossello A",,753770,DTCT0024844,6000239,DTCC01091700,1640794,44948
CHEMBL1795861,P14780,,KGOHHLONXFWMRE-SFHVURJKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21514700,IC50,=,21,NM,,,,,,,,,,,,,,Inhibition of human MMP9 by fluorometric assay,,Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.,Eur. J. Med. Chem.,2011,46,7,"Nuti E, Casalini F, Santamaria S, Gabelloni P, Bendinelli S, Da Pozzo E, Costa B, Marinelli L, La Pietra V, Novellino E, Margarida Bernardo M, Fridman R, Da Settimo F, Martini C, Rossello A",,753770,DTCT0024844,6000246,DTCC01091701,1861595,44948
CHEMBL1795862,P14780,,OTEWYJZEFZRZKI-XMMPIXPASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21514700,IC50,=,4.3,NM,,,,,,,,,,,,,,Inhibition of human MMP9 by fluorometric assay,,Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.,Eur. J. Med. Chem.,2011,46,7,"Nuti E, Casalini F, Santamaria S, Gabelloni P, Bendinelli S, Da Pozzo E, Costa B, Marinelli L, La Pietra V, Novellino E, Margarida Bernardo M, Fridman R, Da Settimo F, Martini C, Rossello A",,753770,DTCT0024844,6000254,DTCC01091702,767378,44948
CHEMBL179616,P14780,,DGZZVIWCMGVHGV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15713379,IC50,=,19.6,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.,Bioorg. Med. Chem. Lett.,2005,15,5,"Rossello A, Nuti E, Carelli P, Orlandini E, Macchia M, Nencetti S, Zandomeneghi M, Balzano F, Uccello Barretta G, Albini A, Benelli R, Cercignani G, Murphy G, Balsamo A",,305737,DTCT0024844,1747770,DTCC00381916,487942,18841
CHEMBL1796298,P14780,,YNSKBMXZDCLQIV-MHZLTWQESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22153941,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9 using Mca-Pro-cyclohexyl-Ala-Gly-Nva-His-Ala- Dap(Dnp)-NH2 as substrate by fluorometric analysis,,Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.,Bioorg. Med. Chem. Lett.,2012,22,1,"De Savi C, Morley AD, Nash I, Karoutchi G, Page K, Ting A, Gerhardt S",,798833,DTCT0024844,7601085,DTCC01092132,1927204,47049
CHEMBL1800089,P14780,,VMWGPLRCSWOQJR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,0.1,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005838,DTCC01095116,1622971,45214
CHEMBL1801044,P14780,,XQXSQQVRMVVPJW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,0.4,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005863,DTCC01094745,1557976,45214
CHEMBL1801045,P14780,,KOPIIXVBCHXDHO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,2.9,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005862,DTCC01094746,1747121,45214
CHEMBL1801046,P14780,,HBYRXCFAHCMHAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16220987,KI,=,0.3,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14743566,DTCC01094747,2108425,69259
CHEMBL1801046,P14780,,HBYRXCFAHCMHAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,0.3,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005861,DTCC01094747,1364426,45214
CHEMBL1801047,P14780,,RDFQXFRQTOWZEQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,5,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005860,DTCC01094748,1525962,45214
CHEMBL1801048,P14780,,PKAAOTCIUWGSDS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,<,0.1,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005859,DTCC01094749,1590328,45214
CHEMBL1801049,P14780,,NUTUARVYQWFZAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,<,0.1,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005858,DTCC01094750,1429088,45214
CHEMBL1801050,P14780,,SPEYRVQKGFNUCY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,1.7,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005857,DTCC01094751,2070708,45214
CHEMBL1801051,P14780,,VFDSDRZNXLFCFF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,42.5,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005856,DTCC01094752,1811467,45214
CHEMBL1801052,P14780,,QLTNWLFWQKKDEO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,0.2,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005854,DTCC01094753,1105534,45214
CHEMBL1801053,P14780,,UZMULMICABXSNQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,<,0.1,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005853,DTCC01094754,1779150,45214
CHEMBL1801054,P14780,,PGEMRSCSFPLCBF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,0.25,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005852,DTCC01094755,1940371,45214
CHEMBL1801056,P14780,,GXZSIAVJNPWNMR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,1.5,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005851,DTCC01094757,1811468,45214
CHEMBL1801057,P14780,,QJNGNVJSSUXWBO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,1.1,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005850,DTCC01094758,1687244,45214
CHEMBL1801393,P14780,,JATUSZYMCBLDQS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,0.6,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005830,DTCC01095085,1622970,45214
CHEMBL1801394,P14780,,OTKHAYOLIGHFRB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,0.1,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005829,DTCC01095086,1557980,45214
CHEMBL1801396,P14780,,QDGVTWBFTFHWOG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,0.1,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005828,DTCC01095088,1072789,45214
CHEMBL1801397,P14780,,WVUXCTUJEGJKKV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,<,0.1,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005827,DTCC01095089,1299069,45214
CHEMBL1801398,P14780,,QURZZKPWFKUXBF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,0.18,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005826,DTCC01095090,555801,45214
CHEMBL1801399,P14780,,HYIVZTPHVNIXFU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,<,0.1,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005825,DTCC01095091,1266628,45214
CHEMBL1801412,P14780,,ASZIRMQBBYBMMU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,0.2,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6006665,DTCC01095102,523654,45214
CHEMBL1801413,P14780,,SIEIWCDBNIGNIG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,2,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005849,DTCC01095103,846766,45214
CHEMBL1801415,P14780,,SXSIQUOYBXOPSS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,2.2,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005848,DTCC01095105,1396864,45214
CHEMBL1801417,P14780,,SFEPJGMZSMIONR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,0.21,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005847,DTCC01095107,263382,45214
CHEMBL1801418,P14780,,JNCKLKQBIMZPBF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,82.3,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005846,DTCC01095108,1525968,45214
CHEMBL1801419,P14780,,SYYRIPAKWJBIOW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,3.8,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005845,DTCC01095109,1072790,45214
CHEMBL1801420,P14780,,LMIHEFSBOIGKDH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,0.3,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005844,DTCC01095110,879231,45214
CHEMBL1801421,P14780,,BDONYXHHXNTUSW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,0.27,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005843,DTCC01095111,1557981,45214
CHEMBL1801422,P14780,,ZHIRJJYNGRGHQQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,<,0.1,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005842,DTCC01095112,1718593,45214
CHEMBL1801423,P14780,,XFBRPTYLOIFAQR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,1.9,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005841,DTCC01095113,1429093,45214
CHEMBL1801424,P14780,,AOPZFYOXZYZEAC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,2.3,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005840,DTCC01095114,101933,45214
CHEMBL1801425,P14780,,DZCGIZPIPKWUIX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,4,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005839,DTCC01095115,1779153,45214
CHEMBL1801426,P14780,,LTCNKRUYOJZZJO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,1.9,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005837,DTCC01095117,1843781,45214
CHEMBL1801427,P14780,,JKRVXAWKSWVVCV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,1.5,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005836,DTCC01095118,1169008,45214
CHEMBL1801428,P14780,,ORSWNUGKUNQTLF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,0.25,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005835,DTCC01095119,1687248,45214
CHEMBL1801429,P14780,,LCYYUMHWMVOGPC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,0.22,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005834,DTCC01095120,717206,45214
CHEMBL1801430,P14780,SC-77964,NBRBWZJMBITNBC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,0.15,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005832,DTCC00034383,620315,45214
CHEMBL1801430,P14780,SC-77964,NBRBWZJMBITNBC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23999043,IC50,<,1,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,Design and synthesis of MMP inhibitors with appended fluorescent tags for imaging and visualization of matrix metalloproteinase enzymes.,Bioorg. Med. Chem. Lett.,2013,23,20,"Freskos JN, Asmelash B, Gaston KR, Karwa A, Marzan TA, Nickols MA, Rogers TE, Schoenstein T, Sympson CJ, Vu B",,985895,DTCT0024844,12592010,DTCC00034383,642622,55953
CHEMBL1801431,P14780,,IXVDOEAUVAJHER-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20726512,IC50,=,0.2,NM,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as cleavage of fluorogenic peptide MCAPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by fluorometric assay,,"Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.",J. Med. Chem.,2010,53,18,"Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J",,754463,DTCT0024844,6005831,DTCC01095121,263383,45214
CHEMBL180239,P14780,CURCUMIN PYRAZOLE,LKLASFRCXLTNMY-FCXRPNKRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19128977,ACTIVITY,,,,,cell_based,,,,,,,,,,,Caco-2,Reduction of MMP9 activity in TNF-alpha/IL1-beta-stimulated human Caco-2 cells at 50 uM treated 1 hr before stimulation by zymography,Active,Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloproteinases.,Bioorg. Med. Chem.,2009,17,3,"Claramunt RM, Bouissane L, Cabildo MP, Cornago MP, Elguero J, Radziwon A, Medina C",,516049,DTCT0024844,2701375,DTCC00383783,1276142,32369
CHEMBL180239,P14780,CURCUMIN PYRAZOLE,LKLASFRCXLTNMY-FCXRPNKRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19128977,IC50,=,19400,NM,,cell_based,,,,,,,,,,,Caco-2,Reduction of MMP9 activity in TNF-alpha/IL1-beta-stimulated human Caco-2 cells treated 1 hr before stimulation by zymography,,Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloproteinases.,Bioorg. Med. Chem.,2009,17,3,"Claramunt RM, Bouissane L, Cabildo MP, Cornago MP, Elguero J, Radziwon A, Medina C",,516050,DTCT0024844,2701378,DTCC00383783,1276142,32369
CHEMBL180275,P14780,,JGGFVHVZVBWBKF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15686921,KI,=,0.72,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13).,Bioorg. Med. Chem. Lett.,2005,15,4,"Kim SH, Pudzianowski AT, Leavitt KJ, Barbosa J, McDonnell PA, Metzler WJ, Rankin BM, Liu R, Vaccaro W, Pitts W",,302481,DTCT0024844,1744900,DTCC00381599,1360845,18787
CHEMBL180275,P14780,,JGGFVHVZVBWBKF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,0.724,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258725,DTCC00381599,1361905,24803
CHEMBL180616,P14780,,FKICHBNUXJBKPB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15686921,KI,=,0.72,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13).,Bioorg. Med. Chem. Lett.,2005,15,4,"Kim SH, Pudzianowski AT, Leavitt KJ, Barbosa J, McDonnell PA, Metzler WJ, Rankin BM, Liu R, Vaccaro W, Pitts W",,302481,DTCT0024844,1744364,DTCC00381808,713599,18787
CHEMBL180616,P14780,,FKICHBNUXJBKPB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,0.724,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258727,DTCC00381808,714627,24803
CHEMBL180616,P14780,,FKICHBNUXJBKPB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,KI,=,0.7,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278527,DTCC00381808,730979,25112
CHEMBL181,P14780,DIAZOXIDE,GDLBFKVLRPITMI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7368229,DTCC00110806,800574,46191
CHEMBL181,P14780,DIAZOXIDE,GDLBFKVLRPITMI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7368230,DTCC00110806,800574,46191
CHEMBL181244,P14780,,PHGLPDURIUEELR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15713379,IC50,=,200,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.,Bioorg. Med. Chem. Lett.,2005,15,5,"Rossello A, Nuti E, Carelli P, Orlandini E, Macchia M, Nencetti S, Zandomeneghi M, Balzano F, Uccello Barretta G, Albini A, Benelli R, Cercignani G, Murphy G, Balsamo A",,305737,DTCT0024844,1747767,DTCC00381891,1586743,18841
CHEMBL181244,P14780,,PHGLPDURIUEELR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,IC50,=,200,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2457474,DTCC00381891,1600108,32556
CHEMBL181244,P14780,,PHGLPDURIUEELR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19606871,IC50,=,200,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.",J. Med. Chem.,2009,52,15,"Nuti E, Casalini F, Avramova SI, Santamaria S, Cercignani G, Marinelli L, La Pietra V, Novellino E, Orlandini E, Nencetti S, Tuccinardi T, Martinelli A, Lim NH, Visse R, Nagase H, Rossello A",,571085,DTCT0024844,2859475,DTCC00381891,1588877,34421
CHEMBL181244,P14780,,PHGLPDURIUEELR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20180536,IC50,=,200,NM,,,,,,,,,,,,,,Inhibition of MMP9 by fluorometric assay,,Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.,J. Med. Chem.,2010,53,6,"Nuti E, Casalini F, Avramova SI, Santamaria S, Fabbi M, Ferrini S, Marinelli L, La Pietra V, Limongelli V, Novellino E, Cercignani G, Orlandini E, Nencetti S, Rossello A",,624094,DTCT0024844,3285987,DTCC00381891,1601174,38228
CHEMBL181244,P14780,,PHGLPDURIUEELR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23287054,IC50,=,200,NM,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin),,Sulphonamides: Deserving class as MMP inhibitors?,Eur. J. Med. Chem.,2013,60,,"Jain P, Saravanan C, Singh SK",,944094,DTCT0024844,11835661,DTCC00381891,1612259,53820
CHEMBL1812912,P14780,,VYBROWXFFJWNIK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,INHIBITION,=,64,%,,,,,,,,,,,,,,Inhibition of MMP9 isolated from PMA-stimulated human HT1080 cells at 0.5 uM incubated for 48 hrs by gelatin zymography,,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762824,DTCT0024844,6058067,DTCC01100197,1364478,45525
CHEMBL1812913,P14780,,QUSQFIPNDNBHNU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,INHIBITION,=,62,%,,,,,,,,,,,,,,Inhibition of MMP9 isolated from PMA-stimulated human HT1080 cells at 0.5 uM incubated for 48 hrs by gelatin zymography,,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762824,DTCT0024844,6058068,DTCC01100198,684900,45525
CHEMBL1812914,P14780,,ULEKRRIQMQVQCC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,5.2,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058087,DTCC01100199,1875918,45525
CHEMBL1812914,P14780,,ULEKRRIQMQVQCC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,INHIBITION,=,37,%,,,,,,,,,,,,,,Inhibition of MMP9 isolated from PMA-stimulated human HT1080 cells at 0.5 uM incubated for 48 hrs by gelatin zymography,,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762824,DTCT0024844,6058069,DTCC01100199,1875918,45525
CHEMBL1812915,P14780,,XWFPIEBIPUMISV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,27,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058088,DTCC01100200,231075,45525
CHEMBL1812915,P14780,,XWFPIEBIPUMISV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,INHIBITION,=,69,%,,,,,,,,,,,,,,Inhibition of MMP9 isolated from PMA-stimulated human HT1080 cells at 0.5 uM incubated for 48 hrs by gelatin zymography,,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762824,DTCT0024844,6058070,DTCC01100200,231075,45525
CHEMBL1812916,P14780,,NTEFOOINKPGXDL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,INHIBITION,=,25,%,,,,,,,,,,,,,,Inhibition of MMP9 isolated from PMA-stimulated human HT1080 cells at 0.5 uM incubated for 48 hrs by gelatin zymography,,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762824,DTCT0024844,6058071,DTCC01100201,1655191,45525
CHEMBL1812917,P14780,,RXBGONZYRFPJLF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,INHIBITION,=,55,%,,,,,,,,,,,,,,Inhibition of MMP9 isolated from PMA-stimulated human HT1080 cells at 0.5 uM incubated for 48 hrs by gelatin zymography,,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762824,DTCT0024844,6058072,DTCC01100202,1747170,45525
CHEMBL1812918,P14780,,VEWFRRMUFDSOSK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,131,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058089,DTCC01100203,911906,45525
CHEMBL1812918,P14780,,VEWFRRMUFDSOSK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,INHIBITION,=,53,%,,,,,,,,,,,,,,Inhibition of MMP9 isolated from PMA-stimulated human HT1080 cells at 0.5 uM incubated for 48 hrs by gelatin zymography,,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762824,DTCT0024844,6058073,DTCC01100203,911906,45525
CHEMBL1812919,P14780,,XMLQRYVULFQRSB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,INHIBITION,=,42,%,,,,,,,,,,,,,,Inhibition of MMP9 isolated from PMA-stimulated human HT1080 cells at 0.5 uM incubated for 48 hrs by gelatin zymography,,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762824,DTCT0024844,6058074,DTCC01100204,1747171,45525
CHEMBL1812920,P14780,,WGLLEESJSUVMDV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,14,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058090,DTCC01100205,1364479,45525
CHEMBL1812920,P14780,,WGLLEESJSUVMDV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,INHIBITION,=,49,%,,,,,,,,,,,,,,Inhibition of MMP9 isolated from PMA-stimulated human HT1080 cells at 0.5 uM incubated for 48 hrs by gelatin zymography,,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762824,DTCT0024844,6058075,DTCC01100205,1364479,45525
CHEMBL1812921,P14780,,CHCJEQKHZPVJHX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,16,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058091,DTCC01100206,101981,45525
CHEMBL1812922,P14780,,WVVVZTYNCILRDX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,1.1,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058092,DTCC01100207,943418,45525
CHEMBL1812923,P14780,,NRMRNHPDYBGTNJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,26,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058093,DTCC01100208,1331812,45525
CHEMBL1812924,P14780,,QFGVLITXAHSQBT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,1.5,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058094,DTCC01100209,166647,45525
CHEMBL1812925,P14780,,KTLLOXQGVQXBSF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,1.9,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058095,DTCC01100210,134363,45525
CHEMBL1812925,P14780,,KTLLOXQGVQXBSF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,INHIBITION,=,28,%,,,,,,,,,,,,,,Inhibition of MMP9 isolated from PMA-stimulated human HT1080 cells at 0.5 uM incubated for 48 hrs by gelatin zymography,,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762824,DTCT0024844,6058076,DTCC01100210,134363,45525
CHEMBL1812926,P14780,,QEINCUZDRZTOOF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,43,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058096,DTCC01100211,1493705,45525
CHEMBL1812927,P14780,,QPEQHAHYPSQKRM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,43,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058097,DTCC01100212,1875919,45525
CHEMBL1812928,P14780,,YAPNDZAGUYDTAT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,45,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058098,DTCC01100213,1137893,45525
CHEMBL1812929,P14780,,LKINTHUDVVLELA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,13,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058099,DTCC01100214,427204,45525
CHEMBL1812930,P14780,,QBHSAKPHKDFXFL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,19,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058100,DTCC01100215,198576,45525
CHEMBL1812931,P14780,,BRWGFVQABBELKB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,28,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058101,DTCC01100216,394642,45525
CHEMBL1812932,P14780,,LPZDWWQSUZYCFI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,110,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058102,DTCC01100217,717253,45525
CHEMBL1812933,P14780,,TUQNORHNSISTNL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,14,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058103,DTCC01100218,1461217,45525
CHEMBL1812934,P14780,,SRDYHGFRYLKSRU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,36,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058104,DTCC01100219,1779200,45525
CHEMBL1812935,P14780,,UQMCTVPIBFCEDP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,1190,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058105,DTCC01100220,1299130,45525
CHEMBL1812936,P14780,,IXXYMFNUAAIVKF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,70,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058106,DTCC01100221,1169053,45525
CHEMBL1812937,P14780,,ZTHKEEDWHVZQDO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,155,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058107,DTCC01100222,1266675,45525
CHEMBL1812938,P14780,,NQGQRKWSZKBYDE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,376,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058108,DTCC01100223,523706,45525
CHEMBL1812939,P14780,,YDTMRMDLJOKXKX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,28,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058109,DTCC01100224,1875920,45525
CHEMBL1812940,P14780,,ZPEQVNOXLLWMPR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,191,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058110,DTCC01100225,231076,45525
CHEMBL1812941,P14780,,AXNVQQUJSUYTRG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,2.88,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058111,DTCC01100226,1558035,45525
CHEMBL1812942,P14780,,YVNVOGMCBLDQFU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,215,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058112,DTCC01100227,1811513,45525
CHEMBL1812943,P14780,,XYTCENJSUIYBRC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,25,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058113,DTCC01100228,846810,45525
CHEMBL1812944,P14780,,UYQVBRVYZIDHBO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,34,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058114,DTCC01100229,1973545,45525
CHEMBL1812945,P14780,,ARFMWLMOXLXDGE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,51,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058115,DTCC01100230,846811,45525
CHEMBL1812946,P14780,,FUERCCVUUPZPGY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,120,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058116,DTCC01100231,1623019,45525
CHEMBL1812947,P14780,,XTZTWPVOIONTJV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,198,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058117,DTCC01100232,943419,45525
CHEMBL1812948,P14780,,PIKKDCBNCJTTFT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,44,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058118,DTCC01100233,1973546,45525
CHEMBL1812949,P14780,,ZEWXBNFTMNRQJG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,282,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058119,DTCC01100234,198577,45525
CHEMBL1812950,P14780,,RSZPITUDITYSGB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,87,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058120,DTCC01100235,652844,45525
CHEMBL1812951,P14780,,USAJQJNNFJUVKH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,62,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058121,DTCC01100236,813915,45525
CHEMBL1812952,P14780,,RKVSAYKAVLLLNQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,173,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058122,DTCC01100237,1875921,45525
CHEMBL1812953,P14780,,DOIOPNJCLRHYSK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,77,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058123,DTCC01100238,134364,45525
CHEMBL1812954,P14780,,DMTJHOMQGPRBLZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,81,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058124,DTCC01100239,1266676,45525
CHEMBL1812955,P14780,,GJSXROUEXIBCNX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,24,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058125,DTCC01100240,943420,45525
CHEMBL1812956,P14780,,GSBYGPBBULKZJD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,74,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058126,DTCC01100241,166648,45525
CHEMBL1812957,P14780,,DEHVVEMMIHMAJO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,93,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058127,DTCC01100242,394643,45525
CHEMBL1812958,P14780,,DIHUJPNEHNNZDZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,214,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058128,DTCC01100243,1655192,45525
CHEMBL1812959,P14780,,BSIHEYODNDRSAE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,698,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058129,DTCC01100244,717254,45525
CHEMBL1812960,P14780,,YEXBEMGSRCFPBW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,978,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058130,DTCC01100245,1940429,45525
CHEMBL1812961,P14780,,WGBMLJASUBPVSN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,15,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058131,DTCC01100246,1137894,45525
CHEMBL1812962,P14780,,CIQLLFNYQWGPMA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,57,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058132,DTCC01100247,1590387,45525
CHEMBL1812963,P14780,,OZDWWCLOUIHTHL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,28,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058133,DTCC01100248,1072831,45525
CHEMBL1812964,P14780,,FOAPZIUAOJQVMW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,80,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058134,DTCC01100249,1266677,45525
CHEMBL1812965,P14780,,GWNUFFZRDMNVCF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21764590,IC50,=,76,NM,,,,,,,,,,,,,,"Inhibition of AMPA-activated human recombinant MMP9 using fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 by fluorogenic assay",,N-substituted homopiperazine barbiturates as gelatinase inhibitors.,Bioorg. Med. Chem.,2011,19,16,"Wang J, Medina C, Radomski MW, Gilmer JF",,762826,DTCT0024844,6058135,DTCC01100250,1169054,45525
CHEMBL181682,P14780,,VWGKXDUPRHRCAO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16002291,IC50,>,101000,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors.,Bioorg. Med. Chem. Lett.,2005,15,16,"Dublanchet AC, Ducrot P, Andrianjara C, O'Gara M, Morales R, Compère D, Denis A, Blais S, Cluzeau P, Courté K, Hamon J, Moreau F, Prunet ML, Tertre A",,305122,DTCT0024844,1742482,DTCC00381375,142259,9478
CHEMBL181707,P14780,,SLZDRBFQRQKNPL-QWRGUYRKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15341955,KI,=,9000,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9,,Synthesis and evaluation of novel oxazoline MMP inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,19,"Cook GR, Manivannan E, Underdahl T, Lukacova V, Zhang Y, Balaz S",,302310,DTCT0024844,1771974,DTCC00389520,402882,17054
CHEMBL181807,P14780,,RLQDDFZTFKMONF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1766885,DTCC00387593,2046737,18194
CHEMBL182,P14780,GANCICLOVIR,IRSCQMHQWWYFCW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7316540,DTCC00437788,639580,46191
CHEMBL182,P14780,GANCICLOVIR,IRSCQMHQWWYFCW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7316541,DTCC00437788,639580,46191
CHEMBL1821978,P14780,,QDLPFXRBZXAZRL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23428964,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin) up to 50 uM,Not Active,Selective aminopeptidase-N (CD13) inhibitors with relevance to cancer chemotherapy.,Bioorg. Med. Chem.,2013,21,7,"Schmitt C, Voegelin M, Marin A, Schmitt M, Schegg F, Hénon P, Guenot D, Tarnus C",,951225,DTCT0024844,11846960,DTCC01103969,1107149,54192
CHEMBL182730,P14780,,VMEQJHZAHNCRQC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1768285,DTCC00387769,337382,18194
CHEMBL182879,P14780,,GNDJOJQVOFQQBM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15582436,IC50,,,,,cell_based,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9 expressed in Sf9 insect cells; NA:Not active,Not Active,"N-hydroxy-2-(naphthalene-2-ylsulfanyl)-acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity.",Bioorg. Med. Chem. Lett.,2005,15,1,"Lee J, Shim JS, Jung SA, Lee ST, Kwon HJ",,306425,DTCT0024844,1757708,DTCC00385215,757396,18428
CHEMBL1830129,P14780,N-PHENYLCINNAMAMIDE,FIIZQHKGJMRJIL-VAWYXSNFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,7.98,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833593,DTCC01108397,1029669,53968
CHEMBL1830130,P14780,N-M-TOLYLCINNAMAMIDE,DCZZGCCJBFBLOX-ZHACJKMWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,1896.92,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833583,DTCC01108398,56334,53968
CHEMBL1830131,P14780,N-(3-CHLOROPHENYL)CINNAMAMIDE,ZUKRPXSFAZWKHZ-MDZDMXLPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,1812.91,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833577,DTCC01108399,351093,53968
CHEMBL1830141,P14780,,IZXYYBWPDVJZIX-BQYQJAHWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,1948.29,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833614,DTCC01108409,1962737,53968
CHEMBL1830143,P14780,,KZKTWYPRMCPYNI-RMKNXTFCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,1819.27,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833595,DTCC00128735,577251,53968
CHEMBL183431,P14780,,VTKKCTKODCNOOX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1767151,DTCC00387678,109915,18194
CHEMBL1834417,P14780,,SSPSTNTXKUWFJP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21866961,KI,=,3100,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain assessed as hydrolysis of MOCAcPLGLA2pr(Dnp)AR-NH2 by fluorescence spectrofluorometry ,,Selective water-soluble gelatinase inhibitor prodrugs.,J. Med. Chem.,2011,54,19,"Gooyit M, Lee M, Schroeder VA, Ikejiri M, Suckow MA, Mobashery S, Chang M",,771289,DTCT0024844,6116340,DTCC01109919,2039082,46049
CHEMBL1834418,P14780,,DJLYTRGAMWVKBZ-IJHRGXPZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21866961,KI,=,1600,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain assessed as hydrolysis of MOCAcPLGLA2pr(Dnp)AR-NH2 by fluorescence spectrofluorometry ,,Selective water-soluble gelatinase inhibitor prodrugs.,J. Med. Chem.,2011,54,19,"Gooyit M, Lee M, Schroeder VA, Ikejiri M, Suckow MA, Mobashery S, Chang M",,771289,DTCT0024844,6116339,DTCC01109920,1138000,46049
CHEMBL1834419,P14780,,OUATTZIRQSVXDL-DAFXYXGESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21866961,KI,=,4300,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain assessed as hydrolysis of MOCAcPLGLA2pr(Dnp)AR-NH2 by fluorescence spectrofluorometry ,,Selective water-soluble gelatinase inhibitor prodrugs.,J. Med. Chem.,2011,54,19,"Gooyit M, Lee M, Schroeder VA, Ikejiri M, Suckow MA, Mobashery S, Chang M",,771289,DTCT0024844,6116338,DTCC01109921,717366,46049
CHEMBL1834420,P14780,,OWKCGOUEJMBBRA-NNBQYGFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21866961,KI,=,19600,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain assessed as hydrolysis of MOCAcPLGLA2pr(Dnp)AR-NH2 by fluorescence spectrofluorometry ,,Selective water-soluble gelatinase inhibitor prodrugs.,J. Med. Chem.,2011,54,19,"Gooyit M, Lee M, Schroeder VA, Ikejiri M, Suckow MA, Mobashery S, Chang M",,771289,DTCT0024844,6116337,DTCC01109922,198681,46049
CHEMBL1834421,P14780,,DNICZPICBHCWNG-FALYVICWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21866961,KI,=,18700,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain assessed as hydrolysis of MOCAcPLGLA2pr(Dnp)AR-NH2 by fluorescence spectrofluorometry ,,Selective water-soluble gelatinase inhibitor prodrugs.,J. Med. Chem.,2011,54,19,"Gooyit M, Lee M, Schroeder VA, Ikejiri M, Suckow MA, Mobashery S, Chang M",,771289,DTCT0024844,6116336,DTCC01109923,1940556,46049
CHEMBL1834422,P14780,,AGULWCWMDMKUSF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21866961,KI,=,870,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain assessed as hydrolysis of MOCAcPLGLA2pr(Dnp)AR-NH2 by fluorescence spectrofluorometry ,,Selective water-soluble gelatinase inhibitor prodrugs.,J. Med. Chem.,2011,54,19,"Gooyit M, Lee M, Schroeder VA, Ikejiri M, Suckow MA, Mobashery S, Chang M",,771289,DTCT0024844,6116341,DTCC01109924,1072947,46049
CHEMBL1834423,P14780,,FANDWSFYLCHFFT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21866961,KI,=,490000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain assessed as hydrolysis of MOCAcPLGLA2pr(Dnp)AR-NH2 by fluorescence spectrofluorometry ,,Selective water-soluble gelatinase inhibitor prodrugs.,J. Med. Chem.,2011,54,19,"Gooyit M, Lee M, Schroeder VA, Ikejiri M, Suckow MA, Mobashery S, Chang M",,771289,DTCT0024844,6116342,DTCC01109925,166772,46049
CHEMBL1834425,P14780,,FOCZQHBXIUOIJR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26386821,IC50,=,611,NM,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 2 hrs prior to testing measured for 15 mins by fluorometric analysis,,"Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.",Bioorg. Med. Chem.,2015,23,20,"Yan Y, Chen X, Yang X, Zhang J, Xu W, Zhang Y",,1518636,DTCT0024844,14550519,DTCC01109927,1615466,63755
CHEMBL1834425,P14780,,FOCZQHBXIUOIJR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26386821,INHIBITION,=,96.7,%,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate at 10 uM incubated for 2 hrs prior to testing measured for 15 mins by fluorometric analysis relative to control,,"Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.",Bioorg. Med. Chem.,2015,23,20,"Yan Y, Chen X, Yang X, Zhang J, Xu W, Zhang Y",,1518638,DTCT0024844,14550546,DTCC01109927,1615466,63755
CHEMBL183791,P14780,,ZJOWVJCIVPTYBC-UPVQGACJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1770461,DTCC00388720,1981695,18194
CHEMBL183828,P14780,,GZPFSVVEOIXUBD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1769765,DTCC00387598,1113642,18194
CHEMBL183868,P14780,,LCIIHDPWZSSNGB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1768681,DTCC00387868,1663052,18194
CHEMBL184,P14780,ACYCLOVIR,MKUXAQIIEYXACX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7289720,DTCC00438001,51442,46191
CHEMBL184,P14780,ACYCLOVIR,MKUXAQIIEYXACX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7289721,DTCC00438001,51442,46191
CHEMBL184020,P14780,,WRDDVWWWIRVWCJ-YFOSEYIMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15341955,KI,>,100000,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9,,Synthesis and evaluation of novel oxazoline MMP inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,19,"Cook GR, Manivannan E, Underdahl T, Lukacova V, Zhang Y, Balaz S",,302310,DTCT0024844,1770195,DTCC00389257,1048476,17054
CHEMBL184029,P14780,,SNSSHVAHZRRZIQ-UWVGGRQHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15341955,KI,>,2000000,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9,,Synthesis and evaluation of novel oxazoline MMP inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,19,"Cook GR, Manivannan E, Underdahl T, Lukacova V, Zhang Y, Balaz S",,302310,DTCT0024844,1771842,DTCC00389414,1724730,17054
CHEMBL184058,P14780,,OPQGJZKLYXEBJB-RYUDHWBXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15341955,KI,=,68000,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9,,Synthesis and evaluation of novel oxazoline MMP inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,19,"Cook GR, Manivannan E, Underdahl T, Lukacova V, Zhang Y, Balaz S",,302310,DTCT0024844,1771857,DTCC00389605,369984,17054
CHEMBL184062,P14780,,QDMJDGKLXWJUSU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1766614,DTCC00387550,1948766,18194
CHEMBL184200,P14780,,OOVNTYFKKPGWIY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1769205,DTCC00387611,2014535,18194
CHEMBL184265,P14780,,ZLXSMXRIMOZSHG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1766768,DTCC00387522,174524,18194
CHEMBL184266,P14780,,SUTQJRNQIINAFC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1769663,DTCC00387523,951382,18194
CHEMBL184302,P14780,,KVMYRTIGLLQRFY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,=,1511,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1769258,DTCC00387529,1787170,18194
CHEMBL184492,P14780,,NCCBBRHBDSXVDL-ONGXEEELSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15341955,KI,>,100000,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9,,Synthesis and evaluation of novel oxazoline MMP inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,19,"Cook GR, Manivannan E, Underdahl T, Lukacova V, Zhang Y, Balaz S",,302310,DTCT0024844,1770299,DTCC00389258,887131,17054
CHEMBL184553,P14780,,AENHIDVKFOYIJJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,=,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1768815,DTCC00387561,854875,18194
CHEMBL184594,P14780,,NXVZHPLWCQGDFD-RYUDHWBXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15341955,KI,,,,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9; NA denotes no activity upto solubility limit,No Activity,Synthesis and evaluation of novel oxazoline MMP inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,19,"Cook GR, Manivannan E, Underdahl T, Lukacova V, Zhang Y, Balaz S",,303050,DTCT0024844,1770166,DTCC00389306,1916149,17054
CHEMBL184603,P14780,,XRUIDIXUYZMASL-WXLQDFAISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15341955,KI,,,,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9; NA denotes no activity upto solubility limit,No Activity,Synthesis and evaluation of novel oxazoline MMP inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,19,"Cook GR, Manivannan E, Underdahl T, Lukacova V, Zhang Y, Balaz S",,303050,DTCT0024844,1770170,DTCC00389262,887129,17054
CHEMBL184618,P14780,NEOMYCIN,PGBHMTALBVVCIT-VCIWKGPPSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7405486,DTCC00392052,1894971,46191
CHEMBL184618,P14780,NEOMYCIN,PGBHMTALBVVCIT-VCIWKGPPSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7405487,DTCC00392052,1894971,46191
CHEMBL184731,P14780,,YVZMPLJZOFEXTN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,5000,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1769211,DTCC00387551,789551,18194
CHEMBL184782,P14780,,QKSLJJWUWAALHK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1768689,DTCC00387435,1209204,18194
CHEMBL184885,P14780,,QPQUYVHWOXJEPM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1769091,DTCC00387860,563749,18194
CHEMBL184889,P14780,,JCNKARFKCMFPMK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1768291,DTCC00387709,466623,18194
CHEMBL184942,P14780,,XDBJJTDYSZNDQT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1767051,DTCC00387754,271779,18194
CHEMBL184975,P14780,,ZYBZWGUZKUJPEX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1769217,DTCC00387627,1340070,18194
CHEMBL185,P14780,FLUOROURACIL,GHASVSINZRGABV-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7320569,DTCC00440753,51471,46191
CHEMBL185,P14780,FLUOROURACIL,GHASVSINZRGABV-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7320570,DTCC00440753,51471,46191
CHEMBL185159,P14780,,PGTJOSSSBWAALE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1766892,DTCC00387543,1534047,18194
CHEMBL185160,P14780,,PVWTVPDAGBLFIJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1769772,DTCC00387544,1015993,18194
CHEMBL1852660,P14780,,XFZZDIHCNHYESF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23428964,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin) up to 50 uM,Not Active,Selective aminopeptidase-N (CD13) inhibitors with relevance to cancer chemotherapy.,Bioorg. Med. Chem.,2013,21,7,"Schmitt C, Voegelin M, Marin A, Schmitt M, Schegg F, Hénon P, Guenot D, Tarnus C",,951225,DTCT0024844,11846959,DTCC01113468,1877558,54192
CHEMBL185279,P14780,,NWEMVUGYMZFTLT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1767172,DTCC00387634,32985,18194
CHEMBL185321,P14780,,MBVFAXQWLSRZPW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1769200,DTCC00387430,1724709,18194
CHEMBL185397,P14780,,KCWUMRBDUUZPAL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1768060,DTCC00387675,1663050,18194
CHEMBL185459,P14780,,HOLCLOFNVSKQFD-STQMWFEESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15341955,KI,,,,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9; NA denotes no activity upto solubility limit,No Activity,Synthesis and evaluation of novel oxazoline MMP inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,19,"Cook GR, Manivannan E, Underdahl T, Lukacova V, Zhang Y, Balaz S",,303050,DTCT0024844,1771853,DTCC00389596,1242063,17054
CHEMBL185521,P14780,,IFZNBBFLMYGGPO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1767165,DTCC00387708,1630785,18194
CHEMBL185587,P14780,,GQEXSMDDEGSZJA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1769780,DTCC00387743,109914,18194
CHEMBL18614,P14780,,JXCARHJPSZBVFH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11934587,IC50,=,11,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 1: Structure-based design of novel acetylenic P1' groups.,Bioorg. Med. Chem. Lett.,2002,12,8,"Chen JM, Jin G, Sung A, Levin JI",,105517,DTCT0024844,1121127,DTCC00149659,1049355,5358
CHEMBL18614,P14780,,JXCARHJPSZBVFH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11934588,IC50,=,11,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 activity,,Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.,Bioorg. Med. Chem. Lett.,2002,12,8,"Levin JI, Chen JM, Du MT, Nelson FC, Killar LM, Skala S, Sung A, Jin G, Cowling R, Barone D, March CJ, Mohler KM, Black RA, Skotnicki JS",,105508,DTCT0024844,780853,DTCC00149659,1034297,5465
CHEMBL186422,P14780,QUINOLIN-2-OL,LISFMEBWQUVKPJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,5,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103270,DTCC00000874,1763872,43205
CHEMBL18649,P14780,,MDOGBVLWCBWUMC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11934588,IC50,=,232,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 activity,,Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.,Bioorg. Med. Chem. Lett.,2002,12,8,"Levin JI, Chen JM, Du MT, Nelson FC, Killar LM, Skala S, Sung A, Jin G, Cowling R, Barone D, March CJ, Mohler KM, Black RA, Skotnicki JS",,105508,DTCT0024844,777959,DTCC00150397,1681122,5465
CHEMBL186538,P14780,,FLKISSURPVEJPE-RYUDHWBXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15341955,KI,=,6000,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9,,Synthesis and evaluation of novel oxazoline MMP inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,19,"Cook GR, Manivannan E, Underdahl T, Lukacova V, Zhang Y, Balaz S",,302310,DTCT0024844,1771849,DTCC00389373,1242062,17054
CHEMBL186559,P14780,,JTSGTFRCJJPVQT-SXDPYWSBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15341955,KI,=,94000,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9,,Synthesis and evaluation of novel oxazoline MMP inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,19,"Cook GR, Manivannan E, Underdahl T, Lukacova V, Zhang Y, Balaz S",,302310,DTCT0024844,1770187,DTCC00389314,725291,17054
CHEMBL186648,P14780,,GCUIPMGVKOFNNT-BVAIOKDQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15341955,KI,=,22000,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9,,Synthesis and evaluation of novel oxazoline MMP inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,19,"Cook GR, Manivannan E, Underdahl T, Lukacova V, Zhang Y, Balaz S",,302310,DTCT0024844,1770174,DTCC00389263,1754962,17054
CHEMBL18667,P14780,,JNFDCDGQVIEXPD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11934588,IC50,=,166,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 activity,,Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.,Bioorg. Med. Chem. Lett.,2002,12,8,"Levin JI, Chen JM, Du MT, Nelson FC, Killar LM, Skala S, Sung A, Jin G, Cowling R, Barone D, March CJ, Mohler KM, Black RA, Skotnicki JS",,105508,DTCT0024844,786546,DTCC00150436,355581,5465
CHEMBL186765,P14780,,HDSODEHQNNGCDW-GMAHTHKFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15341955,KI,>,100000,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9,,Synthesis and evaluation of novel oxazoline MMP inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,19,"Cook GR, Manivannan E, Underdahl T, Lukacova V, Zhang Y, Balaz S",,302310,DTCT0024844,1770699,DTCC00389458,660773,17054
CHEMBL186998,P14780,,ZPSAIKXBLPQWSH-IRXDYDNUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15341955,KI,=,24000,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9,,Synthesis and evaluation of novel oxazoline MMP inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,19,"Cook GR, Manivannan E, Underdahl T, Lukacova V, Zhang Y, Balaz S",,302310,DTCT0024844,1771860,DTCC00389549,983723,17054
CHEMBL186999,P14780,,ZBGXAQNJQLZZND-QWRGUYRKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15341955,KI,,,,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9; NA denotes no activity upto solubility limit,No Activity,Synthesis and evaluation of novel oxazoline MMP inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,19,"Cook GR, Manivannan E, Underdahl T, Lukacova V, Zhang Y, Balaz S",,303050,DTCT0024844,1771967,DTCC00389550,1916152,17054
CHEMBL18701,P14780,RO-201724,PDMUULPVBYQBBK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7475288,DTCC00149559,1674149,46191
CHEMBL18701,P14780,RO-201724,PDMUULPVBYQBBK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7475289,DTCC00149559,1674149,46191
CHEMBL187079,P14780,,OMKGAAGLEHDNHH-ZUPSLANMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15341955,KI,=,8000,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9,,Synthesis and evaluation of novel oxazoline MMP inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,19,"Cook GR, Manivannan E, Underdahl T, Lukacova V, Zhang Y, Balaz S",,302310,DTCT0024844,1770178,DTCC00389368,174548,17054
CHEMBL187092,P14780,,LTVIJEFEZVFIST-AZUAARDMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15953722,IC50,=,11,NM,,,,,,,,,,,,,,Inhibitory concentration against MMP-9,,Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13.,Bioorg. Med. Chem. Lett.,2005,15,14,"Noe MC, Natarajan V, Snow SL, Wolf-Gouveia LA, Mitchell PG, Lopresti-Morrow L, Reeves LM, Yocum SA, Otterness I, Bliven MA, Carty TJ, Barberia JT, Sweeney FJ, Liras JL, Vaughn M",,304625,DTCT0024844,1774126,DTCC00390625,681417,18571
CHEMBL187265,P14780,"1,3,6,7-TETRAHYDROXYXANTONE",ZHTQCPCDXKMMLU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,IC50,,,,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain incubated for 20 mins by fluorimetric assay,Not Determined,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827436,DTCT0024844,10535421,DTCC00000833,1779807,48665
CHEMBL187282,P14780,,CIXLOBUCXQISAF-IRXDYDNUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15341955,KI,=,32000,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9,,Synthesis and evaluation of novel oxazoline MMP inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,19,"Cook GR, Manivannan E, Underdahl T, Lukacova V, Zhang Y, Balaz S",,302310,DTCT0024844,1770168,DTCC00389307,1436977,17054
CHEMBL1873703,P14780,DIELDRIN,DFBKLUNHFCTMDC-PICURKEMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7359621,DTCC01123582,800575,46191
CHEMBL1873703,P14780,DIELDRIN,DFBKLUNHFCTMDC-PICURKEMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7359622,DTCC01123582,800575,46191
CHEMBL18742,P14780,,IUPDLWWZWJCNBN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11934588,IC50,,,,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (No data),Not Determined,Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.,Bioorg. Med. Chem. Lett.,2002,12,8,"Levin JI, Chen JM, Du MT, Nelson FC, Killar LM, Skala S, Sung A, Jin G, Cowling R, Barone D, March CJ, Mohler KM, Black RA, Skotnicki JS",,105509,DTCT0024844,334187,DTCC00150112,807759,5465
CHEMBL187733,P14780,,DPQCHTZYBRQXQC-KUFXBUICSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16107143,KI,=,10.99,NM,,,,,,,,,,,,,,Inhibition of MOCAc-Pro-Leu-Gly-Leu-A2p (Dnp)-Ala-Arg-NH2 binding to human matrix metalloprotease-9 (MMP-9),,"A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.",J. Med. Chem.,2005,48,17,"Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S",,307380,DTCT0024844,1815816,DTCC00397180,337470,19409
CHEMBL187808,P14780,,GIORTTRAQVPRSL-RDJZCZTQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15341955,KI,=,94000,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9,,Synthesis and evaluation of novel oxazoline MMP inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,19,"Cook GR, Manivannan E, Underdahl T, Lukacova V, Zhang Y, Balaz S",,302310,DTCT0024844,1770671,DTCC00389354,693006,17054
CHEMBL18797,P14780,SULINDAC SULFIDE,LFWHFZJPXXOYNR-MFOYZWKCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7465403,DTCC00150119,994595,46191
CHEMBL18797,P14780,SULINDAC SULFIDE,LFWHFZJPXXOYNR-MFOYZWKCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7465404,DTCC00150119,994595,46191
CHEMBL18868,P14780,,XNSXZLYFBPIUKQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11934588,IC50,,,,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (No data),Not Determined,Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.,Bioorg. Med. Chem. Lett.,2002,12,8,"Levin JI, Chen JM, Du MT, Nelson FC, Killar LM, Skala S, Sung A, Jin G, Cowling R, Barone D, March CJ, Mohler KM, Black RA, Skotnicki JS",,105509,DTCT0024844,803177,DTCC00150439,937287,5465
CHEMBL18868,P14780,,XNSXZLYFBPIUKQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11934588,INHIBITION,=,61,%,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 at 10 uM,,Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.,Bioorg. Med. Chem. Lett.,2002,12,8,"Levin JI, Chen JM, Du MT, Nelson FC, Killar LM, Skala S, Sung A, Jin G, Cowling R, Barone D, March CJ, Mohler KM, Black RA, Skotnicki JS",,105535,DTCT0024844,803178,DTCC00150439,937287,5465
CHEMBL188894,P14780,,HBBHNZHTEFSNGF-HUUCEWRRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15369398,INHIBITION,=,8,%,,,,,,,,,,,,,,Inhibition of MMP-9 (matrix metalloprotease) at 1 uM,,Macrocyclic inhibitors for peptide deformylase: a structure-activity relationship study of the ring size.,J. Med. Chem.,2004,47,20,"Hu X, Nguyen KT, Jiang VC, Lofland D, Moser HE, Pei D",,307797,DTCT0024844,1790624,DTCC00392759,1936804,19089
CHEMBL188894,P14780,,HBBHNZHTEFSNGF-HUUCEWRRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15369398,INHIBITION,=,11,%,,,,,,,,,,,,,,Inhibition of MMP-9 (matrix metalloprotease) at 10 uM,,Macrocyclic inhibitors for peptide deformylase: a structure-activity relationship study of the ring size.,J. Med. Chem.,2004,47,20,"Hu X, Nguyen KT, Jiang VC, Lofland D, Moser HE, Pei D",,307804,DTCT0024844,1790625,DTCC00392759,1936804,19089
CHEMBL188921,P14780,BUFLOMEDIL,OWYLAEYXIQKAOL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7280337,DTCC00395665,1188065,46191
CHEMBL188921,P14780,BUFLOMEDIL,OWYLAEYXIQKAOL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7280338,DTCC00395665,1188065,46191
CHEMBL18895,P14780,,FODLAGUBVKDEIZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11934588,IC50,=,387,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 activity,,Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.,Bioorg. Med. Chem. Lett.,2002,12,8,"Levin JI, Chen JM, Du MT, Nelson FC, Killar LM, Skala S, Sung A, Jin G, Cowling R, Barone D, March CJ, Mohler KM, Black RA, Skotnicki JS",,105508,DTCT0024844,777964,DTCC00150803,743367,5465
CHEMBL189,P14780,MILRINONE,PZRHRDRVRGEVNW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7424128,DTCC00450749,930081,46191
CHEMBL189,P14780,MILRINONE,PZRHRDRVRGEVNW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7424129,DTCC00450749,930081,46191
CHEMBL189171,P14780,ACEMETACIN,FSQKKOOTNAMONP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7297722,DTCC00393990,800567,46191
CHEMBL189171,P14780,ACEMETACIN,FSQKKOOTNAMONP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7297723,DTCC00393990,800567,46191
CHEMBL189176,P14780,,USYXNFCQBGQYRW-QOBPCVTDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16107143,KI,=,41.78,NM,,,,,,,,,,,,,,Inhibition of MOCAc-Pro-Leu-Gly-Leu-A2p (Dnp)-Ala-Arg-NH2 binding to human matrix metalloprotease-9 (MMP-9),,"A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.",J. Med. Chem.,2005,48,17,"Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S",,307380,DTCT0024844,1815694,DTCC00397158,1819813,19409
CHEMBL189176,P14780,,USYXNFCQBGQYRW-QOBPCVTDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16107143,KI,=,41.8,NM,,,,,,,,,,,,,,Inhibition constant for human matrix metalloprotease-9 (MMP-9),,"A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.",J. Med. Chem.,2005,48,17,"Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S",,302463,DTCT0024844,1815695,DTCC00397158,1819813,19409
CHEMBL189330,P14780,,XRIFBRFEZLXEFP-SIHBAMTISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16107143,KI,=,95.5,NM,,,,,,,,,,,,,,Inhibition of MOCAc-Pro-Leu-Gly-Leu-A2p (Dnp)-Ala-Arg-NH2 binding to human matrix metalloprotease-9 (MMP-9),,"A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.",J. Med. Chem.,2005,48,17,"Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S",,307380,DTCT0024844,1815803,DTCC00397836,1372661,19409
CHEMBL18943,P14780,,ZEZNNQDUSMNIDE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11934588,IC50,=,477,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 activity,,Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.,Bioorg. Med. Chem. Lett.,2002,12,8,"Levin JI, Chen JM, Du MT, Nelson FC, Killar LM, Skala S, Sung A, Jin G, Cowling R, Barone D, March CJ, Mohler KM, Black RA, Skotnicki JS",,105508,DTCT0024844,785158,DTCC00150790,1455020,5465
CHEMBL189591,P14780,,BKBMJVASMYYCKO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15908214,KI,>,2130,NM,,,,,,,,,,,,,,In vitro binding affinity against matrix metalloprotease 9,,"Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.",Bioorg. Med. Chem. Lett.,2005,15,12,"Duan JJ, Lu Z, Wasserman ZR, Liu RQ, Covington MB, Decicco CP",,302347,DTCT0024844,1800089,DTCC00398075,584553,16433
CHEMBL189690,P14780,,QSFJZGINKPYVRC-IYOGPWPASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16107143,KI,=,0.0794,NM,,,,,,,,,,,,,,Inhibition of MOCAc-Pro-Leu-Gly-Leu-A2p (Dnp)-Ala-Arg-NH2 binding to human matrix metalloprotease-9 (MMP-9),,"A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.",J. Med. Chem.,2005,48,17,"Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S",,307380,DTCT0024844,1815807,DTCC00397583,1340167,19409
CHEMBL189945,P14780,,DWFUVVZGNJNHKO-FOEZPWHWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16107143,KI,=,38.28,NM,,,,,,,,,,,,,,Inhibition of MOCAc-Pro-Leu-Gly-Leu-A2p (Dnp)-Ala-Arg-NH2 binding to human matrix metalloprotease-9 (MMP-9),,"A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.",J. Med. Chem.,2005,48,17,"Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S",,307380,DTCT0024844,1815815,DTCC00397328,1501761,19409
CHEMBL190,P14780,THEOPHYLLINE,ZFXYFBGIUFBOJW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7465899,DTCC00451755,413979,46191
CHEMBL190,P14780,THEOPHYLLINE,ZFXYFBGIUFBOJW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7465900,DTCC00451755,413979,46191
CHEMBL19005,P14780,,PDBHRMUGMOPNOC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11934587,IC50,=,304,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 1: Structure-based design of novel acetylenic P1' groups.,Bioorg. Med. Chem. Lett.,2002,12,8,"Chen JM, Jin G, Sung A, Levin JI",,105517,DTCT0024844,1095547,DTCC00150235,1949738,5358
CHEMBL19005,P14780,,PDBHRMUGMOPNOC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11934588,IC50,=,304,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 activity,,Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.,Bioorg. Med. Chem. Lett.,2002,12,8,"Levin JI, Chen JM, Du MT, Nelson FC, Killar LM, Skala S, Sung A, Jin G, Cowling R, Barone D, March CJ, Mohler KM, Black RA, Skotnicki JS",,105508,DTCT0024844,790613,DTCC00150235,1934079,5465
CHEMBL19019,P14780,NALTREXONE,DQCKKXVULJGBQN-XFWGSAIBSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7409541,DTCC00149948,88632,46191
CHEMBL19019,P14780,NALTREXONE,DQCKKXVULJGBQN-XFWGSAIBSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7409542,DTCC00149948,88632,46191
CHEMBL190215,P14780,,CEGUOXMMRKISPK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15908214,KI,=,138,NM,,,,,,,,,,,,,,In vitro binding affinity against matrix metalloprotease 9,,"Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.",Bioorg. Med. Chem. Lett.,2005,15,12,"Duan JJ, Lu Z, Wasserman ZR, Liu RQ, Covington MB, Decicco CP",,302347,DTCT0024844,1800243,DTCC00398109,1457816,16433
CHEMBL190232,P14780,,IBUXWZOBVVWCHD-GFTAOQHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16107143,KI,=,0.6,NM,,,,,,,,,,,,,,Inhibition of MOCAc-Pro-Leu-Gly-Leu-A2p (Dnp)-Ala-Arg-NH2 binding to human matrix metalloprotease-9 (MMP-9),,"A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.",J. Med. Chem.,2005,48,17,"Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S",,307380,DTCT0024844,1815808,DTCC00397896,951493,19409
CHEMBL1902627,P14780,CLORPRENALINE,SSMSBSWKLKKXGG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7350150,DTCC01151693,866018,46191
CHEMBL1902627,P14780,CLORPRENALINE,SSMSBSWKLKKXGG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7350151,DTCC01151693,866018,46191
CHEMBL1902981,P14780,EPERISONE,SQUNAWUMZGQQJD-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7306934,DTCC01152035,348399,46191
CHEMBL1902981,P14780,EPERISONE,SQUNAWUMZGQQJD-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7306935,DTCC01152035,348399,46191
CHEMBL190493,P14780,,RBLCSCFFNCADJO-HSYKDVHTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16107143,KI,=,349,NM,,,,,,,,,,,,,,Inhibition constant for human matrix metalloprotease-9 (MMP-9),,"A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.",J. Med. Chem.,2005,48,17,"Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S",,302463,DTCT0024844,1815684,DTCC00397634,1663135,19409
CHEMBL190493,P14780,,RBLCSCFFNCADJO-HSYKDVHTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16107143,KI,=,349.14,NM,,,,,,,,,,,,,,Inhibition of MOCAc-Pro-Leu-Gly-Leu-A2p (Dnp)-Ala-Arg-NH2 binding to human matrix metalloprotease-9 (MMP-9),,"A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.",J. Med. Chem.,2005,48,17,"Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S",,307380,DTCT0024844,1815683,DTCC00397634,1663135,19409
CHEMBL190621,P14780,,BJNHISLNENZLDD-PXWGLLCJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16107143,KI,=,0.1,NM,,,,,,,,,,,,,,Inhibition of MOCAc-Pro-Leu-Gly-Leu-A2p (Dnp)-Ala-Arg-NH2 binding to human matrix metalloprotease-9 (MMP-9),,"A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.",J. Med. Chem.,2005,48,17,"Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S",,307380,DTCT0024844,1815814,DTCC00397477,1177106,19409
CHEMBL190683,P14780,,MDDQQIMYYBMNMU-BXWDTWGJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16107143,KI,=,316.23,NM,,,,,,,,,,,,,,Inhibition of MOCAc-Pro-Leu-Gly-Leu-A2p (Dnp)-Ala-Arg-NH2 binding to human matrix metalloprotease-9 (MMP-9),,"A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.",J. Med. Chem.,2005,48,17,"Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S",,307380,DTCT0024844,1815916,DTCC00397776,951492,19409
CHEMBL190712,P14780,,AVBJISHPTVGUMF-NCOWXEORSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16107143,KI,=,1.13,NM,,,,,,,,,,,,,,Inhibition of MOCAc-Pro-Leu-Gly-Leu-A2p (Dnp)-Ala-Arg-NH2 binding to human matrix metalloprotease-9 (MMP-9),,"A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.",J. Med. Chem.,2005,48,17,"Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S",,307380,DTCT0024844,1815818,DTCC00397687,887207,19409
CHEMBL190713,P14780,,PCAPSCAFNCUGDE-HOPWYFMXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16107143,KI,=,6.47,NM,,,,,,,,,,,,,,Inhibition of MOCAc-Pro-Leu-Gly-Leu-A2p (Dnp)-Ala-Arg-NH2 binding to human matrix metalloprotease-9 (MMP-9),,"A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.",J. Med. Chem.,2005,48,17,"Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S",,307380,DTCT0024844,1815688,DTCC00397867,1501763,19409
CHEMBL1908355,P14780,TENIDAP,LXIKEPCNDFVJKC-QXMHVHEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7454776,DTCC01156858,1285881,46191
CHEMBL1908355,P14780,TENIDAP,LXIKEPCNDFVJKC-QXMHVHEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7454777,DTCC01156858,1285881,46191
CHEMBL190871,P14780,,FFOFJMKSEMVOQQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15857146,IC50,=,19,NM,,,,,,,,,,,,,,In vitro inhibition of human Matrix metalloprotease 9,,C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging.,J. Med. Chem.,2005,48,9,"Breyholz HJ, Schäfers M, Wagner S, Höltke C, Faust A, Rabeneck H, Levkau B, Schober O, Kopka K",,305380,DTCT0024844,1828950,DTCC00399816,951511,19718
CHEMBL1909048,P14780,,RBCUCXILXJXLTB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7291624,DTCC00128929,444633,46191
CHEMBL1909048,P14780,,RBCUCXILXJXLTB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7291625,DTCC00128929,444633,46191
CHEMBL1909049,P14780,,FSIWGHXVLYRBFQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7297197,DTCC00128930,930074,46191
CHEMBL1909049,P14780,,FSIWGHXVLYRBFQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7297198,DTCC00128930,930074,46191
CHEMBL1909050,P14780,,DLDAZIVPAOLETE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7299946,DTCC01157054,413966,46191
CHEMBL1909050,P14780,,DLDAZIVPAOLETE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7299947,DTCC01157054,413966,46191
CHEMBL1909051,P14780,,LUHHARLTABWBTO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7301737,DTCC01157055,1480342,46191
CHEMBL1909051,P14780,,LUHHARLTABWBTO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7301738,DTCC01157055,1480342,46191
CHEMBL1909054,P14780,CARBOXYMETHYLCELLULOSE,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7360058,DTCC01157056,768475,46191
CHEMBL1909054,P14780,CARBOXYMETHYLCELLULOSE,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7360059,DTCC01157056,768475,46191
CHEMBL1909055,P14780,COBALTOUS CHLORIDE,,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7369708,DTCC01157057,1992803,46191
CHEMBL1909055,P14780,COBALTOUS CHLORIDE,,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7369709,DTCC01157057,1992803,46191
CHEMBL1909056,P14780,COBALT(II) ACETYLACETONATE,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7339598,DTCC01157058,736258,46191
CHEMBL1909056,P14780,COBALT(II) ACETYLACETONATE,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7339599,DTCC01157058,736258,46191
CHEMBL1909057,P14780,COPPER(II) OXIDE,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7356807,DTCC01157059,1318440,46191
CHEMBL1909057,P14780,COPPER(II) OXIDE,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7356808,DTCC01157059,1318440,46191
CHEMBL1909062,P14780,LEAD (II) ACETATE,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7420838,DTCC01157060,1609549,46191
CHEMBL1909062,P14780,LEAD (II) ACETATE,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7420839,DTCC01157060,1609549,46191
CHEMBL1909063,P14780,LEAD(IV) ACETATE,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7425110,DTCC01157061,1765974,46191
CHEMBL1909063,P14780,LEAD(IV) ACETATE,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7425111,DTCC01157061,1765974,46191
CHEMBL1909064,P14780,LIPOPOLYSACCHARIDE E. COLI O55:B5,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7412460,DTCC01157062,898291,46191
CHEMBL1909064,P14780,LIPOPOLYSACCHARIDE E. COLI O55:B5,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7412461,DTCC01157062,898291,46191
CHEMBL1909065,P14780,LYSERGOL,RWVUEZAROXKXRT-VQLSFVLHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7427589,DTCC01157063,510303,46191
CHEMBL1909065,P14780,LYSERGOL,RWVUEZAROXKXRT-VQLSFVLHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7427590,DTCC01157063,510303,46191
CHEMBL1909067,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7412764,DTCC01157064,1734058,46191
CHEMBL1909067,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7412765,DTCC01157064,1734058,46191
CHEMBL1909068,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7417118,DTCC01157065,1059333,46191
CHEMBL1909068,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7417119,DTCC01157065,1059333,46191
CHEMBL1909069,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7421409,DTCC01157066,1253326,46191
CHEMBL1909069,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7421410,DTCC01157066,1253326,46191
CHEMBL1909070,P14780,NAFENOPIN,XJGBDJOMWKAZJS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7437165,DTCC01157067,866020,46191
CHEMBL1909070,P14780,NAFENOPIN,XJGBDJOMWKAZJS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7437166,DTCC01157067,866020,46191
CHEMBL1909071,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7375667,DTCC01157068,1765978,46191
CHEMBL1909071,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7375668,DTCC01157068,1765978,46191
CHEMBL1909072,P14780,PIPAMAZINE,OSJJYEUEJRVVOD-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7395990,DTCC01157069,1927019,46191
CHEMBL1909072,P14780,PIPAMAZINE,OSJJYEUEJRVVOD-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7395991,DTCC01157069,1927019,46191
CHEMBL1909073,P14780,PIPERILATE ETHOBROMIDE,VPUGSHLBERYQGC-UHFFFAOYSA-M,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7404646,DTCC01157070,348403,46191
CHEMBL1909073,P14780,PIPERILATE ETHOBROMIDE,VPUGSHLBERYQGC-UHFFFAOYSA-M,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7404647,DTCC01157070,348403,46191
CHEMBL1909074,P14780,POLYVINYLPYRROLIDONE,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7400430,DTCC01157071,1059338,46191
CHEMBL1909074,P14780,POLYVINYLPYRROLIDONE,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7400431,DTCC01157071,1059338,46191
CHEMBL1909075,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7383788,DTCC01157072,606972,46191
CHEMBL1909075,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7383789,DTCC01157072,606972,46191
CHEMBL1909076,P14780,,RSTSYGXUDMJEFP-SECBINFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7475406,DTCC01157073,1894973,46191
CHEMBL1909076,P14780,,RSTSYGXUDMJEFP-SECBINFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7475407,DTCC01157073,1894973,46191
CHEMBL1909078,P14780,SODIUM ARSENITE,PTLRDCMBXHILCL-UHFFFAOYSA-M,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7458264,DTCC01157074,1351117,46191
CHEMBL1909078,P14780,SODIUM ARSENITE,PTLRDCMBXHILCL-UHFFFAOYSA-M,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7458265,DTCC01157074,1351117,46191
CHEMBL1909079,P14780,STANNOUS FLUORIDE,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7460578,DTCC01157075,671794,46191
CHEMBL1909079,P14780,STANNOUS FLUORIDE,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7460579,DTCC01157075,671794,46191
CHEMBL1909080,P14780,STRONTIUM CHLORIDE HEXAHYDRATE,AMGRXJSJSONEEG-UHFFFAOYSA-L,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7486639,DTCC01157076,1124455,46191
CHEMBL1909080,P14780,STRONTIUM CHLORIDE HEXAHYDRATE,AMGRXJSJSONEEG-UHFFFAOYSA-L,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7486640,DTCC01157076,1124455,46191
CHEMBL1909083,P14780,ZIRCONIUM(IV) CHLORIDE,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7452524,DTCC01157077,120980,46191
CHEMBL1909083,P14780,ZIRCONIUM(IV) CHLORIDE,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7452525,DTCC01157077,120980,46191
CHEMBL190936,P14780,,INGVNDTUNOZHOP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15908214,KI,>,2130,NM,,,,,,,,,,,,,,In vitro binding affinity against matrix metalloprotease 9,,"Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.",Bioorg. Med. Chem. Lett.,2005,15,12,"Duan JJ, Lu Z, Wasserman ZR, Liu RQ, Covington MB, Decicco CP",,302347,DTCT0024844,1800213,DTCC00398012,7206,16433
CHEMBL191,P14780,LOSARTAN,PSIFNNKUMBGKDQ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7410396,DTCC00475883,1705876,46191
CHEMBL191,P14780,LOSARTAN,PSIFNNKUMBGKDQ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7410397,DTCC00475883,1705876,46191
CHEMBL191076,P14780,,XTJZQNUILYKCRX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15908214,KI,=,850,NM,,,,,,,,,,,,,,In vitro binding affinity against matrix metalloprotease 9,,"Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.",Bioorg. Med. Chem. Lett.,2005,15,12,"Duan JJ, Lu Z, Wasserman ZR, Liu RQ, Covington MB, Decicco CP",,302347,DTCT0024844,1800065,DTCC00398004,1361039,16433
CHEMBL191135,P14780,,MXGYLPKHTGTZKG-SMFUYQKNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16107143,KI,=,42.66,NM,,,,,,,,,,,,,,Inhibition of MOCAc-Pro-Leu-Gly-Leu-A2p (Dnp)-Ala-Arg-NH2 binding to human matrix metalloprotease-9 (MMP-9),,"A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.",J. Med. Chem.,2005,48,17,"Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S",,307380,DTCT0024844,1815692,DTCC00397302,499563,19409
CHEMBL191135,P14780,,MXGYLPKHTGTZKG-SMFUYQKNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16107143,KI,=,42.7,NM,,,,,,,,,,,,,,Inhibition constant for human matrix metalloprotease-9 (MMP-9),,"A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.",J. Med. Chem.,2005,48,17,"Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S",,302463,DTCT0024844,1815693,DTCC00397302,499563,19409
CHEMBL191318,P14780,,NQUUIXIBNFFYTG-GFTAOQHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16107143,KI,=,16.71,NM,,,,,,,,,,,,,,Inhibition of MOCAc-Pro-Leu-Gly-Leu-A2p (Dnp)-Ala-Arg-NH2 binding to human matrix metalloprotease-9 (MMP-9),,"A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.",J. Med. Chem.,2005,48,17,"Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S",,307380,DTCT0024844,1815689,DTCC00397698,563834,19409
CHEMBL191360,P14780,,HEICZDBUMBAABJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15908214,KI,>,2130,NM,,,,,,,,,,,,,,In vitro binding affinity against matrix metalloprotease 9,,"Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.",Bioorg. Med. Chem. Lett.,2005,15,12,"Duan JJ, Lu Z, Wasserman ZR, Liu RQ, Covington MB, Decicco CP",,302347,DTCT0024844,1800400,DTCC00398432,1328331,16433
CHEMBL1914702,P14780,,CRPIWCWIMAOUCX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21548582,IC50,=,22900,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.",J. Med. Chem.,2011,54,13,"Neelarapu R, Holzle DL, Velaparthi S, Bai H, Brunsteiner M, Blond SY, Petukhov PA",,785746,DTCT0024844,7517247,DTCC01159563,153491,46348
CHEMBL1914702,P14780,,CRPIWCWIMAOUCX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21548582,RATIO IC50,=,458000,,,,,,,,,,,,,,,Selectivity ratio of compound IC50 to GM6001 IC50 for MMP9,,"Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.",J. Med. Chem.,2011,54,13,"Neelarapu R, Holzle DL, Velaparthi S, Bai H, Brunsteiner M, Blond SY, Petukhov PA",,785738,DTCT0024844,7517259,DTCC01159563,153491,46348
CHEMBL1914708,P14780,,IGNPXOQRVRXSKJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21548582,ACTIVITY,>,70,%,,,,,,,,,,,,,,Inhibition of MMP9 assessed as activity remaining at 10 mM,,"Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.",J. Med. Chem.,2011,54,13,"Neelarapu R, Holzle DL, Velaparthi S, Bai H, Brunsteiner M, Blond SY, Petukhov PA",,785742,DTCT0024844,7517253,DTCC01159569,185603,46348
CHEMBL1914708,P14780,,IGNPXOQRVRXSKJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21548582,RATIO IC50,,,,,,,,,,,,,,,,,Selectivity ratio of compound IC50 to GM6001 IC50 for MMP9,Not Determined,"Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.",J. Med. Chem.,2011,54,13,"Neelarapu R, Holzle DL, Velaparthi S, Bai H, Brunsteiner M, Blond SY, Petukhov PA",,785738,DTCT0024844,7517260,DTCC01159569,185603,46348
CHEMBL1916049,P14780,,GETDIWSMCUZGCD-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21925881,IC50,=,1117,NM,,,,,,,,,,,,,,Inhibition of human MMP9 catalytic domain (amino acids 107 to 446) using acetyl-Cys(Eu)-Pro-Leu-Gly-Leu-Lys-(QSY7)-Ala-Arg-amide as substrate preincubated for 1 hrs before substrate addition measured after 15 mins by fluorimetry,,Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.,Bioorg. Med. Chem. Lett.,2011,21,21,"Wilson LJ, Wang B, Yang SM, Scannevin RH, Burke SL, Karnachi P, Rhodes KJ, Murray WV",,787971,DTCT0024844,7525331,DTCC01160858,458488,46368
CHEMBL1916050,P14780,,GETDIWSMCUZGCD-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21925881,IC50,=,0.58,NM,,,,,,,,,,,,,,Inhibition of human MMP9 catalytic domain (amino acids 107 to 446) using acetyl-Cys(Eu)-Pro-Leu-Gly-Leu-Lys-(QSY7)-Ala-Arg-amide as substrate preincubated for 1 hrs before substrate addition measured after 15 mins by fluorimetry,,Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.,Bioorg. Med. Chem. Lett.,2011,21,21,"Wilson LJ, Wang B, Yang SM, Scannevin RH, Burke SL, Karnachi P, Rhodes KJ, Murray WV",,787971,DTCT0024844,7525332,DTCC01160859,685161,46368
CHEMBL1916051,P14780,,SUTULEKUSDXPBW-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21925881,IC50,=,5.9,NM,,,,,,,,,,,,,,Inhibition of human MMP9 catalytic domain (amino acids 107 to 446) using acetyl-Cys(Eu)-Pro-Leu-Gly-Leu-Lys-(QSY7)-Ala-Arg-amide as substrate preincubated for 1 hrs before substrate addition measured after 15 mins by fluorimetry,,Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.,Bioorg. Med. Chem. Lett.,2011,21,21,"Wilson LJ, Wang B, Yang SM, Scannevin RH, Burke SL, Karnachi P, Rhodes KJ, Murray WV",,787971,DTCT0024844,7525333,DTCC01160860,1844049,46368
CHEMBL1916052,P14780,,HVOVPPVRLMOBHI-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21925881,IC50,>,1000,NM,,,,,,,,,,,,,,Inhibition of human MMP9 catalytic domain (amino acids 107 to 446) using acetyl-Cys(Eu)-Pro-Leu-Gly-Leu-Lys-(QSY7)-Ala-Arg-amide as substrate preincubated for 1 hrs before substrate addition measured after 15 mins by fluorimetry,,Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.,Bioorg. Med. Chem. Lett.,2011,21,21,"Wilson LJ, Wang B, Yang SM, Scannevin RH, Burke SL, Karnachi P, Rhodes KJ, Murray WV",,787971,DTCT0024844,7525334,DTCC01160861,1779448,46368
CHEMBL1916053,P14780,,RHVLZBAJLKIMQO-GOSISDBHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21925881,IC50,=,1.3,NM,,,,,,,,,,,,,,Inhibition of human MMP9 catalytic domain (amino acids 107 to 446) using acetyl-Cys(Eu)-Pro-Leu-Gly-Leu-Lys-(QSY7)-Ala-Arg-amide as substrate preincubated for 1 hrs before substrate addition measured after 15 mins by fluorimetry,,Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.,Bioorg. Med. Chem. Lett.,2011,21,21,"Wilson LJ, Wang B, Yang SM, Scannevin RH, Burke SL, Karnachi P, Rhodes KJ, Murray WV",,787971,DTCT0024844,7525335,DTCC01160862,394878,46368
CHEMBL1916054,P14780,,XAOJSOMIBKILNZ-JOCHJYFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21925881,IC50,=,0.46,NM,,,,,,,,,,,,,,Inhibition of human MMP9 catalytic domain (amino acids 107 to 446) using acetyl-Cys(Eu)-Pro-Leu-Gly-Leu-Lys-(QSY7)-Ala-Arg-amide as substrate preincubated for 1 hrs before substrate addition measured after 15 mins by fluorimetry,,Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.,Bioorg. Med. Chem. Lett.,2011,21,21,"Wilson LJ, Wang B, Yang SM, Scannevin RH, Burke SL, Karnachi P, Rhodes KJ, Murray WV",,787971,DTCT0024844,7525336,DTCC01160863,749845,46368
CHEMBL1916055,P14780,,GXKVUIPBWQPVAL-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21925881,IC50,=,5091,NM,,,,,,,,,,,,,,Inhibition of human MMP9 catalytic domain (amino acids 107 to 446) using acetyl-Cys(Eu)-Pro-Leu-Gly-Leu-Lys-(QSY7)-Ala-Arg-amide as substrate preincubated for 1 hrs before substrate addition measured after 15 mins by fluorimetry,,Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.,Bioorg. Med. Chem. Lett.,2011,21,21,"Wilson LJ, Wang B, Yang SM, Scannevin RH, Burke SL, Karnachi P, Rhodes KJ, Murray WV",,787971,DTCT0024844,7525337,DTCC01160864,1940715,46368
CHEMBL1916056,P14780,,RLGVFNMHAUPJOV-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21925881,IC50,=,1506,NM,,,,,,,,,,,,,,Inhibition of human MMP9 catalytic domain (amino acids 107 to 446) using acetyl-Cys(Eu)-Pro-Leu-Gly-Leu-Lys-(QSY7)-Ala-Arg-amide as substrate preincubated for 1 hrs before substrate addition measured after 15 mins by fluorimetry,,Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.,Bioorg. Med. Chem. Lett.,2011,21,21,"Wilson LJ, Wang B, Yang SM, Scannevin RH, Burke SL, Karnachi P, Rhodes KJ, Murray WV",,787971,DTCT0024844,7525338,DTCC01160865,1332076,46368
CHEMBL1916057,P14780,,QHXQILHKQUVTBK-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21925881,IC50,=,2,NM,,,,,,,,,,,,,,Inhibition of human MMP9 catalytic domain (amino acids 107 to 446) using acetyl-Cys(Eu)-Pro-Leu-Gly-Leu-Lys-(QSY7)-Ala-Arg-amide as substrate preincubated for 1 hrs before substrate addition measured after 15 mins by fluorimetry,,Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.,Bioorg. Med. Chem. Lett.,2011,21,21,"Wilson LJ, Wang B, Yang SM, Scannevin RH, Burke SL, Karnachi P, Rhodes KJ, Murray WV",,787971,DTCT0024844,7525339,DTCC01160866,296910,46368
CHEMBL191613,P14780,"2,4-DICHLOROPHENYLAMINOMETHYLENEBISPHOSPHONIC ACID",KASHBTOPZJTDFP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24071448,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain (unknown origin) using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured after 2 to 4 hrs by fluorometric assay,,Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.,Bioorg. Med. Chem.,2013,21,21,"Tauro M, Laghezza A, Loiodice F, Agamennone M, Campestre C, Tortorella P",,990168,DTCT0024844,12629001,DTCC00399306,383982,56259
CHEMBL1916201,P14780,,QOXMDHVVENYQFJ-GOSISDBHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21925881,IC50,=,1,NM,,,,,,,,,,,,,,Inhibition of human MMP9 catalytic domain (amino acids 107 to 446) using acetyl-Cys(Eu)-Pro-Leu-Gly-Leu-Lys-(QSY7)-Ala-Arg-amide as substrate preincubated for 1 hrs before substrate addition measured after 15 mins by fluorimetry,,Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.,Bioorg. Med. Chem. Lett.,2011,21,21,"Wilson LJ, Wang B, Yang SM, Scannevin RH, Burke SL, Karnachi P, Rhodes KJ, Murray WV",,787971,DTCT0024844,7525340,DTCC01160998,1876213,46368
CHEMBL1916202,P14780,,NPPGCZWIPTWDAM-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21925881,IC50,=,2,NM,,,,,,,,,,,,,,Inhibition of human MMP9 catalytic domain (amino acids 107 to 446) using acetyl-Cys(Eu)-Pro-Leu-Gly-Leu-Lys-(QSY7)-Ala-Arg-amide as substrate preincubated for 1 hrs before substrate addition measured after 15 mins by fluorimetry,,Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.,Bioorg. Med. Chem. Lett.,2011,21,21,"Wilson LJ, Wang B, Yang SM, Scannevin RH, Burke SL, Karnachi P, Rhodes KJ, Murray WV",,787971,DTCT0024844,7525341,DTCC01160999,814212,46368
CHEMBL1916203,P14780,,AFAZTSCLENHGJT-OAHLLOKOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21925881,IC50,=,23,NM,,,,,,,,,,,,,,Inhibition of human MMP9 catalytic domain (amino acids 107 to 446) using acetyl-Cys(Eu)-Pro-Leu-Gly-Leu-Lys-(QSY7)-Ala-Arg-amide as substrate preincubated for 1 hrs before substrate addition measured after 15 mins by fluorimetry,,Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.,Bioorg. Med. Chem. Lett.,2011,21,21,"Wilson LJ, Wang B, Yang SM, Scannevin RH, Burke SL, Karnachi P, Rhodes KJ, Murray WV",,787971,DTCT0024844,7525342,DTCC01161000,685164,46368
CHEMBL1916204,P14780,,NSMCPQNAHIFGCB-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21925881,IC50,=,12,NM,,,,,,,,,,,,,,Inhibition of human MMP9 catalytic domain (amino acids 107 to 446) using acetyl-Cys(Eu)-Pro-Leu-Gly-Leu-Lys-(QSY7)-Ala-Arg-amide as substrate preincubated for 1 hrs before substrate addition measured after 15 mins by fluorimetry,,Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.,Bioorg. Med. Chem. Lett.,2011,21,21,"Wilson LJ, Wang B, Yang SM, Scannevin RH, Burke SL, Karnachi P, Rhodes KJ, Murray WV",,787971,DTCT0024844,7525343,DTCC01161001,1073094,46368
CHEMBL1916205,P14780,,CUGNLRWAORUYPI-CQSZACIVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21925881,IC50,=,9,NM,,,,,,,,,,,,,,Inhibition of human MMP9 catalytic domain (amino acids 107 to 446) using acetyl-Cys(Eu)-Pro-Leu-Gly-Leu-Lys-(QSY7)-Ala-Arg-amide as substrate preincubated for 1 hrs before substrate addition measured after 15 mins by fluorimetry,,Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.,Bioorg. Med. Chem. Lett.,2011,21,21,"Wilson LJ, Wang B, Yang SM, Scannevin RH, Burke SL, Karnachi P, Rhodes KJ, Murray WV",,787971,DTCT0024844,7525344,DTCC01161002,1526277,46368
CHEMBL1916206,P14780,,KTGKATYAFOIELE-CYBMUJFWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21925881,IC50,=,16,NM,,,,,,,,,,,,,,Inhibition of human MMP9 catalytic domain (amino acids 107 to 446) using acetyl-Cys(Eu)-Pro-Leu-Gly-Leu-Lys-(QSY7)-Ala-Arg-amide as substrate preincubated for 1 hrs before substrate addition measured after 15 mins by fluorimetry,,Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.,Bioorg. Med. Chem. Lett.,2011,21,21,"Wilson LJ, Wang B, Yang SM, Scannevin RH, Burke SL, Karnachi P, Rhodes KJ, Murray WV",,787971,DTCT0024844,7525345,DTCC01161003,2071014,46368
CHEMBL1916207,P14780,,AFHDVSQBDWGAQU-CQSZACIVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21925881,IC50,=,11,NM,,,,,,,,,,,,,,Inhibition of human MMP9 catalytic domain (amino acids 107 to 446) using acetyl-Cys(Eu)-Pro-Leu-Gly-Leu-Lys-(QSY7)-Ala-Arg-amide as substrate preincubated for 1 hrs before substrate addition measured after 15 mins by fluorimetry,,Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.,Bioorg. Med. Chem. Lett.,2011,21,21,"Wilson LJ, Wang B, Yang SM, Scannevin RH, Burke SL, Karnachi P, Rhodes KJ, Murray WV",,787971,DTCT0024844,7525346,DTCC01161004,1397221,46368
CHEMBL1916208,P14780,,OXHLNRMJXSJQIA-JOCHJYFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21925881,IC50,>,1000,NM,,,,,,,,,,,,,,Inhibition of human MMP9 catalytic domain (amino acids 107 to 446) using acetyl-Cys(Eu)-Pro-Leu-Gly-Leu-Lys-(QSY7)-Ala-Arg-amide as substrate preincubated for 1 hrs before substrate addition measured after 15 mins by fluorimetry,,Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.,Bioorg. Med. Chem. Lett.,2011,21,21,"Wilson LJ, Wang B, Yang SM, Scannevin RH, Burke SL, Karnachi P, Rhodes KJ, Murray WV",,787971,DTCT0024844,7525347,DTCC01161005,1073095,46368
CHEMBL1916209,P14780,,TVNIMIJQBWZCGY-OAQYLSRUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21925881,IC50,>,1000,NM,,,,,,,,,,,,,,Inhibition of human MMP9 catalytic domain (amino acids 107 to 446) using acetyl-Cys(Eu)-Pro-Leu-Gly-Leu-Lys-(QSY7)-Ala-Arg-amide as substrate preincubated for 1 hrs before substrate addition measured after 15 mins by fluorimetry,,Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.,Bioorg. Med. Chem. Lett.,2011,21,21,"Wilson LJ, Wang B, Yang SM, Scannevin RH, Burke SL, Karnachi P, Rhodes KJ, Murray WV",,787971,DTCT0024844,7525348,DTCC01161006,362159,46368
CHEMBL1916210,P14780,,YBTXAIOMVIXCOD-HSZRJFAPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21925881,IC50,=,0.22,NM,,,,,,,,,,,,,,Inhibition of human MMP9 catalytic domain (amino acids 107 to 446) using acetyl-Cys(Eu)-Pro-Leu-Gly-Leu-Lys-(QSY7)-Ala-Arg-amide as substrate preincubated for 1 hrs before substrate addition measured after 15 mins by fluorimetry,,Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.,Bioorg. Med. Chem. Lett.,2011,21,21,"Wilson LJ, Wang B, Yang SM, Scannevin RH, Burke SL, Karnachi P, Rhodes KJ, Murray WV",,787971,DTCT0024844,7525349,DTCC01161007,1655475,46368
CHEMBL1916211,P14780,,SRFKWSJTGCWGBQ-XMMPIXPASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21925881,IC50,=,0.21,NM,,,,,,,,,,,,,,Inhibition of human MMP9 catalytic domain (amino acids 107 to 446) using acetyl-Cys(Eu)-Pro-Leu-Gly-Leu-Lys-(QSY7)-Ala-Arg-amide as substrate preincubated for 1 hrs before substrate addition measured after 15 mins by fluorimetry,,Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.,Bioorg. Med. Chem. Lett.,2011,21,21,"Wilson LJ, Wang B, Yang SM, Scannevin RH, Burke SL, Karnachi P, Rhodes KJ, Murray WV",,787971,DTCT0024844,7525350,DTCC01161008,2071015,46368
CHEMBL1916212,P14780,,ZODGWBSBSVHUNW-XMMPIXPASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21925881,IC50,=,0.2,NM,,,,,,,,,,,,,,Inhibition of human MMP9 catalytic domain (amino acids 107 to 446) using acetyl-Cys(Eu)-Pro-Leu-Gly-Leu-Lys-(QSY7)-Ala-Arg-amide as substrate preincubated for 1 hrs before substrate addition measured after 15 mins by fluorimetry,,Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.,Bioorg. Med. Chem. Lett.,2011,21,21,"Wilson LJ, Wang B, Yang SM, Scannevin RH, Burke SL, Karnachi P, Rhodes KJ, Murray WV",,787971,DTCT0024844,7525351,DTCC01161009,1299421,46368
CHEMBL1916213,P14780,,XLEZHEBRRDABNS-LJQANCHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21925881,IC50,=,17,NM,,,,,,,,,,,,,,Inhibition of human MMP9 catalytic domain (amino acids 107 to 446) using acetyl-Cys(Eu)-Pro-Leu-Gly-Leu-Lys-(QSY7)-Ala-Arg-amide as substrate preincubated for 1 hrs before substrate addition measured after 15 mins by fluorimetry,,Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.,Bioorg. Med. Chem. Lett.,2011,21,21,"Wilson LJ, Wang B, Yang SM, Scannevin RH, Burke SL, Karnachi P, Rhodes KJ, Murray WV",,787971,DTCT0024844,7525352,DTCC01161010,879542,46368
CHEMBL1916214,P14780,,GLGMQKYHXRSKKD-HXUWFJFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21925881,IC50,=,11,NM,,,,,,,,,,,,,,Inhibition of human MMP9 catalytic domain (amino acids 107 to 446) using acetyl-Cys(Eu)-Pro-Leu-Gly-Leu-Lys-(QSY7)-Ala-Arg-amide as substrate preincubated for 1 hrs before substrate addition measured after 15 mins by fluorimetry,,Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.,Bioorg. Med. Chem. Lett.,2011,21,21,"Wilson LJ, Wang B, Yang SM, Scannevin RH, Burke SL, Karnachi P, Rhodes KJ, Murray WV",,787971,DTCT0024844,7525353,DTCC01161011,491719,46368
CHEMBL1916215,P14780,,OQNMPVNWQUKGKU-HSZRJFAPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21925881,IC50,=,0.8,NM,,,,,,,,,,,,,,Inhibition of human MMP9 catalytic domain (amino acids 107 to 446) using acetyl-Cys(Eu)-Pro-Leu-Gly-Leu-Lys-(QSY7)-Ala-Arg-amide as substrate preincubated for 1 hrs before substrate addition measured after 15 mins by fluorimetry,,Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.,Bioorg. Med. Chem. Lett.,2011,21,21,"Wilson LJ, Wang B, Yang SM, Scannevin RH, Burke SL, Karnachi P, Rhodes KJ, Murray WV",,787971,DTCT0024844,7525354,DTCC01161012,1008192,46368
CHEMBL191625,P14780,"PENTANE-2,4-DIONE",YRKCREAYFQTBPV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,-17,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103219,DTCC00001048,1957906,43205
CHEMBL1916397,P14780,,OVRCVYWNUUCNIN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21851064,IC50,=,25000,NM,,cell_based,,,,,,,,,,,MDA-MB-231,Inhibition of human MMP-9 activity in human MDA-MB-231 cells assessed as ECM degradation after 24 hrs by gelatin zymography assay,,"Virtual Screening Targeting the Urokinase Receptor, Biochemical and Cell-Based Studies, Synthesis, Pharmacokinetic Characterization, and Effect on Breast Tumor Metastasis.",J. Med. Chem.,2011,54,20,"Wang F, Li J, Sinn AL, Knabe WE, Khanna M, Jo I, Silver JM, Oh K, Li L, Sandusky GE, Sledge GW, Nakshatri H, Jones DR, Pollok KE, Meroueh SO",,786188,DTCT0024844,7528659,DTCC01161195,134606,46466
CHEMBL1916397,P14780,,OVRCVYWNUUCNIN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21851064,INHIBITION,,,,,cell_based,,,,,,,,,,,MDA-MB-231,Inhibition of human MMP-9 activity in human MDA-MB-231 cells assessed as ECM degradation after 24 hrs by gelatin zymography assay,Dose-dependent effect,"Virtual Screening Targeting the Urokinase Receptor, Biochemical and Cell-Based Studies, Synthesis, Pharmacokinetic Characterization, and Effect on Breast Tumor Metastasis.",J. Med. Chem.,2011,54,20,"Wang F, Li J, Sinn AL, Knabe WE, Khanna M, Jo I, Silver JM, Oh K, Li L, Sandusky GE, Sledge GW, Nakshatri H, Jones DR, Pollok KE, Meroueh SO",,786188,DTCT0024844,7528661,DTCC01161195,134606,46466
CHEMBL1916398,P14780,,LBWJINHCNQHNMV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21851064,IC50,=,25000,NM,,cell_based,,,,,,,,,,,MDA-MB-231,Inhibition of human MMP-9 activity in human MDA-MB-231 cells assessed as ECM degradation after 24 hrs by gelatin zymography assay,,"Virtual Screening Targeting the Urokinase Receptor, Biochemical and Cell-Based Studies, Synthesis, Pharmacokinetic Characterization, and Effect on Breast Tumor Metastasis.",J. Med. Chem.,2011,54,20,"Wang F, Li J, Sinn AL, Knabe WE, Khanna M, Jo I, Silver JM, Oh K, Li L, Sandusky GE, Sledge GW, Nakshatri H, Jones DR, Pollok KE, Meroueh SO",,786188,DTCT0024844,7528660,DTCC01161196,879544,46466
CHEMBL1916398,P14780,,LBWJINHCNQHNMV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21851064,INHIBITION,=,93,%,,cell_based,,,,,,,,,,,MDA-MB-231,Inhibition of human MMP-9 activity in human MDA-MB-231 cells assessed as ECM degradation at 50 uM after 24 hrs by gelatin zymography assay,,"Virtual Screening Targeting the Urokinase Receptor, Biochemical and Cell-Based Studies, Synthesis, Pharmacokinetic Characterization, and Effect on Breast Tumor Metastasis.",J. Med. Chem.,2011,54,20,"Wang F, Li J, Sinn AL, Knabe WE, Khanna M, Jo I, Silver JM, Oh K, Li L, Sandusky GE, Sledge GW, Nakshatri H, Jones DR, Pollok KE, Meroueh SO",,786189,DTCT0024844,7528663,DTCC01161196,879544,46466
CHEMBL1916398,P14780,,LBWJINHCNQHNMV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21851064,INHIBITION,,,,,cell_based,,,,,,,,,,,MDA-MB-231,Inhibition of human MMP-9 activity in human MDA-MB-231 cells assessed as ECM degradation after 24 hrs by gelatin zymography assay,Dose-dependent effect,"Virtual Screening Targeting the Urokinase Receptor, Biochemical and Cell-Based Studies, Synthesis, Pharmacokinetic Characterization, and Effect on Breast Tumor Metastasis.",J. Med. Chem.,2011,54,20,"Wang F, Li J, Sinn AL, Knabe WE, Khanna M, Jo I, Silver JM, Oh K, Li L, Sandusky GE, Sledge GW, Nakshatri H, Jones DR, Pollok KE, Meroueh SO",,786188,DTCT0024844,7528662,DTCC01161196,879544,46466
CHEMBL191986,P14780,,WHDVUUKXFNOVHH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15857146,IC50,=,20,NM,,,,,,,,,,,,,,In vitro inhibition of human Matrix metalloprotease 9,,C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging.,J. Med. Chem.,2005,48,9,"Breyholz HJ, Schäfers M, Wagner S, Höltke C, Faust A, Rabeneck H, Levkau B, Schober O, Kopka K",,305380,DTCT0024844,1828964,DTCC00399791,563857,19718
CHEMBL192,P14780,SILDENAFIL,BNRNXUUZRGQAQC-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7479992,DTCC00477686,639584,46191
CHEMBL192,P14780,SILDENAFIL,BNRNXUUZRGQAQC-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7479993,DTCC00477686,639584,46191
CHEMBL192121,P14780,,KMYAHTGTYRRWEK-IYOGPWPASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16107143,KI,=,4.56,NM,,,,,,,,,,,,,,Inhibition of MOCAc-Pro-Leu-Gly-Leu-A2p (Dnp)-Ala-Arg-NH2 binding to human matrix metalloprotease-9 (MMP-9),,"A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.",J. Med. Chem.,2005,48,17,"Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S",,307380,DTCT0024844,1815687,DTCC00397582,1437050,19409
CHEMBL19215,P14780,METERGOLINE,WZHJKEUHNJHDLS-QTGUNEKASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7417322,DTCC00150357,315666,46191
CHEMBL19215,P14780,METERGOLINE,WZHJKEUHNJHDLS-QTGUNEKASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7417323,DTCC00150357,315666,46191
CHEMBL192204,P14780,,JXUDAYOKNXBKHH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15908214,KI,>,2130,NM,,,,,,,,,,,,,,In vitro binding affinity against matrix metalloprotease 9,,"Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.",Bioorg. Med. Chem. Lett.,2005,15,12,"Duan JJ, Lu Z, Wasserman ZR, Liu RQ, Covington MB, Decicco CP",,302347,DTCT0024844,1800388,DTCC00398406,7207,16433
CHEMBL19224,P14780,PAPAVERINE,XQYZDYMELSJDRZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7371856,DTCC00150178,1351115,46191
CHEMBL19224,P14780,PAPAVERINE,XQYZDYMELSJDRZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7371857,DTCC00150178,1351115,46191
CHEMBL192249,P14780,,QZPPOPJGCFXELG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15857146,IC50,=,2,NM,,,,,,,,,,,,,,In vitro inhibition of human Matrix metalloprotease 9,,C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging.,J. Med. Chem.,2005,48,9,"Breyholz HJ, Schäfers M, Wagner S, Höltke C, Faust A, Rabeneck H, Levkau B, Schober O, Kopka K",,305380,DTCT0024844,1828754,DTCC00399982,370097,19718
CHEMBL19236,P14780,MOXONIDINE,WPNJAUFVNXKLIM-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7430785,DTCC00150160,1894970,46191
CHEMBL19236,P14780,MOXONIDINE,WPNJAUFVNXKLIM-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7432792,DTCC00150160,1894970,46191
CHEMBL192370,P14780,,VQFRAJKJRLAZOI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15857146,IC50,=,26,NM,,,,,,,,,,,,,,In vitro inhibition of human Matrix metalloprotease 9,,C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging.,J. Med. Chem.,2005,48,9,"Breyholz HJ, Schäfers M, Wagner S, Höltke C, Faust A, Rabeneck H, Levkau B, Schober O, Kopka K",,305380,DTCT0024844,1828942,DTCC00400311,1884071,19718
CHEMBL19269,P14780,,LNMKFTOPZCDAED-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11934588,IC50,=,643,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 activity,,Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.,Bioorg. Med. Chem. Lett.,2002,12,8,"Levin JI, Chen JM, Du MT, Nelson FC, Killar LM, Skala S, Sung A, Jin G, Cowling R, Barone D, March CJ, Mohler KM, Black RA, Skotnicki JS",,105508,DTCT0024844,776520,DTCC00150802,421007,5465
CHEMBL192719,P14780,,TZNUGSCRBFBAFR-PXWGLLCJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16107143,KI,=,3.42,NM,,,,,,,,,,,,,,Inhibition of MOCAc-Pro-Leu-Gly-Leu-A2p (Dnp)-Ala-Arg-NH2 binding to human matrix metalloprotease-9 (MMP-9),,"A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.",J. Med. Chem.,2005,48,17,"Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S",,307380,DTCT0024844,1815690,DTCC00397223,174620,19409
CHEMBL192740,P14780,,ZUPKLHSUDRAJGD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15857146,IC50,,,,,,,,,,,,,,,,,In vitro inhibition of human Matrix metalloprotease 9; I.A.=inactive,Not Active,C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging.,J. Med. Chem.,2005,48,9,"Breyholz HJ, Schäfers M, Wagner S, Höltke C, Faust A, Rabeneck H, Levkau B, Schober O, Kopka K",,305809,DTCT0024844,1828767,DTCC00399933,1242175,19718
CHEMBL19278,P14780,,WGPIMMRNIAYWBT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11934588,IC50,=,28,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 activity,,Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.,Bioorg. Med. Chem. Lett.,2002,12,8,"Levin JI, Chen JM, Du MT, Nelson FC, Killar LM, Skala S, Sung A, Jin G, Cowling R, Barone D, March CJ, Mohler KM, Black RA, Skotnicki JS",,105508,DTCT0024844,801753,DTCC00150852,1034298,5465
CHEMBL19279,P14780,,CSVWGAZPMRHMHB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11934588,IC50,=,455,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 activity,,Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.,Bioorg. Med. Chem. Lett.,2002,12,8,"Levin JI, Chen JM, Du MT, Nelson FC, Killar LM, Skala S, Sung A, Jin G, Cowling R, Barone D, March CJ, Mohler KM, Black RA, Skotnicki JS",,105508,DTCT0024844,811558,DTCC00150553,127998,5465
CHEMBL192872,P14780,,IOHMRAKHDYVRJZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15857146,IC50,=,4,NM,,,,,,,,,,,,,,In vitro inhibition of human Matrix metalloprotease 9,,C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging.,J. Med. Chem.,2005,48,9,"Breyholz HJ, Schäfers M, Wagner S, Höltke C, Faust A, Rabeneck H, Levkau B, Schober O, Kopka K",,305380,DTCT0024844,1828750,DTCC00399770,110032,19718
CHEMBL19299,P14780,LOXOPROFEN,YMBXTVYHTMGZDW-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7419055,DTCC00151156,1960076,46191
CHEMBL19299,P14780,LOXOPROFEN,YMBXTVYHTMGZDW-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7419056,DTCC00151156,1960076,46191
CHEMBL193,P14780,NIFEDIPINE,HYIMSNHJOBLJNT-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7401269,DTCC00485676,51493,46191
CHEMBL193,P14780,NIFEDIPINE,HYIMSNHJOBLJNT-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7401270,DTCC00485676,51493,46191
CHEMBL193080,P14780,,SQYRXZTYDRVAMZ-UBIBJYAGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16107143,KI,=,14.19,NM,,,,,,,,,,,,,,Inhibition of MOCAc-Pro-Leu-Gly-Leu-A2p (Dnp)-Ala-Arg-NH2 binding to human matrix metalloprotease-9 (MMP-9),,"A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.",J. Med. Chem.,2005,48,17,"Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S",,307380,DTCT0024844,1815805,DTCC00397916,370069,19409
CHEMBL193084,P14780,,HNINPFHHNYDBSH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15908214,KI,>,2130,NM,,,,,,,,,,,,,,In vitro binding affinity against matrix metalloprotease 9,,"Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.",Bioorg. Med. Chem. Lett.,2005,15,12,"Duan JJ, Lu Z, Wasserman ZR, Liu RQ, Covington MB, Decicco CP",,302347,DTCT0024844,1800207,DTCC00398196,227645,16433
CHEMBL193124,P14780,,RTKNMWBYPISZDZ-SIHBAMTISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16107143,KI,=,2.03,NM,,,,,,,,,,,,,,Inhibition of MOCAc-Pro-Leu-Gly-Leu-A2p (Dnp)-Ala-Arg-NH2 binding to human matrix metalloprotease-9 (MMP-9),,"A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.",J. Med. Chem.,2005,48,17,"Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S",,307380,DTCT0024844,1815685,DTCC00397893,628614,19409
CHEMBL19320,P14780,,VXXLUYPODYWRKE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11934588,IC50,,,,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (No data),Not Determined,Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.,Bioorg. Med. Chem. Lett.,2002,12,8,"Levin JI, Chen JM, Du MT, Nelson FC, Killar LM, Skala S, Sung A, Jin G, Cowling R, Barone D, March CJ, Mohler KM, Black RA, Skotnicki JS",,105509,DTCT0024844,783718,DTCC00150440,2064635,5465
CHEMBL193316,P14780,,QKXIBRKQCXPSEK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15908214,KI,>,2130,NM,,,,,,,,,,,,,,In vitro binding affinity against matrix metalloprotease 9,,"Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.",Bioorg. Med. Chem. Lett.,2005,15,12,"Duan JJ, Lu Z, Wasserman ZR, Liu RQ, Covington MB, Decicco CP",,302347,DTCT0024844,1802360,DTCC00398156,1619558,16433
CHEMBL1933865,P14780,,FMGFJOARXWKCIE-XYOKQWHBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22082667,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors.,Bioorg. Med. Chem.,2011,19,24,"Li B, Cardinale SC, Butler MM, Pai R, Nuss JE, Peet NP, Bavari S, Bowlin TL",,796069,DTCT0024844,7586733,DTCC01168266,1494036,46860
CHEMBL1933882,P14780,,IAQAYKRJOOBBTO-ZRDIBKRKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22082667,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors.,Bioorg. Med. Chem.,2011,19,24,"Li B, Cardinale SC, Butler MM, Pai R, Nuss JE, Peet NP, Bavari S, Bowlin TL",,796069,DTCT0024844,7586734,DTCC01168283,1779521,46860
CHEMBL193482,P14780,ESTRIOL,PROQIPRRNZUXQM-ZXXIGWHRSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7315595,DTCC00405591,348401,46191
CHEMBL193482,P14780,ESTRIOL,PROQIPRRNZUXQM-ZXXIGWHRSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7315596,DTCC00405591,348401,46191
CHEMBL1935291,P14780,,MUMVNZHARHFSLP-SFHVURJKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22153340,IC50,=,1970,NM,,,,,,,,,,,,,,Inhibition of human MMP-9,,Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD).,Bioorg. Med. Chem. Lett.,2012,22,1,"Wu Y, Li J, Wu J, Morgan P, Xu X, Rancati F, Vallese S, Raveglia L, Hotchandani R, Fuller N, Bard J, Cunningham K, Fish S, Krykbaev R, Tam S, Goldman SJ, Williams C, Mansour TS, Saiah E, Sypek J, Li W",,796150,DTCT0024844,7576412,DTCC01169633,51895,46933
CHEMBL193610,P14780,,ZPCIKQLLQORQCV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16134930,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibitory concentration against matrix metalloprotease 9,,"4-Aryl-1,2,3-triazole: a novel template for a reversible methionine aminopeptidase 2 inhibitor, optimized to inhibit angiogenesis in vivo.",J. Med. Chem.,2005,48,18,"Kallander LS, Lu Q, Chen W, Tomaszek T, Yang G, Tew D, Meek TD, Hofmann GA, Schulz-Pritchard CK, Smith WW, Janson CA, Ryan MD, Zhang GF, Johanson KO, Kirkpatrick RB, Ho TF, Fisher PW, Mattern MR, Johnson RK, Hansbury MJ, Winkler JD, Ward KW, Veber DF, Thompson SK",,321281,DTCT0024844,1849806,DTCC00405459,271953,19859
CHEMBL19371,P14780,,BRHXKZALFBLRIF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11934588,IC50,=,800,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 activity,,Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.,Bioorg. Med. Chem. Lett.,2002,12,8,"Levin JI, Chen JM, Du MT, Nelson FC, Killar LM, Skala S, Sung A, Jin G, Cowling R, Barone D, March CJ, Mohler KM, Black RA, Skotnicki JS",,105508,DTCT0024844,780858,DTCC00150615,1034299,5465
CHEMBL193945,P14780,,OCBYWAVDKLDIDI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15908214,KI,=,85,NM,,,,,,,,,,,,,,In vitro binding affinity against matrix metalloprotease 9,,"Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.",Bioorg. Med. Chem. Lett.,2005,15,12,"Duan JJ, Lu Z, Wasserman ZR, Liu RQ, Covington MB, Decicco CP",,302347,DTCT0024844,1800231,DTCC00398285,875794,16433
CHEMBL1939844,P14780,,FTRCUXMVUJZMHT-CYBMUJFWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22017477,IC50,=,690,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate preincubated for 4 hrs measured every 15 secs for 20 mins by fluorescence analysis,,"Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases.",J. Med. Chem.,2011,54,24,"Marques SM, Tuccinardi T, Nuti E, Santamaria S, André V, Rossello A, Martinelli A, Santos MA",,799125,DTCT0024844,7595881,DTCC01171473,2071098,47023
CHEMBL1939845,P14780,,JVBFGGAYMSJQBZ-GOSISDBHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22017477,IC50,=,660,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate preincubated for 4 hrs measured every 15 secs for 20 mins by fluorescence analysis,,"Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases.",J. Med. Chem.,2011,54,24,"Marques SM, Tuccinardi T, Nuti E, Santamaria S, André V, Rossello A, Martinelli A, Santos MA",,799125,DTCT0024844,7595882,DTCC01171474,1811871,47023
CHEMBL1939846,P14780,,RQCBSNJRFVZHOS-GOSISDBHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22017477,IC50,=,30,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate preincubated for 4 hrs measured every 15 secs for 20 mins by fluorescence analysis,,"Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases.",J. Med. Chem.,2011,54,24,"Marques SM, Tuccinardi T, Nuti E, Santamaria S, André V, Rossello A, Martinelli A, Santos MA",,799125,DTCT0024844,7595883,DTCC01171475,1461560,47023
CHEMBL1939876,P14780,,MMJPVSDTLGFIQW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22017539,IC50,=,8900,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 after 30 mins by fluorimetry,,Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13.,J. Med. Chem.,2011,54,23,"Taylor SJ, Abeywardane A, Liang S, Muegge I, Padyana AK, Xiong Z, Hill-Drzewi M, Farmer B, Li X, Collins B, Li JX, Heim-Riether A, Proudfoot J, Zhang Q, Goldberg D, Zuvela-Jelaska L, Zaher H, Li J, Farrow NA",,799154,DTCT0024844,7596040,DTCC01171504,1734238,47024
CHEMBL1940296,P14780,,CWFNNQMBLVACQD-QHCPKHFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22153941,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9 using Mca-Pro-cyclohexyl-Ala-Gly-Nva-His-Ala- Dap(Dnp)-NH2 as substrate by fluorometric analysis,,Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.,Bioorg. Med. Chem. Lett.,2012,22,1,"De Savi C, Morley AD, Nash I, Karoutchi G, Page K, Ting A, Gerhardt S",,798833,DTCT0024844,7601084,DTCC01171915,1124659,47049
CHEMBL1940308,P14780,,RMPYEISUTHEMLW-NDEPHWFRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22153941,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9 using Mca-Pro-cyclohexyl-Ala-Gly-Nva-His-Ala- Dap(Dnp)-NH2 as substrate by fluorometric analysis,,Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.,Bioorg. Med. Chem. Lett.,2012,22,1,"De Savi C, Morley AD, Nash I, Karoutchi G, Page K, Ting A, Gerhardt S",,798833,DTCT0024844,7601083,DTCC01171923,574793,47049
CHEMBL1940308,P14780,,RMPYEISUTHEMLW-NDEPHWFRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22153941,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9 using Mca-Pro-cyclohexyl-Ala-Gly-Nva-His-Ala- Dap(Dnp)-NH2 as substrate by fluorometric analysis,,Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.,Bioorg. Med. Chem. Lett.,2012,22,1,"De Savi C, Morley AD, Nash I, Karoutchi G, Page K, Ting A, Gerhardt S",,798833,DTCT0024844,7601095,DTCC01171923,574793,47049
CHEMBL1940309,P14780,,WHUKRVZMYYJSJL-NDEPHWFRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22153941,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9 using Mca-Pro-cyclohexyl-Ala-Gly-Nva-His-Ala- Dap(Dnp)-NH2 as substrate by fluorometric analysis,,Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.,Bioorg. Med. Chem. Lett.,2012,22,1,"De Savi C, Morley AD, Nash I, Karoutchi G, Page K, Ting A, Gerhardt S",,798833,DTCT0024844,7601094,DTCC01171924,1448056,47049
CHEMBL1940310,P14780,,IERBLZLEQYZHMU-LJAQVGFWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22153941,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9 using Mca-Pro-cyclohexyl-Ala-Gly-Nva-His-Ala- Dap(Dnp)-NH2 as substrate by fluorometric analysis,,Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.,Bioorg. Med. Chem. Lett.,2012,22,1,"De Savi C, Morley AD, Nash I, Karoutchi G, Page K, Ting A, Gerhardt S",,798833,DTCT0024844,7601093,DTCC01171925,1674314,47049
CHEMBL1940311,P14780,,LIYRHLZYJZBQCM-HKBQPEDESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22153941,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9 using Mca-Pro-cyclohexyl-Ala-Gly-Nva-His-Ala- Dap(Dnp)-NH2 as substrate by fluorometric analysis,,Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.,Bioorg. Med. Chem. Lett.,2012,22,1,"De Savi C, Morley AD, Nash I, Karoutchi G, Page K, Ting A, Gerhardt S",,798833,DTCT0024844,7601092,DTCC01171926,1416228,47049
CHEMBL1940312,P14780,,QAOWEZMLHINPHR-LJAQVGFWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22153941,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9 using Mca-Pro-cyclohexyl-Ala-Gly-Nva-His-Ala- Dap(Dnp)-NH2 as substrate by fluorometric analysis,,Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.,Bioorg. Med. Chem. Lett.,2012,22,1,"De Savi C, Morley AD, Nash I, Karoutchi G, Page K, Ting A, Gerhardt S",,798833,DTCT0024844,7601091,DTCC01171927,1830857,47049
CHEMBL1940313,P14780,,BVTIVQKMMMOOTF-PMERELPUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22153941,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9 using Mca-Pro-cyclohexyl-Ala-Gly-Nva-His-Ala- Dap(Dnp)-NH2 as substrate by fluorometric analysis,,Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.,Bioorg. Med. Chem. Lett.,2012,22,1,"De Savi C, Morley AD, Nash I, Karoutchi G, Page K, Ting A, Gerhardt S",,798833,DTCT0024844,7601090,DTCC01171928,1318627,47049
CHEMBL1940314,P14780,,OMQWCWIEQOEJBD-MHZLTWQESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22153941,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9 using Mca-Pro-cyclohexyl-Ala-Gly-Nva-His-Ala- Dap(Dnp)-NH2 as substrate by fluorometric analysis,,Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.,Bioorg. Med. Chem. Lett.,2012,22,1,"De Savi C, Morley AD, Nash I, Karoutchi G, Page K, Ting A, Gerhardt S",,798833,DTCT0024844,7601089,DTCC01171929,1286076,47049
CHEMBL1940315,P14780,,IOEYWFCDGXVEFG-JVHFYALYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22153941,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9 using Mca-Pro-cyclohexyl-Ala-Gly-Nva-His-Ala- Dap(Dnp)-NH2 as substrate by fluorometric analysis,,Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.,Bioorg. Med. Chem. Lett.,2012,22,1,"De Savi C, Morley AD, Nash I, Karoutchi G, Page K, Ting A, Gerhardt S",,798833,DTCT0024844,7601082,DTCC01171930,1734240,47049
CHEMBL1940315,P14780,,IOEYWFCDGXVEFG-JVHFYALYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22153941,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9 using Mca-Pro-cyclohexyl-Ala-Gly-Nva-His-Ala- Dap(Dnp)-NH2 as substrate by fluorometric analysis,,Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.,Bioorg. Med. Chem. Lett.,2012,22,1,"De Savi C, Morley AD, Nash I, Karoutchi G, Page K, Ting A, Gerhardt S",,798833,DTCT0024844,7601087,DTCC01171930,1734241,47049
CHEMBL1940315,P14780,,IOEYWFCDGXVEFG-JVHFYALYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22153941,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9 using Mca-Pro-cyclohexyl-Ala-Gly-Nva-His-Ala- Dap(Dnp)-NH2 as substrate by fluorometric analysis,,Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.,Bioorg. Med. Chem. Lett.,2012,22,1,"De Savi C, Morley AD, Nash I, Karoutchi G, Page K, Ting A, Gerhardt S",,798833,DTCT0024844,7601088,DTCC01171930,1734240,47049
CHEMBL1940316,P14780,,NMPAJDNRYQXHBH-XGCAABAXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22153941,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9 using Mca-Pro-cyclohexyl-Ala-Gly-Nva-His-Ala- Dap(Dnp)-NH2 as substrate by fluorometric analysis,,Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.,Bioorg. Med. Chem. Lett.,2012,22,1,"De Savi C, Morley AD, Nash I, Karoutchi G, Page K, Ting A, Gerhardt S",,798833,DTCT0024844,7601086,DTCC01171931,1830858,47049
CHEMBL194237,P14780,,VRUQYJXYEALKCT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16084720,IC50,=,51,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metallopeptidase 9,,Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2005,15,19,"Levin JI, Chen JM, Laakso LM, Du M, Du X, Venkatesan AM, Sandanayaka V, Zask A, Xu J, Xu W, Zhang Y, Skotnicki JS",,321249,DTCT0024844,1861784,DTCC00408064,2002834,19752
CHEMBL194237,P14780,,VRUQYJXYEALKCT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16084720,IC50,=,51,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metallopeptidase 9,,Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2005,15,19,"Levin JI, Chen JM, Laakso LM, Du M, Du X, Venkatesan AM, Sandanayaka V, Zask A, Xu J, Xu W, Zhang Y, Skotnicki JS",,321249,DTCT0024844,1862304,DTCC00408064,2002835,19752
CHEMBL194377,P14780,,LRMGKWDRORXPRE-SANMLTNESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16153831,INHIBITION,=,64,%,,,,,,,,,,,,,,Percent inhibition at 25 uM against MMP-9,,Synthesis and SAR of highly selective MMP-13 inhibitors.,Bioorg. Med. Chem. Lett.,2005,15,22,"Li J, Rush TS, Li W, DeVincentis D, Du X, Hu Y, Thomason JR, Xiang JS, Skotnicki JS, Tam S, Cunningham KM, Chockalingam PS, Morris EA, Levin JI",,321724,DTCT0024844,1860396,DTCC00407675,110120,19837
CHEMBL194430,P14780,,FXZROVPZUUATHR-SANMLTNESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16153831,INHIBITION,=,51,%,,,,,,,,,,,,,,Percent inhibition at 25 uM against MMP-9,,Synthesis and SAR of highly selective MMP-13 inhibitors.,Bioorg. Med. Chem. Lett.,2005,15,22,"Li J, Rush TS, Li W, DeVincentis D, Du X, Hu Y, Thomason JR, Xiang JS, Skotnicki JS, Tam S, Cunningham KM, Chockalingam PS, Morris EA, Levin JI",,321724,DTCT0024844,1860444,DTCC00407681,596206,19837
CHEMBL1946141,P14780,,BRXGWWVUCIZYMM-VNRZBHCFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22118188,IC50,=,7,NM,,,,,,,,,,,,,,"Inhibition of MMP9 using (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)Ala-Arg-NH2 as substrate preincubated for 30 mins measured after 10 mins by fluorescence analysis",,"A new generation of radiofluorinated pyrimidine-2,4,6-triones as MMP-targeted radiotracers for positron emission tomography.",J. Med. Chem.,2012,55,1,"Schrigten D, Breyholz HJ, Wagner S, Hermann S, Schober O, Schäfers M, Haufe G, Kopka K",,800775,DTCT0024844,7619085,DTCC01174040,736427,47195
CHEMBL1946142,P14780,,HSQOMGXZKXTHEM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22118188,IC50,=,9,NM,,,,,,,,,,,,,,"Inhibition of MMP9 using (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)Ala-Arg-NH2 as substrate preincubated for 30 mins measured after 10 mins by fluorescence analysis",,"A new generation of radiofluorinated pyrimidine-2,4,6-triones as MMP-targeted radiotracers for positron emission tomography.",J. Med. Chem.,2012,55,1,"Schrigten D, Breyholz HJ, Wagner S, Hermann S, Schober O, Schäfers M, Haufe G, Kopka K",,800775,DTCT0024844,7619086,DTCC01174041,866229,47195
CHEMBL1946143,P14780,,BCOFTFDFNHXYGF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22118188,IC50,=,4,NM,,,,,,,,,,,,,,"Inhibition of MMP9 using (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)Ala-Arg-NH2 as substrate preincubated for 30 mins measured after 10 mins by fluorescence analysis",,"A new generation of radiofluorinated pyrimidine-2,4,6-triones as MMP-targeted radiotracers for positron emission tomography.",J. Med. Chem.,2012,55,1,"Schrigten D, Breyholz HJ, Wagner S, Hermann S, Schober O, Schäfers M, Haufe G, Kopka K",,800775,DTCT0024844,7619087,DTCC01174042,1766168,47195
CHEMBL1946144,P14780,,APJIPTNFOKEMIQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22118188,IC50,=,41,NM,,,,,,,,,,,,,,"Inhibition of MMP9 using (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)Ala-Arg-NH2 as substrate preincubated for 30 mins measured after 10 mins by fluorescence analysis",,"A new generation of radiofluorinated pyrimidine-2,4,6-triones as MMP-targeted radiotracers for positron emission tomography.",J. Med. Chem.,2012,55,1,"Schrigten D, Breyholz HJ, Wagner S, Hermann S, Schober O, Schäfers M, Haufe G, Kopka K",,800775,DTCT0024844,7619088,DTCC01174043,1124683,47195
CHEMBL1946145,P14780,,LEIFVUOVYOUZFH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22118188,IC50,=,10,NM,,,,,,,,,,,,,,"Inhibition of MMP9 using (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)Ala-Arg-NH2 as substrate preincubated for 30 mins measured after 10 mins by fluorescence analysis",,"A new generation of radiofluorinated pyrimidine-2,4,6-triones as MMP-targeted radiotracers for positron emission tomography.",J. Med. Chem.,2012,55,1,"Schrigten D, Breyholz HJ, Wagner S, Hermann S, Schober O, Schäfers M, Haufe G, Kopka K",,800775,DTCT0024844,7619089,DTCC01174044,866230,47195
CHEMBL1946146,P14780,,HSWKOBISGMUSTR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22118188,IC50,=,27,NM,,,,,,,,,,,,,,"Inhibition of MMP9 using (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)Ala-Arg-NH2 as substrate preincubated for 30 mins measured after 10 mins by fluorescence analysis",,"A new generation of radiofluorinated pyrimidine-2,4,6-triones as MMP-targeted radiotracers for positron emission tomography.",J. Med. Chem.,2012,55,1,"Schrigten D, Breyholz HJ, Wagner S, Hermann S, Schober O, Schäfers M, Haufe G, Kopka K",,800775,DTCT0024844,7619090,DTCC01174045,704155,47195
CHEMBL1946147,P14780,,GGMOCOYDYRCVAH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22118188,IC50,=,74,NM,,,,,,,,,,,,,,"Inhibition of MMP9 using (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)Ala-Arg-NH2 as substrate preincubated for 30 mins measured after 10 mins by fluorescence analysis",,"A new generation of radiofluorinated pyrimidine-2,4,6-triones as MMP-targeted radiotracers for positron emission tomography.",J. Med. Chem.,2012,55,1,"Schrigten D, Breyholz HJ, Wagner S, Hermann S, Schober O, Schäfers M, Haufe G, Kopka K",,800775,DTCT0024844,7619091,DTCC01174046,185744,47195
CHEMBL1946148,P14780,,LWNWGJXWKYGLPU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22118188,IC50,=,56,NM,,,,,,,,,,,,,,"Inhibition of MMP9 using (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)Ala-Arg-NH2 as substrate preincubated for 30 mins measured after 10 mins by fluorescence analysis",,"A new generation of radiofluorinated pyrimidine-2,4,6-triones as MMP-targeted radiotracers for positron emission tomography.",J. Med. Chem.,2012,55,1,"Schrigten D, Breyholz HJ, Wagner S, Hermann S, Schober O, Schäfers M, Haufe G, Kopka K",,800775,DTCT0024844,7619092,DTCC01174047,1706054,47195
CHEMBL1946149,P14780,,SVUOUTRIPGSFHF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22118188,IC50,=,23,NM,,,,,,,,,,,,,,"Inhibition of MMP9 using (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)Ala-Arg-NH2 as substrate preincubated for 30 mins measured after 10 mins by fluorescence analysis",,"A new generation of radiofluorinated pyrimidine-2,4,6-triones as MMP-targeted radiotracers for positron emission tomography.",J. Med. Chem.,2012,55,1,"Schrigten D, Breyholz HJ, Wagner S, Hermann S, Schober O, Schäfers M, Haufe G, Kopka K",,800775,DTCT0024844,7619093,DTCC01174048,1513025,47195
CHEMBL194627,P14780,,YCIYENASUWAOBH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16084720,IC50,=,108,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metallopeptidase 9,,Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2005,15,19,"Levin JI, Chen JM, Laakso LM, Du M, Du X, Venkatesan AM, Sandanayaka V, Zask A, Xu J, Xu W, Zhang Y, Skotnicki JS",,321249,DTCT0024844,1861764,DTCC00408048,1198212,19752
CHEMBL194627,P14780,,YCIYENASUWAOBH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16084720,IC50,=,108,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metallopeptidase 9,,Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2005,15,19,"Levin JI, Chen JM, Laakso LM, Du M, Du X, Venkatesan AM, Sandanayaka V, Zask A, Xu J, Xu W, Zhang Y, Skotnicki JS",,321249,DTCT0024844,1862283,DTCC00408048,1198214,19752
CHEMBL1946275,P14780,,RWOLXJOULAGHOB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22118188,IC50,=,20,NM,,,,,,,,,,,,,,"Inhibition of MMP9 using (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)Ala-Arg-NH2 as substrate preincubated for 30 mins measured after 10 mins by fluorescence analysis",,"A new generation of radiofluorinated pyrimidine-2,4,6-triones as MMP-targeted radiotracers for positron emission tomography.",J. Med. Chem.,2012,55,1,"Schrigten D, Breyholz HJ, Wagner S, Hermann S, Schober O, Schäfers M, Haufe G, Kopka K",,800775,DTCT0024844,7619094,DTCC01174168,542782,47195
CHEMBL1946276,P14780,,JZIODDCGNMBMLB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22118188,IC50,=,7,NM,,,,,,,,,,,,,,"Inhibition of MMP9 using (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)Ala-Arg-NH2 as substrate preincubated for 30 mins measured after 10 mins by fluorescence analysis",,"A new generation of radiofluorinated pyrimidine-2,4,6-triones as MMP-targeted radiotracers for positron emission tomography.",J. Med. Chem.,2012,55,1,"Schrigten D, Breyholz HJ, Wagner S, Hermann S, Schober O, Schäfers M, Haufe G, Kopka K",,800775,DTCT0024844,7619095,DTCC01174169,1830895,47195
CHEMBL1946277,P14780,,PTJXSKQZLWNDNB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22118188,IC50,=,60,NM,,,,,,,,,,,,,,"Inhibition of MMP9 using (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)Ala-Arg-NH2 as substrate preincubated for 30 mins measured after 10 mins by fluorescence analysis",,"A new generation of radiofluorinated pyrimidine-2,4,6-triones as MMP-targeted radiotracers for positron emission tomography.",J. Med. Chem.,2012,55,1,"Schrigten D, Breyholz HJ, Wagner S, Hermann S, Schober O, Schäfers M, Haufe G, Kopka K",,800775,DTCT0024844,7619096,DTCC01174170,833388,47195
CHEMBL195437,P14780,4-OCTYLPHENOL,NTDQQZYCCIDJRK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7292044,DTCC00405592,1285870,46191
CHEMBL195437,P14780,4-OCTYLPHENOL,NTDQQZYCCIDJRK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7292045,DTCC00405592,1285870,46191
CHEMBL1956115,P14780,,GDYIQUFNICPYHF-GOSISDBHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22175825,KI,>,10000,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,Potent inhibitors of LpxC for the treatment of Gram-negative infections.,J. Med. Chem.,2012,55,2,"Brown MF, Reilly U, Abramite JA, Arcari JT, Oliver R, Barham RA, Che Y, Chen JM, Collantes EM, Chung SW, Desbonnet C, Doty J, Doroski M, Engtrakul JJ, Harris TM, Huband M, Knafels JD, Leach KL, Liu S, Marfat A, Marra A, McElroy E, Melnick M, Menard CA, Montgomery JI, Mullins L, Noe MC, O'Donnell J, Penzien J, Plummer MS, Price LM, Shanmugasundaram V, Thoma C, Uccello DP, Warmus JS, Wishka DG",,806643,DTCT0024844,7652740,DTCC01177834,866270,47510
CHEMBL195743,P14780,,OCQPVQCJWDXDLQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15857146,IC50,=,6,NM,,,,,,,,,,,,,,In vitro inhibition of human Matrix metalloprotease 9,,C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging.,J. Med. Chem.,2005,48,9,"Breyholz HJ, Schäfers M, Wagner S, Höltke C, Faust A, Rabeneck H, Levkau B, Schober O, Kopka K",,305380,DTCT0024844,1828756,DTCC00399903,1916250,19718
CHEMBL1957575,P14780,,UNZVEKIWWIPTLX-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22386984,IC50,=,30000,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 1 hr prior substrate addition measured after 30 mins by spectrofluorimetry,,In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.,Bioorg. Med. Chem.,2012,20,7,"Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I",,805642,DTCT0024844,7640496,DTCC01179260,444870,47642
CHEMBL1957576,P14780,,VMVUOYMLEJABRL-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22386984,IC50,,,,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 1 hr prior substrate addition measured after 30 mins by spectrofluorimetry,Not Determined,In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.,Bioorg. Med. Chem.,2012,20,7,"Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I",,805642,DTCT0024844,7640497,DTCC01179261,2025902,47642
CHEMBL1957577,P14780,,YQCQHFRCABEIDV-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22386984,IC50,,,,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 1 hr prior substrate addition measured after 30 mins by spectrofluorimetry,Not Determined,In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.,Bioorg. Med. Chem.,2012,20,7,"Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I",,805642,DTCT0024844,7640498,DTCC01179262,962706,47642
CHEMBL1957578,P14780,,DBVRYQPCZBWOIA-SNVBAGLBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22386984,IC50,>,500000,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 1 hr prior substrate addition measured after 30 mins by spectrofluorimetry,,In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.,Bioorg. Med. Chem.,2012,20,7,"Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I",,805642,DTCT0024844,7640499,DTCC01179263,348689,47642
CHEMBL1957579,P14780,,KSINVMMDBYSEMQ-SNVBAGLBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22386984,IC50,,,,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 1 hr prior substrate addition measured after 30 mins by spectrofluorimetry,Not Determined,In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.,Bioorg. Med. Chem.,2012,20,7,"Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I",,805642,DTCT0024844,7640500,DTCC01179264,1155933,47642
CHEMBL1957580,P14780,,YSFMLQUQUOQGGE-SNVBAGLBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22386984,IC50,,,,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 1 hr prior substrate addition measured after 30 mins by spectrofluorimetry,Not Determined,In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.,Bioorg. Med. Chem.,2012,20,7,"Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I",,805642,DTCT0024844,7640501,DTCC01179265,414252,47642
CHEMBL1957581,P14780,,QARPMAYBEMTQCF-SNVBAGLBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22386984,IC50,=,430000,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 1 hr prior substrate addition measured after 30 mins by spectrofluorimetry,,In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.,Bioorg. Med. Chem.,2012,20,7,"Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I",,805642,DTCT0024844,7640502,DTCC01179266,962707,47642
CHEMBL1957582,P14780,,BCZYCMUPDFSLAA-SNVBAGLBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22386984,IC50,,,,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 1 hr prior substrate addition measured after 30 mins by spectrofluorimetry,Not Determined,In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.,Bioorg. Med. Chem.,2012,20,7,"Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I",,805642,DTCT0024844,7640503,DTCC01179267,1609805,47642
CHEMBL1957583,P14780,,GWLKAYBSPXJYIE-SNVBAGLBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22386984,IC50,,,,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 1 hr prior substrate addition measured after 30 mins by spectrofluorimetry,Not Determined,In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.,Bioorg. Med. Chem.,2012,20,7,"Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I",,805642,DTCT0024844,7640504,DTCC01179268,1480617,47642
CHEMBL1957584,P14780,,UNZVEKIWWIPTLX-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22386984,IC50,=,144000,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 1 hr prior substrate addition measured after 30 mins by spectrofluorimetry,,In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.,Bioorg. Med. Chem.,2012,20,7,"Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I",,805642,DTCT0024844,7640505,DTCC01179269,962708,47642
CHEMBL1957585,P14780,,VMVUOYMLEJABRL-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22386984,IC50,,,,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 1 hr prior substrate addition measured after 30 mins by spectrofluorimetry,Not Determined,In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.,Bioorg. Med. Chem.,2012,20,7,"Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I",,805642,DTCT0024844,7640506,DTCC01179270,510608,47642
CHEMBL1957586,P14780,,YQCQHFRCABEIDV-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22386984,IC50,,,,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 1 hr prior substrate addition measured after 30 mins by spectrofluorimetry,Not Determined,In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.,Bioorg. Med. Chem.,2012,20,7,"Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I",,805642,DTCT0024844,7640507,DTCC01179271,672048,47642
CHEMBL1957587,P14780,,DBVRYQPCZBWOIA-JTQLQIEISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22386984,IC50,,,,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 1 hr prior substrate addition measured after 30 mins by spectrofluorimetry,Not Determined,In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.,Bioorg. Med. Chem.,2012,20,7,"Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I",,805642,DTCT0024844,7640508,DTCC01179272,1253585,47642
CHEMBL1957588,P14780,,YSFMLQUQUOQGGE-JTQLQIEISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22386984,IC50,,,,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 1 hr prior substrate addition measured after 30 mins by spectrofluorimetry,Not Determined,In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.,Bioorg. Med. Chem.,2012,20,7,"Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I",,805642,DTCT0024844,7640510,DTCC01179273,1480618,47642
CHEMBL1957589,P14780,,QARPMAYBEMTQCF-JTQLQIEISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22386984,IC50,,,,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 1 hr prior substrate addition measured after 30 mins by spectrofluorimetry,Not Determined,In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.,Bioorg. Med. Chem.,2012,20,7,"Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I",,805642,DTCT0024844,7640511,DTCC01179274,1480619,47642
CHEMBL1957590,P14780,,BCZYCMUPDFSLAA-JTQLQIEISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22386984,IC50,,,,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 1 hr prior substrate addition measured after 30 mins by spectrofluorimetry,Not Determined,In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.,Bioorg. Med. Chem.,2012,20,7,"Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I",,805642,DTCT0024844,7640512,DTCC01179275,542835,47642
CHEMBL1957591,P14780,,GWLKAYBSPXJYIE-JTQLQIEISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22386984,IC50,,,,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 1 hr prior substrate addition measured after 30 mins by spectrofluorimetry,Not Determined,In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.,Bioorg. Med. Chem.,2012,20,7,"Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I",,805642,DTCT0024844,7640513,DTCC01179276,542836,47642
CHEMBL1957592,P14780,,ZHIUBXZPUVPTOB-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22386984,IC50,,,,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 1 hr prior substrate addition measured after 30 mins by spectrofluorimetry,Not Determined,In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.,Bioorg. Med. Chem.,2012,20,7,"Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I",,805642,DTCT0024844,7640514,DTCC01179277,962709,47642
CHEMBL1957593,P14780,,HMENVOZJJJXNDF-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22386984,IC50,,,,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 1 hr prior substrate addition measured after 30 mins by spectrofluorimetry,Not Determined,In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.,Bioorg. Med. Chem.,2012,20,7,"Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I",,805642,DTCT0024844,7640515,DTCC01179278,315927,47642
CHEMBL1957594,P14780,,LQQBDPSZMPMYFZ-SJORKVTESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22386984,IC50,,,,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 1 hr prior substrate addition measured after 30 mins by spectrofluorimetry,Not Determined,In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.,Bioorg. Med. Chem.,2012,20,7,"Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I",,805642,DTCT0024844,7640516,DTCC01179279,1351359,47642
CHEMBL1957595,P14780,,ZNKFBFNCKBPGMH-HNNXBMFYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22386984,IC50,=,47000,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 1 hr prior substrate addition measured after 30 mins by spectrofluorimetry,,In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.,Bioorg. Med. Chem.,2012,20,7,"Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I",,805642,DTCT0024844,7640517,DTCC01179280,1318696,47642
CHEMBL1957596,P14780,,TZRWLUAWTLLHBS-HNNXBMFYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22386984,IC50,=,1900,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 1 hr prior substrate addition measured after 30 mins by spectrofluorimetry,,In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.,Bioorg. Med. Chem.,2012,20,7,"Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I",,805642,DTCT0024844,7640518,DTCC01179281,1384002,47642
CHEMBL1957597,P14780,,XYGPNXMBVTVKDQ-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22386984,IC50,=,76000,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 1 hr prior substrate addition measured after 30 mins by spectrofluorimetry,,In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.,Bioorg. Med. Chem.,2012,20,7,"Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I",,805642,DTCT0024844,7640519,DTCC01179282,2025903,47642
CHEMBL1957598,P14780,,UNRBDNFPHSIAEP-HNNXBMFYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22386984,IC50,=,230,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 1 hr prior substrate addition measured after 30 mins by spectrofluorimetry,,In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.,Bioorg. Med. Chem.,2012,20,7,"Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I",,805642,DTCT0024844,7640520,DTCC01179283,1318697,47642
CHEMBL1957599,P14780,,FEUGLHVWLKFXEV-ZDUSSCGKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22386984,IC50,>,50000,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 1 hr prior substrate addition measured after 30 mins by spectrofluorimetry,,In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.,Bioorg. Med. Chem.,2012,20,7,"Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I",,805642,DTCT0024844,7640521,DTCC01179284,1798651,47642
CHEMBL1957600,P14780,,MTFHBXMAOFMWAG-JTQLQIEISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22386984,IC50,=,560,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 1 hr prior substrate addition measured after 30 mins by spectrofluorimetry,,In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.,Bioorg. Med. Chem.,2012,20,7,"Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I",,805642,DTCT0024844,7640522,DTCC01179285,381267,47642
CHEMBL1957601,P14780,,CYFUZHPFHKFWQX-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22386984,IC50,=,2,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 1 hr prior substrate addition measured after 30 mins by spectrofluorimetry,,In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.,Bioorg. Med. Chem.,2012,20,7,"Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I",,805642,DTCT0024844,7640523,DTCC01179286,1642107,47642
CHEMBL1957602,P14780,,UCAJNLLYTGJPBY-HNNXBMFYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22386984,IC50,=,16,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 1 hr prior substrate addition measured after 30 mins by spectrofluorimetry,,In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.,Bioorg. Med. Chem.,2012,20,7,"Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I",,805642,DTCT0024844,7640524,DTCC01179287,1798652,47642
CHEMBL1957603,P14780,,WIOGWLUNCZARAP-HNNXBMFYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22386984,IC50,=,5,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 1 hr prior substrate addition measured after 30 mins by spectrofluorimetry,,In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.,Bioorg. Med. Chem.,2012,20,7,"Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I",,805642,DTCT0024844,7640525,DTCC01179288,1027325,47642
CHEMBL1957604,P14780,,FYFJMQCWKQDEQR-FZADBTJQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22386984,IC50,=,600,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 1 hr prior substrate addition measured after 30 mins by spectrofluorimetry,,In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.,Bioorg. Med. Chem.,2012,20,7,"Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I",,805642,DTCT0024844,7640526,DTCC01179289,1609806,47642
CHEMBL1957605,P14780,,VVEIZVKRPYJCPP-HNNXBMFYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22386984,IC50,=,480,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 1 hr prior substrate addition measured after 30 mins by spectrofluorimetry,,In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.,Bioorg. Med. Chem.,2012,20,7,"Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I",,805642,DTCT0024844,7640527,DTCC01179290,1862951,47642
CHEMBL1957606,P14780,,LXQUQEBAZBLBEJ-HNNXBMFYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22386984,IC50,=,0.5,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 1 hr prior substrate addition measured after 30 mins by spectrofluorimetry,,In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.,Bioorg. Med. Chem.,2012,20,7,"Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I",,805642,DTCT0024844,7640528,DTCC01179291,1513073,47642
CHEMBL195948,P14780,,VJCSPSPTFYXXJB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16084720,IC50,=,88,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metallopeptidase 9,,Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2005,15,19,"Levin JI, Chen JM, Laakso LM, Du M, Du X, Venkatesan AM, Sandanayaka V, Zask A, Xu J, Xu W, Zhang Y, Skotnicki JS",,321249,DTCT0024844,1861769,DTCC00408054,7385,19752
CHEMBL195948,P14780,,VJCSPSPTFYXXJB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16084720,IC50,=,88,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metallopeptidase 9,,Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2005,15,19,"Levin JI, Chen JM, Laakso LM, Du M, Du X, Venkatesan AM, Sandanayaka V, Zask A, Xu J, Xu W, Zhang Y, Skotnicki JS",,321249,DTCT0024844,1862289,DTCC00408054,7386,19752
CHEMBL196,P14780,ASCORBATE,CIWBSHSKHKDKBQ-JLAZNSOCSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7273547,DTCC00506386,282996,46191
CHEMBL196,P14780,ASCORBATE,CIWBSHSKHKDKBQ-JLAZNSOCSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7273548,DTCC00506386,282996,46191
CHEMBL196092,P14780,,SEOIKBYFTLCBTF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16084720,IC50,=,170,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metallopeptidase 9,,Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2005,15,19,"Levin JI, Chen JM, Laakso LM, Du M, Du X, Venkatesan AM, Sandanayaka V, Zask A, Xu J, Xu W, Zhang Y, Skotnicki JS",,321249,DTCT0024844,1861749,DTCC00408040,423945,19752
CHEMBL196092,P14780,,SEOIKBYFTLCBTF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16084720,IC50,=,170,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metallopeptidase 9,,Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2005,15,19,"Levin JI, Chen JM, Laakso LM, Du M, Du X, Venkatesan AM, Sandanayaka V, Zask A, Xu J, Xu W, Zhang Y, Skotnicki JS",,321249,DTCT0024844,1862266,DTCC00408040,423947,19752
CHEMBL19611,P14780,ILOMASTAT,NITYDPDXAAFEIT-DYVFJYSZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,0.57,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1369663,DTCC00151638,1882182,14854
CHEMBL19611,P14780,ILOMASTAT,NITYDPDXAAFEIT-DYVFJYSZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9548812,IC50,=,0.5,NM,,,,,,,,,,,,,,Activity against Matrix metalloprotease-9 (MMP-9).,,Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.,J. Med. Chem.,1998,41,8,"Yamamoto M, Tsujishita H, Hori N, Ohishi Y, Inoue S, Ikeda S, Okada Y",,105225,DTCT0024844,997038,DTCC00151638,1884891,15116
CHEMBL19611,P14780,ILOMASTAT,NITYDPDXAAFEIT-DYVFJYSZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14684295,IC50,=,15,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,1,"Ma D, Wu W, Yang G, Li J, Li J, Ye Q",,105527,DTCT0024844,877402,DTCC00151638,1883350,6330
CHEMBL19611,P14780,ILOMASTAT,NITYDPDXAAFEIT-DYVFJYSZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16420030,IC50,=,15,NM,,,,,,,,,,,,,,Inhibitory activity against MMP9,,Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.,J. Med. Chem.,2006,49,2,"Ma D, Jiang Y, Chen F, Gong LK, Ding K, Xu Y, Wang R, Ge A, Ren J, Li J, Li J, Ye Q",,330169,DTCT0024844,1885653,DTCC00151638,1872716,20234
CHEMBL19611,P14780,ILOMASTAT,NITYDPDXAAFEIT-DYVFJYSZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17512742,IC50,=,0.5,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.,Bioorg. Med. Chem.,2007,15,14,"Moroy G, Denhez C, El Mourabit H, Toribio A, Dassonville A, Decarme M, Renault JH, Mirand C, Bellon G, Sapi J, Alix AJ, Hornebeck W, Bourguet E",,447907,DTCT0024844,2176047,DTCC00151638,1873251,23716
CHEMBL19611,P14780,ILOMASTAT,NITYDPDXAAFEIT-DYVFJYSZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17623656,IC50,=,6.7,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.,J. Biol. Chem.,2007,282,38,"Johnson AR, Pavlovsky AG, Ortwine DF, Prior F, Man CF, Bornemeier DA, Banotai CA, Mueller WT, McConnell P, Yan C, Baragi V, Lesch C, Roark WH, Wilson M, Datta K, Guzman R, Han HK, Dyer RD",,507876,DTCT0024844,2388629,DTCC00151638,1885151,29282
CHEMBL19611,P14780,ILOMASTAT,NITYDPDXAAFEIT-DYVFJYSZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18782669,IC50,=,0.6,NM,,,,,,,,,,,,,,Inhibition of human recombinant pro-MMP9 by spectrofluorimeter,,Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.,Bioorg. Med. Chem.,2008,16,18,"Ledour G, Moroy G, Rouffet M, Bourguet E, Guillaume D, Decarme M, Elmourabit H, Augé F, Alix AJ, Laronze JY, Bellon G, Hornebeck W, Sapi J",,557954,DTCT0024844,2791150,DTCC00151638,1873635,31586
CHEMBL19611,P14780,ILOMASTAT,NITYDPDXAAFEIT-DYVFJYSZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21406033,IC50,=,0.26,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14717311,DTCC00151638,2100971,69105
CHEMBL19611,P14780,ILOMASTAT,NITYDPDXAAFEIT-DYVFJYSZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21548582,IC50,=,0.05,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.",J. Med. Chem.,2011,54,13,"Neelarapu R, Holzle DL, Velaparthi S, Bai H, Brunsteiner M, Blond SY, Petukhov PA",,785746,DTCT0024844,7517248,DTCC00151638,1895024,46348
CHEMBL19611,P14780,ILOMASTAT,NITYDPDXAAFEIT-DYVFJYSZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,27038494,IC50,=,0.55,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 60 mins followed by substrate addition by fluorimetric analysis,,Selective non-zinc binding MMP-2 inhibitors: Novel benzamide Ilomastat analogs with anti-tumor metastasis.,Bioorg. Med. Chem. Lett.,2016,26,9,"Song J, Peng P, Chang J, Liu MM, Yu JM, Zhou L, Sun X.",,1572538,DTCT0024844,220673,DTCC00151638,1881417,66798
CHEMBL19611,P14780,ILOMASTAT,NITYDPDXAAFEIT-DYVFJYSZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,0.2,NM,,,,,,,,,,,,,,Inhibition of human recombinant 92 kDa gelatinase MMP-9 at 100 uM,,,Bioorg. Med. Chem. Lett.,1995,5,15,,,71646,DTCT0024844,681894,DTCC00151638,1870076,1239
CHEMBL19611,P14780,ILOMASTAT,NITYDPDXAAFEIT-DYVFJYSZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION,=,100,%,,,,,,,,,,,,,,Inhibition of human recombinant 92 kDa gelatinase MMP-9 at 10 uM,,,Bioorg. Med. Chem. Lett.,1995,5,15,,,71647,DTCT0024844,681891,DTCC00151638,1870076,1239
CHEMBL19611,P14780,ILOMASTAT,NITYDPDXAAFEIT-DYVFJYSZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,0.69,NM,,,,,,,,,,,,,,Inhibition of human Matrix metalloprotease-9,,,Bioorg. Med. Chem. Lett.,1995,5,4,,,105391,DTCT0024844,842074,DTCC00151638,1882893,1497
CHEMBL19623,P14780,,KEPYRBFIGNMAQF-MJGOQNOKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9548812,IC50,=,11,NM,,,,,,,,,,,,,,Activity against Matrix metalloprotease-9 (MMP-9).,,Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.,J. Med. Chem.,1998,41,8,"Yamamoto M, Tsujishita H, Hori N, Ohishi Y, Inoue S, Ikeda S, Okada Y",,105225,DTCT0024844,982755,DTCC00151639,1917024,15116
CHEMBL196647,P14780,,YZYVVJVNDAWVKA-NCRNUEESSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15837315,IC50,=,983,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 in MMPi assay,,A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs.,Bioorg. Med. Chem. Lett.,2005,15,9,"Rossello A, Nuti E, Catalani MP, Carelli P, Orlandini E, Rapposelli S, Tuccinardi T, Atkinson SJ, Murphy G, Balsamo A",,305685,DTCT0024844,1841394,DTCC00403116,1916287,18987
CHEMBL197877,P14780,,URNZIKDWYXXADG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,INHIBITION,=,31,%,,,,,,,,,,,,,,Inhibition of MMP9 at 10 uM,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429671,DTCT0024844,2041948,DTCC00408175,110472,22157
CHEMBL198039,P14780,,IRPQGYYABIPNQJ-DEOSSOPVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16153831,IC50,,,,,,,,,,,,,,,,,Inhibitory concentration against MMP-9; - = not available,Not Determined,Synthesis and SAR of highly selective MMP-13 inhibitors.,Bioorg. Med. Chem. Lett.,2005,15,22,"Li J, Rush TS, Li W, DeVincentis D, Du X, Hu Y, Thomason JR, Xiang JS, Skotnicki JS, Tam S, Cunningham KM, Chockalingam PS, Morris EA, Levin JI",,321294,DTCT0024844,1860352,DTCC00407671,1048682,19837
CHEMBL198100,P14780,,CYIOQNVVHKTYRH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16084720,IC50,=,209,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metallopeptidase 9,,Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2005,15,19,"Levin JI, Chen JM, Laakso LM, Du M, Du X, Venkatesan AM, Sandanayaka V, Zask A, Xu J, Xu W, Zhang Y, Skotnicki JS",,321249,DTCT0024844,1861796,DTCC00408079,1198213,19752
CHEMBL198100,P14780,,CYIOQNVVHKTYRH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16084720,IC50,=,209,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metallopeptidase 9,,Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2005,15,19,"Levin JI, Chen JM, Laakso LM, Du M, Du X, Venkatesan AM, Sandanayaka V, Zask A, Xu J, Xu W, Zhang Y, Skotnicki JS",,321249,DTCT0024844,1862314,DTCC00408079,1198215,19752
CHEMBL1981977,P14780,N-(2-CHLOROPHENYL)CINNAMAMIDE,FKLXMLNUDVRAJG-ZHACJKMWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,13.87,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833578,DTCC01198303,91233,53968
CHEMBL198262,P14780,,HHHAELOQIYTSIY-DEOSSOPVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16153831,INHIBITION,=,66,%,,,,,,,,,,,,,,Percent inhibition at 25 uM against MMP-9,,Synthesis and SAR of highly selective MMP-13 inhibitors.,Bioorg. Med. Chem. Lett.,2005,15,22,"Li J, Rush TS, Li W, DeVincentis D, Du X, Hu Y, Thomason JR, Xiang JS, Skotnicki JS, Tam S, Cunningham KM, Chockalingam PS, Morris EA, Levin JI",,321724,DTCT0024844,1860306,DTCC00407624,1405256,19837
CHEMBL198389,P14780,,HAWUDCIVXQTNAF-VWLOTQADSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16153831,IC50,,,,,,,,,,,,,,,,,Inhibitory concentration against MMP-9; - = not available,Not Determined,Synthesis and SAR of highly selective MMP-13 inhibitors.,Bioorg. Med. Chem. Lett.,2005,15,22,"Li J, Rush TS, Li W, DeVincentis D, Du X, Hu Y, Thomason JR, Xiang JS, Skotnicki JS, Tam S, Cunningham KM, Chockalingam PS, Morris EA, Levin JI",,321294,DTCT0024844,1860363,DTCC00407672,304937,19837
CHEMBL19843,P14780,,OFCWIPGKPUJTDP-CFVMTHIKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9548812,IC50,=,3.9,NM,,,,,,,,,,,,,,Activity against Matrix metalloprotease-9 (MMP-9).,,Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.,J. Med. Chem.,1998,41,8,"Yamamoto M, Tsujishita H, Hori N, Ohishi Y, Inoue S, Ikeda S, Okada Y",,105225,DTCT0024844,1012779,DTCC00151473,305658,15116
CHEMBL19855,P14780,,RUZDCFCMYATJSO-LJQANCHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11354379,IC50,=,56,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Design and synthesis of 2-oxo-imidazolidine-4-carboxylic acid hydroxyamides as potent matrix metalloproteinase-13 inhibitors.,Bioorg. Med. Chem. Lett.,2001,11,9,"Robinson RP, Laird ER, Donahue KM, Lopresti-Morrow LL, Mitchell PG, Reese MR, Reeves LM, Rouch AI, Stam EJ, Yocum SA",,105529,DTCT0024844,711887,DTCC00151144,581757,4814
CHEMBL199018,P14780,,XTRLBSLKNQZDBD-VWLOTQADSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16153831,IC50,,,,,,,,,,,,,,,,,Inhibitory concentration against MMP-9; - = not available,Not Determined,Synthesis and SAR of highly selective MMP-13 inhibitors.,Bioorg. Med. Chem. Lett.,2005,15,22,"Li J, Rush TS, Li W, DeVincentis D, Du X, Hu Y, Thomason JR, Xiang JS, Skotnicki JS, Tam S, Cunningham KM, Chockalingam PS, Morris EA, Levin JI",,321294,DTCT0024844,1860407,DTCC00407676,822181,19837
CHEMBL199241,P14780,,LSKSBHBGNRQEFN-DEOSSOPVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16153831,INHIBITION,=,51,%,,,,,,,,,,,,,,Percent inhibition at 25 uM against MMP-9,,Synthesis and SAR of highly selective MMP-13 inhibitors.,Bioorg. Med. Chem. Lett.,2005,15,22,"Li J, Rush TS, Li W, DeVincentis D, Du X, Hu Y, Thomason JR, Xiang JS, Skotnicki JS, Tam S, Cunningham KM, Chockalingam PS, Morris EA, Levin JI",,321724,DTCT0024844,1860341,DTCC00407670,1787390,19837
CHEMBL199314,P14780,,JIGAPWRVDSTJDZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16420030,ACTIVITY,,,,,,,,,,,,,,,,,Inhibitory activity against MMP9 upto 50uM,Not Active,Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.,J. Med. Chem.,2006,49,2,"Ma D, Jiang Y, Chen F, Gong LK, Ding K, Xu Y, Wang R, Ge A, Ren J, Li J, Li J, Ye Q",,330178,DTCT0024844,1886082,DTCC00412581,98682,20234
CHEMBL19932,P14780,,RHWGGEKVTPKRQW-CFVMTHIKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9548812,IC50,=,0.9,NM,,,,,,,,,,,,,,Activity against Matrix metalloprotease-9 (MMP-9).,,Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.,J. Med. Chem.,1998,41,8,"Yamamoto M, Tsujishita H, Hori N, Ohishi Y, Inoue S, Ikeda S, Okada Y",,105225,DTCT0024844,982764,DTCC00151595,1308396,15116
CHEMBL199666,P14780,,UOBFNJXLVSPHNN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16420030,IC50,=,1510,NM,,,,,,,,,,,,,,Inhibitory activity against MMP9,,Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.,J. Med. Chem.,2006,49,2,"Ma D, Jiang Y, Chen F, Gong LK, Ding K, Xu Y, Wang R, Ge A, Ren J, Li J, Li J, Ye Q",,330169,DTCT0024844,1886137,DTCC00412724,649762,20234
CHEMBL1998736,P14780,N-(2-FLUOROPHENYL)CINNAMAMIDE,GFAVMCPSQILRPK-ZHACJKMWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,10.58,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833581,DTCC01214148,1158303,53968
CHEMBL199917,P14780,,GJITXIQQHBXCIH-GOSISDBHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16392792,IC50,=,2.7,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.,J. Med. Chem.,2006,49,1,"Pirard B, Matter H",,329822,DTCT0024844,1880238,DTCC00412005,1743962,20214
CHEMBL2,P14780,PRAZOSIN,IENZQIKPVFGBNW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,6963,NM,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7387655,DTCC00132268,1155685,46191
CHEMBL2,P14780,PRAZOSIN,IENZQIKPVFGBNW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Note: corresponding IC50 reported as Active,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7387656,DTCC00132268,1155685,46191
CHEMBL20,P14780,ACETAZOLAMIDE,BZKPWHYZMXOIDC-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7281162,DTCC00133144,51441,46191
CHEMBL20,P14780,ACETAZOLAMIDE,BZKPWHYZMXOIDC-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7281163,DTCC00133144,51441,46191
CHEMBL20043,P14780,,ONJBMYIEKPLUOX-WBVHZDCISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9548812,IC50,=,2.8,NM,,,,,,,,,,,,,,Activity against Matrix metalloprotease-9 (MMP-9).,,Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.,J. Med. Chem.,1998,41,8,"Yamamoto M, Tsujishita H, Hori N, Ohishi Y, Inoue S, Ikeda S, Okada Y",,105225,DTCT0024844,988381,DTCC00151622,2047648,15116
CHEMBL2010824,P14780,,RKZDOJQKLCPUQZ-AIBWNMTMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22342144,KI,>,50000,NM,,,,,,,,,,,,,,Inhibition of MMP-9 using OmniMMP as substrate,,Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain.,Bioorg. Med. Chem. Lett.,2012,22,6,"Jiao GS, Kim S, Moayeri M, Crown D, Thai A, Cregar-Hernandez L, McKasson L, Sankaran B, Lehrer A, Wong T, Johns L, Margosiak SA, Leppla SH, Johnson AT",,811339,DTCT0024844,10427380,DTCC01227244,1811993,47718
CHEMBL201206,P14780,,QTFXITWPRZRHMV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16420030,IC50,=,9290,NM,,,,,,,,,,,,,,Inhibitory activity against MMP9,,Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.,J. Med. Chem.,2006,49,2,"Ma D, Jiang Y, Chen F, Gong LK, Ding K, Xu Y, Wang R, Ge A, Ren J, Li J, Li J, Ye Q",,330169,DTCT0024844,1886139,DTCC00412719,488239,20234
CHEMBL2012836,P14780,,QKBHUOCFQAXIBG-BPGUCPLFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22342144,KI,>,50000,NM,,,,,,,,,,,,,,Inhibition of MMP-9 using OmniMMP as substrate,,Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain.,Bioorg. Med. Chem. Lett.,2012,22,6,"Jiao GS, Kim S, Moayeri M, Crown D, Thai A, Cregar-Hernandez L, McKasson L, Sankaran B, Lehrer A, Wong T, Johns L, Margosiak SA, Leppla SH, Johnson AT",,811339,DTCT0024844,10427382,DTCC01227243,653282,47718
CHEMBL2012837,P14780,,AWFIZJRPXRHSEA-BPGUCPLFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22342144,KI,>,50000,NM,,,,,,,,,,,,,,Inhibition of MMP-9 using OmniMMP as substrate,,Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain.,Bioorg. Med. Chem. Lett.,2012,22,6,"Jiao GS, Kim S, Moayeri M, Crown D, Thai A, Cregar-Hernandez L, McKasson L, Sankaran B, Lehrer A, Wong T, Johns L, Margosiak SA, Leppla SH, Johnson AT",,811339,DTCT0024844,10427378,DTCC01227245,2071212,47718
CHEMBL2012838,P14780,,BPGDVHWVHMDFBK-IQWVOLIVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22342144,KI,=,11000,NM,,,,,,,,,,,,,,Inhibition of MMP-9 using OmniMMP as substrate,,Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain.,Bioorg. Med. Chem. Lett.,2012,22,6,"Jiao GS, Kim S, Moayeri M, Crown D, Thai A, Cregar-Hernandez L, McKasson L, Sankaran B, Lehrer A, Wong T, Johns L, Margosiak SA, Leppla SH, Johnson AT",,811339,DTCT0024844,10427385,DTCC01227246,814410,47718
CHEMBL201298,P14780,3-(4-PHENYLETHYNYLBENZOYL)NONANOIC ACID,RPSYWEPJQQLLJN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16420030,IC50,=,5410,NM,,,,,,,,,,,,,,Inhibitory activity against MMP9,,Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.,J. Med. Chem.,2006,49,2,"Ma D, Jiang Y, Chen F, Gong LK, Ding K, Xu Y, Wang R, Ge A, Ren J, Li J, Li J, Ye Q",,330169,DTCT0024844,1886141,DTCC00001425,617002,20234
CHEMBL20154,P14780,,LPZWIAVKYXCHGC-NVXWUHKLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9548812,IC50,=,1.3,NM,,,,,,,,,,,,,,Activity against Matrix metalloprotease-9 (MMP-9).,,Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.,J. Med. Chem.,1998,41,8,"Yamamoto M, Tsujishita H, Hori N, Ohishi Y, Inoue S, Ikeda S, Okada Y",,105225,DTCT0024844,1004188,DTCC00151563,919876,15116
CHEMBL202875,P14780,,OQWWYXZJKRAMIK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16420030,IC50,=,3600,NM,,,,,,,,,,,,,,Inhibitory activity against MMP9,,Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.,J. Med. Chem.,2006,49,2,"Ma D, Jiang Y, Chen F, Gong LK, Ding K, Xu Y, Wang R, Ge A, Ren J, Li J, Li J, Ye Q",,330169,DTCT0024844,1886142,DTCC00412620,1037173,20234
CHEMBL202932,P14780,,BZVYQWLRCHLAGK-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17088065,IC50,=,8,NM,,cell_based,,,,,,,,,,,,Inhibition of human recombinant MMP9 expressed in mouse myeloma cells,,alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.,Bioorg. Med. Chem.,2007,15,2,"Biasone A, Tortorella P, Campestre C, Agamennone M, Preziuso S, Chiappini M, Nuti E, Carelli P, Rossello A, Mazza F, Gallina C",,432507,DTCT0024844,2061799,DTCC00413183,1263648,22402
CHEMBL203139,P14780,,IIMXFTNJRIHVRA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16420030,ACTIVITY,,,,,,,,,,,,,,,,,Inhibitory activity against MMP9 upto 50uM,Not Active,Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.,J. Med. Chem.,2006,49,2,"Ma D, Jiang Y, Chen F, Gong LK, Ding K, Xu Y, Wang R, Ge A, Ren J, Li J, Li J, Ye Q",,330178,DTCT0024844,1886081,DTCC00412582,1490531,20234
CHEMBL203160,P14780,,XVLVIDNHSWHJBN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16289878,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,Conversion of potent MMP inhibitors into selective TACE inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,4,"Cherney RJ, King BW, Gilmore JL, Liu RQ, Covington MB, Duan JJ, Decicco CP",,334536,DTCT0024844,1895745,DTCC00415520,855174,20373
CHEMBL203199,P14780,,WJAZWFDODWLPHA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16420030,ACTIVITY,,,,,,,,,,,,,,,,,Inhibitory activity against MMP9 upto 50uM,Not Active,Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.,J. Med. Chem.,2006,49,2,"Ma D, Jiang Y, Chen F, Gong LK, Ding K, Xu Y, Wang R, Ge A, Ren J, Li J, Li J, Ye Q",,330178,DTCT0024844,1885319,DTCC00110088,195410,20234
CHEMBL203266,P14780,TRIMETAZIDINE,UHWVSEOVJBQKBE-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7444474,DTCC00417182,381018,46191
CHEMBL203266,P14780,TRIMETAZIDINE,UHWVSEOVJBQKBE-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7444475,DTCC00417182,381018,46191
CHEMBL203972,P14780,,BZIUKEPVFXHVPZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16289878,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,Conversion of potent MMP inhibitors into selective TACE inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,4,"Cherney RJ, King BW, Gilmore JL, Liu RQ, Covington MB, Duan JJ, Decicco CP",,334536,DTCT0024844,1895743,DTCC00415441,1113898,20373
CHEMBL204048,P14780,,CNJHNAILYAGVJU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16289878,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,Conversion of potent MMP inhibitors into selective TACE inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,4,"Cherney RJ, King BW, Gilmore JL, Liu RQ, Covington MB, Duan JJ, Decicco CP",,334536,DTCT0024844,1895747,DTCC00415512,1981982,20373
CHEMBL2040991,P14780,,WYASJWPRGNYFKW-BGERDNNASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,2,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506761,DTCC01239546,943987,48447
CHEMBL2041307,P14780,,IVPPTWCRAFCOFJ-MUMRKEEXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,0.5,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506746,DTCC01239820,2006905,48447
CHEMBL2041308,P14780,,KILYFHYTMDFZTB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,0.34,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506744,DTCC01239821,1169635,48447
CHEMBL2043294,P14780,,HSBWZJKAIHGRCK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,197,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506766,DTCC01241628,1558618,48447
CHEMBL2043424,P14780,,FATWEDBJJYSZOL-XLDGYAMZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,1.1,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506765,DTCC01241735,1365121,48447
CHEMBL2043424,P14780,,FATWEDBJJYSZOL-XLDGYAMZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,1.1,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin),,,MedChemComm,2012,3,11,,,1327985,DTCT0024844,13570939,DTCC01241735,1387287,40045
CHEMBL2043425,P14780,,PIPNMGRIVITFEC-BPGUCPLFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,1.1,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506764,DTCC01241736,1494314,48447
CHEMBL204357,P14780,SR-973,WICQDDCNCVTFDX-VJGNERBWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16473009,KI,=,5,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,9,"Thompson LA, Liauw AY, Ramanjulu MM, Kasireddy-Polam P, Mercer SE, Maduskuie TP, Glicksman M, Roach AH, Meredith JE, Liu RQ, Combs AP, Higaki JN, Cordell B, Seiffert D, Zaczek RC, Robertson DW, Olson RE",,350093,DTCT0024844,1920771,DTCC00001675,1949133,20704
CHEMBL204495,P14780,,JHHLVVDASBMHIL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16289878,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,Conversion of potent MMP inhibitors into selective TACE inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,4,"Cherney RJ, King BW, Gilmore JL, Liu RQ, Covington MB, Duan JJ, Decicco CP",,334536,DTCT0024844,469059,DTCC00415490,1695445,20373
CHEMBL204543,P14780,"NAPHTHALENE-1,2-DIOL",NXPPAOGUKPJVDI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,86,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5102655,DTCC00001534,1892886,43205
CHEMBL204549,P14780,,OZLFXWYCUHTSQI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16289878,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,Conversion of potent MMP inhibitors into selective TACE inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,4,"Cherney RJ, King BW, Gilmore JL, Liu RQ, Covington MB, Duan JJ, Decicco CP",,334536,DTCT0024844,1895746,DTCC00415513,855173,20373
CHEMBL204593,P14780,,LUCFRFDOOYLALP-CYBMUJFWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16338135,IC50,=,2000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection.,Bioorg. Med. Chem. Lett.,2006,16,4,"Xiong Y, Wiltsie J, Woods A, Guo J, Pivnichny JV, Tang W, Bansal A, Cummings RT, Cunningham BR, Friedlander AM, Douglas CM, Salowe SP, Zaller DM, Scolnick EM, Schmatz DM, Bartizal K, Hermes JD, MacCoss M, Chapman KT",,334086,DTCT0024844,1895866,DTCC00415249,1598833,20352
CHEMBL2047536,P14780,,DACARRUBIAXSBX-IBGZPJMESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22175799,IC50,>,20000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using MCA-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2.AcOH as substrate preincubated for 10 mins measured by fluorescence analysis,,"Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis.",J. Med. Chem.,2012,55,2,"Gege C, Bao B, Bluhm H, Boer J, Gallagher BM, Korniski B, Powers TS, Steeneck C, Taveras AG, Baragi VM",,827025,DTCT0024844,10526938,DTCC01242723,653432,48586
CHEMBL2047537,P14780,,CZRLAOXITNZAJA-FQEVSTJZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22175799,IC50,>,20000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using MCA-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2.AcOH as substrate preincubated for 10 mins measured by fluorescence analysis,,"Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis.",J. Med. Chem.,2012,55,2,"Gege C, Bao B, Bluhm H, Boer J, Gallagher BM, Korniski B, Powers TS, Steeneck C, Taveras AG, Baragi VM",,827025,DTCT0024844,10526939,DTCC01242724,1655819,48586
CHEMBL2048502,P14780,MACRATHOIN F,VEBNYMXKXIIGFX-KBXRYBNXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,IC50,=,11610,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain incubated for 20 mins by fluorimetric assay,,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827436,DTCT0024844,10535409,DTCC01243472,1844458,48665
CHEMBL2048502,P14780,MACRATHOIN F,VEBNYMXKXIIGFX-KBXRYBNXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,INHIBITION,>,30,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain at 10 uM incubated for 20 mins by fluorimetric assay,,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827442,DTCT0024844,10535511,DTCC01243472,1844458,48665
CHEMBL2048503,P14780,,MZNIJRAPCCELQX-HWKANZROSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,IC50,,,,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain incubated for 20 mins by fluorimetric assay,Not Determined,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827436,DTCT0024844,10535410,DTCC01243473,492092,48665
CHEMBL2048504,P14780,,FLOHNUCSNZDDJO-DUXPYHPUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,IC50,=,12490,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain incubated for 20 mins by fluorimetric assay,,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827436,DTCT0024844,10535411,DTCC01243474,427800,48665
CHEMBL2048504,P14780,,FLOHNUCSNZDDJO-DUXPYHPUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,INHIBITION,>,30,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain at 10 uM incubated for 20 mins by fluorimetric assay,,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827442,DTCT0024844,10535512,DTCC01243474,427800,48665
CHEMBL2048505,P14780,DIMETHYL LITHOSPERMATE,YAXTXMBBIHBGPZ-ZBBBDWFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,IC50,=,990,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain incubated for 20 mins by fluorimetric assay,,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827436,DTCT0024844,10535412,DTCC01243475,1494333,48665
CHEMBL2048505,P14780,DIMETHYL LITHOSPERMATE,YAXTXMBBIHBGPZ-ZBBBDWFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,INHIBITION,>,30,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain at 10 uM incubated for 20 mins by fluorimetric assay,,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827442,DTCT0024844,10535513,DTCC01243475,1494333,48665
CHEMBL2048506,P14780,,QWHMMEKTFNJGTI-GNBMGSNXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,IC50,=,3460,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain incubated for 20 mins by fluorimetric assay,,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827436,DTCT0024844,10535413,DTCC01243476,1041021,48665
CHEMBL2048506,P14780,,QWHMMEKTFNJGTI-GNBMGSNXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,INHIBITION,>,30,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain at 10 uM incubated for 20 mins by fluorimetric assay,,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827442,DTCT0024844,10535514,DTCC01243476,1041021,48665
CHEMBL2048507,P14780,DAPHNODORIN F,KVPJDVHJFGPPAB-XOHQIPOJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,IC50,=,21240,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain incubated for 20 mins by fluorimetric assay,,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827436,DTCT0024844,10535417,DTCC01243477,2071373,48665
CHEMBL2048507,P14780,DAPHNODORIN F,KVPJDVHJFGPPAB-XOHQIPOJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,INHIBITION,>,30,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain at 10 uM incubated for 20 mins by fluorimetric assay,,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827442,DTCT0024844,10535518,DTCC01243477,2071373,48665
CHEMBL2048508,P14780,"(2R,3S)-DIHYDROMYRICETIN",KJXSIXMJHKAJOD-HUUCEWRRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,IC50,=,28790,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain incubated for 20 mins by fluorimetric assay,,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827436,DTCT0024844,10535419,DTCC00042059,362498,48665
CHEMBL2048508,P14780,"(2R,3S)-DIHYDROMYRICETIN",KJXSIXMJHKAJOD-HUUCEWRRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,INHIBITION,>,30,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain at 10 uM incubated for 20 mins by fluorimetric assay,,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827442,DTCT0024844,10535520,DTCC00042059,362498,48665
CHEMBL2048509,P14780,,FYEZJIXULOZDRT-ARJAWSKDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,IC50,=,9910,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain incubated for 20 mins by fluorimetric assay,,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827436,DTCT0024844,10535423,DTCC01243478,717883,48665
CHEMBL2048509,P14780,,FYEZJIXULOZDRT-ARJAWSKDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,INHIBITION,>,30,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain at 10 uM incubated for 20 mins by fluorimetric assay,,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827442,DTCT0024844,10535522,DTCC01243478,717883,48665
CHEMBL2048510,P14780,,DXXGHDAWCPTRPU-XOSAIJSUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,IC50,,,,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain incubated for 20 mins by fluorimetric assay,Not Determined,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827436,DTCT0024844,10535424,DTCC01243479,556512,48665
CHEMBL2048511,P14780,ALPHA-ISOVALEROXYISOVALERIC ACID,SOJFCTIYHPWXGZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,IC50,=,14280,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain incubated for 20 mins by fluorimetric assay,,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827436,DTCT0024844,10535426,DTCC00042060,264062,48665
CHEMBL2048511,P14780,ALPHA-ISOVALEROXYISOVALERIC ACID,SOJFCTIYHPWXGZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,INHIBITION,>,30,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain at 10 uM incubated for 20 mins by fluorimetric assay,,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827442,DTCT0024844,10535523,DTCC00042060,264062,48665
CHEMBL2048512,P14780,,FQRZOEBSTPAQBJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,IC50,,,,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain incubated for 20 mins by fluorimetric assay,Not Determined,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827436,DTCT0024844,10535428,DTCC01243480,1812174,48665
CHEMBL204987,P14780,,FAMUHUCWJMEIBQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16632358,IC50,=,1.4,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,12,"Zhang YM, Fan X, Xiang B, Chakravarty D, Scannevin R, Burke S, Karnachi P, Rhodes K, Jackson P",,361727,DTCT0024844,1937027,DTCC00422957,1165882,20885
CHEMBL205290,P14780,,VRUYZVHIDJWWTM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16516466,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.",Bioorg. Med. Chem. Lett.,2006,16,10,"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,354461,DTCT0024844,1926501,DTCC00421634,617113,20786
CHEMBL205523,P14780,,HBYOIHRPSQTDLO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16516466,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.",Bioorg. Med. Chem. Lett.,2006,16,10,"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,354461,DTCT0024844,1926520,DTCC00422036,1361292,20786
CHEMBL205596,P14780,CHOLIC ACID,BHQCQFFYRZLCQQ-OELDTZBJSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7360339,DTCC00419527,1027049,46191
CHEMBL205596,P14780,CHOLIC ACID,BHQCQFFYRZLCQQ-OELDTZBJSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7360340,DTCC00419527,1027049,46191
CHEMBL205900,P14780,,XNQVZVNWVMQCPC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16516466,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.",Bioorg. Med. Chem. Lett.,2006,16,10,"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,354461,DTCT0024844,1926514,DTCC00422242,778397,20786
CHEMBL206045,P14780,,IAFQRNRIALQQBK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16632358,IC50,=,25,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,12,"Zhang YM, Fan X, Xiang B, Chakravarty D, Scannevin R, Burke S, Karnachi P, Rhodes K, Jackson P",,361727,DTCT0024844,1937019,DTCC00422970,520536,20885
CHEMBL206254,P14780,,DJBJEUJDVZJUDS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16516466,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.",Bioorg. Med. Chem. Lett.,2006,16,10,"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,354461,DTCT0024844,1926504,DTCC00422256,1652037,20786
CHEMBL2062755,P14780,,MZRQRBAXYNSSEV-GDNBJRDFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18221310,IC50,=,100000,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14714269,DTCC01247043,2099572,67810
CHEMBL2063270,P14780,,CXKWJJJVWDMSAG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,44,NM,,,,,,,,,,,,,,Competitive inhibition of human MMP9 using fluorogenic substrate by Dixon plot analysis,,,ACS Med. Chem. Lett.,2012,3,6,,,831079,DTCT0024844,10566535,DTCC01247512,186720,48923
CHEMBL2063271,P14780,,LEBLJISYPUWAJY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,3000,NM,,,,,,,,,,,,,,Competitive inhibition of human MMP9 using fluorogenic substrate by Dixon plot analysis,,,ACS Med. Chem. Lett.,2012,3,6,,,831079,DTCT0024844,10566536,DTCC01247513,2090921,48923
CHEMBL2063272,P14780,,KUWJZFVZZLSOHK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,290,NM,,,,,,,,,,,,,,Competitive inhibition of human MMP9 using fluorogenic substrate by Dixon plot analysis,,,ACS Med. Chem. Lett.,2012,3,6,,,831079,DTCT0024844,10566537,DTCC01247514,1896167,48923
CHEMBL2063273,P14780,,BGRGANYQQMRQLM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,390,NM,,,,,,,,,,,,,,Competitive inhibition of human MMP9 using fluorogenic substrate by Dixon plot analysis,,,ACS Med. Chem. Lett.,2012,3,6,,,831079,DTCT0024844,10566538,DTCC01247515,316901,48923
CHEMBL2063274,P14780,,AHDPJKYOQXMDIX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,160,NM,,,,,,,,,,,,,,Competitive inhibition of human MMP9 using fluorogenic substrate by Dixon plot analysis,,,ACS Med. Chem. Lett.,2012,3,6,,,831079,DTCT0024844,10566539,DTCC01247516,834451,48923
CHEMBL2063275,P14780,,GPZUWAHQDYJABE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,470,NM,,,,,,,,,,,,,,Competitive inhibition of human MMP9 using fluorogenic substrate by Dixon plot analysis,,,ACS Med. Chem. Lett.,2012,3,6,,,831079,DTCT0024844,10566540,DTCC01247517,1546082,48923
CHEMBL2063276,P14780,,STSMSPOAFPZOFC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,160,NM,,,,,,,,,,,,,,Competitive inhibition of human MMP9 using fluorogenic substrate by Dixon plot analysis,,,ACS Med. Chem. Lett.,2012,3,6,,,831079,DTCT0024844,10566541,DTCC01247518,349672,48923
CHEMBL2063277,P14780,,RMRUTHBBMQENKJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,930,NM,,,,,,,,,,,,,,Competitive inhibition of human MMP9 using fluorogenic substrate by Dixon plot analysis,,,ACS Med. Chem. Lett.,2012,3,6,,,831079,DTCT0024844,10566543,DTCC01247519,543747,48923
CHEMBL2063424,P14780,,UFSIAJGUBRRIFP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22248361,IC50,=,91,NM,,,,,,,,,,,,,,"Inhibition of p-aminophenylmercuric acetate stimulated human recombinant MMP-9 using (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 as substrate after 45 mins by fluorogenic assay",,Design of barbiturate-nitrate hybrids that inhibit MMP-9 activity and secretion.,J. Med. Chem.,2012,55,5,"Wang J, O'Sullivan S, Harmon S, Keaveny R, Radomski MW, Medina C, Gilmer JF",,832804,DTCT0024844,10550755,DTCC01247667,931314,48933
CHEMBL2063425,P14780,,RFSACISSBFAKAJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22248361,IC50,=,47.58,NM,,,,,,,,,,,,,,"Inhibition of p-aminophenylmercuric acetate stimulated human recombinant MMP-9 using (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 as substrate after 45 mins by fluorogenic assay",,Design of barbiturate-nitrate hybrids that inhibit MMP-9 activity and secretion.,J. Med. Chem.,2012,55,5,"Wang J, O'Sullivan S, Harmon S, Keaveny R, Radomski MW, Medina C, Gilmer JF",,832804,DTCT0024844,10550754,DTCC01247668,705155,48933
CHEMBL2063426,P14780,,GBVUVWPIAISPTQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22248361,IC50,=,92,NM,,,,,,,,,,,,,,"Inhibition of p-aminophenylmercuric acetate stimulated human recombinant MMP-9 using (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 as substrate after 45 mins by fluorogenic assay",,Design of barbiturate-nitrate hybrids that inhibit MMP-9 activity and secretion.,J. Med. Chem.,2012,55,5,"Wang J, O'Sullivan S, Harmon S, Keaveny R, Radomski MW, Medina C, Gilmer JF",,832804,DTCT0024844,10550753,DTCC01247669,316905,48933
CHEMBL2063427,P14780,,SOYSLGSCAATJQA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22248361,IC50,=,152,NM,,,,,,,,,,,,,,"Inhibition of p-aminophenylmercuric acetate stimulated human recombinant MMP-9 using (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 as substrate after 45 mins by fluorogenic assay",,Design of barbiturate-nitrate hybrids that inhibit MMP-9 activity and secretion.,J. Med. Chem.,2012,55,5,"Wang J, O'Sullivan S, Harmon S, Keaveny R, Radomski MW, Medina C, Gilmer JF",,832804,DTCT0024844,10550752,DTCC01247670,1156905,48933
CHEMBL2063428,P14780,,SQFVCIISKZFYEN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22248361,IC50,=,212,NM,,,,,,,,,,,,,,"Inhibition of p-aminophenylmercuric acetate stimulated human recombinant MMP-9 using (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 as substrate after 45 mins by fluorogenic assay",,Design of barbiturate-nitrate hybrids that inhibit MMP-9 activity and secretion.,J. Med. Chem.,2012,55,5,"Wang J, O'Sullivan S, Harmon S, Keaveny R, Radomski MW, Medina C, Gilmer JF",,832804,DTCT0024844,10550751,DTCC01247671,575813,48933
CHEMBL2063429,P14780,,BTTWODSMIQJXGA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22248361,IC50,=,104,NM,,,,,,,,,,,,,,"Inhibition of p-aminophenylmercuric acetate stimulated human recombinant MMP-9 using (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 as substrate after 45 mins by fluorogenic assay",,Design of barbiturate-nitrate hybrids that inhibit MMP-9 activity and secretion.,J. Med. Chem.,2012,55,5,"Wang J, O'Sullivan S, Harmon S, Keaveny R, Radomski MW, Medina C, Gilmer JF",,832804,DTCT0024844,10550750,DTCC01247672,1578216,48933
CHEMBL2063430,P14780,,NVBXFVBQTBCCGL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22248361,IC50,=,26,NM,,,,,,,,,,,,,,"Inhibition of p-aminophenylmercuric acetate stimulated human recombinant MMP-9 using (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 as substrate after 45 mins by fluorogenic assay",,Design of barbiturate-nitrate hybrids that inhibit MMP-9 activity and secretion.,J. Med. Chem.,2012,55,5,"Wang J, O'Sullivan S, Harmon S, Keaveny R, Radomski MW, Medina C, Gilmer JF",,832804,DTCT0024844,10550749,DTCC01247673,186722,48933
CHEMBL2063431,P14780,,AXYQUZFSLFKHHC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22248361,IC50,=,145,NM,,,,,,,,,,,,,,"Inhibition of p-aminophenylmercuric acetate stimulated human recombinant MMP-9 using (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 as substrate after 45 mins by fluorogenic assay",,Design of barbiturate-nitrate hybrids that inhibit MMP-9 activity and secretion.,J. Med. Chem.,2012,55,5,"Wang J, O'Sullivan S, Harmon S, Keaveny R, Radomski MW, Medina C, Gilmer JF",,832804,DTCT0024844,10550748,DTCC01247674,1221473,48933
CHEMBL2063432,P14780,,JHWSWPBPMTVCRT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22248361,IC50,=,8.1,NM,,,,,,,,,,,,,,"Inhibition of p-aminophenylmercuric acetate stimulated human recombinant MMP-9 using (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 as substrate after 45 mins by fluorogenic assay",,Design of barbiturate-nitrate hybrids that inhibit MMP-9 activity and secretion.,J. Med. Chem.,2012,55,5,"Wang J, O'Sullivan S, Harmon S, Keaveny R, Radomski MW, Medina C, Gilmer JF",,832804,DTCT0024844,10550747,DTCC01247675,1643031,48933
CHEMBL2063433,P14780,,RIMRTAIVLQRBJS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22248361,IC50,=,12,NM,,,,,,,,,,,,,,"Inhibition of p-aminophenylmercuric acetate stimulated human recombinant MMP-9 using (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 as substrate after 45 mins by fluorogenic assay",,Design of barbiturate-nitrate hybrids that inhibit MMP-9 activity and secretion.,J. Med. Chem.,2012,55,5,"Wang J, O'Sullivan S, Harmon S, Keaveny R, Radomski MW, Medina C, Gilmer JF",,832804,DTCT0024844,10550746,DTCC01247676,154722,48933
CHEMBL2063517,P14780,,MBENXCXDGKNNSS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22248361,IC50,=,97,NM,,,,,,,,,,,,,,"Inhibition of p-aminophenylmercuric acetate stimulated human recombinant MMP-9 using (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 as substrate after 45 mins by fluorogenic assay",,Design of barbiturate-nitrate hybrids that inhibit MMP-9 activity and secretion.,J. Med. Chem.,2012,55,5,"Wang J, O'Sullivan S, Harmon S, Keaveny R, Radomski MW, Medina C, Gilmer JF",,832804,DTCT0024844,10550745,DTCC01247745,1449090,48933
CHEMBL2063518,P14780,,GJZJWROSQYQKJO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22248361,IC50,=,6.2,NM,,,,,,,,,,,,,,"Inhibition of p-aminophenylmercuric acetate stimulated human recombinant MMP-9 using (7-methoxycoumarin-4-yl)-acetyl-pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)-Ala-Arg-NH2 as substrate after 45 mins by fluorogenic assay",,Design of barbiturate-nitrate hybrids that inhibit MMP-9 activity and secretion.,J. Med. Chem.,2012,55,5,"Wang J, O'Sullivan S, Harmon S, Keaveny R, Radomski MW, Medina C, Gilmer JF",,832804,DTCT0024844,10550744,DTCC01247746,1961262,48933
CHEMBL2064540,P14780,,GKLOCXVNLLEZMX-DIPNUNPCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22540974,IC50,=,5,NM,,,,,,,,,,,,,,"Inhibition of MMP9 using (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured for 10 mins by fluorometry",,A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation.,J. Med. Chem.,2012,55,10,"Hugenberg V, Breyholz HJ, Riemann B, Hermann S, Schober O, Schäfers M, Gangadharmath U, Mocharla V, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,832927,DTCT0024844,10563944,DTCC01248689,284246,48958
CHEMBL2064541,P14780,,GDXZUNJRYLVZAT-WJOKGBTCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22540974,IC50,=,0.6,NM,,,,,,,,,,,,,,"Inhibition of MMP9 using (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured for 10 mins by fluorometry",,A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation.,J. Med. Chem.,2012,55,10,"Hugenberg V, Breyholz HJ, Riemann B, Hermann S, Schober O, Schäfers M, Gangadharmath U, Mocharla V, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,832927,DTCT0024844,10563943,DTCC01248690,1254587,48958
CHEMBL2064542,P14780,,YDSGUUACYYBPLW-GDLZYMKVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22540974,IC50,=,0.37,NM,,,,,,,,,,,,,,"Inhibition of MMP9 using (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured for 10 mins by fluorometry",,A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation.,J. Med. Chem.,2012,55,10,"Hugenberg V, Breyholz HJ, Riemann B, Hermann S, Schober O, Schäfers M, Gangadharmath U, Mocharla V, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,832927,DTCT0024844,10563942,DTCC01248691,1028287,48958
CHEMBL2064543,P14780,,HBDUXNUNXGZOCK-VLIRCAPWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22540974,IC50,=,43,NM,,,,,,,,,,,,,,"Inhibition of MMP9 using (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured for 10 mins by fluorometry",,A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation.,J. Med. Chem.,2012,55,10,"Hugenberg V, Breyholz HJ, Riemann B, Hermann S, Schober O, Schäfers M, Gangadharmath U, Mocharla V, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,832927,DTCT0024844,10563945,DTCC01248692,316917,48958
CHEMBL2064544,P14780,,JZHHNBACJYFNCE-LDLOPFEMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22540974,IC50,=,3,NM,,,,,,,,,,,,,,"Inhibition of MMP9 using (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured for 10 mins by fluorometry",,A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation.,J. Med. Chem.,2012,55,10,"Hugenberg V, Breyholz HJ, Riemann B, Hermann S, Schober O, Schäfers M, Gangadharmath U, Mocharla V, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,832927,DTCT0024844,10563946,DTCC01248693,543756,48958
CHEMBL2064545,P14780,,JLXRKMSJFVPFIG-CQSZACIVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22540974,IC50,=,2,NM,,,,,,,,,,,,,,"Inhibition of MMP9 using (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured for 10 mins by fluorometry",,A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation.,J. Med. Chem.,2012,55,10,"Hugenberg V, Breyholz HJ, Riemann B, Hermann S, Schober O, Schäfers M, Gangadharmath U, Mocharla V, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,832927,DTCT0024844,10563947,DTCC01248694,1707024,48958
CHEMBL2064546,P14780,,ANZWBBMLNAIBAB-HSZRJFAPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22540974,IC50,=,7,NM,,,,,,,,,,,,,,"Inhibition of MMP9 using (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured for 10 mins by fluorometry",,A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation.,J. Med. Chem.,2012,55,10,"Hugenberg V, Breyholz HJ, Riemann B, Hermann S, Schober O, Schäfers M, Gangadharmath U, Mocharla V, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,832927,DTCT0024844,10563948,DTCC01248695,186735,48958
CHEMBL2064547,P14780,,LOPZANGJCBIBLO-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22540974,IC50,=,0.03,NM,,,,,,,,,,,,,,"Inhibition of MMP9 using (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured for 10 mins by fluorometry",,A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation.,J. Med. Chem.,2012,55,10,"Hugenberg V, Breyholz HJ, Riemann B, Hermann S, Schober O, Schäfers M, Gangadharmath U, Mocharla V, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,832927,DTCT0024844,10563949,DTCC01248696,382253,48958
CHEMBL2064548,P14780,,FGQWFLDBWZDRJJ-GDLZYMKVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22540974,IC50,=,0.06,NM,,,,,,,,,,,,,,"Inhibition of MMP9 using (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured for 10 mins by fluorometry",,A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation.,J. Med. Chem.,2012,55,10,"Hugenberg V, Breyholz HJ, Riemann B, Hermann S, Schober O, Schäfers M, Gangadharmath U, Mocharla V, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,832927,DTCT0024844,10563950,DTCC01248697,1319659,48958
CHEMBL2064549,P14780,,NRRIJAHIBBGLNH-JOCHJYFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22540974,IC50,=,0.05,NM,,,,,,,,,,,,,,"Inhibition of MMP9 using (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured for 10 mins by fluorometry",,A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation.,J. Med. Chem.,2012,55,10,"Hugenberg V, Breyholz HJ, Riemann B, Hermann S, Schober O, Schäfers M, Gangadharmath U, Mocharla V, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,832927,DTCT0024844,10563951,DTCC01248698,1767171,48958
CHEMBL2064550,P14780,,UMBBJTOZRJURJL-JOCHJYFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22540974,IC50,=,0.9,NM,,,,,,,,,,,,,,"Inhibition of MMP9 using (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured for 10 mins by fluorometry",,A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation.,J. Med. Chem.,2012,55,10,"Hugenberg V, Breyholz HJ, Riemann B, Hermann S, Schober O, Schäfers M, Gangadharmath U, Mocharla V, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,832927,DTCT0024844,10563952,DTCC01248699,1449098,48958
CHEMBL2064551,P14780,,JXMJSOSLBMBYGM-AREMUKBSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22540974,IC50,=,4,NM,,,,,,,,,,,,,,"Inhibition of MMP9 using (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured for 10 mins by fluorometry",,A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation.,J. Med. Chem.,2012,55,10,"Hugenberg V, Breyholz HJ, Riemann B, Hermann S, Schober O, Schäfers M, Gangadharmath U, Mocharla V, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,832927,DTCT0024844,10563953,DTCC01248700,316918,48958
CHEMBL2064552,P14780,,TUYLXABAVZEOSZ-WGVHSKNFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22540974,IC50,=,0.6,NM,,,,,,,,,,,,,,"Inhibition of MMP9 using (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured for 10 mins by fluorometry",,A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation.,J. Med. Chem.,2012,55,10,"Hugenberg V, Breyholz HJ, Riemann B, Hermann S, Schober O, Schäfers M, Gangadharmath U, Mocharla V, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,832927,DTCT0024844,10563954,DTCC01248701,769661,48958
CHEMBL2064553,P14780,,YWHKQQSHVPCBRN-LQFQNGICSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22540974,IC50,>,100000,NM,,,,,,,,,,,,,,"Inhibition of MMP9 using (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured for 10 mins by fluorometry",,A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation.,J. Med. Chem.,2012,55,10,"Hugenberg V, Breyholz HJ, Riemann B, Hermann S, Schober O, Schäfers M, Gangadharmath U, Mocharla V, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,832927,DTCT0024844,10563955,DTCC01248702,1319660,48958
CHEMBL206694,P14780,,QRNDNIUBUODBRF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16632358,IC50,=,120,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,12,"Zhang YM, Fan X, Xiang B, Chakravarty D, Scannevin R, Burke S, Karnachi P, Rhodes K, Jackson P",,361727,DTCT0024844,1937029,DTCC00422951,1905161,20885
CHEMBL2068237,P14780,CISPLATIN,,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7349875,DTCC01249018,51458,46191
CHEMBL2068237,P14780,CISPLATIN,,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7349876,DTCC01249018,51458,46191
CHEMBL206944,P14780,,BRPNMBTUBIMOLD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16632358,IC50,=,4.4,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,12,"Zhang YM, Fan X, Xiang B, Chakravarty D, Scannevin R, Burke S, Karnachi P, Rhodes K, Jackson P",,361727,DTCT0024844,1937039,DTCC00110339,2035841,20885
CHEMBL206993,P14780,,OVSGONSKJHXDJO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16516466,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.",Bioorg. Med. Chem. Lett.,2006,16,10,"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,354461,DTCT0024844,1926507,DTCC00422065,940295,20786
CHEMBL207018,P14780,,MCNQDQIVWJTIBW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16516466,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.",Bioorg. Med. Chem. Lett.,2006,16,10,"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,354461,DTCT0024844,1926511,DTCC00421714,260143,20786
CHEMBL207026,P14780,,MIBJKVVEWJVVMR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16632358,IC50,=,5.1,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,12,"Zhang YM, Fan X, Xiang B, Chakravarty D, Scannevin R, Burke S, Karnachi P, Rhodes K, Jackson P",,361727,DTCT0024844,1937022,DTCC00423331,1522847,20885
CHEMBL207075,P14780,,FAKDVMIECOUVIL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16516466,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.",Bioorg. Med. Chem. Lett.,2006,16,10,"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,354461,DTCT0024844,1926517,DTCC00422051,1840834,20786
CHEMBL207180,P14780,,MIUWEXKKKWGHOC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16516466,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.",Bioorg. Med. Chem. Lett.,2006,16,10,"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,354461,DTCT0024844,1926519,DTCC00422044,972339,20786
CHEMBL207242,P14780,,HCCXAZUXAREIQT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16632358,IC50,=,23,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,12,"Zhang YM, Fan X, Xiang B, Chakravarty D, Scannevin R, Burke S, Karnachi P, Rhodes K, Jackson P",,361727,DTCT0024844,1937031,DTCC00423351,1198385,20885
CHEMBL207305,P14780,,NUVSGXIVCJBRBF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16516466,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.",Bioorg. Med. Chem. Lett.,2006,16,10,"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,354461,DTCT0024844,1926502,DTCC00421580,552632,20786
CHEMBL207305,P14780,,NUVSGXIVCJBRBF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2457276,DTCC00421580,565360,32556
CHEMBL207415,P14780,,ZTSCXJSYCOZWKZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16516466,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.",Bioorg. Med. Chem. Lett.,2006,16,10,"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,354461,DTCT0024844,1926503,DTCC00422266,876063,20786
CHEMBL207468,P14780,,RBUVXLALMRWKQA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16516466,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.",Bioorg. Med. Chem. Lett.,2006,16,10,"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,354461,DTCT0024844,1926522,DTCC00110329,227887,20786
CHEMBL207683,P14780,,NHMWZOLCOOIQJX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16516466,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.",Bioorg. Med. Chem. Lett.,2006,16,10,"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,354461,DTCT0024844,1926505,DTCC00422250,1165868,20786
CHEMBL207709,P14780,,ALAICNBWAOLDPL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16516466,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.",Bioorg. Med. Chem. Lett.,2006,16,10,"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,354461,DTCT0024844,1926518,DTCC00422046,1295959,20786
CHEMBL207726,P14780,,CBKSKDVWCOUHEC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16516466,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.",Bioorg. Med. Chem. Lett.,2006,16,10,"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,354461,DTCT0024844,1926508,DTCC00421740,2035826,20786
CHEMBL207729,P14780,,CVZIHNYAZLXRRS-HNNXBMFYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14718605,IC50,=,12,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14717450,DTCC00110220,2101028,69108
CHEMBL2079587,P14780,STANOZOLOL,LKAJKIOFIWVMDJ-IYRCEVNGSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7469357,DTCC01253362,930087,46191
CHEMBL2079587,P14780,STANOZOLOL,LKAJKIOFIWVMDJ-IYRCEVNGSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7469358,DTCC01253362,930087,46191
CHEMBL207999,P14780,,FQARNXJHFBTHOY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16516466,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.",Bioorg. Med. Chem. Lett.,2006,16,10,"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,354461,DTCT0024844,1926506,DTCC00422073,1004906,20786
CHEMBL208009,P14780,,BODLESUVCQEUII-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16516466,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.",Bioorg. Med. Chem. Lett.,2006,16,10,"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,354461,DTCT0024844,1926524,DTCC00421655,1037257,20786
CHEMBL208022,P14780,,ADROOOBIKREWPX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16516466,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.",Bioorg. Med. Chem. Lett.,2006,16,10,"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,354461,DTCT0024844,1926521,DTCC00421838,260142,20786
CHEMBL208136,P14780,,ORZIBOAGVYKRKN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16632358,IC50,=,258,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,12,"Zhang YM, Fan X, Xiang B, Chakravarty D, Scannevin R, Burke S, Karnachi P, Rhodes K, Jackson P",,361727,DTCT0024844,1937030,DTCC00423360,714019,20885
CHEMBL208172,P14780,,CTANAKVMPKAIQD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16516466,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.",Bioorg. Med. Chem. Lett.,2006,16,10,"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,354461,DTCT0024844,1926512,DTCC00421845,552631,20786
CHEMBL208287,P14780,,XIADLDSNTKDSQZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16632358,IC50,=,96.5,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,12,"Zhang YM, Fan X, Xiang B, Chakravarty D, Scannevin R, Burke S, Karnachi P, Rhodes K, Jackson P",,361727,DTCT0024844,1937042,DTCC00423345,326038,20885
CHEMBL208548,P14780,,XOZSROHJXDJOTN-NXSKXAQUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19161308,ACTIVITY,,,,,,,,,,,,,,,,,Stimulation of MMP9 activity in HUVEC assessed as increase in enzyme activity at 10 nM relative to control,Not Active,Total synthesis of photoactivatable or fluorescent anandamide probes: novel bioactive compounds with angiogenic activity.,J. Med. Chem.,2009,52,4,"Balas L, Durand T, Saha S, Johnson I, Mukhopadhyay S",,494403,DTCT0024844,2595852,DTCC00427081,132090,32132
CHEMBL208548,P14780,,XOZSROHJXDJOTN-NXSKXAQUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19161308,ACTIVITY,,,,,,,,,,,,,,,,,Stimulation of MMP9 activity in HUVEC assessed as increase in enzyme activity at 100 nM relative to control,Not Active,Total synthesis of photoactivatable or fluorescent anandamide probes: novel bioactive compounds with angiogenic activity.,J. Med. Chem.,2009,52,4,"Balas L, Durand T, Saha S, Johnson I, Mukhopadhyay S",,494405,DTCT0024844,2595856,DTCC00427081,132090,32132
CHEMBL208548,P14780,,XOZSROHJXDJOTN-NXSKXAQUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19161308,ACTIVITY,,,,,,,,,,,,,,,,,Stimulation of MMP9 activity in HUVEC assessed as increase in enzyme activity at 1 uM relative to control,Not Active,Total synthesis of photoactivatable or fluorescent anandamide probes: novel bioactive compounds with angiogenic activity.,J. Med. Chem.,2009,52,4,"Balas L, Durand T, Saha S, Johnson I, Mukhopadhyay S",,494407,DTCT0024844,2595860,DTCC00427081,132090,32132
CHEMBL208548,P14780,,XOZSROHJXDJOTN-NXSKXAQUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19161308,ACTIVITY,,,,,,,,,,,,,,,,,Stimulation of MMP9 activity in CB1 receptor knockout HUVEC assessed as increase in enzyme activity at 10 nM relative to control,Not Active,Total synthesis of photoactivatable or fluorescent anandamide probes: novel bioactive compounds with angiogenic activity.,J. Med. Chem.,2009,52,4,"Balas L, Durand T, Saha S, Johnson I, Mukhopadhyay S",,494409,DTCT0024844,2595864,DTCC00427081,132090,32132
CHEMBL208548,P14780,,XOZSROHJXDJOTN-NXSKXAQUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19161308,ACTIVITY,,,,,,,,,,,,,,,,,Stimulation of MMP9 activity in CB1 receptor knockout HUVEC assessed as increase in enzyme activity at 100 nM relative to control,Not Active,Total synthesis of photoactivatable or fluorescent anandamide probes: novel bioactive compounds with angiogenic activity.,J. Med. Chem.,2009,52,4,"Balas L, Durand T, Saha S, Johnson I, Mukhopadhyay S",,494411,DTCT0024844,2595868,DTCC00427081,132090,32132
CHEMBL208548,P14780,,XOZSROHJXDJOTN-NXSKXAQUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19161308,ACTIVITY,,,,,,,,,,,,,,,,,Stimulation of MMP9 activity in CB1 receptor knockout HUVEC assessed as increase in enzyme activity at 1 uM relative to control,Not Active,Total synthesis of photoactivatable or fluorescent anandamide probes: novel bioactive compounds with angiogenic activity.,J. Med. Chem.,2009,52,4,"Balas L, Durand T, Saha S, Johnson I, Mukhopadhyay S",,494598,DTCT0024844,2595872,DTCC00427081,132090,32132
CHEMBL208548,P14780,,XOZSROHJXDJOTN-NXSKXAQUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19161308,ACTIVITY,,,,,,,,,,,,,,,,,Stimulation of MMP9 activity in CB1 receptor knockout HUVEC assessed as increase in enzyme activity in presence of 1 uM anandamide receptor antagonist O-1918 relative to control,Not Active,Total synthesis of photoactivatable or fluorescent anandamide probes: novel bioactive compounds with angiogenic activity.,J. Med. Chem.,2009,52,4,"Balas L, Durand T, Saha S, Johnson I, Mukhopadhyay S",,494600,DTCT0024844,2595876,DTCC00427081,132090,32132
CHEMBL208615,P14780,,NJXYRSYNXFYWJX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16632358,IC50,=,22,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,12,"Zhang YM, Fan X, Xiang B, Chakravarty D, Scannevin R, Burke S, Karnachi P, Rhodes K, Jackson P",,361727,DTCT0024844,1937023,DTCC00423326,1840844,20885
CHEMBL208749,P14780,,NXLDFFHMRBRNMF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16632358,IC50,=,20,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,12,"Zhang YM, Fan X, Xiang B, Chakravarty D, Scannevin R, Burke S, Karnachi P, Rhodes K, Jackson P",,361727,DTCT0024844,1937033,DTCC00423320,714018,20885
CHEMBL20883,P14780,TEGAFUR,WFWLQNSHRPWKFK-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7476457,DTCC00152531,1027060,46191
CHEMBL20883,P14780,TEGAFUR,WFWLQNSHRPWKFK-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7476458,DTCC00152531,1027060,46191
CHEMBL208841,P14780,,BNKOGVVBAYMLMZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16723229,IC50,=,879,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,15,"Park K, Aplasca A, Du MT, Sun L, Zhu Y, Zhang Y, Levin JI",,377987,DTCT0024844,1969686,DTCC00428615,2067649,21111
CHEMBL2088987,P14780,,UBEZABQQAQIAHU-CXAGYDPISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,900,NM,,,,,,,,,,,,,,Inhibition MMP-9 (unknown origin) using Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 5 mins followed by substrate addition measured for 30 mins by fluorometric assay,,,MedChemComm,2015,6,2,,,1527166,DTCT0024844,14586906,DTCC01255821,386875,64111
CHEMBL2088987,P14780,,UBEZABQQAQIAHU-CXAGYDPISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION,=,97,%,,,,,,,,,,,,,,Inhibition MMP-9 (unknown origin) using Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate at 5 uM preincubated for 5 mins followed by substrate addition measured for 30 mins by fluorometric assay,,,MedChemComm,2015,6,2,,,1527164,DTCT0024844,14586888,DTCC01255821,386875,64111
CHEMBL2088988,P14780,,UBEZABQQAQIAHU-SUMWQHHRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION,=,37,%,,,,,,,,,,,,,,Inhibition MMP-9 (unknown origin) using Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate at 5 uM preincubated for 5 mins followed by substrate addition measured for 30 mins by fluorometric assay,,,MedChemComm,2015,6,2,,,1527164,DTCT0024844,14586889,DTCC01255822,159372,64111
CHEMBL2088989,P14780,,ZQYRDNFYQHYIPA-FZKQIMNGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION,=,83,%,,,,,,,,,,,,,,Inhibition MMP-9 (unknown origin) using Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate at 5 uM preincubated for 5 mins followed by substrate addition measured for 30 mins by fluorometric assay,,,MedChemComm,2015,6,2,,,1527164,DTCT0024844,14586883,DTCC01255823,1130243,64111
CHEMBL2088990,P14780,,UCTXPISEYKNHPX-APPDUMDISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,1710,NM,,,,,,,,,,,,,,Inhibition MMP-9 (unknown origin) using Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 5 mins followed by substrate addition measured for 30 mins by fluorometric assay,,,MedChemComm,2015,6,2,,,1527166,DTCT0024844,14586899,DTCC01255824,839224,64111
CHEMBL2088990,P14780,,UCTXPISEYKNHPX-APPDUMDISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION,=,54,%,,,,,,,,,,,,,,Inhibition MMP-9 (unknown origin) using Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate at 5 uM preincubated for 5 mins followed by substrate addition measured for 30 mins by fluorometric assay,,,MedChemComm,2015,6,2,,,1527164,DTCT0024844,14586880,DTCC01255824,839224,64111
CHEMBL2088991,P14780,,UCTXPISEYKNHPX-PIGZYNQJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,560,NM,,,,,,,,,,,,,,Inhibition MMP-9 (unknown origin) using Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 5 mins followed by substrate addition measured for 30 mins by fluorometric assay,,,MedChemComm,2015,6,2,,,1527166,DTCT0024844,14586898,DTCC01255825,321564,64111
CHEMBL2088991,P14780,,UCTXPISEYKNHPX-PIGZYNQJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION,=,94,%,,,,,,,,,,,,,,Inhibition MMP-9 (unknown origin) using Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate at 5 uM preincubated for 5 mins followed by substrate addition measured for 30 mins by fluorometric assay,,,MedChemComm,2015,6,2,,,1527164,DTCT0024844,14586879,DTCC01255825,321564,64111
CHEMBL2088991,P14780,,UCTXPISEYKNHPX-PIGZYNQJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of gelatinolytic activity of pro-MMP9 in human endothelial progenitor cells assessed as reduction in active form of protein at 20 uM by gelatin zymography,Active,,MedChemComm,2015,6,2,,,1527285,DTCT0024844,14586918,DTCC01255825,321564,64111
CHEMBL2088991,P14780,,UCTXPISEYKNHPX-PIGZYNQJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION,,,,,cell_based,,,,,,,,,,,,Inhibition of gelatinolytic activity of pro-MMP9 in human A375P cells assessed as reduction in active form of protein at 20 uM by gelatin zymography,Active,,MedChemComm,2015,6,2,,,1527168,DTCT0024844,14586908,DTCC01255825,321564,64111
CHEMBL2088991,P14780,,UCTXPISEYKNHPX-PIGZYNQJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION,,,,,cell_based,,,,,,,,,,,,Inhibition of gelatinolytic activity of pro-MMP9 in human A375P cells assessed as reduction in active form of protein by gelatin zymography,Dose-dependent effect,,MedChemComm,2015,6,2,,,1527279,DTCT0024844,14586912,DTCC01255825,321564,64111
CHEMBL2088992,P14780,,KSMJBRDXKNNSIK-TVQRCGJNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,,,,,,,,,,,,,Inhibition MMP-9 (unknown origin) using Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 5 mins followed by substrate addition measured for 30 mins by fluorometric assay,Not Active,,MedChemComm,2015,6,2,,,1527166,DTCT0024844,14586901,DTCC01255826,839225,64111
CHEMBL2088992,P14780,,KSMJBRDXKNNSIK-TVQRCGJNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION,,,,,,,,,,,,,,,,,Inhibition MMP-9 (unknown origin) using Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate at 5 uM preincubated for 5 mins followed by substrate addition measured for 30 mins by fluorometric assay,Not Active,,MedChemComm,2015,6,2,,,1527164,DTCT0024844,14586882,DTCC01255826,839225,64111
CHEMBL2088993,P14780,,KSMJBRDXKNNSIK-NOZJJQNGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,100,NM,,,,,,,,,,,,,,Inhibition MMP-9 (unknown origin) using Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 5 mins followed by substrate addition measured for 30 mins by fluorometric assay,,,MedChemComm,2015,6,2,,,1527166,DTCT0024844,14586900,DTCC01255827,255773,64111
CHEMBL2088993,P14780,,KSMJBRDXKNNSIK-NOZJJQNGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION,=,95,%,,,,,,,,,,,,,,Inhibition MMP-9 (unknown origin) using Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate at 5 uM preincubated for 5 mins followed by substrate addition measured for 30 mins by fluorometric assay,,,MedChemComm,2015,6,2,,,1527164,DTCT0024844,14586881,DTCC01255827,255773,64111
CHEMBL2088993,P14780,,KSMJBRDXKNNSIK-NOZJJQNGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION,,,,,cell_based,,,,,,,,,,,,Inhibition of gelatinolytic activity of pro-MMP9 in human A375P cells assessed as reduction in active form of protein at 20 uM by gelatin zymography,Active,,MedChemComm,2015,6,2,,,1527168,DTCT0024844,14586909,DTCC01255827,255773,64111
CHEMBL2088994,P14780,,UAGQDLDHLLZEMM-VNGHWMNVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,360,NM,,,,,,,,,,,,,,Inhibition MMP-9 (unknown origin) using Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 5 mins followed by substrate addition measured for 30 mins by fluorometric assay,,,MedChemComm,2015,6,2,,,1527166,DTCT0024844,14586905,DTCC01255828,191229,64111
CHEMBL2088994,P14780,,UAGQDLDHLLZEMM-VNGHWMNVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION,=,100,%,,,,,,,,,,,,,,Inhibition MMP-9 (unknown origin) using Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate at 5 uM preincubated for 5 mins followed by substrate addition measured for 30 mins by fluorometric assay,,,MedChemComm,2015,6,2,,,1527164,DTCT0024844,14586887,DTCC01255828,191229,64111
CHEMBL2089002,P14780,DEMETHYLWEDELOLACTONE,LUTYTNLPIUCKBJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22926226,INHIBITION,,,,,cell_based,,,,,,,,,,,MDA-MB-231,Inhibition of MMP9 in human MDA-MB-231 cells at 20 uM up to 12 hrs by gelatin-zymogrphy,Active,Demethylwedelolactone derivatives inhibit invasive growth in vitro and lung metastasis of MDA-MB-231 breast cancer cells in nude mice.,Eur. J. Med. Chem.,2012,56,,"Lee YJ, Lin WL, Chen NF, Chuang SK, Tseng TH",,841229,DTCT0024844,10599668,DTCC01255836,1747890,49383
CHEMBL208966,P14780,,NOEGDKHKBSNSLW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16632358,IC50,=,15,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,12,"Zhang YM, Fan X, Xiang B, Chakravarty D, Scannevin R, Burke S, Karnachi P, Rhodes K, Jackson P",,361727,DTCT0024844,1937038,DTCC00423112,1522846,20885
CHEMBL209077,P14780,,SAPCBLWTLXPCAY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16632358,IC50,=,1049,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,12,"Zhang YM, Fan X, Xiang B, Chakravarty D, Scannevin R, Burke S, Karnachi P, Rhodes K, Jackson P",,361727,DTCT0024844,1937046,DTCC00423311,876078,20885
CHEMBL209165,P14780,,XQDJISOXSDMORY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16632358,IC50,=,0.96,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,12,"Zhang YM, Fan X, Xiang B, Chakravarty D, Scannevin R, Burke S, Karnachi P, Rhodes K, Jackson P",,361727,DTCT0024844,1937036,DTCC00423120,293433,20885
CHEMBL209289,P14780,,KTYYQUGYTGYWLG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16632358,IC50,=,31,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,12,"Zhang YM, Fan X, Xiang B, Chakravarty D, Scannevin R, Burke S, Karnachi P, Rhodes K, Jackson P",,361727,DTCT0024844,1937026,DTCC00423127,810707,20885
CHEMBL209465,P14780,,XROIFKGGWPRMAM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16632358,IC50,=,1.2,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,12,"Zhang YM, Fan X, Xiang B, Chakravarty D, Scannevin R, Burke S, Karnachi P, Rhodes K, Jackson P",,361727,DTCT0024844,1937020,DTCC00423391,1102482,20885
CHEMBL2096738,P14780,,FROMXYGXLCSILK-LHSJRXKWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,=,186,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041938,DTCC01256900,1405627,22157
CHEMBL2096739,P14780,,LMLJZJGMFKPKNY-BPNWFJGMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041927,DTCC01256901,1081613,22157
CHEMBL2096740,P14780,,PCASIOOVBSODBH-QOBPCVTDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041923,DTCC01256903,1631355,22157
CHEMBL2096852,P14780,,FROMXYGXLCSILK-QKKBWIMNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,=,148,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041937,DTCC01257002,1209739,22157
CHEMBL2096854,P14780,,LMLJZJGMFKPKNY-KEJDIYNNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041926,DTCC01257003,855452,22157
CHEMBL2096855,P14780,,PCASIOOVBSODBH-MDYZWHIJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041922,DTCC01257004,370549,22157
CHEMBL209930,P14780,,PAMSLXKVBFUENP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16632358,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,12,"Zhang YM, Fan X, Xiang B, Chakravarty D, Scannevin R, Burke S, Karnachi P, Rhodes K, Jackson P",,361727,DTCT0024844,1937047,DTCC00423310,260156,20885
CHEMBL209970,P14780,,CEVLUPQNDFOYSI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16723229,IC50,=,1670,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,15,"Park K, Aplasca A, Du MT, Sun L, Zhu Y, Zhang Y, Levin JI",,377987,DTCT0024844,1969604,DTCC00428551,1426125,21111
CHEMBL209970,P14780,,CEVLUPQNDFOYSI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17064892,IC50,=,1670,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Identification of potent and selective TACE inhibitors via the S1 pocket.,Bioorg. Med. Chem. Lett.,2007,17,1,"Condon JS, Joseph-McCarthy D, Levin JI, Lombart HG, Lovering FE, Sun L, Wang W, Xu W, Zhang Y",,440763,DTCT0024844,2153862,DTCC00428551,1426378,23077
CHEMBL209970,P14780,,CEVLUPQNDFOYSI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,IC50,=,1670,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2456489,DTCC00428551,1438568,32556
CHEMBL209974,P14780,,OJKIUURDWZWFAM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16913712,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human MMP9 at 155 uM,Not Active,Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening.,J. Med. Chem.,2006,49,17,"Schepetkin IA, Khlebnikov AI, Kirpotina LN, Quinn MT",,386399,DTCT0024844,1958745,DTCC00430887,564137,21205
CHEMBL21,P14780,SULFANILAMIDE,FDDDEECHVMSUSB-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7469624,DTCC00133176,88635,46191
CHEMBL21,P14780,SULFANILAMIDE,FDDDEECHVMSUSB-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7469625,DTCC00133176,88635,46191
CHEMBL210133,P14780,,BXOTYZMFPUKYAU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16723229,IC50,=,19,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,15,"Park K, Aplasca A, Du MT, Sun L, Zhu Y, Zhang Y, Levin JI",,377987,DTCT0024844,1969611,DTCC00110503,1619858,21111
CHEMBL2103747,P14780,ACONITINE,XFSBVAOIAHNAPC-FKHWODAVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7287051,DTCC00130938,671783,46191
CHEMBL2103747,P14780,ACONITINE,XFSBVAOIAHNAPC-FKHWODAVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7287052,DTCC00130938,671783,46191
CHEMBL2103774,P14780,TIBOLONE,WZDGZWOAQTVYBX-XOINTXKNSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7470328,DTCC01257131,1416037,46191
CHEMBL2103774,P14780,TIBOLONE,WZDGZWOAQTVYBX-XOINTXKNSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7470329,DTCC01257131,1416037,46191
CHEMBL210441,P14780,,LOZYBBRAEOAORI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16632358,IC50,=,1.8,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,12,"Zhang YM, Fan X, Xiang B, Chakravarty D, Scannevin R, Burke S, Karnachi P, Rhodes K, Jackson P",,361727,DTCT0024844,1937032,DTCC00423321,778415,20885
CHEMBL210517,P14780,,OIBWGGKYJHWGPB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16632358,IC50,=,0.5,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,12,"Zhang YM, Fan X, Xiang B, Chakravarty D, Scannevin R, Burke S, Karnachi P, Rhodes K, Jackson P",,361727,DTCT0024844,1937028,DTCC00422956,1872825,20885
CHEMBL2105617,P14780,AJMALINE,CJDRUOGAGYHKKD-FUIWMBJSSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7294990,DTCC01258909,2089743,46191
CHEMBL2105617,P14780,AJMALINE,CJDRUOGAGYHKKD-FUIWMBJSSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7294991,DTCC01258909,2089743,46191
CHEMBL2105807,P14780,MADURAMICIN,WQGJEAMPBSZCIF-HKSLRPGUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7431883,DTCC01259078,898292,46191
CHEMBL2105807,P14780,MADURAMICIN,WQGJEAMPBSZCIF-HKSLRPGUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7431884,DTCC01259078,898292,46191
CHEMBL2106399,P14780,KITASAMYCIN,IEMDOFXTVAPVLX-YWQHLDGFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7412091,DTCC01259639,800579,46191
CHEMBL2106399,P14780,KITASAMYCIN,IEMDOFXTVAPVLX-YWQHLDGFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7412092,DTCC01259639,800579,46191
CHEMBL2107687,P14780,VALETHAMATE BROMIDE,CEJGGHKJHDHLAZ-UHFFFAOYSA-M,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7442462,DTCC01260864,1512819,46191
CHEMBL2107687,P14780,VALETHAMATE BROMIDE,CEJGGHKJHDHLAZ-UHFFFAOYSA-M,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7442463,DTCC01260864,1512819,46191
CHEMBL2107797,P14780,NORGESTREL,WWYNJERNGUHSAO-CULCCENASA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7397157,DTCC01260973,1894972,46191
CHEMBL2107797,P14780,NORGESTREL,WWYNJERNGUHSAO-CULCCENASA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7397158,DTCC01260973,1894972,46191
CHEMBL211007,P14780,,GNAOSQHBSOBWJQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16632358,IC50,=,14,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,12,"Zhang YM, Fan X, Xiang B, Chakravarty D, Scannevin R, Burke S, Karnachi P, Rhodes K, Jackson P",,361727,DTCT0024844,1937045,DTCC00423315,1295972,20885
CHEMBL211036,P14780,,BOVXSDPQKQCWHM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16632358,IC50,=,9.7,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,12,"Zhang YM, Fan X, Xiang B, Chakravarty D, Scannevin R, Burke S, Karnachi P, Rhodes K, Jackson P",,361727,DTCT0024844,1937024,DTCC00422997,1715682,20885
CHEMBL211037,P14780,,WDCDJEJTWPFGEE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16632358,IC50,=,101,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,12,"Zhang YM, Fan X, Xiang B, Chakravarty D, Scannevin R, Burke S, Karnachi P, Rhodes K, Jackson P",,361727,DTCT0024844,1937018,DTCC00422998,1198386,20885
CHEMBL2111687,P14780,,XJXBTXINGWHTHD-VSYOVCOZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10560745,IC50,=,410,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease (MMP-9),,Selective inhibition of low affinity IgE receptor (CD23) processing: P1' bicyclomethyl substituents.,Bioorg. Med. Chem. Lett.,1999,9,21,"Bailey S, Bolognese B, Faller A, Louis-Flamberg P, MacPherson DT, Mayer RJ, Marshall LA, Milner PH, Mistry J, Smith DG, Ward JG",,105820,DTCT0024844,1412068,DTCC01264077,2077567,3450
CHEMBL2112477,P14780,,XJXBTXINGWHTHD-RJCAOGMDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10560745,IC50,=,230,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease (MMP-9),,Selective inhibition of low affinity IgE receptor (CD23) processing: P1' bicyclomethyl substituents.,Bioorg. Med. Chem. Lett.,1999,9,21,"Bailey S, Bolognese B, Faller A, Louis-Flamberg P, MacPherson DT, Mayer RJ, Marshall LA, Milner PH, Mistry J, Smith DG, Ward JG",,105820,DTCT0024844,1423221,DTCC01264814,1144688,3450
CHEMBL211274,P14780,,NILIMKWDWHKQOZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16723229,IC50,=,972,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,15,"Park K, Aplasca A, Du MT, Sun L, Zhu Y, Zhang Y, Levin JI",,377987,DTCT0024844,1969670,DTCC00428620,227939,21111
CHEMBL2114138,P14780,,IVPPTWCRAFCOFJ-MOPGFXCFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,2.3,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1581945,DTCC01266112,1423987,16699
CHEMBL2114138,P14780,,IVPPTWCRAFCOFJ-MOPGFXCFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,480,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1561143,DTCC01266112,1423986,16699
CHEMBL2114153,P14780,,FLIOXLIZONFFSH-XMMPIXPASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,5,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,791168,DTCC01266127,808586,17339
CHEMBL2114153,P14780,,FLIOXLIZONFFSH-XMMPIXPASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,112,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,774271,DTCC01266127,808585,17339
CHEMBL2114153,P14780,,FLIOXLIZONFFSH-XMMPIXPASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,5.05,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260738,DTCC01266127,811357,24831
CHEMBL211501,P14780,ANTIMYCIN A,UIFFUZWRFRDZJC-SBOOETFBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7259313,DTCC00428375,930076,46191
CHEMBL211501,P14780,ANTIMYCIN A,UIFFUZWRFRDZJC-SBOOETFBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7259314,DTCC00428375,930076,46191
CHEMBL2115165,P14780,ABT-518,IVPPTWCRAFCOFJ-RTBURBONSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,0.5,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1572604,DTCC00045007,550427,16699
CHEMBL2115165,P14780,ABT-518,IVPPTWCRAFCOFJ-RTBURBONSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,1.4,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1576465,DTCC00045007,550426,16699
CHEMBL2115165,P14780,ABT-518,IVPPTWCRAFCOFJ-RTBURBONSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,0.5,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin),,,MedChemComm,2012,3,11,,,1327985,DTCT0024844,13570938,DTCC00045007,578263,40045
CHEMBL211726,P14780,,LWFCUEQJXZSHMP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16723229,IC50,=,68,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,15,"Park K, Aplasca A, Du MT, Sun L, Zhu Y, Zhang Y, Levin JI",,377987,DTCT0024844,1969654,DTCC00428523,326079,21111
CHEMBL211933,P14780,,KHUCIKRVCMDNPU-XFFZJAGNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16913712,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human MMP9 at 100 uM,Not Active,Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening.,J. Med. Chem.,2006,49,17,"Schepetkin IA, Khlebnikov AI, Kirpotina LN, Quinn MT",,386390,DTCT0024844,1958875,DTCC00430567,855307,21205
CHEMBL212205,P14780,,ZUMRSIZQUOZFGG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16723229,IC50,=,1070,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,15,"Park K, Aplasca A, Du MT, Sun L, Zhu Y, Zhang Y, Levin JI",,377987,DTCT0024844,1969695,DTCC00428527,1134656,21111
CHEMBL212406,P14780,,ZKMKAGTWPRBWAK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16913712,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human MMP9 at 175 uM,Not Active,Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening.,J. Med. Chem.,2006,49,17,"Schepetkin IA, Khlebnikov AI, Kirpotina LN, Quinn MT",,386401,DTCT0024844,1958751,DTCC00430864,1949205,21205
CHEMBL212481,P14780,,HNEDFPGSHTUVKZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16723229,IC50,=,454,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,15,"Park K, Aplasca A, Du MT, Sun L, Zhu Y, Zhang Y, Levin JI",,377987,DTCT0024844,1969662,DTCC00428522,1872868,21111
CHEMBL212723,P14780,,WAYCNXGAKFXIKA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16913712,IC50,=,43000,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening.,J. Med. Chem.,2006,49,17,"Schepetkin IA, Khlebnikov AI, Kirpotina LN, Quinn MT",,386349,DTCT0024844,1958902,DTCC00430566,1307874,21205
CHEMBL212852,P14780,,CRWJSQKQKOMKTJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16913712,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human MMP9 at 115 uM,Not Active,Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening.,J. Med. Chem.,2006,49,17,"Schepetkin IA, Khlebnikov AI, Kirpotina LN, Quinn MT",,386389,DTCT0024844,1958861,DTCC00430541,855306,21205
CHEMBL213144,P14780,,WKDDBZZRMADIHU-ZSOIEALJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16913712,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human MMP9 at 100 uM,Not Active,Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening.,J. Med. Chem.,2006,49,17,"Schepetkin IA, Khlebnikov AI, Kirpotina LN, Quinn MT",,386390,DTCT0024844,1958818,DTCC00430717,435473,21205
CHEMBL213158,P14780,,KGOACNOBHXCLBC-PXNMLYILSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16913712,IC50,=,29600,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening.,J. Med. Chem.,2006,49,17,"Schepetkin IA, Khlebnikov AI, Kirpotina LN, Quinn MT",,386349,DTCT0024844,1958903,DTCC00430829,1787604,21205
CHEMBL213575,P14780,,OWKFSBMZASSGMV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16913712,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human MMP9 at 125 uM,Not Active,Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening.,J. Med. Chem.,2006,49,17,"Schepetkin IA, Khlebnikov AI, Kirpotina LN, Quinn MT",,386388,DTCT0024844,1958889,DTCC00430979,1340503,21205
CHEMBL215074,P14780,"3,2'-DIGUANIDINONEAMINE",SOBOASBOKGPTNI-HKEUSBCWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16870442,KI,>,300000,NM,,,,,,,,,,,,,,Activity at MMP9,,Selectively guanidinylated derivatives of neamine. Syntheses and inhibition of anthrax lethal factor protease.,Bioorg. Med. Chem. Lett.,2006,16,19,"Jiao GS, Simo O, Nagata M, O'Malley S, Hemscheidt T, Cregar L, Millis SZ, Goldman ME, Tang C",,393600,DTCT0024844,1981416,DTCC00001986,1852268,21299
CHEMBL2151348,P14780,,NWWZGWZTAZLVRQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23149299,IC50,=,44200,NM,,,,,,,,,,,,,,Inhibition of recombinant MMP9 catalytic site using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg as substrate incubated for 30 mins prior to substrate addition measured after 3 hrs by fluorimetric assay,,"Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9.",Eur. J. Med. Chem.,2012,58,,"Nicolotti O, Catto M, Giangreco I, Barletta M, Leonetti F, Stefanachi A, Pisani L, Cellamare S, Tortorella P, Loiodice F, Carotti A",,854273,DTCT0024844,11370858,DTCC01284445,135194,50870
CHEMBL2151349,P14780,,LXUDTRDQVKIQBB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23149299,INHIBITION,=,11,%,,,,,,,,,,,,,,Inhibition of recombinant MMP9 catalytic site using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg as substrate at 10 uM incubated for 30 mins prior to substrate addition measured after 3 hrs by fluorimetric assay,,"Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9.",Eur. J. Med. Chem.,2012,58,,"Nicolotti O, Catto M, Giangreco I, Barletta M, Leonetti F, Stefanachi A, Pisani L, Cellamare S, Tortorella P, Loiodice F, Carotti A",,854276,DTCT0024844,11370895,DTCC01284446,1106416,50870
CHEMBL2151350,P14780,,NYMLUNFPRGMRNW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23149299,IC50,=,13000,NM,,,,,,,,,,,,,,Inhibition of recombinant MMP9 catalytic site using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg as substrate incubated for 30 mins prior to substrate addition measured after 3 hrs by fluorimetric assay,,"Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9.",Eur. J. Med. Chem.,2012,58,,"Nicolotti O, Catto M, Giangreco I, Barletta M, Leonetti F, Stefanachi A, Pisani L, Cellamare S, Tortorella P, Loiodice F, Carotti A",,854273,DTCT0024844,11370859,DTCC01284447,297496,50870
CHEMBL2151351,P14780,,LGIWFZRBXLCBCI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23149299,INHIBITION,=,8,%,,,,,,,,,,,,,,Inhibition of recombinant MMP9 catalytic site using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg as substrate at 10 uM incubated for 30 mins prior to substrate addition measured after 3 hrs by fluorimetric assay,,"Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9.",Eur. J. Med. Chem.,2012,58,,"Nicolotti O, Catto M, Giangreco I, Barletta M, Leonetti F, Stefanachi A, Pisani L, Cellamare S, Tortorella P, Loiodice F, Carotti A",,854276,DTCT0024844,11370896,DTCC01284448,1941376,50870
CHEMBL2151352,P14780,,QYUJNLGEANWSCR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23149299,IC50,=,517,NM,,,,,,,,,,,,,,Inhibition of recombinant MMP9 catalytic site using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg as substrate incubated for 30 mins prior to substrate addition measured after 3 hrs by fluorimetric assay,,"Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9.",Eur. J. Med. Chem.,2012,58,,"Nicolotti O, Catto M, Giangreco I, Barletta M, Leonetti F, Stefanachi A, Pisani L, Cellamare S, Tortorella P, Loiodice F, Carotti A",,854273,DTCT0024844,11370860,DTCC01284449,1494536,50870
CHEMBL2151353,P14780,,HWKBTEUWFWNXHM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23149299,IC50,=,19800,NM,,,,,,,,,,,,,,Inhibition of recombinant MMP9 catalytic site using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg as substrate incubated for 30 mins prior to substrate addition measured after 3 hrs by fluorimetric assay,,"Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9.",Eur. J. Med. Chem.,2012,58,,"Nicolotti O, Catto M, Giangreco I, Barletta M, Leonetti F, Stefanachi A, Pisani L, Cellamare S, Tortorella P, Loiodice F, Carotti A",,854273,DTCT0024844,11370861,DTCC01284450,1494537,50870
CHEMBL2151354,P14780,,PMSYYJDPQTWTTO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23149299,IC50,=,27500,NM,,,,,,,,,,,,,,Inhibition of recombinant MMP9 catalytic site using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg as substrate incubated for 30 mins prior to substrate addition measured after 3 hrs by fluorimetric assay,,"Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9.",Eur. J. Med. Chem.,2012,58,,"Nicolotti O, Catto M, Giangreco I, Barletta M, Leonetti F, Stefanachi A, Pisani L, Cellamare S, Tortorella P, Loiodice F, Carotti A",,854273,DTCT0024844,11370862,DTCC01284451,1526825,50870
CHEMBL2151355,P14780,,AADOVZDIDBIZSH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23149299,IC50,=,103,NM,,,,,,,,,,,,,,Inhibition of recombinant MMP9 catalytic site using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg as substrate incubated for 30 mins prior to substrate addition measured after 3 hrs by fluorimetric assay,,"Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9.",Eur. J. Med. Chem.,2012,58,,"Nicolotti O, Catto M, Giangreco I, Barletta M, Leonetti F, Stefanachi A, Pisani L, Cellamare S, Tortorella P, Loiodice F, Carotti A",,854273,DTCT0024844,11370863,DTCC01284452,718092,50870
CHEMBL2151356,P14780,,AHVFZGRDMQDODJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23149299,IC50,=,66,NM,,,,,,,,,,,,,,Inhibition of recombinant MMP9 catalytic site using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg as substrate incubated for 30 mins prior to substrate addition measured after 3 hrs by fluorimetric assay,,"Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9.",Eur. J. Med. Chem.,2012,58,,"Nicolotti O, Catto M, Giangreco I, Barletta M, Leonetti F, Stefanachi A, Pisani L, Cellamare S, Tortorella P, Loiodice F, Carotti A",,854273,DTCT0024844,11370864,DTCC01284453,1558882,50870
CHEMBL2151357,P14780,,FHMXFHQIBLHDDW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23149299,IC50,=,561,NM,,,,,,,,,,,,,,Inhibition of recombinant MMP9 catalytic site using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg as substrate incubated for 30 mins prior to substrate addition measured after 3 hrs by fluorimetric assay,,"Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9.",Eur. J. Med. Chem.,2012,58,,"Nicolotti O, Catto M, Giangreco I, Barletta M, Leonetti F, Stefanachi A, Pisani L, Cellamare S, Tortorella P, Loiodice F, Carotti A",,854273,DTCT0024844,11370865,DTCC01284454,231886,50870
CHEMBL2151358,P14780,,AGAWLHFJRLMKEA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23149299,IC50,=,141,NM,,,,,,,,,,,,,,Inhibition of recombinant MMP9 catalytic site using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg as substrate incubated for 30 mins prior to substrate addition measured after 3 hrs by fluorimetric assay,,"Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9.",Eur. J. Med. Chem.,2012,58,,"Nicolotti O, Catto M, Giangreco I, Barletta M, Leonetti F, Stefanachi A, Pisani L, Cellamare S, Tortorella P, Loiodice F, Carotti A",,854273,DTCT0024844,11370866,DTCC01284455,2007154,50870
CHEMBL2151359,P14780,,SDXNOQQCPWCNQG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23149299,IC50,=,21,NM,,,,,,,,,,,,,,Inhibition of recombinant MMP9 catalytic site using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg as substrate incubated for 30 mins prior to substrate addition measured after 3 hrs by fluorimetric assay,,"Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9.",Eur. J. Med. Chem.,2012,58,,"Nicolotti O, Catto M, Giangreco I, Barletta M, Leonetti F, Stefanachi A, Pisani L, Cellamare S, Tortorella P, Loiodice F, Carotti A",,854273,DTCT0024844,11370867,DTCC01284456,814777,50870
CHEMBL2151360,P14780,,NNAGWFHDLZVPJZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23149299,IC50,=,86,NM,,,,,,,,,,,,,,Inhibition of recombinant MMP9 catalytic site using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg as substrate incubated for 30 mins prior to substrate addition measured after 3 hrs by fluorimetric assay,,"Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9.",Eur. J. Med. Chem.,2012,58,,"Nicolotti O, Catto M, Giangreco I, Barletta M, Leonetti F, Stefanachi A, Pisani L, Cellamare S, Tortorella P, Loiodice F, Carotti A",,854273,DTCT0024844,11370868,DTCC01284457,1688074,50870
CHEMBL2151361,P14780,,DUYNKLSOEWBOEC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23149299,IC50,=,650,NM,,,,,,,,,,,,,,Inhibition of recombinant MMP9 catalytic site using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg as substrate incubated for 30 mins prior to substrate addition measured after 3 hrs by fluorimetric assay,,"Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9.",Eur. J. Med. Chem.,2012,58,,"Nicolotti O, Catto M, Giangreco I, Barletta M, Leonetti F, Stefanachi A, Pisani L, Cellamare S, Tortorella P, Loiodice F, Carotti A",,854273,DTCT0024844,11370869,DTCC01284458,1779983,50870
CHEMBL2151362,P14780,,HIPJPXVTDXVQMU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23149299,IC50,=,170,NM,,,,,,,,,,,,,,Inhibition of recombinant MMP9 catalytic site using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg as substrate incubated for 30 mins prior to substrate addition measured after 3 hrs by fluorimetric assay,,"Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9.",Eur. J. Med. Chem.,2012,58,,"Nicolotti O, Catto M, Giangreco I, Barletta M, Leonetti F, Stefanachi A, Pisani L, Cellamare S, Tortorella P, Loiodice F, Carotti A",,854273,DTCT0024844,11370870,DTCC01284459,1397773,50870
CHEMBL2151363,P14780,,OROXFGPUFVFZQS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23149299,IC50,=,1800,NM,,,,,,,,,,,,,,Inhibition of recombinant MMP9 catalytic site using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg as substrate incubated for 30 mins prior to substrate addition measured after 3 hrs by fluorimetric assay,,"Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9.",Eur. J. Med. Chem.,2012,58,,"Nicolotti O, Catto M, Giangreco I, Barletta M, Leonetti F, Stefanachi A, Pisani L, Cellamare S, Tortorella P, Loiodice F, Carotti A",,854273,DTCT0024844,11370871,DTCC01284460,1041255,50870
CHEMBL2151364,P14780,,BHEWROOMWGCNFD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23149299,IC50,=,3010,NM,,,,,,,,,,,,,,Inhibition of recombinant MMP9 catalytic site using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg as substrate incubated for 30 mins prior to substrate addition measured after 3 hrs by fluorimetric assay,,"Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9.",Eur. J. Med. Chem.,2012,58,,"Nicolotti O, Catto M, Giangreco I, Barletta M, Leonetti F, Stefanachi A, Pisani L, Cellamare S, Tortorella P, Loiodice F, Carotti A",,854273,DTCT0024844,11370872,DTCC00131095,1719403,50870
CHEMBL2151365,P14780,,VGXSIAPPDJZRCX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23149299,IC50,=,159,NM,,,,,,,,,,,,,,Inhibition of recombinant MMP9 catalytic site using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg as substrate incubated for 30 mins prior to substrate addition measured after 3 hrs by fluorimetric assay,,"Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9.",Eur. J. Med. Chem.,2012,58,,"Nicolotti O, Catto M, Giangreco I, Barletta M, Leonetti F, Stefanachi A, Pisani L, Cellamare S, Tortorella P, Loiodice F, Carotti A",,854273,DTCT0024844,11370873,DTCC00131096,685778,50870
CHEMBL2151366,P14780,,XMDWOYHLYOJZLU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23149299,INHIBITION,=,21,%,,,,,,,,,,,,,,Inhibition of recombinant MMP9 catalytic site using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg as substrate at 100 uM incubated for 30 mins prior to substrate addition measured after 3 hrs by fluorimetric assay,,"Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9.",Eur. J. Med. Chem.,2012,58,,"Nicolotti O, Catto M, Giangreco I, Barletta M, Leonetti F, Stefanachi A, Pisani L, Cellamare S, Tortorella P, Loiodice F, Carotti A",,854278,DTCT0024844,11370899,DTCC01284461,814778,50870
CHEMBL2151367,P14780,,FJUYBDSGTYSLQA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23149299,INHIBITION,=,28,%,,,,,,,,,,,,,,Inhibition of recombinant MMP9 catalytic site using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg as substrate at 100 uM incubated for 30 mins prior to substrate addition measured after 3 hrs by fluorimetric assay,,"Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9.",Eur. J. Med. Chem.,2012,58,,"Nicolotti O, Catto M, Giangreco I, Barletta M, Leonetti F, Stefanachi A, Pisani L, Cellamare S, Tortorella P, Loiodice F, Carotti A",,854278,DTCT0024844,11370900,DTCC01284462,264295,50870
CHEMBL215269,P14780,"1,3,2',6'-TETRAGUANIDINONEAMINE",BNWODYWXZNMCKX-HKEUSBCWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16870442,KI,>,300000,NM,,,,,,,,,,,,,,Activity at MMP9,,Selectively guanidinylated derivatives of neamine. Syntheses and inhibition of anthrax lethal factor protease.,Bioorg. Med. Chem. Lett.,2006,16,19,"Jiao GS, Simo O, Nagata M, O'Malley S, Hemscheidt T, Cregar L, Millis SZ, Goldman ME, Tang C",,393600,DTCT0024844,1981417,DTCC00001992,1437410,21299
CHEMBL2153737,P14780,,LHVGXRIIQBVWQU-JHOVWCEZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21780776,KI,=,10,NM,,,,,,,,,,,,,,Inhibition of MMP-9,,Remarkable potential of the a-aminophosphonate/phosphinate structural motif in medicinal chemistry.,J. Med. Chem.,2011,54,17,"Mucha A, Kafarski P, Berlicki L",,850717,DTCT0024844,11357594,DTCC01286634,284807,50957
CHEMBL2153738,P14780,,CGPJRIXIBMANTN-PHCUSUGSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21780776,KI,=,148000,NM,,,,,,,,,,,,,,Inhibition of MMP-9,,Remarkable potential of the a-aminophosphonate/phosphinate structural motif in medicinal chemistry.,J. Med. Chem.,2011,54,17,"Mucha A, Kafarski P, Berlicki L",,850717,DTCT0024844,11357595,DTCC01286635,705682,50957
CHEMBL215448,P14780,,GMZMCGWDPXYCHY-ZDLGFXPLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16913712,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human MMP9 at 80 uM,Not Active,Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening.,J. Med. Chem.,2006,49,17,"Schepetkin IA, Khlebnikov AI, Kirpotina LN, Quinn MT",,386385,DTCT0024844,341235,DTCC00430748,532016,21205
CHEMBL215449,P14780,,CDPPDRJSGHLYJL-YVLHZVERSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16913712,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human MMP9 at 75 uM,Not Active,Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening.,J. Med. Chem.,2006,49,17,"Schepetkin IA, Khlebnikov AI, Kirpotina LN, Quinn MT",,386386,DTCT0024844,1969841,DTCC00430749,951819,21205
CHEMBL215715,P14780,,DDPWNYDFUBXVGQ-MLFNNEOSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16870442,KI,>,300000,NM,,,,,,,,,,,,,,Activity at MMP9,,Selectively guanidinylated derivatives of neamine. Syntheses and inhibition of anthrax lethal factor protease.,Bioorg. Med. Chem. Lett.,2006,16,19,"Jiao GS, Simo O, Nagata M, O'Malley S, Hemscheidt T, Cregar L, Millis SZ, Goldman ME, Tang C",,393600,DTCT0024844,1981406,DTCC00433950,1469832,21299
CHEMBL215785,P14780,,ZOKYADHWUHIRCQ-ZVBGSRNCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16913712,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human MMP9 at 90 uM,Not Active,Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening.,J. Med. Chem.,2006,49,17,"Schepetkin IA, Khlebnikov AI, Kirpotina LN, Quinn MT",,386392,DTCT0024844,1958815,DTCC00430750,2047173,21205
CHEMBL21731,P14780,MAPROTILINE,QSLMDECMDJKHMQ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7408468,DTCC00155108,1059332,46191
CHEMBL21731,P14780,MAPROTILINE,QSLMDECMDJKHMQ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7408469,DTCC00155108,1059332,46191
CHEMBL218586,P14780,,KALKLNBLKRHXMI-ROUUACIJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17256836,IC50,>,5000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.",J. Med. Chem.,2007,50,4,"Yao W, Zhuo J, Burns DM, Xu M, Zhang C, Li YL, Qian DQ, He C, Weng L, Shi E, Lin Q, Agrios C, Burn TC, Caulder E, Covington MB, Fridman JS, Friedman S, Katiyar K, Hollis G, Li Y, Liu C, Liu X, Marando CA, Newton R, Pan M, Scherle P, Taylor N, Vaddi K, Wasserman ZR, Wynn R, Yeleswaram S, Jalluri R, Bower M, Zhou BB, Metcalf B",,425541,DTCT0024844,2019790,DTCC00438882,1081562,21880
CHEMBL219104,P14780,,MITLEGOYVUMBJH-IRXDYDNUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17256836,IC50,>,5000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.",J. Med. Chem.,2007,50,4,"Yao W, Zhuo J, Burns DM, Xu M, Zhang C, Li YL, Qian DQ, He C, Weng L, Shi E, Lin Q, Agrios C, Burn TC, Caulder E, Covington MB, Fridman JS, Friedman S, Katiyar K, Hollis G, Li Y, Liu C, Liu X, Marando CA, Newton R, Pan M, Scherle P, Taylor N, Vaddi K, Wasserman ZR, Wynn R, Yeleswaram S, Jalluri R, Bower M, Zhou BB, Metcalf B",,425541,DTCT0024844,2019791,DTCC00438881,661246,21880
CHEMBL219104,P14780,,MITLEGOYVUMBJH-IRXDYDNUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18036818,IC50,>,5000,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.,Bioorg. Med. Chem. Lett.,2008,18,1,"Yao W, Zhuo J, Burns DM, Li YL, Qian DQ, Zhang C, He C, Xu M, Shi E, Li Y, Marando CA, Covington MB, Yang G, Liu X, Pan M, Fridman JS, Scherle P, Wasserman ZR, Hollis G, Vaddi K, Yeleswaram S, Newton R, Friedman S, Metcalf B",,461667,DTCT0024844,2276543,DTCC00438881,650433,25086
CHEMBL219105,P14780,,YCCUTKPNUYYNML-ROUUACIJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17256836,IC50,>,5000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.",J. Med. Chem.,2007,50,4,"Yao W, Zhuo J, Burns DM, Xu M, Zhang C, Li YL, Qian DQ, He C, Weng L, Shi E, Lin Q, Agrios C, Burn TC, Caulder E, Covington MB, Fridman JS, Friedman S, Katiyar K, Hollis G, Li Y, Liu C, Liu X, Marando CA, Newton R, Pan M, Scherle P, Taylor N, Vaddi K, Wasserman ZR, Wynn R, Yeleswaram S, Jalluri R, Bower M, Zhou BB, Metcalf B",,425541,DTCT0024844,2019781,DTCC00438922,1916656,21880
CHEMBL219146,P14780,VINDESINE,HHJUWIANJFBDHT-KOTLKJBCSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7444167,DTCC00110817,833166,46191
CHEMBL219146,P14780,VINDESINE,HHJUWIANJFBDHT-KOTLKJBCSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7444168,DTCC00110817,833166,46191
CHEMBL219916,P14780,DOMPERIDONE,FGXWKSZFVQUSTL-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7370718,DTCC00437363,898287,46191
CHEMBL219916,P14780,DOMPERIDONE,FGXWKSZFVQUSTL-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7370719,DTCC00437363,898287,46191
CHEMBL220362,P14780,ANIASATIN,GEVWHIDSUOMVRI-QWNPAUMXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17027271,IC50,=,5.8,UG.ML-1,,,,,,,,,,,,,,Inhibition of human MMP9 by quenched fluorescense assay,,Natural inhibitors targeting osteoclast-mediated bone resorption.,Bioorg. Med. Chem. Lett.,2006,16,24,"Zeng GZ, Tan NH, Hao XJ, Mu QZ, Li RT",,425101,DTCT0024844,2017654,DTCC00441113,1502223,21854
CHEMBL2203634,P14780,,MWKXYRJSVHPPLM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21413808,IC50,=,1,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synopsis of some recent tactical application of bioisosteres in drug design.,J. Med. Chem.,2011,54,8,,,879305,DTCT0024844,11457595,DTCC01299024,415888,51826
CHEMBL2203635,P14780,,UBHBDSABSVVUTP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21413808,IC50,=,2,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synopsis of some recent tactical application of bioisosteres in drug design.,J. Med. Chem.,2011,54,8,,,879305,DTCT0024844,11457593,DTCC00131528,122882,51826
CHEMBL2203636,P14780,,UCUWDJGEWJWQOY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21413808,IC50,=,1800,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synopsis of some recent tactical application of bioisosteres in drug design.,J. Med. Chem.,2011,54,8,,,879305,DTCT0024844,11457594,DTCC00131529,479973,51826
CHEMBL2203637,P14780,,FUYXUEFCWRUMHG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21413808,IC50,=,87,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synopsis of some recent tactical application of bioisosteres in drug design.,J. Med. Chem.,2011,54,8,,,879305,DTCT0024844,11457592,DTCC00131530,1994784,51826
CHEMBL2203638,P14780,,BGJNPKHDPBUJSP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21413808,IC50,=,10,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synopsis of some recent tactical application of bioisosteres in drug design.,J. Med. Chem.,2011,54,8,,,879305,DTCT0024844,11457396,DTCC00131531,608889,51826
CHEMBL2203639,P14780,,YXQWYGVDVQBPGA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21413808,IC50,=,27,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synopsis of some recent tactical application of bioisosteres in drug design.,J. Med. Chem.,2011,54,8,,,879305,DTCT0024844,11457395,DTCC00131532,673682,51826
CHEMBL2203640,P14780,,JSEADFAWCUECMR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21413808,IC50,=,4500,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synopsis of some recent tactical application of bioisosteres in drug design.,J. Med. Chem.,2011,54,8,,,879305,DTCT0024844,11457394,DTCC00131533,1676000,51826
CHEMBL2203641,P14780,,GISWZMJMNJMSEO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21413808,IC50,=,22,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synopsis of some recent tactical application of bioisosteres in drug design.,J. Med. Chem.,2011,54,8,,,879305,DTCT0024844,11457393,DTCC00131534,1061210,51826
CHEMBL2204087,P14780,,RTOXIYMJLZFAIX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23134659,IC50,>,25000,NM,,,,,,,,,,,,,,Inhibition of para-amino phenylmercuric acetate-activated MMP9 using Mca-P-L-G-L-Dap(Dnp)-A-R-NH2 as substrate after 1 hr by fluorescence assay,,Design and synthesis of procollagen C-proteinase inhibitors.,Bioorg. Med. Chem. Lett.,2012,22,24,"Turtle E, Chow N, Yang C, Sosa S, Bauer U, Brenner M, Solow-Cordero D, Ho WB",,886676,DTCT0024844,11488698,DTCC01299452,738138,52120
CHEMBL2204802,P14780,,HTYBLKDBXIVZAV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23134659,IC50,>,25000,NM,,,,,,,,,,,,,,Inhibition of para-amino phenylmercuric acetate-activated MMP9 using Mca-P-L-G-L-Dap(Dnp)-A-R-NH2 as substrate after 1 hr by fluorescence assay,,Design and synthesis of procollagen C-proteinase inhibitors.,Bioorg. Med. Chem. Lett.,2012,22,24,"Turtle E, Chow N, Yang C, Sosa S, Bauer U, Brenner M, Solow-Cordero D, Ho WB",,886676,DTCT0024844,11488700,DTCC01300083,1514774,52120
CHEMBL2204807,P14780,,CJZYEUWWKSOBJP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23134659,IC50,>,6000,NM,,,,,,,,,,,,,,Inhibition of para-amino phenylmercuric acetate-activated MMP9 using Mca-P-L-G-L-Dap(Dnp)-A-R-NH2 as substrate after 1 hr by fluorescence assay,,Design and synthesis of procollagen C-proteinase inhibitors.,Bioorg. Med. Chem. Lett.,2012,22,24,"Turtle E, Chow N, Yang C, Sosa S, Bauer U, Brenner M, Solow-Cordero D, Ho WB",,886676,DTCT0024844,11488699,DTCC01300088,155442,52120
CHEMBL220501,P14780,,SMNLJWDKCNVQNU-RDJZCZTQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17256836,IC50,>,5000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.",J. Med. Chem.,2007,50,4,"Yao W, Zhuo J, Burns DM, Xu M, Zhang C, Li YL, Qian DQ, He C, Weng L, Shi E, Lin Q, Agrios C, Burn TC, Caulder E, Covington MB, Fridman JS, Friedman S, Katiyar K, Hollis G, Li Y, Liu C, Liu X, Marando CA, Newton R, Pan M, Scherle P, Taylor N, Vaddi K, Wasserman ZR, Wynn R, Yeleswaram S, Jalluri R, Bower M, Zhou BB, Metcalf B",,425541,DTCT0024844,2019788,DTCC00438889,1852360,21880
CHEMBL220975,P14780,,AXVVLBQLURTOIQ-DVRYWGNFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17256836,IC50,>,5000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.",J. Med. Chem.,2007,50,4,"Yao W, Zhuo J, Burns DM, Xu M, Zhang C, Li YL, Qian DQ, He C, Weng L, Shi E, Lin Q, Agrios C, Burn TC, Caulder E, Covington MB, Fridman JS, Friedman S, Katiyar K, Hollis G, Li Y, Liu C, Liu X, Marando CA, Newton R, Pan M, Scherle P, Taylor N, Vaddi K, Wasserman ZR, Wynn R, Yeleswaram S, Jalluri R, Bower M, Zhou BB, Metcalf B",,425541,DTCT0024844,2019715,DTCC00438857,110435,21880
CHEMBL221120,P14780,,IWNGNUDBGMCFNB-RDJZCZTQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17256836,IC50,>,5000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.",J. Med. Chem.,2007,50,4,"Yao W, Zhuo J, Burns DM, Xu M, Zhang C, Li YL, Qian DQ, He C, Weng L, Shi E, Lin Q, Agrios C, Burn TC, Caulder E, Covington MB, Fridman JS, Friedman S, Katiyar K, Hollis G, Li Y, Liu C, Liu X, Marando CA, Newton R, Pan M, Scherle P, Taylor N, Vaddi K, Wasserman ZR, Wynn R, Yeleswaram S, Jalluri R, Bower M, Zhou BB, Metcalf B",,425541,DTCT0024844,2019787,DTCC00438890,110436,21880
CHEMBL221627,P14780,,DNSZKZUFQIXHCV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,INHIBITION,=,25,%,,,,,,,,,,,,,,Inhibition of MMP9 at 10 uM,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429671,DTCT0024844,2041947,DTCC00444519,1437534,22157
CHEMBL221677,P14780,,VAQBMYMELLMZQZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041914,DTCC00111041,1884529,22157
CHEMBL221698,P14780,,XKPUKZQRNSFQLM-JYJNAYRXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17256836,IC50,>,3000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.",J. Med. Chem.,2007,50,4,"Yao W, Zhuo J, Burns DM, Xu M, Zhang C, Li YL, Qian DQ, He C, Weng L, Shi E, Lin Q, Agrios C, Burn TC, Caulder E, Covington MB, Fridman JS, Friedman S, Katiyar K, Hollis G, Li Y, Liu C, Liu X, Marando CA, Newton R, Pan M, Scherle P, Taylor N, Vaddi K, Wasserman ZR, Wynn R, Yeleswaram S, Jalluri R, Bower M, Zhou BB, Metcalf B",,425541,DTCT0024844,2019784,DTCC00438914,532136,21880
CHEMBL221717,P14780,,SEFCVQRMTNTWJO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,=,6,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041908,DTCC00444488,532172,22157
CHEMBL221753,P14780,BENZETHONIUM CHLORIDE,UREZNYTWGJKWBI-UHFFFAOYSA-M,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7261229,DTCC00440345,120969,46191
CHEMBL221753,P14780,BENZETHONIUM CHLORIDE,UREZNYTWGJKWBI-UHFFFAOYSA-M,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7261230,DTCC00440345,120969,46191
CHEMBL221857,P14780,,GGYBWFRTPPVUAZ-HOTGVXAUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17256836,IC50,=,650,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.",J. Med. Chem.,2007,50,4,"Yao W, Zhuo J, Burns DM, Xu M, Zhang C, Li YL, Qian DQ, He C, Weng L, Shi E, Lin Q, Agrios C, Burn TC, Caulder E, Covington MB, Fridman JS, Friedman S, Katiyar K, Hollis G, Li Y, Liu C, Liu X, Marando CA, Newton R, Pan M, Scherle P, Taylor N, Vaddi K, Wasserman ZR, Wynn R, Yeleswaram S, Jalluri R, Bower M, Zhou BB, Metcalf B",,425541,DTCT0024844,2019721,DTCC00438873,1340603,21880
CHEMBL221857,P14780,,GGYBWFRTPPVUAZ-HOTGVXAUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18036818,IC50,=,650,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.,Bioorg. Med. Chem. Lett.,2008,18,1,"Yao W, Zhuo J, Burns DM, Li YL, Qian DQ, Zhang C, He C, Xu M, Shi E, Li Y, Marando CA, Covington MB, Yang G, Liu X, Pan M, Fridman JS, Scherle P, Wasserman ZR, Hollis G, Vaddi K, Yeleswaram S, Newton R, Friedman S, Metcalf B",,461667,DTCT0024844,2276421,DTCC00438873,1329203,25086
CHEMBL221857,P14780,,GGYBWFRTPPVUAZ-HOTGVXAUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19457660,IC50,=,650,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition.,Bioorg. Med. Chem. Lett.,2009,19,13,"Burns DM, Li YL, Shi E, He C, Xu M, Zhuo J, Zhang C, Qian DQ, Li Y, Wynn R, Covington MB, Katiyar K, Marando CA, Fridman JS, Scherle P, Friedman S, Metcalf B, Yao W",,523765,DTCT0024844,2828339,DTCC00438873,1329994,33677
CHEMBL221886,P14780,SISOMICIN,URWAJWIAIPFPJE-YFMIWBNJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7488481,DTCC00443300,703986,46191
CHEMBL221886,P14780,SISOMICIN,URWAJWIAIPFPJE-YFMIWBNJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7488482,DTCC00443300,703986,46191
CHEMBL2220427,P14780,ERYTHROMYCIN ESTOLATE,TYQXKHPOXXXCTP-CSLYCKPJSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7307001,DTCC01305390,639579,46191
CHEMBL2220427,P14780,ERYTHROMYCIN ESTOLATE,TYQXKHPOXXXCTP-CSLYCKPJSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7307002,DTCC01305390,639579,46191
CHEMBL2220442,P14780,FLUVASTATIN,FJLGEFLZQAZZCD-VAWYXSNFSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7312113,DTCC01305406,1059330,46191
CHEMBL2220442,P14780,FLUVASTATIN,FJLGEFLZQAZZCD-VAWYXSNFSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7312114,DTCC01305406,1059330,46191
CHEMBL222282,P14780,,MKEVHBFZBURDHJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041919,DTCC00444529,1566560,22157
CHEMBL222303,P14780,,NPIXRIRDKCZNLD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,=,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041916,DTCC00444432,1049040,22157
CHEMBL222309,P14780,,XWQYRXPGPDOWAJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,=,124,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041925,DTCC00444512,1373173,22157
CHEMBL222397,P14780,,WGANCLOVDGTTMN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,INHIBITION,=,59,%,,,,,,,,,,,,,,Inhibition of MMP9 at 10 uM,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429671,DTCT0024844,2041940,DTCC00444517,305301,22157
CHEMBL222594,P14780,,KTMMYBDZBIJPLY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,=,1262,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041929,DTCC00444499,1340649,22157
CHEMBL222714,P14780,,QFAMXNMLWJDJPV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,=,164,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041944,DTCC00444503,1755545,22157
CHEMBL222854,P14780,,MNQFMKHWJNOSIX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,=,385,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041907,DTCC00444496,239576,22157
CHEMBL222863,P14780,OUABAIN,LPMXVESGRSUGHW-HBYQJFLCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7378033,DTCC00444362,1059335,46191
CHEMBL222863,P14780,OUABAIN,LPMXVESGRSUGHW-HBYQJFLCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7378034,DTCC00444362,1059335,46191
CHEMBL222934,P14780,,YJZSNVXLDDRADS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,=,10,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041909,DTCC00444468,2015109,22157
CHEMBL222935,P14780,,JUKIJVGLFPZICB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041931,DTCC00444494,757981,22157
CHEMBL222936,P14780,,NOIOOWNKXMUESY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041921,DTCC00444521,110471,22157
CHEMBL222992,P14780,,ILUVAAMGYFXXGD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,=,3000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041920,DTCC00444522,1820288,22157
CHEMBL223418,P14780,,CWTPXHBVRVZHBV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,INHIBITION,=,21,%,,,,,,,,,,,,,,Inhibition of MMP9 at 10 uM,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429671,DTCT0024844,2041946,DTCC00444515,435624,22157
CHEMBL223831,P14780,,LJPYOTNMYOBJHB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041911,DTCC00444454,1949369,22157
CHEMBL223888,P14780,,HIBWRSXXRMHOLM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,=,3000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041935,DTCC00444486,370548,22157
CHEMBL224845,P14780,,MWQQOCVRFAKHSC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,INHIBITION,=,52,%,,,,,,,,,,,,,,Inhibition of MMP9 at 10 uM,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429671,DTCT0024844,2041945,DTCC00444509,1114162,22157
CHEMBL225164,P14780,CLOXYQUIN,CTQMJYWDVABFRZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,1,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103378,DTCC00445307,1828598,43205
CHEMBL2252949,P14780,(-)-CAMPHOR,DSSYKIVIOFKYAU-OIBJUYFYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7420723,DTCC01315138,510302,46191
CHEMBL2252949,P14780,(-)-CAMPHOR,DSSYKIVIOFKYAU-OIBJUYFYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7420724,DTCC01315138,510302,46191
CHEMBL225331,P14780,,XMAZUULAIZPAJR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,INHIBITION,=,41,%,,,,,,,,,,,,,,Inhibition of MMP9 at 10 uM,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429671,DTCT0024844,2041939,DTCC00444508,337937,22157
CHEMBL22587,P14780,ITRACONAZOLE,VHVPQPYKVGDNFY-ZPGVKDDISA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7414047,DTCC01738573,51481,46191
CHEMBL22587,P14780,ITRACONAZOLE,VHVPQPYKVGDNFY-ZPGVKDDISA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7414048,DTCC01738573,51481,46191
CHEMBL226149,P14780,,PMVJGZGFFBJYLQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17276072,IC50,=,256000,NM,,cell_based,,,,,,,,,,,,Inhibition of human recombinant MMP9 expressed in mouse myeloma cells,,Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.,Bioorg. Med. Chem.,2007,15,6,"Nuti E, Orlandini E, Nencetti S, Rossello A, Innocenti A, Scozzafava A, Supuran CT",,435728,DTCT0024844,2079350,DTCC00449747,488621,22603
CHEMBL226345,P14780,ADENINE,GFFGJBXGBJISGV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,-3,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103986,DTCC00449510,86517,43205
CHEMBL226438,P14780,,SDEDFYBPNWGZBF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17276072,IC50,=,870,NM,,cell_based,,,,,,,,,,,,Inhibition of human recombinant MMP9 expressed in mouse myeloma cells,,Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.,Bioorg. Med. Chem.,2007,15,6,"Nuti E, Orlandini E, Nencetti S, Rossello A, Innocenti A, Scozzafava A, Supuran CT",,435728,DTCT0024844,2079358,DTCC00449739,1037499,22603
CHEMBL226439,P14780,,ICISPHGVMHWYTI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17276072,IC50,=,3400,NM,,cell_based,,,,,,,,,,,,Inhibition of human recombinant MMP9 expressed in mouse myeloma cells,,Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.,Bioorg. Med. Chem.,2007,15,6,"Nuti E, Orlandini E, Nencetti S, Rossello A, Innocenti A, Scozzafava A, Supuran CT",,435728,DTCT0024844,2079356,DTCC00449741,424345,22603
CHEMBL226439,P14780,,ICISPHGVMHWYTI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20180536,IC50,=,4100,NM,,,,,,,,,,,,,,Inhibition of MMP9 by fluorometric assay,,Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.,J. Med. Chem.,2010,53,6,"Nuti E, Casalini F, Avramova SI, Santamaria S, Fabbi M, Ferrini S, Marinelli L, La Pietra V, Limongelli V, Novellino E, Cercignani G, Orlandini E, Nencetti S, Rossello A",,624094,DTCT0024844,3286005,DTCC00449741,437752,38228
CHEMBL226439,P14780,,ICISPHGVMHWYTI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23287054,IC50,,,,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin),Not Determined,Sulphonamides: Deserving class as MMP inhibitors?,Eur. J. Med. Chem.,2013,60,,"Jain P, Saravanan C, Singh SK",,944094,DTCT0024844,11835660,DTCC00449741,447228,53820
CHEMBL226630,P14780,UK-383367,ARJCBSRIPGJMAD-LLVKDONJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17591762,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Potent and selective nonpeptidic inhibitors of procollagen C-proteinase.,J. Med. Chem.,2007,50,15,"Fish PV, Allan GA, Bailey S, Blagg J, Butt R, Collis MG, Greiling D, James K, Kendall J, McElroy A, McCleverty D, Reed C, Webster R, Whitlock GA",,440140,DTCT0024844,2113795,DTCC00002834,1523163,23023
CHEMBL226630,P14780,UK-383367,ARJCBSRIPGJMAD-LLVKDONJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17591762,INHIBITION,<,50,%,,,,,,,,,,,,,,Inhibition of MMP9 at 10 uM,,Potent and selective nonpeptidic inhibitors of procollagen C-proteinase.,J. Med. Chem.,2007,50,15,"Fish PV, Allan GA, Bailey S, Blagg J, Butt R, Collis MG, Greiling D, James K, Kendall J, McElroy A, McCleverty D, Reed C, Webster R, Whitlock GA",,440146,DTCT0024844,2113823,DTCC00002834,1523163,23023
CHEMBL226630,P14780,UK-383367,ARJCBSRIPGJMAD-LLVKDONJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17591762,INHIBITION,<,50,%,,,,,,,,,,,,,,Inhibition of MMP9 at 100 uM,,Potent and selective nonpeptidic inhibitors of procollagen C-proteinase.,J. Med. Chem.,2007,50,15,"Fish PV, Allan GA, Bailey S, Blagg J, Butt R, Collis MG, Greiling D, James K, Kendall J, McElroy A, McCleverty D, Reed C, Webster R, Whitlock GA",,440152,DTCT0024844,2113851,DTCC00002834,1523163,23023
CHEMBL226630,P14780,UK-383367,ARJCBSRIPGJMAD-LLVKDONJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17591762,INHIBITION,<,50,%,,,,,,,,,,,,,,Inhibition of MMP9 at 30 uM,,Potent and selective nonpeptidic inhibitors of procollagen C-proteinase.,J. Med. Chem.,2007,50,15,"Fish PV, Allan GA, Bailey S, Blagg J, Butt R, Collis MG, Greiling D, James K, Kendall J, McElroy A, McCleverty D, Reed C, Webster R, Whitlock GA",,440158,DTCT0024844,2113880,DTCC00002834,1523163,23023
CHEMBL226630,P14780,UK-383367,ARJCBSRIPGJMAD-LLVKDONJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18945617,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of human MMP9 by fluorescence assay,,"Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: design, synthesis, and evaluation as topically applied, dermal anti-scarring agents.",Bioorg. Med. Chem. Lett.,2008,18,24,"Bailey S, Fish PV, Billotte S, Bordner J, Greiling D, James K, McElroy A, Mills JE, Reed C, Webster R",,518965,DTCT0024844,2690024,DTCC00002834,1535490,32223
CHEMBL226686,P14780,,FRASWKFJOBLAQF-CYBMUJFWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18945617,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP9 by fluorescence assay,Not Determined,"Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: design, synthesis, and evaluation as topically applied, dermal anti-scarring agents.",Bioorg. Med. Chem. Lett.,2008,18,24,"Bailey S, Fish PV, Billotte S, Bordner J, Greiling D, James K, McElroy A, Mills JE, Reed C, Webster R",,518965,DTCT0024844,2690034,DTCC00452728,1726167,32223
CHEMBL226852,P14780,,SWOIHXOGQYPPNC-GFCCVEGCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17591762,IC50,=,50000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Potent and selective nonpeptidic inhibitors of procollagen C-proteinase.,J. Med. Chem.,2007,50,15,"Fish PV, Allan GA, Bailey S, Blagg J, Butt R, Collis MG, Greiling D, James K, Kendall J, McElroy A, McCleverty D, Reed C, Webster R, Whitlock GA",,440140,DTCT0024844,2113798,DTCC00452681,1361615,23023
CHEMBL226852,P14780,,SWOIHXOGQYPPNC-GFCCVEGCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17591762,INHIBITION,<,50,%,,,,,,,,,,,,,,Inhibition of MMP9 at 10 uM,,Potent and selective nonpeptidic inhibitors of procollagen C-proteinase.,J. Med. Chem.,2007,50,15,"Fish PV, Allan GA, Bailey S, Blagg J, Butt R, Collis MG, Greiling D, James K, Kendall J, McElroy A, McCleverty D, Reed C, Webster R, Whitlock GA",,440146,DTCT0024844,2113826,DTCC00452681,1361615,23023
CHEMBL226852,P14780,,SWOIHXOGQYPPNC-GFCCVEGCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17591762,INHIBITION,<,50,%,,,,,,,,,,,,,,Inhibition of MMP9 at 100 uM,,Potent and selective nonpeptidic inhibitors of procollagen C-proteinase.,J. Med. Chem.,2007,50,15,"Fish PV, Allan GA, Bailey S, Blagg J, Butt R, Collis MG, Greiling D, James K, Kendall J, McElroy A, McCleverty D, Reed C, Webster R, Whitlock GA",,440152,DTCT0024844,2113854,DTCC00452681,1361615,23023
CHEMBL226852,P14780,,SWOIHXOGQYPPNC-GFCCVEGCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17591762,INHIBITION,<,50,%,,,,,,,,,,,,,,Inhibition of MMP9 at 30 uM,,Potent and selective nonpeptidic inhibitors of procollagen C-proteinase.,J. Med. Chem.,2007,50,15,"Fish PV, Allan GA, Bailey S, Blagg J, Butt R, Collis MG, Greiling D, James K, Kendall J, McElroy A, McCleverty D, Reed C, Webster R, Whitlock GA",,440158,DTCT0024844,2113883,DTCC00452681,1361615,23023
CHEMBL227484,P14780,,CJTUBZULFXKTAT-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17088065,IC50,=,4.1,NM,,cell_based,,,,,,,,,,,,Inhibition of human recombinant MMP9 expressed in mouse myeloma cells,,alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.,Bioorg. Med. Chem.,2007,15,2,"Biasone A, Tortorella P, Campestre C, Agamennone M, Preziuso S, Chiappini M, Nuti E, Carelli P, Rossello A, Mazza F, Gallina C",,432507,DTCT0024844,2061805,DTCC00447716,326283,22402
CHEMBL227484,P14780,,CJTUBZULFXKTAT-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17088065,IC50,=,4.1,NM,,cell_based,,,,,,,,,,,,Inhibition of human recombinant MMP9 expressed in mouse myeloma cells,,alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.,Bioorg. Med. Chem.,2007,15,2,"Biasone A, Tortorella P, Campestre C, Agamennone M, Preziuso S, Chiappini M, Nuti E, Carelli P, Rossello A, Mazza F, Gallina C",,432507,DTCT0024844,2062001,DTCC00447716,326284,22402
CHEMBL227501,P14780,,WNLZTTHHHYZJMB-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17088065,IC50,=,64,NM,,cell_based,,,,,,,,,,,,Inhibition of human recombinant MMP9 expressed in mouse myeloma cells,,alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.,Bioorg. Med. Chem.,2007,15,2,"Biasone A, Tortorella P, Campestre C, Agamennone M, Preziuso S, Chiappini M, Nuti E, Carelli P, Rossello A, Mazza F, Gallina C",,432507,DTCT0024844,2061802,DTCC00447830,1426294,22402
CHEMBL227553,P14780,,FHZGYMLWCVBBPM-GOSISDBHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17088065,IC50,=,7100,NM,,cell_based,,,,,,,,,,,,Inhibition of human recombinant MMP9 expressed in mouse myeloma cells,,alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.,Bioorg. Med. Chem.,2007,15,2,"Biasone A, Tortorella P, Campestre C, Agamennone M, Preziuso S, Chiappini M, Nuti E, Carelli P, Rossello A, Mazza F, Gallina C",,432507,DTCT0024844,2061801,DTCC00447831,1166105,22402
CHEMBL227565,P14780,,HRNIVSOLWXFPBW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17276072,IC50,=,33000,NM,,cell_based,,,,,,,,,,,,Inhibition of human recombinant MMP9 expressed in mouse myeloma cells,,Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.,Bioorg. Med. Chem.,2007,15,6,"Nuti E, Orlandini E, Nencetti S, Rossello A, Innocenti A, Scozzafava A, Supuran CT",,435728,DTCT0024844,2079355,DTCC00449742,1263674,22603
CHEMBL227566,P14780,,DSHAKCWOEUEDGY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17276072,IC50,=,261000,NM,,cell_based,,,,,,,,,,,,Inhibition of human recombinant MMP9 expressed in mouse myeloma cells,,Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.,Bioorg. Med. Chem.,2007,15,6,"Nuti E, Orlandini E, Nencetti S, Rossello A, Innocenti A, Scozzafava A, Supuran CT",,435728,DTCT0024844,2079349,DTCC00449748,1555229,22603
CHEMBL227567,P14780,,FUTYODHCEHIGHB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17276072,IC50,=,2000,NM,,cell_based,,,,,,,,,,,,Inhibition of human recombinant MMP9 expressed in mouse myeloma cells,,Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.,Bioorg. Med. Chem.,2007,15,6,"Nuti E, Orlandini E, Nencetti S, Rossello A, Innocenti A, Scozzafava A, Supuran CT",,435728,DTCT0024844,2079354,DTCC00449743,260406,22603
CHEMBL227598,P14780,,VKFNDAOTTJONML-LJQANCHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17088065,IC50,=,24,NM,,cell_based,,,,,,,,,,,,Inhibition of human recombinant MMP9 expressed in mouse myeloma cells,,alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.,Bioorg. Med. Chem.,2007,15,2,"Biasone A, Tortorella P, Campestre C, Agamennone M, Preziuso S, Chiappini M, Nuti E, Carelli P, Rossello A, Mazza F, Gallina C",,432507,DTCT0024844,2061808,DTCC00447803,972589,22402
CHEMBL227824,P14780,,RVKPGECPCLBLDB-GOSISDBHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17088065,IC50,=,0.56,NM,,cell_based,,,,,,,,,,,,Inhibition of human recombinant MMP9 expressed in mouse myeloma cells,,alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.,Bioorg. Med. Chem.,2007,15,2,"Biasone A, Tortorella P, Campestre C, Agamennone M, Preziuso S, Chiappini M, Nuti E, Carelli P, Rossello A, Mazza F, Gallina C",,432507,DTCT0024844,2061809,DTCC00447798,940549,22402
CHEMBL227934,P14780,STRYCHNINE,QMGVPVSNSZLJIA-FVWCLLPLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7456383,DTCC00448002,1092350,46191
CHEMBL227934,P14780,STRYCHNINE,QMGVPVSNSZLJIA-FVWCLLPLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7456384,DTCC00448002,1092350,46191
CHEMBL228141,P14780,,AGSXHHFUSDGSSO-LJQANCHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17088065,IC50,=,680,NM,,cell_based,,,,,,,,,,,,Inhibition of human recombinant MMP9 expressed in mouse myeloma cells,,alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.,Bioorg. Med. Chem.,2007,15,2,"Biasone A, Tortorella P, Campestre C, Agamennone M, Preziuso S, Chiappini M, Nuti E, Carelli P, Rossello A, Mazza F, Gallina C",,432507,DTCT0024844,2061800,DTCC00447839,520801,22402
CHEMBL228176,P14780,,PJOVXZAUKZMBRM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17276072,IC50,=,1830,NM,,cell_based,,,,,,,,,,,,Inhibition of human recombinant MMP9 expressed in mouse myeloma cells,,Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.,Bioorg. Med. Chem.,2007,15,6,"Nuti E, Orlandini E, Nencetti S, Rossello A, Innocenti A, Scozzafava A, Supuran CT",,435728,DTCT0024844,2079353,DTCC00449744,293688,22603
CHEMBL228187,P14780,,NZKKRYAESABOSS-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17088065,IC50,=,170,NM,,cell_based,,,,,,,,,,,,Inhibition of human recombinant MMP9 expressed in mouse myeloma cells,,alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.,Bioorg. Med. Chem.,2007,15,2,"Biasone A, Tortorella P, Campestre C, Agamennone M, Preziuso S, Chiappini M, Nuti E, Carelli P, Rossello A, Mazza F, Gallina C",,432507,DTCT0024844,2061804,DTCC00447819,1684493,22402
CHEMBL228188,P14780,,BGBWSADVPWNBME-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17088065,IC50,=,160,NM,,cell_based,,,,,,,,,,,,Inhibition of human recombinant MMP9 expressed in mouse myeloma cells,,alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.,Bioorg. Med. Chem.,2007,15,2,"Biasone A, Tortorella P, Campestre C, Agamennone M, Preziuso S, Chiappini M, Nuti E, Carelli P, Rossello A, Mazza F, Gallina C",,432507,DTCT0024844,2061803,DTCC00447820,1102691,22402
CHEMBL228229,P14780,,JNDVWCINXNIDOF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17276072,IC50,=,141000,NM,,cell_based,,,,,,,,,,,,Inhibition of human recombinant MMP9 expressed in mouse myeloma cells,,Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.,Bioorg. Med. Chem.,2007,15,6,"Nuti E, Orlandini E, Nencetti S, Rossello A, Innocenti A, Scozzafava A, Supuran CT",,435728,DTCT0024844,2079348,DTCC00449749,1263675,22603
CHEMBL228230,P14780,,MTXWGHZYBWXADO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17276072,IC50,=,81500,NM,,cell_based,,,,,,,,,,,,Inhibition of human recombinant MMP9 expressed in mouse myeloma cells,,Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.,Bioorg. Med. Chem.,2007,15,6,"Nuti E, Orlandini E, Nencetti S, Rossello A, Innocenti A, Scozzafava A, Supuran CT",,435728,DTCT0024844,2079347,DTCC00449750,1523089,22603
CHEMBL228230,P14780,,MTXWGHZYBWXADO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26638045,IC50,=,81000,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP9 after 2 hrs using FS-6 as substrate by fluorometry,,"Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors.",Eur. J. Med. Chem.,2016,108,,"Sjli S, Nuti E, Camodeca C, Bilto I, Rossello A, Winberg JO, Sylte I, Adekoya OA.",,1550087,DTCT0024844,59808,DTCC00449750,1519347,65811
CHEMBL228231,P14780,,OISVGEVVTLNTBZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17276072,IC50,=,352000,NM,,cell_based,,,,,,,,,,,,Inhibition of human recombinant MMP9 expressed in mouse myeloma cells,,Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.,Bioorg. Med. Chem.,2007,15,6,"Nuti E, Orlandini E, Nencetti S, Rossello A, Innocenti A, Scozzafava A, Supuran CT",,435728,DTCT0024844,2079345,DTCC00449752,1166128,22603
CHEMBL228267,P14780,,HGNMRIKSORWTLJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17368021,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).",Bioorg. Med. Chem. Lett.,2007,17,10,"Sheppeck JE, Gilmore JL, Tebben A, Xue CB, Liu RQ, Decicco CP, Duan JJ",,438534,DTCT0024844,2101596,DTCC00455485,1437635,22885
CHEMBL229070,P14780,,BDTGEWQPSASMAZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17188863,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2007,17,5,"Sheppeck JE, Gilmore JL, Yang A, Chen XT, Xue CB, Roderick J, Liu RQ, Covington MB, Decicco CP, Duan JJ",,453871,DTCT0024844,2221452,DTCC00455480,391848,24252
CHEMBL229070,P14780,,BDTGEWQPSASMAZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17368021,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).",Bioorg. Med. Chem. Lett.,2007,17,10,"Sheppeck JE, Gilmore JL, Tebben A, Xue CB, Liu RQ, Decicco CP, Duan JJ",,438534,DTCT0024844,2101590,DTCC00455480,403563,22885
CHEMBL229239,P14780,5-FLUOROSALICYLIC ACID,JWPRICQKUNODPZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,21,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5096298,DTCC00002746,183414,43205
CHEMBL229383,P14780,NYSTATIN,VQOXZBDYSJBXMA-VHFLTRTASA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7379987,DTCC00451716,51495,46191
CHEMBL229383,P14780,NYSTATIN,VQOXZBDYSJBXMA-VHFLTRTASA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7379988,DTCC00451716,51495,46191
CHEMBL229844,P14780,N-(4-HYDROXYPHENYL)CINNAMAMIDE,WSRJZGPYPSPGLJ-IZZDOVSWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,6.19,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833588,DTCC00002737,416566,53968
CHEMBL23,P14780,DILTIAZEM,HSUGRBWQSSZJOP-RTWAWAEBSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7361944,DTCC00133282,866019,46191
CHEMBL23,P14780,DILTIAZEM,HSUGRBWQSSZJOP-RTWAWAEBSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7361945,DTCC00133282,866019,46191
CHEMBL230806,P14780,AGELADINE A,QAKGJAQGTQLMFN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21413800,IC50,=,0.79,UG.ML-1,,,,,,,,,,,,,,Inhibition of MMP9,,A one-pot synthesis and biological activity of ageladine A and analogues.,J. Med. Chem.,2011,54,7,"Shengule SR, Loa-Kum-Cheung WL, Parish CR, Blairvacq M, Meijer L, Nakao Y, Karuso P",,853826,DTCT0024844,11368657,DTCC00454296,1189861,50935
CHEMBL2311189,P14780,,ZZEXJLFHXHHYNW-FAUQPBOCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15857146,IC50,=,200,NM,,,,,,,,,,,,,,In vitro inhibition of human Matrix metalloprotease 9,,C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging.,J. Med. Chem.,2005,48,9,"Breyholz HJ, Schäfers M, Wagner S, Höltke C, Faust A, Rabeneck H, Levkau B, Schober O, Kopka K",,305106,DTCT0024844,1828969,DTCC01335054,1469469,19718
CHEMBL2311765,P14780,,WPGRSZLFNFYSPR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23246356,IC50,=,71,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP-9 after 45 mins by fluorogenic assay,,MMP inhibition by barbiturate homodimers.,Bioorg. Med. Chem. Lett.,2013,23,2,"Wang J, Radomski MW, Medina C, Gilmer JF",,935677,DTCT0024844,11750470,DTCC01335238,770711,53282
CHEMBL2311766,P14780,,XLNFBXKUCFOQRQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23246356,IC50,=,131,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP-9 after 45 mins by fluorogenic assay,,MMP inhibition by barbiturate homodimers.,Bioorg. Med. Chem. Lett.,2013,23,2,"Wang J, Radomski MW, Medina C, Gilmer JF",,935677,DTCT0024844,11750469,DTCC01335239,1897286,53282
CHEMBL2311766,P14780,,XLNFBXKUCFOQRQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23246356,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of MMP-9-mediated hepatocyte growth factor-induced human Caco2 cell invasion at 100 nM after 72 hrs by matrigel cell invasion assay,Active,MMP inhibition by barbiturate homodimers.,Bioorg. Med. Chem. Lett.,2013,23,2,"Wang J, Radomski MW, Medina C, Gilmer JF",,935411,DTCT0024844,11750417,DTCC01335239,1897286,53282
CHEMBL2311767,P14780,,DRCOOMXUPYOBBW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23246356,IC50,=,120,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP-9 after 45 mins by fluorogenic assay,,MMP inhibition by barbiturate homodimers.,Bioorg. Med. Chem. Lett.,2013,23,2,"Wang J, Radomski MW, Medina C, Gilmer JF",,935677,DTCT0024844,11750468,DTCC01335240,900591,53282
CHEMBL2311768,P14780,,BZTZPJQXNWROKR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23246356,IC50,=,81,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP-9 after 45 mins by fluorogenic assay,,MMP inhibition by barbiturate homodimers.,Bioorg. Med. Chem. Lett.,2013,23,2,"Wang J, Radomski MW, Medina C, Gilmer JF",,935677,DTCT0024844,11750467,DTCC01335241,674087,53282
CHEMBL2311769,P14780,,BUELAJMDFCPTAV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23246356,IC50,=,222,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP-9 after 45 mins by fluorogenic assay,,MMP inhibition by barbiturate homodimers.,Bioorg. Med. Chem. Lett.,2013,23,2,"Wang J, Radomski MW, Medina C, Gilmer JF",,935677,DTCT0024844,11750466,DTCC01335242,1995132,53282
CHEMBL2311770,P14780,,FHCIUVTYGHWJQR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23246356,IC50,=,144,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP-9 after 45 mins by fluorogenic assay,,MMP inhibition by barbiturate homodimers.,Bioorg. Med. Chem. Lett.,2013,23,2,"Wang J, Radomski MW, Medina C, Gilmer JF",,935677,DTCT0024844,11750465,DTCC01335243,996895,53282
CHEMBL2311771,P14780,,UKASSNVNXOWYDK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23246356,IC50,=,50,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP-9 after 45 mins by fluorogenic assay,,MMP inhibition by barbiturate homodimers.,Bioorg. Med. Chem. Lett.,2013,23,2,"Wang J, Radomski MW, Medina C, Gilmer JF",,935677,DTCT0024844,11750464,DTCC01335244,416242,53282
CHEMBL2311771,P14780,,UKASSNVNXOWYDK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23246356,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of MMP-9-mediated hepatocyte growth factor-induced human Caco2 cell invasion at 100 nM after 72 hrs by matrigel cell invasion assay,Active,MMP inhibition by barbiturate homodimers.,Bioorg. Med. Chem. Lett.,2013,23,2,"Wang J, Radomski MW, Medina C, Gilmer JF",,935411,DTCT0024844,11750416,DTCC01335244,416242,53282
CHEMBL2311772,P14780,,VEDBWSBFHMUYOA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23246356,IC50,=,13,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP-9 after 45 mins by fluorogenic assay,,MMP inhibition by barbiturate homodimers.,Bioorg. Med. Chem. Lett.,2013,23,2,"Wang J, Radomski MW, Medina C, Gilmer JF",,935677,DTCT0024844,11750463,DTCC01335245,1320712,53282
CHEMBL2311773,P14780,,VPYJEILNNUZOBL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23246356,IC50,=,608,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP-9 after 45 mins by fluorogenic assay,,MMP inhibition by barbiturate homodimers.,Bioorg. Med. Chem. Lett.,2013,23,2,"Wang J, Radomski MW, Medina C, Gilmer JF",,935677,DTCT0024844,11750462,DTCC01335246,576898,53282
CHEMBL2311774,P14780,,PHKLGXHLOXCURO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23246356,IC50,=,85,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP-9 after 45 mins by fluorogenic assay,,MMP inhibition by barbiturate homodimers.,Bioorg. Med. Chem. Lett.,2013,23,2,"Wang J, Radomski MW, Medina C, Gilmer JF",,935677,DTCT0024844,11750475,DTCC01335247,1800637,53282
CHEMBL2311774,P14780,,PHKLGXHLOXCURO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23246356,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of MMP-9-mediated hepatocyte growth factor-induced human Caco2 cell invasion at 100 nM after 72 hrs by matrigel cell invasion assay,Active,MMP inhibition by barbiturate homodimers.,Bioorg. Med. Chem. Lett.,2013,23,2,"Wang J, Radomski MW, Medina C, Gilmer JF",,935411,DTCT0024844,11750421,DTCC01335247,1800637,53282
CHEMBL2311775,P14780,,XATUMTIXUAJCSA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23246356,IC50,=,188,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP-9 after 45 mins by fluorogenic assay,,MMP inhibition by barbiturate homodimers.,Bioorg. Med. Chem. Lett.,2013,23,2,"Wang J, Radomski MW, Medina C, Gilmer JF",,935677,DTCT0024844,11750474,DTCC01335248,383300,53282
CHEMBL2311775,P14780,,XATUMTIXUAJCSA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23246356,INHIBITION,=,70,%,,,,,,,,,,,,,,Inhibition of MMP-9-mediated hepatocyte growth factor-induced human Caco2 cell invasion at 10 uM after 72 hrs by matrigel cell invasion assay,,MMP inhibition by barbiturate homodimers.,Bioorg. Med. Chem. Lett.,2013,23,2,"Wang J, Radomski MW, Medina C, Gilmer JF",,935412,DTCT0024844,11750422,DTCC01335248,383300,53282
CHEMBL2311775,P14780,,XATUMTIXUAJCSA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23246356,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of MMP-9-mediated hepatocyte growth factor-induced human Caco2 cell invasion at 100 nM after 72 hrs by matrigel cell invasion assay,Active,MMP inhibition by barbiturate homodimers.,Bioorg. Med. Chem. Lett.,2013,23,2,"Wang J, Radomski MW, Medina C, Gilmer JF",,935411,DTCT0024844,11750420,DTCC01335248,383300,53282
CHEMBL2311776,P14780,,HTUSESRFPXTJLY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23246356,IC50,=,115,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP-9 after 45 mins by fluorogenic assay,,MMP inhibition by barbiturate homodimers.,Bioorg. Med. Chem. Lett.,2013,23,2,"Wang J, Radomski MW, Medina C, Gilmer JF",,935677,DTCT0024844,11750473,DTCC01335249,1768162,53282
CHEMBL2311776,P14780,,HTUSESRFPXTJLY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23246356,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of MMP-9-mediated hepatocyte growth factor-induced human Caco2 cell invasion at 100 nM after 72 hrs by matrigel cell invasion assay,Active,MMP inhibition by barbiturate homodimers.,Bioorg. Med. Chem. Lett.,2013,23,2,"Wang J, Radomski MW, Medina C, Gilmer JF",,935411,DTCT0024844,11750419,DTCC01335249,1768162,53282
CHEMBL2311777,P14780,,LYRSIRCJLISGFP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23246356,IC50,=,121,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP-9 after 45 mins by fluorogenic assay,,MMP inhibition by barbiturate homodimers.,Bioorg. Med. Chem. Lett.,2013,23,2,"Wang J, Radomski MW, Medina C, Gilmer JF",,935677,DTCT0024844,11750472,DTCC01335250,2027994,53282
CHEMBL2311777,P14780,,LYRSIRCJLISGFP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23246356,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of MMP-9-mediated hepatocyte growth factor-induced human Caco2 cell invasion at 100 nM after 72 hrs by matrigel cell invasion assay,Active,MMP inhibition by barbiturate homodimers.,Bioorg. Med. Chem. Lett.,2013,23,2,"Wang J, Radomski MW, Medina C, Gilmer JF",,935411,DTCT0024844,11750418,DTCC01335250,2027994,53282
CHEMBL2311778,P14780,,WDDBBBHPBMFFCX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23246356,IC50,=,80,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP-9 after 45 mins by fluorogenic assay,,MMP inhibition by barbiturate homodimers.,Bioorg. Med. Chem. Lett.,2013,23,2,"Wang J, Radomski MW, Medina C, Gilmer JF",,935677,DTCT0024844,11750471,DTCC01335251,446880,53282
CHEMBL2316256,P14780,,RXBMEHOLQJITJI-LEOXJPRUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23343195,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of human MMP9 using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate by spectrophotometry,Active,Molecular determinants of a selective matrix metalloprotease-12 inhibitor: insights from crystallography and thermodynamic studies.,J. Med. Chem.,2013,56,3,"Czarny B, Stura EA, Devel L, Vera L, Cassar-Lajeunesse E, Beau F, Calderone V, Fragai M, Luchinat C, Dive V",,935213,DTCT0024844,11751205,DTCC01339596,71045,53441
CHEMBL2316257,P14780,,LIUMDGLYGBIKBM-SFYKDHMMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23343195,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of human MMP9 using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate by spectrophotometry,Active,Molecular determinants of a selective matrix metalloprotease-12 inhibitor: insights from crystallography and thermodynamic studies.,J. Med. Chem.,2013,56,3,"Czarny B, Stura EA, Devel L, Vera L, Cassar-Lajeunesse E, Beau F, Calderone V, Fragai M, Luchinat C, Dive V",,935213,DTCT0024844,11751204,DTCC01339597,589403,53441
CHEMBL232086,P14780,,FGPWEPZCTGVLNA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17064892,IC50,=,920,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Identification of potent and selective TACE inhibitors via the S1 pocket.,Bioorg. Med. Chem. Lett.,2007,17,1,"Condon JS, Joseph-McCarthy D, Levin JI, Lombart HG, Lovering FE, Sun L, Wang W, Xu W, Zhang Y",,440763,DTCT0024844,2154028,DTCC00461927,1037560,23077
CHEMBL2326363,P14780,,UIVFNXLDHQCJRY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23458498,IC50,=,107,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin) using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate after 4 hrs by fluorometric assay,,Synthesis and preliminary evaluation in tumor bearing mice of new (18)f-labeled arylsulfone matrix metalloproteinase inhibitors as tracers for positron emission tomography.,J. Med. Chem.,2013,56,6,"Casalini F, Fugazza L, Esposito G, Cabella C, Brioschi C, Cordaro A, D'Angeli L, Bartoli A, Filannino AM, Gringeri CV, Longo DL, Muzio V, Nuti E, Orlandini E, Figlia G, Quattrini A, Tei L, Digilio G, Rossello A, Maiocchi A",,940801,DTCT0024844,11795562,DTCC01344669,199799,53669
CHEMBL2326364,P14780,,XXBXRJDBCMCGGD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23458498,IC50,=,3600,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin) using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate after 4 hrs by fluorometric assay,,Synthesis and preliminary evaluation in tumor bearing mice of new (18)f-labeled arylsulfone matrix metalloproteinase inhibitors as tracers for positron emission tomography.,J. Med. Chem.,2013,56,6,"Casalini F, Fugazza L, Esposito G, Cabella C, Brioschi C, Cordaro A, D'Angeli L, Bartoli A, Filannino AM, Gringeri CV, Longo DL, Muzio V, Nuti E, Orlandini E, Figlia G, Quattrini A, Tei L, Digilio G, Rossello A, Maiocchi A",,940801,DTCT0024844,11795561,DTCC01344670,2040368,53669
CHEMBL2326365,P14780,,CREFCFAJHQSGNR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23458498,IC50,=,1500,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin) using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate after 4 hrs by fluorometric assay,,Synthesis and preliminary evaluation in tumor bearing mice of new (18)f-labeled arylsulfone matrix metalloproteinase inhibitors as tracers for positron emission tomography.,J. Med. Chem.,2013,56,6,"Casalini F, Fugazza L, Esposito G, Cabella C, Brioschi C, Cordaro A, D'Angeli L, Bartoli A, Filannino AM, Gringeri CV, Longo DL, Muzio V, Nuti E, Orlandini E, Figlia G, Quattrini A, Tei L, Digilio G, Rossello A, Maiocchi A",,940801,DTCT0024844,11795560,DTCC01344671,913412,53669
CHEMBL2333287,P14780,,HTYCVVAAKRVDGM-LKCJCFKCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23353736,IC50,=,6700,NM,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin),,Synthesis of derivatives of methyl rosmarinate and their inhibitory activities against matrix metalloproteinase-1 (MMP-1).,Eur. J. Med. Chem.,2013,62,,"Yuan H, Lu W, Wang L, Shan L, Li H, Huang J, Sun Q, Zhang W",,946630,DTCT0024844,11806936,DTCC01346826,868646,53896
CHEMBL2333288,P14780,,HTYCVVAAKRVDGM-IPXXLZSSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23353736,IC50,=,6000,NM,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin),,Synthesis of derivatives of methyl rosmarinate and their inhibitory activities against matrix metalloproteinase-1 (MMP-1).,Eur. J. Med. Chem.,2013,62,,"Yuan H, Lu W, Wang L, Shan L, Li H, Huang J, Sun Q, Zhang W",,946630,DTCT0024844,11806935,DTCC01346827,447178,53896
CHEMBL233629,P14780,,YIIFUMKWGPMPET-LADGPHEKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17276676,IC50,>,2000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,7,"Chen XT, Ghavimi B, Corbett RL, Xue CB, Liu RQ, Covington MB, Qian M, Vaddi KG, Christ DD, Hartman KD, Ribadeneira MD, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,447087,DTCT0024844,2169359,DTCC00464768,1070100,23623
CHEMBL2336335,P14780,N-(4-CHLOROPHENYL)CINNAMAMIDE,LSOIYQMAEOVIGQ-IZZDOVSWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,12.59,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833576,DTCC01349758,1321013,53968
CHEMBL2336336,P14780,,WTSJOZDFIVRLTA-RUDMXATFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,8.22,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833613,DTCC01349759,577250,53968
CHEMBL2336337,P14780,,QQDGGVVFYXVOQK-DHZHZOJOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,7.82,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833611,DTCC01349760,1255977,53968
CHEMBL2336338,P14780,,XWIGBGGXYQBYPB-JXMROGBWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,5.82,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833609,DTCC01349761,835857,53968
CHEMBL2336339,P14780,,OLGQLHIPIBDKPN-RMKNXTFCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,1585.79,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833608,DTCC01349762,1708381,53968
CHEMBL2336340,P14780,,MNOXESDMWKOCBB-XCVCLJGOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,4.25,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833607,DTCC01349763,771008,53968
CHEMBL2336341,P14780,,FCQCRGCQYBHIKM-DHZHZOJOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,5.91,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833606,DTCC01349764,188047,53968
CHEMBL2336342,P14780,,GVKCJQMPJDFTJX-JXMROGBWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,1659.85,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833605,DTCC01349765,188048,53968
CHEMBL2336343,P14780,,NAWGIDSZZLHVGD-NYYWCZLTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,4.32,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833604,DTCC01349766,512972,53968
CHEMBL2336344,P14780,,HKSVMOLUXTUBKV-DHZHZOJOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,5.97,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833603,DTCC01349767,609569,53968
CHEMBL2336345,P14780,,JKVBUPKDMBQGAH-JXMROGBWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,1685.93,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833602,DTCC01349768,416565,53968
CHEMBL2336346,P14780,4-METHYL-(4'-HYDROXY)CINNAMANILIDE,JKPCWPAVEKIDRM-IZZDOVSWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,4.41,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833600,DTCC01349769,2028326,53968
CHEMBL2336347,P14780,,MEZDZNCLUJMWCO-JXMROGBWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,8.93,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833599,DTCC01349770,351094,53968
CHEMBL2336348,P14780,,NFRVALKAEKTXJW-RMKNXTFCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,1628.58,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833598,DTCC01349771,1321014,53968
CHEMBL2336349,P14780,,MMEMOVPZWOUUDC-XCVCLJGOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,8.41,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833597,DTCC01349772,1579681,53968
CHEMBL2336350,P14780,,SWSHUSNBFAYRJI-JXMROGBWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,9.34,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833596,DTCC01349773,2092348,53968
CHEMBL2336351,P14780,,ISQOWKBSJWNQFE-XCVCLJGOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,9.19,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833594,DTCC01349774,1095000,53968
CHEMBL2336352,P14780,N-BENZYLCINNAMAMIDE,MPWRITRYGLHZBT-VAWYXSNFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,8.13,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833592,DTCC01349775,609570,53968
CHEMBL2336353,P14780,N-(2-HYDROXYPHENYL)CINNAMAMIDE,CYJJBQPBDGQQFZ-ZHACJKMWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,7.18,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833590,DTCC01349776,351095,53968
CHEMBL2336354,P14780,N-(3-HYDROXYPHENYL)CINNAMAMIDE,IIFFDQOHESPFOL-MDZDMXLPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,1796.72,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833589,DTCC00045986,1612247,53968
CHEMBL2336355,P14780,N-(2-METHOXYPHENYL)CINNAMAMIDE,RMBQQMJNYKVGEL-VAWYXSNFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,7.29,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833587,DTCC01349777,123576,53968
CHEMBL2336356,P14780,N-(3-METHOXYPHENYL)CINNAMAMIDE,GVTLFGJNTIRUEG-ZHACJKMWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,1976.83,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833586,DTCC00045987,1515435,53968
CHEMBL2336357,P14780,N-(4-METHOXYPHENYL)CINNAMAMIDE,WEMJCDDYUBVWRB-KPKJPENVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,6.21,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833585,DTCC01349778,1190743,53968
CHEMBL2336358,P14780,N-O-TOLYLCINNAMAMIDE,VHCQQXKZAMLIPM-VAWYXSNFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,7.38,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833584,DTCC01349779,932806,53968
CHEMBL2336359,P14780,N-P-TOLYLCINNAMAMIDE,BZTAHBIRTCNRAW-FMIVXFBMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,6.38,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833582,DTCC01349780,1929599,53968
CHEMBL2336360,P14780,N-(3-FLUOROPHENYL)CINNAMAMIDE,SQJXVMSLVGLGQR-MDZDMXLPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,1910.47,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833580,DTCC00045988,1386355,53968
CHEMBL2336361,P14780,N-(4-FLUOROPHENYL)CINNAMAMIDE,FSGUMUYMSDYGOB-IZZDOVSWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,10.26,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833579,DTCC01349781,1450491,53968
CHEMBL2336362,P14780,3-HYDROXY-CINNAMANILIDE,BXDHXEGLUPHJCL-MDZDMXLPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,7.52,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833631,DTCC01349782,1579682,53968
CHEMBL2336363,P14780,,ZGEIJYNGFAYBLZ-MDZDMXLPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,7.57,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833630,DTCC01349783,2092349,53968
CHEMBL2336364,P14780,,KOHQEJQWHDVMAG-MDZDMXLPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,7.63,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833629,DTCC01349784,188049,53968
CHEMBL2336365,P14780,,YFNMOUZZAUENGW-CMDGGOBGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,5.71,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833628,DTCC01349785,447220,53968
CHEMBL2336366,P14780,,GMZUXMRGXGHDIM-BQYQJAHWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,1561.56,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833627,DTCC01349786,835858,53968
CHEMBL2336779,P14780,,WADSTQPPRBFDRC-RUDMXATFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,3.37,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833626,DTCC01350185,1929606,53968
CHEMBL2336780,P14780,,XSGGJVXCEQZANP-MDZDMXLPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,5.82,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833625,DTCC01350186,674449,53968
CHEMBL2336781,P14780,,SBHIDPHFTJXXDA-CMDGGOBGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,1658.63,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833624,DTCC01350187,1833246,53968
CHEMBL2336782,P14780,,KEKJEZHUSREKBJ-BJMVGYQFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,3.42,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833623,DTCC01350188,932809,53968
CHEMBL2336783,P14780,,JAWRIGQGECSYFZ-MDZDMXLPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,5.91,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833622,DTCC01350189,2092344,53968
CHEMBL2336784,P14780,,IMHFDXPRVKWYLM-CMDGGOBGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,1758.72,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833620,DTCC01350190,997224,53968
CHEMBL2336785,P14780,4-METHYL-(3'-HYDROXY)CINNAMANILIDE,JYPMYOZVAOWZEW-JXMROGBWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,3.51,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833619,DTCC01350191,964988,53968
CHEMBL2336786,P14780,,QCDWMGBNZNDWIQ-CMDGGOBGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,8.02,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833618,DTCC01350192,1061925,53968
CHEMBL2336787,P14780,,FTPPVEIEMOLRCH-BQYQJAHWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,1859.82,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833617,DTCC01350193,771013,53968
CHEMBL2336788,P14780,,LEZHWFABXKSTPU-RUDMXATFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,7.79,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833616,DTCC01350194,252608,53968
CHEMBL2336789,P14780,,OMUJIZDFZQJYDG-CMDGGOBGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,8.32,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833615,DTCC01350195,1547464,53968
CHEMBL2337130,P14780,,BEZJPBNIFWANDL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23287054,IC50,,,,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin),Not Determined,Sulphonamides: Deserving class as MMP inhibitors?,Eur. J. Med. Chem.,2013,60,,"Jain P, Saravanan C, Singh SK",,944094,DTCT0024844,11835650,DTCC01350532,56348,53820
CHEMBL2337131,P14780,,AJAHTKZXCRUIAR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23287054,IC50,,,,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin),Not Determined,Sulphonamides: Deserving class as MMP inhibitors?,Eur. J. Med. Chem.,2013,60,,"Jain P, Saravanan C, Singh SK",,944094,DTCT0024844,11835648,DTCC01350533,1061928,53820
CHEMBL2337691,P14780,,ZVJILQAAQQNBOP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24044434,IC50,=,96,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 4 hrs measured every 15 secs for 20 mins by fluorimetric assay,,Selective arylsulfonamide inhibitors of ADAM-17: hit optimization and activity in ovarian cancer cell models.,J. Med. Chem.,2013,56,20,"Nuti E, Casalini F, Santamaria S, Fabbi M, Carbotti G, Ferrini S, Marinelli L, La Pietra V, Novellino E, Camodeca C, Orlandini E, Nencetti S, Rossello A",,984235,DTCT0024844,12586847,DTCC01351074,868999,55984
CHEMBL233842,P14780,,LBHPINDOHXBHHL-UKILVPOCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17276676,IC50,>,2000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,7,"Chen XT, Ghavimi B, Corbett RL, Xue CB, Liu RQ, Covington MB, Qian M, Vaddi KG, Christ DD, Hartman KD, Ribadeneira MD, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,447087,DTCT0024844,2169358,DTCC00464769,1135027,23623
CHEMBL233843,P14780,,XDSDBWPXGOPPFL-UKILVPOCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17276676,IC50,>,2000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,7,"Chen XT, Ghavimi B, Corbett RL, Xue CB, Liu RQ, Covington MB, Qian M, Vaddi KG, Christ DD, Hartman KD, Ribadeneira MD, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,447087,DTCT0024844,2169356,DTCC00464771,326448,23623
CHEMBL233844,P14780,,ZASAXMMLZWOHBG-RBBKRZOGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17276676,IC50,>,2000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,7,"Chen XT, Ghavimi B, Corbett RL, Xue CB, Liu RQ, Covington MB, Qian M, Vaddi KG, Christ DD, Hartman KD, Ribadeneira MD, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,447087,DTCT0024844,2169355,DTCC00464772,1970813,23623
CHEMBL2338554,P14780,SYMPLOSTATIN 5,KPKJQINJXGFAPS-NBGICTFWSA-M,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23350733,ACTIVITY,=,100,%,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin) using (5-FAM/QXLTM) FRET peptide substrate assessed as residual activity at 10 uM incubated for 15 mins prior to substrate addition measured for 2 hrs,,Potent elastase inhibitors from cyanobacteria: structural basis and mechanisms mediating cytoprotective and anti-inflammatory effects in bronchial epithelial cells.,J. Med. Chem.,2013,56,3,"Salvador LA, Taori K, Biggs JS, Jakoncic J, Ostrov DA, Paul VJ, Luesch H",,944685,DTCT0024844,11803596,DTCC01351885,686495,53882
CHEMBL234032,P14780,,IBWSLBQVCNZYSS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17276676,IC50,>,2000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,7,"Chen XT, Ghavimi B, Corbett RL, Xue CB, Liu RQ, Covington MB, Qian M, Vaddi KG, Christ DD, Hartman KD, Ribadeneira MD, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,447087,DTCT0024844,2169354,DTCC00464773,260537,23623
CHEMBL234033,P14780,,UNCGRKPTWVECFJ-PZJWPPBQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17276676,IC50,>,2000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,7,"Chen XT, Ghavimi B, Corbett RL, Xue CB, Liu RQ, Covington MB, Qian M, Vaddi KG, Christ DD, Hartman KD, Ribadeneira MD, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,447087,DTCT0024844,2169353,DTCC00464774,1684679,23623
CHEMBL234034,P14780,,NMHJSIJTDAPUMQ-RBBKRZOGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17276676,IC50,>,2000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,7,"Chen XT, Ghavimi B, Corbett RL, Xue CB, Liu RQ, Covington MB, Qian M, Vaddi KG, Christ DD, Hartman KD, Ribadeneira MD, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,447087,DTCT0024844,2169352,DTCC00464775,876465,23623
CHEMBL234199,P14780,,KEGZCMGJDRKBBL-UKILVPOCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17276676,IC50,>,2000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,7,"Chen XT, Ghavimi B, Corbett RL, Xue CB, Liu RQ, Covington MB, Qian M, Vaddi KG, Christ DD, Hartman KD, Ribadeneira MD, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,447087,DTCT0024844,2169360,DTCC00464767,260536,23623
CHEMBL234350,P14780,,PUHDBKGWNNZTBP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16220987,KI,=,9,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14759281,DTCC00461900,2111482,69259
CHEMBL234350,P14780,,PUHDBKGWNNZTBP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16220987,KI,=,9,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14759930,DTCC00461900,2111482,69259
CHEMBL234350,P14780,,PUHDBKGWNNZTBP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17064892,IC50,=,9,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Identification of potent and selective TACE inhibitors via the S1 pocket.,Bioorg. Med. Chem. Lett.,2007,17,1,"Condon JS, Joseph-McCarthy D, Levin JI, Lombart HG, Lovering FE, Sun L, Wang W, Xu W, Zhang Y",,440763,DTCT0024844,2153863,DTCC00461900,650170,23077
CHEMBL234529,P14780,,QSOYTCHABFMDFV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19053764,IC50,=,53.7,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates.,J. Med. Chem.,2008,51,24,"Marques SM, Nuti E, Rossello A, Supuran CT, Tuccinardi T, Martinelli A, Santos MA",,561988,DTCT0024844,2800854,DTCC00463157,1071223,31524
CHEMBL234530,P14780,,HFLSBITWFGZVGL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19053764,IC50,=,0.51,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates.,J. Med. Chem.,2008,51,24,"Marques SM, Nuti E, Rossello A, Supuran CT, Tuccinardi T, Martinelli A, Santos MA",,561988,DTCT0024844,2800872,DTCC00111741,1071224,31524
CHEMBL234735,P14780,,LQNSDZTXHZUYKJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19053764,IC50,=,66,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates.,J. Med. Chem.,2008,51,24,"Marques SM, Nuti E, Rossello A, Supuran CT, Tuccinardi T, Martinelli A, Santos MA",,561988,DTCT0024844,2800863,DTCC00111742,1685708,31524
CHEMBL234737,P14780,,IIOCRGOBAHXAAI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19053764,IC50,>,300000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates.,J. Med. Chem.,2008,51,24,"Marques SM, Nuti E, Rossello A, Supuran CT, Tuccinardi T, Martinelli A, Santos MA",,561988,DTCT0024844,2800834,DTCC00463160,392918,31524
CHEMBL234926,P14780,ALLYL ALCOHOL,XXROGKLTLUQVRX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7287173,DTCC00463304,1992799,46191
CHEMBL234926,P14780,ALLYL ALCOHOL,XXROGKLTLUQVRX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7287174,DTCC00463304,1992799,46191
CHEMBL235095,P14780,,BUEVFADAMKTXGD-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17956082,IC50,=,0.5,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.,J. Med. Chem.,2007,50,23,"Wagner S, Breyholz HJ, Law MP, Faust A, Höltke C, Schröer S, Haufe G, Levkau B, Schober O, Schäfers M, Kopka K",,451367,DTCT0024844,2204593,DTCC00471862,195973,24059
CHEMBL235318,P14780,,JOIDQCSRISGBOH-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17956082,IC50,=,9820,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.,J. Med. Chem.,2007,50,23,"Wagner S, Breyholz HJ, Law MP, Faust A, Höltke C, Schröer S, Haufe G, Levkau B, Schober O, Schäfers M, Kopka K",,451367,DTCT0024844,2204592,DTCC00471863,67005,24059
CHEMBL235500,P14780,,XKCXKEBZTDNOFH-HNENSFHCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18221310,IC50,=,100000,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14716123,DTCC00471242,2100348,67810
CHEMBL235916,P14780,,WGTWQHQAJDQPEW-LJQANCHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17956082,IC50,=,614,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.,J. Med. Chem.,2007,50,23,"Wagner S, Breyholz HJ, Law MP, Faust A, Höltke C, Schröer S, Haufe G, Levkau B, Schober O, Schäfers M, Kopka K",,451367,DTCT0024844,2204608,DTCC00471841,228357,24059
CHEMBL235997,P14780,,UUIVGJHXTSUZJO-PZJWPPBQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18061445,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).",Bioorg. Med. Chem. Lett.,2008,18,2,"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ",,463237,DTCT0024844,2296500,DTCC00464760,1231233,25233
CHEMBL236130,P14780,,VUFJIPWRAIIGQA-LJQANCHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17956082,IC50,=,15000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.,J. Med. Chem.,2007,50,23,"Wagner S, Breyholz HJ, Law MP, Faust A, Höltke C, Schröer S, Haufe G, Levkau B, Schober O, Schäfers M, Kopka K",,451367,DTCT0024844,2204607,DTCC00471848,1491086,24059
CHEMBL236446,P14780,,QROXNPLBULDOSL-QGRTWZNFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17512742,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.,Bioorg. Med. Chem.,2007,15,14,"Moroy G, Denhez C, El Mourabit H, Toribio A, Dassonville A, Decarme M, Renault JH, Mirand C, Bellon G, Sapi J, Alix AJ, Hornebeck W, Bourguet E",,447907,DTCT0024844,2176045,DTCC00468601,163984,23716
CHEMBL236565,P14780,,REIYGWGAFRRHED-LJQANCHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17956082,IC50,=,1350,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.,J. Med. Chem.,2007,50,23,"Wagner S, Breyholz HJ, Law MP, Faust A, Höltke C, Schröer S, Haufe G, Levkau B, Schober O, Schäfers M, Kopka K",,451367,DTCT0024844,2204599,DTCC00471856,326506,24059
CHEMBL236770,P14780,,YVCXCHMORKNFGU-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17956082,IC50,=,51,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.,J. Med. Chem.,2007,50,23,"Wagner S, Breyholz HJ, Law MP, Faust A, Höltke C, Schröer S, Haufe G, Levkau B, Schober O, Schäfers M, Kopka K",,451367,DTCT0024844,2204597,DTCC00471858,1716115,24059
CHEMBL2367892,P14780,TEICOPLANIN,DDTDNCYHLGRFBM-YZEKDTGTSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7480815,DTCC01364937,1734064,46191
CHEMBL2367892,P14780,TEICOPLANIN,DDTDNCYHLGRFBM-YZEKDTGTSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7480816,DTCC01364937,1734064,46191
CHEMBL236974,P14780,,YJBLORWBSQLNFW-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17956082,IC50,=,5150,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.,J. Med. Chem.,2007,50,23,"Wagner S, Breyholz HJ, Law MP, Faust A, Höltke C, Schröer S, Haufe G, Levkau B, Schober O, Schäfers M, Kopka K",,451367,DTCT0024844,2204603,DTCC00471852,1841312,24059
CHEMBL237078,P14780,,BBUFBPSZYHVWGA-RSKCKNFOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17512742,IC50,=,974,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.,Bioorg. Med. Chem.,2007,15,14,"Moroy G, Denhez C, El Mourabit H, Toribio A, Dassonville A, Decarme M, Renault JH, Mirand C, Bellon G, Sapi J, Alix AJ, Hornebeck W, Bourguet E",,447907,DTCT0024844,2176043,DTCC00468626,972772,23716
CHEMBL237177,P14780,,GYLCNFGXAVLQBI-LJQANCHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17956082,IC50,=,1300,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.,J. Med. Chem.,2007,50,23,"Wagner S, Breyholz HJ, Law MP, Faust A, Höltke C, Schröer S, Haufe G, Levkau B, Schober O, Schäfers M, Kopka K",,451367,DTCT0024844,2204601,DTCC00471854,1905591,24059
CHEMBL23725,P14780,,SXCBCJFEHSPGNX-KSZLIROESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10340614,KI,<,1,NM,,,,,,,,,,,,,,"Inhibition of MMP-9 (matrix metalloprotease-9, gelatinase B)",,Macrocyclic hydroxamate inhibitors of matrix metalloproteinases and TNF-alpha production.,Bioorg. Med. Chem. Lett.,1999,9,9,"Cherney RJ, Wang L, Meyer DT, Xue CB, Arner EC, Copeland RA, Covington MB, Hardman KD, Wasserman ZR, Jaffee BD, Decicco CP",,102117,DTCT0024844,928985,DTCC00158057,822976,3648
CHEMBL23725,P14780,,SXCBCJFEHSPGNX-KSZLIROESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472217,KI,<,1,NM,,,,,,,,,,,,,,In vitro inhibition of human MMP-9.,,"Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.",J. Med. Chem.,2001,44,16,"Xue CB, Voss ME, Nelson DJ, Duan JJ, Cherney RJ, Jacobson IC, He X, Roderick J, Chen L, Corbett RL, Wang L, Meyer DT, Kennedy K, DeGradodagger WF, Hardman KD, Teleha CA, Jaffee BD, Liu RQ, Copeland RA, Covington MB, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105380,DTCT0024844,1676545,DTCC00158057,808788,16346
CHEMBL237384,P14780,,PMSJHLLBCDOJAE-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17956082,IC50,=,414,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.,J. Med. Chem.,2007,50,23,"Wagner S, Breyholz HJ, Law MP, Faust A, Höltke C, Schröer S, Haufe G, Levkau B, Schober O, Schäfers M, Kopka K",,451367,DTCT0024844,2204606,DTCC00471849,521031,24059
CHEMBL2380314,P14780,,ZXVWNUSVQOQAIY-ZEQRLZLVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23631440,KI,=,2.4,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin) using Mca-PLGLDpa-AR-NH2 as substrate preincubated for 30 mins by fluorescence assay,,Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.,J. Med. Chem.,2013,56,11,"Jin Y, Roycik MD, Bosco DB, Cao Q, Constantino MH, Schwartz MA, Sang QX",,959634,DTCT0024844,12429896,DTCC01373961,1256045,54589
CHEMBL2380387,P14780,,WSFQQGCWUCOARG-NMLBUPMWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23631440,KI,=,5.7,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin) using Mca-PLGLDpa-AR-NH2 as substrate preincubated for 30 mins by fluorescence assay,,Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.,J. Med. Chem.,2013,56,11,"Jin Y, Roycik MD, Bosco DB, Cao Q, Constantino MH, Schwartz MA, Sang QX",,959634,DTCT0024844,12429913,DTCC01373946,1865323,54589
CHEMBL2380388,P14780,,KJNZDUKNEQXTSO-LIONHTAISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23631440,KI,=,4.9,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin) using Mca-PLGLDpa-AR-NH2 as substrate preincubated for 30 mins by fluorescence assay,,Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.,J. Med. Chem.,2013,56,11,"Jin Y, Roycik MD, Bosco DB, Cao Q, Constantino MH, Schwartz MA, Sang QX",,959634,DTCT0024844,12429912,DTCC01373947,123665,54589
CHEMBL2380389,P14780,,QDPILJAKSNERSV-YAOOYPAMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23631440,KI,=,3.9,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin) using Mca-PLGLDpa-AR-NH2 as substrate preincubated for 30 mins by fluorescence assay,,Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.,J. Med. Chem.,2013,56,11,"Jin Y, Roycik MD, Bosco DB, Cao Q, Constantino MH, Schwartz MA, Sang QX",,959634,DTCT0024844,12429911,DTCC01373948,1062010,54589
CHEMBL2380390,P14780,,RYDPXGZLAKQPJB-AUAHOFGGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23631440,KI,=,0.98,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin) using Mca-PLGLDpa-AR-NH2 as substrate preincubated for 30 mins by fluorescence assay,,Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.,J. Med. Chem.,2013,56,11,"Jin Y, Roycik MD, Bosco DB, Cao Q, Constantino MH, Schwartz MA, Sang QX",,959634,DTCT0024844,12429910,DTCC01373949,577338,54589
CHEMBL2380391,P14780,,YTQYMJLEQVXIPD-SJORKVTESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23631440,KI,=,970,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin) using Mca-PLGLDpa-AR-NH2 as substrate preincubated for 30 mins by fluorescence assay,,Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.,J. Med. Chem.,2013,56,11,"Jin Y, Roycik MD, Bosco DB, Cao Q, Constantino MH, Schwartz MA, Sang QX",,959634,DTCT0024844,12429909,DTCC01373950,1995520,54589
CHEMBL2380391,P14780,,YTQYMJLEQVXIPD-SJORKVTESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23631440,KI,>,1600,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin) using Mca-PLGLDpa-AR-NH2 as substrate preincubated for 30 mins by fluorescence assay,,Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.,J. Med. Chem.,2013,56,11,"Jin Y, Roycik MD, Bosco DB, Cao Q, Constantino MH, Schwartz MA, Sang QX",,959634,DTCT0024844,12429908,DTCC01373950,1995521,54589
CHEMBL2380392,P14780,,YTQYMJLEQVXIPD-DLBZAZTESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23631440,KI,=,280,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin) using Mca-PLGLDpa-AR-NH2 as substrate preincubated for 30 mins by fluorescence assay,,Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.,J. Med. Chem.,2013,56,11,"Jin Y, Roycik MD, Bosco DB, Cao Q, Constantino MH, Schwartz MA, Sang QX",,959634,DTCT0024844,12429907,DTCC01373951,1929711,54589
CHEMBL2380393,P14780,,IVYZHWRIIPQLOI-QWRGUYRKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23631440,KI,=,9600,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin) using Mca-PLGLDpa-AR-NH2 as substrate preincubated for 30 mins by fluorescence assay,,Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.,J. Med. Chem.,2013,56,11,"Jin Y, Roycik MD, Bosco DB, Cao Q, Constantino MH, Schwartz MA, Sang QX",,959634,DTCT0024844,12429906,DTCC01373952,1929712,54589
CHEMBL2380394,P14780,,XBPHJVRPJAQGKS-IRXDYDNUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23631440,KI,=,630,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin) using Mca-PLGLDpa-AR-NH2 as substrate preincubated for 30 mins by fluorescence assay,,Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.,J. Med. Chem.,2013,56,11,"Jin Y, Roycik MD, Bosco DB, Cao Q, Constantino MH, Schwartz MA, Sang QX",,959634,DTCT0024844,12429905,DTCC01373953,706586,54589
CHEMBL2380395,P14780,,YTQYMJLEQVXIPD-IRXDYDNUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23631440,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin) at 10000 x IC50 incubated up to 72 hrs prior to enzyme addition measured after 30 mins in presence of 20% fetal bovine serum,Active,Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.,J. Med. Chem.,2013,56,11,"Jin Y, Roycik MD, Bosco DB, Cao Q, Constantino MH, Schwartz MA, Sang QX",,959629,DTCT0024844,12429847,DTCC01373954,1962829,54589
CHEMBL2380395,P14780,,YTQYMJLEQVXIPD-IRXDYDNUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23631440,KI,=,25,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin) using Mca-PLGLDpa-AR-NH2 as substrate preincubated for 30 mins by fluorescence assay,,Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.,J. Med. Chem.,2013,56,11,"Jin Y, Roycik MD, Bosco DB, Cao Q, Constantino MH, Schwartz MA, Sang QX",,959634,DTCT0024844,12429904,DTCC01373954,1962829,54589
CHEMBL2380395,P14780,,YTQYMJLEQVXIPD-IRXDYDNUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23631440,KI,=,38,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin) using Mca-PLGLDpa-AR-NH2 as substrate preincubated for 30 mins by fluorescence assay,,Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.,J. Med. Chem.,2013,56,11,"Jin Y, Roycik MD, Bosco DB, Cao Q, Constantino MH, Schwartz MA, Sang QX",,959634,DTCT0024844,12429903,DTCC01373954,1962830,54589
CHEMBL2380396,P14780,,YTQYMJLEQVXIPD-IAGOWNOFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23631440,KI,=,42,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin) using Mca-PLGLDpa-AR-NH2 as substrate preincubated for 30 mins by fluorescence assay,,Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.,J. Med. Chem.,2013,56,11,"Jin Y, Roycik MD, Bosco DB, Cao Q, Constantino MH, Schwartz MA, Sang QX",,959634,DTCT0024844,12429902,DTCC01373955,156243,54589
CHEMBL2380397,P14780,,GPFVSBBSRCFVPP-IRXDYDNUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23631440,KI,=,200000,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin) using Mca-PLGLDpa-AR-NH2 as substrate preincubated for 30 mins by fluorescence assay,,Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.,J. Med. Chem.,2013,56,11,"Jin Y, Roycik MD, Bosco DB, Cao Q, Constantino MH, Schwartz MA, Sang QX",,959634,DTCT0024844,12429901,DTCC01373956,738899,54589
CHEMBL2380398,P14780,,WOUSJKQGCHWOAQ-IRXDYDNUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23631440,KI,=,4300,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin) using Mca-PLGLDpa-AR-NH2 as substrate preincubated for 30 mins by fluorescence assay,,Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.,J. Med. Chem.,2013,56,11,"Jin Y, Roycik MD, Bosco DB, Cao Q, Constantino MH, Schwartz MA, Sang QX",,959634,DTCT0024844,12429900,DTCC01373957,480801,54589
CHEMBL2380399,P14780,,HMRLQVJTSOHCLV-MOGJOVFKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23631440,KI,=,210,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin) using Mca-PLGLDpa-AR-NH2 as substrate preincubated for 30 mins by fluorescence assay,,Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.,J. Med. Chem.,2013,56,11,"Jin Y, Roycik MD, Bosco DB, Cao Q, Constantino MH, Schwartz MA, Sang QX",,959634,DTCT0024844,12429892,DTCC01373958,868764,54589
CHEMBL2380399,P14780,,HMRLQVJTSOHCLV-MOGJOVFKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23631440,KI,=,230,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin) using Mca-PLGLDpa-AR-NH2 as substrate preincubated for 30 mins by fluorescence assay,,Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.,J. Med. Chem.,2013,56,11,"Jin Y, Roycik MD, Bosco DB, Cao Q, Constantino MH, Schwartz MA, Sang QX",,959634,DTCT0024844,12429899,DTCC01373958,868763,54589
CHEMBL2380400,P14780,,UJWXVGWYDPXCST-HOTGVXAUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23631440,KI,=,15,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin) using Mca-PLGLDpa-AR-NH2 as substrate preincubated for 30 mins by fluorescence assay,,Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.,J. Med. Chem.,2013,56,11,"Jin Y, Roycik MD, Bosco DB, Cao Q, Constantino MH, Schwartz MA, Sang QX",,959634,DTCT0024844,12429898,DTCC01373959,1579765,54589
CHEMBL2380401,P14780,,BTCYLUBBXQARQV-IRXDYDNUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23631440,KI,=,1.1,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin) using Mca-PLGLDpa-AR-NH2 as substrate preincubated for 30 mins by fluorescence assay,,Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.,J. Med. Chem.,2013,56,11,"Jin Y, Roycik MD, Bosco DB, Cao Q, Constantino MH, Schwartz MA, Sang QX",,959634,DTCT0024844,12429897,DTCC01373960,706587,54589
CHEMBL2380402,P14780,,MUWDEQLPHWVPPA-GOTSBHOMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23631440,KI,=,1.5,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin) using Mca-PLGLDpa-AR-NH2 as substrate preincubated for 30 mins by fluorescence assay,,Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.,J. Med. Chem.,2013,56,11,"Jin Y, Roycik MD, Bosco DB, Cao Q, Constantino MH, Schwartz MA, Sang QX",,959634,DTCT0024844,12429895,DTCC01373962,156244,54589
CHEMBL2380403,P14780,,FHORSTUZHMJGTR-GUTACTQSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23631440,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin) at 10000 x IC50 incubated up to 72 hrs prior to enzyme addition measured after 30 mins in presence of 20% fetal bovine serum,Active,Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.,J. Med. Chem.,2013,56,11,"Jin Y, Roycik MD, Bosco DB, Cao Q, Constantino MH, Schwartz MA, Sang QX",,959629,DTCT0024844,12429846,DTCC01373963,318346,54589
CHEMBL2380403,P14780,,FHORSTUZHMJGTR-GUTACTQSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23631440,KI,=,3.6,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin) using Mca-PLGLDpa-AR-NH2 as substrate preincubated for 30 mins by fluorescence assay,,Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.,J. Med. Chem.,2013,56,11,"Jin Y, Roycik MD, Bosco DB, Cao Q, Constantino MH, Schwartz MA, Sang QX",,959634,DTCT0024844,12429894,DTCC01373963,318346,54589
CHEMBL2380404,P14780,,NCMGDRDFDQYIHA-GUTACTQSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23631440,KI,=,30000,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin) using Mca-PLGLDpa-AR-NH2 as substrate preincubated for 30 mins by fluorescence assay,,Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.,J. Med. Chem.,2013,56,11,"Jin Y, Roycik MD, Bosco DB, Cao Q, Constantino MH, Schwartz MA, Sang QX",,959634,DTCT0024844,12429893,DTCC01373964,1962831,54589
CHEMBL2380405,P14780,,HMRLQVJTSOHCLV-QNBGGDODSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23631440,KI,=,230,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin) using Mca-PLGLDpa-AR-NH2 as substrate preincubated for 30 mins by fluorescence assay,,Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.,J. Med. Chem.,2013,56,11,"Jin Y, Roycik MD, Bosco DB, Cao Q, Constantino MH, Schwartz MA, Sang QX",,959634,DTCT0024844,12429891,DTCC01373965,1736763,54589
CHEMBL2380406,P14780,,IZCZBRLGTKWIIZ-VWTOLEPZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23631440,KI,=,5.3,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin) using Mca-PLGLDpa-AR-NH2 as substrate preincubated for 30 mins by fluorescence assay,,Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.,J. Med. Chem.,2013,56,11,"Jin Y, Roycik MD, Bosco DB, Cao Q, Constantino MH, Schwartz MA, Sang QX",,959634,DTCT0024844,12429914,DTCC01373966,1515507,54589
CHEMBL2385084,P14780,,GTWOZLUSMOSBEV-JOCHJYFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23688254,IC50,=,21,NM,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dpa(Dnp)-Ala-Arg-NH2 as substrate measured up to 120 mins by fluorescence assay,,"Design, synthesis, and initial evaluation of a high affinity positron emission tomography probe for imaging matrix metalloproteinases 2 and 9.",J. Med. Chem.,2013,56,12,"Selivanova SV, Stellfeld T, Heinrich TK, Müller A, Krämer SD, Schubiger PA, Schibli R, Ametamey SM, Vos B, Meding J, Bauser M, Hütter J, Dinkelborg LM",,960848,DTCT0024844,12447048,DTCC01376345,1127107,54747
CHEMBL2385441,P14780,,QZZBJIXIULKRDH-JOCHJYFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23688254,IC50,=,7,NM,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dpa(Dnp)-Ala-Arg-NH2 as substrate measured up to 120 mins by fluorescence assay,,"Design, synthesis, and initial evaluation of a high affinity positron emission tomography probe for imaging matrix metalloproteinases 2 and 9.",J. Med. Chem.,2013,56,12,"Selivanova SV, Stellfeld T, Heinrich TK, Müller A, Krämer SD, Schubiger PA, Schibli R, Ametamey SM, Vos B, Meding J, Bauser M, Hütter J, Dinkelborg LM",,960848,DTCT0024844,12447051,DTCC01376342,1962853,54747
CHEMBL2385442,P14780,,MLTDQJFAHZGYPI-JOCHJYFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23688254,IC50,=,1.1,NM,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dpa(Dnp)-Ala-Arg-NH2 as substrate measured up to 120 mins by fluorescence assay,,"Design, synthesis, and initial evaluation of a high affinity positron emission tomography probe for imaging matrix metalloproteinases 2 and 9.",J. Med. Chem.,2013,56,12,"Selivanova SV, Stellfeld T, Heinrich TK, Müller A, Krämer SD, Schubiger PA, Schibli R, Ametamey SM, Vos B, Meding J, Bauser M, Hütter J, Dinkelborg LM",,960848,DTCT0024844,12447050,DTCC01376343,1223050,54747
CHEMBL2385443,P14780,,MSXPXCLRTNXLCH-HSZRJFAPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23688254,IC50,=,11,NM,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dpa(Dnp)-Ala-Arg-NH2 as substrate measured up to 120 mins by fluorescence assay,,"Design, synthesis, and initial evaluation of a high affinity positron emission tomography probe for imaging matrix metalloproteinases 2 and 9.",J. Med. Chem.,2013,56,12,"Selivanova SV, Stellfeld T, Heinrich TK, Müller A, Krämer SD, Schubiger PA, Schibli R, Ametamey SM, Vos B, Meding J, Bauser M, Hütter J, Dinkelborg LM",,960848,DTCT0024844,12447049,DTCC01376344,1127106,54747
CHEMBL2385444,P14780,,GGDZUSVGHHPSCC-RUZDIDTESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23688254,IC50,=,97,NM,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dpa(Dnp)-Ala-Arg-NH2 as substrate measured up to 120 mins by fluorescence assay,,"Design, synthesis, and initial evaluation of a high affinity positron emission tomography probe for imaging matrix metalloproteinases 2 and 9.",J. Med. Chem.,2013,56,12,"Selivanova SV, Stellfeld T, Heinrich TK, Müller A, Krämer SD, Schubiger PA, Schibli R, Ametamey SM, Vos B, Meding J, Bauser M, Hütter J, Dinkelborg LM",,960848,DTCT0024844,12447047,DTCC01376346,1256066,54747
CHEMBL2385445,P14780,,XCZGTSRWCUGQHZ-AREMUKBSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23688254,IC50,=,460,NM,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dpa(Dnp)-Ala-Arg-NH2 as substrate measured up to 120 mins by fluorescence assay,,"Design, synthesis, and initial evaluation of a high affinity positron emission tomography probe for imaging matrix metalloproteinases 2 and 9.",J. Med. Chem.,2013,56,12,"Selivanova SV, Stellfeld T, Heinrich TK, Müller A, Krämer SD, Schubiger PA, Schibli R, Ametamey SM, Vos B, Meding J, Bauser M, Hütter J, Dinkelborg LM",,960848,DTCT0024844,12447046,DTCC01376347,318372,54747
CHEMBL2385446,P14780,,LABDSZDDNFHLIV-HXUWFJFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23688254,IC50,=,78,NM,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dpa(Dnp)-Ala-Arg-NH2 as substrate measured up to 120 mins by fluorescence assay,,"Design, synthesis, and initial evaluation of a high affinity positron emission tomography probe for imaging matrix metalloproteinases 2 and 9.",J. Med. Chem.,2013,56,12,"Selivanova SV, Stellfeld T, Heinrich TK, Müller A, Krämer SD, Schubiger PA, Schibli R, Ametamey SM, Vos B, Meding J, Bauser M, Hütter J, Dinkelborg LM",,960848,DTCT0024844,12447045,DTCC01376348,2092443,54747
CHEMBL2385447,P14780,,RYJGACKGNMUBMP-HXUWFJFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23688254,IC50,=,17,NM,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dpa(Dnp)-Ala-Arg-NH2 as substrate measured up to 120 mins by fluorescence assay,,"Design, synthesis, and initial evaluation of a high affinity positron emission tomography probe for imaging matrix metalloproteinases 2 and 9.",J. Med. Chem.,2013,56,12,"Selivanova SV, Stellfeld T, Heinrich TK, Müller A, Krämer SD, Schubiger PA, Schibli R, Ametamey SM, Vos B, Meding J, Bauser M, Hütter J, Dinkelborg LM",,960848,DTCT0024844,12447044,DTCC01376349,1158406,54747
CHEMBL2385448,P14780,,HRNGMFYSJLHLOC-HXUWFJFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23688254,IC50,>,1000,NM,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dpa(Dnp)-Ala-Arg-NH2 as substrate measured up to 120 mins by fluorescence assay,,"Design, synthesis, and initial evaluation of a high affinity positron emission tomography probe for imaging matrix metalloproteinases 2 and 9.",J. Med. Chem.,2013,56,12,"Selivanova SV, Stellfeld T, Heinrich TK, Müller A, Krämer SD, Schubiger PA, Schibli R, Ametamey SM, Vos B, Meding J, Bauser M, Hütter J, Dinkelborg LM",,960848,DTCT0024844,12447043,DTCC01376350,1418783,54747
CHEMBL2385449,P14780,,CJDLHVDTFICCKV-OAQYLSRUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23688254,IC50,=,38,NM,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dpa(Dnp)-Ala-Arg-NH2 as substrate measured up to 120 mins by fluorescence assay,,"Design, synthesis, and initial evaluation of a high affinity positron emission tomography probe for imaging matrix metalloproteinases 2 and 9.",J. Med. Chem.,2013,56,12,"Selivanova SV, Stellfeld T, Heinrich TK, Müller A, Krämer SD, Schubiger PA, Schibli R, Ametamey SM, Vos B, Meding J, Bauser M, Hütter J, Dinkelborg LM",,960848,DTCT0024844,12447042,DTCC01376351,901017,54747
CHEMBL2385450,P14780,,TZMCLEOCJWIHKF-JOCHJYFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23688254,IC50,=,230,NM,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dpa(Dnp)-Ala-Arg-NH2 as substrate measured up to 120 mins by fluorescence assay,,"Design, synthesis, and initial evaluation of a high affinity positron emission tomography probe for imaging matrix metalloproteinases 2 and 9.",J. Med. Chem.,2013,56,12,"Selivanova SV, Stellfeld T, Heinrich TK, Müller A, Krämer SD, Schubiger PA, Schibli R, Ametamey SM, Vos B, Meding J, Bauser M, Hütter J, Dinkelborg LM",,960848,DTCT0024844,12447041,DTCC01376352,674549,54747
CHEMBL2385451,P14780,,YYUVVXFBDREZPQ-HSZRJFAPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23688254,IC50,=,100,NM,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dpa(Dnp)-Ala-Arg-NH2 as substrate measured up to 120 mins by fluorescence assay,,"Design, synthesis, and initial evaluation of a high affinity positron emission tomography probe for imaging matrix metalloproteinases 2 and 9.",J. Med. Chem.,2013,56,12,"Selivanova SV, Stellfeld T, Heinrich TK, Müller A, Krämer SD, Schubiger PA, Schibli R, Ametamey SM, Vos B, Meding J, Bauser M, Hütter J, Dinkelborg LM",,960848,DTCT0024844,12447039,DTCC01376353,1929740,54747
CHEMBL24,P14780,ATENOLOL,METKIMKYRPQLGS-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7263773,DTCC00133283,574620,46191
CHEMBL24,P14780,ATENOLOL,METKIMKYRPQLGS-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7263774,DTCC00133283,574620,46191
CHEMBL24054,P14780,,WTLCAILOHVCKNV-LWSSLDFYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12657268,KI,>,2128,NM,,,,,,,,,,,,,,Affinity for Matrix metalloprotease-9 (MMP-9),,Potent and selective aggrecanase inhibitors containing cyclic P1 substituents.,Bioorg. Med. Chem. Lett.,2003,13,7,"Cherney RJ, Mo R, Meyer DT, Wang L, Yao W, Wasserman ZR, Liu RQ, Covington MB, Tortorella MD, Arner EC, Qian M, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Decicco CP",,105369,DTCT0024844,1342408,DTCC00158861,1455105,6242
CHEMBL240963,P14780,LAWSONE,CSFWPUWCSPOLJW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,85,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103706,DTCC00473933,1057327,43205
CHEMBL241048,P14780,,RYFSQVRNVFCETF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17027261,KI,>,2130,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2007,17,1,"Duan JJ, Chen L, Lu Z, Jiang B, Asakawa N, Sheppeck JE, Liu RQ, Covington MB, Pitts W, Kim SH, Decicco CP",,452974,DTCT0024844,2215318,DTCC00477159,83180,24158
CHEMBL241405,P14780,METHYL ROSMARINATE,XHALVRQBZGZHFE-BBOMDTFKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,IC50,=,610,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain incubated for 20 mins by fluorimetric assay,,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827436,DTCT0024844,10535408,DTCC00474227,1267308,48665
CHEMBL241405,P14780,METHYL ROSMARINATE,XHALVRQBZGZHFE-BBOMDTFKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,INHIBITION,>,30,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain at 10 uM incubated for 20 mins by fluorimetric assay,,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827442,DTCT0024844,10535510,DTCC00474227,1267308,48665
CHEMBL241694,P14780,ETHISTERONE,CHNXZKVNWQUJIB-CEGNMAFCSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7307112,DTCC00474598,1674144,46191
CHEMBL241694,P14780,ETHISTERONE,CHNXZKVNWQUJIB-CEGNMAFCSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7307113,DTCC00474598,1674144,46191
CHEMBL242273,P14780,SAFROLE,ZMQAAUBTXCXRIC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7484041,DTCC00455925,315669,46191
CHEMBL242273,P14780,SAFROLE,ZMQAAUBTXCXRIC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7484042,DTCC00455925,315669,46191
CHEMBL2425930,P14780,,PECBDMOWKLTTSB-HSZRJFAPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23899323,IC50,=,3,NM,,,,,,,,,,,,,,"Inhibition of MMP-9 (unknown origin) using 7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl)Ala-Arg-NH2 as substrate preincubated for 30 mins followed by substrate addition by fluorescence assay",,"Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation.",J. Med. Chem.,2013,56,17,"Hugenberg V, Riemann B, Hermann S, Schober O, Schäfers M, Szardenings K, Lebedev A, Gangadharmath U, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,983464,DTCT0024844,12577915,DTCC01394954,1780885,55760
CHEMBL2425931,P14780,,ZTOBNNQGIRZHDO-CYBMUJFWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23899323,IC50,=,4,NM,,,,,,,,,,,,,,"Inhibition of MMP-9 (unknown origin) using 7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl)Ala-Arg-NH2 as substrate preincubated for 30 mins followed by substrate addition by fluorescence assay",,"Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation.",J. Med. Chem.,2013,56,17,"Hugenberg V, Riemann B, Hermann S, Schober O, Schäfers M, Szardenings K, Lebedev A, Gangadharmath U, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,983464,DTCT0024844,12577914,DTCC01394955,396398,55760
CHEMBL2425932,P14780,,XMVQXBAGOTVZDD-GOSISDBHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23899323,IC50,=,3,NM,,,,,,,,,,,,,,"Inhibition of MMP-9 (unknown origin) using 7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl)Ala-Arg-NH2 as substrate preincubated for 30 mins followed by substrate addition by fluorescence assay",,"Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation.",J. Med. Chem.,2013,56,17,"Hugenberg V, Riemann B, Hermann S, Schober O, Schäfers M, Szardenings K, Lebedev A, Gangadharmath U, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,983464,DTCT0024844,12577913,DTCC01394956,977332,55760
CHEMBL2425933,P14780,,UCWSKTMFEWSSSI-AREMUKBSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23899323,IC50,=,0.4,NM,,,,,,,,,,,,,,"Inhibition of MMP-9 (unknown origin) using 7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl)Ala-Arg-NH2 as substrate preincubated for 30 mins followed by substrate addition by fluorescence assay",,"Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation.",J. Med. Chem.,2013,56,17,"Hugenberg V, Riemann B, Hermann S, Schober O, Schäfers M, Szardenings K, Lebedev A, Gangadharmath U, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,983464,DTCT0024844,12577912,DTCC01394957,589788,55760
CHEMBL2425934,P14780,,BDPAGEAOFNRCNJ-HSZRJFAPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23899323,IC50,=,6,NM,,,,,,,,,,,,,,"Inhibition of MMP-9 (unknown origin) using 7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl)Ala-Arg-NH2 as substrate preincubated for 30 mins followed by substrate addition by fluorescence assay",,"Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation.",J. Med. Chem.,2013,56,17,"Hugenberg V, Riemann B, Hermann S, Schober O, Schäfers M, Szardenings K, Lebedev A, Gangadharmath U, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,983464,DTCT0024844,12577911,DTCC01394958,1720338,55760
CHEMBL2425935,P14780,,WCHOGKFWHQMHQW-CQSZACIVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23899323,IC50,=,4,NM,,,,,,,,,,,,,,"Inhibition of MMP-9 (unknown origin) using 7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl)Ala-Arg-NH2 as substrate preincubated for 30 mins followed by substrate addition by fluorescence assay",,"Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation.",J. Med. Chem.,2013,56,17,"Hugenberg V, Riemann B, Hermann S, Schober O, Schäfers M, Szardenings K, Lebedev A, Gangadharmath U, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,983464,DTCT0024844,12577910,DTCC01394959,945221,55760
CHEMBL2425936,P14780,,WTEZGXPTIFMTCH-LJQANCHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23899323,IC50,=,2,NM,,,,,,,,,,,,,,"Inhibition of MMP-9 (unknown origin) using 7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl)Ala-Arg-NH2 as substrate preincubated for 30 mins followed by substrate addition by fluorescence assay",,"Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation.",J. Med. Chem.,2013,56,17,"Hugenberg V, Riemann B, Hermann S, Schober O, Schäfers M, Szardenings K, Lebedev A, Gangadharmath U, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,983464,DTCT0024844,12577909,DTCC01394960,200173,55760
CHEMBL2425937,P14780,,MIKGRMSWGTVOSA-HHHXNRCGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23899323,IC50,=,10,NM,,,,,,,,,,,,,,"Inhibition of MMP-9 (unknown origin) using 7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl)Ala-Arg-NH2 as substrate preincubated for 30 mins followed by substrate addition by fluorescence assay",,"Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation.",J. Med. Chem.,2013,56,17,"Hugenberg V, Riemann B, Hermann S, Schober O, Schäfers M, Szardenings K, Lebedev A, Gangadharmath U, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,983464,DTCT0024844,12577908,DTCC01394961,1720339,55760
CHEMBL2425938,P14780,,XJNFMEAYBQFDAS-XMMPIXPASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23899323,IC50,=,0.8,NM,,,,,,,,,,,,,,"Inhibition of MMP-9 (unknown origin) using 7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl)Ala-Arg-NH2 as substrate preincubated for 30 mins followed by substrate addition by fluorescence assay",,"Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation.",J. Med. Chem.,2013,56,17,"Hugenberg V, Riemann B, Hermann S, Schober O, Schäfers M, Szardenings K, Lebedev A, Gangadharmath U, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,983464,DTCT0024844,12577907,DTCC01394962,686766,55760
CHEMBL2425939,P14780,,CMKYCYOBCXIZPF-HSZRJFAPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23899323,IC50,=,3,NM,,,,,,,,,,,,,,"Inhibition of MMP-9 (unknown origin) using 7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl)Ala-Arg-NH2 as substrate preincubated for 30 mins followed by substrate addition by fluorescence assay",,"Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation.",J. Med. Chem.,2013,56,17,"Hugenberg V, Riemann B, Hermann S, Schober O, Schäfers M, Szardenings K, Lebedev A, Gangadharmath U, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,983464,DTCT0024844,12577906,DTCC01394963,493235,55760
CHEMBL2425940,P14780,,NXCSXUBVRRHHLE-XMMPIXPASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23899323,IC50,=,11,NM,,,,,,,,,,,,,,"Inhibition of MMP-9 (unknown origin) using 7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl)Ala-Arg-NH2 as substrate preincubated for 30 mins followed by substrate addition by fluorescence assay",,"Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation.",J. Med. Chem.,2013,56,17,"Hugenberg V, Riemann B, Hermann S, Schober O, Schäfers M, Szardenings K, Lebedev A, Gangadharmath U, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,983464,DTCT0024844,12577905,DTCC01394964,622205,55760
CHEMBL2425941,P14780,,NTDGKPHATDVYNT-CQSZACIVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23899323,IC50,=,0.07,NM,,,,,,,,,,,,,,"Inhibition of MMP-9 (unknown origin) using 7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl)Ala-Arg-NH2 as substrate preincubated for 30 mins followed by substrate addition by fluorescence assay",,"Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation.",J. Med. Chem.,2013,56,17,"Hugenberg V, Riemann B, Hermann S, Schober O, Schäfers M, Szardenings K, Lebedev A, Gangadharmath U, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,983464,DTCT0024844,12577904,DTCC01394965,913758,55760
CHEMBL2425942,P14780,,VPDOXKSDXTZFIX-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23899323,IC50,=,7,NM,,,,,,,,,,,,,,"Inhibition of MMP-9 (unknown origin) using 7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl)Ala-Arg-NH2 as substrate preincubated for 30 mins followed by substrate addition by fluorescence assay",,"Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation.",J. Med. Chem.,2013,56,17,"Hugenberg V, Riemann B, Hermann S, Schober O, Schäfers M, Szardenings K, Lebedev A, Gangadharmath U, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,983464,DTCT0024844,12577903,DTCC01394966,428918,55760
CHEMBL2425943,P14780,,ADDYZQRMSCIHFH-HSZRJFAPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23899323,IC50,=,0.2,NM,,,,,,,,,,,,,,"Inhibition of MMP-9 (unknown origin) using 7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl)Ala-Arg-NH2 as substrate preincubated for 30 mins followed by substrate addition by fluorescence assay",,"Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation.",J. Med. Chem.,2013,56,17,"Hugenberg V, Riemann B, Hermann S, Schober O, Schäfers M, Szardenings K, Lebedev A, Gangadharmath U, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,983464,DTCT0024844,12577902,DTCC01394967,1748898,55760
CHEMBL2425944,P14780,,WUGYYDAXBPEKAI-HHHXNRCGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23899323,IC50,=,0.2,NM,,,,,,,,,,,,,,"Inhibition of MMP-9 (unknown origin) using 7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl)Ala-Arg-NH2 as substrate preincubated for 30 mins followed by substrate addition by fluorescence assay",,"Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation.",J. Med. Chem.,2013,56,17,"Hugenberg V, Riemann B, Hermann S, Schober O, Schäfers M, Szardenings K, Lebedev A, Gangadharmath U, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,983464,DTCT0024844,12577901,DTCC01394968,686767,55760
CHEMBL2425946,P14780,,OPJBQWSZZMIIHX-CYBMUJFWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23899323,IC50,=,6,NM,,,,,,,,,,,,,,"Inhibition of MMP-9 (unknown origin) using 7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl)Ala-Arg-NH2 as substrate preincubated for 30 mins followed by substrate addition by fluorescence assay",,"Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation.",J. Med. Chem.,2013,56,17,"Hugenberg V, Riemann B, Hermann S, Schober O, Schäfers M, Szardenings K, Lebedev A, Gangadharmath U, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,983464,DTCT0024844,12577920,DTCC01394970,21657,55760
CHEMBL2425947,P14780,,MFOJAATVHNHXKB-GOSISDBHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23899323,IC50,=,0.07,NM,,,,,,,,,,,,,,"Inhibition of MMP-9 (unknown origin) using 7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl)Ala-Arg-NH2 as substrate preincubated for 30 mins followed by substrate addition by fluorescence assay",,"Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation.",J. Med. Chem.,2013,56,17,"Hugenberg V, Riemann B, Hermann S, Schober O, Schäfers M, Szardenings K, Lebedev A, Gangadharmath U, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,983464,DTCT0024844,12577919,DTCC01394971,331061,55760
CHEMBL2425948,P14780,,LTTRJMCJTUBEGF-AREMUKBSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23899323,IC50,=,2,NM,,,,,,,,,,,,,,"Inhibition of MMP-9 (unknown origin) using 7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl)Ala-Arg-NH2 as substrate preincubated for 30 mins followed by substrate addition by fluorescence assay",,"Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation.",J. Med. Chem.,2013,56,17,"Hugenberg V, Riemann B, Hermann S, Schober O, Schäfers M, Szardenings K, Lebedev A, Gangadharmath U, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,983464,DTCT0024844,12577918,DTCC01394972,1430830,55760
CHEMBL2425949,P14780,,ZXGBSFAKYZEOPJ-HSZRJFAPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23899323,IC50,=,0.3,NM,,,,,,,,,,,,,,"Inhibition of MMP-9 (unknown origin) using 7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl)Ala-Arg-NH2 as substrate preincubated for 30 mins followed by substrate addition by fluorescence assay",,"Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation.",J. Med. Chem.,2013,56,17,"Hugenberg V, Riemann B, Hermann S, Schober O, Schäfers M, Szardenings K, Lebedev A, Gangadharmath U, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,983464,DTCT0024844,12577917,DTCC01394973,525520,55760
CHEMBL2425950,P14780,,SMKRBNFEFJZHAI-JOCHJYFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23899323,IC50,=,0.6,NM,,,,,,,,,,,,,,"Inhibition of MMP-9 (unknown origin) using 7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl)Ala-Arg-NH2 as substrate preincubated for 30 mins followed by substrate addition by fluorescence assay",,"Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation.",J. Med. Chem.,2013,56,17,"Hugenberg V, Riemann B, Hermann S, Schober O, Schäfers M, Szardenings K, Lebedev A, Gangadharmath U, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,983464,DTCT0024844,12577916,DTCC01394974,1909986,55760
CHEMBL2430286,P14780,,GMECKBIBYMNMBA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23999043,IC50,=,4.1,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,Design and synthesis of MMP inhibitors with appended fluorescent tags for imaging and visualization of matrix metalloproteinase enzymes.,Bioorg. Med. Chem. Lett.,2013,23,20,"Freskos JN, Asmelash B, Gaston KR, Karwa A, Marzan TA, Nickols MA, Rogers TE, Schoenstein T, Sympson CJ, Vu B",,985895,DTCT0024844,12592009,DTCC01396239,1736958,55953
CHEMBL2430287,P14780,,JASUYRSWGSPWAS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23999043,IC50,<,1,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,Design and synthesis of MMP inhibitors with appended fluorescent tags for imaging and visualization of matrix metalloproteinase enzymes.,Bioorg. Med. Chem. Lett.,2013,23,20,"Freskos JN, Asmelash B, Gaston KR, Karwa A, Marzan TA, Nickols MA, Rogers TE, Schoenstein T, Sympson CJ, Vu B",,985895,DTCT0024844,12592008,DTCC01396240,2092671,55953
CHEMBL2430288,P14780,,LVPLMOLWCRLVEQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23999043,IC50,<,1,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,Design and synthesis of MMP inhibitors with appended fluorescent tags for imaging and visualization of matrix metalloproteinase enzymes.,Bioorg. Med. Chem. Lett.,2013,23,20,"Freskos JN, Asmelash B, Gaston KR, Karwa A, Marzan TA, Nickols MA, Rogers TE, Schoenstein T, Sympson CJ, Vu B",,985895,DTCT0024844,12592007,DTCC01396241,123894,55953
CHEMBL2430289,P14780,,GWRAQHGIJHUVNF-QNGWXLTQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23999043,IC50,<,1,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,Design and synthesis of MMP inhibitors with appended fluorescent tags for imaging and visualization of matrix metalloproteinase enzymes.,Bioorg. Med. Chem. Lett.,2013,23,20,"Freskos JN, Asmelash B, Gaston KR, Karwa A, Marzan TA, Nickols MA, Rogers TE, Schoenstein T, Sympson CJ, Vu B",,985895,DTCT0024844,12592006,DTCC01396242,1256256,55953
CHEMBL2431015,P14780,,YGTYRNSBOZPWFY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24044434,IC50,=,60,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 4 hrs measured every 15 secs for 20 mins by fluorimetric assay,,Selective arylsulfonamide inhibitors of ADAM-17: hit optimization and activity in ovarian cancer cell models.,J. Med. Chem.,2013,56,20,"Nuti E, Casalini F, Santamaria S, Fabbi M, Carbotti G, Ferrini S, Marinelli L, La Pietra V, Novellino E, Camodeca C, Orlandini E, Nencetti S, Rossello A",,984235,DTCT0024844,12586842,DTCC01396971,803495,55984
CHEMBL2431016,P14780,,IVQNYNVXTUYYFR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24044434,IC50,=,110,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 4 hrs measured every 15 secs for 20 mins by fluorimetric assay,,Selective arylsulfonamide inhibitors of ADAM-17: hit optimization and activity in ovarian cancer cell models.,J. Med. Chem.,2013,56,20,"Nuti E, Casalini F, Santamaria S, Fabbi M, Carbotti G, Ferrini S, Marinelli L, La Pietra V, Novellino E, Camodeca C, Orlandini E, Nencetti S, Rossello A",,984235,DTCT0024844,12586841,DTCC01396972,771296,55984
CHEMBL2431017,P14780,,RMRVSLSYZNRHKL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24044434,IC50,=,76,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 4 hrs measured every 15 secs for 20 mins by fluorimetric assay,,Selective arylsulfonamide inhibitors of ADAM-17: hit optimization and activity in ovarian cancer cell models.,J. Med. Chem.,2013,56,20,"Nuti E, Casalini F, Santamaria S, Fabbi M, Carbotti G, Ferrini S, Marinelli L, La Pietra V, Novellino E, Camodeca C, Orlandini E, Nencetti S, Rossello A",,984235,DTCT0024844,12586840,DTCC01396973,1995757,55984
CHEMBL2431018,P14780,,URIKLEJPYMMEBH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24044434,IC50,=,920,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 4 hrs measured every 15 secs for 20 mins by fluorimetric assay,,Selective arylsulfonamide inhibitors of ADAM-17: hit optimization and activity in ovarian cancer cell models.,J. Med. Chem.,2013,56,20,"Nuti E, Casalini F, Santamaria S, Fabbi M, Carbotti G, Ferrini S, Marinelli L, La Pietra V, Novellino E, Camodeca C, Orlandini E, Nencetti S, Rossello A",,984235,DTCT0024844,12586839,DTCC01396974,57073,55984
CHEMBL2431019,P14780,,GPJRFRUTVIKWFY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24044434,IC50,=,29000,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 4 hrs measured every 15 secs for 20 mins by fluorimetric assay,,Selective arylsulfonamide inhibitors of ADAM-17: hit optimization and activity in ovarian cancer cell models.,J. Med. Chem.,2013,56,20,"Nuti E, Casalini F, Santamaria S, Fabbi M, Carbotti G, Ferrini S, Marinelli L, La Pietra V, Novellino E, Camodeca C, Orlandini E, Nencetti S, Rossello A",,984235,DTCT0024844,12586838,DTCC01396975,771297,55984
CHEMBL2431020,P14780,,WVHOOIOSMOLBGZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24044434,IC50,=,330,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 4 hrs measured every 15 secs for 20 mins by fluorimetric assay,,Selective arylsulfonamide inhibitors of ADAM-17: hit optimization and activity in ovarian cancer cell models.,J. Med. Chem.,2013,56,20,"Nuti E, Casalini F, Santamaria S, Fabbi M, Carbotti G, Ferrini S, Marinelli L, La Pietra V, Novellino E, Camodeca C, Orlandini E, Nencetti S, Rossello A",,984235,DTCT0024844,12586837,DTCC01396976,1029966,55984
CHEMBL2431021,P14780,,VONWNPCXOBRHMT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24044434,IC50,=,51000,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 4 hrs measured every 15 secs for 20 mins by fluorimetric assay,,Selective arylsulfonamide inhibitors of ADAM-17: hit optimization and activity in ovarian cancer cell models.,J. Med. Chem.,2013,56,20,"Nuti E, Casalini F, Santamaria S, Fabbi M, Carbotti G, Ferrini S, Marinelli L, La Pietra V, Novellino E, Camodeca C, Orlandini E, Nencetti S, Rossello A",,984235,DTCT0024844,12586836,DTCC01396977,220582,55984
CHEMBL2431026,P14780,,TZCXUSWHXSLZNB-HSZRJFAPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24044434,IC50,=,11000,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 4 hrs measured every 15 secs for 20 mins by fluorimetric assay,,Selective arylsulfonamide inhibitors of ADAM-17: hit optimization and activity in ovarian cancer cell models.,J. Med. Chem.,2013,56,20,"Nuti E, Casalini F, Santamaria S, Fabbi M, Carbotti G, Ferrini S, Marinelli L, La Pietra V, Novellino E, Camodeca C, Orlandini E, Nencetti S, Rossello A",,984235,DTCT0024844,12586834,DTCC01396982,803496,55984
CHEMBL2431027,P14780,,HJLAUHYNMNIAAR-XMMPIXPASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24044434,IC50,=,4400,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 4 hrs measured every 15 secs for 20 mins by fluorimetric assay,,Selective arylsulfonamide inhibitors of ADAM-17: hit optimization and activity in ovarian cancer cell models.,J. Med. Chem.,2013,56,20,"Nuti E, Casalini F, Santamaria S, Fabbi M, Carbotti G, Ferrini S, Marinelli L, La Pietra V, Novellino E, Camodeca C, Orlandini E, Nencetti S, Rossello A",,984235,DTCT0024844,12586833,DTCC01396983,1191062,55984
CHEMBL2431027,P14780,,HJLAUHYNMNIAAR-XMMPIXPASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26871660,IC50,=,4400,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate after 3 hrs by fluorometric assay,,Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models.,Eur. J. Med. Chem.,2016,111,,"Camodeca C, Nuti E, Tepshi L, Boero S, Tuccinardi T, Stura EA, Poggi A, Zocchi MR, Rossello A.",,1559054,DTCT0024844,101501,DTCC01396983,1162293,66304
CHEMBL2431028,P14780,,QTXVPJOTKLUYMQ-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24044434,IC50,=,1630,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 4 hrs measured every 15 secs for 20 mins by fluorimetric assay,,Selective arylsulfonamide inhibitors of ADAM-17: hit optimization and activity in ovarian cancer cell models.,J. Med. Chem.,2013,56,20,"Nuti E, Casalini F, Santamaria S, Fabbi M, Carbotti G, Ferrini S, Marinelli L, La Pietra V, Novellino E, Camodeca C, Orlandini E, Nencetti S, Rossello A",,984235,DTCT0024844,12586832,DTCC01396984,1897905,55984
CHEMBL2431029,P14780,,QPWBTJDQYIYLND-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24044434,IC50,=,1.4,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 4 hrs measured every 15 secs for 20 mins by fluorimetric assay,,Selective arylsulfonamide inhibitors of ADAM-17: hit optimization and activity in ovarian cancer cell models.,J. Med. Chem.,2013,56,20,"Nuti E, Casalini F, Santamaria S, Fabbi M, Carbotti G, Ferrini S, Marinelli L, La Pietra V, Novellino E, Camodeca C, Orlandini E, Nencetti S, Rossello A",,984235,DTCT0024844,12586846,DTCC01396985,1865390,55984
CHEMBL2431030,P14780,,VCASEBIJMMTOBI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24044434,IC50,=,42,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 4 hrs measured every 15 secs for 20 mins by fluorimetric assay,,Selective arylsulfonamide inhibitors of ADAM-17: hit optimization and activity in ovarian cancer cell models.,J. Med. Chem.,2013,56,20,"Nuti E, Casalini F, Santamaria S, Fabbi M, Carbotti G, Ferrini S, Marinelli L, La Pietra V, Novellino E, Camodeca C, Orlandini E, Nencetti S, Rossello A",,984235,DTCT0024844,12586845,DTCC01396986,1354063,55984
CHEMBL2431031,P14780,,APPNLLFVKPQJGQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24044434,IC50,=,37,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 4 hrs measured every 15 secs for 20 mins by fluorimetric assay,,Selective arylsulfonamide inhibitors of ADAM-17: hit optimization and activity in ovarian cancer cell models.,J. Med. Chem.,2013,56,20,"Nuti E, Casalini F, Santamaria S, Fabbi M, Carbotti G, Ferrini S, Marinelli L, La Pietra V, Novellino E, Camodeca C, Orlandini E, Nencetti S, Rossello A",,984235,DTCT0024844,12586844,DTCC01396987,1579986,55984
CHEMBL2431032,P14780,,LGTBURVEOHTXLS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24044434,IC50,=,690,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 4 hrs measured every 15 secs for 20 mins by fluorimetric assay,,Selective arylsulfonamide inhibitors of ADAM-17: hit optimization and activity in ovarian cancer cell models.,J. Med. Chem.,2013,56,20,"Nuti E, Casalini F, Santamaria S, Fabbi M, Carbotti G, Ferrini S, Marinelli L, La Pietra V, Novellino E, Camodeca C, Orlandini E, Nencetti S, Rossello A",,984235,DTCT0024844,12586843,DTCC01396988,642634,55984
CHEMBL2431901,P14780,,NNQAQGDSGCGFER-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23964961,INH,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin),,Potent histone deacetylase inhibitors derived from 4-(aminomethyl)-N-hydroxybenzamide with high selectivity for the HDAC6 isoform.,J. Med. Chem.,2013,56,18,"Blackburn C, Barrett C, Chin J, Garcia K, Gigstad K, Gould A, Gutierrez J, Harrison S, Hoar K, Lynch C, Rowland RS, Tsu C, Ringeling J, Xu H",,985005,DTCT0024844,12596671,DTCC01397867,1450794,55932
CHEMBL243307,P14780,,KSINVMMDBYSEMQ-JTQLQIEISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22386984,IC50,,,,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 1 hr prior substrate addition measured after 30 mins by spectrofluorimetry,Not Determined,In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.,Bioorg. Med. Chem.,2012,20,7,"Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I",,805642,DTCT0024844,7640509,DTCC00455841,1642106,47642
CHEMBL24347,P14780,,OQHRPJHBPQDYML-HBMCJLEFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10340614,KI,=,1.6,NM,,,,,,,,,,,,,,"Inhibition of MMP-9 (matrix metalloprotease-9, gelatinase B)",,Macrocyclic hydroxamate inhibitors of matrix metalloproteinases and TNF-alpha production.,Bioorg. Med. Chem. Lett.,1999,9,9,"Cherney RJ, Wang L, Meyer DT, Xue CB, Arner EC, Copeland RA, Covington MB, Hardman KD, Wasserman ZR, Jaffee BD, Decicco CP",,102117,DTCT0024844,920576,DTCC00158087,2047698,3648
CHEMBL243664,P14780,ACACETIN,DANYIYRPLHHOCZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25907368,INHIBITION,,,,,cell_based,,,,,,,,,,,,Inhibition of MMP-9 activity in human HT1080 cells at 5 uM by gelatin zymography,Not Active,"Synthesis and discovery of (I-3,II-3)-biacacetin as a novel non-zinc binding inhibitor of MMP-2 and MMP-9.",Bioorg. Med. Chem.,2015,23,13,"Nanjan P, Nambiar J, Nair BG, Banerji A",,1501261,DTCT0024844,14455600,DTCC00459230,1518410,62853
CHEMBL2437163,P14780,,JRAYHZWPXHIVJI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24044937,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of human MMP-9 using NFF-2 as substrate after 90 mins,,Aggrecanase-2 inhibitors based on the acylthiosemicarbazide zinc-binding group.,Eur. J. Med. Chem.,2013,69,,"Maingot L, Elbakali J, Dumont J, Bosc D, Cousaert N, Urban A, Deglane G, Villoutreix B, Nagase H, Sperandio O, Leroux F, Deprez B, Deprez-Poulain R",,986683,DTCT0024844,12607848,DTCC01400189,751355,56087
CHEMBL2437163,P14780,,JRAYHZWPXHIVJI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24044937,INHIBITION,<,10,%,,,,,,,,,,,,,,Inhibition of human MMP-9 using NFF-2 as substrate at 10 uM after 90 mins,,Aggrecanase-2 inhibitors based on the acylthiosemicarbazide zinc-binding group.,Eur. J. Med. Chem.,2013,69,,"Maingot L, Elbakali J, Dumont J, Bosc D, Cousaert N, Urban A, Deglane G, Villoutreix B, Nagase H, Sperandio O, Leroux F, Deprez B, Deprez-Poulain R",,986690,DTCT0024844,12607873,DTCC01400189,751355,56087
CHEMBL24398,P14780,,UACUZULRKJKTHE-CZYKHXBRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11585439,KI,=,4468,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors.",J. Med. Chem.,2001,44,21,"Yao W, Wasserman ZR, Chao M, Reddy G, Shi E, Liu RQ, Covington MB, Arner EC, Pratta MA, Tortorella M, Magolda RL, Newton R, Qian M, Ribadeneira MD, Christ D, Wexler RR, Decicco CP",,105382,DTCT0024844,1422372,DTCC00158787,1693988,16438
CHEMBL24398,P14780,,UACUZULRKJKTHE-CZYKHXBRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12657268,KI,=,4468,NM,,,,,,,,,,,,,,Affinity for Matrix metalloprotease-9 (MMP-9),,Potent and selective aggrecanase inhibitors containing cyclic P1 substituents.,Bioorg. Med. Chem. Lett.,2003,13,7,"Cherney RJ, Mo R, Meyer DT, Wang L, Yao W, Wasserman ZR, Liu RQ, Covington MB, Tortorella MD, Arner EC, Qian M, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Decicco CP",,105369,DTCT0024844,1346685,DTCC00158787,1681214,6242
CHEMBL24398,P14780,,UACUZULRKJKTHE-CZYKHXBRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,KI,=,4468,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2457508,DTCC00158787,1696785,32556
CHEMBL2440429,P14780,,MDQNHUVXMAEAFD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24071448,IC50,=,6000,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain (unknown origin) using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured after 2 to 4 hrs by fluorometric assay,,Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.,Bioorg. Med. Chem.,2013,21,21,"Tauro M, Laghezza A, Loiodice F, Agamennone M, Campestre C, Tortorella P",,990168,DTCT0024844,12628995,DTCC01400793,1158679,56259
CHEMBL2440430,P14780,,GPHBFHLZRQMFLJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24071448,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain (unknown origin) using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured after 2 to 4 hrs by fluorometric assay,,Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.,Bioorg. Med. Chem.,2013,21,21,"Tauro M, Laghezza A, Loiodice F, Agamennone M, Campestre C, Tortorella P",,990168,DTCT0024844,12628999,DTCC01400794,1708742,56259
CHEMBL2440431,P14780,,VRCNSKZUURJQAN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24071448,IC50,=,55000,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain (unknown origin) using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured after 2 to 4 hrs by fluorometric assay,,Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.,Bioorg. Med. Chem.,2013,21,21,"Tauro M, Laghezza A, Loiodice F, Agamennone M, Campestre C, Tortorella P",,990168,DTCT0024844,12628998,DTCC01400795,252959,56259
CHEMBL2440432,P14780,,ZSBBJNVNCGRSOS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24071448,IC50,=,87000,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain (unknown origin) using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured after 2 to 4 hrs by fluorometric assay,,Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.,Bioorg. Med. Chem.,2013,21,21,"Tauro M, Laghezza A, Loiodice F, Agamennone M, Campestre C, Tortorella P",,990168,DTCT0024844,12628997,DTCC01400796,1158680,56259
CHEMBL2440433,P14780,"3,4-DICHLOROPHENYLAMINOMETHYLENEBISPHOSPHONIC ACID",ADHSWFUIIRWNHD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24071448,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain (unknown origin) using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured after 2 to 4 hrs by fluorometric assay,,Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.,Bioorg. Med. Chem.,2013,21,21,"Tauro M, Laghezza A, Loiodice F, Agamennone M, Campestre C, Tortorella P",,990168,DTCT0024844,12629003,DTCC01400797,220619,56259
CHEMBL2440434,P14780,,GSMGLRFAXIPFLS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24071448,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain (unknown origin) using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured after 2 to 4 hrs by fluorometric assay,,Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.,Bioorg. Med. Chem.,2013,21,21,"Tauro M, Laghezza A, Loiodice F, Agamennone M, Campestre C, Tortorella P",,990168,DTCT0024844,12629002,DTCC01400798,1062292,56259
CHEMBL2440435,P14780,,SENUMOHBDKDZCG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24071448,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain (unknown origin) using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured after 2 to 4 hrs by fluorometric assay,,Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.,Bioorg. Med. Chem.,2013,21,21,"Tauro M, Laghezza A, Loiodice F, Agamennone M, Campestre C, Tortorella P",,990168,DTCT0024844,12629006,DTCC01400799,1127369,56259
CHEMBL2440436,P14780,,SCLGFWTXZFUITP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24071448,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain (unknown origin) using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured after 2 to 4 hrs by fluorometric assay,,Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.,Bioorg. Med. Chem.,2013,21,21,"Tauro M, Laghezza A, Loiodice F, Agamennone M, Campestre C, Tortorella P",,990168,DTCT0024844,12629005,DTCC01400800,1321323,56259
CHEMBL2440437,P14780,,ZEZSYIYQVUYORL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24071448,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain (unknown origin) using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured after 2 to 4 hrs by fluorometric assay,,Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.,Bioorg. Med. Chem.,2013,21,21,"Tauro M, Laghezza A, Loiodice F, Agamennone M, Campestre C, Tortorella P",,990168,DTCT0024844,12629009,DTCC01400801,1256310,56259
CHEMBL2440438,P14780,,XQVNOYYFZWUDCV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24071448,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain (unknown origin) using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured after 2 to 4 hrs by fluorometric assay,,Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.,Bioorg. Med. Chem.,2013,21,21,"Tauro M, Laghezza A, Loiodice F, Agamennone M, Campestre C, Tortorella P",,990168,DTCT0024844,12629008,DTCC01400802,1095361,56259
CHEMBL2440439,P14780,(P-TOLYLAMINO)METHYLENEDIPHOSPHONIC ACID,FVJHDPVFVSTFKH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24071448,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain (unknown origin) using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured after 2 to 4 hrs by fluorometric assay,,Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.,Bioorg. Med. Chem.,2013,21,21,"Tauro M, Laghezza A, Loiodice F, Agamennone M, Campestre C, Tortorella P",,990168,DTCT0024844,12629011,DTCC01400803,642669,56259
CHEMBL2440440,P14780,,RBHODZPTKHWXDX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24071448,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain (unknown origin) using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured after 2 to 4 hrs by fluorometric assay,,Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.,Bioorg. Med. Chem.,2013,21,21,"Tauro M, Laghezza A, Loiodice F, Agamennone M, Campestre C, Tortorella P",,990168,DTCT0024844,12629010,DTCC01400804,1062293,56259
CHEMBL2440441,P14780,,AXIAQHKDCQVIKV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24071448,IC50,=,30000,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain (unknown origin) using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured after 2 to 4 hrs by fluorometric assay,,Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.,Bioorg. Med. Chem.,2013,21,21,"Tauro M, Laghezza A, Loiodice F, Agamennone M, Campestre C, Tortorella P",,990168,DTCT0024844,12629013,DTCC01400805,318637,56259
CHEMBL2440578,P14780,,HTWBLJFKBSZUAN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24071448,IC50,=,20000,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain (unknown origin) using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured after 2 to 4 hrs by fluorometric assay,,Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.,Bioorg. Med. Chem.,2013,21,21,"Tauro M, Laghezza A, Loiodice F, Agamennone M, Campestre C, Tortorella P",,990168,DTCT0024844,12629012,DTCC01400943,1938015,56259
CHEMBL2440579,P14780,(4-CHLOROPHENYLAMINO)METHYLENEDIPHOSPHONIC ACID,PPOZCMYPJMEBPT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24071448,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain (unknown origin) using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured after 2 to 4 hrs by fluorometric assay,,Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.,Bioorg. Med. Chem.,2013,21,21,"Tauro M, Laghezza A, Loiodice F, Agamennone M, Campestre C, Tortorella P",,990168,DTCT0024844,12629014,DTCC01400944,416940,56259
CHEMBL2440580,P14780,(PHENYLAMINO)METHYLENEDIPHOSPHONIC ACID,XVNZXEWQQDCZSM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24071448,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain (unknown origin) using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured after 2 to 4 hrs by fluorometric assay,,Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.,Bioorg. Med. Chem.,2013,21,21,"Tauro M, Laghezza A, Loiodice F, Agamennone M, Campestre C, Tortorella P",,990168,DTCT0024844,12629016,DTCC01400945,1515790,56259
CHEMBL2440581,P14780,,CXOBNZQSLVRTMZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24071448,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain (unknown origin) using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured after 2 to 4 hrs by fluorometric assay,,Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.,Bioorg. Med. Chem.,2013,21,21,"Tauro M, Laghezza A, Loiodice F, Agamennone M, Campestre C, Tortorella P",,990168,DTCT0024844,12629015,DTCC01400946,383983,56259
CHEMBL2442878,P14780,,KXYWMKRIKCLADT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24028490,KI,=,12000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP-9 catalytic domain using MOCAcPLGLA2pr(Dnp)AR-NH2 as substrate by fluorescence spectrophotometric analysis,,O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier.,J. Med. Chem.,2013,56,20,"Gooyit M, Song W, Mahasenan KV, Lichtenwalter K, Suckow MA, Schroeder VA, Wolter WR, Mobashery S, Chang M",,991125,DTCT0024844,12640779,DTCC01403249,188424,56235
CHEMBL2442879,P14780,,VFVIUYYQHAEKJX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24028490,KI,=,52000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP-9 catalytic domain using MOCAcPLGLA2pr(Dnp)AR-NH2 as substrate by fluorescence spectrophotometric analysis,,O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier.,J. Med. Chem.,2013,56,20,"Gooyit M, Song W, Mahasenan KV, Lichtenwalter K, Suckow MA, Schroeder VA, Wolter WR, Mobashery S, Chang M",,991125,DTCT0024844,12640778,DTCC01403250,91625,56235
CHEMBL2442880,P14780,,SJWVELZZBPYZRG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24028490,INHIBITION,=,22,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP-9 catalytic domain using MOCAcPLGLA2pr(Dnp)AR-NH2 as substrate at 50 uM by fluorescence spectrophotometric analysis relative to control,,O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier.,J. Med. Chem.,2013,56,20,"Gooyit M, Song W, Mahasenan KV, Lichtenwalter K, Suckow MA, Schroeder VA, Wolter WR, Mobashery S, Chang M",,991002,DTCT0024844,12640772,DTCC01403251,220656,56235
CHEMBL2442881,P14780,,NPWUBXHYMWVDKN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24028490,KI,=,9900,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP-9 catalytic domain using MOCAcPLGLA2pr(Dnp)AR-NH2 as substrate by fluorescence spectrophotometric analysis,,O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier.,J. Med. Chem.,2013,56,20,"Gooyit M, Song W, Mahasenan KV, Lichtenwalter K, Suckow MA, Schroeder VA, Wolter WR, Mobashery S, Chang M",,991125,DTCT0024844,12640777,DTCC01403252,351448,56235
CHEMBL2442882,P14780,,XCRZYFVDWZHDQG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24028490,INHIBITION,=,28,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP-9 catalytic domain using MOCAcPLGLA2pr(Dnp)AR-NH2 as substrate at 50 uM by fluorescence spectrophotometric analysis relative to control,,O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier.,J. Med. Chem.,2013,56,20,"Gooyit M, Song W, Mahasenan KV, Lichtenwalter K, Suckow MA, Schroeder VA, Wolter WR, Mobashery S, Chang M",,991002,DTCT0024844,12640771,DTCC01403253,1547821,56235
CHEMBL2442883,P14780,,IUYSNQXMHWEVJW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24028490,INHIBITION,=,7,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP-9 catalytic domain using MOCAcPLGLA2pr(Dnp)AR-NH2 as substrate at 50 uM by fluorescence spectrophotometric analysis relative to control,,O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier.,J. Med. Chem.,2013,56,20,"Gooyit M, Song W, Mahasenan KV, Lichtenwalter K, Suckow MA, Schroeder VA, Wolter WR, Mobashery S, Chang M",,991002,DTCT0024844,12640770,DTCC01403254,252989,56235
CHEMBL2442884,P14780,,PXYTTWPKWBWEHH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24028490,INHIBITION,=,26,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP-9 catalytic domain using MOCAcPLGLA2pr(Dnp)AR-NH2 as substrate at 50 uM by fluorescence spectrophotometric analysis relative to control,,O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier.,J. Med. Chem.,2013,56,20,"Gooyit M, Song W, Mahasenan KV, Lichtenwalter K, Suckow MA, Schroeder VA, Wolter WR, Mobashery S, Chang M",,991002,DTCT0024844,12640769,DTCC01403255,2092731,56235
CHEMBL2442885,P14780,,NKVKCTYTQNQNIH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24028490,KI,=,180,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP-9 catalytic domain using MOCAcPLGLA2pr(Dnp)AR-NH2 as substrate by fluorescence spectrophotometric analysis,,O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier.,J. Med. Chem.,2013,56,20,"Gooyit M, Song W, Mahasenan KV, Lichtenwalter K, Suckow MA, Schroeder VA, Wolter WR, Mobashery S, Chang M",,991125,DTCT0024844,12640776,DTCC01403256,1256330,56235
CHEMBL2442886,P14780,,LJRIZWAWUQHHTF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24028490,KI,=,860,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP-9 catalytic domain using MOCAcPLGLA2pr(Dnp)AR-NH2 as substrate by fluorescence spectrophotometric analysis,,O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier.,J. Med. Chem.,2013,56,20,"Gooyit M, Song W, Mahasenan KV, Lichtenwalter K, Suckow MA, Schroeder VA, Wolter WR, Mobashery S, Chang M",,991125,DTCT0024844,12640775,DTCC01403257,1354112,56235
CHEMBL2442887,P14780,,KDYJIWZXMZGJQG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24028490,KI,=,1100,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP-9 catalytic domain using MOCAcPLGLA2pr(Dnp)AR-NH2 as substrate by fluorescence spectrophotometric analysis,,O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier.,J. Med. Chem.,2013,56,20,"Gooyit M, Song W, Mahasenan KV, Lichtenwalter K, Suckow MA, Schroeder VA, Wolter WR, Mobashery S, Chang M",,991125,DTCT0024844,12640774,DTCC01403258,2060629,56235
CHEMBL2442888,P14780,,FNTWGXGOCVTLKR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24028490,KI,=,2700,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP-9 catalytic domain using MOCAcPLGLA2pr(Dnp)AR-NH2 as substrate by fluorescence spectrophotometric analysis,,O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier.,J. Med. Chem.,2013,56,20,"Gooyit M, Song W, Mahasenan KV, Lichtenwalter K, Suckow MA, Schroeder VA, Wolter WR, Mobashery S, Chang M",,991125,DTCT0024844,12640773,DTCC01403259,1030030,56235
CHEMBL2442889,P14780,,MWMLZWBDIRKPMD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24028490,KI,=,230,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP-9 catalytic domain using MOCAcPLGLA2pr(Dnp)AR-NH2 as substrate by fluorescence spectrophotometric analysis,,O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier.,J. Med. Chem.,2013,56,20,"Gooyit M, Song W, Mahasenan KV, Lichtenwalter K, Suckow MA, Schroeder VA, Wolter WR, Mobashery S, Chang M",,991125,DTCT0024844,12640784,DTCC01403260,1450847,56235
CHEMBL2442890,P14780,,JOSPLESHDLLQSD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24028490,KI,=,930,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP-9 catalytic domain using MOCAcPLGLA2pr(Dnp)AR-NH2 as substrate by fluorescence spectrophotometric analysis,,O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier.,J. Med. Chem.,2013,56,20,"Gooyit M, Song W, Mahasenan KV, Lichtenwalter K, Suckow MA, Schroeder VA, Wolter WR, Mobashery S, Chang M",,991125,DTCT0024844,12640783,DTCC01403261,1062314,56235
CHEMBL2442891,P14780,,NDWDLJQCZNKAHG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24028490,KI,=,1000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP-9 catalytic domain using MOCAcPLGLA2pr(Dnp)AR-NH2 as substrate by fluorescence spectrophotometric analysis,,O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier.,J. Med. Chem.,2013,56,20,"Gooyit M, Song W, Mahasenan KV, Lichtenwalter K, Suckow MA, Schroeder VA, Wolter WR, Mobashery S, Chang M",,991125,DTCT0024844,12640782,DTCC01403262,481047,56235
CHEMBL2442892,P14780,,FWECVAAARPJXSH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24028490,KI,=,1300,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP-9 catalytic domain using MOCAcPLGLA2pr(Dnp)AR-NH2 as substrate by fluorescence spectrophotometric analysis,,O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier.,J. Med. Chem.,2013,56,20,"Gooyit M, Song W, Mahasenan KV, Lichtenwalter K, Suckow MA, Schroeder VA, Wolter WR, Mobashery S, Chang M",,991125,DTCT0024844,12640781,DTCC01403263,57219,56235
CHEMBL2442893,P14780,,LYYLWOIDTXRRLW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24028490,KI,=,10000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP-9 catalytic domain using MOCAcPLGLA2pr(Dnp)AR-NH2 as substrate by fluorescence spectrophotometric analysis,,O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier.,J. Med. Chem.,2013,56,20,"Gooyit M, Song W, Mahasenan KV, Lichtenwalter K, Suckow MA, Schroeder VA, Wolter WR, Mobashery S, Chang M",,991125,DTCT0024844,12640780,DTCC01403264,1547822,56235
CHEMBL24441,P14780,BETAHISTINE,UUQMNUMQCIQDMZ-UHFFFAOYSA-N,1,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7274189,DTCC00159008,606968,46191
CHEMBL24441,P14780,BETAHISTINE,UUQMNUMQCIQDMZ-UHFFFAOYSA-N,1,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7274190,DTCC00159008,606968,46191
CHEMBL24447,P14780,PHENETHYLCARBAMOYLPHOSPHONIC ACID,GHFCXEYUGIXTHN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15139760,IC50,>,100000,NM,,,,,,,,,,,,,,In vitro inhibitory activity against recombinant matrix metalloprotease-9 was determined,,"Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.",J. Med. Chem.,2004,47,11,"Breuer E, Salomon CJ, Katz Y, Chen W, Lu S, Röschenthaler GV, Hadar R, Reich R",,105518,DTCT0024844,1320462,DTCC00158289,2077403,17838
CHEMBL244883,P14780,METHOTREXATE GAMMA-HYDROXAMIC ACID,YUQBNZUBNMWBAQ-ZDUSSCGKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17127067,INHIBITION,=,61,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 100 uM,,Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs.,Bioorg. Med. Chem.,2007,15,3,"Santos MA, Enyedy EA, Nuti E, Rossello A, Krupenko NI, Krupenko SA",,441105,DTCT0024844,2148785,DTCC00003032,1308171,23121
CHEMBL24510,P14780,FUSARIC ACID,DGMPVYSXXIOGJY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,18,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5096301,DTCC00104041,2055567,43205
CHEMBL245382,P14780,,FXJADKGLMYYRPW-AJTFRIOCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17188863,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2007,17,5,"Sheppeck JE, Gilmore JL, Yang A, Chen XT, Xue CB, Roderick J, Liu RQ, Covington MB, Decicco CP, Duan JJ",,453871,DTCT0024844,2221444,DTCC00478075,359103,24252
CHEMBL245383,P14780,,SXQXJOREJVFQQR-ATIYNZHBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17188863,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2007,17,5,"Sheppeck JE, Gilmore JL, Yang A, Chen XT, Xue CB, Roderick J, Liu RQ, Covington MB, Decicco CP, Duan JJ",,453871,DTCT0024844,2221443,DTCC00478076,326532,24252
CHEMBL245384,P14780,,UTQFFMUHRGYGFM-YIXXDRMTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17188863,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2007,17,5,"Sheppeck JE, Gilmore JL, Yang A, Chen XT, Xue CB, Roderick J, Liu RQ, Covington MB, Decicco CP, Duan JJ",,453871,DTCT0024844,2221441,DTCC00478078,1744537,24252
CHEMBL245416,P14780,L-MIMOSINE,WZNJWVWKTVETCG-YFKPBYRVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7424996,DTCC00474857,2025639,46191
CHEMBL245416,P14780,L-MIMOSINE,WZNJWVWKTVETCG-YFKPBYRVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7424997,DTCC00474857,2025639,46191
CHEMBL245581,P14780,,BNMNXPAFKBDIBX-WIZGVZBGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17188863,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2007,17,5,"Sheppeck JE, Gilmore JL, Yang A, Chen XT, Xue CB, Roderick J, Liu RQ, Covington MB, Decicco CP, Duan JJ",,453871,DTCT0024844,2221440,DTCC00478079,131576,24252
CHEMBL245582,P14780,,CVQRCKDPFUCDTJ-CGHJUBPDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17188863,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2007,17,5,"Sheppeck JE, Gilmore JL, Yang A, Chen XT, Xue CB, Roderick J, Liu RQ, Covington MB, Decicco CP, Duan JJ",,453871,DTCT0024844,2221439,DTCC00478080,811250,24252
CHEMBL245774,P14780,,GHIFQOQBENAQBR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17188863,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2007,17,5,"Sheppeck JE, Gilmore JL, Yang A, Chen XT, Xue CB, Roderick J, Liu RQ, Covington MB, Decicco CP, Duan JJ",,453871,DTCT0024844,2221438,DTCC00478054,228402,24252
CHEMBL245776,P14780,,GHIFQOQBENAQBR-IBGZPJMESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17188863,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2007,17,5,"Sheppeck JE, Gilmore JL, Yang A, Chen XT, Xue CB, Roderick J, Liu RQ, Covington MB, Decicco CP, Duan JJ",,453871,DTCT0024844,2221458,DTCC00478057,228403,24252
CHEMBL24595,P14780,,AXGJYAJONXQKHJ-LWSSLDFYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12657268,KI,=,2099,NM,,,,,,,,,,,,,,Affinity for Matrix metalloprotease-9 (MMP-9),,Potent and selective aggrecanase inhibitors containing cyclic P1 substituents.,Bioorg. Med. Chem. Lett.,2003,13,7,"Cherney RJ, Mo R, Meyer DT, Wang L, Yao W, Wasserman ZR, Liu RQ, Covington MB, Tortorella MD, Arner EC, Qian M, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Decicco CP",,105369,DTCT0024844,1334007,DTCC00158581,743455,6242
CHEMBL24595,P14780,,AXGJYAJONXQKHJ-LWSSLDFYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,KI,=,2099,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2457516,DTCC00158581,759063,32556
CHEMBL245974,P14780,,XTOUSIOCVVYRQR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17188863,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2007,17,5,"Sheppeck JE, Gilmore JL, Yang A, Chen XT, Xue CB, Roderick J, Liu RQ, Covington MB, Decicco CP, Duan JJ",,453871,DTCT0024844,2221455,DTCC00478061,1620304,24252
CHEMBL246171,P14780,,LGAMIUMXRWOVGN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17188863,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2007,17,5,"Sheppeck JE, Gilmore JL, Yang A, Chen XT, Xue CB, Roderick J, Liu RQ, Covington MB, Decicco CP, Duan JJ",,453871,DTCT0024844,2221454,DTCC00478062,1263918,24252
CHEMBL246376,P14780,,UEOYACNTKVVWRI-QFQXNSOFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17188863,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2007,17,5,"Sheppeck JE, Gilmore JL, Yang A, Chen XT, Xue CB, Roderick J, Liu RQ, Covington MB, Decicco CP, Duan JJ",,453871,DTCT0024844,2221449,DTCC00478069,8772,24252
CHEMBL246563,P14780,,GHIFQOQBENAQBR-LJQANCHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17188863,KI,=,1000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2007,17,5,"Sheppeck JE, Gilmore JL, Yang A, Chen XT, Xue CB, Roderick J, Liu RQ, Covington MB, Decicco CP, Duan JJ",,453871,DTCT0024844,2221457,DTCC00477929,1231073,24252
CHEMBL246576,P14780,,SSOHCNKODIJGFS-XHCCPWGMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17188863,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2007,17,5,"Sheppeck JE, Gilmore JL, Yang A, Chen XT, Xue CB, Roderick J, Liu RQ, Covington MB, Decicco CP, Duan JJ",,453871,DTCT0024844,2221448,DTCC00478071,1776382,24252
CHEMBL246577,P14780,,SSOHCNKODIJGFS-UZTOHYMASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17188863,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2007,17,5,"Sheppeck JE, Gilmore JL, Yang A, Chen XT, Xue CB, Roderick J, Liu RQ, Covington MB, Decicco CP, Duan JJ",,453871,DTCT0024844,2221446,DTCC00478072,1361794,24252
CHEMBL246577,P14780,,SSOHCNKODIJGFS-UZTOHYMASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17188863,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2007,17,5,"Sheppeck JE, Gilmore JL, Yang A, Chen XT, Xue CB, Roderick J, Liu RQ, Covington MB, Decicco CP, Duan JJ",,453871,DTCT0024844,2221447,DTCC00478072,1361793,24252
CHEMBL24761,P14780,,HLOJKFSLAAGGSY-HBMCJLEFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10340614,KI,<,1,NM,,,,,,,,,,,,,,"Inhibition of MMP-9 (matrix metalloprotease-9, gelatinase B)",,Macrocyclic hydroxamate inhibitors of matrix metalloproteinases and TNF-alpha production.,Bioorg. Med. Chem. Lett.,1999,9,9,"Cherney RJ, Wang L, Meyer DT, Xue CB, Arner EC, Copeland RA, Covington MB, Hardman KD, Wasserman ZR, Jaffee BD, Decicco CP",,102117,DTCT0024844,932674,DTCC00158058,919947,3648
CHEMBL24761,P14780,,HLOJKFSLAAGGSY-HBMCJLEFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472217,KI,<,1,NM,,,,,,,,,,,,,,In vitro inhibition of human MMP-9.,,"Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.",J. Med. Chem.,2001,44,16,"Xue CB, Voss ME, Nelson DJ, Duan JJ, Cherney RJ, Jacobson IC, He X, Roderick J, Chen L, Corbett RL, Wang L, Meyer DT, Kennedy K, DeGradodagger WF, Hardman KD, Teleha CA, Jaffee BD, Liu RQ, Copeland RA, Covington MB, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105380,DTCT0024844,1640388,DTCC00158058,906593,16346
CHEMBL24763,P14780,,NBMKDWPDVFVJGY-LUKWVAJMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12657268,KI,=,4000,NM,,,,,,,,,,,,,,Affinity for Matrix metalloprotease-9 (MMP-9),,Potent and selective aggrecanase inhibitors containing cyclic P1 substituents.,Bioorg. Med. Chem. Lett.,2003,13,7,"Cherney RJ, Mo R, Meyer DT, Wang L, Yao W, Wasserman ZR, Liu RQ, Covington MB, Tortorella MD, Arner EC, Qian M, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Decicco CP",,105369,DTCT0024844,1343876,DTCC00158730,1772960,6242
CHEMBL24810,P14780,,DTDSTJLDFHAYIW-CGXNFDGLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12657268,KI,=,1490,NM,,,,,,,,,,,,,,Affinity for Matrix metalloprotease-9 (MMP-9),,Potent and selective aggrecanase inhibitors containing cyclic P1 substituents.,Bioorg. Med. Chem. Lett.,2003,13,7,"Cherney RJ, Mo R, Meyer DT, Wang L, Yao W, Wasserman ZR, Liu RQ, Covington MB, Tortorella MD, Arner EC, Qian M, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Decicco CP",,105369,DTCT0024844,1360083,DTCC00158675,1227560,6242
CHEMBL248702,P14780,DEXFENFLURAMINE,DBGIVFWFUFKIQN-VIFPVBQESA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7342295,DTCC00487049,1351109,46191
CHEMBL248702,P14780,DEXFENFLURAMINE,DBGIVFWFUFKIQN-VIFPVBQESA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7342296,DTCC00487049,1351109,46191
CHEMBL249249,P14780,,GAAIGFFCAWTRLA-QPJJXVBHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,>,150000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266575,DTCC00112348,682335,24949
CHEMBL24944,P14780,TRIBROMSALAN,KVSKGMLNBAPGKH-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7448071,DTCC00154630,1830693,46191
CHEMBL24944,P14780,TRIBROMSALAN,KVSKGMLNBAPGKH-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7448072,DTCC00154630,1830693,46191
CHEMBL249859,P14780,HEXYL 6-MERCAPTOPICOLINATE,XQEVBXYFXXEMPD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,109000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266581,DTCC00003789,1103055,24949
CHEMBL249860,P14780,,XRKJHHWDVPLKME-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,>,150000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266427,DTCC00112342,359235,24949
CHEMBL249861,P14780,,KHRGNMHSFZBLQX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,>,150000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266580,DTCC00112343,228510,24949
CHEMBL249862,P14780,,PEIDAZNWHKOSTB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,>,150000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266578,DTCC00112345,2068225,24949
CHEMBL249863,P14780,,SBUBCHFHLBPIDO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,>,150000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266576,DTCC00112347,1652658,24949
CHEMBL25,P14780,ASPIRIN,BSYNRYMUTXBXSQ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7276504,DTCC00133284,51447,46191
CHEMBL25,P14780,ASPIRIN,BSYNRYMUTXBXSQ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7276505,DTCC00133284,51447,46191
CHEMBL250057,P14780,4-FLUOROBENZYL 6-MERCAPTOPICOLINATE,BLOAUADPJKEVHV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,120000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266595,DTCC00003781,1231187,24949
CHEMBL250058,P14780,"2,6-DIFLUOROBENZYL 6-MERCAPTOPICOLINATE",KGUKLAHWSIAZLA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,101000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266594,DTCC00003782,585425,24949
CHEMBL250059,P14780,"2,4,5-TRIFLUOROBENZYL 6-MERCAPTOPICOLINATE",LUIWBJOVQPJOKK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,105000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266592,DTCC00003784,2068224,24949
CHEMBL250069,P14780,3-PHENOXYBENZYL 6-MERCAPTOPICOLINATE,HWVLDNSMUHAKFF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,75000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266584,DTCC00003787,844236,24949
CHEMBL250070,P14780,4-PHENOXYBENZYL 6-MERCAPTOPICOLINATE,UEHKLPHNSUXLCL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,110000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266583,DTCC00003788,1329180,24949
CHEMBL250266,P14780,UK-370106,NSMABJUGSNPHMN-BHYWQNONSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029177,IC50,=,30400,NM,,,,,,,,,,,,,,Inhibition of MMP9,,A novel series of highly selective inhibitors of MMP-3.,Bioorg. Med. Chem. Lett.,2007,17,24,"Whitlock GA, Dack KN, Dickinson RP, Lewis ML",,459994,DTCT0024844,2266850,DTCC00003798,779009,24951
CHEMBL250266,P14780,UK-370106,NSMABJUGSNPHMN-BHYWQNONSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,IC50,=,30400,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2457455,DTCC00003798,791164,32556
CHEMBL251081,P14780,4-CHLOROBENZYL 6-MERCAPTOPICOLINATE,XZZQGEUTXIQYSE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,112000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266591,DTCC00003785,1937772,24949
CHEMBL251276,P14780,,DBLSRXLCLISVHT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,4.96,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260753,DTCC00486021,1103044,24831
CHEMBL251277,P14780,,RBBJRRIKUGFUNE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,6.3,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260752,DTCC00486023,585418,24831
CHEMBL251278,P14780,,YNYCJXFJTBMLCP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,5.05,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260743,DTCC00486026,1873445,24831
CHEMBL251423,P14780,,FUQRLLAMBZIBJF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,>,150000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266588,DTCC00112337,1652657,24949
CHEMBL251424,P14780,,KPHDNQTWSWMHLI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,119000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266587,DTCC00112338,682334,24949
CHEMBL251425,P14780,,KBKONNUEKRQXBR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,150000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266586,DTCC00112339,99413,24949
CHEMBL251426,P14780,,KUFQPJWHPFBJRV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,50000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266585,DTCC00112340,1458628,24949
CHEMBL251465,P14780,,NRFRJBJLCBPJDJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,>,150000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266573,DTCC00112351,1652659,24949
CHEMBL251687,P14780,,QJKJEQWYVVRJOC-AHTKWCMKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10212120,IC50,=,1200,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,Identification of highly selective inhibitors of collagenase-1 from combinatorial libraries of diketopiperazines.,J. Med. Chem.,1999,42,8,"Szardenings AK, Antonenko V, Campbell DA, DeFrancisco N, Ida S, Shi L, Sharkov N, Tien D, Wang Y, Navre M",,105219,DTCT0024844,1322766,DTCC00486936,1820756,15658
CHEMBL251687,P14780,,QJKJEQWYVVRJOC-AHTKWCMKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,1202.26,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258277,DTCC00486936,1808952,24803
CHEMBL251820,P14780,,ZKFYETVHOLUSNG-FQEVSTJZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18068976,IC50,=,25,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutations.,Bioorg. Med. Chem. Lett.,2008,18,2,"Burns DM, He C, Li Y, Scherle P, Liu X, Marando CA, Covington MB, Yang G, Pan M, Turner S, Fridman JS, Hollis G, Vaddi K, Yeleswaram S, Newton R, Friedman S, Metcalf B, Yao W",,461866,DTCT0024844,2278112,DTCC00489350,1808991,25102
CHEMBL251821,P14780,,LVBZYMLTLOAXGK-SANMLTNESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,86,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278591,DTCC00489351,1954617,25112
CHEMBL251827,P14780,,VJUDEGHVGRIZAQ-HXUWFJFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,295,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278572,DTCC00489422,1571619,25112
CHEMBL251831,P14780,,QFDKCGXVQVJGKD-SVMVAKDDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,0.68,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278525,DTCC00489430,1280502,25112
CHEMBL251865,P14780,,GYKATPWJHDSXEC-FQECFTEESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18036818,IC50,=,428,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.,Bioorg. Med. Chem. Lett.,2008,18,1,"Yao W, Zhuo J, Burns DM, Li YL, Qian DQ, Zhang C, He C, Xu M, Shi E, Li Y, Marando CA, Covington MB, Yang G, Liu X, Pan M, Fridman JS, Scherle P, Wasserman ZR, Hollis G, Vaddi K, Yeleswaram S, Newton R, Friedman S, Metcalf B",,461667,DTCT0024844,2276533,DTCC00488431,1971035,25086
CHEMBL251866,P14780,,CFGDWDJLEQTCJQ-PXDATVDWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18242982,KI,=,934,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents.",Bioorg. Med. Chem. Lett.,2008,18,5,"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ",,462363,DTCT0024844,2282324,DTCC00488432,585456,25163
CHEMBL251867,P14780,,CHOIXTQDKMNYCU-FUHWJXTLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18242982,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents.",Bioorg. Med. Chem. Lett.,2008,18,5,"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ",,462363,DTCT0024844,2282321,DTCC00488437,67193,25163
CHEMBL251868,P14780,,UCCRPMLKYDMJAV-PKOBYXMFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18242982,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents.",Bioorg. Med. Chem. Lett.,2008,18,5,"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ",,462363,DTCT0024844,2282319,DTCC00488439,1394305,25163
CHEMBL251884,P14780,,MHXODSYUSQLZGR-ROUUACIJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18036818,IC50,=,111,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.,Bioorg. Med. Chem. Lett.,2008,18,1,"Yao W, Zhuo J, Burns DM, Li YL, Qian DQ, Zhang C, He C, Xu M, Shi E, Li Y, Marando CA, Covington MB, Yang G, Liu X, Pan M, Fridman JS, Scherle P, Wasserman ZR, Hollis G, Vaddi K, Yeleswaram S, Newton R, Friedman S, Metcalf B",,461667,DTCT0024844,2276542,DTCC00488364,260755,25086
CHEMBL251917,P14780,,YVBOXQAMDNUBQA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029177,IC50,=,2420,NM,,,,,,,,,,,,,,Inhibition of MMP9,,A novel series of highly selective inhibitors of MMP-3.,Bioorg. Med. Chem. Lett.,2007,17,24,"Whitlock GA, Dack KN, Dickinson RP, Lewis ML",,459994,DTCT0024844,2266901,DTCC00486122,1296611,24951
CHEMBL251917,P14780,,YVBOXQAMDNUBQA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,IC50,=,2420,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2457466,DTCC00486122,1309117,32556
CHEMBL251937,P14780,,SBJBAOFNJMFNBY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,62000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266648,DTCC00112323,1426656,24949
CHEMBL251994,P14780,,AZIJSGUGQIBFMD-LLGBQNBKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18234496,KI,=,1246,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Alpha,Beta-cyclic-beta-benzamido hydroxamic acids: Novel oxaspiro[4.4]nonane templates for the discovery of potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).",Bioorg. Med. Chem. Lett.,2008,18,4,"Ott GR, Asakawa N, Liu RQ, Covington MB, Qian M, Vaddi K, Newton RC, Trzaskos JM, Christ DD, Galya L, Scholz T, Marshall W, Duan JJ",,462320,DTCT0024844,2282171,DTCC00488624,1182678,25158
CHEMBL252020,P14780,,SKTKKGJWKRRVNC-IBGZPJMESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278590,DTCC00489353,763158,25112
CHEMBL252021,P14780,,YXOSTPQOYPBEJL-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,121,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278589,DTCC00489355,698656,25112
CHEMBL252022,P14780,,HTTNNOVNWHTYRY-IBGZPJMESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,5.4,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278588,DTCC00489357,43745,25112
CHEMBL252024,P14780,,AQXFSOLTNZQWIK-FQEVSTJZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18068976,IC50,>,5000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutations.,Bioorg. Med. Chem. Lett.,2008,18,2,"Burns DM, He C, Li Y, Scherle P, Liu X, Marando CA, Covington MB, Yang G, Pan M, Turner S, Fridman JS, Hollis G, Vaddi K, Yeleswaram S, Newton R, Friedman S, Metcalf B, Yao W",,461866,DTCT0024844,2278105,DTCC00489425,972983,25102
CHEMBL252079,P14780,,IDLHJNPBZBJSDO-ROUUACIJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18036818,IC50,=,110,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.,Bioorg. Med. Chem. Lett.,2008,18,1,"Yao W, Zhuo J, Burns DM, Li YL, Qian DQ, Zhang C, He C, Xu M, Shi E, Li Y, Marando CA, Covington MB, Yang G, Liu X, Pan M, Fridman JS, Scherle P, Wasserman ZR, Hollis G, Vaddi K, Yeleswaram S, Newton R, Friedman S, Metcalf B",,461667,DTCT0024844,2276540,DTCC00488366,294068,25086
CHEMBL252081,P14780,,CADNLTAFOMUWRR-PMACEKPBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18036818,IC50,=,2500,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.,Bioorg. Med. Chem. Lett.,2008,18,1,"Yao W, Zhuo J, Burns DM, Li YL, Qian DQ, Zhang C, He C, Xu M, Shi E, Li Y, Marando CA, Covington MB, Yang G, Liu X, Pan M, Fridman JS, Scherle P, Wasserman ZR, Hollis G, Vaddi K, Yeleswaram S, Newton R, Friedman S, Metcalf B",,461667,DTCT0024844,2276539,DTCC00488367,553293,25086
CHEMBL252246,P14780,,XKPUKZQRNSFQLM-YVZMLIKISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18036818,IC50,>,3000,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.,Bioorg. Med. Chem. Lett.,2008,18,1,"Yao W, Zhuo J, Burns DM, Li YL, Qian DQ, Zhang C, He C, Xu M, Shi E, Li Y, Marando CA, Covington MB, Yang G, Liu X, Pan M, Fridman JS, Scherle P, Wasserman ZR, Hollis G, Vaddi K, Yeleswaram S, Newton R, Friedman S, Metcalf B",,461667,DTCT0024844,2276526,DTCC00488482,1587813,25086
CHEMBL252246,P14780,,XKPUKZQRNSFQLM-YVZMLIKISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19457660,IC50,>,5000,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition.,Bioorg. Med. Chem. Lett.,2009,19,13,"Burns DM, Li YL, Shi E, He C, Xu M, Zhuo J, Zhang C, Qian DQ, Li Y, Wynn R, Covington MB, Katiyar K, Marando CA, Fridman JS, Scherle P, Friedman S, Metcalf B, Yao W",,523765,DTCT0024844,2828336,DTCC00488482,1588619,33677
CHEMBL252278,P14780,,OEHDRCQWQWUTCW-OALUTQOASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18036818,IC50,>,5000,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.,Bioorg. Med. Chem. Lett.,2008,18,1,"Yao W, Zhuo J, Burns DM, Li YL, Qian DQ, Zhang C, He C, Xu M, Shi E, Li Y, Marando CA, Covington MB, Yang G, Liu X, Pan M, Fridman JS, Scherle P, Wasserman ZR, Hollis G, Vaddi K, Yeleswaram S, Newton R, Friedman S, Metcalf B",,461667,DTCT0024844,2276538,DTCC00488369,1070310,25086
CHEMBL252326,P14780,,WIZJUQTZYUHMJA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,66000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266610,DTCC00485908,391969,24949
CHEMBL252327,P14780,CYCLOBUTYL 6-MERCAPTOPICOLINATE,OJWQIHGLXWACCZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,137000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266608,DTCC00003770,2003636,24949
CHEMBL252422,P14780,,BMSDLUUZGPIUGG-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,7.8,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278524,DTCC00489290,1668797,25112
CHEMBL252422,P14780,,BMSDLUUZGPIUGG-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18086526,IC50,=,7.8,NM,,,,,,,,,,,,,,Inhibition of catalytic domain MMP9,,"beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.",Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV",,465911,DTCT0024844,2300354,DTCC00489290,1652743,25438
CHEMBL252426,P14780,,ADRWSFRHTJKETB-IBGZPJMESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,8.8,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278587,DTCC00489366,212331,25112
CHEMBL252442,P14780,,DAWQVDWNIUMYHC-IRXDYDNUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18036818,IC50,=,3048,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.,Bioorg. Med. Chem. Lett.,2008,18,1,"Yao W, Zhuo J, Burns DM, Li YL, Qian DQ, Zhang C, He C, Xu M, Shi E, Li Y, Marando CA, Covington MB, Yang G, Liu X, Pan M, Fridman JS, Scherle P, Wasserman ZR, Hollis G, Vaddi K, Yeleswaram S, Newton R, Friedman S, Metcalf B",,461667,DTCT0024844,2276524,DTCC00488486,260756,25086
CHEMBL252470,P14780,,FXFZIKOEGYQWSD-RBUKOAKNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18242982,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents.",Bioorg. Med. Chem. Lett.,2008,18,5,"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ",,462363,DTCT0024844,2282424,DTCC00488443,650445,25163
CHEMBL252480,P14780,,BYIUYAJXVDVGFA-RBBKRZOGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18242982,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents.",Bioorg. Med. Chem. Lett.,2008,18,5,"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ",,462363,DTCT0024844,2282423,DTCC00488444,260774,25163
CHEMBL252481,P14780,,UVQRQVBDZDEEBU-RBBKRZOGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18242982,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents.",Bioorg. Med. Chem. Lett.,2008,18,5,"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ",,462363,DTCT0024844,2282422,DTCC00488445,1394306,25163
CHEMBL252522,P14780,PHENETHYL 6-MERCAPTOPICOLINATE,VDMYYWJHHLSXLK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,107000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266605,DTCC00003773,1361920,24949
CHEMBL252523,P14780,3-PHENYLPROPYL 6-MERCAPTOPICOLINATE,KVPPTQZVYDXFBC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,112000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266604,DTCC00003774,488954,24949
CHEMBL252556,P14780,IDEBENONE,JGPMMRGNQUBGND-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7332158,DTCC00485000,185554,46191
CHEMBL252556,P14780,IDEBENONE,JGPMMRGNQUBGND-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7332159,DTCC00485000,185554,46191
CHEMBL252557,P14780,GLYCOLIC ACID,AEMRFAOFKBGASW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7312503,DTCC00485664,962448,46191
CHEMBL252557,P14780,GLYCOLIC ACID,AEMRFAOFKBGASW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7312504,DTCC00485664,962448,46191
CHEMBL252627,P14780,,JWVKYLLQNXGDRB-SFHVURJKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18068976,IC50,=,100,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutations.,Bioorg. Med. Chem. Lett.,2008,18,2,"Burns DM, He C, Li Y, Scherle P, Liu X, Marando CA, Covington MB, Yang G, Pan M, Turner S, Fridman JS, Hollis G, Vaddi K, Yeleswaram S, Newton R, Friedman S, Metcalf B, Yao W",,461866,DTCT0024844,2278110,DTCC00489371,2003660,25102
CHEMBL252642,P14780,LIQUIRTIGENIN,FURUXTVZLHCCNA-AWEZNQCLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21866899,ACTIVITY,=,87,%,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as remaining activity at 100 ug/ml after 4 hrs by fluorimetric analysis relative to control,,"Comparative evaluation of two structurally related flavonoids, isoliquiritigenin and liquiritigenin, for their oral infection therapeutic potential.",J. Nat. Prod.,2011,74,9,"Feldman M, Santos J, Grenier D",,776396,DTCT0024844,7503903,DTCC00488566,1092387,46204
CHEMBL252642,P14780,LIQUIRTIGENIN,FURUXTVZLHCCNA-AWEZNQCLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21866899,ACTIVITY,=,95,%,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as remaining activity at 5 ug/ml after 4 hrs by fluorimetric analysis relative to control,,"Comparative evaluation of two structurally related flavonoids, isoliquiritigenin and liquiritigenin, for their oral infection therapeutic potential.",J. Nat. Prod.,2011,74,9,"Feldman M, Santos J, Grenier D",,776394,DTCT0024844,7503907,DTCC00488566,1092387,46204
CHEMBL252642,P14780,LIQUIRTIGENIN,FURUXTVZLHCCNA-AWEZNQCLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21866899,ACTIVITY,=,95,%,,,,,,,,,,,,,,Inhibition of human MMP9 assessed as remaining activity at 25 ug/ml after 4 hrs by fluorimetric analysis relative to control,,"Comparative evaluation of two structurally related flavonoids, isoliquiritigenin and liquiritigenin, for their oral infection therapeutic potential.",J. Nat. Prod.,2011,74,9,"Feldman M, Santos J, Grenier D",,776395,DTCT0024844,7503905,DTCC00488566,1092387,46204
CHEMBL252674,P14780,,HJRCGMHZQDXQAO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17936631,IC50,=,1410,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,"Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation.",Bioorg. Med. Chem.,2008,16,1,"Chun K, Park SK, Kim HM, Choi Y, Kim MH, Park CH, Joe BY, Chun TG, Choi HM, Lee HY, Hong SH, Kim MS, Nam KY, Han G",,461354,DTCT0024844,2274637,DTCC00487740,1442560,25060
CHEMBL252677,P14780,,OHKVFVLOLOFCQJ-ZVUIFXONSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18242982,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents.",Bioorg. Med. Chem. Lett.,2008,18,5,"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ",,462363,DTCT0024844,2282420,DTCC00488447,326700,25163
CHEMBL252678,P14780,,XZAGAORJLXBQCC-VYCPFJESSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18036818,IC50,=,309,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.,Bioorg. Med. Chem. Lett.,2008,18,1,"Yao W, Zhuo J, Burns DM, Li YL, Qian DQ, Zhang C, He C, Xu M, Shi E, Li Y, Marando CA, Covington MB, Yang G, Liu X, Pan M, Fridman JS, Scherle P, Wasserman ZR, Hollis G, Vaddi K, Yeleswaram S, Newton R, Friedman S, Metcalf B",,461667,DTCT0024844,2276531,DTCC00488448,1103077,25086
CHEMBL252713,P14780,,KFLMLACIMFJTMO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,4.24,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260729,DTCC00486079,1905744,24831
CHEMBL252823,P14780,,YQDBAVJLVOFOMZ-MHZLTWQESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,29,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278585,DTCC00489369,2084572,25112
CHEMBL252826,P14780,,KCAMDNAUAMLPGX-HNNXBMFYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,14,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278608,DTCC00489296,1636453,25112
CHEMBL252826,P14780,,KCAMDNAUAMLPGX-HNNXBMFYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18086526,IC50,=,14,NM,,,,,,,,,,,,,,Inhibition of catalytic domain MMP9,,"beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.",Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV",,465911,DTCT0024844,2300337,DTCC00489296,1620497,25438
CHEMBL252827,P14780,,AJNIYVYCXZKNMP-SFHVURJKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,2.4,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278607,DTCC00489298,1954615,25112
CHEMBL252876,P14780,,BEHWVPRIGLRXIG-LPOPLRKUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18242982,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents.",Bioorg. Med. Chem. Lett.,2008,18,5,"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ",,462363,DTCT0024844,2282418,DTCC00488450,2068258,25163
CHEMBL252877,P14780,,ZOHXHAYMXURWLP-MNNMKWMVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18036818,IC50,=,160,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.,Bioorg. Med. Chem. Lett.,2008,18,1,"Yao W, Zhuo J, Burns DM, Li YL, Qian DQ, Zhang C, He C, Xu M, Shi E, Li Y, Marando CA, Covington MB, Yang G, Liu X, Pan M, Fridman JS, Scherle P, Wasserman ZR, Hollis G, Vaddi K, Yeleswaram S, Newton R, Friedman S, Metcalf B",,461667,DTCT0024844,2276530,DTCC00488452,1841474,25086
CHEMBL252917,P14780,,YWDVOYCLYDORQI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,4.29,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260728,DTCC00486080,228506,24831
CHEMBL252965,P14780,,ZFKSAPYYGSUEFY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,88000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266639,DTCC00485869,131684,24949
CHEMBL253032,P14780,,YMEMYNPRLJHTGN-IBGZPJMESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,0.52,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278605,DTCC00489302,1954616,25112
CHEMBL253033,P14780,,NLCRRRBETNPQLX-FQEVSTJZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,1.3,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278604,DTCC00489303,957069,25112
CHEMBL253035,P14780,,OJSMIPQPXMBSTI-FQEVSTJZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18068976,IC50,>,5000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutations.,Bioorg. Med. Chem. Lett.,2008,18,2,"Burns DM, He C, Li Y, Scherle P, Liu X, Marando CA, Covington MB, Yang G, Pan M, Turner S, Fridman JS, Hollis G, Vaddi K, Yeleswaram S, Newton R, Friedman S, Metcalf B, Yao W",,461866,DTCT0024844,2278109,DTCC00489379,1937788,25102
CHEMBL253075,P14780,,NYOFYADPNAWQIO-ZWKOTPCHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18242982,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents.",Bioorg. Med. Chem. Lett.,2008,18,5,"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ",,462363,DTCT0024844,2282416,DTCC00488455,9067,25163
CHEMBL253076,P14780,,QCELJPBZUJYPIW-DLBZAZTESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18242982,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents.",Bioorg. Med. Chem. Lett.,2008,18,5,"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ",,462363,DTCT0024844,2282415,DTCC00488457,1166497,25163
CHEMBL253172,P14780,,CASVJRHAYOMAAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266638,DTCC00485870,521173,24949
CHEMBL253188,P14780,,FBXFLSBLYSCCKI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,103000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266617,DTCC00485897,1231186,24949
CHEMBL253189,P14780,,XVLGIGXPBDHMCN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,114000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266616,DTCC00485898,1394272,24949
CHEMBL253242,P14780,,YFEKLRQLQCUVPO-QFIPXVFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,1.8,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278602,DTCC00489306,1728790,25112
CHEMBL253256,P14780,,QWCJOBSHHHILCA-ROUUACIJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18036818,IC50,=,604,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.,Bioorg. Med. Chem. Lett.,2008,18,1,"Yao W, Zhuo J, Burns DM, Li YL, Qian DQ, Zhang C, He C, Xu M, Shi E, Li Y, Marando CA, Covington MB, Yang G, Liu X, Pan M, Fridman JS, Scherle P, Wasserman ZR, Hollis G, Vaddi K, Yeleswaram S, Newton R, Friedman S, Metcalf B",,461667,DTCT0024844,2276534,DTCC00112461,521199,25086
CHEMBL253275,P14780,BMS-566394,PGVYYPZKXKGBLD-JKSUJKDBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18242982,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents.",Bioorg. Med. Chem. Lett.,2008,18,5,"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ",,462363,DTCT0024844,2282414,DTCC00003908,392011,25163
CHEMBL253275,P14780,BMS-566394,PGVYYPZKXKGBLD-JKSUJKDBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,KI,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2457232,DTCC00003908,404569,32556
CHEMBL253276,P14780,,JADBDFQEPJQPBJ-GOEBONIOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18242982,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents.",Bioorg. Med. Chem. Lett.,2008,18,5,"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ",,462363,DTCT0024844,2282413,DTCC00488458,1037911,25163
CHEMBL253313,P14780,,LCTLPROJUJRGOK-OYGGHGNESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17936631,IC50,=,23,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,"Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation.",Bioorg. Med. Chem.,2008,16,1,"Chun K, Park SK, Kim HM, Choi Y, Kim MH, Park CH, Joe BY, Chun TG, Choi HM, Lee HY, Hong SH, Kim MS, Nam KY, Han G",,461354,DTCT0024844,2274657,DTCC00487736,1954602,25060
CHEMBL253337,P14780,,VAMOVZICEXQQGW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,4.85,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260688,DTCC00486085,424722,24831
CHEMBL253372,P14780,,RZPBUIMYXLDFQU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,94000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266635,DTCC00485872,1426657,24949
CHEMBL253373,P14780,,UFTZDZSQVAEJAG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,76000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266634,DTCC00485873,1776512,24949
CHEMBL253374,P14780,,QQSFVIDGFAOBIT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,3000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266632,DTCC00485875,1198941,24949
CHEMBL253375,P14780,,WAUSDDFKSNPSDE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,60000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266631,DTCC00485876,746944,24949
CHEMBL253376,P14780,BROMHEXINE,OJGDCBLYJGHCIH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7266013,DTCC00112211,444635,46191
CHEMBL253376,P14780,BROMHEXINE,OJGDCBLYJGHCIH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7266014,DTCC00112211,444635,46191
CHEMBL253450,P14780,,BAFXERACAAFQDU-QFIPXVFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,2.8,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278601,DTCC00489311,472501,25112
CHEMBL253489,P14780,,IMWYAYZRQVPCBO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17936631,IC50,=,3050,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,"Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation.",Bioorg. Med. Chem.,2008,16,1,"Chun K, Park SK, Kim HM, Choi Y, Kim MH, Park CH, Joe BY, Chun TG, Choi HM, Lee HY, Hong SH, Kim MS, Nam KY, Han G",,461354,DTCT0024844,2274656,DTCC00487742,1604159,25060
CHEMBL253605,P14780,,OWGKRTPKHBGQCB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,33000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266628,DTCC00485879,746945,24949
CHEMBL253665,P14780,,IVYQYYDKKZBNTO-NRFANRHFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18068976,IC50,>,5000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutations.,Bioorg. Med. Chem. Lett.,2008,18,2,"Burns DM, He C, Li Y, Scherle P, Liu X, Marando CA, Covington MB, Yang G, Pan M, Turner S, Fridman JS, Hollis G, Vaddi K, Yeleswaram S, Newton R, Friedman S, Metcalf B, Yao W",,461866,DTCT0024844,2278108,DTCC00489390,67182,25102
CHEMBL253680,P14780,,LFOGEPKUSWRLCL-JOCHJYFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472202,IC50,=,6.6,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.,J. Med. Chem.,2001,44,16,"Pikul S, Ohler NE, Ciszewski G, Laufersweiler MC, Almstead NG, De B, Natchus MG, Hsieh LC, Janusz MJ, Peng SX, Branch TM, King SL, Taiwo YO, Mieling GE",,105229,DTCT0024844,1312043,DTCC00487204,1035283,16328
CHEMBL253694,P14780,,QBKGBIIDSAFPRG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17936631,IC50,=,24500,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,"Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation.",Bioorg. Med. Chem.,2008,16,1,"Chun K, Park SK, Kim HM, Choi Y, Kim MH, Park CH, Joe BY, Chun TG, Choi HM, Lee HY, Hong SH, Kim MS, Nam KY, Han G",,461354,DTCT0024844,2274654,DTCC00487746,537305,25060
CHEMBL253710,P14780,,HNNDIXHHVAZLIV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17936631,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,"Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation.",Bioorg. Med. Chem.,2008,16,1,"Chun K, Park SK, Kim HM, Choi Y, Kim MH, Park CH, Joe BY, Chun TG, Choi HM, Lee HY, Hong SH, Kim MS, Nam KY, Han G",,461354,DTCT0024844,2274683,DTCC00487750,827765,25060
CHEMBL253801,P14780,,WLDFNVXUZOLFLV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,68000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266642,DTCC00112331,746943,24949
CHEMBL253820,P14780,,SENFKJJTAIUEKU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,69000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266626,DTCC00485881,714644,24949
CHEMBL253823,P14780,,MBMOJYHUZVXHPP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,67000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266624,DTCC00485885,9012,24949
CHEMBL253835,P14780,,KBHIXHPPONXJSH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,>,150,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266615,DTCC00485900,1905754,24949
CHEMBL253892,P14780,,UBYVBDDXGLCPEF-FQEVSTJZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,2.3,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278579,DTCC00489397,1345902,25112
CHEMBL253920,P14780,,KRVYWSXTKLCPHD-IRXDYDNUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18036818,IC50,=,916,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.,Bioorg. Med. Chem. Lett.,2008,18,1,"Yao W, Zhuo J, Burns DM, Li YL, Qian DQ, Zhang C, He C, Xu M, Shi E, Li Y, Marando CA, Covington MB, Yang G, Liu X, Pan M, Fridman JS, Scherle P, Wasserman ZR, Hollis G, Vaddi K, Yeleswaram S, Newton R, Friedman S, Metcalf B",,461667,DTCT0024844,2276536,DTCC00488379,9050,25086
CHEMBL254006,P14780,,KHUYGJKVYSCEOH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,>,150,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266641,DTCC00112332,228514,24949
CHEMBL254038,P14780,,BQQDHHXBQHXQLE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,>,150,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266614,DTCC00485902,1808971,24949
CHEMBL254039,P14780,,YQZDMSWWISKFJU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,70000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266613,DTCC00485903,1135256,24949
CHEMBL254219,P14780,DIGITOXIN,WDJUZGPOPHTGOT-XUDUSOBPSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7346776,DTCC00112296,994591,46191
CHEMBL254219,P14780,DIGITOXIN,WDJUZGPOPHTGOT-XUDUSOBPSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7346777,DTCC00112296,994591,46191
CHEMBL254238,P14780,,MEULEAFJINXPTC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,68000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266623,DTCC00485887,972955,24949
CHEMBL254239,P14780,,XRTFXZGCGQXDQP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,59000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266622,DTCC00485888,585424,24949
CHEMBL254240,P14780,,BNQIAXFYQJNTFD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,67000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266621,DTCC00485890,326666,24949
CHEMBL254293,P14780,,JKSLNLNYDBSARV-QFIPXVFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,0.52,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278596,DTCC00489326,1313205,25112
CHEMBL254295,P14780,,REAAGXUAXYMPTM-QFIPXVFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18068976,IC50,=,535,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutations.,Bioorg. Med. Chem. Lett.,2008,18,2,"Burns DM, He C, Li Y, Scherle P, Liu X, Marando CA, Covington MB, Yang G, Pan M, Turner S, Fridman JS, Hollis G, Vaddi K, Yeleswaram S, Newton R, Friedman S, Metcalf B, Yao W",,461866,DTCT0024844,2278107,DTCC00489402,2003661,25102
CHEMBL254403,P14780,,ZISWMICBHCDCHP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,7000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266603,DTCC00112333,99412,24949
CHEMBL254404,P14780,,XPTXINZCVRFJFR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,119000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266602,DTCC00112334,1103054,24949
CHEMBL254405,P14780,3-(TRIFLUOROMETHYL)BENZYL 6-MERCAPTOPICOLINATE,HQDIBKWVFVAFAT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,126000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266601,DTCC00003775,1037867,24949
CHEMBL254406,P14780,3-METHOXYBENZYL 6-MERCAPTOPICOLINATE,QHNITERHCRUTKV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,93000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266599,DTCC00003777,67171,24949
CHEMBL254448,P14780,,GGTBYVPJZZRXTP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,114000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266620,DTCC00485891,164174,24949
CHEMBL254506,P14780,,RVZZCWYPKFKFQC-QFIPXVFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,0.89,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278594,DTCC00489329,827772,25112
CHEMBL254509,P14780,,NXDUTDHMFGWNPY-NRFANRHFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,2.5,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278577,DTCC00489404,2020187,25112
CHEMBL254510,P14780,,ANOPQMHOFNTJCB-QFIPXVFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18068976,IC50,=,955,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutations.,Bioorg. Med. Chem. Lett.,2008,18,2,"Burns DM, He C, Li Y, Scherle P, Liu X, Marando CA, Covington MB, Yang G, Pan M, Turner S, Fridman JS, Hollis G, Vaddi K, Yeleswaram S, Newton R, Friedman S, Metcalf B, Yao W",,461866,DTCT0024844,2278106,DTCC00489406,940969,25102
CHEMBL254610,P14780,4-PHENOXYBUTYL 6-MERCAPTOPICOLINATE,JINCVTOAYWQJTI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,83000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266597,DTCC00003779,521174,24949
CHEMBL254611,P14780,3-FLUOROBENZYL 6-MERCAPTOPICOLINATE,OHJOCHBVYDYTJP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,107000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266596,DTCC00003780,714645,24949
CHEMBL254627,P14780,,WDNYCRKXDHHDIK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,69000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266647,DTCC00112324,521172,24949
CHEMBL254657,P14780,,PQCTVEFWWXYXGC-VMPITWQZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,73000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266619,DTCC00485895,746946,24949
CHEMBL254718,P14780,,GGFOVHADCXFYBC-VWLOTQADSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,256,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278575,DTCC00489410,1668796,25112
CHEMBL254722,P14780,,XUGIQJJECDDGBH-DOTOQJQBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18242982,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents.",Bioorg. Med. Chem. Lett.,2008,18,5,"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ",,462363,DTCT0024844,2282323,DTCC00488435,1841493,25163
CHEMBL254821,P14780,,IGVYCJWEGFBBOJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,90000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266611,DTCC00485907,1808972,24949
CHEMBL254837,P14780,,IGTOOKSKMAGIMJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,68000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266646,DTCC00112325,2068223,24949
CHEMBL254838,P14780,,BYXJDCBFAJLZRZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,94000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266645,DTCC00112326,1937770,24949
CHEMBL254929,P14780,,PYBCEKGPALJXJE-IBGZPJMESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,2,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278574,DTCC00489412,1668799,25112
CHEMBL255051,P14780,,HLKJVILSXJCTNG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,81000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266643,DTCC00112329,1394271,24949
CHEMBL255171,P14780,,HULXBZPKHGNNND-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17981034,IC50,=,315,NM,,,,,,,,,,,,,,Inhibition of MMP9,,1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Chakaravarty D, Xiang B, Scannevin RH, Huang Z, Ma J, Burke SL, Karnachi P, Rhodes KJ, Jackson PF",,469432,DTCT0024844,2289283,DTCC00501410,844383,25715
CHEMBL255374,P14780,,ZSZOBVLJWIXXND-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17981034,INHIBITION,=,34,%,,,,,,,,,,,,,,Inhibition of MMP9 at 100 uM,,1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Chakaravarty D, Xiang B, Scannevin RH, Huang Z, Ma J, Burke SL, Karnachi P, Rhodes KJ, Jackson PF",,469437,DTCT0024844,2289279,DTCC00501413,1905900,25715
CHEMBL255375,P14780,,RRZNITDSNPAPBH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17981034,IC50,>,1000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Chakaravarty D, Xiang B, Scannevin RH, Huang Z, Ma J, Burke SL, Karnachi P, Rhodes KJ, Jackson PF",,469432,DTCT0024844,2289281,DTCC00501414,1296744,25715
CHEMBL255756,P14780,,RYSSHJFPQIVXNL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17980583,IC50,=,846,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Yang SM, Scannevin RH, Burke SL, Rhodes KJ, Jackson PF",,469152,DTCT0024844,2289055,DTCC00501944,682465,25686
CHEMBL255757,P14780,,JIQWJAWERNKCFL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17980583,IC50,=,21.5,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Yang SM, Scannevin RH, Burke SL, Rhodes KJ, Jackson PF",,469152,DTCT0024844,2289056,DTCC00501945,1776658,25686
CHEMBL255995,P14780,,ROXDKSYNRMRPOM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17981034,IC50,=,33.4,NM,,,,,,,,,,,,,,Inhibition of MMP9,,1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Chakaravarty D, Xiang B, Scannevin RH, Huang Z, Ma J, Burke SL, Karnachi P, Rhodes KJ, Jackson PF",,469432,DTCT0024844,2289311,DTCC00501277,9240,25715
CHEMBL255996,P14780,,LUXNVTGRZAPNHK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17981034,IC50,=,57.5,NM,,,,,,,,,,,,,,Inhibition of MMP9,,1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Chakaravarty D, Xiang B, Scannevin RH, Huang Z, Ma J, Burke SL, Karnachi P, Rhodes KJ, Jackson PF",,469432,DTCT0024844,2289312,DTCC00501279,1937892,25715
CHEMBL256018,P14780,,WUDIIDPVRNKUNH-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18086526,IC50,=,984,NM,,,,,,,,,,,,,,Inhibition of catalytic domain MMP9,,"beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.",Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV",,465911,DTCT0024844,2300328,DTCC00500708,1296688,25438
CHEMBL256066,P14780,,LJTOKVQVUWPBDT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17980583,IC50,=,13.9,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Yang SM, Scannevin RH, Burke SL, Rhodes KJ, Jackson PF",,469152,DTCT0024844,2289059,DTCC00502029,131836,25686
CHEMBL256067,P14780,,GJWCBBLTUFPHCJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17980583,IC50,=,522,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Yang SM, Scannevin RH, Burke SL, Rhodes KJ, Jackson PF",,469152,DTCT0024844,2289060,DTCC00502030,682464,25686
CHEMBL256157,P14780,,PRJCFROAJDAXAD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16220987,KI,=,4.5,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14744862,DTCC00490063,2108850,69259
CHEMBL256157,P14780,,PRJCFROAJDAXAD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18068976,IC50,<,1.5,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutations.,Bioorg. Med. Chem. Lett.,2008,18,2,"Burns DM, He C, Li Y, Scherle P, Liu X, Marando CA, Covington MB, Yang G, Pan M, Turner S, Fridman JS, Hollis G, Vaddi K, Yeleswaram S, Newton R, Friedman S, Metcalf B, Yao W",,461866,DTCT0024844,2278126,DTCC00490063,2003662,25102
CHEMBL256187,P14780,,GYCOCSHXBFMYGU-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18086526,IC50,=,4819,NM,,,,,,,,,,,,,,Inhibition of catalytic domain MMP9,,"beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.",Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV",,465911,DTCT0024844,2300329,DTCC00500752,1394358,25438
CHEMBL256245,P14780,,XZHJCGLTNPMNLE-XTEPFMGCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18061445,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).",Bioorg. Med. Chem. Lett.,2008,18,2,"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ",,463237,DTCT0024844,2296524,DTCC00502063,424775,25233
CHEMBL256438,P14780,,ZCLGRPDLXFVIIK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17980583,IC50,=,31,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Yang SM, Scannevin RH, Burke SL, Rhodes KJ, Jackson PF",,469152,DTCT0024844,2289057,DTCC00501989,359381,25686
CHEMBL256598,P14780,,BEMAWHUATSKVDF-LADGPHEKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18061445,KI,=,1851,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).",Bioorg. Med. Chem. Lett.,2008,18,2,"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ",,463237,DTCT0024844,2296525,DTCC00501616,424774,25233
CHEMBL256621,P14780,,NASYCHQKVXYGPX-PZJWPPBQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18061445,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).",Bioorg. Med. Chem. Lett.,2008,18,2,"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ",,463237,DTCT0024844,2296488,DTCC00501980,521230,25233
CHEMBL256642,P14780,,FGVRDWMLTSAQAQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17981034,IC50,=,693,NM,,,,,,,,,,,,,,Inhibition of MMP9,,1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Chakaravarty D, Xiang B, Scannevin RH, Huang Z, Ma J, Burke SL, Karnachi P, Rhodes KJ, Jackson PF",,469432,DTCT0024844,2289303,DTCC00501078,521328,25715
CHEMBL256681,P14780,,YURFZWNLXFKRFO-RBBKRZOGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18061445,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).",Bioorg. Med. Chem. Lett.,2008,18,2,"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ",,463237,DTCT0024844,2296499,DTCC00501695,1394318,25233
CHEMBL256805,P14780,,TTZQPUPTVJAEIJ-RBBKRZOGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18061445,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).",Bioorg. Med. Chem. Lett.,2008,18,2,"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ",,463237,DTCT0024844,2296526,DTCC00501618,1296649,25233
CHEMBL256843,P14780,,DIWCYPNWGCAUKU-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17981034,IC50,=,57.9,NM,,,,,,,,,,,,,,Inhibition of MMP9,,1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Chakaravarty D, Xiang B, Scannevin RH, Huang Z, Ma J, Burke SL, Karnachi P, Rhodes KJ, Jackson PF",,469432,DTCT0024844,2289302,DTCC00501079,359397,25715
CHEMBL257070,P14780,,GLZLLWJIHUOGHO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17980583,IC50,=,16.4,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Yang SM, Scannevin RH, Burke SL, Rhodes KJ, Jackson PF",,469152,DTCT0024844,2289063,DTCC00502071,1620542,25686
CHEMBL257072,P14780,,GWAXDFHSCOMEEA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17980583,IC50,=,56.1,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Yang SM, Scannevin RH, Burke SL, Rhodes KJ, Jackson PF",,469152,DTCT0024844,2289064,DTCC00502074,1744803,25686
CHEMBL257086,P14780,,CQAUVGAVNXQLQF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17981034,IC50,=,34.9,NM,,,,,,,,,,,,,,Inhibition of MMP9,,1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Chakaravarty D, Xiang B, Scannevin RH, Huang Z, Ma J, Burke SL, Karnachi P, Rhodes KJ, Jackson PF",,469432,DTCT0024844,2289316,DTCC00501324,1394424,25715
CHEMBL257088,P14780,,HAPYOOOJPQOLHH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17980583,IC50,=,2.4,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Yang SM, Scannevin RH, Burke SL, Rhodes KJ, Jackson PF",,469152,DTCT0024844,2289051,DTCC00501372,2068349,25686
CHEMBL257088,P14780,,HAPYOOOJPQOLHH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17981034,IC50,=,2.4,NM,,,,,,,,,,,,,,Inhibition of MMP9,,1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Chakaravarty D, Xiang B, Scannevin RH, Huang Z, Ma J, Burke SL, Karnachi P, Rhodes KJ, Jackson PF",,469432,DTCT0024844,2289319,DTCC00501372,2068358,25715
CHEMBL25719,P14780,GERANIOL,GLZPCOQZEFWAFX-JXMROGBWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7316636,DTCC00159285,898289,46191
CHEMBL25719,P14780,GERANIOL,GLZPCOQZEFWAFX-JXMROGBWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7316637,DTCC00159285,898289,46191
CHEMBL257211,P14780,,RWHRRAZIYVBNOY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17980583,IC50,=,87.9,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Yang SM, Scannevin RH, Burke SL, Rhodes KJ, Jackson PF",,469152,DTCT0024844,2289058,DTCC00501992,779157,25686
CHEMBL257480,P14780,,ISONEAYXNYSTJQ-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17980583,IC50,=,21.1,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Yang SM, Scannevin RH, Burke SL, Rhodes KJ, Jackson PF",,469152,DTCT0024844,2289052,DTCC00501865,1873601,25686
CHEMBL257531,P14780,,LSEJNPTVWWYHHK-NGYIFUPDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18061445,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).",Bioorg. Med. Chem. Lett.,2008,18,2,"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ",,463237,DTCT0024844,2296502,DTCC00501776,521228,25233
CHEMBL257532,P14780,,BVFWOEMSVMBUTK-PIPMEXSNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18061445,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).",Bioorg. Med. Chem. Lett.,2008,18,2,"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ",,463237,DTCT0024844,2296503,DTCC00501778,2068269,25233
CHEMBL257672,P14780,,UEFDPQIFYVNTDS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17981034,IC50,=,5,NM,,,,,,,,,,,,,,Inhibition of MMP9,,1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Chakaravarty D, Xiang B, Scannevin RH, Huang Z, Ma J, Burke SL, Karnachi P, Rhodes KJ, Jackson PF",,469432,DTCT0024844,2289314,DTCC00501316,585573,25715
CHEMBL257673,P14780,,GVTAXPJFCIKNRR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17981034,IC50,=,4.4,NM,,,,,,,,,,,,,,Inhibition of MMP9,,1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Chakaravarty D, Xiang B, Scannevin RH, Huang Z, Ma J, Burke SL, Karnachi P, Rhodes KJ, Jackson PF",,469432,DTCT0024844,2289315,DTCC00501320,553416,25715
CHEMBL257724,P14780,,HFAMBBILJIHLFF-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18086526,IC50,=,933,NM,,,,,,,,,,,,,,Inhibition of catalytic domain MMP9,,"beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.",Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV",,465911,DTCT0024844,2300350,DTCC00500537,1841532,25438
CHEMBL257725,P14780,,QMFXBRFSLXUTKY-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18086526,IC50,=,242,NM,,,,,,,,,,,,,,Inhibition of catalytic domain MMP9,,"beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.",Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV",,465911,DTCT0024844,2300349,DTCC00500538,1426728,25438
CHEMBL257874,P14780,,QVVWOFJAPGVZJV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17981034,IC50,=,158.5,NM,,,,,,,,,,,,,,Inhibition of MMP9,,1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Chakaravarty D, Xiang B, Scannevin RH, Huang Z, Ma J, Burke SL, Karnachi P, Rhodes KJ, Jackson PF",,469432,DTCT0024844,2289318,DTCC00501369,1426798,25715
CHEMBL25788,P14780,,SRGKYQVDQPZBLM-PYNWJHIZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10212120,IC50,=,1180,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,Identification of highly selective inhibitors of collagenase-1 from combinatorial libraries of diketopiperazines.,J. Med. Chem.,1999,42,8,"Szardenings AK, Antonenko V, Campbell DA, DeFrancisco N, Ida S, Shi L, Sharkov N, Tien D, Wang Y, Navre M",,105219,DTCT0024844,1295015,DTCC00163453,1885029,15658
CHEMBL25788,P14780,,SRGKYQVDQPZBLM-PYNWJHIZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,1174.9,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258269,DTCC00163453,1873436,24803
CHEMBL258300,P14780,,SQWGCQTZANCRQT-NRFANRHFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18086526,IC50,=,54,NM,,,,,,,,,,,,,,Inhibition of catalytic domain MMP9,,"beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.",Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV",,465911,DTCT0024844,2300342,DTCC00500377,1296687,25438
CHEMBL258301,P14780,,MDYILYKXSLZVLM-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18086526,IC50,=,243,NM,,,,,,,,,,,,,,Inhibition of catalytic domain MMP9,,"beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.",Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV",,465911,DTCT0024844,2300341,DTCC00500378,1199026,25438
CHEMBL26,P14780,SULPIRIDE,BGRJTUBHPOOWDU-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7476398,DTCC00133325,413978,46191
CHEMBL26,P14780,SULPIRIDE,BGRJTUBHPOOWDU-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7476399,DTCC00133325,413978,46191
CHEMBL26058,P14780,,JCFYPSQTTQQSEU-NGSHPTGOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12657268,KI,=,1741,NM,,,,,,,,,,,,,,Affinity for Matrix metalloprotease-9 (MMP-9),,Potent and selective aggrecanase inhibitors containing cyclic P1 substituents.,Bioorg. Med. Chem. Lett.,2003,13,7,"Cherney RJ, Mo R, Meyer DT, Wang L, Yao W, Wasserman ZR, Liu RQ, Covington MB, Tortorella MD, Arner EC, Qian M, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Decicco CP",,105369,DTCT0024844,1337811,DTCC00158731,1487684,6242
CHEMBL26165,P14780,,QYVIVSNKIUQWOU-NGSHPTGOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12657268,KI,>,2128,NM,,,,,,,,,,,,,,Affinity for Matrix metalloprotease-9 (MMP-9),,Potent and selective aggrecanase inhibitors containing cyclic P1 substituents.,Bioorg. Med. Chem. Lett.,2003,13,7,"Cherney RJ, Mo R, Meyer DT, Wang L, Yao W, Wasserman ZR, Liu RQ, Covington MB, Tortorella MD, Arner EC, Qian M, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Decicco CP",,105369,DTCT0024844,1361240,DTCC00158265,775492,6242
CHEMBL261932,P14780,TANOMASTAT,JXAGDPXECXQWBC-LJQANCHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669559,KI,=,301,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9).,,Protease inhibitors: current status and future prospects.,J. Med. Chem.,2000,43,3,"Leung D, Abbenante G, Fairlie DP",,105389,DTCT0024844,1077307,DTCC00288849,1035816,16063
CHEMBL261932,P14780,TANOMASTAT,JXAGDPXECXQWBC-LJQANCHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,301,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1568636,DTCC00288849,1035158,16699
CHEMBL262397,P14780,,QTGQZAQZBAEHLR-URZIEALYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15837315,IC50,=,8.3,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 in MMPi assay,,A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs.,Bioorg. Med. Chem. Lett.,2005,15,9,"Rossello A, Nuti E, Catalani MP, Carelli P, Orlandini E, Rapposelli S, Tuccinardi T, Atkinson SJ, Murphy G, Balsamo A",,305685,DTCT0024844,1841402,DTCC00403446,337522,18987
CHEMBL26260,P14780,BETA-NAPHTHOFLAVONE,OUGIDAPQYNCXRA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7271234,DTCC00163498,1641845,46191
CHEMBL26260,P14780,BETA-NAPHTHOFLAVONE,OUGIDAPQYNCXRA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7271235,DTCC00163498,1641845,46191
CHEMBL262676,P14780,,HNXQLWUITFQYPE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,1.2,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1606267,DTCC00299222,2045764,15919
CHEMBL262676,P14780,,HNXQLWUITFQYPE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,1.2,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258509,DTCC00299222,2036409,24803
CHEMBL262777,P14780,VANCOMYCIN,MYPYJXKWCTUITO-LYRMYLQWSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7447636,DTCC00189637,51514,46191
CHEMBL262777,P14780,VANCOMYCIN,MYPYJXKWCTUITO-LYRMYLQWSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7447637,DTCC00189637,51514,46191
CHEMBL26278,P14780,,RYYDXOKNSQYIAR-CSQIJOFWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12657268,KI,>,2128,NM,,,,,,,,,,,,,,Affinity for Matrix metalloprotease-9 (MMP-9),,Potent and selective aggrecanase inhibitors containing cyclic P1 substituents.,Bioorg. Med. Chem. Lett.,2003,13,7,"Cherney RJ, Mo R, Meyer DT, Wang L, Yao W, Wasserman ZR, Liu RQ, Covington MB, Tortorella MD, Arner EC, Qian M, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Decicco CP",,105369,DTCT0024844,1354844,DTCC00158774,1423246,6242
CHEMBL263459,P14780,TCMDC-138171,ZLIOUDYFRDHHSM-IKGGRYGDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11708926,IC50,=,51,NM,,,,,,,,,,,,,,Inhibition potency was determined by fluorescence-based peptide assay against matrix metalloprotease-9,,Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,J. Med. Chem.,2001,44,24,"Rabinowitz MH, Andrews RC, Becherer JD, Bickett DM, Bubacz DG, Conway JG, Cowan DJ, Gaul M, Glennon K, Lambert MH, Leesnitzer MA, McDougald DL, Moss ML, Musso DL, Rizzolio MC",,105523,DTCT0024844,1280311,DTCC01743220,648695,16522
CHEMBL26388,P14780,,BBDXBWXBEFUKCK-RAKSCHNQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12657268,KI,>,2128,NM,,,,,,,,,,,,,,Affinity for Matrix metalloprotease-9 (MMP-9),,Potent and selective aggrecanase inhibitors containing cyclic P1 substituents.,Bioorg. Med. Chem. Lett.,2003,13,7,"Cherney RJ, Mo R, Meyer DT, Wang L, Yao W, Wasserman ZR, Liu RQ, Covington MB, Tortorella MD, Arner EC, Qian M, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Decicco CP",,105369,DTCT0024844,1341239,DTCC00158277,646891,6242
CHEMBL264374,P14780,BEZAFIBRATE,IIBYAHWJQTYFKB-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7263017,DTCC00179544,249938,46191
CHEMBL264374,P14780,BEZAFIBRATE,IIBYAHWJQTYFKB-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7263018,DTCC00179544,249938,46191
CHEMBL265216,P14780,,SJPBXYWXFIQQJH-XHNVNVPESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871551,KI,=,2,NM,,,,,,,,,,,,,,Binding affinity was evaluated against matrix metalloprotease-9,,Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,1998,8,7,"Jacobson IC, Reddy PG, Wasserman ZR, Hardman KD, Covington MB, Arner EC, Copeland RA, Decicco CP, Magolda RL",,105373,DTCT0024844,347989,DTCC00365441,649219,3059
CHEMBL265769,P14780,,SQEKFRREQBQUKS-VGSVOMNFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9191969,IC50,=,24000,NM,,,,,,,,,,,,,,The concentration required to achieve 50% inhibition against Matrix metalloprotease-9,,Dual inhibition of human leukocyte elastase and lipid peroxidation: in vitro and in vivo activities of azabicyclo[2.2.2]octane and perhydroindole derivatives.,J. Med. Chem.,1997,40,12,"Portevin B, Lonchampt M, Canet E, De Nanteuil G",,105660,DTCT0024844,1256583,DTCC00204634,1805941,14199
CHEMBL266245,P14780,,BDVACXGBIHLFIX-QQSVUBKYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11738583,KI,=,4.2,NM,,,,,,,,,,,,,,Binding affinity for human gelatinase B (MMP-9),,Potent P1' biphenylmethyl substituted aggrecanase inhibitors.,Bioorg. Med. Chem. Lett.,2002,12,1,"Yao W, Chao M, Wasserman ZR, Liu RQ, Covington MB, Newton R, Christ D, Wexler RR, Decicco CP",,105370,DTCT0024844,1535158,DTCC00135646,1534802,4824
CHEMBL266292,P14780,,SUFSQYXUPYDFHG-CYBMUJFWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11327577,IC50,=,52.5,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Heterocycle-based MMP inhibitors with P2' substituents.,Bioorg. Med. Chem. Lett.,2001,11,8,"Pikul S, Dunham KM, Almstead NG, De B, Natchus MG, Taiwo YO, Williams LE, Hynd BA, Hsieh LC, Janusz MJ, Gu F, Mieling GE",,105362,DTCT0024844,1315163,DTCC00133589,1631533,4760
CHEMBL266335,P14780,,KRMDDILTPWLCKE-QQSVUBKYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11738583,KI,>,2000,NM,,,,,,,,,,,,,,Binding affinity for human gelatinase B (MMP-9),,Potent P1' biphenylmethyl substituted aggrecanase inhibitors.,Bioorg. Med. Chem. Lett.,2002,12,1,"Yao W, Chao M, Wasserman ZR, Liu RQ, Covington MB, Newton R, Christ D, Wexler RR, Decicco CP",,105370,DTCT0024844,1525689,DTCC00135561,207327,4824
CHEMBL266612,P14780,,ZCERGCHRYHXHNX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14980648,IC50,=,10000,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,New heteroarylbenzenesulphonamides as matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,5,"Delbecq F, Cordonnier G, Pommery N, Barbry D, Hénichart JP",,105506,DTCT0024844,737891,DTCC00143029,256945,6676
CHEMBL267044,P14780,LEVOSULPIRIDE,BGRJTUBHPOOWDU-NSHDSACASA-N,2,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7433803,DTCC00136073,1734057,46191
CHEMBL267044,P14780,LEVOSULPIRIDE,BGRJTUBHPOOWDU-NSHDSACASA-N,2,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7433804,DTCC00136073,1734057,46191
CHEMBL267345,P14780,AMPHOTERICIN B,APKFDSVGJQXUKY-INPOYWNPSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7290081,DTCC00139627,51445,46191
CHEMBL267345,P14780,AMPHOTERICIN B,APKFDSVGJQXUKY-INPOYWNPSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7290082,DTCC00139627,51445,46191
CHEMBL267603,P14780,FOLATE GAMMA-L-PHENYLALANINEHYDROXAMIC ACID,WYBGJFMKGROIBY-PMACEKPBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17127067,IC50,=,22000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs.,Bioorg. Med. Chem.,2007,15,3,"Santos MA, Enyedy EA, Nuti E, Rossello A, Krupenko NI, Krupenko SA",,441089,DTCT0024844,2143974,DTCC00003031,2079521,23121
CHEMBL267603,P14780,FOLATE GAMMA-L-PHENYLALANINEHYDROXAMIC ACID,WYBGJFMKGROIBY-PMACEKPBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17127067,RATIO IC50,=,4400,,,,,,,,,,,,,,,Ratio of IC50 of drug to CGS 27023A for human recombinant MMP9,,Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs.,Bioorg. Med. Chem.,2007,15,3,"Santos MA, Enyedy EA, Nuti E, Rossello A, Krupenko NI, Krupenko SA",,441102,DTCT0024844,2144007,DTCC00003031,2079521,23121
CHEMBL267648,P14780,PEFLOXACIN,FHFYDNQZQSQIAI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7389105,DTCC00141792,735393,46191
CHEMBL267648,P14780,PEFLOXACIN,FHFYDNQZQSQIAI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7389106,DTCC00141792,735393,46191
CHEMBL267744,P14780,TICRYNAFEN,AGHANLSBXUWXTB-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7479058,DTCC00134562,1544902,46191
CHEMBL267744,P14780,TICRYNAFEN,AGHANLSBXUWXTB-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7479059,DTCC00134562,1544902,46191
CHEMBL267854,P14780,,BGTGOVQBCQMVIR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17936631,IC50,=,16400,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,"Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation.",Bioorg. Med. Chem.,2008,16,1,"Chun K, Park SK, Kim HM, Choi Y, Kim MH, Park CH, Joe BY, Chun TG, Choi HM, Lee HY, Hong SH, Kim MS, Nam KY, Han G",,461354,DTCT0024844,2274655,DTCC00487744,180218,25060
CHEMBL267894,P14780,AMOBARBITAL,VIROVYVQCGLCII-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7281682,DTCC00134214,1092340,46191
CHEMBL267894,P14780,AMOBARBITAL,VIROVYVQCGLCII-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7281683,DTCC00134214,1092340,46191
CHEMBL267939,P14780,,XDYZXHJJAIXYOR-LJQANCHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11327577,IC50,=,1.8,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Heterocycle-based MMP inhibitors with P2' substituents.,Bioorg. Med. Chem. Lett.,2001,11,8,"Pikul S, Dunham KM, Almstead NG, De B, Natchus MG, Taiwo YO, Williams LE, Hynd BA, Hsieh LC, Janusz MJ, Gu F, Mieling GE",,105362,DTCT0024844,1312866,DTCC00133464,1275453,4760
CHEMBL268114,P14780,,CNDCCBOSTVCBMM-OAHLLOKOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11327577,IC50,=,5.5,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Heterocycle-based MMP inhibitors with P2' substituents.,Bioorg. Med. Chem. Lett.,2001,11,8,"Pikul S, Dunham KM, Almstead NG, De B, Natchus MG, Taiwo YO, Williams LE, Hynd BA, Hsieh LC, Janusz MJ, Gu F, Mieling GE",,105362,DTCT0024844,1315170,DTCC00133623,2015284,4760
CHEMBL268291,P14780,DIMETHYLFORMAMIDE,ZMXDDKWLCZADIW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7420093,DTCC00136577,1765977,46191
CHEMBL268291,P14780,DIMETHYLFORMAMIDE,ZMXDDKWLCZADIW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7420094,DTCC00136577,1765977,46191
CHEMBL268377,P14780,,SRBWJOFRJIEWKS-CYBMUJFWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11327577,IC50,=,4.2,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Heterocycle-based MMP inhibitors with P2' substituents.,Bioorg. Med. Chem. Lett.,2001,11,8,"Pikul S, Dunham KM, Almstead NG, De B, Natchus MG, Taiwo YO, Williams LE, Hynd BA, Hsieh LC, Janusz MJ, Gu F, Mieling GE",,105362,DTCT0024844,1322470,DTCC00133440,2015283,4760
CHEMBL268381,P14780,,TVIRTWMMZYUJOB-INOCPDNRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11738583,KI,=,87,NM,,,,,,,,,,,,,,Binding affinity for human gelatinase B (MMP-9),,Potent P1' biphenylmethyl substituted aggrecanase inhibitors.,Bioorg. Med. Chem. Lett.,2002,12,1,"Yao W, Chao M, Wasserman ZR, Liu RQ, Covington MB, Newton R, Christ D, Wexler RR, Decicco CP",,105370,DTCT0024844,1535162,DTCC00135495,1275478,4824
CHEMBL268680,P14780,,YKDJPMMXYREXJX-NIDLKEISSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11738583,KI,=,277,NM,,,,,,,,,,,,,,Binding affinity for human gelatinase B (MMP-9),,Potent P1' biphenylmethyl substituted aggrecanase inhibitors.,Bioorg. Med. Chem. Lett.,2002,12,1,"Yao W, Chao M, Wasserman ZR, Liu RQ, Covington MB, Newton R, Christ D, Wexler RR, Decicco CP",,105370,DTCT0024844,1555855,DTCC00135634,1755762,4824
CHEMBL268882,P14780,,TZHSKYKMJBHKLJ-NIDLKEISSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11738583,KI,=,150,NM,,,,,,,,,,,,,,Binding affinity for human gelatinase B (MMP-9),,Potent P1' biphenylmethyl substituted aggrecanase inhibitors.,Bioorg. Med. Chem. Lett.,2002,12,1,"Yao W, Chao M, Wasserman ZR, Liu RQ, Covington MB, Newton R, Christ D, Wexler RR, Decicco CP",,105370,DTCT0024844,1533936,DTCC00135725,855684,4824
CHEMBL269019,P14780,,RCXJWFMVFQBLSC-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11327577,IC50,=,3.3,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Heterocycle-based MMP inhibitors with P2' substituents.,Bioorg. Med. Chem. Lett.,2001,11,8,"Pikul S, Dunham KM, Almstead NG, De B, Natchus MG, Taiwo YO, Williams LE, Hynd BA, Hsieh LC, Janusz MJ, Gu F, Mieling GE",,105362,DTCT0024844,1298437,DTCC00133541,1599275,4760
CHEMBL26913,P14780,,JHYKWSMPVGVBAN-STQMWFEESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10212120,IC50,=,2900,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,Identification of highly selective inhibitors of collagenase-1 from combinatorial libraries of diketopiperazines.,J. Med. Chem.,1999,42,8,"Szardenings AK, Antonenko V, Campbell DA, DeFrancisco N, Ida S, Shi L, Sharkov N, Tien D, Wang Y, Navre M",,105219,DTCT0024844,1300047,DTCC00104119,272849,15658
CHEMBL26913,P14780,,JHYKWSMPVGVBAN-STQMWFEESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,IC50,=,2900,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2457404,DTCC00104119,273427,32556
CHEMBL269732,P14780,TACROLIMUS,QJJXYPPXXYFBGM-LFZNUXCKSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7459020,DTCC00132983,1765982,46191
CHEMBL269732,P14780,TACROLIMUS,QJJXYPPXXYFBGM-LFZNUXCKSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7459021,DTCC00132983,1765982,46191
CHEMBL269797,P14780,,QOLXVMJRZKRSEE-ZDUSSCGKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18086526,IC50,=,472,NM,,,,,,,,,,,,,,Inhibition of catalytic domain MMP9,,"beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.",Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV",,465911,DTCT0024844,2300336,DTCC00500247,585502,25438
CHEMBL269815,P14780,,NUHXWSDHKIQRIT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17980583,IC50,>,1000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Yang SM, Scannevin RH, Burke SL, Rhodes KJ, Jackson PF",,469152,DTCT0024844,2289054,DTCC00501899,326814,25686
CHEMBL27,P14780,PROPRANOLOL,AQHHHDLHHXJYJD-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7403006,DTCC00133355,51503,46191
CHEMBL27,P14780,PROPRANOLOL,AQHHHDLHHXJYJD-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7403007,DTCC00133355,51503,46191
CHEMBL270010,P14780,,HMCYLAUUSNONFW-HNNXBMFYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18086526,IC50,=,39,NM,,,,,,,,,,,,,,Inhibition of catalytic domain MMP9,,"beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.",Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV",,465911,DTCT0024844,2300340,DTCC00500332,260824,25438
CHEMBL270023,P14780,,QTXVUOFTEGYFFX-SFHVURJKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18086526,IC50,=,124,NM,,,,,,,,,,,,,,Inhibition of catalytic domain MMP9,,"beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.",Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV",,465911,DTCT0024844,2300347,DTCC00500501,682413,25438
CHEMBL270050,P14780,,YOFJHCFIKFPSLE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18251495,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of MMP9,Not Active,"Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2008,51,4,"Li JJ, Nahra J, Johnson AR, Bunker A, O'Brien P, Yue WS, Ortwine DF, Man CF, Baragi V, Kilgore K, Dyer RD, Han HK",,465550,DTCT0024844,2311297,DTCC00503704,1636500,25409
CHEMBL270050,P14780,,YOFJHCFIKFPSLE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of MMP9,Not Active,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2457320,DTCC00503704,1632393,32556
CHEMBL270083,P14780,CIS-2-AMINOCYCLOHEXYLCARBAMOYLPHOSPHONIC ACID,XHCXISPZIHYKQD-NTSWFWBYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18257543,IC50,=,20000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,"Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis.",J. Med. Chem.,2008,51,5,"Hoffman A, Qadri B, Frant J, Katz Y, Bhusare SR, Breuer E, Hadar R, Reich R",,465798,DTCT0024844,2311840,DTCC00004596,2020286,25428
CHEMBL270083,P14780,CIS-2-AMINOCYCLOHEXYLCARBAMOYLPHOSPHONIC ACID,XHCXISPZIHYKQD-NTSWFWBYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,IC50,=,20000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2457398,DTCC00004596,2016157,32556
CHEMBL270229,P14780,,WPAHDVHPQGUCCP-NRFANRHFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18086526,IC50,=,69,NM,,,,,,,,,,,,,,Inhibition of catalytic domain MMP9,,"beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.",Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV",,465911,DTCT0024844,2300343,DTCC00500419,553364,25438
CHEMBL270230,P14780,,KWWODZMHQNKZHP-QFIPXVFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18086526,IC50,=,93,NM,,,,,,,,,,,,,,Inhibition of catalytic domain MMP9,,"beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.",Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV",,465911,DTCT0024844,2300344,DTCC00500421,294141,25438
CHEMBL270296,P14780,TRANS-2-AMINOCYCLOHEXYLCARBAMOYLPHOSPHONIC ACID,XHCXISPZIHYKQD-PHDIDXHHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18257543,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,"Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis.",J. Med. Chem.,2008,51,5,"Hoffman A, Qadri B, Frant J, Katz Y, Bhusare SR, Breuer E, Hadar R, Reich R",,465798,DTCT0024844,2311848,DTCC00004597,1151799,25428
CHEMBL270299,P14780,BAY-11-7085,VHKZGNPOHPFPER-ONNFQVAWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7269608,DTCC00504714,1220273,46191
CHEMBL270299,P14780,BAY-11-7085,VHKZGNPOHPFPER-ONNFQVAWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7269609,DTCC00504714,1220273,46191
CHEMBL270372,P14780,,XITKJDIGEPUHLE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17980583,IC50,>,1000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Yang SM, Scannevin RH, Burke SL, Rhodes KJ, Jackson PF",,469152,DTCT0024844,2289069,DTCC00502152,811487,25686
CHEMBL270606,P14780,,OYFJDPJIGCMKKI-LADGPHEKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18061445,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).",Bioorg. Med. Chem. Lett.,2008,18,2,"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ",,463237,DTCT0024844,2296497,DTCC00501659,521229,25233
CHEMBL270800,P14780,,CNSXDPYRIAFYKG-LADGPHEKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18061445,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).",Bioorg. Med. Chem. Lett.,2008,18,2,"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ",,463237,DTCT0024844,2296493,DTCC00502180,1037923,25233
CHEMBL270819,P14780,,SVLPSGKSYVCBRQ-LADGPHEKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18061445,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).",Bioorg. Med. Chem. Lett.,2008,18,2,"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ",,463237,DTCT0024844,2296498,DTCC00501660,811411,25233
CHEMBL270868,P14780,,BEGMRZSKEXZQQD-SFHVURJKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18086526,IC50,=,286,NM,,,,,,,,,,,,,,Inhibition of catalytic domain MMP9,,"beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.",Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV",,465911,DTCT0024844,2300346,DTCC00500499,1971104,25438
CHEMBL271234,P14780,,NTFMFANVPWIUGQ-UKILVPOCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18061445,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).",Bioorg. Med. Chem. Lett.,2008,18,2,"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ",,463237,DTCT0024844,2296490,DTCC00502100,1198991,25233
CHEMBL271235,P14780,,SIICAQVADMFEDB-LADGPHEKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18061445,KI,=,1720,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).",Bioorg. Med. Chem. Lett.,2008,18,2,"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ",,463237,DTCT0024844,2296491,DTCC00502102,1776559,25233
CHEMBL271520,P14780,,WVYUBYOZPPLWTR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17981034,IC50,=,32.6,NM,,,,,,,,,,,,,,Inhibition of MMP9,,1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Chakaravarty D, Xiang B, Scannevin RH, Huang Z, Ma J, Burke SL, Karnachi P, Rhodes KJ, Jackson PF",,469432,DTCT0024844,2289306,DTCC00501173,1841596,25715
CHEMBL271720,P14780,,HVBCQBVRPBCTHZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17981034,IC50,=,1.8,NM,,,,,,,,,,,,,,Inhibition of MMP9,,1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Chakaravarty D, Xiang B, Scannevin RH, Huang Z, Ma J, Burke SL, Karnachi P, Rhodes KJ, Jackson PF",,469432,DTCT0024844,2289304,DTCC00501128,1329332,25715
CHEMBL271736,P14780,,JGESVFFMSKZGDK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17981034,IC50,=,1.3,NM,,,,,,,,,,,,,,Inhibition of MMP9,,1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Chakaravarty D, Xiang B, Scannevin RH, Huang Z, Ma J, Burke SL, Karnachi P, Rhodes KJ, Jackson PF",,469432,DTCT0024844,2289308,DTCC00501176,1809117,25715
CHEMBL271866,P14780,,CDYLCTGLLNQEQF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17980583,IC50,=,4,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Yang SM, Scannevin RH, Burke SL, Rhodes KJ, Jackson PF",,469152,DTCT0024844,2289065,DTCC00502114,1103192,25686
CHEMBL271867,P14780,,WKRVNRRBAKSSCD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17980583,IC50,=,7.3,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Yang SM, Scannevin RH, Burke SL, Rhodes KJ, Jackson PF",,469152,DTCT0024844,2289068,DTCC00502115,1555685,25686
CHEMBL272341,P14780,,QZMMDSUYRAUHCK-RBBKRZOGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18061445,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).",Bioorg. Med. Chem. Lett.,2008,18,2,"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ",,463237,DTCT0024844,2296505,DTCC00501813,617765,25233
CHEMBL272528,P14780,,HXQPXYLMOANXKE-HNNXBMFYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18086526,INHIBITION,=,79,%,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain at 10 uM,,"beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.",Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV",,465912,DTCT0024844,2300361,DTCC00500152,1873544,25438
CHEMBL272763,P14780,,RRHRZNYTQKIVLU-SFHVURJKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18086526,IC50,=,91,NM,,,,,,,,,,,,,,Inhibition of catalytic domain MMP9,,"beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.",Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV",,465911,DTCT0024844,2300330,DTCC00500799,359337,25438
CHEMBL272984,P14780,,MTGNXLIVWGHNAC-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18086526,IC50,=,47,NM,,,,,,,,,,,,,,Inhibition of catalytic domain MMP9,,"beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.",Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV",,465911,DTCT0024844,2300331,DTCC00500802,9152,25438
CHEMBL273348,P14780,TOSUFLOXACIN,WUWFMDMBOJLQIV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7464042,DTCC00145035,2025645,46191
CHEMBL273348,P14780,TOSUFLOXACIN,WUWFMDMBOJLQIV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7464043,DTCC00145035,2025645,46191
CHEMBL273762,P14780,,BKQXMGZHHHUCEX-KHEPKPQXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871727,IC50,,,,,,,,,,,,,,,,,In vitro inhibitory activity against gelatinase-B (MMP-9.,Not Tested,"Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.",Bioorg. Med. Chem. Lett.,1998,8,10,"Campbell DA, Xiao XY, Harris D, Ida S, Mortezaei R, Ngu K, Shi L, Tien D, Wang Y, Navre M, Patel DV, Sharr MA, DiJoseph JF, Killar LM, Leone CL, Levin JI, Skotnicki JS",,105235,DTCT0024844,1539704,DTCC00146290,822861,2559
CHEMBL273764,P14780,,IHKCSGLIRGMLDE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11934587,IC50,=,21,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 1: Structure-based design of novel acetylenic P1' groups.,Bioorg. Med. Chem. Lett.,2002,12,8,"Chen JM, Jin G, Sung A, Levin JI",,105517,DTCT0024844,1100880,DTCC00149694,1405954,5358
CHEMBL273764,P14780,,IHKCSGLIRGMLDE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11934588,IC50,=,21,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 activity,,Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.,Bioorg. Med. Chem. Lett.,2002,12,8,"Levin JI, Chen JM, Du MT, Nelson FC, Killar LM, Skala S, Sung A, Jin G, Cowling R, Barone D, March CJ, Mohler KM, Black RA, Skotnicki JS",,105508,DTCT0024844,811553,DTCC00149694,1390919,5465
CHEMBL27408,P14780,,JGCHRDUVHNVKAK-AHTKWCMKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10212120,IC50,=,1300,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,Identification of highly selective inhibitors of collagenase-1 from combinatorial libraries of diketopiperazines.,J. Med. Chem.,1999,42,8,"Szardenings AK, Antonenko V, Campbell DA, DeFrancisco N, Ida S, Shi L, Sharkov N, Tien D, Wang Y, Navre M",,105219,DTCT0024844,1310906,DTCC00163429,1438026,15658
CHEMBL27408,P14780,,JGCHRDUVHNVKAK-AHTKWCMKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,1288.25,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258275,DTCC00163429,1426640,24803
CHEMBL274700,P14780,,CKOFSPSUQNKQAL-HTAVTVPLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871727,IC50,,,,,,,,,,,,,,,,,In vitro inhibitory activity against gelatinase-B (MMP-9.,Not Tested,"Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.",Bioorg. Med. Chem. Lett.,1998,8,10,"Campbell DA, Xiao XY, Harris D, Ida S, Mortezaei R, Ngu K, Shi L, Tien D, Wang Y, Navre M, Patel DV, Sharr MA, DiJoseph JF, Killar LM, Leone CL, Levin JI, Skotnicki JS",,105235,DTCT0024844,1544574,DTCC00146617,1470264,2559
CHEMBL275014,P14780,,QGOLLUPJBACRFO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14980648,IC50,=,1000,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,New heteroarylbenzenesulphonamides as matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,5,"Delbecq F, Cordonnier G, Pommery N, Barbry D, Hénichart JP",,105506,DTCT0024844,731382,DTCC00142925,1902040,6676
CHEMBL275362,P14780,,WWYUUQYLTXYLBK-VQHVLOKHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,7.14,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833649,DTCC00147933,997232,53968
CHEMBL275654,P14780,,YZAPRHDGKDEXIQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,1.7,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1597362,DTCC00230956,1902969,16699
CHEMBL275654,P14780,,YZAPRHDGKDEXIQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,1.7,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506753,DTCC00230956,1908807,48447
CHEMBL275732,P14780,,GPCRWNMOLNNODH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14980648,IC50,,,,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (No data),Not Determined,New heteroarylbenzenesulphonamides as matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,5,"Delbecq F, Cordonnier G, Pommery N, Barbry D, Hénichart JP",,105507,DTCT0024844,749050,DTCC00142996,549467,6676
CHEMBL275742,P14780,DEXPROPRANOLOL,AQHHHDLHHXJYJD-CQSZACIVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7468392,DTCC00140656,1674148,46191
CHEMBL275742,P14780,DEXPROPRANOLOL,AQHHHDLHHXJYJD-CQSZACIVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7468393,DTCC00140656,1674148,46191
CHEMBL27577,P14780,SALICYLAMIDE,SKZKKFZAGNVIMN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,23,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103358,DTCC00161342,183413,43205
CHEMBL27577,P14780,SALICYLAMIDE,SKZKKFZAGNVIMN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7458045,DTCC00161342,185557,46191
CHEMBL27577,P14780,SALICYLAMIDE,SKZKKFZAGNVIMN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7458046,DTCC00161342,185557,46191
CHEMBL276086,P14780,,IVMSMXBRUPDONM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11934588,INHIBITION,=,28,%,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 at 1 uM,,Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.,Bioorg. Med. Chem. Lett.,2002,12,8,"Levin JI, Chen JM, Du MT, Nelson FC, Killar LM, Skala S, Sung A, Jin G, Cowling R, Barone D, March CJ, Mohler KM, Black RA, Skotnicki JS",,105534,DTCT0024844,790608,DTCC00150697,1902110,5465
CHEMBL276119,P14780,,LCQNQVIUMDNDJS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,9,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,477844,DTCC00235150,368245,17340
CHEMBL276119,P14780,,LCQNQVIUMDNDJS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,5.05,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260726,DTCC00235150,359219,24831
CHEMBL276275,P14780,,XDKNQAWYSUZUDU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11934588,IC50,=,1205,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 activity,,Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.,Bioorg. Med. Chem. Lett.,2002,12,8,"Levin JI, Chen JM, Du MT, Nelson FC, Killar LM, Skala S, Sung A, Jin G, Cowling R, Barone D, March CJ, Mohler KM, Black RA, Skotnicki JS",,105508,DTCT0024844,779301,DTCC00150731,1741081,5465
CHEMBL276588,P14780,,WMUOJNZCUBFVBY-LWMIZPGFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871727,IC50,,,,,,,,,,,,,,,,,In vitro inhibitory activity against gelatinase-B (MMP-9.,Not Tested,"Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.",Bioorg. Med. Chem. Lett.,1998,8,10,"Campbell DA, Xiao XY, Harris D, Ida S, Mortezaei R, Ngu K, Shi L, Tien D, Wang Y, Navre M, Patel DV, Sharr MA, DiJoseph JF, Killar LM, Leone CL, Levin JI, Skotnicki JS",,105235,DTCT0024844,1538502,DTCC00146345,2047607,2559
CHEMBL276832,P14780,HYDRALAZINE,RPTUSVTUFVMDQK-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7327759,DTCC00139551,1416032,46191
CHEMBL276832,P14780,HYDRALAZINE,RPTUSVTUFVMDQK-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7327760,DTCC00139551,1416032,46191
CHEMBL277100,P14780,TEMAFLOXACIN,QKDHBVNJCZBTMR-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7485067,DTCC00145004,1124457,46191
CHEMBL277100,P14780,TEMAFLOXACIN,QKDHBVNJCZBTMR-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7485068,DTCC00145004,1124457,46191
CHEMBL277206,P14780,,WZCXPYXIESDPBM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11934588,IC50,=,2827,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 activity,,Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.,Bioorg. Med. Chem. Lett.,2002,12,8,"Levin JI, Chen JM, Du MT, Nelson FC, Killar LM, Skala S, Sung A, Jin G, Cowling R, Barone D, March CJ, Mohler KM, Black RA, Skotnicki JS",,105508,DTCT0024844,792069,DTCC00150705,63360,5465
CHEMBL277474,P14780,ANTIPYRINE,VEQOALNAAJBPNY-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7262254,DTCC00154395,509231,46191
CHEMBL277474,P14780,ANTIPYRINE,VEQOALNAAJBPNY-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7262255,DTCC00154395,509231,46191
CHEMBL277658,P14780,,KOLIYILUYWKKNC-ZRBLBEILSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10340614,KI,<,1,NM,,,,,,,,,,,,,,"Inhibition of MMP-9 (matrix metalloprotease-9, gelatinase B)",,Macrocyclic hydroxamate inhibitors of matrix metalloproteinases and TNF-alpha production.,Bioorg. Med. Chem. Lett.,1999,9,9,"Cherney RJ, Wang L, Meyer DT, Xue CB, Arner EC, Copeland RA, Covington MB, Hardman KD, Wasserman ZR, Jaffee BD, Decicco CP",,102117,DTCT0024844,924109,DTCC00158055,1243068,3648
CHEMBL27769,P14780,STANOLONE,NVKAWKQGWWIWPM-ABEVXSGRSA-N,2,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7465003,DTCC00161007,1318447,46191
CHEMBL27769,P14780,STANOLONE,NVKAWKQGWWIWPM-ABEVXSGRSA-N,2,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7465004,DTCC00161007,1318447,46191
CHEMBL277792,P14780,,KKRBZYCHOUTMBU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10411481,KI,=,3,NM,,,,,,,,,,,,,,Binding affinity against matrix metalloprotease-9 (gelatinase-B).,,Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.,J. Med. Chem.,1999,42,14,"Vassiliou S, Mucha A, Cuniasse P, Georgiadis D, Lucet-Levannier K, Beau F, Kannan R, Murphy G, Knäuper V, Rio MC, Basset P, Yiotakis A, Dive V",,105378,DTCT0024844,1083346,DTCC00249127,615165,15258
CHEMBL277972,P14780,,ZPDVGCNXBJNBDB-MRVPVSSYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,=,567,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1455998,DTCC00197952,949248,17283
CHEMBL278050,P14780,,YVHCMRZCFTYSIV-BBMPLOMVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871727,IC50,=,1.4,NM,,,,,,,,,,,,,,In vitro inhibitory activity against gelatinase-B (MMP-9).,,"Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.",Bioorg. Med. Chem. Lett.,1998,8,10,"Campbell DA, Xiao XY, Harris D, Ida S, Mortezaei R, Ngu K, Shi L, Tien D, Wang Y, Navre M, Patel DV, Sharr MA, DiJoseph JF, Killar LM, Leone CL, Levin JI, Skotnicki JS",,105234,DTCT0024844,1535061,DTCC00146394,1599401,2559
CHEMBL278060,P14780,,JMJKKHVSMQBPSU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11934587,IC50,=,15,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 1: Structure-based design of novel acetylenic P1' groups.,Bioorg. Med. Chem. Lett.,2002,12,8,"Chen JM, Jin G, Sung A, Levin JI",,105517,DTCT0024844,1115325,DTCC00150237,919845,5358
CHEMBL278060,P14780,,JMJKKHVSMQBPSU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11934588,IC50,=,15,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 activity,,Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.,Bioorg. Med. Chem. Lett.,2002,12,8,"Levin JI, Chen JM, Du MT, Nelson FC, Killar LM, Skala S, Sung A, Jin G, Cowling R, Barone D, March CJ, Mohler KM, Black RA, Skotnicki JS",,105508,DTCT0024844,788938,DTCC00150237,905437,5465
CHEMBL278172,P14780,BENZOCAINE,BLFLLBZGZJTVJG-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7269711,DTCC00146075,88623,46191
CHEMBL278172,P14780,BENZOCAINE,BLFLLBZGZJTVJG-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7269712,DTCC00146075,88623,46191
CHEMBL278452,P14780,,GDTJXNTYOVPWCL-KEKNWZKVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871727,IC50,,,,,,,,,,,,,,,,,In vitro inhibitory activity against gelatinase-B (MMP-9.,Not Tested,"Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.",Bioorg. Med. Chem. Lett.,1998,8,10,"Campbell DA, Xiao XY, Harris D, Ida S, Mortezaei R, Ngu K, Shi L, Tien D, Wang Y, Navre M, Patel DV, Sharr MA, DiJoseph JF, Killar LM, Leone CL, Levin JI, Skotnicki JS",,105235,DTCT0024844,1521040,DTCC00146397,1114446,2559
CHEMBL278872,P14780,,ZLSOXSXSNCNKSX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11934588,IC50,=,2,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 activity,,Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.,Bioorg. Med. Chem. Lett.,2002,12,8,"Levin JI, Chen JM, Du MT, Nelson FC, Killar LM, Skala S, Sung A, Jin G, Cowling R, Barone D, March CJ, Mohler KM, Black RA, Skotnicki JS",,105508,DTCT0024844,777954,DTCC00150719,1934080,5465
CHEMBL278927,P14780,,UHMGUSIGEQSULM-HKHBYEJGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871727,IC50,=,780,NM,,,,,,,,,,,,,,In vitro inhibitory activity against gelatinase-B (MMP-9).,,"Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.",Bioorg. Med. Chem. Lett.,1998,8,10,"Campbell DA, Xiao XY, Harris D, Ida S, Mortezaei R, Ngu K, Shi L, Tien D, Wang Y, Navre M, Patel DV, Sharr MA, DiJoseph JF, Killar LM, Leone CL, Levin JI, Skotnicki JS",,105234,DTCT0024844,1542191,DTCC00146332,629430,2559
CHEMBL279078,P14780,,OBJBBLBMOOBABD-BEVDRBHNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9548812,IC50,=,0.3,NM,,,,,,,,,,,,,,Activity against Matrix metalloprotease-9 (MMP-9).,,Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.,J. Med. Chem.,1998,41,8,"Yamamoto M, Tsujishita H, Hori N, Ohishi Y, Inoue S, Ikeda S, Okada Y",,105225,DTCT0024844,982761,DTCC00151610,1308397,15116
CHEMBL279482,P14780,,TUIHSDQRXNNCLL-LSDHHAIUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10882354,IC50,=,82,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Structure-based design and synthesis of a potent matrix metalloproteinase-13 inhibitor based on a pyrrolidinone scaffold.,J. Med. Chem.,2000,43,12,"Robinson RP, Laird ER, Blake JF, Bordner J, Donahue KM, Lopresti-Morrow LL, Mitchell PG, Reese MR, Reeves LM, Stam EJ, Yocum SA",,105511,DTCT0024844,1106733,DTCC00152021,140588,15747
CHEMBL279482,P14780,,TUIHSDQRXNNCLL-LSDHHAIUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11354379,IC50,=,82,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Design and synthesis of 2-oxo-imidazolidine-4-carboxylic acid hydroxyamides as potent matrix metalloproteinase-13 inhibitors.,Bioorg. Med. Chem. Lett.,2001,11,9,"Robinson RP, Laird ER, Donahue KM, Lopresti-Morrow LL, Mitchell PG, Reese MR, Reeves LM, Rouch AI, Stam EJ, Yocum SA",,105529,DTCT0024844,703845,DTCC00152021,128005,4814
CHEMBL279785,P14780,MARIMASTAT,OCSMOTCMPXTDND-OUAUKWLOSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9548812,IC50,=,8,NM,,,,,,,,,,,,,,Activity against Matrix metalloprotease-9 (MMP-9).,,Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.,J. Med. Chem.,1998,41,8,"Yamamoto M, Tsujishita H, Hori N, Ohishi Y, Inoue S, Ikeda S, Okada Y",,105225,DTCT0024844,980297,DTCC00151612,919877,15116
CHEMBL279785,P14780,MARIMASTAT,OCSMOTCMPXTDND-OUAUKWLOSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10397503,IC50,=,1.5,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,"Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors.",Bioorg. Med. Chem. Lett.,1999,9,12,"Hanessian S, Bouzbouz S, Boudon A, Tucker GC, Peyroulan D",,102115,DTCT0024844,513408,DTCC00151612,905843,3181
CHEMBL279785,P14780,MARIMASTAT,OCSMOTCMPXTDND-OUAUKWLOSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11212095,IC50,=,1.6,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.,Bioorg. Med. Chem. Lett.,2001,11,3,"Chollet AM, Le Diguarher T, Murray L, Bertrand M, Tucker GC, Sabatini M, Pierré A, Atassi G, Bonnet J, Casara P",,105358,DTCT0024844,627893,DTCC00151612,906831,4635
CHEMBL279785,P14780,MARIMASTAT,OCSMOTCMPXTDND-OUAUKWLOSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472217,KI,<,1,NM,,,,,,,,,,,,,,In vitro inhibition of human MMP-9.,,"Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.",J. Med. Chem.,2001,44,16,"Xue CB, Voss ME, Nelson DJ, Duan JJ, Cherney RJ, Jacobson IC, He X, Roderick J, Chen L, Corbett RL, Wang L, Meyer DT, Kennedy K, DeGradodagger WF, Hardman KD, Teleha CA, Jaffee BD, Liu RQ, Copeland RA, Covington MB, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105380,DTCT0024844,1669122,DTCC00151612,906592,16346
CHEMBL279785,P14780,MARIMASTAT,OCSMOTCMPXTDND-OUAUKWLOSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,0.79,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1580594,DTCC00151612,906350,16699
CHEMBL279785,P14780,MARIMASTAT,OCSMOTCMPXTDND-OUAUKWLOSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873504,KI,=,11,NM,,,,,,,,,,,,,,Inhibition of recombinant human matrix metalloprotease-9,,Structure--activity relationships of azasugar-based MMP/ADAM inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,16,"Moriyama H, Tsukida T, Inoue Y, Kondo H, Yoshino K, Nishimura S",,105394,DTCT0024844,910435,DTCC00151612,917294,5719
CHEMBL279785,P14780,MARIMASTAT,OCSMOTCMPXTDND-OUAUKWLOSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873505,KI,=,11,NM,,,,,,,,,,,,,,Inhibition of recombinant human matrix metalloprotease-9 (gelatinase B),,"Design, synthesis and evaluation of novel azasugar-based MMP/ADAM inhibitors.",Bioorg. Med. Chem. Lett.,2003,13,16,"Moriyama H, Tsukida T, Inoue Y, Kondo H, Yoshino K, Nishimura S",,105395,DTCT0024844,968727,DTCC00151612,917300,5720
CHEMBL279785,P14780,MARIMASTAT,OCSMOTCMPXTDND-OUAUKWLOSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12930146,IC50,=,1.6,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP9),,Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.,J. Med. Chem.,2003,46,18,"Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P",,105365,DTCT0024844,516914,DTCC00151612,917874,13726
CHEMBL279785,P14780,MARIMASTAT,OCSMOTCMPXTDND-OUAUKWLOSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26653735,IC50,=,10000,NM,,,,,,,,,,,,,,Inhibition of full length human recombinant MMP9 using MCA-Arg-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-Glu-Arg-NH2 as substrate preincubated for 60 mins followed by substrate addition by fluorescence assay,,"Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.",J. Med. Chem.,2016,59,1,"Ruminski PG, Massa M, Strohbach J, Hanau CE, Schmidt M, Scholten JA, Fletcher TR, Hamper BC, Carroll JN, Shieh HS, Caspers N, Collins B, Grapperhaus M, Palmquist KE, Collins J, Baldus JE, Hitchcock J, Kleine HP, Rogers MD, McDonald J, Munie GE, Messing DM, Portolan S, Whiteley LO, Sunyer T, Schnute ME.",,1552516,DTCT0024844,73306,DTCC00151612,915925,65989
CHEMBL279786,P14780,BATIMASTAT,XFILPEOLDIKJHX-QYZOEREBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9548812,IC50,=,0.2,NM,,,,,,,,,,,,,,Activity against Matrix metalloprotease-9 (MMP-9).,,Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.,J. Med. Chem.,1998,41,8,"Yamamoto M, Tsujishita H, Hori N, Ohishi Y, Inoue S, Ikeda S, Okada Y",,105225,DTCT0024844,1014096,DTCC00151611,984634,15116
CHEMBL279786,P14780,BATIMASTAT,XFILPEOLDIKJHX-QYZOEREBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11229773,IC50,=,0.67,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chirality.,Bioorg. Med. Chem. Lett.,2001,11,4,"Fray MJ, Burslem MF, Dickinson RP",,105223,DTCT0024844,1135162,DTCC00151611,983181,4691
CHEMBL279786,P14780,BATIMASTAT,XFILPEOLDIKJHX-QYZOEREBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12877590,IC50,=,0.6,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9 (MMP-9),,"A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.",J. Med. Chem.,2003,46,16,"Fray MJ, Dickinson RP, Huggins JP, Occleston NL",,105239,DTCT0024844,1526047,DTCC00151611,970901,17445
CHEMBL279786,P14780,BATIMASTAT,XFILPEOLDIKJHX-QYZOEREBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15582436,IC50,=,25,NM,,cell_based,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9 expressed in Sf9 insect cells,,"N-hydroxy-2-(naphthalene-2-ylsulfanyl)-acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity.",Bioorg. Med. Chem. Lett.,2005,15,1,"Lee J, Shim JS, Jung SA, Lee ST, Kwon HJ",,306131,DTCT0024844,1757716,DTCC00151611,983688,18428
CHEMBL279964,P14780,,GTBJTISRJIZWKE-HIFRSBDPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9548812,IC50,=,14,NM,,,,,,,,,,,,,,Activity against Matrix metalloprotease-9 (MMP-9).,,Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.,J. Med. Chem.,1998,41,8,"Yamamoto M, Tsujishita H, Hori N, Ohishi Y, Inoue S, Ikeda S, Okada Y",,105225,DTCT0024844,999334,DTCC00151073,1114498,15116
CHEMBL280017,P14780,,RSMQCSLXBNSQJJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,14,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1683007,DTCC00201392,937808,16216
CHEMBL28079,P14780,ZAPRINAST,REZGGXNDEMKIQB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7445065,DTCC00165545,1862720,46191
CHEMBL28079,P14780,ZAPRINAST,REZGGXNDEMKIQB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7445066,DTCC00165545,1862720,46191
CHEMBL280824,P14780,,NZTYUHZJGSVXFH-NPGWBMRXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10212120,IC50,=,4300,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,Identification of highly selective inhibitors of collagenase-1 from combinatorial libraries of diketopiperazines.,J. Med. Chem.,1999,42,8,"Szardenings AK, Antonenko V, Campbell DA, DeFrancisco N, Ida S, Shi L, Sharkov N, Tien D, Wang Y, Navre M",,105219,DTCT0024844,1312021,DTCC00163134,1725804,15658
CHEMBL280824,P14780,,NZTYUHZJGSVXFH-NPGWBMRXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,4265.8,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258271,DTCC00163134,1716219,24803
CHEMBL280998,P14780,CATECHOL,YCIMNLLNPGFGHC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,10,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5102630,DTCC00161195,517323,43205
CHEMBL280998,P14780,CATECHOL,YCIMNLLNPGFGHC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,23367,NM,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7342940,DTCC00161195,541717,46191
CHEMBL280998,P14780,CATECHOL,YCIMNLLNPGFGHC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Note: corresponding IC50 reported as Active,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7342941,DTCC00161195,541717,46191
CHEMBL281196,P14780,,WJSHWQQLHGDLFX-CGXNFDGLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12657268,KI,>,2128,NM,,,,,,,,,,,,,,Affinity for Matrix metalloprotease-9 (MMP-9),,Potent and selective aggrecanase inhibitors containing cyclic P1 substituents.,Bioorg. Med. Chem. Lett.,2003,13,7,"Cherney RJ, Mo R, Meyer DT, Wang L, Yao W, Wasserman ZR, Liu RQ, Covington MB, Tortorella MD, Arner EC, Qian M, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Decicco CP",,105369,DTCT0024844,1360081,DTCC00158333,421082,6242
CHEMBL281371,P14780,,YOZKFIDLBXLPFF-HIFRSBDPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9548812,IC50,=,5,NM,,,,,,,,,,,,,,Activity against Matrix metalloprotease-9 (MMP-9).,,Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.,J. Med. Chem.,1998,41,8,"Yamamoto M, Tsujishita H, Hori N, Ohishi Y, Inoue S, Ikeda S, Okada Y",,105225,DTCT0024844,1015395,DTCC00151650,1437901,15116
CHEMBL281523,P14780,,LVRXAQLWZKPFFI-ZJSPYRCASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12657268,KI,>,2128,NM,,,,,,,,,,,,,,Affinity for Matrix metalloprotease-9 (MMP-9),,Potent and selective aggrecanase inhibitors containing cyclic P1 substituents.,Bioorg. Med. Chem. Lett.,2003,13,7,"Cherney RJ, Mo R, Meyer DT, Wang L, Yao W, Wasserman ZR, Liu RQ, Covington MB, Tortorella MD, Arner EC, Qian M, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Decicco CP",,105369,DTCT0024844,1362726,DTCC00158580,1551997,6242
CHEMBL282468,P14780,CHOLINE CHLORIDE,SGMZJAMFUVOLNK-UHFFFAOYSA-M,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7369073,DTCC00159655,120971,46191
CHEMBL282468,P14780,CHOLINE CHLORIDE,SGMZJAMFUVOLNK-UHFFFAOYSA-M,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7369074,DTCC00159655,120971,46191
CHEMBL282575,P14780,ESTRADIOL BENZOATE,UYIFTLBWAOGQBI-BZDYCCQFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7268583,DTCC00165062,1674141,46191
CHEMBL282575,P14780,ESTRADIOL BENZOATE,UYIFTLBWAOGQBI-BZDYCCQFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7268584,DTCC00165062,1674141,46191
CHEMBL282581,P14780,,UTVKWFNGXGAJBU-NFBCFJMWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10212120,IC50,=,1300,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,Identification of highly selective inhibitors of collagenase-1 from combinatorial libraries of diketopiperazines.,J. Med. Chem.,1999,42,8,"Szardenings AK, Antonenko V, Campbell DA, DeFrancisco N, Ida S, Shi L, Sharkov N, Tien D, Wang Y, Navre M",,105219,DTCT0024844,1305006,DTCC00163079,758484,15658
CHEMBL282581,P14780,,UTVKWFNGXGAJBU-NFBCFJMWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,1288.25,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258270,DTCC00163079,746927,24803
CHEMBL283196,P14780,ALPHA-NAPHTHOFLAVONE,VFMMPHCGEFXGIP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7297932,DTCC00163499,671784,46191
CHEMBL283196,P14780,ALPHA-NAPHTHOFLAVONE,VFMMPHCGEFXGIP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7297933,DTCC00163499,671784,46191
CHEMBL283222,P14780,,SNARYYAZTCOSMO-XPGKHFPBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12657268,KI,=,1302,NM,,,,,,,,,,,,,,Affinity for Matrix metalloprotease-9 (MMP-9),,Potent and selective aggrecanase inhibitors containing cyclic P1 substituents.,Bioorg. Med. Chem. Lett.,2003,13,7,"Cherney RJ, Mo R, Meyer DT, Wang L, Yao W, Wasserman ZR, Liu RQ, Covington MB, Tortorella MD, Arner EC, Qian M, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Decicco CP",,105369,DTCT0024844,1324897,DTCC00158773,517587,6242
CHEMBL283427,P14780,,JHUFDQZOUBDJHZ-KSZLIROESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10340614,KI,=,2.7,NM,,,,,,,,,,,,,,"Inhibition of MMP-9 (matrix metalloprotease-9, gelatinase B)",,Macrocyclic hydroxamate inhibitors of matrix metalloproteinases and TNF-alpha production.,Bioorg. Med. Chem. Lett.,1999,9,9,"Cherney RJ, Wang L, Meyer DT, Xue CB, Arner EC, Copeland RA, Covington MB, Hardman KD, Wasserman ZR, Jaffee BD, Decicco CP",,102117,DTCT0024844,909175,DTCC00158280,34981,3648
CHEMBL283429,P14780,,WBONEAZKRBRCNC-ZNMIVQPWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10340614,KI,<,1,NM,,,,,,,,,,,,,,"Inhibition of MMP-9 (matrix metalloprotease-9, gelatinase B)",,Macrocyclic hydroxamate inhibitors of matrix metalloproteinases and TNF-alpha production.,Bioorg. Med. Chem. Lett.,1999,9,9,"Cherney RJ, Wang L, Meyer DT, Xue CB, Arner EC, Copeland RA, Covington MB, Hardman KD, Wasserman ZR, Jaffee BD, Decicco CP",,102117,DTCT0024844,928981,DTCC00158053,2047699,3648
CHEMBL283580,P14780,,NBBPYGNNDFCNNP-OAHLLOKOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11354379,IC50,=,62,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Design and synthesis of 2-oxo-imidazolidine-4-carboxylic acid hydroxyamides as potent matrix metalloproteinase-13 inhibitors.,Bioorg. Med. Chem. Lett.,2001,11,9,"Robinson RP, Laird ER, Donahue KM, Lopresti-Morrow LL, Mitchell PG, Reese MR, Reeves LM, Rouch AI, Stam EJ, Yocum SA",,105529,DTCT0024844,696878,DTCC00151925,1066552,4814
CHEMBL283690,P14780,,LMEIQGFMYLKIMU-NGSHPTGOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12657268,KI,=,832,NM,,,,,,,,,,,,,,Affinity for Matrix metalloprotease-9 (MMP-9),,Potent and selective aggrecanase inhibitors containing cyclic P1 substituents.,Bioorg. Med. Chem. Lett.,2003,13,7,"Cherney RJ, Mo R, Meyer DT, Wang L, Yao W, Wasserman ZR, Liu RQ, Covington MB, Tortorella MD, Arner EC, Qian M, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Decicco CP",,105369,DTCT0024844,1342410,DTCC00158676,224866,6242
CHEMBL284104,P14780,DIPICOLINIC ACID,WJJMNDUMQPNECX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,-7,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103048,DTCC00159433,280901,43205
CHEMBL284422,P14780,,WQARHIDTTAFNCG-YSTUSHMSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10212120,IC50,=,1500,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,Identification of highly selective inhibitors of collagenase-1 from combinatorial libraries of diketopiperazines.,J. Med. Chem.,1999,42,8,"Szardenings AK, Antonenko V, Campbell DA, DeFrancisco N, Ida S, Shi L, Sharkov N, Tien D, Wang Y, Navre M",,105219,DTCT0024844,1302438,DTCC00163050,1114625,15658
CHEMBL284422,P14780,,WQARHIDTTAFNCG-YSTUSHMSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,1513.56,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258276,DTCC00163050,1103036,24803
CHEMBL285546,P14780,,ZYBCZOFEUHHWME-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12668018,IC50,=,3,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease 9 (MMP-9).,,Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,8,"Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS",,105528,DTCT0024844,1283658,DTCC00174861,529217,6276
CHEMBL286204,P14780,QUINOLINIC ACID,GJAWHXHKYYXBSV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,-8,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103843,DTCC00158604,151276,43205
CHEMBL286254,P14780,,NXWURBSVABUFNT-PMACEKPBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10212120,IC50,=,1700,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,Identification of highly selective inhibitors of collagenase-1 from combinatorial libraries of diketopiperazines.,J. Med. Chem.,1999,42,8,"Szardenings AK, Antonenko V, Campbell DA, DeFrancisco N, Ida S, Shi L, Sharkov N, Tien D, Wang Y, Navre M",,105219,DTCT0024844,1285234,DTCC00163481,1177999,15658
CHEMBL286398,P14780,PROPYLENE GLYCOL,DNIAPMSPPWPWGF-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7372919,DTCC00167384,1798417,46191
CHEMBL286398,P14780,PROPYLENE GLYCOL,DNIAPMSPPWPWGF-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7372920,DTCC00167384,1798417,46191
CHEMBL286848,P14780,,YMQBLRHAACUVFH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12668018,IC50,=,1,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease 9 (MMP-9).,,Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,8,"Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS",,105528,DTCT0024844,1268995,DTCC00173911,884761,6276
CHEMBL287556,P14780,KOJIC ACID,BEJNERDRQOWKJM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,49,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103975,DTCC00159276,1381648,43205
CHEMBL287632,P14780,,FXAWYNXKIRKVPJ-RGBJRUIASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10212120,IC50,=,570,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,Identification of highly selective inhibitors of collagenase-1 from combinatorial libraries of diketopiperazines.,J. Med. Chem.,1999,42,8,"Szardenings AK, Antonenko V, Campbell DA, DeFrancisco N, Ida S, Shi L, Sharkov N, Tien D, Wang Y, Navre M",,105219,DTCT0024844,1307386,DTCC00163114,207631,15658
CHEMBL287632,P14780,,FXAWYNXKIRKVPJ-RGBJRUIASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,575.44,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258278,DTCC00163114,196119,24803
CHEMBL287820,P14780,,NVQUYHFBHXGQLL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12668018,IC50,=,4,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease 9 (MMP-9).,,Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,8,"Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS",,105528,DTCT0024844,1273422,DTCC00174306,1143540,6276
CHEMBL287823,P14780,,RPOHBDSRTDJNFN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12668018,IC50,=,11,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease 9 (MMP-9).,,Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,8,"Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS",,105528,DTCT0024844,1265563,DTCC00174719,626110,6276
CHEMBL287871,P14780,,RAOAFDPXSFVLJD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12668018,IC50,=,1,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease 9 (MMP-9).,,Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,8,"Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS",,105528,DTCT0024844,1272314,DTCC00173934,1304975,6276
CHEMBL287899,P14780,"PYRIDINE-2,3-DIOL",GGOZGYRTNQBSSA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,21,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5096297,DTCC01739869,1316336,43205
CHEMBL288099,P14780,,SMWGTYPHHCYQHB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11378378,IC50,=,150,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2001,11,11,"Baxter AD, Bhogal R, Bird J, Keily JF, Manallack DT, Montana JG, Owen DA, Pitt WR, Watson RJ, Wills RE",,105531,DTCT0024844,1033066,DTCC00173333,647042,4214
CHEMBL288664,P14780,,CFNLVCZTXBNJGL-QBPKDAKJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15006405,KI,=,77.75,NM,,,,,,,,,,,,,,Inhibition of recombinant human matrix metalloprotease-9,,Synthesis and biological activity of selective azasugar-based TACE inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,6,"Tsukida T, Moriyama H, Inoue Y, Kondo H, Yoshino K, Nishimura S",,105397,DTCT0024844,850604,DTCC00180253,1305040,6743
CHEMBL288670,P14780,,TVRLHUWRJSTBAB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12668018,IC50,=,2,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease 9 (MMP-9).,,Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,8,"Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS",,105528,DTCT0024844,1251299,DTCC00174680,948997,6276
CHEMBL288671,P14780,,DWBZTKJXPJGGSU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12668018,IC50,=,33,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease 9 (MMP-9).,,Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,8,"Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS",,105528,DTCT0024844,1258313,DTCC00174681,1563605,6276
CHEMBL288750,P14780,,VTEHMCYSJRSGPC-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,110,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,638514,DTCC00191454,950975,15057
CHEMBL288750,P14780,,VTEHMCYSJRSGPC-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10346925,IC50,=,72,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9 (concentration required for 50% inhibition of enzyme activity),,Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.,J. Med. Chem.,1999,42,10,"Kiyama R, Tamura Y, Watanabe F, Tsuzuki H, Ohtani M, Yodo M",,105524,DTCT0024844,1257468,DTCC00191454,937707,15166
CHEMBL288843,P14780,,RFJSQAZBRWXDMS-QBPKDAKJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15006405,KI,=,118.37,NM,,,,,,,,,,,,,,Inhibition of recombinant human matrix metalloprotease-9,,Synthesis and biological activity of selective azasugar-based TACE inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,6,"Tsukida T, Moriyama H, Inoue Y, Kondo H, Yoshino K, Nishimura S",,105397,DTCT0024844,848171,DTCC00180252,107601,6743
CHEMBL289222,P14780,,UICCGUSKKDLVIN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12668018,IC50,=,100,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease 9 (MMP-9).,,Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,8,"Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS",,105528,DTCT0024844,1283666,DTCC00174370,1402621,6276
CHEMBL289469,P14780,GRANISETRON,MFWNKCLOYSRHCJ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7333875,DTCC00177095,249942,46191
CHEMBL289469,P14780,GRANISETRON,MFWNKCLOYSRHCJ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7333876,DTCC00177095,249942,46191
CHEMBL289604,P14780,,DCZIFTAWIUHEEC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12668018,IC50,=,1162,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease 9 (MMP-9).,,Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,8,"Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS",,105528,DTCT0024844,1283662,DTCC00174383,107527,6276
CHEMBL29,P14780,BENZYLPENICILLIN,JGSARLDLIJGVTE-MBNYWOFBSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7376240,DTCC00133537,51497,46191
CHEMBL29,P14780,BENZYLPENICILLIN,JGSARLDLIJGVTE-MBNYWOFBSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7376241,DTCC00133537,51497,46191
CHEMBL290106,P14780,BITHIONOL,JFIOVJDNOJYLKP-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7274303,DTCC00104360,153440,46191
CHEMBL290106,P14780,BITHIONOL,JFIOVJDNOJYLKP-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7274304,DTCC00104360,153440,46191
CHEMBL290632,P14780,PROCYANIDIN C1,MOJZMWJRUKIQGL-XILRTYJMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20053563,IC50,=,53200,NM,,,,,,,,,,,,,,Inhibition of human neutrophils gelatinase B after 30 mins by fluorescence plate reader,,"Identification of potential and selective collagenase, gelatinase inhibitors from Crataegus pinnatifida.",Bioorg. Med. Chem. Lett.,2010,20,3,"Moon HI, Kim TI, Cho HS, Kim EK",,607931,DTCT0024844,3191709,DTCC00178120,372550,37466
CHEMBL290916,P14780,EDARAVONE,QELUYTUMUWHWMC-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7315396,DTCC00181825,443476,46191
CHEMBL290916,P14780,EDARAVONE,QELUYTUMUWHWMC-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7315397,DTCC00181825,443476,46191
CHEMBL290948,P14780,,OMMFNEZCURCLPN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12668018,IC50,=,2,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease 9 (MMP-9).,,Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,8,"Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS",,105528,DTCT0024844,1282470,DTCC00174557,172191,6276
CHEMBL290952,P14780,,JRKVJTDYMGJJAK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12668018,IC50,=,3,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease 9 (MMP-9).,,Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,8,"Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS",,105528,DTCT0024844,1276617,DTCC00174833,2076465,6276
CHEMBL291133,P14780,,UAFDRTNAZWZUDR-DEOSSOPVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10649971,IC50,=,10000,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9 (MMP-9),,"Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.",J. Med. Chem.,2000,43,2,"O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H",,105233,DTCT0024844,903636,DTCC00185834,1046252,15892
CHEMBL291194,P14780,,CZOWYKOQKWYITK-HXUWFJFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,644113,DTCC00192095,1981306,15057
CHEMBL291194,P14780,,CZOWYKOQKWYITK-HXUWFJFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10346925,IC50,>,20000,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9 (concentration required for 50% inhibition of enzyme activity),,Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.,J. Med. Chem.,1999,42,10,"Kiyama R, Tamura Y, Watanabe F, Tsuzuki H, Ohtani M, Yodo M",,105524,DTCT0024844,1259769,DTCC00192095,1967745,15166
CHEMBL291213,P14780,,SDUKSXDVVHERIX-JOCHJYFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10346925,IC50,=,260,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9 (concentration required for 50% inhibition of enzyme activity),,Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.,J. Med. Chem.,1999,42,10,"Kiyama R, Tamura Y, Watanabe F, Tsuzuki H, Ohtani M, Yodo M",,105524,DTCT0024844,1274782,DTCC00191852,1488014,15166
CHEMBL291264,P14780,,WZZROHGXDJBEMY-KLHDSHLOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15006405,KI,=,12,NM,,,,,,,,,,,,,,Inhibition of recombinant human matrix metalloprotease-9,,Synthesis and biological activity of selective azasugar-based TACE inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,6,"Tsukida T, Moriyama H, Inoue Y, Kondo H, Yoshino K, Nishimura S",,105398,DTCT0024844,850600,DTCC00180286,1434654,6743
CHEMBL291338,P14780,"3,3',4',5-TETRACHLOROSALICYLANILIDE",SJQBHPJLLIJASD-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7293315,DTCC00204573,1447875,46191
CHEMBL291338,P14780,"3,3',4',5-TETRACHLOROSALICYLANILIDE",SJQBHPJLLIJASD-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7293316,DTCC00204573,1447875,46191
CHEMBL291361,P14780,,KTCRMROJXXSPQJ-JRQMZCAUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12781187,INHIBITION,=,17,%,,,,,,,,,,,,,,Inhibition of recombinant human Matrix metalloprotease-9 at 1000 nM,,Discovery of selective phosphonamide-based inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2003,13,12,"Sawa M, Kurokawa K, Inoue Y, Kondo H, Yoshino K",,105367,DTCT0024844,1075856,DTCC00212221,204534,5595
CHEMBL291387,P14780,,IPBVPRHDESNKFG-QIFAOCFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12781187,INHIBITION,=,24,%,,,,,,,,,,,,,,Inhibition of recombinant human Matrix metalloprotease-9 at 1000 nM,,Discovery of selective phosphonamide-based inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2003,13,12,"Sawa M, Kurokawa K, Inoue Y, Kondo H, Yoshino K",,105367,DTCT0024844,1060382,DTCC00211727,852897,5595
CHEMBL291490,P14780,,XRNOJVRNMAQMIM-GJZGRUSLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,19,NM,,,,,,,,,,,,,,Compound was tested for its inhibitory activity against 92 kD gelatinase (MMP-9),,,Bioorg. Med. Chem. Lett.,1996,6,16,,,102114,DTCT0024844,1264189,DTCC00204117,1532028,1749
CHEMBL291714,P14780,,NWSWANFQYXALDR-UWVGGRQHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,>,1000,NM,,,,,,,,,,,,,,Compound was tested for its inhibitory activity against 92 kD gelatinase (MMP-9),,,Bioorg. Med. Chem. Lett.,1996,6,16,,,102114,DTCT0024844,1279975,DTCC00203406,1532027,1749
CHEMBL291884,P14780,,FGGOECPJNJCERE-RTWAWAEBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12781190,KI,,,,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (Not tested),Not Determined,Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2003,13,12,"Duan JJ, Lu Z, Xue CB, He X, Seng JL, Roderick JJ, Wasserman ZR, Liu RQ, Covington MB, Magolda RL, Newton RC, Trzaskos JM, Decicco CP",,105376,DTCT0024844,491430,DTCC00211584,1934791,5598
CHEMBL292431,P14780,,DCSHLVVGHNRVCO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,11,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1719467,DTCC00200601,1325927,16216
CHEMBL292546,P14780,,FDOUDYUDNHWREP-NOZRDPDXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12781190,KI,>,2000,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9,,Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2003,13,12,"Duan JJ, Lu Z, Xue CB, He X, Seng JL, Roderick JJ, Wasserman ZR, Liu RQ, Covington MB, Magolda RL, Newton RC, Trzaskos JM, Decicco CP",,105375,DTCT0024844,491415,DTCC00211950,1326086,5598
CHEMBL292657,P14780,,UALGGXUAYUNRBS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,53,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1703175,DTCC00200819,1584625,16216
CHEMBL29292,P14780,UBENIMEX,VGGGPCQERPFHOB-RDBSUJKOSA-N,2,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15582436,IC50,,,,,cell_based,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9 expressed in Sf9 insect cells; ND:Not determined,Not Determined,"N-hydroxy-2-(naphthalene-2-ylsulfanyl)-acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity.",Bioorg. Med. Chem. Lett.,2005,15,1,"Lee J, Shim JS, Jung SA, Lee ST, Kwon HJ",,306497,DTCT0024844,1757721,DTCC00165773,109891,18428
CHEMBL29292,P14780,UBENIMEX,VGGGPCQERPFHOB-RDBSUJKOSA-N,2,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26386821,IC50,,,,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 2 hrs prior to testing measured for 15 mins by fluorometric analysis,Not Determined,"Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.",Bioorg. Med. Chem.,2015,23,20,"Yan Y, Chen X, Yang X, Zhang J, Xu W, Zhang Y",,1518636,DTCT0024844,14550529,DTCC00165773,94447,63755
CHEMBL29292,P14780,UBENIMEX,VGGGPCQERPFHOB-RDBSUJKOSA-N,2,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26386821,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate at 10 uM incubated for 2 hrs prior to testing measured for 15 mins by fluorometric analysis relative to control,Not Determined,"Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.",Bioorg. Med. Chem.,2015,23,20,"Yan Y, Chen X, Yang X, Zhang J, Xu W, Zhang Y",,1518638,DTCT0024844,14550555,DTCC00165773,94447,63755
CHEMBL29292,P14780,UBENIMEX,VGGGPCQERPFHOB-RDBSUJKOSA-N,2,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7449361,DTCC00165773,120979,46191
CHEMBL29292,P14780,UBENIMEX,VGGGPCQERPFHOB-RDBSUJKOSA-N,2,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7449362,DTCC00165773,120979,46191
CHEMBL293074,P14780,,NSLCGVDBXCHQFK-OAQYLSRUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,>,2128,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1458386,DTCC00197745,107804,17283
CHEMBL293130,P14780,,GSXJUGVSYFOKBS-GJZGRUSLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,41,NM,,,,,,,,,,,,,,Compound was tested for its inhibitory activity against 92 kD gelatinase (MMP-9),,,Bioorg. Med. Chem. Lett.,1996,6,16,,,102114,DTCT0024844,1282315,DTCC00203461,916704,1749
CHEMBL293305,P14780,,BEKYMPWGANBKBK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,10,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1694309,DTCC00201393,1741622,16216
CHEMBL293357,P14780,,DYSNZNGQZPYHHP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,1.2,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1712507,DTCC00200657,808246,16216
CHEMBL293358,P14780,,WPVBITLNIHHKGY-OAHLLOKOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,>,2128,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1449974,DTCC00104969,1531968,17283
CHEMBL293479,P14780,,BHTYFFISFVNOLJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24071448,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain (unknown origin) using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured after 2 to 4 hrs by fluorometric assay,,Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.,Bioorg. Med. Chem.,2013,21,21,"Tauro M, Laghezza A, Loiodice F, Agamennone M, Campestre C, Tortorella P",,990168,DTCT0024844,12629000,DTCC00200892,318636,56259
CHEMBL293492,P14780,CINNAMALDEHYDE,KJPRLNWUNMBNBZ-QPJJXVBHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7362735,DTCC00198978,1124447,46191
CHEMBL293492,P14780,CINNAMALDEHYDE,KJPRLNWUNMBNBZ-QPJJXVBHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7362736,DTCC00198978,1124447,46191
CHEMBL293503,P14780,,GWQRQVFEMGHPMD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,0.6,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1707062,DTCC00201391,1934658,16216
CHEMBL293503,P14780,,GWQRQVFEMGHPMD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,0.6,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1618960,DTCC00201391,1947698,15919
CHEMBL293503,P14780,,GWQRQVFEMGHPMD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,0.603,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258491,DTCC00201391,1937748,24803
CHEMBL293504,P14780,,HOSIVTBRRYYOOH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,30,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1705681,DTCC00200534,1805904,16216
CHEMBL293528,P14780,,MHGISLAIZQKUNW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,0.5,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1696764,DTCC00200538,969875,16216
CHEMBL293774,P14780,,LOYIGNDQOZNJNZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,31,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1707067,DTCC00201035,1773398,16216
CHEMBL293774,P14780,,LOYIGNDQOZNJNZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,31,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1613759,DTCC00201035,1786101,15919
CHEMBL293774,P14780,,LOYIGNDQOZNJNZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,30.9,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258490,DTCC00201035,1776493,24803
CHEMBL294199,P14780,CAPSAICIN,YKPUWZUDDOIDPM-SOFGYWHQSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7276225,DTCC00207211,736256,46191
CHEMBL294199,P14780,CAPSAICIN,YKPUWZUDDOIDPM-SOFGYWHQSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7276226,DTCC00207211,736256,46191
CHEMBL294618,P14780,,LDNXMPSGDXDZPD-GJZGRUSLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,42,NM,,,,,,,,,,,,,,Compound was tested for its inhibitory activity against 92 kD gelatinase (MMP-9),,,Bioorg. Med. Chem. Lett.,1996,6,16,,,102114,DTCT0024844,1271094,DTCC00204162,1532029,1749
CHEMBL294976,P14780,,DJNIILYGNAXATJ-SKNNYEEJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION,=,22,%,,,,,,,,,,,,,,Inhibition of human recombinant 92 kDa gelatinase MMP-9 at 10 uM,,,Bioorg. Med. Chem. Lett.,1995,5,15,,,71647,DTCT0024844,659637,DTCC00184497,1131920,1239
CHEMBL29505,P14780,,CDMGVAYSDQPUKP-NPGWBMRXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10212120,IC50,=,4400,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,Identification of highly selective inhibitors of collagenase-1 from combinatorial libraries of diketopiperazines.,J. Med. Chem.,1999,42,8,"Szardenings AK, Antonenko V, Campbell DA, DeFrancisco N, Ida S, Shi L, Sharkov N, Tien D, Wang Y, Navre M",,105219,DTCT0024844,1320304,DTCC00163370,1788226,15658
CHEMBL29505,P14780,,CDMGVAYSDQPUKP-NPGWBMRXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,4365.16,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258274,DTCC00163370,1776494,24803
CHEMBL295191,P14780,FUTOENONE,SXHVHWXETMBKPP-KXXATPMCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION,=,0,%,,,,,,,,,,,,,,Inhibition of human recombinant 92 kDa gelatinase MMP-9 at 10 uM,,,Bioorg. Med. Chem. Lett.,1995,5,15,,,71647,DTCT0024844,679354,DTCC00184952,1227813,1239
CHEMBL295416,P14780,PIRINIXIC ACID,SZRPDCCEHVWOJX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7378828,DTCC00183846,671791,46191
CHEMBL295416,P14780,PIRINIXIC ACID,SZRPDCCEHVWOJX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7378829,DTCC00183846,671791,46191
CHEMBL295698,P14780,KETOCONAZOLE,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7431198,DTCC00191118,51483,46191
CHEMBL295698,P14780,KETOCONAZOLE,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7431199,DTCC00191118,51483,46191
CHEMBL295710,P14780,,YHQKAILNGYAYKF-OAQYLSRUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,=,981,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1476614,DTCC00197946,367845,17283
CHEMBL295767,P14780,,PDDJIPBOFGXVEP-JBAPVGOWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION,=,44,%,,,,,,,,,,,,,,Inhibition of human recombinant 92 kDa gelatinase MMP-9 at 10 uM,,,Bioorg. Med. Chem. Lett.,1995,5,15,,,71647,DTCT0024844,689450,DTCC00184527,1195709,1239
CHEMBL295798,P14780,,OAXIYDWDKICQCU-PVHODMMVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,5,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1420821,DTCC00191774,434617,12880
CHEMBL295861,P14780,,IOHLXUUXBXQFBO-HXUWFJFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10346925,IC50,=,210,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9 (concentration required for 50% inhibition of enzyme activity),,Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.,J. Med. Chem.,1999,42,10,"Kiyama R, Tamura Y, Watanabe F, Tsuzuki H, Ohtani M, Yodo M",,105524,DTCT0024844,1276993,DTCC00191853,679383,15166
CHEMBL295871,P14780,,JUPHQCOZPHPYPF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10649971,IC50,=,10000,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9 (MMP-9),,"Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.",J. Med. Chem.,2000,43,2,"O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H",,105233,DTCT0024844,927045,DTCC00186639,1402750,15892
CHEMBL296196,P14780,,PTONAIKVYGVBIS-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10649971,IC50,=,16000,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9 (MMP-9),,"Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.",J. Med. Chem.,2000,43,2,"O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H",,105233,DTCT0024844,909627,DTCC00186419,236755,15892
CHEMBL296196,P14780,,PTONAIKVYGVBIS-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17088065,IC50,=,16000,NM,,cell_based,,,,,,,,,,,,Inhibition of human recombinant MMP9 expressed in mouse myeloma cells,,alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.,Bioorg. Med. Chem.,2007,15,2,"Biasone A, Tortorella P, Campestre C, Agamennone M, Preziuso S, Chiappini M, Nuti E, Carelli P, Rossello A, Mazza F, Gallina C",,432507,DTCT0024844,2061916,DTCC00186419,228138,22402
CHEMBL296196,P14780,,PTONAIKVYGVBIS-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,15848.93,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258718,DTCC00186419,228501,24803
CHEMBL296327,P14780,,CLEKQCRHVLOQSA-RUZDIDTESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10346925,IC50,=,8.2,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9 (concentration required for 50% inhibition of enzyme activity),,Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.,J. Med. Chem.,1999,42,10,"Kiyama R, Tamura Y, Watanabe F, Tsuzuki H, Ohtani M, Yodo M",,105524,DTCT0024844,1264676,DTCC00191728,743752,15166
CHEMBL296419,P14780,ASTEMIZOLE,GXDALQBWZGODGZ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7279436,DTCC00186013,413968,46191
CHEMBL296419,P14780,ASTEMIZOLE,GXDALQBWZGODGZ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7279437,DTCC00186013,413968,46191
CHEMBL296761,P14780,,IQVPRIHMNPAIMY-MHZLTWQESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10397503,IC50,=,0.2,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,"Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors.",Bioorg. Med. Chem. Lett.,1999,9,12,"Hanessian S, Bouzbouz S, Boudon A, Tucker GC, Peyroulan D",,102115,DTCT0024844,525493,DTCC00188542,1713326,3181
CHEMBL296817,P14780,,OELFZOQYHXDMPS-HHHXNRCGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10346925,IC50,=,2300,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9 (concentration required for 50% inhibition of enzyme activity),,Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.,J. Med. Chem.,1999,42,10,"Kiyama R, Tamura Y, Watanabe F, Tsuzuki H, Ohtani M, Yodo M",,105524,DTCT0024844,1276991,DTCC00192054,452237,15166
CHEMBL296911,P14780,,TWQZYQBXMVVVCY-NRFANRHFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10397503,IC50,=,2.5,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,"Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors.",Bioorg. Med. Chem. Lett.,1999,9,12,"Hanessian S, Bouzbouz S, Boudon A, Tucker GC, Peyroulan D",,102115,DTCT0024844,526386,DTCC00188240,2796,3181
CHEMBL297488,P14780,,UOHZYJYLFKMPMQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,7,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1698016,DTCC00200864,1034802,16216
CHEMBL297749,P14780,,GZQRNXJPJXICJZ-DEOSSOPVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10649971,IC50,=,7700,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9 (MMP-9),,"Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.",J. Med. Chem.,2000,43,2,"O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H",,105233,DTCT0024844,918814,DTCC00186610,658584,15892
CHEMBL297792,P14780,,YWCLDDLVLSQGSZ-JOCHJYFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,23,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,620752,DTCC00192123,1436535,15057
CHEMBL297792,P14780,,YWCLDDLVLSQGSZ-JOCHJYFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10346925,IC50,=,9.6,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9 (concentration required for 50% inhibition of enzyme activity),,Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.,J. Med. Chem.,1999,42,10,"Kiyama R, Tamura Y, Watanabe F, Tsuzuki H, Ohtani M, Yodo M",,105524,DTCT0024844,1281544,DTCC00192123,1423555,15166
CHEMBL297793,P14780,,YOMOCOIGEKGJBP-XMMPIXPASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10346925,IC50,=,1900,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9 (concentration required for 50% inhibition of enzyme activity),,Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.,J. Med. Chem.,1999,42,10,"Kiyama R, Tamura Y, Watanabe F, Tsuzuki H, Ohtani M, Yodo M",,105524,DTCT0024844,1250453,DTCC00192124,1741517,15166
CHEMBL297959,P14780,,AVYWYSFUVCHTCM-CQSZACIVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,=,993,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1475517,DTCC00198067,236870,17283
CHEMBL29801,P14780,,JMLWJDXZFPKMED-LGTSYYJHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10212120,IC50,=,2600,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,Identification of highly selective inhibitors of collagenase-1 from combinatorial libraries of diketopiperazines.,J. Med. Chem.,1999,42,8,"Szardenings AK, Antonenko V, Campbell DA, DeFrancisco N, Ida S, Shi L, Sharkov N, Tien D, Wang Y, Navre M",,105219,DTCT0024844,1316651,DTCC00163369,305777,15658
CHEMBL29801,P14780,,JMLWJDXZFPKMED-LGTSYYJHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,2570.4,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258272,DTCC00163369,294020,24803
CHEMBL298167,P14780,,PMVTXYIJWIAFKQ-OKZBNKHCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9599226,KI,=,5800,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Macrocyclic amino carboxylates as selective MMP-8 inhibitors.,J. Med. Chem.,1998,41,11,"Cherney RJ, Wang L, Meyer DT, Xue CB, Wasserman ZR, Hardman KD, Welch PK, Covington MB, Copeland RA, Arner EC, DeGrado WF, Decicco CP",,105664,DTCT0024844,1357169,DTCC00193648,323312,14640
CHEMBL298327,P14780,,JXUYPFWFQKLOLF-LJQANCHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10346925,IC50,>,20000,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9 (concentration required for 50% inhibition of enzyme activity),,Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.,J. Med. Chem.,1999,42,10,"Kiyama R, Tamura Y, Watanabe F, Tsuzuki H, Ohtani M, Yodo M",,105524,DTCT0024844,1251568,DTCC00191944,225230,15166
CHEMBL298585,P14780,,SUNISUUNPMHWHY-ROUUACIJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,38,NM,,,,,,,,,,,,,,Compound was tested for its inhibitory activity against 92 kD gelatinase (MMP-9),,,Bioorg. Med. Chem. Lett.,1996,6,16,,,102114,DTCT0024844,1256948,DTCC00204104,2044746,1749
CHEMBL298606,P14780,,MMCVYPKEJGVLMH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,8,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1680255,DTCC00200915,743833,16216
CHEMBL298635,P14780,,BNTJDVFEUJBXMT-GFCCVEGCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,=,8,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1464531,DTCC00198090,2044693,17283
CHEMBL298699,P14780,,MAMDBBMJAYDZQJ-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,14,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,625210,DTCC00192025,1080566,15057
CHEMBL298699,P14780,,MAMDBBMJAYDZQJ-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10346925,IC50,=,24,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9 (concentration required for 50% inhibition of enzyme activity),,Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.,J. Med. Chem.,1999,42,10,"Kiyama R, Tamura Y, Watanabe F, Tsuzuki H, Ohtani M, Yodo M",,105524,DTCT0024844,1264678,DTCC00192025,1067003,15166
CHEMBL298822,P14780,,JMWYGNIQHYKDCH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,10,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1688126,DTCC00201439,1520406,16216
CHEMBL298846,P14780,,ALZQLPXUMAEFBO-HOTGVXAUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,11,NM,,,,,,,,,,,,,,Compound was tested for its inhibitory activity against 92 kD gelatinase (MMP-9),,,Bioorg. Med. Chem. Lett.,1996,6,16,,,102114,DTCT0024844,1276484,DTCC00204140,1914041,1749
CHEMBL298884,P14780,,MGPQYGIRNDXSAA-LLVKDONJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,=,7,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1471726,DTCC00198128,1817550,17283
CHEMBL29897,P14780,,QAKAOVFKLDKHAW-ROUUACIJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9632351,IC50,=,79,NM,,,,,,,,,,,,,,Inhibition of Matrix Metalloprotease-9,,Rational design and combinatorial evaluation of enzyme inhibitor scaffolds: identification of novel inhibitors of matrix metalloproteinases.,J. Med. Chem.,1998,41,13,"Szardenings AK, Harris D, Lam S, Shi L, Tien D, Wang Y, Patel DV, Navre M, Campbell DA",,105510,DTCT0024844,818033,DTCC00163473,1002686,14688
CHEMBL29897,P14780,,QAKAOVFKLDKHAW-ROUUACIJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10212120,IC50,=,79,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,Identification of highly selective inhibitors of collagenase-1 from combinatorial libraries of diketopiperazines.,J. Med. Chem.,1999,42,8,"Szardenings AK, Antonenko V, Campbell DA, DeFrancisco N, Ida S, Shi L, Sharkov N, Tien D, Wang Y, Navre M",,105219,DTCT0024844,1312018,DTCC00163473,1017062,15658
CHEMBL299023,P14780,,CRKJGMQLKRTZPW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,16,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1689352,DTCC00201420,1293406,16216
CHEMBL299091,P14780,,QFPRVWUEWDLNPU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,39,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1715034,DTCC00200999,1325931,16216
CHEMBL299141,P14780,,QJCXYCVUFZIPQG-XMMPIXPASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,=,118,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1445053,DTCC00197459,1628926,17283
CHEMBL299600,P14780,,NJSAPXUDAYVTFL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,7,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1713861,DTCC00200869,1934657,16216
CHEMBL299796,P14780,,SZWRRABFHREDHM-CQSZACIVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,=,1839,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1460709,DTCC00197890,2076718,17283
CHEMBL29986,P14780,,CHCCGVXFROEPOZ-GJZGRUSLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10212120,IC50,>,40000,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,Identification of highly selective inhibitors of collagenase-1 from combinatorial libraries of diketopiperazines.,J. Med. Chem.,1999,42,8,"Szardenings AK, Antonenko V, Campbell DA, DeFrancisco N, Ida S, Shi L, Sharkov N, Tien D, Wang Y, Navre M",,105219,DTCT0024844,1300050,DTCC00163424,823036,15658
CHEMBL299883,P14780,,AWUFNEOCKCVYDD-LLVKDONJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,=,2128,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1463403,DTCC00198065,1046359,17283
CHEMBL299997,P14780,,CZUPUFGAPNROGT-HSZRJFAPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,>,2128,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1482843,DTCC00197584,400627,17283
CHEMBL3,P14780,NICOTINE,SNICXCGAKADSCV-JTQLQIEISA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7396935,DTCC00132283,51492,46191
CHEMBL3,P14780,NICOTINE,SNICXCGAKADSCV-JTQLQIEISA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7396936,DTCC00132283,51492,46191
CHEMBL30,P14780,CIMETIDINE,AQIXAKUUQRKLND-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7358435,DTCC00133542,282997,46191
CHEMBL30,P14780,CIMETIDINE,AQIXAKUUQRKLND-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7358436,DTCC00133542,282997,46191
CHEMBL30008,P14780,FLUNARIZINE,SMANXXCATUTDDT-QPJJXVBHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7324718,DTCC00164139,542576,46191
CHEMBL30008,P14780,FLUNARIZINE,SMANXXCATUTDDT-QPJJXVBHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7324719,DTCC00164139,542576,46191
CHEMBL300153,P14780,,WNEHIZSMNIMSHR-KBPBESRZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,84,NM,,,,,,,,,,,,,,Compound was tested for its inhibitory activity against 92 kD gelatinase (MMP-9),,,Bioorg. Med. Chem. Lett.,1996,6,16,,,102114,DTCT0024844,1258173,DTCC00105197,1752985,1749
CHEMBL30034,P14780,,KIGOGXGZNGEPBS-ROUUACIJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9632351,IC50,=,2365,NM,,,,,,,,,,,,,,Inhibition of Matrix Metalloprotease-9,,Rational design and combinatorial evaluation of enzyme inhibitor scaffolds: identification of novel inhibitors of matrix metalloproteinases.,J. Med. Chem.,1998,41,13,"Szardenings AK, Harris D, Lam S, Shi L, Tien D, Wang Y, Patel DV, Navre M, Campbell DA",,105510,DTCT0024844,856679,DTCC00163758,1741864,14688
CHEMBL30034,P14780,,KIGOGXGZNGEPBS-ROUUACIJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10212120,IC50,=,400,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,Identification of highly selective inhibitors of collagenase-1 from combinatorial libraries of diketopiperazines.,J. Med. Chem.,1999,42,8,"Szardenings AK, Antonenko V, Campbell DA, DeFrancisco N, Ida S, Shi L, Sharkov N, Tien D, Wang Y, Navre M",,105219,DTCT0024844,1297498,DTCC00163758,1756037,15658
CHEMBL300362,P14780,,YRUNEWMUGNJMAR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,5,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1718074,DTCC00200830,1805905,16216
CHEMBL300394,P14780,,OQWWHTLOLOTDPO-CYBMUJFWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,=,751,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1457146,DTCC00198186,1174914,17283
CHEMBL30055,P14780,,GDFUVGWVNSHWCO-NTZARQNWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10212120,IC50,=,3200,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,Identification of highly selective inhibitors of collagenase-1 from combinatorial libraries of diketopiperazines.,J. Med. Chem.,1999,42,8,"Szardenings AK, Antonenko V, Campbell DA, DeFrancisco N, Ida S, Shi L, Sharkov N, Tien D, Wang Y, Navre M",,105219,DTCT0024844,1317943,DTCC00163273,1885028,15658
CHEMBL30055,P14780,,GDFUVGWVNSHWCO-NTZARQNWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,3235.94,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258273,DTCC00163273,1873437,24803
CHEMBL300707,P14780,,FWIXCOHQTREFPI-SSDOTTSWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,=,1050,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1466932,DTCC00197956,1337897,17283
CHEMBL300807,P14780,,DMOIDCGAIGWXGJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,7,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1699215,DTCC00201437,711540,16216
CHEMBL300875,P14780,,XMQKQZXFPKYGLL-IRXDYDNUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,34,NM,,,,,,,,,,,,,,Compound was tested for its inhibitory activity against 92 kD gelatinase (MMP-9),,,Bioorg. Med. Chem. Lett.,1996,6,16,,,102114,DTCT0024844,1276486,DTCC00204105,626419,1749
CHEMBL301085,P14780,,NOYXCNRQZBBVGT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,3,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1693211,DTCC00200557,1520405,16216
CHEMBL301157,P14780,,KJGJYHSHMUFLOA-GFCCVEGCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,=,80,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1468066,DTCC00197887,1849634,17283
CHEMBL301177,P14780,,YDCLZJDJJGSFJZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,18,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1720813,DTCC00200792,96315,16216
CHEMBL301221,P14780,,NFKWBXMFQBYEHG-STQMWFEESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,71,NM,,,,,,,,,,,,,,Compound was tested for its inhibitory activity against 92 kD gelatinase (MMP-9),,,Bioorg. Med. Chem. Lett.,1996,6,16,,,102114,DTCT0024844,1247711,DTCC00203810,1946629,1749
CHEMBL301303,P14780,,KQVRGIRNMDCIEB-LLVKDONJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,=,19,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1448754,DTCC00197897,236869,17283
CHEMBL30134,P14780,,VILDLUTXDBUVFM-ROUUACIJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10212120,IC50,=,1200,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,Identification of highly selective inhibitors of collagenase-1 from combinatorial libraries of diketopiperazines.,J. Med. Chem.,1999,42,8,"Szardenings AK, Antonenko V, Campbell DA, DeFrancisco N, Ida S, Shi L, Sharkov N, Tien D, Wang Y, Navre M",,105219,DTCT0024844,1306244,DTCC00163735,436108,15658
CHEMBL301413,P14780,,XVLBOSGYEHDGOE-STQMWFEESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,49,NM,,,,,,,,,,,,,,Compound was tested for its inhibitory activity against 92 kD gelatinase (MMP-9),,,Bioorg. Med. Chem. Lett.,1996,6,16,,,102114,DTCT0024844,1249932,DTCC00203407,1046421,1749
CHEMBL301469,P14780,,IODSZLVGIASSTE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,76000,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1612441,DTCC00201002,1435961,15919
CHEMBL301786,P14780,,MZISFPSOTJFTTJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,17,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1719462,DTCC00200965,257620,16216
CHEMBL301977,P14780,,ATNNMKHWMHMLHP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,7,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1720803,DTCC00201068,1358752,16216
CHEMBL302002,P14780,,LZYMCZBJTXXZLJ-QHCPKHFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12781190,KI,>,2000,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9,,Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2003,13,12,"Duan JJ, Lu Z, Xue CB, He X, Seng JL, Roderick JJ, Wasserman ZR, Liu RQ, Covington MB, Magolda RL, Newton RC, Trzaskos JM, Decicco CP",,105375,DTCT0024844,491420,DTCC00211783,1520528,5598
CHEMBL302311,P14780,,LUZFASJCLDTWLF-TZIWHRDSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,1.7,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1385044,DTCC00225565,1207413,14854
CHEMBL302368,P14780,,BWPZARSJOUWFCK-XXBNENTESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,5,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1385040,DTCC00225594,108075,14854
CHEMBL302455,P14780,,OWZWNKSSYNZLEH-VPUSJEBWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12781190,KI,>,2000,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9,,Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2003,13,12,"Duan JJ, Lu Z, Xue CB, He X, Seng JL, Roderick JJ, Wasserman ZR, Liu RQ, Covington MB, Magolda RL, Newton RC, Trzaskos JM, Decicco CP",,105375,DTCT0024844,475046,DTCC00212166,1520529,5598
CHEMBL302795,P14780,TENOXICAM,LZNWYQJJBLGYLT-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7459083,DTCC00224436,1641854,46191
CHEMBL302795,P14780,TENOXICAM,LZNWYQJJBLGYLT-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7459084,DTCC00224436,1641854,46191
CHEMBL302941,P14780,,NCKDXXIBASBEEV-MJBXVCDLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514157,KI,=,17,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution.,Bioorg. Med. Chem. Lett.,2001,11,16,"Musso DL, Andersen MW, Andrews RC, Austin R, Beaudet EJ, Becherer JD, Bubacz DG, Bickett DM, Chan JH, Conway JG, Cowan DJ, Gaul MD, Glennon KC, Hedeen KM, Lambert MH, Leesnitzer MA, McDougald DL, Mitchell JL, Moss ML, Rabinowitz MH, Rizzolio MC, Schaller LT, Stanford JB, Tippin T, Warner JR, Whitesell LG, Wiethe RW",,105542,DTCT0024844,915125,DTCC00219780,108019,4390
CHEMBL302954,P14780,,FWNRCECLAVXIOV-GKBBYZSKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,6.9,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1383741,DTCC00224712,29663,14854
CHEMBL303155,P14780,,URVVMIUWONGKFU-IAGOWNOFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,1.5,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1376172,DTCC00225316,1629208,14854
CHEMBL30327,P14780,"2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN",HGUFODBRKLSHSI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7283666,DTCC00168237,833154,46191
CHEMBL30327,P14780,"2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN",HGUFODBRKLSHSI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7283667,DTCC00168237,833154,46191
CHEMBL303352,P14780,2-(3-MERCAPTOPROPYL)PENTANEDIOIC ACID,FNLNSQHJKVQCBP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723961,SELECTIVITY,,,,,,,,,,,,,,,,,Selectivity for zinc metalloprotease over matrix metalloprotease 9(MMP-9) for >=50% inhibition,,Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor.,J. Med. Chem.,2003,46,10,"Majer P, Jackson PF, Delahanty G, Grella BS, Ko YS, Li W, Liu Q, Maclin KM, Poláková J, Shaffer KA, Stoermer D, Vitharana D, Wang EY, Zakrzewski A, Rojas C, Slusher BS, Wozniak KM, Burak E, Limsakun T, Tsukamoto T",,231619,DTCT0024844,926017,DTCC01740607,290990,17301
CHEMBL303352,P14780,2-(3-MERCAPTOPROPYL)PENTANEDIOIC ACID,FNLNSQHJKVQCBP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723961,SELECTIVITY,,,,,,,,,,,,,,,,,Selectivity for zinc metalloprotease over matrix metalloprotease 9(MMP-9) for >=50% stimulation,,Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor.,J. Med. Chem.,2003,46,10,"Majer P, Jackson PF, Delahanty G, Grella BS, Ko YS, Li W, Liu Q, Maclin KM, Poláková J, Shaffer KA, Stoermer D, Vitharana D, Wang EY, Zakrzewski A, Rojas C, Slusher BS, Wozniak KM, Burak E, Limsakun T, Tsukamoto T",,231620,DTCT0024844,926010,DTCC01740607,290990,17301
CHEMBL303370,P14780,,LKSPKYMQSGHZEA-GGAORHGYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12781190,KI,>,2000,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9,,Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2003,13,12,"Duan JJ, Lu Z, Xue CB, He X, Seng JL, Roderick JJ, Wasserman ZR, Liu RQ, Covington MB, Magolda RL, Newton RC, Trzaskos JM, Decicco CP",,105375,DTCT0024844,502423,DTCC00212263,388848,5598
CHEMBL303510,P14780,,QFBSFEVNNJBNOX-MSOLQXFVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12781190,KI,>,2000,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9,,Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2003,13,12,"Duan JJ, Lu Z, Xue CB, He X, Seng JL, Roderick JJ, Wasserman ZR, Liu RQ, Covington MB, Magolda RL, Newton RC, Trzaskos JM, Decicco CP",,105375,DTCT0024844,506227,DTCC00211539,1100109,5598
CHEMBL303666,P14780,,MWNWUYJAANVQLN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514167,IC50,=,3,NM,,,,,,,,,,,,,,In vitro ability to inhibit matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.,Bioorg. Med. Chem. Lett.,2001,11,16,"Levin JI, Chen J, Du M, Hogan M, Kincaid S, Nelson FC, Venkatesan AM, Wehr T, Zask A, DiJoseph J, Killar LM, Skala S, Sung A, Sharr M, Roth C, Jin G, Cowling R, Mohler KM, Black RA, March CJ, Skotnicki JS",,105532,DTCT0024844,979605,DTCC00222357,1488327,4353
CHEMBL303714,P14780,,UCOSRTUSVXHIMK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15214773,INHIBITION,=,65,%,,,,,,,,,,,,,,"Inhibition of gelatinase B, matrix metalloprotease-9 (MMP-9) at 5000 uM",,Fragment-based drug discovery.,J. Med. Chem.,2004,47,14,"Erlanson DA, McDowell RS, O'Brien T",,71663,DTCT0024844,626058,DTCC00223790,270588,17883
CHEMBL3037894,P14780,,MTYCIOUNOCYLSE-VQTJNVASSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,2,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1572597,DTCC01404950,1391779,16699
CHEMBL303918,P14780,,YZDALJROFHNCEI-DYVFJYSZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,100,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1393651,DTCC00226034,237156,14854
CHEMBL3039597,P14780,GENTAMICIN,NPEFREDMMVQEPL-RWPARATISA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7308077,DTCC01405528,51474,46191
CHEMBL3039597,P14780,GENTAMICIN,NPEFREDMMVQEPL-RWPARATISA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7308078,DTCC01405528,51474,46191
CHEMBL303983,P14780,,LJHSZEIWFDSULF-VWNXMTODSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12781190,KI,=,291,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9,,Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2003,13,12,"Duan JJ, Lu Z, Xue CB, He X, Seng JL, Roderick JJ, Wasserman ZR, Liu RQ, Covington MB, Magolda RL, Newton RC, Trzaskos JM, Decicco CP",,105375,DTCT0024844,480900,DTCC00211481,1870378,5598
CHEMBL304045,P14780,,NITYDPDXAAFEIT-CXAGYDPISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,4500,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1399879,DTCC00225519,658972,14854
CHEMBL304281,P14780,,UTERPWJSMDDIGY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,4.4,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1636611,DTCC00227332,562772,15919
CHEMBL304281,P14780,,UTERPWJSMDDIGY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,4.37,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258489,DTCC00227332,553250,24803
CHEMBL304295,P14780,,BGNATPVKWHRROW-QLFBSQMISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514157,KI,=,28,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution.,Bioorg. Med. Chem. Lett.,2001,11,16,"Musso DL, Andersen MW, Andrews RC, Austin R, Beaudet EJ, Becherer JD, Bubacz DG, Bickett DM, Chan JH, Conway JG, Cowan DJ, Gaul MD, Glennon KC, Hedeen KM, Lambert MH, Leesnitzer MA, McDougald DL, Mitchell JL, Moss ML, Rabinowitz MH, Rizzolio MC, Schaller LT, Stanford JB, Tippin T, Warner JR, Whitesell LG, Wiethe RW",,105542,DTCT0024844,910479,DTCC00220257,1370689,4390
CHEMBL304617,P14780,,UKNOMEZXDWRZAF-GMQRUSHYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,3.8,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1379722,DTCC00225488,237157,14854
CHEMBL304730,P14780,,RMZUAMXVNUZHBB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514167,IC50,=,1,NM,,,,,,,,,,,,,,In vitro ability to inhibit matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.,Bioorg. Med. Chem. Lett.,2001,11,16,"Levin JI, Chen J, Du M, Hogan M, Kincaid S, Nelson FC, Venkatesan AM, Wehr T, Zask A, DiJoseph J, Killar LM, Skala S, Sung A, Sharr M, Roth C, Jin G, Cowling R, Mohler KM, Black RA, March CJ, Skotnicki JS",,105532,DTCT0024844,997533,DTCC00222106,1293653,4353
CHEMBL305024,P14780,,AKXUEZCVUDYBQE-KBPBESRZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9632351,IC50,=,370,NM,,,,,,,,,,,,,,Inhibition of Matrix Metalloprotease-9,,Rational design and combinatorial evaluation of enzyme inhibitor scaffolds: identification of novel inhibitors of matrix metalloproteinases.,J. Med. Chem.,1998,41,13,"Szardenings AK, Harris D, Lam S, Shi L, Tien D, Wang Y, Patel DV, Navre M, Campbell DA",,105510,DTCT0024844,824279,DTCC00222867,291136,14688
CHEMBL305069,P14780,2-ACETYLCYCLOPENTANONE,OSWDNIFICGLKEE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,25,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103248,DTCC00223385,1283746,43205
CHEMBL305163,P14780,,OUOMLZAHOSXYHR-GYCJOSAFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12781190,KI,>,2000,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9,,Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2003,13,12,"Duan JJ, Lu Z, Xue CB, He X, Seng JL, Roderick JJ, Wasserman ZR, Liu RQ, Covington MB, Magolda RL, Newton RC, Trzaskos JM, Decicco CP",,105375,DTCT0024844,491425,DTCC00211566,711664,5598
CHEMBL305222,P14780,,MOPRTFSMCQNUCT-HUUCEWRRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,0.96,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1368292,DTCC00225617,1079123,14854
CHEMBL305373,P14780,,FYOBGEVGGRZAKF-DHIUTWEWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12781190,KI,>,2000,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9,,Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2003,13,12,"Duan JJ, Lu Z, Xue CB, He X, Seng JL, Roderick JJ, Wasserman ZR, Liu RQ, Covington MB, Magolda RL, Newton RC, Trzaskos JM, Decicco CP",,105375,DTCT0024844,480895,DTCC00212468,743974,5598
CHEMBL305499,P14780,,AQCACFZZOGNMPR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514167,INHIBITION,=,28,%,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 at 1 uM,,The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.,Bioorg. Med. Chem. Lett.,2001,11,16,"Levin JI, Chen J, Du M, Hogan M, Kincaid S, Nelson FC, Venkatesan AM, Wehr T, Zask A, DiJoseph J, Killar LM, Skala S, Sung A, Sharr M, Roth C, Jin G, Cowling R, Mohler KM, Black RA, March CJ, Skotnicki JS",,105536,DTCT0024844,1008418,DTCC00222632,1552689,4353
CHEMBL305660,P14780,EBASTINE,MJJALKDDGIKVBE-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7308870,DTCC00223547,1704690,46191
CHEMBL305660,P14780,EBASTINE,MJJALKDDGIKVBE-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7308871,DTCC00223547,1704690,46191
CHEMBL305722,P14780,,ZBIYSEFCPUXCRC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,8,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,785557,DTCC00234512,1228326,17339
CHEMBL305722,P14780,,ZBIYSEFCPUXCRC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,8,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506767,DTCC00234512,1234418,48447
CHEMBL305729,P14780,,XNKSQYFVFJZMOA-HUUCEWRRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,237,NM,,,,,,,,,,,,,,"Inhibition of human gelatinase B, MMP9",,,Bioorg. Med. Chem. Lett.,1997,7,17,,,71656,DTCT0024844,1073451,DTCC00230680,917003,2236
CHEMBL305780,P14780,,VZUMDYFAZYINJW-NHCUHLMSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,4.1,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1373607,DTCC00226109,1596639,14854
CHEMBL306043,P14780,GOLD SODIUM THIOMALATE,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7325296,DTCC00225368,1188067,46191
CHEMBL306043,P14780,GOLD SODIUM THIOMALATE,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7325297,DTCC00225368,1188067,46191
CHEMBL306050,P14780,,FATWEDBJJYSZOL-JUPPYLHDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,1.1,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1579247,DTCC00231235,906349,16699
CHEMBL306158,P14780,,AUCTYKZCPSWUEL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,141,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,806434,DTCC00235153,1326329,17339
CHEMBL306158,P14780,,AUCTYKZCPSWUEL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,3.85,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260745,DTCC00235153,1329172,24831
CHEMBL306158,P14780,,AUCTYKZCPSWUEL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,141,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506774,DTCC00235153,1332436,48447
CHEMBL306189,P14780,,SLZZXDGACSPBLI-UTKZUKDTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,0.63,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1395897,DTCC00225534,368141,14854
CHEMBL306224,P14780,,VKWHTWCAMYPFQG-KUHUBIRLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,1.2,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1373611,DTCC00225609,1240175,14854
CHEMBL306276,P14780,,HUVXWBYSMDRXQZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,2,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1558642,DTCC00231003,1870576,16699
CHEMBL306276,P14780,,HUVXWBYSMDRXQZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,2,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506763,DTCC00231003,1876550,48447
CHEMBL306276,P14780,,HUVXWBYSMDRXQZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,2,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin),,,MedChemComm,2012,3,11,,,1327985,DTCT0024844,13570937,DTCC00231003,1898555,40045
CHEMBL306301,P14780,,GPQULZGUYNODGJ-FUKCDUGKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,5.5,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1583277,DTCC00231212,193360,16699
CHEMBL306412,P14780,RO-37-9790,QRXOZHSEEGNRFC-PWSUYJOCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,10.4,NM,,,,,,,,,,,,,,"Inhibition of human gelatinase B, MMP9",,,Bioorg. Med. Chem. Lett.,1997,7,17,,,71656,DTCT0024844,1055710,DTCC01741069,562037,2236
CHEMBL306470,P14780,,AOPYXKATLYBNDC-IERDGZPVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,3,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1373615,DTCC00225336,1629209,14854
CHEMBL306524,P14780,,SMZZZWJJIWYSNC-DVECYGJZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,1.1,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1386177,DTCC00225147,1785317,14854
CHEMBL306577,P14780,,YZCLZWVHSZUTMP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,7,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,809318,DTCC00234582,1773789,17339
CHEMBL306585,P14780,,RYHIQCQLOAVPLG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,2,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1572593,DTCC00230592,873917,16699
CHEMBL306585,P14780,,RYHIQCQLOAVPLG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,2,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506760,DTCC00230592,879868,48447
CHEMBL306617,P14780,,GMRJGTBNERTZIB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,5,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,482341,DTCC00236306,1850069,17340
CHEMBL306617,P14780,,GMRJGTBNERTZIB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,5.3,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260702,DTCC00236306,1841452,24831
CHEMBL306635,P14780,,VKCIBOBTIOCYLR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,19,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105514,DTCT0024844,775679,DTCC00233622,225734,17339
CHEMBL306674,P14780,,NTWPNMLRTBRVIB-IRXDYDNUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9632351,IC50,=,113,NM,,,,,,,,,,,,,,Inhibition of gelatinase-B (Matrix metalloprotease-9),,Rational design and combinatorial evaluation of enzyme inhibitor scaffolds: identification of novel inhibitors of matrix metalloproteinases.,J. Med. Chem.,1998,41,13,"Szardenings AK, Harris D, Lam S, Shi L, Tien D, Wang Y, Patel DV, Navre M, Campbell DA",,105218,DTCT0024844,832266,DTCC00223932,841295,14688
CHEMBL306674,P14780,,NTWPNMLRTBRVIB-IRXDYDNUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9632351,IC50,=,121,NM,,,,,,,,,,,,,,Inhibition of Matrix Metalloprotease-9,,Rational design and combinatorial evaluation of enzyme inhibitor scaffolds: identification of novel inhibitors of matrix metalloproteinases.,J. Med. Chem.,1998,41,13,"Szardenings AK, Harris D, Lam S, Shi L, Tien D, Wang Y, Patel DV, Navre M, Campbell DA",,105659,DTCT0024844,832262,DTCC00223932,841295,14688
CHEMBL306723,P14780,,IOUQKHPLPLPITI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,3,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,793977,DTCC00233944,647728,17339
CHEMBL306724,P14780,,FBSRGDLMHOPCIT-ANYOKISRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,9900,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,,Bioorg. Med. Chem. Lett.,1997,7,18,,,105547,DTCT0024844,1560604,DTCC00232318,335548,2242
CHEMBL306726,P14780,,YXXIQAWIZFAIOP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,1,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1629135,DTCC00227196,1818654,15919
CHEMBL306726,P14780,,YXXIQAWIZFAIOP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,1,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258488,DTCC00227196,1808951,24803
CHEMBL306871,P14780,,HYGHKRXESWZJHZ-JPYJTQIMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,1.4,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1366975,DTCC00225125,1403136,14854
CHEMBL306912,P14780,,CBYPWAIEESKRSM-CZUORRHYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,0.83,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1366979,DTCC00224800,1207412,14854
CHEMBL306985,P14780,,DJHMSJLOZQFJKZ-LYKKTTPLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,620,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,,Bioorg. Med. Chem. Lett.,1997,7,18,,,105547,DTCT0024844,1577132,DTCC00232648,433292,2242
CHEMBL307079,P14780,,CBLOGBROLDHLEE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514167,IC50,=,15,NM,,,,,,,,,,,,,,In vitro ability to inhibit matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.,Bioorg. Med. Chem. Lett.,2001,11,16,"Levin JI, Chen J, Du M, Hogan M, Kincaid S, Nelson FC, Venkatesan AM, Wehr T, Zask A, DiJoseph J, Killar LM, Skala S, Sung A, Sharr M, Roth C, Jin G, Cowling R, Mohler KM, Black RA, March CJ, Skotnicki JS",,105532,DTCT0024844,1004653,DTCC00221921,421716,4353
CHEMBL307090,P14780,,YUPQCEGDWHZIJW-GCJKJVERSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,1.1,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1373620,DTCC00225129,1435145,14854
CHEMBL307145,P14780,PYROGALLOL,WQGWDDDVZFFDIG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7398775,DTCC00231461,1220280,46191
CHEMBL307145,P14780,PYROGALLOL,WQGWDDDVZFFDIG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7398776,DTCC00231461,1220280,46191
CHEMBL307182,P14780,,MJUMZXKGECTNMD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11206467,IC50,=,31,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position.,Bioorg. Med. Chem. Lett.,2001,11,2,"Levin JI, Du MT, DiJoseph JF, Killar LM, Sung A, Walter T, Sharr MA, Roth CE, Moy FJ, Powers R, Jin G, Cowling R, Skotnicki JS",,105222,DTCT0024844,599886,DTCC00234900,323784,4515
CHEMBL307182,P14780,,MJUMZXKGECTNMD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,30.9,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258696,DTCC00234900,326646,24803
CHEMBL307192,P14780,RO-32-3555,GFUITADOEPNRML-IAGOWNOFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,59,NM,,,,,,,,,,,,,,"Inhibition of human gelatinase B, MMP9",,,Bioorg. Med. Chem. Lett.,1997,7,17,,,71656,DTCT0024844,1087958,DTCC01741068,820155,2236
CHEMBL307252,P14780,,JRBJMWFZOMECPK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,197,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,800915,DTCC00234779,421871,17339
CHEMBL307252,P14780,,JRBJMWFZOMECPK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,3.71,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260756,DTCC00234779,424721,24831
CHEMBL307372,P14780,,IBBWGNRWVQJYIM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,1.4,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1586960,DTCC00231528,1002773,16699
CHEMBL307372,P14780,,IBBWGNRWVQJYIM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,1.4,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506745,DTCC00231528,1008539,48447
CHEMBL307413,P14780,,VWWHTVYUWIWLPA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,0.26,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1562527,DTCC00230955,1359109,16699
CHEMBL307413,P14780,,VWWHTVYUWIWLPA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,0.26,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506754,DTCC00230955,1365096,48447
CHEMBL307773,P14780,,CVMOEYXHQALNTG-SOLBZPMBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514157,KI,=,89,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution.,Bioorg. Med. Chem. Lett.,2001,11,16,"Musso DL, Andersen MW, Andrews RC, Austin R, Beaudet EJ, Becherer JD, Bubacz DG, Bickett DM, Chan JH, Conway JG, Cowan DJ, Gaul MD, Glennon KC, Hedeen KM, Lambert MH, Leesnitzer MA, McDougald DL, Mitchell JL, Moss ML, Rabinowitz MH, Rizzolio MC, Schaller LT, Stanford JB, Tippin T, Warner JR, Whitesell LG, Wiethe RW",,105542,DTCT0024844,920774,DTCC00219822,626590,4390
CHEMBL307915,P14780,,GXQXFRYCUXQDFS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,4.1,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1590937,DTCC00231253,906351,16699
CHEMBL307915,P14780,,GXQXFRYCUXQDFS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,4.1,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506747,DTCC00231253,912528,48447
CHEMBL307990,P14780,,VZKDMHBTNFCZIW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514167,IC50,=,144,NM,,,,,,,,,,,,,,In vitro ability to inhibit matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.,Bioorg. Med. Chem. Lett.,2001,11,16,"Levin JI, Chen J, Du M, Hogan M, Kincaid S, Nelson FC, Venkatesan AM, Wehr T, Zask A, DiJoseph J, Killar LM, Skala S, Sung A, Sharr M, Roth C, Jin G, Cowling R, Mohler KM, Black RA, March CJ, Skotnicki JS",,105532,DTCT0024844,985337,DTCC00222701,64166,4353
CHEMBL308012,P14780,,MYGNBBVBBNZVCZ-GCJKJVERSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,1.7,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1369569,DTCC00224756,204695,14854
CHEMBL308032,P14780,,BAYJYFFPKRGRAF-BEFAXECRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,580,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1397428,DTCC00225465,1849940,14854
CHEMBL308084,P14780,,XRIJPQABKMSHIA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11206467,IC50,=,27,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position.,Bioorg. Med. Chem. Lett.,2001,11,2,"Levin JI, Du MT, DiJoseph JF, Killar LM, Sung A, Walter T, Sharr MA, Roth CE, Moy FJ, Powers R, Jin G, Cowling R, Skotnicki JS",,105222,DTCT0024844,598902,DTCC00234892,1520762,4515
CHEMBL308084,P14780,,XRIJPQABKMSHIA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,26.92,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258693,DTCC00234892,1523433,24803
CHEMBL308228,P14780,,DRZSKJBSLSLPQN-IOMROCGXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,2.5,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1403419,DTCC00225486,658973,14854
CHEMBL308264,P14780,,YJNJISQXBXDEOV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,4.1,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1585805,DTCC00231092,906352,16699
CHEMBL308264,P14780,,YJNJISQXBXDEOV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,4.1,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506738,DTCC00231092,912531,48447
CHEMBL308305,P14780,,QRWJUWNAJTZLAE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11206467,IC50,=,650,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position.,Bioorg. Med. Chem. Lett.,2001,11,2,"Levin JI, Du MT, DiJoseph JF, Killar LM, Sung A, Walter T, Sharr MA, Roth CE, Moy FJ, Powers R, Jin G, Cowling R, Skotnicki JS",,105222,DTCT0024844,610338,DTCC00234733,1391810,4515
CHEMBL308305,P14780,,QRWJUWNAJTZLAE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,645.65,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258688,DTCC00234733,1394252,24803
CHEMBL308397,P14780,,BAIUIZQDBMFOMK-AOYPEHQESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,1.7,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1399732,DTCC00224637,497653,14854
CHEMBL3084281,P14780,,FVYBFRCALRJYHO-SFHVURJKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,4.08,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260739,DTCC01407258,67166,24831
CHEMBL3084282,P14780,,VKCIBOBTIOCYLR-RUZDIDTESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,4.72,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260737,DTCC01407259,746936,24831
CHEMBL3084283,P14780,,KDJZFDKCOPXERM-HSZRJFAPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,4.68,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260733,DTCC01407260,1005468,24831
CHEMBL3084284,P14780,,OQOVBCVMAHMMFY-LJQANCHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,4.2,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260742,DTCC01407261,2036425,24831
CHEMBL3084285,P14780,,IOUQKHPLPLPITI-HHHXNRCGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,5.52,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260731,DTCC01407262,359218,24831
CHEMBL3084287,P14780,,JQVXQUOPUHBHAD-XMMPIXPASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,4.96,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260732,DTCC01407264,675554,24831
CHEMBL3084288,P14780,,JGDVFBCMNUSQQW-HXUWFJFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,3.92,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260741,DTCC01407265,1841451,24831
CHEMBL3084289,P14780,,XBLZKAPRZBJHCZ-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,4.96,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260757,DTCC01407266,661779,24831
CHEMBL308429,P14780,,GBFCSIJILLHVFK-KDOFPFPSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,7.9,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1388714,DTCC00225516,1499818,14854
CHEMBL3084290,P14780,,ZBIYSEFCPUXCRC-NRFANRHFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,5.1,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260755,DTCC01407267,99404,24831
CHEMBL3084291,P14780,,CEYDMEZCBBKZBI-QHCPKHFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,4.89,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260735,DTCC01407268,1971008,24831
CHEMBL3084292,P14780,,YZCLZWVHSZUTMP-SSEXGKCCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,5.15,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260734,DTCC01407269,779001,24831
CHEMBL3084293,P14780,,BCVFMUCILNFXOC-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,4.42,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260744,DTCC01407270,359217,24831
CHEMBL3084294,P14780,,UNQHIMAGAUGZGX-RUZDIDTESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,4.82,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260736,DTCC01407271,553261,24831
CHEMBL3084295,P14780,,VEUYFZWVWBJLBT-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,5.05,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260747,DTCC01407272,1873444,24831
CHEMBL3084803,P14780,ASTROMICIN,BIDUPMYXGFNAEJ-APGVDKLISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7260850,DTCC01407776,768473,46191
CHEMBL3084803,P14780,ASTROMICIN,BIDUPMYXGFNAEJ-APGVDKLISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7260851,DTCC01407776,768473,46191
CHEMBL3085155,P14780,,IQNGGJYKFADFHE-HSZRJFAPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,174,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,785564,DTCC01408122,808584,17339
CHEMBL3085155,P14780,,IQNGGJYKFADFHE-HSZRJFAPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,3.76,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260740,DTCC01408122,811356,24831
CHEMBL3085156,P14780,,KDSNJNDUIRTNNR-LJQANCHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,INHIBITION,=,88,%,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 at 10 uM,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105548,DTCT0024844,807786,DTCC01408123,1293773,17339
CHEMBL3085322,P14780,,YYOVZJXOBZVIQK-LHSJRXKWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,=,399,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041930,DTCC01408281,1146517,22157
CHEMBL308598,P14780,,NGIYDDHHYYPZFT-UTKZUKDTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,13,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1368297,DTCC00225496,755586,14854
CHEMBL308799,P14780,,WLKRWBCBYSPLIM-ZBFHGGJFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,184,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,,Bioorg. Med. Chem. Lett.,1997,7,18,,,105547,DTCT0024844,1578663,DTCC00232649,1946971,2242
CHEMBL309053,P14780,,WCYAWVVNZFAEIQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,2,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1559923,DTCC00231209,161499,16699
CHEMBL309053,P14780,,WCYAWVVNZFAEIQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,2,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506739,DTCC00231209,167241,48447
CHEMBL309105,P14780,,ZAMIBNJCPAMMPI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514167,IC50,=,153,NM,,,,,,,,,,,,,,In vitro ability to inhibit matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.,Bioorg. Med. Chem. Lett.,2001,11,16,"Levin JI, Chen J, Du M, Hogan M, Kincaid S, Nelson FC, Venkatesan AM, Wehr T, Zask A, DiJoseph J, Killar LM, Skala S, Sung A, Sharr M, Roth C, Jin G, Cowling R, Mohler KM, Black RA, March CJ, Skotnicki JS",,105532,DTCT0024844,986595,DTCC00222545,1132336,4353
CHEMBL309311,P14780,,ZBDXZEGIXHCDMC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,3,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,493175,DTCC00236109,853157,17340
CHEMBL309311,P14780,,ZBDXZEGIXHCDMC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,5.52,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260687,DTCC00236109,844228,24831
CHEMBL309329,P14780,,LEFXWKHWSSYLEF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,0.3,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1577827,DTCC00230831,1617664,16699
CHEMBL309329,P14780,,LEFXWKHWSSYLEF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,0.3,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506756,DTCC00230831,1623586,48447
CHEMBL309329,P14780,,LEFXWKHWSSYLEF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,0.3,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin),,,MedChemComm,2012,3,11,,,1327985,DTCT0024844,13570934,DTCC00230831,1645491,40045
CHEMBL309416,P14780,,HYZDHISHDZBYBQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,16,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,505397,DTCC00235722,1305618,17340
CHEMBL309416,P14780,,HYZDHISHDZBYBQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,4.8,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260711,DTCC00235722,1296600,24831
CHEMBL309492,P14780,,SRPXVKQVZQEPFT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,4,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,510281,DTCC00235698,2012791,17340
CHEMBL309492,P14780,,SRPXVKQVZQEPFT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,5.4,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260712,DTCC00235698,2003628,24831
CHEMBL309599,P14780,,UQRFKNRXERPSMG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,49,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,813632,DTCC00234016,1100340,17339
CHEMBL309794,P14780,,IONSTZXMLPCJLY-LYKKTTPLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,19200,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,,Bioorg. Med. Chem. Lett.,1997,7,18,,,105547,DTCT0024844,1564491,DTCC00232570,497728,2242
CHEMBL3098140,P14780,,IXLCFCNNNMLJGB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967752,DTCC01415025,1781062,56747
CHEMBL3098970,P14780,,FMQDUWHUNHYION-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967713,DTCC01414969,977521,56747
CHEMBL3098971,P14780,,KUWITRRRTWJWEH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967712,DTCC01414970,1942535,56747
CHEMBL3098972,P14780,,RRBWARKCKQZWSS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967711,DTCC01414971,1942536,56747
CHEMBL3098973,P14780,,PJHLFDHNSCEUHH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967710,DTCC01414972,1910165,56747
CHEMBL3098974,P14780,,SKTZUJXBBMFYSO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967709,DTCC01414973,1430983,56747
CHEMBL3098975,P14780,,HFSAYBUCPISHDM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967708,DTCC01414974,1301154,56747
CHEMBL3098976,P14780,,QDUURMOCNHCNJJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967707,DTCC01414975,751484,56747
CHEMBL3098977,P14780,,DESXZWFECCAMDZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967706,DTCC01414976,654755,56747
CHEMBL3098978,P14780,,GMABWOBIAJLEQW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967705,DTCC01414977,331245,56747
CHEMBL3098979,P14780,,YZUPESIQOXCRSA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967704,DTCC01414978,815921,56747
CHEMBL3098980,P14780,,PCHQUGVDOUEULT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967703,DTCC01414979,1107556,56747
CHEMBL3098981,P14780,,HOQLRJLKHSSAKF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967702,DTCC01414980,1366519,56747
CHEMBL3098982,P14780,,MGXKAGFNCFDKPU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967701,DTCC01414981,881189,56747
CHEMBL3098983,P14780,,GXMZJYQHWZXWNU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967700,DTCC01414982,168585,56747
CHEMBL3098984,P14780,,LSFJPPDHCVZFRX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967699,DTCC01414983,1430984,56747
CHEMBL3098985,P14780,,PLJVCYPAXNKNKW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967745,DTCC01414984,396580,56747
CHEMBL3098986,P14780,,SDKWHDPKUPAWRY-BJMVGYQFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967744,DTCC01414985,493432,56747
CHEMBL3098987,P14780,,GFIWCUVRRWFESB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967743,DTCC01414986,686944,56747
CHEMBL3098988,P14780,,AOXONKNLKIEEBA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967742,DTCC01414987,589931,56747
CHEMBL3098989,P14780,,FIUYSURTKKYEDA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967741,DTCC01414988,1689155,56747
CHEMBL3098990,P14780,,KVOKJFRUAUXLHL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967739,DTCC01414989,1749076,56747
CHEMBL3098991,P14780,,ANFMYRKZJHLOSU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,=,11000,NM,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967738,DTCC01414990,22239,56747
CHEMBL3098992,P14780,,PGHNOSVSTPOXIT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,=,9400,NM,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967737,DTCC01414991,1689156,56747
CHEMBL3098993,P14780,,SPESLXVICSJNCE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967736,DTCC01414992,1074909,56747
CHEMBL3098994,P14780,,RCNCHPFUXGOZGH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,=,17000,NM,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967735,DTCC01414993,622373,56747
CHEMBL3098995,P14780,,JLKMHPQPJGBCMF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967734,DTCC01414994,815922,56747
CHEMBL3098996,P14780,,NYJRNGVGQKPVRE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,=,16000,NM,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967733,DTCC01414995,1268697,56747
CHEMBL3098997,P14780,,VXBMJGKJUKMXBQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,=,48000,NM,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967732,DTCC01414996,557784,56747
CHEMBL3098998,P14780,,OZSUUDMPEBQBRO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,=,50000,NM,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967731,DTCC01414997,1877994,56747
CHEMBL3098999,P14780,,NXRPTEFIGACZTL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967730,DTCC01414998,1235769,56747
CHEMBL3099000,P14780,,RZROLGMBGCSWEZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967729,DTCC01414999,589932,56747
CHEMBL3099001,P14780,,KOFGJWPCYUALFK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967728,DTCC01415000,1624976,56747
CHEMBL3099002,P14780,,CCYDYOCFYSKEGA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967727,DTCC01415001,1430985,56747
CHEMBL3099003,P14780,,TUKSWFLHFRJGMM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967726,DTCC01415002,1398930,56747
CHEMBL3099004,P14780,,BNHFCBNFRCYXGE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967725,DTCC01415003,525692,56747
CHEMBL3099005,P14780,,VFOVZOHRPOQLCC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967724,DTCC01415004,525693,56747
CHEMBL3099006,P14780,,SEOQHQDMNOFMLJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967723,DTCC01415005,1975499,56747
CHEMBL3099007,P14780,,HOFPMWLVJOCYDY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967722,DTCC01415006,104016,56747
CHEMBL3099008,P14780,,XGOORLCDBSBZGZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967721,DTCC01415007,1975500,56747
CHEMBL3099009,P14780,,RIQJMJBCFFXAJI-JXMROGBWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967720,DTCC01415008,622374,56747
CHEMBL3099010,P14780,,FNYDWXXYOKJFBK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967719,DTCC01415009,298637,56747
CHEMBL3099011,P14780,,RCUFBQVYNBKVJY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967718,DTCC01415010,1749077,56747
CHEMBL3099012,P14780,,LRRFGDGRJAEVSV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967717,DTCC01415011,2072736,56747
CHEMBL3099013,P14780,,AFYIKLPMOLPVKR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967716,DTCC01415012,1845726,56747
CHEMBL3099014,P14780,,DAUOFACYVCSTFD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967715,DTCC01415013,396579,56747
CHEMBL3099015,P14780,,NNABYHMOVRMMJL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967714,DTCC01415014,977522,56747
CHEMBL3099020,P14780,,GTACRKCNWXMANA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967758,DTCC01415019,429084,56747
CHEMBL3099021,P14780,,UWRXZDGYOHTHAE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967757,DTCC01415020,2040888,56747
CHEMBL3099022,P14780,,ICGDNMDQIYYXNT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967756,DTCC01415021,589933,56747
CHEMBL3099023,P14780,,PBOHPAFRZVKLCQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967755,DTCC01415022,654756,56747
CHEMBL3099024,P14780,,JPJOBAFONMJCQM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967754,DTCC01415023,1942537,56747
CHEMBL3099025,P14780,,SWDOCRRVPCGTPK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967753,DTCC01415024,1813522,56747
CHEMBL3099026,P14780,,JGZQIJCTAZEDIP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967751,DTCC01415026,719216,56747
CHEMBL3099027,P14780,,LESDLVOWEBFVRJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967750,DTCC01415027,265538,56747
CHEMBL3099028,P14780,,LFUWVWQSTXWMLN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967749,DTCC01415028,589934,56747
CHEMBL3099029,P14780,,DVRYCISNGRIQDW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967748,DTCC01415029,815923,56747
CHEMBL3099030,P14780,,NJNVKCVHTIPQFP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967747,DTCC01415030,71632,56747
CHEMBL3099031,P14780,,MTGACTLWRZXJNY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,=,1700,NM,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967746,DTCC01415031,2072737,56747
CHEMBL31,P14780,GATIFLOXACIN,XUBOMFCQGDBHNK-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7320777,DTCC00133611,185553,46191
CHEMBL31,P14780,GATIFLOXACIN,XUBOMFCQGDBHNK-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7320778,DTCC00133611,185553,46191
CHEMBL310008,P14780,,QZURMXFXKAPVRT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23287054,IC50,,,,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin),Not Determined,Sulphonamides: Deserving class as MMP inhibitors?,Eur. J. Med. Chem.,2013,60,,"Jain P, Saravanan C, Singh SK",,944094,DTCT0024844,11835652,DTCC00241016,1736689,53820
CHEMBL310057,P14780,,KASLMAICRUMQME-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,45,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,502950,DTCC00235869,401029,17340
CHEMBL310057,P14780,,KASLMAICRUMQME-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,4.35,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260707,DTCC00235869,391961,24831
CHEMBL310073,P14780,,MTFCRDDKUHOORR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15109641,IC50,,,,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 at 100 uM (inactive),Not Active,Rational design and synthesis of novel heparan sulfate mimetic compounds as antiadhesive agents.,Bioorg. Med. Chem. Lett.,2004,14,10,"Ishida K, Simizu S, Teruya T, Wierzba MK, Osada H",,105504,DTCT0024844,1434202,DTCC00241701,1326421,6359
CHEMBL310249,P14780,,HJPHCDCNWWBUEA-GCJKJVERSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,1.5,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1378544,DTCC00224949,1596641,14854
CHEMBL310324,P14780,,UZVVYDVVOHQVFV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,452,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,510271,DTCC00235796,1338306,17340
CHEMBL310324,P14780,,UZVVYDVVOHQVFV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,3.34,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260717,DTCC00235796,1329173,24831
CHEMBL310338,P14780,,JQVXQUOPUHBHAD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,11,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105514,DTCT0024844,785568,DTCC00234433,1488455,17339
CHEMBL310338,P14780,,JQVXQUOPUHBHAD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,11,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506783,DTCC00234433,1494309,48447
CHEMBL310340,P14780,,MIMMUUIYLKITIG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,9.2,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,486994,DTCC00235086,1693446,17340
CHEMBL310342,P14780,,MWFBMGWABXFCCK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,364,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,508981,DTCC00236268,562091,17340
CHEMBL310342,P14780,,MWFBMGWABXFCCK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,3.44,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260715,DTCC00236268,553262,24831
CHEMBL310359,P14780,,PXEJSEMEBWDTJZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11206468,IC50,=,900,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2001,11,2,"Levin JI, Gu Y, Nelson FC, Zask A, DiJoseph JF, Sharr MA, Sung A, Jin G, Cowling R, Chanda P, Cosmi S, Hsiao CL, Edris W, Wilhelm J, Killar LM, Skotnicki JS",,105521,DTCT0024844,1306007,DTCC00237034,1596776,4516
CHEMBL3103958,P14780,,HCMITHCVVSIPJQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24361522,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of PMA-induced MMP9 activity in HAoSMC at 25 uM after 24 hrs by gelatin zymography relative to control,Active,"A novel 2,3-diphenyl-4H-pyrido[1,2-a]pyrimidin-4-one derivative inhibits endothelial cell dysfunction and smooth muscle cell proliferation/activation.",Eur. J. Med. Chem.,2014,72,,"Del Turco S, Sartini S, Sentieri C, Saponaro C, Navarra T, Dario B, Da Settimo F, La Motta C, Basta G",,1283528,DTCT0024844,12983210,DTCC01417245,739352,56924
CHEMBL310472,P14780,,BLCLPMFYNMXITO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,4,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,796730,DTCC00233912,356484,17339
CHEMBL310555,P14780,OXYQUINOLINE,MCJGNVYPOGVAJF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,78,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103331,DTCC00239255,1090149,43205
CHEMBL310555,P14780,OXYQUINOLINE,MCJGNVYPOGVAJF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7384635,DTCC00239255,1092347,46191
CHEMBL310555,P14780,OXYQUINOLINE,MCJGNVYPOGVAJF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7384636,DTCC00239255,1092347,46191
CHEMBL310608,P14780,,BCVFMUCILNFXOC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,38,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,795310,DTCC00105982,96681,17339
CHEMBL310608,P14780,,BCVFMUCILNFXOC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,38,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506775,DTCC00105982,102638,48447
CHEMBL310649,P14780,,YEKVTHFNPVYQBX-DJZRFWRSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9873598,IC50,=,9.2,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,The synthesis and biological activity of a novel series of diazepine MMP inhibitors.,Bioorg. Med. Chem. Lett.,1998,8,19,"Levin JI, DiJoseph JF, Killar LM, Sung A, Walter T, Sharr MA, Roth CE, Skotnicki JS, Albright JD",,105513,DTCT0024844,588044,DTCC00252090,129095,2791
CHEMBL310655,P14780,,CTCOBJWAVVPWJG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9873598,IC50,=,9.1,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,The synthesis and biological activity of a novel series of diazepine MMP inhibitors.,Bioorg. Med. Chem. Lett.,1998,8,19,"Levin JI, DiJoseph JF, Killar LM, Sung A, Walter T, Sharr MA, Roth CE, Skotnicki JS, Albright JD",,105513,DTCT0024844,610095,DTCC00252278,582785,2791
CHEMBL310684,P14780,,FJXZBLKBEVSCAB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,39,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,495603,DTCC00235084,1403250,17340
CHEMBL310688,P14780,,XGMBTNMILCXDFB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,0.5,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,786922,DTCC00234643,421870,17339
CHEMBL310688,P14780,,XGMBTNMILCXDFB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,0.5,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506770,DTCC00234643,427774,48447
CHEMBL311004,P14780,,FNURWSLLBXZLRC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472202,IC50,=,7.3,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.,J. Med. Chem.,2001,44,16,"Pikul S, Ohler NE, Ciszewski G, Laufersweiler MC, Almstead NG, De B, Natchus MG, Hsieh LC, Janusz MJ, Peng SX, Branch TM, King SL, Taiwo YO, Mieling GE",,105229,DTCT0024844,1291621,DTCC00242427,582684,16328
CHEMBL3110281,P14780,,QQYCFXUASOHQCY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24304348,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin) using omniMMP as fluorogenic substrate at 10 uM preincubated for 30 mins followed by substrate addition measured after 30 mins by fluorescence assay,Not Active,Synthesis and structure-activity relationship of 3-hydroxypyridine-2-thione-based histone deacetylase inhibitors.,J. Med. Chem.,2013,56,24,"Sodji QH, Patil V, Kornacki JR, Mrksich M, Oyelere AK",,1286648,DTCT0024844,12997865,DTCC01420618,1107623,57022
CHEMBL3110287,P14780,,YYRBBLSWPCHZTE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24304348,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin) using omniMMP as fluorogenic substrate at 10 uM preincubated for 30 mins followed by substrate addition measured after 30 mins by fluorescence assay,Not Active,Synthesis and structure-activity relationship of 3-hydroxypyridine-2-thione-based histone deacetylase inhibitors.,J. Med. Chem.,2013,56,24,"Sodji QH, Patil V, Kornacki JR, Mrksich M, Oyelere AK",,1286648,DTCT0024844,12997866,DTCC01420624,945416,57022
CHEMBL311097,P14780,,SBYCYYMPCYJMTP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472202,IC50,=,176.5,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.,J. Med. Chem.,2001,44,16,"Pikul S, Ohler NE, Ciszewski G, Laufersweiler MC, Almstead NG, De B, Natchus MG, Hsieh LC, Janusz MJ, Peng SX, Branch TM, King SL, Taiwo YO, Mieling GE",,105229,DTCT0024844,1305052,DTCC00242342,193495,16328
CHEMBL311141,P14780,,ORLPHOALLZATDZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,7.2,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1573744,DTCC00231182,841379,16699
CHEMBL311266,P14780,,YUWSFQQPCKKPJG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472202,IC50,<,0.4,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.,J. Med. Chem.,2001,44,16,"Pikul S, Ohler NE, Ciszewski G, Laufersweiler MC, Almstead NG, De B, Natchus MG, Hsieh LC, Janusz MJ, Peng SX, Branch TM, King SL, Taiwo YO, Mieling GE",,105229,DTCT0024844,1307405,DTCC00242099,744290,16328
CHEMBL311266,P14780,,YUWSFQQPCKKPJG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472202,IC50,=,55,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.,J. Med. Chem.,2001,44,16,"Pikul S, Ohler NE, Ciszewski G, Laufersweiler MC, Almstead NG, De B, Natchus MG, Hsieh LC, Janusz MJ, Peng SX, Branch TM, King SL, Taiwo YO, Mieling GE",,105229,DTCT0024844,1319108,DTCC00242099,744289,16328
CHEMBL311304,P14780,,COEXRWHXVMMHEF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,11,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,800919,DTCC00234364,841411,17339
CHEMBL311304,P14780,,COEXRWHXVMMHEF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,11,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506769,DTCC00234364,847421,48447
CHEMBL311336,P14780,,ZGSTVUAZFACDLH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,27,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1603754,DTCC00243756,820899,15919
CHEMBL311336,P14780,,ZGSTVUAZFACDLH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,26.92,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258500,DTCC00243756,811346,24803
CHEMBL311350,P14780,PIROMIDIC ACID,RCIMBBZXSXFZBV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7383162,DTCC00230394,1862718,46191
CHEMBL311350,P14780,PIROMIDIC ACID,RCIMBBZXSXFZBV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7383163,DTCC00230394,1862718,46191
CHEMBL311357,P14780,,DTPBPOWGEIFZGM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,1,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,500337,DTCC00236210,1564343,17340
CHEMBL311357,P14780,,DTPBPOWGEIFZGM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,6,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260692,DTCC00236210,1555546,24831
CHEMBL311368,P14780,,FDKIFIWQKFBOTH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11206467,IC50,=,13,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position.,Bioorg. Med. Chem. Lett.,2001,11,2,"Levin JI, Du MT, DiJoseph JF, Killar LM, Sung A, Walter T, Sharr MA, Roth CE, Moy FJ, Powers R, Jin G, Cowling R, Skotnicki JS",,105222,DTCT0024844,590576,DTCC00234927,1163670,4515
CHEMBL311368,P14780,,FDKIFIWQKFBOTH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,12.88,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258695,DTCC00234927,1166449,24803
CHEMBL311393,P14780,,ASDFSRLSQAJCEU-ZVAWYAOSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,290,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,,Bioorg. Med. Chem. Lett.,1997,7,18,,,105547,DTCT0024844,1591647,DTCC00232297,1175294,2242
CHEMBL311436,P14780,,JZKQUJKQSKTEON-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,3,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,497945,DTCC00236036,303007,17340
CHEMBL311436,P14780,,JZKQUJKQSKTEON-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,5.52,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2259531,DTCC00236036,294032,24831
CHEMBL311469,P14780,2-ACETYLAMINOFLUORENE,CZIHNRWJTSTCEX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7300040,DTCC00242606,2025633,46191
CHEMBL311469,P14780,2-ACETYLAMINOFLUORENE,CZIHNRWJTSTCEX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7300041,DTCC00242606,2025633,46191
CHEMBL311509,P14780,,NRADMZCIASMSFG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11206467,IC50,=,23,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position.,Bioorg. Med. Chem. Lett.,2001,11,2,"Levin JI, Du MT, DiJoseph JF, Killar LM, Sung A, Walter T, Sharr MA, Roth CE, Moy FJ, Powers R, Jin G, Cowling R, Skotnicki JS",,105222,DTCT0024844,589441,DTCC00234450,647735,4515
CHEMBL311509,P14780,,NRADMZCIASMSFG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11206468,IC50,=,23,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2001,11,2,"Levin JI, Gu Y, Nelson FC, Zask A, DiJoseph JF, Sharr MA, Sung A, Jin G, Cowling R, Chanda P, Cosmi S, Hsiao CL, Edris W, Wilhelm J, Killar LM, Skotnicki JS",,105505,DTCT0024844,1297187,DTCC00234450,659106,4516
CHEMBL311509,P14780,,NRADMZCIASMSFG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,22.91,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258697,DTCC00234450,650402,24803
CHEMBL311618,P14780,,RZTCAABKSWEFOJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,3.9,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1583273,DTCC00230830,291224,16699
CHEMBL311618,P14780,,RZTCAABKSWEFOJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,3.9,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506740,DTCC00230830,297259,48447
CHEMBL311768,P14780,,KQTIZOWWQVTBNZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11206467,IC50,=,346,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position.,Bioorg. Med. Chem. Lett.,2001,11,2,"Levin JI, Du MT, DiJoseph JF, Killar LM, Sung A, Walter T, Sharr MA, Roth CE, Moy FJ, Powers R, Jin G, Cowling R, Skotnicki JS",,105222,DTCT0024844,600964,DTCC00234593,970237,4515
CHEMBL31184,P14780,BENZO[DEF]CHRYSENE,FMMWHPNWAFZXNH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7264143,DTCC00168186,866017,46191
CHEMBL31184,P14780,BENZO[DEF]CHRYSENE,FMMWHPNWAFZXNH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7264144,DTCC00168186,866017,46191
CHEMBL311932,P14780,,JIRXORZYIXSWOB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20180536,IC50,=,4.8,NM,,,,,,,,,,,,,,Inhibition of MMP9 by fluorometric assay,,Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.,J. Med. Chem.,2010,53,6,"Nuti E, Casalini F, Avramova SI, Santamaria S, Fabbi M, Ferrini S, Marinelli L, La Pietra V, Limongelli V, Novellino E, Cercignani G, Orlandini E, Nencetti S, Rossello A",,624094,DTCT0024844,3286011,DTCC00243867,598684,38228
CHEMBL311932,P14780,,JIRXORZYIXSWOB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23287054,IC50,=,34,NM,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin),,Sulphonamides: Deserving class as MMP inhibitors?,Eur. J. Med. Chem.,2013,60,,"Jain P, Saravanan C, Singh SK",,944094,DTCT0024844,11835659,DTCC00243867,609579,53820
CHEMBL311932,P14780,,JIRXORZYIXSWOB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26386821,IC50,=,5.9,NM,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 2 hrs prior to testing measured for 15 mins by fluorometric analysis,,"Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.",Bioorg. Med. Chem.,2015,23,20,"Yan Y, Chen X, Yang X, Zhang J, Xu W, Zhang Y",,1518636,DTCT0024844,14550528,DTCC00243867,580433,63755
CHEMBL311932,P14780,,JIRXORZYIXSWOB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26386821,INHIBITION,=,100,%,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate at 10 uM incubated for 2 hrs prior to testing measured for 15 mins by fluorometric analysis relative to control,,"Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.",Bioorg. Med. Chem.,2015,23,20,"Yan Y, Chen X, Yang X, Zhang J, Xu W, Zhang Y",,1518638,DTCT0024844,14550554,DTCC00243867,580433,63755
CHEMBL311966,P14780,,RKPWDSLUQARCLB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,23,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,807782,DTCC00234644,1035190,17339
CHEMBL311966,P14780,,RKPWDSLUQARCLB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,4.64,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260754,DTCC00234644,1037862,24831
CHEMBL311966,P14780,,RKPWDSLUQARCLB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,23,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506768,DTCC00234644,1040999,48447
CHEMBL312100,P14780,,IOANZCGEYMTXEK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472202,IC50,=,13.9,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.,J. Med. Chem.,2001,44,16,"Pikul S, Ohler NE, Ciszewski G, Laufersweiler MC, Almstead NG, De B, Natchus MG, Hsieh LC, Janusz MJ, Peng SX, Branch TM, King SL, Taiwo YO, Mieling GE",,105229,DTCT0024844,1301289,DTCC00242298,1773867,16328
CHEMBL3121393,P14780,,JULRCIKIEZPCEQ-BRJLIKDPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24531227,INHIBITION,,,,,cell_based,,,,,,,,,,,,Inhibition of MMP-9 in human THP1 cells assessed as inhibition of PMA-induced monocyte to macrophage transformation at 10 uM incubated for 2 hrs prior to PMA challenge measured after 48 hrs by gelation zymography,Active,"Synthesis of novel 1,2-benzothiazine 1,1-dioxide-3-ethanone oxime N-aryl acetamide ether derivatives as potent anti-inflammatory agents and inhibitors of monocyte-to-macrophage transformation.",Eur. J. Med. Chem.,2014,75,,"Gannarapu MR, Vasamsetti SB, Punna N, Royya NK, Pamulaparthy SR, Nanubolu JB, Kotamraju S, Banda N",,1294017,DTCT0024844,13037025,DTCC01425778,945473,57400
CHEMBL3121396,P14780,,MGJQGCOHBPXRAX-KBKYJPHKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24531227,INHIBITION,=,75,%,,cell_based,,,,,,,,,,,,Inhibition of MMP-9 in human THP1 cells assessed as inhibition of PMA-induced monocyte to macrophage transformation at 10 uM incubated for 2 hrs prior to PMA challenge measured after 48 hrs by gelation zymography,,"Synthesis of novel 1,2-benzothiazine 1,1-dioxide-3-ethanone oxime N-aryl acetamide ether derivatives as potent anti-inflammatory agents and inhibitors of monocyte-to-macrophage transformation.",Eur. J. Med. Chem.,2014,75,,"Gannarapu MR, Vasamsetti SB, Punna N, Royya NK, Pamulaparthy SR, Nanubolu JB, Kotamraju S, Banda N",,1294017,DTCT0024844,13037036,DTCC01425781,1720609,57400
CHEMBL312218,P14780,,HBPRCALADDGDIK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23134659,IC50,=,50,NM,,,,,,,,,,,,,,Inhibition of para-amino phenylmercuric acetate-activated MMP9 using Mca-P-L-G-L-Dap(Dnp)-A-R-NH2 as substrate after 1 hr by fluorescence assay,,Design and synthesis of procollagen C-proteinase inhibitors.,Bioorg. Med. Chem. Lett.,2012,22,24,"Turtle E, Chow N, Yang C, Sosa S, Bauer U, Brenner M, Solow-Cordero D, Ho WB",,886676,DTCT0024844,11488692,DTCC00242814,1676008,52120
CHEMBL312429,P14780,,GNNAXEPAOIUDTH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,5,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,491906,DTCC00235603,1723009,17340
CHEMBL312429,P14780,,GNNAXEPAOIUDTH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,5.3,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260723,DTCC00235603,675880,24831
CHEMBL312432,P14780,,GWQPVXKPORBEIM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,6,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,481316,DTCC00235967,853156,17340
CHEMBL312432,P14780,,GWQPVXKPORBEIM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,5.22,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260673,DTCC00235967,844229,24831
CHEMBL312585,P14780,,RBRSAOMOZVVQSQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,484,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,504180,DTCC00235699,691269,17340
CHEMBL312585,P14780,,RBRSAOMOZVVQSQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,3.32,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260713,DTCC00235699,682328,24831
CHEMBL312770,P14780,,FTWZRZIOCFAVKU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,13,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,496714,DTCC00235821,2077096,17340
CHEMBL312770,P14780,,FTWZRZIOCFAVKU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,4.89,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260719,DTCC00235821,2068214,24831
CHEMBL312800,P14780,,CKAKIHRIUBAWGM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15109641,IC50,,,,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 at 100 uM (inactive),Not Active,Rational design and synthesis of novel heparan sulfate mimetic compounds as antiadhesive agents.,Bioorg. Med. Chem. Lett.,2004,14,10,"Ishida K, Simizu S, Teruya T, Wierzba MK, Osada H",,105504,DTCT0024844,1431428,DTCC00241699,1552893,6359
CHEMBL312944,P14780,,JXPHXPUEWNVYDK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15109641,IC50,,,,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 at 100 uM (inactive),Not Active,Rational design and synthesis of novel heparan sulfate mimetic compounds as antiadhesive agents.,Bioorg. Med. Chem. Lett.,2004,14,10,"Ishida K, Simizu S, Teruya T, Wierzba MK, Osada H",,105504,DTCT0024844,1409578,DTCC00242436,1742068,6359
CHEMBL313168,P14780,,APKANDPILBIUDO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9873598,IC50,=,18,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,The synthesis and biological activity of a novel series of diazepine MMP inhibitors.,Bioorg. Med. Chem. Lett.,1998,8,19,"Levin JI, DiJoseph JF, Killar LM, Sung A, Walter T, Sharr MA, Roth CE, Skotnicki JS, Albright JD",,105513,DTCT0024844,606777,DTCC00252091,1806451,2791
CHEMBL313199,P14780,,CIXKGTRSLSCVMK-ZNMIVQPWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472217,KI,=,1.1,NM,,,,,,,,,,,,,,In vitro inhibition of human MMP-9.,,"Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.",J. Med. Chem.,2001,44,16,"Xue CB, Voss ME, Nelson DJ, Duan JJ, Cherney RJ, Jacobson IC, He X, Roderick J, Chen L, Corbett RL, Wang L, Meyer DT, Kennedy K, DeGradodagger WF, Hardman KD, Teleha CA, Jaffee BD, Liu RQ, Copeland RA, Covington MB, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105380,DTCT0024844,1650304,DTCC00251388,744381,16346
CHEMBL313340,P14780,,IMQVPVWXNJYVAS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472202,IC50,=,415,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.,J. Med. Chem.,2001,44,16,"Pikul S, Ohler NE, Ciszewski G, Laufersweiler MC, Almstead NG, De B, Natchus MG, Hsieh LC, Janusz MJ, Peng SX, Branch TM, King SL, Taiwo YO, Mieling GE",,105229,DTCT0024844,1297513,DTCC00242488,577853,16328
CHEMBL313360,P14780,,UFJUEKAJZPTZED-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10411481,KI,=,10,NM,,,,,,,,,,,,,,Binding affinity against matrix metalloprotease-9 (gelatinase-B).,,Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.,J. Med. Chem.,1999,42,14,"Vassiliou S, Mucha A, Cuniasse P, Georgiadis D, Lucet-Levannier K, Beau F, Kannan R, Murphy G, Knäuper V, Rio MC, Basset P, Yiotakis A, Dive V",,105378,DTCT0024844,1078552,DTCC00249036,1424200,15258
CHEMBL313386,P14780,,XYZHDRSTLPUTBX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10411481,KI,=,675,NM,,,,,,,,,,,,,,Binding affinity against matrix metalloprotease-9 (gelatinase-B).,,Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.,J. Med. Chem.,1999,42,14,"Vassiliou S, Mucha A, Cuniasse P, Georgiadis D, Lucet-Levannier K, Beau F, Kannan R, Murphy G, Knäuper V, Rio MC, Basset P, Yiotakis A, Dive V",,105378,DTCT0024844,1084514,DTCC00249347,291450,15258
CHEMBL313472,P14780,,RFNUTMXSNZMOSL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10411481,KI,=,8,NM,,,,,,,,,,,,,,Binding affinity against matrix metalloprotease-9 (gelatinase-B).,,Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.,J. Med. Chem.,1999,42,14,"Vassiliou S, Mucha A, Cuniasse P, Georgiadis D, Lucet-Levannier K, Beau F, Kannan R, Murphy G, Knäuper V, Rio MC, Basset P, Yiotakis A, Dive V",,105378,DTCT0024844,1059540,DTCC00249282,1002960,15258
CHEMBL313493,P14780,METHANESULFONIC ACID METHYL ESTER,MBABOKRGFJTBAE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7417443,DTCC00245877,671790,46191
CHEMBL313493,P14780,METHANESULFONIC ACID METHYL ESTER,MBABOKRGFJTBAE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7417444,DTCC00245877,671790,46191
CHEMBL313896,P14780,,NFDNOGJHVSTSMJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10411481,KI,=,13,NM,,,,,,,,,,,,,,Binding affinity against matrix metalloprotease-9 (gelatinase-B).,,Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.,J. Med. Chem.,1999,42,14,"Vassiliou S, Mucha A, Cuniasse P, Georgiadis D, Lucet-Levannier K, Beau F, Kannan R, Murphy G, Knäuper V, Rio MC, Basset P, Yiotakis A, Dive V",,105378,DTCT0024844,1085848,DTCC00249106,422043,15258
CHEMBL314199,P14780,,GKNHTZOPKGQBHE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10411481,INHIBITION,=,45,%,,,,,,,,,,,,,,"Inhibition of Matrix metalloprotease-9, gelatinase-B at 2 uM",,Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.,J. Med. Chem.,1999,42,14,"Vassiliou S, Mucha A, Cuniasse P, Georgiadis D, Lucet-Levannier K, Beau F, Kannan R, Murphy G, Knäuper V, Rio MC, Basset P, Yiotakis A, Dive V",,105366,DTCT0024844,1084521,DTCC00249345,291449,15258
CHEMBL31422,P14780,MALTOL,XPCTZQVDEJYUGT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,32,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103807,DTCC00167287,604861,43205
CHEMBL3142588,P14780,,NMJSZUFFJMVVTC-BBRMVZONSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12217351,KI,=,15000,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.",Bioorg. Med. Chem. Lett.,2002,12,19,"Scozzafava A, Supuran CT",,105377,DTCT0024844,1045738,DTCC01434962,776475,5080
CHEMBL3142589,P14780,,LBXQNROQWCXYOR-JSGCOSHPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12217351,KI,=,14000,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.",Bioorg. Med. Chem. Lett.,2002,12,19,"Scozzafava A, Supuran CT",,105377,DTCT0024844,1048216,DTCC01434963,4100,5080
CHEMBL3142590,P14780,,CPXWXSPXARFAMY-UGSOOPFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12217351,KI,=,10000,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.",Bioorg. Med. Chem. Lett.,2002,12,19,"Scozzafava A, Supuran CT",,105377,DTCT0024844,1032055,DTCC01434964,1359339,5080
CHEMBL3142591,P14780,,KXEOBTKKJDNBQP-YWZLYKJASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12217351,KI,=,53000,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.",Bioorg. Med. Chem. Lett.,2002,12,19,"Scozzafava A, Supuran CT",,105377,DTCT0024844,1025917,DTCC01434965,938350,5080
CHEMBL3142592,P14780,,YPHZPHWJIIIDPD-WPRPVWTQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12217351,KI,=,2000,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.",Bioorg. Med. Chem. Lett.,2002,12,19,"Scozzafava A, Supuran CT",,105377,DTCT0024844,1054600,DTCC01434966,776476,5080
CHEMBL3142593,P14780,,BUTLOPCSKDMNBW-LRDDRELGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12217351,KI,=,14000,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.",Bioorg. Med. Chem. Lett.,2002,12,19,"Scozzafava A, Supuran CT",,105377,DTCT0024844,1042212,DTCC01434967,1870833,5080
CHEMBL3142594,P14780,,FBWGSUGKKLTDRD-BBRMVZONSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12217351,KI,=,4000,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.",Bioorg. Med. Chem. Lett.,2002,12,19,"Scozzafava A, Supuran CT",,105377,DTCT0024844,1020955,DTCC01434968,1682213,5080
CHEMBL3142596,P14780,,NUHCNKSHBIFLOX-HOCLYGCPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12217351,KI,=,7000,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.",Bioorg. Med. Chem. Lett.,2002,12,19,"Scozzafava A, Supuran CT",,105377,DTCT0024844,1045743,DTCC01434970,1035400,5080
CHEMBL3142598,P14780,,OLEDPIQVUZOZBZ-WMZOPIPTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12217351,KI,=,29000,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.",Bioorg. Med. Chem. Lett.,2002,12,19,"Scozzafava A, Supuran CT",,105377,DTCT0024844,1028477,DTCC01434972,486381,5080
CHEMBL3142599,P14780,,GHEPWMPGSKBGIP-KXBFYZLASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12217351,KI,=,44000,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.",Bioorg. Med. Chem. Lett.,2002,12,19,"Scozzafava A, Supuran CT",,105377,DTCT0024844,1019733,DTCC01434973,938351,5080
CHEMBL3142600,P14780,,HBSLPEMCEWWBRI-NHYWBVRUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12217351,KI,=,17000,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.",Bioorg. Med. Chem. Lett.,2002,12,19,"Scozzafava A, Supuran CT",,105377,DTCT0024844,1040946,DTCC01434974,4099,5080
CHEMBL3142601,P14780,,OMBKWZNZMXWHMG-LRDDRELGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12217351,KI,=,5000,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.",Bioorg. Med. Chem. Lett.,2002,12,19,"Scozzafava A, Supuran CT",,105377,DTCT0024844,1040942,DTCC01434975,1035401,5080
CHEMBL3142602,P14780,,CLSZSRWILIUAGI-GUYCJALGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12217351,KI,=,21000,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.",Bioorg. Med. Chem. Lett.,2002,12,19,"Scozzafava A, Supuran CT",,105377,DTCT0024844,1054605,DTCC01434976,841609,5080
CHEMBL3142605,P14780,,KXLQATQMHVLQBR-YOEHRIQHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12217351,KI,=,5000,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.",Bioorg. Med. Chem. Lett.,2002,12,19,"Scozzafava A, Supuran CT",,105377,DTCT0024844,1047029,DTCC01434979,1132658,5080
CHEMBL3142606,P14780,,QULPHXDROMVDLR-LRDDRELGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12217351,KI,=,400,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.",Bioorg. Med. Chem. Lett.,2002,12,19,"Scozzafava A, Supuran CT",,105377,DTCT0024844,1050772,DTCC01434980,615188,5080
CHEMBL3142607,P14780,,IKFXTEOZLBAELL-LRDDRELGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12217351,KI,=,300,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.",Bioorg. Med. Chem. Lett.,2002,12,19,"Scozzafava A, Supuran CT",,105377,DTCT0024844,1020960,DTCC01434981,970460,5080
CHEMBL3142608,P14780,,QJVFJOYLFWWFDX-JXFKEZNVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12217351,KI,=,50000,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.",Bioorg. Med. Chem. Lett.,2002,12,19,"Scozzafava A, Supuran CT",,105377,DTCT0024844,1040955,DTCC01434982,1968441,5080
CHEMBL3142610,P14780,,CRCHRLLZPJQYMX-LRDDRELGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12217351,KI,=,18000,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.",Bioorg. Med. Chem. Lett.,2002,12,19,"Scozzafava A, Supuran CT",,105377,DTCT0024844,1032050,DTCC01434984,529938,5080
CHEMBL3142611,P14780,,YBPBIDCTKSJPFD-AAEUAGOBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12217351,KI,=,10000,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.",Bioorg. Med. Chem. Lett.,2002,12,19,"Scozzafava A, Supuran CT",,105377,DTCT0024844,1022252,DTCC01434985,1682214,5080
CHEMBL3142612,P14780,,RRKJXTGNGHGKTN-QYTXMFFNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12217351,KI,=,40000,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.",Bioorg. Med. Chem. Lett.,2002,12,19,"Scozzafava A, Supuran CT",,105377,DTCT0024844,1027170,DTCC01434986,906605,5080
CHEMBL3142613,P14780,,PNEADTFJKOWMPK-YOEHRIQHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12217351,KI,=,45000,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.",Bioorg. Med. Chem. Lett.,2002,12,19,"Scozzafava A, Supuran CT",,105377,DTCT0024844,1022257,DTCC01434987,1585216,5080
CHEMBL3142614,P14780,,WXEFGNPPQHTRDV-LRDDRELGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12217351,KI,=,18000,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.",Bioorg. Med. Chem. Lett.,2002,12,19,"Scozzafava A, Supuran CT",,105377,DTCT0024844,1029602,DTCC01434988,1935200,5080
CHEMBL3142615,P14780,,DNTCJTLVTZKQNR-YOEHRIQHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12217351,KI,=,20000,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.",Bioorg. Med. Chem. Lett.,2002,12,19,"Scozzafava A, Supuran CT",,105377,DTCT0024844,1040937,DTCC01434989,1002989,5080
CHEMBL3142618,P14780,,LOGSBACCMCSGPF-YOEHRIQHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12217351,KI,=,16000,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.",Bioorg. Med. Chem. Lett.,2002,12,19,"Scozzafava A, Supuran CT",,105377,DTCT0024844,1032045,DTCC01434992,1935201,5080
CHEMBL3142625,P14780,,BXPQIAVWFZXLFI-LRDDRELGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12217351,KI,=,15000,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.",Bioorg. Med. Chem. Lett.,2002,12,19,"Scozzafava A, Supuran CT",,105377,DTCT0024844,1018323,DTCC01434999,1935199,5080
CHEMBL3142626,P14780,,NQPVYHWCSWOQOG-LRDDRELGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12217351,KI,=,21000,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.",Bioorg. Med. Chem. Lett.,2002,12,19,"Scozzafava A, Supuran CT",,105377,DTCT0024844,1053298,DTCC01435000,129099,5080
CHEMBL3142627,P14780,,XRDWNRBIEZYTNT-LRDDRELGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12217351,KI,=,18000,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.",Bioorg. Med. Chem. Lett.,2002,12,19,"Scozzafava A, Supuran CT",,105377,DTCT0024844,1020946,DTCC01435001,1456061,5080
CHEMBL314565,P14780,,YQEMFOGNUTYMTJ-URCIPWINSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10411481,INHIBITION,=,14,%,,,,,,,,,,,,,,"Inhibition of Matrix metalloprotease-9, gelatinase-B at 2 uM",,Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.,J. Med. Chem.,1999,42,14,"Vassiliou S, Mucha A, Cuniasse P, Georgiadis D, Lucet-Levannier K, Beau F, Kannan R, Murphy G, Knäuper V, Rio MC, Basset P, Yiotakis A, Dive V",,105366,DTCT0024844,1059533,DTCC00248816,2065651,15258
CHEMBL315046,P14780,,JPTZDOYPNCQOTF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10411481,KI,=,110,NM,,,,,,,,,,,,,,Binding affinity against matrix metalloprotease-9 (gelatinase-B).,,Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.,J. Med. Chem.,1999,42,14,"Vassiliou S, Mucha A, Cuniasse P, Georgiadis D, Lucet-Levannier K, Beau F, Kannan R, Murphy G, Knäuper V, Rio MC, Basset P, Yiotakis A, Dive V",,105378,DTCT0024844,1092141,DTCC00249105,291444,15258
CHEMBL315114,P14780,,IIBGHLQTRXDEKI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472202,IC50,=,9.1,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.,J. Med. Chem.,2001,44,16,"Pikul S, Ohler NE, Ciszewski G, Laufersweiler MC, Almstead NG, De B, Natchus MG, Hsieh LC, Janusz MJ, Peng SX, Branch TM, King SL, Taiwo YO, Mieling GE",,105229,DTCT0024844,1297520,DTCC00106157,1838801,16328
CHEMBL315843,P14780,,WYBFHVSAXDKMJV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10411481,KI,=,6,NM,,,,,,,,,,,,,,Binding affinity against matrix metalloprotease-9 (gelatinase-B).,,Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.,J. Med. Chem.,1999,42,14,"Vassiliou S, Mucha A, Cuniasse P, Georgiadis D, Lucet-Levannier K, Beau F, Kannan R, Murphy G, Knäuper V, Rio MC, Basset P, Yiotakis A, Dive V",,105378,DTCT0024844,1073913,DTCC00248711,1326511,15258
CHEMBL315900,P14780,,KSMVGBPYLIRIKO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10411481,INHIBITION,=,0,%,,,,,,,,,,,,,,"Inhibition of Matrix metalloprotease-9, gelatinase-B at 2 uM",,Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.,J. Med. Chem.,1999,42,14,"Vassiliou S, Mucha A, Cuniasse P, Georgiadis D, Lucet-Levannier K, Beau F, Kannan R, Murphy G, Knäuper V, Rio MC, Basset P, Yiotakis A, Dive V",,105366,DTCT0024844,1062033,DTCC00249774,1100495,15258
CHEMBL315901,P14780,,LHVGXRIIQBVWQU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10411481,KI,=,110,NM,,,,,,,,,,,,,,Binding affinity against matrix metalloprotease-9 (gelatinase-B).,,Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.,J. Med. Chem.,1999,42,14,"Vassiliou S, Mucha A, Cuniasse P, Georgiadis D, Lucet-Levannier K, Beau F, Kannan R, Murphy G, Knäuper V, Rio MC, Basset P, Yiotakis A, Dive V",,105378,DTCT0024844,1062041,DTCC00249775,1035362,15258
CHEMBL316169,P14780,,JRCGNOYYZQLNTH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,35,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1616262,DTCC00243846,1723666,15919
CHEMBL316169,P14780,,JRCGNOYYZQLNTH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,34.67,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258504,DTCC00243846,1716218,24803
CHEMBL316200,P14780,,MERYKHOGOUEPIA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10411481,KI,=,35,NM,,,,,,,,,,,,,,Binding affinity against matrix metalloprotease-9 (gelatinase-B).,,Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.,J. Med. Chem.,1999,42,14,"Vassiliou S, Mucha A, Cuniasse P, Georgiadis D, Lucet-Levannier K, Beau F, Kannan R, Murphy G, Knäuper V, Rio MC, Basset P, Yiotakis A, Dive V",,105378,DTCT0024844,1063245,DTCC00248814,582756,15258
CHEMBL316298,P14780,,TXTZEVLHPGQYAR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873518,IC50,=,14,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotein-9,,Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2003,13,16,"Levin JI, Chen JM, Cheung K, Cole D, Crago C, Santos ED, Du X, Khafizova G, MacEwan G, Niu C, Salaski EJ, Zask A, Cummons T, Sung A, Xu J, Zhang Y, Xu W, Ayral-Kaloustian S, Jin G, Cowling R, Barone D, Mohler KM, Black RA, Skotnicki JS",,105519,DTCT0024844,772475,DTCC00260167,679858,5733
CHEMBL316298,P14780,,TXTZEVLHPGQYAR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,14.13,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258119,DTCC00260167,682313,24803
CHEMBL316332,P14780,,RSWUWSKXIDLCIR-PYNWJHIZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,9,NM,,,,,,,,,,,,,,"Inhibition of matrix metalloprotease-9, MMP-9",,,Bioorg. Med. Chem. Lett.,1997,7,21,,,102116,DTCT0024844,1316171,DTCC00257829,1196483,2323
CHEMBL316489,P14780,,UGMUJIKGJCCUOY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12270165,IC50,=,2,NM,,,,,,,,,,,,,,Concentration required in vitro to inhibit Matrix metalloprotease-9,,Benzodiazepine inhibitors of the MMPs and TACE.,Bioorg. Med. Chem. Lett.,2002,12,20,"Nelson FC, Delos Santos E, Levin JI, Chen JM, Skotnicki JS, DiJoseph JF, Sharr MA, Sung A, Killar LM, Cowling R, Jin G, Roth CE, Albright JD",,105515,DTCT0024844,1535232,DTCC00263295,270284,5143
CHEMBL316561,P14780,PROGLUMIDE,DGMKFQYCZXERLX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7379194,DTCC00259031,1383781,46191
CHEMBL316561,P14780,PROGLUMIDE,DGMKFQYCZXERLX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7379195,DTCC00259031,1383781,46191
CHEMBL316822,P14780,,UTFGYUICVDXOSK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12270165,IC50,=,2,NM,,,,,,,,,,,,,,Concentration required in vitro to inhibit Matrix metalloprotease-9,,Benzodiazepine inhibitors of the MMPs and TACE.,Bioorg. Med. Chem. Lett.,2002,12,20,"Nelson FC, Delos Santos E, Levin JI, Chen JM, Skotnicki JS, DiJoseph JF, Sharr MA, Sung A, Killar LM, Cowling R, Jin G, Roth CE, Albright JD",,105515,DTCT0024844,1529290,DTCC00263703,368551,5143
CHEMBL316892,P14780,8-HYDROXY QUINALDINE,NBYLBWHHTUWMER-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,34,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103240,DTCC00262976,508351,43205
CHEMBL316928,P14780,,AYPPVQRNMZPQMU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873518,IC50,=,130,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotein-9,,Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2003,13,16,"Levin JI, Chen JM, Cheung K, Cole D, Crago C, Santos ED, Du X, Khafizova G, MacEwan G, Niu C, Salaski EJ, Zask A, Cummons T, Sung A, Xu J, Zhang Y, Xu W, Ayral-Kaloustian S, Jin G, Cowling R, Barone D, Mohler KM, Black RA, Skotnicki JS",,105519,DTCT0024844,783670,DTCC00260084,1294087,5733
CHEMBL316928,P14780,,AYPPVQRNMZPQMU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,128.82,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258118,DTCC00260084,1296586,24803
CHEMBL316978,P14780,,KCKFHONGIZWYTN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11543675,IC50,=,4.3,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.",J. Med. Chem.,2001,44,19,"Hanessian S, Moitessier N, Gauchet C, Viau M",,105230,DTCT0024844,1381867,DTCC00273603,530282,16392
CHEMBL316997,P14780,(CYCLOPENTYLAMINO)CARBONYLPHOSPHONIC ACID,CYCCYWRSDZSMIF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15139760,IC50,>,100000,NM,,,,,,,,,,,,,,In vitro inhibitory activity against recombinant matrix metalloprotease-9 was determined,,"Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.",J. Med. Chem.,2004,47,11,"Breuer E, Salomon CJ, Katz Y, Chen W, Lu S, Röschenthaler GV, Hadar R, Reich R",,105518,DTCT0024844,1297666,DTCC00261231,303295,17838
CHEMBL317132,P14780,,VGAPHGIXAQRVAL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11212095,IC50,=,0.6,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.,Bioorg. Med. Chem. Lett.,2001,11,3,"Chollet AM, Le Diguarher T, Murray L, Bertrand M, Tucker GC, Sabatini M, Pierré A, Atassi G, Bonnet J, Casara P",,105358,DTCT0024844,649004,DTCC00269579,1067913,4635
CHEMBL317307,P14780,,IISMJBOLNRKABL-JJXSEGSLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873505,KI,=,47,NM,,,,,,,,,,,,,,Inhibition of recombinant human matrix metalloprotease-9 (gelatinase B),,"Design, synthesis and evaluation of novel azasugar-based MMP/ADAM inhibitors.",Bioorg. Med. Chem. Lett.,2003,13,16,"Moriyama H, Tsukida T, Inoue Y, Kondo H, Yoshino K, Nishimura S",,105395,DTCT0024844,943921,DTCC00256256,1207711,5720
CHEMBL317508,P14780,,ITDDXQSXMTUIFM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11212095,IC50,=,0.6,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.,Bioorg. Med. Chem. Lett.,2001,11,3,"Chollet AM, Le Diguarher T, Murray L, Bertrand M, Tucker GC, Sabatini M, Pierré A, Atassi G, Bonnet J, Casara P",,105358,DTCT0024844,625726,DTCC00269558,1067912,4635
CHEMBL317624,P14780,,GHKVZKUXCOXDAW-AWEZNQCLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873518,IC50,=,224,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotein-9,,Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2003,13,16,"Levin JI, Chen JM, Cheung K, Cole D, Crago C, Santos ED, Du X, Khafizova G, MacEwan G, Niu C, Salaski EJ, Zask A, Cummons T, Sung A, Xu J, Zhang Y, Xu W, Ayral-Kaloustian S, Jin G, Cowling R, Barone D, Mohler KM, Black RA, Skotnicki JS",,105519,DTCT0024844,777890,DTCC00260027,1132719,5733
CHEMBL317624,P14780,,GHKVZKUXCOXDAW-AWEZNQCLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,223.87,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258123,DTCC00260027,1135233,24803
CHEMBL318252,P14780,,ODPDWLUYVWCNHO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15125955,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,Reverse hydroxamate-based selective TACE inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,11,"Kamei N, Tanaka T, Kawai K, Miyawaki K, Okuyama A, Murakami Y, Arakawa Y, Haino M, Harada T, Shimano M",,105525,DTCT0024844,1378637,DTCC00265469,917418,6400
CHEMBL318252,P14780,,ODPDWLUYVWCNHO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2456477,DTCC00265469,920644,32556
CHEMBL318664,P14780,PENTAN-3-YLCARBAMOYLPHOSPHONIC ACID,NBDIMGROXSSYHE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15139760,IC50,>,100000,NM,,,,,,,,,,,,,,In vitro inhibitory activity against recombinant matrix metalloprotease-9 was determined,,"Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.",J. Med. Chem.,2004,47,11,"Breuer E, Salomon CJ, Katz Y, Chen W, Lu S, Röschenthaler GV, Hadar R, Reich R",,105518,DTCT0024844,1319238,DTCC01741840,723827,17838
CHEMBL318795,P14780,,QYMKPTMAFMKKTC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11212095,IC50,=,221,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.,Bioorg. Med. Chem. Lett.,2001,11,3,"Chollet AM, Le Diguarher T, Murray L, Bertrand M, Tucker GC, Sabatini M, Pierré A, Atassi G, Bonnet J, Casara P",,105358,DTCT0024844,633445,DTCC00269560,1871037,4635
CHEMBL318922,P14780,,SDPZKVFCJYXZLE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11677139,IC50,=,7,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.,Bioorg. Med. Chem. Lett.,2001,11,22,"Levin JI, Chen JM, Du MT, Nelson FC, Wehr T, DiJoseph JF, Killar LM, Skala S, Sung A, Sharr MA, Roth CE, Jin G, Cowling R, Di L, Sherman M, Xu ZB, March CJ, Mohler KM, Black RA, Skotnicki JS",,105530,DTCT0024844,1619953,DTCC00268369,1618093,4590
CHEMBL319040,P14780,,MVTUAPMXVXQWFM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11543675,IC50,=,2.5,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.",J. Med. Chem.,2001,44,19,"Hanessian S, Moitessier N, Gauchet C, Viau M",,105230,DTCT0024844,1404226,DTCC00273183,1980402,16392
CHEMBL319075,P14780,,LLVLFZAKVKFNSB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15163180,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of recombinant human Matrix metalloprotease-9,,Sultam hydroxamates as novel matrix metalloproteinase inhibitors.,J. Med. Chem.,2004,47,12,"Cherney RJ, Mo R, Meyer DT, Hardman KD, Liu RQ, Covington MB, Qian M, Wasserman ZR, Christ DD, Trzaskos JM, Newton RC, Decicco CP",,105386,DTCT0024844,655347,DTCC00269143,1935390,18131
CHEMBL319244,P14780,CAFFEIC ACID PHENETHYL ESTER,SWUARLUWKZWEBQ-VQHVLOKHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7261981,DTCC00274084,88625,46191
CHEMBL319244,P14780,CAFFEIC ACID PHENETHYL ESTER,SWUARLUWKZWEBQ-VQHVLOKHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7261982,DTCC00274084,88625,46191
CHEMBL319341,P14780,,YYZDREAOBMTNAP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11677139,IC50,=,1,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.,Bioorg. Med. Chem. Lett.,2001,11,22,"Levin JI, Chen JM, Du MT, Nelson FC, Wehr T, DiJoseph JF, Killar LM, Skala S, Sung A, Sharr MA, Roth CE, Jin G, Cowling R, Di L, Sherman M, Xu ZB, March CJ, Mohler KM, Black RA, Skotnicki JS",,105530,DTCT0024844,1632657,DTCC00269065,1456234,4590
CHEMBL319782,P14780,,QBIHWFSRXVWUDN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15125955,IC50,=,28000,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,Reverse hydroxamate-based selective TACE inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,11,"Kamei N, Tanaka T, Kawai K, Miyawaki K, Okuyama A, Murakami Y, Arakawa Y, Haino M, Harada T, Shimano M",,105525,DTCT0024844,1398531,DTCC00265485,1338612,6400
CHEMBL319808,P14780,,QRDJMZMVDBUNNQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12270165,IC50,=,187,NM,,,,,,,,,,,,,,Concentration required in vitro to inhibit Matrix metalloprotease-9,,Benzodiazepine inhibitors of the MMPs and TACE.,Bioorg. Med. Chem. Lett.,2002,12,20,"Nelson FC, Delos Santos E, Levin JI, Chen JM, Skotnicki JS, DiJoseph JF, Sharr MA, Sung A, Killar LM, Cowling R, Jin G, Roth CE, Albright JD",,105515,DTCT0024844,1523652,DTCC00263064,1980295,5143
CHEMBL319887,P14780,,HEYGZWVOCCBCPY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11677139,IC50,=,10,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.,Bioorg. Med. Chem. Lett.,2001,11,22,"Levin JI, Chen JM, Du MT, Nelson FC, Wehr T, DiJoseph JF, Killar LM, Skala S, Sung A, Sharr MA, Roth CE, Jin G, Cowling R, Di L, Sherman M, Xu ZB, March CJ, Mohler KM, Black RA, Skotnicki JS",,105530,DTCT0024844,1600780,DTCC00269081,193779,4590
CHEMBL319902,P14780,,JIYWMQDJGOAJMD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11677139,IC50,=,3,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.,Bioorg. Med. Chem. Lett.,2001,11,22,"Levin JI, Chen JM, Du MT, Nelson FC, Wehr T, DiJoseph JF, Killar LM, Skala S, Sung A, Sharr MA, Roth CE, Jin G, Cowling R, Di L, Sherman M, Xu ZB, March CJ, Mohler KM, Black RA, Skotnicki JS",,105530,DTCT0024844,1633948,DTCC00268967,193778,4590
CHEMBL320383,P14780,,IPNPHTJFPPPVQA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11677139,IC50,=,11,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.,Bioorg. Med. Chem. Lett.,2001,11,22,"Levin JI, Chen JM, Du MT, Nelson FC, Wehr T, DiJoseph JF, Killar LM, Skala S, Sung A, Sharr MA, Roth CE, Jin G, Cowling R, Di L, Sherman M, Xu ZB, March CJ, Mohler KM, Black RA, Skotnicki JS",,105530,DTCT0024844,1622501,DTCC00268367,841777,4590
CHEMBL320402,P14780,,TWQZYQBXMVVVCY-OAQYLSRUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11543676,IC50,=,2.5,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors.,J. Med. Chem.,2001,44,19,"Hanessian S, MacKay DB, Moitessier N",,105231,DTCT0024844,1182605,DTCC00273854,1521206,16385
CHEMBL320442,P14780,,NQHPVFGLBXTGFR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11543675,IC50,=,1,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.",J. Med. Chem.,2001,44,19,"Hanessian S, Moitessier N, Gauchet C, Viau M",,105230,DTCT0024844,1381862,DTCC00273104,627204,16392
CHEMBL321055,P14780,,QDICWLMZEKDVEQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15163180,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of recombinant human Matrix metalloprotease-9,,Sultam hydroxamates as novel matrix metalloproteinase inhibitors.,J. Med. Chem.,2004,47,12,"Cherney RJ, Mo R, Meyer DT, Hardman KD, Liu RQ, Covington MB, Qian M, Wasserman ZR, Christ DD, Trzaskos JM, Newton RC, Decicco CP",,105386,DTCT0024844,461432,DTCC00269070,1392183,18131
CHEMBL321213,P14780,,UVGAWIJNBYCHSP-LBPRGKRZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11563922,KI,=,130,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.",J. Med. Chem.,2001,44,20,"Schröder J, Henke A, Wenzel H, Brandstetter H, Stammler HG, Stammler A, Pfeiffer WD, Tschesche H",,105381,DTCT0024844,1681721,DTCC00282582,874479,16424
CHEMBL3215298,P14780,ABAMECTIN,IBSREHMXUMOFBB-JFUDTMANSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7286933,DTCC01462720,2025634,46191
CHEMBL3215298,P14780,ABAMECTIN,IBSREHMXUMOFBB-JFUDTMANSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7286934,DTCC01462720,2025634,46191
CHEMBL321556,P14780,,DQDPBMDGDOPPLK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873518,IC50,=,309,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotein-9,,Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2003,13,16,"Levin JI, Chen JM, Cheung K, Cole D, Crago C, Santos ED, Du X, Khafizova G, MacEwan G, Niu C, Salaski EJ, Zask A, Cummons T, Sung A, Xu J, Zhang Y, Xu W, Ayral-Kaloustian S, Jin G, Cowling R, Barone D, Mohler KM, Black RA, Skotnicki JS",,105519,DTCT0024844,814658,DTCC00259627,550742,5733
CHEMBL321556,P14780,,DQDPBMDGDOPPLK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,309.03,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258129,DTCC00259627,553249,24803
CHEMBL3215861,P14780,,CHLPUMOYKYJFFH-PFNYCKIMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21634430,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of MMP9 at 10 uM,Not Active,"Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.",J. Med. Chem.,2011,54,13,"Wang H, Yu N, Chen D, Lee KC, Lye PL, Chang JW, Deng W, Ng MC, Lu T, Khoo ML, Poulsen A, Sangthongpitag K, Wu X, Hu C, Goh KC, Wang X, Fang L, Goh KL, Khng HH, Goh SK, Yeo P, Liu X, Bonday Z, Wood JM, Dymock BW, Kantharaj E, Sun ET",,768286,DTCT0024844,6108551,DTCC01463279,1446956,45875
CHEMBL321633,P14780,,REZSPXZZCJTZIK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15177439,IC50,=,1.4,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.,Bioorg. Med. Chem. Lett.,2004,14,13,"Reiter LA, Robinson RP, McClure KF, Jones CS, Reese MR, Mitchell PG, Otterness IG, Bliven ML, Liras J, Cortina SR, Donahue KM, Eskra JD, Griffiths RJ, Lame ME, Lopez-Anaya A, Martinelli GJ, McGahee SM, Yocum SA, Lopresti-Morrow LL, Tobiassen LM, Vaughn-Bowser ML",,105526,DTCT0024844,1495040,DTCC00288306,1915036,6475
CHEMBL3221177,P14780,,VZDQUYBTCHUAJS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,0.53,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin),,,MedChemComm,2012,3,11,,,1327985,DTCT0024844,13570933,DTCC01468106,1801936,40045
CHEMBL3221178,P14780,,QYMSAHRHXPUNSA-MUMRKEEXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,0.32,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin),,,MedChemComm,2012,3,11,,,1327985,DTCT0024844,13570935,DTCC01468107,1645492,40045
CHEMBL3221179,P14780,,GPQULZGUYNODGJ-FUBQLUNQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,5.5,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin),,,MedChemComm,2012,3,11,,,1327985,DTCT0024844,13570940,DTCC01468108,1030666,40045
CHEMBL3221863,P14780,,BJIOETDXHXZDRQ-LEAFIULHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,1156,NM,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin) by fluorescence-based FRET assay,,,MedChemComm,2011,2,10,,,1328286,DTCT0024844,13574315,DTCC01468798,1845949,39059
CHEMBL3221864,P14780,,OKHKINWJYOOKOF-GGXMVOPNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,1210,NM,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin) by fluorescence-based FRET assay,,,MedChemComm,2011,2,10,,,1328286,DTCT0024844,13574316,DTCC01468799,396851,39059
CHEMBL322412,P14780,,ZAVWWISQYKVWCT-GFOWMXPYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11543676,IC50,=,9.2,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors.,J. Med. Chem.,2001,44,19,"Hanessian S, MacKay DB, Moitessier N",,105231,DTCT0024844,1194620,DTCC00273571,615409,16385
CHEMBL322433,P14780,,NVAYQDCPVGCOHV-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15163180,KI,=,10,NM,,,,,,,,,,,,,,Inhibition of recombinant human Matrix metalloprotease-9,,Sultam hydroxamates as novel matrix metalloproteinase inhibitors.,J. Med. Chem.,2004,47,12,"Cherney RJ, Mo R, Meyer DT, Hardman KD, Liu RQ, Covington MB, Qian M, Wasserman ZR, Christ DD, Trzaskos JM, Newton RC, Decicco CP",,105386,DTCT0024844,659119,DTCC00269212,1839095,18131
CHEMBL322619,P14780,,FCHACJJPJSMUHO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11543675,IC50,=,1.88,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.",J. Med. Chem.,2001,44,19,"Hanessian S, Moitessier N, Gauchet C, Viau M",,105230,DTCT0024844,1404218,DTCC00273331,820634,16392
CHEMBL322795,P14780,,LEDMBBYIVRLZAS-GFCCVEGCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11563922,KI,=,50,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.",J. Med. Chem.,2001,44,20,"Schröder J, Henke A, Wenzel H, Brandstetter H, Stammler HG, Stammler A, Pfeiffer WD, Tschesche H",,105381,DTCT0024844,1707160,DTCC00282335,389662,16424
CHEMBL322888,P14780,,VOEOVKSVTSGALB-ZGTCLIOFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11543676,IC50,=,50,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors.,J. Med. Chem.,2001,44,19,"Hanessian S, MacKay DB, Moitessier N",,105231,DTCT0024844,1183567,DTCC00273544,583007,16385
CHEMBL323090,P14780,,ZUICQLWFCKUDMO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11543675,IC50,=,0.01,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.",J. Med. Chem.,2001,44,19,"Hanessian S, Moitessier N, Gauchet C, Viau M",,105230,DTCT0024844,1393107,DTCC00273716,627205,16392
CHEMBL32310,P14780,,KXPIKWNUKVNKRA-ZNZIZOMTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10360755,KI,=,2,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,"P1, P2'-linked macrocyclic amine derivatives as matrix metalloproteinase inhibitors.",Bioorg. Med. Chem. Lett.,1999,9,10,"Duan JJ, Chen L, Xue CB, Wasserman ZR, Hardman KD, Covington MB, Copeland RR, Arner EC, Decicco CP",,105543,DTCT0024844,1596694,DTCC00171114,1563576,3139
CHEMBL323148,P14780,,YUYXLIRWRFFNDS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11212095,IC50,=,199,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.,Bioorg. Med. Chem. Lett.,2001,11,3,"Chollet AM, Le Diguarher T, Murray L, Bertrand M, Tucker GC, Sabatini M, Pierré A, Atassi G, Bonnet J, Casara P",,105358,DTCT0024844,640135,DTCC00269613,615363,4635
CHEMBL323228,P14780,,IJCQDLHWIZVIEL-VNQPRFMTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10560745,IC50,=,190,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease (MMP-9),,Selective inhibition of low affinity IgE receptor (CD23) processing: P1' bicyclomethyl substituents.,Bioorg. Med. Chem. Lett.,1999,9,21,"Bailey S, Bolognese B, Faller A, Louis-Flamberg P, MacPherson DT, Mayer RJ, Marshall LA, Milner PH, Mistry J, Smith DG, Ward JG",,105820,DTCT0024844,1430424,DTCC00278972,141082,3450
CHEMBL32325,P14780,,UHNRWKXPDCQTKE-FSSWDIPSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10360755,KI,=,6,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,"P1, P2'-linked macrocyclic amine derivatives as matrix metalloproteinase inhibitors.",Bioorg. Med. Chem. Lett.,1999,9,10,"Duan JJ, Chen L, Xue CB, Wasserman ZR, Hardman KD, Covington MB, Copeland RR, Arner EC, Decicco CP",,105543,DTCT0024844,1594052,DTCC00171177,1692760,3139
CHEMBL323371,P14780,,PRCRNUDMWULKSO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11212095,IC50,=,1,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.,Bioorg. Med. Chem. Lett.,2001,11,3,"Chollet AM, Le Diguarher T, Murray L, Bertrand M, Tucker GC, Sabatini M, Pierré A, Atassi G, Bonnet J, Casara P",,105358,DTCT0024844,640141,DTCC00269593,389494,4635
CHEMBL323575,P14780,,WNQMYJZKTYVQPU-BPGUCPLFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11543676,IC50,=,4.4,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors.,J. Med. Chem.,2001,44,19,"Hanessian S, MacKay DB, Moitessier N",,105231,DTCT0024844,1180467,DTCC00273545,1742428,16385
CHEMBL3235911,P14780,,RNBZJLOFSRJJMQ-RUPCYPOASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26192023,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin) using Mca-KLPGL-Dnp-AR as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorescence assay,,SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.,J. Med. Chem.,2015,58,15,"Knapinska AM, Dreymuller D, Ludwig A, Smith L, Golubkov V, Sohail A, Fridman R, Giulianotti M, LaVoi TM, Houghten RA, Fields GB, Minond D",,1505521,DTCT0024844,14475895,DTCC01474946,235426,63066
CHEMBL3235911,P14780,,RNBZJLOFSRJJMQ-RUPCYPOASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26192023,INHIBITION,=,13,%,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin) using Mca-KLPGL-Dnp-AR as substrate at 100 uM preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorescence assay relative to control,,SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.,J. Med. Chem.,2015,58,15,"Knapinska AM, Dreymuller D, Ludwig A, Smith L, Golubkov V, Sohail A, Fridman R, Giulianotti M, LaVoi TM, Houghten RA, Fields GB, Minond D",,1505525,DTCT0024844,14475967,DTCC01474946,235426,63066
CHEMBL3235912,P14780,,ILECMSXDFSLYHA-XOXLXNDPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26192023,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin) using Mca-KLPGL-Dnp-AR as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorescence assay,,SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.,J. Med. Chem.,2015,58,15,"Knapinska AM, Dreymuller D, Ludwig A, Smith L, Golubkov V, Sohail A, Fridman R, Giulianotti M, LaVoi TM, Houghten RA, Fields GB, Minond D",,1505521,DTCT0024844,14475893,DTCC01474947,1433423,63066
CHEMBL3235912,P14780,,ILECMSXDFSLYHA-XOXLXNDPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26192023,INHIBITION,=,0,%,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin) using Mca-KLPGL-Dnp-AR as substrate at 100 uM preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorescence assay relative to control,,SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.,J. Med. Chem.,2015,58,15,"Knapinska AM, Dreymuller D, Ludwig A, Smith L, Golubkov V, Sohail A, Fridman R, Giulianotti M, LaVoi TM, Houghten RA, Fields GB, Minond D",,1505525,DTCT0024844,14475969,DTCC01474947,1433423,63066
CHEMBL323612,P14780,CP-471474,QCOQJYRPDUMCNP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23287054,IC50,=,13,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using (7-amino-4-methyl-coumarin)-Pro-Leu-Gly-Leu-(dinitrophenylamine)-Ala-Arg- NH2 as substrate by fluorimetric analysis,,Sulphonamides: Deserving class as MMP inhibitors?,Eur. J. Med. Chem.,2013,60,,"Jain P, Saravanan C, Singh SK",,944578,DTCT0024844,11835662,DTCC01742415,1450499,53820
CHEMBL323874,P14780,,LGRKPVBTQGGKSY-CRAIPNDOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11585439,KI,=,21200,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors.",J. Med. Chem.,2001,44,21,"Yao W, Wasserman ZR, Chao M, Reddy G, Shi E, Liu RQ, Covington MB, Arner EC, Pratta MA, Tortorella M, Magolda RL, Newton R, Qian M, Ribadeneira MD, Christ D, Wexler RR, Decicco CP",,105382,DTCT0024844,1411256,DTCC00287105,820749,16438
CHEMBL323885,P14780,,NRVATKFKFLOMDK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14711305,KI,=,148000,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Evaluation of P1'-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11.,J. Med. Chem.,2004,47,2,"Matziari M, Beau F, Cuniasse P, Dive V, Yiotakis A",,105371,DTCT0024844,1265942,DTCC00287362,1079825,17924
CHEMBL323929,P14780,,FQRGCXYNQQKTLK-ARNLJNQMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11585440,KI,=,1170,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.",J. Med. Chem.,2001,44,21,"Xue CB, He X, Corbett RL, Roderick J, Wasserman ZR, Liu RQ, Jaffee BD, Covington MB, Qian M, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105383,DTCT0024844,1285153,DTCC00287903,1047307,16439
CHEMBL324369,P14780,,ZUZHAPXKYPLQLC-ABAIWWIYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,20,NM,,,,,,,,,,,,,,Inhibition of human Matrix metalloprotease-9,,,Bioorg. Med. Chem. Lett.,1995,5,4,,,105391,DTCT0024844,829873,DTCC00293038,1947632,1497
CHEMBL324549,P14780,,KNGLZBYFVBOFMQ-IARZGTGTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11585440,KI,>,2000,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.",J. Med. Chem.,2001,44,21,"Xue CB, He X, Corbett RL, Roderick J, Wasserman ZR, Liu RQ, Jaffee BD, Covington MB, Qian M, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105383,DTCT0024844,1285147,DTCC00287206,1723526,16439
CHEMBL324550,P14780,,USDVPRSOSNTZAZ-IARZGTGTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11585440,KI,=,183,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.",J. Med. Chem.,2001,44,21,"Xue CB, He X, Corbett RL, Roderick J, Wasserman ZR, Liu RQ, Jaffee BD, Covington MB, Qian M, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105383,DTCT0024844,1304877,DTCC00287207,1468156,16439
CHEMBL324891,P14780,,YDDMVPLLJTZTQL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14711305,KI,=,35600,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Evaluation of P1'-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11.,J. Med. Chem.,2004,47,2,"Matziari M, Beau F, Cuniasse P, Dive V, Yiotakis A",,105372,DTCT0024844,1257647,DTCC00287325,30861,17924
CHEMBL325015,P14780,,NCIVMBVZAUECOS-IEBWSBKVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,11,NM,,,,,,,,,,,,,,Inhibition of human Matrix metalloprotease-9,,,Bioorg. Med. Chem. Lett.,1995,5,4,,,105391,DTCT0024844,822165,DTCC00293439,917740,1497
CHEMBL325048,P14780,,ZYIMYAJZHPOFQU-XPKDYRNWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11585439,KI,=,162,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors.",J. Med. Chem.,2001,44,21,"Yao W, Wasserman ZR, Chao M, Reddy G, Shi E, Liu RQ, Covington MB, Arner EC, Pratta MA, Tortorella M, Magolda RL, Newton R, Qian M, Ribadeneira MD, Christ D, Wexler RR, Decicco CP",,105382,DTCT0024844,1422367,DTCC00287138,1597338,16438
CHEMBL325163,P14780,,RWKJBOMUESGCBO-REUBFRLUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11585440,KI,>,2000,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.",J. Med. Chem.,2001,44,21,"Xue CB, He X, Corbett RL, Roderick J, Wasserman ZR, Liu RQ, Jaffee BD, Covington MB, Qian M, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105383,DTCT0024844,1311920,DTCC00287408,1500490,16439
CHEMBL325163,P14780,,RWKJBOMUESGCBO-REUBFRLUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643312,KI,>,2000,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 1: lead identification.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105545,DTCT0024844,486628,DTCC00287408,1489451,6009
CHEMBL325163,P14780,,RWKJBOMUESGCBO-REUBFRLUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,KI,>,2000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2457311,DTCC00287408,1503285,32556
CHEMBL325372,P14780,METHYLPARABEN,LXCFILQKKLGQFO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7434547,DTCC00280408,315667,46191
CHEMBL325372,P14780,METHYLPARABEN,LXCFILQKKLGQFO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7434548,DTCC00280408,315667,46191
CHEMBL325421,P14780,,QMTWRDGSYLQRRX-IARZGTGTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11585440,KI,=,91,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.",J. Med. Chem.,2001,44,21,"Xue CB, He X, Corbett RL, Roderick J, Wasserman ZR, Liu RQ, Jaffee BD, Covington MB, Qian M, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105383,DTCT0024844,1293738,DTCC00286953,1079821,16439
CHEMBL325749,P14780,,GQNHFEIKUYMXAQ-DHZHZOJOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,7.83,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833610,DTCC00289313,545134,53968
CHEMBL32596,P14780,,JYPUUSQERHUIDJ-USQNYJEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10360755,KI,=,13,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,"P1, P2'-linked macrocyclic amine derivatives as matrix metalloproteinase inhibitors.",Bioorg. Med. Chem. Lett.,1999,9,10,"Duan JJ, Chen L, Xue CB, Wasserman ZR, Hardman KD, Covington MB, Copeland RR, Arner EC, Decicco CP",,105543,DTCT0024844,1587462,DTCC00171178,28573,3139
CHEMBL32631,P14780,,PYHVMKLBOIYJOG-VJBWXMMDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10360755,KI,=,19,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,"P1, P2'-linked macrocyclic amine derivatives as matrix metalloproteinase inhibitors.",Bioorg. Med. Chem. Lett.,1999,9,10,"Duan JJ, Chen L, Xue CB, Wasserman ZR, Hardman KD, Covington MB, Copeland RR, Arner EC, Decicco CP",,105543,DTCT0024844,1585152,DTCC00171113,1466837,3139
CHEMBL326489,P14780,,MDNBGABATBOAOY-YCLCTBJKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12877590,IC50,=,560,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9 (MMP-9),,"A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.",J. Med. Chem.,2003,46,16,"Fray MJ, Dickinson RP, Huggins JP, Occleston NL",,105239,DTCT0024844,1547325,DTCC00293235,258687,17445
CHEMBL327108,P14780,,ONKQNWHNBOMBCR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14711305,KI,=,3910,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Evaluation of P1'-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11.,J. Med. Chem.,2004,47,2,"Matziari M, Beau F, Cuniasse P, Dive V, Yiotakis A",,105371,DTCT0024844,1256340,DTCC00287264,917661,17924
CHEMBL327262,P14780,,JXGACOLDOLFHQF-LGTSYYJHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,40,NM,,,,,,,,,,,,,,"Inhibition of matrix metalloprotease-9, MMP-9",,,Bioorg. Med. Chem. Lett.,1997,7,21,,,102116,DTCT0024844,1309284,DTCC00257763,1968516,2323
CHEMBL327442,P14780,,RWPUCYUUOPJZLU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9873598,IC50,=,3.3,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,The synthesis and biological activity of a novel series of diazepine MMP inhibitors.,Bioorg. Med. Chem. Lett.,1998,8,19,"Levin JI, DiJoseph JF, Killar LM, Sung A, Walter T, Sharr MA, Roth CE, Skotnicki JS, Albright JD",,105513,DTCT0024844,606773,DTCC00252084,1456056,2791
CHEMBL32749,P14780,FERULIC ACID,KSEBMYQBYZTDHS-HWKANZROSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7313837,DTCC00171237,1544898,46191
CHEMBL32749,P14780,FERULIC ACID,KSEBMYQBYZTDHS-HWKANZROSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7313838,DTCC00171237,1544898,46191
CHEMBL327578,P14780,,KFASYAQTQCGPKV-YLFCFFPRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873504,KI,=,0.93,NM,,,,,,,,,,,,,,Inhibition of recombinant human matrix metalloprotease-9,,Structure--activity relationships of azasugar-based MMP/ADAM inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,16,"Moriyama H, Tsukida T, Inoue Y, Kondo H, Yoshino K, Nishimura S",,105394,DTCT0024844,924283,DTCC00255474,1046980,5719
CHEMBL327617,P14780,,COMOZYQMQPSLMB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10411481,KI,=,23,NM,,,,,,,,,,,,,,Binding affinity against matrix metalloprotease-9 (gelatinase-B).,,Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.,J. Med. Chem.,1999,42,14,"Vassiliou S, Mucha A, Cuniasse P, Georgiadis D, Lucet-Levannier K, Beau F, Kannan R, Murphy G, Knäuper V, Rio MC, Basset P, Yiotakis A, Dive V",,105378,DTCT0024844,1056158,DTCC00249769,1806421,15258
CHEMBL327621,P14780,,KPJZJSWNHXZALM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9873598,IC50,=,2,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,The synthesis and biological activity of a novel series of diazepine MMP inhibitors.,Bioorg. Med. Chem. Lett.,1998,8,19,"Levin JI, DiJoseph JF, Killar LM, Sung A, Walter T, Sharr MA, Roth CE, Skotnicki JS, Albright JD",,105513,DTCT0024844,592625,DTCC00251938,1100515,2791
CHEMBL327641,P14780,,DVBWYFQJLIUTJA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10411481,KI,=,70,NM,,,,,,,,,,,,,,Binding affinity against matrix metalloprotease-9 (gelatinase-B).,,Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.,J. Med. Chem.,1999,42,14,"Vassiliou S, Mucha A, Cuniasse P, Georgiadis D, Lucet-Levannier K, Beau F, Kannan R, Murphy G, Knäuper V, Rio MC, Basset P, Yiotakis A, Dive V",,105378,DTCT0024844,1059526,DTCC00249776,776445,15258
CHEMBL328090,P14780,,LKMAUWKMMZAHHV-ZCNNSNEGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472217,KI,=,3.3,NM,,,,,,,,,,,,,,In vitro inhibition of human MMP-9.,,"Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.",J. Med. Chem.,2001,44,16,"Xue CB, Voss ME, Nelson DJ, Duan JJ, Cherney RJ, Jacobson IC, He X, Roderick J, Chen L, Corbett RL, Wang L, Meyer DT, Kennedy K, DeGradodagger WF, Hardman KD, Teleha CA, Jaffee BD, Liu RQ, Copeland RA, Covington MB, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105380,DTCT0024844,1660466,DTCC00251849,96867,16346
CHEMBL328199,P14780,,GZISYEQJJGPWOA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15125955,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,Reverse hydroxamate-based selective TACE inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,11,"Kamei N, Tanaka T, Kawai K, Miyawaki K, Okuyama A, Murakami Y, Arakawa Y, Haino M, Harada T, Shimano M",,105525,DTCT0024844,1365848,DTCC00265331,1047084,6400
CHEMBL328255,P14780,,ZMAQPMCPZORBHF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9873598,IC50,=,4.8,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,The synthesis and biological activity of a novel series of diazepine MMP inhibitors.,Bioorg. Med. Chem. Lett.,1998,8,19,"Levin JI, DiJoseph JF, Killar LM, Sung A, Walter T, Sharr MA, Roth CE, Skotnicki JS, Albright JD",,105513,DTCT0024844,605615,DTCC00252298,1520943,2791
CHEMBL328645,P14780,,HAKDXLDJTCFTIE-HFTWOUSFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15125955,IC50,=,20000,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,Reverse hydroxamate-based selective TACE inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,11,"Kamei N, Tanaka T, Kawai K, Miyawaki K, Okuyama A, Murakami Y, Arakawa Y, Haino M, Harada T, Shimano M",,105525,DTCT0024844,1386234,DTCC00265462,982320,6400
CHEMBL328751,P14780,,LAGAITXTFHYXGS-CQSZACIVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873518,IC50,=,42,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotein-9,,Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2003,13,16,"Levin JI, Chen JM, Cheung K, Cole D, Crago C, Santos ED, Du X, Khafizova G, MacEwan G, Niu C, Salaski EJ, Zask A, Cummons T, Sung A, Xu J, Zhang Y, Xu W, Ayral-Kaloustian S, Jin G, Cowling R, Barone D, Mohler KM, Black RA, Skotnicki JS",,105519,DTCT0024844,807311,DTCC00260082,1774064,5733
CHEMBL328751,P14780,,LAGAITXTFHYXGS-CQSZACIVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,41.69,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258125,DTCC00260082,1776488,24803
CHEMBL328886,P14780,,YQEMFOGNUTYMTJ-BUAFSUBRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10411481,KI,=,10,NM,,,,,,,,,,,,,,Binding affinity against matrix metalloprotease-9 (gelatinase-B).,,Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.,J. Med. Chem.,1999,42,14,"Vassiliou S, Mucha A, Cuniasse P, Georgiadis D, Lucet-Levannier K, Beau F, Kannan R, Murphy G, Knäuper V, Rio MC, Basset P, Yiotakis A, Dive V",,105378,DTCT0024844,1085841,DTCC00249311,1326512,15258
CHEMBL328910,P14780,"2,4-DIHYDROXYBENZOIC ACID",UIAFKZKHHVMJGS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,-8,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5102617,DTCC00254453,1828599,43205
CHEMBL329002,P14780,,MQOPTJYOSJSPJX-UBFHEZILSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,30,NM,,,,,,,,,,,,,,"Inhibition of matrix metalloprotease-9, MMP-9",,,Bioorg. Med. Chem. Lett.,1997,7,21,,,102116,DTCT0024844,1322235,DTCC00257795,1488748,2323
CHEMBL329043,P14780,,WEJRAOYHTAOVFY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15163180,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of recombinant human Matrix metalloprotease-9,,Sultam hydroxamates as novel matrix metalloproteinase inhibitors.,J. Med. Chem.,2004,47,12,"Cherney RJ, Mo R, Meyer DT, Hardman KD, Liu RQ, Covington MB, Qian M, Wasserman ZR, Christ DD, Trzaskos JM, Newton RC, Decicco CP",,105386,DTCT0024844,693860,DTCC00269044,1633413,18131
CHEMBL329145,P14780,,RMAHZBKEPFXNHG-GJZGRUSLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,90,NM,,,,,,,,,,,,,,"Inhibition of matrix metalloprotease-9, MMP-9",,,Bioorg. Med. Chem. Lett.,1997,7,21,,,102116,DTCT0024844,1310507,DTCC00257135,129155,2323
CHEMBL329558,P14780,,AQVWDVBVCMNHDC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9873598,IC50,=,4,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,The synthesis and biological activity of a novel series of diazepine MMP inhibitors.,Bioorg. Med. Chem. Lett.,1998,8,19,"Levin JI, DiJoseph JF, Killar LM, Sung A, Walter T, Sharr MA, Roth CE, Skotnicki JS, Albright JD",,105513,DTCT0024844,598594,DTCC00252299,582786,2791
CHEMBL329617,P14780,,LSAOZCAKUIANSQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11327602,IC50,=,11000,NM,,,,,,,,,,,,,,"Inhibition of Gelatinase B, matrix metalloprotease-9",,"Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors.",Bioorg. Med. Chem. Lett.,2001,11,8,"Foley LH, Palermo R, Dunten P, Wang P",,71657,DTCT0024844,971600,DTCC00256444,1981571,4784
CHEMBL329651,P14780,,BRKOQUQULDVEDN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10411481,KI,=,44,NM,,,,,,,,,,,,,,Binding affinity against matrix metalloprotease-9 (gelatinase-B).,,Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.,J. Med. Chem.,1999,42,14,"Vassiliou S, Mucha A, Cuniasse P, Georgiadis D, Lucet-Levannier K, Beau F, Kannan R, Murphy G, Knäuper V, Rio MC, Basset P, Yiotakis A, Dive V",,105378,DTCT0024844,1084507,DTCC00249770,1903191,15258
CHEMBL329784,P14780,(CYCLOHEXYLAMINO)CARBONYLPHOSPHONIC ACID,QQRCALUVCOFAOX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15139760,IC50,>,100000,NM,,,,,,,,,,,,,,In vitro inhibitory activity against recombinant matrix metalloprotease-9 was determined,,"Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.",J. Med. Chem.,2004,47,11,"Breuer E, Salomon CJ, Katz Y, Chen W, Lu S, Röschenthaler GV, Hadar R, Reich R",,105518,DTCT0024844,1291833,DTCC00261567,401327,17838
CHEMBL329967,P14780,,BVQJLICESKJIJB-IADYIPOJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15125955,IC50,=,40000,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,Reverse hydroxamate-based selective TACE inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,11,"Kamei N, Tanaka T, Kawai K, Miyawaki K, Okuyama A, Murakami Y, Arakawa Y, Haino M, Harada T, Shimano M",,105525,DTCT0024844,1388722,DTCC00265510,659401,6400
CHEMBL33,P14780,LEVOFLOXACIN,GSDSWSVVBLHKDQ-JTQLQIEISA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7429541,DTCC00133684,51486,46191
CHEMBL33,P14780,LEVOFLOXACIN,GSDSWSVVBLHKDQ-JTQLQIEISA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7429542,DTCC00133684,51486,46191
CHEMBL330028,P14780,,BGKNBDGHNBOSGD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23287054,IC50,,,,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin),Not Determined,Sulphonamides: Deserving class as MMP inhibitors?,Eur. J. Med. Chem.,2013,60,,"Jain P, Saravanan C, Singh SK",,944094,DTCT0024844,11835658,DTCC00252259,1158307,53820
CHEMBL330588,P14780,,PAAGUAHWPSXIJP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12270165,IC50,=,2,NM,,,,,,,,,,,,,,Concentration required in vitro to inhibit Matrix metalloprotease-9,,Benzodiazepine inhibitors of the MMPs and TACE.,Bioorg. Med. Chem. Lett.,2002,12,20,"Nelson FC, Delos Santos E, Levin JI, Chen JM, Skotnicki JS, DiJoseph JF, Sharr MA, Sung A, Killar LM, Cowling R, Jin G, Roth CE, Albright JD",,105515,DTCT0024844,1541053,DTCC00263354,1785726,5143
CHEMBL330727,P14780,,WOZRCMBDSXXEAJ-RFQIPJPRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873505,KI,=,21,NM,,,,,,,,,,,,,,Inhibition of recombinant human matrix metalloprotease-9 (gelatinase B),,"Design, synthesis and evaluation of novel azasugar-based MMP/ADAM inhibitors.",Bioorg. Med. Chem. Lett.,2003,13,16,"Moriyama H, Tsukida T, Inoue Y, Kondo H, Yoshino K, Nishimura S",,105395,DTCT0024844,963615,DTCC00106483,1207710,5720
CHEMBL330731,P14780,,ZRMAXAMITMCTTB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10411481,KI,=,280,NM,,,,,,,,,,,,,,Binding affinity against matrix metalloprotease-9 (gelatinase-B).,,Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.,J. Med. Chem.,1999,42,14,"Vassiliou S, Mucha A, Cuniasse P, Georgiadis D, Lucet-Levannier K, Beau F, Kannan R, Murphy G, Knäuper V, Rio MC, Basset P, Yiotakis A, Dive V",,105378,DTCT0024844,1083339,DTCC00249768,1713982,15258
CHEMBL330857,P14780,,VLTOUUSTKONGKC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,4.3,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1625324,DTCC00299273,31105,15919
CHEMBL330857,P14780,,VLTOUUSTKONGKC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,4.27,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258502,DTCC00299273,8954,24803
CHEMBL330950,P14780,,GJCGJVYGHHRTHL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,>,100000,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1605180,DTCC00298620,627501,15919
CHEMBL331095,P14780,,CRPDTHYTIJXWLZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,1.3,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1715018,DTCC00302754,1714460,16065
CHEMBL331114,P14780,,UTOKQYCFEAMQLH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,13000,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1631630,DTCC00299140,950357,15919
CHEMBL331308,P14780,,RFJAQRMGTCPTHM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,>,100000,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1601071,DTCC00298795,303681,15919
CHEMBL331311,P14780,,CDVYEYANHXGLCX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,4,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1631606,DTCC00298873,433997,15919
CHEMBL331311,P14780,,CDVYEYANHXGLCX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,3.98,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258498,DTCC00298873,424705,24803
CHEMBL331342,P14780,,VKUYLANQOAKALN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,1.3,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1620361,DTCC00299210,1818652,15919
CHEMBL331342,P14780,,VKUYLANQOAKALN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,1.29,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258496,DTCC00299210,1808950,24803
CHEMBL331669,P14780,,AUIKJLRMPLDORG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,96,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1617676,DTCC00299154,1468302,15919
CHEMBL331669,P14780,,AUIKJLRMPLDORG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,95.5,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258507,DTCC00299154,1458608,24803
CHEMBL332120,P14780,,HLJHTDAQDAFOFS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,28,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1627939,DTCC00299400,108901,15919
CHEMBL332120,P14780,,HLJHTDAQDAFOFS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,28.18,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258484,DTCC00299400,99390,24803
CHEMBL332134,P14780,,DNGGPLKVDUPXFN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,1.9,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1708420,DTCC00302701,712684,16065
CHEMBL332145,P14780,,BLBYFZDCNCBJTH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,73000,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1602496,DTCC00298760,1597482,15919
CHEMBL332302,P14780,,YGXMCNARAMUPPX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,1.8,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1680205,DTCC00303015,1164477,16065
CHEMBL332362,P14780,,ZQFMPAUDTOJXIB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,1700,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1629143,DTCC00298575,141317,15919
CHEMBL332406,P14780,,VSJBIWYXNLUPIE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,89,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1636604,DTCC00299016,1818653,15919
CHEMBL332406,P14780,,VSJBIWYXNLUPIE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,89.13,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258503,DTCC00299016,1808949,24803
CHEMBL332429,P14780,,CSAFQHHGNGUQOL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,121,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1607481,DTCC00299120,498462,15919
CHEMBL332429,P14780,,CSAFQHHGNGUQOL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,120.23,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258448,DTCC00299120,488944,24803
CHEMBL332439,P14780,,KTJYZIRNJPDNBW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,21000,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1602488,DTCC00298787,1338994,15919
CHEMBL332755,P14780,,XFNJKSWXHKYCFN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,1.2,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1631598,DTCC00299302,917813,15919
CHEMBL332755,P14780,,XFNJKSWXHKYCFN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,1.2,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258501,DTCC00299302,909278,24803
CHEMBL332858,P14780,,HJAQLIVSMXUHPV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,125,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1599869,DTCC00299089,530553,15919
CHEMBL332858,P14780,,HJAQLIVSMXUHPV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,125.89,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258442,DTCC00299089,521152,24803
CHEMBL332891,P14780,,SNQRPCRWYVZYNW-YGRLFVJLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,500,NM,,,,,,,,,,,,,,Inhibition of human Matrix metalloprotease-9,,,Bioorg. Med. Chem. Lett.,1995,5,4,,,105391,DTCT0024844,854575,DTCC00293462,1338923,1497
CHEMBL333122,P14780,,AUBKGBIPPZSEKF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,83000,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1616278,DTCC00298761,950354,15919
CHEMBL333248,P14780,,JCUTWTFOYUXMPS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,120,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1618952,DTCC00299397,1629815,15919
CHEMBL333248,P14780,,JCUTWTFOYUXMPS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,120.23,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258446,DTCC00299397,1620392,24803
CHEMBL333532,P14780,2-HYDROXYSULFAMOYL-BENZOIC ACID,USQRZPGPLTUIHD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,100,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1603762,DTCC01742806,950356,15919
CHEMBL333567,P14780,,IFUFBKYZHPAPTH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9733482,IC50,,,,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (not determined),Not Determined,"Discovery of potent, achiral matrix metalloproteinase inhibitors.",J. Med. Chem.,1998,41,19,"Pikul S, McDow Dunham KL, Almstead NG, De B, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Rydel T, Dunaway CM, Gu F, Mieling GE",,105361,DTCT0024844,1545442,DTCC00295351,357152,14767
CHEMBL333586,P14780,,QYFKTMNLZHLRIH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,0.6,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1718038,DTCC00303017,907231,16065
CHEMBL333729,P14780,,BCWUIVYEXBBRHO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9733482,IC50,=,3.9,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,"Discovery of potent, achiral matrix metalloproteinase inhibitors.",J. Med. Chem.,1998,41,19,"Pikul S, McDow Dunham KL, Almstead NG, De B, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Rydel T, Dunaway CM, Gu F, Mieling GE",,105360,DTCT0024844,1520538,DTCC00295403,1839410,14767
CHEMBL3337869,P14780,,AARSEFXVCWMMKV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25192810,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using fluorescence peptide Cy3-PLGLK(Cy5Q)AR-NH2 substrate by fluorescence assay,,"Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1¿ binding site.",Bioorg. Med. Chem.,2014,22,19,"Nara H, Sato K, Naito T, Mototani H, Oki H, Yamamoto Y, Kuno H, Santou T, Kanzaki N, Terauchi J, Uchikawa O, Kori M",,1442066,DTCT0024844,13992252,DTCC01523362,1322384,59837
CHEMBL3337869,P14780,,AARSEFXVCWMMKV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25264600,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using Cy3-PLGLK(Cy5Q)AR-NH2 as substrate after 40 mins by spectrofluorimetry,,"Discovery of Novel, Highly Potent, and Selective Quinazoline-2-carboxamide-Based Matrix Metalloproteinase (MMP)-13 Inhibitors without a Zinc Binding Group Using a Structure-Based Design Approach.",J. Med. Chem.,2014,57,21,"Nara H, Sato K, Naito T, Mototani H, Oki H, Yamamoto Y, Kuno H, Santou T, Kanzaki N, Terauchi J, Uchikawa O, Kori M",,1431424,DTCT0024844,13989092,DTCC01523362,1302071,60036
CHEMBL3337894,P14780,,CDQRIIUMNLMHRH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25192810,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using fluorescence peptide Cy3-PLGLK(Cy5Q)AR-NH2 substrate by fluorescence assay,,"Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1¿ binding site.",Bioorg. Med. Chem.,2014,22,19,"Nara H, Sato K, Naito T, Mototani H, Oki H, Yamamoto Y, Kuno H, Santou T, Kanzaki N, Terauchi J, Uchikawa O, Kori M",,1442066,DTCT0024844,13992253,DTCC01523387,966370,59837
CHEMBL333896,P14780,,VOESHNWTIDIZCL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,137,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1617684,DTCC00299583,238021,15919
CHEMBL333896,P14780,,VOESHNWTIDIZCL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,138.04,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258447,DTCC00299583,228499,24803
CHEMBL333973,P14780,2-METHOXYBENZENETHIOL,DSCJETUEDFKYGN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,17,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5102660,DTCC01742611,734155,43205
CHEMBL334107,P14780,,NWAZOLPVSMLDTN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9733482,IC50,=,101,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,"Discovery of potent, achiral matrix metalloproteinase inhibitors.",J. Med. Chem.,1998,41,19,"Pikul S, McDow Dunham KL, Almstead NG, De B, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Rydel T, Dunaway CM, Gu F, Mieling GE",,105360,DTCT0024844,1525230,DTCC00295376,97361,14767
CHEMBL334255,P14780,CETYLPYRIDINIUM BROMIDE,DVBJBNKEBPCGSY-UHFFFAOYSA-M,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7338736,DTCC00294369,510299,46191
CHEMBL334255,P14780,CETYLPYRIDINIUM BROMIDE,DVBJBNKEBPCGSY-UHFFFAOYSA-M,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7338737,DTCC00294369,510299,46191
CHEMBL334403,P14780,,FAEZTVRCESNVJN-NCOADZHNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11708926,IC50,=,13,NM,,,,,,,,,,,,,,Inhibition potency was determined by fluorescence-based peptide assay against matrix metalloprotease-9,,Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,J. Med. Chem.,2001,44,24,"Rabinowitz MH, Andrews RC, Becherer JD, Bickett DM, Bubacz DG, Conway JG, Cowan DJ, Gaul M, Glennon K, Lambert MH, Leesnitzer MA, McDougald DL, Moss ML, Musso DL, Rizzolio MC",,105523,DTCT0024844,1284042,DTCC00317608,1935934,16522
CHEMBL334446,P14780,,SAHHDJPYSWCBQK-SFTDATJTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643312,KI,,876,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 1: lead identification.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105545,DTCT0024844,479730,DTCC00318326,1294786,6009
CHEMBL334468,P14780,,WXBITLRZKLGBHW-ROUUACIJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643312,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 1: lead identification.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105545,DTCT0024844,502444,DTCC00318770,874890,6009
CHEMBL334567,P14780,,KIKBZIXCMWKZEI-NCOADZHNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11708926,IC50,=,22,NM,,,,,,,,,,,,,,Inhibition potency was determined by fluorescence-based peptide assay against matrix metalloprotease-9,,Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,J. Med. Chem.,2001,44,24,"Rabinowitz MH, Andrews RC, Becherer JD, Bickett DM, Bubacz DG, Conway JG, Cowan DJ, Gaul M, Glennon K, Lambert MH, Leesnitzer MA, McDougald DL, Moss ML, Musso DL, Rizzolio MC",,105523,DTCT0024844,1259734,DTCC00317250,1133425,16522
CHEMBL3350037,P14780,,DEQANNDTNATYII-JDBXKHNRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7388694,DTCC01529235,510306,46191
CHEMBL3350037,P14780,,DEQANNDTNATYII-JDBXKHNRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7388695,DTCC01529235,510306,46191
CHEMBL335009,P14780,,LAQQWJARJKOYJJ-PBDJWPIDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11708926,IC50,=,115,NM,,,,,,,,,,,,,,Inhibition potency was determined by fluorescence-based peptide assay against matrix metalloprotease-9,,Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,J. Med. Chem.,2001,44,24,"Rabinowitz MH, Andrews RC, Becherer JD, Bickett DM, Bubacz DG, Conway JG, Cowan DJ, Gaul M, Glennon K, Lambert MH, Leesnitzer MA, McDougald DL, Moss ML, Musso DL, Rizzolio MC",,105523,DTCT0024844,1257444,DTCC00317888,1133426,16522
CHEMBL3350246,P14780,,RBRFAUFMZOIMMS-OSPHWJPCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,=,1000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041933,DTCC01529440,1146516,22157
CHEMBL3350685,P14780,,RBRFAUFMZOIMMS-BXKMTCNYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,=,1500,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041934,DTCC01529877,1916681,22157
CHEMBL3350758,P14780,,OLQSPMWFVKDWRQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23999043,IC50,=,1.6,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,Design and synthesis of MMP inhibitors with appended fluorescent tags for imaging and visualization of matrix metalloproteinase enzymes.,Bioorg. Med. Chem. Lett.,2013,23,20,"Freskos JN, Asmelash B, Gaston KR, Karwa A, Marzan TA, Nickols MA, Rogers TE, Schoenstein T, Sympson CJ, Vu B",,985895,DTCT0024844,12592005,DTCC01529950,803489,55953
CHEMBL335177,P14780,,RSQQVXDXQWIKTP-IRXDYDNUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643312,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 1: lead identification.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105545,DTCT0024844,498813,DTCC00318329,1262287,6009
CHEMBL3355722,P14780,,VGWZAHYVUANFST-QYZOEREBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25438884,IC50,=,19.5,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 fluorogenic substrate,,"A dual inhibitor of matrix metalloproteinases and a disintegrin and metalloproteinases, [¹8F]FB-ML5, as a molecular probe for non-invasive MMP/ADAM-targeted imaging.",Bioorg. Med. Chem.,2015,23,1,"Matusiak N, Castelli R, Tuin AW, Overkleeft HS, Wisastra R, Dekker FJ, Prély LM, Bischoff RP, van Waarde A, Dierckx RA, Elsinga PH",,1441828,DTCT0024844,14004869,DTCC01533159,137038,60339
CHEMBL3355723,P14780,,CHCWPXOCMTZBSY-VJTSUQJLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25438884,IC50,=,31.5,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 fluorogenic substrate,,"A dual inhibitor of matrix metalloproteinases and a disintegrin and metalloproteinases, [¹8F]FB-ML5, as a molecular probe for non-invasive MMP/ADAM-targeted imaging.",Bioorg. Med. Chem.,2015,23,1,"Matusiak N, Castelli R, Tuin AW, Overkleeft HS, Wisastra R, Dekker FJ, Prély LM, Bischoff RP, van Waarde A, Dierckx RA, Elsinga PH",,1441828,DTCT0024844,14004867,DTCC01533160,1269485,60339
CHEMBL3355724,P14780,,KFGQNXFUJFZCKJ-RDAHNBDFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25438884,IC50,=,2420,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 fluorogenic substrate,,"A dual inhibitor of matrix metalloproteinases and a disintegrin and metalloproteinases, [¹8F]FB-ML5, as a molecular probe for non-invasive MMP/ADAM-targeted imaging.",Bioorg. Med. Chem.,2015,23,1,"Matusiak N, Castelli R, Tuin AW, Overkleeft HS, Wisastra R, Dekker FJ, Prély LM, Bischoff RP, van Waarde A, Dierckx RA, Elsinga PH",,1441828,DTCT0024844,14004866,DTCC01533161,623136,60339
CHEMBL3359091,P14780,,YNHGVYGMFAREOF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25264600,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using Cy3-PLGLK(Cy5Q)AR-NH2 as substrate after 40 mins by spectrofluorimetry,,"Discovery of Novel, Highly Potent, and Selective Quinazoline-2-carboxamide-Based Matrix Metalloproteinase (MMP)-13 Inhibitors without a Zinc Binding Group Using a Structure-Based Design Approach.",J. Med. Chem.,2014,57,21,"Nara H, Sato K, Naito T, Mototani H, Oki H, Yamamoto Y, Kuno H, Santou T, Kanzaki N, Terauchi J, Uchikawa O, Kori M",,1431424,DTCT0024844,13989091,DTCC01536542,1108444,60036
CHEMBL3359462,P14780,,XIWMYPMMJBLNNV-YRNVUSSQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25467291,INHIBITION,=,18.77,%,,cell_based,,,,,,,,,,,,Inhibition of MMP9 activity in human H1299 cells at 5 uM after 24 hrs by gelatin zymography,,Discovery of 2-[2-(5-nitrofuran-2-yl)vinyl]quinoline derivatives as a novel type of antimetastatic agents.,Bioorg. Med. Chem.,2015,23,1,"Tseng CH, Tzeng CC, Chiu CC, Hsu CY, Chou CK, Chen YL",,1443725,DTCT0024844,13849367,DTCC01536916,998876,60525
CHEMBL3359462,P14780,,XIWMYPMMJBLNNV-YRNVUSSQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25467291,INHIBITION,=,31.48,%,,cell_based,,,,,,,,,,,,Inhibition of MMP9 activity in human H1299 cells at 2 uM after 24 hrs by gelatin zymography,,Discovery of 2-[2-(5-nitrofuran-2-yl)vinyl]quinoline derivatives as a novel type of antimetastatic agents.,Bioorg. Med. Chem.,2015,23,1,"Tseng CH, Tzeng CC, Chiu CC, Hsu CY, Chou CK, Chen YL",,1443596,DTCT0024844,13849366,DTCC01536916,998876,60525
CHEMBL3359462,P14780,,XIWMYPMMJBLNNV-YRNVUSSQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25467291,INHIBITION,=,63.85,%,,cell_based,,,,,,,,,,,,Inhibition of MMP9 activity in human H1299 cells at 1 uM after 24 hrs by gelatin zymography,,Discovery of 2-[2-(5-nitrofuran-2-yl)vinyl]quinoline derivatives as a novel type of antimetastatic agents.,Bioorg. Med. Chem.,2015,23,1,"Tseng CH, Tzeng CC, Chiu CC, Hsu CY, Chou CK, Chen YL",,1443595,DTCT0024844,13849365,DTCC01536916,998876,60525
CHEMBL3359462,P14780,,XIWMYPMMJBLNNV-YRNVUSSQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25467291,INHIBITION,,,,,cell_based,,,,,,,,,,,,Inhibition of MMP9 activity in human H1299 cells after 24 hrs by gelatin zymography,Dose-dependent effect,Discovery of 2-[2-(5-nitrofuran-2-yl)vinyl]quinoline derivatives as a novel type of antimetastatic agents.,Bioorg. Med. Chem.,2015,23,1,"Tseng CH, Tzeng CC, Chiu CC, Hsu CY, Chou CK, Chen YL",,1443594,DTCT0024844,13849364,DTCC01536916,998876,60525
CHEMBL3359657,P14780,,DFSJOYHCSMRYOD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25265401,IC50,=,43.9,NM,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin),,"Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors.",J. Med. Chem.,2014,57,24,"Fabre B, Ramos A, de Pascual-Teresa B",,1433221,DTCT0024844,13993817,DTCC01537099,364793,60040
CHEMBL3359658,P14780,,SKWAAHKOPIVFIC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25265401,IC50,=,346.4,NM,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin),,"Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors.",J. Med. Chem.,2014,57,24,"Fabre B, Ramos A, de Pascual-Teresa B",,1433221,DTCT0024844,13993818,DTCC01537100,882038,60040
CHEMBL336425,P14780,,YKVNFNGMIAJYOQ-PMPSAXMXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11708926,IC50,=,13,NM,,,,,,,,,,,,,,Inhibition potency was determined by fluorescence-based peptide assay against matrix metalloprotease-9,,Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,J. Med. Chem.,2001,44,24,"Rabinowitz MH, Andrews RC, Becherer JD, Bickett DM, Bubacz DG, Conway JG, Cowan DJ, Gaul M, Glennon K, Lambert MH, Leesnitzer MA, McDougald DL, Moss ML, Musso DL, Rizzolio MC",,105523,DTCT0024844,1258552,DTCC00317268,1424905,16522
CHEMBL336786,P14780,,QXSADLFWPARWTP-QSBPQZLJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11708926,IC50,=,143,NM,,,,,,,,,,,,,,Inhibition potency was determined by fluorescence-based peptide assay against matrix metalloprotease-9,,Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,J. Med. Chem.,2001,44,24,"Rabinowitz MH, Andrews RC, Becherer JD, Bickett DM, Bubacz DG, Conway JG, Cowan DJ, Gaul M, Glennon K, Lambert MH, Leesnitzer MA, McDougald DL, Moss ML, Musso DL, Rizzolio MC",,105523,DTCT0024844,1269201,DTCC00317484,422831,16522
CHEMBL336832,P14780,,XORDSICOUVZNCB-AHWVRZQESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643313,KI,>,2128,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105546,DTCT0024844,1054555,DTCC00318198,1915389,6011
CHEMBL336900,P14780,,VLXGWLLECQNRLI-IRXDYDNUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643312,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 1: lead identification.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105545,DTCT0024844,497524,DTCC00318807,258980,6009
CHEMBL337042,P14780,,FWJFNXPZKLJJSG-QYZOEREBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11708926,IC50,=,55,NM,,,,,,,,,,,,,,Inhibition potency was determined by fluorescence-based peptide assay against matrix metalloprotease-9,,Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,J. Med. Chem.,2001,44,24,"Rabinowitz MH, Andrews RC, Becherer JD, Bickett DM, Bubacz DG, Conway JG, Cowan DJ, Gaul M, Glennon K, Lambert MH, Leesnitzer MA, McDougald DL, Moss ML, Musso DL, Rizzolio MC",,105523,DTCT0024844,1261010,DTCC00317889,2001796,16522
CHEMBL337045,P14780,,FUDBZSGMQCENEH-BDXSIMOUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11708926,IC50,=,48,NM,,,,,,,,,,,,,,Inhibition potency was determined by fluorescence-based peptide assay against matrix metalloprotease-9,,Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,J. Med. Chem.,2001,44,24,"Rabinowitz MH, Andrews RC, Becherer JD, Bickett DM, Bubacz DG, Conway JG, Cowan DJ, Gaul M, Glennon K, Lambert MH, Leesnitzer MA, McDougald DL, Moss ML, Musso DL, Rizzolio MC",,105523,DTCT0024844,1258567,DTCC00317455,1553764,16522
CHEMBL337309,P14780,TAXIFOLIN,CXQWRCVTCMQVQX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,IC50,=,32020,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain incubated for 20 mins by fluorimetric assay,,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827436,DTCT0024844,10535420,DTCC00321631,912570,48665
CHEMBL337309,P14780,TAXIFOLIN,CXQWRCVTCMQVQX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,INHIBITION,>,30,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain at 10 uM incubated for 20 mins by fluorimetric assay,,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827442,DTCT0024844,10535521,DTCC00321631,912570,48665
CHEMBL337512,P14780,,HDTMIVHMPQVMJD-AABGKKOBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11708926,IC50,=,11,NM,,,,,,,,,,,,,,Inhibition potency was determined by fluorescence-based peptide assay against matrix metalloprotease-9,,Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,J. Med. Chem.,2001,44,24,"Rabinowitz MH, Andrews RC, Becherer JD, Bickett DM, Bubacz DG, Conway JG, Cowan DJ, Gaul M, Glennon K, Lambert MH, Leesnitzer MA, McDougald DL, Moss ML, Musso DL, Rizzolio MC",,105523,DTCT0024844,1284036,DTCC00317763,1553765,16522
CHEMBL337849,P14780,,ODDGTPKMNMBICU-UPVQGACJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643313,KI,>,2128,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105546,DTCT0024844,1042141,DTCC00318200,336563,6011
CHEMBL337946,P14780,,DAAIDRXNEKWJIQ-LQGLAIQGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12930146,IC50,=,4,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP9),,Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.,J. Med. Chem.,2003,46,18,"Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P",,105365,DTCT0024844,522118,DTCC00304579,1436012,13726
CHEMBL337986,P14780,,FSFVECJWHSGENK-MZBJOSPHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12930146,IC50,=,47,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP9),,Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.,J. Med. Chem.,2003,46,18,"Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P",,105365,DTCT0024844,543945,DTCC00304730,724287,13726
CHEMBL338007,P14780,,JDOCJRYXQAWUOO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,1.9,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1713846,DTCC00303044,938928,16065
CHEMBL338077,P14780,,QKXUIPRJJWLPIY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,3,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1688095,DTCC00302395,324604,16065
CHEMBL338223,P14780,,VPTHOUBPDJAAER-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,5,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1703165,DTCC00302941,1521507,16065
CHEMBL338453,P14780,,JZJWCJQEWXNHBE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,17,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1711252,DTCC00302163,1585796,16065
CHEMBL338790,P14780,,SSMIFVHARFVINF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7280959,DTCC00302791,1512803,46191
CHEMBL338790,P14780,,SSMIFVHARFVINF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7280960,DTCC00302791,1512803,46191
CHEMBL338877,P14780,,QOOGIVWLICWQOB-HARLFGEKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12930146,IC50,=,30,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP9),,Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.,J. Med. Chem.,2003,46,18,"Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P",,105365,DTCT0024844,533629,DTCC00304546,1629864,13726
CHEMBL339137,P14780,,IDKKXCKXGPPWMS-MZBJOSPHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12930146,IC50,=,24,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP9),,Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.,J. Med. Chem.,2003,46,18,"Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P",,105365,DTCT0024844,521065,DTCC00304581,76740,13726
CHEMBL33915,P14780,,SCDTVKKBOXTTSJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11378378,IC50,=,2500,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2001,11,11,"Baxter AD, Bhogal R, Bird J, Keily JF, Manallack DT, Montana JG, Owen DA, Pitt WR, Watson RJ, Wills RE",,105531,DTCT0024844,1023413,DTCC00173329,743590,4214
CHEMBL3392650,P14780,,MAVDNGWEBZTACC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,82,NM,,,,,,,,,,,,,,"BindingDB_Patents: Enzyme Assay. The molecules are tested in dose-response studies on the following enzymes MMP1, MMP3, MMP9, ADAMS and ADAM10 according to the same protocol as that described for the TACE enzyme in example 28 but with different substrates (MMP R and D system reference: P126-990 and ADAM R and D system reference: ES003).",320818,"N-[2-hydroxycarbamoyl-2-(piperazinyl) ethyl] benzamide compounds, their preparation and their use as TACE inhibitors",,2015,,,,,1536182,DTCT0024844,175727,DTCC01539841,754518,65180
CHEMBL339315,P14780,,CJLBNTMKOCAXSY-GKCIPKSASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12930146,IC50,>,100,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP9),,Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.,J. Med. Chem.,2003,46,18,"Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P",,105365,DTCT0024844,542952,DTCC00304908,1533087,13726
CHEMBL339380,P14780,,DWPJTZNVLPANSJ-FPOVZHCZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643313,KI,>,2128,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105546,DTCT0024844,1040889,DTCC00318291,854059,6011
CHEMBL339381,P14780,,ZAUSLRXPYLUTHB-KJFGXLEFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11708926,IC50,=,89,NM,,,,,,,,,,,,,,Inhibition potency was determined by fluorescence-based peptide assay against matrix metalloprotease-9,,Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,J. Med. Chem.,2001,44,24,"Rabinowitz MH, Andrews RC, Becherer JD, Bickett DM, Bubacz DG, Conway JG, Cowan DJ, Gaul M, Glennon K, Lambert MH, Leesnitzer MA, McDougald DL, Moss ML, Musso DL, Rizzolio MC",,105523,DTCT0024844,1264655,DTCC00317485,129863,16522
CHEMBL3394285,P14780,,ABKAFUZUCJSIKV-ZZXKWVIFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26753813,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 expressed in Escherichia coli using (5-FAM/QXLTM) FRET peptide as substrate,,Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid.,Bioorg. Med. Chem.,2016,24,4,"Ai T, Qiu L, Xie J, Geraghty RJ, Chen L.",,1547675,DTCT0024844,50486,DTCC01541321,1869229,65891
CHEMBL3394306,P14780,,DPMAWPWZDLKEFJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25490700,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain (107 to 449 aa) expressed in Escherichia coli,Active,Hydroxamic acids block replication of hepatitis C virus.,J. Med. Chem.,2015,58,2,"Ai T, Xu Y, Qiu L, Geraghty RJ, Chen L",,1461378,DTCT0024844,14029926,DTCC01541343,740501,61325
CHEMBL339588,P14780,,QKYPFBUZQDJQHX-DQMJNTIXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12930146,IC50,=,3,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP9),,Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.,J. Med. Chem.,2003,46,18,"Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P",,105365,DTCT0024844,539250,DTCC00304182,1915219,13726
CHEMBL339610,P14780,,FWGPCZGIMGDSOM-APTRMMRNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12930146,IC50,=,16,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP9),,Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.,J. Med. Chem.,2003,46,18,"Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P",,105365,DTCT0024844,521077,DTCC00304804,1339064,13726
CHEMBL33977,P14780,,FDJBYAHLPYLRKD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11378378,IC50,=,6000,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2001,11,11,"Baxter AD, Bhogal R, Bird J, Keily JF, Manallack DT, Montana JG, Owen DA, Pitt WR, Watson RJ, Wills RE",,105531,DTCT0024844,1035541,DTCC00173295,1805633,4214
CHEMBL33980,P14780,,GTRSMAWFAMXNCF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12668018,IC50,=,6,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease 9 (MMP-9).,,Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,8,"Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS",,105528,DTCT0024844,1274452,DTCC00174678,1304977,6276
CHEMBL339903,P14780,,WQWMOIIWRWXUJY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,2.3,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1716498,DTCC00302725,648520,16065
CHEMBL340345,P14780,,JIIMVBXHLBKVOM-SNRMKQJTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12930146,IC50,=,642,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP9),,Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.,J. Med. Chem.,2003,46,18,"Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P",,105365,DTCT0024844,523135,DTCC00304892,336391,13726
CHEMBL340455,P14780,,AXIUEWMOHLWPSR-MZBJOSPHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12930146,IC50,=,13,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP9),,Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.,J. Med. Chem.,2003,46,18,"Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P",,105365,DTCT0024844,541133,DTCC00304315,917875,13726
CHEMBL340461,P14780,,RAPHEYPJGISJNU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,1.1,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1607489,DTCC00298841,1371597,15919
CHEMBL340461,P14780,,RAPHEYPJGISJNU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,1.1,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258497,DTCC00298841,1361900,24803
CHEMBL340771,P14780,,HIYYLOFJQXHPRU-OPXMRZJTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12930146,IC50,=,24,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP9),,Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.,J. Med. Chem.,2003,46,18,"Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P",,105365,DTCT0024844,526007,DTCC00304552,1786179,13726
CHEMBL34085,P14780,,UEXHODHUQXSZDN-AABGKKOBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10360755,KI,=,21,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,"P1, P2'-linked macrocyclic amine derivatives as matrix metalloproteinase inhibitors.",Bioorg. Med. Chem. Lett.,1999,9,10,"Duan JJ, Chen L, Xue CB, Wasserman ZR, Hardman KD, Covington MB, Copeland RR, Arner EC, Decicco CP",,105543,DTCT0024844,1574366,DTCC00172830,1660617,3139
CHEMBL340923,P14780,,BSHJFYSJFLAHQN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,1.8,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1690786,DTCC00302218,842153,16065
CHEMBL340978,P14780,BENOXAPROFEN,MITFXPHMIHQXPI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7278335,DTCC00314414,510297,46191
CHEMBL340978,P14780,BENOXAPROFEN,MITFXPHMIHQXPI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7278336,DTCC00314414,510297,46191
CHEMBL341249,P14780,,IFCFGMLOBSUCSN-NWVWQQAFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12930146,IC50,=,512,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP9),,Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.,J. Med. Chem.,2003,46,18,"Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P",,105365,DTCT0024844,530756,DTCC00304771,627569,13726
CHEMBL341380,P14780,,JNLVNYQWIZOKGL-UNMCSNQZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643313,KI,>,2128,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105546,DTCT0024844,1030758,DTCC00318209,821146,6011
CHEMBL34139,P14780,GENACONAZOLE,HFGZFHCWKKQGIS-NOZJJQNGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7333646,DTCC00173585,1416030,46191
CHEMBL34139,P14780,GENACONAZOLE,HFGZFHCWKKQGIS-NOZJJQNGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7333647,DTCC00173585,1416030,46191
CHEMBL3415744,P14780,,BSGRHLVKBVAVEG-XZOQPEGZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25899333,INHIBITION,,,,,cell_based,,,,,,,,,,,,Inhibition of MMP9 in human PC3 cells assessed as reduction in MMP-mediated gelatinolytic activity at cytotoxic IC50 level incubated for 24 hrs by zymography,Active,"Synthesis, crystal structure and effect of indeno[1,2-b]indole derivatives on prostate cancer in vitro. Potential effect against MMP-9.",Eur. J. Med. Chem.,2015,96,,"Lobo G, Monasterios M, Rodrigues J, Gamboa N, Capparelli MV, Martínez-Cuevas J, Lein M, Jung K, Abramjuk C, Charris J",,1470998,DTCT0024844,14097548,DTCC01552141,166161,40989
CHEMBL341702,P14780,,JKNLEZFIFUXSHW-OALUTQOASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643312,KI,,1358,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 1: lead identification.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105545,DTCT0024844,350186,DTCC00319027,1424916,6009
CHEMBL3417742,P14780,,GHWPTWVNZOSEBR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25686153,INHIBITION,>,90,%,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin),,"Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead.",J. Med. Chem.,2015,58,5,"Orbe J, Sánchez-Arias JA, Rabal O, Rodríguez JA, Salicio A, Ugarte A, Belzunce M, Xu M, Wu W, Tan H, Ma H, Páramo JA, Oyarzabal J",,1472775,DTCT0024844,14105409,DTCC01554158,1140955,61965
CHEMBL3417745,P14780,,PJTIDEQBVYCKIC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25686153,INHIBITION,>,90,%,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin),,"Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead.",J. Med. Chem.,2015,58,5,"Orbe J, Sánchez-Arias JA, Rabal O, Rodríguez JA, Salicio A, Ugarte A, Belzunce M, Xu M, Wu W, Tan H, Ma H, Páramo JA, Oyarzabal J",,1472775,DTCT0024844,14105410,DTCC01554161,1561095,61965
CHEMBL3417751,P14780,,ZUZGJCNWNOCKEB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25686153,INHIBITION,>,90,%,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin),,"Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead.",J. Med. Chem.,2015,58,5,"Orbe J, Sánchez-Arias JA, Rabal O, Rodríguez JA, Salicio A, Ugarte A, Belzunce M, Xu M, Wu W, Tan H, Ma H, Páramo JA, Oyarzabal J",,1472775,DTCT0024844,14105411,DTCC01554167,946456,61965
CHEMBL3417763,P14780,,MKCKIGOKGYMJOH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25686153,INHIBITION,>,90,%,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin),,"Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead.",J. Med. Chem.,2015,58,5,"Orbe J, Sánchez-Arias JA, Rabal O, Rodríguez JA, Salicio A, Ugarte A, Belzunce M, Xu M, Wu W, Tan H, Ma H, Páramo JA, Oyarzabal J",,1472775,DTCT0024844,14105412,DTCC01554179,1976632,61965
CHEMBL3417764,P14780,,ZQKGUWOTJVDTGX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25686153,INHIBITION,>,90,%,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin),,"Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead.",J. Med. Chem.,2015,58,5,"Orbe J, Sánchez-Arias JA, Rabal O, Rodríguez JA, Salicio A, Ugarte A, Belzunce M, Xu M, Wu W, Tan H, Ma H, Páramo JA, Oyarzabal J",,1472775,DTCT0024844,14105413,DTCC01554180,1943630,61965
CHEMBL341817,P14780,,DENDBTOOZOCPQJ-ZEQRLZLVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643313,KI,>,2128,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105546,DTCT0024844,1050701,DTCC00319355,2078018,6011
CHEMBL34206,P14780,,SYAAEFMNVNGONW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11378378,IC50,=,5,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2001,11,11,"Baxter AD, Bhogal R, Bird J, Keily JF, Manallack DT, Montana JG, Owen DA, Pitt WR, Watson RJ, Wills RE",,105531,DTCT0024844,1018308,DTCC00173335,290571,4214
CHEMBL342210,P14780,,CQRAUIRVDKNRIO-ZDUSSCGKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10579818,IC50,=,3.6,NM,,,,,,,,,,,,,,Inhibition of gelatinase-B (Matrix metalloprotease-9),,"Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.",J. Med. Chem.,1999,42,22,"Almstead NG, Bradley RS, Pikul S, De B, Natchus MG, Taiwo YO, Gu F, Williams LE, Hynd BA, Janusz MJ, Dunaway CM, Mieling GE",,105226,DTCT0024844,1367834,DTCC00325532,238281,15412
CHEMBL342248,P14780,,RRETZYBLLSHELY-LBPRGKRZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10579818,IC50,,,,,,,,,,,,,,,,,Inhibition of gelatinase-B (Matrix metalloprotease-9) (not determined),Not Determined,"Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.",J. Med. Chem.,1999,42,22,"Almstead NG, Bradley RS, Pikul S, De B, Natchus MG, Taiwo YO, Gu F, Williams LE, Hynd BA, Janusz MJ, Dunaway CM, Mieling GE",,105227,DTCT0024844,1384558,DTCC00326418,854146,15412
CHEMBL34259,P14780,METHOTREXATE,FBOZXECLQNJBKD-ZDUSSCGKSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7438661,DTCC00173293,1351113,46191
CHEMBL34259,P14780,METHOTREXATE,FBOZXECLQNJBKD-ZDUSSCGKSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7438662,DTCC00173293,1351113,46191
CHEMBL3426196,P14780,,VNXONCMUSHASMK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25835200,INHIBITION,,,,,cell_based,,,,,,,,,,,,Inhibition of MMP-9 in human MDA-MB-231 cells at 1 to 7.5 uM after 24 hrs by gelatin zymographic method,Active,Synthesis of ß-Carboline-Based N-Heterocyclic Carbenes and Their Antiproliferative and Antimetastatic Activities against Human Breast Cancer Cells.,J. Med. Chem.,2015,58,8,"Dighe SU, Khan S, Soni I, Jain P, Shukla S, Yadav R, Sen P, Meeran SM, Batra S",,1476323,DTCT0024844,14131314,DTCC01556764,201600,62217
CHEMBL3426201,P14780,,RPBXFJFZRHCIJS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25835200,INHIBITION,,,,,cell_based,,,,,,,,,,,,Inhibition of MMP-9 in human MDA-MB-231 cells at 1 to 5 uM after 24 hrs by gelatin zymographic method,Active,Synthesis of ß-Carboline-Based N-Heterocyclic Carbenes and Their Antiproliferative and Antimetastatic Activities against Human Breast Cancer Cells.,J. Med. Chem.,2015,58,8,"Dighe SU, Khan S, Soni I, Jain P, Shukla S, Yadav R, Sen P, Meeran SM, Batra S",,1476324,DTCT0024844,14131316,DTCC01556769,882247,62217
CHEMBL3426203,P14780,,LIJFKOIJICPMRL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25835200,INHIBITION,,,,,cell_based,,,,,,,,,,,,Inhibition of MMP-9 in human MDA-MB-231 cells at 1 to 7.5 uM after 24 hrs by gelatin zymographic method,Active,Synthesis of ß-Carboline-Based N-Heterocyclic Carbenes and Their Antiproliferative and Antimetastatic Activities against Human Breast Cancer Cells.,J. Med. Chem.,2015,58,8,"Dighe SU, Khan S, Soni I, Jain P, Shukla S, Yadav R, Sen P, Meeran SM, Batra S",,1476323,DTCT0024844,14131315,DTCC01556771,1561123,62217
CHEMBL342687,P14780,,LDBLVRGRVILSTH-ZEQRLZLVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643313,KI,>,2128,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105546,DTCT0024844,1049478,DTCC00318959,1015227,6011
CHEMBL342713,P14780,,ZISSKBQNAGMCRC-ROUUACIJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643312,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 1: lead identification.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105545,DTCT0024844,475103,DTCC00319026,162462,6009
CHEMBL342870,P14780,,TZGDIJWAFCVLEH-ZEQRLZLVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643313,KI,>,1656,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105546,DTCT0024844,1052049,DTCC00318936,303902,6011
CHEMBL343216,P14780,,BRSYUNJNYYWNHY-SZNDQCEHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12408705,KI,=,39,NM,,,,,,,,,,,,,,Affinity towards Matrix metalloprotease-9 (MMP-9),,"Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.",J. Med. Chem.,2002,45,23,"Duan JJ, Chen L, Wasserman ZR, Lu Z, Liu RQ, Covington MB, Qian M, Hardman KD, Magolda RL, Newton RC, Christ DD, Wexler RR, Decicco CP",,105374,DTCT0024844,710076,DTCC00333624,1371990,17028
CHEMBL34353,P14780,,LQNNJMYUCBDMHA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11378378,IC50,=,150,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2001,11,11,"Baxter AD, Bhogal R, Bird J, Keily JF, Manallack DT, Montana JG, Owen DA, Pitt WR, Watson RJ, Wills RE",,105531,DTCT0024844,1015892,DTCC00173334,1520107,4214
CHEMBL343548,P14780,,FGMZHMTZHZNKCA-ZEQRLZLVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643313,KI,>,465,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105546,DTCT0024844,1036684,DTCC00318906,1404241,6011
CHEMBL343721,P14780,,IKJVWZDFWJUWCD-ROUUACIJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643312,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 1: lead identification.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105545,DTCT0024844,479724,DTCC00318771,519366,6009
CHEMBL34411,P14780,,AXTUTMYETKQSJS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12668018,IC50,=,2,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease 9 (MMP-9).,,Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,8,"Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS",,105528,DTCT0024844,1252333,DTCC00174308,1784775,6276
CHEMBL34418,P14780,,ZZVSRSRVYMQUCW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12668018,IC50,=,9,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease 9 (MMP-9).,,Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,8,"Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS",,105528,DTCT0024844,1252337,DTCC00175216,1849351,6276
CHEMBL34431,P14780,CILOSTAMIDE,UIAYVIIHMORPSJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7349798,DTCC00173669,1894963,46191
CHEMBL34431,P14780,CILOSTAMIDE,UIAYVIIHMORPSJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7349799,DTCC00173669,1894963,46191
CHEMBL344843,P14780,,SXUMCLTUZSYGJQ-FPOVZHCZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643313,KI,>,2128,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105546,DTCT0024844,1019665,DTCC00317789,1533259,6011
CHEMBL345135,P14780,,ZYFGPOVGVCHWKW-AWEZNQCLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,>,1000000,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,627414,DTCC00350712,1274347,15057
CHEMBL345200,P14780,,ISNHZTGWQYYHNX-LJQANCHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,61,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,646290,DTCC00350698,1145547,15057
CHEMBL345238,P14780,,QWWYGFMPRICJFQ-JOCHJYFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,629623,DTCC00350851,1501237,15057
CHEMBL345244,P14780,,UAZHKINNICKCCP-WSMRJJHLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,12,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1427025,DTCC00353507,1915756,12880
CHEMBL345597,P14780,,NLABJQQLMHAJIL-JOCHJYFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,32,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,631634,DTCC00350721,1274348,15057
CHEMBL345640,P14780,,IHNXSBCQZROJCS-PKTZIBPZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,70,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1427028,DTCC00353657,595629,12880
CHEMBL345768,P14780,THIOURACIL,ZEMGGZBWXRYJHK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,44,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103800,DTCC00337992,1283745,43205
CHEMBL346118,P14780,,UPCAIRKRFXQRRM-HXUWFJFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,30,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,641834,DTCC00350479,1436534,15057
CHEMBL346118,P14780,,UPCAIRKRFXQRRM-HXUWFJFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17027271,IC50,=,0.0028,UG.ML-1,,,,,,,,,,,,,,Inhibition of human MMP9 by quenched fluorescense assay,,Natural inhibitors targeting osteoclast-mediated bone resorption.,Bioorg. Med. Chem. Lett.,2006,16,24,"Zeng GZ, Tan NH, Hao XJ, Mu QZ, Li RT",,425101,DTCT0024844,2017653,DTCC00350479,1437489,21854
CHEMBL346256,P14780,,RBLCSCFFNCADJO-DNOBIOAJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831905,KI,>,800,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,New strategy for antedrug application: development of metalloproteinase inhibitors as antipsoriatic drugs.,J. Med. Chem.,2002,45,4,"Sawa M, Tsukamoto T, Kiyoi T, Kurokawa K, Nakajima F, Nakada Y, Yokota K, Inoue Y, Kondo H, Yoshino K",,105379,DTCT0024844,577518,DTCC00345318,854711,17148
CHEMBL346256,P14780,,RBLCSCFFNCADJO-DNOBIOAJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11844676,KI,>,800,NM,,,,,,,,,,,,,,Inhibitory constant against recombinant human gelatinase B (Matrix metalloprotease-9),,Encounter with unexpected collagenase-1 selective inhibitor: switchover of inhibitor binding pocket induced by fluorine atom.,Bioorg. Med. Chem. Lett.,2002,12,4,"Sawa M, Kondo H, Nishimura S",,105400,DTCT0024844,1406538,DTCC00345318,842676,5346
CHEMBL346265,P14780,,JSUMSNXSMOEZBZ-JOCHJYFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,4.1,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,632930,DTCC00350909,1339620,15057
CHEMBL346575,P14780,,OATYFBJQDLKLNJ-QGFSVNGOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11844676,KI,=,24.1,NM,,,,,,,,,,,,,,Inhibitory constant against recombinant human gelatinase B (Matrix metalloprotease-9),,Encounter with unexpected collagenase-1 selective inhibitor: switchover of inhibitor binding pocket induced by fluorine atom.,Bioorg. Med. Chem. Lett.,2002,12,4,"Sawa M, Kondo H, Nishimura S",,105400,DTCT0024844,1437189,DTCC00345668,1229718,5346
CHEMBL34660,P14780,,NYEXRVCCRODWLT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12668018,IC50,=,8,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease 9 (MMP-9).,,Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,8,"Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS",,105528,DTCT0024844,1277919,DTCC00174410,107528,6276
CHEMBL34666,P14780,,NKZQXGVLDOUMQF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12668018,IC50,>,1000,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease 9 (MMP-9).,,Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,8,"Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS",,105528,DTCT0024844,1266671,DTCC00174313,1784777,6276
CHEMBL346920,P14780,,ZYFGPOVGVCHWKW-CQSZACIVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,730,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,644112,DTCC00350503,595582,15057
CHEMBL347021,P14780,,KFUADVZPCULIED-KWMCUTETSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11844676,KI,>,800,NM,,,,,,,,,,,,,,Inhibitory constant against recombinant human gelatinase B (Matrix metalloprotease-9),,Encounter with unexpected collagenase-1 selective inhibitor: switchover of inhibitor binding pocket induced by fluorine atom.,Bioorg. Med. Chem. Lett.,2002,12,4,"Sawa M, Kondo H, Nishimura S",,105400,DTCT0024844,1429475,DTCC00345408,1229719,5346
CHEMBL347138,P14780,,YKCFIBZBJVGNQA-HSZRJFAPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,17,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,645179,DTCC00350933,2046332,15057
CHEMBL347209,P14780,,SQYRXZTYDRVAMZ-UKPGIYTDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11844676,KI,=,14.2,NM,,,,,,,,,,,,,,Inhibitory constant against recombinant human gelatinase B (Matrix metalloprotease-9),,Encounter with unexpected collagenase-1 selective inhibitor: switchover of inhibitor binding pocket induced by fluorine atom.,Bioorg. Med. Chem. Lett.,2002,12,4,"Sawa M, Kondo H, Nishimura S",,105400,DTCT0024844,1441081,DTCC00345299,1360430,5346
CHEMBL347249,P14780,,PEYDLXUGPQEGEZ-SXOMAYOGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,88,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1424553,DTCC00353292,206212,12880
CHEMBL347440,P14780,,DZWVTHAIOWIVNT-ZQHDKMAOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831905,KI,=,3.68,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,New strategy for antedrug application: development of metalloproteinase inhibitors as antipsoriatic drugs.,J. Med. Chem.,2002,45,4,"Sawa M, Tsukamoto T, Kiyoi T, Kurokawa K, Nakajima F, Nakada Y, Yokota K, Inoue Y, Kondo H, Yoshino K",,105379,DTCT0024844,545047,DTCC00345289,886960,17148
CHEMBL347440,P14780,,DZWVTHAIOWIVNT-ZQHDKMAOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11844676,KI,=,3.68,NM,,,,,,,,,,,,,,Inhibitory constant against recombinant human gelatinase B (Matrix metalloprotease-9),,Encounter with unexpected collagenase-1 selective inhibitor: switchover of inhibitor binding pocket induced by fluorine atom.,Bioorg. Med. Chem. Lett.,2002,12,4,"Sawa M, Kondo H, Nishimura S",,105400,DTCT0024844,1408736,DTCC00345289,875202,5346
CHEMBL347612,P14780,,HAEIZFMEOGTXJF-LJQANCHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,1200,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,654239,DTCC00350594,2078400,15057
CHEMBL347658,P14780,,VTULZRYBMWMKHT-HXUWFJFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,580,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,636343,DTCC00350889,304323,15057
CHEMBL347847,P14780,,VZUNCTCGDYWBLP-AREMUKBSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,1320,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,638516,DTCC00350409,854434,15057
CHEMBL347883,P14780,,ZJYCLDORACELQK-AYLZSAKASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11844676,KI,>,800,NM,,,,,,,,,,,,,,Inhibitory constant against recombinant human gelatinase B (Matrix metalloprotease-9),,Encounter with unexpected collagenase-1 selective inhibitor: switchover of inhibitor binding pocket induced by fluorine atom.,Bioorg. Med. Chem. Lett.,2002,12,4,"Sawa M, Kondo H, Nishimura S",,105400,DTCT0024844,1407593,DTCC00345300,1936267,5346
CHEMBL34808,P14780,,ZORDGSDKVXISJV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12668018,IC50,=,2,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease 9 (MMP-9).,,Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,8,"Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS",,105528,DTCT0024844,1272306,DTCC00174442,1784776,6276
CHEMBL348088,P14780,,LIECXDHTIYQPFE-OAQYLSRUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,86,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,643000,DTCC00350458,1948342,15057
CHEMBL348129,P14780,,CFINSGSIDZSUDX-HXUWFJFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,840,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,635276,DTCC00350736,141921,15057
CHEMBL348335,P14780,,MDWFJTBWOFNAQX-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,40,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,646299,DTCC00351046,1662620,15057
CHEMBL348755,P14780,,QTEIHMLBMPKKIZ-RPWUZVMVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,101,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1408826,DTCC00353752,660389,12880
CHEMBL348784,P14780,,JYFVLQFUNILWSZ-SGNDLWITSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,580,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1436104,DTCC00353481,1404664,12880
CHEMBL348826,P14780,,ZPYLLHLHJRMHKM-RPBOFIJWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,15,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1419519,DTCC00352938,1915757,12880
CHEMBL349798,P14780,,IAOGVQLLIKLDLH-HSZRJFAPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,1100,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,631642,DTCC00350723,141922,15057
CHEMBL349800,P14780,,SHHQJBCQHBRODF-UXHICEINSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,30,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1420825,DTCC00352961,1786771,12880
CHEMBL35,P14780,FUROSEMIDE,ZZUFCTLCJUWOSV-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7324913,DTCC00133917,51472,46191
CHEMBL35,P14780,FUROSEMIDE,ZZUFCTLCJUWOSV-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7324914,DTCC00133917,51472,46191
CHEMBL350140,P14780,,DXBIPBLPCDPKOH-VJBWXMMDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,4.8,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1443449,DTCC00352840,1819328,12880
CHEMBL35059,P14780,,UQNGOLQNCCYWJR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12668018,IC50,=,595,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease 9 (MMP-9).,,Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,8,"Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS",,105528,DTCT0024844,1281222,DTCC00175184,107530,6276
CHEMBL350674,P14780,,DIYSOYKZARVATO-OAQYLSRUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,23,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,637384,DTCC00350578,1080567,15057
CHEMBL350789,P14780,,BOROQFAWARDBDC-RPBOFIJWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,6.7,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1411012,DTCC00353885,1176698,12880
CHEMBL351110,P14780,,WLJNZEMUQWWHSY-JOCHJYFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,641837,DTCC00350823,466181,15057
CHEMBL351344,P14780,,UEGCVARAGOWYMY-RVHYNSKXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,69,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1439745,DTCC00353588,304369,12880
CHEMBL351363,P14780,,DAGYTGGBYWXSKA-JOCHJYFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,180,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,629620,DTCC00350521,918437,15057
CHEMBL351806,P14780,,JBYHBQIDTNHWJF-FQEVSTJZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,800,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,636337,DTCC00350520,1241595,15057
CHEMBL351806,P14780,,JBYHBQIDTNHWJF-FQEVSTJZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24074025,IC50,=,310,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin),,Investigating the selectivity of metalloenzyme inhibitors.,J. Med. Chem.,2013,56,20,"Day JA, Cohen SM",,987739,DTCT0024844,12617814,DTCC00350520,1235642,56109
CHEMBL351887,P14780,,WSCXNRYTEGYOOB-VJBWXMMDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,59,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1408863,DTCC00353448,563379,12880
CHEMBL351888,P14780,,IZXHKSIJYAXOFC-DUGVZXTISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,14,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1438572,DTCC00352919,499093,12880
CHEMBL351968,P14780,,OMXCPVVQAGTBGJ-PVHODMMVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,3.8,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1413642,DTCC00352920,628129,12880
CHEMBL352066,P14780,,FICMSWGEHHLVLO-UXHICEINSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,82,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1431972,DTCC00353629,109555,12880
CHEMBL352068,P14780,,IPBUPOIKMNEPGS-ULNSLHSMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,4.5,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1429585,DTCC00353368,692555,12880
CHEMBL352231,P14780,,PAILGNIROCKBQU-ZNZIZOMTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,7.4,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1423507,DTCC00353537,1598163,12880
CHEMBL352232,P14780,,FRRDNYNCIZOSSI-ZNZIZOMTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,2.1,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1407673,DTCC00352800,1662652,12880
CHEMBL353074,P14780,,FKLZXNUKTHNKLL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION RATIO,~,23,%,,,,,,,,,,,,,,Inhibition of collagen IV degradation by matrix metalloprotease-9 at 10 uM,,,Bioorg. Med. Chem. Lett.,1997,7,7,,,105538,DTCT0024844,669357,DTCC00364453,1694935,2474
CHEMBL353074,P14780,,FKLZXNUKTHNKLL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION RATIO,~,41,%,,,,,,,,,,,,,,Inhibition of collagen IV degradation by matrix metalloprotease-9 at 100 uM,,,Bioorg. Med. Chem. Lett.,1997,7,7,,,105537,DTCT0024844,669358,DTCC00364453,1694935,2474
CHEMBL353382,P14780,,SRVJEHMEZKLIMK-TWOQFEAHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871551,KI,<,1,NM,,,,,,,,,,,,,,Binding affinity was evaluated against matrix metalloprotease-9,,Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,1998,8,7,"Jacobson IC, Reddy PG, Wasserman ZR, Hardman KD, Covington MB, Arner EC, Copeland RA, Decicco CP, Magolda RL",,105373,DTCT0024844,478552,DTCC00365163,681136,3059
CHEMBL353383,P14780,,ZLRCEJNKSZLBHZ-SFYKDHMMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871551,KI,>,213,NM,,,,,,,,,,,,,,Binding affinity was evaluated against matrix metalloprotease-9,,Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,1998,8,7,"Jacobson IC, Reddy PG, Wasserman ZR, Hardman KD, Covington MB, Arner EC, Copeland RA, Decicco CP, Magolda RL",,105373,DTCT0024844,488896,DTCC00364600,227275,3059
CHEMBL353536,P14780,,SQYRXZTYDRVAMZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,=,14.2,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1409287,DTCC00372444,32662,17147
CHEMBL35433,P14780,,KGVROUUAKSRCEI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12668018,IC50,=,4,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease 9 (MMP-9).,,Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,8,"Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS",,105528,DTCT0024844,1270177,DTCC00174561,1046111,6276
CHEMBL3545252,P14780,DOCETAXEL HYDRATE,XCDIRYDKECHIPE-QHEQPUDQSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7366314,DTCC01631667,51465,46191
CHEMBL3545252,P14780,DOCETAXEL HYDRATE,XCDIRYDKECHIPE-QHEQPUDQSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7366315,DTCC01631667,51465,46191
CHEMBL35476,P14780,,CTGVDIGFCHCCJU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11378378,IC50,=,400,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2001,11,11,"Baxter AD, Bhogal R, Bird J, Keily JF, Manallack DT, Montana JG, Owen DA, Pitt WR, Watson RJ, Wills RE",,105531,DTCT0024844,1042180,DTCC00173371,1002127,4214
CHEMBL355418,P14780,,XCMRAHNFEHFBSX-DZNDNOMISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871551,KI,=,1,NM,,,,,,,,,,,,,,Binding affinity was evaluated against matrix metalloprotease-9,,Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,1998,8,7,"Jacobson IC, Reddy PG, Wasserman ZR, Hardman KD, Covington MB, Arner EC, Copeland RA, Decicco CP, Magolda RL",,105373,DTCT0024844,493849,DTCC00364599,454326,3059
CHEMBL355727,P14780,,FYJZCIXAWTVIOU-IUCAKERBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,INHIBITION,=,35,%,,,,,,,,,,,,,,Percent remaining enzyme activity (RA) in human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105368,DTCT0024844,1096955,DTCC00371202,2067064,5419
CHEMBL355727,P14780,,FYJZCIXAWTVIOU-IUCAKERBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,KI,=,9000,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105399,DTCT0024844,1096954,DTCC00371202,2067064,5419
CHEMBL355745,P14780,,KZEKPHQHOHAGJZ-ZYLNGJIFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871551,KI,=,4,NM,,,,,,,,,,,,,,Binding affinity was evaluated against matrix metalloprotease-9,,Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,1998,8,7,"Jacobson IC, Reddy PG, Wasserman ZR, Hardman KD, Covington MB, Arner EC, Copeland RA, Decicco CP, Magolda RL",,105373,DTCT0024844,488893,DTCC00365410,162990,3059
CHEMBL355752,P14780,,GPPXSZZXGYMBHW-QKFKETGDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9888835,IC50,=,32.5,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease 9,,Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.,J. Med. Chem.,1999,42,1,"Pikul S, McDow Dunham KL, Almstead NG, De B, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Mieling GE",,105359,DTCT0024844,1144685,DTCC00372315,854716,15162
CHEMBL355756,P14780,,JAWBGTRXBCUBLS-JTQLQIEISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,INHIBITION,=,25,%,,,,,,,,,,,,,,Percent remaining enzyme activity (RA) in human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105368,DTCT0024844,1111695,DTCC00371502,1904588,5419
CHEMBL355756,P14780,,JAWBGTRXBCUBLS-JTQLQIEISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,KI,=,14000,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105399,DTCT0024844,1111694,DTCC00371502,1904588,5419
CHEMBL355797,P14780,,QSFJZGINKPYVRC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,=,0.08,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1431013,DTCC00370549,109746,17147
CHEMBL3559671,P14780,POLYVINYL ALCOHOL,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7396119,DTCC01642718,1155684,46191
CHEMBL3559671,P14780,POLYVINYL ALCOHOL,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7396120,DTCC01642718,1155684,46191
CHEMBL35606,P14780,,KQYGUXCNMQFLRN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12668018,IC50,=,7,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease 9 (MMP-9).,,Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,8,"Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS",,105528,DTCT0024844,1281226,DTCC00174582,1304976,6276
CHEMBL356124,P14780,,ZJOQXNGTEXFLLO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14684295,IC50,=,4100,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,1,"Ma D, Wu W, Yang G, Li J, Li J, Ye Q",,105527,DTCT0024844,880004,DTCC00334202,173919,6330
CHEMBL356975,P14780,,GDUSADXUOJTTQS-YGRLFVJLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12408705,KI,=,242,NM,,,,,,,,,,,,,,Affinity towards Matrix metalloprotease-9 (MMP-9),,"Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.",J. Med. Chem.,2002,45,23,"Duan JJ, Chen L, Wasserman ZR, Lu Z, Liu RQ, Covington MB, Qian M, Hardman KD, Magolda RL, Newton RC, Christ DD, Wexler RR, Decicco CP",,105374,DTCT0024844,727537,DTCC00333540,1404419,17028
CHEMBL35707,P14780,,CBFHYDZLOMACOM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12668018,IC50,=,2,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease 9 (MMP-9).,,Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,8,"Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS",,105528,DTCT0024844,1282474,DTCC00175185,204122,6276
CHEMBL357675,P14780,,BDLXCRNZHKNUCS-VFNWGFHPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12408705,KI,=,29,NM,,,,,,,,,,,,,,Affinity towards Matrix metalloprotease-9 (MMP-9),,"Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.",J. Med. Chem.,2002,45,23,"Duan JJ, Chen L, Wasserman ZR, Lu Z, Liu RQ, Covington MB, Qian M, Hardman KD, Magolda RL, Newton RC, Christ DD, Wexler RR, Decicco CP",,105374,DTCT0024844,711172,DTCC00333595,1501022,17028
CHEMBL357995,P14780,BOPINDOLOL,UUOJIACWOAYWEZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7280230,DTCC00343658,510298,46191
CHEMBL357995,P14780,BOPINDOLOL,UUOJIACWOAYWEZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7280231,DTCC00343658,510298,46191
CHEMBL358149,P14780,,YYRRVFYCIQQYHU-CQGGRAHPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11844676,KI,=,483,NM,,,,,,,,,,,,,,Inhibitory constant against recombinant human gelatinase B (Matrix metalloprotease-9),,Encounter with unexpected collagenase-1 selective inhibitor: switchover of inhibitor binding pocket induced by fluorine atom.,Bioorg. Med. Chem. Lett.,2002,12,4,"Sawa M, Kondo H, Nishimura S",,105400,DTCT0024844,1441078,DTCC00345847,1197503,5346
CHEMBL358539,P14780,,OVUDWXYTKUKYAX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14684295,IC50,=,30,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,1,"Ma D, Wu W, Yang G, Li J, Li J, Ye Q",,105527,DTCT0024844,880014,DTCC00334156,1565409,6330
CHEMBL3585671,P14780,,LQIRFLYUTCRGAT-FLFKKZLDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25907368,INHIBITION,,,,,cell_based,,,,,,,,,,,,Inhibition of MMP-9 activity in human HT1080 cells at 10 uM by gelatin zymography,Not Active,"Synthesis and discovery of (I-3,II-3)-biacacetin as a novel non-zinc binding inhibitor of MMP-2 and MMP-9.",Bioorg. Med. Chem.,2015,23,13,"Nanjan P, Nambiar J, Nair BG, Banerji A",,1501255,DTCT0024844,14455619,DTCC01648639,1868283,62853
CHEMBL3585672,P14780,,IULHPNNAVFLEJM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25907368,INHIBITION,,,,,cell_based,,,,,,,,,,,,Inhibition of MMP-9 activity in human HT1080 cells by gelatin zymography,Not Active,"Synthesis and discovery of (I-3,II-3)-biacacetin as a novel non-zinc binding inhibitor of MMP-2 and MMP-9.",Bioorg. Med. Chem.,2015,23,13,"Nanjan P, Nambiar J, Nair BG, Banerji A",,1501257,DTCT0024844,14455610,DTCC01648640,1389372,62853
CHEMBL3585673,P14780,,NWIQXDRMJSLWLD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25907368,INHIBITION,,,,,cell_based,,,,,,,,,,,,Inhibition of MMP-9 activity in human HT1080 cells by gelatin zymography,Not Active,"Synthesis and discovery of (I-3,II-3)-biacacetin as a novel non-zinc binding inhibitor of MMP-2 and MMP-9.",Bioorg. Med. Chem.,2015,23,13,"Nanjan P, Nambiar J, Nair BG, Banerji A",,1501257,DTCT0024844,14455609,DTCC01648641,1421696,62853
CHEMBL3585674,P14780,,UZJOXJSGSOVPMN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25907368,INHIBITION,,,,,cell_based,,,,,,,,,,,,Inhibition of MMP-9 activity in human HT1080 cells by gelatin zymography,Not Active,"Synthesis and discovery of (I-3,II-3)-biacacetin as a novel non-zinc binding inhibitor of MMP-2 and MMP-9.",Bioorg. Med. Chem.,2015,23,13,"Nanjan P, Nambiar J, Nair BG, Banerji A",,1501257,DTCT0024844,14455608,DTCC01648642,516013,62853
CHEMBL3585675,P14780,,UCJISPPCLJRDKX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25907368,INHIBITION,,,,,cell_based,,,,,,,,,,,,Inhibition of MMP-9 activity in human HT1080 cells by gelatin zymography,Not Active,"Synthesis and discovery of (I-3,II-3)-biacacetin as a novel non-zinc binding inhibitor of MMP-2 and MMP-9.",Bioorg. Med. Chem.,2015,23,13,"Nanjan P, Nambiar J, Nair BG, Banerji A",,1501257,DTCT0024844,14455607,DTCC01648643,483754,62853
CHEMBL3585676,P14780,,IOHWFKJACXNPSY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25907368,INHIBITION,,,,,cell_based,,,,,,,,,,,,Inhibition of MMP-9 activity in human HT1080 cells at 10 uM by gelatin zymography,Not Active,"Synthesis and discovery of (I-3,II-3)-biacacetin as a novel non-zinc binding inhibitor of MMP-2 and MMP-9.",Bioorg. Med. Chem.,2015,23,13,"Nanjan P, Nambiar J, Nair BG, Banerji A",,1501255,DTCT0024844,14455618,DTCC01648644,1518409,62853
CHEMBL3585678,P14780,,DMOBTVZLAWXNMN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25907368,INHIBITION,=,90,%,,cell_based,,,,,,,,,,,,Inhibition of MMP-9 activity in human HT1080 cells at 10 uM by gelatin zymography,,"Synthesis and discovery of (I-3,II-3)-biacacetin as a novel non-zinc binding inhibitor of MMP-2 and MMP-9.",Bioorg. Med. Chem.,2015,23,13,"Nanjan P, Nambiar J, Nair BG, Banerji A",,1501255,DTCT0024844,14455617,DTCC01648646,1771397,62853
CHEMBL3585678,P14780,,DMOBTVZLAWXNMN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25907368,INHIBITION,=,90,%,,cell_based,,,,,,,,,,,,Inhibition of MMP-9 activity in human HT1080 cells at 5 uM by gelatin zymography,,"Synthesis and discovery of (I-3,II-3)-biacacetin as a novel non-zinc binding inhibitor of MMP-2 and MMP-9.",Bioorg. Med. Chem.,2015,23,13,"Nanjan P, Nambiar J, Nair BG, Banerji A",,1501261,DTCT0024844,14455599,DTCC01648646,1771397,62853
CHEMBL3585678,P14780,,DMOBTVZLAWXNMN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25907368,INHIBITION,,,,,cell_based,,,,,,,,,,,,Inhibition of MMP-9 activity in human HT1080 cells by gelatin zymography,Dose-dependent effect,"Synthesis and discovery of (I-3,II-3)-biacacetin as a novel non-zinc binding inhibitor of MMP-2 and MMP-9.",Bioorg. Med. Chem.,2015,23,13,"Nanjan P, Nambiar J, Nair BG, Banerji A",,1501257,DTCT0024844,14455605,DTCC01648646,1771397,62853
CHEMBL3585759,P14780,,FAOKYLWYCBQYDT-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25921268,IC50,=,8800,NM,,,,,,,,,,,,,,"Inhibition of human active MMP9 using (7-methoxycoumarin-4-yl) acetyl pro-Leu-Gly-Leu-[3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl]-Ala-Arg-NH2 fluorogenic substrate assessed as fluorescent product release",,New matrix metalloproteinase inhibitors based on ¿-fluorinated a-aminocarboxylic and a-aminohydroxamic acids.,Bioorg. Med. Chem.,2015,23,13,"Behrends M, Wagner S, Kopka K, Schober O, Schäfers M, Kumbhar S, Waller M, Haufe G",,1501468,DTCT0024844,14456763,DTCC01648728,753888,62860
CHEMBL3585760,P14780,,FAOKYLWYCBQYDT-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25921268,IC50,=,100000,NM,,,,,,,,,,,,,,"Inhibition of human active MMP9 using (7-methoxycoumarin-4-yl) acetyl pro-Leu-Gly-Leu-[3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl]-Ala-Arg-NH2 fluorogenic substrate assessed as fluorescent product release",,New matrix metalloproteinase inhibitors based on ¿-fluorinated a-aminocarboxylic and a-aminohydroxamic acids.,Bioorg. Med. Chem.,2015,23,13,"Behrends M, Wagner S, Kopka K, Schober O, Schäfers M, Kumbhar S, Waller M, Haufe G",,1501468,DTCT0024844,14456764,DTCC01648729,1238347,62860
CHEMBL3585761,P14780,,UOJWLSDRILDSBX-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25921268,IC50,=,4.6,NM,,,,,,,,,,,,,,"Inhibition of human active MMP9 using (7-methoxycoumarin-4-yl) acetyl pro-Leu-Gly-Leu-[3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl]-Ala-Arg-NH2 fluorogenic substrate assessed as fluorescent product release",,New matrix metalloproteinase inhibitors based on ¿-fluorinated a-aminocarboxylic and a-aminohydroxamic acids.,Bioorg. Med. Chem.,2015,23,13,"Behrends M, Wagner S, Kopka K, Schober O, Schäfers M, Kumbhar S, Waller M, Haufe G",,1501468,DTCT0024844,14456765,DTCC01648730,2043261,62860
CHEMBL3585762,P14780,,UOJWLSDRILDSBX-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25921268,IC50,=,700,NM,,,,,,,,,,,,,,"Inhibition of human active MMP9 using (7-methoxycoumarin-4-yl) acetyl pro-Leu-Gly-Leu-[3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl]-Ala-Arg-NH2 fluorogenic substrate assessed as fluorescent product release",,New matrix metalloproteinase inhibitors based on ¿-fluorinated a-aminocarboxylic and a-aminohydroxamic acids.,Bioorg. Med. Chem.,2015,23,13,"Behrends M, Wagner S, Kopka K, Schober O, Schäfers M, Kumbhar S, Waller M, Haufe G",,1501468,DTCT0024844,14456766,DTCC01648731,138718,62860
CHEMBL3585763,P14780,,ZZNYWQSQHHAWBQ-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25921268,IC50,=,100000,NM,,,,,,,,,,,,,,"Inhibition of human active MMP9 using (7-methoxycoumarin-4-yl) acetyl pro-Leu-Gly-Leu-[3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl]-Ala-Arg-NH2 fluorogenic substrate assessed as fluorescent product release",,New matrix metalloproteinase inhibitors based on ¿-fluorinated a-aminocarboxylic and a-aminohydroxamic acids.,Bioorg. Med. Chem.,2015,23,13,"Behrends M, Wagner S, Kopka K, Schober O, Schäfers M, Kumbhar S, Waller M, Haufe G",,1501468,DTCT0024844,14456767,DTCC01648732,1142243,62860
CHEMBL3585764,P14780,,ZZNYWQSQHHAWBQ-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25921268,IC50,=,100000,NM,,,,,,,,,,,,,,"Inhibition of human active MMP9 using (7-methoxycoumarin-4-yl) acetyl pro-Leu-Gly-Leu-[3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl]-Ala-Arg-NH2 fluorogenic substrate assessed as fluorescent product release",,New matrix metalloproteinase inhibitors based on ¿-fluorinated a-aminocarboxylic and a-aminohydroxamic acids.,Bioorg. Med. Chem.,2015,23,13,"Behrends M, Wagner S, Kopka K, Schober O, Schäfers M, Kumbhar S, Waller M, Haufe G",,1501468,DTCT0024844,14456768,DTCC01648733,202839,62860
CHEMBL3585765,P14780,,VKRNXLAHYIGGFO-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25921268,IC50,=,12.3,NM,,,,,,,,,,,,,,"Inhibition of human active MMP9 using (7-methoxycoumarin-4-yl) acetyl pro-Leu-Gly-Leu-[3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl]-Ala-Arg-NH2 fluorogenic substrate assessed as fluorescent product release",,New matrix metalloproteinase inhibitors based on ¿-fluorinated a-aminocarboxylic and a-aminohydroxamic acids.,Bioorg. Med. Chem.,2015,23,13,"Behrends M, Wagner S, Kopka K, Schober O, Schäfers M, Kumbhar S, Waller M, Haufe G",,1501468,DTCT0024844,14456769,DTCC01648734,657216,62860
CHEMBL3585766,P14780,,VKRNXLAHYIGGFO-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25921268,IC50,=,3,NM,,,,,,,,,,,,,,"Inhibition of human active MMP9 using (7-methoxycoumarin-4-yl) acetyl pro-Leu-Gly-Leu-[3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl]-Ala-Arg-NH2 fluorogenic substrate assessed as fluorescent product release",,New matrix metalloproteinase inhibitors based on ¿-fluorinated a-aminocarboxylic and a-aminohydroxamic acids.,Bioorg. Med. Chem.,2015,23,13,"Behrends M, Wagner S, Kopka K, Schober O, Schäfers M, Kumbhar S, Waller M, Haufe G",,1501468,DTCT0024844,14456770,DTCC01648735,786014,62860
CHEMBL3585767,P14780,,FFXVPKULVPXOFT-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25921268,IC50,=,1700,NM,,,,,,,,,,,,,,"Inhibition of human active MMP9 using (7-methoxycoumarin-4-yl) acetyl pro-Leu-Gly-Leu-[3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl]-Ala-Arg-NH2 fluorogenic substrate assessed as fluorescent product release",,New matrix metalloproteinase inhibitors based on ¿-fluorinated a-aminocarboxylic and a-aminohydroxamic acids.,Bioorg. Med. Chem.,2015,23,13,"Behrends M, Wagner S, Kopka K, Schober O, Schäfers M, Kumbhar S, Waller M, Haufe G",,1501468,DTCT0024844,14456771,DTCC01648736,1433392,62860
CHEMBL3585768,P14780,,FFXVPKULVPXOFT-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25921268,IC50,=,100000,NM,,,,,,,,,,,,,,"Inhibition of human active MMP9 using (7-methoxycoumarin-4-yl) acetyl pro-Leu-Gly-Leu-[3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl]-Ala-Arg-NH2 fluorogenic substrate assessed as fluorescent product release",,New matrix metalloproteinase inhibitors based on ¿-fluorinated a-aminocarboxylic and a-aminohydroxamic acids.,Bioorg. Med. Chem.,2015,23,13,"Behrends M, Wagner S, Kopka K, Schober O, Schäfers M, Kumbhar S, Waller M, Haufe G",,1501468,DTCT0024844,14456772,DTCC01648737,1401376,62860
CHEMBL3585769,P14780,,ZJBBKJOUNAIIJA-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25921268,IC50,=,0.54,NM,,,,,,,,,,,,,,"Inhibition of human active MMP9 using (7-methoxycoumarin-4-yl) acetyl pro-Leu-Gly-Leu-[3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl]-Ala-Arg-NH2 fluorogenic substrate assessed as fluorescent product release",,New matrix metalloproteinase inhibitors based on ¿-fluorinated a-aminocarboxylic and a-aminohydroxamic acids.,Bioorg. Med. Chem.,2015,23,13,"Behrends M, Wagner S, Kopka K, Schober O, Schäfers M, Kumbhar S, Waller M, Haufe G",,1501468,DTCT0024844,14456774,DTCC01648738,1912533,62860
CHEMBL3585770,P14780,,ZJBBKJOUNAIIJA-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25921268,IC50,=,6.4,NM,,,,,,,,,,,,,,"Inhibition of human active MMP9 using (7-methoxycoumarin-4-yl) acetyl pro-Leu-Gly-Leu-[3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl]-Ala-Arg-NH2 fluorogenic substrate assessed as fluorescent product release",,New matrix metalloproteinase inhibitors based on ¿-fluorinated a-aminocarboxylic and a-aminohydroxamic acids.,Bioorg. Med. Chem.,2015,23,13,"Behrends M, Wagner S, Kopka K, Schober O, Schäfers M, Kumbhar S, Waller M, Haufe G",,1501468,DTCT0024844,14456775,DTCC01648739,268028,62860
CHEMBL3585771,P14780,,OLYCJZWCGNXHMV-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25921268,IC50,=,100000,NM,,,,,,,,,,,,,,"Inhibition of human active MMP9 using (7-methoxycoumarin-4-yl) acetyl pro-Leu-Gly-Leu-[3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl]-Ala-Arg-NH2 fluorogenic substrate assessed as fluorescent product release",,New matrix metalloproteinase inhibitors based on ¿-fluorinated a-aminocarboxylic and a-aminohydroxamic acids.,Bioorg. Med. Chem.,2015,23,13,"Behrends M, Wagner S, Kopka K, Schober O, Schäfers M, Kumbhar S, Waller M, Haufe G",,1501468,DTCT0024844,14456776,DTCC01648740,1271106,62860
CHEMBL3585772,P14780,,OLYCJZWCGNXHMV-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25921268,IC50,=,100000,NM,,,,,,,,,,,,,,"Inhibition of human active MMP9 using (7-methoxycoumarin-4-yl) acetyl pro-Leu-Gly-Leu-[3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl]-Ala-Arg-NH2 fluorogenic substrate assessed as fluorescent product release",,New matrix metalloproteinase inhibitors based on ¿-fluorinated a-aminocarboxylic and a-aminohydroxamic acids.,Bioorg. Med. Chem.,2015,23,13,"Behrends M, Wagner S, Kopka K, Schober O, Schäfers M, Kumbhar S, Waller M, Haufe G",,1501468,DTCT0024844,14456777,DTCC01648741,1783523,62860
CHEMBL3585773,P14780,,FWGLYVKGDMYORU-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25921268,IC50,=,8.3,NM,,,,,,,,,,,,,,"Inhibition of human active MMP9 using (7-methoxycoumarin-4-yl) acetyl pro-Leu-Gly-Leu-[3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl]-Ala-Arg-NH2 fluorogenic substrate assessed as fluorescent product release",,New matrix metalloproteinase inhibitors based on ¿-fluorinated a-aminocarboxylic and a-aminohydroxamic acids.,Bioorg. Med. Chem.,2015,23,13,"Behrends M, Wagner S, Kopka K, Schober O, Schäfers M, Kumbhar S, Waller M, Haufe G",,1501468,DTCT0024844,14456778,DTCC01648742,1401377,62860
CHEMBL3585774,P14780,,FWGLYVKGDMYORU-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25921268,IC50,=,4.9,NM,,,,,,,,,,,,,,"Inhibition of human active MMP9 using (7-methoxycoumarin-4-yl) acetyl pro-Leu-Gly-Leu-[3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl]-Ala-Arg-NH2 fluorogenic substrate assessed as fluorescent product release",,New matrix metalloproteinase inhibitors based on ¿-fluorinated a-aminocarboxylic and a-aminohydroxamic acids.,Bioorg. Med. Chem.,2015,23,13,"Behrends M, Wagner S, Kopka K, Schober O, Schäfers M, Kumbhar S, Waller M, Haufe G",,1501468,DTCT0024844,14456779,DTCC01648743,235396,62860
CHEMBL359251,P14780,,GOWUYJZGNHYGEC-SZNDQCEHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12408705,KI,=,40,NM,,,,,,,,,,,,,,Affinity towards Matrix metalloprotease-9 (MMP-9),,"Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.",J. Med. Chem.,2002,45,23,"Duan JJ, Chen L, Wasserman ZR, Lu Z, Liu RQ, Covington MB, Qian M, Hardman KD, Magolda RL, Newton RC, Christ DD, Wexler RR, Decicco CP",,105374,DTCT0024844,706630,DTCC00333183,1339394,17028
CHEMBL3593549,P14780,,DFINJLCZWBDBQX-KDNYSNCWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26192023,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin) using Mca-KLPGL-Dnp-AR as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorescence assay,,SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.,J. Med. Chem.,2015,58,15,"Knapinska AM, Dreymuller D, Ludwig A, Smith L, Golubkov V, Sohail A, Fridman R, Giulianotti M, LaVoi TM, Houghten RA, Fields GB, Minond D",,1505521,DTCT0024844,14475897,DTCC01651896,333622,63066
CHEMBL3593549,P14780,,DFINJLCZWBDBQX-KDNYSNCWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26192023,INHIBITION,=,0,%,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin) using Mca-KLPGL-Dnp-AR as substrate at 100 uM preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorescence assay relative to control,,SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.,J. Med. Chem.,2015,58,15,"Knapinska AM, Dreymuller D, Ludwig A, Smith L, Golubkov V, Sohail A, Fridman R, Giulianotti M, LaVoi TM, Houghten RA, Fields GB, Minond D",,1505525,DTCT0024844,14475966,DTCC01651896,333622,63066
CHEMBL3593550,P14780,,SWCOKZUOBSVFCL-NROLRVEYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26192023,IC50,,,,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin) using Mca-KLPGL-Dnp-AR as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorescence assay,Not Determined,SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.,J. Med. Chem.,2015,58,15,"Knapinska AM, Dreymuller D, Ludwig A, Smith L, Golubkov V, Sohail A, Fridman R, Giulianotti M, LaVoi TM, Houghten RA, Fields GB, Minond D",,1505521,DTCT0024844,14475896,DTCC01651897,2010871,63066
CHEMBL3593551,P14780,,ZEPWGRQYGKUKNA-KFIZHRIMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26192023,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin) using Mca-KLPGL-Dnp-AR as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorescence assay,,SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.,J. Med. Chem.,2015,58,15,"Knapinska AM, Dreymuller D, Ludwig A, Smith L, Golubkov V, Sohail A, Fridman R, Giulianotti M, LaVoi TM, Houghten RA, Fields GB, Minond D",,1505521,DTCT0024844,14475894,DTCC01651898,818354,63066
CHEMBL3593551,P14780,,ZEPWGRQYGKUKNA-KFIZHRIMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26192023,INHIBITION,=,0,%,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin) using Mca-KLPGL-Dnp-AR as substrate at 100 uM preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorescence assay relative to control,,SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.,J. Med. Chem.,2015,58,15,"Knapinska AM, Dreymuller D, Ludwig A, Smith L, Golubkov V, Sohail A, Fridman R, Giulianotti M, LaVoi TM, Houghten RA, Fields GB, Minond D",,1505525,DTCT0024844,14475968,DTCC01651898,818354,63066
CHEMBL3593552,P14780,,QABDTPJMJYQBCF-KQQMQGIYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26192023,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin) using Mca-KLPGL-Dnp-AR as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorescence assay,,SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.,J. Med. Chem.,2015,58,15,"Knapinska AM, Dreymuller D, Ludwig A, Smith L, Golubkov V, Sohail A, Fridman R, Giulianotti M, LaVoi TM, Houghten RA, Fields GB, Minond D",,1505521,DTCT0024844,14475892,DTCC01651899,980185,63066
CHEMBL3593552,P14780,,QABDTPJMJYQBCF-KQQMQGIYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26192023,INHIBITION,=,0,%,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin) using Mca-KLPGL-Dnp-AR as substrate at 100 uM preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorescence assay relative to control,,SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.,J. Med. Chem.,2015,58,15,"Knapinska AM, Dreymuller D, Ludwig A, Smith L, Golubkov V, Sohail A, Fridman R, Giulianotti M, LaVoi TM, Houghten RA, Fields GB, Minond D",,1505525,DTCT0024844,14475970,DTCC01651899,980185,63066
CHEMBL359424,P14780,,MJJPSHCMTYJCDM-PXAZEXFGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12408705,KI,=,11,NM,,,,,,,,,,,,,,Affinity towards Matrix metalloprotease-9 (MMP-9),,"Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.",J. Med. Chem.,2002,45,23,"Duan JJ, Chen L, Wasserman ZR, Lu Z, Liu RQ, Covington MB, Qian M, Hardman KD, Magolda RL, Newton RC, Christ DD, Wexler RR, Decicco CP",,105374,DTCT0024844,694966,DTCC00333516,854231,17028
CHEMBL359569,P14780,,QNVRWDPZVVAENF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1768822,DTCC00387628,271775,18194
CHEMBL359625,P14780,,UJCQVXJYOKSWGB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1767158,DTCC00387768,304744,18194
CHEMBL359716,P14780,,RAGDORVOHODYFH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15686921,KI,=,1.2,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13).,Bioorg. Med. Chem. Lett.,2005,15,4,"Kim SH, Pudzianowski AT, Leavitt KJ, Barbosa J, McDonnell PA, Metzler WJ, Rankin BM, Liu R, Vaccaro W, Pitts W",,302481,DTCT0024844,1744794,DTCC00381579,1586741,18787
CHEMBL359716,P14780,,RAGDORVOHODYFH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,1.2,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258726,DTCC00381579,1587774,24803
CHEMBL360193,P14780,,ZWTFDOKRWKJVER-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15908214,KI,>,2130,NM,,,,,,,,,,,,,,In vitro binding affinity against matrix metalloprotease 9,,"Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.",Bioorg. Med. Chem. Lett.,2005,15,12,"Duan JJ, Lu Z, Wasserman ZR, Liu RQ, Covington MB, Decicco CP",,302347,DTCT0024844,1800219,DTCC00398283,358362,16433
CHEMBL36021,P14780,,BYFPJSOGSJVRJE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12668018,IC50,=,11,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease 9 (MMP-9).,,Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,8,"Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS",,105528,DTCT0024844,1265558,DTCC00174822,107531,6276
CHEMBL360435,P14780,,XBNDSEPFWMXMHZ-RYUDHWBXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15341955,KI,>,2000000,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9,,Synthesis and evaluation of novel oxazoline MMP inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,19,"Cook GR, Manivannan E, Underdahl T, Lukacova V, Zhang Y, Balaz S",,302310,DTCT0024844,1771843,DTCC00389419,1883976,17054
CHEMBL360509,P14780,,WXVPWVLIIPQGLY-QWRGUYRKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15341955,KI,>,4000000,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9,,Synthesis and evaluation of novel oxazoline MMP inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,19,"Cook GR, Manivannan E, Underdahl T, Lukacova V, Zhang Y, Balaz S",,302310,DTCT0024844,1771846,DTCC00389512,369983,17054
CHEMBL360609,P14780,,YKSIUQZREKHXCH-AEFFLSMTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15369398,INHIBITION,=,54,%,,,,,,,,,,,,,,Inhibition of MMP-9 (matrix metalloprotease) at 1 uM,,Macrocyclic inhibitors for peptide deformylase: a structure-activity relationship study of the ring size.,J. Med. Chem.,2004,47,20,"Hu X, Nguyen KT, Jiang VC, Lofland D, Moser HE, Pei D",,307797,DTCT0024844,1789960,DTCC00392956,616784,19089
CHEMBL360609,P14780,,YKSIUQZREKHXCH-AEFFLSMTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15369398,INHIBITION,=,89,%,,,,,,,,,,,,,,Inhibition of MMP-9 (matrix metalloprotease) at 10 uM,,Macrocyclic inhibitors for peptide deformylase: a structure-activity relationship study of the ring size.,J. Med. Chem.,2004,47,20,"Hu X, Nguyen KT, Jiang VC, Lofland D, Moser HE, Pei D",,307804,DTCT0024844,1789961,DTCC00392956,616784,19089
CHEMBL360860,P14780,,IZFSBROZVUFQDL-BQBZGAKWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15341955,KI,,,,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9; NA denotes no activity upto solubility limit,No Activity,Synthesis and evaluation of novel oxazoline MMP inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,19,"Cook GR, Manivannan E, Underdahl T, Lukacova V, Zhang Y, Balaz S",,303050,DTCT0024844,1771457,DTCC00389413,142339,17054
CHEMBL360868,P14780,,ALWUFFCDYONNPP-JSGCOSHPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15341955,KI,>,100000,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9,,Synthesis and evaluation of novel oxazoline MMP inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,19,"Cook GR, Manivannan E, Underdahl T, Lukacova V, Zhang Y, Balaz S",,302310,DTCT0024844,1770688,DTCC00389493,1048477,17054
CHEMBL361034,P14780,,IKZDCRKJMJCCPS-ONGXEEELSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15341955,KI,>,100000,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9,,Synthesis and evaluation of novel oxazoline MMP inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,19,"Cook GR, Manivannan E, Underdahl T, Lukacova V, Zhang Y, Balaz S",,302310,DTCT0024844,1770674,DTCC00389435,1883974,17054
CHEMBL361376,P14780,,JTEXDSSTTHRJGK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1769265,DTCC00387599,1015992,18194
CHEMBL361449,P14780,,NKJYIBRDRYQXFN-MOPGFXCFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15369398,INHIBITION,=,8,%,,,,,,,,,,,,,,Inhibition of MMP-9 (matrix metalloprotease) at 1 uM,,Macrocyclic inhibitors for peptide deformylase: a structure-activity relationship study of the ring size.,J. Med. Chem.,2004,47,20,"Hu X, Nguyen KT, Jiang VC, Lofland D, Moser HE, Pei D",,307797,DTCT0024844,1791006,DTCC00392763,1295652,19089
CHEMBL361449,P14780,,NKJYIBRDRYQXFN-MOPGFXCFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15369398,INHIBITION,=,8,%,,,,,,,,,,,,,,Inhibition of MMP-9 (matrix metalloprotease) at 10 uM,,Macrocyclic inhibitors for peptide deformylase: a structure-activity relationship study of the ring size.,J. Med. Chem.,2004,47,20,"Hu X, Nguyen KT, Jiang VC, Lofland D, Moser HE, Pei D",,307804,DTCT0024844,1791007,DTCC00392763,1295652,19089
CHEMBL361527,P14780,,QBWALRVIJDSECI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15686921,KI,=,0.87,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13).,Bioorg. Med. Chem. Lett.,2005,15,4,"Kim SH, Pudzianowski AT, Leavitt KJ, Barbosa J, McDonnell PA, Metzler WJ, Rankin BM, Liu R, Vaccaro W, Pitts W",,302481,DTCT0024844,1745332,DTCC00381643,1360847,18787
CHEMBL361527,P14780,,QBWALRVIJDSECI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15686921,KI,=,7.2,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13).,Bioorg. Med. Chem. Lett.,2005,15,4,"Kim SH, Pudzianowski AT, Leavitt KJ, Barbosa J, McDonnell PA, Metzler WJ, Rankin BM, Liu R, Vaccaro W, Pitts W",,302481,DTCT0024844,1745338,DTCC00381643,1360848,18787
CHEMBL361527,P14780,,QBWALRVIJDSECI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,7.24,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258728,DTCC00381643,1361904,24803
CHEMBL3617400,P14780,,NUFBSNVYZRUJSW-XMMPIXPASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26263024,IC50,=,9,NM,,,,,,,,,,,,,,Inhibition of recombinant human activated-MMP9 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as fluorogenic substrate incubated for 4 hrs followed by substrate addition measured every 10 secs for 20 mins by fluorometric assay,,N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.,J. Med. Chem.,2015,58,18,"Nuti E, Cantelmo AR, Gallo C, Bruno A, Bassani B, Camodeca C, Tuccinardi T, Vera L, Orlandini E, Nencetti S, Stura EA, Martinelli A, Dive V, Albini A, Rossello A",,1518239,DTCT0024844,14545622,DTCC01663485,1291518,63632
CHEMBL3617401,P14780,,KUDQLMASLRCXLF-LJQANCHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26263024,IC50,=,8.6,NM,,,,,,,,,,,,,,Inhibition of recombinant human activated-MMP9 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as fluorogenic substrate incubated for 4 hrs followed by substrate addition measured every 10 secs for 20 mins by fluorometric assay,,N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.,J. Med. Chem.,2015,58,18,"Nuti E, Cantelmo AR, Gallo C, Bruno A, Bassani B, Camodeca C, Tuccinardi T, Vera L, Orlandini E, Nencetti S, Stura EA, Martinelli A, Dive V, Albini A, Rossello A",,1518239,DTCT0024844,14545623,DTCC01663486,839147,63632
CHEMBL3617402,P14780,,QHHHTEGVVKPDKH-HXUWFJFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26263024,IC50,=,6.5,NM,,,,,,,,,,,,,,Inhibition of recombinant human activated-MMP9 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as fluorogenic substrate incubated for 4 hrs followed by substrate addition measured every 10 secs for 20 mins by fluorometric assay,,N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.,J. Med. Chem.,2015,58,18,"Nuti E, Cantelmo AR, Gallo C, Bruno A, Bassani B, Camodeca C, Tuccinardi T, Vera L, Orlandini E, Nencetti S, Stura EA, Martinelli A, Dive V, Albini A, Rossello A",,1518239,DTCT0024844,14545624,DTCC01663487,126658,63632
CHEMBL3617403,P14780,,NJZUERVIVLYZMO-RUZDIDTESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26263024,IC50,=,6.4,NM,,,,,,,,,,,,,,Inhibition of recombinant human activated-MMP9 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as fluorogenic substrate incubated for 4 hrs followed by substrate addition measured every 10 secs for 20 mins by fluorometric assay,,N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.,J. Med. Chem.,2015,58,18,"Nuti E, Cantelmo AR, Gallo C, Bruno A, Bassani B, Camodeca C, Tuccinardi T, Vera L, Orlandini E, Nencetti S, Stura EA, Martinelli A, Dive V, Albini A, Rossello A",,1518239,DTCT0024844,14545626,DTCC01663488,94439,63632
CHEMBL3617404,P14780,,UJKKQEHHLXCTJE-OAQYLSRUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26263024,IC50,=,2,NM,,,,,,,,,,,,,,Inhibition of recombinant human activated-MMP9 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as fluorogenic substrate incubated for 4 hrs followed by substrate addition measured every 10 secs for 20 mins by fluorometric assay,,N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.,J. Med. Chem.,2015,58,18,"Nuti E, Cantelmo AR, Gallo C, Bruno A, Bassani B, Camodeca C, Tuccinardi T, Vera L, Orlandini E, Nencetti S, Stura EA, Martinelli A, Dive V, Albini A, Rossello A",,1518239,DTCT0024844,14545627,DTCC01663489,1161438,63632
CHEMBL3617404,P14780,,UJKKQEHHLXCTJE-OAQYLSRUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26263024,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of MMP9 gelatinase activity in human HUVEC by gel zymography,Dose-dependent effect,N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.,J. Med. Chem.,2015,58,18,"Nuti E, Cantelmo AR, Gallo C, Bruno A, Bassani B, Camodeca C, Tuccinardi T, Vera L, Orlandini E, Nencetti S, Stura EA, Martinelli A, Dive V, Albini A, Rossello A",,1518253,DTCT0024844,14545671,DTCC01663489,1161438,63632
CHEMBL3617404,P14780,,UJKKQEHHLXCTJE-OAQYLSRUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26263024,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of MMP9 gelatinase activity in human HUVEC at 0.1 uM by gel zymography,Active,N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.,J. Med. Chem.,2015,58,18,"Nuti E, Cantelmo AR, Gallo C, Bruno A, Bassani B, Camodeca C, Tuccinardi T, Vera L, Orlandini E, Nencetti S, Stura EA, Martinelli A, Dive V, Albini A, Rossello A",,1518257,DTCT0024844,14545676,DTCC01663489,1161438,63632
CHEMBL3617405,P14780,,WVPKYEATTXWJLC-AREMUKBSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26263024,IC50,=,2.9,NM,,,,,,,,,,,,,,Inhibition of recombinant human activated-MMP9 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as fluorogenic substrate incubated for 4 hrs followed by substrate addition measured every 10 secs for 20 mins by fluorometric assay,,N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.,J. Med. Chem.,2015,58,18,"Nuti E, Cantelmo AR, Gallo C, Bruno A, Bassani B, Camodeca C, Tuccinardi T, Vera L, Orlandini E, Nencetti S, Stura EA, Martinelli A, Dive V, Albini A, Rossello A",,1518239,DTCT0024844,14545628,DTCC01663490,1739733,63632
CHEMBL3617406,P14780,,RAYJCTCOKFKWEF-CQSZACIVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26263024,IC50,=,3900,NM,,,,,,,,,,,,,,Inhibition of recombinant human activated-MMP9 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as fluorogenic substrate incubated for 4 hrs followed by substrate addition measured every 10 secs for 20 mins by fluorometric assay,,N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.,J. Med. Chem.,2015,58,18,"Nuti E, Cantelmo AR, Gallo C, Bruno A, Bassani B, Camodeca C, Tuccinardi T, Vera L, Orlandini E, Nencetti S, Stura EA, Martinelli A, Dive V, Albini A, Rossello A",,1518239,DTCT0024844,14545629,DTCC01663491,871801,63632
CHEMBL3617406,P14780,,RAYJCTCOKFKWEF-CQSZACIVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26263024,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of MMP9 gelatinase activity in human HUVEC at 0.001 to 10 uM by gel zymography,Not Active,N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.,J. Med. Chem.,2015,58,18,"Nuti E, Cantelmo AR, Gallo C, Bruno A, Bassani B, Camodeca C, Tuccinardi T, Vera L, Orlandini E, Nencetti S, Stura EA, Martinelli A, Dive V, Albini A, Rossello A",,1518259,DTCT0024844,14545678,DTCC01663491,871801,63632
CHEMBL3617407,P14780,,WQCXDERWRJMJQA-RUZDIDTESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26263024,IC50,=,0.43,NM,,,,,,,,,,,,,,Inhibition of recombinant human activated-MMP9 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as fluorogenic substrate incubated for 4 hrs followed by substrate addition measured every 10 secs for 20 mins by fluorometric assay,,N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.,J. Med. Chem.,2015,58,18,"Nuti E, Cantelmo AR, Gallo C, Bruno A, Bassani B, Camodeca C, Tuccinardi T, Vera L, Orlandini E, Nencetti S, Stura EA, Martinelli A, Dive V, Albini A, Rossello A",,1518239,DTCT0024844,14545630,DTCC01663492,2063303,63632
CHEMBL3617407,P14780,,WQCXDERWRJMJQA-RUZDIDTESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26263024,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of MMP9 gelatinase activity in human HUVEC by gel zymography,Dose-dependent effect,N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.,J. Med. Chem.,2015,58,18,"Nuti E, Cantelmo AR, Gallo C, Bruno A, Bassani B, Camodeca C, Tuccinardi T, Vera L, Orlandini E, Nencetti S, Stura EA, Martinelli A, Dive V, Albini A, Rossello A",,1518253,DTCT0024844,14545672,DTCC01663492,2063303,63632
CHEMBL3617407,P14780,,WQCXDERWRJMJQA-RUZDIDTESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26263024,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of MMP9 gelatinase activity in human HUVEC at 0.001 uM by gel zymography,Active,N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.,J. Med. Chem.,2015,58,18,"Nuti E, Cantelmo AR, Gallo C, Bruno A, Bassani B, Camodeca C, Tuccinardi T, Vera L, Orlandini E, Nencetti S, Stura EA, Martinelli A, Dive V, Albini A, Rossello A",,1518255,DTCT0024844,14545674,DTCC01663492,2063303,63632
CHEMBL3617407,P14780,,WQCXDERWRJMJQA-RUZDIDTESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26263024,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of MMP9 in HUVEC assessed as suppression of protein release at 10 uM after 24 hrs by Western blot analysis,Active,N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.,J. Med. Chem.,2015,58,18,"Nuti E, Cantelmo AR, Gallo C, Bruno A, Bassani B, Camodeca C, Tuccinardi T, Vera L, Orlandini E, Nencetti S, Stura EA, Martinelli A, Dive V, Albini A, Rossello A",,1518361,DTCT0024844,14545680,DTCC01663492,2063303,63632
CHEMBL3617407,P14780,,WQCXDERWRJMJQA-RUZDIDTESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26263024,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of MMP9 in HUVEC assessed as suppression of protein production at 10 uM after 24 hrs by Western blot analysis,Active,N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.,J. Med. Chem.,2015,58,18,"Nuti E, Cantelmo AR, Gallo C, Bruno A, Bassani B, Camodeca C, Tuccinardi T, Vera L, Orlandini E, Nencetti S, Stura EA, Martinelli A, Dive V, Albini A, Rossello A",,1518363,DTCT0024844,14545682,DTCC01663492,2063303,63632
CHEMBL3617407,P14780,,WQCXDERWRJMJQA-RUZDIDTESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26263024,RATIO IC50,=,15,,,,,,,,,,,,,,,Ratio of ARP101 IC50 to compound IC50 for recombinant human activated-MMP9 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as fluorogenic substrate incubated for 4 hrs followed by substrate addition measured every 10 secs for 20 mins by fluorometric assay,,N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.,J. Med. Chem.,2015,58,18,"Nuti E, Cantelmo AR, Gallo C, Bruno A, Bassani B, Camodeca C, Tuccinardi T, Vera L, Orlandini E, Nencetti S, Stura EA, Martinelli A, Dive V, Albini A, Rossello A",,1518371,DTCT0024844,14545687,DTCC01663492,2063303,63632
CHEMBL3618461,P14780,,FOCZQHBXIUOIJR-UQKRIMTDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26386821,IC50,=,709.7,NM,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 2 hrs prior to testing measured for 15 mins by fluorometric analysis,,"Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.",Bioorg. Med. Chem.,2015,23,20,"Yan Y, Chen X, Yang X, Zhang J, Xu W, Zhang Y",,1518636,DTCT0024844,14550517,DTCC01664557,288988,63755
CHEMBL3618461,P14780,,FOCZQHBXIUOIJR-UQKRIMTDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26386821,INHIBITION,=,98.3,%,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate at 10 uM incubated for 2 hrs prior to testing measured for 15 mins by fluorometric analysis relative to control,,"Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.",Bioorg. Med. Chem.,2015,23,20,"Yan Y, Chen X, Yang X, Zhang J, Xu W, Zhang Y",,1518638,DTCT0024844,14550544,DTCC01664557,288988,63755
CHEMBL3618462,P14780,,FOCZQHBXIUOIJR-PFEQFJNWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26386821,IC50,=,833,NM,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 2 hrs prior to testing measured for 15 mins by fluorometric analysis,,"Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.",Bioorg. Med. Chem.,2015,23,20,"Yan Y, Chen X, Yang X, Zhang J, Xu W, Zhang Y",,1518636,DTCT0024844,14550518,DTCC01664558,935907,63755
CHEMBL3618462,P14780,,FOCZQHBXIUOIJR-PFEQFJNWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26386821,INHIBITION,=,97.4,%,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate at 10 uM incubated for 2 hrs prior to testing measured for 15 mins by fluorometric analysis relative to control,,"Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.",Bioorg. Med. Chem.,2015,23,20,"Yan Y, Chen X, Yang X, Zhang J, Xu W, Zhang Y",,1518638,DTCT0024844,14550545,DTCC01664558,935907,63755
CHEMBL3618463,P14780,,QNKSDDQPRLWOEC-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26386821,IC50,=,677.2,NM,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 2 hrs prior to testing measured for 15 mins by fluorometric analysis,,"Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.",Bioorg. Med. Chem.,2015,23,20,"Yan Y, Chen X, Yang X, Zhang J, Xu W, Zhang Y",,1518636,DTCT0024844,14550520,DTCC01664559,580432,63755
CHEMBL3618463,P14780,,QNKSDDQPRLWOEC-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26386821,INHIBITION,=,91.1,%,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate at 10 uM incubated for 2 hrs prior to testing measured for 15 mins by fluorometric analysis relative to control,,"Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.",Bioorg. Med. Chem.,2015,23,20,"Yan Y, Chen X, Yang X, Zhang J, Xu W, Zhang Y",,1518638,DTCT0024844,14550547,DTCC01664559,580432,63755
CHEMBL3618464,P14780,,QNKSDDQPRLWOEC-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26386821,IC50,=,428.6,NM,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 2 hrs prior to testing measured for 15 mins by fluorometric analysis,,"Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.",Bioorg. Med. Chem.,2015,23,20,"Yan Y, Chen X, Yang X, Zhang J, Xu W, Zhang Y",,1518636,DTCT0024844,14550521,DTCC01664560,709675,63755
CHEMBL3618464,P14780,,QNKSDDQPRLWOEC-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26386821,INHIBITION,=,96.2,%,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate at 10 uM incubated for 2 hrs prior to testing measured for 15 mins by fluorometric analysis relative to control,,"Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.",Bioorg. Med. Chem.,2015,23,20,"Yan Y, Chen X, Yang X, Zhang J, Xu W, Zhang Y",,1518638,DTCT0024844,14550548,DTCC01664560,709675,63755
CHEMBL3618465,P14780,,WWTIQZDEOKXNTE-HJPURHCSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26386821,IC50,,,,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 2 hrs prior to testing measured for 15 mins by fluorometric analysis,Not Determined,"Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.",Bioorg. Med. Chem.,2015,23,20,"Yan Y, Chen X, Yang X, Zhang J, Xu W, Zhang Y",,1518636,DTCT0024844,14550524,DTCC01664561,2096289,63755
CHEMBL3618465,P14780,,WWTIQZDEOKXNTE-HJPURHCSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26386821,IC50,,,,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 2 hrs prior to testing measured for 15 mins by fluorometric analysis,Not Determined,"Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.",Bioorg. Med. Chem.,2015,23,20,"Yan Y, Chen X, Yang X, Zhang J, Xu W, Zhang Y",,1518636,DTCT0024844,14550525,DTCC01664561,2096295,63755
CHEMBL3618465,P14780,,WWTIQZDEOKXNTE-HJPURHCSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26386821,INHIBITION,=,3.4,%,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate at 10 uM incubated for 2 hrs prior to testing measured for 15 mins by fluorometric analysis relative to control,,"Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.",Bioorg. Med. Chem.,2015,23,20,"Yan Y, Chen X, Yang X, Zhang J, Xu W, Zhang Y",,1518638,DTCT0024844,14550551,DTCC01664561,2096295,63755
CHEMBL3618465,P14780,,WWTIQZDEOKXNTE-HJPURHCSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26386821,INHIBITION,=,23.7,%,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate at 10 uM incubated for 2 hrs prior to testing measured for 15 mins by fluorometric analysis relative to control,,"Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.",Bioorg. Med. Chem.,2015,23,20,"Yan Y, Chen X, Yang X, Zhang J, Xu W, Zhang Y",,1518638,DTCT0024844,14550550,DTCC01664561,2096289,63755
CHEMBL3618466,P14780,,WWTIQZDEOKXNTE-MWTRTKDXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26386821,IC50,,,,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 2 hrs prior to testing measured for 15 mins by fluorometric analysis,Not Determined,"Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.",Bioorg. Med. Chem.,2015,23,20,"Yan Y, Chen X, Yang X, Zhang J, Xu W, Zhang Y",,1518636,DTCT0024844,14550526,DTCC01664562,288989,63755
CHEMBL3618466,P14780,,WWTIQZDEOKXNTE-MWTRTKDXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26386821,IC50,,,,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 2 hrs prior to testing measured for 15 mins by fluorometric analysis,Not Determined,"Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.",Bioorg. Med. Chem.,2015,23,20,"Yan Y, Chen X, Yang X, Zhang J, Xu W, Zhang Y",,1518636,DTCT0024844,14550527,DTCC01664562,288990,63755
CHEMBL3618466,P14780,,WWTIQZDEOKXNTE-MWTRTKDXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26386821,INHIBITION,=,24.8,%,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate at 10 uM incubated for 2 hrs prior to testing measured for 15 mins by fluorometric analysis relative to control,,"Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.",Bioorg. Med. Chem.,2015,23,20,"Yan Y, Chen X, Yang X, Zhang J, Xu W, Zhang Y",,1518638,DTCT0024844,14550553,DTCC01664562,288990,63755
CHEMBL3618466,P14780,,WWTIQZDEOKXNTE-MWTRTKDXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26386821,INHIBITION,=,34.4,%,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate at 10 uM incubated for 2 hrs prior to testing measured for 15 mins by fluorometric analysis relative to control,,"Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.",Bioorg. Med. Chem.,2015,23,20,"Yan Y, Chen X, Yang X, Zhang J, Xu W, Zhang Y",,1518638,DTCT0024844,14550552,DTCC01664562,288989,63755
CHEMBL36191,P14780,,JAVKQWAQQAGPFN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12668018,IC50,=,8,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease 9 (MMP-9).,,Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,8,"Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS",,105528,DTCT0024844,1265554,DTCC00174276,1979257,6276
CHEMBL362099,P14780,,SHTFVFWWLRULMZ-JQWIXIFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15341955,KI,>,100000,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9,,Synthesis and evaluation of novel oxazoline MMP inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,19,"Cook GR, Manivannan E, Underdahl T, Lukacova V, Zhang Y, Balaz S",,302310,DTCT0024844,1770683,DTCC00389390,1851836,17054
CHEMBL362100,P14780,,HTTGXWWZNURROV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1766621,DTCC00387621,337380,18194
CHEMBL3621216,P14780,,ARAZNEJIUPWBGX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26346367,IC50,=,11970,NM,,,,,,,,,,,,,,Inhibition of APMA-activated human recombinant MMP9 incubated for 5 mins using 4-nitrophenylacetate substrate by esterase assay,,"Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.",Bioorg. Med. Chem. Lett.,2015,25,20,"Yan XQ, Wang ZC, Li Z, Wang PF, Qiu HY, Chen LW, Lu XY, Lv PC, Zhu HL",,1519999,DTCT0024844,14571561,DTCC01665642,560370,63889
CHEMBL3622219,P14780,,CQSZJPKSXWNIRM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26346367,IC50,=,10890,NM,,,,,,,,,,,,,,Inhibition of APMA-activated human recombinant MMP9 incubated for 5 mins using 4-nitrophenylacetate substrate by esterase assay,,"Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.",Bioorg. Med. Chem. Lett.,2015,25,20,"Yan XQ, Wang ZC, Li Z, Wang PF, Qiu HY, Chen LW, Lu XY, Lv PC, Zhu HL",,1519999,DTCT0024844,14571558,DTCC01665640,1848258,63889
CHEMBL3622220,P14780,,LIWWLVIGWDNERW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26346367,IC50,=,5430,NM,,,,,,,,,,,,,,Inhibition of APMA-activated human recombinant MMP9 incubated for 5 mins using 4-nitrophenylacetate substrate by esterase assay,,"Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.",Bioorg. Med. Chem. Lett.,2015,25,20,"Yan XQ, Wang ZC, Li Z, Wang PF, Qiu HY, Chen LW, Lu XY, Lv PC, Zhu HL",,1519999,DTCT0024844,14571559,DTCC01665641,1173522,63889
CHEMBL3622221,P14780,,JMFFPPYXIAJJHS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26346367,IC50,=,4290,NM,,,,,,,,,,,,,,Inhibition of APMA-activated human recombinant MMP9 incubated for 5 mins using 4-nitrophenylacetate substrate by esterase assay,,"Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.",Bioorg. Med. Chem. Lett.,2015,25,20,"Yan XQ, Wang ZC, Li Z, Wang PF, Qiu HY, Chen LW, Lu XY, Lv PC, Zhu HL",,1519999,DTCT0024844,14571562,DTCC01665643,1238494,63889
CHEMBL3622222,P14780,,PSLZAPBDBBDPPN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26346367,IC50,=,6720,NM,,,,,,,,,,,,,,Inhibition of APMA-activated human recombinant MMP9 incubated for 5 mins using 4-nitrophenylacetate substrate by esterase assay,,"Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.",Bioorg. Med. Chem. Lett.,2015,25,20,"Yan XQ, Wang ZC, Li Z, Wang PF, Qiu HY, Chen LW, Lu XY, Lv PC, Zhu HL",,1519999,DTCT0024844,14571563,DTCC01665644,1594970,63889
CHEMBL3622223,P14780,,IRKAGORJCMYCAB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26346367,IC50,=,7970,NM,,,,,,,,,,,,,,Inhibition of APMA-activated human recombinant MMP9 incubated for 5 mins using 4-nitrophenylacetate substrate by esterase assay,,"Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.",Bioorg. Med. Chem. Lett.,2015,25,20,"Yan XQ, Wang ZC, Li Z, Wang PF, Qiu HY, Chen LW, Lu XY, Lv PC, Zhu HL",,1519999,DTCT0024844,14571564,DTCC01665645,1978148,63889
CHEMBL3622224,P14780,,JOXOSYLMICYIJG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26346367,IC50,=,12870,NM,,,,,,,,,,,,,,Inhibition of APMA-activated human recombinant MMP9 incubated for 5 mins using 4-nitrophenylacetate substrate by esterase assay,,"Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.",Bioorg. Med. Chem. Lett.,2015,25,20,"Yan XQ, Wang ZC, Li Z, Wang PF, Qiu HY, Chen LW, Lu XY, Lv PC, Zhu HL",,1519999,DTCT0024844,14571565,DTCC01665646,1945161,63889
CHEMBL3622225,P14780,,BRRWKZSRWJEFEJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26346367,IC50,=,15960,NM,,,,,,,,,,,,,,Inhibition of APMA-activated human recombinant MMP9 incubated for 5 mins using 4-nitrophenylacetate substrate by esterase assay,,"Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.",Bioorg. Med. Chem. Lett.,2015,25,20,"Yan XQ, Wang ZC, Li Z, Wang PF, Qiu HY, Chen LW, Lu XY, Lv PC, Zhu HL",,1519999,DTCT0024844,14571566,DTCC01665647,1303819,63889
CHEMBL3622226,P14780,,GKUKGTPBNZYOOU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26346367,IC50,=,1870,NM,,,,,,,,,,,,,,Inhibition of APMA-activated human recombinant MMP9 incubated for 5 mins using 4-nitrophenylacetate substrate by esterase assay,,"Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.",Bioorg. Med. Chem. Lett.,2015,25,20,"Yan XQ, Wang ZC, Li Z, Wang PF, Qiu HY, Chen LW, Lu XY, Lv PC, Zhu HL",,1519999,DTCT0024844,14571567,DTCC01665648,786190,63889
CHEMBL3622784,P14780,,DLFXYHXMQWTTSB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26346367,IC50,=,8610,NM,,,,,,,,,,,,,,Inhibition of APMA-activated human recombinant MMP9 incubated for 5 mins using 4-nitrophenylacetate substrate by esterase assay,,"Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.",Bioorg. Med. Chem. Lett.,2015,25,20,"Yan XQ, Wang ZC, Li Z, Wang PF, Qiu HY, Chen LW, Lu XY, Lv PC, Zhu HL",,1519999,DTCT0024844,14571568,DTCC01666211,1880629,63889
CHEMBL3622785,P14780,,UQLGCIRFNNFGKZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26346367,IC50,=,3190,NM,,,,,,,,,,,,,,Inhibition of APMA-activated human recombinant MMP9 incubated for 5 mins using 4-nitrophenylacetate substrate by esterase assay,,"Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.",Bioorg. Med. Chem. Lett.,2015,25,20,"Yan XQ, Wang ZC, Li Z, Wang PF, Qiu HY, Chen LW, Lu XY, Lv PC, Zhu HL",,1519999,DTCT0024844,14571569,DTCC01666212,1465764,63889
CHEMBL3622786,P14780,,HSEFAXKXEWSOGH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26346367,IC50,=,5470,NM,,,,,,,,,,,,,,Inhibition of APMA-activated human recombinant MMP9 incubated for 5 mins using 4-nitrophenylacetate substrate by esterase assay,,"Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.",Bioorg. Med. Chem. Lett.,2015,25,20,"Yan XQ, Wang ZC, Li Z, Wang PF, Qiu HY, Chen LW, Lu XY, Lv PC, Zhu HL",,1519999,DTCT0024844,14571570,DTCC01666213,947920,63889
CHEMBL3622787,P14780,,WHZFAJYEXJWWSI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26346367,IC50,=,33750,NM,,,,,,,,,,,,,,Inhibition of APMA-activated human recombinant MMP9 incubated for 5 mins using 4-nitrophenylacetate substrate by esterase assay,,"Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.",Bioorg. Med. Chem. Lett.,2015,25,20,"Yan XQ, Wang ZC, Li Z, Wang PF, Qiu HY, Chen LW, Lu XY, Lv PC, Zhu HL",,1519999,DTCT0024844,14571571,DTCC01666214,947921,63889
CHEMBL3622788,P14780,,DTOSICPIIPECKT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26346367,IC50,=,7910,NM,,,,,,,,,,,,,,Inhibition of APMA-activated human recombinant MMP9 incubated for 5 mins using 4-nitrophenylacetate substrate by esterase assay,,"Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.",Bioorg. Med. Chem. Lett.,2015,25,20,"Yan XQ, Wang ZC, Li Z, Wang PF, Qiu HY, Chen LW, Lu XY, Lv PC, Zhu HL",,1519999,DTCT0024844,14571572,DTCC01666215,657353,63889
CHEMBL3622789,P14780,,BIAVIKBVTJZJOG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26346367,IC50,=,8720,NM,,,,,,,,,,,,,,Inhibition of APMA-activated human recombinant MMP9 incubated for 5 mins using 4-nitrophenylacetate substrate by esterase assay,,"Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.",Bioorg. Med. Chem. Lett.,2015,25,20,"Yan XQ, Wang ZC, Li Z, Wang PF, Qiu HY, Chen LW, Lu XY, Lv PC, Zhu HL",,1519999,DTCT0024844,14571573,DTCC01666216,851413,63889
CHEMBL3622790,P14780,,XMVTYJNGLRSMOT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26346367,IC50,=,5920,NM,,,,,,,,,,,,,,Inhibition of APMA-activated human recombinant MMP9 incubated for 5 mins using 4-nitrophenylacetate substrate by esterase assay,,"Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.",Bioorg. Med. Chem. Lett.,2015,25,20,"Yan XQ, Wang ZC, Li Z, Wang PF, Qiu HY, Chen LW, Lu XY, Lv PC, Zhu HL",,1519999,DTCT0024844,14571574,DTCC01666217,689555,63889
CHEMBL3622791,P14780,,QBDCDXFJSXBXGX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26346367,IC50,=,4680,NM,,,,,,,,,,,,,,Inhibition of APMA-activated human recombinant MMP9 incubated for 5 mins using 4-nitrophenylacetate substrate by esterase assay,,"Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.",Bioorg. Med. Chem. Lett.,2015,25,20,"Yan XQ, Wang ZC, Li Z, Wang PF, Qiu HY, Chen LW, Lu XY, Lv PC, Zhu HL",,1519999,DTCT0024844,14571575,DTCC01666218,1498228,63889
CHEMBL3622792,P14780,,GXTKOOYKFOIAAT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26346367,IC50,=,5960,NM,,,,,,,,,,,,,,Inhibition of APMA-activated human recombinant MMP9 incubated for 5 mins using 4-nitrophenylacetate substrate by esterase assay,,"Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.",Bioorg. Med. Chem. Lett.,2015,25,20,"Yan XQ, Wang ZC, Li Z, Wang PF, Qiu HY, Chen LW, Lu XY, Lv PC, Zhu HL",,1519999,DTCT0024844,14571576,DTCC01666219,1205820,63889
CHEMBL3622793,P14780,,CYWCRGAEIMKYTA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26346367,IC50,=,13890,NM,,,,,,,,,,,,,,Inhibition of APMA-activated human recombinant MMP9 incubated for 5 mins using 4-nitrophenylacetate substrate by esterase assay,,"Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.",Bioorg. Med. Chem. Lett.,2015,25,20,"Yan XQ, Wang ZC, Li Z, Wang PF, Qiu HY, Chen LW, Lu XY, Lv PC, Zhu HL",,1519999,DTCT0024844,14571577,DTCC01666220,1562492,63889
CHEMBL3622794,P14780,,RLILVSDCEHRYOZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26346367,IC50,=,6910,NM,,,,,,,,,,,,,,Inhibition of APMA-activated human recombinant MMP9 incubated for 5 mins using 4-nitrophenylacetate substrate by esterase assay,,"Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.",Bioorg. Med. Chem. Lett.,2015,25,20,"Yan XQ, Wang ZC, Li Z, Wang PF, Qiu HY, Chen LW, Lu XY, Lv PC, Zhu HL",,1519999,DTCT0024844,14571578,DTCC01666221,1945168,63889
CHEMBL3622795,P14780,,XJWLMPXBCDULME-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26346367,IC50,=,4950,NM,,,,,,,,,,,,,,Inhibition of APMA-activated human recombinant MMP9 incubated for 5 mins using 4-nitrophenylacetate substrate by esterase assay,,"Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.",Bioorg. Med. Chem. Lett.,2015,25,20,"Yan XQ, Wang ZC, Li Z, Wang PF, Qiu HY, Chen LW, Lu XY, Lv PC, Zhu HL",,1519999,DTCT0024844,14571579,DTCC01666222,560374,63889
CHEMBL3622796,P14780,,SOQUQUULZBJGPR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26346367,IC50,=,18960,NM,,,,,,,,,,,,,,Inhibition of APMA-activated human recombinant MMP9 incubated for 5 mins using 4-nitrophenylacetate substrate by esterase assay,,"Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.",Bioorg. Med. Chem. Lett.,2015,25,20,"Yan XQ, Wang ZC, Li Z, Wang PF, Qiu HY, Chen LW, Lu XY, Lv PC, Zhu HL",,1519999,DTCT0024844,14571580,DTCC01666223,1659674,63889
CHEMBL3622797,P14780,,WEUFMBNLGSJUJM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26346367,IC50,=,18310,NM,,,,,,,,,,,,,,Inhibition of APMA-activated human recombinant MMP9 incubated for 5 mins using 4-nitrophenylacetate substrate by esterase assay,,"Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.",Bioorg. Med. Chem. Lett.,2015,25,20,"Yan XQ, Wang ZC, Li Z, Wang PF, Qiu HY, Chen LW, Lu XY, Lv PC, Zhu HL",,1519999,DTCT0024844,14571581,DTCC01666224,1369102,63889
CHEMBL3622798,P14780,,QUGGOMITCPEQQZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26346367,IC50,=,19810,NM,,,,,,,,,,,,,,Inhibition of APMA-activated human recombinant MMP9 incubated for 5 mins using 4-nitrophenylacetate substrate by esterase assay,,"Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.",Bioorg. Med. Chem. Lett.,2015,25,20,"Yan XQ, Wang ZC, Li Z, Wang PF, Qiu HY, Chen LW, Lu XY, Lv PC, Zhu HL",,1519999,DTCT0024844,14571582,DTCC01666225,1336527,63889
CHEMBL3622799,P14780,,BDBAYMZOFMAWRY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26346367,IC50,=,5880,NM,,,,,,,,,,,,,,Inhibition of APMA-activated human recombinant MMP9 incubated for 5 mins using 4-nitrophenylacetate substrate by esterase assay,,"Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.",Bioorg. Med. Chem. Lett.,2015,25,20,"Yan XQ, Wang ZC, Li Z, Wang PF, Qiu HY, Chen LW, Lu XY, Lv PC, Zhu HL",,1519999,DTCT0024844,14571583,DTCC01666226,851414,63889
CHEMBL3622800,P14780,,SRPCXEFYFVDUFQ-KBKZQPOHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26346367,IC50,=,2520,NM,,,,,,,,,,,,,,Inhibition of APMA-activated human recombinant MMP9 incubated for 5 mins using 4-nitrophenylacetate substrate by esterase assay,,"Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.",Bioorg. Med. Chem. Lett.,2015,25,20,"Yan XQ, Wang ZC, Li Z, Wang PF, Qiu HY, Chen LW, Lu XY, Lv PC, Zhu HL",,1519999,DTCT0024844,14571584,DTCC01666227,333771,63889
CHEMBL362651,P14780,,PKVXJRTWUNPBJP-RUZDIDTESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15713379,IC50,=,16,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.,Bioorg. Med. Chem. Lett.,2005,15,5,"Rossello A, Nuti E, Carelli P, Orlandini E, Macchia M, Nencetti S, Zandomeneghi M, Balzano F, Uccello Barretta G, Albini A, Benelli R, Cercignani G, Murphy G, Balsamo A",,305737,DTCT0024844,1745774,DTCC00381850,1936708,18841
CHEMBL362651,P14780,,PKVXJRTWUNPBJP-RUZDIDTESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15837315,IC50,=,16,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 in MMPi assay,,A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs.,Bioorg. Med. Chem. Lett.,2005,15,9,"Rossello A, Nuti E, Catalani MP, Carelli P, Orlandini E, Rapposelli S, Tuccinardi T, Atkinson SJ, Murphy G, Balsamo A",,305685,DTCT0024844,1841416,DTCC00381850,1948929,18987
CHEMBL362678,P14780,,DGZZVIWCMGVHGV-IBGZPJMESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15713379,IC50,=,13,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.,Bioorg. Med. Chem. Lett.,2005,15,5,"Rossello A, Nuti E, Carelli P, Orlandini E, Macchia M, Nencetti S, Zandomeneghi M, Balzano F, Uccello Barretta G, Albini A, Benelli R, Cercignani G, Murphy G, Balsamo A",,305737,DTCT0024844,1747888,DTCC00381819,1969977,18841
CHEMBL362912,P14780,,URXHOHGQEBFJOX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15857146,IC50,,,,,,,,,,,,,,,,,In vitro inhibition of human Matrix metalloprotease 9; n.d.=not determined,Not Determined,C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging.,J. Med. Chem.,2005,48,9,"Breyholz HJ, Schäfers M, Wagner S, Höltke C, Faust A, Rabeneck H, Levkau B, Schober O, Kopka K",,305979,DTCT0024844,1828760,DTCC00399798,1755052,19718
CHEMBL36309,P14780,,FHAJCDXKKGQJQW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12668018,IC50,=,244,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease 9 (MMP-9).,,Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,8,"Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS",,105528,DTCT0024844,1277923,DTCC00174418,1817295,6276
CHEMBL363261,P14780,,SGKYEMLYQFTLEW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1768297,DTCC00387635,32986,18194
CHEMBL363351,P14780,,KADFIIKJGHEHDF-SIHBAMTISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16107143,KI,=,80.17,NM,,,,,,,,,,,,,,Inhibition of MOCAc-Pro-Leu-Gly-Leu-A2p (Dnp)-Ala-Arg-NH2 binding to human matrix metalloprotease-9 (MMP-9),,"A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.",J. Med. Chem.,2005,48,17,"Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S",,307380,DTCT0024844,1815800,DTCC00397941,887209,19409
CHEMBL3633817,P14780,,ZQYRDNFYQHYIPA-SCLBCKFNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,1200,NM,,,,,,,,,,,,,,Inhibition MMP-9 (unknown origin) using Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 5 mins followed by substrate addition measured for 30 mins by fluorometric assay,,,MedChemComm,2015,6,2,,,1527166,DTCT0024844,14586902,DTCC01670821,1550629,64111
CHEMBL3633817,P14780,,ZQYRDNFYQHYIPA-SCLBCKFNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION,=,91,%,,,,,,,,,,,,,,Inhibition MMP-9 (unknown origin) using Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate at 5 uM preincubated for 5 mins followed by substrate addition measured for 30 mins by fluorometric assay,,,MedChemComm,2015,6,2,,,1527164,DTCT0024844,14586884,DTCC01670821,1550629,64111
CHEMBL3633818,P14780,,WIGAWQAOMBSMTI-VGOFRKELSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,590,NM,,,,,,,,,,,,,,Inhibition MMP-9 (unknown origin) using Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 5 mins followed by substrate addition measured for 30 mins by fluorometric assay,,,MedChemComm,2015,6,2,,,1527166,DTCT0024844,14586903,DTCC01670822,1932749,64111
CHEMBL3633818,P14780,,WIGAWQAOMBSMTI-VGOFRKELSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION,=,100,%,,,,,,,,,,,,,,Inhibition MMP-9 (unknown origin) using Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate at 5 uM preincubated for 5 mins followed by substrate addition measured for 30 mins by fluorometric assay,,,MedChemComm,2015,6,2,,,1527164,DTCT0024844,14586885,DTCC01670822,1932749,64111
CHEMBL3633819,P14780,,WIGAWQAOMBSMTI-HTAPYJJXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,60,NM,,,,,,,,,,,,,,Inhibition MMP-9 (unknown origin) using Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 5 mins followed by substrate addition measured for 30 mins by fluorometric assay,,,MedChemComm,2015,6,2,,,1527166,DTCT0024844,14586904,DTCC01670823,1900808,64111
CHEMBL3633819,P14780,,WIGAWQAOMBSMTI-HTAPYJJXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION,=,100,%,,,,,,,,,,,,,,Inhibition MMP-9 (unknown origin) using Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate at 5 uM preincubated for 5 mins followed by substrate addition measured for 30 mins by fluorometric assay,,,MedChemComm,2015,6,2,,,1527164,DTCT0024844,14586886,DTCC01670823,1900808,64111
CHEMBL3633819,P14780,,WIGAWQAOMBSMTI-HTAPYJJXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION,,,,,cell_based,,,,,,,,,,,,Inhibition of gelatinolytic activity of pro-MMP9 in human A375P cells assessed as reduction in active form of protein at 20 uM by gelatin zymography,Active,,MedChemComm,2015,6,2,,,1527168,DTCT0024844,14586910,DTCC01670823,1900808,64111
CHEMBL363424,P14780,,RBLCSCFFNCADJO-XZATXCMXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16107143,KI,=,5.05,NM,,,,,,,,,,,,,,Inhibition constant for human matrix metalloprotease-9 (MMP-9),,"A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.",J. Med. Chem.,2005,48,17,"Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S",,302463,DTCT0024844,1815678,DTCC00397578,1405168,19409
CHEMBL363424,P14780,,RBLCSCFFNCADJO-XZATXCMXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16107143,KI,=,5.05,NM,,,,,,,,,,,,,,Inhibition of MOCAc-Pro-Leu-Gly-Leu-A2p (Dnp)-Ala-Arg-NH2 binding to human matrix metalloprotease-9 (MMP-9),,"A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.",J. Med. Chem.,2005,48,17,"Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S",,307381,DTCT0024844,1815677,DTCC00397578,1405168,19409
CHEMBL363451,P14780,,IGCXXFVEWDCCKV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1766908,DTCC00387667,1598534,18194
CHEMBL363675,P14780,,ASAPWKWJXIHFER-AAEUAGOBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15341955,KI,=,88000,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9,,Synthesis and evaluation of novel oxazoline MMP inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,19,"Cook GR, Manivannan E, Underdahl T, Lukacova V, Zhang Y, Balaz S",,302310,DTCT0024844,1770301,DTCC00389348,109933,17054
CHEMBL363719,P14780,,VIJGBSAWWJKQHY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15908214,KI,>,2130,NM,,,,,,,,,,,,,,In vitro binding affinity against matrix metalloprotease 9,,"Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.",Bioorg. Med. Chem. Lett.,2005,15,12,"Duan JJ, Lu Z, Wasserman ZR, Liu RQ, Covington MB, Decicco CP",,302347,DTCT0024844,1800095,DTCC00398373,488094,16433
CHEMBL363732,P14780,,YDTKUAMJIYPIGB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1769251,DTCC00387578,725267,18194
CHEMBL363953,P14780,,MEFLBZIMEXKFFU-HKUYNNGSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15341955,KI,=,81000,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9,,Synthesis and evaluation of novel oxazoline MMP inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,19,"Cook GR, Manivannan E, Underdahl T, Lukacova V, Zhang Y, Balaz S",,302310,DTCT0024844,1770695,DTCC00389451,1948789,17054
CHEMBL363968,P14780,,VACPECYZKUSTIV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1766901,DTCC00387733,304743,18194
CHEMBL3639695,P14780,,PZMQNEDVJSDLAW-SFTDATJTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247680,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,182136,DTCC01703280,1130506,64498
CHEMBL3639744,P14780,,SAIHVCSOGMUZPK-OALUTQOASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247714,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,170320,DTCC01708180,1615862,64498
CHEMBL364212,P14780,,HVCMNEIPCJLAQO-IXLVIVEVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15341955,KI,>,100000,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9,,Synthesis and evaluation of novel oxazoline MMP inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,19,"Cook GR, Manivannan E, Underdahl T, Lukacova V, Zhang Y, Balaz S",,302310,DTCT0024844,1770191,DTCC00389323,1469364,17054
CHEMBL364322,P14780,,FVDGHPCOVWFGOL-RDJZCZTQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15341955,KI,>,200000,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9,,Synthesis and evaluation of novel oxazoline MMP inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,19,"Cook GR, Manivannan E, Underdahl T, Lukacova V, Zhang Y, Balaz S",,302310,DTCT0024844,1770680,DTCC00389389,1754964,17054
CHEMBL3643914,P14780,,XYPVMSYCSIAWKF-DEOSSOPVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,>,10000,NM,,,,,,,,,,,,,,"BindingDB_Patents: Enzymatic Assay. The products are solubilized in DMSO at a concentration of 10 mM. A serial 3-fold dilution over 10 points is carried out so as to have a concentration range of from 10 uM to 0.5 nM final concentration. The TACE enzyme is an internal production (carried out according to the publication protein Eng Des Sel 2006, 19,155-161) and is added so as to have a signal equivalent to 6 times the background noise in 2 h at 37C. The reaction is carried out in 50 mM Tris buffered medium containing 4% glycerol, pH 7.4. The fluorescent substrate is MCA-Pro-Leu-Ala-Val-(Dpa)-Arg-Ser-Ser-Arg-NH2 (R and D systems, reference: ES003). The substrate is cleaved by the enzyme between the alanine and the valine, thus releasing a fluorescent peptide (excitation: 320 nm, emission: 420 nm). The substrate is used at 40 uM. The reaction is carried out in a final volume of 10 ul (4 ul inhibitor, 4 ul substrate, 2 ul enzyme) in a low volume 384-well plate (Corning reference: 3676).",255761,"Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics",,2014,,,,,1535042,DTCT0024844,167468,DTCC01676227,1336121,64597
CHEMBL3643916,P14780,,KHOXRRQYROMPSZ-QHCPKHFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,>,10000,NM,,,,,,,,,,,,,,"BindingDB_Patents: Enzymatic Assay. The products are solubilized in DMSO at a concentration of 10 mM. A serial 3-fold dilution over 10 points is carried out so as to have a concentration range of from 10 uM to 0.5 nM final concentration. The TACE enzyme is an internal production (carried out according to the publication protein Eng Des Sel 2006, 19,155-161) and is added so as to have a signal equivalent to 6 times the background noise in 2 h at 37C. The reaction is carried out in 50 mM Tris buffered medium containing 4% glycerol, pH 7.4. The fluorescent substrate is MCA-Pro-Leu-Ala-Val-(Dpa)-Arg-Ser-Ser-Arg-NH2 (R and D systems, reference: ES003). The substrate is cleaved by the enzyme between the alanine and the valine, thus releasing a fluorescent peptide (excitation: 320 nm, emission: 420 nm). The substrate is used at 40 uM. The reaction is carried out in a final volume of 10 ul (4 ul inhibitor, 4 ul substrate, 2 ul enzyme) in a low volume 384-well plate (Corning reference: 3676).",255762,"Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics",,2014,,,,,1535042,DTCT0024844,168620,DTCC01676229,431255,64597
CHEMBL364485,P14780,,NQYWUYPYYFALAI-SIHBAMTISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16107143,KI,=,51.88,NM,,,,,,,,,,,,,,Inhibition of MOCAc-Pro-Leu-Gly-Leu-A2p (Dnp)-Ala-Arg-NH2 binding to human matrix metalloprotease-9 (MMP-9),,"A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.",J. Med. Chem.,2005,48,17,"Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S",,307380,DTCT0024844,1815798,DTCC00397658,499564,19409
CHEMBL364485,P14780,,NQYWUYPYYFALAI-SIHBAMTISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16107143,KI,=,51.9,NM,,,,,,,,,,,,,,Inhibition constant for human matrix metalloprotease-9 (MMP-9),,"A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.",J. Med. Chem.,2005,48,17,"Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S",,302463,DTCT0024844,1815799,DTCC00397658,499564,19409
CHEMBL364547,P14780,,HFCXLBPJFPHTAN-PDNQZYNLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16107143,KI,=,59.16,NM,,,,,,,,,,,,,,Inhibition of MOCAc-Pro-Leu-Gly-Leu-A2p (Dnp)-Ala-Arg-NH2 binding to human matrix metalloprotease-9 (MMP-9),,"A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.",J. Med. Chem.,2005,48,17,"Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S",,307380,DTCT0024844,1815804,DTCC00397663,1146054,19409
CHEMBL364589,P14780,,TUZYRFJHUHCUNQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1768171,DTCC00387692,1501650,18194
CHEMBL364694,P14780,,PIHNCDLSZQOOPU-DIERRCTGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16107143,KI,=,32.14,NM,,,,,,,,,,,,,,Inhibition of MOCAc-Pro-Leu-Gly-Leu-A2p (Dnp)-Ala-Arg-NH2 binding to human matrix metalloprotease-9 (MMP-9),,"A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.",J. Med. Chem.,2005,48,17,"Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S",,307380,DTCT0024844,1815801,DTCC00397775,1598643,19409
CHEMBL364713,P14780,NOSCAPINE,AKNNEGZIBPJZJG-MSOLQXFVSA-N,1,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7405810,DTCC00398932,898293,46191
CHEMBL364713,P14780,NOSCAPINE,AKNNEGZIBPJZJG-MSOLQXFVSA-N,1,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7405811,DTCC00398932,898293,46191
CHEMBL364775,P14780,,HGHDQFUGOIJFTI-QWRGUYRKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15341955,KI,,,,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9; F denotes no activity was observed upto the concentration that fluorescence could be compensated for,Fluorescence interfered with assay,Synthesis and evaluation of novel oxazoline MMP inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,19,"Cook GR, Manivannan E, Underdahl T, Lukacova V, Zhang Y, Balaz S",,303734,DTCT0024844,465657,DTCC00389612,725294,17054
CHEMBL364783,P14780,,UGLZDULKIKNNBG-STQMWFEESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15341955,KI,=,65000,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9,,Synthesis and evaluation of novel oxazoline MMP inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,19,"Cook GR, Manivannan E, Underdahl T, Lukacova V, Zhang Y, Balaz S",,302310,DTCT0024844,1770183,DTCC00389369,789574,17054
CHEMBL364875,P14780,,MCBALNMZVCCHAP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1769395,DTCC00387548,1724710,18194
CHEMBL364979,P14780,,NUMGTAZEZUDGNC-YADHBBJMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15369398,INHIBITION,=,4,%,,,,,,,,,,,,,,Inhibition of MMP-9 (matrix metalloprotease) at 1 uM,,Macrocyclic inhibitors for peptide deformylase: a structure-activity relationship study of the ring size.,J. Med. Chem.,2004,47,20,"Hu X, Nguyen KT, Jiang VC, Lofland D, Moser HE, Pei D",,307797,DTCT0024844,1790995,DTCC00392916,98440,19089
CHEMBL364979,P14780,,NUMGTAZEZUDGNC-YADHBBJMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15369398,INHIBITION,=,5,%,,,,,,,,,,,,,,Inhibition of MMP-9 (matrix metalloprotease) at 10 uM,,Macrocyclic inhibitors for peptide deformylase: a structure-activity relationship study of the ring size.,J. Med. Chem.,2004,47,20,"Hu X, Nguyen KT, Jiang VC, Lofland D, Moser HE, Pei D",,307804,DTCT0024844,1790996,DTCC00392916,98440,19089
CHEMBL365031,P14780,,NGBXKQSVMZPDNE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1769655,DTCC00387577,499471,18194
CHEMBL365167,P14780,,NPIWTBAYANSBHN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15908214,KI,>,2130,NM,,,,,,,,,,,,,,In vitro binding affinity against matrix metalloprotease 9,,"Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.",Bioorg. Med. Chem. Lett.,2005,15,12,"Duan JJ, Lu Z, Wasserman ZR, Liu RQ, Covington MB, Decicco CP",,302347,DTCT0024844,1800394,DTCC00398407,1037012,16433
CHEMBL365386,P14780,,MUEJBYPIDLKGKN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15908214,KI,>,2130,NM,,,,,,,,,,,,,,In vitro binding affinity against matrix metalloprotease 9,,"Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.",Bioorg. Med. Chem. Lett.,2005,15,12,"Duan JJ, Lu Z, Wasserman ZR, Liu RQ, Covington MB, Decicco CP",,302347,DTCT0024844,1800406,DTCC00398433,1425801,16433
CHEMBL365588,P14780,,LXKHXLQQHKRMFP-SMAGUSHISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16107143,KI,=,5.2,NM,,,,,,,,,,,,,,Inhibition of MOCAc-Pro-Leu-Gly-Leu-A2p (Dnp)-Ala-Arg-NH2 binding to human matrix metalloprotease-9 (MMP-9),,"A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.",J. Med. Chem.,2005,48,17,"Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S",,307380,DTCT0024844,1815819,DTCC00397513,142426,19409
CHEMBL365632,P14780,,PGPCNXNVLLYCGR-MOPGFXCFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15369398,INHIBITION,=,61,%,,,,,,,,,,,,,,Inhibition of MMP-9 (matrix metalloprotease) at 1 uM,,Macrocyclic inhibitors for peptide deformylase: a structure-activity relationship study of the ring size.,J. Med. Chem.,2004,47,20,"Hu X, Nguyen KT, Jiang VC, Lofland D, Moser HE, Pei D",,307797,DTCT0024844,1789843,DTCC00392926,908338,19089
CHEMBL365632,P14780,,PGPCNXNVLLYCGR-MOPGFXCFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15369398,INHIBITION,=,94,%,,,,,,,,,,,,,,Inhibition of MMP-9 (matrix metalloprotease) at 10 uM,,Macrocyclic inhibitors for peptide deformylase: a structure-activity relationship study of the ring size.,J. Med. Chem.,2004,47,20,"Hu X, Nguyen KT, Jiang VC, Lofland D, Moser HE, Pei D",,307804,DTCT0024844,1789844,DTCC00392926,908338,19089
CHEMBL365827,P14780,,SBLYYHZLEQXVEB-TYDXBBDOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15341955,KI,=,40000,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9,,Synthesis and evaluation of novel oxazoline MMP inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,19,"Cook GR, Manivannan E, Underdahl T, Lukacova V, Zhang Y, Balaz S",,302310,DTCT0024844,1771854,DTCC00389597,2046753,17054
CHEMBL365905,P14780,,UXWAVVXCMUJGHD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1768163,DTCC00387755,499472,18194
CHEMBL365910,P14780,,RANUWAUPDVMUKD-NHCUHLMSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15369398,INHIBITION,=,4,%,,,,,,,,,,,,,,Inhibition of MMP-9 (matrix metalloprotease) at 1 uM,,Macrocyclic inhibitors for peptide deformylase: a structure-activity relationship study of the ring size.,J. Med. Chem.,2004,47,20,"Hu X, Nguyen KT, Jiang VC, Lofland D, Moser HE, Pei D",,307797,DTCT0024844,1790869,DTCC00392611,908333,19089
CHEMBL365910,P14780,,RANUWAUPDVMUKD-NHCUHLMSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15369398,INHIBITION,=,6,%,,,,,,,,,,,,,,Inhibition of MMP-9 (matrix metalloprotease) at 10 uM,,Macrocyclic inhibitors for peptide deformylase: a structure-activity relationship study of the ring size.,J. Med. Chem.,2004,47,20,"Hu X, Nguyen KT, Jiang VC, Lofland D, Moser HE, Pei D",,307804,DTCT0024844,1790870,DTCC00392611,908333,19089
CHEMBL365947,P14780,,WXPUJRINFGPEGC-VWLOTQADSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16153831,IC50,,,,,,,,,,,,,,,,,Inhibitory concentration against MMP-9; - = not available,Not Determined,Synthesis and SAR of highly selective MMP-13 inhibitors.,Bioorg. Med. Chem. Lett.,2005,15,22,"Li J, Rush TS, Li W, DeVincentis D, Du X, Hu Y, Thomason JR, Xiang JS, Skotnicki JS, Tam S, Cunningham KM, Chockalingam PS, Morris EA, Levin JI",,321294,DTCT0024844,1860385,DTCC00407674,1695368,19837
CHEMBL365990,P14780,,KLUMXQDRHKUFQH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15857146,IC50,,,,,,,,,,,,,,,,,In vitro inhibition of human Matrix metalloprotease 9; n.d.=not determined,Not Determined,C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging.,J. Med. Chem.,2005,48,9,"Breyholz HJ, Schäfers M, Wagner S, Höltke C, Faust A, Rabeneck H, Levkau B, Schober O, Kopka K",,305979,DTCT0024844,1828747,DTCC00399922,271890,19718
CHEMBL366060,P14780,,HYJDMXKMWHHPTM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15908214,KI,,,,,,,,,,,,,,,,,In vitro binding affinity against matrix metalloprotease 9; NT= Not tested,Not Determined,"Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.",Bioorg. Med. Chem. Lett.,2005,15,12,"Duan JJ, Lu Z, Wasserman ZR, Liu RQ, Covington MB, Decicco CP",,302628,DTCT0024844,1798577,DTCC00398339,130820,16433
CHEMBL366111,P14780,,WJULIBHPWZXMJA-IEBWSBKVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15324896,IC50,=,5.3,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease 9,,3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase.,Bioorg. Med. Chem. Lett.,2004,14,18,"Noe MC, Snow SL, Wolf-Gouveia LA, Mitchell PG, Lopresti-Morrow L, Reeves LM, Yocum SA, Liras JL, Vaughn M",,305044,DTCT0024844,1768936,DTCC00388400,142333,18227
CHEMBL366478,P14780,,RBLCSCFFNCADJO-UEEDVJNSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,=,5.05,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1419883,DTCC00371830,1786982,17147
CHEMBL366956,P14780,,DKXJVAHFRHPDKE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11327602,IC50,>,50000,NM,,,,,,,,,,,,,,"Inhibition of Gelatinase B, matrix metalloprotease-9",,"Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors.",Bioorg. Med. Chem. Lett.,2001,11,8,"Foley LH, Palermo R, Dunten P, Wang P",,71657,DTCT0024844,958520,DTCC00372967,206471,4784
CHEMBL366997,P14780,,UOBVGDSSMCMKCH-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,INHIBITION,=,1,%,,,,,,,,,,,,,,Percent remaining enzyme activity (RA) in human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105368,DTCT0024844,1103411,DTCC00371651,681217,5419
CHEMBL366997,P14780,,UOBVGDSSMCMKCH-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,KI,=,2000,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105399,DTCT0024844,1103410,DTCC00371651,681217,5419
CHEMBL3670691,P14780,,FBDOWURNGYMLPJ-IBGZPJMESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,120,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247674,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,173032,DTCC01703274,839513,64498
CHEMBL3670692,P14780,,KOVQMCGGWATESY-YADHBBJMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247675,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,165752,DTCC01703275,127019,64498
CHEMBL3670693,P14780,,KOVQMCGGWATESY-FCHUYYIVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,5000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247676,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,182299,DTCC01703276,1098405,64498
CHEMBL3670694,P14780,,KOVQMCGGWATESY-FGZHOGPDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,5000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247677,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,173460,DTCC01703277,289306,64498
CHEMBL3670695,P14780,,QCVLVTVGVJUODZ-UNMCSNQZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247678,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,179732,DTCC01703278,2031908,64498
CHEMBL3670696,P14780,,MFTZEUCXFCXINH-UNMCSNQZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247679,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,180950,DTCC01703279,1518861,64498
CHEMBL3670697,P14780,,CNPRJTXDIHRZPF-ZEQRLZLVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,10000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247681,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,178019,DTCC01703281,1357220,64498
CHEMBL3670698,P14780,,LFUNCOOVDREPBK-GOTSBHOMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247682,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,165606,DTCC01703282,1711859,64498
CHEMBL3670699,P14780,,QDHXNZRPVLUOML-DQEYMECFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,605,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247683,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,165997,DTCC01703283,774361,64498
CHEMBL3670700,P14780,,HCTHWCGSCVVHLJ-ZDUSSCGKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247685,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,161712,DTCC01703284,1583049,64498
CHEMBL3670701,P14780,,FFHINXVCVWQCSG-VXKWHMMOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247686,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,174745,DTCC01703285,904397,64498
CHEMBL3670702,P14780,,HXOLPPZDNXMRHR-UNMCSNQZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247687,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,172518,DTCC01703286,1357221,64498
CHEMBL3670703,P14780,,BMJUABISSDGKOA-UNMCSNQZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247688,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,169417,DTCC01703287,580739,64498
CHEMBL3670704,P14780,,NZUPMMOEPOVBQE-SFTDATJTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247689,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,179263,DTCC01703288,1680152,64498
CHEMBL3670705,P14780,,JUEZHKLAFJJQNE-VXKWHMMOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247690,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,166091,DTCC01703289,1389860,64498
CHEMBL3670706,P14780,,OFRXWZGHEVNQHU-VXKWHMMOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247691,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,180371,DTCC01703290,1836770,64498
CHEMBL3670707,P14780,,VFEIVMVXXWQZER-VXKWHMMOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247692,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,171063,DTCC01703291,1259462,64498
CHEMBL3670708,P14780,,IIUXBHAJTPNCIR-KKSFZXQISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247693,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,177776,DTCC01703292,1291821,64498
CHEMBL3670709,P14780,,KNJBHXZWYFARSA-HOTGVXAUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247694,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,177595,DTCC01703293,1647965,64498
CHEMBL3670710,P14780,,FRXRVVOCWBNHOQ-HOTGVXAUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,5000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247695,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,179664,DTCC01703294,1065482,64498
CHEMBL3670711,P14780,,MNXXFUIRJNLTHG-KBPBESRZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247696,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,160629,DTCC01703295,1771871,64498
CHEMBL3670712,P14780,,XNQPIVCSZRQAQO-HOTGVXAUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,5000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247697,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,157547,DTCC01703296,420053,64498
CHEMBL3670713,P14780,,ACXIBBRPTTWRDM-PMACEKPBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,10000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247698,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,164992,DTCC01703297,839514,64498
CHEMBL3670714,P14780,,RAOGWYCOADLHPD-SFTDATJTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247699,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,167688,DTCC01703298,548550,64498
CHEMBL3670715,P14780,,AVFCHUYQSZAIFE-VXKWHMMOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,235,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247700,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,179743,DTCC01703299,1998926,64498
CHEMBL3670716,P14780,,GSEYFLJSDKPLAI-KBPBESRZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247701,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,158012,DTCC01703300,1550906,64498
CHEMBL3670717,P14780,,VIPIKALUTUDDKU-IRXDYDNUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247702,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,157175,DTCC01703301,1771872,64498
CHEMBL3670718,P14780,,YUQQWAKBRAEWQZ-ROUUACIJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247703,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,182073,DTCC01703302,710012,64498
CHEMBL3670719,P14780,,PLIPLRCYJWMTFY-HOTGVXAUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,5000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247704,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,168039,DTCC01703303,968343,64498
CHEMBL3670720,P14780,,BFJIOGLKGISOKV-GJZGRUSLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,199,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247705,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,167907,DTCC01703304,1226403,64498
CHEMBL3670721,P14780,,UOTSSZSXOLHXGG-ROUUACIJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247706,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,178327,DTCC01703305,1291822,64498
CHEMBL36715,P14780,PIRACETAM,GMZVRMREEHBGGF-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7374536,DTCC00176308,1383779,46191
CHEMBL36715,P14780,PIRACETAM,GMZVRMREEHBGGF-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7374537,DTCC00176308,1383779,46191
CHEMBL367331,P14780,,AWCFKZLKKUVLGN-KFJBMODSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,INHIBITION,=,18,%,,,,,,,,,,,,,,Percent remaining enzyme activity (RA) in human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105368,DTCT0024844,1095532,DTCC00371299,1036733,5419
CHEMBL367331,P14780,,AWCFKZLKKUVLGN-KFJBMODSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,KI,=,4000,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105399,DTCT0024844,1095531,DTCC00371299,1036733,5419
CHEMBL367524,P14780,,XWZIZWWEAJZAMO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11327602,IC50,=,696,NM,,,,,,,,,,,,,,"Inhibition of Gelatinase B, matrix metalloprotease-9",,"Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors.",Bioorg. Med. Chem. Lett.,2001,11,8,"Foley LH, Palermo R, Dunten P, Wang P",,71657,DTCT0024844,971605,DTCC00374233,174399,4784
CHEMBL3675541,P14780,,RESDGLIYQGGYGR-HOTGVXAUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247707,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,175095,DTCC01708173,1615861,64498
CHEMBL3675542,P14780,,AEOWLQGPNGMHBP-ROUUACIJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,141,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247708,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,182898,DTCC01708174,613076,64498
CHEMBL3675543,P14780,,XLKQIIIKETWLMI-HKUYNNGSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,618,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247709,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,172589,DTCC01708175,742365,64498
CHEMBL3675544,P14780,,YWXFICBFTYVHJU-PMACEKPBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247710,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,164131,DTCC01708176,1324414,64498
CHEMBL3675545,P14780,,JYGPMNNMAQCQMG-PMACEKPBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247711,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,182712,DTCC01708177,645830,64498
CHEMBL3675546,P14780,,VXYUSBYRYYLNHT-PMACEKPBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247712,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,168692,DTCC01708178,2031940,64498
CHEMBL3675547,P14780,,DKTMPYACSYBQIF-VXKWHMMOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,5000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247713,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,174167,DTCC01708179,1194373,64498
CHEMBL3675548,P14780,,IIRLMDJELCRLPB-DQEYMECFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247715,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,172038,DTCC01708181,548584,64498
CHEMBL3675549,P14780,,MXXLMDWJDJQNCZ-KXBFYZLASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247716,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,164907,DTCC01708182,968371,64498
CHEMBL3675550,P14780,,OTOPPWBRBAVQCM-VXKWHMMOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,5000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247717,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,162682,DTCC01708183,450759,64498
CHEMBL3675551,P14780,,LHURUBKIFBZDNZ-OALUTQOASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247718,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,159769,DTCC01708184,2031941,64498
CHEMBL3675552,P14780,,MTMSSQNYFAAJSR-VXKWHMMOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,5000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247719,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,157508,DTCC01708185,321876,64498
CHEMBL3675553,P14780,,XTHLTIMASWPNRH-AKRCKQFNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247720,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,167185,DTCC01708186,904423,64498
CHEMBL3675554,P14780,,SJWYFGLDVUQIEF-DEOSSOPVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247721,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,172290,DTCC01708187,1259488,64498
CHEMBL3675555,P14780,,HXQNDQXHRNVKIA-PMACEKPBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247722,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,176064,DTCC01708188,127053,64498
CHEMBL3675556,P14780,,UIEDXQBYCVBGGE-PMACEKPBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247723,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,170685,DTCC01708189,1966318,64498
CHEMBL3675557,P14780,,BBERXYYXGJGELS-PMACEKPBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,685,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247724,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,180728,DTCC01708190,127054,64498
CHEMBL3675558,P14780,,YUUVADHCMFJYGO-PMACEKPBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247725,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,157371,DTCC01708191,872152,64498
CHEMBL3675559,P14780,,MVSSFLIDOBOIBL-PMACEKPBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247726,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,157643,DTCC01708192,1098436,64498
CHEMBL3675560,P14780,,YWAKWFLUKNCYMP-PMACEKPBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,391,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247727,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,168931,DTCC01708193,1194374,64498
CHEMBL3675561,P14780,,FHLZDDVMTVCEOC-SFTDATJTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,5000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247728,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,166477,DTCC01708194,1804477,64498
CHEMBL3675562,P14780,,ZQBDVTJLOHIYJN-SFTDATJTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,5000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247729,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,160799,DTCC01708195,1550939,64498
CHEMBL3675563,P14780,,MXFJZXDWWXHXMV-UIOOFZCWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247730,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,184226,DTCC01708196,645831,64498
CHEMBL3675563,P14780,,MXFJZXDWWXHXMV-UIOOFZCWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,5000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247741,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,158176,DTCC01708196,645831,64498
CHEMBL3675564,P14780,,RIICMTINBCLPOY-UIOOFZCWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247731,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,180089,DTCC01708197,806748,64498
CHEMBL3675565,P14780,,BVKYTKVUMKYONQ-NSOVKSMOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247732,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,168159,DTCC01708198,1389896,64498
CHEMBL3675566,P14780,,XHPUXKQBUUHEIP-DQEYMECFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247733,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,162537,DTCC01708199,1130545,64498
CHEMBL3675567,P14780,,NHZSRXRDEWWJJS-CONSDPRKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247734,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,157084,DTCC01708200,1065520,64498
CHEMBL3675568,P14780,,MDMQULYGCYNXQN-DFBJGRDBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,10000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247735,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,176763,DTCC01708201,321877,64498
CHEMBL3675569,P14780,,SAJAWNZBKHGJOW-MBMZGMDYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247736,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,173602,DTCC01708202,1550940,64498
CHEMBL3675570,P14780,,ZQUJAHCTHDEZMJ-DQEYMECFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247737,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,181564,DTCC01708203,211,64498
CHEMBL3675571,P14780,,CKYKLNXMCJIGPN-NSOVKSMOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247738,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,175199,DTCC01708204,839552,64498
CHEMBL3675572,P14780,,WLZQVNRDQZYTID-PEFOLFAWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,5000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247739,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,178996,DTCC01708205,2063689,64498
CHEMBL3675573,P14780,,OUZMHHWAGJCAFA-PMERELPUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,645,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247740,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,159830,DTCC01708206,1000927,64498
CHEMBL3675574,P14780,,TYSBKRRVVCMKQG-NSOVKSMOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,10000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247742,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,162827,DTCC01708207,1518882,64498
CHEMBL3675575,P14780,,BICNEVCTASLTLM-DQEYMECFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247743,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,174907,DTCC01708208,1161801,64498
CHEMBL3675576,P14780,,CWSSLFKLYYDKBD-CONSDPRKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,10000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247744,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,166196,DTCC01708209,516548,64498
CHEMBL3675577,P14780,,NLIWJNDBQYUCSF-DFBJGRDBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,5000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247745,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,181436,DTCC01708210,321878,64498
CHEMBL3675578,P14780,,KHHNQNYSKXXUCV-NSOVKSMOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,50000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247746,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,173137,DTCC01708211,2063690,64498
CHEMBL3675579,P14780,,KAUWQENTXQTKQG-DQEYMECFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,5000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247747,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,169785,DTCC01708212,1771918,64498
CHEMBL3675580,P14780,,IADFBNIHFKDTRS-NSOVKSMOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,100000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247748,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,168515,DTCC01708213,1194375,64498
CHEMBL3675581,P14780,,CXPHOOFGGKZGTC-IRXDYDNUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247749,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,161977,DTCC01708214,212,64498
CHEMBL3675582,P14780,,GIEQMQWMJSYCKB-IRXDYDNUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247750,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,179103,DTCC01708215,1033284,64498
CHEMBL3675583,P14780,,CPYISUHNJGFCRY-OALUTQOASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247751,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,171254,DTCC01708216,1486575,64498
CHEMBL3675584,P14780,,VCJGVCZITQVJET-HOTGVXAUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247752,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,175608,DTCC01708217,1901139,64498
CHEMBL3675585,P14780,,QQGKYSPTORHWNZ-VXKWHMMOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,859,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247753,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,175793,DTCC01708218,1804478,64498
CHEMBL3675586,P14780,,UWVBDELWTIGPFO-BBRMVZONSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,5000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247754,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,180936,DTCC01708219,62372,64498
CHEMBL3675587,P14780,,ZMGHGYMGQVMACZ-OALUTQOASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247755,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,169797,DTCC01708220,1486576,64498
CHEMBL3675588,P14780,,GWHSSPUFNDIEEQ-HOTGVXAUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247756,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,162156,DTCC01708221,677985,64498
CHEMBL3675589,P14780,,CTCTZAXBKWKMKL-OALUTQOASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247757,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,160687,DTCC01708222,904424,64498
CHEMBL3675590,P14780,,PXQPONLRTWLOTH-IJHRGXPZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247758,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,164271,DTCC01708223,1000928,64498
CHEMBL3675591,P14780,,DUPWUQYVKWCUOG-NRFANRHFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,284,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247759,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,180850,DTCC01708224,839553,64498
CHEMBL3675592,P14780,,KEHDBOGRIVHUBV-ROUUACIJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,242,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247760,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,167387,DTCC01708225,968372,64498
CHEMBL3675593,P14780,,QFGALMYSDQBVRH-VXKWHMMOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,874,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247761,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,167501,DTCC01708226,936273,64498
CHEMBL3675594,P14780,,ZWXRGJMHGHMUMB-SFTDATJTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247762,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,159524,DTCC01708227,1740101,64498
CHEMBL3675595,P14780,,VLFDPMJDVIHWPI-ROUUACIJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247763,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,163491,DTCC01708228,645832,64498
CHEMBL3675596,P14780,,KGPPRBTYRFIDAL-GOTSBHOMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,5000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247767,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,184284,DTCC01708229,904425,64498
CHEMBL3675597,P14780,,MUGAWCXYWNGHML-GOTSBHOMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,5000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247768,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,172446,DTCC01708230,420085,64498
CHEMBL3675598,P14780,,JMWVTDZGNUFBMO-VXKWHMMOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247769,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,174628,DTCC01708231,1740102,64498
CHEMBL3675599,P14780,,UUDTVMMARAFNKG-VXKWHMMOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,5000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247770,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,172991,DTCC01708232,904426,64498
CHEMBL3675600,P14780,,GOLLITFKIKKRMV-DQEYMECFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,5000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247771,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,167315,DTCC01708233,1259489,64498
CHEMBL3675601,P14780,,BLDFRIYOIZRRJI-ZEQRLZLVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,5000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247772,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,162099,DTCC01708234,645833,64498
CHEMBL3675602,P14780,,FXBVEEBXIZYGRY-DQEYMECFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,5000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247773,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,161756,DTCC01708235,580782,64498
CHEMBL3675603,P14780,,FKTHQTYGTOEBAW-MHZLTWQESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,396,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247775,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,169608,DTCC01708236,159656,64498
CHEMBL3675604,P14780,,KSDQQJBQFBNDIC-ROUUACIJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,10000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247776,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,183516,DTCC01708237,159657,64498
CHEMBL3675605,P14780,,NIAIEBGBRXKPAO-NHTMILBNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,248222,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,156815,DTCC01708238,256074,64498
CHEMBL3675606,P14780,,MMIHYNVQXYWTFM-PKTZIBPZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20817735,KI,=,10000,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14747512,DTCC01708239,2106911,69686
CHEMBL3675606,P14780,,MMIHYNVQXYWTFM-PKTZIBPZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22689580,KI,=,10000,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14747511,DTCC01708239,2106910,68703
CHEMBL3675606,P14780,,MMIHYNVQXYWTFM-PKTZIBPZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,5000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247766,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,184532,DTCC01708239,1901140,64498
CHEMBL3675607,P14780,,KDDWLGBIYXTPJG-FQEVSTJZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22689580,KI,=,2628,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14759266,DTCC01708240,2111479,68703
CHEMBL3675607,P14780,,KDDWLGBIYXTPJG-FQEVSTJZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22689580,KI,=,2628,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14759915,DTCC01708240,2111479,68703
CHEMBL3675607,P14780,,KDDWLGBIYXTPJG-FQEVSTJZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,>,1000,NM,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. The inhibition tests and the evaluation of the inhibition constants (Ki) on the various MMPs were carried out as described by Devel et al. (Devel et al. 2006 J. Biol. Chem. (7)).,247774,Pseudodipeptides as MMP inhibitors,,2014,,,,,1535379,DTCT0024844,185022,DTCC01708240,289344,64498
CHEMBL367710,P14780,,HFCXLBPJFPHTAN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,=,59.2,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1416486,DTCC00371039,1209047,17147
CHEMBL367722,P14780,,AEBYYXPQFGRZDC-FCHUYYIVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,INHIBITION,=,13,%,,,,,,,,,,,,,,Percent remaining enzyme activity (RA) in human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105368,DTCT0024844,1118069,DTCC00371709,681216,5419
CHEMBL367722,P14780,,AEBYYXPQFGRZDC-FCHUYYIVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,KI,=,7500,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105399,DTCT0024844,1118068,DTCC00371709,681216,5419
CHEMBL367959,P14780,,IHNYAHCZDRILEC-AAEUAGOBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,INHIBITION,=,9,%,,,,,,,,,,,,,,Percent remaining enzyme activity (RA) in human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105368,DTCT0024844,1094285,DTCC00373679,1554396,5419
CHEMBL367959,P14780,,IHNYAHCZDRILEC-AAEUAGOBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,KI,=,5500,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105399,DTCT0024844,1094284,DTCC00373679,1554396,5419
CHEMBL368180,P14780,,ONDDWGCONIGAEF-RARQCXRASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,INHIBITION,=,11,%,,,,,,,,,,,,,,Percent remaining enzyme activity (RA) in human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105368,DTCT0024844,1104959,DTCC00371855,520001,5419
CHEMBL368180,P14780,,ONDDWGCONIGAEF-RARQCXRASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,KI,=,3200,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105399,DTCT0024844,1104958,DTCC00371855,520001,5419
CHEMBL368205,P14780,,LICJLIVFDQFASY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,=,9.12,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1417563,DTCC00373685,1851653,17147
CHEMBL368347,P14780,(+)-SECOISOLARICIRESINOL,PUETUDUXMCLALY-HOTGVXAUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,IC50,,,,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain incubated for 20 mins by fluorimetric assay,Not Determined,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827436,DTCT0024844,10535422,DTCC00371311,1812173,48665
CHEMBL368857,P14780,,GMNFREWQYNXZAF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,=,6.36,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1411447,DTCC00109175,951234,17147
CHEMBL368966,P14780,,DBMDIXBZZAINQH-MBSDFSHPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,INHIBITION,=,22,%,,,,,,,,,,,,,,Percent remaining enzyme activity (RA) in human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105368,DTCT0024844,1131288,DTCC00371356,1683653,5419
CHEMBL369184,P14780,,LWQVGCDPZDYMHI-BBRMVZONSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,INHIBITION,=,1,%,,,,,,,,,,,,,,Percent remaining enzyme activity (RA) in human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105368,DTCT0024844,1121061,DTCC00371503,1743528,5419
CHEMBL369184,P14780,,LWQVGCDPZDYMHI-BBRMVZONSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,KI,=,900,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105399,DTCT0024844,1121060,DTCC00371503,1743528,5419
CHEMBL369317,P14780,,ODABXNMRQKCARG-GOSISDBHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15713379,IC50,=,4517,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.,Bioorg. Med. Chem. Lett.,2005,15,5,"Rossello A, Nuti E, Carelli P, Orlandini E, Macchia M, Nencetti S, Zandomeneghi M, Balzano F, Uccello Barretta G, Albini A, Benelli R, Cercignani G, Murphy G, Balsamo A",,305737,DTCT0024844,1745777,DTCC00381878,6892,18841
CHEMBL369419,P14780,,BNFQSPBDDPIXCF-SECBINFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,INHIBITION,=,7,%,,,,,,,,,,,,,,Percent remaining enzyme activity (RA) in human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105368,DTCT0024844,1107699,DTCC00370757,1069142,5419
CHEMBL369419,P14780,,BNFQSPBDDPIXCF-SECBINFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,KI,=,3300,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105399,DTCT0024844,1107698,DTCC00370757,1069142,5419
CHEMBL369495,P14780,,FWBWWWORJVQVID-YOEHRIQHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,INHIBITION,=,3,%,,,,,,,,,,,,,,Percent remaining enzyme activity (RA) in human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105368,DTCT0024844,1104954,DTCC00370781,487803,5419
CHEMBL369495,P14780,,FWBWWWORJVQVID-YOEHRIQHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,KI,=,600,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105399,DTCT0024844,1104953,DTCC00370781,487803,5419
CHEMBL369536,P14780,,QQULKIIBIKMAGK-QWRGUYRKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15341955,KI,,,,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9; NA denotes no activity upto solubility limit,No Activity,Synthesis and evaluation of novel oxazoline MMP inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,19,"Cook GR, Manivannan E, Underdahl T, Lukacova V, Zhang Y, Balaz S",,303050,DTCT0024844,1715902,DTCC00389511,1209229,17054
CHEMBL36994,P14780,ANIRACETAM,ZXNRTKGTQJPIJK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7273418,DTCC00176277,1447877,46191
CHEMBL36994,P14780,ANIRACETAM,ZXNRTKGTQJPIJK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7273419,DTCC00176277,1447877,46191
CHEMBL36999,P14780,,JMTSRJRSBJJBGP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12668018,IC50,=,6,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease 9 (MMP-9).,,Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,8,"Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS",,105528,DTCT0024844,1263073,DTCC00174438,1752641,6276
CHEMBL370032,P14780,,GMNFREWQYNXZAF-UEWHNOOISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16107143,KI,=,6.35,NM,,,,,,,,,,,,,,Inhibition of MOCAc-Pro-Leu-Gly-Leu-A2p (Dnp)-Ala-Arg-NH2 binding to human matrix metalloprotease-9 (MMP-9),,"A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.",J. Med. Chem.,2005,48,17,"Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S",,307380,DTCT0024844,1815691,DTCC00397476,370066,19409
CHEMBL370129,P14780,,KQEHQRICYJKJLB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16084720,IC50,=,21,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metallopeptidase 9,,Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2005,15,19,"Levin JI, Chen JM, Laakso LM, Du M, Du X, Venkatesan AM, Sandanayaka V, Zask A, Xu J, Xu W, Zhang Y, Skotnicki JS",,321249,DTCT0024844,1861754,DTCC00408041,1808244,19752
CHEMBL370129,P14780,,KQEHQRICYJKJLB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16084720,IC50,=,21,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metallopeptidase 9,,Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2005,15,19,"Levin JI, Chen JM, Laakso LM, Du M, Du X, Venkatesan AM, Sandanayaka V, Zask A, Xu J, Xu W, Zhang Y, Skotnicki JS",,321249,DTCT0024844,1862273,DTCC00408041,1808245,19752
CHEMBL370333,P14780,,HOXYEQZQHOZJQN-NDEPHWFRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16153831,IC50,,,,,,,,,,,,,,,,,Inhibitory concentration against MMP-9; - = not available,Not Determined,Synthesis and SAR of highly selective MMP-13 inhibitors.,Bioorg. Med. Chem. Lett.,2005,15,22,"Li J, Rush TS, Li W, DeVincentis D, Du X, Hu Y, Thomason JR, Xiang JS, Skotnicki JS, Tam S, Cunningham KM, Chockalingam PS, Morris EA, Levin JI",,321294,DTCT0024844,1860433,DTCC00407680,370185,19837
CHEMBL3704903,P14780,,GHBQSNPRMVUGFE-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,>,10000,NM,,,,,,,,,,,,,,"BindingDB_Patents: Enzyme Assay. The molecules are tested in dose-response studies on the following enzymes MMP1, MMP3, MMP9, ADAMS and ADAM10 according to the same protocol as that described for the TACE enzyme in example 28 but with different substrates (MMP R and D system reference: P126-990 and ADAM R and D system reference: ES003).",320815,"N-[2-hydroxycarbamoyl-2-(piperazinyl) ethyl] benzamide compounds, their preparation and their use as TACE inhibitors",,2015,,,,,1536182,DTCT0024844,165317,DTCC01737547,366999,65180
CHEMBL3704910,P14780,,PNRXTCCMSJTZGK-DEOSSOPVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,>,10000,NM,,,,,,,,,,,,,,"BindingDB_Patents: Enzyme Assay. The molecules are tested in dose-response studies on the following enzymes MMP1, MMP3, MMP9, ADAMS and ADAM10 according to the same protocol as that described for the TACE enzyme in example 28 but with different substrates (MMP R and D system reference: P126-990 and ADAM R and D system reference: ES003).",320816,"N-[2-hydroxycarbamoyl-2-(piperazinyl) ethyl] benzamide compounds, their preparation and their use as TACE inhibitors",,2015,,,,,1536182,DTCT0024844,174207,DTCC01737554,1337005,65180
CHEMBL3704919,P14780,,PWHWIWBGOFSUOR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,>,10000,NM,,,,,,,,,,,,,,"BindingDB_Patents: Enzyme Assay. The molecules are tested in dose-response studies on the following enzymes MMP1, MMP3, MMP9, ADAMS and ADAM10 according to the same protocol as that described for the TACE enzyme in example 28 but with different substrates (MMP R and D system reference: P126-990 and ADAM R and D system reference: ES003).",320817,"N-[2-hydroxycarbamoyl-2-(piperazinyl) ethyl] benzamide compounds, their preparation and their use as TACE inhibitors",,2015,,,,,1536182,DTCT0024844,170534,DTCC01737563,1784183,65180
CHEMBL370631,P14780,,RPOIZUWTBLHTNU-YTTGMZPUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16153831,IC50,,,,,,,,,,,,,,,,,Inhibitory concentration against MMP-9; - = not available,Not Determined,Synthesis and SAR of highly selective MMP-13 inhibitors.,Bioorg. Med. Chem. Lett.,2005,15,22,"Li J, Rush TS, Li W, DeVincentis D, Du X, Hu Y, Thomason JR, Xiang JS, Skotnicki JS, Tam S, Cunningham KM, Chockalingam PS, Morris EA, Levin JI",,321294,DTCT0024844,338871,DTCC00407679,1566231,19837
CHEMBL370662,P14780,(3-BROMOPHENYLAMINO)METHYLENEDIPHOSPHONIC ACID,SYHPXVAOJHTCRU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24071448,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain (unknown origin) using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured after 2 to 4 hrs by fluorometric assay,,Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.,Bioorg. Med. Chem.,2013,21,21,"Tauro M, Laghezza A, Loiodice F, Agamennone M, Campestre C, Tortorella P",,990168,DTCT0024844,12629004,DTCC00001220,2060610,56259
CHEMBL370685,P14780,,GIJHNOWTLZLFTF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15857146,IC50,=,1,NM,,,,,,,,,,,,,,In vitro inhibition of human Matrix metalloprotease 9,,C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging.,J. Med. Chem.,2005,48,9,"Breyholz HJ, Schäfers M, Wagner S, Höltke C, Faust A, Rabeneck H, Levkau B, Schober O, Kopka K",,305380,DTCT0024844,1828774,DTCC00400047,271894,19718
CHEMBL370825,P14780,,SQODILRODCBOCF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16084720,IC50,=,221,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metallopeptidase 9,,Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2005,15,19,"Levin JI, Chen JM, Laakso LM, Du M, Du X, Venkatesan AM, Sandanayaka V, Zask A, Xu J, Xu W, Zhang Y, Skotnicki JS",,321249,DTCT0024844,1861791,DTCC00408078,1554839,19752
CHEMBL370825,P14780,,SQODILRODCBOCF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16084720,IC50,=,221,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metallopeptidase 9,,Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2005,15,19,"Levin JI, Chen JM, Laakso LM, Du M, Du X, Venkatesan AM, Sandanayaka V, Zask A, Xu J, Xu W, Zhang Y, Skotnicki JS",,321249,DTCT0024844,1862309,DTCC00408078,1554843,19752
CHEMBL371199,P14780,,CKPNTYRTTDOFLD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15908214,KI,>,2130,NM,,,,,,,,,,,,,,In vitro binding affinity against matrix metalloprotease 9,,"Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.",Bioorg. Med. Chem. Lett.,2005,15,12,"Duan JJ, Lu Z, Wasserman ZR, Liu RQ, Covington MB, Decicco CP",,302347,DTCT0024844,1800412,DTCC00398230,843308,16433
CHEMBL371362,P14780,,RLVHPDACJUGNSL-ZRTDVJLTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16107143,KI,=,277.97,NM,,,,,,,,,,,,,,Inhibition of MOCAc-Pro-Leu-Gly-Leu-A2p (Dnp)-Ala-Arg-NH2 binding to human matrix metalloprotease-9 (MMP-9),,"A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.",J. Med. Chem.,2005,48,17,"Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S",,307380,DTCT0024844,1815802,DTCC00397607,142428,19409
CHEMBL371600,P14780,,IUOUVCOHELGZDO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15857146,IC50,=,14,NM,,,,,,,,,,,,,,In vitro inhibition of human Matrix metalloprotease 9,,C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging.,J. Med. Chem.,2005,48,9,"Breyholz HJ, Schäfers M, Wagner S, Höltke C, Faust A, Rabeneck H, Levkau B, Schober O, Kopka K",,305380,DTCT0024844,1828778,DTCC00400451,531691,19718
CHEMBL37161,P14780,FENBENDAZOLE,HDDSHPAODJUKPD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7332934,DTCC00174892,2089748,46191
CHEMBL37161,P14780,FENBENDAZOLE,HDDSHPAODJUKPD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7332935,DTCC00174892,2089748,46191
CHEMBL371781,P14780,,WZUCVDGGDSHNQU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15908214,KI,>,2130,NM,,,,,,,,,,,,,,In vitro binding affinity against matrix metalloprotease 9,,"Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.",Bioorg. Med. Chem. Lett.,2005,15,12,"Duan JJ, Lu Z, Wasserman ZR, Liu RQ, Covington MB, Decicco CP",,302347,DTCT0024844,1800225,DTCC00398284,1361040,16433
CHEMBL372188,P14780,"5-[4-(4-BROMO-PHENOXY)-PHENYL]-5-[4-(3-TRIBUTYLSTANNANYL-BENZOYL)-PIPERAZIN-1-YL]-PYRIMIDINE-2,4,6-TRIONE",,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15857146,IC50,,,,,,,,,,,,,,,,,In vitro inhibition of human Matrix metalloprotease 9; n.d.=not determined,Not Determined,C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging.,J. Med. Chem.,2005,48,9,"Breyholz HJ, Schäfers M, Wagner S, Höltke C, Faust A, Rabeneck H, Levkau B, Schober O, Kopka K",,305979,DTCT0024844,1828961,DTCC00399923,174648,19718
CHEMBL372263,P14780,,OCXZZMWHJAJWII-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15857146,IC50,=,550,NM,,,,,,,,,,,,,,In vitro inhibition of human Matrix metalloprotease 9,,C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging.,J. Med. Chem.,2005,48,9,"Breyholz HJ, Schäfers M, Wagner S, Höltke C, Faust A, Rabeneck H, Levkau B, Schober O, Kopka K",,305380,DTCT0024844,1828946,DTCC00399894,77779,19718
CHEMBL372470,P14780,,OXKSBCZGUUDVJJ-HJZHLRNFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16107143,KI,=,6.58,NM,,,,,,,,,,,,,,Inhibition of MOCAc-Pro-Leu-Gly-Leu-A2p (Dnp)-Ala-Arg-NH2 binding to human matrix metalloprotease-9 (MMP-9),,"A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.",J. Med. Chem.,2005,48,17,"Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S",,307380,DTCT0024844,1815686,DTCC00397728,1209299,19409
CHEMBL372659,P14780,,CPNHPERKWKQFHI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15908214,KI,>,2130,NM,,,,,,,,,,,,,,In vitro binding affinity against matrix metalloprotease 9,,"Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.",Bioorg. Med. Chem. Lett.,2005,15,12,"Duan JJ, Lu Z, Wasserman ZR, Liu RQ, Covington MB, Decicco CP",,302347,DTCT0024844,1800083,DTCC00398190,130821,16433
CHEMBL372702,P14780,,PTSHMCCZVCAMNJ-WNEYBHKTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16107143,KI,=,0.31,NM,,,,,,,,,,,,,,Inhibition of MOCAc-Pro-Leu-Gly-Leu-A2p (Dnp)-Ala-Arg-NH2 binding to human matrix metalloprotease-9 (MMP-9),,"A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.",J. Med. Chem.,2005,48,17,"Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S",,307380,DTCT0024844,1815806,DTCC00397755,854976,19409
CHEMBL372705,P14780,,KTPFSPDDZUMWHL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15857146,IC50,=,57,NM,,,,,,,,,,,,,,In vitro inhibition of human Matrix metalloprotease 9,,C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging.,J. Med. Chem.,2005,48,9,"Breyholz HJ, Schäfers M, Wagner S, Höltke C, Faust A, Rabeneck H, Levkau B, Schober O, Kopka K",,305380,DTCT0024844,1828954,DTCC00400020,596115,19718
CHEMBL372795,P14780,STREPTOMYCIN,UCSJYZPVAKXKNQ-HZYVHMACSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7478098,DTCC00411395,51509,46191
CHEMBL372795,P14780,STREPTOMYCIN,UCSJYZPVAKXKNQ-HZYVHMACSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7478099,DTCC00411395,51509,46191
CHEMBL372908,P14780,,XRGWUGBXRHDGDG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16084720,IC50,=,71,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metallopeptidase 9,,Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2005,15,19,"Levin JI, Chen JM, Laakso LM, Du M, Du X, Venkatesan AM, Sandanayaka V, Zask A, Xu J, Xu W, Zhang Y, Skotnicki JS",,321249,DTCT0024844,1861779,DTCC00408063,66390,19752
CHEMBL372908,P14780,,XRGWUGBXRHDGDG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16084720,IC50,=,71,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metallopeptidase 9,,Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2005,15,19,"Levin JI, Chen JM, Laakso LM, Du M, Du X, Venkatesan AM, Sandanayaka V, Zask A, Xu J, Xu W, Zhang Y, Skotnicki JS",,321249,DTCT0024844,1862299,DTCC00408063,66391,19752
CHEMBL372914,P14780,,IJXPNMMIIHZGBN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15857146,IC50,=,10,NM,,,,,,,,,,,,,,In vitro inhibition of human Matrix metalloprotease 9,,C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging.,J. Med. Chem.,2005,48,9,"Breyholz HJ, Schäfers M, Wagner S, Höltke C, Faust A, Rabeneck H, Levkau B, Schober O, Kopka K",,305380,DTCT0024844,1828957,DTCC00399924,2014659,19718
CHEMBL373154,P14780,,WOGNSQDLIXXYFU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15908214,KI,=,2040,NM,,,,,,,,,,,,,,In vitro binding affinity against matrix metalloprotease 9,,"Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.",Bioorg. Med. Chem. Lett.,2005,15,12,"Duan JJ, Lu Z, Wasserman ZR, Liu RQ, Covington MB, Decicco CP",,302347,DTCT0024844,1800237,DTCC00398286,1715489,16433
CHEMBL373275,P14780,,JJPRJMIBECZYNN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16420030,ACTIVITY,,,,,,,,,,,,,,,,,Inhibitory activity against MMP9 upto 50uM,Not Active,Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.,J. Med. Chem.,2006,49,2,"Ma D, Jiang Y, Chen F, Gong LK, Ding K, Xu Y, Wang R, Ge A, Ren J, Li J, Li J, Ye Q",,330178,DTCT0024844,1886083,DTCC00110065,66437,20234
CHEMBL373311,P14780,,LAHYEFDNWASMJY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15908214,KI,>,2130,NM,,,,,,,,,,,,,,In vitro binding affinity against matrix metalloprotease 9,,"Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.",Bioorg. Med. Chem. Lett.,2005,15,12,"Duan JJ, Lu Z, Wasserman ZR, Liu RQ, Covington MB, Decicco CP",,302347,DTCT0024844,1800071,DTCC00398032,2035576,16433
CHEMBL373438,P14780,,VEMPUXZNKSUVFD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041924,DTCC00444513,305297,22157
CHEMBL373532,P14780,,SCOVLRMEIYKGOU-IRXDYDNUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17256836,IC50,=,113,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.",J. Med. Chem.,2007,50,4,"Yao W, Zhuo J, Burns DM, Xu M, Zhang C, Li YL, Qian DQ, He C, Weng L, Shi E, Lin Q, Agrios C, Burn TC, Caulder E, Covington MB, Fridman JS, Friedman S, Katiyar K, Hollis G, Li Y, Liu C, Liu X, Marando CA, Newton R, Pan M, Scherle P, Taylor N, Vaddi K, Wasserman ZR, Wynn R, Yeleswaram S, Jalluri R, Bower M, Zhou BB, Metcalf B",,425541,DTCT0024844,2019792,DTCC00438874,467214,21880
CHEMBL373532,P14780,,SCOVLRMEIYKGOU-IRXDYDNUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18036818,IC50,=,113,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.,Bioorg. Med. Chem. Lett.,2008,18,1,"Yao W, Zhuo J, Burns DM, Li YL, Qian DQ, Zhang C, He C, Xu M, Shi E, Li Y, Marando CA, Covington MB, Yang G, Liu X, Pan M, Fridman JS, Scherle P, Wasserman ZR, Hollis G, Vaddi K, Yeleswaram S, Newton R, Friedman S, Metcalf B",,461667,DTCT0024844,2276544,DTCC00438874,455616,25086
CHEMBL373694,P14780,,CDIBBFPULKXHGN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041928,DTCC00444500,855451,22157
CHEMBL373721,P14780,,WZGKUAJQZGCNHS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17276072,IC50,=,330,NM,,cell_based,,,,,,,,,,,,Inhibition of human recombinant MMP9 expressed in mouse myeloma cells,,Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.,Bioorg. Med. Chem.,2007,15,6,"Nuti E, Orlandini E, Nencetti S, Rossello A, Innocenti A, Scozzafava A, Supuran CT",,435728,DTCT0024844,2079357,DTCC00449740,358851,22603
CHEMBL373831,P14780,,XAUUSUAZNMIGRK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,=,18,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041943,DTCC00444490,1049041,22157
CHEMBL373853,P14780,,CDQQKPZINNWUDS-ROUUACIJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17256836,IC50,>,5000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.",J. Med. Chem.,2007,50,4,"Yao W, Zhuo J, Burns DM, Xu M, Zhang C, Li YL, Qian DQ, He C, Weng L, Shi E, Lin Q, Agrios C, Burn TC, Caulder E, Covington MB, Fridman JS, Friedman S, Katiyar K, Hollis G, Li Y, Liu C, Liu X, Marando CA, Newton R, Pan M, Scherle P, Taylor N, Vaddi K, Wasserman ZR, Wynn R, Yeleswaram S, Jalluri R, Bower M, Zhou BB, Metcalf B",,425541,DTCT0024844,2019786,DTCC00438907,790106,21880
CHEMBL374114,P14780,,MDNQMINKKFNDQI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041913,DTCC00444446,757982,22157
CHEMBL374377,P14780,,VWKXFDZWHLCIIU-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17088065,IC50,=,59,NM,,cell_based,,,,,,,,,,,,Inhibition of human recombinant MMP9 expressed in mouse myeloma cells,,alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.,Bioorg. Med. Chem.,2007,15,2,"Biasone A, Tortorella P, Campestre C, Agamennone M, Preziuso S, Chiappini M, Nuti E, Carelli P, Rossello A, Mazza F, Gallina C",,432507,DTCT0024844,2061807,DTCC00447804,1684492,22402
CHEMBL374478,P14780,RIFAMPICIN,JQXXHWHPUNPDRT-WLSIYKJHSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7479549,DTCC00437710,51504,46191
CHEMBL374478,P14780,RIFAMPICIN,JQXXHWHPUNPDRT-WLSIYKJHSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7479550,DTCC00437710,51504,46191
CHEMBL374953,P14780,,RLWLGGMXWQFGGX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041915,DTCC00444440,1787760,22157
CHEMBL375013,P14780,,IWSABXACJQMTBL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041918,DTCC00444530,1566561,22157
CHEMBL3751971,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26638045,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP9 after 2 hrs using FS-6 as substrate by fluorometry,,"Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors.",Eur. J. Med. Chem.,2016,108,,"Sjli S, Nuti E, Camodeca C, Bilto I, Rossello A, Winberg JO, Sylte I, Adekoya OA.",,1550087,DTCT0024844,59805,DTCC00071689,1162219,65811
CHEMBL3751997,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26810711,IC50,=,19,NM,,,,,,,,,,,,,,"Inhibition of human MMP9 using (7-methoxycoumarin-4-yl) acetyl pro-Leu-Gly-Leu-[3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl]-Ala-Arg-NH2 as substrate preincubated for 30 mins followed by substrate addition by microplate reader analysis",,Fluorinated matrix metalloproteinases inhibitors--Phosphonate based potential probes for positron emission tomography.,Bioorg. Med. Chem.,2016,24,4,"Beutel B, Daniliuc CG, Riemann B, Schafers M, Haufe G.",,1549577,DTCT0024844,50636,DTCC00072284,355028,65936
CHEMBL3752374,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26638045,IC50,=,8200,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP9 after 2 hrs using FS-6 as substrate by fluorometry,,"Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors.",Eur. J. Med. Chem.,2016,108,,"Sjli S, Nuti E, Camodeca C, Bilto I, Rossello A, Winberg JO, Sylte I, Adekoya OA.",,1550087,DTCT0024844,59806,DTCC00071690,1259964,65811
CHEMBL3752419,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26810711,IC50,>,100000,NM,,,,,,,,,,,,,,"Inhibition of human MMP9 using (7-methoxycoumarin-4-yl) acetyl pro-Leu-Gly-Leu-[3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl]-Ala-Arg-NH2 as substrate preincubated for 30 mins followed by substrate addition by microplate reader analysis",,Fluorinated matrix metalloproteinases inhibitors--Phosphonate based potential probes for positron emission tomography.,Bioorg. Med. Chem.,2016,24,4,"Beutel B, Daniliuc CG, Riemann B, Schafers M, Haufe G.",,1549577,DTCT0024844,50637,DTCC00072285,1804884,65936
CHEMBL3752513,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26638045,IC50,=,2000,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP9 after 2 hrs using FS-6 as substrate by fluorometry,,"Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors.",Eur. J. Med. Chem.,2016,108,,"Sjli S, Nuti E, Camodeca C, Bilto I, Rossello A, Winberg JO, Sylte I, Adekoya OA.",,1550087,DTCT0024844,59854,DTCC00071692,1837252,65811
CHEMBL3752564,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26810711,IC50,=,8.85,NM,,,,,,,,,,,,,,"Inhibition of human MMP9 using (7-methoxycoumarin-4-yl) acetyl pro-Leu-Gly-Leu-[3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl]-Ala-Arg-NH2 as substrate preincubated for 30 mins followed by substrate addition by microplate reader analysis",,Fluorinated matrix metalloproteinases inhibitors--Phosphonate based potential probes for positron emission tomography.,Bioorg. Med. Chem.,2016,24,4,"Beutel B, Daniliuc CG, Riemann B, Schafers M, Haufe G.",,1549577,DTCT0024844,50630,DTCC00072278,95261,65936
CHEMBL3752747,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26810711,IC50,=,393,NM,,,,,,,,,,,,,,"Inhibition of human MMP9 using (7-methoxycoumarin-4-yl) acetyl pro-Leu-Gly-Leu-[3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl]-Ala-Arg-NH2 as substrate preincubated for 30 mins followed by substrate addition by microplate reader analysis",,Fluorinated matrix metalloproteinases inhibitors--Phosphonate based potential probes for positron emission tomography.,Bioorg. Med. Chem.,2016,24,4,"Beutel B, Daniliuc CG, Riemann B, Schafers M, Haufe G.",,1549577,DTCT0024844,50632,DTCC00072280,1324856,65936
CHEMBL3752826,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26810711,IC50,>,100000,NM,,,,,,,,,,,,,,"Inhibition of human MMP9 using (7-methoxycoumarin-4-yl) acetyl pro-Leu-Gly-Leu-[3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl]-Ala-Arg-NH2 as substrate preincubated for 30 mins followed by substrate addition by microplate reader analysis",,Fluorinated matrix metalloproteinases inhibitors--Phosphonate based potential probes for positron emission tomography.,Bioorg. Med. Chem.,2016,24,4,"Beutel B, Daniliuc CG, Riemann B, Schafers M, Haufe G.",,1549577,DTCT0024844,50633,DTCC00072281,1933521,65936
CHEMBL375318,P14780,,XKOVTPPNKADGLU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,INHIBITION,=,20,%,,,,,,,,,,,,,,Inhibition of MMP9 at 10 uM,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429671,DTCT0024844,2041941,DTCC00444456,1534612,22157
CHEMBL375319,P14780,2-(4-METHOXYBENZENESULFONYL)OCTANOIC ACID HYDROXYAMIDE,VMCQYTNLTZJCIG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,=,119,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041936,DTCC00002420,1755544,22157
CHEMBL37537,P14780,PROTOCATECHUIC ACID,YQUVCSBJEUQKSH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,-1,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103919,DTCC00174549,313612,43205
CHEMBL3753984,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26638045,IC50,=,26000,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP9 after 2 hrs using FS-6 as substrate by fluorometry,,"Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors.",Eur. J. Med. Chem.,2016,108,,"Sjli S, Nuti E, Camodeca C, Bilto I, Rossello A, Winberg JO, Sylte I, Adekoya OA.",,1550087,DTCT0024844,59803,DTCC00071688,1901590,65811
CHEMBL3754094,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26638045,IC50,=,5.3,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP9 after 2 hrs using FS-6 as substrate by fluorometry,,"Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors.",Eur. J. Med. Chem.,2016,108,,"Sjli S, Nuti E, Camodeca C, Bilto I, Rossello A, Winberg JO, Sylte I, Adekoya OA.",,1550087,DTCT0024844,59802,DTCC00071687,516993,65811
CHEMBL3754100,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26638045,IC50,=,6200,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP9 after 2 hrs using FS-6 as substrate by fluorometry,,"Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors.",Eur. J. Med. Chem.,2016,108,,"Sjli S, Nuti E, Camodeca C, Bilto I, Rossello A, Winberg JO, Sylte I, Adekoya OA.",,1550087,DTCT0024844,59807,DTCC00071691,840004,65811
CHEMBL375418,P14780,,ZCDHAHOTIYZFKF-HOTGVXAUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17256836,IC50,=,77,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.",J. Med. Chem.,2007,50,4,"Yao W, Zhuo J, Burns DM, Xu M, Zhang C, Li YL, Qian DQ, He C, Weng L, Shi E, Lin Q, Agrios C, Burn TC, Caulder E, Covington MB, Fridman JS, Friedman S, Katiyar K, Hollis G, Li Y, Liu C, Liu X, Marando CA, Newton R, Pan M, Scherle P, Taylor N, Vaddi K, Wasserman ZR, Wynn R, Yeleswaram S, Jalluri R, Bower M, Zhou BB, Metcalf B",,425541,DTCT0024844,2019783,DTCC00438915,1566520,21880
CHEMBL375418,P14780,,ZCDHAHOTIYZFKF-HOTGVXAUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18036818,IC50,=,77,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.,Bioorg. Med. Chem. Lett.,2008,18,1,"Yao W, Zhuo J, Burns DM, Li YL, Qian DQ, Zhang C, He C, Xu M, Shi E, Li Y, Marando CA, Covington MB, Yang G, Liu X, Pan M, Fridman JS, Scherle P, Wasserman ZR, Hollis G, Vaddi K, Yeleswaram S, Newton R, Friedman S, Metcalf B",,461667,DTCT0024844,2276525,DTCC00438915,1555575,25086
CHEMBL3754243,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26810711,IC50,=,18.5,NM,,,,,,,,,,,,,,"Inhibition of human MMP9 using (7-methoxycoumarin-4-yl) acetyl pro-Leu-Gly-Leu-[3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl]-Ala-Arg-NH2 as substrate preincubated for 30 mins followed by substrate addition by microplate reader analysis",,Fluorinated matrix metalloproteinases inhibitors--Phosphonate based potential probes for positron emission tomography.,Bioorg. Med. Chem.,2016,24,4,"Beutel B, Daniliuc CG, Riemann B, Schafers M, Haufe G.",,1549577,DTCT0024844,50631,DTCC00072279,1869235,65936
CHEMBL3754302,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26810711,IC50,=,96.4,NM,,,,,,,,,,,,,,"Inhibition of human MMP9 using (7-methoxycoumarin-4-yl) acetyl pro-Leu-Gly-Leu-[3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl]-Ala-Arg-NH2 as substrate preincubated for 30 mins followed by substrate addition by microplate reader analysis",,Fluorinated matrix metalloproteinases inhibitors--Phosphonate based potential probes for positron emission tomography.,Bioorg. Med. Chem.,2016,24,4,"Beutel B, Daniliuc CG, Riemann B, Schafers M, Haufe G.",,1549577,DTCT0024844,50634,DTCC00072282,840009,65936
CHEMBL3754314,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26810711,IC50,>,100000,NM,,,,,,,,,,,,,,"Inhibition of human MMP9 using (7-methoxycoumarin-4-yl) acetyl pro-Leu-Gly-Leu-[3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl]-Ala-Arg-NH2 as substrate preincubated for 30 mins followed by substrate addition by microplate reader analysis",,Fluorinated matrix metalloproteinases inhibitors--Phosphonate based potential probes for positron emission tomography.,Bioorg. Med. Chem.,2016,24,4,"Beutel B, Daniliuc CG, Riemann B, Schafers M, Haufe G.",,1549577,DTCT0024844,50635,DTCC00072283,62801,65936
CHEMBL376180,P14780,AMINOPTERIN,TVZGACDUOSZQKY-LBPRGKRZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7286059,DTCC00445374,120968,46191
CHEMBL376180,P14780,AMINOPTERIN,TVZGACDUOSZQKY-LBPRGKRZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7286060,DTCC00445374,120968,46191
CHEMBL376314,P14780,,TXIMSNHHNJBLTN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,=,2500,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041932,DTCC00444493,564292,22157
CHEMBL376316,P14780,P-DODECYLAMINOPHENOL,UFCRKZJPBDDMSF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23953690,INHIBITION,=,50,%,,cell_based,,,,,,,,,,,,Inhibition of MMP9 activity in human HT1080 cells at 1 uM after 24 hrs,,Inhibitory effects of p-dodecylaminophenol on the invasiveness of human fibrosarcoma cell line HT1080.,Bioorg. Med. Chem.,2013,21,19,"Takahashi N, Takeda K, Imai M",,980577,DTCT0024844,12548208,DTCC00002586,783399,55644
CHEMBL376557,P14780,,BUKCBCDGRPOFJP-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17088065,IC50,=,21,NM,,cell_based,,,,,,,,,,,,Inhibition of human recombinant MMP9 expressed in mouse myeloma cells,,alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.,Bioorg. Med. Chem.,2007,15,2,"Biasone A, Tortorella P, Campestre C, Agamennone M, Preziuso S, Chiappini M, Nuti E, Carelli P, Rossello A, Mazza F, Gallina C",,432507,DTCT0024844,2061806,DTCC00447810,1005132,22402
CHEMBL376841,P14780,,NXFJEQASTSQSQQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17276072,IC50,=,2200,NM,,cell_based,,,,,,,,,,,,Inhibition of human recombinant MMP9 expressed in mouse myeloma cells,,Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.,Bioorg. Med. Chem.,2007,15,6,"Nuti E, Orlandini E, Nencetti S, Rossello A, Innocenti A, Scozzafava A, Supuran CT",,435728,DTCT0024844,2079359,DTCC00449738,778662,22603
CHEMBL3770688,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26871660,IC50,=,4500,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate after 3 hrs by fluorometric assay,,Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models.,Eur. J. Med. Chem.,2016,111,,"Camodeca C, Nuti E, Tepshi L, Boero S, Tuccinardi T, Stura EA, Poggi A, Zocchi MR, Rossello A.",,1559054,DTCT0024844,101500,DTCC00079604,62862,66304
CHEMBL3770935,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26871660,IC50,=,24000,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate after 3 hrs by fluorometric assay,,Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models.,Eur. J. Med. Chem.,2016,111,,"Camodeca C, Nuti E, Tepshi L, Boero S, Tuccinardi T, Stura EA, Poggi A, Zocchi MR, Rossello A.",,1559054,DTCT0024844,101499,DTCC00079605,678496,66304
CHEMBL377112,P14780,,SKLSVPSTTVFNGB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16632358,IC50,=,0.6,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,12,"Zhang YM, Fan X, Xiang B, Chakravarty D, Scannevin R, Burke S, Karnachi P, Rhodes K, Jackson P",,361727,DTCT0024844,1937021,DTCC00423371,1775948,20885
CHEMBL377317,P14780,,SFHMNFHDIRPFKM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16723229,IC50,=,191,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,15,"Park K, Aplasca A, Du MT, Sun L, Zhu Y, Zhang Y, Levin JI",,377987,DTCT0024844,1969646,DTCC00428531,778474,21111
CHEMBL377317,P14780,,SFHMNFHDIRPFKM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17064892,IC50,=,191,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Identification of potent and selective TACE inhibitors via the S1 pocket.,Bioorg. Med. Chem. Lett.,2007,17,1,"Condon JS, Joseph-McCarthy D, Levin JI, Lombart HG, Lovering FE, Sun L, Wang W, Xu W, Zhang Y",,440763,DTCT0024844,2154024,DTCC00428531,778734,23077
CHEMBL377700,P14780,,QDDDNZKRPVNLGQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16420030,IC50,=,10030,NM,,,,,,,,,,,,,,Inhibitory activity against MMP9,,Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.,J. Med. Chem.,2006,49,2,"Ma D, Jiang Y, Chen F, Gong LK, Ding K, Xu Y, Wang R, Ge A, Ren J, Li J, Li J, Ye Q",,330169,DTCT0024844,1886138,DTCC00412723,1102373,20234
CHEMBL377862,P14780,,KRGBAILWDVNOCW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16723229,IC50,=,907,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,15,"Park K, Aplasca A, Du MT, Sun L, Zhu Y, Zhang Y, Levin JI",,377987,DTCT0024844,1969631,DTCC00428540,649907,21111
CHEMBL37788,P14780,,XPLPBRFYVPFHDL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12668018,IC50,=,2,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease 9 (MMP-9).,,Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,8,"Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS",,105528,DTCT0024844,1248965,DTCC00174389,1206846,6276
CHEMBL37837,P14780,,ULIBGNMOWDICPU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12668018,IC50,=,2,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease 9 (MMP-9).,,Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,8,"Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS",,105528,DTCT0024844,1270169,DTCC00174855,400345,6276
CHEMBL378575,P14780,,WMQMSHMVCOAVEN-CLTKARDFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16913712,IC50,=,105900,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening.,J. Med. Chem.,2006,49,17,"Schepetkin IA, Khlebnikov AI, Kirpotina LN, Quinn MT",,386349,DTCT0024844,1958905,DTCC00430807,435472,21205
CHEMBL37858,P14780,SARAFLOXACIN,XBHBWNFJWIASRO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7479907,DTCC00180187,51508,46191
CHEMBL37858,P14780,SARAFLOXACIN,XBHBWNFJWIASRO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7479908,DTCC00180187,51508,46191
CHEMBL378740,P14780,,JGNJABZIGHTRNB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16632358,IC50,=,10005,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,12,"Zhang YM, Fan X, Xiang B, Chakravarty D, Scannevin R, Burke S, Karnachi P, Rhodes K, Jackson P",,361727,DTCT0024844,1937017,DTCC00423304,843579,20885
CHEMBL378860,P14780,,KIBZYGPSCVIUCQ-MYKKPKGFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16913712,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human MMP9 at 100 uM,Not Active,Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening.,J. Med. Chem.,2006,49,17,"Schepetkin IA, Khlebnikov AI, Kirpotina LN, Quinn MT",,386390,DTCT0024844,1958852,DTCC00430565,370394,21205
CHEMBL378878,P14780,,CQLFBASNQPHDMA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16632358,IC50,=,53,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,12,"Zhang YM, Fan X, Xiang B, Chakravarty D, Scannevin R, Burke S, Karnachi P, Rhodes K, Jackson P",,361727,DTCT0024844,1937034,DTCC00423316,293432,20885
CHEMBL379220,P14780,,PFPAVZNBPUOGBR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16632358,IC50,=,0.8,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,12,"Zhang YM, Fan X, Xiang B, Chakravarty D, Scannevin R, Burke S, Karnachi P, Rhodes K, Jackson P",,361727,DTCT0024844,1937025,DTCC00423128,1263448,20885
CHEMBL379247,P14780,,VFGCXHQYVYXXSU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16420030,IC50,=,3390,NM,,,,,,,,,,,,,,Inhibitory activity against MMP9,,Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.,J. Med. Chem.,2006,49,2,"Ma D, Jiang Y, Chen F, Gong LK, Ding K, Xu Y, Wang R, Ge A, Ren J, Li J, Li J, Ye Q",,330169,DTCT0024844,1886140,DTCC00412626,584720,20234
CHEMBL379271,P14780,,FHIQJWGHFZCTKT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16632358,IC50,=,2124,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,12,"Zhang YM, Fan X, Xiang B, Chakravarty D, Scannevin R, Burke S, Karnachi P, Rhodes K, Jackson P",,361727,DTCT0024844,1937043,DTCC00423344,843580,20885
CHEMBL3792842,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,27038494,IC50,=,7.75,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 60 mins followed by substrate addition by fluorimetric analysis,,Selective non-zinc binding MMP-2 inhibitors: Novel benzamide Ilomastat analogs with anti-tumor metastasis.,Bioorg. Med. Chem. Lett.,2016,26,9,"Song J, Peng P, Chang J, Liu MM, Yu JM, Zhou L, Sun X.",,1572538,DTCT0024844,220685,DTCC00088746,236375,66798
CHEMBL3792916,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,27038494,IC50,=,1579.01,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 60 mins followed by substrate addition by fluorimetric analysis,,Selective non-zinc binding MMP-2 inhibitors: Novel benzamide Ilomastat analogs with anti-tumor metastasis.,Bioorg. Med. Chem. Lett.,2016,26,9,"Song J, Peng P, Chang J, Liu MM, Yu JM, Zhou L, Sun X.",,1572538,DTCT0024844,220663,DTCC00088745,1402350,66798
CHEMBL3792940,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,27038494,IC50,=,13.52,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 60 mins followed by substrate addition by fluorimetric analysis,,Selective non-zinc binding MMP-2 inhibitors: Novel benzamide Ilomastat analogs with anti-tumor metastasis.,Bioorg. Med. Chem. Lett.,2016,26,9,"Song J, Peng P, Chang J, Liu MM, Yu JM, Zhou L, Sun X.",,1572538,DTCT0024844,220703,DTCC00088752,1402351,66798
CHEMBL379315,P14780,,UVJAUFAPWQEHBT-YVLHZVERSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16913712,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human MMP9 at 100 uM,Not Active,Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening.,J. Med. Chem.,2006,49,17,"Schepetkin IA, Khlebnikov AI, Kirpotina LN, Quinn MT",,386390,DTCT0024844,1958819,DTCC00430716,1663507,21205
CHEMBL3793231,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,27038494,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 60 mins followed by substrate addition by fluorimetric analysis,,Selective non-zinc binding MMP-2 inhibitors: Novel benzamide Ilomastat analogs with anti-tumor metastasis.,Bioorg. Med. Chem. Lett.,2016,26,9,"Song J, Peng P, Chang J, Liu MM, Yu JM, Zhou L, Sun X.",,1572538,DTCT0024844,220688,DTCC00088747,1692542,66798
CHEMBL3793480,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,27038494,IC50,=,27.32,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 60 mins followed by substrate addition by fluorimetric analysis,,Selective non-zinc binding MMP-2 inhibitors: Novel benzamide Ilomastat analogs with anti-tumor metastasis.,Bioorg. Med. Chem. Lett.,2016,26,9,"Song J, Peng P, Chang J, Liu MM, Yu JM, Zhou L, Sun X.",,1572538,DTCT0024844,220697,DTCC00088750,1946023,66798
CHEMBL3794076,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,27038494,IC50,=,7297.04,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 60 mins followed by substrate addition by fluorimetric analysis,,Selective non-zinc binding MMP-2 inhibitors: Novel benzamide Ilomastat analogs with anti-tumor metastasis.,Bioorg. Med. Chem. Lett.,2016,26,9,"Song J, Peng P, Chang J, Liu MM, Yu JM, Zhou L, Sun X.",,1572538,DTCT0024844,220694,DTCC00088749,496860,66798
CHEMBL3794468,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,27038494,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 60 mins followed by substrate addition by fluorimetric analysis,,Selective non-zinc binding MMP-2 inhibitors: Novel benzamide Ilomastat analogs with anti-tumor metastasis.,Bioorg. Med. Chem. Lett.,2016,26,9,"Song J, Peng P, Chang J, Liu MM, Yu JM, Zhou L, Sun X.",,1572538,DTCT0024844,220691,DTCC00088748,2011853,66798
CHEMBL3794512,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,27038494,IC50,=,155.19,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate preincubated for 60 mins followed by substrate addition by fluorimetric analysis,,Selective non-zinc binding MMP-2 inhibitors: Novel benzamide Ilomastat analogs with anti-tumor metastasis.,Bioorg. Med. Chem. Lett.,2016,26,9,"Song J, Peng P, Chang J, Liu MM, Yu JM, Zhou L, Sun X.",,1572538,DTCT0024844,220700,DTCC00088751,819325,66798
CHEMBL379469,P14780,,IGMJBXNPPIZSAX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16289878,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,Conversion of potent MMP inhibitors into selective TACE inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,4,"Cherney RJ, King BW, Gilmore JL, Liu RQ, Covington MB, Duan JJ, Decicco CP",,334536,DTCT0024844,1895744,DTCC00415423,1242357,20373
CHEMBL379653,P14780,,XSFJTFAYDHIPHP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16632358,IC50,=,114,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,12,"Zhang YM, Fan X, Xiang B, Chakravarty D, Scannevin R, Burke S, Karnachi P, Rhodes K, Jackson P",,361727,DTCT0024844,1937041,DTCC00422941,1619807,20885
CHEMBL379763,P14780,,MXMCYIBSFFNNTF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16723229,IC50,=,19,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,15,"Park K, Aplasca A, Du MT, Sun L, Zhu Y, Zhang Y, Levin JI",,377987,DTCT0024844,1969597,DTCC00428552,131113,21111
CHEMBL38,P14780,TRETINOIN,SHGAZHPCJJPHSC-YCNIQYBTSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23953690,INHIBITION,,,,,cell_based,,,,,,,,,,,,Inhibition of MMP9 activity in human HT1080 cells at 1 uM after 24 hrs,Not Active,Inhibitory effects of p-dodecylaminophenol on the invasiveness of human fibrosarcoma cell line HT1080.,Bioorg. Med. Chem.,2013,21,19,"Takahashi N, Takeda K, Imai M",,980577,DTCT0024844,12548206,DTCC00134063,21562,55644
CHEMBL38,P14780,TRETINOIN,SHGAZHPCJJPHSC-YCNIQYBTSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7453407,DTCC00134063,51513,46191
CHEMBL38,P14780,TRETINOIN,SHGAZHPCJJPHSC-YCNIQYBTSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7453408,DTCC00134063,51513,46191
CHEMBL380049,P14780,,NPWNPFHGYNOBOO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16723229,IC50,=,591,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,15,"Park K, Aplasca A, Du MT, Sun L, Zhu Y, Zhang Y, Levin JI",,377987,DTCT0024844,1969717,DTCC00428568,1393760,21111
CHEMBL380895,P14780,,YVFLHFYMDLEMFY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16516466,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.",Bioorg. Med. Chem. Lett.,2006,16,10,"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,354461,DTCT0024844,1926523,DTCC00110328,520521,20786
CHEMBL38106,P14780,,JXIIDVGEPSOIKK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12668018,IC50,=,5,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease 9 (MMP-9).,,Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,8,"Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS",,105528,DTCT0024844,1272310,DTCC00174560,690615,6276
CHEMBL381173,P14780,,SFSKPKLATIXRLH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16516466,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.",Bioorg. Med. Chem. Lett.,2006,16,10,"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,354461,DTCT0024844,1926509,DTCC00421728,1165867,20786
CHEMBL381189,P14780,,NSZHVJWSFHBPMB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16392792,KI,=,6600,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.,J. Med. Chem.,2006,49,1,"Pirard B, Matter H",,329822,DTCT0024844,1880239,DTCC00411959,391231,20214
CHEMBL381224,P14780,,QFTWPDUNHCKGKX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16084720,IC50,=,251,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metallopeptidase 9,,Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2005,15,19,"Levin JI, Chen JM, Laakso LM, Du M, Du X, Venkatesan AM, Sandanayaka V, Zask A, Xu J, Xu W, Zhang Y, Skotnicki JS",,321249,DTCT0024844,1861774,DTCC00408055,1295815,19752
CHEMBL381224,P14780,,QFTWPDUNHCKGKX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16084720,IC50,=,251,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metallopeptidase 9,,Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2005,15,19,"Levin JI, Chen JM, Laakso LM, Du M, Du X, Venkatesan AM, Sandanayaka V, Zask A, Xu J, Xu W, Zhang Y, Skotnicki JS",,321249,DTCT0024844,1862294,DTCC00408055,1295816,19752
CHEMBL38180,P14780,,XQRSTZJAXGSSTI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12668018,IC50,=,2,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease 9 (MMP-9).,,Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,8,"Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS",,105528,DTCT0024844,1279047,DTCC00174371,2044435,6276
CHEMBL381953,P14780,,QRWVORUSUQDRRN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16516466,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.",Bioorg. Med. Chem. Lett.,2006,16,10,"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,354461,DTCT0024844,1926510,DTCC00421715,7598,20786
CHEMBL382201,P14780,,BZVYQWLRCHLAGK-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17088065,INHIBITION,=,40,%,,cell_based,,,,,,,,,,,,Inhibition of human recombinant MMP9 expressed in mouse myeloma cells at 100 uM,,alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.,Bioorg. Med. Chem.,2007,15,2,"Biasone A, Tortorella P, Campestre C, Agamennone M, Preziuso S, Chiappini M, Nuti E, Carelli P, Rossello A, Mazza F, Gallina C",,432513,DTCT0024844,2061732,DTCC00413190,552885,22402
CHEMBL382227,P14780,,VYVUMCRZVGOXEK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16632358,IC50,=,1.4,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,12,"Zhang YM, Fan X, Xiang B, Chakravarty D, Scannevin R, Burke S, Karnachi P, Rhodes K, Jackson P",,361727,DTCT0024844,1937044,DTCC00423333,1134601,20885
CHEMBL382352,P14780,,MJYOLQLJRBLLML-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16516466,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.",Bioorg. Med. Chem. Lett.,2006,16,10,"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,354461,DTCT0024844,1926513,DTCC00421659,227888,20786
CHEMBL3826991,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,27452283,IC50,=,5494,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 by colorimetric analysis,,Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.,Bioorg. Med. Chem.,2016,24,18,"Adhikari N, Halder AK, Mallick S, Saha A, Saha KD, Jha T.",,1589854,DTCT0024844,325980,DTCC00102286,517273,67557
CHEMBL3827024,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,27452283,IC50,=,2093,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 by colorimetric analysis,,Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.,Bioorg. Med. Chem.,2016,24,18,"Adhikari N, Halder AK, Mallick S, Saha A, Saha KD, Jha T.",,1589854,DTCT0024844,325973,DTCC00102293,1422907,67557
CHEMBL3827073,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,27452283,IC50,=,492,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 by colorimetric analysis,,Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.,Bioorg. Med. Chem.,2016,24,18,"Adhikari N, Halder AK, Mallick S, Saha A, Saha KD, Jha T.",,1589854,DTCT0024844,325982,DTCC00102284,1869506,67557
CHEMBL3827162,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,27452283,IC50,=,5715,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 by colorimetric analysis,,Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.,Bioorg. Med. Chem.,2016,24,18,"Adhikari N, Halder AK, Mallick S, Saha A, Saha KD, Jha T.",,1589854,DTCT0024844,317025,DTCC00102280,1422905,67557
CHEMBL3827196,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,27452283,IC50,=,5991,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 by colorimetric analysis,,Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.,Bioorg. Med. Chem.,2016,24,18,"Adhikari N, Halder AK, Mallick S, Saha A, Saha KD, Jha T.",,1589854,DTCT0024844,325978,DTCC00102288,192237,67557
CHEMBL3827243,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,27452283,IC50,=,880,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 by colorimetric analysis,,Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.,Bioorg. Med. Chem.,2016,24,18,"Adhikari N, Halder AK, Mallick S, Saha A, Saha KD, Jha T.",,1589854,DTCT0024844,325972,DTCC00102294,192238,67557
CHEMBL3827250,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,27452283,IC50,=,714.9,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 by colorimetric analysis,,Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.,Bioorg. Med. Chem.,2016,24,18,"Adhikari N, Halder AK, Mallick S, Saha A, Saha KD, Jha T.",,1589854,DTCT0024844,317028,DTCC00102277,1162527,67557
CHEMBL3827306,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,27452283,IC50,=,11280,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 by colorimetric analysis,,Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.,Bioorg. Med. Chem.,2016,24,18,"Adhikari N, Halder AK, Mallick S, Saha A, Saha KD, Jha T.",,1589854,DTCT0024844,325952,DTCC00102275,646584,67557
CHEMBL3827453,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,27452283,IC50,=,5882,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 by colorimetric analysis,,Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.,Bioorg. Med. Chem.,2016,24,18,"Adhikari N, Halder AK, Mallick S, Saha A, Saha KD, Jha T.",,1589854,DTCT0024844,317024,DTCC00102281,646585,67557
CHEMBL3827615,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,27452283,IC50,=,636,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 by colorimetric analysis,,Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.,Bioorg. Med. Chem.,2016,24,18,"Adhikari N, Halder AK, Mallick S, Saha A, Saha KD, Jha T.",,1589854,DTCT0024844,317023,DTCC00102282,1099203,67557
CHEMBL3827640,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,27452283,IC50,=,8170,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 by colorimetric analysis,,Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.,Bioorg. Med. Chem.,2016,24,18,"Adhikari N, Halder AK, Mallick S, Saha A, Saha KD, Jha T.",,1589854,DTCT0024844,317027,DTCC00102278,160391,67557
CHEMBL3827680,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,27452283,IC50,=,6740,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 by colorimetric analysis,,Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.,Bioorg. Med. Chem.,2016,24,18,"Adhikari N, Halder AK, Mallick S, Saha A, Saha KD, Jha T.",,1589854,DTCT0024844,325974,DTCC00102292,1454773,67557
CHEMBL3827735,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,27452283,IC50,=,4282,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 by colorimetric analysis,,Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.,Bioorg. Med. Chem.,2016,24,18,"Adhikari N, Halder AK, Mallick S, Saha A, Saha KD, Jha T.",,1589854,DTCT0024844,317022,DTCC00102283,1227213,67557
CHEMBL3827781,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,27452283,IC50,=,7407,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 by colorimetric analysis,,Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.,Bioorg. Med. Chem.,2016,24,18,"Adhikari N, Halder AK, Mallick S, Saha A, Saha KD, Jha T.",,1589854,DTCT0024844,317029,DTCC00102276,1066313,67557
CHEMBL382781,P14780,,WAYKDGBJSUBARX-NCRNUEESSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15837315,IC50,>,30000,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 in MMPi assay,,A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs.,Bioorg. Med. Chem. Lett.,2005,15,9,"Rossello A, Nuti E, Catalani MP, Carelli P, Orlandini E, Rapposelli S, Tuccinardi T, Atkinson SJ, Murphy G, Balsamo A",,305685,DTCT0024844,1841408,DTCC00403447,110078,18987
CHEMBL3827869,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,27452283,IC50,=,7432,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 by colorimetric analysis,,Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.,Bioorg. Med. Chem.,2016,24,18,"Adhikari N, Halder AK, Mallick S, Saha A, Saha KD, Jha T.",,1589854,DTCT0024844,325951,DTCC00102272,1099202,67557
CHEMBL3828051,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,27452283,IC50,=,7001,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 by colorimetric analysis,,Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.,Bioorg. Med. Chem.,2016,24,18,"Adhikari N, Halder AK, Mallick S, Saha A, Saha KD, Jha T.",,1589854,DTCT0024844,325981,DTCC00102285,840318,67557
CHEMBL3828088,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,27452283,IC50,=,38449,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 by colorimetric analysis,,Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.,Bioorg. Med. Chem.,2016,24,18,"Adhikari N, Halder AK, Mallick S, Saha A, Saha KD, Jha T.",,1589854,DTCT0024844,325954,DTCC00102273,872904,67557
CHEMBL3828226,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,27452283,IC50,=,1155,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 by colorimetric analysis,,Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.,Bioorg. Med. Chem.,2016,24,18,"Adhikari N, Halder AK, Mallick S, Saha A, Saha KD, Jha T.",,1589854,DTCT0024844,325971,DTCC00102295,1805194,67557
CHEMBL3828270,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,27452283,IC50,=,1824,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 by colorimetric analysis,,Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.,Bioorg. Med. Chem.,2016,24,18,"Adhikari N, Halder AK, Mallick S, Saha A, Saha KD, Jha T.",,1589854,DTCT0024844,325970,DTCC00102296,840319,67557
CHEMBL3828315,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,27452283,IC50,=,8710,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 by colorimetric analysis,,Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.,Bioorg. Med. Chem.,2016,24,18,"Adhikari N, Halder AK, Mallick S, Saha A, Saha KD, Jha T.",,1589854,DTCT0024844,325953,DTCC00102274,256786,67557
CHEMBL3828527,P14780,,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,27452283,IC50,=,8500,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 by colorimetric analysis,,Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.,Bioorg. Med. Chem.,2016,24,18,"Adhikari N, Halder AK, Mallick S, Saha A, Saha KD, Jha T.",,1589854,DTCT0024844,317026,DTCC00102279,1967037,67557
CHEMBL382975,P14780,,CVZIHNYAZLXRRS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16084720,IC50,=,12,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metallopeptidase 9,,Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2005,15,19,"Levin JI, Chen JM, Laakso LM, Du M, Du X, Venkatesan AM, Sandanayaka V, Zask A, Xu J, Xu W, Zhang Y, Skotnicki JS",,321249,DTCT0024844,1861801,DTCC00408095,681606,19752
CHEMBL382975,P14780,,CVZIHNYAZLXRRS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16084720,IC50,=,12,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metallopeptidase 9,,Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2005,15,19,"Levin JI, Chen JM, Laakso LM, Du M, Du X, Venkatesan AM, Sandanayaka V, Zask A, Xu J, Xu W, Zhang Y, Skotnicki JS",,321249,DTCT0024844,1862319,DTCC00408095,681608,19752
CHEMBL382975,P14780,,CVZIHNYAZLXRRS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17064892,IC50,=,71,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Identification of potent and selective TACE inhibitors via the S1 pocket.,Bioorg. Med. Chem. Lett.,2007,17,1,"Condon JS, Joseph-McCarthy D, Levin JI, Lombart HG, Lovering FE, Sun L, Wang W, Xu W, Zhang Y",,440763,DTCT0024844,2153864,DTCC00408095,682039,23077
CHEMBL383193,P14780,,UHEMMICIPFAOHZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16632358,IC50,=,1.6,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,12,"Zhang YM, Fan X, Xiang B, Chakravarty D, Scannevin R, Burke S, Karnachi P, Rhodes K, Jackson P",,361727,DTCT0024844,1937035,DTCC00423262,1004917,20885
CHEMBL38352,P14780,,GKDAXRUOVHMLSA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12668018,IC50,=,2,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease 9 (MMP-9).,,Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,8,"Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS",,105528,DTCT0024844,1270173,DTCC00174852,1272408,6276
CHEMBL383943,P14780,,CDXRSHKKQZISJY-CDJQDVQCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16913712,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human MMP9 at 135 uM,Not Active,Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening.,J. Med. Chem.,2006,49,17,"Schepetkin IA, Khlebnikov AI, Kirpotina LN, Quinn MT",,386387,DTCT0024844,1969840,DTCC00430778,1469808,21205
CHEMBL384467,P14780,DEXAMETHASONE,UREBDLICKHMUKA-CXSFZGCWSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7370167,DTCC00437785,639578,46191
CHEMBL384467,P14780,DEXAMETHASONE,UREBDLICKHMUKA-CXSFZGCWSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7370168,DTCC00437785,639578,46191
CHEMBL384665,P14780,,CWGOBWMKFRWKPM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041912,DTCC00444447,1982245,22157
CHEMBL385312,P14780,,KRJQQXQOPZJOSC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,=,148,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041942,DTCC00444483,629107,22157
CHEMBL385899,P14780,,KPJFDQSBTSOUHJ-YBEGLDIGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16913712,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human MMP9 at 90 uM,Not Active,Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening.,J. Med. Chem.,2006,49,17,"Schepetkin IA, Khlebnikov AI, Kirpotina LN, Quinn MT",,386392,DTCT0024844,1958805,DTCC00430779,693402,21205
CHEMBL386313,P14780,,DASVXRJADIYRNJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16913712,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human MMP9 at 160 uM,Not Active,Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening.,J. Med. Chem.,2006,49,17,"Schepetkin IA, Khlebnikov AI, Kirpotina LN, Quinn MT",,386396,DTCT0024844,1958761,DTCC00430863,661149,21205
CHEMBL386364,P14780,,RJZWEPFYPQHKQE-PUOZGBORSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16913712,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human MMP9 at 120 uM,Not Active,Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening.,J. Med. Chem.,2006,49,17,"Schepetkin IA, Khlebnikov AI, Kirpotina LN, Quinn MT",,386391,DTCT0024844,1958848,DTCC00430693,1916542,21205
CHEMBL386614,P14780,,CWGRXFKQAMAUHJ-BOPFTXTBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16913712,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human MMP9 at 125 uM,Not Active,Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening.,J. Med. Chem.,2006,49,17,"Schepetkin IA, Khlebnikov AI, Kirpotina LN, Quinn MT",,386388,DTCT0024844,1958807,DTCC00430751,1502120,21205
CHEMBL386630,P14780,TESTOSTERONE,MUMGGOZAMZWBJJ-DYKIIFRCSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7483151,DTCC00437190,477923,46191
CHEMBL386630,P14780,TESTOSTERONE,MUMGGOZAMZWBJJ-DYKIIFRCSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7483152,DTCC00437190,477923,46191
CHEMBL387202,P14780,,NJCBPLQYZDLBCA-IRXDYDNUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17256836,IC50,>,5000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.",J. Med. Chem.,2007,50,4,"Yao W, Zhuo J, Burns DM, Xu M, Zhang C, Li YL, Qian DQ, He C, Weng L, Shi E, Lin Q, Agrios C, Burn TC, Caulder E, Covington MB, Fridman JS, Friedman S, Katiyar K, Hollis G, Li Y, Liu C, Liu X, Marando CA, Newton R, Pan M, Scherle P, Taylor N, Vaddi K, Wasserman ZR, Wynn R, Yeleswaram S, Jalluri R, Bower M, Zhou BB, Metcalf B",,425541,DTCT0024844,2019782,DTCC00438921,1663624,21880
CHEMBL387202,P14780,,NJCBPLQYZDLBCA-IRXDYDNUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19457660,IC50,>,5000,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition.,Bioorg. Med. Chem. Lett.,2009,19,13,"Burns DM, Li YL, Shi E, He C, Xu M, Zhuo J, Zhang C, Qian DQ, Li Y, Wynn R, Covington MB, Katiyar K, Marando CA, Fridman JS, Scherle P, Friedman S, Metcalf B, Yao W",,523765,DTCT0024844,2828340,DTCC00438921,1653468,33677
CHEMBL38737,P14780,THIOACETAMIDE,YUKQRDCYNOVPGJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7483274,DTCC00179105,88637,46191
CHEMBL38737,P14780,THIOACETAMIDE,YUKQRDCYNOVPGJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7483275,DTCC00179105,88637,46191
CHEMBL388124,P14780,,FABNMTMBXQFDAV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17368021,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).",Bioorg. Med. Chem. Lett.,2007,17,10,"Sheppeck JE, Gilmore JL, Tebben A, Xue CB, Liu RQ, Decicco CP, Duan JJ",,438534,DTCT0024844,2101597,DTCC00455482,1146629,22885
CHEMBL388309,P14780,,SUZRJMQBDIHWSQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17276072,IC50,=,125000,NM,,cell_based,,,,,,,,,,,,Inhibition of human recombinant MMP9 expressed in mouse myeloma cells,,Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.,Bioorg. Med. Chem.,2007,15,6,"Nuti E, Orlandini E, Nencetti S, Rossello A, Innocenti A, Scozzafava A, Supuran CT",,435728,DTCT0024844,2079346,DTCC00449751,1970663,22603
CHEMBL38851,P14780,,XZWFHJUEAVOHHG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11212095,IC50,=,655,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.,Bioorg. Med. Chem. Lett.,2001,11,3,"Chollet AM, Le Diguarher T, Murray L, Bertrand M, Tucker GC, Sabatini M, Pierré A, Atassi G, Bonnet J, Casara P",,105358,DTCT0024844,643367,DTCC00180222,1261750,4635
CHEMBL388590,P14780,BENZBROMARONE,WHQCHUCQKNIQEC-UHFFFAOYSA-N,1,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7258319,DTCC00445492,153438,46191
CHEMBL388590,P14780,BENZBROMARONE,WHQCHUCQKNIQEC-UHFFFAOYSA-N,1,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7258320,DTCC00445492,153438,46191
CHEMBL388757,P14780,N6-BENZYLADENOSINE,MRPKNNSABYPGBF-LSCFUAHRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21035348,ACTIVITY,,,,,cell_based,,,,,,,,,,,,Induction of MMP9 activity in human T24 cells after 1 hr by zymography,Not Active,N6-Alkyladenosines: Synthesis and evaluation of in vitro anticancer activity.,Bioorg. Med. Chem.,2010,18,23,"Ottria R, Casati S, Baldoli E, Maier JA, Ciuffreda P",,687669,DTCT0024844,3605394,DTCC00449987,1919205,42024
CHEMBL388879,P14780,,UYVVHTPVCDOQRA-IRXDYDNUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17127067,INHIBITION,=,61,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 100 uM,,Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs.,Bioorg. Med. Chem.,2007,15,3,"Santos MA, Enyedy EA, Nuti E, Rossello A, Krupenko NI, Krupenko SA",,441105,DTCT0024844,2148752,DTCC00460189,2015254,23121
CHEMBL388982,P14780,,UZLNTZNPSMNCRL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17276072,IC50,=,286,NM,,cell_based,,,,,,,,,,,,Inhibition of human recombinant MMP9 expressed in mouse myeloma cells,,Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.,Bioorg. Med. Chem.,2007,15,6,"Nuti E, Orlandini E, Nencetti S, Rossello A, Innocenti A, Scozzafava A, Supuran CT",,435728,DTCT0024844,2079351,DTCC00449746,163842,22603
CHEMBL389020,P14780,,NEGPFWDWNNSJRQ-CYBMUJFWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17591762,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Potent and selective nonpeptidic inhibitors of procollagen C-proteinase.,J. Med. Chem.,2007,50,15,"Fish PV, Allan GA, Bailey S, Blagg J, Butt R, Collis MG, Greiling D, James K, Kendall J, McElroy A, McCleverty D, Reed C, Webster R, Whitlock GA",,440140,DTCT0024844,2113797,DTCC00452712,195826,23023
CHEMBL389020,P14780,,NEGPFWDWNNSJRQ-CYBMUJFWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17591762,INHIBITION,<,50,%,,,,,,,,,,,,,,Inhibition of MMP9 at 10 uM,,Potent and selective nonpeptidic inhibitors of procollagen C-proteinase.,J. Med. Chem.,2007,50,15,"Fish PV, Allan GA, Bailey S, Blagg J, Butt R, Collis MG, Greiling D, James K, Kendall J, McElroy A, McCleverty D, Reed C, Webster R, Whitlock GA",,440146,DTCT0024844,2113825,DTCC00452712,195826,23023
CHEMBL389020,P14780,,NEGPFWDWNNSJRQ-CYBMUJFWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17591762,INHIBITION,<,50,%,,,,,,,,,,,,,,Inhibition of MMP9 at 100 uM,,Potent and selective nonpeptidic inhibitors of procollagen C-proteinase.,J. Med. Chem.,2007,50,15,"Fish PV, Allan GA, Bailey S, Blagg J, Butt R, Collis MG, Greiling D, James K, Kendall J, McElroy A, McCleverty D, Reed C, Webster R, Whitlock GA",,440152,DTCT0024844,2113853,DTCC00452712,195826,23023
CHEMBL389020,P14780,,NEGPFWDWNNSJRQ-CYBMUJFWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17591762,INHIBITION,<,50,%,,,,,,,,,,,,,,Inhibition of MMP9 at 30 uM,,Potent and selective nonpeptidic inhibitors of procollagen C-proteinase.,J. Med. Chem.,2007,50,15,"Fish PV, Allan GA, Bailey S, Blagg J, Butt R, Collis MG, Greiling D, James K, Kendall J, McElroy A, McCleverty D, Reed C, Webster R, Whitlock GA",,440158,DTCT0024844,2113882,DTCC00452712,195826,23023
CHEMBL389020,P14780,,NEGPFWDWNNSJRQ-CYBMUJFWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,KI,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2457531,DTCC00452712,208200,32556
CHEMBL389621,P14780,HYDROCORTISONE,JYGXADMDTFJGBT-VWUMJDOOSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7306469,DTCC00445397,800578,46191
CHEMBL389621,P14780,HYDROCORTISONE,JYGXADMDTFJGBT-VWUMJDOOSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7306470,DTCC00445397,800578,46191
CHEMBL389691,P14780,,SBINJYYFUVHVNU-UPVQGACJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17368021,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).",Bioorg. Med. Chem. Lett.,2007,17,10,"Sheppeck JE, Gilmore JL, Tebben A, Xue CB, Liu RQ, Decicco CP, Duan JJ",,438534,DTCT0024844,2101594,DTCC00455488,952027,22885
CHEMBL389898,P14780,,HTKNWYDCBWYORK-HXUWFJFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17088065,IC50,,,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant MMP9 expressed in mouse myeloma cells,Not Determined,alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.,Bioorg. Med. Chem.,2007,15,2,"Biasone A, Tortorella P, Campestre C, Agamennone M, Preziuso S, Chiappini M, Nuti E, Carelli P, Rossello A, Mazza F, Gallina C",,432507,DTCT0024844,2061992,DTCC00447846,1555210,22402
CHEMBL391362,P14780,,SXQXJOREJVFQQR-BKMJKUGQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17188863,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2007,17,5,"Sheppeck JE, Gilmore JL, Yang A, Chen XT, Xue CB, Roderick J, Liu RQ, Covington MB, Decicco CP, Duan JJ",,453871,DTCT0024844,2221442,DTCC00478077,99287,24252
CHEMBL391509,P14780,,FNYMWMSAYUTPPB-IJULCPIYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17512742,IC50,=,38,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.,Bioorg. Med. Chem.,2007,15,14,"Moroy G, Denhez C, El Mourabit H, Toribio A, Dassonville A, Decarme M, Renault JH, Mirand C, Bellon G, Sapi J, Alix AJ, Hornebeck W, Bourguet E",,447907,DTCT0024844,2176042,DTCC00468628,909116,23716
CHEMBL392088,P14780,,BXSPGECKGKAUCR-GOSISDBHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17956082,IC50,=,1330,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.,J. Med. Chem.,2007,50,23,"Wagner S, Breyholz HJ, Law MP, Faust A, Höltke C, Schröer S, Haufe G, Levkau B, Schober O, Schäfers M, Kopka K",,451367,DTCT0024844,2204604,DTCC00471851,714474,24059
CHEMBL392172,P14780,,PFPQINANHHJKFH-LJQANCHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17188863,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2007,17,5,"Sheppeck JE, Gilmore JL, Yang A, Chen XT, Xue CB, Roderick J, Liu RQ, Covington MB, Decicco CP, Duan JJ",,453871,DTCT0024844,2221453,DTCC00478065,1620305,24252
CHEMBL392308,P14780,,KJOVWWTWOVUHSB-LJQANCHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17956082,IC50,=,69,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.,J. Med. Chem.,2007,50,23,"Wagner S, Breyholz HJ, Law MP, Faust A, Höltke C, Schröer S, Haufe G, Levkau B, Schober O, Schäfers M, Kopka K",,451367,DTCT0024844,2204600,DTCC00471855,1873303,24059
CHEMBL392312,P14780,,VMWZNZVYBAZMKQ-UKILVPOCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17276676,IC50,>,2000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,7,"Chen XT, Ghavimi B, Corbett RL, Xue CB, Liu RQ, Covington MB, Qian M, Vaddi KG, Christ DD, Hartman KD, Ribadeneira MD, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,447087,DTCT0024844,2169361,DTCC00464766,260535,23623
CHEMBL392571,P14780,,PUBARVPHTAEUJQ-GOSISDBHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17956082,IC50,=,7,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.,J. Med. Chem.,2007,50,23,"Wagner S, Breyholz HJ, Law MP, Faust A, Höltke C, Schröer S, Haufe G, Levkau B, Schober O, Schäfers M, Kopka K",,451367,DTCT0024844,2204598,DTCC00471857,1905592,24059
CHEMBL392572,P14780,,DFWYBNIMFAUWSX-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17956082,IC50,=,103,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.,J. Med. Chem.,2007,50,23,"Wagner S, Breyholz HJ, Law MP, Faust A, Höltke C, Schröer S, Haufe G, Levkau B, Schober O, Schäfers M, Kopka K",,451367,DTCT0024844,2204595,DTCC00471860,99252,24059
CHEMBL392974,P14780,,UEVLLYXFWPWEDN-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17956082,IC50,=,35000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.,J. Med. Chem.,2007,50,23,"Wagner S, Breyholz HJ, Law MP, Faust A, Höltke C, Schröer S, Haufe G, Levkau B, Schober O, Schäfers M, Kopka K",,451367,DTCT0024844,2204594,DTCC00471861,293894,24059
CHEMBL393444,P14780,,UEOYACNTKVVWRI-HFZDXXHNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17188863,KI,=,179,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2007,17,5,"Sheppeck JE, Gilmore JL, Yang A, Chen XT, Xue CB, Roderick J, Liu RQ, Covington MB, Decicco CP, Duan JJ",,453871,DTCT0024844,2221450,DTCC00478068,424602,24252
CHEMBL393445,P14780,,SSOHCNKODIJGFS-WINIVTDRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17188863,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2007,17,5,"Sheppeck JE, Gilmore JL, Yang A, Chen XT, Xue CB, Roderick J, Liu RQ, Covington MB, Decicco CP, Duan JJ",,453871,DTCT0024844,2221445,DTCC00478074,424603,24252
CHEMBL393793,P14780,,NKCMINBLFYGDJZ-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17956082,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.,J. Med. Chem.,2007,50,23,"Wagner S, Breyholz HJ, Law MP, Faust A, Höltke C, Schröer S, Haufe G, Levkau B, Schober O, Schäfers M, Kopka K",,451367,DTCT0024844,2204605,DTCC00471850,1329038,24059
CHEMBL393828,P14780,,FGEXLQKMIJWUIY-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17956082,IC50,=,281,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.,J. Med. Chem.,2007,50,23,"Wagner S, Breyholz HJ, Law MP, Faust A, Höltke C, Schröer S, Haufe G, Levkau B, Schober O, Schäfers M, Kopka K",,451367,DTCT0024844,2204610,DTCC00471838,1361759,24059
CHEMBL393829,P14780,,NVEOTSPQRXNTEA-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17956082,IC50,=,821,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.,J. Med. Chem.,2007,50,23,"Wagner S, Breyholz HJ, Law MP, Faust A, Höltke C, Schröer S, Haufe G, Levkau B, Schober O, Schäfers M, Kopka K",,451367,DTCT0024844,2204609,DTCC00471839,1491085,24059
CHEMBL393863,P14780,,MKDLVNDURLPYMP-HXUWFJFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17188863,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2007,17,5,"Sheppeck JE, Gilmore JL, Yang A, Chen XT, Xue CB, Roderick J, Liu RQ, Covington MB, Decicco CP, Duan JJ",,453871,DTCT0024844,2221456,DTCC00477930,1296486,24252
CHEMBL395110,P14780,MEPAZINE,CBHCDHNUZWWAPP-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7430082,DTCC00464417,477046,46191
CHEMBL395110,P14780,MEPAZINE,CBHCDHNUZWWAPP-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7430083,DTCC00464417,477046,46191
CHEMBL396294,P14780,FOLATE GAMMA-HYDROXAMIC ACID,TZBJIYPNYFAUQG-LBPRGKRZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17127067,INHIBITION,=,53,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 100 uM,,Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs.,Bioorg. Med. Chem.,2007,15,3,"Santos MA, Enyedy EA, Nuti E, Rossello A, Krupenko NI, Krupenko SA",,441105,DTCT0024844,2143975,DTCC00003030,143060,23121
CHEMBL396296,P14780,METHOTREXATE GAMMA-L-PHENYLALANINEHYDROXAMIC ACID,QHQOEZXEZMHMER-SFTDATJTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17127067,IC50,=,15000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs.,Bioorg. Med. Chem.,2007,15,3,"Santos MA, Enyedy EA, Nuti E, Rossello A, Krupenko NI, Krupenko SA",,441089,DTCT0024844,2143977,DTCC00003033,952076,23121
CHEMBL396296,P14780,METHOTREXATE GAMMA-L-PHENYLALANINEHYDROXAMIC ACID,QHQOEZXEZMHMER-SFTDATJTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17127067,RATIO IC50,=,3000,,,,,,,,,,,,,,,Ratio of IC50 of drug to CGS 27023A for human recombinant MMP9,,Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs.,Bioorg. Med. Chem.,2007,15,3,"Santos MA, Enyedy EA, Nuti E, Rossello A, Krupenko NI, Krupenko SA",,441102,DTCT0024844,2144032,DTCC00003033,952076,23121
CHEMBL398265,P14780,,VJUDEGHVGRIZAQ-FQEVSTJZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,1.9,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278571,DTCC00489424,1987318,25112
CHEMBL398331,P14780,,JZEPJLQIDIDDKA-HNNXBMFYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,4.7,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278609,DTCC00489294,860749,25112
CHEMBL398331,P14780,,JZEPJLQIDIDDKA-HNNXBMFYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18086526,IC50,=,4.7,NM,,,,,,,,,,,,,,Inhibition of catalytic domain MMP9,,"beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.",Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV",,465911,DTCT0024844,2300339,DTCC00489294,844317,25438
CHEMBL398350,P14780,,YMEMYNPRLJHTGN-LJQANCHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,31,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278606,DTCC00489300,569480,25112
CHEMBL398351,P14780,,AIVGSEYFSRMFJB-NRFANRHFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,1.7,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278603,DTCC00489304,569481,25112
CHEMBL398405,P14780,,SFWRCXWXHAIKBP-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17956082,IC50,=,23,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.,J. Med. Chem.,2007,50,23,"Wagner S, Breyholz HJ, Law MP, Faust A, Höltke C, Schröer S, Haufe G, Levkau B, Schober O, Schäfers M, Kopka K",,451367,DTCT0024844,2204591,DTCC00471864,2036268,24059
CHEMBL398440,P14780,CHLOROXYLENOL,OSDLLIBGSJNGJE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7364554,DTCC00485552,1059329,46191
CHEMBL398440,P14780,CHLOROXYLENOL,OSDLLIBGSJNGJE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7364555,DTCC00485552,1059329,46191
CHEMBL398450,P14780,,HKAAGCIEBUZLMO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,67000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266627,DTCC00485880,1776513,24949
CHEMBL398602,P14780,,SAQZCMSCRMAPLW-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17956082,IC50,=,6930,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.,J. Med. Chem.,2007,50,23,"Wagner S, Breyholz HJ, Law MP, Faust A, Höltke C, Schröer S, Haufe G, Levkau B, Schober O, Schäfers M, Kopka K",,451367,DTCT0024844,2204590,DTCC00471865,1684738,24059
CHEMBL398641,P14780,,XMVZJCLXRBLZHB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029177,IC50,=,406,NM,,,,,,,,,,,,,,Inhibition of MMP9,,A novel series of highly selective inhibitors of MMP-3.,Bioorg. Med. Chem. Lett.,2007,17,24,"Whitlock GA, Dack KN, Dickinson RP, Lewis ML",,459994,DTCT0024844,2266898,DTCC00486121,1523447,24951
CHEMBL398644,P14780,,BHIHZVBFDJREPF-FQEVSTJZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,1.9,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278578,DTCC00489400,83309,25112
CHEMBL398662,P14780,4-(TRIFLUOROMETHYL)BENZYL 6-MERCAPTOPICOLINATE,UXTIYMFTTMKCDA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,141000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266600,DTCC00003776,1458627,24949
CHEMBL398838,P14780,,NZJFWCGEQFWBKH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,67000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266612,DTCC00485905,1394273,24949
CHEMBL398892,P14780,,RQUBDDXSSKDSJC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,50000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266633,DTCC00485874,972954,24949
CHEMBL399029,P14780,,OOPDBSPAOGDGKV-MRUHUIDDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,1.1,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278583,DTCC00489376,375660,25112
CHEMBL399070,P14780,,ZQZVJUAJNUFNDE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,69000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266644,DTCC00112327,1458626,24949
CHEMBL399304,P14780,,LHAPHQLKKIRONO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,85000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266630,DTCC00485877,1426658,24949
CHEMBL399351,P14780,,JGSJEYLQTZAQRG-IBGZPJMESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18068976,IC50,=,78,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutations.,Bioorg. Med. Chem. Lett.,2008,18,2,"Burns DM, He C, Li Y, Scherle P, Liu X, Marando CA, Covington MB, Yang G, Pan M, Turner S, Fridman JS, Hollis G, Vaddi K, Yeleswaram S, Newton R, Friedman S, Metcalf B, Yao W",,461866,DTCT0024844,2278077,DTCC00489339,1744698,25102
CHEMBL399504,P14780,,NQYVTZONPGFIAQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,109000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266618,DTCC00485896,1005476,24949
CHEMBL399565,P14780,,OOMMMKWDYHOZLE-QFIPXVFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,1.3,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278595,DTCC00489328,1571618,25112
CHEMBL399566,P14780,,ROZSKUGTEUMAMI-QFIPXVFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,20,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278593,DTCC00489332,1119400,25112
CHEMBL399684,P14780,,KNRYOABLFLVDOM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,71000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266629,DTCC00485878,1905753,24949
CHEMBL399685,P14780,,GBDUKEUKPOMNDD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,81000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266625,DTCC00485883,359234,24949
CHEMBL399908,P14780,4-METHOXYBENZYL 6-MERCAPTOPICOLINATE,YSTUWPYBTHJZLL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,95000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266598,DTCC00003778,1587794,24949
CHEMBL399997,P14780,2-BROMOBENZYL 6-MERCAPTOPICOLINATE,BYAIZTJWUFLESC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,>,150000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266589,DTCC00003786,1841459,24949
CHEMBL399998,P14780,,KKLDLTCISAWVLM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,>,150000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266574,DTCC00112349,359236,24949
CHEMBL399999,P14780,,JXNVCUFWCAJVAU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,90000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266582,DTCC00112341,909304,24949
CHEMBL4,P14780,OFLOXACIN,GSDSWSVVBLHKDQ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7392958,DTCC00132314,1641850,46191
CHEMBL4,P14780,OFLOXACIN,GSDSWSVVBLHKDQ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7392959,DTCC00132314,1641850,46191
CHEMBL40,P14780,PHENOBARBITAL,DDBREPKUVSBGFI-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7384990,DTCC00134072,51499,46191
CHEMBL40,P14780,PHENOBARBITAL,DDBREPKUVSBGFI-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7384991,DTCC00134072,51499,46191
CHEMBL400192,P14780,,SETBBCAYVFZDCA-QFIPXVFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,23,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278600,DTCC00489312,1313204,25112
CHEMBL400193,P14780,,SJARSEBFYXSCRJ-QHCPKHFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,7.1,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278599,DTCC00489314,1247936,25112
CHEMBL400206,P14780,,BUDIJDXJWOVXRJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17064892,IC50,=,90000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Identification of potent and selective TACE inhibitors via the S1 pocket.,Bioorg. Med. Chem. Lett.,2007,17,1,"Condon JS, Joseph-McCarthy D, Levin JI, Lombart HG, Lovering FE, Sun L, Wang W, Xu W, Zhang Y",,440763,DTCT0024844,2153865,DTCC00461899,972679,23077
CHEMBL400285,P14780,,USBYYTHGWSZFCH-MRUHUIDDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,0.46,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278573,DTCC00489417,1086857,25112
CHEMBL400357,P14780,,HWCTXADEOSNKAL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,>,150000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266730,DTCC00112350,650414,24949
CHEMBL400358,P14780,,JKVLJXIAJUKATA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,>,150000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266732,DTCC00485909,1905755,24949
CHEMBL400445,P14780,,XTJBWIGVMWHTBK-VWLOTQADSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,68,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278586,DTCC00489368,1475076,25112
CHEMBL400449,P14780,"2,5-DIFLUOROBENZYL 6-MERCAPTOPICOLINATE",WZHYWMHDTQCLHR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,140000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266593,DTCC00003783,1937771,24949
CHEMBL400591,P14780,,PJEQSSFWNBHRSL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,5.52,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260730,DTCC00486077,1426649,24831
CHEMBL400641,P14780,,HMSHXTUFXMZOJG-IBGZPJMESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,2.9,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278584,DTCC00489373,1668798,25112
CHEMBL400784,P14780,,DMFDGAVDVQNWSQ-DVECYGJZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,1.5,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278598,DTCC00489321,763157,25112
CHEMBL400785,P14780,,DMFDGAVDVQNWSQ-CYFREDJKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,0.54,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278597,DTCC00489324,244700,25112
CHEMBL400850,P14780,,DYVOQIGOSGKBQO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,>,150000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266579,DTCC00112344,1394274,24949
CHEMBL400851,P14780,,FFKBKVNEQNIDAM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,>,150000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266577,DTCC00112346,260739,24949
CHEMBL400994,P14780,,AMHKVYCKWPXXHK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,4.41,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260721,DTCC00112357,488948,24831
CHEMBL401263,P14780,,KRGIXMSVPSMLII-JTHBVZDNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18061445,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).",Bioorg. Med. Chem. Lett.,2008,18,2,"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ",,463237,DTCT0024844,2296528,DTCC00488619,1361969,25233
CHEMBL401263,P14780,,KRGIXMSVPSMLII-JTHBVZDNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18234496,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Alpha,Beta-cyclic-beta-benzamido hydroxamic acids: Novel oxaspiro[4.4]nonane templates for the discovery of potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).",Bioorg. Med. Chem. Lett.,2008,18,4,"Ott GR, Asakawa N, Liu RQ, Covington MB, Qian M, Vaddi K, Newton RC, Trzaskos JM, Christ DD, Galya L, Scholz T, Marshall W, Duan JJ",,462320,DTCT0024844,2282170,DTCC00488619,1378406,25158
CHEMBL401404,P14780,,MXIFPAKFUUYAMN-QHCPKHFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,0.62,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278592,DTCC00489349,1857409,25112
CHEMBL40143,P14780,ABT-770,IIHFBHZWJNGWRC-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11412980,IC50,=,120,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,"Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.",Bioorg. Med. Chem. Lett.,2001,11,12,"Curtin ML, Florjancic AS, Heyman HR, Michaelides MR, Garland RB, Holms JH, Steinman DH, Dellaria JF, Gong J, Wada CK, Guo Y, Elmore IB, Tapang P, Albert DH, Magoc TJ, Marcotte PA, Bouska JJ, Goodfellow CL, Bauch JL, Marsh KC, Morgan DW, Davidsen SK",,105364,DTCT0024844,1450795,DTCC01739757,464200,4274
CHEMBL40143,P14780,ABT-770,IIHFBHZWJNGWRC-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,IC50,=,120,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2457391,DTCC01739757,468359,32556
CHEMBL401445,P14780,,RTWRPNRMLWESPM-VLBBBODESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17512742,IC50,=,45,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.,Bioorg. Med. Chem.,2007,15,14,"Moroy G, Denhez C, El Mourabit H, Toribio A, Dassonville A, Decarme M, Renault JH, Mirand C, Bellon G, Sapi J, Alix AJ, Hornebeck W, Bourguet E",,447907,DTCT0024844,2176044,DTCC00468604,1808775,23716
CHEMBL401453,P14780,,JRRSWIJDZJXIAR-LADGPHEKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17276676,IC50,>,2000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,7,"Chen XT, Ghavimi B, Corbett RL, Xue CB, Liu RQ, Covington MB, Qian M, Vaddi KG, Christ DD, Hartman KD, Ribadeneira MD, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,447087,DTCT0024844,2169357,DTCC00464770,1328990,23623
CHEMBL401454,P14780,,CKGRNUKOQHVJOB-RBBKRZOGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17276676,IC50,>,2000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,7,"Chen XT, Ghavimi B, Corbett RL, Xue CB, Liu RQ, Covington MB, Qian M, Vaddi KG, Christ DD, Hartman KD, Ribadeneira MD, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,447087,DTCT0024844,2169351,DTCC00464776,617508,23623
CHEMBL401471,P14780,,AZIJSGUGQIBFMD-CAKYRVLISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18234496,KI,=,1447,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Alpha,Beta-cyclic-beta-benzamido hydroxamic acids: Novel oxaspiro[4.4]nonane templates for the discovery of potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).",Bioorg. Med. Chem. Lett.,2008,18,4,"Ott GR, Asakawa N, Liu RQ, Covington MB, Qian M, Vaddi K, Newton RC, Trzaskos JM, Christ DD, Galya L, Scholz T, Marshall W, Duan JJ",,462320,DTCT0024844,2282172,DTCC00488623,1182677,25158
CHEMBL401821,P14780,,VAYOACRDUZWWKM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18086526,IC50,=,5.5,NM,,,,,,,,,,,,,,Inhibition of catalytic domain MMP9,,"beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.",Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV",,465911,DTCT0024844,2300353,DTCC00500630,1296686,25438
CHEMBL401824,P14780,,CYLJDKJSOJVUOS-PZJWPPBQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18061445,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).",Bioorg. Med. Chem. Lett.,2008,18,2,"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ",,463237,DTCT0024844,2296501,DTCC00112994,1070343,25233
CHEMBL401870,P14780,,RAJATBMMJHSJNJ-FQECFTEESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18036818,IC50,=,677,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.,Bioorg. Med. Chem. Lett.,2008,18,1,"Yao W, Zhuo J, Burns DM, Li YL, Qian DQ, Zhang C, He C, Xu M, Shi E, Li Y, Marando CA, Covington MB, Yang G, Liu X, Pan M, Fridman JS, Scherle P, Wasserman ZR, Hollis G, Vaddi K, Yeleswaram S, Newton R, Friedman S, Metcalf B",,461667,DTCT0024844,2276529,DTCC00488459,294069,25086
CHEMBL401979,P14780,,DIZGMOHGYCJEBO-JTHBVZDNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18061445,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).",Bioorg. Med. Chem. Lett.,2008,18,2,"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ",,463237,DTCT0024844,2296527,DTCC00501693,67201,25233
CHEMBL402309,P14780,,AIMZNBMNWSVLMC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17980583,IC50,=,45.8,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Yang SM, Scannevin RH, Burke SL, Rhodes KJ, Jackson PF",,469152,DTCT0024844,2289066,DTCC00502113,9220,25686
CHEMBL402310,P14780,,SCABKVASOUSOGA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17980583,IC50,=,809,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Yang SM, Scannevin RH, Burke SL, Rhodes KJ, Jackson PF",,469152,DTCT0024844,2289067,DTCC00502116,1937886,25686
CHEMBL402393,P14780,,SXDMGWZDRWQMPS-DLBZAZTESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18282708,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE): discovery of indole, benzofuran, imidazopyridine and pyrazolopyridine P1' substituents.",Bioorg. Med. Chem. Lett.,2008,18,6,"Lu Z, Ott GR, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos J, Duan JJ",,463865,DTCT0024844,2317287,DTCC00499750,957099,25272
CHEMBL402393,P14780,,SXDMGWZDRWQMPS-DLBZAZTESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2456525,DTCC00499750,952985,32556
CHEMBL402436,P14780,,SDNMPMDMJTYOAW-AZUAARDMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18242982,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents.",Bioorg. Med. Chem. Lett.,2008,18,5,"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ",,462363,DTCT0024844,2282318,DTCC00488433,1873486,25163
CHEMBL402554,P14780,,OMPYFSXSVDORIO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17981034,IC50,=,4.9,NM,,,,,,,,,,,,,,Inhibition of MMP9,,1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Chakaravarty D, Xiang B, Scannevin RH, Huang Z, Ma J, Burke SL, Karnachi P, Rhodes KJ, Jackson PF",,469432,DTCT0024844,2289309,DTCC00501225,260890,25715
CHEMBL402639,P14780,,PDLSPVLGWRRTFM-NRFANRHFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18086526,IC50,=,344,NM,,,,,,,,,,,,,,Inhibition of catalytic domain MMP9,,"beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.",Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV",,465911,DTCT0024844,2300345,DTCC00500457,1523522,25438
CHEMBL402720,P14780,BENZYL 6-MERCAPTOPICOLINATE,VZXSYHPSVIVBDS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,88000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266606,DTCC00003772,391970,24949
CHEMBL402745,P14780,,LFOGEPKUSWRLCL-QFIPXVFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472202,IC50,=,71.5,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.,J. Med. Chem.,2001,44,16,"Pikul S, Ohler NE, Ciszewski G, Laufersweiler MC, Almstead NG, De B, Natchus MG, Hsieh LC, Janusz MJ, Peng SX, Branch TM, King SL, Taiwo YO, Mieling GE",,105229,DTCT0024844,1316694,DTCC00487205,808682,16328
CHEMBL402746,P14780,,OXTQTRNMDRGLGO-RBBKRZOGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18061445,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).",Bioorg. Med. Chem. Lett.,2008,18,2,"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ",,463237,DTCT0024844,2296413,DTCC00487834,1744721,25233
CHEMBL402747,P14780,,CARKQNSZFCLNKM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18054488,KI,=,6300,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Novel thiol-based TACE inhibitors. Part 2: Rational design, synthesis, and SAR of thiol-containing aryl sulfones.",Bioorg. Med. Chem. Lett.,2008,18,1,"Bandarage UK, Wang T, Come JH, Perola E, Wei Y, Rao BG",,461730,DTCT0024844,2277151,DTCC00487839,196172,25093
CHEMBL402747,P14780,,CARKQNSZFCLNKM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,KI,=,6300,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2456469,DTCC00487839,208204,32556
CHEMBL402750,P14780,,UNYQRNBJIKAMKU-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18086526,IC50,=,1489,NM,,,,,,,,,,,,,,Inhibition of catalytic domain MMP9,,"beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.",Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV",,465911,DTCT0024844,2300327,DTCC00500628,1744760,25438
CHEMBL402794,P14780,BIS(2-ETHYLHEXYL)PHTHALATE,BJQHLKABXJIVAM-BGYRXZFFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7265929,DTCC00499603,153439,46191
CHEMBL402794,P14780,BIS(2-ETHYLHEXYL)PHTHALATE,BJQHLKABXJIVAM-BGYRXZFFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7265930,DTCC00499603,153439,46191
CHEMBL402954,P14780,,MAXWOEDRRCSRHI-OALUTQOASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18036818,IC50,=,190,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.,Bioorg. Med. Chem. Lett.,2008,18,1,"Yao W, Zhuo J, Burns DM, Li YL, Qian DQ, Zhang C, He C, Xu M, Shi E, Li Y, Marando CA, Covington MB, Yang G, Liu X, Pan M, Fridman JS, Scherle P, Wasserman ZR, Hollis G, Vaddi K, Yeleswaram S, Newton R, Friedman S, Metcalf B",,461667,DTCT0024844,2276541,DTCC00488365,553292,25086
CHEMBL402990,P14780,,JUDXBTMVZVWJNP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17936631,IC50,=,5660,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,"Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation.",Bioorg. Med. Chem.,2008,16,1,"Chun K, Park SK, Kim HM, Choi Y, Kim MH, Park CH, Joe BY, Chun TG, Choi HM, Lee HY, Hong SH, Kim MS, Nam KY, Han G",,461354,DTCT0024844,2274653,DTCC00487747,1760569,25060
CHEMBL402991,P14780,,OMHMZZGGFHEFEP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17936631,IC50,,,,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,Not Determined,"Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation.",Bioorg. Med. Chem.,2008,16,1,"Chun K, Park SK, Kim HM, Choi Y, Kim MH, Park CH, Joe BY, Chun TG, Choi HM, Lee HY, Hong SH, Kim MS, Nam KY, Han G",,461354,DTCT0024844,2274652,DTCC00487748,1475065,25060
CHEMBL403,P14780,SULBACTAM,FKENQMMABCRJMK-RITPCOANSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7460715,DTCC00132361,671795,46191
CHEMBL403,P14780,SULBACTAM,FKENQMMABCRJMK-RITPCOANSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7460716,DTCC00132361,671795,46191
CHEMBL403089,P14780,,BNMLMEDMDSOEPR-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18086526,IC50,=,13,NM,,,,,,,,,,,,,,Inhibition of catalytic domain MMP9,,"beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.",Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV",,465911,DTCT0024844,2300352,DTCC00112969,1587883,25438
CHEMBL403110,P14780,,UHKFCKGWGNVWOQ-SFHVURJKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18086526,IC50,=,44,NM,,,,,,,,,,,,,,Inhibition of catalytic domain MMP9,,"beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.",Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV",,465911,DTCT0024844,2300332,DTCC00500149,455682,25438
CHEMBL403169,P14780,,VOASHVXIDJYPJH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18086526,IC50,=,31,NM,,,,,,,,,,,,,,Inhibition of catalytic domain MMP9,,"beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.",Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV",,465911,DTCT0024844,2300357,DTCC00500714,553363,25438
CHEMBL403185,P14780,,PEAOAVRAGQRJEO-AKQSQHNNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18036818,IC50,=,451,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.,Bioorg. Med. Chem. Lett.,2008,18,1,"Yao W, Zhuo J, Burns DM, Li YL, Qian DQ, Zhang C, He C, Xu M, Shi E, Li Y, Marando CA, Covington MB, Yang G, Liu X, Pan M, Fridman JS, Scherle P, Wasserman ZR, Hollis G, Vaddi K, Yeleswaram S, Newton R, Friedman S, Metcalf B",,461667,DTCT0024844,2276532,DTCC00488434,909316,25086
CHEMBL403186,P14780,,WMWPLQAXVKBJIC-PZJWPPBQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18242982,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents.",Bioorg. Med. Chem. Lett.,2008,18,5,"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ",,462363,DTCT0024844,2282322,DTCC00488436,260773,25163
CHEMBL403380,P14780,,JLFCWOIZNQXZMP-ICSRJNTNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18036818,IC50,>,5000,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.,Bioorg. Med. Chem. Lett.,2008,18,1,"Yao W, Zhuo J, Burns DM, Li YL, Qian DQ, Zhang C, He C, Xu M, Shi E, Li Y, Marando CA, Covington MB, Yang G, Liu X, Pan M, Fridman JS, Scherle P, Wasserman ZR, Hollis G, Vaddi K, Yeleswaram S, Newton R, Friedman S, Metcalf B",,461667,DTCT0024844,2276537,DTCC00488376,972978,25086
CHEMBL403401,P14780,,GIYCAHCPFIZYMQ-LADGPHEKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18061445,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).",Bioorg. Med. Chem. Lett.,2008,18,2,"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ",,463237,DTCT0024844,2296495,DTCC00501582,1809018,25233
CHEMBL403412,P14780,,NZHYOLNTGNGMON-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17981034,IC50,=,3.6,NM,,,,,,,,,,,,,,Inhibition of MMP9,,1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Chakaravarty D, Xiang B, Scannevin RH, Huang Z, Ma J, Burke SL, Karnachi P, Rhodes KJ, Jackson PF",,469432,DTCT0024844,2289313,DTCC00501278,1135414,25715
CHEMBL403620,P14780,,SMWUMKAFRZUPSV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17980583,IC50,>,1000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Yang SM, Scannevin RH, Burke SL, Rhodes KJ, Jackson PF",,469152,DTCT0024844,2289061,DTCC00502069,1873600,25686
CHEMBL404,P14780,TAZOBACTAM,LPQZKKCYTLCDGQ-WEDXCCLWSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7472094,DTCC00132373,88636,46191
CHEMBL404,P14780,TAZOBACTAM,LPQZKKCYTLCDGQ-WEDXCCLWSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7472095,DTCC00132373,88636,46191
CHEMBL404010,P14780,,IYGKJIOIZXNZOC-RBUKOAKNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18242982,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents.",Bioorg. Med. Chem. Lett.,2008,18,5,"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ",,462363,DTCT0024844,2282417,DTCC00488451,1037910,25163
CHEMBL404132,P14780,,KAJHXHOIEARPHN-IRXDYDNUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18036818,IC50,=,1268,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.,Bioorg. Med. Chem. Lett.,2008,18,1,"Yao W, Zhuo J, Burns DM, Li YL, Qian DQ, Zhang C, He C, Xu M, Shi E, Li Y, Marando CA, Covington MB, Yang G, Liu X, Pan M, Fridman JS, Scherle P, Wasserman ZR, Hollis G, Vaddi K, Yeleswaram S, Newton R, Friedman S, Metcalf B",,461667,DTCT0024844,2276535,DTCC00488393,844255,25086
CHEMBL404162,P14780,,JJARNQDLIPGYKD-UKILVPOCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18061445,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).",Bioorg. Med. Chem. Lett.,2008,18,2,"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ",,463237,DTCT0024844,2296492,DTCC00502141,1103112,25233
CHEMBL404205,P14780,ISOPROPYL 6-MERCAPTOPICOLINATE,QJUDBPJUUNCMKI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,132000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266609,DTCC00003769,2003635,24949
CHEMBL404270,P14780,,HSRYNFLYAOMHLV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18086526,IC50,=,383,NM,,,,,,,,,,,,,,Inhibition of catalytic domain MMP9,,"beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.",Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV",,465911,DTCT0024844,2300274,DTCC00500756,1103147,25438
CHEMBL404382,P14780,,JFELXNYVJCRVPT-ZVUIFXONSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18242982,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents.",Bioorg. Med. Chem. Lett.,2008,18,5,"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ",,462363,DTCT0024844,2282421,DTCC00488446,99450,25163
CHEMBL404409,P14780,,IDSXRTDVRWTZOK-FQEVSTJZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18068976,IC50,=,22,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutations.,Bioorg. Med. Chem. Lett.,2008,18,2,"Burns DM, He C, Li Y, Scherle P, Liu X, Marando CA, Covington MB, Yang G, Pan M, Turner S, Fridman JS, Hollis G, Vaddi K, Yeleswaram S, Newton R, Friedman S, Metcalf B, Yao W",,461866,DTCT0024844,2278111,DTCC00489354,1296629,25102
CHEMBL404520,P14780,CHLORTETRACYCLINE,CYDMQBQPVICBEU-XRNKAMNCSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7341122,DTCC00502280,1027048,46191
CHEMBL404520,P14780,CHLORTETRACYCLINE,CYDMQBQPVICBEU-XRNKAMNCSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7341123,DTCC00502280,1027048,46191
CHEMBL404673,P14780,,XNUPVUIWOKTWNU-RBUKOAKNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18242982,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents.",Bioorg. Med. Chem. Lett.,2008,18,5,"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ",,462363,DTCT0024844,2282412,DTCC00488441,1166496,25163
CHEMBL404752,P14780,,QRKISYORPUCMMH-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18086526,INHIBITION,<,10,%,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain at 10 uM,,"beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.",Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV",,465912,DTCT0024844,2300359,DTCC00500588,392066,25438
CHEMBL404811,P14780,DIGITONIN,UVYVLBIGDKGWPX-YCCXZQINSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7342491,DTCC00199357,249941,46191
CHEMBL404811,P14780,DIGITONIN,UVYVLBIGDKGWPX-YCCXZQINSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7342492,DTCC00199357,249941,46191
CHEMBL404882,P14780,,JZMCRZFBCUTVMT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18086526,IC50,=,6.6,NM,,,,,,,,,,,,,,Inhibition of catalytic domain MMP9,,"beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.",Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV",,465911,DTCT0024844,2300356,DTCC00500711,2003722,25438
CHEMBL404893,P14780,,BNMLMEDMDSOEPR-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18086526,IC50,=,3.8,NM,,,,,,,,,,,,,,Inhibition of catalytic domain MMP9,,"beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.",Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV",,465911,DTCT0024844,2300351,DTCC00500586,99499,25438
CHEMBL405600,P14780,,CTEBTZSRXSZTCW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,36,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1709813,DTCC00105079,63907,16216
CHEMBL405651,P14780,,WUXSSALNWBMRKU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10411481,KI,=,44,NM,,,,,,,,,,,,,,Binding affinity against matrix metalloprotease-9 (gelatinase-B).,,Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.,J. Med. Chem.,1999,42,14,"Vassiliou S, Mucha A, Cuniasse P, Georgiadis D, Lucet-Levannier K, Beau F, Kannan R, Murphy G, Knäuper V, Rio MC, Basset P, Yiotakis A, Dive V",,105378,DTCT0024844,1072668,DTCC00106276,291445,15258
CHEMBL40583,P14780,3-METHYLCHOLANTHRENE,PPQNQXQZIWHJRB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7290603,DTCC00181233,1894962,46191
CHEMBL40583,P14780,3-METHYLCHOLANTHRENE,PPQNQXQZIWHJRB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7290604,DTCC00181233,1894962,46191
CHEMBL406,P14780,INDAPAMIDE,NDDAHWYSQHTHNT-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7422401,DTCC00132717,1609547,46191
CHEMBL406,P14780,INDAPAMIDE,NDDAHWYSQHTHNT-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7422402,DTCC00132717,1609547,46191
CHEMBL406939,P14780,,SLHHOJZYTMNFRR-OKXSDPAFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831905,KI,=,4.46,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,New strategy for antedrug application: development of metalloproteinase inhibitors as antipsoriatic drugs.,J. Med. Chem.,2002,45,4,"Sawa M, Tsukamoto T, Kiyoi T, Kurokawa K, Nakajima F, Nakada Y, Yokota K, Inoue Y, Kondo H, Yoshino K",,105379,DTCT0024844,553318,DTCC00345288,951239,17148
CHEMBL406939,P14780,,SLHHOJZYTMNFRR-OKXSDPAFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11844676,KI,=,4.46,NM,,,,,,,,,,,,,,Inhibitory constant against recombinant human gelatinase B (Matrix metalloprotease-9),,Encounter with unexpected collagenase-1 selective inhibitor: switchover of inhibitor binding pocket induced by fluorine atom.,Bioorg. Med. Chem. Lett.,2002,12,4,"Sawa M, Kondo H, Nishimura S",,105400,DTCT0024844,1429478,DTCC00345288,939447,5346
CHEMBL407,P14780,FLUMAZENIL,OFBIFZUFASYYRE-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7322464,DTCC00132733,1609545,46191
CHEMBL407,P14780,FLUMAZENIL,OFBIFZUFASYYRE-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7322465,DTCC00132733,1609545,46191
CHEMBL407030,P14780,GAMMA-CYCLODEXTRIN,MIFVTYPADKEWAV-HGRQBIKSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7312257,DTCC00003162,88629,46191
CHEMBL407030,P14780,GAMMA-CYCLODEXTRIN,MIFVTYPADKEWAV-HGRQBIKSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7312258,DTCC00003162,88629,46191
CHEMBL407135,P14780,COLISTINE,YKQOSKADJPQZHB-YNWHQGOSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7352457,DTCC00494880,1705874,46191
CHEMBL407135,P14780,COLISTINE,YKQOSKADJPQZHB-YNWHQGOSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7352458,DTCC00494880,1705874,46191
CHEMBL407176,P14780,,DPCOBXCUZAXERT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17980583,IC50,>,1000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Yang SM, Scannevin RH, Burke SL, Rhodes KJ, Jackson PF",,469152,DTCT0024844,2289053,DTCC00501896,585562,25686
CHEMBL407443,P14780,,PONKMSIAUNHYAM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11543675,IC50,=,0.6,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.",J. Med. Chem.,2001,44,19,"Hanessian S, Moitessier N, Gauchet C, Viau M",,105230,DTCT0024844,1373017,DTCC00273294,1723389,16392
CHEMBL407540,P14780,,AMUGNOPZMAZKFD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10411481,KI,=,60,NM,,,,,,,,,,,,,,Binding affinity against matrix metalloprotease-9 (gelatinase-B).,,Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.,J. Med. Chem.,1999,42,14,"Vassiliou S, Mucha A, Cuniasse P, Georgiadis D, Lucet-Levannier K, Beau F, Kannan R, Murphy G, Knäuper V, Rio MC, Basset P, Yiotakis A, Dive V",,105378,DTCT0024844,1056151,DTCC00249365,356662,15258
CHEMBL408,P14780,TROGLITAZONE,GXPHKUHSUJUWKP-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7450059,DTCC00132763,800583,46191
CHEMBL408,P14780,TROGLITAZONE,GXPHKUHSUJUWKP-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7450060,DTCC00132763,800583,46191
CHEMBL408366,P14780,,WIAJGSYMEDWMGP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17981034,IC50,=,0.87,NM,,,,,,,,,,,,,,Inhibition of MMP9,,1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Chakaravarty D, Xiang B, Scannevin RH, Huang Z, Ma J, Burke SL, Karnachi P, Rhodes KJ, Jackson PF",,469432,DTCT0024844,2289305,DTCC00501132,1971170,25715
CHEMBL408682,P14780,,OHYRHJPFKZKXOS-XGHQBKJUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871551,KI,<,1,NM,,,,,,,,,,,,,,Binding affinity was evaluated against matrix metalloprotease-9,,Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,1998,8,7,"Jacobson IC, Reddy PG, Wasserman ZR, Hardman KD, Covington MB, Arner EC, Copeland RA, Decicco CP, Magolda RL",,105373,DTCT0024844,488890,DTCC00364246,487712,3059
CHEMBL408906,P14780,,GBUFCNZUHLSHNE-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18086526,IC50,=,54,NM,,,,,,,,,,,,,,Inhibition of catalytic domain MMP9,,"beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.",Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV",,465911,DTCT0024844,2300335,DTCC00500248,650497,25438
CHEMBL409536,P14780,,PLBINCOCFGQAJM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17623656,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.,J. Biol. Chem.,2007,282,38,"Johnson AR, Pavlovsky AG, Ortwine DF, Prior F, Man CF, Bornemeier DA, Banotai CA, Mueller WT, McConnell P, Yan C, Baragi V, Lesch C, Roark WH, Wilson M, Datta K, Guzman R, Han HK, Dyer RD",,507876,DTCT0024844,2388611,DTCC00503784,1950627,29282
CHEMBL409536,P14780,,PLBINCOCFGQAJM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18251495,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2008,51,4,"Li JJ, Nahra J, Johnson AR, Bunker A, O'Brien P, Yue WS, Ortwine DF, Man CF, Baragi V, Kilgore K, Dyer RD, Han HK",,465550,DTCT0024844,2311309,DTCC00503784,1954666,25409
CHEMBL409536,P14780,,PLBINCOCFGQAJM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of MMP9 up to 100 uM,Not Active,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497431,DTCT0024844,2457337,DTCC00503784,1950505,32556
CHEMBL409536,P14780,,PLBINCOCFGQAJM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25265401,IC50,>,30000,NM,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin),,"Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors.",J. Med. Chem.,2014,57,24,"Fabre B, Ramos A, de Pascual-Teresa B",,1433221,DTCT0024844,13993819,DTCC00503784,1943413,60040
CHEMBL41,P14780,FLUOXETINE,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7324835,DTCC00134078,1609546,46191
CHEMBL41,P14780,FLUOXETINE,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7324836,DTCC00134078,1609546,46191
CHEMBL410259,P14780,,ABOVSYRJLZIGMD-CTNGQTDRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,1.2,NM,,,,,,,,,,,,,,Inhibition of human Matrix metalloprotease-9,,,Bioorg. Med. Chem. Lett.,1995,5,4,,,105391,DTCT0024844,833842,DTCC00247104,1850728,1497
CHEMBL411,P14780,DIETHYLSTILBESTROL,RGLYKWWBQGJZGM-ISLYRVAYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7363884,DTCC00132930,2057648,46191
CHEMBL411,P14780,DIETHYLSTILBESTROL,RGLYKWWBQGJZGM-ISLYRVAYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7363885,DTCC00132930,2057648,46191
CHEMBL411519,P14780,,KATLUBNAFTZQRL-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18086526,IC50,=,28,NM,,,,,,,,,,,,,,Inhibition of catalytic domain MMP9,,"beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.",Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV",,465911,DTCT0024844,2300348,DTCC00500503,1103148,25438
CHEMBL412873,P14780,SPARTEINE,SLRCCWJSBJZJBV-TUVASFSCSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7480137,DTCC00141609,1674150,46191
CHEMBL412873,P14780,SPARTEINE,SLRCCWJSBJZJBV-TUVASFSCSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7480138,DTCC00141609,1674150,46191
CHEMBL412910,P14780,,HDOJQDDADGGFGH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12270165,IC50,=,4,NM,,,,,,,,,,,,,,Concentration required in vitro to inhibit Matrix metalloprotease-9,,Benzodiazepine inhibitors of the MMPs and TACE.,Bioorg. Med. Chem. Lett.,2002,12,20,"Nelson FC, Delos Santos E, Levin JI, Chen JM, Skotnicki JS, DiJoseph JF, Sharr MA, Sung A, Killar LM, Cowling R, Jin G, Roth CE, Albright JD",,105515,DTCT0024844,1537568,DTCC00263141,1207792,5143
CHEMBL413,P14780,SIROLIMUS,QFJCIRLUMZQUOT-HPLJOQBZSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7457687,DTCC00132982,477921,46191
CHEMBL413,P14780,SIROLIMUS,QFJCIRLUMZQUOT-HPLJOQBZSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7457688,DTCC00132982,477921,46191
CHEMBL413965,P14780,FELBINAC,QRZAKQDHEVVFRX-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7324333,DTCC00106501,1285874,46191
CHEMBL413965,P14780,FELBINAC,QRZAKQDHEVVFRX-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7324334,DTCC00106501,1285874,46191
CHEMBL414804,P14780,OXALIPLATIN,ZROHGHOFXNOHSO-BNTLRKBRSA-L,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7382391,DTCC00333435,736264,46191
CHEMBL414804,P14780,OXALIPLATIN,ZROHGHOFXNOHSO-BNTLRKBRSA-L,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7382392,DTCC00333435,736264,46191
CHEMBL415,P14780,CLOMIPRAMINE,GDLIGKIOYRNHDA-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7369562,DTCC00133038,217576,46191
CHEMBL415,P14780,CLOMIPRAMINE,GDLIGKIOYRNHDA-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7369563,DTCC00133038,217576,46191
CHEMBL415324,P14780,TRANILAST,NZHGWWWHIYHZNX-CSKARUKUSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7447965,DTCC00281196,1674153,46191
CHEMBL415324,P14780,TRANILAST,NZHGWWWHIYHZNX-CSKARUKUSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7447966,DTCC00281196,1674153,46191
CHEMBL41543,P14780,,PHNLCHMJDSSPDQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7294443,DTCC00180007,866015,46191
CHEMBL41543,P14780,,PHNLCHMJDSSPDQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7294444,DTCC00180007,866015,46191
CHEMBL415482,P14780,,GETQXLAMYOMSJS-GOSISDBHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11327577,IC50,=,1,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Heterocycle-based MMP inhibitors with P2' substituents.,Bioorg. Med. Chem. Lett.,2001,11,8,"Pikul S, Dunham KM, Almstead NG, De B, Natchus MG, Taiwo YO, Williams LE, Hynd BA, Hsieh LC, Janusz MJ, Gu F, Mieling GE",,105362,DTCT0024844,1311762,DTCC00133489,1725495,4760
CHEMBL415690,P14780,BETADEX,WHGYBXFWUBPSRW-FOUAGVGXSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7262903,DTCC00463534,249937,46191
CHEMBL415690,P14780,BETADEX,WHGYBXFWUBPSRW-FOUAGVGXSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7262904,DTCC00463534,249937,46191
CHEMBL415879,P14780,PHENANTHROLINE,DGEZNRSVGBDHLK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,86,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103955,DTCC00177236,247838,43205
CHEMBL415949,P14780,,KZZUIFPIPUBRFP-OAHLLOKOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,>,2128,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1464525,DTCC00198130,1239887,17283
CHEMBL416,P14780,METHOXSALEN,QXKHYNVANLEOEG-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7408780,DTCC00133091,1765976,46191
CHEMBL416,P14780,METHOXSALEN,QXKHYNVANLEOEG-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7408781,DTCC00133091,1765976,46191
CHEMBL416173,P14780,,UFJYSWCFYDZPKS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11934587,IC50,=,389,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 1: Structure-based design of novel acetylenic P1' groups.,Bioorg. Med. Chem. Lett.,2002,12,8,"Chen JM, Jin G, Sung A, Levin JI",,105517,DTCT0024844,1098332,DTCC00149696,1146885,5358
CHEMBL416173,P14780,,UFJYSWCFYDZPKS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11934588,IC50,=,389,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 activity,,Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.,Bioorg. Med. Chem. Lett.,2002,12,8,"Levin JI, Chen JM, Du MT, Nelson FC, Killar LM, Skala S, Sung A, Jin G, Cowling R, Barone D, March CJ, Mohler KM, Black RA, Skotnicki JS",,105508,DTCT0024844,816031,DTCC00149696,1131549,5465
CHEMBL416304,P14780,,SILYLRSFWCVUFM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,25,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1707076,DTCC00200716,1034801,16216
CHEMBL416306,P14780,,DNEUAPIVDBXPFN-JOCHJYFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,>,2128,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1458392,DTCC00197460,1046360,17283
CHEMBL417,P14780,EPIRUBICIN,AOJJSUZBOXZQNB-VTZDEGQISA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7315517,DTCC00133135,671788,46191
CHEMBL417,P14780,EPIRUBICIN,AOJJSUZBOXZQNB-VTZDEGQISA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7315518,DTCC00133135,671788,46191
CHEMBL417061,P14780,,BLYOONREWFOUNV-FIYSCABWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11738583,KI,=,3422,NM,,,,,,,,,,,,,,Binding affinity for human gelatinase B (MMP-9),,Potent P1' biphenylmethyl substituted aggrecanase inhibitors.,Bioorg. Med. Chem. Lett.,2002,12,1,"Yao W, Chao M, Wasserman ZR, Liu RQ, Covington MB, Newton R, Christ D, Wexler RR, Decicco CP",,105370,DTCT0024844,1529222,DTCC00103480,564494,4824
CHEMBL417086,P14780,,WGUOMVALEOXXIU-ABHNRTSZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871727,IC50,,,,,,,,,,,,,,,,,In vitro inhibitory activity against gelatinase-B (MMP-9.,Not Tested,"Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.",Bioorg. Med. Chem. Lett.,1998,8,10,"Campbell DA, Xiao XY, Harris D, Ida S, Mortezaei R, Ngu K, Shi L, Tien D, Wang Y, Navre M, Patel DV, Sharr MA, DiJoseph JF, Killar LM, Leone CL, Levin JI, Skotnicki JS",,105235,DTCT0024844,1547970,DTCC00146363,1016872,2559
CHEMBL417144,P14780,,ZAXFGRVMMQJZLL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12668018,IC50,=,95,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease 9 (MMP-9).,,Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,8,"Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS",,105528,DTCT0024844,1279054,DTCC00174415,690614,6276
CHEMBL417200,P14780,,HSJPSXSXQYYJSY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,9,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1700491,DTCC00200548,421498,16216
CHEMBL417212,P14780,,RGHQIKPHUVHVFH-NOZRDPDXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12781190,KI,>,2000,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9,,Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2003,13,12,"Duan JJ, Lu Z, Xue CB, He X, Seng JL, Roderick JJ, Wasserman ZR, Liu RQ, Covington MB, Magolda RL, Newton RC, Trzaskos JM, Decicco CP",,105375,DTCT0024844,504953,DTCC00212058,1067263,5598
CHEMBL417411,P14780,,JTEKRZIXTMGGJR-GJZUVCINSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12781190,KI,>,2000,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9,,Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2003,13,12,"Duan JJ, Lu Z, Xue CB, He X, Seng JL, Roderick JJ, Wasserman ZR, Liu RQ, Covington MB, Magolda RL, Newton RC, Trzaskos JM, Decicco CP",,105375,DTCT0024844,488916,DTCC00211599,1741749,5598
CHEMBL417537,P14780,BB-16,XDJHCLNLKWGZCM-IAOVAPTHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9599225,KI,=,0.13,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (Matrix metalloprotease-9),,Design and synthesis of cyclic inhibitors of matrix metalloproteinases and TNF-alpha production.,J. Med. Chem.,1998,41,11,"Xue CB, He X, Roderick J, DeGrado WF, Cherney RJ, Hardman KD, Nelson DJ, Copeland RA, Jaffee BD, Decicco CP",,105662,DTCT0024844,575742,DTCC01740029,1239828,14639
CHEMBL417537,P14780,BB-16,XDJHCLNLKWGZCM-IAOVAPTHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472217,KI,<,1,NM,,,,,,,,,,,,,,In vitro inhibition of human MMP-9.,,"Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.",J. Med. Chem.,2001,44,16,"Xue CB, Voss ME, Nelson DJ, Duan JJ, Cherney RJ, Jacobson IC, He X, Roderick J, Chen L, Corbett RL, Wang L, Meyer DT, Kennedy K, DeGradodagger WF, Hardman KD, Teleha CA, Jaffee BD, Liu RQ, Copeland RA, Covington MB, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105380,DTCT0024844,1678865,DTCC01740029,1228536,16346
CHEMBL417749,P14780,,IHPUTEIJIZVYPC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,50,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1699210,DTCC00201248,679478,16216
CHEMBL417757,P14780,,MXZLDTSVPDTTAN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,23,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1690797,DTCC00201006,1358751,16216
CHEMBL418053,P14780,,DCWUWJBJOHDJGB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12668018,IC50,=,11,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease 9 (MMP-9).,,Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,8,"Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS",,105528,DTCT0024844,1259395,DTCC00174540,1596083,6276
CHEMBL41821,P14780,,NXWFYCXTAINJMY-BRSBDYLESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15006405,KI,=,98.2,NM,,,,,,,,,,,,,,Inhibition of recombinant human matrix metalloprotease-9,,Synthesis and biological activity of selective azasugar-based TACE inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,6,"Tsukida T, Moriyama H, Inoue Y, Kondo H, Yoshino K, Nishimura S",,105397,DTCT0024844,835896,DTCC00180268,1013753,6743
CHEMBL418442,P14780,,INVXSBCIDABVMG-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10649971,IC50,=,64000,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9 (MMP-9),,"Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.",J. Med. Chem.,2000,43,2,"O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H",,105233,DTCT0024844,904795,DTCC00186442,1046249,15892
CHEMBL418442,P14780,,INVXSBCIDABVMG-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17088065,IC50,=,64000,NM,,cell_based,,,,,,,,,,,,Inhibition of human recombinant MMP9 expressed in mouse myeloma cells,,alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.,Bioorg. Med. Chem.,2007,15,2,"Biasone A, Tortorella P, Campestre C, Agamennone M, Preziuso S, Chiappini M, Nuti E, Carelli P, Rossello A, Mazza F, Gallina C",,432507,DTCT0024844,2061974,DTCC00186442,1037472,22402
CHEMBL418442,P14780,,INVXSBCIDABVMG-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,64565.42,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258721,DTCC00186442,1037853,24803
CHEMBL418476,P14780,,JTEKRZIXTMGGJR-NVQXNPDNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12781190,KI,>,2000,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9,,Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2003,13,12,"Duan JJ, Lu Z, Xue CB, He X, Seng JL, Roderick JJ, Wasserman ZR, Liu RQ, Covington MB, Magolda RL, Newton RC, Trzaskos JM, Decicco CP",,105375,DTCT0024844,492746,DTCC00211543,743973,5598
CHEMBL418655,P14780,,RBLCSCFFNCADJO-MYUZEXMDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,=,349,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1424988,DTCC00211377,1469171,17147
CHEMBL418655,P14780,,RBLCSCFFNCADJO-MYUZEXMDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12781187,INHIBITION,=,18,%,,,,,,,,,,,,,,Inhibition of recombinant human Matrix metalloprotease-9 at 1000 nM,,Discovery of selective phosphonamide-based inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2003,13,12,"Sawa M, Kurokawa K, Inoue Y, Kondo H, Yoshino K",,105367,DTCT0024844,1055886,DTCC00211377,1467317,5595
CHEMBL418715,P14780,,ZAMDOHCMZRPYMW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14980648,IC50,=,700,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,New heteroarylbenzenesulphonamides as matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,5,"Delbecq F, Cordonnier G, Pommery N, Barbry D, Hénichart JP",,105506,DTCT0024844,741881,DTCC00142952,1648931,6676
CHEMBL418725,P14780,,BJBDOOZTEPGOJP-TVKKRMFBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871727,IC50,=,6,NM,,,,,,,,,,,,,,In vitro inhibitory activity against gelatinase-B (MMP-9).,,"Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.",Bioorg. Med. Chem. Lett.,1998,8,10,"Campbell DA, Xiao XY, Harris D, Ida S, Mortezaei R, Ngu K, Shi L, Tien D, Wang Y, Navre M, Patel DV, Sharr MA, DiJoseph JF, Killar LM, Leone CL, Levin JI, Skotnicki JS",,105234,DTCT0024844,1521037,DTCC00146358,1725618,2559
CHEMBL418737,P14780,,PTUSTBHDXAVNPJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11934588,IC50,=,857,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 activity,,Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.,Bioorg. Med. Chem. Lett.,2002,12,8,"Levin JI, Chen JM, Du MT, Nelson FC, Killar LM, Skala S, Sung A, Jin G, Cowling R, Barone D, March CJ, Mohler KM, Black RA, Skotnicki JS",,105508,DTCT0024844,779296,DTCC00150827,451786,5465
CHEMBL418971,P14780,BISPHENOL A,IISBACLAFKSPIT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7271365,DTCC00260853,88624,46191
CHEMBL418971,P14780,BISPHENOL A,IISBACLAFKSPIT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7271366,DTCC00260853,88624,46191
CHEMBL419292,P14780,,FNZTUGDYJXXGEG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15109641,IC50,,,,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 at 100 uM (inactive),Not Active,Rational design and synthesis of novel heparan sulfate mimetic compounds as antiadhesive agents.,Bioorg. Med. Chem. Lett.,2004,14,10,"Ishida K, Simizu S, Teruya T, Wierzba MK, Osada H",,105504,DTCT0024844,1408367,DTCC00241886,1742067,6359
CHEMBL419301,P14780,,AILNNKVMFUWMQL-NFBKMPQASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,3.8,NM,,,,,,,,,,,,,,Inhibition of human Matrix metalloprotease-9,,,Bioorg. Med. Chem. Lett.,1995,5,4,,,105391,DTCT0024844,837374,DTCC00247295,1306247,1497
CHEMBL41943,P14780,,IIHFBHZWJNGWRC-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11412980,IC50,=,1200,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,"Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.",Bioorg. Med. Chem. Lett.,2001,11,12,"Curtin ML, Florjancic AS, Heyman HR, Michaelides MR, Garland RB, Holms JH, Steinman DH, Dellaria JF, Gong J, Wada CK, Guo Y, Elmore IB, Tapang P, Albert DH, Magoc TJ, Marcotte PA, Bouska JJ, Goodfellow CL, Bauch JL, Marsh KC, Morgan DW, Davidsen SK",,105364,DTCT0024844,1472603,DTCC00179722,172253,4274
CHEMBL419430,P14780,,GUHYZHHGWPARCR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,4.1,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1700467,DTCC00302952,2066272,16065
CHEMBL419503,P14780,,AHSZJHCTCQGTRY-GBJTYRQASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873504,KI,=,64,NM,,,,,,,,,,,,,,Inhibition of recombinant human matrix metalloprotease-9,,Structure--activity relationships of azasugar-based MMP/ADAM inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,16,"Moriyama H, Tsukida T, Inoue Y, Kondo H, Yoshino K, Nishimura S",,105394,DTCT0024844,899675,DTCC00255638,1046981,5719
CHEMBL419607,P14780,,WQCOVODIHQDZNG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,22,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1698005,DTCC00303281,1101115,16065
CHEMBL419648,P14780,,NLPICQLAIKGJBE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,10,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,500331,DTCC00235460,1370861,17340
CHEMBL419648,P14780,,NLPICQLAIKGJBE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,5,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260698,DTCC00235460,1361910,24831
CHEMBL419750,P14780,,VTRJTXRAOIMSTL-ZDUSSCGKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11563922,KI,=,320,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.",J. Med. Chem.,2001,44,20,"Schröder J, Henke A, Wenzel H, Brandstetter H, Stammler HG, Stammler A, Pfeiffer WD, Tschesche H",,105381,DTCT0024844,1719487,DTCC00282282,258562,16424
CHEMBL419751,P14780,,CHAFUQVXOKHDCA-APWZRJJASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11585439,KI,=,3.2,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors.",J. Med. Chem.,2001,44,21,"Yao W, Wasserman ZR, Chao M, Reddy G, Shi E, Liu RQ, Covington MB, Arner EC, Pratta MA, Tortorella M, Magolda RL, Newton R, Qian M, Ribadeneira MD, Christ D, Wexler RR, Decicco CP",,105382,DTCT0024844,1429718,DTCC00287233,205368,16438
CHEMBL419868,P14780,,TVHNMQFVUGWIID-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9873598,IC50,=,31,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,The synthesis and biological activity of a novel series of diazepine MMP inhibitors.,Bioorg. Med. Chem. Lett.,1998,8,19,"Levin JI, DiJoseph JF, Killar LM, Sung A, Walter T, Sharr MA, Roth CE, Skotnicki JS, Albright JD",,105513,DTCT0024844,606769,DTCC00252056,356696,2791
CHEMBL419896,P14780,,KBRVEWFSDCONMH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15125955,IC50,=,12000,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,Reverse hydroxamate-based selective TACE inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,11,"Kamei N, Tanaka T, Kawai K, Miyawaki K, Okuyama A, Murakami Y, Arakawa Y, Haino M, Harada T, Shimano M",,105525,DTCT0024844,1403501,DTCC00265483,1047085,6400
CHEMBL419995,P14780,,WYWAKLNLTJVWAB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514167,IC50,=,2,NM,,,,,,,,,,,,,,In vitro ability to inhibit matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.,Bioorg. Med. Chem. Lett.,2001,11,16,"Levin JI, Chen J, Du M, Hogan M, Kincaid S, Nelson FC, Venkatesan AM, Wehr T, Zask A, DiJoseph J, Killar LM, Skala S, Sung A, Sharr M, Roth C, Jin G, Cowling R, Mohler KM, Black RA, March CJ, Skotnicki JS",,105532,DTCT0024844,984282,DTCC00223183,1713683,4353
CHEMBL42,P14780,CLOZAPINE,QZUDBNBUXVUHMW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7365315,DTCC00134115,51460,46191
CHEMBL42,P14780,CLOZAPINE,QZUDBNBUXVUHMW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7365316,DTCC00134115,51460,46191
CHEMBL420,P14780,GUANABENZ,WDZVGELJXXEGPV-YIXHJXPBSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7316902,DTCC00133212,1416031,46191
CHEMBL420,P14780,GUANABENZ,WDZVGELJXXEGPV-YIXHJXPBSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7316903,DTCC00133212,1416031,46191
CHEMBL420023,P14780,,HUTRBECWDORHKF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,28,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,502955,DTCC00235854,1240290,17340
CHEMBL420023,P14780,,HUTRBECWDORHKF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,4.55,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260696,DTCC00235854,1231177,24831
CHEMBL420487,P14780,,QDCHOZJXLIIHRT-BJZITVGISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11585439,KI,=,166,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors.",J. Med. Chem.,2001,44,21,"Yao W, Wasserman ZR, Chao M, Reddy G, Shi E, Liu RQ, Covington MB, Arner EC, Pratta MA, Tortorella M, Magolda RL, Newton R, Qian M, Ribadeneira MD, Christ D, Wexler RR, Decicco CP",,105382,DTCT0024844,1418548,DTCC00286603,885959,16438
CHEMBL420656,P14780,,WHTRIFCXCJYQKX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11543675,IC50,=,0.5,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.",J. Med. Chem.,2001,44,19,"Hanessian S, Moitessier N, Gauchet C, Viau M",,105230,DTCT0024844,1400614,DTCC00273612,2013184,16392
CHEMBL420657,P14780,,ZPNXAVJYHSAOKF-YSSMNDQQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11543676,IC50,=,0.9,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors.,J. Med. Chem.,2001,44,19,"Hanessian S, MacKay DB, Moitessier N",,105231,DTCT0024844,1176098,DTCC00273546,1424440,16385
CHEMBL42067,P14780,,UKLIIGXGTPSYBF-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10649971,IC50,=,100000,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9 (MMP-9),,"Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.",J. Med. Chem.,2000,43,2,"O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H",,105233,DTCT0024844,901109,DTCC00186535,658583,15892
CHEMBL420932,P14780,,JBXOGQUSYPCSQK-KDOFPFPSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,0.76,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1394808,DTCC00225652,75833,14854
CHEMBL421,P14780,SULFASALAZINE,NCEXYHBECQHGNR-QZQOTICOSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7478362,DTCC00133232,2025643,46191
CHEMBL421,P14780,SULFASALAZINE,NCEXYHBECQHGNR-QZQOTICOSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7478363,DTCC00133232,2025643,46191
CHEMBL421029,P14780,,UGEYJONPMBOKNN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11543675,IC50,=,0.3,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.",J. Med. Chem.,2001,44,19,"Hanessian S, Moitessier N, Gauchet C, Viau M",,105230,DTCT0024844,1404222,DTCC00273395,562502,16392
CHEMBL421131,P14780,,ZXJIVLSCJKOYTD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11206468,IC50,=,104,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2001,11,2,"Levin JI, Gu Y, Nelson FC, Zask A, DiJoseph JF, Sharr MA, Sung A, Jin G, Cowling R, Chanda P, Cosmi S, Hsiao CL, Edris W, Wilhelm J, Killar LM, Skotnicki JS",,105521,DTCT0024844,1309444,DTCC00237580,1499945,4516
CHEMBL42114,P14780,,LKVAANCBUJLQIE-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10649971,IC50,=,20000,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9 (MMP-9),,"Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.",J. Med. Chem.,2000,43,2,"O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H",,105233,DTCT0024844,901103,DTCC00186439,1046251,15892
CHEMBL42114,P14780,,LKVAANCBUJLQIE-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,19952.62,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258714,DTCC00186439,1037854,24803
CHEMBL421295,P14780,,REGRZFZFPDDXIW-SOFGYWHQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,5.28,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833646,DTCC00220986,1736684,53968
CHEMBL421644,P14780,,XSGJDCITTFQFMZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,3,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1681651,DTCC00302815,648521,16065
CHEMBL421699,P14780,,XFKRGURHEZYQDK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11206468,IC50,=,15,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2001,11,2,"Levin JI, Gu Y, Nelson FC, Zask A, DiJoseph JF, Sharr MA, Sung A, Jin G, Cowling R, Chanda P, Cosmi S, Hsiao CL, Edris W, Wilhelm J, Killar LM, Skotnicki JS",,105505,DTCT0024844,1293503,DTCC00237568,1111984,4516
CHEMBL421699,P14780,,XFKRGURHEZYQDK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23287054,IC50,=,15,NM,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin),,Sulphonamides: Deserving class as MMP inhibitors?,Eur. J. Med. Chem.,2013,60,,"Jain P, Saravanan C, Singh SK",,944094,DTCT0024844,11835656,DTCC00237568,1126998,53820
CHEMBL421882,P14780,,GJOCABIDMCKCEG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23287054,IC50,,,,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin),Not Determined,Sulphonamides: Deserving class as MMP inhibitors?,Eur. J. Med. Chem.,2013,60,,"Jain P, Saravanan C, Singh SK",,944094,DTCT0024844,11835657,DTCC00252532,1158308,53820
CHEMBL422,P14780,TRIFLUOPERAZINE,ZEWQUBUPAILYHI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7441290,DTCC00133320,962453,46191
CHEMBL422,P14780,TRIFLUOPERAZINE,ZEWQUBUPAILYHI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7441291,DTCC00133320,962453,46191
CHEMBL422250,P14780,,IIABJCHWKFZJBK-ZDUSSCGKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11563922,KI,=,80,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.",J. Med. Chem.,2001,44,20,"Schröder J, Henke A, Wenzel H, Brandstetter H, Stammler HG, Stammler A, Pfeiffer WD, Tschesche H",,105381,DTCT0024844,1708543,DTCC00281784,389664,16424
CHEMBL422251,P14780,,JOKZNFFZUNYVMR-GOSISDBHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11563922,KI,>,15000,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,"Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.",J. Med. Chem.,2001,44,20,"Schröder J, Henke A, Wenzel H, Brandstetter H, Stammler HG, Stammler A, Pfeiffer WD, Tschesche H",,105381,DTCT0024844,1719503,DTCC00282610,906992,16424
CHEMBL422266,P14780,,RFUWBCJNXALDEH-COPCDDAFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8277511,KI,=,450,NM,,,,,,,,,,,,,,Inhibition of human fibroblast gelatinase B,,Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides.,J. Med. Chem.,1993,36,26,"Chapman KT, Kopka IE, Durette PL, Esser CK, Lanza TJ, Izquierdo-Martin M, Niedzwiecki L, Chang B, Harrison RK, Kuo DW",,71658,DTCT0024844,1254808,DTCC00318566,1145155,12304
CHEMBL422266,P14780,,RFUWBCJNXALDEH-COPCDDAFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8277511,KI,=,760,NM,,,,,,,,,,,,,,Inhibition of rabbit fibroblast gelatinase B,,Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides.,J. Med. Chem.,1993,36,26,"Chapman KT, Kopka IE, Durette PL, Esser CK, Lanza TJ, Izquierdo-Martin M, Niedzwiecki L, Chang B, Harrison RK, Kuo DW",,71661,DTCT0024844,1254664,DTCC00318566,1145155,12304
CHEMBL422821,P14780,,JOHYDRPBWMKVTC-ZEQRLZLVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643313,KI,=,768,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105546,DTCT0024844,1038173,DTCC00318980,1468511,6011
CHEMBL422948,P14780,,YIEJUKBUYFONED-XXBNENTESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,1.9,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1377319,DTCC00224757,853033,14854
CHEMBL423192,P14780,ANISOMYCIN,YKJYKKNCCRKFSL-RDBSUJKOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7279332,DTCC00329526,866016,46191
CHEMBL423192,P14780,ANISOMYCIN,YKJYKKNCCRKFSL-RDBSUJKOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7279333,DTCC00329526,866016,46191
CHEMBL42351,P14780,,WIFYOBIYNQFFIB-KXXATPMCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION,=,0,%,,,,,,,,,,,,,,Inhibition of human recombinant 92 kDa gelatinase MMP-9 at 10 uM,,,Bioorg. Med. Chem. Lett.,1995,5,15,,,71647,DTCT0024844,665625,DTCC00184570,711361,1239
CHEMBL423906,P14780,,WWXZQIVISJRIMS-VXKWHMMOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643313,KI,=,306,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105546,DTCT0024844,1028410,DTCC00319004,238219,6011
CHEMBL424,P14780,SALICYLIC ACID,YGSDEFSMJLZEOE-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,12,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103310,DTCC00133347,47753,43205
CHEMBL424,P14780,SALICYLIC ACID,YGSDEFSMJLZEOE-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7462419,DTCC00133347,51507,46191
CHEMBL424,P14780,SALICYLIC ACID,YGSDEFSMJLZEOE-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7462420,DTCC00133347,51507,46191
CHEMBL424130,P14780,,QMIAXILIKVOPKK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14684295,IC50,=,1882,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,1,"Ma D, Wu W, Yang G, Li J, Li J, Ye Q",,105527,DTCT0024844,878645,DTCC00334179,109304,6330
CHEMBL42420,P14780,PD-169469,GJOCABIDMCKCEG-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10649971,IC50,=,1500,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9 (MMP-9),,"Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.",J. Med. Chem.,2000,43,2,"O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H",,105233,DTCT0024844,927057,DTCC01739891,1272542,15892
CHEMBL424407,P14780,,LXWURXRPEDVFGY-PMACEKPBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10212120,IC50,=,52,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,Identification of highly selective inhibitors of collagenase-1 from combinatorial libraries of diketopiperazines.,J. Med. Chem.,1999,42,8,"Szardenings AK, Antonenko V, Campbell DA, DeFrancisco N, Ida S, Shi L, Sharkov N, Tien D, Wang Y, Navre M",,105219,DTCT0024844,1310903,DTCC00163454,1341144,15658
CHEMBL42442,P14780,OXFENDAZOLE,BEZZFPOZAYTVHN-UHFFFAOYSA-N,2,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7395350,DTCC00184703,282999,46191
CHEMBL42442,P14780,OXFENDAZOLE,BEZZFPOZAYTVHN-UHFFFAOYSA-N,2,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7395351,DTCC00184703,282999,46191
CHEMBL424792,P14780,,YUJRJOZBUOBIHX-QWRGUYRKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15341955,KI,=,33000,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9,,Synthesis and evaluation of novel oxazoline MMP inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,19,"Cook GR, Manivannan E, Underdahl T, Lukacova V, Zhang Y, Balaz S",,302310,DTCT0024844,1771970,DTCC00389519,1436981,17054
CHEMBL425020,P14780,,PYNQNWZHEDOQHX-VWLOTQADSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16153831,INHIBITION,=,76,%,,,,,,,,,,,,,,Percent inhibition at 25 uM against MMP-9,,Synthesis and SAR of highly selective MMP-13 inhibitors.,Bioorg. Med. Chem. Lett.,2005,15,22,"Li J, Rush TS, Li W, DeVincentis D, Du X, Hu Y, Thomason JR, Xiang JS, Skotnicki JS, Tam S, Cunningham KM, Chockalingam PS, Morris EA, Levin JI",,321724,DTCT0024844,1860374,DTCC00407673,1177224,19837
CHEMBL425316,P14780,,BJNHISLNENZLDD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,=,0.1,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1431018,DTCC00370635,1695014,17147
CHEMBL425415,P14780,,PACKAWWLZSBYDP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16516466,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.",Bioorg. Med. Chem. Lett.,2006,16,10,"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,354461,DTCT0024844,1926516,DTCC00422057,98764,20786
CHEMBL425783,P14780,,KSOLTKWEALJMDR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16723229,IC50,=,2120,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,15,"Park K, Aplasca A, Du MT, Sun L, Zhu Y, Zhang Y, Levin JI",,377987,DTCT0024844,1969678,DTCC00428619,1296018,21111
CHEMBL425844,P14780,,IAGAVMMBKLNEPN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831905,KI,>,800,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,New strategy for antedrug application: development of metalloproteinase inhibitors as antipsoriatic drugs.,J. Med. Chem.,2002,45,4,"Sawa M, Tsukamoto T, Kiyoi T, Kurokawa K, Nakajima F, Nakada Y, Yokota K, Inoue Y, Kondo H, Yoshino K",,105379,DTCT0024844,559185,DTCC00372236,304589,17148
CHEMBL426123,P14780,(-)-THALIDOMIDE,UEJJHQNACJXSKW-VIFPVBQESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7299859,DTCC00001569,1609540,46191
CHEMBL426123,P14780,(-)-THALIDOMIDE,UEJJHQNACJXSKW-VIFPVBQESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7299860,DTCC00001569,1609540,46191
CHEMBL426319,P14780,,VBMFIGJMAPMVAU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16632358,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,12,"Zhang YM, Fan X, Xiang B, Chakravarty D, Scannevin R, Burke S, Karnachi P, Rhodes K, Jackson P",,361727,DTCT0024844,1937040,DTCC00110338,1808389,20885
CHEMBL426388,P14780,,RINLHBFSMHCDCB-ZWBSKUQPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17256836,IC50,>,5000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.",J. Med. Chem.,2007,50,4,"Yao W, Zhuo J, Burns DM, Xu M, Zhang C, Li YL, Qian DQ, He C, Weng L, Shi E, Lin Q, Agrios C, Burn TC, Caulder E, Covington MB, Fridman JS, Friedman S, Katiyar K, Hollis G, Li Y, Liu C, Liu X, Marando CA, Newton R, Pan M, Scherle P, Taylor N, Vaddi K, Wasserman ZR, Wynn R, Yeleswaram S, Jalluri R, Bower M, Zhou BB, Metcalf B",,425541,DTCT0024844,2019785,DTCC00438908,1114131,21880
CHEMBL426434,P14780,,YCBSBKZAEBKTSY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1766630,DTCC00387570,1274763,18194
CHEMBL426449,P14780,,CDUNTBSHRUTDFM-FXBVVIMESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16107143,KI,=,3.8,NM,,,,,,,,,,,,,,Inhibition of MOCAc-Pro-Leu-Gly-Leu-A2p (Dnp)-Ala-Arg-NH2 binding to human matrix metalloprotease-9 (MMP-9),,"A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.",J. Med. Chem.,2005,48,17,"Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S",,307380,DTCT0024844,1815817,DTCC00397413,1016073,19409
CHEMBL426581,P14780,,UHYUCCHEBUTXHO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,INHIBITION,=,5,%,,,,,,,,,,,,,,Percent remaining enzyme activity (RA) in human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105368,DTCT0024844,1118073,DTCC00370748,325445,5419
CHEMBL426729,P14780,,PSKIOMJBUJPQBG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041917,DTCC00444431,1502269,22157
CHEMBL42710,P14780,EUGENOL,RRAFCDWBNXTKKO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7311563,DTCC00183810,1253322,46191
CHEMBL42710,P14780,EUGENOL,RRAFCDWBNXTKKO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7311564,DTCC00183810,1253322,46191
CHEMBL427216,P14780,GLICLAZIDE,BOVGTQGAOIONJV-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7320873,DTCC00422269,800576,46191
CHEMBL427216,P14780,GLICLAZIDE,BOVGTQGAOIONJV-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7320874,DTCC00422269,800576,46191
CHEMBL427366,P14780,,USIMDPVZFWUXPH-VWLOTQADSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16153831,INHIBITION,=,55,%,,,,,,,,,,,,,,Percent inhibition at 25 uM against MMP-9,,Synthesis and SAR of highly selective MMP-13 inhibitors.,Bioorg. Med. Chem. Lett.,2005,15,22,"Li J, Rush TS, Li W, DeVincentis D, Du X, Hu Y, Thomason JR, Xiang JS, Skotnicki JS, Tam S, Cunningham KM, Chockalingam PS, Morris EA, Levin JI",,321724,DTCT0024844,1860418,DTCC00407677,1113845,19837
CHEMBL427526,P14780,(R)-IBUPROPHEN,HEFNNWSXXWATRW-SNVBAGLBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7472762,DTCC00396930,671793,46191
CHEMBL427526,P14780,(R)-IBUPROPHEN,HEFNNWSXXWATRW-SNVBAGLBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7472763,DTCC00396930,671793,46191
CHEMBL427616,P14780,,KKVTZTBYJGHGCO-LJQANCHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11327577,IC50,=,0.5,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Heterocycle-based MMP inhibitors with P2' substituents.,Bioorg. Med. Chem. Lett.,2001,11,8,"Pikul S, Dunham KM, Almstead NG, De B, Natchus MG, Taiwo YO, Williams LE, Hynd BA, Hsieh LC, Janusz MJ, Gu F, Mieling GE",,105362,DTCT0024844,1284944,DTCC00133624,2079565,4760
CHEMBL428,P14780,TROVAFLOXACIN,WVPSKSLAZQPAKQ-CDMJZVDBSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7442345,DTCC00133538,1577011,46191
CHEMBL428,P14780,TROVAFLOXACIN,WVPSKSLAZQPAKQ-CDMJZVDBSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7442346,DTCC00133538,1577011,46191
CHEMBL428554,P14780,,SZTBUYMVXLGMJO-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17956082,IC50,=,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.,J. Med. Chem.,2007,50,23,"Wagner S, Breyholz HJ, Law MP, Faust A, Höltke C, Schröer S, Haufe G, Levkau B, Schober O, Schäfers M, Kopka K",,451367,DTCT0024844,2204596,DTCC00471859,488834,24059
CHEMBL428591,P14780,,WHHTZGVOGIKLTQ-SANMLTNESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,17,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278576,DTCC00489407,957068,25112
CHEMBL428647,P14780,PACLITAXEL,RCINICONZNJXQF-MZXODVADSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7393259,DTCC00138918,51496,46191
CHEMBL428647,P14780,PACLITAXEL,RCINICONZNJXQF-MZXODVADSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7393260,DTCC00138918,51496,46191
CHEMBL428762,P14780,,AGNZRJUBGONHIU-WEVVVXLNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,>,150000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266572,DTCC00485910,164175,24949
CHEMBL428880,P14780,CROMOLYN,IMZMKUWMOSJXDT-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7339735,DTCC00138605,671787,46191
CHEMBL428880,P14780,CROMOLYN,IMZMKUWMOSJXDT-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7339736,DTCC00138605,671787,46191
CHEMBL429,P14780,LABETALOL,SGUAFYQXFOLMHL-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7429286,DTCC00133676,120973,46191
CHEMBL429,P14780,LABETALOL,SGUAFYQXFOLMHL-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7429287,DTCC00133676,120973,46191
CHEMBL429023,P14780,ROTENONE,JUVIOZPCNVVQFO-HBGVWJBISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7488153,DTCC00134556,1027058,46191
CHEMBL429023,P14780,ROTENONE,JUVIOZPCNVVQFO-HBGVWJBISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7488154,DTCC00134556,1027058,46191
CHEMBL429123,P14780,,UUKCYLIDEZGIBS-IBGZPJMESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,1.7,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278580,DTCC00489392,1857410,25112
CHEMBL429336,P14780,,KWWNNPAPYSJGQH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12668018,IC50,=,2,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease 9 (MMP-9).,,Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,8,"Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS",,105528,DTCT0024844,1259399,DTCC00174624,819574,6276
CHEMBL42938,P14780,,AGRDSOUIPBKOKQ-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10649971,IC50,=,3800,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9 (MMP-9),,"Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.",J. Med. Chem.,2000,43,2,"O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H",,105233,DTCT0024844,930633,DTCC00185902,1531845,15892
CHEMBL429431,P14780,,GJFWRLSCEYCXSO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17981034,IC50,=,4.8,NM,,,,,,,,,,,,,,Inhibition of MMP9,,1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Chakaravarty D, Xiang B, Scannevin RH, Huang Z, Ma J, Burke SL, Karnachi P, Rhodes KJ, Jackson PF",,469432,DTCT0024844,2289307,DTCC00501172,650548,25715
CHEMBL429444,P14780,,VKZVNFAGQVZFTI-RBBKRZOGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17276676,IC50,>,2000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,7,"Chen XT, Ghavimi B, Corbett RL, Xue CB, Liu RQ, Covington MB, Qian M, Vaddi KG, Christ DD, Hartman KD, Ribadeneira MD, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,447087,DTCT0024844,2169327,DTCC00464765,1135026,23623
CHEMBL429486,P14780,,SKGCSJBALNLNLA-FQEVSTJZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,3.2,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278582,DTCC00489377,505178,25112
CHEMBL429571,P14780,,VPPPUOKULYHXCC-HNNXBMFYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18086526,IC50,=,104,NM,,,,,,,,,,,,,,Inhibition of catalytic domain MMP9,,"beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.",Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV",,465911,DTCT0024844,2300334,DTCC00500246,1458715,25438
CHEMBL429589,P14780,,MUYREESVDCFSSL-RBBKRZOGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18061445,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).",Bioorg. Med. Chem. Lett.,2008,18,2,"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ",,463237,DTCT0024844,2296496,DTCC00501584,1135311,25233
CHEMBL42962,P14780,,VDQWNVBJBNZACE-ZOIVMXBYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION,=,8,%,,,,,,,,,,,,,,Inhibition of human recombinant 92 kDa gelatinase MMP-9 at 10 uM,,,Bioorg. Med. Chem. Lett.,1995,5,15,,,71647,DTCT0024844,676843,DTCC00184953,1584442,1239
CHEMBL429669,P14780,,ZMPZOWIAKRPTEQ-SFTDATJTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18036818,IC50,=,2623,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.,Bioorg. Med. Chem. Lett.,2008,18,1,"Yao W, Zhuo J, Burns DM, Li YL, Qian DQ, Zhang C, He C, Xu M, Shi E, Li Y, Marando CA, Covington MB, Yang G, Liu X, Pan M, Fridman JS, Scherle P, Wasserman ZR, Hollis G, Vaddi K, Yeleswaram S, Newton R, Friedman S, Metcalf B",,461667,DTCT0024844,2276528,DTCC00112467,585443,25086
CHEMBL429800,P14780,,NSDMBIOAMTZMED-LJQANCHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17956082,IC50,=,50,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.,J. Med. Chem.,2007,50,23,"Wagner S, Breyholz HJ, Law MP, Faust A, Höltke C, Schröer S, Haufe G, Levkau B, Schober O, Schäfers M, Kopka K",,451367,DTCT0024844,2204602,DTCC00471853,876522,24059
CHEMBL429800,P14780,,NSDMBIOAMTZMED-LJQANCHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22540974,IC50,=,50,NM,,,,,,,,,,,,,,"Inhibition of MMP9 using (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured for 10 mins by fluorometry",,A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation.,J. Med. Chem.,2012,55,10,"Hugenberg V, Breyholz HJ, Riemann B, Hermann S, Schober O, Schäfers M, Gangadharmath U, Mocharla V, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,832927,DTCT0024844,10563941,DTCC00471853,899521,48958
CHEMBL429800,P14780,,NSDMBIOAMTZMED-LJQANCHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23899323,IC50,=,50,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin),,"Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation.",J. Med. Chem.,2013,56,17,"Hugenberg V, Riemann B, Hermann S, Schober O, Schäfers M, Szardenings K, Lebedev A, Gangadharmath U, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,983458,DTCT0024844,12575115,DTCC00471853,881014,55760
CHEMBL429927,P14780,,BMSDLUUZGPIUGG-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18086526,IC50,=,12,NM,,,,,,,,,,,,,,Inhibition of catalytic domain MMP9,,"beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.",Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV",,465911,DTCT0024844,2300355,DTCC00500665,1070386,25438
CHEMBL430210,P14780,,ZJGVSDUUDCVLEO-NRFANRHFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18083558,IC50,=,4.8,NM,,,,,,,,,,,,,,Inhibition of MMP9,,beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.,Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV",,461907,DTCT0024844,2278581,DTCC00489381,860750,25112
CHEMBL430612,P14780,,IVFPKTAJBISJDW-YKSBVNFPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,13,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1395986,DTCC00226002,853032,14854
CHEMBL43063,P14780,,NZVNFHULUBKMQI-VWLOTQADSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10649971,IC50,=,4800,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9 (MMP-9),,"Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.",J. Med. Chem.,2000,43,2,"O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H",,105233,DTCT0024844,904825,DTCC00186612,755163,15892
CHEMBL43064,P14780,CINNARIZINE,DERZBLKQOCDDDZ-JLHYYAGUSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7367084,DTCC01738588,930078,46191
CHEMBL43064,P14780,CINNARIZINE,DERZBLKQOCDDDZ-JLHYYAGUSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7367085,DTCC01738588,930078,46191
CHEMBL43065,P14780,OXYRESVERATROL,PDHAOJSHSJQANO-OWOJBTEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,IC50,,,,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain incubated for 20 mins by fluorimetric assay,Not Determined,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827436,DTCT0024844,10535425,DTCC00185244,1169674,48665
CHEMBL430664,P14780,,LXRKTOCLXUHNEM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12270165,IC50,=,0.7,NM,,,,,,,,,,,,,,Concentration required in vitro to inhibit Matrix metalloprotease-9,,Benzodiazepine inhibitors of the MMPs and TACE.,Bioorg. Med. Chem. Lett.,2002,12,20,"Nelson FC, Delos Santos E, Levin JI, Chen JM, Skotnicki JS, DiJoseph JF, Sharr MA, Sung A, Killar LM, Cowling R, Jin G, Roth CE, Albright JD",,105515,DTCT0024844,1528067,DTCC00263053,1467892,5143
CHEMBL43087,P14780,,WSWMIGCNSWBCNT-KBUPBQIOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15006405,KI,=,14.24,NM,,,,,,,,,,,,,,Inhibition of recombinant human matrix metalloprotease-9,,Synthesis and biological activity of selective azasugar-based TACE inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,6,"Tsukida T, Moriyama H, Inoue Y, Kondo H, Yoshino K, Nishimura S",,105397,DTCT0024844,832298,DTCC00180267,949058,6743
CHEMBL43087,P14780,,WSWMIGCNSWBCNT-KBUPBQIOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15055993,KI,=,14,NM,,,,,,,,,,,,,,Inhibition of human recombinant matrix metalloprotease 9,,Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents.,J. Med. Chem.,2004,47,8,"Moriyama H, Tsukida T, Inoue Y, Yokota K, Yoshino K, Kondo H, Miura N, Nishimura S",,105384,DTCT0024844,1366768,DTCC00180267,937857,18075
CHEMBL431015,P14780,,VAIKNTWLUDEQKJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11206468,INHIBITION,=,38,%,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 at 0.3 uM,,Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2001,11,2,"Levin JI, Gu Y, Nelson FC, Zask A, DiJoseph JF, Sharr MA, Sung A, Jin G, Cowling R, Chanda P, Cosmi S, Hsiao CL, Edris W, Wilhelm J, Killar LM, Skotnicki JS",,105541,DTCT0024844,1311751,DTCC00236979,1046773,4516
CHEMBL431057,P14780,,XQJGASWZRFSCKP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873518,IC50,=,74,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotein-9,,Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2003,13,16,"Levin JI, Chen JM, Cheung K, Cole D, Crago C, Santos ED, Du X, Khafizova G, MacEwan G, Niu C, Salaski EJ, Zask A, Cummons T, Sung A, Xu J, Zhang Y, Xu W, Ayral-Kaloustian S, Jin G, Cowling R, Barone D, Mohler KM, Black RA, Skotnicki JS",,105519,DTCT0024844,807317,DTCC00260571,2034056,5733
CHEMBL43113,P14780,,MZIZOOUSSMSGAV-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10649971,IC50,=,3900,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9 (MMP-9),,"Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.",J. Med. Chem.,2000,43,2,"O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H",,105233,DTCT0024844,908484,DTCC00186443,1979397,15892
CHEMBL43113,P14780,,MZIZOOUSSMSGAV-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,3890.45,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258716,DTCC00186443,1970998,24803
CHEMBL431226,P14780,,IDKUTWZTCGVYET-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15125955,IC50,=,40000,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,Reverse hydroxamate-based selective TACE inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,11,"Kamei N, Tanaka T, Kawai K, Miyawaki K, Okuyama A, Murakami Y, Arakawa Y, Haino M, Harada T, Shimano M",,105525,DTCT0024844,1381121,DTCC00265456,982319,6400
CHEMBL431268,P14780,,PBUKUIIGUHJHQN-OJSMNCEXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,50,NM,,,,,,,,,,,,,,"Inhibition of matrix metalloprotease-9, MMP-9",,,Bioorg. Med. Chem. Lett.,1997,7,21,,,102116,DTCT0024844,1316168,DTCC00258271,1294064,2323
CHEMBL43147,P14780,,BGKNBDGHNBOSGD-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10649971,IC50,=,26000,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9 (MMP-9),,"Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.",J. Med. Chem.,2000,43,2,"O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H",,105233,DTCT0024844,904783,DTCC00186340,787356,15892
CHEMBL43147,P14780,,BGKNBDGHNBOSGD-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,25703.96,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258709,DTCC00186340,778991,24803
CHEMBL43152,P14780,PD-166793,GJOCABIDMCKCEG-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10649971,IC50,=,7900,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9 (MMP-9),,"Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.",J. Med. Chem.,2000,43,2,"O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H",,105233,DTCT0024844,915395,DTCC01739899,2012246,15892
CHEMBL43152,P14780,PD-166793,GJOCABIDMCKCEG-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,7943.28,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258720,DTCC01739899,2003622,24803
CHEMBL431680,P14780,,DQLDJYJWPVFOFC-REUBFRLUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11585440,KI,=,1787,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.",J. Med. Chem.,2001,44,21,"Xue CB, He X, Corbett RL, Roderick J, Wasserman ZR, Liu RQ, Jaffee BD, Covington MB, Qian M, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105383,DTCT0024844,1294910,DTCC00286954,336147,16439
CHEMBL431926,P14780,,JRXNWTIRACLYGX-LJQANCHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,<,2.1,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1471720,DTCC00197857,852749,17283
CHEMBL43206,P14780,,NEOOWKPSCAQYPI-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10649971,IC50,=,100000,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9 (MMP-9),,"Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.",J. Med. Chem.,2000,43,2,"O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H",,105233,DTCT0024844,931897,DTCC00186341,1111450,15892
CHEMBL43206,P14780,,NEOOWKPSCAQYPI-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258719,DTCC00186341,1103039,24803
CHEMBL432223,P14780,,VDDKIBQLKXMKIW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,1.7,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1617692,DTCC00298906,595003,15919
CHEMBL432223,P14780,,VDDKIBQLKXMKIW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,1.7,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258482,DTCC00298906,585406,24803
CHEMBL432307,P14780,,UJVIDDIDLMDARE-JTQLQIEISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10649971,IC50,=,9500,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9 (MMP-9),,"Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.",J. Med. Chem.,2000,43,2,"O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H",,105233,DTCT0024844,911873,DTCC00186526,1467007,15892
CHEMBL432333,P14780,,VOKDMWUXBXSQQZ-VWNXMTODSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12781190,KI,>,2000,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9,,Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2003,13,12,"Duan JJ, Lu Z, Xue CB, He X, Seng JL, Roderick JJ, Wasserman ZR, Liu RQ, Covington MB, Magolda RL, Newton RC, Trzaskos JM, Decicco CP",,105375,DTCT0024844,488911,DTCC00212057,1455649,5598
CHEMBL432583,P14780,,XHPRSCKHNNCQRZ-IXDOHACOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10560745,IC50,=,640,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease (MMP-9),,Selective inhibition of low affinity IgE receptor (CD23) processing: P1' bicyclomethyl substituents.,Bioorg. Med. Chem. Lett.,1999,9,21,"Bailey S, Bolognese B, Faller A, Louis-Flamberg P, MacPherson DT, Mayer RJ, Marshall LA, Milner PH, Mistry J, Smith DG, Ward JG",,105820,DTCT0024844,1431635,DTCC00278788,108679,3450
CHEMBL43276,P14780,,GSCKLBZEPMMUCA-FQEVSTJZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10649971,IC50,=,27000,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9 (MMP-9),,"Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.",J. Med. Chem.,2000,43,2,"O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H",,105233,DTCT0024844,906087,DTCC00185835,658585,15892
CHEMBL432770,P14780,,QUIDRRLYQSJQMX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10411481,KI,=,30,NM,,,,,,,,,,,,,,Binding affinity against matrix metalloprotease-9 (gelatinase-B).,,Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.,J. Med. Chem.,1999,42,14,"Vassiliou S, Mucha A, Cuniasse P, Georgiadis D, Lucet-Levannier K, Beau F, Kannan R, Murphy G, Knäuper V, Rio MC, Basset P, Yiotakis A, Dive V",,105378,DTCT0024844,1056166,DTCC00249346,161690,15258
CHEMBL432842,P14780,,YPHZFHQBHSELGO-QUCCMNQESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9548812,IC50,=,3.3,NM,,,,,,,,,,,,,,Activity against Matrix metalloprotease-9 (MMP-9).,,Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.,J. Med. Chem.,1998,41,8,"Yamamoto M, Tsujishita H, Hori N, Ohishi Y, Inoue S, Ikeda S, Okada Y",,105225,DTCT0024844,980292,DTCC00151632,1725664,15116
CHEMBL432882,P14780,,NQPIHEUUYRAYII-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,0.54,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,653064,DTCC00186511,2046333,15057
CHEMBL432882,P14780,,NQPIHEUUYRAYII-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10649971,IC50,=,3,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9 (MMP-9),,"Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.",J. Med. Chem.,2000,43,2,"O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H",,105233,DTCT0024844,917733,DTCC00186511,2044570,15892
CHEMBL432990,P14780,,NMVSNTFENGJBJY-XFAFFCHDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11585440,KI,=,21,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.",J. Med. Chem.,2001,44,21,"Xue CB, He X, Corbett RL, Roderick J, Wasserman ZR, Liu RQ, Jaffee BD, Covington MB, Qian M, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105383,DTCT0024844,1304870,DTCC00287734,1273601,16439
CHEMBL433257,P14780,HARRINGTONINE,HAVJATCHLFRDHY-KSZYUSJVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7310677,DTCC00188822,1447883,46191
CHEMBL433257,P14780,HARRINGTONINE,HAVJATCHLFRDHY-KSZYUSJVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7310678,DTCC00188822,1447883,46191
CHEMBL433262,P14780,,VHCRBJFCQRNNFG-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10649971,IC50,=,18,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9 (MMP-9),,"Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.",J. Med. Chem.,2000,43,2,"O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H",,105233,DTCT0024844,934330,DTCC00185901,1660789,15892
CHEMBL433381,P14780,,CFUYAVWBVRZFLA-OTWHNJEPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472217,KI,=,2.1,NM,,,,,,,,,,,,,,In vitro inhibition of human MMP-9.,,"Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.",J. Med. Chem.,2001,44,16,"Xue CB, Voss ME, Nelson DJ, Duan JJ, Cherney RJ, Jacobson IC, He X, Roderick J, Chen L, Corbett RL, Wang L, Meyer DT, Kennedy K, DeGradodagger WF, Hardman KD, Teleha CA, Jaffee BD, Liu RQ, Copeland RA, Covington MB, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105380,DTCT0024844,1672866,DTCC00251792,1488671,16346
CHEMBL433426,P14780,,GJLVFYXHGPXLCC-QUCCMNQESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9548812,IC50,=,0.2,NM,,,,,,,,,,,,,,Activity against Matrix metalloprotease-9 (MMP-9).,,Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.,J. Med. Chem.,1998,41,8,"Yamamoto M, Tsujishita H, Hori N, Ohishi Y, Inoue S, Ikeda S, Okada Y",,105225,DTCT0024844,998142,DTCC00151649,1081960,15116
CHEMBL433816,P14780,,DYKLASPWVUKEIT-QYZOEREBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9548812,IC50,=,45,NM,,,,,,,,,,,,,,Activity against Matrix metalloprotease-9 (MMP-9).,,Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.,J. Med. Chem.,1998,41,8,"Yamamoto M, Tsujishita H, Hori N, Ohishi Y, Inoue S, Ikeda S, Okada Y",,105225,DTCT0024844,990676,DTCC00151405,1725663,15116
CHEMBL433902,P14780,,OEVLRZHPDAKFSL-RPBOFIJWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,32,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1418358,DTCC00353751,466217,12880
CHEMBL433981,P14780,,RBLCSCFFNCADJO-MKAWVKDUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,>,800,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1422594,DTCC00372420,531405,17147
CHEMBL434,P14780,ISOPROTERENOL,JWZZKOKVBUJMES-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7439602,DTCC00133870,315665,46191
CHEMBL434,P14780,ISOPROTERENOL,JWZZKOKVBUJMES-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7439603,DTCC00133870,315665,46191
CHEMBL434063,P14780,GW1929,QTQMRBZOBKYXCG-MHZLTWQESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7327701,DTCC01743578,994594,46191
CHEMBL434063,P14780,GW1929,QTQMRBZOBKYXCG-MHZLTWQESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7327702,DTCC01743578,994594,46191
CHEMBL434187,P14780,,LMASIGSKSCEZDY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16084720,IC50,,,,,,,,,,,,,,,,,Inhibitory activity against matrix metallopeptidase 9; Not tested,Not Determined,Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2005,15,19,"Levin JI, Chen JM, Laakso LM, Du M, Du X, Venkatesan AM, Sandanayaka V, Zask A, Xu J, Xu W, Zhang Y, Skotnicki JS",,321340,DTCT0024844,1861816,DTCC00408121,163466,19752
CHEMBL434187,P14780,,LMASIGSKSCEZDY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16084720,IC50,,,,,,,,,,,,,,,,,Inhibitory activity against matrix metallopeptidase 9; Not tested,Not Determined,Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2005,15,19,"Levin JI, Chen JM, Laakso LM, Du M, Du X, Venkatesan AM, Sandanayaka V, Zask A, Xu J, Xu W, Zhang Y, Skotnicki JS",,321340,DTCT0024844,1862334,DTCC00408121,163469,19752
CHEMBL434348,P14780,,HUNBFLZYPNPINY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15357971,KI,>,2100,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,17,"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP",,302676,DTCT0024844,1768807,DTCC00387612,77658,18194
CHEMBL434567,P14780,,CKZHFOKQZRZCPF-ROUUACIJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17256836,IC50,=,428,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.",J. Med. Chem.,2007,50,4,"Yao W, Zhuo J, Burns DM, Xu M, Zhang C, Li YL, Qian DQ, He C, Weng L, Shi E, Lin Q, Agrios C, Burn TC, Caulder E, Covington MB, Fridman JS, Friedman S, Katiyar K, Hollis G, Li Y, Liu C, Liu X, Marando CA, Newton R, Pan M, Scherle P, Taylor N, Vaddi K, Wasserman ZR, Wynn R, Yeleswaram S, Jalluri R, Bower M, Zhou BB, Metcalf B",,425541,DTCT0024844,2019780,DTCC00438928,33872,21880
CHEMBL434567,P14780,,CKZHFOKQZRZCPF-ROUUACIJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,IC50,=,304,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2457494,DTCC00438928,36639,32556
CHEMBL43479,P14780,,UKLIIGXGTPSYBF-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10649971,IC50,=,27,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9 (MMP-9),,"Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.",J. Med. Chem.,2000,43,2,"O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H",,105233,DTCT0024844,910703,DTCC00186429,107667,15892
CHEMBL435,P14780,HYDROCHLOROTHIAZIDE,JZUFKLXOESDKRF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7336331,DTCC00133916,1285877,46191
CHEMBL435,P14780,HYDROCHLOROTHIAZIDE,JZUFKLXOESDKRF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7336332,DTCC00133916,1285877,46191
CHEMBL435206,P14780,,COEWKMGFIMMVCE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669564,IC50,=,28,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9 (MMP-9),,Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.,J. Med. Chem.,2000,43,3,"Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S",,105228,DTCT0024844,1700449,DTCC00302719,1262122,16065
CHEMBL435271,P14780,,NKAFEKVEMSYZIX-SFYKDHMMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9871551,KI,=,5,NM,,,,,,,,,,,,,,Binding affinity was evaluated against matrix metalloprotease-9,,Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,1998,8,7,"Jacobson IC, Reddy PG, Wasserman ZR, Hardman KD, Covington MB, Arner EC, Copeland RA, Decicco CP, Magolda RL",,105373,DTCT0024844,476130,DTCC00364329,1425460,3059
CHEMBL435399,P14780,,HWWUSFMLISZBRB-GOTSBHOMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14643313,KI,>,2128,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9),,"Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.",Bioorg. Med. Chem. Lett.,2003,13,24,"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP",,105546,DTCT0024844,1042136,DTCC00318376,1980922,6011
CHEMBL435462,P14780,,YYRRVFYCIQQYHU-JWRCQZCYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831905,KI,=,4.97,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,New strategy for antedrug application: development of metalloproteinase inhibitors as antipsoriatic drugs.,J. Med. Chem.,2002,45,4,"Sawa M, Tsukamoto T, Kiyoi T, Kurokawa K, Nakajima F, Nakada Y, Yokota K, Inoue Y, Kondo H, Yoshino K",,105379,DTCT0024844,564055,DTCC00345291,1404891,17148
CHEMBL435462,P14780,,YYRRVFYCIQQYHU-JWRCQZCYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11844676,KI,=,4.97,NM,,,,,,,,,,,,,,Inhibitory constant against recombinant human gelatinase B (Matrix metalloprotease-9),,Encounter with unexpected collagenase-1 selective inhibitor: switchover of inhibitor binding pocket induced by fluorine atom.,Bioorg. Med. Chem. Lett.,2002,12,4,"Sawa M, Kondo H, Nishimura S",,105400,DTCT0024844,1422070,DTCC00345291,1392847,5346
CHEMBL435690,P14780,,QGNGZCPBWQOYKN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15857146,IC50,=,2,NM,,,,,,,,,,,,,,In vitro inhibition of human Matrix metalloprotease 9,,C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging.,J. Med. Chem.,2005,48,9,"Breyholz HJ, Schäfers M, Wagner S, Höltke C, Faust A, Rabeneck H, Levkau B, Schober O, Kopka K",,305380,DTCT0024844,1828770,DTCC00399828,855009,19718
CHEMBL435713,P14780,,YEIKCNCZZRBAHT-UGSOOPFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,INHIBITION,=,1,%,,,,,,,,,,,,,,Percent remaining enzyme activity (RA) in human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105368,DTCT0024844,1132634,DTCC00373308,1328008,5419
CHEMBL435713,P14780,,YEIKCNCZZRBAHT-UGSOOPFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11958997,KI,=,100,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (matrix metalloprotease-9),,Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2002,12,6,"Krumme D, Tschesche H",,105399,DTCT0024844,1132633,DTCC00373308,1328008,5419
CHEMBL436049,P14780,,XRIFBRFEZLXEFP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,=,95.6,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1417572,DTCC00371043,499304,17147
CHEMBL436324,P14780,,ZTVJLUOPMWIKSV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16084720,IC50,=,14,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metallopeptidase 9,,Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2005,15,19,"Levin JI, Chen JM, Laakso LM, Du M, Du X, Venkatesan AM, Sandanayaka V, Zask A, Xu J, Xu W, Zhang Y, Skotnicki JS",,321249,DTCT0024844,1861759,DTCC00408047,584672,19752
CHEMBL436324,P14780,,ZTVJLUOPMWIKSV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16084720,IC50,=,14,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metallopeptidase 9,,Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2005,15,19,"Levin JI, Chen JM, Laakso LM, Du M, Du X, Venkatesan AM, Sandanayaka V, Zask A, Xu J, Xu W, Zhang Y, Skotnicki JS",,321249,DTCT0024844,1862278,DTCC00408047,584674,19752
CHEMBL436326,P14780,,YDMULAZNHVGCAM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15857146,IC50,=,26,NM,,,,,,,,,,,,,,In vitro inhibition of human Matrix metalloprotease 9,,C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging.,J. Med. Chem.,2005,48,9,"Breyholz HJ, Schäfers M, Wagner S, Höltke C, Faust A, Rabeneck H, Levkau B, Schober O, Kopka K",,305380,DTCT0024844,1828763,DTCC00400024,1340194,19718
CHEMBL43644,P14780,,VHCRBJFCQRNNFG-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10649971,IC50,=,84000,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9 (MMP-9),,"Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.",J. Med. Chem.,2000,43,2,"O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H",,105233,DTCT0024844,904835,DTCC00186536,172340,15892
CHEMBL436623,P14780,,YCHWBZQRFSMZCL-PVHODMMVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,8126708,IC50,=,15,NM,,,,,,,,,,,,,,Activity against human gelatinase (MMP-9).,,Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.,J. Med. Chem.,1994,37,5,"Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M",,102113,DTCT0024844,1425857,DTCC00353587,789183,12880
CHEMBL436950,P14780,,ISGKPJSIGMKCEK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16516466,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.",Bioorg. Med. Chem. Lett.,2006,16,10,"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ",,354461,DTCT0024844,1926525,DTCC00421635,908661,20786
CHEMBL436977,P14780,2-(4-METHOXYBENZENESULFANYL)OCTANOIC ACID HYDROXYAMIDE,WEBZGXZPLFJJPD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,INHIBITION,=,67,%,,,,,,,,,,,,,,Inhibition of MMP9 at 10 uM,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429671,DTCT0024844,2041862,DTCC00002419,1884528,22157
CHEMBL437,P14780,SULFATHIAZOLE,JNMRHUJNCSQMMB-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7482670,DTCC00133961,1027059,46191
CHEMBL437,P14780,SULFATHIAZOLE,JNMRHUJNCSQMMB-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7482671,DTCC00133961,1027059,46191
CHEMBL437002,P14780,,LEVTWCPGXIVKEH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7294353,DTCC00473690,1734052,46191
CHEMBL437002,P14780,,LEVTWCPGXIVKEH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7294354,DTCC00473690,1734052,46191
CHEMBL437407,P14780,,HTUGJHMFYMFUPL-IKCVQBBRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18242982,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents.",Bioorg. Med. Chem. Lett.,2008,18,5,"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ",,462363,DTCT0024844,2282419,DTCC00488449,260775,25163
CHEMBL438,P14780,SULFAMERAZINE,QPPBRPIAZZHUNT-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7486754,DTCC00133994,1798418,46191
CHEMBL438,P14780,SULFAMERAZINE,QPPBRPIAZZHUNT-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7486755,DTCC00133994,1798418,46191
CHEMBL438519,P14780,,MXFDANXBAJYGHL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,127000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266637,DTCC00485871,1005475,24949
CHEMBL438528,P14780,,BVFWOEMSVMBUTK-RBDMOPTHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18061445,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).",Bioorg. Med. Chem. Lett.,2008,18,2,"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ",,463237,DTCT0024844,2296504,DTCC00501777,1135310,25233
CHEMBL438810,P14780,"1,3,2'-TRIGUANIDINONEAMINE",ZPDRGOJGQGWHOF-HKEUSBCWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16870442,KI,>,300000,NM,,,,,,,,,,,,,,Activity at MMP9,,Selectively guanidinylated derivatives of neamine. Syntheses and inhibition of anthrax lethal factor protease.,Bioorg. Med. Chem. Lett.,2006,16,19,"Jiao GS, Simo O, Nagata M, O'Malley S, Hemscheidt T, Cregar L, Millis SZ, Goldman ME, Tang C",,393600,DTCT0024844,1981415,DTCC00001996,1048918,21299
CHEMBL43882,P14780,TRICHLOROETHANE,UBOXGVDOUJQMTN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7453539,DTCC00104711,1830694,46191
CHEMBL43882,P14780,TRICHLOROETHANE,UBOXGVDOUJQMTN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7453540,DTCC00104711,1830694,46191
CHEMBL438832,P14780,,WVHHDPGQZGEEGP-CYVLTUHYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16913712,IC50,=,60100,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening.,J. Med. Chem.,2006,49,17,"Schepetkin IA, Khlebnikov AI, Kirpotina LN, Quinn MT",,386349,DTCT0024844,1958901,DTCC00430694,1787605,21205
CHEMBL439,P14780,SULFADIAZINE,SEEPANYCNGTZFQ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7473836,DTCC00133995,1734063,46191
CHEMBL439,P14780,SULFADIAZINE,SEEPANYCNGTZFQ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7473837,DTCC00133995,1734063,46191
CHEMBL439012,P14780,,JBPHFUSOSQRLMX-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17591762,IC50,=,61000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Potent and selective nonpeptidic inhibitors of procollagen C-proteinase.,J. Med. Chem.,2007,50,15,"Fish PV, Allan GA, Bailey S, Blagg J, Butt R, Collis MG, Greiling D, James K, Kendall J, McElroy A, McCleverty D, Reed C, Webster R, Whitlock GA",,440140,DTCT0024844,2113796,DTCC00452723,1715977,23023
CHEMBL439012,P14780,,JBPHFUSOSQRLMX-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17591762,INHIBITION,<,50,%,,,,,,,,,,,,,,Inhibition of MMP9 at 10 uM,,Potent and selective nonpeptidic inhibitors of procollagen C-proteinase.,J. Med. Chem.,2007,50,15,"Fish PV, Allan GA, Bailey S, Blagg J, Butt R, Collis MG, Greiling D, James K, Kendall J, McElroy A, McCleverty D, Reed C, Webster R, Whitlock GA",,440146,DTCT0024844,2113824,DTCC00452723,1715977,23023
CHEMBL439012,P14780,,JBPHFUSOSQRLMX-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17591762,INHIBITION,<,50,%,,,,,,,,,,,,,,Inhibition of MMP9 at 100 uM,,Potent and selective nonpeptidic inhibitors of procollagen C-proteinase.,J. Med. Chem.,2007,50,15,"Fish PV, Allan GA, Bailey S, Blagg J, Butt R, Collis MG, Greiling D, James K, Kendall J, McElroy A, McCleverty D, Reed C, Webster R, Whitlock GA",,440152,DTCT0024844,2113852,DTCC00452723,1715977,23023
CHEMBL439012,P14780,,JBPHFUSOSQRLMX-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17591762,INHIBITION,<,50,%,,,,,,,,,,,,,,Inhibition of MMP9 at 30 uM,,Potent and selective nonpeptidic inhibitors of procollagen C-proteinase.,J. Med. Chem.,2007,50,15,"Fish PV, Allan GA, Bailey S, Blagg J, Butt R, Collis MG, Greiling D, James K, Kendall J, McElroy A, McCleverty D, Reed C, Webster R, Whitlock GA",,440158,DTCT0024844,2113881,DTCC00452723,1715977,23023
CHEMBL439066,P14780,,LBCLZTXMMZKWOQ-AZGAKELHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18061445,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).",Bioorg. Med. Chem. Lett.,2008,18,2,"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ",,463237,DTCT0024844,2296489,DTCC00502017,973006,25233
CHEMBL439931,P14780,,UGBFTDFVLBACAS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,0.9,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1712501,DTCC00201013,1132089,16216
CHEMBL439944,P14780,,WWNOVCQMRIZSRV-UTUOFQBUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,2.4,NM,,,,,,,,,,,,,,"Inhibition of human gelatinase B, MMP9",,,Bioorg. Med. Chem. Lett.,1997,7,17,,,71656,DTCT0024844,1055715,DTCC00230313,1914352,2236
CHEMBL44,P14780,GENISTEIN,TZBJGXHYKVUXJN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7303803,DTCC00134437,2089749,46191
CHEMBL44,P14780,GENISTEIN,TZBJGXHYKVUXJN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7303804,DTCC00134437,2089749,46191
CHEMBL440398,P14780,,SIMKLZXUJGLRHO-HNNXBMFYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18086526,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of catalytic domain MMP9,,"beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.",Bioorg. Med. Chem. Lett.,2008,18,3,"Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV",,465911,DTCT0024844,2300333,DTCC00500201,294142,25438
CHEMBL440498,P14780,RS-130830,ROSNVSQTEGHUKU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669559,KI,=,0.58,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9).,,Protease inhibitors: current status and future prospects.,J. Med. Chem.,2000,43,3,"Leung D, Abbenante G, Fairlie DP",,105389,DTCT0024844,1060826,DTCC01741261,583202,16063
CHEMBL440498,P14780,RS-130830,ROSNVSQTEGHUKU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,3,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,488098,DTCC01741261,594282,17340
CHEMBL440498,P14780,RS-130830,ROSNVSQTEGHUKU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15686921,KI,=,0.55,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13).,Bioorg. Med. Chem. Lett.,2005,15,4,"Kim SH, Pudzianowski AT, Leavitt KJ, Barbosa J, McDonnell PA, Metzler WJ, Rankin BM, Liu R, Vaccaro W, Pitts W",,302481,DTCT0024844,1745327,DTCC01741261,584379,18787
CHEMBL440498,P14780,RS-130830,ROSNVSQTEGHUKU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16220987,KI,=,1,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14741469,DTCC01741261,2107724,69259
CHEMBL440498,P14780,RS-130830,ROSNVSQTEGHUKU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19422229,IC50,=,2,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13.",J. Med. Chem.,2009,52,11,"Monovich LG, Tommasi RA, Fujimoto RA, Blancuzzi V, Clark K, Cornell WD, Doti R, Doughty J, Fang J, Farley D, Fitt J, Ganu V, Goldberg R, Goldstein R, Lavoie S, Kulathila R, Macchia W, Parker DT, Melton R, O'Byrne E, Pastor G, Pellas T, Quadros E, Reel N, Roland DM, Sakane Y, Singh H, Skiles J, Somers J, Toscano K, Wigg A, Zhou S, Zhu L, Shieh WC, Xue S, McQuire LW",,500585,DTCT0024844,2824185,DTCC01741261,585998,33635
CHEMBL440498,P14780,RS-130830,ROSNVSQTEGHUKU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25192810,IC50,=,0.11,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using fluorescence peptide Cy3-PLGLK(Cy5Q)AR-NH2 substrate by fluorescence assay,,"Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1¿ binding site.",Bioorg. Med. Chem.,2014,22,19,"Nara H, Sato K, Naito T, Mototani H, Oki H, Yamamoto Y, Kuno H, Santou T, Kanzaki N, Terauchi J, Uchikawa O, Kori M",,1442066,DTCT0024844,13992254,DTCC01741261,611029,59837
CHEMBL440498,P14780,RS-130830,ROSNVSQTEGHUKU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25264600,IC50,=,0.11,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using Cy3-PLGLK(Cy5Q)AR-NH2 as substrate after 40 mins by spectrofluorimetry,,"Discovery of Novel, Highly Potent, and Selective Quinazoline-2-carboxamide-Based Matrix Metalloproteinase (MMP)-13 Inhibitors without a Zinc Binding Group Using a Structure-Based Design Approach.",J. Med. Chem.,2014,57,21,"Nara H, Sato K, Naito T, Mototani H, Oki H, Yamamoto Y, Kuno H, Santou T, Kanzaki N, Terauchi J, Uchikawa O, Kori M",,1431424,DTCT0024844,13989090,DTCC01741261,590804,60036
CHEMBL44062,P14780,,QVNUOLHHXUUNEH-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10649971,IC50,=,4900,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9 (MMP-9),,"Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.",J. Med. Chem.,2000,43,2,"O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H",,105233,DTCT0024844,927033,DTCC00104684,367719,15892
CHEMBL440714,P14780,,QTXKDSNGGLBSKK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,31,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1616270,DTCC00298905,465562,15919
CHEMBL440714,P14780,,QTXKDSNGGLBSKK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,30.9,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258481,DTCC00298905,455571,24803
CHEMBL440921,P14780,,JDHBSANRAFEDMI-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,40,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,629625,DTCC00351020,1436536,15057
CHEMBL441084,P14780,,GBQQHIUTXSUOPE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,5,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1627923,DTCC00299221,1144920,15919
CHEMBL441084,P14780,,GBQQHIUTXSUOPE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,5.01,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258510,DTCC00299221,1135235,24803
CHEMBL441502,P14780,,GXQYQFOZGUYSTC-HZPDHXFCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15369398,INHIBITION,=,5,%,,,,,,,,,,,,,,Inhibition of MMP-9 (matrix metalloprotease) at 1 uM,,Macrocyclic inhibitors for peptide deformylase: a structure-activity relationship study of the ring size.,J. Med. Chem.,2004,47,20,"Hu X, Nguyen KT, Jiang VC, Lofland D, Moser HE, Pei D",,307797,DTCT0024844,1789827,DTCC00392620,1360974,19089
CHEMBL441502,P14780,,GXQYQFOZGUYSTC-HZPDHXFCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15369398,INHIBITION,=,9,%,,,,,,,,,,,,,,Inhibition of MMP-9 (matrix metalloprotease) at 10 uM,,Macrocyclic inhibitors for peptide deformylase: a structure-activity relationship study of the ring size.,J. Med. Chem.,2004,47,20,"Hu X, Nguyen KT, Jiang VC, Lofland D, Moser HE, Pei D",,307804,DTCT0024844,1789828,DTCC00392620,1360974,19089
CHEMBL441662,P14780,,AKNDZTHCJLFZCF-HNNXBMFYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10579818,IC50,=,3.7,NM,,,,,,,,,,,,,,Inhibition of gelatinase-B (Matrix metalloprotease-9),,"Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.",J. Med. Chem.,1999,42,22,"Almstead NG, Bradley RS, Pikul S, De B, Natchus MG, Taiwo YO, Gu F, Williams LE, Hynd BA, Janusz MJ, Dunaway CM, Mieling GE",,105226,DTCT0024844,1367842,DTCC00326356,1565298,15412
CHEMBL441687,P14780,GLYCYRRHIZIN,LPLVUJXQOOQHMX-QWBHMCJMSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7316779,DTCC00424760,1992805,46191
CHEMBL441687,P14780,GLYCYRRHIZIN,LPLVUJXQOOQHMX-QWBHMCJMSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7316780,DTCC00424760,1992805,46191
CHEMBL441901,P14780,,QFAVBCHJZGCQGB-UKILVPOCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18061445,KI,>,2128,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,"Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).",Bioorg. Med. Chem. Lett.,2008,18,2,"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ",,463237,DTCT0024844,2296494,DTCC00502182,131739,25233
CHEMBL442,P14780,ERGOTAMINE,XCGSFFUVFURLIX-VFGNJEKYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7332552,DTCC00134058,1027052,46191
CHEMBL442,P14780,ERGOTAMINE,XCGSFFUVFURLIX-VFGNJEKYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7332553,DTCC00134058,1027052,46191
CHEMBL442057,P14780,,BBUAWDNXWDAMGY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17276072,IC50,=,370,NM,,cell_based,,,,,,,,,,,,Inhibition of human recombinant MMP9 expressed in mouse myeloma cells,,Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.,Bioorg. Med. Chem.,2007,15,6,"Nuti E, Orlandini E, Nencetti S, Rossello A, Innocenti A, Scozzafava A, Supuran CT",,435728,DTCT0024844,2079352,DTCC00449745,1905404,22603
CHEMBL442286,P14780,CYCLOHEXYL 6-MERCAPTOPICOLINATE,FHNKYBYJCSINOT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,91000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266607,DTCC00003771,779008,24949
CHEMBL442421,P14780,,RWKNBRIIHLUCGT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17188863,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2007,17,5,"Sheppeck JE, Gilmore JL, Yang A, Chen XT, Xue CB, Roderick J, Liu RQ, Covington MB, Decicco CP, Duan JJ",,453871,DTCT0024844,2221451,DTCC00478066,488866,24252
CHEMBL442435,P14780,,UUCAXRPZQYPLCB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,5.7,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260699,DTCC00486084,1166455,24831
CHEMBL443,P14780,SULFAMETHOXAZOLE,JLKIGFTWXXRPMT-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7465272,DTCC00134101,315670,46191
CHEMBL443,P14780,SULFAMETHOXAZOLE,JLKIGFTWXXRPMT-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7465273,DTCC00134101,315670,46191
CHEMBL44311,P14780,,LGIBSSWDUBGUGL-CFZCINTLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION,=,0,%,,,,,,,,,,,,,,Inhibition of human recombinant 92 kDa gelatinase MMP-9 at 10 uM,,,Bioorg. Med. Chem. Lett.,1995,5,15,,,71647,DTCT0024844,667998,DTCC00184566,96153,1239
CHEMBL44383,P14780,,MDWFJTBWOFNAQX-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10649971,IC50,=,2200,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9 (MMP-9),,"Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.",J. Med. Chem.,2000,43,2,"O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H",,105233,DTCT0024844,920972,DTCC00186509,593751,15892
CHEMBL44383,P14780,,MDWFJTBWOFNAQX-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472202,IC50,=,747,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.,J. Med. Chem.,2001,44,16,"Pikul S, Ohler NE, Ciszewski G, Laufersweiler MC, Almstead NG, De B, Natchus MG, Hsieh LC, Janusz MJ, Peng SX, Branch TM, King SL, Taiwo YO, Mieling GE",,105229,DTCT0024844,1297401,DTCC00186509,582683,16328
CHEMBL44383,P14780,,MDWFJTBWOFNAQX-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12798337,IC50,=,2200,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents.,Bioorg. Med. Chem. Lett.,2003,13,13,"Fei X, Zheng QH, Liu X, Wang JQ, Sun HB, Mock BH, Stone KL, Miller KD, Sledge GW, Hutchins GD",,105220,DTCT0024844,1398934,DTCC00186509,594169,5629
CHEMBL44383,P14780,,MDWFJTBWOFNAQX-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,2187.76,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258715,DTCC00186509,585412,24803
CHEMBL44407,P14780,,AZKZIIQQPAZCKN-LLJXTTFASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION,=,0,%,,,,,,,,,,,,,,Inhibition of human recombinant 92 kDa gelatinase MMP-9 at 10 uM,,,Bioorg. Med. Chem. Lett.,1995,5,15,,,71647,DTCT0024844,689446,DTCC00184503,323229,1239
CHEMBL444279,P14780,,XFIGJGXIKVKUNO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17981034,IC50,=,1387,NM,,,,,,,,,,,,,,Inhibition of MMP9,,1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Chakaravarty D, Xiang B, Scannevin RH, Huang Z, Ma J, Burke SL, Karnachi P, Rhodes KJ, Jackson PF",,469432,DTCT0024844,2289317,DTCC00501370,294200,25715
CHEMBL444522,P14780,,ZDPCJJXVDVOFRD-BZRAAQBKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19007202,ACTIVITY,=,103,%,,,,,,,,,,,,,,Inhibition of MMP9 at 10 uM by fluorimetric assay,,Development of novel G-protein-coupled receptor 54 agonists with resistance to degradation by matrix metalloproteinase.,J. Med. Chem.,2008,51,23,"Tomita K, Oishi S, Ohno H, Peiper SC, Fujii N",,495831,DTCT0024844,2586303,DTCC00565052,1821475,32055
CHEMBL44455,P14780,,PLCPLXITTDSMSK-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10649971,IC50,=,38000,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9 (MMP-9),,"Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.",J. Med. Chem.,2000,43,2,"O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H",,105233,DTCT0024844,923307,DTCC00186527,626251,15892
CHEMBL44455,P14780,,PLCPLXITTDSMSK-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,38018.94,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258710,DTCC00186527,617703,24803
CHEMBL444633,P14780,RIFABUTIN,ATEBXHFBFRCZMA-VXTBVIBXSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7475175,DTCC00465352,1092349,46191
CHEMBL444633,P14780,RIFABUTIN,ATEBXHFBFRCZMA-VXTBVIBXSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7475176,DTCC00465352,1092349,46191
CHEMBL444664,P14780,,JTRIMPIOJZGKFB-XWRHLKSWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19007202,ACTIVITY,=,102.1,%,,,,,,,,,,,,,,Inhibition of MMP9 at 10 uM by fluorimetric assay,,Development of novel G-protein-coupled receptor 54 agonists with resistance to degradation by matrix metalloproteinase.,J. Med. Chem.,2008,51,23,"Tomita K, Oishi S, Ohno H, Peiper SC, Fujii N",,495831,DTCT0024844,2586306,DTCC00565049,371783,32055
CHEMBL445,P14780,NORTRIPTYLINE,PHVGLTMQBUFIQQ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7401472,DTCC00134116,1092345,46191
CHEMBL445,P14780,NORTRIPTYLINE,PHVGLTMQBUFIQQ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7401473,DTCC00134116,1092345,46191
CHEMBL445206,P14780,ISOEUGENOL,BJIOGJUNALELMI-ARJAWSKDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7431094,DTCC00115215,1830686,46191
CHEMBL445206,P14780,ISOEUGENOL,BJIOGJUNALELMI-ARJAWSKDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7431095,DTCC00115215,1830686,46191
CHEMBL445611,P14780,,JXLOCCNKUYGHHM-JBAPVGOWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION,=,0,%,,,,,,,,,,,,,,Inhibition of human recombinant 92 kDa gelatinase MMP-9 at 10 uM,,,Bioorg. Med. Chem. Lett.,1995,5,15,,,71647,DTCT0024844,686936,DTCC00184502,1681480,1239
CHEMBL445717,P14780,,KMMSPMPORWBMTE-QBDLAISOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19457660,IC50,=,1788,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition.,Bioorg. Med. Chem. Lett.,2009,19,13,"Burns DM, Li YL, Shi E, He C, Xu M, Zhuo J, Zhang C, Qian DQ, Li Y, Wynn R, Covington MB, Katiyar K, Marando CA, Fridman JS, Scherle P, Friedman S, Metcalf B, Yao W",,523765,DTCT0024844,2828337,DTCC00554189,164925,33677
CHEMBL445939,P14780,,NMJHXOZWEMYWQH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18029173,IC50,=,67000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and evaluation of novel heterocyclic MMP inhibitors.,Bioorg. Med. Chem. Lett.,2007,17,24,"Hayashi R, Jin X, Cook GR",,459970,DTCT0024844,2266414,DTCC00112322,424730,24949
CHEMBL445971,P14780,,PHMPGOJWLISPFK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,KI,=,180,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2457371,DTCC00115941,371585,32556
CHEMBL445994,P14780,,MYTAFXBNPKBRNX-KBPBESRZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17719700,IC50,>,300000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,Peptidyl 3-substituted 1-hydroxyureas as isosteric analogues of succinylhydroxamate MMP inhibitors.,Eur. J. Med. Chem.,2008,43,5,"Campestre C, Tortorella P, Agamennone M, Preziuso S, Biasone A, Nuti E, Rossello A, Gallina C",,510908,DTCT0024844,2438469,DTCC00512741,1809282,30977
CHEMBL446,P14780,SULFAMETHAZINE,ASWVTGNCAZCNNR-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7456502,DTCC00134119,574627,46191
CHEMBL446,P14780,SULFAMETHAZINE,ASWVTGNCAZCNNR-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7456503,DTCC00134119,574627,46191
CHEMBL44618,P14780,CHLOROFORM,HEDRZPFGACZZDS-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7360252,DTCC00187868,1383774,46191
CHEMBL44618,P14780,CHLOROFORM,HEDRZPFGACZZDS-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7360253,DTCC00187868,1383774,46191
CHEMBL446457,P14780,,YZXVQIOBIKCYRB-IRXDYDNUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18036818,IC50,=,1499,NM,,,,,,,,,,,,,,Binding affinity to MMP9,,Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.,Bioorg. Med. Chem. Lett.,2008,18,1,"Yao W, Zhuo J, Burns DM, Li YL, Qian DQ, Zhang C, He C, Xu M, Shi E, Li Y, Marando CA, Covington MB, Yang G, Liu X, Pan M, Fridman JS, Scherle P, Wasserman ZR, Hollis G, Vaddi K, Yeleswaram S, Newton R, Friedman S, Metcalf B",,461667,DTCT0024844,2276527,DTCC00488479,99430,25086
CHEMBL44657,P14780,ETOPOSIDE,VJJPUSNTGOMMGY-MRVIYFEKSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7337074,DTCC00188464,51468,46191
CHEMBL44657,P14780,ETOPOSIDE,VJJPUSNTGOMMGY-MRVIYFEKSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7337075,DTCC00188464,51468,46191
CHEMBL446702,P14780,,CLASZRHZKWOEPB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16632358,IC50,=,4.9,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2006,16,12,"Zhang YM, Fan X, Xiang B, Chakravarty D, Scannevin R, Burke S, Karnachi P, Rhodes K, Jackson P",,361727,DTCT0024844,1937037,DTCC00423119,584849,20885
CHEMBL446709,P14780,,FUBZFCWMCGQOOE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin) at 24.88 uM after 16 hr by gelatin zymographic analysis,Active,,Med Chem Res,2011,20,7,,,912853,DTCT0024844,11590503,DTCC00444686,1611744,36632
CHEMBL446709,P14780,,FUBZFCWMCGQOOE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin) after 16 hr by gelatin zymographic analysis,Dose-dependent effect,,Med Chem Res,2011,20,7,,,912854,DTCT0024844,11590504,DTCC00444686,1611744,36632
CHEMBL447,P14780,SECOBARBITAL,KQPKPCNLIDLUMF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,2643,NM,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7458164,DTCC00134177,1862719,46191
CHEMBL447,P14780,SECOBARBITAL,KQPKPCNLIDLUMF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Note: corresponding IC50 reported as Active,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7458165,DTCC00134177,1862719,46191
CHEMBL447457,P14780,,YDDMVPLLJTZTQL-LAABSITASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,KI,=,35.6,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2457430,DTCC00115970,79316,32556
CHEMBL447787,P14780,,HWRTYSUSQVJAGF-RBBKRZOGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18242982,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents.",Bioorg. Med. Chem. Lett.,2008,18,5,"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ",,462363,DTCT0024844,2282320,DTCC00488438,1684915,25163
CHEMBL44814,P14780,CARBON TETRACHLORIDE,VZGDMQKNWNREIO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7351399,DTCC00187852,1512806,46191
CHEMBL44814,P14780,CARBON TETRACHLORIDE,VZGDMQKNWNREIO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7351400,DTCC00187852,1512806,46191
CHEMBL448207,P14780,,ZDPCJJXVDVOFRD-MZNXXXKPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19007202,ACTIVITY,=,104.5,%,,,,,,,,,,,,,,Inhibition of MMP9 at 10 uM by fluorimetric assay,,Development of novel G-protein-coupled receptor 54 agonists with resistance to degradation by matrix metalloproteinase.,J. Med. Chem.,2008,51,23,"Tomita K, Oishi S, Ohno H, Peiper SC, Fujii N",,495831,DTCT0024844,2586304,DTCC00565051,791347,32055
CHEMBL448246,P14780,,RRXQHLQCQYPPMF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18358729,ACTIVITY,=,0,%,,,,,,,,,,,,,,Inhibition recombinant MMP9 at 100 uM,,High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate.,Bioorg. Med. Chem.,2009,17,3,"Lauer-Fields JL, Minond D, Chase PS, Baillargeon PE, Saldanha SA, Stawikowska R, Hodder P, Fields GB",,518895,DTCT0024844,2708873,DTCC00516462,2047968,32215
CHEMBL448246,P14780,,RRXQHLQCQYPPMF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18364257,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 200 uM by HxBP-Rh probe-based competitive activity based protein profiling assay in presence of 200 uM HxBP-alkyne,Active,Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.,Bioorg. Med. Chem.,2009,17,3,"Nakai R, Salisbury CM, Rosen H, Cravatt BF",,518929,DTCT0024844,2709052,DTCC00516462,2047969,32218
CHEMBL448246,P14780,,RRXQHLQCQYPPMF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18364257,IC50,=,160,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 by fluorogenic substrate assay,,Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.,Bioorg. Med. Chem.,2009,17,3,"Nakai R, Salisbury CM, Rosen H, Cravatt BF",,518918,DTCT0024844,2709033,DTCC00516462,2047969,32218
CHEMBL448399,P14780,HYDROXYTOLUIC ACID,WHSXTWFYRGOBGO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,14,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103114,DTCC00565293,1703863,43205
CHEMBL44884,P14780,ETHAMBUTOL,AEUTYOVWOVBAKS-UWVGGRQHSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7328402,DTCC00187691,381010,46191
CHEMBL44884,P14780,ETHAMBUTOL,AEUTYOVWOVBAKS-UWVGGRQHSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7328403,DTCC00187691,381010,46191
CHEMBL44898,P14780,,YWAPUIQWVUXRRW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10649971,IC50,=,6700,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9 (MMP-9),,"Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.",J. Med. Chem.,2000,43,2,"O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H",,105233,DTCT0024844,902229,DTCC00104686,1046250,15892
CHEMBL45,P14780,MELATONIN,DRLFMBDRBRZALE-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7417235,DTCC00134723,50368,46191
CHEMBL45,P14780,MELATONIN,DRLFMBDRBRZALE-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7417236,DTCC00134723,50368,46191
CHEMBL450327,P14780,,XVUIGVGFVWRFJO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,24,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1635499,DTCC00227650,1338995,15919
CHEMBL450327,P14780,,XVUIGVGFVWRFJO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,23.99,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258487,DTCC00227650,1329166,24803
CHEMBL45040,P14780,,AGRDSOUIPBKOKQ-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10649971,IC50,=,59000,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9 (MMP-9),,"Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.",J. Med. Chem.,2000,43,2,"O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H",,105233,DTCT0024844,930621,DTCC00186467,1467008,15892
CHEMBL45040,P14780,,AGRDSOUIPBKOKQ-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,58884.37,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258712,DTCC00186467,1458610,24803
CHEMBL450431,P14780,,NRHSKONRJVZHAX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,44,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103347,DTCC00571871,896234,43205
CHEMBL450721,P14780,,SBTMZMWGVVORIF-CYBMUJFWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19053764,IC50,=,62,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates.,J. Med. Chem.,2008,51,24,"Marques SM, Nuti E, Rossello A, Supuran CT, Tuccinardi T, Martinelli A, Santos MA",,561988,DTCT0024844,2800818,DTCC00562380,973846,31524
CHEMBL450923,P14780,,GCPYOJSLSJRNKG-ZDWAKIIJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19007202,ACTIVITY,=,100.4,%,,,,,,,,,,,,,,Inhibition of MMP9 at 10 uM by fluorimetric assay,,Development of novel G-protein-coupled receptor 54 agonists with resistance to degradation by matrix metalloproteinase.,J. Med. Chem.,2008,51,23,"Tomita K, Oishi S, Ohno H, Peiper SC, Fujii N",,495831,DTCT0024844,2586300,DTCC00565055,501249,32055
CHEMBL450938,P14780,(3-NITROPHENYLAMINO)METHYLENEDIPHOSPHONIC ACID,VPXZTOOBAWPNGR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24071448,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain (unknown origin) using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured after 2 to 4 hrs by fluorometric assay,,Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.,Bioorg. Med. Chem.,2013,21,21,"Tauro M, Laghezza A, Loiodice F, Agamennone M, Campestre C, Tortorella P",,990168,DTCT0024844,12629007,DTCC00406538,156505,56259
CHEMBL451,P14780,CHLORDIAZEPOXIDE,ANTSCNMPPGJYLG-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7351598,DTCC00134272,574622,46191
CHEMBL451,P14780,CHLORDIAZEPOXIDE,ANTSCNMPPGJYLG-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7351599,DTCC00134272,574622,46191
CHEMBL45162,P14780,,CQIQKDQFHVTTKM-NDEPHWFRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10397503,IC50,=,8,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,"Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors.",Bioorg. Med. Chem. Lett.,1999,9,12,"Hanessian S, Bouzbouz S, Boudon A, Tucker GC, Peyroulan D",,102115,DTCT0024844,528389,DTCC00188800,1099852,3181
CHEMBL452,P14780,CLONAZEPAM,DGBIGWXXNGSACT-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7337276,DTCC00134302,574623,46191
CHEMBL452,P14780,CLONAZEPAM,DGBIGWXXNGSACT-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7337277,DTCC00134302,574623,46191
CHEMBL452082,P14780,,RMPMGGGCHRCWIU-KGLIPLIRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17719700,IC50,=,200000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,Peptidyl 3-substituted 1-hydroxyureas as isosteric analogues of succinylhydroxamate MMP inhibitors.,Eur. J. Med. Chem.,2008,43,5,"Campestre C, Tortorella P, Agamennone M, Preziuso S, Biasone A, Nuti E, Rossello A, Gallina C",,510908,DTCT0024844,2438447,DTCC00512738,9768,30977
CHEMBL452083,P14780,,MOPRTFSMCQNUCT-GJZGRUSLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17719700,IC50,=,150,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,Peptidyl 3-substituted 1-hydroxyureas as isosteric analogues of succinylhydroxamate MMP inhibitors.,Eur. J. Med. Chem.,2008,43,5,"Campestre C, Tortorella P, Agamennone M, Preziuso S, Biasone A, Nuti E, Rossello A, Gallina C",,510908,DTCT0024844,2438460,DTCC00512739,1841747,30977
CHEMBL45245,P14780,PHENANTHRIDIN-6(5H)-ONE,RZFVLEJOHSLEFR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7283994,DTCC01739960,2057642,46191
CHEMBL45245,P14780,PHENANTHRIDIN-6(5H)-ONE,RZFVLEJOHSLEFR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7283995,DTCC01739960,2057642,46191
CHEMBL452584,P14780,,MXMAVZMWYSUCJZ-SFTDATJTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17719700,IC50,>,300000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,Peptidyl 3-substituted 1-hydroxyureas as isosteric analogues of succinylhydroxamate MMP inhibitors.,Eur. J. Med. Chem.,2008,43,5,"Campestre C, Tortorella P, Agamennone M, Preziuso S, Biasone A, Nuti E, Rossello A, Gallina C",,510908,DTCT0024844,2438466,DTCC00512740,261085,30977
CHEMBL452630,P14780,ANETHOLE,RUVINXPYWBROJD-ONEGZZNKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24328151,INHIBITION,,,,,cell_based,,,,,,,,,,,,Inhibition of MMP9 in human DU145 cells after 24 hrs by SDS-PAGE gelatin zymography assay,Dose-dependent effect,Regulation of Crosstalk between Epithelial to Mesenchymal Transition Molecules and MMP-9 Mediates the Antimetastatic Activity of Anethole in DU145 Prostate Cancer Cells.,J. Nat. Prod.,2014,77,1,"Ha B, Ko H, Kim B, Sohn EJ, Jung JH, Kim JS, Yoon JJ, Won G, Kim JH, Jung DB, Yun M, Shim B, Kim SH",,1284159,DTCT0024844,12984831,DTCC00507541,2028880,56877
CHEMBL452861,P14780,(-)-PROPANOLOL ,AQHHHDLHHXJYJD-AWEZNQCLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7471040,DTCC00515151,1253328,46191
CHEMBL452861,P14780,(-)-PROPANOLOL ,AQHHHDLHHXJYJD-AWEZNQCLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7471041,DTCC00515151,1253328,46191
CHEMBL452947,P14780,,JUTPCQYEVUKCAU-MNNSJKJDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18782669,IC50,,,,,,,,,,,,,,,,,Inhibition of human recombinant pro-MMP9 by spectrofluorimeter,Not Determined,Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.,Bioorg. Med. Chem.,2008,16,18,"Ledour G, Moroy G, Rouffet M, Bourguet E, Guillaume D, Decarme M, Elmourabit H, Augé F, Alix AJ, Laronze JY, Bellon G, Hornebeck W, Sapi J",,557954,DTCT0024844,2791159,DTCC00514936,392324,31586
CHEMBL453,P14780,SULFISOXAZOLE,NHUHCSRWZMLRLA-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7456643,DTCC00134318,477922,46191
CHEMBL453,P14780,SULFISOXAZOLE,NHUHCSRWZMLRLA-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7456644,DTCC00134318,477922,46191
CHEMBL45357,P14780,,FCYBWLNLMVDLRH-AWEZNQCLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10397503,IC50,=,7,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,"Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors.",Bioorg. Med. Chem. Lett.,1999,9,12,"Hanessian S, Bouzbouz S, Boudon A, Tucker GC, Peyroulan D",,102115,DTCT0024844,539687,DTCC00188708,808145,3181
CHEMBL453956,P14780,,GCPYOJSLSJRNKG-BCJWCAIOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19007202,ACTIVITY,=,103.4,%,,,,,,,,,,,,,,Inhibition of MMP9 at 10 uM by fluorimetric assay,,Development of novel G-protein-coupled receptor 54 agonists with resistance to degradation by matrix metalloproteinase.,J. Med. Chem.,2008,51,23,"Tomita K, Oishi S, Ohno H, Peiper SC, Fujii N",,495831,DTCT0024844,2586299,DTCC00565056,1535855,32055
CHEMBL454808,P14780,"2,6-DIHYDROXYBENZOIC ACID",AKEUNCKRJATALU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,-11,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103276,DTCC00005081,86519,43205
CHEMBL45483,P14780,SC-44463,QYZPDCGWIJYZMN-ZBFHGGJFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11585439,KI,<,1,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors.",J. Med. Chem.,2001,44,21,"Yao W, Wasserman ZR, Chao M, Reddy G, Shi E, Liu RQ, Covington MB, Arner EC, Pratta MA, Tortorella M, Magolda RL, Newton R, Qian M, Ribadeneira MD, Christ D, Wexler RR, Decicco CP",,105382,DTCT0024844,1416204,DTCC01740008,401646,16438
CHEMBL45483,P14780,SC-44463,QYZPDCGWIJYZMN-ZBFHGGJFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,<,10,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,,Bioorg. Med. Chem. Lett.,1997,7,18,,,105547,DTCT0024844,1585246,DTCC01740008,400992,2242
CHEMBL455409,P14780,,LCTLPROJUJRGOK-FOZCRLHDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19095454,IC50,=,23,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Current perspective of TACE inhibitors: a review.,Bioorg. Med. Chem.,2009,17,2,"DasGupta S, Murumkar PR, Giridhar R, Yadav MR",,495050,DTCT0024844,2595474,DTCC00517016,1470653,32093
CHEMBL456,P14780,ETHACRYNIC ACID,AVOLMBLBETYQHX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7324081,DTCC00134433,1155679,46191
CHEMBL456,P14780,ETHACRYNIC ACID,AVOLMBLBETYQHX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7324082,DTCC00134433,1155679,46191
CHEMBL45631,P14780,,USEJKZYMWYHGSP-KSZLIROESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9599225,KI,=,1.8,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (Matrix metalloprotease-9),,Design and synthesis of cyclic inhibitors of matrix metalloproteinases and TNF-alpha production.,J. Med. Chem.,1998,41,11,"Xue CB, He X, Roderick J, DeGrado WF, Cherney RJ, Hardman KD, Nelson DJ, Copeland RA, Jaffee BD, Decicco CP",,105662,DTCT0024844,566474,DTCC00192340,1402804,14639
CHEMBL45631,P14780,,USEJKZYMWYHGSP-KSZLIROESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472217,KI,=,1.8,NM,,,,,,,,,,,,,,In vitro inhibition of human MMP-9.,,"Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.",J. Med. Chem.,2001,44,16,"Xue CB, Voss ME, Nelson DJ, Duan JJ, Cherney RJ, Jacobson IC, He X, Roderick J, Chen L, Corbett RL, Wang L, Meyer DT, Kennedy K, DeGradodagger WF, Hardman KD, Teleha CA, Jaffee BD, Liu RQ, Copeland RA, Covington MB, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105380,DTCT0024844,1654035,DTCC00192340,1391994,16346
CHEMBL456774,P14780,,LKJAZJMUPQPJNA-GOSISDBHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19053764,IC50,=,27.7,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates.,J. Med. Chem.,2008,51,24,"Marques SM, Nuti E, Rossello A, Supuran CT, Tuccinardi T, Martinelli A, Santos MA",,561988,DTCT0024844,2800823,DTCC00562381,1809896,31524
CHEMBL456807,P14780,PHENYLHYDRAZINE,HKOOXMFOFWEVGF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7404543,DTCC00514646,413975,46191
CHEMBL456807,P14780,PHENYLHYDRAZINE,HKOOXMFOFWEVGF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7404544,DTCC00514646,413975,46191
CHEMBL456911,P14780,RO-28-2653,NJKTYSXXGARILV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22118188,IC50,=,7,NM,,,,,,,,,,,,,,"Inhibition of MMP9 using (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)Ala-Arg-NH2 as substrate preincubated for 30 mins measured after 10 mins by fluorescence analysis",,"A new generation of radiofluorinated pyrimidine-2,4,6-triones as MMP-targeted radiotracers for positron emission tomography.",J. Med. Chem.,2012,55,1,"Schrigten D, Breyholz HJ, Wagner S, Hermann S, Schober O, Schäfers M, Haufe G, Kopka K",,800775,DTCT0024844,7619123,DTCC00007863,866231,47195
CHEMBL457,P14780,GEMFIBROZIL,HEMJJKBWTPKOJG-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7329380,DTCC00134705,1285875,46191
CHEMBL457,P14780,GEMFIBROZIL,HEMJJKBWTPKOJG-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7329381,DTCC00134705,1285875,46191
CHEMBL457299,P14780,ETHYLENE GLYCOL,LYCAIKOWRPUZTN-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7315709,DTCC00525050,1383777,46191
CHEMBL457299,P14780,ETHYLENE GLYCOL,LYCAIKOWRPUZTN-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7315710,DTCC00525050,1383777,46191
CHEMBL458019,P14780,PARAQUAT DICHLORIDE,FIKAKWIAUPDISJ-UHFFFAOYSA-L,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7376114,DTCC00549932,283000,46191
CHEMBL458019,P14780,PARAQUAT DICHLORIDE,FIKAKWIAUPDISJ-UHFFFAOYSA-L,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7376115,DTCC00549932,283000,46191
CHEMBL459,P14780,METHYLDOPA,CJCSPKMFHVPWAR-JTQLQIEISA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7426004,DTCC00135281,185555,46191
CHEMBL459,P14780,METHYLDOPA,CJCSPKMFHVPWAR-JTQLQIEISA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7426005,DTCC00135281,185555,46191
CHEMBL45906,P14780,,LPSDGPPONMJJGK-JOCHJYFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10346925,IC50,=,1700,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9 (concentration required for 50% inhibition of enzyme activity),,Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.,J. Med. Chem.,1999,42,10,"Kiyama R, Tamura Y, Watanabe F, Tsuzuki H, Ohtani M, Yodo M",,105524,DTCT0024844,1281546,DTCC00192096,1902533,15166
CHEMBL46,P14780,ONDANSETRON,FELGMEQIXOGIFQ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7405922,DTCC00134875,315668,46191
CHEMBL46,P14780,ONDANSETRON,FELGMEQIXOGIFQ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7405923,DTCC00134875,315668,46191
CHEMBL460291,P14780,LACIDIPINE,GKQPCPXONLDCMU-CCEZHUSRSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7433541,DTCC00514659,736260,46191
CHEMBL460291,P14780,LACIDIPINE,GKQPCPXONLDCMU-CCEZHUSRSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7433542,DTCC00514659,736260,46191
CHEMBL460499,P14780,CARMOFUR,AOCCBINRVIKJHY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7364359,DTCC00515303,51452,46191
CHEMBL460499,P14780,CARMOFUR,AOCCBINRVIKJHY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7364360,DTCC00515303,51452,46191
CHEMBL460725,P14780,,QHDIXGPUTSAIJX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19173605,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,Extra binding region induced by non-zinc chelating inhibitors into the S1' subsite of matrix metalloproteinase 8 (MMP-8).,J. Med. Chem.,2009,52,4,"Pochetti G, Montanari R, Gege C, Chevrier C, Taveras AG, Mazza F",,494621,DTCT0024844,2596038,DTCC00517113,715017,32135
CHEMBL460899,P14780,,ITADELAVAWJACR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19173605,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,Extra binding region induced by non-zinc chelating inhibitors into the S1' subsite of matrix metalloproteinase 8 (MMP-8).,J. Med. Chem.,2009,52,4,"Pochetti G, Montanari R, Gege C, Chevrier C, Taveras AG, Mazza F",,494621,DTCT0024844,2596047,DTCC00114032,1166828,32135
CHEMBL460899,P14780,,ITADELAVAWJACR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22689580,IC50,=,10000,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14718582,DTCC00114032,2101638,68703
CHEMBL460899,P14780,,ITADELAVAWJACR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25265401,IC50,>,2500,NM,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin),,"Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors.",J. Med. Chem.,2014,57,24,"Fabre B, Ramos A, de Pascual-Teresa B",,1433221,DTCT0024844,13993821,DTCC00114032,1171843,60040
CHEMBL461727,P14780,AMYGDALIN,XUCIJNAGGSZNQT-JHSLDZJXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7281781,DTCC00113956,1674140,46191
CHEMBL461727,P14780,AMYGDALIN,XUCIJNAGGSZNQT-JHSLDZJXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7281782,DTCC00113956,1674140,46191
CHEMBL46183,P14780,,ZKUXVTKGURJPOW-YESZJQIVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9599226,KI,=,9800,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Macrocyclic amino carboxylates as selective MMP-8 inhibitors.,J. Med. Chem.,1998,41,11,"Cherney RJ, Wang L, Meyer DT, Xue CB, Wasserman ZR, Hardman KD, Welch PK, Covington MB, Copeland RA, Arner EC, DeGrado WF, Decicco CP",,105664,DTCT0024844,1347402,DTCC00193499,969802,14640
CHEMBL462547,P14780,URETHANE,JOYRKODLDBILNP-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7451224,DTCC00513785,1155688,46191
CHEMBL462547,P14780,URETHANE,JOYRKODLDBILNP-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7451225,DTCC00513785,1155688,46191
CHEMBL462627,P14780,,MNYLANCSXOSQBA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18358729,ACTIVITY,=,27,%,,,,,,,,,,,,,,Inhibition recombinant MMP9 at 100 uM,,High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate.,Bioorg. Med. Chem.,2009,17,3,"Lauer-Fields JL, Minond D, Chase PS, Baillargeon PE, Saldanha SA, Stawikowska R, Hodder P, Fields GB",,518895,DTCT0024844,2708868,DTCC00516390,758694,32215
CHEMBL462628,P14780,,ITQDPSGUKJGOJF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18358729,ACTIVITY,=,3,%,,,,,,,,,,,,,,Inhibition recombinant MMP9 at 100 uM,,High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate.,Bioorg. Med. Chem.,2009,17,3,"Lauer-Fields JL, Minond D, Chase PS, Baillargeon PE, Saldanha SA, Stawikowska R, Hodder P, Fields GB",,518895,DTCT0024844,2708869,DTCC00516392,565008,32215
CHEMBL462629,P14780,,XEXZOINHSIFHFY-XFXZXTDPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18358729,ACTIVITY,=,99,%,,,,,,,,,,,,,,Inhibition recombinant MMP9 at 100 uM,,High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate.,Bioorg. Med. Chem.,2009,17,3,"Lauer-Fields JL, Minond D, Chase PS, Baillargeon PE, Saldanha SA, Stawikowska R, Hodder P, Fields GB",,518895,DTCT0024844,2708870,DTCC00516393,175688,32215
CHEMBL466059,P14780,,GYETWAWIKBOMPE-OAQYLSRUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19422229,IC50,=,10,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13.",J. Med. Chem.,2009,52,11,"Monovich LG, Tommasi RA, Fujimoto RA, Blancuzzi V, Clark K, Cornell WD, Doti R, Doughty J, Fang J, Farley D, Fitt J, Ganu V, Goldberg R, Goldstein R, Lavoie S, Kulathila R, Macchia W, Parker DT, Melton R, O'Byrne E, Pastor G, Pellas T, Quadros E, Reel N, Roland DM, Sakane Y, Singh H, Skiles J, Somers J, Toscano K, Wigg A, Zhou S, Zhu L, Shieh WC, Xue S, McQuire LW",,500585,DTCT0024844,2824186,DTCC00536373,164710,33635
CHEMBL467,P14780,HYDROXYUREA,VSNHCAURESNICA-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7319322,DTCC00136099,1155681,46191
CHEMBL467,P14780,HYDROXYUREA,VSNHCAURESNICA-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7319323,DTCC00136099,1155681,46191
CHEMBL468,P14780,THALIDOMIDE,UEJJHQNACJXSKW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7461489,DTCC00136280,348406,46191
CHEMBL468,P14780,THALIDOMIDE,UEJJHQNACJXSKW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7461490,DTCC00136280,348406,46191
CHEMBL46818,P14780,,UWHPJOBPMXNVII-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10649971,IC50,=,4900,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9 (MMP-9),,"Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.",J. Med. Chem.,2000,43,2,"O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H",,105233,DTCT0024844,931903,DTCC00185806,464278,15892
CHEMBL46818,P14780,,UWHPJOBPMXNVII-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,4897.79,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258717,DTCC00185806,455579,24803
CHEMBL46830,P14780,,ZGWIOFHKEXLJPC-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10649971,IC50,=,17000,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9 (MMP-9),,"Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.",J. Med. Chem.,2000,43,2,"O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H",,105233,DTCT0024844,924610,DTCC00186466,1979398,15892
CHEMBL46830,P14780,,ZGWIOFHKEXLJPC-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,16982.44,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258711,DTCC00186466,1970999,24803
CHEMBL468900,P14780,,NHPBWKYFMTXWAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of MMP9 up to 100 uM,Not Active,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497431,DTCT0024844,2457347,DTCC00530186,2016158,32556
CHEMBL469,P14780,KETOROLAC,OZWKMVRBQXNZKK-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7439700,DTCC00136324,120972,46191
CHEMBL469,P14780,KETOROLAC,OZWKMVRBQXNZKK-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7439701,DTCC00136324,120972,46191
CHEMBL469912,P14780,PUROMYCIN,RXWNCPJZOCPEPQ-NVWDDTSBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7385888,DTCC00511258,477920,46191
CHEMBL469912,P14780,PUROMYCIN,RXWNCPJZOCPEPQ-NVWDDTSBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7385889,DTCC00511258,477920,46191
CHEMBL47,P14780,VITAMIN E,GVJHHUAWPYXKBD-IEOSBIPESA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7299415,DTCC00135004,348395,46191
CHEMBL47,P14780,VITAMIN E,GVJHHUAWPYXKBD-IEOSBIPESA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7300688,DTCC00135004,348395,46191
CHEMBL47076,P14780,,WLJUNQUGIMIQDZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10649971,IC50,=,2300,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9 (MMP-9),,"Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.",J. Med. Chem.,2000,43,2,"O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H",,105233,DTCT0024844,924616,DTCC00104690,1467009,15892
CHEMBL471,P14780,SOTALOL,ZBMZVLHSJCTVON-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7471406,DTCC00136675,88634,46191
CHEMBL471,P14780,SOTALOL,ZBMZVLHSJCTVON-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7471407,DTCC00136675,88634,46191
CHEMBL471537,P14780,,GSWRTFGMHRKLKT-AREMUKBSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19053764,IC50,=,0.21,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates.,J. Med. Chem.,2008,51,24,"Marques SM, Nuti E, Rossello A, Supuran CT, Tuccinardi T, Martinelli A, Santos MA",,561988,DTCT0024844,2800881,DTCC00514690,489269,31524
CHEMBL472,P14780,GLYBURIDE,ZNNLBTZKUZBEKO-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7303910,DTCC00136719,51475,46191
CHEMBL472,P14780,GLYBURIDE,ZNNLBTZKUZBEKO-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7303911,DTCC00136719,51475,46191
CHEMBL47244,P14780,PICROTOXININ,PIMZUZSSNYHVCU-YKWPQBAZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7343896,DTCC00186559,217577,46191
CHEMBL47244,P14780,PICROTOXININ,PIMZUZSSNYHVCU-YKWPQBAZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7343897,DTCC00186559,217577,46191
CHEMBL47254,P14780,,HXNNABWLGZRTMD-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10649971,IC50,=,20000,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9 (MMP-9),,"Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.",J. Med. Chem.,2000,43,2,"O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H",,105233,DTCT0024844,904813,DTCC00186592,1596218,15892
CHEMBL47254,P14780,,HXNNABWLGZRTMD-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,19952.62,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258713,DTCC00186592,1587773,24803
CHEMBL472833,P14780,,OXILFLCUDLSQBZ-WHECAKDPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19007202,ACTIVITY,=,100.9,%,,,,,,,,,,,,,,Inhibition of MMP9 at 10 uM by fluorimetric assay,,Development of novel G-protein-coupled receptor 54 agonists with resistance to degradation by matrix metalloproteinase.,J. Med. Chem.,2008,51,23,"Tomita K, Oishi S, Ohno H, Peiper SC, Fujii N",,495831,DTCT0024844,2586307,DTCC00565048,1726541,32055
CHEMBL472899,P14780,,ZRAUMSIZBNBIFE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19053764,IC50,=,3.2,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates.,J. Med. Chem.,2008,51,24,"Marques SM, Nuti E, Rossello A, Supuran CT, Tuccinardi T, Martinelli A, Santos MA",,561988,DTCT0024844,2800899,DTCC00514692,1296946,31524
CHEMBL473107,P14780,,YNKDEHKXKOAEBW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18358729,ACTIVITY,=,100,%,,,,,,,,,,,,,,Inhibition recombinant MMP9 at 100 uM,,High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate.,Bioorg. Med. Chem.,2009,17,3,"Lauer-Fields JL, Minond D, Chase PS, Baillargeon PE, Saldanha SA, Stawikowska R, Hodder P, Fields GB",,518895,DTCT0024844,2708875,DTCC00515624,984986,32215
CHEMBL473314,P14780,,DIPCWZOATLQURP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18358729,ACTIVITY,=,75,%,,,,,,,,,,,,,,Inhibition recombinant MMP9 at 100 uM,,High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate.,Bioorg. Med. Chem.,2009,17,3,"Lauer-Fields JL, Minond D, Chase PS, Baillargeon PE, Saldanha SA, Stawikowska R, Hodder P, Fields GB",,518895,DTCT0024844,2708876,DTCC00515689,305973,32215
CHEMBL473326,P14780,,HKDAECHYHSQLRG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18364257,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 200 uM by HxBP-Rh probe-based competitive activity based protein profiling assay in presence of 200 uM HxBP-alkyne,Not Active,Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.,Bioorg. Med. Chem.,2009,17,3,"Nakai R, Salisbury CM, Rosen H, Cravatt BF",,518929,DTCT0024844,2709050,DTCC00516458,694221,32218
CHEMBL473326,P14780,,HKDAECHYHSQLRG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18364257,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 by fluorogenic substrate assay,,Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.,Bioorg. Med. Chem.,2009,17,3,"Nakai R, Salisbury CM, Rosen H, Cravatt BF",,518918,DTCT0024844,2709031,DTCC00516458,694221,32218
CHEMBL473326,P14780,,HKDAECHYHSQLRG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22018790,INHIBITION,=,10,%,,,,,,,,,,,,,,Inhibition of recombinant MMP9 using triple-helical fTHP-15 as substrate at 40 uM after 4 hrs by FRET assay,,"Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.",Bioorg. Med. Chem. Lett.,2011,21,23,"Roth J, Minond D, Darout E, Liu Q, Lauer J, Hodder P, Fields GB, Roush WR",,799265,DTCT0024844,7596112,DTCC00516458,704135,47025
CHEMBL473326,P14780,,HKDAECHYHSQLRG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25330343,INHIBITION,>,10,%,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 using GRIGFL substrate up to 20 uM,,Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.,J. Med. Chem.,2014,57,22,"Spicer TP, Jiang J, Taylor AB, Choi JY, Hart PJ, Roush WR, Fields GB, Hodder PS, Minond D",,1435007,DTCT0024844,14018311,DTCC00516458,687799,60192
CHEMBL473327,P14780,,ZHNBFYMZDUSWSL-OWBHPGMISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18358729,ACTIVITY,=,81,%,,,,,,,,,,,,,,Inhibition recombinant MMP9 at 100 uM,,High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate.,Bioorg. Med. Chem.,2009,17,3,"Lauer-Fields JL, Minond D, Chase PS, Baillargeon PE, Saldanha SA, Stawikowska R, Hodder P, Fields GB",,518895,DTCT0024844,2708871,DTCC00516459,597255,32215
CHEMBL475534,P14780,NITRENDIPINE,PVHUJELLJLJGLN-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7401381,DTCC00514677,88633,46191
CHEMBL475534,P14780,NITRENDIPINE,PVHUJELLJLJGLN-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7401382,DTCC00514677,88633,46191
CHEMBL475540,P14780,,IQGHPUPMOUUHPP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18358729,ACTIVITY,=,14,%,,,,,,,,,,,,,,Inhibition recombinant MMP9 at 100 uM,,High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate.,Bioorg. Med. Chem.,2009,17,3,"Lauer-Fields JL, Minond D, Chase PS, Baillargeon PE, Saldanha SA, Stawikowska R, Hodder P, Fields GB",,518895,DTCT0024844,2708865,DTCC00515616,1178193,32215
CHEMBL475540,P14780,,IQGHPUPMOUUHPP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18364257,IC50,=,14000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 by fluorogenic substrate assay,,Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.,Bioorg. Med. Chem.,2009,17,3,"Nakai R, Salisbury CM, Rosen H, Cravatt BF",,518918,DTCT0024844,2709034,DTCC00515616,1178199,32218
CHEMBL475742,P14780,,RLJYCZREXIWYAI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18358729,ACTIVITY,=,27,%,,,,,,,,,,,,,,Inhibition recombinant MMP9 at 100 uM,,High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate.,Bioorg. Med. Chem.,2009,17,3,"Lauer-Fields JL, Minond D, Chase PS, Baillargeon PE, Saldanha SA, Stawikowska R, Hodder P, Fields GB",,518895,DTCT0024844,2708866,DTCC00515618,2015780,32215
CHEMBL476,P14780,DACARBAZINE,FDKXTQMXEQVLRF-ZHACJKMWSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,556,NM,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7361311,DTCC00136858,800573,46191
CHEMBL476,P14780,DACARBAZINE,FDKXTQMXEQVLRF-ZHACJKMWSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Note: corresponding IC50 reported as Active,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7361312,DTCC00136858,800573,46191
CHEMBL47728,P14780,,XXNCZTSFXIANIO-FQEVSTJZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10397503,IC50,=,0.2,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,"Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors.",Bioorg. Med. Chem. Lett.,1999,9,12,"Hanessian S, Bouzbouz S, Boudon A, Tucker GC, Peyroulan D",,102115,DTCT0024844,531210,DTCC00188668,1584488,3181
CHEMBL478053,P14780,,GCPYOJSLSJRNKG-AOPVIXITSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19007202,ACTIVITY,=,107.5,%,,,,,,,,,,,,,,Inhibition of MMP9 at 10 uM by fluorimetric assay,,Development of novel G-protein-coupled receptor 54 agonists with resistance to degradation by matrix metalloproteinase.,J. Med. Chem.,2008,51,23,"Tomita K, Oishi S, Ohno H, Peiper SC, Fujii N",,495831,DTCT0024844,2586302,DTCC00565053,1050257,32055
CHEMBL479,P14780,THIORIDAZINE,KLBQZWRITKRQQV-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7461592,DTCC00137035,185558,46191
CHEMBL479,P14780,THIORIDAZINE,KLBQZWRITKRQQV-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7461593,DTCC00137035,185558,46191
CHEMBL47971,P14780,,JWTZXWCNQFZKDO-HSZRJFAPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10346925,IC50,=,7.3,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9 (concentration required for 50% inhibition of enzyme activity),,Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.,J. Med. Chem.,1999,42,10,"Kiyama R, Tamura Y, Watanabe F, Tsuzuki H, Ohtani M, Yodo M",,105524,DTCT0024844,1251570,DTCC00191978,647232,15166
CHEMBL480,P14780,LANSOPRAZOLE,MJIHNNLFOKEZEW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7416560,DTCC00137040,1027055,46191
CHEMBL480,P14780,LANSOPRAZOLE,MJIHNNLFOKEZEW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7416561,DTCC00137040,1027055,46191
CHEMBL48039,P14780,,GEHDRTPNVZSFGI-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10346925,IC50,=,870,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9 (concentration required for 50% inhibition of enzyme activity),,Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.,J. Med. Chem.,1999,42,10,"Kiyama R, Tamura Y, Watanabe F, Tsuzuki H, Ohtani M, Yodo M",,105524,DTCT0024844,1259773,DTCC00191452,2033291,15166
CHEMBL481,P14780,IRINOTECAN,UWKQSNNFCGGAFS-XIFFEERXSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7422523,DTCC00137047,381014,46191
CHEMBL481,P14780,IRINOTECAN,UWKQSNNFCGGAFS-XIFFEERXSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7422524,DTCC00137047,381014,46191
CHEMBL481599,P14780,,IJCIXCWAMXHVQD-HWKANZROSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19128977,ACTIVITY,,,,,cell_based,,,,,,,,,,,Caco-2,Reduction of MMP9 activity in TNF-alpha/IL1-beta-stimulated human Caco-2 cells at 50 uM treated 1 hr before stimulation by zymography,Active,Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloproteinases.,Bioorg. Med. Chem.,2009,17,3,"Claramunt RM, Bouissane L, Cabildo MP, Cornago MP, Elguero J, Radziwon A, Medina C",,516049,DTCT0024844,2701377,DTCC00531566,856340,32369
CHEMBL481599,P14780,,IJCIXCWAMXHVQD-HWKANZROSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19128977,IC50,=,17600,NM,,cell_based,,,,,,,,,,,Caco-2,Reduction of MMP9 activity in TNF-alpha/IL1-beta-stimulated human Caco-2 cells treated 1 hr before stimulation by zymography,,Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloproteinases.,Bioorg. Med. Chem.,2009,17,3,"Claramunt RM, Bouissane L, Cabildo MP, Cornago MP, Elguero J, Radziwon A, Medina C",,516050,DTCT0024844,2701381,DTCC00531566,856340,32369
CHEMBL481600,P14780,,VWIIDPQXPFILEL-GQCTYLIASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19128977,ACTIVITY,,,,,cell_based,,,,,,,,,,,Caco-2,Reduction of MMP9 activity in TNF-alpha/IL1-beta-stimulated human Caco-2 cells at 50 uM treated 1 hr before stimulation by zymography,Active,Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloproteinases.,Bioorg. Med. Chem.,2009,17,3,"Claramunt RM, Bouissane L, Cabildo MP, Cornago MP, Elguero J, Radziwon A, Medina C",,516049,DTCT0024844,2701376,DTCC00531567,2080299,32369
CHEMBL481600,P14780,,VWIIDPQXPFILEL-GQCTYLIASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19128977,IC50,=,8000,NM,,cell_based,,,,,,,,,,,Caco-2,Reduction of MMP9 activity in TNF-alpha/IL1-beta-stimulated human Caco-2 cells treated 1 hr before stimulation by zymography,,Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloproteinases.,Bioorg. Med. Chem.,2009,17,3,"Claramunt RM, Bouissane L, Cabildo MP, Cornago MP, Elguero J, Radziwon A, Medina C",,516050,DTCT0024844,2701380,DTCC00531567,2080299,32369
CHEMBL48256,P14780,,DOXXSEYJDIFFAY-KMDXXIMOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9599226,KI,=,288,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Macrocyclic amino carboxylates as selective MMP-8 inhibitors.,J. Med. Chem.,1998,41,11,"Cherney RJ, Wang L, Meyer DT, Xue CB, Wasserman ZR, Hardman KD, Welch PK, Covington MB, Copeland RA, Arner EC, DeGrado WF, Decicco CP",,105664,DTCT0024844,1359476,DTCC00193645,1099889,14640
CHEMBL48258,P14780,,PGWQPFWCLKSUIC-DYEKYZERSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9599225,KI,=,2.6,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (Matrix metalloprotease-9),,Design and synthesis of cyclic inhibitors of matrix metalloproteinases and TNF-alpha production.,J. Med. Chem.,1998,41,11,"Xue CB, He X, Roderick J, DeGrado WF, Cherney RJ, Hardman KD, Nelson DJ, Copeland RA, Jaffee BD, Decicco CP",,105662,DTCT0024844,548590,DTCC00191817,400574,14639
CHEMBL48258,P14780,,PGWQPFWCLKSUIC-DYEKYZERSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472217,KI,=,2.6,NM,,,,,,,,,,,,,,In vitro inhibition of human MMP-9.,,"Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.",J. Med. Chem.,2001,44,16,"Xue CB, Voss ME, Nelson DJ, Duan JJ, Cherney RJ, Jacobson IC, He X, Roderick J, Chen L, Corbett RL, Wang L, Meyer DT, Kennedy K, DeGradodagger WF, Hardman KD, Teleha CA, Jaffee BD, Liu RQ, Copeland RA, Covington MB, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105380,DTCT0024844,1654031,DTCC00191817,389300,16346
CHEMBL48310,P14780,HINOKITIOL,FUWUEFKEXZQKKA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,99,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103695,DTCC00192828,1763870,43205
CHEMBL48368,P14780,,SHIWHCHRVQEPMU-AREMUKBSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10346925,IC50,=,12,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9 (concentration required for 50% inhibition of enzyme activity),,Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.,J. Med. Chem.,1999,42,10,"Kiyama R, Tamura Y, Watanabe F, Tsuzuki H, Ohtani M, Yodo M",,105524,DTCT0024844,1251566,DTCC00191757,1870153,15166
CHEMBL483857,P14780,2-((4-PHENOXYPHENYLSULFONYL)METHYL)THIIRANE,LSONWRHLFZYHIN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,KI,=,600,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2457377,DTCC00007664,1756562,32556
CHEMBL483857,P14780,2-((4-PHENOXYPHENYLSULFONYL)METHYL)THIIRANE,LSONWRHLFZYHIN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,ACTIVITY,=,0.14,10'-3/M/S,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain assessed as association rate constant by substrate hydrolysis based fluorescence spectrophotometry,,,ACS Med. Chem. Lett.,2011,2,2,,,702121,DTCT0024844,5066013,DTCC00007664,1746732,42713
CHEMBL483857,P14780,2-((4-PHENOXYPHENYLSULFONYL)METHYL)THIIRANE,LSONWRHLFZYHIN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,ACTIVITY,=,7.1,10'-3/M/S,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain assessed as dissociation rate constant by substrate hydrolysis based fluorescence spectrophotometry,,,ACS Med. Chem. Lett.,2011,2,2,,,702129,DTCT0024844,5066042,DTCC00007664,1746732,42713
CHEMBL483857,P14780,2-((4-PHENOXYPHENYLSULFONYL)METHYL)THIIRANE,LSONWRHLFZYHIN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,600,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain by substrate hydrolysis based fluorescence spectrophotometry,,,ACS Med. Chem. Lett.,2011,2,2,,,702135,DTCT0024844,5066080,DTCC00007664,1746732,42713
CHEMBL483857,P14780,2-((4-PHENOXYPHENYLSULFONYL)METHYL)THIIRANE,LSONWRHLFZYHIN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,600,NM,,,,,,,,,,,,,,Competitive inhibition of human MMP9 using fluorogenic substrate by Dixon plot analysis,,,ACS Med. Chem. Lett.,2012,3,6,,,831079,DTCT0024844,10566534,DTCC00007664,1767161,48923
CHEMBL484261,P14780,,VMOSDDURWLNMNG-GXFFZTMASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,IC50,=,777,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2456505,DTCC00115945,888681,32556
CHEMBL484262,P14780,,BBCCMNOZBPHYAJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,IC50,=,5500,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2456495,DTCC00546798,1470988,32556
CHEMBL48449,P14780,CANTHARIDIN,DHZBEENLJMYSHQ-XCVPVQRUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7273267,DTCC00189104,1544894,46191
CHEMBL48449,P14780,CANTHARIDIN,DHZBEENLJMYSHQ-XCVPVQRUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7273268,DTCC00189104,1544894,46191
CHEMBL485259,P14780,EUCALYPTOL,WEEGYLXZBRQIMU-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7307243,DTCC00539560,542575,46191
CHEMBL485259,P14780,EUCALYPTOL,WEEGYLXZBRQIMU-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7307244,DTCC00539560,542575,46191
CHEMBL485492,P14780,,QNKSDDQPRLWOEC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,KI,=,130,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2457364,DTCC00115942,306350,32556
CHEMBL485492,P14780,,QNKSDDQPRLWOEC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21866961,KI,=,130,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain assessed as hydrolysis of MOCAcPLGLA2pr(Dnp)AR-NH2 by fluorescence spectrofluorometry ,,Selective water-soluble gelatinase inhibitor prodrugs.,J. Med. Chem.,2011,54,19,"Gooyit M, Lee M, Schroeder VA, Ikejiri M, Suckow MA, Mobashery S, Chang M",,771289,DTCT0024844,6116380,DTCC00115942,296761,46049
CHEMBL485492,P14780,,QNKSDDQPRLWOEC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21866961,KI,=,130,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 assessed as hydrolysis of MOCAcPLGLA2pr(Dnp)AR-NH2 by fluorescence spectrofluorometry ,,Selective water-soluble gelatinase inhibitor prodrugs.,J. Med. Chem.,2011,54,19,"Gooyit M, Lee M, Schroeder VA, Ikejiri M, Suckow MA, Mobashery S, Chang M",,771364,DTCT0024844,6116319,DTCC00115942,296761,46049
CHEMBL485492,P14780,,QNKSDDQPRLWOEC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26386821,IC50,=,529.1,NM,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 2 hrs prior to testing measured for 15 mins by fluorometric analysis,,"Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.",Bioorg. Med. Chem.,2015,23,20,"Yan Y, Chen X, Yang X, Zhang J, Xu W, Zhang Y",,1518636,DTCT0024844,14550523,DTCC00115942,288987,63755
CHEMBL485492,P14780,,QNKSDDQPRLWOEC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26386821,INHIBITION,=,97.2,%,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate at 10 uM incubated for 2 hrs prior to testing measured for 15 mins by fluorometric analysis relative to control,,"Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.",Bioorg. Med. Chem.,2015,23,20,"Yan Y, Chen X, Yang X, Zhang J, Xu W, Zhang Y",,1518638,DTCT0024844,14550549,DTCC00115942,288987,63755
CHEMBL485549,P14780,NIFURSOL,XXUXXCZCUGIGPP-WLRTZDKTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7375469,DTCC00563507,2057651,46191
CHEMBL485549,P14780,NIFURSOL,XXUXXCZCUGIGPP-WLRTZDKTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7375470,DTCC00563507,2057651,46191
CHEMBL486368,P14780,,LDSFSKFATNBTBV-GUBZILKMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19007202,ACTIVITY,=,1.8,%,,,,,,,,,,,,,,Inhibition of MMP9 at 1.3 uM by fluorimetric assay,,Development of novel G-protein-coupled receptor 54 agonists with resistance to degradation by matrix metalloproteinase.,J. Med. Chem.,2008,51,23,"Tomita K, Oishi S, Ohno H, Peiper SC, Fujii N",,495833,DTCT0024844,2586297,DTCC00117134,501251,32055
CHEMBL48786,P14780,,WMVFFTPYCGKWCT-PCCBWWKXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9599226,KI,=,404,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Macrocyclic amino carboxylates as selective MMP-8 inhibitors.,J. Med. Chem.,1998,41,11,"Cherney RJ, Wang L, Meyer DT, Xue CB, Wasserman ZR, Hardman KD, Welch PK, Covington MB, Copeland RA, Arner EC, DeGrado WF, Decicco CP",,105664,DTCT0024844,1355640,DTCC00193466,1934553,14640
CHEMBL487894,P14780,DIPYRONE SODIUM,DJGAAPFSPWAYTJ-UHFFFAOYSA-M,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7353387,DTCC00513255,1416028,46191
CHEMBL487894,P14780,DIPYRONE SODIUM,DJGAAPFSPWAYTJ-UHFFFAOYSA-M,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7353388,DTCC00513255,1416028,46191
CHEMBL488,P14780,AMINOGLUTETHIMIDE,ROBVIMPUHSLWNV-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7302410,DTCC00137354,477910,46191
CHEMBL488,P14780,AMINOGLUTETHIMIDE,ROBVIMPUHSLWNV-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7302411,DTCC00137354,477910,46191
CHEMBL488025,P14780,EXISULIND,MVGSNCBCUWPVDA-MFOYZWKCSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7469749,DTCC00113831,1674151,46191
CHEMBL488025,P14780,EXISULIND,MVGSNCBCUWPVDA-MFOYZWKCSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7469750,DTCC00113831,1674151,46191
CHEMBL488617,P14780,,YQOYDTYUPFCPKG-AMGIVPHBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18782669,IC50,=,11,NM,,,,,,,,,,,,,,Inhibition of human recombinant pro-MMP9 by spectrofluorimeter,,Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.,Bioorg. Med. Chem.,2008,16,18,"Ledour G, Moroy G, Rouffet M, Bourguet E, Guillaume D, Decarme M, Elmourabit H, Augé F, Alix AJ, Laronze JY, Bellon G, Hornebeck W, Sapi J",,557954,DTCT0024844,2791151,DTCC00514928,650740,31586
CHEMBL489100,P14780,BMS-561392,QVNZBDLTUKCPGJ-SHQCIBLASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,389,NM,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin) by fluorescence-based FRET assay,,,MedChemComm,2011,2,10,,,1328286,DTCT0024844,13574317,DTCC00005548,590183,39059
CHEMBL49,P14780,BUSPIRONE,QWCRAEMEVRGPNT-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7266118,DTCC00135177,120970,46191
CHEMBL49,P14780,BUSPIRONE,QWCRAEMEVRGPNT-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7266119,DTCC00135177,120970,46191
CHEMBL490,P14780,PAROXETINE,AHOUBRCZNHFOSL-YOEHRIQHSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7380417,DTCC00137638,1188071,46191
CHEMBL490,P14780,PAROXETINE,AHOUBRCZNHFOSL-YOEHRIQHSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7380418,DTCC00137638,1188071,46191
CHEMBL49080,P14780,CLENBUTEROL,STJMRWALKKWQGH-UHFFFAOYSA-N,1,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7345700,DTCC00193265,1155678,46191
CHEMBL49080,P14780,CLENBUTEROL,STJMRWALKKWQGH-UHFFFAOYSA-N,1,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7345701,DTCC00193265,1155678,46191
CHEMBL491643,P14780,,AQXFSOLTNZQWIK-HXUWFJFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,IC50,>,5000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2457503,DTCC00546723,306348,32556
CHEMBL49185,P14780,,YYNNRJWNBXEQTP-CQSZACIVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10346925,IC50,>,20000,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9 (concentration required for 50% inhibition of enzyme activity),,Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.,J. Med. Chem.,1999,42,10,"Kiyama R, Tamura Y, Watanabe F, Tsuzuki H, Ohtani M, Yodo M",,105524,DTCT0024844,1272555,DTCC00191572,1649407,15166
CHEMBL49186,P14780,,VFURABQMPHTDQE-JOCHJYFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10346925,IC50,=,340,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9 (concentration required for 50% inhibition of enzyme activity),,Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.,J. Med. Chem.,1999,42,10,"Kiyama R, Tamura Y, Watanabe F, Tsuzuki H, Ohtani M, Yodo M",,105524,DTCT0024844,1271491,DTCC00191573,1067002,15166
CHEMBL493,P14780,BROMOCRIPTINE,OZVBMTJYIDMWIL-AYFBDAFISA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7274405,DTCC00137993,1544893,46191
CHEMBL493,P14780,BROMOCRIPTINE,OZVBMTJYIDMWIL-AYFBDAFISA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7274406,DTCC00137993,1544893,46191
CHEMBL493985,P14780,,JCIYJOANUUNJFK-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18442906,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,Not Active,Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.,Bioorg. Med. Chem. Lett.,2008,18,11,"Subramaniam R, Haldar MK, Tobwala S, Ganguly B, Srivastava DK, Mallik S",,552276,DTCT0024844,2558311,DTCC00541234,791102,28839
CHEMBL49411,P14780,,JBYHBQIDTNHWJF-HXUWFJFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,=,240,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,637386,DTCC00191340,466182,15057
CHEMBL49411,P14780,,JBYHBQIDTNHWJF-HXUWFJFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10346925,IC50,=,2700,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9 (concentration required for 50% inhibition of enzyme activity),,Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.,J. Med. Chem.,1999,42,10,"Kiyama R, Tamura Y, Watanabe F, Tsuzuki H, Ohtani M, Yodo M",,105524,DTCT0024844,1250455,DTCC00191340,452238,15166
CHEMBL49413,P14780,,ZDCLAWKUXDCGDW-GOSISDBHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10346925,IC50,=,4.4,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9 (concentration required for 50% inhibition of enzyme activity),,Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.,J. Med. Chem.,1999,42,10,"Kiyama R, Tamura Y, Watanabe F, Tsuzuki H, Ohtani M, Yodo M",,105524,DTCT0024844,1257466,DTCC00192052,1967744,15166
CHEMBL494615,P14780,,CXFIAAHFJJRRLJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18442906,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,Not Active,Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.,Bioorg. Med. Chem. Lett.,2008,18,11,"Subramaniam R, Haldar MK, Tobwala S, Ganguly B, Srivastava DK, Mallik S",,552276,DTCT0024844,2558282,DTCC00115647,1535580,28839
CHEMBL494643,P14780,,FZONFSJIDBMCOM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18442906,KI,=,212000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.,Bioorg. Med. Chem. Lett.,2008,18,11,"Subramaniam R, Haldar MK, Tobwala S, Ganguly B, Srivastava DK, Mallik S",,552276,DTCT0024844,2558281,DTCC00541231,1885517,28839
CHEMBL494644,P14780,,CZJNIILYDQDLMZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18442906,KI,=,150000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.,Bioorg. Med. Chem. Lett.,2008,18,11,"Subramaniam R, Haldar MK, Tobwala S, Ganguly B, Srivastava DK, Mallik S",,552276,DTCT0024844,2558279,DTCC00541233,2080427,28839
CHEMBL49499,P14780,,PBUVCYINXCCIRF-RUZDIDTESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10346925,IC50,=,2000,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9 (concentration required for 50% inhibition of enzyme activity),,Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.,J. Med. Chem.,1999,42,10,"Kiyama R, Tamura Y, Watanabe F, Tsuzuki H, Ohtani M, Yodo M",,105524,DTCT0024844,1251572,DTCC00191428,2065049,15166
CHEMBL495502,P14780,,OBBSDCUMPDPHQF-BEEZEEGUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,KI,>,3000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2457263,DTCC00547246,1983210,32556
CHEMBL495621,P14780,,OVRNSWPIJUFVHN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19464885,IC50,>,12000,NM,,,,,,,,,,,,,,inhibition of human recombinant MMP9 catalytic domain,,Synthesis and activity of quinolinylmethyl P1' alpha-sulfone piperidine hydroxamate inhibitors of TACE.,Bioorg. Med. Chem. Lett.,2009,19,13,"Zhang C, Lovering F, Behnke M, Zask A, Sandanayaka V, Sun L, Zhu Y, Xu W, Zhang Y, Levin JI",,523799,DTCT0024844,2832675,DTCC00553772,1178656,33699
CHEMBL495778,P14780,PENICILLIC ACID,YCOFRPYSZKIPBQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7371981,DTCC00115404,866022,46191
CHEMBL495778,P14780,PENICILLIC ACID,YCOFRPYSZKIPBQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7371982,DTCC00115404,866022,46191
CHEMBL495797,P14780,,VXPAAABROXRBQT-XHXISMBCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19457660,IC50,>,5000,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition.,Bioorg. Med. Chem. Lett.,2009,19,13,"Burns DM, Li YL, Shi E, He C, Xu M, Zhuo J, Zhang C, Qian DQ, Li Y, Wynn R, Covington MB, Katiyar K, Marando CA, Fridman JS, Scherle P, Friedman S, Metcalf B, Yao W",,523765,DTCT0024844,2828338,DTCC00554190,715467,33677
CHEMBL495831,P14780,,DVAPUVGZYOTZOY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19464885,IC50,=,12000,NM,,,,,,,,,,,,,,inhibition of human recombinant MMP9 catalytic domain,,Synthesis and activity of quinolinylmethyl P1' alpha-sulfone piperidine hydroxamate inhibitors of TACE.,Bioorg. Med. Chem. Lett.,2009,19,13,"Zhang C, Lovering F, Behnke M, Zask A, Sandanayaka V, Sun L, Zhu Y, Xu W, Zhang Y, Levin JI",,523799,DTCT0024844,2833341,DTCC00553832,2048412,33699
CHEMBL496,P14780,HEXACHLOROPHENE,ACGUYXCXAPNIKK-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7314956,DTCC00138998,1765973,46191
CHEMBL496,P14780,HEXACHLOROPHENE,ACGUYXCXAPNIKK-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7314957,DTCC00138998,1765973,46191
CHEMBL496092,P14780,,MTAQTXQYHQORQK-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18442906,INHIBITION,=,9.3,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 10 uM,,Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.,Bioorg. Med. Chem. Lett.,2008,18,11,"Subramaniam R, Haldar MK, Tobwala S, Ganguly B, Srivastava DK, Mallik S",,552277,DTCT0024844,2558337,DTCC00541353,1853383,28839
CHEMBL496093,P14780,,QBPIFDDGZXMEBW-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18442906,KI,=,221000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.,Bioorg. Med. Chem. Lett.,2008,18,11,"Subramaniam R, Haldar MK, Tobwala S, Ganguly B, Srivastava DK, Mallik S",,552276,DTCT0024844,2558318,DTCC00541354,500988,28839
CHEMBL496496,P14780,,AHDKTZLZWZOZGC-SFHVURJKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18442906,KI,=,4200,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.,Bioorg. Med. Chem. Lett.,2008,18,11,"Subramaniam R, Haldar MK, Tobwala S, Ganguly B, Srivastava DK, Mallik S",,552276,DTCT0024844,2558320,DTCC00541298,240532,28839
CHEMBL496527,P14780,IM-491,RJSKOAOWDAMMHR-FYYLOGMGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,KI,>,2128,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2457284,DTCC00007697,436647,32556
CHEMBL496628,P14780,,SPGSQKKTHWOODB-BVSLBCMMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19457660,IC50,=,683,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition.,Bioorg. Med. Chem. Lett.,2009,19,13,"Burns DM, Li YL, Shi E, He C, Xu M, Zhuo J, Zhang C, Qian DQ, Li Y, Wynn R, Covington MB, Katiyar K, Marando CA, Fridman JS, Scherle P, Friedman S, Metcalf B, Yao W",,523765,DTCT0024844,2828345,DTCC00554399,1971829,33677
CHEMBL496702,P14780,,UNWSPZORFGSVQL-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18442906,KI,=,329000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.,Bioorg. Med. Chem. Lett.,2008,18,11,"Subramaniam R, Haldar MK, Tobwala S, Ganguly B, Srivastava DK, Mallik S",,552276,DTCT0024844,2558319,DTCC00541299,208125,28839
CHEMBL49671,P14780,,HWLNAJHPYNDARJ-HXUWFJFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9484512,IC50,>,50000,NM,,,,,,,,,,,,,,Inhibitory activity against human gelatinase B (Matrix metalloprotease-9),,Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.,J. Med. Chem.,1998,41,4,"Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M",,105238,DTCT0024844,634041,DTCC00191760,1981305,15057
CHEMBL49671,P14780,,HWLNAJHPYNDARJ-HXUWFJFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10346925,IC50,>,20000,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9 (concentration required for 50% inhibition of enzyme activity),,Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.,J. Med. Chem.,1999,42,10,"Kiyama R, Tamura Y, Watanabe F, Tsuzuki H, Ohtani M, Yodo M",,105524,DTCT0024844,1274784,DTCC00191760,1967746,15166
CHEMBL496715,P14780,,MOKPWPXQMULGAW-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18442906,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,Not Active,Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.,Bioorg. Med. Chem. Lett.,2008,18,11,"Subramaniam R, Haldar MK, Tobwala S, Ganguly B, Srivastava DK, Mallik S",,552276,DTCT0024844,2558307,DTCC00541409,2048291,28839
CHEMBL496716,P14780,,HKDOGDQOXPWJEG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18442906,KI,=,2750,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.,Bioorg. Med. Chem. Lett.,2008,18,11,"Subramaniam R, Haldar MK, Tobwala S, Ganguly B, Srivastava DK, Mallik S",,552276,DTCT0024844,2558287,DTCC00541152,759012,28839
CHEMBL496717,P14780,,WBWFDDZAXKMHEG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18442906,KI,=,227,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.,Bioorg. Med. Chem. Lett.,2008,18,11,"Subramaniam R, Haldar MK, Tobwala S, Ganguly B, Srivastava DK, Mallik S",,552276,DTCT0024844,2558265,DTCC00541154,662260,28839
CHEMBL496829,P14780,,ZABUEZYWKJKVJI-MZBJOSPHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19457660,IC50,>,5000,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition.,Bioorg. Med. Chem. Lett.,2009,19,13,"Burns DM, Li YL, Shi E, He C, Xu M, Zhuo J, Zhang C, Qian DQ, Li Y, Wynn R, Covington MB, Katiyar K, Marando CA, Fridman JS, Scherle P, Friedman S, Metcalf B, Yao W",,523765,DTCT0024844,2828346,DTCC00554401,1167262,33677
CHEMBL496921,P14780,,WGWWAORTMDCLGL-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18442906,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,Not Active,Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.,Bioorg. Med. Chem. Lett.,2008,18,11,"Subramaniam R, Haldar MK, Tobwala S, Ganguly B, Srivastava DK, Mallik S",,552276,DTCT0024844,2558306,DTCC00541410,759014,28839
CHEMBL496942,P14780,,FLTYDFYSVZBKOB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17623656,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.,J. Biol. Chem.,2007,282,38,"Johnson AR, Pavlovsky AG, Ortwine DF, Prior F, Man CF, Bornemeier DA, Banotai CA, Mueller WT, McConnell P, Yan C, Baragi V, Lesch C, Roark WH, Wilson M, Datta K, Guzman R, Han HK, Dyer RD",,507876,DTCT0024844,2388630,DTCC00547183,1983321,29282
CHEMBL496942,P14780,,FLTYDFYSVZBKOB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of MMP9 up to 100 uM,Not Active,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497431,DTCT0024844,2457329,DTCC00547183,1983207,32556
CHEMBL496942,P14780,,FLTYDFYSVZBKOB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25265401,IC50,>,30000,NM,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin),,"Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors.",J. Med. Chem.,2014,57,24,"Fabre B, Ramos A, de Pascual-Teresa B",,1433221,DTCT0024844,13993820,DTCC00547183,1976454,60040
CHEMBL497026,P14780,,SPGSQKKTHWOODB-GFUWAVFVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19457660,IC50,=,1876,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition.,Bioorg. Med. Chem. Lett.,2009,19,13,"Burns DM, Li YL, Shi E, He C, Xu M, Zhuo J, Zhang C, Qian DQ, Li Y, Wynn R, Covington MB, Katiyar K, Marando CA, Fridman JS, Scherle P, Friedman S, Metcalf B, Yao W",,523765,DTCT0024844,2828343,DTCC00554324,779794,33677
CHEMBL497222,P14780,,AVCGYVHCLDMOAW-GFUWAVFVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19457660,IC50,=,2500,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition.,Bioorg. Med. Chem. Lett.,2009,19,13,"Burns DM, Li YL, Shi E, He C, Xu M, Zhuo J, Zhang C, Qian DQ, Li Y, Wynn R, Covington MB, Katiyar K, Marando CA, Fridman JS, Scherle P, Friedman S, Metcalf B, Yao W",,523765,DTCT0024844,2828344,DTCC00554325,1874229,33677
CHEMBL497761,P14780,,ZUAZPXLMAVHRDA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18442906,KI,=,39,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.,Bioorg. Med. Chem. Lett.,2008,18,11,"Subramaniam R, Haldar MK, Tobwala S, Ganguly B, Srivastava DK, Mallik S",,552276,DTCT0024844,2558290,DTCC00541206,1374178,28839
CHEMBL497762,P14780,,BCGORVDYJLTYKW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18442906,KI,=,1700,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.,Bioorg. Med. Chem. Lett.,2008,18,11,"Subramaniam R, Haldar MK, Tobwala S, Ganguly B, Srivastava DK, Mallik S",,552276,DTCT0024844,2558289,DTCC00541207,1374179,28839
CHEMBL497772,P14780,,KQIFSUSWYMDFOC-AREMUKBSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,IC50,>,7000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2457436,DTCC00547182,823604,32556
CHEMBL497961,P14780,,YVDDNQUHTODDIP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18442906,KI,=,2.6,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.,Bioorg. Med. Chem. Lett.,2008,18,11,"Subramaniam R, Haldar MK, Tobwala S, Ganguly B, Srivastava DK, Mallik S",,552276,DTCT0024844,2558284,DTCC00541150,1341658,28839
CHEMBL497962,P14780,,LJLSVOSAAMOXNZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18442906,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,Not Active,Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.,Bioorg. Med. Chem. Lett.,2008,18,11,"Subramaniam R, Haldar MK, Tobwala S, Ganguly B, Srivastava DK, Mallik S",,552276,DTCT0024844,2558283,DTCC00541151,1341659,28839
CHEMBL497985,P14780,,HJNKYGBTSGQBDU-HOCLYGCPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,IC50,>,5000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2457485,DTCC00547304,630170,32556
CHEMBL498,P14780,CHLORPROPAMIDE,RKWGIWYCVPQPMF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7371253,DTCC00139298,1253319,46191
CHEMBL498,P14780,CHLORPROPAMIDE,RKWGIWYCVPQPMF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7371254,DTCC00139298,1253319,46191
CHEMBL498350,P14780,,AUJFRDPIKGEOPW-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18442906,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,Not Active,Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.,Bioorg. Med. Chem. Lett.,2008,18,11,"Subramaniam R, Haldar MK, Tobwala S, Ganguly B, Srivastava DK, Mallik S",,552276,DTCT0024844,2558309,DTCC00541301,1821257,28839
CHEMBL498568,P14780,,MTSBODCUBIWEJX-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18442906,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,Not Active,Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.,Bioorg. Med. Chem. Lett.,2008,18,11,"Subramaniam R, Haldar MK, Tobwala S, Ganguly B, Srivastava DK, Mallik S",,552276,DTCT0024844,2558305,DTCC00541411,1309059,28839
CHEMBL498847,P14780,SECNIDAZOLE,KPQZUUQMTUIKBP-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7488384,DTCC00550707,1765980,46191
CHEMBL498847,P14780,SECNIDAZOLE,KPQZUUQMTUIKBP-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7488385,DTCC00550707,1765980,46191
CHEMBL498915,P14780,,NIPJJOWPCLBDGS-CLOONOSVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18782669,IC50,=,8.5,NM,,,,,,,,,,,,,,Inhibition of human recombinant pro-MMP9 by spectrofluorimeter,,Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.,Bioorg. Med. Chem.,2008,16,18,"Ledour G, Moroy G, Rouffet M, Bourguet E, Guillaume D, Decarme M, Elmourabit H, Augé F, Alix AJ, Laronze JY, Bellon G, Hornebeck W, Sapi J",,557954,DTCT0024844,2791152,DTCC00514929,67486,31586
CHEMBL499,P14780,TIMOLOL,BLJRIMJGRPQVNF-JTQLQIEISA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7483347,DTCC00139310,1894976,46191
CHEMBL499,P14780,TIMOLOL,BLJRIMJGRPQVNF-JTQLQIEISA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7483348,DTCC00139310,1894976,46191
CHEMBL499815,P14780,ATRACTYLOSIDE,IUCNQFHEWLYECJ-CXCSZTQTSA-L,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7269341,DTCC00539373,1765970,46191
CHEMBL499815,P14780,ATRACTYLOSIDE,IUCNQFHEWLYECJ-CXCSZTQTSA-L,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7269342,DTCC00539373,1765970,46191
CHEMBL50,P14780,QUERCETIN,REFJWTPEDVJJIY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,IC50,=,1610,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain incubated for 20 mins by fluorimetric assay,,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827436,DTCT0024844,10535415,DTCC00135230,18482,48665
CHEMBL50,P14780,QUERCETIN,REFJWTPEDVJJIY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,INHIBITION,>,30,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain at 10 uM incubated for 20 mins by fluorimetric assay,,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827442,DTCT0024844,10535516,DTCC00135230,18482,48665
CHEMBL500,P14780,PINDOLOL,JZQKKSLKJUAGIC-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7387418,DTCC00139321,736265,46191
CHEMBL500,P14780,PINDOLOL,JZQKKSLKJUAGIC-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7387419,DTCC00139321,736265,46191
CHEMBL500351,P14780,,XMFWHLZTTUUQHL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18358729,ACTIVITY,=,66,%,,,,,,,,,,,,,,Inhibition recombinant MMP9 at 100 uM,,High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate.,Bioorg. Med. Chem.,2009,17,3,"Lauer-Fields JL, Minond D, Chase PS, Baillargeon PE, Saldanha SA, Stawikowska R, Hodder P, Fields GB",,518895,DTCT0024844,2708872,DTCC00516461,984995,32215
CHEMBL500351,P14780,,XMFWHLZTTUUQHL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18364257,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 200 uM by HxBP-Rh probe-based competitive activity based protein profiling assay in presence of 200 uM HxBP-alkyne,Not Active,Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.,Bioorg. Med. Chem.,2009,17,3,"Nakai R, Salisbury CM, Rosen H, Cravatt BF",,518929,DTCT0024844,2709051,DTCC00516461,984998,32218
CHEMBL500351,P14780,,XMFWHLZTTUUQHL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18364257,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 by fluorogenic substrate assay,,Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.,Bioorg. Med. Chem.,2009,17,3,"Nakai R, Salisbury CM, Rosen H, Cravatt BF",,518918,DTCT0024844,2709032,DTCC00516461,984998,32218
CHEMBL501043,P14780,,KYBRPVZTHIQEEP-NJGSGMGMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19007202,ACTIVITY,=,98.9,%,,,,,,,,,,,,,,Inhibition of MMP9 at 10 uM by fluorimetric assay,,Development of novel G-protein-coupled receptor 54 agonists with resistance to degradation by matrix metalloproteinase.,J. Med. Chem.,2008,51,23,"Tomita K, Oishi S, Ohno H, Peiper SC, Fujii N",,495831,DTCT0024844,2586305,DTCC00565050,371784,32055
CHEMBL501715,P14780,,RMPMGGGCHRCWIU-KBPBESRZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17719700,IC50,=,20000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,Peptidyl 3-substituted 1-hydroxyureas as isosteric analogues of succinylhydroxamate MMP inhibitors.,Eur. J. Med. Chem.,2008,43,5,"Campestre C, Tortorella P, Agamennone M, Preziuso S, Biasone A, Nuti E, Rossello A, Gallina C",,510908,DTCT0024844,2438441,DTCC00560261,100290,30977
CHEMBL50228,P14780,,NSZHVJWSFHBPMB-OKZBNKHCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9599226,KI,=,6600,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Macrocyclic amino carboxylates as selective MMP-8 inhibitors.,J. Med. Chem.,1998,41,11,"Cherney RJ, Wang L, Meyer DT, Xue CB, Wasserman ZR, Hardman KD, Welch PK, Covington MB, Copeland RA, Arner EC, DeGrado WF, Decicco CP",,105664,DTCT0024844,1349981,DTCC00193676,969803,14640
CHEMBL50228,P14780,,NSZHVJWSFHBPMB-OKZBNKHCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,KI,=,6600,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2457443,DTCC00193676,985350,32556
CHEMBL502412,P14780,,YDMXGNNTWVZROI-PQGRUEKFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19109023,KCAT/KM,=,20000,/M/S,,,,,,,,,,,,,,Ratio of kcat/km for MMP9 assessed as drug cleavage,,Development of an optimized activatable MMP-14 targeted SPECT imaging probe.,Bioorg. Med. Chem.,2009,17,2,"Watkins GA, Jones EF, Scott Shell M, VanBrocklin HF, Pan MH, Hanrahan SM, Feng JJ, He J, Sounni NE, Dill KA, Contag CH, Coussens LM, Franc BL",,496176,DTCT0024844,2590003,DTCC00516905,2036776,32112
CHEMBL502620,P14780,ACLARUBICIN,USZYSDMBJDPRIF-SVEJIMAYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7284109,DTCC00522599,1383771,46191
CHEMBL502620,P14780,ACLARUBICIN,USZYSDMBJDPRIF-SVEJIMAYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7284110,DTCC00522599,1383771,46191
CHEMBL502674,P14780,,MLPPJTCCWGPRTB-MYVCOICNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18782669,IC50,=,18,NM,,,,,,,,,,,,,,Inhibition of human recombinant pro-MMP9 by spectrofluorimeter,,Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.,Bioorg. Med. Chem.,2008,16,18,"Ledour G, Moroy G, Rouffet M, Bourguet E, Guillaume D, Decarme M, Elmourabit H, Augé F, Alix AJ, Laronze JY, Bellon G, Hornebeck W, Sapi J",,557954,DTCT0024844,2791158,DTCC00514935,877015,31586
CHEMBL502896,P14780,CETRAXATE HYDROCHLORIDE,USROQQUKEBHOFF-SKKCDYJJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7368861,DTCC00521861,477913,46191
CHEMBL502896,P14780,CETRAXATE HYDROCHLORIDE,USROQQUKEBHOFF-SKKCDYJJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7368862,DTCC00521861,477913,46191
CHEMBL503,P14780,LOVASTATIN,PCZOHLXUXFIOCF-BXMDZJJMSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7414717,DTCC00140133,1480347,46191
CHEMBL503,P14780,LOVASTATIN,PCZOHLXUXFIOCF-BXMDZJJMSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7414718,DTCC00140133,1480347,46191
CHEMBL503052,P14780,,GCPYOJSLSJRNKG-YNJWEERUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19007202,ACTIVITY,=,109.4,%,,,,,,,,,,,,,,Inhibition of MMP9 at 10 uM by fluorimetric assay,,Development of novel G-protein-coupled receptor 54 agonists with resistance to degradation by matrix metalloproteinase.,J. Med. Chem.,2008,51,23,"Tomita K, Oishi S, Ohno H, Peiper SC, Fujii N",,495831,DTCT0024844,2586301,DTCC00565054,436832,32055
CHEMBL503231,P14780,,NFPKLGKUZSGXBR-BHYWQNONSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,IC50,=,560,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2457449,DTCC00547118,888687,32556
CHEMBL503470,P14780,,HLLDDDNIWYZZJY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18358729,ACTIVITY,=,100,%,,,,,,,,,,,,,,Inhibition recombinant MMP9 at 100 uM,,High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate.,Bioorg. Med. Chem.,2009,17,3,"Lauer-Fields JL, Minond D, Chase PS, Baillargeon PE, Saldanha SA, Stawikowska R, Hodder P, Fields GB",,518895,DTCT0024844,2708874,DTCC00516463,1082310,32215
CHEMBL503651,P14780,,ZBCPKTFDPDVKFC-ABFWBJRFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18782669,IC50,=,2563,NM,,,,,,,,,,,,,,Inhibition of human recombinant pro-MMP9 by spectrofluorimeter,,Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.,Bioorg. Med. Chem.,2008,16,18,"Ledour G, Moroy G, Rouffet M, Bourguet E, Guillaume D, Decarme M, Elmourabit H, Augé F, Alix AJ, Laronze JY, Bellon G, Hornebeck W, Sapi J",,557954,DTCT0024844,2791154,DTCC00514931,714988,31586
CHEMBL504,P14780,DIMETHYL SULFOXIDE,IAZDPXIOMUYVGZ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7370677,DTCC00140586,1798409,46191
CHEMBL504,P14780,DIMETHYL SULFOXIDE,IAZDPXIOMUYVGZ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7370678,DTCC00140586,1798409,46191
CHEMBL50437,P14780,,OGKMZGGDXJSOLE-RUZDIDTESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10346925,IC50,=,2700,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9 (concentration required for 50% inhibition of enzyme activity),,Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.,J. Med. Chem.,1999,42,10,"Kiyama R, Tamura Y, Watanabe F, Tsuzuki H, Ohtani M, Yodo M",,105524,DTCT0024844,1259771,DTCC00191942,1870152,15166
CHEMBL50445,P14780,,CBAVXLBMIZUDPK-HXUWFJFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10346925,IC50,=,210,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9 (concentration required for 50% inhibition of enzyme activity),,Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.,J. Med. Chem.,1999,42,10,"Kiyama R, Tamura Y, Watanabe F, Tsuzuki H, Ohtani M, Yodo M",,105524,DTCT0024844,1248122,DTCC00192022,1649408,15166
CHEMBL504760,P14780,CAMPHOR,DSSYKIVIOFKYAU-XCBNKYQSSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7352690,DTCC00113446,217578,46191
CHEMBL504760,P14780,CAMPHOR,DSSYKIVIOFKYAU-XCBNKYQSSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7352691,DTCC00113446,217578,46191
CHEMBL504873,P14780,ISOACTEOSIDE,FNMHEHXNBNCPCI-QEOJJFGVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,IC50,=,14280,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain incubated for 20 mins by fluorimetric assay,,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827436,DTCT0024844,10535414,DTCC00506630,1169673,48665
CHEMBL504873,P14780,ISOACTEOSIDE,FNMHEHXNBNCPCI-QEOJJFGVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22658537,INHIBITION,>,30,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 catalytic domain at 10 uM incubated for 20 mins by fluorimetric assay,,Natural products as a gold mine for selective matrix metalloproteinases inhibitors.,Bioorg. Med. Chem.,2012,20,13,"Wang L, Li X, Zhang S, Lu W, Liao S, Liu X, Shan L, Shen X, Jiang H, Zhang W, Huang J, Li H",,827442,DTCT0024844,10535515,DTCC00506630,1169673,48665
CHEMBL50588,P14780,EMETINE,AUVVAXYIELKVAI-CKBKHPSWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7319624,DTCC00195239,216401,46191
CHEMBL50588,P14780,EMETINE,AUVVAXYIELKVAI-CKBKHPSWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7319625,DTCC00195239,216401,46191
CHEMBL506,P14780,PRIMAQUINE,INDBQLZJXZLFIT-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7374797,DTCC00140892,1155686,46191
CHEMBL506,P14780,PRIMAQUINE,INDBQLZJXZLFIT-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7374798,DTCC00140892,1155686,46191
CHEMBL506247,P14780,TANNIC ACID,LRBQNJMCXXYXIU-PPKXGCFTSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7467730,DTCC00524002,444643,46191
CHEMBL506247,P14780,TANNIC ACID,LRBQNJMCXXYXIU-PPKXGCFTSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7467731,DTCC00524002,444643,46191
CHEMBL506570,P14780,,WSVIQCQIJLDTEK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,42,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5102644,DTCC00571870,1381649,43205
CHEMBL507420,P14780,,PTUCPHGSAFOJAU-MGONOCMRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,KI,=,1265,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2457421,DTCC00115971,1788790,32556
CHEMBL508102,P14780,CARBIMAZOLE,CFOYWRHIYXMDOT-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7266481,DTCC00566137,1351108,46191
CHEMBL508102,P14780,CARBIMAZOLE,CFOYWRHIYXMDOT-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7266482,DTCC00566137,1351108,46191
CHEMBL508112,P14780,BENZOTHIAZYL DISULFIDE,AFZSMODLJJCVPP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7275463,DTCC00534219,606967,46191
CHEMBL508112,P14780,BENZOTHIAZYL DISULFIDE,AFZSMODLJJCVPP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7275464,DTCC00534219,606967,46191
CHEMBL508335,P14780,,ODFXJYBYTABKHA-BTYSJIOQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18782669,IC50,=,3,NM,,,,,,,,,,,,,,Inhibition of human recombinant pro-MMP9 by spectrofluorimeter,,Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.,Bioorg. Med. Chem.,2008,16,18,"Ledour G, Moroy G, Rouffet M, Bourguet E, Guillaume D, Decarme M, Elmourabit H, Augé F, Alix AJ, Laronze JY, Bellon G, Hornebeck W, Sapi J",,557954,DTCT0024844,2791153,DTCC00514930,877014,31586
CHEMBL508335,P14780,,ODFXJYBYTABKHA-BTYSJIOQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18782669,KI,=,3.6,NM,,,,,,,,,,,,,,Inhibition of human recombinant pro-MMP9 by spectrofluorimeter,,Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.,Bioorg. Med. Chem.,2008,16,18,"Ledour G, Moroy G, Rouffet M, Bourguet E, Guillaume D, Decarme M, Elmourabit H, Augé F, Alix AJ, Laronze JY, Bellon G, Hornebeck W, Sapi J",,557954,DTCT0024844,2791222,DTCC00514930,877014,31586
CHEMBL508338,P14780,THIOMERSAL,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7478982,DTCC00113560,962452,46191
CHEMBL508338,P14780,THIOMERSAL,,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7478983,DTCC00113560,962452,46191
CHEMBL508461,P14780,,VMTJQZUZINLEKC-JOCHJYFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,IC50,=,980,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2457354,DTCC00115944,1950497,32556
CHEMBL509,P14780,MECLOFENAMIC ACID,SBDNJUWAMKYJOX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7429965,DTCC00140998,510304,46191
CHEMBL509,P14780,MECLOFENAMIC ACID,SBDNJUWAMKYJOX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7429966,DTCC00140998,510304,46191
CHEMBL509027,P14780,,WRHZVMBBRYBTKZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,-20,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103050,DTCC00541055,669654,43205
CHEMBL509270,P14780,,HDFXAYMYXQRRFT-ATRWTNPRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18782669,IC50,=,732,NM,,,,,,,,,,,,,,Inhibition of human recombinant pro-MMP9 by spectrofluorimeter,,Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.,Bioorg. Med. Chem.,2008,16,18,"Ledour G, Moroy G, Rouffet M, Bourguet E, Guillaume D, Decarme M, Elmourabit H, Augé F, Alix AJ, Laronze JY, Bellon G, Hornebeck W, Sapi J",,557954,DTCT0024844,2791156,DTCC00514933,132052,31586
CHEMBL509346,P14780,,QEEFWEXKMRZIRZ-RTYIMRNCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18782669,IC50,=,827,NM,,,,,,,,,,,,,,Inhibition of human recombinant pro-MMP9 by spectrofluorimeter,,Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.,Bioorg. Med. Chem.,2008,16,18,"Ledour G, Moroy G, Rouffet M, Bourguet E, Guillaume D, Decarme M, Elmourabit H, Augé F, Alix AJ, Laronze JY, Bellon G, Hornebeck W, Sapi J",,557954,DTCT0024844,2791157,DTCC00514934,1588158,31586
CHEMBL510082,P14780,,MYTAFXBNPKBRNX-KGLIPLIRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17719700,IC50,>,300000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,Peptidyl 3-substituted 1-hydroxyureas as isosteric analogues of succinylhydroxamate MMP inhibitors.,Eur. J. Med. Chem.,2008,43,5,"Campestre C, Tortorella P, Agamennone M, Preziuso S, Biasone A, Nuti E, Rossello A, Gallina C",,510908,DTCT0024844,2438475,DTCC00512742,1971363,30977
CHEMBL510139,P14780,CITRININ,CQIUKKVOEOPUDV-IYSWYEEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7362793,DTCC00525343,249940,46191
CHEMBL510139,P14780,CITRININ,CQIUKKVOEOPUDV-IYSWYEEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7362794,DTCC00525343,249940,46191
CHEMBL510694,P14780,,LCLWTUJSVDCASO-JLSHBGBKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18782669,IC50,=,1246,NM,,,,,,,,,,,,,,Inhibition of human recombinant pro-MMP9 by spectrofluorimeter,,Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.,Bioorg. Med. Chem.,2008,16,18,"Ledour G, Moroy G, Rouffet M, Bourguet E, Guillaume D, Decarme M, Elmourabit H, Augé F, Alix AJ, Laronze JY, Bellon G, Hornebeck W, Sapi J",,557954,DTCT0024844,2791155,DTCC00514932,1716557,31586
CHEMBL511,P14780,PYRILAMINE,YECBIJXISLIIDS-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7394491,DTCC00141084,1830688,46191
CHEMBL511,P14780,PYRILAMINE,YECBIJXISLIIDS-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7394492,DTCC00141084,1830688,46191
CHEMBL513,P14780,CARMUSTINE,DLGOEMSEDOSKAD-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7368772,DTCC00141242,1383773,46191
CHEMBL513,P14780,CARMUSTINE,DLGOEMSEDOSKAD-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7368773,DTCC00141242,1383773,46191
CHEMBL513597,P14780,,ZAAJQVMPSOBCJC-JJGXFYADSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19161308,ACTIVITY,,,,,,,,,,,,,,,,,Stimulation of MMP9 activity in HUVEC assessed as increase in enzyme activity at 10 nM relative to control,Not Active,Total synthesis of photoactivatable or fluorescent anandamide probes: novel bioactive compounds with angiogenic activity.,J. Med. Chem.,2009,52,4,"Balas L, Durand T, Saha S, Johnson I, Mukhopadhyay S",,494403,DTCT0024844,2595853,DTCC00517385,99765,32132
CHEMBL513597,P14780,,ZAAJQVMPSOBCJC-JJGXFYADSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19161308,ACTIVITY,,,,,,,,,,,,,,,,,Stimulation of MMP9 activity in HUVEC assessed as increase in enzyme activity at 100 nM relative to control,Not Active,Total synthesis of photoactivatable or fluorescent anandamide probes: novel bioactive compounds with angiogenic activity.,J. Med. Chem.,2009,52,4,"Balas L, Durand T, Saha S, Johnson I, Mukhopadhyay S",,494405,DTCT0024844,2595857,DTCC00517385,99765,32132
CHEMBL513597,P14780,,ZAAJQVMPSOBCJC-JJGXFYADSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19161308,ACTIVITY,,,,,,,,,,,,,,,,,Stimulation of MMP9 activity in HUVEC assessed as increase in enzyme activity at 1 uM relative to control,Not Active,Total synthesis of photoactivatable or fluorescent anandamide probes: novel bioactive compounds with angiogenic activity.,J. Med. Chem.,2009,52,4,"Balas L, Durand T, Saha S, Johnson I, Mukhopadhyay S",,494407,DTCT0024844,2595861,DTCC00517385,99765,32132
CHEMBL513597,P14780,,ZAAJQVMPSOBCJC-JJGXFYADSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19161308,ACTIVITY,,,,,,,,,,,,,,,,,Stimulation of MMP9 activity in CB1 receptor knockout HUVEC assessed as increase in enzyme activity at 10 nM relative to control,Not Active,Total synthesis of photoactivatable or fluorescent anandamide probes: novel bioactive compounds with angiogenic activity.,J. Med. Chem.,2009,52,4,"Balas L, Durand T, Saha S, Johnson I, Mukhopadhyay S",,494409,DTCT0024844,2595865,DTCC00517385,99765,32132
CHEMBL513597,P14780,,ZAAJQVMPSOBCJC-JJGXFYADSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19161308,ACTIVITY,,,,,,,,,,,,,,,,,Stimulation of MMP9 activity in CB1 receptor knockout HUVEC assessed as increase in enzyme activity at 100 nM relative to control,Not Active,Total synthesis of photoactivatable or fluorescent anandamide probes: novel bioactive compounds with angiogenic activity.,J. Med. Chem.,2009,52,4,"Balas L, Durand T, Saha S, Johnson I, Mukhopadhyay S",,494411,DTCT0024844,2595869,DTCC00517385,99765,32132
CHEMBL513597,P14780,,ZAAJQVMPSOBCJC-JJGXFYADSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19161308,ACTIVITY,,,,,,,,,,,,,,,,,Stimulation of MMP9 activity in CB1 receptor knockout HUVEC assessed as increase in enzyme activity at 1 uM relative to control,Not Active,Total synthesis of photoactivatable or fluorescent anandamide probes: novel bioactive compounds with angiogenic activity.,J. Med. Chem.,2009,52,4,"Balas L, Durand T, Saha S, Johnson I, Mukhopadhyay S",,494598,DTCT0024844,2595873,DTCC00517385,99765,32132
CHEMBL513597,P14780,,ZAAJQVMPSOBCJC-JJGXFYADSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19161308,ACTIVITY,,,,,,,,,,,,,,,,,Stimulation of MMP9 activity in CB1 receptor knockout HUVEC assessed as increase in enzyme activity in presence of 1 uM anandamide receptor antagonist O-1918 relative to control,Not Active,Total synthesis of photoactivatable or fluorescent anandamide probes: novel bioactive compounds with angiogenic activity.,J. Med. Chem.,2009,52,4,"Balas L, Durand T, Saha S, Johnson I, Mukhopadhyay S",,494600,DTCT0024844,2595877,DTCC00517385,99765,32132
CHEMBL514,P14780,LOMUSTINE,GQYIWUVLTXOXAJ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7429646,DTCC00141290,1765975,46191
CHEMBL514,P14780,LOMUSTINE,GQYIWUVLTXOXAJ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7429647,DTCC00141290,1765975,46191
CHEMBL514138,P14780,CGS-27023A,ZVYIZSNCEAHMCF-UNTBIKODSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9258358,KI,=,8,NM,,,,,,,,,,,,,,"Inhibition of recombinant human 92 kDa gelatinase B, Matrix metalloprotease-9 (MMP-9)",,"Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits.",J. Med. Chem.,1997,40,16,"MacPherson LJ, Bayburt EK, Capparelli MP, Carroll BJ, Goldstein R, Justice MR, Zhu L, Hu S, Melton RA, Fryer L, Goldberg RL, Doughty JR, Spirito S, Blancuzzi V, Wilson D, O'Byrne EM, Ganu V, Parker DT",,105396,DTCT0024844,1289480,DTCC00514693,1228441,14264
CHEMBL514138,P14780,CGS-27023A,ZVYIZSNCEAHMCF-UNTBIKODSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9733482,IC50,=,4.3,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,"Discovery of potent, achiral matrix metalloproteinase inhibitors.",J. Med. Chem.,1998,41,19,"Pikul S, McDow Dunham KL, Almstead NG, De B, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Rydel T, Dunaway CM, Gu F, Mieling GE",,105360,DTCT0024844,1544204,DTCC00514693,1229057,14767
CHEMBL514138,P14780,CGS-27023A,ZVYIZSNCEAHMCF-UNTBIKODSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9733482,KI,=,8,NM,,,,,,,,,,,,,,Inhibition of truncated gelatinase B (Matrix metalloprotease-9),,"Discovery of potent, achiral matrix metalloproteinase inhibitors.",J. Med. Chem.,1998,41,19,"Pikul S, McDow Dunham KL, Almstead NG, De B, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Rydel T, Dunaway CM, Gu F, Mieling GE",,105402,DTCT0024844,1544207,DTCC00514693,1229057,14767
CHEMBL514138,P14780,CGS-27023A,ZVYIZSNCEAHMCF-UNTBIKODSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9873598,IC50,=,8.8,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,The synthesis and biological activity of a novel series of diazepine MMP inhibitors.,Bioorg. Med. Chem. Lett.,1998,8,19,"Levin JI, DiJoseph JF, Killar LM, Sung A, Walter T, Sharr MA, Roth CE, Skotnicki JS, Albright JD",,105513,DTCT0024844,610091,DTCC00514693,1228540,2791
CHEMBL514138,P14780,CGS-27023A,ZVYIZSNCEAHMCF-UNTBIKODSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9888835,IC50,=,4.3,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease 9,,Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.,J. Med. Chem.,1999,42,1,"Pikul S, McDow Dunham KL, Almstead NG, De B, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Mieling GE",,105359,DTCT0024844,1170614,DTCC00514693,1241881,15162
CHEMBL514138,P14780,CGS-27023A,ZVYIZSNCEAHMCF-UNTBIKODSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9888835,KI,=,8,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease 9,,Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.,J. Med. Chem.,1999,42,1,"Pikul S, McDow Dunham KL, Almstead NG, De B, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Mieling GE",,105392,DTCT0024844,1170615,DTCC00514693,1241881,15162
CHEMBL514138,P14780,CGS-27023A,ZVYIZSNCEAHMCF-UNTBIKODSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10450979,KI,=,8,NM,,,,,,,,,,,,,,Inhibition of human Matrix metalloprotease-9,,Synthesis of an array of potential matrix metalloproteinase inhibitors using a sequence of polymer-supported reagents.,Bioorg. Med. Chem. Lett.,1999,9,14,"Caldarelli M, Habermann J, Ley SV",,105544,DTCT0024844,1560600,DTCC00514693,1228109,3238
CHEMBL514138,P14780,CGS-27023A,ZVYIZSNCEAHMCF-UNTBIKODSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10579818,IC50,=,4.3,NM,,,,,,,,,,,,,,Inhibition of gelatinase-B (Matrix metalloprotease-9),,"Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.",J. Med. Chem.,1999,42,22,"Almstead NG, Bradley RS, Pikul S, De B, Natchus MG, Taiwo YO, Gu F, Williams LE, Hynd BA, Janusz MJ, Dunaway CM, Mieling GE",,105226,DTCT0024844,1395526,DTCC00514693,1241292,15412
CHEMBL514138,P14780,CGS-27023A,ZVYIZSNCEAHMCF-UNTBIKODSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10669559,KI,=,8,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9).,,Protease inhibitors: current status and future prospects.,J. Med. Chem.,2000,43,3,"Leung D, Abbenante G, Fairlie DP",,105389,DTCT0024844,1083291,DTCC00514693,1228978,16063
CHEMBL514138,P14780,CGS-27023A,ZVYIZSNCEAHMCF-UNTBIKODSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11206467,IC50,=,9,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position.,Bioorg. Med. Chem. Lett.,2001,11,2,"Levin JI, Du MT, DiJoseph JF, Killar LM, Sung A, Walter T, Sharr MA, Roth CE, Moy FJ, Powers R, Jin G, Cowling R, Skotnicki JS",,105222,DTCT0024844,596368,DTCC00514693,1228333,4515
CHEMBL514138,P14780,CGS-27023A,ZVYIZSNCEAHMCF-UNTBIKODSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11327577,IC50,=,4.3,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Heterocycle-based MMP inhibitors with P2' substituents.,Bioorg. Med. Chem. Lett.,2001,11,8,"Pikul S, Dunham KM, Almstead NG, De B, Natchus MG, Taiwo YO, Williams LE, Hynd BA, Hsieh LC, Janusz MJ, Gu F, Mieling GE",,105362,DTCT0024844,1321331,DTCC00514693,1242834,4760
CHEMBL514138,P14780,CGS-27023A,ZVYIZSNCEAHMCF-UNTBIKODSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514167,IC50,=,9,NM,,,,,,,,,,,,,,In vitro ability to inhibit matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.,Bioorg. Med. Chem. Lett.,2001,11,16,"Levin JI, Chen J, Du M, Hogan M, Kincaid S, Nelson FC, Venkatesan AM, Wehr T, Zask A, DiJoseph J, Killar LM, Skala S, Sung A, Sharr M, Roth C, Jin G, Cowling R, Mohler KM, Black RA, March CJ, Skotnicki JS",,105532,DTCT0024844,987777,DTCC00514693,1228201,4353
CHEMBL514138,P14780,CGS-27023A,ZVYIZSNCEAHMCF-UNTBIKODSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11677139,IC50,=,9,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.,Bioorg. Med. Chem. Lett.,2001,11,22,"Levin JI, Chen JM, Du MT, Nelson FC, Wehr T, DiJoseph JF, Killar LM, Skala S, Sung A, Sharr MA, Roth CE, Jin G, Cowling R, Di L, Sherman M, Xu ZB, March CJ, Mohler KM, Black RA, Skotnicki JS",,105530,DTCT0024844,1618583,DTCC00514693,1228738,4590
CHEMBL514138,P14780,CGS-27023A,ZVYIZSNCEAHMCF-UNTBIKODSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,9,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,791172,DTCC00514693,1228327,17339
CHEMBL514138,P14780,CGS-27023A,ZVYIZSNCEAHMCF-UNTBIKODSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,9,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,477858,DTCC00514693,1240289,17340
CHEMBL514138,P14780,CGS-27023A,ZVYIZSNCEAHMCF-UNTBIKODSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12930146,IC50,=,10,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP9),,Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.,J. Med. Chem.,2003,46,18,"Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P",,105365,DTCT0024844,526002,DTCC00514693,1241045,13726
CHEMBL514138,P14780,CGS-27023A,ZVYIZSNCEAHMCF-UNTBIKODSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,14980648,IC50,=,3000,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,New heteroarylbenzenesulphonamides as matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,5,"Delbecq F, Cordonnier G, Pommery N, Barbry D, Hénichart JP",,105506,DTCT0024844,741879,DTCC00514693,1227362,6676
CHEMBL514138,P14780,CGS-27023A,ZVYIZSNCEAHMCF-UNTBIKODSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15713379,IC50,=,8,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.,Bioorg. Med. Chem. Lett.,2005,15,5,"Rossello A, Nuti E, Carelli P, Orlandini E, Macchia M, Nencetti S, Zandomeneghi M, Balzano F, Uccello Barretta G, Albini A, Benelli R, Cercignani G, Murphy G, Balsamo A",,305737,DTCT0024844,1745883,DTCC00514693,1230128,18841
CHEMBL514138,P14780,CGS-27023A,ZVYIZSNCEAHMCF-UNTBIKODSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15857146,IC50,=,60,NM,,,,,,,,,,,,,,In vitro inhibition of human Matrix metalloprotease 9,,C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging.,J. Med. Chem.,2005,48,9,"Breyholz HJ, Schäfers M, Wagner S, Höltke C, Faust A, Rabeneck H, Levkau B, Schober O, Kopka K",,305106,DTCT0024844,1828967,DTCC00514693,1242174,19718
CHEMBL514138,P14780,CGS-27023A,ZVYIZSNCEAHMCF-UNTBIKODSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16338135,IC50,=,8,NM,,,,,,,,,,,,,,Inhibition of MMP9,,The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection.,Bioorg. Med. Chem. Lett.,2006,16,4,"Xiong Y, Wiltsie J, Woods A, Guo J, Pivnichny JV, Tang W, Bansal A, Cummings RT, Cunningham BR, Friedlander AM, Douglas CM, Salowe SP, Zaller DM, Scolnick EM, Schmatz DM, Bartizal K, Hermes JD, MacCoss M, Chapman KT",,334086,DTCT0024844,1895871,DTCC00514693,1242354,20352
CHEMBL514138,P14780,CGS-27023A,ZVYIZSNCEAHMCF-UNTBIKODSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17127067,IC50,=,5,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs.,Bioorg. Med. Chem.,2007,15,3,"Santos MA, Enyedy EA, Nuti E, Rossello A, Krupenko NI, Krupenko SA",,441089,DTCT0024844,2146216,DTCC00514693,1242789,23121
CHEMBL514138,P14780,CGS-27023A,ZVYIZSNCEAHMCF-UNTBIKODSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17276072,IC50,=,4.8,NM,,cell_based,,,,,,,,,,,,Inhibition of human recombinant MMP9 expressed in mouse myeloma cells,,Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.,Bioorg. Med. Chem.,2007,15,6,"Nuti E, Orlandini E, Nencetti S, Rossello A, Innocenti A, Scozzafava A, Supuran CT",,435728,DTCT0024844,2079329,DTCC00514693,1230837,22603
CHEMBL514138,P14780,CGS-27023A,ZVYIZSNCEAHMCF-UNTBIKODSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17956082,IC50,=,6,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.,J. Med. Chem.,2007,50,23,"Wagner S, Breyholz HJ, Law MP, Faust A, Höltke C, Schröer S, Haufe G, Levkau B, Schober O, Schäfers M, Kopka K",,451367,DTCT0024844,2204547,DTCC00514693,1231041,24059
CHEMBL514138,P14780,CGS-27023A,ZVYIZSNCEAHMCF-UNTBIKODSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19053764,IC50,=,5,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates.,J. Med. Chem.,2008,51,24,"Marques SM, Nuti E, Rossello A, Supuran CT, Tuccinardi T, Martinelli A, Santos MA",,561988,DTCT0024844,2800906,DTCC00514693,1231512,31524
CHEMBL514138,P14780,CGS-27023A,ZVYIZSNCEAHMCF-UNTBIKODSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19422229,IC50,=,6.8,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13.",J. Med. Chem.,2009,52,11,"Monovich LG, Tommasi RA, Fujimoto RA, Blancuzzi V, Clark K, Cornell WD, Doti R, Doughty J, Fang J, Farley D, Fitt J, Ganu V, Goldberg R, Goldstein R, Lavoie S, Kulathila R, Macchia W, Parker DT, Melton R, O'Byrne E, Pastor G, Pellas T, Quadros E, Reel N, Roland DM, Sakane Y, Singh H, Skiles J, Somers J, Toscano K, Wigg A, Zhou S, Zhu L, Shieh WC, Xue S, McQuire LW",,500585,DTCT0024844,2824183,DTCC00514693,1231748,33635
CHEMBL514138,P14780,CGS-27023A,ZVYIZSNCEAHMCF-UNTBIKODSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20180536,IC50,=,4.8,NM,,,,,,,,,,,,,,Inhibition of MMP9 by fluorometric assay,,Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.,J. Med. Chem.,2010,53,6,"Nuti E, Casalini F, Avramova SI, Santamaria S, Fabbi M, Ferrini S, Marinelli L, La Pietra V, Limongelli V, Novellino E, Cercignani G, Orlandini E, Nencetti S, Rossello A",,624094,DTCT0024844,3286042,DTCC00514693,1244871,38228
CHEMBL514138,P14780,CGS-27023A,ZVYIZSNCEAHMCF-UNTBIKODSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21514700,IC50,=,4.8,NM,,,,,,,,,,,,,,Inhibition of human MMP9 by fluorometric assay,,Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.,Eur. J. Med. Chem.,2011,46,7,"Nuti E, Casalini F, Santamaria S, Gabelloni P, Bendinelli S, Da Pozzo E, Costa B, Marinelli L, La Pietra V, Novellino E, Margarida Bernardo M, Fridman R, Da Settimo F, Martini C, Rossello A",,753770,DTCT0024844,6000261,DTCC00514693,1252235,44948
CHEMBL514138,P14780,CGS-27023A,ZVYIZSNCEAHMCF-UNTBIKODSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22540974,IC50,=,6,NM,,,,,,,,,,,,,,"Inhibition of MMP9 using (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured for 10 mins by fluorometry",,A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation.,J. Med. Chem.,2012,55,10,"Hugenberg V, Breyholz HJ, Riemann B, Hermann S, Schober O, Schäfers M, Gangadharmath U, Mocharla V, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,832927,DTCT0024844,10563939,DTCC00514693,1254588,48958
CHEMBL514138,P14780,CGS-27023A,ZVYIZSNCEAHMCF-UNTBIKODSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23287054,KI,=,8,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,Sulphonamides: Deserving class as MMP inhibitors?,Eur. J. Med. Chem.,2013,60,,"Jain P, Saravanan C, Singh SK",,944588,DTCT0024844,11835713,DTCC00514693,1255984,53820
CHEMBL514138,P14780,CGS-27023A,ZVYIZSNCEAHMCF-UNTBIKODSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25921268,KI,=,8,NM,,,,,,,,,,,,,,"Inhibition of human active MMP9 using (7-methoxycoumarin-4-yl) acetyl pro-Leu-Gly-Leu-[3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl]-Ala-Arg-NH2 fluorogenic substrate assessed as fluorescent product release",,New matrix metalloproteinase inhibitors based on ¿-fluorinated a-aminocarboxylic and a-aminohydroxamic acids.,Bioorg. Med. Chem.,2015,23,13,"Behrends M, Wagner S, Kopka K, Schober O, Schäfers M, Kumbhar S, Waller M, Haufe G",,1501468,DTCT0024844,14456761,DTCC00514693,1238346,62860
CHEMBL514495,P14780,,PTRVCICYKILIEH-SQFISAMPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18358729,ACTIVITY,=,100,%,,,,,,,,,,,,,,Inhibition recombinant MMP9 at 100 uM,,High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate.,Bioorg. Med. Chem.,2009,17,3,"Lauer-Fields JL, Minond D, Chase PS, Baillargeon PE, Saldanha SA, Stawikowska R, Hodder P, Fields GB",,518895,DTCT0024844,2708867,DTCC00515685,78922,32215
CHEMBL515,P14780,CHLORAMBUCIL,JCKYGMPEJWAADB-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7343037,DTCC00141382,477914,46191
CHEMBL515,P14780,CHLORAMBUCIL,JCKYGMPEJWAADB-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7343038,DTCC00141382,477914,46191
CHEMBL515083,P14780,,QVAVQQVTOJMLHH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19053764,IC50,=,322,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates.,J. Med. Chem.,2008,51,24,"Marques SM, Nuti E, Rossello A, Supuran CT, Tuccinardi T, Martinelli A, Santos MA",,561988,DTCT0024844,2800892,DTCC00514691,521492,31524
CHEMBL515390,P14780,,MCVFKNHXPZRVBQ-VLIAUNLRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12408705,KI,=,35,NM,,,,,,,,,,,,,,Affinity towards Matrix metalloprotease-9 (MMP-9),,"Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.",J. Med. Chem.,2002,45,23,"Duan JJ, Chen L, Wasserman ZR, Lu Z, Liu RQ, Covington MB, Qian M, Hardman KD, Magolda RL, Newton RC, Christ DD, Wexler RR, Decicco CP",,105374,DTCT0024844,726186,DTCC00516662,627883,17028
CHEMBL51557,P14780,,TXFHRXOVMCSUEC-OAQYLSRUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,>,2128,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1462200,DTCC00104960,1752916,17283
CHEMBL515914,P14780,AZARIBINE,QQOBRRFOVWGIMD-OJAKKHQRSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7258036,DTCC00514747,477912,46191
CHEMBL515914,P14780,AZARIBINE,QQOBRRFOVWGIMD-OJAKKHQRSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7258037,DTCC00514747,477912,46191
CHEMBL515980,P14780,,KBZNOZAJAJRTII-GOSISDBHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19053764,IC50,=,0.77,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates.,J. Med. Chem.,2008,51,24,"Marques SM, Nuti E, Rossello A, Supuran CT, Tuccinardi T, Martinelli A, Santos MA",,561988,DTCT0024844,2800828,DTCC00562382,2004561,31524
CHEMBL516,P14780,CYPROHEPTADINE,JJCFRYNCJDLXIK-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7369943,DTCC00141384,833160,46191
CHEMBL516,P14780,CYPROHEPTADINE,JJCFRYNCJDLXIK-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7369944,DTCC00141384,833160,46191
CHEMBL51658,P14780,,APCYYZKHCZUJGB-CYBMUJFWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,>,2128,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1449980,DTCC00104979,1563910,17283
CHEMBL51735,P14780,,ZZFYPMWQKLOJIR-MRXNPFEDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,<,2.1,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1446413,DTCC00198124,916618,17283
CHEMBL517712,P14780,ATROPINE,RKUNBYITZUJHSG-SPUOUPEWSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7272132,DTCC00507754,1577004,46191
CHEMBL517712,P14780,ATROPINE,RKUNBYITZUJHSG-SPUOUPEWSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7272133,DTCC00507754,1577004,46191
CHEMBL517970,P14780,,RWKHWCXMRSXBCY-LVZGIILASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19375915,ACTIVITY,,,,,,,,,,,,,,,,,Reduction of gelatinolytic activity of MMP9 in phorbol myristate acetate-stimulated human HT1080 cells at 40 and 60 ug/ml,Active,The inhibitory mechanism of a novel cationic glucosamine derivative against MMP-2 and MMP-9 expressions.,Bioorg. Med. Chem. Lett.,2009,19,10,"Mendis E, Kim MM, Rajapakse N, Kim SK",,578119,DTCT0024844,2884681,DTCC00544866,306697,34969
CHEMBL517970,P14780,,RWKHWCXMRSXBCY-LVZGIILASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19375915,FC,=,3,,,,,,,,,,,,,,,Inhibition of MMP9 gene promoter activity in phorbol myristate acetate-stimulated human HT1080 cells at 60 ug/ml by luciferase reporter gene assay relative to control,,The inhibitory mechanism of a novel cationic glucosamine derivative against MMP-2 and MMP-9 expressions.,Bioorg. Med. Chem. Lett.,2009,19,10,"Mendis E, Kim MM, Rajapakse N, Kim SK",,578125,DTCT0024844,2884689,DTCC00544866,306697,34969
CHEMBL517970,P14780,,RWKHWCXMRSXBCY-LVZGIILASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19375915,INHIBITION,=,50,%,,,,,,,,,,,,,,Inhibition of MMP9 gelatinolytic activity in phorbol myristate acetate-stimulated human HT1080 cells at 60 ug/ml by gelatin zymography relative to control,,The inhibitory mechanism of a novel cationic glucosamine derivative against MMP-2 and MMP-9 expressions.,Bioorg. Med. Chem. Lett.,2009,19,10,"Mendis E, Kim MM, Rajapakse N, Kim SK",,578121,DTCT0024844,2884684,DTCC00544866,306697,34969
CHEMBL517970,P14780,,RWKHWCXMRSXBCY-LVZGIILASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19375915,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of MMP9 in phorbol myristate acetate-stimulated human HT1080 cells by gelatin zymography relative to control,Active,The inhibitory mechanism of a novel cationic glucosamine derivative against MMP-2 and MMP-9 expressions.,Bioorg. Med. Chem. Lett.,2009,19,10,"Mendis E, Kim MM, Rajapakse N, Kim SK",,578117,DTCT0024844,2884683,DTCC00544866,306697,34969
CHEMBL517970,P14780,,RWKHWCXMRSXBCY-LVZGIILASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19375915,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of MMP9 gene promoter activity in phorbol myristate acetate-stimulated human HT1080 cells by luciferase reporter gene assay,Dose-dependent effect,The inhibitory mechanism of a novel cationic glucosamine derivative against MMP-2 and MMP-9 expressions.,Bioorg. Med. Chem. Lett.,2009,19,10,"Mendis E, Kim MM, Rajapakse N, Kim SK",,578123,DTCT0024844,2884691,DTCC00544866,306697,34969
CHEMBL517970,P14780,,RWKHWCXMRSXBCY-LVZGIILASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19375915,INHIBITION,,,,,cell_based,,,,,,,,,,,,Inhibition of MMP9 gelatinolytic activity in human HT1080 cells at upto 60 ug/ml by gelatin zymography relative to control,Not Active,The inhibitory mechanism of a novel cationic glucosamine derivative against MMP-2 and MMP-9 expressions.,Bioorg. Med. Chem. Lett.,2009,19,10,"Mendis E, Kim MM, Rajapakse N, Kim SK",,578144,DTCT0024844,2884709,DTCC00544866,306697,34969
CHEMBL51862,P14780,,DBYYJEGRUPLGLD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,14,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1681669,DTCC00201061,1261010,16216
CHEMBL519182,P14780,,QCRHPVVZVMWEGQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,INHIBITION,=,52,%,,,,,,,,,,,,,,Inhibition of MMP9 at 10 uM,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,492658,DTCT0024844,2456500,DTCC00546797,273422,32556
CHEMBL51966,P14780,,YNTPPOZAYYWSFD-SSDOTTSWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,=,100,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1466936,DTCC00197921,1693042,17283
CHEMBL520785,P14780,,VALKNOMNTXYCBM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,KI,=,100,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2457361,DTCC00115943,1535639,32556
CHEMBL521,P14780,IBUPROFEN,HEFNNWSXXWATRW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7323573,DTCC00141944,833161,46191
CHEMBL521,P14780,IBUPROFEN,HEFNNWSXXWATRW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7323574,DTCC00141944,833161,46191
CHEMBL52129,P14780,,WSGAVYSGAQDOGU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,>,2128,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1462196,DTCC00198187,75557,17283
CHEMBL521589,P14780,BAMBUTEROL,ANZXOIAKUNOVQU-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7266957,DTCC00514881,1318439,46191
CHEMBL521589,P14780,BAMBUTEROL,ANZXOIAKUNOVQU-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7266958,DTCC00514881,1318439,46191
CHEMBL521689,P14780,,NUJPTPCEVGHZJB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18442906,KI,=,124000,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.,Bioorg. Med. Chem. Lett.,2008,18,11,"Subramaniam R, Haldar MK, Tobwala S, Ganguly B, Srivastava DK, Mallik S",,552276,DTCT0024844,2558280,DTCC00541232,759013,28839
CHEMBL521716,P14780,,HKMHBYGNETWHNU-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18442906,INHIBITION,=,7.5,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 10 uM,,Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.,Bioorg. Med. Chem. Lett.,2008,18,11,"Subramaniam R, Haldar MK, Tobwala S, Ganguly B, Srivastava DK, Mallik S",,552277,DTCT0024844,2558338,DTCC00541355,2016080,28839
CHEMBL521719,P14780,,ZFHJWQWVJPMAIW-IRXDYDNUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19457660,IC50,=,577,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition.,Bioorg. Med. Chem. Lett.,2009,19,13,"Burns DM, Li YL, Shi E, He C, Xu M, Zhuo J, Zhang C, Qian DQ, Li Y, Wynn R, Covington MB, Katiyar K, Marando CA, Fridman JS, Scherle P, Friedman S, Metcalf B, Yao W",,523765,DTCT0024844,2828341,DTCC00554260,1427426,33677
CHEMBL521881,P14780,,KMXBOSHQPUWBNW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18442906,KI,=,7900,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.,Bioorg. Med. Chem. Lett.,2008,18,11,"Subramaniam R, Haldar MK, Tobwala S, Ganguly B, Srivastava DK, Mallik S",,552276,DTCT0024844,2558288,DTCC00541099,1917632,28839
CHEMBL52209,P14780,,QUKDWRYJPHUXQR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,8,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103267,DTCC00193427,1024887,43205
CHEMBL522573,P14780,,IOKFKKPJNRYPSH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18442906,KI,=,150,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.,Bioorg. Med. Chem. Lett.,2008,18,11,"Subramaniam R, Haldar MK, Tobwala S, Ganguly B, Srivastava DK, Mallik S",,552276,DTCT0024844,2558285,DTCC00541153,1821255,28839
CHEMBL523034,P14780,,MKAIHDAGQJQAHA-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19278250,IC50,=,1300,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,"A selective matrix metalloprotease 12 inhibitor for potential treatment of chronic obstructive pulmonary disease (COPD): discovery of (S)-2-(8-(methoxycarbonylamino)dibenzo[b,d]furan-3-sulfonamido)-3-methylbutanoic acid (MMP408).",J. Med. Chem.,2009,52,7,"Li W, Li J, Wu Y, Wu J, Hotchandani R, Cunningham K, McFadyen I, Bard J, Morgan P, Schlerman F, Xu X, Tam S, Goldman SJ, Williams C, Sypek J, Mansour TS",,566462,DTCT0024844,2482790,DTCC00534180,682924,33018
CHEMBL523076,P14780,,JQTQTEMWCRRECT-LLQWEQGGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19457660,IC50,=,1443,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition.,Bioorg. Med. Chem. Lett.,2009,19,13,"Burns DM, Li YL, Shi E, He C, Xu M, Zhuo J, Zhang C, Qian DQ, Li Y, Wynn R, Covington MB, Katiyar K, Marando CA, Fridman JS, Scherle P, Friedman S, Metcalf B, Yao W",,523765,DTCT0024844,2828342,DTCC00554323,1264840,33677
CHEMBL523956,P14780,,YGNQFXKRHBOPDC-CZYKHXBRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,KI,<,1,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2457514,DTCC00546724,1243693,32556
CHEMBL52423,P14780,,KFIXLPNCOAUSPO-CYBMUJFWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,=,3.6,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1475511,DTCC00198085,2044694,17283
CHEMBL52440,P14780,DEXTROMETHORPHAN,MKXZASYAUGDDCJ-NJAFHUGGSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7355162,DTCC00195499,315664,46191
CHEMBL52440,P14780,DEXTROMETHORPHAN,MKXZASYAUGDDCJ-NJAFHUGGSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7355163,DTCC00195499,315664,46191
CHEMBL524823,P14780,,NVYQSYIBQGEVEY-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18442906,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,Not Active,Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.,Bioorg. Med. Chem. Lett.,2008,18,11,"Subramaniam R, Haldar MK, Tobwala S, Ganguly B, Srivastava DK, Mallik S",,552276,DTCT0024844,2558310,DTCC00541300,694526,28839
CHEMBL52531,P14780,,WEACEEZKOJLZFG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,8,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1716534,DTCC00200795,161166,16216
CHEMBL52532,P14780,,ONOMIQQPBDQZDA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,29,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1686729,DTCC00200796,1423651,16216
CHEMBL526,P14780,PROPOFOL,OLBCVFGFOZPWHH-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7398661,DTCC00142061,51502,46191
CHEMBL526,P14780,PROPOFOL,OLBCVFGFOZPWHH-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7398662,DTCC00142061,51502,46191
CHEMBL526275,P14780,,MAGWNEHRCOWYCF-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18442906,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,Not Active,Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.,Bioorg. Med. Chem. Lett.,2008,18,11,"Subramaniam R, Haldar MK, Tobwala S, Ganguly B, Srivastava DK, Mallik S",,552276,DTCT0024844,2558308,DTCC00541356,1470931,28839
CHEMBL526460,P14780,,YPKIDRAXEHHNGA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18442906,KI,=,230,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.,Bioorg. Med. Chem. Lett.,2008,18,11,"Subramaniam R, Haldar MK, Tobwala S, Ganguly B, Srivastava DK, Mallik S",,552276,DTCT0024844,2558286,DTCC00541208,1885515,28839
CHEMBL52659,P14780,,HEHZCMROVKSJTK-LLVKDONJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,=,96,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1471732,DTCC00197898,29140,17283
CHEMBL527,P14780,PIROXICAM,QYSPLQLAKJAUJT-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7387520,DTCC00142164,866023,46191
CHEMBL527,P14780,PIROXICAM,QYSPLQLAKJAUJT-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7387521,DTCC00142164,866023,46191
CHEMBL52808,P14780,,FEFNNGHDRQMMNY-OAQYLSRUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,>,2128,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1452491,DTCC00198221,852750,17283
CHEMBL52815,P14780,,KDIMQQWECGDHDT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,>,2128,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1472984,DTCC00197982,690878,17283
CHEMBL52893,P14780,,WIOHNTSOYPKJIX-LLVKDONJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,=,1209,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1470454,DTCC00198181,497394,17283
CHEMBL529,P14780,AZITHROMYCIN,MQTOSJVFKKJCRP-BICOPXKESA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7272273,DTCC00142593,1512804,46191
CHEMBL529,P14780,AZITHROMYCIN,MQTOSJVFKKJCRP-BICOPXKESA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7272274,DTCC00142593,1512804,46191
CHEMBL52994,P14780,,NJSIDFBPVWKNNH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,15,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1689347,DTCC00201450,808248,16216
CHEMBL53009,P14780,,RTBPRRSADWSXAD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,22,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1720808,DTCC00200715,1773397,16216
CHEMBL53044,P14780,,WPXAJFJACNOICK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,8,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1715029,DTCC00200878,1681643,16216
CHEMBL53051,P14780,,KOFNJKLYWDTWHZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,14,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1681679,DTCC00200549,614602,16216
CHEMBL53055,P14780,,RNWFVTPNHGOAMY-GOSISDBHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,=,2128,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1472988,DTCC00198278,981637,17283
CHEMBL53091,P14780,,YTZCQIFAVXLXHV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,16,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1718064,DTCC00200970,1293404,16216
CHEMBL53094,P14780,,WYVILPRSBDCCKY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,29,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1712442,DTCC00201456,1423652,16216
CHEMBL531,P14780,PERGOLIDE,YEHCICAEULNIGD-MZMPZRCHSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7389211,DTCC00142656,1318444,46191
CHEMBL531,P14780,PERGOLIDE,YEHCICAEULNIGD-MZMPZRCHSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7389212,DTCC00142656,1318444,46191
CHEMBL53116,P14780,,JGJZJJQMNAKKDG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,21,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1711290,DTCC00201046,485829,16216
CHEMBL53123,P14780,,YGLAUESDHXXPSW-HXUWFJFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,>,2128,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1446407,DTCC00198248,593879,17283
CHEMBL532,P14780,ERYTHROMYCIN,ULGZDMOVFRHVEP-RWJQBGPGSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7336829,DTCC00142668,51467,46191
CHEMBL532,P14780,ERYTHROMYCIN,ULGZDMOVFRHVEP-RWJQBGPGSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7336830,DTCC00142668,51467,46191
CHEMBL53233,P14780,,DXGJDBTUJCUBRD-GFCCVEGCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,=,3,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1476620,DTCC00198100,1913977,17283
CHEMBL53250,P14780,,HTAGYDAMQNRLDD-JOCHJYFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,>,2128,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1463397,DTCC00198196,1305245,17283
CHEMBL534,P14780,KETOTIFEN,ZCVMWBYGMWKGHF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7407795,DTCC00142999,217580,46191
CHEMBL534,P14780,KETOTIFEN,ZCVMWBYGMWKGHF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7407796,DTCC00142999,217580,46191
CHEMBL53457,P14780,,AQKDLUIAUGFUEC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,17,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1711275,DTCC00201027,647325,16216
CHEMBL53463,P14780,DOXORUBICIN,AOJJSUZBOXZQNB-TZSSRYMLSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7325908,DTCC00196573,51466,46191
CHEMBL53463,P14780,DOXORUBICIN,AOJJSUZBOXZQNB-TZSSRYMLSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7325909,DTCC00196573,51466,46191
CHEMBL53643,P14780,,PFUFYTLQYUUPMX-GFCCVEGCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,<,2.1,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1475522,DTCC00198125,1239888,17283
CHEMBL538028,P14780,,ZBMBWHUMSXZQLX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9873598,IC50,=,157,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,The synthesis and biological activity of a novel series of diazepine MMP inhibitors.,Bioorg. Med. Chem. Lett.,1998,8,19,"Levin JI, DiJoseph JF, Killar LM, Sung A, Walter T, Sharr MA, Roth CE, Skotnicki JS, Albright JD",,105513,DTCT0024844,601983,DTCC00580479,2033969,2791
CHEMBL53840,P14780,,ZBXHSBNGFNIURJ-VXKWHMMOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,21,NM,,,,,,,,,,,,,,Compound was tested for its inhibitory activity against 92 kD gelatinase (MMP-9),,,Bioorg. Med. Chem. Lett.,1996,6,16,,,102114,DTCT0024844,1260597,DTCC00204106,1881963,1749
CHEMBL53847,P14780,,SKADGQGCAOBKKC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,3.1,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1696774,DTCC00200740,582202,16216
CHEMBL538881,P14780,,PLLAWDNBRCNJGX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19359184,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human MMP9 up to 100 uM by fluorescence peptide cleavage assay,Not Active,Structure-activity relationship studies of a novel series of anthrax lethal factor inhibitors.,Bioorg. Med. Chem.,2009,17,9,"Johnson SL, Chen LH, Barile E, Emdadi A, Sabet M, Yuan H, Wei J, Guiney D, Pellecchia M",,575334,DTCT0024844,2877489,DTCC00584492,1363011,34590
CHEMBL539171,P14780,,PTSHMCCZVCAMNJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831904,KI,=,0.31,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP-9)(gelatinase-B).,,New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.,J. Med. Chem.,2002,45,4,"Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H",,105387,DTCT0024844,1417577,DTCC00372443,531404,17147
CHEMBL53949,P14780,,FTUOECQUSPMQQZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,27,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1707057,DTCC00200918,1325929,16216
CHEMBL539683,P14780,,WJFKRCVNGHZYFA-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10649971,IC50,=,65000,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9 (MMP-9),,"Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.",J. Med. Chem.,2000,43,2,"O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H",,105233,DTCT0024844,904807,DTCC00186441,400504,15892
CHEMBL539787,P14780,,WNDMJNCVTIBVCL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9873598,IC50,=,60,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,The synthesis and biological activity of a novel series of diazepine MMP inhibitors.,Bioorg. Med. Chem. Lett.,1998,8,19,"Levin JI, DiJoseph JF, Killar LM, Sung A, Walter T, Sharr MA, Roth CE, Skotnicki JS, Albright JD",,105513,DTCT0024844,591472,DTCC00580203,1002985,2791
CHEMBL539930,P14780,,LNJYGNLGJFKFCM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17981034,IC50,=,4.2,NM,,,,,,,,,,,,,,Inhibition of MMP9,,1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.,Bioorg. Med. Chem. Lett.,2008,18,1,"Zhang YM, Fan X, Chakaravarty D, Xiang B, Scannevin RH, Huang Z, Ma J, Burke SL, Karnachi P, Rhodes KJ, Jackson PF",,469432,DTCT0024844,2289310,DTCC00501228,1841595,25715
CHEMBL54,P14780,HALOPERIDOL,LNEPOXFFQSENCJ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7336241,DTCC00135385,51476,46191
CHEMBL54,P14780,HALOPERIDOL,LNEPOXFFQSENCJ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7336242,DTCC00135385,51476,46191
CHEMBL54021,P14780,,WBMFTZHBDMFDSO-MRVPVSSYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,=,104,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1482839,DTCC00197953,593878,17283
CHEMBL540445,P14780,PARTHENOLIDE,KTEXNACQROZXEV-SLXBATTESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7384754,DTCC00556195,574624,46191
CHEMBL540445,P14780,PARTHENOLIDE,KTEXNACQROZXEV-SLXBATTESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7384755,DTCC00556195,574624,46191
CHEMBL54049,P14780,,XGAYQDWZIPRBPF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,9,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103200,DTCC00200085,1445792,43205
CHEMBL54054,P14780,,FEWWJFPIJXNCFE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,0.8,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1718069,DTCC00201389,96316,16216
CHEMBL540952,P14780,(CYCLOPROPYLAMINO)CARBONYLPHOSPHONIC ACID,XNEFJXZBPPJDHR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15139760,IC50,>,100000,NM,,,,,,,,,,,,,,In vitro inhibitory activity against recombinant matrix metalloprotease-9 was determined,,"Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.",J. Med. Chem.,2004,47,11,"Breuer E, Salomon CJ, Katz Y, Chen W, Lu S, Röschenthaler GV, Hadar R, Reich R",,105518,DTCT0024844,1298912,DTCC00261593,1305900,17838
CHEMBL541,P14780,BENZOIC ACID,WPYMKLBDIGXBTP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7272515,DTCC00143343,833157,46191
CHEMBL541,P14780,BENZOIC ACID,WPYMKLBDIGXBTP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7272516,DTCC00143343,833157,46191
CHEMBL54126,P14780,NEOSTIGMINE BROMIDE,LULNWZDBKTWDGK-UHFFFAOYSA-M,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7375343,DTCC00197200,1027056,46191
CHEMBL54126,P14780,NEOSTIGMINE BROMIDE,LULNWZDBKTWDGK-UHFFFAOYSA-M,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7375344,DTCC00197200,1027056,46191
CHEMBL54176,P14780,,INYTUGGDZCKECJ-KBPBESRZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,82,NM,,,,,,,,,,,,,,Compound was tested for its inhibitory activity against 92 kD gelatinase (MMP-9),,,Bioorg. Med. Chem. Lett.,1996,6,16,,,102114,DTCT0024844,1264191,DTCC00203346,1785079,1749
CHEMBL542068,P14780,,KEHWHWRDWNFHCR-HWKASLJMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10340614,KI,=,12.8,NM,,,,,,,,,,,,,,"Inhibition of MMP-9 (matrix metalloprotease-9, gelatinase B)",,Macrocyclic hydroxamate inhibitors of matrix metalloproteinases and TNF-alpha production.,Bioorg. Med. Chem. Lett.,1999,9,9,"Cherney RJ, Wang L, Meyer DT, Xue CB, Arner EC, Copeland RA, Covington MB, Hardman KD, Wasserman ZR, Jaffee BD, Decicco CP",,102117,DTCT0024844,933784,DTCC00573209,1308445,3648
CHEMBL542088,P14780,,YHLIANIUQRLCCV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11378378,IC50,=,15,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2001,11,11,"Baxter AD, Bhogal R, Bird J, Keily JF, Manallack DT, Montana JG, Owen DA, Pitt WR, Watson RJ, Wills RE",,105531,DTCT0024844,1042185,DTCC00573690,1099676,4214
CHEMBL54292,P14780,,WJPORLWHPJGLSC-HSZRJFAPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,>,2128,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1459477,DTCC00198035,916619,17283
CHEMBL54406,P14780,,UTVAYVOWTJFEEU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,21,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1711295,DTCC00200736,1488101,16216
CHEMBL54436,P14780,,RCGPSTRFXVIUQB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,2.8,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1712496,DTCC00201253,1391445,16216
CHEMBL54440,P14780,MEVASTATIN,AJLFOPYRIVGYMJ-INTXDZFKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7438898,DTCC00201440,51490,46191
CHEMBL54440,P14780,MEVASTATIN,AJLFOPYRIVGYMJ-INTXDZFKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7438899,DTCC00201440,51490,46191
CHEMBL54483,P14780,,CNZGQRARNYMASL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,1,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1704476,DTCC00200539,518045,16216
CHEMBL545,P14780,ALCOHOL,LFQSCWFLJHTTHZ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7332685,DTCC00143522,1416029,46191
CHEMBL545,P14780,ALCOHOL,LFQSCWFLJHTTHZ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7332686,DTCC00143522,1416029,46191
CHEMBL54501,P14780,,HHSADBHNZPOTTJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,33,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1698026,DTCC00200582,1132088,16216
CHEMBL54535,P14780,,VURZBHKGMIEEFK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,1.4,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1691942,DTCC00201047,969874,16216
CHEMBL54566,P14780,,IYEVXJPUTMBOTO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,28,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1696759,DTCC00200735,808247,16216
CHEMBL54617,P14780,,DFPDFXUEOXPMIV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,9,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1689358,DTCC00200815,1067099,16216
CHEMBL54621,P14780,,ACSSJLXQNWFMSO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,3,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1711285,DTCC00201400,1902622,16216
CHEMBL54663,P14780,,MAPLEBZZVBOXKC-OAQYLSRUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12723945,KI,=,347,NM,,,,,,,,,,,,,,In vitro inhibitory activity against broad spectrum matrix metalloprotease-9 (MMP-9),,"Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.",J. Med. Chem.,2003,46,10,"Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT, Wasserman ZR, Hardman KD, Liu RQ, Covington MB, Qian M, Mandlekar S, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105385,DTCT0024844,1468123,DTCC00198092,1913978,17283
CHEMBL54697,P14780,,SESYXDSEOCRODR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,12,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1680260,DTCC00201436,193005,16216
CHEMBL547,P14780,ISOTRETINOIN,SHGAZHPCJJPHSC-XFYACQKRSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7409724,DTCC00143769,930080,46191
CHEMBL547,P14780,ISOTRETINOIN,SHGAZHPCJJPHSC-XFYACQKRSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7409725,DTCC00143769,930080,46191
CHEMBL549,P14780,CITALOPRAM,WSEQXVZVJXJVFP-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7354165,DTCC00144121,444637,46191
CHEMBL549,P14780,CITALOPRAM,WSEQXVZVJXJVFP-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7354166,DTCC00144121,444637,46191
CHEMBL54904,P14780,,GHHVNOZFZMDYFQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,1.3,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1688121,DTCC00200547,1163303,16216
CHEMBL54915,P14780,,PCQHVURJJBFBQG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,7,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1691937,DTCC00200608,711539,16216
CHEMBL54965,P14780,,HVHBPSLGXXXKOR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,6,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1708469,DTCC00200812,969876,16216
CHEMBL54981,P14780,,YMYDSTVSNKTLJM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,16,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1681674,DTCC00200987,1293405,16216
CHEMBL549884,P14780,,FXHXSGLQLDHFTR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19359184,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human MMP9 up to 100 uM by fluorescence peptide cleavage assay,Not Active,Structure-activity relationship studies of a novel series of anthrax lethal factor inhibitors.,Bioorg. Med. Chem.,2009,17,9,"Johnson SL, Chen LH, Barile E, Emdadi A, Sabet M, Yuan H, Wei J, Guiney D, Pellecchia M",,575334,DTCT0024844,2877498,DTCC00590661,1745708,34590
CHEMBL55,P14780,PENTAMIDINE,XDRYMKDFEDOLFX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7380544,DTCC00135468,51498,46191
CHEMBL55,P14780,PENTAMIDINE,XDRYMKDFEDOLFX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7380545,DTCC00135468,51498,46191
CHEMBL550038,P14780,,FWPVXLYOKAOERT-SFHVURJKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19725580,IC50,=,318,NM,,,,,,,,,,,,,,Inhibition of human MMP9,,Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma.,J. Med. Chem.,2009,52,17,"Li W, Li J, Wu Y, Rancati F, Vallese S, Raveglia L, Wu J, Hotchandani R, Fuller N, Cunningham K, Morgan P, Fish S, Krykbaev R, Xu X, Tam S, Goldman SJ, Abraham W, Williams C, Sypek J, Mansour TS",,579258,DTCT0024844,2894757,DTCC00589403,941987,34869
CHEMBL550081,P14780,,RPWGPXSVYLHGRZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19606871,IC50,=,77,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.",J. Med. Chem.,2009,52,15,"Nuti E, Casalini F, Avramova SI, Santamaria S, Cercignani G, Marinelli L, La Pietra V, Novellino E, Orlandini E, Nencetti S, Tuccinardi T, Martinelli A, Lim NH, Visse R, Nagase H, Rossello A",,571085,DTCT0024844,2859478,DTCC00590514,489960,34421
CHEMBL550148,P14780,,NKGRTRASISLCCZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19606871,IC50,=,34,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.",J. Med. Chem.,2009,52,15,"Nuti E, Casalini F, Avramova SI, Santamaria S, Cercignani G, Marinelli L, La Pietra V, Novellino E, Orlandini E, Nencetti S, Tuccinardi T, Martinelli A, Lim NH, Visse R, Nagase H, Rossello A",,571085,DTCT0024844,2859477,DTCC00592085,1588878,34421
CHEMBL550148,P14780,,NKGRTRASISLCCZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20180536,IC50,=,34,NM,,,,,,,,,,,,,,Inhibition of MMP9 by fluorometric assay,,Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.,J. Med. Chem.,2010,53,6,"Nuti E, Casalini F, Avramova SI, Santamaria S, Fabbi M, Ferrini S, Marinelli L, La Pietra V, Limongelli V, Novellino E, Cercignani G, Orlandini E, Nencetti S, Rossello A",,624094,DTCT0024844,3285999,DTCC00592085,1601175,38228
CHEMBL550350,P14780,,DKTYDWAJILHINP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19606871,IC50,=,1100,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.",J. Med. Chem.,2009,52,15,"Nuti E, Casalini F, Avramova SI, Santamaria S, Cercignani G, Marinelli L, La Pietra V, Novellino E, Orlandini E, Nencetti S, Tuccinardi T, Martinelli A, Lim NH, Visse R, Nagase H, Rossello A",,571085,DTCT0024844,2859481,DTCC00592090,1653714,34421
CHEMBL550548,P14780,,UTCUOTDVVXFCLJ-AREMUKBSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19606871,IC50,=,69,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.",J. Med. Chem.,2009,52,15,"Nuti E, Casalini F, Avramova SI, Santamaria S, Cercignani G, Marinelli L, La Pietra V, Novellino E, Orlandini E, Nencetti S, Tuccinardi T, Martinelli A, Lim NH, Visse R, Nagase H, Rossello A",,571085,DTCT0024844,2859488,DTCC00592094,327760,34421
CHEMBL550628,P14780,,FRFSAUPOCJTACG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19606871,IC50,=,4400,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.",J. Med. Chem.,2009,52,15,"Nuti E, Casalini F, Avramova SI, Santamaria S, Cercignani G, Marinelli L, La Pietra V, Novellino E, Orlandini E, Nencetti S, Tuccinardi T, Martinelli A, Lim NH, Visse R, Nagase H, Rossello A",,571085,DTCT0024844,2859484,DTCC00589012,1038878,34421
CHEMBL550961,P14780,DIAZEPINOMICIN,SALVHVNECODMJP-GNUCVDFRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20056543,IC50,=,0.6,UG.ML-1,,,,,,,,,,,,,,Inhibition of MMP9,,Anti-invasive and anti-angiogenic activities of naturally occurring dibenzodiazepine BU-4664L and its derivatives.,Bioorg. Med. Chem. Lett.,2010,20,3,"Miyanaga S, Sakurai H, Saiki I, Onaka H, Igarashi Y",,608223,DTCT0024844,3195701,DTCC00592150,501978,37479
CHEMBL55107,P14780,,OPYOHFRGHGDNSJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,43,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1716529,DTCC00201049,614603,16216
CHEMBL55110,P14780,,UGMRVUAZVAXFHK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,2,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1693206,DTCC00201048,323389,16216
CHEMBL55110,P14780,,UGMRVUAZVAXFHK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,2,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1627931,DTCC00201048,336295,15919
CHEMBL55110,P14780,,UGMRVUAZVAXFHK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,2,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258492,DTCC00201048,326643,24803
CHEMBL55154,P14780,,HIWQTXDWQYKMGH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,9,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1686724,DTCC00200813,1805903,16216
CHEMBL55236,P14780,,UJKQHAYQMMMAEL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,44,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1699205,DTCC00201249,1227975,16216
CHEMBL553025,P14780,VINORELBINE BASE,GBABOYUKABKIAF-IELIFDKJSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7445880,DTCC00587683,1027061,46191
CHEMBL553025,P14780,VINORELBINE BASE,GBABOYUKABKIAF-IELIFDKJSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7445881,DTCC00587683,1027061,46191
CHEMBL55310,P14780,N-HYDROXY-BENZENESULFONAMIDE,BRMDATNYMUMZLN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,78000,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1626743,DTCC01740306,31107,15919
CHEMBL55371,P14780,,IXFMBXNLOHKCPT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24071448,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain (unknown origin) using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured after 2 to 4 hrs by fluorometric assay,,Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.,Bioorg. Med. Chem.,2013,21,21,"Tauro M, Laghezza A, Loiodice F, Agamennone M, Campestre C, Tortorella P",,990168,DTCT0024844,12628996,DTCC00200900,383980,56259
CHEMBL554269,P14780,,OBHHLEXVYGNCHI-INFYBVPRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19093877,ACTIVITY,,,,,,,,,,,,,,,,,Binding affinity to MMP9 assessed as enzyme mediated cleavage of compound by measuring increase in fluorescence after 16 hrs by HPLC-MS,Not Active,Photodynamic molecular beacon triggered by fibroblast activation protein on cancer-associated fibroblasts for diagnosis and treatment of epithelial cancers.,J. Med. Chem.,2009,52,2,"Lo PC, Chen J, Stefflova K, Warren MS, Navab R, Bandarchi B, Mullins S, Tsao M, Cheng JD, Zheng G",,495039,DTCT0024844,2594658,DTCC00582506,1049706,32091
CHEMBL55521,P14780,,MOHDKNTXJIGORP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,0.7,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1698031,DTCC00200537,290900,16216
CHEMBL55522,P14780,,HGCCQMHYESJBML-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,1.6,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1715039,DTCC00200741,1741621,16216
CHEMBL55561,P14780,,RGDPJPMKLABBRX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,23,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1699220,DTCC00200776,1325928,16216
CHEMBL555957,P14780,,HIEBUDJHJYAXFV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19359184,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human MMP9 up to 100 uM by fluorescence peptide cleavage assay,Not Active,Structure-activity relationship studies of a novel series of anthrax lethal factor inhibitors.,Bioorg. Med. Chem.,2009,17,9,"Johnson SL, Chen LH, Barile E, Emdadi A, Sabet M, Yuan H, Wei J, Guiney D, Pellecchia M",,575334,DTCT0024844,2877497,DTCC00587576,68229,34590
CHEMBL556645,P14780,,KNWGEVZOUCQOLE-VWLOTQADSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19625186,IC50,=,24000,NM,,,,,,,,,,,,,,Inhibition of MMP1,,"3,4-Disubstituted benzofuran P1' MMP-13 inhibitors: optimization of selectivity and reduction of protein binding.",Bioorg. Med. Chem. Lett.,2009,19,16,"Li W, Hu Y, Li J, Thomason JR, DeVincentis D, Du X, Wu J, Hotchandani R, Rush TS, Skotnicki JS, Tam S, Chockalingam PS, Morris EA, Levin JI",,581473,DTCT0024844,2904570,DTCC00593100,651477,35265
CHEMBL556645,P14780,,KNWGEVZOUCQOLE-VWLOTQADSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19625186,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"3,4-Disubstituted benzofuran P1' MMP-13 inhibitors: optimization of selectivity and reduction of protein binding.",Bioorg. Med. Chem. Lett.,2009,19,16,"Li W, Hu Y, Li J, Thomason JR, DeVincentis D, Du X, Wu J, Hotchandani R, Rush TS, Skotnicki JS, Tam S, Chockalingam PS, Morris EA, Levin JI",,581472,DTCT0024844,2904568,DTCC00593100,651477,35265
CHEMBL55744,P14780,,BITXXJKMASUYME-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,14,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1690792,DTCC00200914,1805906,16216
CHEMBL557555,P14780,CIPROFIBRATE,KPSRODZRAIWAKH-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7371482,DTCC00590844,1447879,46191
CHEMBL557555,P14780,CIPROFIBRATE,KPSRODZRAIWAKH-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7371483,DTCC00590844,1447879,46191
CHEMBL558,P14780,MEXILETINE,VLPIATFUUWWMKC-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7409023,DTCC00145505,1351114,46191
CHEMBL558,P14780,MEXILETINE,VLPIATFUUWWMKC-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7409024,DTCC00145505,1351114,46191
CHEMBL558100,P14780,,KOTPGHDHHVOARW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19359184,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human MMP9 up to 100 uM by fluorescence peptide cleavage assay,Not Active,Structure-activity relationship studies of a novel series of anthrax lethal factor inhibitors.,Bioorg. Med. Chem.,2009,17,9,"Johnson SL, Chen LH, Barile E, Emdadi A, Sabet M, Yuan H, Wei J, Guiney D, Pellecchia M",,575334,DTCT0024844,2877499,DTCC00593863,327781,34590
CHEMBL558549,P14780,BRARTEMICIN,UZVUYEBJQAEAGM-SHSJKSAASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19358565,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of MMP9,Not Evaluated,"Brartemicin, an inhibitor of tumor cell invasion from the actinomycete Nonomuraea sp.",J. Nat. Prod.,2009,72,5,"Igarashi Y, Mogi T, Yanase S, Miyanaga S, Fujita T, Sakurai H, Saiki I, Ohsaki A",,576354,DTCT0024844,2861036,DTCC00585890,1726653,34693
CHEMBL558551,P14780,(R)-THALIDOMIDE,UEJJHQNACJXSKW-SECBINFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7302790,DTCC00022784,1220271,46191
CHEMBL558551,P14780,(R)-THALIDOMIDE,UEJJHQNACJXSKW-SECBINFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7302791,DTCC00022784,1220271,46191
CHEMBL55907,P14780,,JVBPIOHSXSYBRG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,25,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1711270,DTCC00201010,225329,16216
CHEMBL559147,P14780,Y-27632,IYOZTVGMEWJPKR-IJLUTSLNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7451464,DTCC00589732,1798420,46191
CHEMBL559147,P14780,Y-27632,IYOZTVGMEWJPKR-IJLUTSLNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7451465,DTCC00589732,1798420,46191
CHEMBL55931,P14780,,RROGIBUBPIHVIJ-KBPBESRZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,41,NM,,,,,,,,,,,,,,Compound was tested for its inhibitory activity against 92 kD gelatinase (MMP-9),,,Bioorg. Med. Chem. Lett.,1996,6,16,,,102114,DTCT0024844,1278940,DTCC00204103,1563976,1749
CHEMBL55984,P14780,,XCCIACQOXSWRJQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,2.5,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1712512,DTCC00200742,937807,16216
CHEMBL560224,P14780,,MLMHMIQLMFUEPG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19359184,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human MMP9 up to 100 uM by fluorescence peptide cleavage assay,Not Active,Structure-activity relationship studies of a novel series of anthrax lethal factor inhibitors.,Bioorg. Med. Chem.,2009,17,9,"Johnson SL, Chen LH, Barile E, Emdadi A, Sabet M, Yuan H, Wei J, Guiney D, Pellecchia M",,575334,DTCT0024844,2877501,DTCC00587567,2004713,34590
CHEMBL56025,P14780,,ULPVLGUDYQAPPV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,2.5,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1707072,DTCC00201417,1488102,16216
CHEMBL56065,P14780,,NEUXHEKNAOUEQU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,11,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1698021,DTCC00200847,1681642,16216
CHEMBL560837,P14780,,LBKCSOUMADYGHM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19606871,IC50,=,160,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.",J. Med. Chem.,2009,52,15,"Nuti E, Casalini F, Avramova SI, Santamaria S, Cercignani G, Marinelli L, La Pietra V, Novellino E, Orlandini E, Nencetti S, Tuccinardi T, Martinelli A, Lim NH, Visse R, Nagase H, Rossello A",,571085,DTCT0024844,2859479,DTCC00122971,1717205,34421
CHEMBL561,P14780,LOMEFLOXACIN,ZEKZLJVOYLTDKK-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7425348,DTCC00145731,1480346,46191
CHEMBL561,P14780,LOMEFLOXACIN,ZEKZLJVOYLTDKK-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7425349,DTCC00145731,1480346,46191
CHEMBL561036,P14780,,HZTQDRLCDGHQSA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19606871,IC50,=,44,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.",J. Med. Chem.,2009,52,15,"Nuti E, Casalini F, Avramova SI, Santamaria S, Cercignani G, Marinelli L, La Pietra V, Novellino E, Orlandini E, Nencetti S, Tuccinardi T, Martinelli A, Lim NH, Visse R, Nagase H, Rossello A",,571085,DTCT0024844,2859480,DTCC00122972,748051,34421
CHEMBL561038,P14780,,WVAIZSKMOMDPIT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19606871,IC50,=,110,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.",J. Med. Chem.,2009,52,15,"Nuti E, Casalini F, Avramova SI, Santamaria S, Cercignani G, Marinelli L, La Pietra V, Novellino E, Orlandini E, Nencetti S, Tuccinardi T, Martinelli A, Lim NH, Visse R, Nagase H, Rossello A",,571085,DTCT0024844,2859483,DTCC00122975,910381,34421
CHEMBL561039,P14780,,KJDPTHLLJDQIMT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19606871,IC50,=,680,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.",J. Med. Chem.,2009,52,15,"Nuti E, Casalini F, Avramova SI, Santamaria S, Cercignani G, Marinelli L, La Pietra V, Novellino E, Orlandini E, Nencetti S, Tuccinardi T, Martinelli A, Lim NH, Visse R, Nagase H, Rossello A",,571085,DTCT0024844,2859486,DTCC00122976,715703,34421
CHEMBL561625,P14780,,PZJJOMPTIHBGHO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19606871,IC50,=,34,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.",J. Med. Chem.,2009,52,15,"Nuti E, Casalini F, Avramova SI, Santamaria S, Cercignani G, Marinelli L, La Pietra V, Novellino E, Orlandini E, Nencetti S, Tuccinardi T, Martinelli A, Lim NH, Visse R, Nagase H, Rossello A",,571085,DTCT0024844,2859476,DTCC00587403,1492221,34421
CHEMBL561625,P14780,,PZJJOMPTIHBGHO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20180536,IC50,=,34,NM,,,,,,,,,,,,,,Inhibition of MMP9 by fluorometric assay,,Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.,J. Med. Chem.,2010,53,6,"Nuti E, Casalini F, Avramova SI, Santamaria S, Fabbi M, Ferrini S, Marinelli L, La Pietra V, Limongelli V, Novellino E, Cercignani G, Orlandini E, Nencetti S, Rossello A",,624094,DTCT0024844,3285993,DTCC00587403,1504395,38228
CHEMBL561630,P14780,,JSQUVSOHRBZSNW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19606871,IC50,=,250,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.",J. Med. Chem.,2009,52,15,"Nuti E, Casalini F, Avramova SI, Santamaria S, Cercignani G, Marinelli L, La Pietra V, Novellino E, Orlandini E, Nencetti S, Tuccinardi T, Martinelli A, Lim NH, Visse R, Nagase H, Rossello A",,571085,DTCT0024844,2859487,DTCC00587413,489961,34421
CHEMBL562,P14780,GRISEOFULVIN,DDUHZTYCFQRHIY-RBHXEPJQSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7308327,DTCC00145751,800577,46191
CHEMBL562,P14780,GRISEOFULVIN,DDUHZTYCFQRHIY-RBHXEPJQSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7308328,DTCC00145751,800577,46191
CHEMBL562003,P14780,,FSIUHCOQNBURSE-VWLOTQADSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19625186,IC50,=,12000,NM,,,,,,,,,,,,,,Inhibition of MMP1,,"3,4-Disubstituted benzofuran P1' MMP-13 inhibitors: optimization of selectivity and reduction of protein binding.",Bioorg. Med. Chem. Lett.,2009,19,16,"Li W, Hu Y, Li J, Thomason JR, DeVincentis D, Du X, Wu J, Hotchandani R, Rush TS, Skotnicki JS, Tam S, Chockalingam PS, Morris EA, Levin JI",,581473,DTCT0024844,2904569,DTCC00586782,1071452,35265
CHEMBL562003,P14780,,FSIUHCOQNBURSE-VWLOTQADSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19625186,IC50,>,10000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"3,4-Disubstituted benzofuran P1' MMP-13 inhibitors: optimization of selectivity and reduction of protein binding.",Bioorg. Med. Chem. Lett.,2009,19,16,"Li W, Hu Y, Li J, Thomason JR, DeVincentis D, Du X, Wu J, Hotchandani R, Rush TS, Skotnicki JS, Tam S, Chockalingam PS, Morris EA, Levin JI",,581472,DTCT0024844,2904567,DTCC00586782,1071452,35265
CHEMBL56289,P14780,,IQTIGUJOCAYBRM-HOTGVXAUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,24,NM,,,,,,,,,,,,,,Compound was tested for its inhibitory activity against 92 kD gelatinase (MMP-9),,,Bioorg. Med. Chem. Lett.,1996,6,16,,,102114,DTCT0024844,1254571,DTCC00203835,1752984,1749
CHEMBL563,P14780,FLURBIPROFEN,SYTBZMRGLBWNTM-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7303528,DTCC00145756,1447882,46191
CHEMBL563,P14780,FLURBIPROFEN,SYTBZMRGLBWNTM-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7303529,DTCC00145756,1447882,46191
CHEMBL563026,P14780,,MRYXWLVKWYVRPC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19606871,IC50,=,3200,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.",J. Med. Chem.,2009,52,15,"Nuti E, Casalini F, Avramova SI, Santamaria S, Cercignani G, Marinelli L, La Pietra V, Novellino E, Orlandini E, Nencetti S, Tuccinardi T, Martinelli A, Lim NH, Visse R, Nagase H, Rossello A",,571085,DTCT0024844,2859485,DTCC00584342,327759,34421
CHEMBL56337,P14780,EPALRESTAT,CHNUOJQWGUIOLD-NFZZJPOKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7336765,DTCC00204779,2025636,46191
CHEMBL56337,P14780,EPALRESTAT,CHNUOJQWGUIOLD-NFZZJPOKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7336766,DTCC00204779,2025636,46191
CHEMBL56367,P14780,NIMESULIDE,HYWYRSMBCFDLJT-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7379782,DTCC00201992,736262,46191
CHEMBL56367,P14780,NIMESULIDE,HYWYRSMBCFDLJT-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7379783,DTCC00201992,736262,46191
CHEMBL563679,P14780,,ZQBRASLBYJYZLM-CMDGGOBGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19606871,IC50,=,2300,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.",J. Med. Chem.,2009,52,15,"Nuti E, Casalini F, Avramova SI, Santamaria S, Cercignani G, Marinelli L, La Pietra V, Novellino E, Orlandini E, Nencetti S, Tuccinardi T, Martinelli A, Lim NH, Visse R, Nagase H, Rossello A",,571085,DTCT0024844,2859482,DTCC00587409,425709,34421
CHEMBL564,P14780,PROMAZINE,ZGUGWUXLJSTTMA-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7383500,DTCC00145816,413977,46191
CHEMBL564,P14780,PROMAZINE,ZGUGWUXLJSTTMA-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7383501,DTCC00145816,413977,46191
CHEMBL564201,P14780,6-AZAURIDINE,WYXSYVWAUAUWLD-SHUUEZRQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7269469,DTCC00485142,768474,46191
CHEMBL564201,P14780,6-AZAURIDINE,WYXSYVWAUAUWLD-SHUUEZRQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7269470,DTCC00485142,768474,46191
CHEMBL56498,P14780,,CSPDSJARPZQPMQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,1.3,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1696769,DTCC00200743,1584624,16216
CHEMBL565,P14780,CLOFIBRATE,KNHUKKLJHYUCFP-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7358595,DTCC00145838,1641847,46191
CHEMBL565,P14780,CLOFIBRATE,KNHUKKLJHYUCFP-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7358596,DTCC00145838,1641847,46191
CHEMBL56564,P14780,TROPISETRON,ZNRGQMMCGHDTEI-ITGUQSILSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7440741,DTCC00204705,736266,46191
CHEMBL56564,P14780,TROPISETRON,ZNRGQMMCGHDTEI-ITGUQSILSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7440742,DTCC00204705,736266,46191
CHEMBL566233,P14780,,YLTJCMLZAIRVFF-FHWLQOOXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19635666,IC50,>,5000,NM,,,,,,,,,,,,,,Inhibition of MMP-9,,Discovery of novel selective HER-2 sheddase inhibitors through optimization of P1 moiety.,Bioorg. Med. Chem. Lett.,2009,19,17,"Li YL, Shi E, Burns D, Li Y, Covington MB, Pan M, Scherle P, Friedman S, Metcalf B, Yao W",,598558,DTCT0024844,3101270,DTCC00607716,1745918,36106
CHEMBL566534,P14780,ARTEMETHER,SXYIRMFQILZOAM-HVNFFKDJSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7267947,DTCC00600123,736254,46191
CHEMBL566534,P14780,ARTEMETHER,SXYIRMFQILZOAM-HVNFFKDJSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7267948,DTCC00600123,736254,46191
CHEMBL567,P14780,PERPHENAZINE,RGCVKNLCSQQDEP-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7397779,DTCC00145901,1798415,46191
CHEMBL567,P14780,PERPHENAZINE,RGCVKNLCSQQDEP-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7397780,DTCC00145901,1798415,46191
CHEMBL567597,P14780,ARTEMISININ,BLUAFEHZUWYNDE-DKGJTOOQSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7270604,DTCC00601707,1960072,46191
CHEMBL567597,P14780,ARTEMISININ,BLUAFEHZUWYNDE-DKGJTOOQSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7270605,DTCC00601707,1960072,46191
CHEMBL567893,P14780,GRASSYSTATIN A,JZYWSTGTBRHGTL-BIXXXADNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19715320,ACTIVITY,=,81,%,,,,,,,,,,,,,,Inhibition of MMP9 assessed as residual activity at 10 uM after 10 to 15 mins by fluorescence assay relative to control,,"Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.",J. Med. Chem.,2009,52,18,"Kwan JC, Eksioglu EA, Liu C, Paul VJ, Luesch H",,600018,DTCT0024844,3096286,DTCC00604795,1039098,36236
CHEMBL567893,P14780,GRASSYSTATIN A,JZYWSTGTBRHGTL-BIXXXADNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19715320,IC50,=,5000,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain after 10 to 15 mins by fluorescence assay,,"Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.",J. Med. Chem.,2009,52,18,"Kwan JC, Eksioglu EA, Liu C, Paul VJ, Luesch H",,600075,DTCT0024844,3096343,DTCC00604795,1039098,36236
CHEMBL567940,P14780,,VPNMZNYQFRFELQ-BZSNNMDCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19635666,IC50,=,5000,NM,,,,,,,,,,,,,,Inhibition of MMP-9,,Discovery of novel selective HER-2 sheddase inhibitors through optimization of P1 moiety.,Bioorg. Med. Chem. Lett.,2009,19,17,"Li YL, Shi E, Burns D, Li Y, Covington MB, Pan M, Scherle P, Friedman S, Metcalf B, Yao W",,598558,DTCT0024844,3101276,DTCC00607747,1907035,36106
CHEMBL56821,P14780,,LNAFKWVAFRZAIO-RYUDHWBXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,71,NM,,,,,,,,,,,,,,Compound was tested for its inhibitory activity against 92 kD gelatinase (MMP-9),,,Bioorg. Med. Chem. Lett.,1996,6,16,,,102114,DTCT0024844,1276488,DTCC00204161,269628,1749
CHEMBL568346,P14780,,JRJYBZYDJRBFTK-FHWLQOOXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19635666,IC50,>,5000,NM,,,,,,,,,,,,,,Inhibition of MMP-9,,Discovery of novel selective HER-2 sheddase inhibitors through optimization of P1 moiety.,Bioorg. Med. Chem. Lett.,2009,19,17,"Li YL, Shi E, Burns D, Li Y, Covington MB, Pan M, Scherle P, Friedman S, Metcalf B, Yao W",,598558,DTCT0024844,3101271,DTCC00607719,780275,36106
CHEMBL56837,P14780,,WLWNRAWQDZRXMB-QBPKDAKJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15055993,KI,=,0.097,NM,,,,,,,,,,,,,,Inhibition of human recombinant matrix metalloprotease 9,,Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents.,J. Med. Chem.,2004,47,8,"Moriyama H, Tsukida T, Inoue Y, Yokota K, Yoshino K, Kondo H, Miura N, Nishimura S",,105384,DTCT0024844,1382073,DTCC00205431,1163372,18075
CHEMBL569,P14780,PROCAINE,MFDFERRIHVXMIY-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7396384,DTCC00145963,930084,46191
CHEMBL569,P14780,PROCAINE,MFDFERRIHVXMIY-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7396385,DTCC00145963,930084,46191
CHEMBL569369,P14780,,VLHQDFRXDXPKGX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19359184,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human MMP9 up to 100 uM by fluorescence peptide cleavage assay,Not Active,Structure-activity relationship studies of a novel series of anthrax lethal factor inhibitors.,Bioorg. Med. Chem.,2009,17,9,"Johnson SL, Chen LH, Barile E, Emdadi A, Sabet M, Yuan H, Wei J, Guiney D, Pellecchia M",,575334,DTCT0024844,2877500,DTCC00589175,554301,34590
CHEMBL569370,P14780,,FHAKHNFPYWASFY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19359184,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human MMP9 up to 100 uM by fluorescence peptide cleavage assay,Not Active,Structure-activity relationship studies of a novel series of anthrax lethal factor inhibitors.,Bioorg. Med. Chem.,2009,17,9,"Johnson SL, Chen LH, Barile E, Emdadi A, Sabet M, Yuan H, Wei J, Guiney D, Pellecchia M",,575334,DTCT0024844,2877496,DTCC00589178,2069298,34590
CHEMBL569388,P14780,,YDJAXPJDHWQNLF-YPJRHXLCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19635666,IC50,=,498,NM,,,,,,,,,,,,,,Inhibition of MMP-9,,Discovery of novel selective HER-2 sheddase inhibitors through optimization of P1 moiety.,Bioorg. Med. Chem. Lett.,2009,19,17,"Li YL, Shi E, Burns D, Li Y, Covington MB, Pan M, Scherle P, Friedman S, Metcalf B, Yao W",,598558,DTCT0024844,3101268,DTCC00607671,1524734,36106
CHEMBL569389,P14780,,JOTYZMGPCUSZKL-FHWLQOOXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19635666,IC50,,,,,,,,,,,,,,,,,Inhibition of MMP-9,Not Determined,Discovery of novel selective HER-2 sheddase inhibitors through optimization of P1 moiety.,Bioorg. Med. Chem. Lett.,2009,19,17,"Li YL, Shi E, Burns D, Li Y, Covington MB, Pan M, Scherle P, Friedman S, Metcalf B, Yao W",,598558,DTCT0024844,3101279,DTCC00607672,1104343,36106
CHEMBL56951,P14780,,PFPVZWIKTNGHGO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10794702,KI,=,21,NM,,,,,,,,,,,,,,Inhibitory activity against the Matrix metalloprotease-9,,Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.,J. Med. Chem.,2000,43,9,"Scozzafava A, Supuran CT",,105390,DTCT0024844,1711280,DTCC00201024,1325930,16216
CHEMBL569523,P14780,,VYQCGLSQVFJHIQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19914829,RATIO,=,58,,,,,,,,,,,,,,,Ratio of Kinact to Ki for MMP9,,Benzylidene cyclopentenediones: First irreversible inhibitors against botulinum neurotoxin A's zinc endopeptidase.,Bioorg. Med. Chem. Lett.,2010,20,1,"Capková K, Hixon MS, Pellett S, Barbieri JT, Johnson EA, Janda KD",,606602,DTCT0024844,3171721,DTCC00613872,437525,36801
CHEMBL57,P14780,NEVIRAPINE,NQDJXKOVJZTUJA-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7384006,DTCC00135799,51491,46191
CHEMBL57,P14780,NEVIRAPINE,NQDJXKOVJZTUJA-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7384007,DTCC00135799,51491,46191
CHEMBL57056,P14780,,RJZXHPMTMXLYGU-ROUUACIJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,15,NM,,,,,,,,,,,,,,Compound was tested for its inhibitory activity against 92 kD gelatinase (MMP-9),,,Bioorg. Med. Chem. Lett.,1996,6,16,,,102114,DTCT0024844,1266532,DTCC00204139,885079,1749
CHEMBL571,P14780,KETOPROFEN,DKYWVDODHFEZIM-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7435449,DTCC00145969,2025638,46191
CHEMBL571,P14780,KETOPROFEN,DKYWVDODHFEZIM-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7435450,DTCC00145969,2025638,46191
CHEMBL572,P14780,NITROFURANTOIN,NXFQHRVNIOXGAQ-YCRREMRBSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7405731,DTCC00145970,1927018,46191
CHEMBL572,P14780,NITROFURANTOIN,NXFQHRVNIOXGAQ-YCRREMRBSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7405732,DTCC00145970,1927018,46191
CHEMBL572045,P14780,,MIUJFEWUCGLALV-VABKMULXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19635666,IC50,=,5000,NM,,,,,,,,,,,,,,Inhibition of MMP-9,,Discovery of novel selective HER-2 sheddase inhibitors through optimization of P1 moiety.,Bioorg. Med. Chem. Lett.,2009,19,17,"Li YL, Shi E, Burns D, Li Y, Covington MB, Pan M, Scherle P, Friedman S, Metcalf B, Yao W",,598558,DTCT0024844,3101283,DTCC00607708,1363250,36106
CHEMBL572091,P14780,,FQSNZGGDFVIKEV-UFYCRDLUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19635666,IC50,=,5000,NM,,,,,,,,,,,,,,Inhibition of MMP-9,,Discovery of novel selective HER-2 sheddase inhibitors through optimization of P1 moiety.,Bioorg. Med. Chem. Lett.,2009,19,17,"Li YL, Shi E, Burns D, Li Y, Covington MB, Pan M, Scherle P, Friedman S, Metcalf B, Yao W",,598558,DTCT0024844,3101278,DTCC00607644,490182,36106
CHEMBL572302,P14780,,PFMDDCHUGSRIJN-FKBYEOEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19635666,IC50,=,5000,NM,,,,,,,,,,,,,,Inhibition of MMP-9,,Discovery of novel selective HER-2 sheddase inhibitors through optimization of P1 moiety.,Bioorg. Med. Chem. Lett.,2009,19,17,"Li YL, Shi E, Burns D, Li Y, Covington MB, Pan M, Scherle P, Friedman S, Metcalf B, Yao W",,598558,DTCT0024844,3101281,DTCC00607698,229826,36106
CHEMBL572780,P14780,,ZCRWOWSOWBMWGI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19775099,IC50,=,69,NM,,,,,,,,,,,,,,Inhibition of para-aminophenylmercuric acetate-activated human recombinant pro-MMP9 catalytic domain after 4 hrs by fluorimetry,,"Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.",J. Med. Chem.,2009,52,20,"Nuti E, Panelli L, Casalini F, Avramova SI, Orlandini E, Santamaria S, Nencetti S, Tuccinardi T, Martinelli A, Cercignani G, D'Amelio N, Maiocchi A, Uggeri F, Rossello A",,591599,DTCT0024844,3044407,DTCC00597333,618949,35647
CHEMBL572982,P14780,,ILGSIIFHQGOKKV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19703773,IC50,=,10500,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors.,Bioorg. Med. Chem. Lett.,2009,19,19,"Holmes IP, Gaines S, Watson SP, Lorthioir O, Walker A, Baddeley SJ, Herbert S, Egan D, Convery MA, Singh OM, Gross JW, Strelow JM, Smith RH, Amour AJ, Brown D, Martin SL",,592282,DTCT0024844,3044573,DTCC00598166,824314,35947
CHEMBL572982,P14780,,ILGSIIFHQGOKKV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19703773,IC50,=,16500,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors.,Bioorg. Med. Chem. Lett.,2009,19,19,"Holmes IP, Gaines S, Watson SP, Lorthioir O, Walker A, Baddeley SJ, Herbert S, Egan D, Convery MA, Singh OM, Gross JW, Strelow JM, Smith RH, Amour AJ, Brown D, Martin SL",,592282,DTCT0024844,3044576,DTCC00598166,824313,35947
CHEMBL572982,P14780,,ILGSIIFHQGOKKV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19703773,IC50,=,19100,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9,,The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors.,Bioorg. Med. Chem. Lett.,2009,19,19,"Holmes IP, Gaines S, Watson SP, Lorthioir O, Walker A, Baddeley SJ, Herbert S, Egan D, Convery MA, Singh OM, Gross JW, Strelow JM, Smith RH, Amour AJ, Brown D, Martin SL",,592282,DTCT0024844,3044574,DTCC00598166,824315,35947
CHEMBL573,P14780,NIACIN,PVNIIMVLHYAWGP-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7388368,DTCC00146015,381015,46191
CHEMBL573,P14780,NIACIN,PVNIIMVLHYAWGP-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7388369,DTCC00146015,381015,46191
CHEMBL573714,P14780,,ITWGWXCEGHFMHT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19775099,IC50,=,98,NM,,,,,,,,,,,,,,Inhibition of para-aminophenylmercuric acetate-activated human recombinant pro-MMP9 catalytic domain after 4 hrs by fluorimetry,,"Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.",J. Med. Chem.,2009,52,20,"Nuti E, Panelli L, Casalini F, Avramova SI, Orlandini E, Santamaria S, Nencetti S, Tuccinardi T, Martinelli A, Cercignani G, D'Amelio N, Maiocchi A, Uggeri F, Rossello A",,591599,DTCT0024844,3044415,DTCC00597369,1427807,35647
CHEMBL573714,P14780,,ITWGWXCEGHFMHT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26638045,IC50,=,98,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP9 after 2 hrs using FS-6 as substrate by fluorometry,,"Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors.",Eur. J. Med. Chem.,2016,108,,"Sjli S, Nuti E, Camodeca C, Bilto I, Rossello A, Winberg JO, Sylte I, Adekoya OA.",,1550087,DTCT0024844,59804,DTCC00597369,1422628,65811
CHEMBL573715,P14780,,YOMXWXIANUYIMH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19775099,IC50,=,0.8,NM,,,,,,,,,,,,,,Inhibition of para-aminophenylmercuric acetate-activated human recombinant pro-MMP9 catalytic domain after 4 hrs by fluorimetry,,"Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.",J. Med. Chem.,2009,52,20,"Nuti E, Panelli L, Casalini F, Avramova SI, Orlandini E, Santamaria S, Nencetti S, Tuccinardi T, Martinelli A, Cercignani G, D'Amelio N, Maiocchi A, Uggeri F, Rossello A",,591599,DTCT0024844,3044387,DTCC00597370,1297783,35647
CHEMBL573934,P14780,,OREDIHYKGISTDR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19775099,IC50,=,930,NM,,,,,,,,,,,,,,Inhibition of para-aminophenylmercuric acetate-activated human recombinant pro-MMP9 catalytic domain after 4 hrs by fluorimetry,,"Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.",J. Med. Chem.,2009,52,20,"Nuti E, Panelli L, Casalini F, Avramova SI, Orlandini E, Santamaria S, Nencetti S, Tuccinardi T, Martinelli A, Cercignani G, D'Amelio N, Maiocchi A, Uggeri F, Rossello A",,591599,DTCT0024844,3044456,DTCC00597353,327896,35647
CHEMBL573935,P14780,,HGICQEUHJFERNR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19775099,IC50,=,7300,NM,,,,,,,,,,,,,,Inhibition of para-aminophenylmercuric acetate-activated human recombinant pro-MMP9 catalytic domain after 4 hrs by fluorimetry,,"Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.",J. Med. Chem.,2009,52,20,"Nuti E, Panelli L, Casalini F, Avramova SI, Orlandini E, Santamaria S, Nencetti S, Tuccinardi T, Martinelli A, Cercignani G, D'Amelio N, Maiocchi A, Uggeri F, Rossello A",,591599,DTCT0024844,3044496,DTCC00597354,393223,35647
CHEMBL573936,P14780,,FIPYOKGRSDJCAR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19775099,IC50,=,730,NM,,,,,,,,,,,,,,Inhibition of para-aminophenylmercuric acetate-activated human recombinant pro-MMP9 catalytic domain after 4 hrs by fluorimetry,,"Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.",J. Med. Chem.,2009,52,20,"Nuti E, Panelli L, Casalini F, Avramova SI, Orlandini E, Santamaria S, Nencetti S, Tuccinardi T, Martinelli A, Cercignani G, D'Amelio N, Maiocchi A, Uggeri F, Rossello A",,591599,DTCT0024844,3044451,DTCC00597355,1427806,35647
CHEMBL574,P14780,P-TOLUENESULFONAMIDE,LMYRWZFENFIFIT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,-7,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103101,DTCC00146038,508352,43205
CHEMBL574370,P14780,,YYBFXMXFWMJGLB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19775099,IC50,=,310,NM,,,,,,,,,,,,,,Inhibition of para-aminophenylmercuric acetate-activated human recombinant pro-MMP9 catalytic domain after 4 hrs by fluorimetry,,"Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.",J. Med. Chem.,2009,52,20,"Nuti E, Panelli L, Casalini F, Avramova SI, Orlandini E, Santamaria S, Nencetti S, Tuccinardi T, Martinelli A, Cercignani G, D'Amelio N, Maiocchi A, Uggeri F, Rossello A",,591599,DTCT0024844,3044434,DTCC00597263,12430,35647
CHEMBL574589,P14780,,WQRJSSRVHCJAKB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19775099,IC50,=,7700,NM,,,,,,,,,,,,,,Inhibition of para-aminophenylmercuric acetate-activated human recombinant pro-MMP9 catalytic domain after 4 hrs by fluorimetry,,"Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.",J. Med. Chem.,2009,52,20,"Nuti E, Panelli L, Casalini F, Avramova SI, Orlandini E, Santamaria S, Nencetti S, Tuccinardi T, Martinelli A, Cercignani G, D'Amelio N, Maiocchi A, Uggeri F, Rossello A",,591599,DTCT0024844,3044498,DTCC00597341,1071501,35647
CHEMBL574605,P14780,,CPUBMGYGVNFLPZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19775099,IC50,=,340,NM,,,,,,,,,,,,,,Inhibition of para-aminophenylmercuric acetate-activated human recombinant pro-MMP9 catalytic domain after 4 hrs by fluorimetry,,"Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.",J. Med. Chem.,2009,52,20,"Nuti E, Panelli L, Casalini F, Avramova SI, Orlandini E, Santamaria S, Nencetti S, Tuccinardi T, Martinelli A, Cercignani G, D'Amelio N, Maiocchi A, Uggeri F, Rossello A",,591599,DTCT0024844,3044436,DTCC00597298,327895,35647
CHEMBL57551,P14780,,PGBCLSYOJJBRSJ-ROUUACIJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,80,NM,,,,,,,,,,,,,,Compound was tested for its inhibitory activity against 92 kD gelatinase (MMP-9),,,Bioorg. Med. Chem. Lett.,1996,6,16,,,102114,DTCT0024844,1265407,DTCC00105196,1078899,1749
CHEMBL575881,P14780,,ABXUEPSHNXWTBZ-LJQANCHMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19775099,IC50,=,24000,NM,,,,,,,,,,,,,,Inhibition of para-aminophenylmercuric acetate-activated human recombinant pro-MMP9 catalytic domain after 4 hrs by fluorimetry,,"Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.",J. Med. Chem.,2009,52,20,"Nuti E, Panelli L, Casalini F, Avramova SI, Orlandini E, Santamaria S, Nencetti S, Tuccinardi T, Martinelli A, Cercignani G, D'Amelio N, Maiocchi A, Uggeri F, Rossello A",,591599,DTCT0024844,3044912,DTCC00597225,1653861,35647
CHEMBL575895,P14780,,QPFIKHZWPMXTRS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19775099,IC50,=,24000,NM,,,,,,,,,,,,,,Inhibition of para-aminophenylmercuric acetate-activated human recombinant pro-MMP9 catalytic domain after 4 hrs by fluorimetry,,"Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.",J. Med. Chem.,2009,52,20,"Nuti E, Panelli L, Casalini F, Avramova SI, Orlandini E, Santamaria S, Nencetti S, Tuccinardi T, Martinelli A, Cercignani G, D'Amelio N, Maiocchi A, Uggeri F, Rossello A",,591599,DTCT0024844,3044513,DTCC00597330,1427805,35647
CHEMBL575896,P14780,,MYZHQACPXTZCJY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19775099,IC50,=,690,NM,,,,,,,,,,,,,,Inhibition of para-aminophenylmercuric acetate-activated human recombinant pro-MMP9 catalytic domain after 4 hrs by fluorimetry,,"Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.",J. Med. Chem.,2009,52,20,"Nuti E, Panelli L, Casalini F, Avramova SI, Orlandini E, Santamaria S, Nencetti S, Tuccinardi T, Martinelli A, Cercignani G, D'Amelio N, Maiocchi A, Uggeri F, Rossello A",,591599,DTCT0024844,3044447,DTCC00597331,554423,35647
CHEMBL57644,P14780,,SSQXFNKOLMHXPO-DDHJBXDOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15055993,KI,=,2,NM,,,,,,,,,,,,,,Inhibition of human recombinant matrix metalloprotease 9,,Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents.,J. Med. Chem.,2004,47,8,"Moriyama H, Tsukida T, Inoue Y, Yokota K, Yoshino K, Kondo H, Miura N, Nishimura S",,105384,DTCT0024844,1396890,DTCC00205510,1520468,18075
CHEMBL576762,P14780,,RPBGCJQDVJCGSK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19775099,IC50,=,51000,NM,,,,,,,,,,,,,,Inhibition of para-aminophenylmercuric acetate-activated human recombinant pro-MMP9 catalytic domain after 4 hrs by fluorimetry,,"Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.",J. Med. Chem.,2009,52,20,"Nuti E, Panelli L, Casalini F, Avramova SI, Orlandini E, Santamaria S, Nencetti S, Tuccinardi T, Martinelli A, Cercignani G, D'Amelio N, Maiocchi A, Uggeri F, Rossello A",,591599,DTCT0024844,3044522,DTCC00597340,1265255,35647
CHEMBL578,P14780,ENALAPRIL,GBXSMTUPTTWBMN-XIRDDKMYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7323877,DTCC00146157,49658,46191
CHEMBL578,P14780,ENALAPRIL,GBXSMTUPTTWBMN-XIRDDKMYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7323878,DTCC00146157,49658,46191
CHEMBL579067,P14780,,YMAXKJGQKQACFZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19775099,IC50,=,420,NM,,,,,,,,,,,,,,Inhibition of para-aminophenylmercuric acetate-activated human recombinant pro-MMP9 catalytic domain after 4 hrs by fluorimetry,,"Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.",J. Med. Chem.,2009,52,20,"Nuti E, Panelli L, Casalini F, Avramova SI, Orlandini E, Santamaria S, Nencetti S, Tuccinardi T, Martinelli A, Cercignani G, D'Amelio N, Maiocchi A, Uggeri F, Rossello A",,591599,DTCT0024844,3044442,DTCC00597343,812562,35647
CHEMBL579068,P14780,,HSMGGAWDRKACFW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19775099,IC50,=,20000,NM,,,,,,,,,,,,,,Inhibition of para-aminophenylmercuric acetate-activated human recombinant pro-MMP9 catalytic domain after 4 hrs by fluorimetry,,"Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.",J. Med. Chem.,2009,52,20,"Nuti E, Panelli L, Casalini F, Avramova SI, Orlandini E, Santamaria S, Nencetti S, Tuccinardi T, Martinelli A, Cercignani G, D'Amelio N, Maiocchi A, Uggeri F, Rossello A",,591599,DTCT0024844,3044509,DTCC00597380,1842555,35647
CHEMBL58,P14780,MITOXANTRONE,KKZJGLLVHKMTCM-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7407026,DTCC00103487,1092344,46191
CHEMBL58,P14780,MITOXANTRONE,KKZJGLLVHKMTCM-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7407027,DTCC00103487,1092344,46191
CHEMBL580,P14780,LORAZEPAM,DIWRORZWFLOCLC-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7406092,DTCC00146251,1285879,46191
CHEMBL580,P14780,LORAZEPAM,DIWRORZWFLOCLC-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7406093,DTCC00146251,1285879,46191
CHEMBL583,P14780,GREPAFLOXACIN,AIJTTZAVMXIJGM-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7304044,DTCC00146380,542577,46191
CHEMBL583,P14780,GREPAFLOXACIN,AIJTTZAVMXIJGM-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7304045,DTCC00146380,542577,46191
CHEMBL584,P14780,NELFINAVIR,QAGYKUNXZHXKMR-HKWSIXNMSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7401137,DTCC01738575,1798414,46191
CHEMBL584,P14780,NELFINAVIR,QAGYKUNXZHXKMR-HKWSIXNMSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7401138,DTCC01738575,1798414,46191
CHEMBL584116,P14780,,PDNKMRBXZXHUFT-ACRUOGEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19635666,IC50,=,5000,NM,,,,,,,,,,,,,,Inhibition of MMP-9,,Discovery of novel selective HER-2 sheddase inhibitors through optimization of P1 moiety.,Bioorg. Med. Chem. Lett.,2009,19,17,"Li YL, Shi E, Burns D, Li Y, Covington MB, Pan M, Scherle P, Friedman S, Metcalf B, Yao W",,598558,DTCT0024844,3101280,DTCC00607673,360595,36106
CHEMBL584120,P14780,,XLCDJKIIBWOGQT-UFYCRDLUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19635666,IC50,>,5000,NM,,,,,,,,,,,,,,Inhibition of MMP-9,,Discovery of novel selective HER-2 sheddase inhibitors through optimization of P1 moiety.,Bioorg. Med. Chem. Lett.,2009,19,17,"Li YL, Shi E, Burns D, Li Y, Covington MB, Pan M, Scherle P, Friedman S, Metcalf B, Yao W",,598558,DTCT0024844,3101269,DTCC00607697,262112,36106
CHEMBL584122,P14780,,OAJUMLCSJOEUON-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19775099,IC50,=,410,NM,,,,,,,,,,,,,,Inhibition of para-aminophenylmercuric acetate-activated human recombinant pro-MMP9 catalytic domain after 4 hrs by fluorimetry,,"Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.",J. Med. Chem.,2009,52,20,"Nuti E, Panelli L, Casalini F, Avramova SI, Orlandini E, Santamaria S, Nencetti S, Tuccinardi T, Martinelli A, Cercignani G, D'Amelio N, Maiocchi A, Uggeri F, Rossello A",,591599,DTCT0024844,3044441,DTCC00597332,715843,35647
CHEMBL584147,P14780,,XORCBTCEBZUVES-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19775099,IC50,=,3000,NM,,,,,,,,,,,,,,Inhibition of para-aminophenylmercuric acetate-activated human recombinant pro-MMP9 catalytic domain after 4 hrs by fluorimetry,,"Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.",J. Med. Chem.,2009,52,20,"Nuti E, Panelli L, Casalini F, Avramova SI, Orlandini E, Santamaria S, Nencetti S, Tuccinardi T, Martinelli A, Cercignani G, D'Amelio N, Maiocchi A, Uggeri F, Rossello A",,591599,DTCT0024844,3044482,DTCC00597381,2037631,35647
CHEMBL584334,P14780,,KSBCPHOBEZMZNM-FHWLQOOXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19635666,IC50,=,5000,NM,,,,,,,,,,,,,,Inhibition of MMP-9,,Discovery of novel selective HER-2 sheddase inhibitors through optimization of P1 moiety.,Bioorg. Med. Chem. Lett.,2009,19,17,"Li YL, Shi E, Burns D, Li Y, Covington MB, Pan M, Scherle P, Friedman S, Metcalf B, Yao W",,598558,DTCT0024844,3101277,DTCC00607643,1686084,36106
CHEMBL584365,P14780,,DJZNIZCARKSSDE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19775099,IC50,=,94,NM,,,,,,,,,,,,,,Inhibition of para-aminophenylmercuric acetate-activated human recombinant pro-MMP9 catalytic domain after 4 hrs by fluorimetry,,"Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.",J. Med. Chem.,2009,52,20,"Nuti E, Panelli L, Casalini F, Avramova SI, Orlandini E, Santamaria S, Nencetti S, Tuccinardi T, Martinelli A, Cercignani G, D'Amelio N, Maiocchi A, Uggeri F, Rossello A",,591599,DTCT0024844,3044414,DTCC00597271,165336,35647
CHEMBL585,P14780,TRIAMTERENE,FNYLWPVRPXGIIP-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7446196,DTCC00146599,1674154,46191
CHEMBL585,P14780,TRIAMTERENE,FNYLWPVRPXGIIP-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7446197,DTCC00146599,1674154,46191
CHEMBL585299,P14780,,YYMXPNNILUETLE-UFYCRDLUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19635666,IC50,>,5000,NM,,,,,,,,,,,,,,Inhibition of MMP-9,,Discovery of novel selective HER-2 sheddase inhibitors through optimization of P1 moiety.,Bioorg. Med. Chem. Lett.,2009,19,17,"Li YL, Shi E, Burns D, Li Y, Covington MB, Pan M, Scherle P, Friedman S, Metcalf B, Yao W",,598558,DTCT0024844,3101274,DTCC00607737,619058,36106
CHEMBL585376,P14780,,BZWDHUMJSSLVCR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19775099,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of para-aminophenylmercuric acetate-activated human recombinant pro-MMP9 catalytic domain after 4 hrs by fluorimetry,,"Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.",J. Med. Chem.,2009,52,20,"Nuti E, Panelli L, Casalini F, Avramova SI, Orlandini E, Santamaria S, Nencetti S, Tuccinardi T, Martinelli A, Cercignani G, D'Amelio N, Maiocchi A, Uggeri F, Rossello A",,591599,DTCT0024844,3044545,DTCC00597342,100632,35647
CHEMBL58546,P14780,,MAYCNKJOJLHPKK-QWRGUYRKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,>,1000,NM,,,,,,,,,,,,,,Compound was tested for its inhibitory activity against 92 kD gelatinase (MMP-9),,,Bioorg. Med. Chem. Lett.,1996,6,16,,,102114,DTCT0024844,1260599,DTCC00204141,107859,1749
CHEMBL58577,P14780,,LQZDEWIIFWHTLX-BRSBDYLESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15055993,KI,=,7.4,NM,,,,,,,,,,,,,,Inhibition of human recombinant matrix metalloprotease 9,,Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents.,J. Med. Chem.,2004,47,8,"Moriyama H, Tsukida T, Inoue Y, Yokota K, Yoshino K, Kondo H, Miura N, Nishimura S",,105384,DTCT0024844,1385968,DTCC00205932,743899,18075
CHEMBL585886,P14780,,KMMXFFDNBCQBEI-UFYCRDLUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19635666,IC50,>,5000,NM,,,,,,,,,,,,,,Inhibition of MMP-9,,Discovery of novel selective HER-2 sheddase inhibitors through optimization of P1 moiety.,Bioorg. Med. Chem. Lett.,2009,19,17,"Li YL, Shi E, Burns D, Li Y, Covington MB, Pan M, Scherle P, Friedman S, Metcalf B, Yao W",,598558,DTCT0024844,3101275,DTCC00607746,1842659,36106
CHEMBL586042,P14780,,QHTFXHUNNOAYME-BSOSBYQFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19635666,IC50,>,5000,NM,,,,,,,,,,,,,,Inhibition of MMP-9,,Discovery of novel selective HER-2 sheddase inhibitors through optimization of P1 moiety.,Bioorg. Med. Chem. Lett.,2009,19,17,"Li YL, Shi E, Burns D, Li Y, Covington MB, Pan M, Scherle P, Friedman S, Metcalf B, Yao W",,598558,DTCT0024844,3101273,DTCC00607731,1972305,36106
CHEMBL588119,P14780,SULOCTIDIL,BFCDFTHTSVTWOG-YLJYHZDGSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7472049,DTCC00123899,2057654,46191
CHEMBL588119,P14780,SULOCTIDIL,BFCDFTHTSVTWOG-YLJYHZDGSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7472050,DTCC00123899,2057654,46191
CHEMBL589679,P14780,,QZHTVRKTPPIILZ-ICNOJOBBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20060717,RATIO,<,1,,,,,,,,,,,,,,,Ratio Kcat to Ki for MMP9,,Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents.,Bioorg. Med. Chem. Lett.,2010,20,3,"Hu Z, Jiang X, Albright CF, Graciani N, Yue E, Zhang M, Zhang SY, Bruckner R, Diamond M, Dowling R, Rafalski M, Yeleswaram S, Trainor GL, Seitz SP, Han W",,609254,DTCT0024844,3180414,DTCC00620082,748432,37498
CHEMBL589710,P14780,,FIGGEGWDYUINOK-ULKIPEBDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20060717,RATIO,=,79,,,,,,,,,,,,,,,Ratio Kcat to Ki for MMP9,,Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents.,Bioorg. Med. Chem. Lett.,2010,20,3,"Hu Z, Jiang X, Albright CF, Graciani N, Yue E, Zhang M, Zhang SY, Bruckner R, Diamond M, Dowling R, Rafalski M, Yeleswaram S, Trainor GL, Seitz SP, Han W",,609254,DTCT0024844,3180408,DTCC00620088,1395728,37498
CHEMBL589760,P14780,,QLPKUSVWQWRECK-LLRGJTHUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20060717,RATIO,>,120,,,,,,,,,,,,,,,Ratio Kcat to Ki for MMP9,,Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents.,Bioorg. Med. Chem. Lett.,2010,20,3,"Hu Z, Jiang X, Albright CF, Graciani N, Yue E, Zhang M, Zhang SY, Bruckner R, Diamond M, Dowling R, Rafalski M, Yeleswaram S, Trainor GL, Seitz SP, Han W",,609254,DTCT0024844,3180413,DTCC00620083,1654132,37498
CHEMBL589761,P14780,,YVQBEOXREDVQBP-VTBTYGGHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20060717,RATIO,=,390,,,,,,,,,,,,,,,Ratio Kcat to Ki for MMP9,,Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents.,Bioorg. Med. Chem. Lett.,2010,20,3,"Hu Z, Jiang X, Albright CF, Graciani N, Yue E, Zhang M, Zhang SY, Bruckner R, Diamond M, Dowling R, Rafalski M, Yeleswaram S, Trainor GL, Seitz SP, Han W",,609254,DTCT0024844,3180410,DTCC00620086,1039311,37498
CHEMBL589762,P14780,,WHZAMGQVPGHHBH-HKPJPKSRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20060717,RATIO,>,120,,,,,,,,,,,,,,,Ratio Kcat to Ki for MMP9,,Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents.,Bioorg. Med. Chem. Lett.,2010,20,3,"Hu Z, Jiang X, Albright CF, Graciani N, Yue E, Zhang M, Zhang SY, Bruckner R, Diamond M, Dowling R, Rafalski M, Yeleswaram S, Trainor GL, Seitz SP, Han W",,609254,DTCT0024844,3180404,DTCC00620092,1200301,37498
CHEMBL589763,P14780,,CQUQBNMIEIDWPI-LDNUBHSTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20060717,RATIO,=,43,,,,,,,,,,,,,,,Ratio Kcat to Ki for MMP9,,Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents.,Bioorg. Med. Chem. Lett.,2010,20,3,"Hu Z, Jiang X, Albright CF, Graciani N, Yue E, Zhang M, Zhang SY, Bruckner R, Diamond M, Dowling R, Rafalski M, Yeleswaram S, Trainor GL, Seitz SP, Han W",,609254,DTCT0024844,3180401,DTCC00620095,1136717,37498
CHEMBL589764,P14780,,UEBHASPTCLODRO-FNYWWBFVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20060717,RATIO,=,107,,,,,,,,,,,,,,,Ratio Kcat to Ki for MMP9,,Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents.,Bioorg. Med. Chem. Lett.,2010,20,3,"Hu Z, Jiang X, Albright CF, Graciani N, Yue E, Zhang M, Zhang SY, Bruckner R, Diamond M, Dowling R, Rafalski M, Yeleswaram S, Trainor GL, Seitz SP, Han W",,609254,DTCT0024844,3180395,DTCC00620101,1778015,37498
CHEMBL589886,P14780,,CWUJMCRFVRZWMX-BASHDASISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20060717,RATIO,=,68,,,,,,,,,,,,,,,Ratio Kcat to Ki for MMP9,,Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents.,Bioorg. Med. Chem. Lett.,2010,20,3,"Hu Z, Jiang X, Albright CF, Graciani N, Yue E, Zhang M, Zhang SY, Bruckner R, Diamond M, Dowling R, Rafalski M, Yeleswaram S, Trainor GL, Seitz SP, Han W",,609254,DTCT0024844,3180389,DTCC00620107,1492589,37498
CHEMBL589996,P14780,,QDIKAYSONRRSHM-FXWROETPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20060717,RATIO,>,120,,,,,,,,,,,,,,,Ratio Kcat to Ki for MMP9,,Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents.,Bioorg. Med. Chem. Lett.,2010,20,3,"Hu Z, Jiang X, Albright CF, Graciani N, Yue E, Zhang M, Zhang SY, Bruckner R, Diamond M, Dowling R, Rafalski M, Yeleswaram S, Trainor GL, Seitz SP, Han W",,609254,DTCT0024844,3180394,DTCC00620102,1460098,37498
CHEMBL589997,P14780,,AKDGBIXCKDWCJO-WJCZHFNKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20060717,RATIO,=,68,,,,,,,,,,,,,,,Ratio Kcat to Ki for MMP9,,Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents.,Bioorg. Med. Chem. Lett.,2010,20,3,"Hu Z, Jiang X, Albright CF, Graciani N, Yue E, Zhang M, Zhang SY, Bruckner R, Diamond M, Dowling R, Rafalski M, Yeleswaram S, Trainor GL, Seitz SP, Han W",,609254,DTCT0024844,3180392,DTCC00620104,586915,37498
CHEMBL59023,P14780,,RRLGEVWMENCJGJ-IRLDBZIGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,0.31,NM,,,,,,,,,,,,,,Inhibition of human Matrix metalloprotease-9,,,Bioorg. Med. Chem. Lett.,1995,5,4,,,105391,DTCT0024844,850837,DTCC00208380,465491,1497
CHEMBL592228,P14780,,SXEONTJNLWOUBB-MYXCDZCHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20053563,IC50,=,2300,NM,,,,,,,,,,,,,,Inhibition of human neutrophils gelatinase B after 30 mins by fluorescence plate reader,,"Identification of potential and selective collagenase, gelatinase inhibitors from Crataegus pinnatifida.",Bioorg. Med. Chem. Lett.,2010,20,3,"Moon HI, Kim TI, Cho HS, Kim EK",,607931,DTCT0024844,3191713,DTCC00619790,1568517,37466
CHEMBL592329,P14780,,PBYRKMXDROOXMU-KCXYZFMFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20053563,IC50,=,27300,NM,,,,,,,,,,,,,,Inhibition of human neutrophils gelatinase B after 30 mins by fluorescence plate reader,,"Identification of potential and selective collagenase, gelatinase inhibitors from Crataegus pinnatifida.",Bioorg. Med. Chem. Lett.,2010,20,3,"Moon HI, Kim TI, Cho HS, Kim EK",,607931,DTCT0024844,3191711,DTCC00619789,307315,37466
CHEMBL592373,P14780,,QRFZGLTZLZZHCM-NWYMYRDLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20053563,IC50,=,39200,NM,,,,,,,,,,,,,,Inhibition of human neutrophils gelatinase B after 30 mins by fluorescence plate reader,,"Identification of potential and selective collagenase, gelatinase inhibitors from Crataegus pinnatifida.",Bioorg. Med. Chem. Lett.,2010,20,3,"Moon HI, Kim TI, Cho HS, Kim EK",,607931,DTCT0024844,3191715,DTCC00619791,1697703,37466
CHEMBL59338,P14780,,AZODBPSQRNONKH-NVXWUHKLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,1.5,NM,,,,,,,,,,,,,,Inhibition of human recombinant Gelatinase B (MMP-9),,,Bioorg. Med. Chem. Lett.,1997,7,2,,,71654,DTCT0024844,685716,DTCC00208350,3213,2288
CHEMBL59423,P14780,,LFUPNENXYUZZTP-KBPBESRZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,102,NM,,,,,,,,,,,,,,Compound was tested for its inhibitory activity against 92 kD gelatinase (MMP-9),,,Bioorg. Med. Chem. Lett.,1996,6,16,,,102114,DTCT0024844,1264193,DTCC00204189,1046423,1749
CHEMBL595,P14780,PIOGLITAZONE,HYAFETHFCAUJAY-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7391718,DTCC00148462,1318445,46191
CHEMBL595,P14780,PIOGLITAZONE,HYAFETHFCAUJAY-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7391719,DTCC00148462,1318445,46191
CHEMBL59692,P14780,,KTCRMROJXXSPQJ-PDNQZYNLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12781187,KI,=,165,NM,,,,,,,,,,,,,,Inhibition of recombinant human Matrix metalloprotease-9,,Discovery of selective phosphonamide-based inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2003,13,12,"Sawa M, Kurokawa K, Inoue Y, Kondo H, Yoshino K",,105393,DTCT0024844,1068791,DTCC00212222,236996,5595
CHEMBL597,P14780,PHENTOLAMINE,MRBDMNSDAVCSSF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7395880,DTCC00148793,1641852,46191
CHEMBL597,P14780,PHENTOLAMINE,MRBDMNSDAVCSSF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7395881,DTCC00148793,1641852,46191
CHEMBL597791,P14780,,VONBUAGYAZLFEO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20155918,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of human MMP9,Not Active,Synthesis and biological evaluation of botulinum neurotoxin a protease inhibitors.,J. Med. Chem.,2010,53,5,"Li B, Pai R, Cardinale SC, Butler MM, Peet NP, Moir DT, Bavari S, Bowlin TL",,609719,DTCT0024844,3205558,DTCC00615344,663181,37163
CHEMBL599,P14780,MELOXICAM,ZRVUJXDFFKFLMG-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7421530,DTCC00149080,638767,46191
CHEMBL599,P14780,MELOXICAM,ZRVUJXDFFKFLMG-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7421531,DTCC00149080,638767,46191
CHEMBL59968,P14780,,VQXXXMXDXGETFY-DWXRJYCRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12781190,KI,=,1299,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9,,Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2003,13,12,"Duan JJ, Lu Z, Xue CB, He X, Seng JL, Roderick JJ, Wasserman ZR, Liu RQ, Covington MB, Magolda RL, Newton RC, Trzaskos JM, Decicco CP",,105375,DTCT0024844,504958,DTCC00211655,2065284,5598
CHEMBL6,P14780,INDOMETHACIN,CGIGDMFJXJATDK-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7430967,DTCC00132340,51479,46191
CHEMBL6,P14780,INDOMETHACIN,CGIGDMFJXJATDK-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7430968,DTCC00132340,51479,46191
CHEMBL600325,P14780,PROSCILLARIDIN,MYEJFUXQJGHEQK-ALRJYLEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7381538,DTCC00486948,1705878,46191
CHEMBL600325,P14780,PROSCILLARIDIN,MYEJFUXQJGHEQK-ALRJYLEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7381539,DTCC00486948,1705878,46191
CHEMBL601266,P14780,,MPPBYRPSQFFWRI-KSEVBTLESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20060717,RATIO,>,120,,,,,,,,,,,,,,,Ratio Kcat to Ki for MMP9,,Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents.,Bioorg. Med. Chem. Lett.,2010,20,3,"Hu Z, Jiang X, Albright CF, Graciani N, Yue E, Zhang M, Zhang SY, Bruckner R, Diamond M, Dowling R, Rafalski M, Yeleswaram S, Trainor GL, Seitz SP, Han W",,609254,DTCT0024844,3180393,DTCC00620103,586914,37498
CHEMBL601474,P14780,,GCPDHEUDCRIVRM-DHLBNNOGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20060717,RATIO,=,85,,,,,,,,,,,,,,,Ratio Kcat to Ki for MMP9,,Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents.,Bioorg. Med. Chem. Lett.,2010,20,3,"Hu Z, Jiang X, Albright CF, Graciani N, Yue E, Zhang M, Zhang SY, Bruckner R, Diamond M, Dowling R, Rafalski M, Yeleswaram S, Trainor GL, Seitz SP, Han W",,609254,DTCT0024844,3180391,DTCC00620105,1039313,37498
CHEMBL601475,P14780,,KETPAISALUWJRR-OAVYBYCVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20060717,RATIO,=,25,,,,,,,,,,,,,,,Ratio Kcat to Ki for MMP9,,Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents.,Bioorg. Med. Chem. Lett.,2010,20,3,"Hu Z, Jiang X, Albright CF, Graciani N, Yue E, Zhang M, Zhang SY, Bruckner R, Diamond M, Dowling R, Rafalski M, Yeleswaram S, Trainor GL, Seitz SP, Han W",,609254,DTCT0024844,3180390,DTCC00620106,554715,37498
CHEMBL602301,P14780,,FHIUBRXIZJRTHF-FBVZUCIOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20060717,RATIO,<,1,,,,,,,,,,,,,,,Ratio Kcat to Ki for MMP9,,Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents.,Bioorg. Med. Chem. Lett.,2010,20,3,"Hu Z, Jiang X, Albright CF, Graciani N, Yue E, Zhang M, Zhang SY, Bruckner R, Diamond M, Dowling R, Rafalski M, Yeleswaram S, Trainor GL, Seitz SP, Han W",,609254,DTCT0024844,3180412,DTCC00620084,1717573,37498
CHEMBL602302,P14780,,KTAORHMSVCAETQ-UUXDBVTOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20060717,RATIO,=,1,,,,,,,,,,,,,,,Ratio Kcat to Ki for MMP9,,Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents.,Bioorg. Med. Chem. Lett.,2010,20,3,"Hu Z, Jiang X, Albright CF, Graciani N, Yue E, Zhang M, Zhang SY, Bruckner R, Diamond M, Dowling R, Rafalski M, Yeleswaram S, Trainor GL, Seitz SP, Han W",,609254,DTCT0024844,3180411,DTCC00620085,910784,37498
CHEMBL602303,P14780,,IUOZLSPXKIQNGM-YGSUAAAGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20060717,RATIO,>,120,,,,,,,,,,,,,,,Ratio Kcat to Ki for MMP9,,Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents.,Bioorg. Med. Chem. Lett.,2010,20,3,"Hu Z, Jiang X, Albright CF, Graciani N, Yue E, Zhang M, Zhang SY, Bruckner R, Diamond M, Dowling R, Rafalski M, Yeleswaram S, Trainor GL, Seitz SP, Han W",,609254,DTCT0024844,3180409,DTCC00620087,1039312,37498
CHEMBL602508,P14780,,YHPSBACDAFARBS-OMYDOWJBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20060717,RATIO,<,1,,,,,,,,,,,,,,,Ratio Kcat to Ki for MMP9,,Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents.,Bioorg. Med. Chem. Lett.,2010,20,3,"Hu Z, Jiang X, Albright CF, Graciani N, Yue E, Zhang M, Zhang SY, Bruckner R, Diamond M, Dowling R, Rafalski M, Yeleswaram S, Trainor GL, Seitz SP, Han W",,609254,DTCT0024844,3180406,DTCC00620090,1746071,37498
CHEMBL602509,P14780,,LPZYDQQHEPEWGM-ZMLVVKDOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20060717,RATIO,=,34,,,,,,,,,,,,,,,Ratio Kcat to Ki for MMP9,,Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents.,Bioorg. Med. Chem. Lett.,2010,20,3,"Hu Z, Jiang X, Albright CF, Graciani N, Yue E, Zhang M, Zhang SY, Bruckner R, Diamond M, Dowling R, Rafalski M, Yeleswaram S, Trainor GL, Seitz SP, Han W",,609254,DTCT0024844,3180405,DTCC00620091,1265490,37498
CHEMBL602510,P14780,,BHGGSEGLXWNHKI-IQVHGFSNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20060717,RATIO,=,43,,,,,,,,,,,,,,,Ratio Kcat to Ki for MMP9,,Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents.,Bioorg. Med. Chem. Lett.,2010,20,3,"Hu Z, Jiang X, Albright CF, Graciani N, Yue E, Zhang M, Zhang SY, Bruckner R, Diamond M, Dowling R, Rafalski M, Yeleswaram S, Trainor GL, Seitz SP, Han W",,609254,DTCT0024844,3180403,DTCC00620093,878120,37498
CHEMBL602511,P14780,,UQIFQWMHIQGZOA-IJGIEEHNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20060717,RATIO,=,73,,,,,,,,,,,,,,,Ratio Kcat to Ki for MMP9,,Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents.,Bioorg. Med. Chem. Lett.,2010,20,3,"Hu Z, Jiang X, Albright CF, Graciani N, Yue E, Zhang M, Zhang SY, Bruckner R, Diamond M, Dowling R, Rafalski M, Yeleswaram S, Trainor GL, Seitz SP, Han W",,609254,DTCT0024844,3180402,DTCC00620094,2037891,37498
CHEMBL602512,P14780,,QUFHCGIQHWBHRW-HFMZJWALSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20060717,RATIO,=,38,,,,,,,,,,,,,,,Ratio Kcat to Ki for MMP9,,Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents.,Bioorg. Med. Chem. Lett.,2010,20,3,"Hu Z, Jiang X, Albright CF, Graciani N, Yue E, Zhang M, Zhang SY, Bruckner R, Diamond M, Dowling R, Rafalski M, Yeleswaram S, Trainor GL, Seitz SP, Han W",,609254,DTCT0024844,3180399,DTCC00620097,1460097,37498
CHEMBL602513,P14780,,QLSQTUSZZCKABS-MBEKMZCTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20060717,RATIO,=,64,,,,,,,,,,,,,,,Ratio Kcat to Ki for MMP9,,Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents.,Bioorg. Med. Chem. Lett.,2010,20,3,"Hu Z, Jiang X, Albright CF, Graciani N, Yue E, Zhang M, Zhang SY, Bruckner R, Diamond M, Dowling R, Rafalski M, Yeleswaram S, Trainor GL, Seitz SP, Han W",,609254,DTCT0024844,3180397,DTCC00620099,165568,37498
CHEMBL602708,P14780,,LITXUKDGYSQFSD-FNYWWBFVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20060717,RATIO,=,55,,,,,,,,,,,,,,,Ratio Kcat to Ki for MMP9,,Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents.,Bioorg. Med. Chem. Lett.,2010,20,3,"Hu Z, Jiang X, Albright CF, Graciani N, Yue E, Zhang M, Zhang SY, Bruckner R, Diamond M, Dowling R, Rafalski M, Yeleswaram S, Trainor GL, Seitz SP, Han W",,609254,DTCT0024844,3180396,DTCC00620100,619221,37498
CHEMBL603,P14780,ZAFIRLUKAST,YEEZWCHGZNKEEK-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7441883,DTCC00150003,1830696,46191
CHEMBL603,P14780,ZAFIRLUKAST,YEEZWCHGZNKEEK-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7441884,DTCC00150003,1830696,46191
CHEMBL603308,P14780,,FEBYOUNMPSRCSF-JZBCIKKISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20060717,RATIO,=,34,,,,,,,,,,,,,,,Ratio Kcat to Ki for MMP9,,Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents.,Bioorg. Med. Chem. Lett.,2010,20,3,"Hu Z, Jiang X, Albright CF, Graciani N, Yue E, Zhang M, Zhang SY, Bruckner R, Diamond M, Dowling R, Rafalski M, Yeleswaram S, Trainor GL, Seitz SP, Han W",,609254,DTCT0024844,3180407,DTCC00620089,1428086,37498
CHEMBL603309,P14780,,OVISQYITSPXJSG-QQJJXHBYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20060717,RATIO,=,52,,,,,,,,,,,,,,,Ratio Kcat to Ki for MMP9,,Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents.,Bioorg. Med. Chem. Lett.,2010,20,3,"Hu Z, Jiang X, Albright CF, Graciani N, Yue E, Zhang M, Zhang SY, Bruckner R, Diamond M, Dowling R, Rafalski M, Yeleswaram S, Trainor GL, Seitz SP, Han W",,609254,DTCT0024844,3180400,DTCC00620096,910785,37498
CHEMBL603310,P14780,,PPJQVOJWNQJPRU-SWJJWXSQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20060717,RATIO,=,120,,,,,,,,,,,,,,,Ratio Kcat to Ki for MMP9,,Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents.,Bioorg. Med. Chem. Lett.,2010,20,3,"Hu Z, Jiang X, Albright CF, Graciani N, Yue E, Zhang M, Zhang SY, Bruckner R, Diamond M, Dowling R, Rafalski M, Yeleswaram S, Trainor GL, Seitz SP, Han W",,609254,DTCT0024844,3180398,DTCC00620098,12972,37498
CHEMBL603656,P14780,,KOTGODCEORJYIF-QAQDUYKDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20005097,KI,>,25000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,2010,20,2,"Schnute ME, O'Brien PM, Nahra J, Morris M, Howard Roark W, Hanau CE, Ruminski PG, Scholten JA, Fletcher TR, Hamper BC, Carroll JN, Patt WC, Shieh HS, Collins B, Pavlovsky AG, Palmquist KE, Aston KW, Hitchcock J, Rogers MD, McDonald J, Johnson AR, Munie GE, Wittwer AJ, Man CF, Settle SL, Nemirovskiy O, Vickery LE, Agawal A, Dyer RD, Sunyer T",,605229,DTCT0024844,3176041,DTCC00610540,534004,36915
CHEMBL60373,P14780,,SBXPRGGYMRGODQ-IRLDBZIGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12781190,KI,>,2000,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9,,Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2003,13,12,"Duan JJ, Lu Z, Xue CB, He X, Seng JL, Roderick JJ, Wasserman ZR, Liu RQ, Covington MB, Magolda RL, Newton RC, Trzaskos JM, Decicco CP",,105375,DTCT0024844,475051,DTCC00211747,906130,5598
CHEMBL604365,P14780,,CNPHGGDFYWHAFF-SEBRQYJASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20060717,RATIO,=,79,,,,,,,,,,,,,,,Ratio Kcat to Ki for MMP9,,Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents.,Bioorg. Med. Chem. Lett.,2010,20,3,"Hu Z, Jiang X, Albright CF, Graciani N, Yue E, Zhang M, Zhang SY, Bruckner R, Diamond M, Dowling R, Rafalski M, Yeleswaram S, Trainor GL, Seitz SP, Han W",,609254,DTCT0024844,3180388,DTCC00620108,393496,37498
CHEMBL605201,P14780,,XDBOLPFDJWTESQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20005097,IC50,>,100000,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,2010,20,2,"Schnute ME, O'Brien PM, Nahra J, Morris M, Howard Roark W, Hanau CE, Ruminski PG, Scholten JA, Fletcher TR, Hamper BC, Carroll JN, Patt WC, Shieh HS, Collins B, Pavlovsky AG, Palmquist KE, Aston KW, Hitchcock J, Rogers MD, McDonald J, Johnson AR, Munie GE, Wittwer AJ, Man CF, Settle SL, Nemirovskiy O, Vickery LE, Agawal A, Dyer RD, Sunyer T",,605229,DTCT0024844,3176019,DTCC00610415,953811,36915
CHEMBL60536,P14780,,YFXAPTTTXDTWSV-QBPKDAKJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15055993,KI,=,47,NM,,,,,,,,,,,,,,Inhibition of human recombinant matrix metalloprotease 9,,Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents.,J. Med. Chem.,2004,47,8,"Moriyama H, Tsukida T, Inoue Y, Yokota K, Yoshino K, Kondo H, Miura N, Nishimura S",,105384,DTCT0024844,1402047,DTCC00205931,1455567,18075
CHEMBL606759,P14780,GLUCOSAMINE,MSWZFWKMSRAUBD-UKFBFLRUSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19375915,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of MMP9 gelatinolytic activity in phorbol myristate acetate-stimulated human HT1080 cells at 60 ug/ml by gelatin zymography relative to control,Not Active,The inhibitory mechanism of a novel cationic glucosamine derivative against MMP-2 and MMP-9 expressions.,Bioorg. Med. Chem. Lett.,2009,19,10,"Mendis E, Kim MM, Rajapakse N, Kim SK",,578121,DTCT0024844,2884687,DTCC00626110,759418,34969
CHEMBL608,P14780,PROBUCOL,FYPMFJGVHOHGLL-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7387793,DTCC00150969,962450,46191
CHEMBL608,P14780,PROBUCOL,FYPMFJGVHOHGLL-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7387794,DTCC00150969,962450,46191
CHEMBL60889,P14780,MOSAPRIDE,YPELFRMCRYSPKZ-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7428518,DTCC00208987,217581,46191
CHEMBL60889,P14780,MOSAPRIDE,YPELFRMCRYSPKZ-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7428519,DTCC00208987,217581,46191
CHEMBL61,P14780,PODOFILOX,YJGVMLPVUAXIQN-XVVDYKMHSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7391821,DTCC00136120,51501,46191
CHEMBL61,P14780,PODOFILOX,YJGVMLPVUAXIQN-XVVDYKMHSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7391822,DTCC00136120,51501,46191
CHEMBL610755,P14780,,STBDFWKKHLAONS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19914829,RATIO,=,61,,,,,,,,,,,,,,,Ratio of Kinact to Ki for MMP9,,Benzylidene cyclopentenediones: First irreversible inhibitors against botulinum neurotoxin A's zinc endopeptidase.,Bioorg. Med. Chem. Lett.,2010,20,1,"Capková K, Hixon MS, Pellett S, Barbieri JT, Johnson EA, Janda KD",,606602,DTCT0024844,3171720,DTCC00613871,2049236,36801
CHEMBL611,P14780,TERAZOSIN,VCKUSRYTPJJLNI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7463503,DTCC00103842,2025644,46191
CHEMBL611,P14780,TERAZOSIN,VCKUSRYTPJJLNI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7463504,DTCC00103842,2025644,46191
CHEMBL61193,P14780,,WLWNRAWQDZRXMB-YLFCFFPRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873504,KI,=,0.06,NM,,,,,,,,,,,,,,Inhibition of recombinant human matrix metalloprotease-9,,Structure--activity relationships of azasugar-based MMP/ADAM inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,16,"Moriyama H, Tsukida T, Inoue Y, Kondo H, Yoshino K, Nishimura S",,105394,DTCT0024844,905721,DTCC00205699,1914636,5719
CHEMBL61193,P14780,,WLWNRAWQDZRXMB-YLFCFFPRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15055993,KI,=,0.06,NM,,,,,,,,,,,,,,Inhibition of human recombinant matrix metalloprotease 9,,Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents.,J. Med. Chem.,2004,47,8,"Moriyama H, Tsukida T, Inoue Y, Yokota K, Yoshino K, Kondo H, Miura N, Nishimura S",,105384,DTCT0024844,1366762,DTCC00205699,1902686,18075
CHEMBL61193,P14780,,WLWNRAWQDZRXMB-YLFCFFPRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,19095454,KI,=,0.061,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Current perspective of TACE inhibitors: a review.,Bioorg. Med. Chem.,2009,17,2,"DasGupta S, Murumkar PR, Giridhar R, Yadav MR",,495050,DTCT0024844,2595470,DTCC00205699,1917358,32093
CHEMBL614,P14780,PYRAZINAMIDE,IPEHBUMCGVEMRF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7390212,DTCC00151678,898296,46191
CHEMBL614,P14780,PYRAZINAMIDE,IPEHBUMCGVEMRF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7390213,DTCC00151678,898296,46191
CHEMBL621,P14780,TRAZODONE,PHLBKPHSAVXXEF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7451665,DTCC00154041,51512,46191
CHEMBL621,P14780,TRAZODONE,PHLBKPHSAVXXEF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7451666,DTCC00154041,51512,46191
CHEMBL62193,P14780,SULFADIMETHOXINE,ZZORFUFYDOWNEF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7478215,DTCC00208934,703987,46191
CHEMBL62193,P14780,SULFADIMETHOXINE,ZZORFUFYDOWNEF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7478216,DTCC00208934,703987,46191
CHEMBL622,P14780,ETODOLAC,NNYBQONXHNTVIJ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7332797,DTCC00154070,153443,46191
CHEMBL622,P14780,ETODOLAC,NNYBQONXHNTVIJ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7332798,DTCC00154070,153443,46191
CHEMBL62259,P14780,,RBLCSCFFNCADJO-CLYVBNDRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11831905,KI,=,5.05,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (MMP-9),,New strategy for antedrug application: development of metalloproteinase inhibitors as antipsoriatic drugs.,J. Med. Chem.,2002,45,4,"Sawa M, Tsukamoto T, Kiyoi T, Kurokawa K, Nakajima F, Nakada Y, Yokota K, Inoue Y, Kondo H, Yoshino K",,105379,DTCT0024844,573305,DTCC00211752,206431,17148
CHEMBL62259,P14780,,RBLCSCFFNCADJO-CLYVBNDRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11844676,KI,=,5.05,NM,,,,,,,,,,,,,,Inhibitory constant against recombinant human gelatinase B (Matrix metalloprotease-9),,Encounter with unexpected collagenase-1 selective inhibitor: switchover of inhibitor binding pocket induced by fluorine atom.,Bioorg. Med. Chem. Lett.,2002,12,4,"Sawa M, Kondo H, Nishimura S",,105400,DTCT0024844,1409876,DTCC00211752,194682,5346
CHEMBL62259,P14780,,RBLCSCFFNCADJO-CLYVBNDRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12781187,KI,=,5.05,NM,,,,,,,,,,,,,,Inhibition of recombinant human Matrix metalloprotease-9,,Discovery of selective phosphonamide-based inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2003,13,12,"Sawa M, Kurokawa K, Inoue Y, Kondo H, Yoshino K",,105393,DTCT0024844,1080583,DTCC00211752,204533,5595
CHEMBL62455,P14780,,VJDIWGRVXNTKIX-HNAYVOBHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12781190,KI,>,2000,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9,,Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2003,13,12,"Duan JJ, Lu Z, Xue CB, He X, Seng JL, Roderick JJ, Wasserman ZR, Liu RQ, Covington MB, Magolda RL, Newton RC, Trzaskos JM, Decicco CP",,105375,DTCT0024844,496310,DTCC00211980,1552577,5598
CHEMBL625,P14780,THIABENDAZOLE,WJCNZQLZVWNLKY-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7470251,DTCC00154204,217588,46191
CHEMBL625,P14780,THIABENDAZOLE,WJCNZQLZVWNLKY-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7470252,DTCC00154204,217588,46191
CHEMBL6273,P14780,FLEROXACIN,XBJBPGROQZJDOJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7330928,DTCC00132376,1220277,46191
CHEMBL6273,P14780,FLEROXACIN,XBJBPGROQZJDOJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7330929,DTCC00132376,1220277,46191
CHEMBL62740,P14780,,DHZSRYYUAYXLLX-OXQOHEQNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12781190,KI,>,2000,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9,,Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2003,13,12,"Duan JJ, Lu Z, Xue CB, He X, Seng JL, Roderick JJ, Wasserman ZR, Liu RQ, Covington MB, Magolda RL, Newton RC, Trzaskos JM, Decicco CP",,105375,DTCT0024844,509820,DTCC00212466,1681779,5598
CHEMBL628,P14780,PENTOXIFYLLINE,BYPFEZZEUUWMEJ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7384879,DTCC00154570,1641851,46191
CHEMBL628,P14780,PENTOXIFYLLINE,BYPFEZZEUUWMEJ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7384880,DTCC00154570,1641851,46191
CHEMBL629,P14780,AMITRIPTYLINE,KRMDCWKBEZIMAB-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7298267,DTCC00154602,477911,46191
CHEMBL629,P14780,AMITRIPTYLINE,KRMDCWKBEZIMAB-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7298268,DTCC00154602,477911,46191
CHEMBL62964,P14780,,CHRGPXOYOHYPAP-GGAORHGYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12781190,KI,>,2000,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9,,Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2003,13,12,"Duan JJ, Lu Z, Xue CB, He X, Seng JL, Roderick JJ, Wasserman ZR, Liu RQ, Covington MB, Magolda RL, Newton RC, Trzaskos JM, Decicco CP",,105375,DTCT0024844,349033,DTCC00212261,711665,5598
CHEMBL631,P14780,PROPAFENONE,JWHAUXFOSRPERK-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7390096,DTCC00154637,1927020,46191
CHEMBL631,P14780,PROPAFENONE,JWHAUXFOSRPERK-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7390097,DTCC00154637,1927020,46191
CHEMBL632,P14780,BETAMETHASONE,UREBDLICKHMUKA-DVTGEIKXSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7277146,DTCC00154673,1188064,46191
CHEMBL632,P14780,BETAMETHASONE,UREBDLICKHMUKA-DVTGEIKXSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7277147,DTCC00154673,1188064,46191
CHEMBL63272,P14780,,DHZSRYYUAYXLLX-OXJNMPFZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12781190,KI,>,2000,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9,,Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2003,13,12,"Duan JJ, Lu Z, Xue CB, He X, Seng JL, Roderick JJ, Wasserman ZR, Liu RQ, Covington MB, Magolda RL, Newton RC, Trzaskos JM, Decicco CP",,105375,DTCT0024844,497501,DTCC00211493,257750,5598
CHEMBL633,P14780,AMIODARONE,IYIKLHRQXLHMJQ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7292766,DTCC00154700,768472,46191
CHEMBL633,P14780,AMIODARONE,IYIKLHRQXLHMJQ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7292767,DTCC00154700,768472,46191
CHEMBL63323,P14780,NIFLUMIC ACID,JZFPYUNJRRFVQU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7405613,DTCC00211494,639583,46191
CHEMBL63323,P14780,NIFLUMIC ACID,JZFPYUNJRRFVQU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7405614,DTCC00211494,639583,46191
CHEMBL635,P14780,PREDNISONE,XOFYZVNMUHMLCC-ZPOLXVRWSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7396243,DTCC00154731,381016,46191
CHEMBL635,P14780,PREDNISONE,XOFYZVNMUHMLCC-ZPOLXVRWSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7396244,DTCC00154731,381016,46191
CHEMBL63560,P14780,(R)-BICALUTAMIDE,LKJPYSCBVHEWIU-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7283491,DTCC00216573,833153,46191
CHEMBL63560,P14780,(R)-BICALUTAMIDE,LKJPYSCBVHEWIU-KRWDZBQOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7283492,DTCC00216573,833153,46191
CHEMBL637,P14780,VENLAFAXINE,PNVNVHUZROJLTJ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7451357,DTCC00154763,1512820,46191
CHEMBL637,P14780,VENLAFAXINE,PNVNVHUZROJLTJ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7451358,DTCC00154763,1512820,46191
CHEMBL64,P14780,ISONIAZID,QRXWMOHMRWLFEY-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7435354,DTCC00136222,51480,46191
CHEMBL64,P14780,ISONIAZID,QRXWMOHMRWLFEY-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7435355,DTCC00136222,51480,46191
CHEMBL640,P14780,PROCAINAMIDE,REQCZEXYDRLIBE-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7392086,DTCC00154806,1577009,46191
CHEMBL640,P14780,PROCAINAMIDE,REQCZEXYDRLIBE-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7392087,DTCC00154806,1577009,46191
CHEMBL642,P14780,ACEBUTOLOL,GOEMGAFJFRBGGG-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7292158,DTCC00154812,1798405,46191
CHEMBL642,P14780,ACEBUTOLOL,GOEMGAFJFRBGGG-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7292159,DTCC00154812,1798405,46191
CHEMBL64262,P14780,,YYHIIRGQRSUJIF-NOZRDPDXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12781190,KI,>,2000,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9,,Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2003,13,12,"Duan JJ, Lu Z, Xue CB, He X, Seng JL, Roderick JJ, Wasserman ZR, Liu RQ, Covington MB, Magolda RL, Newton RC, Trzaskos JM, Decicco CP",,105375,DTCT0024844,501113,DTCC00212056,1806024,5598
CHEMBL64281,P14780,,QTGLVPVEYPPUEP-LAUBAEHRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12781190,KI,>,2000,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9,,Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2003,13,12,"Duan JJ, Lu Z, Xue CB, He X, Seng JL, Roderick JJ, Wasserman ZR, Liu RQ, Covington MB, Magolda RL, Newton RC, Trzaskos JM, Decicco CP",,105375,DTCT0024844,478566,DTCC00211507,388847,5598
CHEMBL643,P14780,PROMETHAZINE,PWWVAXIEGOYWEE-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7385798,DTCC00154825,1188074,46191
CHEMBL643,P14780,PROMETHAZINE,PWWVAXIEGOYWEE-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7385799,DTCC00154825,1188074,46191
CHEMBL6437,P14780,MIANSERIN,UEQUQVLFIPOEMF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7411307,DTCC00132673,1383778,46191
CHEMBL6437,P14780,MIANSERIN,UEQUQVLFIPOEMF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7411308,DTCC00132673,1383778,46191
CHEMBL64571,P14780,,IPBVPRHDESNKFG-FTHRPBJHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12781187,KI,=,23.7,NM,,,,,,,,,,,,,,Inhibition of recombinant human Matrix metalloprotease-9,,Discovery of selective phosphonamide-based inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2003,13,12,"Sawa M, Kurokawa K, Inoue Y, Kondo H, Yoshino K",,105393,DTCT0024844,1061691,DTCC00211729,1629078,5595
CHEMBL64586,P14780,,DCPYFXNPRQTWHH-CTNGQTDRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12781190,KI,=,1964,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9,,Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2003,13,12,"Duan JJ, Lu Z, Xue CB, He X, Seng JL, Roderick JJ, Wasserman ZR, Liu RQ, Covington MB, Magolda RL, Newton RC, Trzaskos JM, Decicco CP",,105375,DTCT0024844,488906,DTCC00211948,128647,5598
CHEMBL6466,P14780,COUMARIN,ZYGHJZDHTFUPRJ-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7369844,DTCC00133265,833159,46191
CHEMBL6466,P14780,COUMARIN,ZYGHJZDHTFUPRJ-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7369845,DTCC00133265,833159,46191
CHEMBL64689,P14780,,SLHHOJZYTMNFRR-WTPASJBYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11844676,KI,=,411,NM,,,,,,,,,,,,,,Inhibitory constant against recombinant human gelatinase B (Matrix metalloprotease-9),,Encounter with unexpected collagenase-1 selective inhibitor: switchover of inhibitor binding pocket induced by fluorine atom.,Bioorg. Med. Chem. Lett.,2002,12,4,"Sawa M, Kondo H, Nishimura S",,105400,DTCT0024844,1406541,DTCC00211726,1327684,5346
CHEMBL64739,P14780,,FTQUTXYBANDKFP-CTNGQTDRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12781190,KI,>,2000,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9,,Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).,Bioorg. Med. Chem. Lett.,2003,13,12,"Duan JJ, Lu Z, Xue CB, He X, Seng JL, Roderick JJ, Wasserman ZR, Liu RQ, Covington MB, Magolda RL, Newton RC, Trzaskos JM, Decicco CP",,105375,DTCT0024844,348652,DTCC00212434,388849,5598
CHEMBL648,P14780,CYCLIZINE,UVKZSORBKUEBAZ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7352590,DTCC00154967,381007,46191
CHEMBL648,P14780,CYCLIZINE,UVKZSORBKUEBAZ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7352591,DTCC00154967,381007,46191
CHEMBL64894,P14780,GENTIAN VIOLET,ZXJXZNDDNMQXFV-UHFFFAOYSA-M,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7312360,DTCC00212699,703981,46191
CHEMBL64894,P14780,GENTIAN VIOLET,ZXJXZNDDNMQXFV-UHFFFAOYSA-M,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7312361,DTCC00212699,703981,46191
CHEMBL649,P14780,NADOLOL,VWPOSFSPZNDTMJ-UCWKZMIHSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7432928,DTCC00154988,2057650,46191
CHEMBL649,P14780,NADOLOL,VWPOSFSPZNDTMJ-UCWKZMIHSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7432929,DTCC00154988,2057650,46191
CHEMBL65,P14780,CAMPTOTHECIN,VSJKWCGYPAHWDS-FQEVSTJZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7267806,DTCC00136347,51451,46191
CHEMBL65,P14780,CAMPTOTHECIN,VSJKWCGYPAHWDS-FQEVSTJZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7267807,DTCC00136347,51451,46191
CHEMBL650,P14780,METHYLPREDNISOLONE,VHRSUDSXCMQTMA-PJHHCJLFSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7438781,DTCC00154993,1447885,46191
CHEMBL650,P14780,METHYLPREDNISOLONE,VHRSUDSXCMQTMA-PJHHCJLFSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7438782,DTCC00154993,1447885,46191
CHEMBL653,P14780,NIZATIDINE,SGXXNSQHWDMGGP-IZZDOVSWSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7375588,DTCC00155018,866021,46191
CHEMBL653,P14780,NIZATIDINE,SGXXNSQHWDMGGP-IZZDOVSWSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7375589,DTCC00155018,866021,46191
CHEMBL657,P14780,DIPHENHYDRAMINE,ZZVUWRFHKOJYTH-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7340550,DTCC00155038,1285873,46191
CHEMBL657,P14780,DIPHENHYDRAMINE,ZZVUWRFHKOJYTH-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7340551,DTCC00155038,1285873,46191
CHEMBL6572,P14780,,QPEZTCMCOIDQRV-SMDDNHRTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11327577,IC50,,,,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (not determined),Not Determined,Heterocycle-based MMP inhibitors with P2' substituents.,Bioorg. Med. Chem. Lett.,2001,11,8,"Pikul S, Dunham KM, Almstead NG, De B, Natchus MG, Taiwo YO, Williams LE, Hynd BA, Hsieh LC, Janusz MJ, Gu F, Mieling GE",,105363,DTCT0024844,1316354,DTCC00133465,34547,4760
CHEMBL659,P14780,GALANTAMINE,ASUTZQLVASHGKV-JDFRZJQESA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7303668,DTCC00155049,994592,46191
CHEMBL659,P14780,GALANTAMINE,ASUTZQLVASHGKV-JDFRZJQESA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7303669,DTCC00155049,994592,46191
CHEMBL660,P14780,AMANTADINE,DKNWSYNQZKUICI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7285932,DTCC00155056,1285872,46191
CHEMBL660,P14780,AMANTADINE,DKNWSYNQZKUICI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7285933,DTCC00155056,1285872,46191
CHEMBL66098,P14780,,ZWYFAUSBUXUGKC-QJPTWQEYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514157,KI,=,33,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution.,Bioorg. Med. Chem. Lett.,2001,11,16,"Musso DL, Andersen MW, Andrews RC, Austin R, Beaudet EJ, Becherer JD, Bubacz DG, Bickett DM, Chan JH, Conway JG, Cowan DJ, Gaul MD, Glennon KC, Hedeen KM, Lambert MH, Leesnitzer MA, McDougald DL, Mitchell JL, Moss ML, Rabinowitz MH, Rizzolio MC, Schaller LT, Stanford JB, Tippin T, Warner JR, Whitesell LG, Wiethe RW",,105542,DTCT0024844,900806,DTCC00220206,723370,4390
CHEMBL661,P14780,ALPRAZOLAM,VREFGVBLTWBCJP-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7302286,DTCC00155057,994588,46191
CHEMBL661,P14780,ALPRAZOLAM,VREFGVBLTWBCJP-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7302287,DTCC00155057,994588,46191
CHEMBL66181,P14780,,WEQCLTHHZZNFDV-ZNMIVQPWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514157,KI,=,17,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution.,Bioorg. Med. Chem. Lett.,2001,11,16,"Musso DL, Andersen MW, Andrews RC, Austin R, Beaudet EJ, Becherer JD, Bubacz DG, Bickett DM, Chan JH, Conway JG, Cowan DJ, Gaul MD, Glennon KC, Hedeen KM, Lambert MH, Leesnitzer MA, McDougald DL, Mitchell JL, Moss ML, Rabinowitz MH, Rizzolio MC, Schaller LT, Stanford JB, Tippin T, Warner JR, Whitesell LG, Wiethe RW",,105542,DTCT0024844,909383,DTCC00219789,1882120,4390
CHEMBL666,P14780,FOSCARNET,ZJAOAACCNHFJAH-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7316396,DTCC00155151,1765971,46191
CHEMBL666,P14780,FOSCARNET,ZJAOAACCNHFJAH-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7316397,DTCC00155151,1765971,46191
CHEMBL66970,P14780,,RGDBGIBFYROBCD-YNEHKIRRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514157,KI,=,21,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution.,Bioorg. Med. Chem. Lett.,2001,11,16,"Musso DL, Andersen MW, Andrews RC, Austin R, Beaudet EJ, Becherer JD, Bubacz DG, Bickett DM, Chan JH, Conway JG, Cowan DJ, Gaul MD, Glennon KC, Hedeen KM, Lambert MH, Leesnitzer MA, McDougald DL, Mitchell JL, Moss ML, Rabinowitz MH, Rizzolio MC, Schaller LT, Stanford JB, Tippin T, Warner JR, Whitesell LG, Wiethe RW",,105542,DTCT0024844,921863,DTCC00219913,1785265,4390
CHEMBL672,P14780,FENOFIBRATE,YMTINGFKWWXKFG-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7305224,DTCC01738591,1220276,46191
CHEMBL672,P14780,FENOFIBRATE,YMTINGFKWWXKFG-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7305225,DTCC01738591,1220276,46191
CHEMBL67291,P14780,,JBDQTGJGXFAHIQ-VQHVLOKHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,7.25,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833648,DTCC00220573,964993,53968
CHEMBL67498,P14780,CAFFEIC ACID PHENETHYL AMIDE,QOWABIXYAFJMQE-VQHVLOKHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,7.28,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833647,DTCC00220542,447224,53968
CHEMBL67590,P14780,,FJRQWHSKVHCEKG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514167,IC50,=,189,NM,,,,,,,,,,,,,,In vitro ability to inhibit matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.,Bioorg. Med. Chem. Lett.,2001,11,16,"Levin JI, Chen J, Du M, Hogan M, Kincaid S, Nelson FC, Venkatesan AM, Wehr T, Zask A, DiJoseph J, Killar LM, Skala S, Sung A, Sharr M, Roth C, Jin G, Cowling R, Mohler KM, Black RA, March CJ, Skotnicki JS",,105532,DTCT0024844,999974,DTCC00222546,1968113,4353
CHEMBL67830,P14780,,SVJNLPDHJMHQCE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25907368,INHIBITION,,,,,cell_based,,,,,,,,,,,,Inhibition of MMP-9 activity in human HT1080 cells by gelatin zymography,Not Active,"Synthesis and discovery of (I-3,II-3)-biacacetin as a novel non-zinc binding inhibitor of MMP-2 and MMP-9.",Bioorg. Med. Chem.,2015,23,13,"Nanjan P, Nambiar J, Nair BG, Banerji A",,1501257,DTCT0024844,14455606,DTCC00216955,1739582,62853
CHEMBL679,P14780,EPINEPHRINE,UCTWMZQNUQWSLP-VIFPVBQESA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7311243,DTCC00156188,1512808,46191
CHEMBL679,P14780,EPINEPHRINE,UCTWMZQNUQWSLP-VIFPVBQESA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7311244,DTCC00156188,1512808,46191
CHEMBL68049,P14780,,ZRSUANFPMBWMDZ-YKSBVNFPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,69,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1399736,DTCC00224780,1661211,14854
CHEMBL68149,P14780,,IWLYSDNBOSWMRQ-JWQCQUIFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,3.5,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1398507,DTCC00224685,1817827,14854
CHEMBL68196,P14780,,ZQENIBLYGGLKSO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514167,IC50,=,4,NM,,,,,,,,,,,,,,In vitro ability to inhibit matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.,Bioorg. Med. Chem. Lett.,2001,11,16,"Levin JI, Chen J, Du M, Hogan M, Kincaid S, Nelson FC, Venkatesan AM, Wehr T, Zask A, DiJoseph J, Killar LM, Skala S, Sung A, Sharr M, Roth C, Jin G, Cowling R, Mohler KM, Black RA, March CJ, Skotnicki JS",,105532,DTCT0024844,1001185,DTCC00222818,323651,4353
CHEMBL68212,P14780,,QYEGLTVXUKXPSD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514167,IC50,=,7,NM,,,,,,,,,,,,,,In vitro ability to inhibit matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.,Bioorg. Med. Chem. Lett.,2001,11,16,"Levin JI, Chen J, Du M, Hogan M, Kincaid S, Nelson FC, Venkatesan AM, Wehr T, Zask A, DiJoseph J, Killar LM, Skala S, Sung A, Sharr M, Roth C, Jin G, Cowling R, Mohler KM, Black RA, March CJ, Skotnicki JS",,105532,DTCT0024844,1003590,DTCC00222631,1934882,4353
CHEMBL68271,P14780,,MQDWBVIPJPRWIJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514167,IC50,=,7,NM,,,,,,,,,,,,,,In vitro ability to inhibit matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.,Bioorg. Med. Chem. Lett.,2001,11,16,"Levin JI, Chen J, Du M, Hogan M, Kincaid S, Nelson FC, Venkatesan AM, Wehr T, Zask A, DiJoseph J, Killar LM, Skala S, Sung A, Sharr M, Roth C, Jin G, Cowling R, Mohler KM, Black RA, March CJ, Skotnicki JS",,105532,DTCT0024844,999970,DTCC00222783,1806122,4353
CHEMBL683,P14780,CLOFIBRIC ACID,TXCGAZHTZHNUAI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7362895,DTCC00156551,1894964,46191
CHEMBL683,P14780,CLOFIBRIC ACID,TXCGAZHTZHNUAI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7362896,DTCC00156551,1894964,46191
CHEMBL68427,P14780,,TUCRGTOIEKYIRD-FNORWQNLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,1642.27,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833645,DTCC00220988,1418674,53968
CHEMBL685,P14780,MEBENDAZOLE,OPXLLQIJSORQAM-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7425676,DTCC00156769,800580,46191
CHEMBL685,P14780,MEBENDAZOLE,OPXLLQIJSORQAM-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7425677,DTCC00156769,800580,46191
CHEMBL68542,P14780,,PCSKPZLQCNGMCY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514167,IC50,=,2,NM,,,,,,,,,,,,,,In vitro ability to inhibit matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.,Bioorg. Med. Chem. Lett.,2001,11,16,"Levin JI, Chen J, Du M, Hogan M, Kincaid S, Nelson FC, Venkatesan AM, Wehr T, Zask A, DiJoseph J, Killar LM, Skala S, Sung A, Sharr M, Roth C, Jin G, Cowling R, Mohler KM, Black RA, March CJ, Skotnicki JS",,105532,DTCT0024844,1013365,DTCC00222105,225597,4353
CHEMBL68553,P14780,,AHCJFAZGYUITPV-BFHYXJOUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514157,KI,=,34,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution.,Bioorg. Med. Chem. Lett.,2001,11,16,"Musso DL, Andersen MW, Andrews RC, Austin R, Beaudet EJ, Becherer JD, Bubacz DG, Bickett DM, Chan JH, Conway JG, Cowan DJ, Gaul MD, Glennon KC, Hedeen KM, Lambert MH, Leesnitzer MA, McDougald DL, Mitchell JL, Moss ML, Rabinowitz MH, Rizzolio MC, Schaller LT, Stanford JB, Tippin T, Warner JR, Whitesell LG, Wiethe RW",,105542,DTCT0024844,900812,DTCC00220529,140487,4390
CHEMBL686,P14780,MEFENAMIC ACID,HYYBABOKPJLUIN-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7408583,DTCC00157071,1416034,46191
CHEMBL686,P14780,MEFENAMIC ACID,HYYBABOKPJLUIN-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7408584,DTCC00157071,1416034,46191
CHEMBL68667,P14780,,YPFZRQMUNBCBEG-YEBPUJJMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514157,KI,=,73,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution.,Bioorg. Med. Chem. Lett.,2001,11,16,"Musso DL, Andersen MW, Andrews RC, Austin R, Beaudet EJ, Becherer JD, Bubacz DG, Bickett DM, Chan JH, Conway JG, Cowan DJ, Gaul MD, Glennon KC, Hedeen KM, Lambert MH, Leesnitzer MA, McDougald DL, Mitchell JL, Moss ML, Rabinowitz MH, Rizzolio MC, Schaller LT, Stanford JB, Tippin T, Warner JR, Whitesell LG, Wiethe RW",,105542,DTCT0024844,928053,DTCC00220499,1144056,4390
CHEMBL68812,P14780,,VPADZEAGMFRILI-ZNMIVQPWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514157,KI,=,98,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution.,Bioorg. Med. Chem. Lett.,2001,11,16,"Musso DL, Andersen MW, Andrews RC, Austin R, Beaudet EJ, Becherer JD, Bubacz DG, Bickett DM, Chan JH, Conway JG, Cowan DJ, Gaul MD, Glennon KC, Hedeen KM, Lambert MH, Leesnitzer MA, McDougald DL, Mitchell JL, Moss ML, Rabinowitz MH, Rizzolio MC, Schaller LT, Stanford JB, Tippin T, Warner JR, Whitesell LG, Wiethe RW",,105542,DTCT0024844,928047,DTCC00219778,1914232,4390
CHEMBL68890,P14780,,NDJSPXLINRRDIS-DYVFJYSZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,0.54,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1387372,DTCC00224920,2012678,14854
CHEMBL689,P14780,MANNITOL,FBPFZTCFMRRESA-KVTDHHQDSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7406201,DTCC00157212,1960078,46191
CHEMBL689,P14780,MANNITOL,FBPFZTCFMRRESA-KVTDHHQDSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7406202,DTCC00157212,1960078,46191
CHEMBL69024,P14780,,BCORPMHFJPQWGD-WOJBJXKFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,1.5,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1385048,DTCC00224864,302885,14854
CHEMBL69048,P14780,,RISXEMMNXJMKFX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514167,INHIBITION,=,43,%,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 at 1 uM,,The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.,Bioorg. Med. Chem. Lett.,2001,11,16,"Levin JI, Chen J, Du M, Hogan M, Kincaid S, Nelson FC, Venkatesan AM, Wehr T, Zask A, DiJoseph J, Killar LM, Skala S, Sung A, Sharr M, Roth C, Jin G, Cowling R, Mohler KM, Black RA, March CJ, Skotnicki JS",,105536,DTCT0024844,1005834,DTCC00222617,1293652,4353
CHEMBL69072,P14780,,MXPPQWXYSRGIMR-UZLBHIALSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,26,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1383737,DTCC00224774,2012677,14854
CHEMBL691,P14780,ETHINYL ESTRADIOL,BFPYWIDHMRZLRN-SLHNCBLASA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7336947,DTCC00158050,2089747,46191
CHEMBL691,P14780,ETHINYL ESTRADIOL,BFPYWIDHMRZLRN-SLHNCBLASA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7336948,DTCC00158050,2089747,46191
CHEMBL69145,P14780,,WKTQKJFJPJOVNX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514167,IC50,=,125,NM,,,,,,,,,,,,,,In vitro ability to inhibit matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.,Bioorg. Med. Chem. Lett.,2001,11,16,"Levin JI, Chen J, Du M, Hogan M, Kincaid S, Nelson FC, Venkatesan AM, Wehr T, Zask A, DiJoseph J, Killar LM, Skala S, Sung A, Sharr M, Roth C, Jin G, Cowling R, Mohler KM, Black RA, March CJ, Skotnicki JS",,105532,DTCT0024844,1008410,DTCC00223257,1741858,4353
CHEMBL69194,P14780,,WGUQAEXNOBFCNK-KBPBESRZSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9632351,IC50,=,2365,NM,,,,,,,,,,,,,,Inhibition of Matrix Metalloprotease-9,,Rational design and combinatorial evaluation of enzyme inhibitor scaffolds: identification of novel inhibitors of matrix metalloproteinases.,J. Med. Chem.,1998,41,13,"Szardenings AK, Harris D, Lam S, Shi L, Tien D, Wang Y, Patel DV, Navre M, Campbell DA",,105510,DTCT0024844,823088,DTCC00222733,1359016,14688
CHEMBL69268,P14780,,CBKKHHSQVZVIBM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514167,IC50,=,8,NM,,,,,,,,,,,,,,In vitro ability to inhibit matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.,Bioorg. Med. Chem. Lett.,2001,11,16,"Levin JI, Chen J, Du M, Hogan M, Kincaid S, Nelson FC, Venkatesan AM, Wehr T, Zask A, DiJoseph J, Killar LM, Skala S, Sung A, Sharr M, Roth C, Jin G, Cowling R, Mohler KM, Black RA, March CJ, Skotnicki JS",,105532,DTCT0024844,1010802,DTCC00222781,1649724,4353
CHEMBL69323,P14780,,SKDNVHHXHPMJHN-PMACEKPBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9632351,IC50,=,87,NM,,,,,,,,,,,,,,Inhibition of Matrix Metalloprotease-9,,Rational design and combinatorial evaluation of enzyme inhibitor scaffolds: identification of novel inhibitors of matrix metalloproteinases.,J. Med. Chem.,1998,41,13,"Szardenings AK, Harris D, Lam S, Shi L, Tien D, Wang Y, Patel DV, Navre M, Campbell DA",,105510,DTCT0024844,819276,DTCC00222906,550338,14688
CHEMBL69418,P14780,,UWHDYIJAXRNLQS-XQLPTFJDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514157,KI,=,29,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution.,Bioorg. Med. Chem. Lett.,2001,11,16,"Musso DL, Andersen MW, Andrews RC, Austin R, Beaudet EJ, Becherer JD, Bubacz DG, Bickett DM, Chan JH, Conway JG, Cowan DJ, Gaul MD, Glennon KC, Hedeen KM, Lambert MH, Leesnitzer MA, McDougald DL, Mitchell JL, Moss ML, Rabinowitz MH, Rizzolio MC, Schaller LT, Stanford JB, Tippin T, Warner JR, Whitesell LG, Wiethe RW",,105542,DTCT0024844,915119,DTCC00219781,1532163,4390
CHEMBL695,P14780,TRIMETHADIONE,IRYJRGCIQBGHIV-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7446321,DTCC00158510,1830695,46191
CHEMBL695,P14780,TRIMETHADIONE,IRYJRGCIQBGHIV-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7446322,DTCC00158510,1830695,46191
CHEMBL69506,P14780,,UIHJPRDGPQZWAH-WOJBJXKFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,2.7,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1402227,DTCC00225596,1661212,14854
CHEMBL69569,P14780,,ZDRROEWAOPXRJQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514167,IC50,=,3448,NM,,,,,,,,,,,,,,In vitro ability to inhibit matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.,Bioorg. Med. Chem. Lett.,2001,11,16,"Levin JI, Chen J, Du M, Hogan M, Kincaid S, Nelson FC, Venkatesan AM, Wehr T, Zask A, DiJoseph J, Killar LM, Skala S, Sung A, Sharr M, Roth C, Jin G, Cowling R, Mohler KM, Black RA, March CJ, Skotnicki JS",,105532,DTCT0024844,998695,DTCC00222440,1035038,4353
CHEMBL69596,P14780,,IQHWFMFCBUDMAF-FZKCQIBNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514157,KI,=,24,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution.,Bioorg. Med. Chem. Lett.,2001,11,16,"Musso DL, Andersen MW, Andrews RC, Austin R, Beaudet EJ, Becherer JD, Bubacz DG, Bickett DM, Chan JH, Conway JG, Cowan DJ, Gaul MD, Glennon KC, Hedeen KM, Lambert MH, Leesnitzer MA, McDougald DL, Mitchell JL, Moss ML, Rabinowitz MH, Rizzolio MC, Schaller LT, Stanford JB, Tippin T, Warner JR, Whitesell LG, Wiethe RW",,105542,DTCT0024844,913919,DTCC00220500,2076952,4390
CHEMBL696,P14780,ETHOSUXIMIDE,HAPOVYFOVVWLRS-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7311432,DTCC00158516,88627,46191
CHEMBL696,P14780,ETHOSUXIMIDE,HAPOVYFOVVWLRS-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7311433,DTCC00158516,88627,46191
CHEMBL6966,P14780,VERAPAMIL,SGTNSNPWRIOYBX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7453220,DTCC00133226,51515,46191
CHEMBL6966,P14780,VERAPAMIL,SGTNSNPWRIOYBX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7453221,DTCC00133226,51515,46191
CHEMBL69726,P14780,,NTWPNMLRTBRVIB-SJORKVTESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9632351,IC50,=,7000,NM,,,,,,,,,,,,,,Inhibition of gelatinase-B (Matrix metalloprotease-9),,Rational design and combinatorial evaluation of enzyme inhibitor scaffolds: identification of novel inhibitors of matrix metalloproteinases.,J. Med. Chem.,1998,41,13,"Szardenings AK, Harris D, Lam S, Shi L, Tien D, Wang Y, Patel DV, Navre M, Campbell DA",,105218,DTCT0024844,828025,DTCC00223929,1870492,14688
CHEMBL6973,P14780,,DRWHINQPSIPRHF-LLVKDONJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11327577,IC50,=,24.1,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Heterocycle-based MMP inhibitors with P2' substituents.,Bioorg. Med. Chem. Lett.,2001,11,8,"Pikul S, Dunham KM, Almstead NG, De B, Natchus MG, Taiwo YO, Williams LE, Hynd BA, Hsieh LC, Janusz MJ, Gu F, Mieling GE",,105362,DTCT0024844,1301011,DTCC00133507,110647,4760
CHEMBL698,P14780,TETRACAINE,GKCBAIGFKIBETG-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7487378,DTCC00158693,866024,46191
CHEMBL698,P14780,TETRACAINE,GKCBAIGFKIBETG-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7487379,DTCC00158693,866024,46191
CHEMBL69803,P14780,,QEFITTUAKPOZPK-KRXBUXKQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23375794,IC50,=,2.35,NM,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 using succinylated gelatin as substrate incubated for 30 mins prior to substrate addition measured after 60 mins,,Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.,Bioorg. Med. Chem. Lett.,2013,23,5,"Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA",,948150,DTCT0024844,11833644,DTCC00220717,91234,53968
CHEMBL7002,P14780,CIGLITAZONE,YZFWTZACSRHJQD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7345531,DTCC00133474,413970,46191
CHEMBL7002,P14780,CIGLITAZONE,YZFWTZACSRHJQD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7345532,DTCC00133474,413970,46191
CHEMBL70049,P14780,,VWIDRIAWTQJPLN-KDOFPFPSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,22,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1393595,DTCC00225610,1435144,14854
CHEMBL701,P14780,BACLOFEN,KPYSYYIEGFHWSV-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7261113,DTCC00159319,1318438,46191
CHEMBL701,P14780,BACLOFEN,KPYSYYIEGFHWSV-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7261114,DTCC00159319,1318438,46191
CHEMBL70110,P14780,,LCWFIBYPSAWVLI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,10,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103064,DTCC00224425,1349087,43205
CHEMBL70176,P14780,,AINJYWXKBKRQSX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11206467,DOSE,=,50,MG KG-1,,,,,,,,,,,,,,Dose at which the compound was equipotent with CGS-27023 against matrix metalloprotease-9 in the dialysis tubing implant assay,,The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position.,Bioorg. Med. Chem. Lett.,2001,11,2,"Levin JI, Du MT, DiJoseph JF, Killar LM, Sung A, Walter T, Sharr MA, Roth CE, Moy FJ, Powers R, Jin G, Cowling R, Skotnicki JS",,105657,DTCT0024844,603578,DTCC00222284,257991,4515
CHEMBL70176,P14780,,AINJYWXKBKRQSX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11206467,ED50,=,33,MG.KG-1,,organism_based,,,,,,,,,,,,Tested the po dose effective against Matrix metalloprotease-9 in the dialysis tubing implant assay,,The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position.,Bioorg. Med. Chem. Lett.,2001,11,2,"Levin JI, Du MT, DiJoseph JF, Killar LM, Sung A, Walter T, Sharr MA, Roth CE, Moy FJ, Powers R, Jin G, Cowling R, Skotnicki JS",,105658,DTCT0024844,603580,DTCC00222284,257991,4515
CHEMBL70176,P14780,,AINJYWXKBKRQSX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11206467,IC50,=,5,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position.,Bioorg. Med. Chem. Lett.,2001,11,2,"Levin JI, Du MT, DiJoseph JF, Killar LM, Sung A, Walter T, Sharr MA, Roth CE, Moy FJ, Powers R, Jin G, Cowling R, Skotnicki JS",,105222,DTCT0024844,603577,DTCC00222284,257991,4515
CHEMBL70176,P14780,,AINJYWXKBKRQSX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11206468,IC50,=,5,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2001,11,2,"Levin JI, Gu Y, Nelson FC, Zask A, DiJoseph JF, Sharr MA, Sung A, Jin G, Cowling R, Chanda P, Cosmi S, Hsiao CL, Edris W, Wilhelm J, Killar LM, Skotnicki JS",,105505,DTCT0024844,1287482,DTCC00222284,269983,4516
CHEMBL70176,P14780,,AINJYWXKBKRQSX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514167,IC50,=,5,NM,,,,,,,,,,,,,,In vitro ability to inhibit matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.,Bioorg. Med. Chem. Lett.,2001,11,16,"Levin JI, Chen J, Du M, Hogan M, Kincaid S, Nelson FC, Venkatesan AM, Wehr T, Zask A, DiJoseph J, Killar LM, Skala S, Sung A, Sharr M, Roth C, Jin G, Cowling R, Mohler KM, Black RA, March CJ, Skotnicki JS",,105532,DTCT0024844,988864,DTCC00222284,257857,4353
CHEMBL70176,P14780,,AINJYWXKBKRQSX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11677139,IC50,=,5,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.,Bioorg. Med. Chem. Lett.,2001,11,22,"Levin JI, Chen JM, Du MT, Nelson FC, Wehr T, DiJoseph JF, Killar LM, Skala S, Sung A, Sharr MA, Roth CE, Jin G, Cowling R, Di L, Sherman M, Xu ZB, March CJ, Mohler KM, Black RA, Skotnicki JS",,105530,DTCT0024844,1635161,DTCC00222284,258369,4590
CHEMBL70176,P14780,,AINJYWXKBKRQSX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11677139,IC50,=,7,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.,Bioorg. Med. Chem. Lett.,2001,11,22,"Levin JI, Chen JM, Du MT, Nelson FC, Wehr T, DiJoseph JF, Killar LM, Skala S, Sung A, Sharr MA, Roth CE, Jin G, Cowling R, Di L, Sherman M, Xu ZB, March CJ, Mohler KM, Black RA, Skotnicki JS",,105530,DTCT0024844,1603353,DTCC00222284,258371,4590
CHEMBL70176,P14780,,AINJYWXKBKRQSX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11677139,IC50,=,8,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.,Bioorg. Med. Chem. Lett.,2001,11,22,"Levin JI, Chen JM, Du MT, Nelson FC, Wehr T, DiJoseph JF, Killar LM, Skala S, Sung A, Sharr MA, Roth CE, Jin G, Cowling R, Di L, Sherman M, Xu ZB, March CJ, Mohler KM, Black RA, Skotnicki JS",,105530,DTCT0024844,1609699,DTCC00222284,258370,4590
CHEMBL70176,P14780,,AINJYWXKBKRQSX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,5.01,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258698,DTCC00222284,260722,24803
CHEMBL702,P14780,PIPERACILLIN,IVBHGBMCVLDMKU-GXNBUGAJSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7400295,DTCC00159449,962449,46191
CHEMBL702,P14780,PIPERACILLIN,IVBHGBMCVLDMKU-GXNBUGAJSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7400296,DTCC00159449,962449,46191
CHEMBL70207,P14780,,LSGQQGGAWBOKIB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514167,IC50,=,554,NM,,,,,,,,,,,,,,In vitro ability to inhibit matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.,Bioorg. Med. Chem. Lett.,2001,11,16,"Levin JI, Chen J, Du M, Hogan M, Kincaid S, Nelson FC, Venkatesan AM, Wehr T, Zask A, DiJoseph J, Killar LM, Skala S, Sung A, Sharr M, Roth C, Jin G, Cowling R, Mohler KM, Black RA, March CJ, Skotnicki JS",,105532,DTCT0024844,1014665,DTCC00222731,291130,4353
CHEMBL70315,P14780,,KXYFKTLZKSANJT-SJLPKXTDSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,0.7,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1381111,DTCC00226033,29662,14854
CHEMBL70354,P14780,,CVRRBTAXFZBMPH-KAYWLYCHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,3.6,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1380994,DTCC00225598,1914295,14854
CHEMBL70398,P14780,,OKGPERFMUXABQD-UTUOFQBUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,2.3,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1386228,DTCC00225984,1403135,14854
CHEMBL70406,P14780,,OUMHWPMKRPJGKY-XDAJTCOGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,6.3,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1382343,DTCC00224975,1693318,14854
CHEMBL70417,P14780,,BOHIPQBVCFMFFK-GCJKJVERSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,0.78,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1382339,DTCC00225271,433223,14854
CHEMBL70426,P14780,,SBOCVCYAEHVMEA-UZLBHIALSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,8.7,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1368301,DTCC00225464,1564220,14854
CHEMBL70430,P14780,,UMZQUWRHZNAVMN-ILBGXUMGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,0.58,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1365750,DTCC00225049,1596640,14854
CHEMBL70492,P14780,,FYGGOGPIPBSHEF-IEBWSBKVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,1.3,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1393599,DTCC00224896,335444,14854
CHEMBL70570,P14780,,CJQLPOBRKZCBHK-VXGBXAGGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,2.5,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1368418,DTCC00225946,335443,14854
CHEMBL70571,P14780,,JHRIMEDFWCLALJ-PVAVHDDUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,1.7,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1395990,DTCC00225947,204694,14854
CHEMBL70586,P14780,SPIRADOLINE,NYKCGQQJNVPOLU-ONTIZHBOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7488619,DTCC00226650,1318446,46191
CHEMBL70586,P14780,SPIRADOLINE,NYKCGQQJNVPOLU-ONTIZHBOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7488620,DTCC00226650,1318446,46191
CHEMBL70639,P14780,,UHJDYMMCTFTTSW-JKSUJKDBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,18,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1388630,DTCC00225490,1111858,14854
CHEMBL707,P14780,DOXAZOSIN,RUZYUOTYCVRMRZ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7347007,DTCC00159683,1992804,46191
CHEMBL707,P14780,DOXAZOSIN,RUZYUOTYCVRMRZ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7347008,DTCC00159683,1992804,46191
CHEMBL70927,P14780,DEFERIPRONE,TZXKOCQBRNJULO-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7352794,DTCC00224426,348396,46191
CHEMBL70927,P14780,DEFERIPRONE,TZXKOCQBRNJULO-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7352795,DTCC00224426,348396,46191
CHEMBL70953,P14780,,UKNOMEZXDWRZAF-GSMMQLOJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,74,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1372218,DTCC00225487,1079125,14854
CHEMBL70957,P14780,,RGJXGQMBVWRXCQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514167,IC50,,,,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 (Not tested),Not Determined,The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.,Bioorg. Med. Chem. Lett.,2001,11,16,"Levin JI, Chen J, Du M, Hogan M, Kincaid S, Nelson FC, Venkatesan AM, Wehr T, Zask A, DiJoseph J, Killar LM, Skala S, Sung A, Sharr M, Roth C, Jin G, Cowling R, Mohler KM, Black RA, March CJ, Skotnicki JS",,105533,DTCT0024844,982027,DTCC00222702,1741859,4353
CHEMBL70965,P14780,,FNRRTPCWYWKARV-VGSWGCGISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,0.68,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1372223,DTCC00225239,140536,14854
CHEMBL71,P14780,CHLORPROMAZINE,ZPEIMTDSQAKGNT-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7368928,DTCC00137262,51456,46191
CHEMBL71,P14780,CHLORPROMAZINE,ZPEIMTDSQAKGNT-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7368929,DTCC00137262,51456,46191
CHEMBL710,P14780,FINASTERIDE,DBEPLOCGEIEOCV-WSBQPABSSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7322323,DTCC00159940,348402,46191
CHEMBL710,P14780,FINASTERIDE,DBEPLOCGEIEOCV-WSBQPABSSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7322324,DTCC00159940,348402,46191
CHEMBL71007,P14780,,QVIMBPCQZGHONM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514167,IC50,=,46,NM,,,,,,,,,,,,,,In vitro ability to inhibit matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.,Bioorg. Med. Chem. Lett.,2001,11,16,"Levin JI, Chen J, Du M, Hogan M, Kincaid S, Nelson FC, Venkatesan AM, Wehr T, Zask A, DiJoseph J, Killar LM, Skala S, Sung A, Sharr M, Roth C, Jin G, Cowling R, Mohler KM, Black RA, March CJ, Skotnicki JS",,105532,DTCT0024844,1005826,DTCC00222874,323652,4353
CHEMBL71014,P14780,,XQEHCUFTCDJVSN-ZWKOTPCHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,26,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1383745,DTCC00225460,820108,14854
CHEMBL71071,P14780,,QUSCQVGYLGWIJY-NRYAXDJKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,3.7,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1379726,DTCC00225563,1079124,14854
CHEMBL7108,P14780,,VAQNHYAKIUNIKM-CYBMUJFWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11327577,IC50,=,1.1,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Heterocycle-based MMP inhibitors with P2' substituents.,Bioorg. Med. Chem. Lett.,2001,11,8,"Pikul S, Dunham KM, Almstead NG, De B, Natchus MG, Taiwo YO, Williams LE, Hynd BA, Hsieh LC, Janusz MJ, Gu F, Mieling GE",,105362,DTCT0024844,1286296,DTCC00133441,1209922,4760
CHEMBL711,P14780,PHENINDIONE,NFBAXHOPROOJAW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7380649,DTCC00159969,185556,46191
CHEMBL711,P14780,PHENINDIONE,NFBAXHOPROOJAW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7380650,DTCC00159969,185556,46191
CHEMBL71120,P14780,,NTWPNMLRTBRVIB-IAGOWNOFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9632351,IC50,>,40000,NM,,,,,,,,,,,,,,Inhibition of gelatinase-B (Matrix metalloprotease-9),,Rational design and combinatorial evaluation of enzyme inhibitor scaffolds: identification of novel inhibitors of matrix metalloproteinases.,J. Med. Chem.,1998,41,13,"Szardenings AK, Harris D, Lam S, Shi L, Tien D, Wang Y, Patel DV, Navre M, Campbell DA",,105218,DTCT0024844,845184,DTCC00223876,550337,14688
CHEMBL712,P14780,ANISINDIONE,XRCFXMGQEVUZFC-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7276376,DTCC00160027,574619,46191
CHEMBL712,P14780,ANISINDIONE,XRCFXMGQEVUZFC-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7276377,DTCC00160027,574619,46191
CHEMBL71227,P14780,,PYSVMZGECWVLOT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514167,IC50,=,952,NM,,,,,,,,,,,,,,In vitro ability to inhibit matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.,Bioorg. Med. Chem. Lett.,2001,11,16,"Levin JI, Chen J, Du M, Hogan M, Kincaid S, Nelson FC, Venkatesan AM, Wehr T, Zask A, DiJoseph J, Killar LM, Skala S, Sung A, Sharr M, Roth C, Jin G, Cowling R, Mohler KM, Black RA, March CJ, Skotnicki JS",,105532,DTCT0024844,984286,DTCC00223155,1488329,4353
CHEMBL71309,P14780,,WRNMBFWQBKEBIX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514167,IC50,=,5,NM,,,,,,,,,,,,,,In vitro ability to inhibit matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.,Bioorg. Med. Chem. Lett.,2001,11,16,"Levin JI, Chen J, Du M, Hogan M, Kincaid S, Nelson FC, Venkatesan AM, Wehr T, Zask A, DiJoseph J, Killar LM, Skala S, Sung A, Sharr M, Roth C, Jin G, Cowling R, Mohler KM, Black RA, March CJ, Skotnicki JS",,105532,DTCT0024844,1013370,DTCC00222389,1488328,4353
CHEMBL714,P14780,ALBUTEROL,NDAUXUAQIAJITI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7488269,DTCC00160256,962451,46191
CHEMBL714,P14780,ALBUTEROL,NDAUXUAQIAJITI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7488270,DTCC00160256,962451,46191
CHEMBL71436,P14780,,MLRVULAXCZJAAN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514167,IC50,=,232,NM,,,,,,,,,,,,,,In vitro ability to inhibit matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.,Bioorg. Med. Chem. Lett.,2001,11,16,"Levin JI, Chen J, Du M, Hogan M, Kincaid S, Nelson FC, Venkatesan AM, Wehr T, Zask A, DiJoseph J, Killar LM, Skala S, Sung A, Sharr M, Roth C, Jin G, Cowling R, Mohler KM, Black RA, March CJ, Skotnicki JS",,105532,DTCT0024844,1008414,DTCC00223207,1326197,4353
CHEMBL71468,P14780,,GPKYERMOQBHGRC-KDOFPFPSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,42,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1368313,DTCC00224782,1046648,14854
CHEMBL71482,P14780,,YSZLQAVPFNEECF-BEFAXECRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,0.41,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1402230,DTCC00225535,1014237,14854
CHEMBL715,P14780,OLANZAPINE,KVWDHTXUZHCGIO-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7397239,DTCC00160346,1512814,46191
CHEMBL715,P14780,OLANZAPINE,KVWDHTXUZHCGIO-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7397240,DTCC00160346,1512814,46191
CHEMBL71573,P14780,,NTWPNMLRTBRVIB-DLBZAZTESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9632351,IC50,=,12000,NM,,,,,,,,,,,,,,Inhibition of gelatinase-B (Matrix metalloprotease-9),,Rational design and combinatorial evaluation of enzyme inhibitor scaffolds: identification of novel inhibitors of matrix metalloproteinases.,J. Med. Chem.,1998,41,13,"Szardenings AK, Harris D, Lam S, Shi L, Tien D, Wang Y, Patel DV, Navre M, Campbell DA",,105218,DTCT0024844,822975,DTCC00223905,1520641,14688
CHEMBL716,P14780,QUETIAPINE,URKOMYMAXPYINW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7403118,DTCC00160380,1734062,46191
CHEMBL716,P14780,QUETIAPINE,URKOMYMAXPYINW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7403119,DTCC00160380,1734062,46191
CHEMBL71618,P14780,,USFNQSYWKLKGHX-RTBURBONSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,0.99,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1380999,DTCC00224917,787755,14854
CHEMBL71630,P14780,,DEDGVHPWRWYTIC-IXCJQBJRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,6.5,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1368309,DTCC00224922,981927,14854
CHEMBL71645,P14780,,WMBVCTBFQRRSBU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514167,IC50,=,152,NM,,,,,,,,,,,,,,In vitro ability to inhibit matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.,Bioorg. Med. Chem. Lett.,2001,11,16,"Levin JI, Chen J, Du M, Hogan M, Kincaid S, Nelson FC, Venkatesan AM, Wehr T, Zask A, DiJoseph J, Killar LM, Skala S, Sung A, Sharr M, Roth C, Jin G, Cowling R, Mohler KM, Black RA, March CJ, Skotnicki JS",,105532,DTCT0024844,1005830,DTCC00222542,776154,4353
CHEMBL71645,P14780,,WMBVCTBFQRRSBU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18790648,IC50,=,152,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,Bioorg. Med. Chem.,2008,16,19,"Georgiadis D, Yiotakis A",,497408,DTCT0024844,2457471,DTCC00222542,791163,32556
CHEMBL71686,P14780,,RRSNDPJAXNKWJB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514167,IC50,=,8,NM,,,,,,,,,,,,,,In vitro ability to inhibit matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.,Bioorg. Med. Chem. Lett.,2001,11,16,"Levin JI, Chen J, Du M, Hogan M, Kincaid S, Nelson FC, Venkatesan AM, Wehr T, Zask A, DiJoseph J, Killar LM, Skala S, Sung A, Sharr M, Roth C, Jin G, Cowling R, Mohler KM, Black RA, March CJ, Skotnicki JS",,105532,DTCT0024844,1012109,DTCC00222576,257858,4353
CHEMBL717,P14780,MEDROXYPROGESTERONE ACETATE,PSGAAPLEWMOORI-PEINSRQWSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7434237,DTCC00160710,1188069,46191
CHEMBL717,P14780,MEDROXYPROGESTERONE ACETATE,PSGAAPLEWMOORI-PEINSRQWSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7438467,DTCC00160710,1188070,46191
CHEMBL717,P14780,MEDROXYPROGESTERONE ACETATE,PSGAAPLEWMOORI-PEINSRQWSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7434238,DTCC00160710,1188069,46191
CHEMBL717,P14780,MEDROXYPROGESTERONE ACETATE,PSGAAPLEWMOORI-PEINSRQWSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7438468,DTCC00160710,1188070,46191
CHEMBL71713,P14780,,OFIZOTOQCJTVRO-UTKZUKDTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,7.1,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1391194,DTCC00225339,1753206,14854
CHEMBL71725,P14780,,CZYVJSTWDMVAFM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11514167,IC50,=,24,NM,,,,,,,,,,,,,,In vitro ability to inhibit matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.,Bioorg. Med. Chem. Lett.,2001,11,16,"Levin JI, Chen J, Du M, Hogan M, Kincaid S, Nelson FC, Venkatesan AM, Wehr T, Zask A, DiJoseph J, Killar LM, Skala S, Sung A, Sharr M, Roth C, Jin G, Cowling R, Mohler KM, Black RA, March CJ, Skotnicki JS",,105532,DTCT0024844,1002333,DTCC00222387,711786,4353
CHEMBL71800,P14780,,LWHRQCDZIRQSAN-KAYWLYCHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,3,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1386181,DTCC00225114,75834,14854
CHEMBL71801,P14780,,NITYDPDXAAFEIT-GUYCJALGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,270,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1392423,DTCC00225088,949541,14854
CHEMBL71995,P14780,,VXXBOZLJRUCYLE-BEFAXECRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,0.9,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1390047,DTCC00225710,1946874,14854
CHEMBL72,P14780,DESIPRAMINE,HCYAFALTSJYZDH-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7357133,DTCC00137288,1124448,46191
CHEMBL72,P14780,DESIPRAMINE,HCYAFALTSJYZDH-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7357134,DTCC00137288,1124448,46191
CHEMBL720,P14780,BENZYL ALCOHOL,WVDDGKGOMKODPV-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7280022,DTCC00161432,1641844,46191
CHEMBL720,P14780,BENZYL ALCOHOL,WVDDGKGOMKODPV-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7280023,DTCC00161432,1641844,46191
CHEMBL723,P14780,CARVEDILOL,OGHNVEJMJSYVRP-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7338623,DTCC00162415,993764,46191
CHEMBL723,P14780,CARVEDILOL,OGHNVEJMJSYVRP-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7338624,DTCC00162415,993764,46191
CHEMBL72337,P14780,,PJVJLPSYNZOOCE-JWQCQUIFSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,5.3,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1368305,DTCC00225298,302884,14854
CHEMBL72457,P14780,,XIYFEESCIBNMIC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,15,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103304,DTCC00224003,1185922,43205
CHEMBL726,P14780,FLUPHENAZINE,PLDUPXSUYLZYBN-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7329100,DTCC00162562,1734056,46191
CHEMBL726,P14780,FLUPHENAZINE,PLDUPXSUYLZYBN-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7329101,DTCC00162562,1734056,46191
CHEMBL72628,P14780,2-PICOLINIC ACID,SIOXPEMLGUPBBT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,0,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103071,DTCC00227813,1251244,43205
CHEMBL72678,P14780,,UTMWGWRRRXPAQY-PBHICJAKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,1.6,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1403423,DTCC00224830,1661210,14854
CHEMBL727,P14780,THIOGUANINE,WYWHKKSPHMUBEB-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7457255,DTCC00162578,120978,46191
CHEMBL727,P14780,THIOGUANINE,WYWHKKSPHMUBEB-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7457256,DTCC00162578,120978,46191
CHEMBL72743,P14780,,QZRDSGNFNCBFPU-HXOBKFHXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,3,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1395893,DTCC00225158,1564219,14854
CHEMBL72788,P14780,,GNHMOHGVWISYSN-IERDGZPVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,1.7,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1390043,DTCC00225656,755585,14854
CHEMBL728,P14780,PROCHLORPERAZINE,WIKYUJGCLQQFNW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7405033,DTCC00162902,1512815,46191
CHEMBL728,P14780,PROCHLORPERAZINE,WIKYUJGCLQQFNW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7405034,DTCC00162902,1512815,46191
CHEMBL7301,P14780,FENRETINIDE,AKJHMTWEGVYYSE-FXILSDISSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23953690,INHIBITION,,,,,cell_based,,,,,,,,,,,,Inhibition of MMP9 activity in human HT1080 cells at 1 uM after 24 hrs,Not Active,Inhibitory effects of p-dodecylaminophenol on the invasiveness of human fibrosarcoma cell line HT1080.,Bioorg. Med. Chem.,2013,21,19,"Takahashi N, Takeda K, Imai M",,980577,DTCT0024844,12548207,DTCC00132924,1942336,55644
CHEMBL73115,P14780,,DELQFJJGDSPFBM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15214773,IC50,=,13000,NM,,,,,,,,,,,,,,"Inhibition of gelatinase B, matrix metalloprotease-9 (MMP-9)",,Fragment-based drug discovery.,J. Med. Chem.,2004,47,14,"Erlanson DA, McDowell RS, O'Brien T",,71662,DTCT0024844,632653,DTCC00224379,2045666,17883
CHEMBL73173,P14780,2-CARBOXYPYRIDINE 1-OXIDE,FHYMLBVGNFVFBT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,8,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103268,DTCC01740992,1510695,43205
CHEMBL734,P14780,ACETOHYDROXAMIC ACID,RRUDCFGSUDOHDG-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,-12,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103846,DTCC00163357,637574,43205
CHEMBL73652,P14780,,ZAGFXXPMKXEROI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,1.8,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1597359,DTCC00230720,614971,16699
CHEMBL73652,P14780,,ZAGFXXPMKXEROI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,1.8,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506742,DTCC00230720,621009,48447
CHEMBL73763,P14780,,OLEYZXUQGOKVKT-KFWWJZLASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,2.8,NM,,,,,,,,,,,,,,"Inhibition of human gelatinase B, MMP9",,,Bioorg. Med. Chem. Lett.,1997,7,17,,,71656,DTCT0024844,1080530,DTCC00230328,1144162,2236
CHEMBL73866,P14780,,DFIPAYGHEIHLSB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,0.9,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1584592,DTCC00230832,1806225,16699
CHEMBL73866,P14780,,DFIPAYGHEIHLSB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,0.9,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506755,DTCC00230832,1812127,48447
CHEMBL7390,P14780,,SUSMVCKSLVPRCL-QGZVFWFLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11327577,IC50,=,6.8,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Heterocycle-based MMP inhibitors with P2' substituents.,Bioorg. Med. Chem. Lett.,2001,11,8,"Pikul S, Dunham KM, Almstead NG, De B, Natchus MG, Taiwo YO, Williams LE, Hynd BA, Hsieh LC, Janusz MJ, Gu F, Mieling GE",,105362,DTCT0024844,1310680,DTCC00133540,693701,4760
CHEMBL73928,P14780,,YHQIGEQPWJUUHA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,2.2,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1565049,DTCC00231252,711867,16699
CHEMBL73928,P14780,,YHQIGEQPWJUUHA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,2.2,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506748,DTCC00231252,717850,48447
CHEMBL741,P14780,LAMOTRIGINE,PYZRQGJRPPTADH-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7412192,DTCC00164108,1512811,46191
CHEMBL741,P14780,LAMOTRIGINE,PYZRQGJRPPTADH-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7412193,DTCC00164108,1512811,46191
CHEMBL74151,P14780,,SZXOIWIFZQPGPC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,9.7,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1563886,DTCC00231065,614972,16699
CHEMBL74175,P14780,,LICFKTFLYQYXDH-ZIAGYGMSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,2.8,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1385036,DTCC00225651,1499819,14854
CHEMBL74182,P14780,,FFEXFXFAIZBMGO-BWKNWUBXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9457244,KI,=,1.1,NM,,,,,,,,,,,,,,The compound was tested for its binding affinity towards 92 kDa gelatinase (Matrix metalloprotease-9),,Matrix metalloproteinase inhibitors: a structure-activity study.,J. Med. Chem.,1998,41,2,"Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE",,105401,DTCT0024844,1390039,DTCC00225310,1240177,14854
CHEMBL742,P14780,KETAMINE,YQEZLKZALYSWHR-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7426921,DTCC00164207,1862716,46191
CHEMBL742,P14780,KETAMINE,YQEZLKZALYSWHR-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7426922,DTCC00164207,1862716,46191
CHEMBL74365,P14780,,ANRXCWSBJHOAED-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,37,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1559927,DTCC00231119,518390,16699
CHEMBL74365,P14780,,ANRXCWSBJHOAED-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,37,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506749,DTCC00231119,524287,48447
CHEMBL744,P14780,RILUZOLE,FTALBRSUTCGOEG-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7488045,DTCC00164269,348405,46191
CHEMBL744,P14780,RILUZOLE,FTALBRSUTCGOEG-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7488046,DTCC00164269,348405,46191
CHEMBL74670,P14780,,KYOFVPKPPTUVKK-KURKYZTESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,4.3,NM,,,,,,,,,,,,,,"Inhibition of human gelatinase B, MMP9",,,Bioorg. Med. Chem. Lett.,1997,7,17,,,71656,DTCT0024844,1069942,DTCC00230314,335515,2236
CHEMBL748,P14780,PRALIDOXIME CHLORIDE,HIGSLXSBYYMVKI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7404788,DTCC00164888,1798416,46191
CHEMBL748,P14780,PRALIDOXIME CHLORIDE,HIGSLXSBYYMVKI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7404789,DTCC00164888,1798416,46191
CHEMBL74812,P14780,,ZBQMJMAWFWQVBB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,12,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1571241,DTCC00230567,1681988,16699
CHEMBL75094,P14780,PRINOMASTAT,YKPYIPVDTNNYCN-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10579818,IC50,<,0.4,NM,,,,,,,,,,,,,,Inhibition of gelatinase-B (Matrix metalloprotease-9),,"Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.",J. Med. Chem.,1999,42,22,"Almstead NG, Bradley RS, Pikul S, De B, Natchus MG, Taiwo YO, Gu F, Williams LE, Hynd BA, Janusz MJ, Dunaway CM, Mieling GE",,105226,DTCT0024844,1369141,DTCC00231104,336627,15412
CHEMBL75094,P14780,PRINOMASTAT,YKPYIPVDTNNYCN-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11212095,IC50,=,0.2,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.,Bioorg. Med. Chem. Lett.,2001,11,3,"Chollet AM, Le Diguarher T, Murray L, Bertrand M, Tucker GC, Sabatini M, Pierré A, Atassi G, Bonnet J, Casara P",,105358,DTCT0024844,628950,DTCC00231104,324195,4635
CHEMBL75094,P14780,PRINOMASTAT,YKPYIPVDTNNYCN-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,0.048,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1565056,DTCC00231104,323739,16699
CHEMBL75094,P14780,PRINOMASTAT,YKPYIPVDTNNYCN-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12930146,IC50,=,0.2,NM,,,,,,,,,,,,,,Inhibitory activity against matrix metalloprotease-9 (MMP9),,Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.,J. Med. Chem.,2003,46,18,"Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P",,105365,DTCT0024844,532647,DTCC00231104,336390,13726
CHEMBL75094,P14780,PRINOMASTAT,YKPYIPVDTNNYCN-INIZCTEOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15713379,IC50,=,0.26,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.,Bioorg. Med. Chem. Lett.,2005,15,5,"Rossello A, Nuti E, Carelli P, Orlandini E, Macchia M, Nencetti S, Zandomeneghi M, Balzano F, Uccello Barretta G, Albini A, Benelli R, Cercignani G, Murphy G, Balsamo A",,305737,DTCT0024844,1745895,DTCC00231104,325586,18841
CHEMBL75114,P14780,,QYMSAHRHXPUNSA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,0.32,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1572589,DTCC00230626,1391780,16699
CHEMBL75139,P14780,,SBVGWUXDJBPGDG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,1.4,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1592230,DTCC00231254,614970,16699
CHEMBL75139,P14780,,SBVGWUXDJBPGDG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,1.4,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506743,DTCC00231254,621008,48447
CHEMBL75154,P14780,,BYBOLCACCXBYNF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,10,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1576460,DTCC00231570,193361,16699
CHEMBL75164,P14780,,UWWZSLPTPKEDCJ-ZYMOGRSISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,0.092,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1592240,DTCC00231183,711866,16699
CHEMBL75164,P14780,,UWWZSLPTPKEDCJ-ZYMOGRSISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,0.092,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506758,DTCC00231183,717844,48447
CHEMBL75164,P14780,,UWWZSLPTPKEDCJ-ZYMOGRSISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,0.092,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin),,,MedChemComm,2012,3,11,,,1327985,DTCT0024844,13570936,DTCC00231183,739815,40045
CHEMBL75189,P14780,,ZOYPENCXBQHGNW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,1.7,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1561138,DTCC00230630,356450,16699
CHEMBL75189,P14780,,ZOYPENCXBQHGNW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,1.7,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506759,DTCC00230630,362452,48447
CHEMBL75302,P14780,,LSWGUPLJLWZCIM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,0.96,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1588318,DTCC00230776,518391,16699
CHEMBL75302,P14780,,LSWGUPLJLWZCIM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,37,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506741,DTCC00230776,524291,48447
CHEMBL75419,P14780,,SXXYGGYNEUHILZ-ANYOKISRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,1500,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,,Bioorg. Med. Chem. Lett.,1997,7,18,,,105547,DTCT0024844,1569305,DTCC00232298,1240250,2242
CHEMBL75435,P14780,DEXKETOPROFEN,DKYWVDODHFEZIM-NSHDSACASA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7350849,DTCC00229147,1447880,46191
CHEMBL75435,P14780,DEXKETOPROFEN,DKYWVDODHFEZIM-NSHDSACASA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7350850,DTCC00229147,1447880,46191
CHEMBL75437,P14780,,ZIOWEXJTMJYIOK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,120,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1572584,DTCC00231652,128855,16699
CHEMBL75464,P14780,,PIPNMGRIVITFEC-VQCQRNETSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,1.1,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1566231,DTCC00230825,808541,16699
CHEMBL75487,P14780,,IAPIGLKJGZQTIG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,0.91,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1568631,DTCC00231094,1261335,16699
CHEMBL75529,P14780,,OFKCKYMJSALCIS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,0.86,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1563890,DTCC00231180,1326294,16699
CHEMBL75567,P14780,,YUAGFRRWRZNRHN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,0.9,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1562522,DTCC00230957,1067475,16699
CHEMBL75567,P14780,,YUAGFRRWRZNRHN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,0.9,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506752,DTCC00230957,1073431,48447
CHEMBL75618,P14780,,NATAXQWJZDVABL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,6.2,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1565046,DTCC00231568,744168,16699
CHEMBL75641,P14780,,OQOVBCVMAHMMFY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,63,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,772999,DTCC00233928,1903002,17339
CHEMBL75641,P14780,,OQOVBCVMAHMMFY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,63,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506777,DTCC00233928,1908821,48447
CHEMBL7568,P14780,QUINACRINE,GPKJTRJOBQGKQK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7372998,DTCC00134204,2089751,46191
CHEMBL7568,P14780,QUINACRINE,GPKJTRJOBQGKQK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7372999,DTCC00134204,2089751,46191
CHEMBL757,P14780,NANDROLONE,NPAGDVCDWIYMMC-IZPLOLCNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7388254,DTCC00166843,930082,46191
CHEMBL757,P14780,NANDROLONE,NPAGDVCDWIYMMC-IZPLOLCNSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7388255,DTCC00166843,930082,46191
CHEMBL75702,P14780,,UNQHIMAGAUGZGX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,15,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,811947,DTCC00235118,1968256,17339
CHEMBL75880,P14780,PERHEXILINE,CYXKNKQEMFBLER-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7393472,DTCC00230384,1124453,46191
CHEMBL75880,P14780,PERHEXILINE,CYXKNKQEMFBLER-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7393473,DTCC00230384,1124453,46191
CHEMBL75925,P14780,,JEALYKJUQQXXBO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,79,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,773003,DTCC00233980,647729,17339
CHEMBL76038,P14780,,UZMHOPNYRMEVNJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,71,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,779775,DTCC00234584,518429,17339
CHEMBL76043,P14780,,JGARQZXVQXLEJV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,0.34,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1569941,DTCC00231566,1617665,16699
CHEMBL76137,P14780,,UTDYWIPXAVCYCE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,13,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,486989,DTCC00235111,529874,17340
CHEMBL76137,P14780,,UTDYWIPXAVCYCE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,4.89,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260722,DTCC00235111,521159,24831
CHEMBL762,P14780,OXYMETAZOLINE,WYWIFABBXFUGLM-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7375981,DTCC00167236,2025641,46191
CHEMBL762,P14780,OXYMETAZOLINE,WYWIFABBXFUGLM-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7375982,DTCC00167236,2025641,46191
CHEMBL76222,P14780,REBIMASTAT,GTXSRFUZSLTDFX-HRCADAONSA-N,2,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,25,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1562532,DTCC00231103,1326293,16699
CHEMBL76356,P14780,,XGFRXSAFARHCLC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,23,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,785573,DTCC00234583,2065482,17339
CHEMBL76488,P14780,,BKJCTJQMBGJOHN-RMKNXTFCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,16,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,796722,DTCC00234578,1649862,17339
CHEMBL76488,P14780,,BKJCTJQMBGJOHN-RMKNXTFCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,4.8,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260750,DTCC00234578,1652649,24831
CHEMBL76488,P14780,,BKJCTJQMBGJOHN-RMKNXTFCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,16,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506772,DTCC00234578,1655800,48447
CHEMBL765,P14780,GUANETHIDINE,ACGDKVXYNVEAGU-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7321134,DTCC00167701,2089750,46191
CHEMBL765,P14780,GUANETHIDINE,ACGDKVXYNVEAGU-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7321135,DTCC00167701,2089750,46191
CHEMBL76606,P14780,,DLFIQQOMKGGVGI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11206467,IC50,=,23,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position.,Bioorg. Med. Chem. Lett.,2001,11,2,"Levin JI, Du MT, DiJoseph JF, Killar LM, Sung A, Walter T, Sharr MA, Roth CE, Moy FJ, Powers R, Jin G, Cowling R, Skotnicki JS",,105222,DTCT0024844,592894,DTCC00234734,1391811,4515
CHEMBL76606,P14780,,DLFIQQOMKGGVGI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12217351,KI,=,23,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.",Bioorg. Med. Chem. Lett.,2002,12,19,"Scozzafava A, Supuran CT",,105377,DTCT0024844,1025857,DTCC00234734,1392003,5080
CHEMBL76606,P14780,,DLFIQQOMKGGVGI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,22.91,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258699,DTCC00234734,1394253,24803
CHEMBL76619,P14780,,PPTJZFSGDMWVFF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,51,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,789480,DTCC00234556,2033780,17339
CHEMBL76673,P14780,,XBLZKAPRZBJHCZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,11,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,782818,DTCC00234511,1391807,17339
CHEMBL76673,P14780,,XBLZKAPRZBJHCZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,11,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506780,DTCC00234511,1397548,48447
CHEMBL76674,P14780,,CEYDMEZCBBKZBI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,13,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,806444,DTCC00234579,1455888,17339
CHEMBL76674,P14780,,CEYDMEZCBBKZBI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,13,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506782,DTCC00234579,1461808,48447
CHEMBL76757,P14780,,MMRISAVXAFHOJP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,1.1,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1569945,DTCC00231621,1870575,16699
CHEMBL768,P14780,ESMOLOL,AQNDDEOPVVGCPG-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7311323,DTCC00167907,1253321,46191
CHEMBL768,P14780,ESMOLOL,AQNDDEOPVVGCPG-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7311324,DTCC00167907,1253321,46191
CHEMBL76836,P14780,,PRBMKJZQAUSBQV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,3,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,490637,DTCC00235113,1693445,17340
CHEMBL76836,P14780,,PRBMKJZQAUSBQV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,5.52,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260701,DTCC00235113,1684878,24831
CHEMBL76847,P14780,,YJOSMOCGEMCNLK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,26,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,507899,DTCC00236332,1111969,17340
CHEMBL76847,P14780,,YJOSMOCGEMCNLK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,4.59,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260703,DTCC00236332,1103047,24831
CHEMBL76856,P14780,,KLYIBVBIKFMTRO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,12,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,508986,DTCC00235473,917080,17340
CHEMBL76856,P14780,,KLYIBVBIKFMTRO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,4.92,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260709,DTCC00235473,909295,24831
CHEMBL76878,P14780,,FVYBFRCALRJYHO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,83,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,809314,DTCC00233595,1617699,17339
CHEMBL76878,P14780,,FVYBFRCALRJYHO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,83,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506779,DTCC00233595,1623611,48447
CHEMBL76888,P14780,,QDJTVBZWIYKRMZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,9,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,799533,DTCC00105981,744206,17339
CHEMBL76888,P14780,,QDJTVBZWIYKRMZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,9,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506776,DTCC00105981,750184,48447
CHEMBL76904,P14780,TYRPHOSTIN 23,VTJXFTPMFYAJJU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7445649,DTCC00233094,1765983,46191
CHEMBL76904,P14780,TYRPHOSTIN 23,VTJXFTPMFYAJJU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7445650,DTCC00233094,1765983,46191
CHEMBL76970,P14780,,COMDPQPBGQXLMK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,35,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,792611,DTCC00234499,128900,17339
CHEMBL76970,P14780,,COMDPQPBGQXLMK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,4.46,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260751,DTCC00234499,131674,24831
CHEMBL76970,P14780,,COMDPQPBGQXLMK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,35,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506771,DTCC00234499,134957,48447
CHEMBL76974,P14780,,WUQMFARMJJXJMN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11206467,IC50,=,6,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position.,Bioorg. Med. Chem. Lett.,2001,11,2,"Levin JI, Du MT, DiJoseph JF, Killar LM, Sung A, Walter T, Sharr MA, Roth CE, Moy FJ, Powers R, Jin G, Cowling R, Skotnicki JS",,105222,DTCT0024844,617534,DTCC00234562,744210,4515
CHEMBL76974,P14780,,WUQMFARMJJXJMN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,6.03,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258690,DTCC00234562,746932,24803
CHEMBL77013,P14780,,IJQHRVZFTGGUJN-ZVAWYAOSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,210,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,,Bioorg. Med. Chem. Lett.,1997,7,18,,,105547,DTCT0024844,1581200,DTCC00232677,400993,2242
CHEMBL77125,P14780,,KDJZFDKCOPXERM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,21,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,815165,DTCC00233913,776279,17339
CHEMBL77176,P14780,,CWVWYGJTCDBSIW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,17,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,512796,DTCC00235142,1947019,17340
CHEMBL77176,P14780,,CWVWYGJTCDBSIW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,4.77,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260724,DTCC00235142,1937758,24831
CHEMBL772,P14780,RESERPINE,QEVHRUUCFGRFIF-MDEJGZGSSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7462056,DTCC00168399,1992810,46191
CHEMBL772,P14780,RESERPINE,QEVHRUUCFGRFIF-MDEJGZGSSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7462057,DTCC00168399,1992810,46191
CHEMBL77207,P14780,,ZGEUEQMPAIUHSM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,2930,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,809310,DTCC00235130,1838712,17339
CHEMBL77207,P14780,,ZGEUEQMPAIUHSM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,2.53,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260746,DTCC00235130,1841450,24831
CHEMBL77237,P14780,,WTWNYQALQSSSPL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11206467,IC50,=,440,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position.,Bioorg. Med. Chem. Lett.,2001,11,2,"Levin JI, Du MT, DiJoseph JF, Killar LM, Sung A, Walter T, Sharr MA, Roth CE, Moy FJ, Powers R, Jin G, Cowling R, Skotnicki JS",,105222,DTCT0024844,600967,DTCC00234311,1067511,4515
CHEMBL773,P14780,GLYCINE,DHMQDGOQFOQNFH-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7308193,DTCC00168448,1544900,46191
CHEMBL773,P14780,GLYCINE,DHMQDGOQFOQNFH-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7308194,DTCC00168448,1544900,46191
CHEMBL77505,P14780,,MLJSRWALBCZDCB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,649,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,495609,DTCC00235797,1111968,17340
CHEMBL77505,P14780,,MLJSRWALBCZDCB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,3.19,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260718,DTCC00235797,1103045,24831
CHEMBL7756,P14780,,HTNLSTWGHBHDPS-CQSZACIVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11327577,IC50,=,4.1,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Heterocycle-based MMP inhibitors with P2' substituents.,Bioorg. Med. Chem. Lett.,2001,11,8,"Pikul S, Dunham KM, Almstead NG, De B, Natchus MG, Taiwo YO, Williams LE, Hynd BA, Hsieh LC, Janusz MJ, Gu F, Mieling GE",,105362,DTCT0024844,1292489,DTCC00133590,207299,4760
CHEMBL77614,P14780,,VHCKBWRQDKOUOA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11206468,INHIBITION,=,57,%,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 at 10 uM,,Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2001,11,2,"Levin JI, Gu Y, Nelson FC, Zask A, DiJoseph JF, Sharr MA, Sung A, Jin G, Cowling R, Chanda P, Cosmi S, Hsiao CL, Edris W, Wilhelm J, Killar LM, Skotnicki JS",,105540,DTCT0024844,1300996,DTCC00237033,2045094,4516
CHEMBL77675,P14780,"N,N'-DIPHENYL-GUANIDINE",OWRCNXZUPFZXOS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7291713,DTCC01741294,1155675,46191
CHEMBL77675,P14780,"N,N'-DIPHENYL-GUANIDINE",OWRCNXZUPFZXOS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7291714,DTCC01741294,1155675,46191
CHEMBL77874,P14780,,WGXKBOQJZAHOOA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,4.9,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1592235,DTCC00230728,225702,16699
CHEMBL77874,P14780,,WGXKBOQJZAHOOA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,0.49,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506757,DTCC00230728,231644,48447
CHEMBL78052,P14780,,GSMKHTZLWUPIAS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,0.79,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1586964,DTCC00231005,1455853,16699
CHEMBL78052,P14780,,GSMKHTZLWUPIAS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,0.79,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506762,DTCC00231005,1461793,48447
CHEMBL78145,P14780,,MJYMJQBCXIIWTG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,0.53,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1571244,DTCC00231530,1902970,16699
CHEMBL78145,P14780,,MJYMJQBCXIIWTG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,0.53,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506751,DTCC00231530,1908808,48447
CHEMBL78213,P14780,,CATBJIHGLQLCIT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11754593,IC50,=,0.98,NM,,,,,,,,,,,,,,In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay,,"Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.",J. Med. Chem.,2002,45,1,"Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK",,105522,DTCT0024844,1566228,DTCC00231510,744167,16699
CHEMBL78213,P14780,,CATBJIHGLQLCIT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,0.98,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506750,DTCC00231510,750167,48447
CHEMBL78255,P14780,,YMQWZRPLMNNHEU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,10,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,511556,DTCC00235631,1240288,17340
CHEMBL78255,P14780,,YMQWZRPLMNNHEU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15566296,IC50,=,10,NM,,,,,,,,,,,,,,Inhibition of MMP9,,"Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.",J. Med. Chem.,2004,47,25,"Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D",,429670,DTCT0024844,2041910,DTCC00235631,1242637,22157
CHEMBL78255,P14780,,YMQWZRPLMNNHEU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,5,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260720,DTCC00235631,1231176,24831
CHEMBL78299,P14780,,FLIOXLIZONFFSH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,9,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,806438,DTCC00233654,1163666,17339
CHEMBL78299,P14780,,FLIOXLIZONFFSH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,9,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,494367,DTCC00233654,1175336,17340
CHEMBL783,P14780,NATEGLINIDE,OELFLUMRDSZNSF-BRWVUGGUSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7396817,DTCC00170640,1512813,46191
CHEMBL783,P14780,NATEGLINIDE,OELFLUMRDSZNSF-BRWVUGGUSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7396818,DTCC00170640,1512813,46191
CHEMBL78337,P14780,,WUWBMHSDQYCLTI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,2,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,496719,DTCC00236212,1596758,17340
CHEMBL78337,P14780,,WUWBMHSDQYCLTI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,5.7,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260694,DTCC00236212,1587779,24831
CHEMBL78369,P14780,,ATFPFLNWBZIBTJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,3,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,477854,DTCC00236026,1144221,17340
CHEMBL78369,P14780,,ATFPFLNWBZIBTJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,3,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,501543,DTCC00236026,1144222,17340
CHEMBL78369,P14780,,ATFPFLNWBZIBTJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,5.52,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260695,DTCC00236026,1135247,24831
CHEMBL78478,P14780,,NAXMTMYDSBOGMZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,3,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,511562,DTCC00235843,1111970,17340
CHEMBL78478,P14780,,NAXMTMYDSBOGMZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,5.52,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260706,DTCC00235843,1103046,24831
CHEMBL78508,P14780,,CXFQYPXLXLPGNM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,4,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,491919,DTCC00235770,1403251,17340
CHEMBL78508,P14780,,CXFQYPXLXLPGNM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,5.4,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260689,DTCC00235770,1394260,24831
CHEMBL78549,P14780,,AUWOIDNULNLPBA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,1,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,491912,DTCC00236211,303008,17340
CHEMBL78549,P14780,,AUWOIDNULNLPBA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,6,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260693,DTCC00236211,294031,24831
CHEMBL78611,P14780,,WWVKBGIBCFSFOJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,5,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,506607,DTCC00235866,1693444,17340
CHEMBL78611,P14780,,WWVKBGIBCFSFOJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,5.3,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260704,DTCC00235866,1684877,24831
CHEMBL787,P14780,MONTELUKAST,UCHDWCPVSPXUMX-TZIWLTJVSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7424233,DTCC00171266,1798413,46191
CHEMBL787,P14780,MONTELUKAST,UCHDWCPVSPXUMX-TZIWLTJVSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7424234,DTCC00171266,1798413,46191
CHEMBL78709,P14780,,IEGOFALJZJPJJD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,374,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,510276,DTCC00236199,1753310,17340
CHEMBL78709,P14780,,IEGOFALJZJPJJD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,3.43,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260714,DTCC00236199,1744667,24831
CHEMBL78798,P14780,,GQEYBNSJJQDDLY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,2,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,483514,DTCC00235788,562092,17340
CHEMBL78798,P14780,,GQEYBNSJJQDDLY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,5.7,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260700,DTCC00235788,553263,24831
CHEMBL788,P14780,IDOXURIDINE,XQFRJNBWHJMXHO-RRKCRQDMSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7336459,DTCC00171444,510301,46191
CHEMBL788,P14780,IDOXURIDINE,XQFRJNBWHJMXHO-RRKCRQDMSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7336460,DTCC00171444,510301,46191
CHEMBL78826,P14780,,QCBWOUQUDIILOW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11206468,IC50,=,236,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2001,11,2,"Levin JI, Gu Y, Nelson FC, Zask A, DiJoseph JF, Sharr MA, Sung A, Jin G, Cowling R, Chanda P, Cosmi S, Hsiao CL, Edris W, Wilhelm J, Killar LM, Skotnicki JS",,105521,DTCT0024844,1302178,DTCC00237661,853169,4516
CHEMBL78826,P14780,,QCBWOUQUDIILOW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23287054,IC50,=,236,NM,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin),,Sulphonamides: Deserving class as MMP inhibitors?,Eur. J. Med. Chem.,2013,60,,"Jain P, Saravanan C, Singh SK",,944094,DTCT0024844,11835654,DTCC00237661,868683,53820
CHEMBL78909,P14780,,WZTNVCMELDPHHH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,1,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,484686,DTCC00236008,1014343,17340
CHEMBL78909,P14780,,WZTNVCMELDPHHH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,6,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2259287,DTCC00236008,1005469,24831
CHEMBL78934,P14780,,NYBGUTIMRHCTPX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,20,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,477849,DTCC00236028,2077097,17340
CHEMBL78934,P14780,,NYBGUTIMRHCTPX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,4.7,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260676,DTCC00236028,2068215,24831
CHEMBL78962,P14780,,NPFGSGCFKYSLPI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,6,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,510268,DTCC00235604,335601,17340
CHEMBL78962,P14780,,NPFGSGCFKYSLPI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,5.22,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260725,DTCC00235604,326659,24831
CHEMBL79,P14780,LIDOCAINE,NNJVILVZKWQKPM-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7438044,DTCC00137707,1609550,46191
CHEMBL79,P14780,LIDOCAINE,NNJVILVZKWQKPM-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7438045,DTCC00137707,1609550,46191
CHEMBL790,P14780,CHLORHEXIDINE,GHXZTYHSJHQHIJ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20053563,IC50,=,7630,NM,,,,,,,,,,,,,,Inhibition of human neutrophils gelatinase B after 30 mins by fluorescence plate reader,,"Identification of potential and selective collagenase, gelatinase inhibitors from Crataegus pinnatifida.",Bioorg. Med. Chem. Lett.,2010,20,3,"Moon HI, Kim TI, Cho HS, Kim EK",,607931,DTCT0024844,3191717,DTCC00172379,1918621,37466
CHEMBL79111,P14780,,WRYYVCSFLUPFIQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,43,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,482346,DTCC00235855,1499929,17340
CHEMBL79111,P14780,,WRYYVCSFLUPFIQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,4.37,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260697,DTCC00235855,1491230,24831
CHEMBL79267,P14780,,UYFGGWJRPCRSHW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472202,IC50,=,137,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.,J. Med. Chem.,2001,44,16,"Pikul S, Ohler NE, Ciszewski G, Laufersweiler MC, Almstead NG, De B, Natchus MG, Hsieh LC, Janusz MJ, Peng SX, Branch TM, King SL, Taiwo YO, Mieling GE",,105229,DTCT0024844,1322796,DTCC00242002,1163761,16328
CHEMBL79433,P14780,,IMKDKHQDFFLOKK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,1,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,494310,DTCC00235743,75938,17340
CHEMBL79433,P14780,,IMKDKHQDFFLOKK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,6,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260691,DTCC00235743,67167,24831
CHEMBL79636,P14780,,VECQGWFFKYPCMA-OWCLPIDISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human recombinant Matrix metalloprotease-9 at 10e-4 M (No significant activity),Not Active,,Bioorg. Med. Chem. Lett.,1997,7,19,,,105221,DTCT0024844,1500922,DTCC00241234,1838786,2263
CHEMBL79857,P14780,,VEYIMQVTPXPUHA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,45,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103797,DTCC00238936,701896,43205
CHEMBL799,P14780,CILOSTAZOL,RRGUKTPIGVIEKM-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7354102,DTCC00173670,2057647,46191
CHEMBL799,P14780,CILOSTAZOL,RRGUKTPIGVIEKM-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7354103,DTCC00173670,2057647,46191
CHEMBL79906,P14780,,QPSBVVFMTSFAJY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472202,IC50,=,1760,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.,J. Med. Chem.,2001,44,16,"Pikul S, Ohler NE, Ciszewski G, Laufersweiler MC, Almstead NG, De B, Natchus MG, Hsieh LC, Janusz MJ, Peng SX, Branch TM, King SL, Taiwo YO, Mieling GE",,105229,DTCT0024844,1313205,DTCC00242125,1903109,16328
CHEMBL79948,P14780,,DTEROUBEWKRJFQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15109641,IC50,,,,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 at 100 uM (inactive),Not Active,Rational design and synthesis of novel heparan sulfate mimetic compounds as antiadhesive agents.,Bioorg. Med. Chem. Lett.,2004,14,10,"Ishida K, Simizu S, Teruya T, Wierzba MK, Osada H",,105504,DTCT0024844,1411848,DTCC00242133,1455980,6359
CHEMBL8,P14780,CIPROFLOXACIN,MYSWGUAQZAJSOK-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7341350,DTCC00103423,51457,46191
CHEMBL8,P14780,CIPROFLOXACIN,MYSWGUAQZAJSOK-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7341351,DTCC00103423,51457,46191
CHEMBL80,P14780,NALOXONE,UZHSEJADLWPNLE-GRGSLBFTSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7416055,DTCC00137855,1155683,46191
CHEMBL80,P14780,NALOXONE,UZHSEJADLWPNLE-GRGSLBFTSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7416056,DTCC00137855,1155683,46191
CHEMBL80146,P14780,,NPMTYGOUEKCULB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,58,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,782822,DTCC00234502,1326328,17339
CHEMBL80146,P14780,,NPMTYGOUEKCULB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,58,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506784,DTCC00234502,1332434,48447
CHEMBL80183,P14780,,RHTOEITZKIINCY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,11,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,495619,DTCC00236108,464823,17340
CHEMBL80183,P14780,,RHTOEITZKIINCY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,4.96,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260686,DTCC00236108,455590,24831
CHEMBL802,P14780,MINOXIDIL,ZFMITUMMTDLWHR-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7428426,DTCC00174151,1641849,46191
CHEMBL802,P14780,MINOXIDIL,ZFMITUMMTDLWHR-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7428427,DTCC00174151,1641849,46191
CHEMBL80248,P14780,,HBIQJOZNDMPMAG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,107,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,813629,DTCC00234535,1261382,17339
CHEMBL80248,P14780,,HBIQJOZNDMPMAG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,3.97,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260630,DTCC00234535,1264018,24831
CHEMBL80248,P14780,,HBIQJOZNDMPMAG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,107,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506781,DTCC00234535,1267288,48447
CHEMBL80272,P14780,,CBMKHOZXSARYNG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11206467,IC50,=,2,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position.,Bioorg. Med. Chem. Lett.,2001,11,2,"Levin JI, Du MT, DiJoseph JF, Killar LM, Sung A, Walter T, Sharr MA, Roth CE, Moy FJ, Powers R, Jin G, Cowling R, Skotnicki JS",,105222,DTCT0024844,584833,DTCC00234861,1359148,4515
CHEMBL80272,P14780,,CBMKHOZXSARYNG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,2,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258692,DTCC00234861,1361903,24803
CHEMBL803,P14780,CYTARABINE,UHDGCWIWMRVCDJ-CCXZUQQUSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7348388,DTCC00174264,51462,46191
CHEMBL803,P14780,CYTARABINE,UHDGCWIWMRVCDJ-CCXZUQQUSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7348389,DTCC00174264,51462,46191
CHEMBL80300,P14780,,CXRZYJPQMZBWAW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11206467,IC50,=,4,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position.,Bioorg. Med. Chem. Lett.,2001,11,2,"Levin JI, Du MT, DiJoseph JF, Killar LM, Sung A, Walter T, Sharr MA, Roth CE, Moy FJ, Powers R, Jin G, Cowling R, Skotnicki JS",,105222,DTCT0024844,608111,DTCC00234829,1035195,4515
CHEMBL80300,P14780,,CXRZYJPQMZBWAW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,3.98,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258691,DTCC00234829,1037852,24803
CHEMBL80321,P14780,,KHORRYDPPCADSY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,14,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,495613,DTCC00236078,949647,17340
CHEMBL80322,P14780,,LKRHPZIUVGMVCY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11206467,IC50,=,353,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position.,Bioorg. Med. Chem. Lett.,2001,11,2,"Levin JI, Du MT, DiJoseph JF, Killar LM, Sung A, Walter T, Sharr MA, Roth CE, Moy FJ, Powers R, Jin G, Cowling R, Skotnicki JS",,105222,DTCT0024844,617531,DTCC00234772,744209,4515
CHEMBL80361,P14780,,VEUYFZWVWBJLBT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,9,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,796726,DTCC00235159,1326330,17339
CHEMBL80361,P14780,,VEUYFZWVWBJLBT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,9,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506773,DTCC00235159,1332437,48447
CHEMBL80378,P14780,,JGDVFBCMNUSQQW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,120,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,793973,DTCC00234445,356485,17339
CHEMBL80378,P14780,,JGDVFBCMNUSQQW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,120,NM,,,,,,,,,,,,,,Inhibition of MMP9,,,ACS Med. Chem. Lett.,2011,2,6,,,825929,DTCT0024844,10506778,DTCC00234445,362473,48447
CHEMBL80401,P14780,,QZAKHVZDCIZWMH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,19,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,500326,DTCC00235502,368246,17340
CHEMBL80401,P14780,,QZAKHVZDCIZWMH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,4.72,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260710,DTCC00235502,359220,24831
CHEMBL80412,P14780,,UVYWXUJXEFVRIM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,128,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,793969,DTCC00235160,1682007,17339
CHEMBL80412,P14780,,UVYWXUJXEFVRIM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,3.89,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260748,DTCC00235160,1684876,24831
CHEMBL80413,P14780,,ZUJXLCINYDKZGV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,INHIBITION,=,27,%,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 at 10 uM,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105548,DTCT0024844,816480,DTCC00235161,841412,17339
CHEMBL80453,P14780,,FBLQAKOTTHGGBJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,44,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,480110,DTCC00235840,1564342,17340
CHEMBL80453,P14780,,FBLQAKOTTHGGBJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,4.36,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260705,DTCC00235840,1555545,24831
CHEMBL80496,P14780,,WJPFHUMULGZBAI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,0,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,788063,DTCC00234526,711907,17339
CHEMBL80565,P14780,,FQZUGHBEAWJYRZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773041,IC50,=,447,NM,,,,,,,,,,,,,,In vitro inhibition of matrix metalloprotease-9,,"Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R",,105512,DTCT0024844,785560,DTCC00234549,3717,17339
CHEMBL80565,P14780,,FQZUGHBEAWJYRZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,3.35,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260749,DTCC00234549,8973,24831
CHEMBL806,P14780,FLUTAMIDE,MKXKFYHWDHIYRV-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7307802,DTCC00175006,1253324,46191
CHEMBL806,P14780,FLUTAMIDE,MKXKFYHWDHIYRV-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7307803,DTCC00175006,1253324,46191
CHEMBL80732,P14780,,HHLQXXSIVVEBOY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,2,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,493171,DTCC00235771,1370860,17340
CHEMBL80732,P14780,,HHLQXXSIVVEBOY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,5.7,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260690,DTCC00235771,1361911,24831
CHEMBL80798,P14780,,UYOSMJLYSRXRLI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,6,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,505402,DTCC00236064,2012792,17340
CHEMBL80798,P14780,,UYOSMJLYSRXRLI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,5.22,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260685,DTCC00236064,2003629,24831
CHEMBL808,P14780,ECONAZOLE,LEZWWPYKPKIXLL-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,6997,NM,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7311138,DTCC00175675,1764791,46191
CHEMBL808,P14780,ECONAZOLE,LEZWWPYKPKIXLL-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Note: corresponding IC50 reported as Active,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7311139,DTCC00175675,1764791,46191
CHEMBL80814,P14780,,VUXKPYYMTYYYCJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,34,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,476636,DTCC00235499,1207516,17340
CHEMBL80814,P14780,,VUXKPYYMTYYYCJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,4.47,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260708,DTCC00235499,1198932,24831
CHEMBL80894,P14780,,IEYUPLSSJBQATP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11206467,IC50,=,64,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position.,Bioorg. Med. Chem. Lett.,2001,11,2,"Levin JI, Du MT, DiJoseph JF, Killar LM, Sung A, Walter T, Sharr MA, Roth CE, Moy FJ, Powers R, Jin G, Cowling R, Skotnicki JS",,105222,DTCT0024844,613850,DTCC00234863,1838715,4515
CHEMBL80894,P14780,,IEYUPLSSJBQATP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,64.57,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258694,DTCC00234863,1841442,24803
CHEMBL809,P14780,SERTRALINE,VGKDLMBJGBXTGI-SJCJKPOMSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7471272,DTCC00176302,1414866,46191
CHEMBL809,P14780,SERTRALINE,VGKDLMBJGBXTGI-SJCJKPOMSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7471273,DTCC00176302,1414866,46191
CHEMBL80911,P14780,,DDHYHOSBNZTEDO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,2,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,510288,DTCC00235759,594283,17340
CHEMBL80969,P14780,,NZSGHPOSLLMCJS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,10,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,484682,DTCC00234610,820230,17340
CHEMBL80969,P14780,,NZSGHPOSLLMCJS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,5,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260727,DTCC00234610,811358,24831
CHEMBL81,P14780,RALOXIFENE,GZUITABIAKMVPG-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7479431,DTCC01738582,1960080,46191
CHEMBL81,P14780,RALOXIFENE,GZUITABIAKMVPG-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7479432,DTCC01738582,1960080,46191
CHEMBL81113,P14780,,BDCJZZXWIQJYLP-FIWHBWSRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11206468,IC50,=,181,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2001,11,2,"Levin JI, Gu Y, Nelson FC, Zask A, DiJoseph JF, Sharr MA, Sung A, Jin G, Cowling R, Chanda P, Cosmi S, Hsiao CL, Edris W, Wilhelm J, Killar LM, Skotnicki JS",,105521,DTCT0024844,1318848,DTCC00237078,1785427,4516
CHEMBL81113,P14780,,BDCJZZXWIQJYLP-FIWHBWSRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23287054,IC50,=,181,NM,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin),,Sulphonamides: Deserving class as MMP inhibitors?,Eur. J. Med. Chem.,2013,60,,"Jain P, Saravanan C, Singh SK",,944094,DTCT0024844,11835655,DTCC00237078,1800998,53820
CHEMBL81398,P14780,,SNUSZUYTMHKCPM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,33,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103806,DTCC00239383,927980,43205
CHEMBL817,P14780,TOLAZAMIDE,OUDSBRTVNLOZBN-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7470450,DTCC00178466,1285883,46191
CHEMBL817,P14780,TOLAZAMIDE,OUDSBRTVNLOZBN-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7470451,DTCC00178466,1285883,46191
CHEMBL81763,P14780,,GJICTISPMDMSQH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12773042,IC50,=,138,NM,,,,,,,,,,,,,,In vitro inhibitory activity against matrix metalloprotease-9.,,"Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.",J. Med. Chem.,2003,46,12,"Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB",,105516,DTCT0024844,497940,DTCC00236269,755674,17340
CHEMBL81763,P14780,,GJICTISPMDMSQH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17590339,LOG(10^6/IC50),=,3.86,,,,,,,,,,,,,,,Inhibition of MMP9,,QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.,Bioorg. Med. Chem.,2007,15,18,"Fernández M, Caballero J",,459102,DTCT0024844,2260716,DTCC00236269,746937,24831
CHEMBL81865,P14780,,HSFVQJYOIWZCLO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11206468,INHIBITION,=,67,%,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9 at 10 uM,,Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2001,11,2,"Levin JI, Gu Y, Nelson FC, Zask A, DiJoseph JF, Sharr MA, Sung A, Jin G, Cowling R, Chanda P, Cosmi S, Hsiao CL, Edris W, Wilhelm J, Killar LM, Skotnicki JS",,105540,DTCT0024844,1293507,DTCC00237600,269984,4516
CHEMBL81977,P14780,3-AMINOBENZAMIDE,GSCPDZHWVNUUFI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7289270,DTCC00237769,1798404,46191
CHEMBL81977,P14780,3-AMINOBENZAMIDE,GSCPDZHWVNUUFI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7289271,DTCC00237769,1798404,46191
CHEMBL820,P14780,BUSULFAN,COVZYZSDYWQREU-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,5215,NM,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7268895,DTCC00178870,898285,46191
CHEMBL820,P14780,BUSULFAN,COVZYZSDYWQREU-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Note: corresponding IC50 reported as Active,DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7268896,DTCC00178870,898285,46191
CHEMBL82113,P14780,,PYGZWPVJQNBFNS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472202,IC50,=,597,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.,J. Med. Chem.,2001,44,16,"Pikul S, Ohler NE, Ciszewski G, Laufersweiler MC, Almstead NG, De B, Natchus MG, Hsieh LC, Janusz MJ, Peng SX, Branch TM, King SL, Taiwo YO, Mieling GE",,105229,DTCT0024844,1290353,DTCC00242452,1773868,16328
CHEMBL82115,P14780,,FJAZVXUPZQSZKI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15109641,IC50,,,,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 at 100 uM (inactive),Not Active,Rational design and synthesis of novel heparan sulfate mimetic compounds as antiadhesive agents.,Bioorg. Med. Chem. Lett.,2004,14,10,"Ishida K, Simizu S, Teruya T, Wierzba MK, Osada H",,105504,DTCT0024844,1410584,DTCC00241670,1163766,6359
CHEMBL82169,P14780,,LFOGEPKUSWRLCL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472202,IC50,=,5.4,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.,J. Med. Chem.,2001,44,16,"Pikul S, Ohler NE, Ciszewski G, Laufersweiler MC, Almstead NG, De B, Natchus MG, Hsieh LC, Janusz MJ, Peng SX, Branch TM, King SL, Taiwo YO, Mieling GE",,105229,DTCT0024844,1298768,DTCC00241974,550551,16328
CHEMBL822,P14780,TERBINAFINE,DOMXUEMWDBAQBQ-WEVVVXLNSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7467859,DTCC00179021,833164,46191
CHEMBL822,P14780,TERBINAFINE,DOMXUEMWDBAQBQ-WEVVVXLNSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7467860,DTCC00179021,833164,46191
CHEMBL82487,P14780,,OCVZODLPTGAJKD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11206468,IC50,=,70,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotease-9,,Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases.,Bioorg. Med. Chem. Lett.,2001,11,2,"Levin JI, Gu Y, Nelson FC, Zask A, DiJoseph JF, Sharr MA, Sung A, Jin G, Cowling R, Chanda P, Cosmi S, Hsiao CL, Edris W, Wilhelm J, Killar LM, Skotnicki JS",,105521,DTCT0024844,1318843,DTCC00237282,433336,4516
CHEMBL82597,P14780,,YHUAHVPZGNXPMS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,13,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103751,DTCC00238679,1892887,43205
CHEMBL826,P14780,ENOXACIN,IDYZIJYBMGIQMJ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7328197,DTCC00179302,1219085,46191
CHEMBL826,P14780,ENOXACIN,IDYZIJYBMGIQMJ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7328198,DTCC00179302,1219085,46191
CHEMBL82744,P14780,,RZAFOWVSSSTSEO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15109641,IC50,,,,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 at 100 uM (inactive),Not Active,Rational design and synthesis of novel heparan sulfate mimetic compounds as antiadhesive agents.,Bioorg. Med. Chem. Lett.,2004,14,10,"Ishida K, Simizu S, Teruya T, Wierzba MK, Osada H",,105504,DTCT0024844,1406077,DTCC00242671,776374,6359
CHEMBL828,P14780,PHENOTHIAZINE,WJFKNYWRSNBZNX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7393603,DTCC00179549,1734060,46191
CHEMBL828,P14780,PHENOTHIAZINE,WJFKNYWRSNBZNX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7393604,DTCC00179549,1734060,46191
CHEMBL82868,P14780,,QCLOBJCDRHHNCL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,42,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1613743,DTCC00243186,950353,15919
CHEMBL82868,P14780,,QCLOBJCDRHHNCL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,41.69,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258508,DTCC00243186,940924,24803
CHEMBL83,P14780,TAMOXIFEN,NKANXQFJJICGDU-QPLCGJKRSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7463384,DTCC00137911,51510,46191
CHEMBL83,P14780,TAMOXIFEN,NKANXQFJJICGDU-QPLCGJKRSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7463385,DTCC00137911,51510,46191
CHEMBL832,P14780,SULFINPYRAZONE,MBGGBVCUIVRRBF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7486894,DTCC00181706,1124456,46191
CHEMBL832,P14780,SULFINPYRAZONE,MBGGBVCUIVRRBF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7486895,DTCC00181706,1124456,46191
CHEMBL83209,P14780,,URNFYSXQOHQAJN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23287054,IC50,,,,,,,,,,,,,,,,,Inhibition of MMP9 (unknown origin),Not Determined,Sulphonamides: Deserving class as MMP inhibitors?,Eur. J. Med. Chem.,2013,60,,"Jain P, Saravanan C, Singh SK",,944094,DTCT0024844,11835651,DTCC00240463,1995454,53820
CHEMBL83282,P14780,,ICFOTHUAZLHTNP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472202,IC50,=,50.8,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.,J. Med. Chem.,2001,44,16,"Pikul S, Ohler NE, Ciszewski G, Laufersweiler MC, Almstead NG, De B, Natchus MG, Hsieh LC, Janusz MJ, Peng SX, Branch TM, King SL, Taiwo YO, Mieling GE",,105229,DTCT0024844,1292790,DTCC00242039,1585074,16328
CHEMBL833,P14780,TICLOPIDINE,PHWBOXQYWZNQIN-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7474697,DTCC00181784,1285882,46191
CHEMBL833,P14780,TICLOPIDINE,PHWBOXQYWZNQIN-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7474698,DTCC00181784,1285882,46191
CHEMBL83368,P14780,,HGCZRPPCNXJXAB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472202,IC50,=,11.7,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.,J. Med. Chem.,2001,44,16,"Pikul S, Ohler NE, Ciszewski G, Laufersweiler MC, Almstead NG, De B, Natchus MG, Hsieh LC, Janusz MJ, Peng SX, Branch TM, King SL, Taiwo YO, Mieling GE",,105229,DTCT0024844,1287856,DTCC00242344,323868,16328
CHEMBL83508,P14780,,WLZISXXOYYGJNT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,=,143,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1612432,DTCC00243572,238020,15919
CHEMBL83508,P14780,,WLZISXXOYYGJNT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,KI,=,144.54,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258449,DTCC00243572,228498,24803
CHEMBL83508,P14780,,WLZISXXOYYGJNT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20180536,IC50,=,130,NM,,,,,,,,,,,,,,Inhibition of MMP9 by fluorometric assay,,Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.,J. Med. Chem.,2010,53,6,"Nuti E, Casalini F, Avramova SI, Santamaria S, Fabbi M, Ferrini S, Marinelli L, La Pietra V, Limongelli V, Novellino E, Cercignani G, Orlandini E, Nencetti S, Rossello A",,624094,DTCT0024844,3286018,DTCC00243572,241678,38228
CHEMBL83616,P14780,,JXAGDPXECXQWBC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472202,IC50,=,3110,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.,J. Med. Chem.,2001,44,16,"Pikul S, Ohler NE, Ciszewski G, Laufersweiler MC, Almstead NG, De B, Natchus MG, Hsieh LC, Janusz MJ, Peng SX, Branch TM, King SL, Taiwo YO, Mieling GE",,105229,DTCT0024844,1310937,DTCC00242500,1773869,16328
CHEMBL83668,P14780,TOLNAFTATE,FUSNMLFNXJSCDI-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7479186,DTCC00242570,1124458,46191
CHEMBL83668,P14780,TOLNAFTATE,FUSNMLFNXJSCDI-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7479187,DTCC00242570,1124458,46191
CHEMBL838,P14780,BENAZEPRIL,XPCFTKFZXHTYIP-PMACEKPBSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7275375,DTCC00182957,574621,46191
CHEMBL838,P14780,BENAZEPRIL,XPCFTKFZXHTYIP-PMACEKPBSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7275376,DTCC00182957,574621,46191
CHEMBL83955,P14780,,ILTCMGUVAAYHSE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472202,IC50,=,94.9,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.,J. Med. Chem.,2001,44,16,"Pikul S, Ohler NE, Ciszewski G, Laufersweiler MC, Almstead NG, De B, Natchus MG, Hsieh LC, Janusz MJ, Peng SX, Branch TM, King SL, Taiwo YO, Mieling GE",,105229,DTCT0024844,1316685,DTCC00242203,1067615,16328
CHEMBL84,P14780,TOPOTECAN,UCFGDBYHRUNTLO-QHCPKHFHSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7487699,DTCC00138393,315672,46191
CHEMBL84,P14780,TOPOTECAN,UCFGDBYHRUNTLO-QHCPKHFHSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7487700,DTCC00138393,315672,46191
CHEMBL841,P14780,LOPERAMIDE,RDOIQAHITMMDAJ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7433901,DTCC00183381,1092343,46191
CHEMBL841,P14780,LOPERAMIDE,RDOIQAHITMMDAJ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7433902,DTCC00183381,1092343,46191
CHEMBL84103,P14780,,JKJGTZQYWJTZFT-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15109641,IC50,,,,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 at 100 uM (inactive),Not Active,Rational design and synthesis of novel heparan sulfate mimetic compounds as antiadhesive agents.,Bioorg. Med. Chem. Lett.,2004,14,10,"Ishida K, Simizu S, Teruya T, Wierzba MK, Osada H",,105504,DTCT0024844,1439324,DTCC00241700,3883,6359
CHEMBL84158,P14780,TIAPRIDE,JTVPZMFULRWINT-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7465978,DTCC00241707,1734065,46191
CHEMBL84158,P14780,TIAPRIDE,JTVPZMFULRWINT-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7465979,DTCC00241707,1734065,46191
CHEMBL8432,P14780,,MJTVUROZTDIMFT-MZEQIWSPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11738583,KI,=,309,NM,,,,,,,,,,,,,,Binding affinity for human gelatinase B (MMP-9),,Potent P1' biphenylmethyl substituted aggrecanase inhibitors.,Bioorg. Med. Chem. Lett.,2002,12,1,"Yao W, Chao M, Wasserman ZR, Liu RQ, Covington MB, Newton R, Christ D, Wexler RR, Decicco CP",,105370,DTCT0024844,1528011,DTCC00135333,239783,4824
CHEMBL844,P14780,BRIMONIDINE,XYLJNLCSTIOKRM-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7260174,DTCC00183812,2057645,46191
CHEMBL844,P14780,BRIMONIDINE,XYLJNLCSTIOKRM-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7260175,DTCC00183812,2057645,46191
CHEMBL84401,P14780,,DISLBCKXFDUIBD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15109641,IC50,,,,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 at 100 uM (inactive),Not Active,Rational design and synthesis of novel heparan sulfate mimetic compounds as antiadhesive agents.,Bioorg. Med. Chem. Lett.,2004,14,10,"Ishida K, Simizu S, Teruya T, Wierzba MK, Osada H",,105504,DTCT0024844,1409588,DTCC00242647,193501,6359
CHEMBL84416,P14780,,VECQGWFFKYPCMA-HRCADAONSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,ACTIVITY,,,,,,,,,,,,,,,,,Inhibition of human recombinant Matrix metalloprotease-9 at 10e-4 M (No significant activity),Not Active,,Bioorg. Med. Chem. Lett.,1997,7,19,,,105221,DTCT0024844,1490652,DTCC00241209,128959,2263
CHEMBL84417,P14780,,CLKBXQUHUHIIKD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15109641,IC50,,,,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 at 100 uM (inactive),Not Active,Rational design and synthesis of novel heparan sulfate mimetic compounds as antiadhesive agents.,Bioorg. Med. Chem. Lett.,2004,14,10,"Ishida K, Simizu S, Teruya T, Wierzba MK, Osada H",,105504,DTCT0024844,1415432,DTCC00241851,193500,6359
CHEMBL8447,P14780,,KFCGJOUPNCPHDL-NOOIUNMQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11738583,KI,=,1085,NM,,,,,,,,,,,,,,Binding affinity for human gelatinase B (MMP-9),,Potent P1' biphenylmethyl substituted aggrecanase inhibitors.,Bioorg. Med. Chem. Lett.,2002,12,1,"Yao W, Chao M, Wasserman ZR, Liu RQ, Covington MB, Newton R, Christ D, Wexler RR, Decicco CP",,105370,DTCT0024844,1552006,DTCC00135696,1340847,4824
CHEMBL84492,P14780,,DDIURNOVEIWZCF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15109641,IC50,,,,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 at 100 uM (inactive),Not Active,Rational design and synthesis of novel heparan sulfate mimetic compounds as antiadhesive agents.,Bioorg. Med. Chem. Lett.,2004,14,10,"Ishida K, Simizu S, Teruya T, Wierzba MK, Osada H",,105504,DTCT0024844,1431438,DTCC00242646,1649958,6359
CHEMBL84543,P14780,,NPXKPNYJEQAEFA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15109641,IC50,,,,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 at 100 uM (inactive),Not Active,Rational design and synthesis of novel heparan sulfate mimetic compounds as antiadhesive agents.,Bioorg. Med. Chem. Lett.,2004,14,10,"Ishida K, Simizu S, Teruya T, Wierzba MK, Osada H",,105504,DTCT0024844,1301022,DTCC00242074,1649959,6359
CHEMBL8466,P14780,,DLHFXODLXJAOSF-XRODADMRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11738583,KI,=,17.2,NM,,,,,,,,,,,,,,Binding affinity for human gelatinase B (MMP-9),,Potent P1' biphenylmethyl substituted aggrecanase inhibitors.,Bioorg. Med. Chem. Lett.,2002,12,1,"Yao W, Chao M, Wasserman ZR, Liu RQ, Covington MB, Newton R, Christ D, Wexler RR, Decicco CP",,105370,DTCT0024844,1539821,DTCC00135786,272550,4824
CHEMBL8496,P14780,,KLPLOGXKUWGLSE-XRODADMRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11738583,KI,<,2.11,NM,,,,,,,,,,,,,,Binding affinity for human gelatinase B (MMP-9),,Potent P1' biphenylmethyl substituted aggrecanase inhibitors.,Bioorg. Med. Chem. Lett.,2002,12,1,"Yao W, Chao M, Wasserman ZR, Liu RQ, Covington MB, Newton R, Christ D, Wexler RR, Decicco CP",,105370,DTCT0024844,1529230,DTCC00135818,370756,4824
CHEMBL85,P14780,RISPERIDONE,RAPZEAPATHNIPO-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7466571,DTCC00138594,1383782,46191
CHEMBL85,P14780,RISPERIDONE,RAPZEAPATHNIPO-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7466572,DTCC00138594,1383782,46191
CHEMBL850,P14780,SPARFLOXACIN,DZZWHBIBMUVIIW-DTORHVGOSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7475779,DTCC00185794,1124454,46191
CHEMBL850,P14780,SPARFLOXACIN,DZZWHBIBMUVIIW-DTORHVGOSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7475780,DTCC00185794,1124454,46191
CHEMBL85026,P14780,,IRVGVLJCCVMVAY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472202,IC50,=,2990,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.,J. Med. Chem.,2001,44,16,"Pikul S, Ohler NE, Ciszewski G, Laufersweiler MC, Almstead NG, De B, Natchus MG, Hsieh LC, Janusz MJ, Peng SX, Branch TM, King SL, Taiwo YO, Mieling GE",,105229,DTCT0024844,1286653,DTCC00242319,421955,16328
CHEMBL85030,P14780,CGS-25966,ZGSTVUAZFACDLH-GOSISDBHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22540974,KI,=,27,NM,,,,,,,,,,,,,,"Inhibition of MMP9 using (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured for 10 mins by fluorometry",,A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation.,J. Med. Chem.,2012,55,10,"Hugenberg V, Breyholz HJ, Riemann B, Hermann S, Schober O, Schäfers M, Gangadharmath U, Mocharla V, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,832927,DTCT0024844,10563940,DTCC01741458,543755,48958
CHEMBL85030,P14780,CGS-25966,ZGSTVUAZFACDLH-GOSISDBHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,23899323,KI,=,27,NM,,,,,,,,,,,,,,Inhibition of MMP-9 (unknown origin),,"Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation.",J. Med. Chem.,2013,56,17,"Hugenberg V, Riemann B, Hermann S, Schober O, Schäfers M, Szardenings K, Lebedev A, Gangadharmath U, Kolb H, Walsh J, Zhang W, Kopka K, Wagner S",,983458,DTCT0024844,12575116,DTCC01741458,525519,55760
CHEMBL85030,P14780,CGS-25966,ZGSTVUAZFACDLH-GOSISDBHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,25921268,KI,=,27,NM,,,,,,,,,,,,,,"Inhibition of human active MMP9 using (7-methoxycoumarin-4-yl) acetyl pro-Leu-Gly-Leu-[3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl]-Ala-Arg-NH2 fluorogenic substrate assessed as fluorescent product release",,New matrix metalloproteinase inhibitors based on ¿-fluorinated a-aminocarboxylic and a-aminohydroxamic acids.,Bioorg. Med. Chem.,2015,23,13,"Behrends M, Wagner S, Kopka K, Schober O, Schäfers M, Kumbhar S, Waller M, Haufe G",,1501468,DTCT0024844,14456760,DTCC01741458,527978,62860
CHEMBL85139,P14780,RUTAECARPINE,ACVGWSKVRYFWRP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17027271,IC50,=,7.95,UG.ML-1,,,,,,,,,,,,,,Inhibition of human MMP9 by quenched fluorescense assay,,Natural inhibitors targeting osteoclast-mediated bone resorption.,Bioorg. Med. Chem. Lett.,2006,16,24,"Zeng GZ, Tan NH, Hao XJ, Mu QZ, Li RT",,425101,DTCT0024844,2017652,DTCC00244509,1599059,21854
CHEMBL852,P14780,MELPHALAN,SGDBTWWWUNNDEQ-LBPRGKRZSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7425799,DTCC00185853,249079,46191
CHEMBL852,P14780,MELPHALAN,SGDBTWWWUNNDEQ-LBPRGKRZSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7425800,DTCC00185853,249079,46191
CHEMBL85374,P14780,,BLYHHTXBRXLLOI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472202,IC50,=,18.7,NM,,,,,,,,,,,,,,In vitro inhibition of human matrix metalloprotease-9,,Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.,J. Med. Chem.,2001,44,16,"Pikul S, Ohler NE, Ciszewski G, Laufersweiler MC, Almstead NG, De B, Natchus MG, Hsieh LC, Janusz MJ, Peng SX, Branch TM, King SL, Taiwo YO, Mieling GE",,105229,DTCT0024844,1320331,DTCC00242381,1455978,16328
CHEMBL8553,P14780,,RDDJLUVPXZTDCT-QQSVUBKYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11738583,KI,=,2.8,NM,,,,,,,,,,,,,,Binding affinity for human gelatinase B (MMP-9),,Potent P1' biphenylmethyl substituted aggrecanase inhibitors.,Bioorg. Med. Chem. Lett.,2002,12,1,"Yao W, Chao M, Wasserman ZR, Liu RQ, Covington MB, Newton R, Christ D, Wexler RR, Decicco CP",,105370,DTCT0024844,1529226,DTCC00135425,1146741,4824
CHEMBL856,P14780,PRIMIDONE,DQMZLTXERSFNPB-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7379096,DTCC00186106,1674147,46191
CHEMBL856,P14780,PRIMIDONE,DQMZLTXERSFNPB-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7379097,DTCC00186106,1674147,46191
CHEMBL85728,P14780,"4,4'-METHYLENEDIANILINE",YBRVSVVVWCFQMG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7294757,DTCC00242937,1318436,46191
CHEMBL85728,P14780,"4,4'-METHYLENEDIANILINE",YBRVSVVVWCFQMG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7294758,DTCC00242937,1318436,46191
CHEMBL85744,P14780,,ZGTPJERIIBYCFG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10411481,KI,=,65,NM,,,,,,,,,,,,,,Binding affinity against matrix metalloprotease-9 (gelatinase-B).,,Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.,J. Med. Chem.,1999,42,14,"Vassiliou S, Mucha A, Cuniasse P, Georgiadis D, Lucet-Levannier K, Beau F, Kannan R, Murphy G, Knäuper V, Rio MC, Basset P, Yiotakis A, Dive V",,105378,DTCT0024844,1093443,DTCC00248613,1002961,15258
CHEMBL86,P14780,METOCLOPRAMIDE,TTWJBBZEZQICBI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7413184,DTCC00138614,51488,46191
CHEMBL86,P14780,METOCLOPRAMIDE,TTWJBBZEZQICBI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7413185,DTCC00138614,51488,46191
CHEMBL862,P14780,GUANFACINE,INJOMKTZOLKMBF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7325411,DTCC00186365,1351111,46191
CHEMBL862,P14780,GUANFACINE,INJOMKTZOLKMBF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7325412,DTCC00186365,1351111,46191
CHEMBL86304,P14780,MOCLOBEMIDE,YHXISWVBGDMDLQ-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7411341,DTCC00246764,833162,46191
CHEMBL86304,P14780,MOCLOBEMIDE,YHXISWVBGDMDLQ-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7411342,DTCC00246764,833162,46191
CHEMBL86390,P14780,,HCCYYUWFQWPMDZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10411481,KI,=,55,NM,,,,,,,,,,,,,,Binding affinity against matrix metalloprotease-9 (gelatinase-B).,,Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.,J. Med. Chem.,1999,42,14,"Vassiliou S, Mucha A, Cuniasse P, Georgiadis D, Lucet-Levannier K, Beau F, Kannan R, Murphy G, Knäuper V, Rio MC, Basset P, Yiotakis A, Dive V",,105378,DTCT0024844,1072661,DTCC00248612,452924,15258
CHEMBL865,P14780,VALDECOXIB,LNPDTQAFDNKSHK-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7440855,DTCC00187234,866025,46191
CHEMBL865,P14780,VALDECOXIB,LNPDTQAFDNKSHK-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7440856,DTCC00187234,866025,46191
CHEMBL8655,P14780,,FPXJIRSUGPCTBC-QQSVUBKYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11738583,KI,=,691,NM,,,,,,,,,,,,,,Binding affinity for human gelatinase B (MMP-9),,Potent P1' biphenylmethyl substituted aggrecanase inhibitors.,Bioorg. Med. Chem. Lett.,2002,12,1,"Yao W, Chao M, Wasserman ZR, Liu RQ, Covington MB, Newton R, Christ D, Wexler RR, Decicco CP",,105370,DTCT0024844,1535166,DTCC00135623,143114,4824
CHEMBL866,P14780,MYCOPHENOLIC ACID,HPNSFSBZBAHARI-RUDMXATFSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7407129,DTCC00188298,120975,46191
CHEMBL866,P14780,MYCOPHENOLIC ACID,HPNSFSBZBAHARI-RUDMXATFSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7407130,DTCC00188298,120975,46191
CHEMBL86754,P14780,IODOQUINOL,UXZFQZANDVDGMM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7439467,DTCC00246886,1220278,46191
CHEMBL86754,P14780,IODOQUINOL,UXZFQZANDVDGMM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7439468,DTCC00246886,1220278,46191
CHEMBL870,P14780,ALENDRONIC ACID,OGSPWJRAVKPPFI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7300598,DTCC00190086,800568,46191
CHEMBL870,P14780,ALENDRONIC ACID,OGSPWJRAVKPPFI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7300599,DTCC00190086,800568,46191
CHEMBL8702,P14780,,WHHWDHNQTWOJFL-PFATUAPWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11738583,KI,=,5.4,NM,,,,,,,,,,,,,,Binding affinity for human gelatinase B (MMP-9),,Potent P1' biphenylmethyl substituted aggrecanase inhibitors.,Bioorg. Med. Chem. Lett.,2002,12,1,"Yao W, Chao M, Wasserman ZR, Liu RQ, Covington MB, Newton R, Christ D, Wexler RR, Decicco CP",,105370,DTCT0024844,1526881,DTCC00135672,1852611,4824
CHEMBL871,P14780,ETIDRONIC ACID,DBVJJBKOTRCVKF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7328511,DTCC00190087,542574,46191
CHEMBL871,P14780,ETIDRONIC ACID,DBVJJBKOTRCVKF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7328512,DTCC00190087,542574,46191
CHEMBL87159,P14780,,SFORRVNMTYAPLQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10411481,KI,=,10,NM,,,,,,,,,,,,,,Binding affinity against matrix metalloprotease-9 (gelatinase-B).,,Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.,J. Med. Chem.,1999,42,14,"Vassiliou S, Mucha A, Cuniasse P, Georgiadis D, Lucet-Levannier K, Beau F, Kannan R, Murphy G, Knäuper V, Rio MC, Basset P, Yiotakis A, Dive V",,105378,DTCT0024844,1065671,DTCC00248280,291448,15258
CHEMBL87223,P14780,AMINOQUINURIDE,HOUSDILKOJMENG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,=,100000,NM,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967759,DTCC00247009,1268698,56747
CHEMBL87229,P14780,,IYJLBIPCLHKYKU-YADHBBJMSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,=,3.3,NM,,,,,,,,,,,,,,Inhibition of human Matrix metalloprotease-9,,,Bioorg. Med. Chem. Lett.,1995,5,4,,,105391,DTCT0024844,819548,DTCC00247084,594918,1497
CHEMBL87285,P14780,ANDROSTERONE,QGXBDMJGAMFCBF-HLUDHZFRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7283391,DTCC00245174,930075,46191
CHEMBL87285,P14780,ANDROSTERONE,QGXBDMJGAMFCBF-HLUDHZFRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7270476,DTCC00245174,930075,46191
CHEMBL87300,P14780,,BVONHINTCXADCU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10411481,KI,=,6,NM,,,,,,,,,,,,,,Binding affinity against matrix metalloprotease-9 (gelatinase-B).,,Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.,J. Med. Chem.,1999,42,14,"Vassiliou S, Mucha A, Cuniasse P, Georgiadis D, Lucet-Levannier K, Beau F, Kannan R, Murphy G, Knäuper V, Rio MC, Basset P, Yiotakis A, Dive V",,105378,DTCT0024844,1056172,DTCC00248279,291447,15258
CHEMBL87699,P14780,,CANDCUWSRJILKW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24290062,IC50,,,,,,,,,,,,,,,,,Inhibition of human MMP-9 after 60 mins by FRET assay,Not Determined,Small molecule inhibitors of anthrax lethal factor toxin.,Bioorg. Med. Chem.,2014,22,1,"Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP",,1281777,DTCT0024844,12967740,DTCC00247248,1720527,56747
CHEMBL877,P14780,TRANEXAMIC ACID,GYDJEQRTZSCIOI-LJGSYFOKSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7446086,DTCC00192310,1544904,46191
CHEMBL877,P14780,TRANEXAMIC ACID,GYDJEQRTZSCIOI-LJGSYFOKSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7446087,DTCC00192310,1544904,46191
CHEMBL87786,P14780,,UERCGTJUVRFNRO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10411481,KI,=,245,NM,,,,,,,,,,,,,,Binding affinity against matrix metalloprotease-9 (gelatinase-B).,,Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.,J. Med. Chem.,1999,42,14,"Vassiliou S, Mucha A, Cuniasse P, Georgiadis D, Lucet-Levannier K, Beau F, Kannan R, Murphy G, Knäuper V, Rio MC, Basset P, Yiotakis A, Dive V",,105378,DTCT0024844,1084528,DTCC00248815,1456037,15258
CHEMBL878,P14780,METOLAZONE,AQCHWTWZEMGIFD-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7417540,DTCC00192311,1253327,46191
CHEMBL878,P14780,METOLAZONE,AQCHWTWZEMGIFD-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7417541,DTCC00192311,1253327,46191
CHEMBL88,P14780,CYCLOPHOSPHAMIDE,CMSMOCZEIVJLDB-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7361209,DTCC00139205,994590,46191
CHEMBL88,P14780,CYCLOPHOSPHAMIDE,CMSMOCZEIVJLDB-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7361210,DTCC00139205,994590,46191
CHEMBL880,P14780,FAMCICLOVIR,GGXKWVWZWMLJEH-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7315842,DTCC00192933,444642,46191
CHEMBL880,P14780,FAMCICLOVIR,GGXKWVWZWMLJEH-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7315843,DTCC00192933,444642,46191
CHEMBL88187,P14780,,BVNHOVTUHKATJL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10411481,KI,=,55,NM,,,,,,,,,,,,,,Binding affinity against matrix metalloprotease-9 (gelatinase-B).,,Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.,J. Med. Chem.,1999,42,14,"Vassiliou S, Mucha A, Cuniasse P, Georgiadis D, Lucet-Levannier K, Beau F, Kannan R, Murphy G, Knäuper V, Rio MC, Basset P, Yiotakis A, Dive V",,105378,DTCT0024844,1082198,DTCC00249128,323966,15258
CHEMBL88188,P14780,,LWTYDGJEOHWGQD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10411481,KI,=,22,NM,,,,,,,,,,,,,,Binding affinity against matrix metalloprotease-9 (gelatinase-B).,,Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.,J. Med. Chem.,1999,42,14,"Vassiliou S, Mucha A, Cuniasse P, Georgiadis D, Lucet-Levannier K, Beau F, Kannan R, Murphy G, Knäuper V, Rio MC, Basset P, Yiotakis A, Dive V",,105378,DTCT0024844,1092148,DTCC00249129,582755,15258
CHEMBL88220,P14780,,VOBIZCCABUHCMX-ZNMIVQPWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472217,KI,=,12.8,NM,,,,,,,,,,,,,,In vitro inhibition of human MMP-9.,,"Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.",J. Med. Chem.,2001,44,16,"Xue CB, Voss ME, Nelson DJ, Duan JJ, Cherney RJ, Jacobson IC, He X, Roderick J, Chen L, Corbett RL, Wang L, Meyer DT, Kennedy K, DeGradodagger WF, Hardman KD, Teleha CA, Jaffee BD, Liu RQ, Copeland RA, Covington MB, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105380,DTCT0024844,1660461,DTCC00251888,161719,16346
CHEMBL88427,P14780,,QPXBSLSYKHMQGZ-XHSDSOJGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472217,KI,<,1,NM,,,,,,,,,,,,,,In vitro inhibition of human MMP-9.,,"Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.",J. Med. Chem.,2001,44,16,"Xue CB, Voss ME, Nelson DJ, Duan JJ, Cherney RJ, Jacobson IC, He X, Roderick J, Chen L, Corbett RL, Wang L, Meyer DT, Kennedy K, DeGradodagger WF, Hardman KD, Teleha CA, Jaffee BD, Liu RQ, Copeland RA, Covington MB, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105380,DTCT0024844,1671746,DTCC00251886,1742178,16346
CHEMBL88520,P14780,,HFAGTNGCAZYYLZ-OTWHNJEPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472217,KI,=,0.9,NM,,,,,,,,,,,,,,In vitro inhibition of human MMP-9.,,"Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.",J. Med. Chem.,2001,44,16,"Xue CB, Voss ME, Nelson DJ, Duan JJ, Cherney RJ, Jacobson IC, He X, Roderick J, Chen L, Corbett RL, Wang L, Meyer DT, Kennedy K, DeGradodagger WF, Hardman KD, Teleha CA, Jaffee BD, Liu RQ, Copeland RA, Covington MB, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105380,DTCT0024844,1674084,DTCC00251150,291473,16346
CHEMBL88559,P14780,,NAVKLAFIVRMQMW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9873598,IC50,=,23,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,The synthesis and biological activity of a novel series of diazepine MMP inhibitors.,Bioorg. Med. Chem. Lett.,1998,8,19,"Levin JI, DiJoseph JF, Killar LM, Sung A, Walter T, Sharr MA, Roth CE, Skotnicki JS, Albright JD",,105513,DTCT0024844,604477,DTCC00252279,1456057,2791
CHEMBL888,P14780,GEMCITABINE,SDUQYLNIPVEERB-QPPQHZFASA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7325057,DTCC00194280,51473,46191
CHEMBL888,P14780,GEMCITABINE,SDUQYLNIPVEERB-QPPQHZFASA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7325058,DTCC00194280,51473,46191
CHEMBL88972,P14780,"PYRIDINE-2,5-DICARBOXYLIC ACID",LVPMIMZXDYBCDF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,-2,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103044,DTCC00250420,2087684,43205
CHEMBL89057,P14780,,RIOJMNDNYHZZFM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10411481,KI,=,7,NM,,,,,,,,,,,,,,Binding affinity against matrix metalloprotease-9 (gelatinase-B).,,Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.,J. Med. Chem.,1999,42,14,"Vassiliou S, Mucha A, Cuniasse P, Georgiadis D, Lucet-Levannier K, Beau F, Kannan R, Murphy G, Knäuper V, Rio MC, Basset P, Yiotakis A, Dive V",,105378,DTCT0024844,1082205,DTCC00249245,1838879,15258
CHEMBL891,P14780,CLOXACILLIN,LQOLIRLGBULYKD-JKIFEVAISA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7360987,DTCC00194952,2089744,46191
CHEMBL891,P14780,CLOXACILLIN,LQOLIRLGBULYKD-JKIFEVAISA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7360988,DTCC00194952,2089744,46191
CHEMBL894,P14780,BUPROPION,SNPPWIUOZRMYNY-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7263208,DTCC00195238,800571,46191
CHEMBL894,P14780,BUPROPION,SNPPWIUOZRMYNY-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7263209,DTCC00195238,800571,46191
CHEMBL8943,P14780,,VXDKQRWTOJFQKH-BJZITVGISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11585439,KI,=,3324,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors.",J. Med. Chem.,2001,44,21,"Yao W, Wasserman ZR, Chao M, Reddy G, Shi E, Liu RQ, Covington MB, Arner EC, Pratta MA, Tortorella M, Magolda RL, Newton R, Qian M, Ribadeneira MD, Christ D, Wexler RR, Decicco CP",,105382,DTCT0024844,1409058,DTCC00135827,1468155,16438
CHEMBL8943,P14780,,VXDKQRWTOJFQKH-BJZITVGISA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11738583,KI,=,3324,NM,,,,,,,,,,,,,,Binding affinity for human gelatinase B (MMP-9),,Potent P1' biphenylmethyl substituted aggrecanase inhibitors.,Bioorg. Med. Chem. Lett.,2002,12,1,"Yao W, Chao M, Wasserman ZR, Liu RQ, Covington MB, Newton R, Christ D, Wexler RR, Decicco CP",,105370,DTCT0024844,1519786,DTCC00135827,1470173,4824
CHEMBL895,P14780,NALBUPHINE,NETZHAKZCGBWSS-CEDHKZHLSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7407260,DTCC00195307,413972,46191
CHEMBL895,P14780,NALBUPHINE,NETZHAKZCGBWSS-CEDHKZHLSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7407261,DTCC00195307,413972,46191
CHEMBL897,P14780,PROBENECID,DBABZHXKTCFAPX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7383428,DTCC00195516,1188073,46191
CHEMBL897,P14780,PROBENECID,DBABZHXKTCFAPX-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7383429,DTCC00195516,1188073,46191
CHEMBL898,P14780,DIFLUNISAL,HUPFGZXOMWLGNK-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7338169,DTCC00195664,477917,46191
CHEMBL898,P14780,DIFLUNISAL,HUPFGZXOMWLGNK-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7338170,DTCC00195664,477917,46191
CHEMBL9,P14780,NORFLOXACIN,OGJPXUAPXNRGGI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7392863,DTCC00132409,51494,46191
CHEMBL9,P14780,NORFLOXACIN,OGJPXUAPXNRGGI-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7392864,DTCC00132409,51494,46191
CHEMBL900,P14780,ORPHENADRINE,QVYRGXJJSLMXQH-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7373775,DTCC00195771,217582,46191
CHEMBL900,P14780,ORPHENADRINE,QVYRGXJJSLMXQH-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7373776,DTCC00195771,217582,46191
CHEMBL902,P14780,FAMOTIDINE,XUFQPHANEAPEMJ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7320078,DTCC00196201,1155680,46191
CHEMBL902,P14780,FAMOTIDINE,XUFQPHANEAPEMJ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7320079,DTCC00196201,1155680,46191
CHEMBL90321,P14780,,SSQXFNKOLMHXPO-IRCOFANPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873504,KI,=,4.8,NM,,,,,,,,,,,,,,Inhibition of recombinant human matrix metalloprotease-9,,Structure--activity relationships of azasugar-based MMP/ADAM inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,16,"Moriyama H, Tsukida T, Inoue Y, Kondo H, Yoshino K, Nishimura S",,105394,DTCT0024844,922974,DTCC00255629,1980200,5719
CHEMBL90337,P14780,,IKFMCZJWBBXODH-MJBXVCDLSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472217,KI,=,3.6,NM,,,,,,,,,,,,,,In vitro inhibition of human MMP-9.,,"Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.",J. Med. Chem.,2001,44,16,"Xue CB, Voss ME, Nelson DJ, Duan JJ, Cherney RJ, Jacobson IC, He X, Roderick J, Chen L, Corbett RL, Wang L, Meyer DT, Kennedy K, DeGradodagger WF, Hardman KD, Teleha CA, Jaffee BD, Liu RQ, Copeland RA, Covington MB, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105380,DTCT0024844,1641648,DTCC00250805,225944,16346
CHEMBL90555,P14780,VINCRISTINE,OGWKCGZFUXNPDA-XQKSVPLYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7442581,DTCC00249955,51516,46191
CHEMBL90555,P14780,VINCRISTINE,OGWKCGZFUXNPDA-XQKSVPLYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7442582,DTCC00249955,51516,46191
CHEMBL90622,P14780,,RZDDQWJXBRPPTM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,10411481,KI,=,6,NM,,,,,,,,,,,,,,Binding affinity against matrix metalloprotease-9 (gelatinase-B).,,Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.,J. Med. Chem.,1999,42,14,"Vassiliou S, Mucha A, Cuniasse P, Georgiadis D, Lucet-Levannier K, Beau F, Kannan R, Murphy G, Knäuper V, Rio MC, Basset P, Yiotakis A, Dive V",,105378,DTCT0024844,1090999,DTCC00249364,1742142,15258
CHEMBL90806,P14780,,SSQXFNKOLMHXPO-WYUUTHIRSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873504,KI,=,82,NM,,,,,,,,,,,,,,Inhibition of recombinant human matrix metalloprotease-9,,Structure--activity relationships of azasugar-based MMP/ADAM inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,16,"Moriyama H, Tsukida T, Inoue Y, Kondo H, Yoshino K, Nishimura S",,105394,DTCT0024844,912778,DTCC00255639,401254,5719
CHEMBL9086,P14780,,LNOUSIQMHQJZBP-WIOYSNFSSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11738583,KI,=,347,NM,,,,,,,,,,,,,,Binding affinity for human gelatinase B (MMP-9),,Potent P1' biphenylmethyl substituted aggrecanase inhibitors.,Bioorg. Med. Chem. Lett.,2002,12,1,"Yao W, Chao M, Wasserman ZR, Liu RQ, Covington MB, Newton R, Christ D, Wexler RR, Decicco CP",,105370,DTCT0024844,1522343,DTCC00135631,629319,4824
CHEMBL90978,P14780,,AOPSFGSGYVNAEJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,9873598,IC50,=,1.2,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9 (MMP-9),,The synthesis and biological activity of a novel series of diazepine MMP inhibitors.,Bioorg. Med. Chem. Lett.,1998,8,19,"Levin JI, DiJoseph JF, Killar LM, Sung A, Walter T, Sharr MA, Roth CE, Skotnicki JS, Albright JD",,105513,DTCT0024844,614800,DTCC00252083,1424235,2791
CHEMBL91,P14780,MICONAZOLE,BYBLEWFAAKGYCD-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7415582,DTCC00139665,1317286,46191
CHEMBL91,P14780,MICONAZOLE,BYBLEWFAAKGYCD-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7415583,DTCC00139665,1317286,46191
CHEMBL914,P14780,FEXOFENADINE,RWTNPBWLLIMQHL-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7318087,DTCC00198847,413971,46191
CHEMBL914,P14780,FEXOFENADINE,RWTNPBWLLIMQHL-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7318088,DTCC00198847,413971,46191
CHEMBL91636,P14780,,DONMTDNLNMLOIC-OTWHNJEPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472217,KI,=,1.2,NM,,,,,,,,,,,,,,In vitro inhibition of human MMP-9.,,"Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.",J. Med. Chem.,2001,44,16,"Xue CB, Voss ME, Nelson DJ, Duan JJ, Cherney RJ, Jacobson IC, He X, Roderick J, Chen L, Corbett RL, Wang L, Meyer DT, Kennedy K, DeGradodagger WF, Hardman KD, Teleha CA, Jaffee BD, Liu RQ, Copeland RA, Covington MB, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105380,DTCT0024844,1647511,DTCC00251443,1261581,16346
CHEMBL91636,P14780,,DONMTDNLNMLOIC-OTWHNJEPSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11585440,KI,=,1.2,NM,,,,,,,,,,,,,,Inhibition of human matrix metalloprotease-9,,"Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.",J. Med. Chem.,2001,44,21,"Xue CB, He X, Corbett RL, Roderick J, Wasserman ZR, Liu RQ, Jaffee BD, Covington MB, Qian M, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105383,DTCT0024844,1304864,DTCC00251443,1273600,16439
CHEMBL917,P14780,FLOXURIDINE,ODKNJVUHOIMIIZ-RRKCRQDMSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7297609,DTCC00199915,1609542,46191
CHEMBL917,P14780,FLOXURIDINE,ODKNJVUHOIMIIZ-RRKCRQDMSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7297610,DTCC00199915,1609542,46191
CHEMBL918,P14780,PHENACEMIDE,XPFRXWCVYUEORT-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7402118,DTCC00199924,1577008,46191
CHEMBL918,P14780,PHENACEMIDE,XPFRXWCVYUEORT-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7402119,DTCC00199924,1577008,46191
CHEMBL923,P14780,RISEDRONIC ACID,IIDJRNMFWXDHID-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7462193,DTCC00200598,1927022,46191
CHEMBL923,P14780,RISEDRONIC ACID,IIDJRNMFWXDHID-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7462194,DTCC00200598,1927022,46191
CHEMBL92385,P14780,,AMVCYHOEVISGQB-IPYPFGDCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11472217,KI,=,3.9,NM,,,,,,,,,,,,,,In vitro inhibition of human MMP-9.,,"Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.",J. Med. Chem.,2001,44,16,"Xue CB, Voss ME, Nelson DJ, Duan JJ, Cherney RJ, Jacobson IC, He X, Roderick J, Chen L, Corbett RL, Wang L, Meyer DT, Kennedy K, DeGradodagger WF, Hardman KD, Teleha CA, Jaffee BD, Liu RQ, Copeland RA, Covington MB, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP",,105380,DTCT0024844,1660458,DTCC00250839,1903218,16346
CHEMBL924,P14780,ZOLEDRONIC ACID,XRASPMIURGNCCH-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24071448,IC50,=,52000,NM,,,,,,,,,,,,,,Inhibition of MMP9 catalytic domain (unknown origin) using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured after 2 to 4 hrs by fluorometric assay,,Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.,Bioorg. Med. Chem.,2013,21,21,"Tauro M, Laghezza A, Loiodice F, Agamennone M, Campestre C, Tortorella P",,990168,DTCT0024844,12629018,DTCC00200651,1095364,56259
CHEMBL92401,P14780,IPRONIAZID,NYMGNSNKLVNMIA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7413915,DTCC00256735,1992806,46191
CHEMBL92401,P14780,IPRONIAZID,NYMGNSNKLVNMIA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7413916,DTCC00256735,1992806,46191
CHEMBL92512,P14780,,RSWUWSKXIDLCIR-ULQDDVLXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,5,NM,,,,,,,,,,,,,,"Inhibition of matrix metalloprotease-9, MMP-9",,,Bioorg. Med. Chem. Lett.,1997,7,21,,,102116,DTCT0024844,1311591,DTCC00257798,518678,2323
CHEMBL926,P14780,DOBUTAMINE,JRWZLRBJNMZMFE-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7361989,DTCC00105095,1383776,46191
CHEMBL926,P14780,DOBUTAMINE,JRWZLRBJNMZMFE-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7361990,DTCC00105095,1383776,46191
CHEMBL92767,P14780,,SSQXFNKOLMHXPO-QCNOEVLYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873504,KI,=,157,NM,,,,,,,,,,,,,,Inhibition of recombinant human matrix metalloprotease-9,,Structure--activity relationships of azasugar-based MMP/ADAM inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,16,"Moriyama H, Tsukida T, Inoue Y, Kondo H, Yoshino K, Nishimura S",,105394,DTCT0024844,918540,DTCC00255894,1914635,5719
CHEMBL92767,P14780,,SSQXFNKOLMHXPO-QCNOEVLYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873505,KI,=,157,NM,,,,,,,,,,,,,,Inhibition of recombinant human matrix metalloprotease-9 (gelatinase B),,"Design, synthesis and evaluation of novel azasugar-based MMP/ADAM inhibitors.",Bioorg. Med. Chem. Lett.,2003,13,16,"Moriyama H, Tsukida T, Inoue Y, Kondo H, Yoshino K, Nishimura S",,105395,DTCT0024844,968723,DTCC00255894,1914640,5720
CHEMBL92835,P14780,,SJEBBPDOLJCLQH-OJSMNCEXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,31,NM,,,,,,,,,,,,,,"Inhibition of matrix metalloprotease-9, MMP-9",,,Bioorg. Med. Chem. Lett.,1997,7,21,,,102116,DTCT0024844,1306830,DTCC00258294,1196484,2323
CHEMBL92927,P14780,,ZOPDCQZNGWSOLM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873518,IC50,=,40,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotein-9,,Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2003,13,16,"Levin JI, Chen JM, Cheung K, Cole D, Crago C, Santos ED, Du X, Khafizova G, MacEwan G, Niu C, Salaski EJ, Zask A, Cummons T, Sung A, Xu J, Zhang Y, Xu W, Ayral-Kaloustian S, Jin G, Cowling R, Barone D, Mohler KM, Black RA, Skotnicki JS",,105519,DTCT0024844,783664,DTCC00259628,1456145,5733
CHEMBL92927,P14780,,ZOPDCQZNGWSOLM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,39.81,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258128,DTCC00259628,1458607,24803
CHEMBL92970,P14780,,RSWUWSKXIDLCIR-YESZJQIVSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,30,NM,,,,,,,,,,,,,,"Inhibition of matrix metalloprotease-9, MMP-9",,,Bioorg. Med. Chem. Lett.,1997,7,21,,,102116,DTCT0024844,1295707,DTCC00257891,356750,2323
CHEMBL93,P14780,ZILEUTON,MWLSOWXNZPKENC-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7448795,DTCC00139913,51518,46191
CHEMBL93,P14780,ZILEUTON,MWLSOWXNZPKENC-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7448796,DTCC00139913,51518,46191
CHEMBL93067,P14780,,FABJTKDLHAAFNV-DGAVXFQQSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873505,KI,=,310,NM,,,,,,,,,,,,,,Inhibition of recombinant human matrix metalloprotease-9 (gelatinase B),,"Design, synthesis and evaluation of novel azasugar-based MMP/ADAM inhibitors.",Bioorg. Med. Chem. Lett.,2003,13,16,"Moriyama H, Tsukida T, Inoue Y, Kondo H, Yoshino K, Nishimura S",,105395,DTCT0024844,951750,DTCC00255808,917299,5720
CHEMBL93155,P14780,,DCCBWHQCASKYJR-NTZARQNWSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,3,NM,,,,,,,,,,,,,,"Inhibition of matrix metalloprotease-9, MMP-9",,,Bioorg. Med. Chem. Lett.,1997,7,21,,,102116,DTCT0024844,1300779,DTCC00258060,1163956,2323
CHEMBL932,P14780,DIPYRIDAMOLE,IZEKFCXSFNUWAM-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7349084,DTCC00202383,444640,46191
CHEMBL932,P14780,DIPYRIDAMOLE,IZEKFCXSFNUWAM-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7349085,DTCC00202383,444640,46191
CHEMBL93320,P14780,,CXNJLMYOAJTOHP-ADUPEVMXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,1,NM,,,,,,,,,,,,,,"Inhibition of matrix metalloprotease-9, MMP-9",,,Bioorg. Med. Chem. Lett.,1997,7,21,,,102116,DTCT0024844,1318619,DTCC00257892,1163955,2323
CHEMBL93357,P14780,,FYYNAVTYOZPHTC-JWDFLIAJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,30,NM,,,,,,,,,,,,,,"Inhibition of matrix metalloprotease-9, MMP-9",,,Bioorg. Med. Chem. Lett.,1997,7,21,,,102116,DTCT0024844,1287266,DTCC00258033,2065748,2323
CHEMBL934,P14780,METYRAPONE,FJLBFSROUSIWMA-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7430404,DTCC00202598,1992807,46191
CHEMBL934,P14780,METYRAPONE,FJLBFSROUSIWMA-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7430405,DTCC00202598,1992807,46191
CHEMBL936,P14780,DIPHENIDOL,OGAKLTJNUQRZJU-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7344821,DTCC00202761,1416027,46191
CHEMBL936,P14780,DIPHENIDOL,OGAKLTJNUQRZJU-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7344822,DTCC00202761,1416027,46191
CHEMBL93620,P14780,,LQZDEWIIFWHTLX-BSDSXHPESA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873504,KI,=,6.1,NM,,,,,,,,,,,,,,Inhibition of recombinant human matrix metalloprotease-9,,Structure--activity relationships of azasugar-based MMP/ADAM inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,16,"Moriyama H, Tsukida T, Inoue Y, Kondo H, Yoshino K, Nishimura S",,105394,DTCT0024844,901961,DTCC00255502,1144452,5719
CHEMBL93645,P14780,ACECLOFENAC,MNIPYSSQXLZQLJ-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7294871,DTCC00256586,1285871,46191
CHEMBL93645,P14780,ACECLOFENAC,MNIPYSSQXLZQLJ-UHFFFAOYSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7294872,DTCC00256586,1285871,46191
CHEMBL93720,P14780,,SSQXFNKOLMHXPO-USZNOCQGSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873504,KI,=,780,NM,,,,,,,,,,,,,,Inhibition of recombinant human matrix metalloprotease-9,,Structure--activity relationships of azasugar-based MMP/ADAM inhibitors.,Bioorg. Med. Chem. Lett.,2003,13,16,"Moriyama H, Tsukida T, Inoue Y, Kondo H, Yoshino K, Nishimura S",,105394,DTCT0024844,922978,DTCC00255641,949872,5719
CHEMBL94,P14780,PHYSOSTIGMINE,PIJVFDBKTWXHHD-HIFRSBDPSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7378728,DTCC00139956,1862717,46191
CHEMBL94,P14780,PHYSOSTIGMINE,PIJVFDBKTWXHHD-HIFRSBDPSA-N,3,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7378729,DTCC00139956,1862717,46191
CHEMBL940,P14780,GABAPENTIN,UGJMXCAKCUNAIE-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7329236,DTCC00204291,2025637,46191
CHEMBL940,P14780,GABAPENTIN,UGJMXCAKCUNAIE-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7329237,DTCC00204291,2025637,46191
CHEMBL941,P14780,IMATINIB,KTUFNOKKBVMGRW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7313077,DTCC01738580,51477,46191
CHEMBL941,P14780,IMATINIB,KTUFNOKKBVMGRW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7313078,DTCC01738580,51477,46191
CHEMBL9419,P14780,METACETAMOL,QLNWXBAGRTUKKI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7286608,DTCC00136686,477909,46191
CHEMBL9419,P14780,METACETAMOL,QLNWXBAGRTUKKI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7286609,DTCC00136686,477909,46191
CHEMBL942,P14780,BISACODYL,KHOITXIGCFIULA-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7268712,DTCC00204742,736255,46191
CHEMBL942,P14780,BISACODYL,KHOITXIGCFIULA-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7268713,DTCC00204742,736255,46191
CHEMBL94256,P14780,,DKPAZQOKVRHHON-ADUPEVMXSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,6,NM,,,,,,,,,,,,,,"Inhibition of matrix metalloprotease-9, MMP-9",,,Bioorg. Med. Chem. Lett.,1997,7,21,,,102116,DTCT0024844,1322238,DTCC00257864,1035462,2323
CHEMBL94346,P14780,(PROPYLAMINO)CARBONYLPHOSPHONIC ACID,KMYNAIWKMORGAF-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15139760,IC50,=,20000,NM,,,,,,,,,,,,,,In vitro inhibitory activity against recombinant matrix metalloprotease-9 was determined,,"Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.",J. Med. Chem.,2004,47,11,"Breuer E, Salomon CJ, Katz Y, Chen W, Lu S, Röschenthaler GV, Hadar R, Reich R",,105518,DTCT0024844,1288013,DTCC00260739,1850377,17838
CHEMBL94348,P14780,(ETHYLAMINO)CARBONYLPHOSPHONIC ACID,IZWWUWVUAGTWGV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15139760,IC50,=,3000,NM,,,,,,,,,,,,,,In vitro inhibitory activity against recombinant matrix metalloprotease-9 was determined,,"Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.",J. Med. Chem.,2004,47,11,"Breuer E, Salomon CJ, Katz Y, Chen W, Lu S, Röschenthaler GV, Hadar R, Reich R",,105518,DTCT0024844,1319230,DTCC00260740,949944,17838
CHEMBL94357,P14780,,AOGWJSJATLXUOJ-OAHLLOKOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873518,IC50,=,11,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotein-9,,Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2003,13,16,"Levin JI, Chen JM, Cheung K, Cole D, Crago C, Santos ED, Du X, Khafizova G, MacEwan G, Niu C, Salaski EJ, Zask A, Cummons T, Sung A, Xu J, Zhang Y, Xu W, Ayral-Kaloustian S, Jin G, Cowling R, Barone D, Mohler KM, Black RA, Skotnicki JS",,105519,DTCT0024844,797550,DTCC00260144,776546,5733
CHEMBL94357,P14780,,AOGWJSJATLXUOJ-OAHLLOKOSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,10.96,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258124,DTCC00260144,778984,24803
CHEMBL94363,P14780,,LRYRCUJGWNCKPO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873518,IC50,=,1377,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotein-9,,Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2003,13,16,"Levin JI, Chen JM, Cheung K, Cole D, Crago C, Santos ED, Du X, Khafizova G, MacEwan G, Niu C, Salaski EJ, Zask A, Cummons T, Sung A, Xu J, Zhang Y, Xu W, Ayral-Kaloustian S, Jin G, Cowling R, Barone D, Mohler KM, Black RA, Skotnicki JS",,105519,DTCT0024844,788892,DTCC00260174,422142,5733
CHEMBL94363,P14780,,LRYRCUJGWNCKPO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,1380.38,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258145,DTCC00260174,424711,24803
CHEMBL94386,P14780,,DFRHCKHXGKQVLI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873518,IC50,=,1511,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotein-9,,Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2003,13,16,"Levin JI, Chen JM, Cheung K, Cole D, Crago C, Santos ED, Du X, Khafizova G, MacEwan G, Niu C, Salaski EJ, Zask A, Cummons T, Sung A, Xu J, Zhang Y, Xu W, Ayral-Kaloustian S, Jin G, Cowling R, Barone D, Mohler KM, Black RA, Skotnicki JS",,105519,DTCT0024844,801720,DTCC00260505,582862,5733
CHEMBL945,P14780,AMILORIDE,XSDQTOBWRPYKKA-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7296723,DTCC00205274,2057644,46191
CHEMBL945,P14780,AMILORIDE,XSDQTOBWRPYKKA-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7296724,DTCC00205274,2057644,46191
CHEMBL94518,P14780,,RLUGMDBAWBLDJQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873518,IC50,=,111,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotein-9,,Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2003,13,16,"Levin JI, Chen JM, Cheung K, Cole D, Crago C, Santos ED, Du X, Khafizova G, MacEwan G, Niu C, Salaski EJ, Zask A, Cummons T, Sung A, Xu J, Zhang Y, Xu W, Ayral-Kaloustian S, Jin G, Cowling R, Barone D, Mohler KM, Black RA, Skotnicki JS",,105519,DTCT0024844,776439,DTCC00260575,938424,5733
CHEMBL94643,P14780,,RMUMGJZUGCOZOV-LLVKDONJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873518,IC50,=,68,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotein-9,,Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2003,13,16,"Levin JI, Chen JM, Cheung K, Cole D, Crago C, Santos ED, Du X, Khafizova G, MacEwan G, Niu C, Salaski EJ, Zask A, Cummons T, Sung A, Xu J, Zhang Y, Xu W, Ayral-Kaloustian S, Jin G, Cowling R, Barone D, Mohler KM, Black RA, Skotnicki JS",,105519,DTCT0024844,814663,DTCC00260178,1100601,5733
CHEMBL94643,P14780,,RMUMGJZUGCOZOV-LLVKDONJSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,67.61,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258126,DTCC00260178,1103033,24803
CHEMBL94715,P14780,,XRLMAIWPTHLVKY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873518,IC50,=,753,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotein-9,,Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2003,13,16,"Levin JI, Chen JM, Cheung K, Cole D, Crago C, Santos ED, Du X, Khafizova G, MacEwan G, Niu C, Salaski EJ, Zask A, Cummons T, Sung A, Xu J, Zhang Y, Xu W, Ayral-Kaloustian S, Jin G, Cowling R, Barone D, Mohler KM, Black RA, Skotnicki JS",,105519,DTCT0024844,775107,DTCC00260052,1585289,5733
CHEMBL94715,P14780,,XRLMAIWPTHLVKY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,758.58,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258114,DTCC00260052,1587767,24803
CHEMBL94715,P14780,,XRLMAIWPTHLVKY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,24044434,IC50,=,890,NM,,,,,,,,,,,,,,Inhibition of recombinant human MMP-9 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 4 hrs measured every 15 secs for 20 mins by fluorimetric assay,,Selective arylsulfonamide inhibitors of ADAM-17: hit optimization and activity in ovarian cancer cell models.,J. Med. Chem.,2013,56,20,"Nuti E, Casalini F, Santamaria S, Fabbi M, Carbotti G, Ferrini S, Marinelli L, La Pietra V, Novellino E, Camodeca C, Orlandini E, Nencetti S, Rossello A",,984235,DTCT0024844,12586835,DTCC00260052,1612575,55984
CHEMBL94948,P14780,,FNRFZJFDQHKMHF-SNVBAGLBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873518,IC50,=,796,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotein-9,,Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2003,13,16,"Levin JI, Chen JM, Cheung K, Cole D, Crago C, Santos ED, Du X, Khafizova G, MacEwan G, Niu C, Salaski EJ, Zask A, Cummons T, Sung A, Xu J, Zhang Y, Xu W, Ayral-Kaloustian S, Jin G, Cowling R, Barone D, Mohler KM, Black RA, Skotnicki JS",,105519,DTCT0024844,807305,DTCC00259598,486464,5733
CHEMBL94948,P14780,,FNRFZJFDQHKMHF-SNVBAGLBSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,794.33,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258127,DTCC00259598,488937,24803
CHEMBL95,P14780,TACRINE,YLJREFDVOIBQDA-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7454713,DTCC00140002,283001,46191
CHEMBL95,P14780,TACRINE,YLJREFDVOIBQDA-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7454714,DTCC00140002,283001,46191
CHEMBL95068,P14780,PIPERIDIN-1-YLCARBONYLPHOSPHONIC ACID,LPCNDTNDDXIPDM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15139760,IC50,=,500,NM,,,,,,,,,,,,,,In vitro inhibitory activity against recombinant matrix metalloprotease-9 was determined,,"Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.",J. Med. Chem.,2004,47,11,"Breuer E, Salomon CJ, Katz Y, Chen W, Lu S, Röschenthaler GV, Hadar R, Reich R",,105518,DTCT0024844,1290507,DTCC01741836,820511,17838
CHEMBL9514,P14780,NOCODAZOLE,KYRVNWMVYQXFEU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7379903,DTCC00136712,2025640,46191
CHEMBL9514,P14780,NOCODAZOLE,KYRVNWMVYQXFEU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7379904,DTCC00136712,2025640,46191
CHEMBL95237,P14780,,IHERVMJHCHNTKO-YJJOXIQCSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17512742,IC50,=,17,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.,Bioorg. Med. Chem.,2007,15,14,"Moroy G, Denhez C, El Mourabit H, Toribio A, Dassonville A, Decarme M, Renault JH, Mirand C, Bellon G, Sapi J, Alix AJ, Hornebeck W, Bourguet E",,447907,DTCT0024844,2176046,DTCC00263307,520985,23716
CHEMBL95262,P14780,,DWAPKTBJQHYHER-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12270165,IC50,=,95.5,NM,,,,,,,,,,,,,,Concentration required in vitro to inhibit Matrix metalloprotease-9,,Benzodiazepine inhibitors of the MMPs and TACE.,Bioorg. Med. Chem. Lett.,2002,12,20,"Nelson FC, Delos Santos E, Levin JI, Chen JM, Skotnicki JS, DiJoseph JF, Sharr MA, Sung A, Killar LM, Cowling R, Jin G, Roth CE, Albright JD",,105515,DTCT0024844,1536387,DTCC00263282,270283,5143
CHEMBL954,P14780,ENCLOMIPHENE,GKIRPKYJQBWNGO-OCEACIFDSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7365194,DTCC00208231,1383775,46191
CHEMBL954,P14780,ENCLOMIPHENE,GKIRPKYJQBWNGO-OCEACIFDSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7365195,DTCC00208231,1383775,46191
CHEMBL95414,P14780,,FUYGKZYSHSZHFI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15125955,IC50,=,28000,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,Reverse hydroxamate-based selective TACE inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,11,"Kamei N, Tanaka T, Kawai K, Miyawaki K, Okuyama A, Murakami Y, Arakawa Y, Haino M, Harada T, Shimano M",,105525,DTCT0024844,1401124,DTCC00264967,1079590,6400
CHEMBL95460,P14780,,BLQAAMGUGMNRQN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12270165,IC50,=,33,NM,,,,,,,,,,,,,,Concentration required in vitro to inhibit Matrix metalloprotease-9,,Benzodiazepine inhibitors of the MMPs and TACE.,Bioorg. Med. Chem. Lett.,2002,12,20,"Nelson FC, Delos Santos E, Levin JI, Chen JM, Skotnicki JS, DiJoseph JF, Sharr MA, Sung A, Killar LM, Cowling R, Jin G, Roth CE, Albright JD",,105515,DTCT0024844,1534013,DTCC00263280,1629611,5143
CHEMBL95486,P14780,,ZMVFZGHWXXXQJL-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12270165,IC50,=,8,NM,,,,,,,,,,,,,,Concentration required in vitro to inhibit Matrix metalloprotease-9,,Benzodiazepine inhibitors of the MMPs and TACE.,Bioorg. Med. Chem. Lett.,2002,12,20,"Nelson FC, Delos Santos E, Levin JI, Chen JM, Skotnicki JS, DiJoseph JF, Sharr MA, Sung A, Killar LM, Cowling R, Jin G, Roth CE, Albright JD",,105515,DTCT0024844,1541049,DTCC00263781,368552,5143
CHEMBL95693,P14780,,ASLUWSDEBRNVJV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12270165,IC50,=,35.8,NM,,,,,,,,,,,,,,Concentration required in vitro to inhibit Matrix metalloprotease-9,,Benzodiazepine inhibitors of the MMPs and TACE.,Bioorg. Med. Chem. Lett.,2002,12,20,"Nelson FC, Delos Santos E, Levin JI, Chen JM, Skotnicki JS, DiJoseph JF, Sharr MA, Sung A, Killar LM, Cowling R, Jin G, Roth CE, Albright JD",,105515,DTCT0024844,1557108,DTCC00263252,853457,5143
CHEMBL95708,P14780,,FMPSZEWYBZCYDN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12270165,IC50,=,2,NM,,,,,,,,,,,,,,Concentration required in vitro to inhibit Matrix metalloprotease-9,,Benzodiazepine inhibitors of the MMPs and TACE.,Bioorg. Med. Chem. Lett.,2002,12,20,"Nelson FC, Delos Santos E, Levin JI, Chen JM, Skotnicki JS, DiJoseph JF, Sharr MA, Sung A, Killar LM, Cowling R, Jin G, Roth CE, Albright JD",,105515,DTCT0024844,1528071,DTCC00263067,1014632,5143
CHEMBL95763,P14780,(CYCLOBUTYLAMINO)CARBONYLPHOSPHONIC ACID,UILNVWQPBYOCJX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15139760,IC50,>,100000,NM,,,,,,,,,,,,,,In vitro inhibitory activity against recombinant matrix metalloprotease-9 was determined,,"Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.",J. Med. Chem.,2004,47,11,"Breuer E, Salomon CJ, Katz Y, Chen W, Lu S, Röschenthaler GV, Hadar R, Reich R",,105518,DTCT0024844,1286796,DTCC00261232,788164,17838
CHEMBL95764,P14780,GLYPHOSATE,XDDAORKBJWWYJS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7321016,DTCC00263189,1894968,46191
CHEMBL95764,P14780,GLYPHOSATE,XDDAORKBJWWYJS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7321017,DTCC00263189,1894968,46191
CHEMBL95807,P14780,,VCKCQHDSLLCTDH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12270165,IC50,=,1,NM,,,,,,,,,,,,,,Concentration required in vitro to inhibit Matrix metalloprotease-9,,Benzodiazepine inhibitors of the MMPs and TACE.,Bioorg. Med. Chem. Lett.,2002,12,20,"Nelson FC, Delos Santos E, Levin JI, Chen JM, Skotnicki JS, DiJoseph JF, Sharr MA, Sung A, Killar LM, Cowling R, Jin G, Roth CE, Albright JD",,105515,DTCT0024844,1524643,DTCC00263111,30422,5143
CHEMBL95897,P14780,,VAQOTZQDXZDBJK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION RATIO,~,2,%,,,,,,,,,,,,,,Inhibition of collagen IV degradation by matrix metalloprotease-9 at 10 uM,,,Bioorg. Med. Chem. Lett.,1997,7,7,,,105538,DTCT0024844,659822,DTCC00264636,918612,2474
CHEMBL95897,P14780,,VAQOTZQDXZDBJK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,INHIBITION RATIO,~,18,%,,,,,,,,,,,,,,Inhibition of collagen IV degradation by matrix metalloprotease-9 at 100 uM,,,Bioorg. Med. Chem. Lett.,1997,7,7,,,105537,DTCT0024844,659823,DTCC00264636,918612,2474
CHEMBL959,P14780,RIMANTADINE,UBCHPRBFMUDMNC-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7457820,DTCC00208870,574626,46191
CHEMBL959,P14780,RIMANTADINE,UBCHPRBFMUDMNC-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7457821,DTCC00208870,574626,46191
CHEMBL960,P14780,LEFLUNOMIDE,VHOGYURTWQBHIL-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7429408,DTCC00208904,249943,46191
CHEMBL960,P14780,LEFLUNOMIDE,VHOGYURTWQBHIL-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7429409,DTCC00208904,249943,46191
CHEMBL96049,P14780,,DIIAIQCOHXBJHI-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12270165,IC50,=,0.6,NM,,,,,,,,,,,,,,Concentration required in vitro to inhibit Matrix metalloprotease-9,,Benzodiazepine inhibitors of the MMPs and TACE.,Bioorg. Med. Chem. Lett.,2002,12,20,"Nelson FC, Delos Santos E, Levin JI, Chen JM, Skotnicki JS, DiJoseph JF, Sharr MA, Sung A, Killar LM, Cowling R, Jin G, Roth CE, Albright JD",,105515,DTCT0024844,1534006,DTCC00263035,1980294,5143
CHEMBL96396,P14780,,XDSILIXRMZXTNX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873518,IC50,=,160,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotein-9,,Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2003,13,16,"Levin JI, Chen JM, Cheung K, Cole D, Crago C, Santos ED, Du X, Khafizova G, MacEwan G, Niu C, Salaski EJ, Zask A, Cummons T, Sung A, Xu J, Zhang Y, Xu W, Ayral-Kaloustian S, Jin G, Cowling R, Barone D, Mohler KM, Black RA, Skotnicki JS",,105519,DTCT0024844,793498,DTCC00106556,841675,5733
CHEMBL96396,P14780,,XDSILIXRMZXTNX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,158.49,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258120,DTCC00106556,844210,24803
CHEMBL964,P14780,DISULFIRAM,AUZONCFQVSMFAP-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7357704,DTCC00209451,1318441,46191
CHEMBL964,P14780,DISULFIRAM,AUZONCFQVSMFAP-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7357705,DTCC00209451,1318441,46191
CHEMBL96417,P14780,,VMOSDDURWLNMNG-JLOHTSLTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873518,IC50,=,777,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotein-9,,Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2003,13,16,"Levin JI, Chen JM, Cheung K, Cole D, Crago C, Santos ED, Du X, Khafizova G, MacEwan G, Niu C, Salaski EJ, Zask A, Cummons T, Sung A, Xu J, Zhang Y, Xu W, Ayral-Kaloustian S, Jin G, Cowling R, Barone D, Mohler KM, Black RA, Skotnicki JS",,105519,DTCT0024844,810078,DTCC00260137,1553080,5733
CHEMBL96417,P14780,,VMOSDDURWLNMNG-JLOHTSLTSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,776.25,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258121,DTCC00260137,1555525,24803
CHEMBL96419,P14780,,RWOPWLLDIYQNCW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873518,IC50,=,53,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotein-9 at 10 uM,,Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2003,13,16,"Levin JI, Chen JM, Cheung K, Cole D, Crago C, Santos ED, Du X, Khafizova G, MacEwan G, Niu C, Salaski EJ, Zask A, Cummons T, Sung A, Xu J, Zhang Y, Xu W, Ayral-Kaloustian S, Jin G, Cowling R, Barone D, Mohler KM, Black RA, Skotnicki JS",,105520,DTCT0024844,803112,DTCC00260569,258277,5733
CHEMBL96438,P14780,(DIBUTYLAMINO)CARBONYLPHOSPHONIC ACID,NEQAQLUTBGWNLE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15139760,IC50,>,100000,NM,,,,,,,,,,,,,,In vitro inhibitory activity against recombinant matrix metalloprotease-9 was determined,,"Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.",J. Med. Chem.,2004,47,11,"Breuer E, Salomon CJ, Katz Y, Chen W, Lu S, Röschenthaler GV, Hadar R, Reich R",,105518,DTCT0024844,1307520,DTCC00261385,465117,17838
CHEMBL96473,P14780,,LTRFXCQZLSSSPG-UBFHEZILSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,=,32,NM,,,,,,,,,,,,,,"Inhibition of matrix metalloprotease-9, MMP-9",,,Bioorg. Med. Chem. Lett.,1997,7,21,,,102116,DTCT0024844,1298178,DTCC00257913,129156,2323
CHEMBL96636,P14780,,BTZMVJPRQAIPRP-HXUWFJFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873518,IC50,=,349,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotein-9,,Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2003,13,16,"Levin JI, Chen JM, Cheung K, Cole D, Crago C, Santos ED, Du X, Khafizova G, MacEwan G, Niu C, Salaski EJ, Zask A, Cummons T, Sung A, Xu J, Zhang Y, Xu W, Ayral-Kaloustian S, Jin G, Cowling R, Barone D, Mohler KM, Black RA, Skotnicki JS",,105519,DTCT0024844,792001,DTCC00260134,96942,5733
CHEMBL96636,P14780,,BTZMVJPRQAIPRP-HXUWFJFHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,346.74,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258116,DTCC00260134,99386,24803
CHEMBL96637,P14780,,JBVXKMHBLNDBBV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873518,IC50,=,4,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotein-9,,Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2003,13,16,"Levin JI, Chen JM, Cheung K, Cole D, Crago C, Santos ED, Du X, Khafizova G, MacEwan G, Niu C, Salaski EJ, Zask A, Cummons T, Sung A, Xu J, Zhang Y, Xu W, Ayral-Kaloustian S, Jin G, Cowling R, Barone D, Mohler KM, Black RA, Skotnicki JS",,105519,DTCT0024844,801715,DTCC00260135,518705,5733
CHEMBL96637,P14780,,JBVXKMHBLNDBBV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,3.98,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258117,DTCC00260135,521147,24803
CHEMBL97034,P14780,(ISOPROPYLAMINO)CARBONYLPHOSPHONIC ACID,ZBIIKTYRXGHZSP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15139760,IC50,=,2000,NM,,,,,,,,,,,,,,In vitro inhibitory activity against recombinant matrix metalloprotease-9 was determined,,"Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.",J. Med. Chem.,2004,47,11,"Breuer E, Salomon CJ, Katz Y, Chen W, Lu S, Röschenthaler GV, Hadar R, Reich R",,105518,DTCT0024844,1307512,DTCC00261507,335874,17838
CHEMBL97057,P14780,(DIETHYLAMINO)CARBONYLPHOSPHONIC ACID,DCJBWQGCBUBISK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15139760,IC50,>,100000,NM,,,,,,,,,,,,,,In vitro inhibitory activity against recombinant matrix metalloprotease-9 was determined,,"Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.",J. Med. Chem.,2004,47,11,"Breuer E, Salomon CJ, Katz Y, Chen W, Lu S, Röschenthaler GV, Hadar R, Reich R",,105518,DTCT0024844,1296413,DTCC00261591,1240575,17838
CHEMBL972,P14780,SELEGILINE,MEZLKOACVSPNER-GFCCVEGCSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7462531,DTCC00210689,51433,46191
CHEMBL972,P14780,SELEGILINE,MEZLKOACVSPNER-GFCCVEGCSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7462532,DTCC00210689,51433,46191
CHEMBL97388,P14780,(METHYLAMINO)CARBONYLPHOSPHONIC ACID,DKRGQDKOWKPDBY-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15139760,IC50,>,100000,NM,,,,,,,,,,,,,,In vitro inhibitory activity against recombinant matrix metalloprotease-9 was determined,,"Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.",J. Med. Chem.,2004,47,11,"Breuer E, Salomon CJ, Katz Y, Chen W, Lu S, Röschenthaler GV, Hadar R, Reich R",,105518,DTCT0024844,1314465,DTCC00261329,659364,17838
CHEMBL97389,P14780,SODIUM HYDROGEN (BUTYLAMINO)CARBONYLPHOSPHONATE,XZWWCSRZYGUJCH-UHFFFAOYSA-M,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15139760,IC50,>,100000,NM,,,,,,,,,,,,,,In vitro inhibitory activity against recombinant matrix metalloprotease-9 was determined,,"Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.",J. Med. Chem.,2004,47,11,"Breuer E, Salomon CJ, Katz Y, Chen W, Lu S, Röschenthaler GV, Hadar R, Reich R",,105518,DTCT0024844,1318101,DTCC00261330,368532,17838
CHEMBL975,P14780,MESNA,XOGTZOOQQBDUSI-UHFFFAOYSA-M,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7408696,DTCC00211154,1960079,46191
CHEMBL975,P14780,MESNA,XOGTZOOQQBDUSI-UHFFFAOYSA-M,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7408697,DTCC00211154,1960079,46191
CHEMBL97510,P14780,(SEC-BUTYLAMINO)CARBONYLPHOSPHONIC ACID,FRMUISNHCCQMGM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15139760,IC50,>,100000,NM,,,,,,,,,,,,,,In vitro inhibitory activity against recombinant matrix metalloprotease-9 was determined,,"Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.",J. Med. Chem.,2004,47,11,"Breuer E, Salomon CJ, Katz Y, Chen W, Lu S, Röschenthaler GV, Hadar R, Reich R",,105518,DTCT0024844,1305208,DTCC01741841,1273346,17838
CHEMBL976,P14780,PRAZIQUANTEL,FSVJFNAIGNNGKK-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7383304,DTCC00213280,1383780,46191
CHEMBL976,P14780,PRAZIQUANTEL,FSVJFNAIGNNGKK-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7383305,DTCC00213280,1383780,46191
CHEMBL97614,P14780,(CYCLOHEPTYLAMINO)CARBONYLPHOSPHONIC ACID,PZCAQCXIXVTXSS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15139760,IC50,>,100000,NM,,,,,,,,,,,,,,In vitro inhibitory activity against recombinant matrix metalloprotease-9 was determined,,"Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.",J. Med. Chem.,2004,47,11,"Breuer E, Salomon CJ, Katz Y, Chen W, Lu S, Röschenthaler GV, Hadar R, Reich R",,105518,DTCT0024844,1313343,DTCC00261524,1753576,17838
CHEMBL97709,P14780,(CYCLOOCTYLAMINO)CARBONYLPHOSPHONIC ACID,RDECIIJACWTCQB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15139760,IC50,>,100000,NM,,,,,,,,,,,,,,In vitro inhibitory activity against recombinant matrix metalloprotease-9 was determined,,"Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.",J. Med. Chem.,2004,47,11,"Breuer E, Salomon CJ, Katz Y, Chen W, Lu S, Röschenthaler GV, Hadar R, Reich R",,105518,DTCT0024844,1309957,DTCC00261479,917368,17838
CHEMBL97762,P14780,,LXSYXSGOVAASBA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873518,IC50,=,18,NM,,,,,,,,,,,,,,Inhibition of Matrix metalloprotein-9 at 10 uM,,Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2003,13,16,"Levin JI, Chen JM, Cheung K, Cole D, Crago C, Santos ED, Du X, Khafizova G, MacEwan G, Niu C, Salaski EJ, Zask A, Cummons T, Sung A, Xu J, Zhang Y, Xu W, Ayral-Kaloustian S, Jin G, Cowling R, Barone D, Mohler KM, Black RA, Skotnicki JS",,105520,DTCT0024844,804505,DTCC00260537,1196503,5733
CHEMBL97788,P14780,,YQCWPKHRHVYSBQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12270165,IC50,=,2,NM,,,,,,,,,,,,,,Concentration required in vitro to inhibit Matrix metalloprotease-9,,Benzodiazepine inhibitors of the MMPs and TACE.,Bioorg. Med. Chem. Lett.,2002,12,20,"Nelson FC, Delos Santos E, Levin JI, Chen JM, Skotnicki JS, DiJoseph JF, Sharr MA, Sung A, Killar LM, Cowling R, Jin G, Roth CE, Albright JD",,105515,DTCT0024844,1524649,DTCC00263190,885716,5143
CHEMBL97790,P14780,,PRQWPDFKJBVNKQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12270165,IC50,=,228,NM,,,,,,,,,,,,,,Concentration required in vitro to inhibit Matrix metalloprotease-9,,Benzodiazepine inhibitors of the MMPs and TACE.,Bioorg. Med. Chem. Lett.,2002,12,20,"Nelson FC, Delos Santos E, Levin JI, Chen JM, Skotnicki JS, DiJoseph JF, Sharr MA, Sung A, Killar LM, Cowling R, Jin G, Roth CE, Albright JD",,105515,DTCT0024844,1548148,DTCC00263227,1273366,5143
CHEMBL97838,P14780,MORPHOLIN-4-YLCARBONYLPHOSPHONIC ACID,XUDXDIFMUCLQQH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15139760,IC50,>,100000,NM,,,,,,,,,,,,,,In vitro inhibitory activity against recombinant matrix metalloprotease-9 was determined,,"Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.",J. Med. Chem.,2004,47,11,"Breuer E, Salomon CJ, Katz Y, Chen W, Lu S, Röschenthaler GV, Hadar R, Reich R",,105518,DTCT0024844,1313352,DTCC01741839,1564617,17838
CHEMBL97898,P14780,,PLYLMXDSDZFWLJ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12270165,IC50,=,2,NM,,,,,,,,,,,,,,Concentration required in vitro to inhibit Matrix metalloprotease-9,,Benzodiazepine inhibitors of the MMPs and TACE.,Bioorg. Med. Chem. Lett.,2002,12,20,"Nelson FC, Delos Santos E, Levin JI, Chen JM, Skotnicki JS, DiJoseph JF, Sharr MA, Sung A, Killar LM, Cowling R, Jin G, Roth CE, Albright JD",,105515,DTCT0024844,1549327,DTCC00262551,1564629,5143
CHEMBL97908,P14780,,XJFYJIMKKGZKGX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12270165,IC50,=,13,NM,,,,,,,,,,,,,,Concentration required in vitro to inhibit Matrix metalloprotease-9,,Benzodiazepine inhibitors of the MMPs and TACE.,Bioorg. Med. Chem. Lett.,2002,12,20,"Nelson FC, Delos Santos E, Levin JI, Chen JM, Skotnicki JS, DiJoseph JF, Sharr MA, Sung A, Killar LM, Cowling R, Jin G, Roth CE, Albright JD",,105515,DTCT0024844,1543426,DTCC00263178,270282,5143
CHEMBL97951,P14780,CYCLOHEXYLMETHYLCARBAMOYLPHOSPHONIC ACID,XBMRQHZMWARLEG-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15139760,IC50,=,1000,NM,,,,,,,,,,,,,,In vitro inhibitory activity against recombinant matrix metalloprotease-9 was determined,,"Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.",J. Med. Chem.,2004,47,11,"Breuer E, Salomon CJ, Katz Y, Chen W, Lu S, Röschenthaler GV, Hadar R, Reich R",,105518,DTCT0024844,1320470,DTCC00106572,1273345,17838
CHEMBL97962,P14780,,YPEMWYFQTIBRAB-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12270165,IC50,=,4,NM,,,,,,,,,,,,,,Concentration required in vitro to inhibit Matrix metalloprotease-9,,Benzodiazepine inhibitors of the MMPs and TACE.,Bioorg. Med. Chem. Lett.,2002,12,20,"Nelson FC, Delos Santos E, Levin JI, Chen JM, Skotnicki JS, DiJoseph JF, Sharr MA, Sung A, Killar LM, Cowling R, Jin G, Roth CE, Albright JD",,105515,DTCT0024844,1543422,DTCC00263179,1597073,5143
CHEMBL98,P14780,VORINOSTAT,WAEXFXRVDQXREF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26386821,IC50,,,,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 2 hrs prior to testing measured for 15 mins by fluorometric analysis,Not Determined,"Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.",Bioorg. Med. Chem.,2015,23,20,"Yan Y, Chen X, Yang X, Zhang J, Xu W, Zhang Y",,1518636,DTCT0024844,14550530,DTCC00141645,1032901,63755
CHEMBL98,P14780,VORINOSTAT,WAEXFXRVDQXREF-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,26386821,INHIBITION,,,,,,,,,,,,,,,,,Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate at 10 uM incubated for 2 hrs prior to testing measured for 15 mins by fluorometric analysis relative to control,Not Determined,"Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.",Bioorg. Med. Chem.,2015,23,20,"Yan Y, Chen X, Yang X, Zhang J, Xu W, Zhang Y",,1518638,DTCT0024844,14550556,DTCC00141645,1032901,63755
CHEMBL980,P14780,GUAIFENESIN,HSRJKNPTNIJEKV-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7312637,DTCC00214269,994593,46191
CHEMBL980,P14780,GUAIFENESIN,HSRJKNPTNIJEKV-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7312638,DTCC00214269,994593,46191
CHEMBL98061,P14780,,QCHHXEMLMRDLDA-OAQYLSRUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12873518,IC50,=,11,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotein-9,,Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.,Bioorg. Med. Chem. Lett.,2003,13,16,"Levin JI, Chen JM, Cheung K, Cole D, Crago C, Santos ED, Du X, Khafizova G, MacEwan G, Niu C, Salaski EJ, Zask A, Cummons T, Sung A, Xu J, Zhang Y, Xu W, Ayral-Kaloustian S, Jin G, Cowling R, Barone D, Mohler KM, Black RA, Skotnicki JS",,105519,DTCT0024844,782232,DTCC00260544,1650137,5733
CHEMBL98061,P14780,,QCHHXEMLMRDLDA-OAQYLSRUSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,17275314,IC50,=,10.96,NM,,,,,,,,,,,,,,Inhibition of MMP9,,Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,Bioorg. Med. Chem.,2007,15,6,"Verma RP, Hansch C",,458932,DTCT0024844,2258115,DTCC00260544,1652637,24803
CHEMBL98202,P14780,,KQXZHGMAVQYCLA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15125955,IC50,=,31000,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,Reverse hydroxamate-based selective TACE inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,11,"Kamei N, Tanaka T, Kawai K, Miyawaki K, Okuyama A, Murakami Y, Arakawa Y, Haino M, Harada T, Shimano M",,105525,DTCT0024844,1386240,DTCC00265444,401371,6400
CHEMBL983,P14780,SUCCINYLCHOLINE CHLORIDE,YOEWQQVKRJEPAE-UHFFFAOYSA-L,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7485006,DTCC00215702,1674152,46191
CHEMBL983,P14780,SUCCINYLCHOLINE CHLORIDE,YOEWQQVKRJEPAE-UHFFFAOYSA-L,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7485007,DTCC00215702,1674152,46191
CHEMBL98328,P14780,N-HYDROXY-METHANESULFONAMIDE,YKSVNSKYIUPAKW-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11020282,KI,>,100,NM,,,,,,,,,,,,,,Inhibitory activity against Matrix metalloprotease-9,,"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.",J. Med. Chem.,2000,43,20,"Scozzafava A, Supuran CT",,105388,DTCT0024844,1622874,DTCC01741913,1014996,15919
CHEMBL98350,P14780,LY-294002,CZQHHVNHHHRRDU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7423306,DTCC00262208,1960077,46191
CHEMBL98350,P14780,LY-294002,CZQHHVNHHHRRDU-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7423307,DTCC00262208,1960077,46191
CHEMBL98390,P14780,,AYWKRESAZCSENH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15125955,IC50,=,90000,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,Reverse hydroxamate-based selective TACE inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,11,"Kamei N, Tanaka T, Kawai K, Miyawaki K, Okuyama A, Murakami Y, Arakawa Y, Haino M, Harada T, Shimano M",,105525,DTCT0024844,1403507,DTCC00265682,691581,6400
CHEMBL98852,P14780,,VDOSRWCTGZRCFD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15125955,IC50,=,50000,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,Reverse hydroxamate-based selective TACE inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,11,"Kamei N, Tanaka T, Kawai K, Miyawaki K, Okuyama A, Murakami Y, Arakawa Y, Haino M, Harada T, Shimano M",,105525,DTCT0024844,1364697,DTCC00265511,949990,6400
CHEMBL989,P14780,FLUOCINOLONE ACETONIDE,FEBLZLNTKCEFIT-VSXGLTOVSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7303466,DTCC00218597,1351110,46191
CHEMBL989,P14780,FLUOCINOLONE ACETONIDE,FEBLZLNTKCEFIT-VSXGLTOVSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7303467,DTCC00218597,1351110,46191
CHEMBL990,P14780,BUTENAFINE,ABJKWBDEJIDSJZ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7274524,DTCC00218762,1862713,46191
CHEMBL990,P14780,BUTENAFINE,ABJKWBDEJIDSJZ-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7274525,DTCC00218762,1862713,46191
CHEMBL99045,P14780,,QSRYPQMSBYPAQC-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15125955,IC50,=,53000,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,Reverse hydroxamate-based selective TACE inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,11,"Kamei N, Tanaka T, Kawai K, Miyawaki K, Okuyama A, Murakami Y, Arakawa Y, Haino M, Harada T, Shimano M",,105525,DTCT0024844,1382456,DTCC00264808,1403621,6400
CHEMBL99072,P14780,,OOCSYABQMHKMLM-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,12270165,IC50,=,1.4,NM,,,,,,,,,,,,,,Concentration required in vitro to inhibit Matrix metalloprotease-9,,Benzodiazepine inhibitors of the MMPs and TACE.,Bioorg. Med. Chem. Lett.,2002,12,20,"Nelson FC, Delos Santos E, Levin JI, Chen JM, Skotnicki JS, DiJoseph JF, Sharr MA, Sung A, Killar LM, Cowling R, Jin G, Roth CE, Albright JD",,105515,DTCT0024844,1523645,DTCC00262903,1785725,5143
CHEMBL991,P14780,STAVUDINE,XNKLLVCARDGLGL-JGVFFNPUSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7473718,DTCC00220129,1927023,46191
CHEMBL991,P14780,STAVUDINE,XNKLLVCARDGLGL-JGVFFNPUSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7473719,DTCC00220129,1927023,46191
CHEMBL99365,P14780,,YFYQFPIGOKJLFD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15125955,IC50,=,53000,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,Reverse hydroxamate-based selective TACE inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,11,"Kamei N, Tanaka T, Kawai K, Miyawaki K, Okuyama A, Murakami Y, Arakawa Y, Haino M, Harada T, Shimano M",,105525,DTCT0024844,1394862,DTCC00265479,562406,6400
CHEMBL99733,P14780,,PIZFUXJESIVHOO-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15163180,KI,=,702,NM,,,,,,,,,,,,,,Inhibition of recombinant human Matrix metalloprotease-9,,Sultam hydroxamates as novel matrix metalloproteinase inhibitors.,J. Med. Chem.,2004,47,12,"Cherney RJ, Mo R, Meyer DT, Hardman KD, Liu RQ, Covington MB, Qian M, Wasserman ZR, Christ DD, Trzaskos JM, Newton RC, Decicco CP",,105386,DTCT0024844,671274,DTCC00269145,582953,18131
CHEMBL99745,P14780,,KSLUOGMHCJCRLQ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,11677139,IC50,=,2,NM,,,,,,,,,,,,,,In vitro inhibition of Matrix metalloprotease-9.,,The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.,Bioorg. Med. Chem. Lett.,2001,11,22,"Levin JI, Chen JM, Du MT, Nelson FC, Wehr T, DiJoseph JF, Killar LM, Skala S, Sung A, Sharr MA, Roth CE, Jin G, Cowling R, Di L, Sherman M, Xu ZB, March CJ, Mohler KM, Black RA, Skotnicki JS",,105530,DTCT0024844,1602201,DTCC00269611,1132821,4590
CHEMBL998,P14780,LORATADINE,JCCNYMKQOSZNPW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,IC50,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7438129,DTCC00223343,1253325,46191
CHEMBL998,P14780,LORATADINE,JCCNYMKQOSZNPW-UHFFFAOYSA-N,4,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,,KI,,,,,cell_based,,,,,,,,,,,Mammalian cells,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),DrugMatrix in vitro pharmacology data,,,,,"Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program",,774676,DTCT0024844,7438130,DTCC00223343,1253325,46191
CHEMBL99932,P14780,8-AMINOQUINOLINE,WREVVZMUNPAPOV-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21189019,INHIBITION,=,57,%,,,,,,,,,,,,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,J. Med. Chem.,2011,54,2,"Jacobsen JA, Fullagar JL, Miller MT, Cohen SM",,715234,DTCT0024844,5103891,DTCC00265364,540480,43205
CHEMBL99995,P14780,,CDDCBQKBUFNWAE-NTBLAEGASA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,15125955,IC50,=,45000,NM,,,,,,,,,,,,,,Inhibition of matrix metalloprotease-9,,Reverse hydroxamate-based selective TACE inhibitors.,Bioorg. Med. Chem. Lett.,2004,14,11,"Kamei N, Tanaka T, Kawai K, Miyawaki K, Okuyama A, Murakami Y, Arakawa Y, Haino M, Harada T, Shimano M",,105525,DTCT0024844,1383852,DTCC00265558,853474,6400
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16220987,KI,=,2.5,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14745307,DTCC01744004,2108945,69259
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16220987,KI,=,30,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14754609,DTCC01744004,2108945,69259
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18221310,IC50,=,25000,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14708298,DTCC01744004,2096566,67810
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18221310,IC50,=,27400,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14725608,DTCC01744004,2096566,67810
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18221310,IC50,=,50000,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14706202,DTCC01744004,2096566,67810
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18221310,IC50,=,64900,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14705281,DTCC01744004,2096566,67810
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18221310,IC50,=,64900,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14725269,DTCC01744004,2096566,67810
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18221310,IC50,=,100000,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14704738,DTCC01744004,2096566,67810
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18221310,IC50,=,100000,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14705092,DTCC01744004,2096566,67810
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18221310,IC50,=,100000,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14705288,DTCC01744004,2096566,67810
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18221310,IC50,=,100000,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14707426,DTCC01744004,2096566,67810
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18221310,IC50,=,100000,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14707497,DTCC01744004,2096566,67810
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18221310,IC50,=,100000,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14707675,DTCC01744004,2096566,67810
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18221310,IC50,=,100000,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14709354,DTCC01744004,2096566,67810
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18221310,IC50,=,100000,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14711732,DTCC01744004,2096566,67810
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18221310,IC50,=,100000,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14712368,DTCC01744004,2096566,67810
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18221310,IC50,=,100000,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14719603,DTCC01744004,2096566,67810
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18221310,IC50,=,100000,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14720694,DTCC01744004,2096566,67810
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18221310,IC50,=,100000,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14720770,DTCC01744004,2096566,67810
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18221310,IC50,=,100000,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14722309,DTCC01744004,2096566,67810
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18221310,IC50,=,100000,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14722935,DTCC01744004,2096566,67810
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18221310,IC50,=,100000,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14722965,DTCC01744004,2096566,67810
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18221310,IC50,=,100000,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14723196,DTCC01744004,2096566,67810
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18221310,IC50,=,100000,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14723403,DTCC01744004,2096566,67810
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18221310,IC50,=,100000,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14726560,DTCC01744004,2096566,67810
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20817735,KI,=,850,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14753299,DTCC01744004,2110394,69686
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21827363,IC50,=,750,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14723765,DTCC01744004,2096753,67989
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21827363,IC50,=,900,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14723761,DTCC01744004,2096753,67989
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21827363,IC50,=,2750,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14723987,DTCC01744004,2096753,67989
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21827363,IC50,=,3500,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14710281,DTCC01744004,2096753,67989
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21827363,IC50,=,8650,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14709359,DTCC01744004,2096753,67989
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22689580,IC50,=,300,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14725235,DTCC01744004,2098141,68703
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22689580,KI,=,91,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14745583,DTCC01744004,2098141,68703
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22689580,KI,=,100,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14753298,DTCC01744004,2098141,68703
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22689580,KI,=,1328,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14749095,DTCC01744004,2098141,68703
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22689580,KI,=,2188,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14751480,DTCC01744004,2098141,68703
,P14780,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,22689580,KI,=,2232,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14746896,DTCC01744004,2098141,68703
,P14780,AC1NSUQX,PFEOKQKYEJFZNV-WZUFQYTHSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18221310,IC50,=,100000,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14721993,DTCC01745046,2102476,67810
,P14780,AC1NZN6N,WYRWIZUSWGLKCX-ZCXUNETKSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,18221310,IC50,=,25000,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14712860,DTCC01744726,2098847,67810
,P14780,AGN-PC-00AW7I,ZBOSPOSQGJWURE-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16220987,KI,=,7,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14746239,DTCC01746086,2109118,69259
,P14780,AGN-PC-00B1B8,QVHYJMPAZNGFHN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16220987,KI,=,0.7,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14753705,DTCC01745743,2103471,69259
,P14780,AGN-PC-00B1IZ,BEQXRWLSEUIFKP-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16220987,KI,=,3,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14747799,DTCC01746160,2109488,69259
,P14780,AGN-PC-00BMEK,QYCUMAKSYBUWER-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16220987,KI,=,0.4,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14753765,DTCC01746699,2110472,69259
,P14780,AGN-PC-00C7AZ,SWYRTBQMGJFWDS-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16220987,KI,=,0.29,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14729793,DTCC01745814,2103978,69259
,P14780,AGN-PC-00COJ9,WDPVPUZANMBBLA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16220987,KI,=,1.1,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14732732,DTCC01745926,2104739,69259
,P14780,AGN-PC-00D2VZ,NKHJMAWHLPBSOA-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16220987,KI,=,9.4,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14752275,DTCC01746561,2110229,69259
,P14780,AGN-PC-00ERPQ,YLRBOIVJMWEGGX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16220987,KI,=,0.6,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14745120,DTCC01745987,2108904,69259
,P14780,ALPHA-SULFONE 27B,LFIZWBFUWVSLOR-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16220987,KI,=,5,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14755209,DTCC01746809,2110669,69259
,P14780,ALPHA-SULFONE 27I,NWFAIXPOXVQZQD-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16220987,KI,=,1,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14757532,DTCC01746901,2111161,69259
,P14780,ALPHA-SULFONE 35G,KLWUGXOQJJWEBZ-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16220987,KI,=,8,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14754583,DTCC01746770,2110582,69259
,P14780,ALPHA-SULFONE 35H,XJMDDZUUIUEEJH-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,16220987,KI,=,14.7,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14746922,DTCC01746132,2109290,69259
,P14780,BI-102C8,SSQUTXCOTMRKGX-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20308072,IC50,=,100000,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14710174,DTCC01744594,2098163,68371
,P14780,BI-92G11,NUSZCZOBSDRJEK-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,20308072,IC50,=,50000,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14707326,DTCC01744374,2097426,68371
,P14780,INHIBITOR A,AUFRSHPKGODFMN-UHFFFAOYSA-N,0,MATRIX METALLOPROTEINASE 9,MMP9,Enzyme,,,21406033,IC50,=,537,NM,,,,,,,,,,,,,,,,,,,,,,,,DTCT0024844,14720883,DTCC01744979,2102115,69105
